



**Australian Government**  

---

**Department of Health and Ageing**

# **SCHEDULE OF PHARMACEUTICAL BENEFITS**

This Schedule is also available on the internet at

[www.pbs.gov.au](http://www.pbs.gov.au)

**EFFECTIVE 1 OCTOBER 2008 -**

**31 OCTOBER 2008**

**(ALL PREVIOUS EDITIONS CANCELLED)**

© Commonwealth of Australia 2008  
ISSN 1037-3667

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at <http://www.ag.gov.au/cca>

This Schedule provides information on the arrangements for the prescribing and supply of pharmaceutical benefits. These arrangements operate under the *National Health Act 1953*. However, at the time of printing, the relevant legislation giving authority for the changes included in this issue of the Schedule may still be subject to the usual Parliamentary scrutiny. This book is not a legal document, and, in cases of discrepancy, the legislation will be the source document for payment for the supply of pharmaceutical benefits. The legislation is available from the Federal Register of Legislative Instruments website at <http://www.frli.gov.au>.

# Contents

|                                                                                                               |           |
|---------------------------------------------------------------------------------------------------------------|-----------|
| <b>SUMMARY OF CHANGES .....</b>                                                                               | <b>5</b>  |
| <b>ADDRESSES - MEDICARE AUSTRALIA .....</b>                                                                   | <b>8</b>  |
| <b>AUTHORITY PRESCRIPTIONS APPLICATIONS .</b>                                                                 | <b>9</b>  |
| <b>REQUESTS FOR DRUGS VIA THE SPECIAL ACCESS SCHEME (SAS) .....</b>                                           | <b>9</b>  |
| <b>POISONS INFORMATION CENTRES .....</b>                                                                      | <b>10</b> |
| <b>DRUG INFORMATION CENTRES .....</b>                                                                         | <b>10</b> |
| <b>LIST OF CONTACT OFFICERS FOR RECALLS OF THERAPEUTIC GOODS .....</b>                                        | <b>12</b> |
| <b>INDEX OF MANUFACTURERS' CODES .....</b>                                                                    | <b>13</b> |
| <b>SECTION 1 - EXPLANATORY NOTES</b>                                                                          |           |
| INTRODUCTION .....                                                                                            | 25        |
| 1. THE SCHEDULE - WHERE TO FIND WHAT .....                                                                    | 25        |
| Section 1 .....                                                                                               | 25        |
| Section 2 .....                                                                                               | 26        |
| Section 3 .....                                                                                               | 26        |
| Section 4 .....                                                                                               | 26        |
| Repatriation Schedule of Pharmaceutical Benefits .....                                                        | 26        |
| 2. PRESCRIBING MEDICINES                                                                                      |           |
| - INFORMATION FOR PBS PRESCRIBERS .....                                                                       | 26        |
| PBS prescribers .....                                                                                         | 26        |
| PBS Prescription forms .....                                                                                  | 26        |
| <i>Ordering forms</i> .....                                                                                   | 27        |
| Preparing general PBS prescriptions .....                                                                     | 28        |
| <i>Do's and Don't's</i> .....                                                                                 | 28        |
| <i>Writing the PBS prescription</i> .....                                                                     | 29        |
| Restrictions .....                                                                                            | 29        |
| Authority PBS prescriptions .....                                                                             | 29        |
| <i>Authority required PBS Prescriptions</i> .....                                                             | 29        |
| <i>Authority required (STREAMLINED) PBS Prescriptions</i> .....                                               | 30        |
| <i>Writing authority PBS prescriptions</i> .....                                                              | 31        |
| Maximum quantities and repeats .....                                                                          | 31        |
| Regulation 24 .....                                                                                           | 32        |
| Urgent cases .....                                                                                            | 32        |
| Drugs of addiction .....                                                                                      | 32        |
| Emergency drug (doctor's bag) supplies .....                                                                  | 33        |
| Improving the capacity of the PBS to meet particular Aboriginal and Torres Strait Islander health needs ..... | 33        |
| <i>How to prescribe these items?</i> .....                                                                    | 33        |
| <i>Aboriginal and Torres Strait Islander identification</i> .....                                             | 33        |
| <i>Asking about Aboriginal and/or Torres Strait Islander identification</i> .....                             | 34        |
| <i>Aboriginal and Torres Strait Islander health</i> .....                                                     | 34        |
| <i>Communication and cultural issues</i> .....                                                                | 34        |
| 3. SUPPLYING MEDICINES - WHAT PHARMACISTS NEED TO KNOW .....                                                  | 35        |
| Eligible suppliers .....                                                                                      | 35        |
| <i>Approval conditions for pharmacists</i> .....                                                              | 35        |
| Before supplying pharmaceutical benefits .....                                                                | 36        |
| Supplying pharmaceutical benefits .....                                                                       | 36        |
| <i>Do's and Don't's</i> .....                                                                                 | 36        |
| <i>What to do if the Schedule changes</i> .....                                                               | 37        |
| Suspected forgery .....                                                                                       | 37        |
| Regulation 24 .....                                                                                           | 37        |
| Repeat authorisations .....                                                                                   | 37        |
| <i>Preparing Repeat Authorisation Forms</i> .....                                                             | 38        |
| <i>Repeat authorisations for injectables and solvents</i> .....                                               | 38        |
| <i>Repeat authorisations for deferred supply</i> .....                                                        | 38        |
| Authority PBS prescriptions .....                                                                             | 38        |
| Urgent cases .....                                                                                            | 39        |
| Receipts .....                                                                                                | 39        |
| Emergency drug (doctor's bag) supplies .....                                                                  | 39        |
| 4. PATIENT CHARGES .....                                                                                      | 39        |
| Type of patient .....                                                                                         | 39        |
| Establishing entitlement .....                                                                                | 40        |
| What to charge .....                                                                                          | 40        |
| <i>Patient contribution</i> .....                                                                             | 40        |
| <i>Patient contributions for early supply of some PBS medicines</i> .....                                     | 41        |
| <i>Special patient contributions, brand premiums and therapeutic group premiums</i> .....                     | 41        |
| <i>Solvents</i> .....                                                                                         | 42        |
| <i>Increased quantities</i> .....                                                                             | 42        |
| <i>Regulation 24</i> .....                                                                                    | 42        |
| <i>After hours</i> .....                                                                                      | 42        |
| <i>Delivery</i> .....                                                                                         | 42        |
| 5. THE SAFETY NET SCHEME .....                                                                                | 42        |
| Safety net thresholds .....                                                                                   | 43        |
| <i>Safety net cross-over arrangements</i> .....                                                               | 43        |
| Recording PBS prescriptions .....                                                                             | 44        |
| Hospital PRF's .....                                                                                          | 45        |
| Multi-item forms .....                                                                                        | 45        |
| Qualifying PBS prescriptions .....                                                                            | 45        |
| Lost PRF's .....                                                                                              | 45        |
| Retrospective entitlement and patient refunds .....                                                           | 45        |
| Applying for a Safety Net Entitlement/Concession Card .....                                                   | 46        |
| Issuing a Safety Net Entitlement/Concession Card .....                                                        | 46        |
| Issuing supplementary cards .....                                                                             | 46        |
| Notification to Medicare Australia and claim for payment .....                                                | 47        |
| Lost Safety Net Entitlement/Concession Cards .....                                                            | 47        |

|                                                     |     |
|-----------------------------------------------------|-----|
| Pharmacy record of issued cards .....               | 47  |
| <b>6. MEDICARE AUSTRALIA ENTITLEMENT</b>            |     |
| CHECKS .....                                        | 47  |
| <i>General Patients</i> .....                       | 47  |
| <i>Concessional Patients</i> .....                  | 47  |
| Entitlement checking procedures .....               | 47  |
| <i>General Patients</i> .....                       | 47  |
| <i>Concessional Patients</i> .....                  | 48  |
| <i>Step by step</i> .....                           | 48  |
| <b>7. HOW PHARMACISTS CLAIM</b>                     |     |
| REIMBURSEMENT: INFORMATION                          |     |
| REQUIRED .....                                      | 48  |
| PBS Prescription identification .....               | 48  |
| Serial numbers .....                                | 49  |
| <i>Repeat authorisations for authority PBS</i>      |     |
| <i>prescriptions</i> .....                          | 49  |
| <i>Repeat authorisations for deferred supply</i> .. | 49  |
| <i>Injectable item ordered with a solvent</i> ..... | 50  |
| Dropper containers .....                            | 50  |
| Extemporaneously-prepared pharmaceutical            |     |
| benefits not listed in the Standard                 |     |
| Formulae List .....                                 | 50  |
| <i>PBS prescriptions paid on an average</i>         |     |
| <i>price basis</i> .....                            | 50  |
| <i>Pricing non-pre-priced extemporaneous</i>        |     |
| <i>preparations</i> .....                           | 50  |
| RPBS prescriptions for items not included in        |     |
| either the PBS or RPBS Schedule .....               | 50  |
| Payment to Pharmacists for Dispensing               |     |
| Premium-free Substitutable Medicines .....          | 50  |
| <b>8. HOW PHARMACISTS CLAIM</b>                     |     |
| REIMBURSEMENT: DOCUMENTS TO BE                      |     |
| SUBMITTED .....                                     | 50  |
| Completing the claim form .....                     | 51  |
| Lodging claims .....                                | 51  |
| Reconciliation statements .....                     | 51  |
| <b>9. PRICING PBS PRESCRIPTION</b> .....            | 52  |
| Pricing principles .....                            | 52  |
| Pricing dates .....                                 | 52  |
| Pricing ready-prepared items .....                  | 52  |
| <i>For maximum quantities</i> .....                 | 52  |
| <i>For lesser quantities</i> .....                  | 52  |
| <i>Wastage table percentage</i> .....               | 53  |
| Pricing extemporaneously-prepared items .....       | 53  |
| <i>General</i> .....                                | 53  |
| <i>Pricing of ingredients</i> .....                 | 54  |
| <i>Pricing PBS prescriptions where extra</i>        |     |
| <i>ingredients are added to a formula</i> .....     | 55  |
| <i>Containers</i> .....                             | 55  |
| <i>Special provisions for extemporaneous</i>        |     |
| <i>PBS prescriptions outside the</i>                |     |
| <i>Standard Formulae List</i> .....                 | 55  |
| <b>10. MISCELLANEOUS</b> .....                      | 55  |
| References .....                                    | 55  |
| Standards .....                                     | 55  |
| Legislation .....                                   | 56  |
| <b>THERAPEUTIC INDEX</b> .....                      | 57  |
| <b>SECTION 2 - READY-PREPARED</b>                   |     |
| <b>PHARMACEUTICAL BENEFITS</b> .....                | 65  |
| Contents .....                                      | 65  |
| Symbols .....                                       | 66  |
| Emergency Drug (Doctor's Bag) Supplies .....        | 69  |
| Special Pharmaceutical Benefits .....               | 72  |
| General Pharmaceutical Benefits .....               | 75  |
| Pharmaceutical Benefits for Palliative Care .....   | 453 |
| Pharmaceutical Benefits for Dental Use .....        | 473 |
| Pharmaceutical Benefits for Optometrical Use .....  | 500 |
| Items Available under Special Arrangements          |     |
| (section 100) .....                                 | 505 |
| <b>SECTION 3 - STANDARD PACKS AND PRICES</b> .      | 640 |
| Container Prices and Fees for Ready                 |     |
| Prepared Pharmaceutical Benefits .....              | 640 |
| Standard Packs and Prices for Ready                 |     |
| Prepared Pharmaceutical Benefits .....              | 641 |
| <b>SECTION 4</b>                                    |     |
| <b>- EXTEMPORANEOUSLY-PREPARED</b>                  |     |
| <b>PHARMACEUTICAL BENEFITS</b> .....                | 655 |
| Drug Tariff .....                                   | 656 |
| Container Prices .....                              | 660 |
| Standard Formula Preparations Explanation .....     | 661 |
| Table of Codes, Maximum Quantities,                 |     |
| and Number of Repeats                               |     |
| for Extemporaneously Prepared                       |     |
| Pharmaceutical Benefits .....                       | 664 |
| <b>REPATRIATION PHARMACEUTICAL BENEFITS</b>         | 665 |
| Beneficiaries' Entitlement Cards .....              | 666 |
| Explanatory Notes .....                             | 668 |
| Summary of Changes - Introduction .....             | 674 |
| Therapeutic Index for RPBS Schedule .....           | 675 |
| SECTION 1 - Drugs, Medicines and Dressing ....      | 679 |
| SECTION 2 - Standard Packs and Prices .....         | 723 |
| <b>GENERIC/PROPRIETARY INDEX</b> .....              | 727 |

## PHARMACEUTICAL BENEFITS

These changes to the Schedule of Pharmaceutical Benefits are effective from 1 October 2008. The Schedule is updated on the first day of each month and is available on the Internet at [www.pbs.gov.au](http://www.pbs.gov.au).

### Fees, Patient Contributions and Safety Net Thresholds

The following fees, patient contributions and safety net thresholds apply as at 1 October 2008 and are included, where applicable, in prices published in the Schedule—

|                                          |                                      |           |
|------------------------------------------|--------------------------------------|-----------|
| Dispensing Fees:                         | Ready-prepared                       | \$5.99    |
|                                          | Dangerous drug fee                   | \$2.71    |
|                                          | Extemporaneously-prepared            | \$8.03    |
|                                          | Allowable additional patient charge* | \$3.63    |
| Additional Fees (for safety net prices): | Ready-prepared                       | \$1.03    |
|                                          | Extemporaneously-prepared            | \$1.39    |
| Patient Co-payments:                     | General                              | \$31.30   |
|                                          | Concessional                         | \$5.00    |
| Safety Net Thresholds:                   | General                              | \$1141.80 |
|                                          | Concessional                         | \$290.00  |
| Safety Net Card Issue Fee:               |                                      | \$7.86    |

\*The allowable additional patient charge is a discretionary charge to general patients if a pharmaceutical item has a dispensed price for maximum quantity less than the general patient co-payment. The pharmacist may charge general patients the allowable additional fee but the fee cannot take the cost of the prescription above the general patient co-payment for the medicine. This fee does not count towards the Safety Net threshold.

## SUMMARY OF CHANGES

### ADDITIONS

#### Additions - Items

|       |                                                                                                                                              |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------|
| 9195Y | <b>Enoxaparin sodium</b> , Solution for injection 40 mg (4,000 i.u. anti-Xa) in 0.4 mL ( <i>Clexane</i> )                                    |
| 9196B | <b>Enoxaparin sodium</b> , Solution for injection 40 mg (4,000 i.u. anti-Xa) in 0.4 mL ( <i>Clexane</i> ) ( <b>Diff. Max. Qty and Rpts</b> ) |
| 9194X | <b>Paliperidone</b> , Tablet 12 mg (prolonged release) ( <i>Invega</i> )                                                                     |

#### Additions - Brands

|       |                                                                                                                 |
|-------|-----------------------------------------------------------------------------------------------------------------|
| 2751T | <i>Ozlodip</i> , RA — <b>Amlodipine</b> , Tablet 5 mg (as besylate)                                             |
| 2752W | <i>Ozlodip</i> , RA — <b>Amlodipine</b> , Tablet 10 mg (as besylate)                                            |
| 1884E | <i>APO-Amoxycillin</i> , TX — <b>Amoxycillin</b> , Capsule 250 mg                                               |
| 3301R | <i>APO-Amoxycillin</i> , TX — <b>Amoxycillin</b> , Capsule 250 mg ( <b>Dental</b> )                             |
| 1889K | <i>APO-Amoxycillin</i> , TX — <b>Amoxycillin</b> , Capsule 500 mg                                               |
| 3300Q | <i>APO-Amoxycillin</i> , TX — <b>Amoxycillin</b> , Capsule 500 mg ( <b>Dental</b> )                             |
| 2580T | <i>PU</i> — <b>Cisplatin</b> , I.V. injection 100 mg in 100 mL                                                  |
| 1473M | <i>Fluconazole Hexal</i> , SZ — <b>Fluconazole</b> , Solution for I.V. infusion 100 mg in 50 mL                 |
| 1474N | <i>Fluconazole Hexal</i> , SZ — <b>Fluconazole</b> , Solution for I.V. infusion 200 mg in 100 mL                |
| 8559L | <i>Gabahexal 600 mg</i> , SZ — <b>Gabapentin</b> , Tablet 600 mg                                                |
| 2848X | <i>Lamotrigine Sandoz</i> , SZ — <b>Lamotrigine</b> , Tablet 25 mg                                              |
| 2849Y | <i>Lamotrigine Sandoz</i> , SZ — <b>Lamotrigine</b> , Tablet 50 mg                                              |
| 2850B | <i>Lamotrigine Sandoz</i> , SZ — <b>Lamotrigine</b> , Tablet 100 mg                                             |
| 2851C | <i>Lamotrigine Sandoz</i> , SZ — <b>Lamotrigine</b> , Tablet 200 mg                                             |
| 2833D | <i>Pravastatin-GA 10</i> , GN; <i>Pravastatin generichealth</i> , GQ — <b>Pravastatin sodium</b> , Tablet 10 mg |
| 2834E | <i>Pravastatin-GA 20</i> , GN; <i>Pravastatin generichealth</i> , GQ — <b>Pravastatin sodium</b> , Tablet 20 mg |
| 8197K | <i>Pravastatin-GA 40</i> , GN; <i>Pravastatin generichealth</i> , GQ — <b>Pravastatin sodium</b> , Tablet 40 mg |
| 8829Q | <i>Pravastatin-GA 80</i> , GN; <i>Pravastatin generichealth</i> , GQ — <b>Pravastatin sodium</b> , Tablet 80 mg |
| 2236Q | <i>Sertraline-GA</i> , GM — <b>Sertraline hydrochloride</b> , Tablet 50 mg (base)                               |

2237R *Sertraline-GA, GM* — **Sertraline hydrochloride**, Tablet 100 mg (base)

*Additions - Bioequivalence indicator*

The bioequivalence indicator (<sup>a</sup>) has been added to the following **brand**:

1473M **Fluconazole**, Solution for I.V. infusion 100 mg in 50 mL (*Diflucan*)

*Additions - Notes*

1393H **Levonorgestrel with ethinyloestradiol**, Tablets 150 micrograms-30 micrograms, 21 (*Microgynon 30*)

1394J **Levonorgestrel with ethinyloestradiol**, Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets (*Levlen ED, Microgynon 30 ED*)

2772X **Norethisterone with ethinyloestradiol**, Tablets 500 micrograms-35 micrograms, 21 (*Brevinor*)

2774B **Norethisterone with ethinyloestradiol**, Pack containing 21 tablets 500 micrograms-35 micrograms and 7 inert tablets (*Norimin 28 Day, Brevinor*)

2773Y **Norethisterone with ethinyloestradiol**, Tablets 1 mg-35 micrograms, 21 (*Brevinor-1*)

2775C **Norethisterone with ethinyloestradiol**, Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets (*Norimin-1 28 Day, Brevinor-1*)

**DELETIONS**

*Deletions - Items*

1883D **Amoxycillin**, Chewable tablet 250 mg (*Amoxil*)

3303W **Amoxycillin**, Chewable tablet 250 mg (*Amoxil*) (**Dental**)

*Deletions - Brands*

2236Q *Sertraline-DP, GM* — **Sertraline hydrochloride**, Tablet 50 mg (base)

2237R *Sertraline-DP, GM* — **Sertraline hydrochloride**, Tablet 100 mg (base)

**ALTERATIONS**

*Alterations - Manufacturer's Code*

|       |                                                                                                                                          | <i>From</i> | <i>To</i> |
|-------|------------------------------------------------------------------------------------------------------------------------------------------|-------------|-----------|
| 2544X | <b>Biperiden hydrochloride</b> , Tablet 2 mg ( <i>Akineton</i> )                                                                         | AB          | LM        |
| 8658Q | <b>Cyclosporin</b> , Capsule 25 mg ( <i>Cicloral</i> )                                                                                   | HX          | SZ        |
| 8659R | <b>Cyclosporin</b> , Capsule 50 mg ( <i>Cicloral</i> )                                                                                   | HX          | SZ        |
| 8660T | <b>Cyclosporin</b> , Capsule 100 mg ( <i>Cicloral</i> )                                                                                  | HX          | SZ        |
| 2750R | <b>Erythromycin ethyl succinate</b> , Tablet 400 mg (base) ( <i>E.E.S. 400 Filmtab</i> )                                                 | AB          | LM        |
| 3336N | <b>Erythromycin ethyl succinate</b> , Tablet 400 mg (base) ( <i>E.E.S. 400 Filmtab</i> ) ( <b>Dental</b> )                               | AB          | LM        |
| 2424N | <b>Erythromycin ethyl succinate</b> , Powder for oral liquid 200 mg (base) per 5 mL, 100 mL ( <i>E.E.S. 200</i> )                        | AB          | LM        |
| 3334L | <b>Erythromycin ethyl succinate</b> , Powder for oral liquid 200 mg (base) per 5 mL, 100 mL ( <i>E.E.S. 200</i> ) ( <b>Dental</b> )      | AB          | LM        |
| 2428T | <b>Erythromycin ethyl succinate</b> , Powder for oral liquid 400 mg (base) per 5 mL, 100 mL ( <i>E.E.S. Granules</i> )                   | AB          | LM        |
| 3337P | <b>Erythromycin ethyl succinate</b> , Powder for oral liquid 400 mg (base) per 5 mL, 100 mL ( <i>E.E.S. Granules</i> ) ( <b>Dental</b> ) | AB          | LM        |
| 1397M | <b>Erythromycin lactobionate</b> , Powder for I.V. infusion 1 g (base) ( <i>Erythrocin-I.V.</i> )                                        | AB          | LM        |
| 5088T | <b>Erythromycin lactobionate</b> , Powder for I.V. infusion 1 g (base) ( <i>Erythrocin-I.V.</i> ) ( <b>Dental</b> )                      | AB          | LM        |
| 8541M | <b>Hydromorphone hydrochloride</b> , Tablet 2 mg ( <i>Dilaudid</i> )                                                                     | AB          | MF        |
| 5115F | <b>Hydromorphone hydrochloride</b> , Tablet 2 mg ( <i>Dilaudid</i> ) ( <b>Dental</b> )                                                   | AB          | MF        |
| 8542N | <b>Hydromorphone hydrochloride</b> , Tablet 4 mg ( <i>Dilaudid</i> )                                                                     | AB          | MF        |

|       |                                                                                                                                                                                                                              |    |    |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|
| 5116G | <b>Hydromorphone hydrochloride</b> , Tablet 4 mg ( <i>Dilaudid</i> ) ( <b>Dental</b> )                                                                                                                                       | AB | MF |
| 8543P | <b>Hydromorphone hydrochloride</b> , Tablet 8 mg ( <i>Dilaudid</i> )                                                                                                                                                         | AB | MF |
| 5117H | <b>Hydromorphone hydrochloride</b> , Tablet 8 mg ( <i>Dilaudid</i> ) ( <b>Dental</b> )                                                                                                                                       | AB | MF |
| 8420E | <b>Hydromorphone hydrochloride</b> , Injection 2 mg in 1 mL ( <i>Dilaudid</i> )                                                                                                                                              | AB | MF |
| 5129Y | <b>Hydromorphone hydrochloride</b> , Injection 2 mg in 1 mL ( <i>Dilaudid</i> ) ( <b>Dental</b> )                                                                                                                            | AB | MF |
| 8421F | <b>Hydromorphone hydrochloride</b> , Injection 10 mg in 1 mL ( <i>Dilaudid-HP</i> )                                                                                                                                          | AB | MF |
| 5130B | <b>Hydromorphone hydrochloride</b> , Injection 10 mg in 1 mL ( <i>Dilaudid-HP</i> ) ( <b>Dental</b> )                                                                                                                        | AB | MF |
| 8422G | <b>Hydromorphone hydrochloride</b> , Injection 50 mg in 5 mL ( <i>Dilaudid-HP</i> )                                                                                                                                          | AB | MF |
| 5131C | <b>Hydromorphone hydrochloride</b> , Injection 50 mg in 5 mL ( <i>Dilaudid-HP</i> ) ( <b>Dental</b> )                                                                                                                        | AB | MF |
| 8423H | <b>Hydromorphone hydrochloride</b> , Injection 500 mg in 50 mL ( <i>Dilaudid-HP</i> )                                                                                                                                        | AB | MF |
| 8424J | <b>Hydromorphone hydrochloride</b> , Oral liquid 1 mg per mL, 473 mL ( <i>Dilaudid</i> )                                                                                                                                     | AB | MF |
| 5132D | <b>Hydromorphone hydrochloride</b> , Oral liquid 1 mg per mL, 473 mL ( <i>Dilaudid</i> ) ( <b>Dental</b> )                                                                                                                   | AB | MF |
| 8253J | <b>Reteplase (recombinant plasminogen activator)</b> , Pack containing 2 vials powder for injection 10 units, 2 single use pre-filled syringes with solvent, 2 reconstitution spikes and 2 needles ( <i>Rapilysin 10 U</i> ) | RO | TA |

#### *Alterations - Restrictions*

|       |                                                                      |
|-------|----------------------------------------------------------------------|
| 8689H | <b>Rosiglitazone maleate</b> , Tablet 4 mg (base) ( <i>Avandia</i> ) |
| 8690J | <b>Rosiglitazone maleate</b> , Tablet 8 mg (base) ( <i>Avandia</i> ) |

## SECTION 100 - HIGHLY SPECIALISED DRUGS PROGRAM

### ADDITIONS

#### *Additions - Item*

|       |                                                                                   |
|-------|-----------------------------------------------------------------------------------|
| 9632Y | <b>Clozapine</b> , Oral liquid 50 mg per mL, 100 mL ( <i>Clopine Suspension</i> ) |
|-------|-----------------------------------------------------------------------------------|

### ALTERATIONS

#### *Alterations - Manufacturer's Code*

|       |                                                         | <i>From</i> | <i>To</i> |
|-------|---------------------------------------------------------|-------------|-----------|
| 6352H | <b>Cyclosporin</b> , Capsule 25 mg ( <i>Cicloral</i> )  | HX          | SZ        |
| 6353J | <b>Cyclosporin</b> , Capsule 50 mg ( <i>Cicloral</i> )  | HX          | SZ        |
| 6354K | <b>Cyclosporin</b> , Capsule 100 mg ( <i>Cicloral</i> ) | HX          | SZ        |

### ADVANCE NOTICES

#### *Advance Notices - Deletion of Items*

The following item will be deleted from the Highly Specialised Drugs Program on 1 **December** 2008:

Item discontinued by the manufacturer —

|       |                                                                       |
|-------|-----------------------------------------------------------------------|
| 6331F | <b>Nelfinavir mesylate</b> , Tablet 250 mg (base) ( <i>Viracept</i> ) |
|-------|-----------------------------------------------------------------------|

The following item will be deleted from the Schedule of Pharmaceutical Benefits on 1 **January** 2009:

Item discontinued by the manufacturer —

|       |                                                                  |
|-------|------------------------------------------------------------------|
| 1036M | <b>Aminoglutethimide</b> , Tablet 250 mg ( <i>Cytadren 250</i> ) |
|-------|------------------------------------------------------------------|

# Addresses — Medicare Australia

Medicare Australia has responsibility for the operational aspects of the Pharmaceutical Benefits Scheme (PBS). This responsibility covers the processing of pharmaceutical benefit and safety net claims, authority applications and supply of PBS stationery used by medical practitioners, participating dental practitioners and approved pharmacists. Procedures for ordering prescription forms are set out in Section 1 of this Schedule.

**NEW SOUTH WALES and  
AUSTRALIAN CAPITAL TERRITORY**

Pharmaceutical Benefits Branch  
130 George Street  
Parramatta NSW 2150  
**General and IME**                      **Tel: 132 290**  
**enquiries—**

Orange Service Centre  
189 Anson Street  
Orange NSW 2800  
**General and IME**                      **Tel: 132 290**  
**enquiries—**

**VICTORIA**  
Pharmaceutical Branch  
Level 10  
595 Collins Street  
Melbourne VIC 3000  
**General and IME**                      **Tel: 132 290**  
**enquiries—**

**QUEENSLAND**  
Pharmaceutical Services Branch  
143 Turbot Street  
Brisbane QLD 4000  
**General and IME**                      **Tel: 132 290**  
**enquiries—**

**SOUTH AUSTRALIA and NORTHERN  
TERRITORY**  
Pharmaceutical Services Branch  
209 Greenhill Road  
Eastwood SA 5063  
**General and IME**                      **Tel: 132 290**  
**enquiries—**

**WESTERN AUSTRALIA**  
Pharmaceutical Benefits Branch  
11th Floor, Bankwest Tower  
108 St George's Terrace  
Perth WA 6000  
**General and IME**                      **Tel: 132 290**  
**enquiries—**

**TASMANIA**  
Pharmaceutical Branch  
242 Liverpool Street  
Hobart TAS 7000  
**General and IME**                      **Tel: 132 290**  
**enquiries—**

**NATIONAL PROGRAM  
MANAGEMENT**  
Pharmaceutical Benefits Branch  
Medicare Australia  
134 Reed Street  
Tuggeranong ACT 2900  
Telephone— (02) 6124 6333  
**Website—** [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)  
**Email—** [pbs@medicareaustralia.gov.au](mailto:pbs@medicareaustralia.gov.au)



## Authority Prescription Applications

Authority required benefits fall into two categories – *Authority required* and *Authority required (STREAMLINED)*. The process in which an authority PBS prescription can be prescribed will depend on the type of Authority required benefit.

Prior approval is required for Authority required items as well as all requests for increased quantities and/or repeats for any category of PBS item.

Prior approval is not required for Authority required (STREAMLINED) items except if increased quantities and/or repeats are required (see Explanatory Notes for details).

Approval is obtained by lodging an application using the REPLY PAID mail service or by using Medicare Australia's FREECALL telephone number:

### Mail Applications:

REPLY PAID No. 9857  
PBS Authorities Section  
Medicare Australia  
GPO Box 9857  
In your capital city

### Telephone Applications:

Free call 1800 888 333  
Australia-wide—24 hour service

For telephone applications please have the following information available:

### Patient:

Medicare number  
Surname  
First name  
Full residential address (including postcode)

### PBS Authority Prescription Number:

Top right hand side of the handwritten PBS Authority Form

### Your Prescriber Number:

Located below your address block on the personalised forms

### Drug Information:

PBS item  
Quantity required and number of repeats  
Daily dose  
Disease or purpose information

---

## Requests for Drugs via the Special Access Scheme (SAS)

Requests for individual patient approval to obtain drugs that are available only through the SAS may be directed to a delegate within the Drug Safety and Evaluation Branch, Therapeutic Goods Administration, telephone (02) 6232 8111, facsimile (02) 6232 8112, or by mail to PO Box 100 Woden ACT 2606.

---

## Department of Veterans' Affairs

Details of the approving authority for the Department of Veterans' Affairs are listed at the front of the Repatriation Schedule of Pharmaceutical Benefits.

---

## Telephone Interpreter Service

A 24-hour, seven days a week telephone service is available by contacting 131 450.

The translating service (TIS) can provide immediate assistance over the telephone or arrange for an interpreter to go to a location specified in either city or country areas. The TIS service has access to 2000 professional interpreters, covering over 100 languages and dialects.

## Poisons Information Centres

**Phone 131 126 from anywhere in Australia — 24 hours — for information and advice on the treatment of poisoning, bites and stings.**

### NSW

The New Children's  
Hospital  
Hawkesbury Road  
Westmead NSW 2148  
Tel: (02) 9845 3111

### VIC

Royal Children's Hospital  
Flemington Road  
Parkville VIC 3052  
Tel: (03) 9345 5680

### QLD

Pharmacy Department  
Royal Children's Hospital  
Herston QLD 4029  
Tel: 131 126

### WA

Sir Charles Gairdner  
Hospital  
Hospital Avenue  
Nedlands WA 6009  
Tel: 131 126

### TAS

Tel: 131 126

### NT

Tel: 131 126

### ACT

Tel: 131 126

## Drug Information Centres

### NSW

Drug Information  
Pharmacist  
New South Wales  
Medicines Information  
Centre  
PO Box 766  
Darlinghurst NSW 2010  
Tel: (02) 8382 2136

Drug Information  
Pharmacists  
Hunter Drug Information  
Service  
Newcastle Mater  
Misericordiae Hospital  
Locked Bag 7  
Hunter Regional Mail  
Centre NSW 2310  
Tel: (02) 4921 1278  
(02) 4921 1328

### QLD

Assistant Director of  
Pharmacy  
Queensland Drug  
Information Ctr  
Royal Brisbane Hospital  
E Floor, Block 7  
Herston Road  
Herston QLD 4029  
Tel: (07) 3636 7098  
(07) 3636 7599

### WA

Drug Information  
Pharmacist  
Sir Charles Gairdner  
Hospital  
Hospital Avenue  
Nedlands WA 6009  
Tel: (08) 9346 2923

### TAS

Drug Information  
Pharmacist  
Royal Hobart Hospital  
GPO Box 1061L  
Hobart TAS 7001  
Tel: (03) 6222 8737

### NT

Drug Information  
Pharmacist  
Royal Darwin Hospital  
PO Box 41326  
Casuarina NT 0811  
Tel: (08) 8922 8424

### ACT

Drug Information  
Pharmacist  
Canberra Hospital  
Yamba Drive  
Garran ACT 2605  
Tel: (02) 6244 3333

**VIC**

Drug Information  
Pharmacist  
Austin & Repatriation  
Medical Centre  
Studley Road  
Heidelberg VIC 3084  
Tel: (03) 9496 5668

Drug Information  
Pharmacist  
Drug Information Centre  
Southern Health Care  
Network  
Monash Medical Centre  
246 Clayton Road  
Clayton VIC 3168  
Tel:(03) 9594 2361

**SA**

Drug Information  
Pharmacist  
Royal Adelaide Hospital  
North Terrace  
Adelaide SA 5000  
Tel: (08) 8222 5546

Drug Information  
Pharmacist  
Flinders Medical Centre  
Bedford Park SA 5042  
Tel: (08) 8204 5301

Drug Information  
Pharmacist  
Queen Elizabeth Hospital  
Woodville Road  
Woodville SA 5011  
Tel: (08) 8222 6777

**National  
Prescribing Service  
(NPS)**

Therapeutic Advice and  
Information Service  
(TAIS)  
Level 7, 418A Elizabeth  
Street  
Surry Hills NSW 2010  
Tel: 1300 138 677  
Fax: (03) 9459 4546  
Email: [tais@nps.org.au](mailto:tais@nps.org.au)  
Web: [www.nps.org.au](http://www.nps.org.au)

# List of Contact Officers for Recalls of Therapeutic Goods

**For details of consumer level recalls only — telephone 1800 020 512**

These officers may be contacted—

- to obtain information about current recalls
- to report suspected problems relating to the quality, safety or efficacy of a therapeutic good

## Australian Recall Coordinator

Office of Devices, Blood and Tissues  
Therapeutic Goods Administration  
Department of Health and Ageing  
PO Box 100  
Woden ACT 2606  
*Mr P K Harrison (02) 6232 8636*  
*Mr T Byrne (02) 6232 8637*

## Australian Capital Territory

ACT Health  
GPO Box 825  
Canberra ACT 2601  
*Ms J Strang (02) 6205 0961*

## New South Wales

Department of Health, NSW  
PO Box 103  
Gladesville NSW 1675  
*Mr J E Lumby (02) 9879 3214*

## Victoria

Department of Human Services  
Drugs and Poisons Unit  
GPO Box 1670N  
Melbourne VIC 3001  
*Mr K Moyle 1300 364 545*  
*Mr R Bell 1300 364 545*

## Queensland

Queensland Department of Health  
GPO Box 48  
Brisbane QLD 4001  
*Drugs—*  
*Mr A Hawkins (07) 3234 0349*  
*Mr C Healey (07) 3234 0960*  
*Therapeutic Devices—*  
*Mr C Healey (07) 3234 0960*  
*Mr D Jones (07) 3406 8068*

## South Australia

Drug Policies and Programs  
Metropolitan Health Division  
South Australian Department of Health  
PO Box 287  
Rundle Mall SA 5000  
*Mr W Dollman (08) 8226 7110*  
*Ms E Anear (08) 8226 7387*

## Western Australia

Health Department of WA  
PO Box 8172, Perth Business Centre  
Perth WA 6849  
*Mr M Patterson (08) 9388 4980*

## Tasmania

Department of Health and Human Services  
GPO Box 125B  
Hobart TAS 7001  
*Drugs—*  
*Mr J Galloway (03) 6233 2064*  
*Ms M Sharpe (03) 6233 3766*  
*Therapeutic Devices—*  
*Mr A L Wilkins (03) 6233 3913*

## Northern Territory

Department of Health and Community  
Services  
PO Box 40596  
Casuarina NT 0811  
*Ms H Stone (08) 8922 7035*

# Index of Manufacturers' Codes

| <i>Code</i> | <i>Manufacturer</i> |
|-------------|---------------------|
|-------------|---------------------|

|    |                                                                                                                                                                    |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| AB | Abbott Australasia Pty Ltd<br>Sir Joseph Banks Corporate Park<br>32-34 Lord Street Botany NSW 2019<br>Tel: (02) 9384 9700<br>Fax: (02) 9384 9800                   |
| AC | Alberto Culver Company<br>14 Loyalty Road<br>North Rocks NSW 2151<br>Tel: (02) 9630 5099<br>Fax: (02) 9683 5026                                                    |
| AE | AFT Pharmaceuticals Pty Limited<br>Unit 2, Level 5<br>255 George Street NSW 2000<br>Tel: 1800 097 639<br>Fax: 1800 097 810                                         |
| AF | Alphapharm Pty Limited<br>Chase Building 2<br>Wentworth Park Road Glebe NSW 2037<br>Tel: (02) 9298 3999<br>Fax: (02) 9566 4686                                     |
| AG | Allergan Australia Pty Ltd<br>77 Ridge Street<br>Gordon NSW 2072<br>Tel: 1800 252 224<br>Fax: (02) 9498 0290                                                       |
| AL | Alphapharm Medical<br>A Division of Alphapharm Pty Limited<br>Chase Building 2<br>Wentworth Park Road Glebe NSW 2037<br>Tel: (02) 9298 3999<br>Fax: (02) 9566 4686 |
| AN | Amgen Australia Pty Ltd<br>Level 7, 123 Epping Road<br>North Ryde NSW 2113<br>Tel: (02) 9870 1333<br>Fax: (02) 9870 1344                                           |
| AP | AstraZeneca Pty Ltd<br>Alma Road<br>North Ryde NSW 2113<br>Tel: (02) 9978 3500<br>Fax: (02) 9978 3700                                                              |

| <i>Code</i> | <i>Manufacturer</i> |
|-------------|---------------------|
|-------------|---------------------|

|    |                                                                                                                                                                                                                |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| AQ | Alcon Laboratories (Australia) Pty Ltd<br>Allambie Grove Park<br>25 Frenchs Forest Road East Frenchs Forest<br>NSW 2086<br>Tel: 1800 025 004<br>Fax: (02) 9452 5209                                            |
| AS | Aspen Pharmacare Australia Pty Ltd<br>First Floor<br>34-36 Chandos Street St Leonards NSW<br>2065<br>Tel: (02) 8436 8300<br>Fax: (02) 9901 3540                                                                |
| AT | Actelion Pharmaceuticals Australia<br>Pty Ltd<br>Level 2 West, Suites 48-50<br>7 Narabang Way Belrose NSW 2085<br>Tel: (02) 9486 4600<br>Fax: (02) 9986 1344                                                   |
| AV | Aventis Pharma<br>Division of Sanofi-Aventis Australia Pty<br>Limited<br>Building D, Talavera Corporate Centre<br>12-24 Talavera Road Macquarie Park NSW<br>2113<br>Tel: (02) 8666 2000<br>Fax: (02) 8666 3000 |
| AW | Arrow Pharmaceuticals Pty Ltd<br>A member of Sigma Group of Companies<br>96 Merrindale Drive<br>Croydon Vic 3136<br>Tel: (03) 9839 2800<br>Fax: (03) 9839 2753                                                 |
| AX | Sanofi Pasteur Pty Limited<br>Building D, Talavera Corporate Centre<br>12-24 Talavera Road Macquarie Park NSW<br>2113<br>Tel: 1800 829 468<br>Fax: 1800 829 329                                                |
| BB | Blackmores Ltd<br>23 Roseberry Street<br>Balgowlah NSW 2093<br>Tel: (02) 9951 0111<br>Fax: (02) 9949 1954                                                                                                      |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                         |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BC          | Bristol Laboratories<br>A Division of Bristol-Myers Squibb<br>Australia Pty Ltd<br>556 Princes Highway<br>Noble Park Vic 3174<br>Tel: (03) 9213 4000<br>Fax: (03) 9701 1518 |
| BD          | Biogen Idec Australia Pty Ltd<br>Suite 2, Level 4<br>123 Epping Road North Ryde NSW 2113<br>Tel: (02) 8875 3900<br>Fax: (02) 9889 1162                                      |
| BE          | BDF Australia Ltd<br>112-118 Talavera Road<br>North Ryde NSW 2113<br>Tel: 1800 269 933<br>Fax: (02) 9887 3487                                                               |
| BF          | Bellwether Pharma Limited<br>Suite 2, Level 2<br>71 Epping Road North Ryde NSW 2113<br>Tel: (02) 8875 5700<br>Fax: (02) 9889 2250                                           |
| BG          | Biochemie Australia<br>A Division of Sandoz Pty Ltd<br>Level 4, Suite 7-19<br>100 Harris Street Pyrmont NSW 2009<br>Tel: (02) 9566 1500<br>Fax: (02) 9566 1458              |
| BI          | Biotech Pharmaceuticals Pty Ltd<br>83 Cherry Lane<br>Laverton North Vic 3026<br>Tel: (03) 9278 7555<br>Fax: (03) 9369 6730                                                  |
| BK          | Becton Dickinson Pty Ltd<br>80 Rushdale Street<br>Knoxfield Vic 3180<br>Tel: (03) 9764 2444<br>Fax: (03) 9764 2550                                                          |
| BN          | Bayer Australia Limited<br>875 Pacific Highway<br>Pymble NSW 2073<br>Tel: (02) 9391 6000<br>Fax: (02) 9988 3311                                                             |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                                         |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BP          | British Pharmaceuticals<br>Unit A, 31-33 Sirius Road<br>Lane Cove NSW 2066<br>Tel: (02) 9428 9411<br>Fax: (02) 9428 1732                                                                    |
| BQ          | Bristol-Myers Squibb Pharmaceuticals<br>A Division of Bristol-Myers Squibb<br>Australia Pty Ltd<br>556 Princes Highway<br>Noble Park Vic 3174<br>Tel: (03) 9213 4000<br>Fax: (03) 9701 1518 |
| BR          | B. Braun Australia Pty Ltd<br>Norwest Business Park<br>17 Lexington Drive Bella Vista NSW 2153<br>Tel: (02) 9629 0200<br>Fax: (02) 9629 0299                                                |
| BU          | Bausch & Lomb Surgical<br>A Division of Bausch & Lomb (Australia)<br>Pty Ltd<br>Level 4, 113 Wicks Road<br>North Ryde NSW 2113<br>Tel: (02) 9887 1444<br>Fax: (02) 9888 9642                |
| BV          | B.S.N.<br>315 Ferntree Gully Road<br>Mount Waverley Vic 3149<br>Tel: (03) 8540 6777<br>Fax: 1800 671 000                                                                                    |
| BX          | Baxter Healthcare Pty Limited<br>1 Baxter Drive<br>Old Toongabbie NSW 2146<br>Tel: (02) 9848 1111<br>Fax: (02) 9848 1123                                                                    |
| BY          | Boehringer Ingelheim Pty Limited<br>85 Waterloo Road<br>North Ryde NSW 2113<br>Tel: (02) 8875 8800<br>Fax: (02) 8875 8801                                                                   |
| CC          | ConvaTec<br>A Division of Bristol-Myers Squibb<br>Australia Pty Ltd<br>606 Hawthorn Road<br>East Brighton Vic 3187<br>Tel: 1800 335 276<br>Fax: (03) 9525 0920                              |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                     |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CF          | CNS Pharma Pty Ltd<br>Level 5, Deutsche Bank Place<br>126 Phillip Street Sydney NSW 2000<br>Tel: (02) 9629 0638<br>Fax: (02) 9629 0688                                  |
| CH          | Chem mart Pty Limited<br>Level 7, 5 Queens Road<br>Melbourne Vic 3004<br>Tel: (03) 9918 2500<br>Fax: (03) 9918 2006                                                     |
| CO          | Chemists' Own Pty Ltd<br>A member of Sigma Group of Companies<br>96 Merrindale Drive<br>Croydon Vic 3136<br>Tel: (03) 9839 2800<br>Fax: (03) 9839 2753                  |
| CR          | Pharmacor Limited<br>5/36 Campbell Avenue<br>Cromer NSW 2099<br>Tel: (02) 9981 4470<br>Fax: (02) 9981 4475                                                              |
| CS          | CSL Limited<br>45 Poplar Road<br>Parkville Vic 3052<br>Tel: (03) 9389 1911<br>Fax: (03) 9388 2351                                                                       |
| CT          | Coloplast Pty Ltd<br>33 Gilby Road<br>Mount Waverley Vic 3149<br>Tel: 1800 673 317<br>Fax: (03) 9541 1199                                                               |
| CX          | Contact Lens Centre Australia Pty Ltd<br>Unit D6, Hallmark Business Park<br>Cnr Westall and Centre Roads Clayton Vic 3168<br>Tel: (03) 9543 1811<br>Fax: (03) 9543 8066 |
| DB          | Diabetes Association of Australia<br>26 Arundel Street<br>Glebe NSW 2037<br>Tel: 1800 451 737<br>Fax: (02) 9566 4235                                                    |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                           |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DN          | Digiland Pty Ltd<br>Paragon Building<br>Suite 7, 799 Springvale Road Mulgrave Vic 3170<br>Tel: (03) 8545 0500<br>Fax: (03) 9561 7349                                          |
| DT          | DermaTech Laboratories Pty Ltd<br>Unit 17, 167 Prospect Highway<br>Seven Hills NSW 2147<br>Tel: (02) 9624 5874<br>Fax: (02) 9624 8822                                         |
| EO          | Ego Pharmaceuticals Pty Ltd<br>21-31 Malcolm Road<br>Braeside Vic 3195<br>Tel: (03) 9587 1088<br>Fax: (03) 9580 7647                                                          |
| ES          | EBOS Group Pty Ltd<br>Unit 2, 109 Vanessa Street<br>Kingsgrove NSW 2208<br>Tel: (02) 9502 8410<br>Fax: (02) 9502 8411                                                         |
| EX          | Essex Laboratories<br>Level 4, 66 Waterloo Road<br>North Ryde NSW 2113<br>Tel: (02) 8988 8000<br>Fax: (02) 9852 7500                                                          |
| FA          | F.H. Faulding & Co. Limited<br>Level 6, 390 St Kilda Road<br>Melbourne Vic 3004<br>Tel: (03) 9868 0700<br>Fax: (03) 9868 0111                                                 |
| FB          | Pierre Fabre Medicament Australia Pty Limited<br>Unit 26B, Parkview Business Centre<br>1 Maitland Place Baulkham Hills NSW 2153<br>Tel: (02) 8858 2800<br>Fax: (02) 8858 2888 |
| FH          | Faulding Healthcare Pty Ltd<br>87 Yarraman Place<br>Virginia Qld 4014<br>Tel: (07) 3212 8777<br>Fax: (07) 3212 8790                                                           |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                            |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FK          | PharmaLink Pty Ltd<br>Level 8, 67 Albert Avenue<br>Chatswood NSW 2067<br>Tel: (02) 9080 7200<br>Fax: (02) 9080 7201                                                            |
| FL          | C. B. Fleet Co. (Aust.) Pty Ltd<br>25 Macbeth Street<br>Braeside Vic 3195<br>Tel: (03) 9580 2755<br>Fax: (03) 9580 2899                                                        |
| FM          | Fawns and McAllan Pty Ltd<br>A member of Sigma Group of Companies<br>96 Merrindale Drive<br>Croydon Vic 3136<br>Tel: (03) 9839 2800<br>Fax: (03) 9839 2753                     |
| FP          | Ferring Pharmaceuticals Pty Ltd<br>Suite 2B, Level 2<br>802 Pacific Highway Gordon NSW 2072<br>Tel: (02) 9497 2300<br>Fax: (02) 9497 2399                                      |
| FR          | Charles E. Frosst<br>Division of Merck Sharp & Dohme<br>(Australia) Pty Ltd<br>54-68 Ferndell Street<br>South Granville NSW 2142<br>Tel: (02) 9795 9500<br>Fax: (02) 9795 9595 |
| GA          | Galderma Australia Pty Ltd<br>Suite 4, 13B Narabang Way<br>Belrose NSW 2085<br>Tel: (02) 9479 0600<br>Fax: (02) 9986 1699                                                      |
| GC          | GlaxoSmithKline Consumer Healthcare<br>82 Hughes Avenue<br>Ermington NSW 2115<br>Tel: (02) 9684 0888<br>Fax: (02) 9684 6958                                                    |
| GH          | Goldshield Healthcare<br>(Australia) Pty Ltd<br>Suite 3, Level 1<br>118-124 Willoughby Road Crows Nest<br>NSW 2059<br>Tel: (02) 9431 6333<br>Fax: (02) 9906 7147               |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                            |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| GI          | Gilead Sciences Pty Ltd<br>Level 1, 128 Jolimont Road<br>East Melbourne Vic 3002<br>Tel: (03) 9272 4400<br>Fax: (03) 9272 4435                 |
| GK          | GlaxoSmithKline Australia Pty Ltd<br>1061 Mountain Highway<br>Boronia Vic 3155<br>Tel: (03) 9721 6000<br>Fax: (03) 9729 5319                   |
| GM          | Genepharm Pty Ltd<br>3/10 Inglewood Place<br>Norwest Business Park Baulkham Hills<br>NSW 2153<br>Tel: 1800 678 302<br>Fax: (02) 8818 2122      |
| GN          | Genepharm Australasia Limited<br>Level 1, 263 City Road<br>Southbank Vic 3006<br>Tel: 1800 508 168<br>Fax: (03) 9699 8333                      |
| GP          | GP Laboratories<br>A Division of Pfizer Pty Limited<br>38-42 Wharf Road<br>West Ryde NSW 2114<br>Tel: (02) 9850 3333<br>Fax: (02) 9858 1347    |
| GQ          | Generic Health Pty Ltd<br>Suite 1, Level 1<br>1175 Toorak Road Camberwell Vic 3124<br>Tel: (03) 9809 7900<br>Fax: (03) 9809 7999               |
| GX          | GenRx<br>A Division of Apotex Pty Ltd<br>66 Waterloo Road<br>North Ryde NSW 2113<br>Tel: (02) 8877 8333<br>Fax: (02) 8877 8377                 |
| GZ          | Genzyme Australasia Pty Ltd<br>Level 1, Building C<br>12-24 Talavera Road North Ryde NSW<br>2113<br>Tel: (02) 9978 3900<br>Fax: (02) 9889 3900 |



| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HA          | Hamilton Laboratories Pty Ltd<br>217 Flinders Street<br>Adelaide SA 5000<br>Tel: (08) 8223 2957<br>Fax: (08) 8232 1480                                                |
| HC          | Biotech Healthcare<br>A division of Biotech Pharmaceuticals Pty Ltd<br>83 Cherry Lane<br>Laverton North Vic 3026<br>Tel: (03) 9278 7555<br>Fax: (03) 9369 6730        |
| HH          | Hospira Pty Ltd<br>(David Bull Laboratories, Faulding Pharmaceuticals) Level 6, 390 St Kilda Road Melbourne Vic 3004<br>Tel: (03) 9868 0700<br>Fax: (03) 9868 0111    |
| HO          | Hollister (Distributed in Australia by Liberty Medical Pty Ltd)<br>Unit 6, 345 Ingles Street<br>Port Melbourne Vic 3207<br>Tel: (03) 9673 4300<br>Fax: (03) 9646 4018 |
| HR          | Paul Hartmann Pty Ltd<br>27-28/11-21 Underwood Road<br>Homebush NSW 2140<br>Tel: 1800 805 839<br>Fax: (02) 8762 7100                                                  |
| HS          | healthsense<br>115 Sherriff Street<br>Underdale SA 5032<br>Tel: (08) 8408 3200<br>Fax: (08) 8408 3383                                                                 |
| HX          | Hexal Australia Pty Ltd<br>Level 4, Suite 7-19<br>100 Harris Street Pyrmont NSW 2009<br>Tel: (02) 9566 1500<br>Fax: (02) 9566 1458                                    |
| IA          | iNova Pharmaceuticals (Australia) Pty Limited<br>9-15 Chilvers Road<br>Thornleigh NSW 2120<br>Tel: (02) 9875 6333<br>Fax: (02) 9875 6416                              |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                                      |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IQ          | Ioquin<br>A Division of Alcon Laboratories (Australia) Pty Ltd<br>Allambie Grove Park<br>25 Frenchs Forest Road East Frenchs Forest NSW 2086<br>Tel: 1800 025 004<br>Fax: (02) 9452 5209 |
| IS          | Ipsen Pty Ltd<br>Suite 6, 40 Montclair Avenue<br>Glen Waverley Vic 3150<br>Tel: (03) 8544 8100<br>Fax: (03) 9562 5152                                                                    |
| IT          | InterPharma Pty Ltd<br>Suite 3, 14 Sydney Road<br>Manly NSW 2095<br>Tel: (02) 9976 6876<br>Fax: (02) 9976 6859                                                                           |
| IZ          | Intensive Care Products Pty Ltd<br>Level 1, APP House<br>14 Rodborough Road Frenchs Forest NSW 2086<br>Tel: (02) 9984 2280<br>Fax: (02) 9984 2222                                        |
| JC          | Janssen-Cilag Pty Ltd<br>1-5 Khartoum Road<br>North Ryde NSW 2113<br>Tel: (02) 8875 3333<br>Fax: (02) 8875 3300                                                                          |
| JJ          | Johnson & Johnson Medical<br>1-5 Khartoum Road<br>North Ryde NSW 2113<br>Tel: (02) 9878 9111<br>Fax: 1800 808 233                                                                        |
| JT          | Johnson & Johnson Pacific Pty Limited<br>45 Jones Street<br>Ultimo NSW 2007<br>Tel: 13 1565<br>Fax: (02) 8260 8102                                                                       |
| KC          | Kimberly-Clark Australia Pty Ltd<br>52 Alfred Street South<br>Milsons Point NSW 2061<br>Tel: (02) 9963 8888<br>Fax: (02) 9957 5687                                                       |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                                   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| KE          | Kendall Australasia Pty Ltd<br>22 Giffnock Avenue<br>North Ryde NSW 2113<br>Tel: 1800 252 467<br>Fax: (02) 9888 7378                                                                  |
| KN          | Knoll<br>A Division of Abbott Australasia Pty Ltd<br>Captain Cook Drive<br>Kurnell NSW 2231<br>Tel: (02) 9668 9711<br>Fax: (02) 9668 8459                                             |
| KR          | Kenral Division of<br>Pharmacia Australia Pty Limited<br>59 Kirby Street<br>Rydalmere NSW 2116<br>Tel: (02) 9848 3000<br>Fax: (02) 9848 3333                                          |
| KY          | Key Pharmaceuticals Pty Ltd<br>12 Lyonpark Road<br>Macquarie Park NSW 2113<br>Tel: (02) 8113 6200<br>Fax: (02) 8113 6222                                                              |
| LB          | Life Bioscience Pty Ltd<br>80 Millewa Avenue<br>Malvern East Vic 3145<br>Tel: 1800 114 610<br>Fax: (03) 8660 2785                                                                     |
| LM          | Link Medical Products Pty Ltd<br>Level 1, Bridgepoint Centre<br>3 Brady Street Mosman NSW 2088<br>Tel: (02) 9960 0150<br>Fax: (02) 9960 0149                                          |
| LN          | Lennon Healthcare<br>A Division of Aspen Pharmacare Australia<br>Pty Ltd<br>First Floor<br>34-36 Chandos Street St Leonards NSW<br>2065<br>Tel: (02) 8436 8300<br>Fax: (02) 9901 3540 |
| LU          | Lundbeck Australia Pty Ltd<br>Unit 1, 10 Inglewood Place<br>Norwest Business Park Baulkham Hills<br>NSW 2153<br>Tel: (02) 9836 1655<br>Fax: (02) 9836 1755                            |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                           |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| LY          | Eli Lilly Australia Pty Limited<br>112 Wharf Road<br>West Ryde NSW 2114<br>Tel: (02) 9325 4444<br>Fax: (02) 9325 4410                                         |
| MD          | Macarthur Research<br>Division of Roche Products Pty Ltd<br>4-10 Inman Road<br>Dee Why NSW 2099<br>Tel: (02) 9454 9000<br>Fax: (02) 9981 3229                 |
| ME          | Menley & James<br>Division of GlaxoSmithKline Australia Pty<br>Ltd<br>1061 Mountain Highway<br>Boronia Vic 3155<br>Tel: (03) 9721 6000<br>Fax: (03) 9729 5319 |
| MF          | Mundipharma Pty Ltd<br>Level 26, 6 O'Connell Street<br>Sydney NSW 2000<br>Tel: (02) 9231 7200<br>Fax: (02) 9223 0011                                          |
| MH          | Molnlycke Health Care Pty Ltd<br>Building 1, Ground Floor<br>14 Aquatic Drive Frenchs Forest NSW 2086<br>Tel: (02) 9453 1144<br>Fax: (02) 9453 1155           |
| MI          | Meditech Int. Pty Ltd<br>Unit 5, 36 Campbell Avenue<br>Cromer NSW 2099<br>Tel: (02) 9981 4470<br>Fax: (02) 9981 4475                                          |
| MK          | Merck Sharp & Dohme (Australia) Pty Ltd<br>54-68 Ferndell Street<br>South Granville NSW 2142<br>Tel: (02) 9795 9500<br>Fax: (02) 9795 9595                    |
| MM          | 3M Pharmaceuticals Australia Pty Ltd<br>9-15 Chilvers Road<br>Thornleigh NSW 2120<br>Tel: (02) 9875 6333<br>Fax: (02) 9875 6416                               |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                                |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MQ          | Alphapharm Pharmaceuticals<br>Chase Building 2<br>Wentworth Park Road Glebe NSW 2037<br>Tel: (02) 9298 3999<br>Fax: (02) 9566 4686                                                 |
| MS          | Abbott Diabetes Care<br>(A Division of Abbott Australasia Pty Ltd)<br>666 Doncaster Road<br>Doncaster Vic 3108<br>Tel: (03) 9843 7100<br>Fax: (03) 9855 8020                       |
| MT          | Mentholatum Australasia Pty Ltd<br>12-16 Janine Street<br>Scoresby Vic 3179<br>Tel: (03) 9763 0322<br>Fax: (03) 9763 2699                                                          |
| MW          | McGaw Biomed Australia Pty Ltd<br>c/- B. Braun Australia Pty Ltd<br>Norwest Business Park 17 Lexington Drive<br>Bella Vista NSW 2153<br>Tel: (02) 9629 0200<br>Fax: (02) 9629 0299 |
| NA          | National Diagnostic Products<br>22/39 Herbert Street<br>St Leonards NSW 2065<br>Tel: (02) 9432 8100<br>Fax: (02) 9432 1151                                                         |
| NC          | Novartis Consumer Health Australasia<br>Pty Ltd<br>327-333 Police Road<br>Mulgrave Vic 3170<br>Tel: (03) 9701 2711<br>Fax: (03) 9701 2911                                          |
| NE          | Norgine Pty Limited<br>3/14 Rodborough Road<br>Frenchs Forest NSW 2086<br>Tel: (02) 9972 7500<br>Fax: (02) 9972 7522                                                               |
| NF          | FlexPen Products of<br>Novo Nordisk Pharmaceuticals Pty Ltd<br>Level 3, 21 Solent Circuit<br>Baulkham Hills NSW 2153<br>Tel: (02) 8858 3600<br>Fax: (02) 8858 3799                 |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                         |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NI          | InnoLet Products of<br>Novo Nordisk Pharmaceuticals Pty Ltd<br>Level 3, 21 Solent Circuit<br>Baulkham Hills NSW 2153<br>Tel: (02) 8858 3600<br>Fax: (02) 8858 3799          |
| NL          | NovoLet Products of<br>Novo Nordisk Pharmaceuticals Pty Ltd<br>Level 3, 21 Solent Circuit<br>Baulkham Hills NSW 2153<br>Tel: (02) 8858 3600<br>Fax: (02) 8858 3799          |
| NM          | Novartis Medicines<br>A Division of Novartis Pharmaceuticals<br>Australia Pty Ltd<br>54 Waterloo Road<br>North Ryde NSW 2113<br>Tel: (02) 9805 3555<br>Fax: (02) 9887 4551  |
| NO          | Novo Nordisk Pharmaceuticals Pty Ltd<br>Level 3, 21 Solent Circuit<br>Baulkham Hills NSW 2153<br>Tel: (02) 8858 3600<br>Fax: (02) 8858 3799                                 |
| NQ          | Nycomed Pty Ltd<br>2 Lyonpark Road<br>North Ryde NSW 2113<br>Tel: (02) 9859 6900<br>Fax: (02) 9859 6950                                                                     |
| NT          | Nestlé Australia Ltd<br>60 Bathurst Street<br>Sydney NSW 2000<br>Tel: (02) 9931 2345<br>Fax: (02) 9931 2610                                                                 |
| NU          | Nutricia Australia Pty Limited<br>Talavera Corporate Centre<br>Level 4, Building D 12-24 Talavera Road<br>North Ryde NSW 2113<br>Tel: (02) 8875 0300<br>Fax: (02) 8978 4841 |
| NV          | Novartis Pharmaceuticals<br>Australia Pty Ltd<br>54 Waterloo Road<br>North Ryde NSW 2113<br>Tel: (02) 9805 3555<br>Fax: (02) 9887 4551                                      |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                     |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| OA          | Orphan Australia Pty Ltd<br>48 Kangan Drive<br>Berwick Vic 3806<br>Tel: (03) 9769 5744<br>Fax: (03) 9769 5944                                           |
| OB          | Oral B Laboratories Pty Ltd<br>Level 3, 90 Mount Street<br>North Sydney NSW 2060<br>Tel: (02) 9957 6499<br>Fax: (02) 9957 5383                          |
| OL          | Owen Laboratories<br>Division of Galderma Australia Pty Ltd<br>9 Rodborough Road<br>Frenchs Forest NSW 2086<br>Tel: 1800 800 765<br>Fax: (02) 9975 5374 |
| OM          | Colgate Oral Care<br>345 George Street<br>Sydney NSW 2000<br>Tel: (02) 9229 5600<br>Fax: (02) 9232 8448                                                 |
| ON          | Orion Laboratories Pty Ltd<br>25-29 Delawney Street<br>Balcatta WA 6021<br>Tel: (08) 9441 7800<br>Fax: (08) 9441 7888                                   |
| OR          | Organon (Australia) Pty Limited<br>31-33 Sirius Road<br>Lane Cove NSW 2066<br>Tel: (02) 9428 9411<br>Fax: (02) 9428 1732                                |
| OZ          | Medical Specialties Australia Pty Ltd<br>54 Gibbes Street<br>Chatswood NSW 2067<br>Tel: (02) 9417 7955<br>Fax: (02) 9417 5779                           |
| PC          | Pfizer Consumer Healthcare Pty Ltd<br>32 Cawarra Road<br>Caringbah NSW 2229<br>Tel: (02) 9710 6500<br>Fax: (02) 9710 6644                               |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                           |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| PD          | Parke Davis Pty Ltd<br>32 Cawarra Road<br>Caringbah NSW 2229<br>Tel: (02) 9710 6500<br>Fax: (02) 9710 6400                                    |
| PE          | Pacific EyeCare<br>A Division of Allergan Australia Pty Ltd<br>77 Ridge Street<br>Gordon NSW 2072<br>Tel: 1800 252 224<br>Fax: (02) 9498 0290 |
| PF          | Pfizer Pty Limited<br>38-42 Wharf Road<br>West Ryde NSW 2114<br>Tel: (02) 9850 3333<br>Fax: (02) 9858 1347                                    |
| PH          | Pharmacia Australia Pty Limited<br>38-42 Wharf Road<br>West Ryde NSW 2114<br>Tel: (02) 9850 3333<br>Fax: (02) 9858 1347                       |
| PI          | Pharmion Pty Ltd<br>Level 1, 476 St Kilda Road<br>Melbourne Vic 3004<br>Tel: (03) 9869 8000<br>Fax: (03) 9869 8099                            |
| PK          | Pharmatel Fresenius Kabi Pty Ltd<br>Unit 6, 6-18 Bridge Road<br>Hornsby NSW 2077<br>Tel: (02) 9472 2222<br>Fax: (02) 9472 2255                |
| PL          | Phebra<br>332 Burns Bay Road<br>Lane Cove NSW 2066<br>Tel: (02) 9420 9199<br>Fax: (02) 9420 9177                                              |
| PM          | PMC Pharma<br>A Division of AstraZeneca Pty Ltd<br>Alma Road<br>North Ryde NSW 2113<br>Tel: (02) 9978 3500<br>Fax: (02) 9978 3700             |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                         |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PP          | Petrus Pharmaceuticals Pty Ltd<br>Level 3, IBM Building<br>1060 Hay Street West Perth WA 6005<br>Tel: (08) 9368 5954<br>Fax: (08) 9368 6692                 |
| PU          | Pharmacia & Upjohn Pty Limited<br>38-42 Wharf Road<br>West Ryde NSW 2114<br>Tel: (02) 9850 3333<br>Fax: (02) 9858 1347                                      |
| PX          | Point of Care Diagnostics Australia Pty Ltd<br>Unit 14, 76 Reserve Road<br>Artarmon NSW 2064<br>Tel: (02) 9437 1355<br>Fax: (02) 9437 1399                  |
| PY          | Procter & Gamble Pharmaceuticals Australia Pty Ltd<br>99 Phillip Street<br>Parramatta NSW 2150<br>Tel: (02) 9685 4500<br>Fax: (02) 9685 4777                |
| PZ          | Prohealth Asia Pacific Pty Ltd<br>Suite 108A, 20 Lexington Drive<br>Bella Vista NSW 2153<br>Tel: 1300 024 784<br>Fax: 1300 008 463                          |
| RA          | Ranbaxy Australia Pty Limited<br>Suite 4.02, Level 4<br>Building D 12-24 Talavera Road North<br>Ryde NSW 2113<br>Tel: (02) 9647 1172<br>Fax: (02) 9647 1172 |
| RC          | Reckitt Benckiser (Australia) Pty Limited<br>44 Wharf Road<br>West Ryde NSW 2114<br>Tel: (02) 9857 2000<br>Fax: (02) 9857 2004                              |
| RD          | Roche Diagnostics Australia Pty Ltd<br>31 Victoria Avenue<br>Castle Hill NSW 2154<br>Tel: (02) 9899 7999<br>Fax: (02) 9634 4696                             |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                                                                        |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RE          | Real-RL<br>Division of GlaxoSmithKline Australia Pty Ltd<br>1061 Mountain Highway<br>Boronia Vic 3155<br>Tel: (03) 9721 6000<br>Fax: (03) 9721 5319                                                                        |
| RO          | Roche Products Pty Ltd<br>4-10 Inman Road<br>Dee Why NSW 2099<br>Tel: (02) 9454 9000<br>Fax: (02) 9971 7401                                                                                                                |
| SB          | Nutricia Australia - Clinical<br>A division of Nutricia Australia Pty Limited<br>Talavera Corporate Centre Level 4, Building<br>D 12-24 Talavera Road North Ryde NSW<br>2113<br>Tel: (02) 8875 0300<br>Fax: (02) 8978 4841 |
| SC          | Schering Pty Ltd<br>Australian Subsidiary of Schering AG,<br>Berlin<br>875 Pacific Highway<br>Pymble NSW 2073<br>Tel: (02) 9391 6000<br>Fax: (02) 9988 3311                                                                |
| SE          | Servier Laboratories (Aust.) Pty Ltd<br>8 Cato Street<br>Hawthorn Vic 3122<br>Tel: (03) 8823 7333<br>Fax: (03) 9822 9790                                                                                                   |
| SG          | Merck Serono Australia Pty Ltd<br>Unit 3-4, 25 Frenchs Forest Road East<br>Frenchs Forest NSW 2086<br>Tel: (02) 8977 4100<br>Fax: (02) 9975 1516                                                                           |
| SH          | Schering-Plough Pty Ltd<br>Level 4, 66 Waterloo Road<br>North Ryde NSW 2113<br>Tel: (02) 8988 8000<br>Fax: (02) 9852 7500                                                                                                  |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                                                  |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SI          | Sigma Pharmaceuticals (Australia ) Pty<br>Ltd A member of Sigma Group of<br>Companies<br>96 Merrindale Drive<br>Croydon Vic 3136<br>Tel: (03) 9839 2800<br>Fax: (03) 9839 2753                       |
| SJ          | Sharpe Laboratories Pty Ltd<br>12 Hope Street<br>Ermington NSW 2115<br>Tel: (02) 9858 5622<br>Fax: (02) 9858 5957                                                                                    |
| SM          | Solvay Pharmaceuticals<br>Division of Solvay Biosciences Pty Ltd<br>Level 1, Building 2<br>Pymble Corporate Centre 20 Bridge Street<br>Pymble NSW 2073<br>Tel: (02) 9440 0977<br>Fax: (02) 9440 0910 |
| SN          | Smith & Nephew Healthcare<br>315 Ferntree Gully Road<br>Mount Waverley Vic 3149<br>Tel: (03) 8540 6777<br>Fax: 1800 671 000                                                                          |
| SS          | SSL Australia Pty Ltd<br>225 Beach Road<br>Mordialloc Vic 3195<br>Tel: 1800 999 155<br>Fax: (03) 9587 6870                                                                                           |
| SU          | Sauter Laboratories (Aust.) Pty Ltd<br>4-10 Inman Road<br>Dee Why NSW 2099<br>Tel: (02) 9454 9000<br>Fax: (02) 9981 3229                                                                             |
| SW          | Sanofi-Aventis Australia Pty Ltd<br>Building D, Talavera Corporate Centre<br>12-24 Talavera Road Macquarie Park NSW<br>2113<br>Tel: (02) 8666 2000<br>Fax: (02) 8666 3000                            |
| SX          | Stiefel Laboratories Pty Limited<br>Unit 14, 5 Salisbury Road<br>Castle Hill NSW 2154<br>Tel: (02) 9894 5088<br>Fax: (02) 9894 5016                                                                  |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                               |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| SY          | Schering AG<br>875 Pacific Highway<br>Pymble NSW 2073<br>Tel: (02) 9391 6000<br>Fax: (02) 9988 3311                                               |
| SZ          | Sandoz Pty Ltd<br>Level 4, Suite 7-19<br>100 Harris Street Pymont NSW 2009<br>Tel: (02) 9566 1500<br>Fax: (02) 9566 1458                          |
| TA          | Actavis Australia Pty Ltd<br>Deacons<br>225 George Street Sydney NSW 2000<br>Tel: (08) 8267 6121<br>Fax: (08) 8267 6121                           |
| TM          | Technipro Marketing Pty Ltd<br>Unit 10, 13 Berry Street<br>Clyde NSW 2142<br>Tel: (02) 9897 5899<br>Fax: (02) 9897 5799                           |
| TW          | Terry White Chemists<br>Level 7, 5 Queens Road<br>Melbourne Vic 3004<br>Tel: (03) 9918 2500<br>Fax: (03) 9918 2006                                |
| TX          | Apotex Pty Ltd<br>66 Waterloo Road<br>North Ryde NSW 2113<br>Tel: (02) 8877 8333<br>Fax: (02) 8877 8377                                           |
| UC          | UCB Pharma<br>A Division of UCB Australia Pty Ltd<br>Level 1, 1155 Malvern Road<br>Malvern Vic 3144<br>Tel: (03) 9828 1800<br>Fax: (03) 9828 1860 |
| UM          | Unomedical Pty Ltd<br>11-17 Wilmette Place<br>Mona Vale NSW 2103<br>Tel: (02) 9997 8033<br>Fax: (02) 9997 3760                                    |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                                                                      |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| VF          | Vitaflo Australia Pty Ltd<br>110 Fyans Street<br>South Geelong Vic 3220<br>Tel: (03) 5229 8222<br>Fax: (03) 5229 8225                                                                                                    |
| VT          | Valeant Pharmaceuticals Australasia<br>Pty Ltd<br>Level 1, 85 St Hilliers Road<br>Auburn NSW 2144<br>Tel: (02) 9648 4266<br>Fax: (02) 9648 4655                                                                          |
| WA          | Winthrop Pharmaceuticals<br>Division of Sanofi-Aventis Australia Pty<br>Limited<br>Building D, Talavera Corporate Centre<br>12-24 Talavera Road Macquarie Park NSW<br>2113<br>Tel: (02) 8666 2000<br>Fax: (02) 8666 3000 |
| WF          | MedWatchDog Pty Limited<br>27 Goodwin Street<br>West Ryde NSW 2114<br>Tel: (02) 9809 0665<br>Fax: (02) 9989 8469                                                                                                         |
| WT          | Wyeth Consumer Healthcare Pty Ltd<br>17-19 Solent Circuit<br>Norwest Business Park Baulkham Hills<br>NSW 2153<br>Tel: 1800 555 057<br>Fax: (02) 9023 0016                                                                |
| WX          | Wyeth Australia Pty Limited<br>17-19 Solent Circuit<br>Norwest Business Park Baulkham Hills<br>NSW 2153<br>Tel: (02) 9761 8200<br>Fax: (02) 9023 0000                                                                    |
| WY          | Wyeth Pharmaceuticals<br>Division of Wyeth Australia Pty Limited<br>17-19 Solent Circuit<br>Norwest Business Park Baulkham Hills<br>NSW 2153<br>Tel: (02) 9761 8200<br>Fax: (02) 9023 0000                               |

| <i>Code</i> | <i>Manufacturer</i>                                                                                                                                                |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| XF          | Max Pharma<br>Suite 2, 210 Whitehorse Road<br>Balwyn Vic 3103<br>Tel: (03) 9888 5222<br>Fax: (03) 9888 5288                                                        |
| XP          | Aaxis Pacific Pty Ltd<br>24-32 Forge Street<br>Blacktown NSW 2148<br>Tel: (02) 9881 3333<br>Fax: (02) 9881 3322                                                    |
| YM          | Symbion Pharmacy Services Pty Ltd<br>Level 7, 5 Queens Road<br>Melbourne Vic 3004<br>Tel: (03) 9918 2000<br>Fax: (03) 9918 2006                                    |
| ZP          | Spirit Pharmaceuticals Pty Ltd<br>Suite 50, The Upper Deck<br>Jones Bay Wharf 26-32 Pirrama Road<br>Pyrmont NSW 2009<br>Tel: (02) 9571 5522<br>Fax: (02) 9571 6644 |





# Section 1 — Explanatory Notes

## Introduction

These Explanatory Notes are provided to help doctors, dentists, optometrists and pharmacists work within the Australian Government's Pharmaceutical Benefits Scheme (PBS).

The PBS is a system of subsidising the cost of most prescription medicines. The subsidies are available to all Australian residents and eligible foreign visitors, i.e., people from countries which have Reciprocal Health Care Agreements with Australia. These countries are the United Kingdom, Ireland, New Zealand, Malta, Italy, Sweden, the Netherlands, Finland, and Norway.

The aim of the PBS, which has been in operation since 1948, is to provide reliable and affordable access to a wide range of necessary medicines.

The Schedule of Pharmaceutical Benefits referred to throughout as the 'Schedule' – lists all the medicinal products available under the PBS, and explains the uses for which they can be subsidised.

The Schedule is produced monthly by the Australian Department of Health and Ageing (effective on the first day of each month).

It is vital therefore that doctors, dentists, optometrists and pharmacists remain up to date with information on which medicines are included in or excluded from the Schedule, which PBS prescribers may prescribe certain medicines, whether restrictions apply to the medicines, and how much patients should pay.

Queries relating to the PBS can be made to the Pharmaceutical Branches of Medicare Australia (telephone 132 290 Mondays to Saturdays, during business hours). Queries relating to the Repatriation Pharmaceutical Benefits Scheme (RPBS) can be made to the State offices of the Department of Veterans' Affairs (DVA) (telephone 1800 552 580).

## 1. The Schedule — Where to Find What

The Schedule of Pharmaceutical Benefits is divided into sections. At the start of the Schedule, immediately after the table of contents, is a summary of any changes to listed items. This is followed by a list of important information sources, contacts and addresses, then an index of manufacturers' codes.

The last pages of the Schedule provide a generic/proprietary index of PBS and RPBS ready-prepared items.

### Section 1

Section 1 is what you are reading, the Explanatory Notes. It outlines the correct way to prescribe and supply pharmaceutical benefits; patient charges; who qualifies for concessions; how the Safety Net system works; and, for pharmacists, how to claim reimbursement for PBS items.

Please note that except where indicated, the term '**prescriber**' is used in this section to cover doctors, dentists and optometrists who work within the PBS.

And except where stated otherwise, the term '**pharmacist**' means a pharmacist approved to supply medicines under the PBS.

## Section 2

This section lists ready-prepared items, and includes the form, manner of administration, brand and brand equivalents which may be prescribed, and the maximum quantity and number of repeats for each item.

Emergency drug (doctor's bag) supplies are also listed at the beginning of this section.

Any medicines that have restrictions on how they can be prescribed are printed in ***bold italics***. Items appearing in more than one therapeutic group are cross-referenced.

The second page of Section 2 explains symbols used throughout the Schedule.

The use of 'NOTE' in this section is used to clarify how some pharmaceutical benefits should be prescribed.

The use of 'CAUTION' is to warn of known adverse reactions from, or precautions to be taken with, a particular pharmaceutical benefit. (The absence of a cautionary note does not imply reactions may not happen.)

Separate lists at the end of Section 2 relate to items that can be prescribed by dentists and optometrists who work within the PBS. These are followed by a list of items that are made available under special arrangements for doctors to prescribe.

## Section 3

This section lists container prices, fees related to dispensing, standard packs and prices for ready-prepared preparations.

## Section 4

This section deals with extemporaneous preparations. It lists the ingredients which can be used, a table of maximum quantities and number of repeats, container prices, and a list of standard formula preparations and prices (based on formularies in common use and referred to in the Schedule as the Standard Formulae List).

Restrictions applying to the use of a pharmaceutical benefit are indicated against the item.

## Repatriation Schedule of Pharmaceutical Benefits

After Section 4, the Schedule provides information about pharmaceutical benefits under the RPBS. These may only be prescribed to DVA beneficiaries holding one of the repatriation health cards (see details under '4. Patient Charges').

## 2. Prescribing Medicines — Information for PBS Prescribers

### PBS prescribers

Pharmaceutical benefits can only be prescribed by registered doctors, and by dentists and optometrists who are approved to prescribe within the PBS.

### PBS Prescription forms

Standard PBS prescription forms are available from Medicare Australia for prescribing pharmaceutical benefits.

For doctors:

- *Personalised forms* – are printed with the doctor's name, qualifications, practice address/es, telephone number and prescriber number (which relates to pharmaceutical benefits). They are only provided to doctors who have a Medicare provider number.

- *Non-personalised (blank) forms* – are distributed as an emergency supply (usually when a doctor has temporarily run out of personalised forms).
- *Locum forms* – have the doctor's name, prescriber number and telephone number (if available) and a space to record the practice where the doctor is working.
- *PBS/RPBS Authority Prescription Forms* – can be in personalised, non-personalised or locum format.
- *Computer PBS prescription forms* – are either continuous or single sheet. On the reverse side they list the name, address and telephone number of the practice, and in the case of a sole doctor practice, the doctor's name.

For dentists:

- *Personalised forms* – have the dentist's name, qualifications, practice address/es, telephone number and prescriber number.
- *Non-personalised (blank) forms* – are distributed for emergency supply only.

For optometrists:

- *Personalised forms* – have the optometrist's name, qualifications, practice address/es, telephone number and prescriber number. These forms can be also be used to prescribe authority-required PBS/RPBS items.

PBS prescription forms for PBS prescribers are supplied free of charge.

The inclusion of the prescriber number on a PBS prescription enables the pharmacist to be sure the prescription is from a legitimate prescriber and satisfies State/Territory legislation. A PBS prescription written by a dentist or optometrist must include the person's approval number as a PBS prescriber.

PBS prescriptions should be provided to the patient in duplicate, as both parts make up a valid PBS prescription. The patient should be reminded to present both the original and the duplicate copy to the pharmacist.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted. Only a medical practitioner providing medical services within a participating public hospital may prescribe the subsidised medication. The States of Victoria, Queensland and Western Australia and the Northern Territory have agreed to implement these arrangements.

### **Ordering forms**

Prescribers are asked not to over order. Getting the right amount of forms helps to reduce the cost to taxpayers and helps to reduce paper wastage. Also, the pads may deteriorate if stored over time.

Order forms for standard and authority PBS prescription forms are available from Medicare Australia stationery officers. Contact details are listed in the front of the Schedule. Order forms for computer PBS prescription form stationery are obtained from Medicare Australia (at the address below). Orders should be sent to:

Prescription Pad Order Clerk  
Pharmaceutical Branch  
Medicare Australia  
GPO Box 9826  
Sydney NSW 2001  
Telephone (02) 9895 3295

Orders for PBS prescription stationery will only be accepted by application in writing and through the channels mentioned above.

## Preparing general PBS prescriptions

### *Do's and Don't's*

A PBS prescription is only valid when it is written by a doctor, dentist or optometrist.

The PBS prescription must be for the treatment of the person named on the PBS prescription. A PBS prescription may only be written for the treatment of one person.

A prescriber cannot write more than one PBS prescription for the same pharmaceutical benefit for the same person on the same day.

Up to **three** pharmaceutical benefit items may be included on a single PBS prescription form except for Authority required, Authority required (STREAMLINED) items and optometrist items. These items must be written on individual forms. Pharmaceutical benefits and non-pharmaceutical benefits should not be listed together on the one PBS prescription form.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical services within a participating public hospital may prescribe the subsidised medication. The States of Victoria, Queensland and Western Australia and the Northern Territory have agreed to implement these arrangements.

If an item has a particular manner of administration it may not, as a pharmaceutical benefit, be administered in any other way, e.g., an ophthalmic preparation may not be prescribed for topical use.

If an item is restricted, and the use for the patient is different from the use specified in the restriction, it cannot be prescribed as a pharmaceutical benefit. The prescriber should write the prescription as a non-PBS private prescription. If a standard PBS prescription form is used for this purpose the 'PBS/RPBS' text must be clearly struck out. It should also be endorsed 'non-PBS'.

Prescribers must heed State/Territory laws when prescribing drugs listed as narcotic, specified or restricted in the poisons legislation of the particular State or Territory. Legislative requirements in some States/Territories are such that prescribers may be required to prescribe a drug of addiction on a separate PBS prescription. Optometrists must ensure that prescriptions written under the PBS fall within the limits of the prescribing approval granted to the person under State or Territory requirements. It is the optometrist's responsibility to ensure that PBS prescriptions comply with all aspects of his/her prescribing approval. Inclusion of a PBS medicine in the optometrist listings does NOT confer approval for an optometrist to prescribe that medicine if not authorised to do so in the particular State or Territory.

A prescriber cannot prescribe a narcotic drug for him/herself.

Prescribers are issued with individual PBS prescription pads by Medicare Australia for their own use – these pads should not be used by other prescribers, as this can cause confusion through incorrect pharmacy records.

Doctors should, and dentists and optometrists are required to, include their prescriber number on non-personalised PBS prescriptions.

The following admixtures are not pharmaceutical benefits:

- the admixture of two or more ready-prepared items listed in the Schedule; or
- the admixture of a ready-prepared item and one or more extemporaneous drugs listed in Section 4 of the Schedule; or
- the admixture of a non-pharmaceutical benefit item with a pharmaceutical benefit item.

### **Writing the PBS prescription**

The following rules apply for writing PBS prescriptions:

- they must be written in indelible form (i.e., ink or ball-point pen) in the prescriber's own handwriting (exceptions must be approved by Medicare Australia's Chief Executive Officer) either on the standard PBS prescription, or on paper approximately 18 cm x 12 cm, or they can be generated by computer on a form approved by Medicare Australia. For patient safety reasons, both the original and the duplicate must be legible;
- they must record the prescriber's name and address (and, in the case of dentists and optometrists, the prescriber number), the patient's name, address and entitlement status, and whether the prescription is under the PBS or RPBS;
- they should completely identify the pharmaceutical benefit by detailing the item, dose, form, strength, quantity and instructions for use;
- they should indicate where brand substitution is not permitted. PBS prescriptions must not be prepared using a computer prescribing program that contains a default which would result in all prescriptions being indicated as Brand Substitution Not Permitted;
- where 'solvent required' is included after the form, the volume and number of ampoules must be specified; and
- they must be signed by the prescriber and dated. Forward or back dating is not permitted.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical services within a participating public hospital may prescribe the subsidised medication. The States of Victoria, Queensland and Western Australia and the Northern Territory have agreed to implement these arrangements.

### **Restrictions**

Pharmaceutical benefits listed in the Schedule fall into three broad categories:

*Unrestricted benefits* –have no restrictions on their therapeutic uses;

*Restricted benefits* –can only be prescribed for specific therapeutic uses (noted as Restricted benefit); and

*Authority required benefits* –Authority required benefits fall into two categories:

- *Authority required benefits* are restricted benefits that require prior approval from Medicare Australia or the DVA (noted as **Authority required**)
- *Authority required (STREAMLINED) benefits* are restricted benefits that do not require prior approval from Medicare Australia or the DVA but require the recording of a streamlined authority code (noted as **Authority required (STREAMLINED)**).

### **Authority PBS prescriptions**

Authority required benefits fall into two categories – *Authority required* and *Authority required (STREAMLINED)*.

Only doctors and optometrists (not dentists) can write authority PBS prescriptions.

Authority PBS prescriptions cannot have retrospective approval.

### **Authority required PBS Prescriptions**

Approval of authority PBS prescriptions by Medicare Australia may be sought by:

- posting an Authority Prescription Form to Medicare Australia - after approval, Medicare Australia will forward both copies of the prescription to the patient or the prescriber (if it is to be sent direct to the patient, the prescriber should mark the box next to the patient's details);
- calling Medicare Australia Authority Freecall service (1800 888 333); or
- using Medicare Australia PBS authorities website at [www.medicareaustralia.gov.au/providers](http://www.medicareaustralia.gov.au/providers).

Approval of authority prescriptions by the DVA may be obtained either by posting an Authority Prescription Form to the DVA, or by using the DVA Authority Freecall service (1800 552 580).

An authority PBS/RPBS prescription is not valid until it has been approved by Medicare Australia or the DVA. Without this approval, a pharmacist must not supply the item as a PBS/RPBS benefit.

Each Authority required PBS/RPBS item must be written on an Authority PBS/RPBS prescription form, one item per form. Authority PBS prescription forms provide for the following:

- the patient/pharmacist copy, which records prescriber, patient, and pharmaceutical benefit item details. Where required a repeat authorisation, which is used for repeat supply, is attached to the pharmacist/patient copy until the last supply is made. The patient/pharmacist copy is then retained by the pharmacist;
- the Medicare Australia/DVA copy which records prescriber, patient, and pharmaceutical benefit item details. After the first dispensing, the Medicare Australia/DVA copy is forwarded to Medicare Australia for processing and payment;
- the prescriber's copy (for computer generated scripts, this is the tear off portion at the base of the script) or Prescriber/Medicare Australia/DVA copy (for handwritten scripts this is the long white copy), is kept by Medicare Australia or the DVA for record purposes when approval is sought in writing. When approval is by telephone or by the authorities website, the prescriber must keep this copy for 12 months. This copy must record the daily dose, details of the disease, clinical justification for using the item, the patient's age (if the patient is a child) and whether the patient has previously received an authority for this pharmaceutical benefit.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical services within a participating public hospital may prescribe the subsidised medication. The States of Victoria, Queensland and Western Australia and the Northern Territory have agreed to implement these arrangements.

### ***Authority required (STREAMLINED) PBS Prescriptions***

Prior approval is not required from Medicare Australia or DVA to prescribe an Authority required (STREAMLINED) item (except where increased quantities and/or repeats are required). Instead the authority prescription form must include a four digit streamlined authority code.

This code is listed with the corresponding restriction for each Authority required (STREAMLINED) item and the prescriber must write the code on the authority PBS/RPBS prescription form. An authority prescription for an Authority required (STREAMLINED) item is not valid unless the code is included on the prescription form. Without the streamlined authority code, a pharmacist must not supply the item as a PBS benefit.

There are no Authority Required (STREAMLINED) items in the Repatriation Schedule of Pharmaceutical Benefits.

Authority required (STREAMLINED) PBS prescriptions must be written on an Authority PBS/RPBS Prescription Form, this includes:

- the pharmacist/patient copy, which records prescriber, patient, and pharmaceutical benefit item details. The prescription is given directly to the patient to be dispensed at their pharmacy;

- the Medicare Australia/DVA copy which records prescriber, patient, and pharmaceutical benefit item details. After the first dispensing, the Medicare Australia/DVA copy is forwarded to Medicare Australia for processing and payment;
- the prescriber's copy is kept by the prescriber for 12 months. This copy must record the daily dose, details of the disease, clinical justification for using the item, the patient's age (if the patient is a child) and whether the patient has previously received an authority for this pharmaceutical benefit.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical services within a participating public hospital may prescribe the subsidised medication. The States of Victoria, Queensland and Western Australia and the Northern Territory have agreed to implement these arrangements.

### ***Writing authority PBS prescriptions***

The following rules apply:

- only one item may be prescribed per PBS prescription;
- PBS prescriptions must be completed by prescribers in writing, unless otherwise approved by Medicare Australia;
- prescribers should include their name, address, telephone number and **prescriber number** (not provider number);
- prescribers must include the patient's name, address and entitlement status (i.e. whether they are a 'concessional' or 'general patient');
- prescribers must indicate when brand substitution is not permitted. PBS prescriptions must not be prepared using a computer prescribing program that contains a default which would result in all PBS prescriptions being indicated as Brand Substitution Not Permitted;
- in certain circumstances, the prescriber must provide additional information to Medicare Australia with the authority application; and
- the PBS prescription must be signed by the prescriber and dated.

Posted applications which lack necessary information, and therefore cannot be approved, will be returned for correction. If the matter can be clarified via telephone, an Authority to Prescribe Form may be prepared by Medicare Australia or the DVA and sent to the prescriber.

In the case of authority PBS prescriptions approved by telephone, the approval number must be included on the PBS prescription to enable the pharmacist to supply the medication. A prescriber who is granted approval but decides not to continue with the therapy should advise Medicare Australia.

In the case of Authority required (STREAMLINED) prescriptions, the streamlined authority code must be written on the PBS/RPBS prescription form. This enables the pharmacist to supply the medication as a PBS benefit.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical services within a participating public hospital may prescribe the subsidised medication. The States of Victoria, Queensland and Western Australia and the Northern Territory have agreed to implement these arrangements.

### **Maximum quantities and repeats**

The maximum quantity and number of repeats allowed for PBS items are recommended by the Pharmaceutical Benefits Advisory Committee (PBAC). In the case of RPBS items, the recommendations are made by the Repatriation Pharmaceutical Reference Committee (RPRC).

Only doctors and optometrists (not dentists) can prescribe repeats.

PBS prescriptions and repeats can be for any quantity up to the maximum. It is not necessary to prescribe the maximum quantity if a lesser quantity is sufficient for the patient's needs. Please clearly indicate the number of tablets, capsules, etc. required and the number of repeats needed, and **do not use** abbreviations such as 'Max. Qty', 'M.Q.', or 'M.R.'.

If a prescriber feels the maximum quantity or number of repeats should be increased for a particular patient, he or she must complete an Authority PBS Prescription Form (see procedures above under 'Authority PBS Prescriptions'). The provision of increased quantities and repeats on authority PBS prescriptions is intended to provide approximately one month's therapy which may be repeated (if clinically appropriate) to provide 6 months' therapy in total. This situation usually arises where higher than normal dosages are required.

Approval for increased quantities and repeats of Authority required, Authority required (STREAMLINED) and Restricted benefit PBS items will be granted only where the reason for the PBS prescription is consistent with the indications published in the Schedule.

Approval for increased quantities and repeats extends only to the provision of a pharmaceutical benefit for the patient and does not imply approval of any aspects of the patient's care, which are the responsibility of the treating prescriber.

## Regulation 24

Under this regulation, original and repeat supplies of pharmaceutical benefits can be supplied at the one time if a doctor is first satisfied that certain conditions apply, then endorses the PBS prescription 'Regulation 24'. RPBS prescriptions may be endorsed 'hardship conditions apply'.

The doctor must first be satisfied all the following conditions apply:

- the maximum PBS quantity is insufficient for the patient's treatment; **AND**
- the patient has a chronic illness or lives in a remote area where access to PBS supplies is limited; **AND**
- the patient would suffer great hardship trying to get the pharmaceutical benefit on separate occasions.

Regulation 24 does not apply for supply of pharmaceutical benefits on optometrist prescriptions.

## Urgent cases

In urgent cases and where State/Territory law allows, a prescriber may telephone a pharmacist and ask that a PBS prescription be supplied. He/she must then forward the written PBS prescription and duplicate to the pharmacist within **seven days of the date of supply**.

This also applies to 'Authority required' authority PBS prescriptions provided prior approval has been given by Medicare Australia or DVA. The follow-up written PBS prescription must include the approval number provided over the phone by Medicare Australia or DVA.

## Drugs of addiction

Prescribers must heed State/Territory laws when prescribing drugs listed as narcotic, specified or restricted and must notify, or receive approval from, the appropriate health authority.

When a PBS/RPBS authority application is for a drug of addiction (other than dexamphetamine sulfate), the following guidelines apply:

- the maximum quantity authorised is generally for one month's therapy (e.g., one week's therapy with three repeats);
- where supply for a longer period is warranted, quantities are usually for up to three months' therapy;
- telephone approvals are limited to one month's therapy.



Doctors should also state the interval of repeat where repeats are called for, and ensure State/Territory health authorities are notified about ongoing treatment.

### **Emergency drug (doctor's bag) supplies**

Certain pharmaceutical benefits are provided without charge to doctors who in turn can supply them free to patients for emergency use.

A doctor must fill out and sign the Emergency Drug (Doctor's Bag) Order Form in triplicate and give the original and duplicate to a pharmacist. Each form is valid for the month indicated on the form.

Doctors can order the maximum quantity of an item provided they do not already have the maximum quantity on hand. Doctors can only get items once a month. They can also ask for a particular brand of a pharmaceutical benefit. If it is unavailable, they must specify another listed brand, and initial the alteration.

A receipt must be signed by the doctor, or by an authorised representative, when supplies are received.

### **Improving the capacity of the PBS to meet particular Aboriginal and Torres Strait Islander health needs**

The PBS includes listings to support the treatment of conditions common in Aboriginal and Torres Strait Islander health settings. These listings are specifically for your patients who identify as Aboriginal and/or Torres Strait Islander persons. Some listings will be medicines recently added to the PBS; others may contain specific restrictions for existing PBS items.

A significant proportion of the higher levels of illness experienced by Aboriginal and Torres Strait Islanders may be addressed through better access to appropriate medicines. The PBS aims to provide greater choice in therapeutic options and to address:

- the greater burden of disease experienced by Aboriginal and Torres Strait Islander peoples; and
- morbidity almost exclusively seen in this population.

#### ***How to prescribe these items?***

These items are available as "Authority PBS prescriptions". You should obtain approval from Medicare Australia before prescribing these items for patients who identify as Aboriginal and/or Torres Strait Islander persons through the Authority Freecall service [1800 888 333], on line or by mail.

Only doctors (not dentists) can write Authority PBS prescriptions and your patients will be required to pay their normal PBS co-payment.

Special arrangements apply in remote area Aboriginal Health Services for supplying these PBS items.

### ***Aboriginal and Torres Strait Islander identification***

Establishing a client's background may have clinical significance and should be part of routine medical history taking. In the case of Aboriginal and Torres Strait Islander people, this is also relevant to establish eligibility for services such as health checks, specific immunisation programs, and the some PBS items.

Improving the level of identification of Aboriginal and Torres Strait Islander people will also assist in developing initiatives to meet particular needs.

For the purposes of these PBS items a person is Aboriginal and/or Torres Strait Islander if the person identifies himself or herself as being an Aboriginal and/or Torres Strait Islander. Clients should be asked to self-identify either verbally or by completing a form.

- Some people may give this information without being asked.

- It is important not to assume that a person is or is not Aboriginal or Torres Strait Islander.

### **Asking about Aboriginal and/or Torres Strait Islander identification**

Practitioners should ensure that each person attending their practice has the opportunity to identify if they are Aboriginal or Torres Strait Islander. An environment which maintains confidentiality and provides an explanation for this question if requested will assist this process.

- The inquiry may be made verbally and recorded by the general practitioner as part of routine medical history taking at first consultation, or by a receptionist or other staff member. An appropriate question to ask is:  
"Are you (is this child) of Aboriginal or Torres Strait Islander origin?"
- Alternatively, the question may be included on a client self-history or practice record form, using a standard question such as:  
"Are you (is this child) of Aboriginal or Torres Strait Islander origin?"
  - Yes - Aboriginal
  - Yes - Torres Strait Islander
  - Yes - Aboriginal and Torres Strait Islander
  - No

### **Aboriginal and Torres Strait Islander health**

Major causes of excess mortality in Aboriginal and Torres Strait Islander peoples are:

- circulatory conditions (including ischaemic heart disease, hypertension, cerebrovascular disease and rheumatic heart disease);
- external causes (including accident and injury);
- endocrine causes (mainly type two diabetes and its complications); and
- respiratory conditions.

Causes of morbidity vary but include the risk factors and precursors of all of these. They also include infections of the respiratory system, the ears (in particular, chronic suppurative otitis media), the eyes (trachoma in some settings), the skin and the gastrointestinal system. End-stage renal disease is a major cause of hospitalisations, and much early renal disease remains undetected. In some settings, sexually transmissible infections are common.

Living environments affect health and may be compromised by overcrowding, limited access to clean water and sanitation, and poverty. Social and family life may be negatively influenced by an excessive burden of care for family members, by substance use and sometimes by family violence.

### **Communication and cultural issues**

Aboriginal cultures are numerous and diverse in language, customs, non-verbal and verbal communication, geographical locations and experiences. Torres Strait Islanders are a separate people with a distinctly different culture and identity. Aboriginal and Torres Strait Islander people often perceive health differently from other Australians.

*For Aboriginal and Torres Strait Islander peoples health does not just entail the freedom of the individual from sickness but requires support for healthy and interdependent relationships between families, communities, land, sea and spirit. The focus must be on spiritual, cultural, emotional and social well-being as well as physical health*

Source: National Aboriginal and Torres Strait Islander Health Council. National Strategic Framework for Aboriginal and Torres Strait Islander Health 2003-2013, Context. Canberra: Commonwealth of Australia; 2004.

To provide effective primary health care to Aboriginal and Torres Strait Islander clients, you need to be aware of the issues surrounding this diversity, and which may have an impact on the delivery of services.

- Aboriginal and Torres Strait Islander people may be reluctant to use mainstream medical services. This may be because of a lack of understanding of the mainstream health system and previous negative experiences within the mainstream health care system.
- Access to adequate health care may be hindered by family obligations (often extended family), lack of transport or money, or geographical isolation.
- English may be the person's second, third or even fourth language. Therefore it may be appropriate to consider the use of an interpreter.
- Aboriginal and Torres Strait Islander people may be reluctant to consult a health care provider of the opposite sex, particularly with regard to women's and men's health issues.

The differences between the cultural and language backgrounds of health service providers and patients, whether urban, rural or remote, may range from minor to extreme.

You should:

- Make efforts to ensure waiting rooms are welcoming to Aboriginal and Torres Strait Islander people, including displaying relevant posters and pamphlets;
- Provide a relaxed setting for the consultation (e.g. sit next to your patient rather than across a desk);
- Allow time at the first consultation to build rapport and trust;
- Ensure the person understands clearly what the service entails and the details of any procedures involved, and possible follow-up or referral requirements;
- Obtain health promotion information appropriate for Aboriginal and Torres Strait Islander patients;
- Allow the patient to have family members present if desired. When inviting family or community members to accompany a patient, ensure the patient fully consents to their attendance and that the community/family members are fully aware of the need for confidentiality;
- Provide gender appropriate staff where possible, for both male and female patients, especially in regard to pap smears, mammograms, sexual health checks, pregnancy checks, antenatal care and postnatal care;
- Encourage all staff in the practice to attend Aboriginal and Torres Strait Islander Cultural Awareness programs, which are widely available;
- Ensure practice staff have awareness of appropriate referral and/or support organisations for Aboriginal and Torres Strait Islander patients; and
- Develop partnerships with local Aboriginal and Torres Strait Islander community organisations.

For more information, [pbs-indigenous@health.gov.au](mailto:pbs-indigenous@health.gov.au)

### 3. Supplying Medicines — What Pharmacists Need to Know

#### Eligible suppliers

Pharmaceutical benefits are mainly supplied by approved pharmacists – pharmacists who comply with certain conditions. These pharmacists are approved to dispense pharmaceutical benefits from a particular pharmacy.

Other suppliers include approved doctors (usually practising in isolated areas), Friendly Society pharmacies, and approved hospitals. All suppliers are issued with approval numbers by Medicare Australia. They should follow the procedures in these Explanatory Notes.

Unapproved pharmacists *cannot* supply pharmaceutical benefits.

#### **Approval conditions for pharmacists**

A pharmacist approved to supply medicines under the PBS:

- can only supply benefits from the pharmacy that he/she is operating;
- will not supply to anyone any pharmaceutical benefit that attracts a Commonwealth contribution for free, or for a price that is less than the relevant patient contribution;
- will clearly advertise that any offer for free or cut-price medicines does not include pharmaceutical benefits which have a Commonwealth contribution;
- will not pay rebates or refunds of patient contributions;
- will publicly display a notice setting out the pharmacy's normal trading hours;
- is obliged to supply pharmaceutical benefits at the pharmacy at any hour if a PBS prescription is marked 'urgent' and initialled by the prescriber;
- will keep adequate stocks for the supply of pharmaceutical benefits;
- may be called on by Medicare Australia to provide details of stocks of pharmaceutical benefits or preparations for pharmaceutical benefits; and
- must keep the duplicates of all old format PBS prescriptions, and the patient/pharmacist copies of all new format PBS prescriptions, with a Commonwealth contribution for at least one year from the date of supply. This includes PBS prescriptions ordering repeats when it is the final supply, and order forms for emergency drug (doctor's bag) supplies. Please note that some State/Territory laws require these copies to be kept for longer periods.

### **Before supplying pharmaceutical benefits**

Several steps must be taken before a pharmaceutical benefit is supplied.

Firstly, a pharmacist must endorse the PBS prescription and duplicate with his/her name and approved supplier number.

Secondly, a PBS prescription identifying number must be given to the PBS prescription item on both the PBS prescription and duplicate. Any recognised series of numbers may be used.

If more than one item is on a PBS prescription, a separate identifying number should be allocated to each item.

In the case of a repeat authorisation, the same PBS prescription identifying number(s) must be carried through for each item. A pharmacist must also allocate his/her own identifying number on the repeat authorisation. It must be written alongside the date and place of supply.

### **Supplying pharmaceutical benefits**

#### ***Do's and Don't's***

Except in urgent cases (see details under '2. Prescribing Medicines ... Urgent cases'), pharmacists are authorised to supply pharmaceutical benefits only after they receive:

- the pharmacist/patient and Medicare Australia or DVA copies of a valid PBS prescription which is not more than 12 months old; or
- the pharmacist/patient and Medicare Australia or DVA copies of an approved authority PBS prescription or an authority to prescribe which is not more than 12 months old; or
- a repeat authorisation attached to a patient/pharmacist PBS prescription not more than 12 months after the date of the original PBS prescription.

A pharmacist must not supply an Authority required (STREAMLINED) item unless the prescriber has written the four digit streamlined authority code on an authority PBS/RPBS prescription.

A pharmaceutical benefit cannot be supplied more times than specified in the PBS prescription.

A pharmacist cannot add to, delete from, or alter a PBS prescription in any other way. However, there may be circumstances where after contacting a prescriber, the pharmacist can clarify the prescriber's intentions and endorse the PBS prescription accordingly.

Once a pharmaceutical benefit has been supplied to a patient, it may not be supplied to that patient again:

- on the same day or within the next 20 days, if it is a benefit (other than an eye preparation) that has five or more repeats allowed in the Schedule; or
- on the same day or within the next four days (e.g., if a pharmaceutical benefit is supplied on a Monday, it cannot be supplied again to that patient until the next Saturday) in the case of other benefits.

Exceptions to this are:

- when a PBS prescription is endorsed with the words 'Regulation 24' or 'hardship conditions apply' (see below under 'Regulation 24'); and
- If a pharmacist believes a repeat supply is needed without delay for the treatment of the person, or a previous supply has been destroyed, lost or stolen. In this case, the pharmacist can provide another supply but must write 'immediate supply necessary' and sign the PBS prescription.

A pharmacist can supply an alternative pharmaceutical benefit without reference to the prescriber, provided that:

- the PBS prescription does not indicate that only the pharmaceutical benefit prescribed is to be supplied (ie substitution is not permitted); and
- the Schedule states that the prescribed benefit and the substitute benefits are equivalent; and
- supply of the substitute benefit does not contravene relevant State/Territory law; and
- the substitute benefit is a listed brand in the Schedule.

Pharmacists must heed State/Territory laws when supplying drugs listed as narcotic, specified or restricted in legislation of the particular State or Territory.

### ***What to do if the Schedule changes***

If an item or brand is deleted from the Schedule, it *cannot* be supplied as a pharmaceutical benefit from the date the deletion takes effect – regardless of whether the PBS prescription was written before this date. This includes repeat authorisations. (Special conditions applying to RPBS prescriptions are detailed in the RPBS Explanatory Notes.)

However, if restrictions on the prescribing of a pharmaceutical benefit change, or the maximum quantity or number of repeats is altered in the Schedule, valid PBS prescriptions written before the date of effect of the change *may* still be supplied as pharmaceutical benefits, under the conditions applying at the date of prescribing.

### **Suspected forgery**

Pharmacists should take all reasonable steps to satisfy themselves that all items on a PBS prescription were written by a doctor, dentist or an optometrist.

### **Regulation 24**

This regulation allows pharmacists to supply a pharmaceutical benefit and all of its repeats at the one time.

The PBS prescription must be endorsed by the doctor with the words 'Regulation 24' if it is an item under the PBS, or 'hardship conditions apply' if it is being supplied under the RPBS. (For more information see under `2. Prescribing Medicines ... Regulation 24'). Regulation 24 does not apply for supply of pharmaceutical benefits on optometrist prescriptions.

### **Repeat authorisations**

When a PBS prescription calls for repeat supplies, the pharmacist shall prepare a Repeat Authorisation Form, except when the PBS prescription is marked 'Regulation 24'.

The repeat may be requested on a standard PBS prescription, an authority PBS prescription or an Authority to Prescribe Form, or on an earlier repeat authorisation. In the latter case, it must come with the duplicate PBS prescription, or in the new format, the "patient/pharmacist copy".

### ***Preparing Repeat Authorisation Forms***

A Repeat Authorisation Form must show:

- the category of benefit (concession or general) – by placing a cross (x) in the relevant box;
- the patient's name and full address;
- in the case of repeats authorised on authority PBS prescriptions, the authority prescription number;
- details of the original PBS prescription stating the item, form, strength, quantity and directions;
- if substitution has occurred, the name of the brand actually supplied;
- for the first supply, the pharmacy name, address and approval number, the date of the original PBS prescription and the allotted PBS prescription identifying number;
- for subsequent supplies, the pharmacy approval number, and the date and PBS prescription number of the original prescription;
- the number of times the item is to be repeated and the number of times it has been supplied;
- the name and pharmacy approval number of the pharmacist issuing the repeat authorisation; and
- the date of supply.

When a repeat authorisation is prepared for any further repeats or deferred supply, a pharmacist must attach the duplicate copy of an old format PBS prescription, or the patient/pharmacist copy of a new format PBS prescription, and give both to the patient at the time of supply.

### ***Repeat authorisations for injectables and solvents***

Where an injectable pharmaceutical benefit requires a solvent, both items should be treated as one pharmaceutical benefit. If repeats are needed, only one repeat authorisation is to be prepared. Details of the injectable and the solvent should appear in the space provided for the 'original prescription transcription'.

### ***Repeat authorisations for deferred supply***

When a PBS prescription orders a number of pharmaceutical benefit items, but the patient does not need all of the items at the same time, a separate repeat authorisation for each deferred item must be prepared. The words 'original supply deferred' should be indicated across the relevant item on the original PBS prescription, its duplicate, and on the repeat authorisation.

Deferred items must not be claimed on the original PBS prescription.

The Repeat Authorisation Form when it is used for a deferred supply, is issued in the same way as normal repeat authorisations except that:

- '0' is to be inserted in the space for 'no. of times already dispensed'; and
- if no repeats are ordered, '0' is to be inserted in the space for 'no. of repeats authorised'.

Supplying a benefit on a deferred supply repeat authorisation is to be treated as if it is the first time of supply. If repeats are directed, the normal procedure for repeat authorisations applies. Details of the pharmacy at which the deferred supply was authorised are to be written onto subsequent repeat authorisations.

### ***Authority PBS prescriptions***

If a pharmacist is presented with an authority PBS prescription and is not sure if it has been approved, he or she should contact Medicare Australia. Please note that Medicare Australia will not provide clinical information.

If the authority PBS/RPBS prescription is for an Authority required (STREAMLINED) item the pharmacist should ensure that the prescriber has written the four digit streamlined authority code on the prescription, this enables the pharmacist to supply the item as a PBS benefit.

### **Urgent cases**

In urgent cases and where State/Territory law allows, pharmacists can supply a pharmaceutical benefit to a person without a PBS prescription, provided details of the prescription are given by the prescriber via telephone or other means. The prescriber must then forward the written PBS prescription and duplicate to the pharmacist within **seven days of the date of supply**.

Where a pharmaceutical benefit needs prior approval from Medicare Australia or the DVA, the prescriber must obtain approval and then advise the pharmacist of the PBS prescription and approval details. Only an original supply can be provided in this manner, not repeats.

### **Receipts**

A person receiving a pharmaceutical benefit item must sign and date a receipt for it. If the person is not the patient, that person must also endorse the PBS prescription or repeat authorisation with his/her address. A receipt cannot be obtained until supply of the benefit has been made.

If a pharmaceutical benefit has to be sent through the post, by rail, or by other means, and a receipt is not practical, the pharmacist must certify on the PBS prescription or repeat authorisation that the benefit has been supplied, and write the date of supply and details of how it was sent. For example, if a pharmaceutical benefit is mailed to a patient on 1 April 2006, the pharmacist should write: "Certified supplied – mailed to patient 1 April 2006 (name of pharmacist) (signature of pharmacist) (date of certification)".

If an item is supplied in an urgent case, or to a person who cannot read or write, the pharmacist should sign and date a statement on the PBS prescription or repeat authorisation, stating the item has been supplied and the date on which it was supplied, and explaining why there is no receipt. For example, if a pharmaceutical benefit is supplied to a patient with a broken arm on 1 May 2006, the pharmacist should write: "Certified supplied 1 May 2006 – patient has a broken arm and is unable to sign (name of pharmacist) (signature of pharmacist) (date of certification)".

Only the pharmacist approved to supply pharmaceutical benefits can certify supply.

### **Emergency drug (doctor's bag) supplies**

Pharmacists may supply certain pharmaceutical benefit items free of charge to doctors for emergencies if they receive an Emergency Drug (Doctor's Bag) Order Form in duplicate, signed by the doctor.

Pharmacists must be satisfied the form was completed by a doctor and includes the doctor's name and address. If a pharmacist does not know the doctor, he/she should confirm the doctor's registration and endorse this on the back of the form.

For more information about emergency supplies see under '2. Prescribing Medicines ... Emergency drug (doctor's bag) supplies'.

## **4. Patient Charges**

### **Type of patient**

There are two types of PBS beneficiaries – general patients and concessional patients. General patients hold a Medicare card. Concessional patients hold a Medicare card and one of the following cards from Centrelink or the DVA:

- Pensioner Concession Card
- Commonwealth Seniors Health Card
- Health Care Card
- Repatriation Health Card For All Conditions (gold) – concessional patients under RPBS
- Repatriation Health Card For Specific Conditions (white) – only regarded as concessional patients for RPBS prescriptions unless they hold a separate entitlement from Centrelink, otherwise they are general patients
- Repatriation Pharmaceutical Benefits Card (orange) – concessional patients under RPBS
- Safety Net Concession Card or Safety Net Entitlement Card are also issued by Medicare Australia.

The above concessional patients are recognised by public hospitals in all States and Territories apart from South Australia (where DVA beneficiaries are treated as general patients) and New South Wales (where holders of a white DVA card are treated as general patients).

Under the Reciprocal Health Care Agreements (RHCA), visitors from participating countries (see the introduction of this section for the list of countries) are treated as general patients – they do not have concessional entitlements. To receive pharmaceutical benefits, these visitors may need to present a temporary Medicare card or their passport. Pharmacists should contact Medicare Australia if they have queries about these arrangements.

## Establishing entitlement

PBS prescription forms supplied by Medicare Australia have spaces provided for details of a patient's entitlement status. Anyone can enter this information, which must include:

- a cross (x) in the appropriate box to indicate the level of patient contribution; and
- the complete Medicare number (including individual reference number) or complete Veteran file number on the card; and
- if applicable, the complete concession number on the card.

The person who signs the receipt for pharmaceutical benefits also accepts responsibility for the validity of the entitlement information on the PBS prescription.

All PBS prescriptions must have a Medicare or Veteran file number. All concessional PBS prescriptions must have a concession number. However, it is not necessary for the Medicare (Veteran file) or the concession number to be endorsed on the PBS prescription if it is included in the electronic prescription details supplied by a pharmacist who is using the Claims Transmission System.

## What to charge

### ***Patient contribution***

Under the PBS, the maximum cost for a pharmaceutical benefit item at a pharmacy is \$31.30 for general patients and \$5.00 for concessional patients (except where a special patient contribution, a brand premium, or a therapeutic group premium applies). General patients who have reached the safety net threshold (see details under '5. The Safety Net Scheme') receive pharmaceutical benefit items at the concessional rate of \$5.00.

Patients who have a Safety Net Entitlement Card (see details under '5. The Safety Net Scheme') receive PBS items for free, except when a special patient contribution, brand premium, or therapeutic group premium applies.



The contribution rate for general patients as outpatients at public hospitals throughout Australia is \$25.00. The exception is Queensland and hospitals participating in the pharmaceutical reforms where they pay the safety net value of an item when it is listed in the Schedule (see details under '5. The Safety Net Scheme'), or up to \$31.30 for items not listed in the Schedule. The public hospital pharmaceutical reforms enable participating public hospitals to prescribe and supply pharmaceutical medication from the Pharmaceutical Benefits Scheme to outpatients and patients upon discharge. A range of chemotherapy drugs will also be available for day-admitted and non-admitted chemotherapy patients.

The contribution rate for concessional patients in all public hospitals is \$5.00.

The supply of a pharmaceutical benefit or a Repatriation pharmaceutical benefit to a patient is a GST-free supply. Goods and services tax must not be included in the price charged to a patient for the supply of a benefit under the PBS or RPBS.

It is the patient's responsibility to meet any charge lawfully demanded by an approved pharmacist, otherwise supply may be refused.

The patient contribution rates are usually adjusted on 1 January each year in line with inflation.

### ***Patient contributions for early supply of some PBS medicines***

Prescriptions for some pharmaceutical benefits are not eligible for Safety Net benefits if resupplied within 20 days of a previous supply of the same pharmaceutical benefit for the same person under the PBS or the RPBS. This is known as the 'Safety Net 20 day rule' which came into effect on 1 January 2006.

Where a prescription is subject to the Safety Net 20 day rule, exclusion from Safety Net benefits has the following effects:

- the patient contribution does not count towards the Safety Net
- after the Safety Net threshold is reached, the usual patient payment amount for the corresponding entitlement level (not the Safety Net amount) applies.

For example: The payment for such a prescription for a patient with a Safety Net Entitlement Card would be \$5.00 – not free. For a general patient with a Safety Net Concession Card, the usual general patient amount (up to \$31.30) would apply – not the Safety Net concessional amount of \$5.00.

The Safety Net 20 day rule does not apply to PBS/RPBS prescriptions originating from hospitals or day hospital facilities.

### ***Special patient contributions, brand premiums and therapeutic group premiums***

A special patient contribution is payable for a pharmaceutical benefit when there is a disagreement between the manufacturer and the Government over the price for that pharmaceutical benefit. The extra charge for a higher priced product is paid by the patient, together with their usual patient contribution. Other than for bleomycin sulfate, exemptions on medical grounds are available. For RPBS special patient contribution arrangements see the RPBS Explanatory Notes.

Under the brand premium arrangements, Commonwealth reimbursement to pharmacists is based on the lowest-priced brand. Patients pay the difference for higher-priced brands, on top of their usual patient contribution.

Under the therapeutic group premium arrangements, Commonwealth reimbursement to pharmacists is based on the lowest priced benefit items within identified therapeutic groups. Patients pay the difference for higher priced items. Exemptions on medical grounds are available, but must be granted by Medicare Australia.

The Schedule's special patient contributions, brand premiums and therapeutic group premiums apply to maximum quantities. When a quantity is less than, or – on an authority or regulation 24 PBS prescription - more than, the maximum, the contributions or premiums will be a fraction or multiple of the maximum quantity, using standard pricing rules.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical services within a participating public hospital may prescribe the subsidised medication. The States of Victoria, Queensland and Western Australia and the Northern Territory have agreed to implement these arrangements.

### ***Solvents***

Where a solvent is prescribed as a part of a pharmaceutical benefit, only one patient contribution is charged.

### ***Increased quantities***

Where a prescriber has written an authority PBS prescription for a quantity greater than the maximum, the relevant patient contribution should be made for each supply of the increased maximum quantity.

### ***Regulation 24***

For 'Regulation 24' PBS prescriptions, a pharmacist should charge the usual patient contribution for the original and for each repeat quantity needed to make up the total supply (plus any special patient contribution, brand premium or therapeutic group premium, for the original and each repeat quantity in the total supply, if applicable).

### ***After hours***

A pharmacist may charge an extra fee if he/she supplies a PBS item outside his/her pharmacy's normal trading hours. The charge is paid by the patient and does not count towards the safety net.

### ***Delivery***

A charge can be added for delivering pharmaceutical benefits from the pharmacy. This charge does not count towards the safety net. For RPBS delivery arrangements refer to the RPBS Explanatory Notes.

## **5. The Safety Net Scheme**

The Safety Net Scheme is designed to protect those patients and their families who require a large number of PBS and RPBS items, and applies to each calendar year.

For the purposes of the scheme, the family includes:

- the spouse or de facto spouse;
- family members under the age of 16 who are in the care and control of the patient; or
- dependent full-time students under the age of 25.

The scheme requires pharmacists, on request by patients, to record the supply of PBS and RPBS items on Prescription Record Forms (PRF's). When patients reach a certain spending level (or Safety Net threshold) within a calendar year, they qualify to receive PBS or RPBS items at a cheaper price or free of charge for the rest of that year. The reductions do not apply to special patient contributions, brand premiums or therapeutic group premiums – these charges must still be met by patients.

The Safety Net threshold may be reached by accumulating eligible patient contributions for PBS prescriptions supplied through community pharmacies and hospitals, or out-patient medications supplied by public hospitals, or a combination of both.

Pharmaceutical benefit items (including authority items) can only be counted towards the safety net threshold when prescribed and supplied according to the Schedule's conditions. A medicine supplied by a pharmacist who is not approved to supply pharmaceutical benefits cannot count towards the Safety Net.

Prescriptions for some pharmaceutical benefits are not eligible for Safety Net benefits if resupplied within 20 days of a previous supply of the same pharmaceutical benefit for the same person under the PBS or RPBS. For such prescriptions, the patient contribution cannot count towards the Safety Net (see also details under '4. Patient Charges' and '7. How Pharmacists Claim Reimbursement'). This does not apply to out-patient medications in public hospitals or to any prescriptions originating from a hospital or day hospital facility.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical services within a participating public hospital may prescribe the subsidised medication. The States of Victoria, Queensland and Western Australia and the Northern Territory have agreed to implement these arrangements.

## **Safety net thresholds**

There are two safety net thresholds – one for general patients and the other for concessional patients.

The general patient safety net threshold is currently \$1141.80. When patients and/or their families reach this amount, they can apply for a Safety Net Concession Card and pay only \$5.00 per PBS prescription for the rest of the calendar year.

The concessional safety net threshold is \$290.00 (this also applies to gold, white or orange card holders under the RPBS). Once patients and/or their families reach this amount, they can apply for a Safety Net Entitlement Card and receive items free of charge for the rest of the calendar year.

Brand premiums, therapeutic group premiums and special patient contributions do not count towards the safety net thresholds.

The safety net thresholds are adjusted on 1 January each year in line with inflation. In addition, thresholds increase by an amount equivalent to two co-payments on 1 January of each year from 2006 to 2009.

## ***Safety net cross-over arrangements***

Some patients and/or members of their families will change between general patient and concessional patient categories during the calendar year. Patients should apply for the safety net card appropriate to their status at the time they apply.

Concessional patients who were previously general patients can apply for a Safety Net Entitlement Card once they reach the threshold of \$290.00. In this case, any pharmaceutical benefits previously supplied at the general rate in that calendar year will need to be converted to the rate of \$5.00 per item.

General patients who were previously concessional patients can apply for a Safety Net Concession Card when they reach the general threshold of \$1141.80. In this case, any pharmaceutical benefits previously supplied at the concessional rate in that calendar year will be counted at the rate of \$5.00 per item.

In the case of families where one parent holds a concession card and other family members are general patients, the family can choose to apply for either a Safety Net Entitlement Card or a Safety Net Concession Card.

To receive a Safety Net Entitlement Card, all pharmaceutical benefits (including general PBS prescriptions) are counted at \$5.00 per item until the \$290.00 threshold is reached. To receive a Safety Net Concession Card, general pharmaceutical benefits are counted at the general rate of up to \$31.30 per item and concessional pharmaceutical benefits at \$5.00 per item, until the threshold of \$1141.80 is reached.

White DVA card holders can either be general or concessional patients (depending on their Centrelink entitlements). If they are being treated for a specific disability accepted by the DVA, they are also supplied with specific items under the RPBS at the concessional rate of \$5.00 per item. Therefore, these patients are encouraged to maintain a concessional PRF, plus a general PRF for those items not covered under the RPBS.

White card holders may choose at any time during the year to count contributions made at the general level towards the concessional safety net threshold. The patient receives a credit of \$5.00 for each PBS prescription item purchased. Alternatively, he/she can count contributions at the concessional level towards the general safety net, and receive a credit of \$5.00 for each RPBS prescription item purchased.

Those with gold or orange cards receive all of their prescription items under the RPBS, and only pay \$5.00 for each item.

Dependants of white, gold or orange card holders are treated separately and may be either general patients or concessional patients. Their prescriptions may be included in the cross-over arrangements.

## Recording PBS prescriptions

There are two types of PRF's to record PBS prescription items. One (a blue form) is used by general and concessional patients and veterans who pay for items at community pharmacies. It is available from community pharmacies, Medicare offices and Medicare Australia in each State. The other form (grey) is used by out-patients who pay for items at public hospital pharmacies, and is available through hospital out-patient departments or Medicare Australia State offices.

Patients should record their status (general or concessional) in the appropriate box on the front of the PRF, state their Centrelink, DVA and/or Safety Net Concession/Entitlement Card number, and list family members covered. General patients must also record their Medicare number when applying for a Safety Net Concession Card.

Details to be entered on the form by the pharmacist are:

- date of supply;
- PBS/RPBS code number of the item (for community pharmacies only);
- the safety net value of the item (for community pharmacies only);
- pharmacist's approval number (for community pharmacies only);
- item identification – medicine code, name of medicine or abbreviation (for public hospitals only);
- hospital charge (for public hospitals only);
- hospital safety net number (for public hospitals only); and
- signature of the authorised person making the entry.

Community pharmacists should record in the 'safety net value' column:

- the patient contribution when it is less than the PBS dispensed price; or
- the safety net value shown in this Schedule, or any lesser amount charged, if the PBS dispensed price is less than or equal to the patient contribution. The pharmacist may discount the price for these items.

Some computer software suppliers provide a special label to record this information on the PRF. Some suppliers also provide a computer printout option that is an acceptable replacement for the PRF.

The patient is responsible for maintenance and storage of the PRF. However, it may be kept in the pharmacy. An individual (or family) may have more than one PRF.

### **Hospital PRF's**

Items to be recorded on a hospital PRF must be approved by the hospital's pharmaceutical advisory committee. They can be listed on a hospital's formulary (a list of pharmaceutical items approved by the committee for the treatment of particular illnesses), or authorised on a patient-by-patient basis.

### **Multi-item forms**

If a patient submits a multi-item PBS prescription form, which would take the PRF past the safety net expenditure limit, any items in excess are to be treated as entitled items once the Safety Net Entitlement/Concession Card is issued.

These excess items should be treated as 'deferred supply' items.

For example, if a family has \$1110.00 recorded on their PRF and they have a new PBS prescription for three items, the first item should be supplied at the general rate. If the second item would take the family over the threshold of \$1141.80, the pharmacist should then issue a Safety Net Concession Card and supply the other two items at the concessional rate. This involves the deferral of two items, entry of the Safety Net Concession Card number into the computer, and the subsequent supply of these items.

### **Qualifying PBS prescriptions**

A PBS prescription should be supplied at either the concessional rate or free of charge, as appropriate, when the safety net value or hospital charge for that PBS prescription takes the PRF over the qualifying amount for a Safety Net Entitlement/Concession Card.

### **Lost PRF's**

If a PRF has been lost, stolen or destroyed, a pharmacist may prepare a duplicate copy, but is under no obligation to do so.

### **Retrospective entitlement and patient refunds**

Responsibility for claiming entitlements rests with the patient. If items accumulated on a PRF have already exceeded the safety net limit, then the cost to the patient of those items in excess of the limit cannot be refunded by a pharmacist.

However, a patient may get a refund in the following circumstances:

- The patient failed to apply for his/her Safety Net Entitlement/Concession Card on reaching the safety net threshold —
  - The patient should write to Medicare Australia and provide copies of pharmacy accounts or a signed statement from the pharmacist giving the date of supply, description and cost of items supplied and paid for. A copy of the relevant PRF's should also be provided. If they are not available, the patient should give the name of the pharmacy where the card was issued and the number on the card, so Medicare Australia can locate the PRF's through its records. Cash refunds are not available in these circumstances cheques are issued. Patients can write to the Medicare Australia office in their State. Contact details are provided in the front of the Schedule.
- The patient cannot satisfy a pharmacist that he/she has a current entitlement and is charged the general patient price —
  - The pharmacist should issue the patient with a receipt and a claim form (provided to the pharmacist by Medicare Australia). The patient can then get a refund from Medicare Australia via Medicare offices or PBS processing centres. RPBS prescription refunds are paid at DVA State offices.

Medicare Australia can only pay refunds for PBS items supplied through approved pharmacies. Refunds for hospital supplied items should be referred to the relevant State/Territory hospital or health department. Refunds cannot be made where the patient was charged the general or concessional amount instead of the Safety Net concessional or Safety Net entitlement amount, respectively, as a result of the Safety Net 20 day rule. Receipts for prescriptions where the Safety Net 20 day rule has applied must include 'SN20DR' to indicate the reason for the amount charged.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a medical practitioner providing medical services within a participating public hospital may prescribe the subsidised medication. The States of Victoria, Queensland and Western Australia and the Northern Territory have agreed to implement these arrangements.

### **Applying for a Safety Net Entitlement/Concession Card**

Once the safety net threshold has been reached, any adult patient covered by the PRF can complete the application and declaration on the back of the form or the computer-generated application to get a Safety Net Entitlement/Concession Card. Please note that software packages that produce computer generated applications must be approved by Medicare Australia.

If the card is issued to a dependent child or student, it should be in the name of a parent.

When issuing entitlement/concession cards, pharmacists do not have to check all PRF details. However, they should ensure each entry has been signed and that the PRF total qualifies the patient for the relevant safety net card.

In the case of a concession card, pharmacists should check that the patient's Medicare card number is on the PRF.

### **Issuing a Safety Net Entitlement/Concession Card**

When satisfied that the individual or family is entitled, the pharmacist should issue the next blank Safety Net Entitlement/Concession Card with the following details:

- the names of family members covered. If there are more than eight family members, a second card should be issued listing the card holder and family members not listed on the first card. The PRF has space to record that two cards have been issued;
- the two-character code to indicate the relationship to the card holder. Applicable codes are:
  - SP spouse;
  - DC child under 16 years; and
  - DS dependent full-time student under 25 years.

The pharmacist should be satisfied that only family members are listed on the card. The unused space on the card should be ruled through to prevent extra names being added. The sticky label from the Safety Net Entitlement/Concession Card, pre-printed with the card number, should be attached to the PRF. The pharmacist should sign and stamp each PRF with the pharmacy's stamp. He/she must then enter the card issue details on a Safety Net – Claim for Payment Form.

### **Issuing supplementary cards**

A pharmacist can give a card holder a supplementary card for a spouse or dependant only at the time the original card is issued. The duplicate card should be recorded in the additional box on the PRF.

Requests for supplementary cards at a later stage should be referred to Medicare Australia State offices, as should requests to add a new family member to the original card (e.g., a new baby or adopted child).

### **Notification to Medicare Australia and claim for payment**

Payment for issuing a Safety Net Entitlement/Concession Card is made after the Safety Net - Claim for Payment Form is sent to Medicare Australia's State office, no later than one month after a card is issued.

Each form must be accompanied by all supporting documentation (PRF's and cancelled or void Safety Net Entitlement/Concession Cards).

Payment will not be made for void cards.

### **Lost Safety Net Entitlement/Concession Cards**

When a card has been lost, damaged, stolen or destroyed, a pharmacist cannot re-issue a patient with a replacement card. The original card holder (or spouse) must apply to Medicare Australia's office in his/her State.

### **Pharmacy record of issued cards**

A record of all cards issued must be kept at the pharmacy from which the pharmacist is approved to supply pharmaceutical benefits. The duplicate ('bookfast') copy in the Safety Net – Claim for Payment book is provided for this purpose.

## **6. Medicare Australia Entitlement Checks**

### ***General Patients***

Medicare Australia validates a patient's entitlement to pharmaceutical benefits by checking Medicare and/or Veteran file numbers in pharmacist's claims. If a number is not recorded correctly, a patient cannot be identified against Medicare Australia's Pharmaceutical Benefits Entitlement File and entitlement cannot be established.

If the Medicare or Veteran file number provided in the pharmacists' claims is incorrect or the number and the name supplied do not match Medicare Australia records to enable patient identification, an appropriate warning or rejection code will be returned to the pharmacy. These notifications of missing or incorrect Medicare or Veteran file numbers are provided to pharmacists in their reconciliation statement produced after the claim period has been paid by Medicare Australia.

Special numbers are available for use in certain circumstances for eligible people who are unable to provide a Medicare number.

### ***Concessional Patients***

Medicare Australia routinely validates a patient's entitlement to free or concessional benefits by checking concessional numbers in pharmacists' claims. If a number is not recorded correctly, a patient cannot be identified against Medicare Australia's Pharmaceutical Benefits Entitlement File and entitlement cannot be established.

When a number is found to be from a card which was incorrect, expired at the time of supply or entitlement was withdrawn, warning or rejection codes will be returned to the pharmacy to assist with validation of concessional entitlement in relation to future claims from the same patient.

## **Entitlement checking procedures**

### ***General Patients***

Once a pharmacist has been notified by Medicare Australia of an incorrect Medicare or Veteran file number he/she should correct the number for future claims by:

- updating his/her system to reflect the correct number provided by Medicare Australia (if patient consent to do so has been obtained); or
- speaking to the patient; or
- obtaining patient consent and calling Medicare Australia on the Improved Monitoring of Entitlements (IME) hotline (1300 302 122).

If the patient presents a Medicare card that appears correct, but according to Medicare Australia is not a valid number, or not a valid number for that person, a pharmacist may use a special number. A photocopy of the card, or a form must accompany the use of this number. The form is available on Medicare Australia's website or by calling 132 290.

### ***Concessional Patients***

Once a pharmacist has been notified by Medicare Australia of an incorrect concessional entitlement number, he/she should view the entitlement card to confirm the entitlement number, and start and end dates, when the patient next presents a PBS prescription.

### ***Step by step***

Pharmacists should take the following steps where concession entitlement does not appear to be valid or current:

- Re-confirm entitlement with the cardholder/customer;
- Contact Medicare Australia on 132 290, with consent, to confirm the cardholder/customer concession status;
- If Medicare Australia advises that the cardholder/customer is concessionally entitled to receive the PBS medicines on that day, supply the prescription as a concessional entitlement;
- If Medicare Australia advises that the cardholder/customer is not concessionally entitled to receive the PBS medicines on that day, supply as a general prescription. Provide the customer with the information sheet "Your entitlement card" which explains entitlement checking to the customer and the steps they can follow if they are concessionally entitled.

## **7. How Pharmacists Claim Reimbursement: Information Required**

Medicare Australia uses a computerised system for pricing PBS prescriptions, repeat authorisations and emergency drug (doctor's bag) orders, and for calculating claims.

The payment system is designed to pay pharmacists correctly for the pharmaceutical benefits they supply. It is essential instructions are followed carefully and that each document includes all relevant information. Accurate and complete data ensures claim payment is not delayed.

### **PBS Prescription identification**

Pharmacists must include certain information on each PBS prescription sent in for claim, as specified below. It is important that this information is entered correctly and in the right place on the PBS prescription. This information will be included in a sticker produced by pharmacy software.

The sticker should be placed on the extreme left front of a PBS prescription, opposite each item being claimed. It must not obscure any details written by the prescriber. Most prescribers use PBS prescriptions, which have space for the sticker. If a sticker is not used, a PBS prescription identification stamp can be used or the information can be written in the same place, and in the same order.

Pharmacists should avoid writing over, or placing the sticker over, the prescriber number pre-printed on PBS/RPBS prescriptions, or the prescriber number box on PBS dental and optometrist prescriptions.



The sticker is not necessary for current repeat authorisation, emergency drug (doctor's bag), or for old style authority PBS prescription and authority to prescribe forms, as they have printed spaces for the necessary details. However, it is required for the new format authority PBS prescription forms.

The following information should be entered next to the appropriate letter on the sticker or stamp:

- 'S' — the serial number for the claim
- 'A' —
  - (a) the price claimed for pricing elected PBS prescriptions, exceptional PBS prescriptions and RPBS non-scheduled prescriptions (see under 'Extemporaneously-prepared pharmaceutical benefits not listed in the Standard Formulae List' for explanations of pricing elected PBS prescriptions and exceptional PBS prescriptions); and/or
  - (b) confirmation that the PBS prescription is endorsed 'Regulation 24' or the RPBS prescription is endorsed 'hardship conditions apply'; and/or
  - (c) a claim for a glass dropper bottle where applicable; and/or
  - (d) any clarification of the prescription which will assist Medicare Australia payment processing.
- 'No.' — the PBS prescription identifying number.

## Serial numbers

PBS prescription, repeat authorisation, authority PBS prescription, and emergency drug (doctor's bag) forms submitted in each claim must bear consecutive serial numbers starting with:

- 1 – for emergency drug (doctor's bag) supplies;
- 1 – for general benefits;
- C1 – for concessional and Safety Net Concession Card benefits;
- E1 – for Safety Net Entitlement Card benefits; and
- R1 – for RPBS benefits.

Each serial number should also be noted on any document kept by the pharmacist for record purposes.

Each emergency drug (doctor's bag) item should be given a serial number, e.g., if there are five items on the first form in the claim, the first item on the second form in the claim will start with the serial number 6.

For prescriptions subject to the Safety Net 20 day rule, the serial number corresponds to the resulting payment category for the pharmaceutical benefit as supplied, not the patient's entitlement category.

### ***Repeat authorisations for authority PBS prescriptions***

When a benefit is supplied on a repeat authorisation which needed an authority PBS prescription, the serial number must be prefixed with the letter 'A' for a general benefit; 'AC' for a concessional benefit or a benefit supplied to a Safety Net Concession Card holder; 'AE' for a Safety Net Entitlement Card holder; or 'AR' for a RPBS benefit.

### ***Repeat authorisations for deferred supply***

When a benefit is supplied on a repeat authorisation prepared for deferred supply, the serial number must be prefixed with the letter 'D' for a general benefit; 'DC' for a concessional benefit or a benefit supplied to a Safety Net Concession Card holder; 'DE' for a Safety Net Entitlement Card holder; or 'DR' for a RPBS benefit.

***Injectable item ordered with a solvent***

When both an injectable item and a solvent are to be supplied, only one serial number is used. This number should be placed on the left hand side of the prescription, opposite the injectable item.

**Dropper containers**

Dispensed prices for extemporaneously-prepared eye drops, ear drops and nasal instillations include the price of a polythene dropper container. However, if a glass dropper container is supplied, payment should be claimed by writing 'glass bottle' in box 'A' of the stamp.

**Extemporaneously-prepared pharmaceutical benefits not listed in the Standard Formulae List**

When a formula is not listed on the Standard Formulae List, the PBS prescription is paid at an average of 10 g/mL rate for the type of preparation, unless the pharmacist elects otherwise. A pharmacist may price an exceptional PBS prescription, or elect to price all non-pre-priced extemporaneous PBS prescriptions.

***PBS prescriptions paid on an average price basis***

If the PBS prescription is to be claimed as an exceptional PBS prescription, the pharmacist should write details of the formula supplied on the PBS prescription or repeat authorisation form; price the PBS prescription in accordance with the pricing principles (as detailed in '9. Pricing PBS Prescriptions'); and enter the calculated price on the sticker.

An exceptional PBS prescription is for an extemporaneously-prepared pharmaceutical benefit that is not included in the Standard Formulae List and for which the price of the ingredients (based on basic pricing rules) is twice or more than the recovery price of the ingredients calculated on an average price basis. Further information on pricing PBS prescriptions can be accessed from the booklet titled *Explanation of Current Pricing* on the Medicare Australia's website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au) (PBS publications for Health Care Providers).

***Pricing non-pre-priced extemporaneous preparations***

Pharmacists should notify Medicare Australia when they elect to price non-pre-priced extemporaneous preparations. Each PBS prescription should be priced in accordance with the pricing principles and that price entered on the sticker.

**RPBS prescriptions for items not included in either the PBS or RPBS Schedule**

When a prescription for a RPBS patient is for an item not included in either the PBS or the RPBS Schedule, the price claimed should be entered on the sticker. Full details on pricing and availability of such items under the RPBS are set out in the RPBS Explanatory Notes.

**Payment to Pharmacists for Dispensing Premium-free Substitutable Medicines**

Premium Free Dispensing Incentive payments will commence for eligible PBS listed products dispensed from 1 August 2008. Premium Free Dispensing Incentive payments will be available to approved suppliers to dispense a substitutable, premium-free medicine. The payment will be available only for PBS items which attract a Government subsidy. This includes PBS items supplied to DVA entitled consumers.

A number of conditions and criteria apply to receive this payment. Scripts will be assessed for validity and the Premium Free Dispensing Incentive payment will be paid by Medicare Australia. Further information on this payment can be found on the Medicare Australia website at: <http://www.medicareaustralia.gov.au/provider/pbs/pharmacists/reforms.shtml#dispensing>

**8. How Pharmacists Claim Reimbursement: Documents to be Submitted**

A claim for pharmaceutical benefits consists of:

- the original and duplicate of a completed Claim for Payment Form;
- the original orders for emergency drug (doctor's bag) supplies in a separate bundle;
- the originals of all old format PBS prescriptions and authority PBS prescriptions, the Medicare Australia/DVA copies of new format PBS prescriptions and authority PBS prescriptions, and all repeat authorisations, separated into four bundles for benefits supplied to the general public; concessional beneficiaries/Safety Net Concession Card holders; Safety Net Entitlement Card holders and RPBS patients.

PBS prescriptions in each bundle should be in serial number order, with serial number 1 at the top of the bundle.

PBS prescriptions subject to the Safety Net 20 day rule are bundled according to the resulting payment category. For prescription forms with multiple PBS items, where the Safety Net 20 day rule would result in different payment categories for different items, dispensing via 'deferred supply' should be used where necessary to allow all items to be included in the correct bundles.

PBS prescriptions in the wrong bundle may be returned to the pharmacist for clarification. If appropriate, they can be resubmitted in the correct bundle in the next claim period.

### **Completing the claim form**

The claimant's name, address of the pharmacy from which the pharmacist is approved to supply pharmaceutical benefits, approval number, and claim period number should be entered on the Claim for Payment Form. These details should match the latest written information held by Medicare Australia, or payments can be delayed while clarification is sought.

The claim period number should state how many claims have been submitted so far in a calendar year, e.g., the sixth claim submitted by an approved pharmacist in 2005 should have a claim period number of 0506.

The first and last serial numbers given to items in each bundle are to be entered on the Claim for Payment Form.

A total claim amount is not required – this will be calculated by Medicare Australia after the PBS prescriptions have been individually priced.

The declaration must be signed by the pharmacist approved to supply pharmaceutical benefits, unless he/she has made arrangements through Medicare Australia for another pharmacist to sign it.

### **Lodging claims**

A claim may be lodged at any time during the month at the relevant Medicare Australia State office. Unless other arrangements have been made with Medicare Australia, the following conditions apply:

- only one claim period can exist and only one claim can be lodged per month;
- the claim period shall cover pharmaceutical benefits supplied during one month; and
- the claim shall be sent within 30 days from when the benefits were supplied.

Claims for pharmaceutical benefits supplied over 18 months earlier may not be accepted for computer processing. Pharmacists with such claims should contact Medicare Australia.

### **Reconciliation statements**

As mentioned earlier, a pharmacist will receive a PBS reconciliation statement after a claim period has been processed. It provides details of each prescription for each brand of each pharmaceutical benefit item supplied in that claim period.

Reasons for non-payment of any item are coded, with the code numbers explained in the statement.

PBS prescriptions and repeat authorisations not accepted for payment will be returned, with the exception of PBS prescriptions with a dispensed price equal to or less than the patient contribution. Any other items on those PBS prescriptions that have been paid will have been cancelled.

If a PBS prescription was not accepted and can be re-submitted, it must be given a new serial number and included in a subsequent claim period.

If a PBS prescription is finally rejected for payment and a pharmacist is not satisfied with the decision, he/she may apply to the Administrative Appeals Tribunal for a review of that decision.

## 9. Pricing PBS Prescriptions

### Pricing principles

The same pricing principles apply to all PBS prescriptions.

For ready-prepared pharmaceutical benefits, payment is made on the basis of the lowest-priced brand.

For a pharmaceutical benefit not listed as a ready-prepared item, and where a formulation title is stated but no formulary specified, payment is made on the basis of precedence given to formularies by State/Territory legislation.

Prices published in the Schedule do not include any component for goods and services tax (GST).

Further information on pricing PBS prescriptions can be accessed from the booklet titled *Explanation of Current Pricing* on the Medicare Australia's website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au) (PBS publications for Health Care Providers).

### Pricing dates

Ready-prepared pharmaceutical benefits are priced on the first day of April, August and December for items supplied as from each of those days respectively.

Extemporaneously-prepared pharmaceutical benefits and containers are priced on the first day of May each year for items supplied as from the first day of August that year.

### Pricing ready-prepared items

#### *For maximum quantities*

The price payable for a pharmaceutical benefit is shown in the Schedule against the item. The price is for the maximum quantity available.

If the prescription is for an injectable item and solvent, the price of each is added together, but only one dispensing fee is payable.

The maximum quantity of some pharmaceutical benefits, such as eye drops and oral suspensions, has been determined as a single pack corresponding to the manufacturer's pack. These packs cannot be broken, so if a PBS prescription calls for less, the maximum quantity should be supplied and claimed from Medicare Australia. Packs not to be broken are indicated by a double dagger (‡) in the Schedule.

#### *For lesser quantities*

For items where the standard pack is the same as the maximum quantity, and the pack can be broken, the price payable for a lesser quantity is established as follows:

- an amount equal to the dispensing fee, and if applicable the dangerous drug fee, is deducted from the benefit price as shown in the Schedule;
- to this new amount, a wastage percentage is applied, determined from the Wastage Factor Table;
- then the amount equal to the dispensing fee, dangerous drug fee (if applicable), and appropriate container fee, is added.

In no case shall the price for a broken quantity be more than the dispensed price of the Schedule's maximum quantity.

When a standard pack is not the same as the maximum quantity, the price of the pharmaceutical benefit concerned has an asterisk next to it and the standard pack rate is set out in Section 3 of the Schedule. The price payable for the quantity supplied is established by:

- applying the appropriate wastage table percentage to the standard pack rate;
- then adding an amount equivalent to the dispensing fee, the dangerous drug fee where applicable, and the appropriate container fee.

In no case shall the supply of a broken quantity, which is less than the item's maximum quantity, cost more than the dispensed price for the maximum quantity.

No container fee is payable when the quantity of pharmaceutical benefit supplied is more than the quantity contained in the standard pack.

### ***Wastage table percentage***

The following Wastage Factor Table is used to calculate the price payable for quantities supplied from the standard pack.

### **Wastage Factor Table**

|            |                                                                                 |
|------------|---------------------------------------------------------------------------------|
| Column A - | 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100  |
| Column B - | 10, 18, 26, 32, 38, 44, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, 94, 98, 100 |

The appropriate wastage table percentage is as follows:

- the percentage of the amount supplied from the amount in the standard pack is determined; and
- where this percentage is the same as a percentage listed in Column A of the table, the percentage used is the figure shown in Column B; or
- where the percentage is not the same as a percentage in Column A, then the nearest upward percentage in Column A applies, and the percentage used is the figure in Column B.

For example, 24 tablets are supplied from a standard pack of 100. Thus 24 per cent of the number contained in the standard pack is supplied. As this percentage does not appear in Column A, the next higher (i.e., 25 per cent) is used. Reading down from 25 per cent to Column B, the wastage table percentage is found to be 38 per cent.

### **Pricing extemporaneously-prepared items**

#### ***General***

The price payable for supplying the maximum quantity of standard formula preparations is shown in the Standard Formulae List.

The following principles apply in determining prices of all pre-priced extemporaneous formulae on the list.

They also apply when a pharmacist elects to price extemporaneous PBS prescriptions outside the list, including exceptional PBS prescriptions.

The amount payable is the sum of:

- the recovery price of each ingredient as shown in the Drug Tariff;
- the price of the appropriate container as shown in the price section; and
- a dispensing fee as shown in the price section.

### ***Pricing of ingredients***

When the quantity dispensed is not specified in the Drug Tariff, the recovery price is as follows:

1. determine the basic pricing unit relative to the quantity dispensed by referring to the following table:

| <b>Quantity</b>                         | <b>Basic Pricing Unit</b> |
|-----------------------------------------|---------------------------|
| Up to and including 700 mg              | 100 mg price rate         |
| Over 700 mg and up to and including 1 g | price as if 1 g           |
| Over 1 g and up to and including 7 g    | 1 g price rate            |
| Over 7 g and up to and including 10 g   | price as if 10 g          |
| Over 10 g and up to and including 80 g  | 10 g price rate           |
| Over 80 g and up to and including 90 g  | price as if 80 g          |
| Over 90 g                               | 100 g price rate          |

2. find the recovery price of the basic pricing unit by applying the following quantity divisors to the recovery price shown for the ingredient in the Drug Tariff:
  - 100 g price is 500 g price divided by 5, or 1 kg price divided by 10
  - 10 g price is 100 g price plus 12.5 per cent divided by 10
  - 1 g price is 10 g price plus 25 per cent divided by 10
  - 100 mg price is 1 g price plus 25 per cent divided by 10
3. find the recovery price by multiplying the price of the basic pricing unit – as established in 2. – by the fraction that the quantity dispensed bears to the basic pricing unit.

For pricing purposes the quantity is to be taken to the next upward 50 milligrams or 0.05 millilitres.

The minimum recovery price for any ingredient is one cent. In other cases where a fraction of a cent occurs, the price is to be taken to the nearest cent (a half cent being taken up to the next cent).

In no case shall the recovery price for a quantity of an ingredient exceed the recovery price for a greater quantity of that ingredient.

Where liquids are purchased by weight, the recovery price includes the 'Specific Gravity Factor'.

Special pricing provisions apply to drugs marked '(a)' or '(b)' in the Drug Tariff.

For drugs marked '(a)', the pricing rules shown above apply to quantities up to the quantity listed in the Drug Tariff. Greater quantities are priced on a linear basis: the recovery price is ascertained by multiplying the fraction that the quantity dispensed bears to the quantity listed in the Drug Tariff by the price shown for the quantity listed.

Drugs marked '(b)' are packed sterile or are unstable, and all quantities are priced as if whole pack(s) were required. The recovery price is ascertained by multiplying the fraction that the quantity dispensed bears to the quantity listed in the Drug Tariff, taken to the next whole number, by the price shown for the quantity listed.

### ***Pricing PBS prescriptions where extra ingredients are added to a formula***

Where the vehicle is liquid and one or more solid ingredients are added, displacement of the liquid by the solid ingredients is disregarded for pricing purposes.

### ***Containers***

When a quantity is for more than the container sizes listed in this Schedule, payment will be made as if that quantity had been supplied in the minimum number of containers necessary to supply that quantity.

A double size container is allowed for bulk powders.

### ***Special provisions for extemporaneous PBS prescriptions outside the Standard Formulae List***

If a pharmacist elects to price extemporaneous PBS prescriptions outside the Standard Formulae List, there can be no variation for three months. This applies to all extemporaneously-prepared formulae not on the list, and includes both PBS and RPBS prescriptions.

If a pharmacist does not elect to price out these PBS prescriptions, he/she will be paid at an average reimbursement rate.

Under this system, payment is made on the basis of an average 10 g/mL rate applied to the category of preparation concerned, i.e., the price will be determined by multiplying the appropriate 10 g/mL rate by the number of 10 g/mL units supplied and adding container and dispensing fees. For example, an 80 mL mixture would be priced at eight times the average 10 mL rate for mixtures, with container and dispensing fee added.

The average 10 g/mL rate for each type of preparation is calculated monthly. It applies to PBS prescriptions supplied in the following month.

PBS prescriptions ordering a combination of standard formula preparations fall outside the scope of the Standard Formulae List and therefore are subject to this section.

Any variant to a formula included in the list (adding or deleting an ingredient or varying the dose) takes the formula dispensed outside the list.

When an ingredient is added to a standard formula and the recovery price for the standard formula plus additive under the average price system is less than for the standard formula alone, the pharmacist may have the PBS prescription priced as a basic standard formula item.

## **10. Miscellaneous**

### **References**

This Schedule identifies monographs of the British Pharmacopoeia, the British Pharmaceutical Codex, and the Australian Pharmaceutical Formulary and Handbook by the letters BP, BPC and APF respectively. References to all editions of the BPC and to earlier editions of the BP and APF also include the year of publication or the number of the edition.

### **Standards**

Pharmacists can only supply under the PBS medicines which, or whose ingredients, conform to the standards of composition or purity prescribed. These standards are those specified in the *Therapeutic Goods Act 1989*.

## Legislation

Copies of the *National Health Act 1953* and the *National Health (Pharmaceutical Benefits) Regulations 1960* are available from Government AusInfo shops in each capital city. The Act and the Regulations may also be accessed through the Attorney-General's Department website at [www.comlaw.gov.au](http://www.comlaw.gov.au).



## **THERAPEUTIC INDEX**

## THERAPEUTIC INDEX

---

### ALIMENTARY TRACT AND METABOLISM 75

#### STOMATOLOGICAL PREPARATIONS 75

*Stomatological preparations 75*

#### DRUGS FOR ACID RELATED DISORDERS 75

*Antacids 75*

*Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) 76*

#### DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 83

*Belladonna and derivatives, plain 83*

*Propulsives 83*

#### ANTIEMETICS AND ANTINAUSEANTS 84

*Antiemetics and antinauseants 84*

#### BILE AND LIVER THERAPY 87

*Bile therapy 87*

#### LAXATIVES 88

*Laxatives 88*

#### ANTIIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ ANTIINFECTIVE AGENTS 90

*Intestinal antiinfectives 90*

*Electrolytes with carbohydrates 91*

*Antipropulsives 91*

*Intestinal antiinflammatory agents 92*

#### DIGESTIVES, INCL. ENZYMES 94

*Digestives, incl. enzymes 94*

#### DRUGS USED IN DIABETES 95

*Insulins and analogues 95*

*Blood glucose lowering drugs, excl. insulins 97*

#### VITAMINS 104

*Vitamin A and D, incl. combinations of the two 104*

*Vitamin B<sub>1</sub>, plain and in combination with vitamin B<sub>6</sub> and vitamin B<sub>12</sub> 104*

#### MINERAL SUPPLEMENTS 105

*Calcium 105*

*Potassium 105*

#### ANABOLIC AGENTS FOR SYSTEMIC USE 105

*Anabolic steroids 105*

### BLOOD AND BLOOD FORMING ORGANS 106

#### ANTITHROMBOTIC AGENTS 106

*Antithrombotic agents 106*

#### ANTHEMORRHAGICS 111

*Antifibrinolytics 111*

#### ANTIANEMIC PREPARATIONS 111

*Iron preparations 111*

*Vitamin B<sub>12</sub> and folic acid 112*

#### BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS 113

*Blood and related products 113*

*I.V. solutions 113*

### CARDIOVASCULAR SYSTEM 114

#### CARDIAC THERAPY 114

*Cardiac glycosides 114*

*Antiarrhythmics, class I and III 114*

*Cardiac stimulants excl. cardiac glycosides 115*

*Vasodilators used in cardiac diseases 116*

#### ANTIHYPERTENSIVES 118

*Antiadrenergic agents, centrally acting 118*

*Antiadrenergic agents, peripherally acting 118*

*Arteriolar smooth muscle, agents acting on 119*

#### DIURETICS 119

*Low-ceiling diuretics, thiazides 119*

*Low-ceiling diuretics, excl. thiazides 119*

*High-ceiling diuretics 120*

## THERAPEUTIC INDEX

---

- Potassium-sparing agents 121*
- Diuretics and potassium-sparing agents in combination 122*
- PERIPHERAL VASODILATORS 122
  - Peripheral vasodilators 122*
- BETA BLOCKING AGENTS 122
  - Beta blocking agents 122*
- CALCIUM CHANNEL BLOCKERS 126
  - Selective calcium channel blockers with mainly vascular effects 126*
  - Selective calcium channel blockers with direct cardiac effects 128*
- AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 130
  - ACE inhibitors, plain 130*
  - ACE inhibitors, combinations 138*
  - Angiotensin II antagonists, plain 140*
  - Angiotensin II antagonists, combinations 141*
- LIPID MODIFYING AGENTS 142
  - Lipid modifying agents, plain 146*
  - Lipid modifying agents, combinations 153*
- DERMATOLOGICALS 155**
  - ANTIFUNGALS FOR DERMATOLOGICAL USE 155
    - Antifungals for topical use 155*
    - Antifungals for systemic use 156*
  - ANTIPSORIATICS 157
    - Antipsoriatics for topical use 157*
    - Antipsoriatics for systemic use 158*
  - ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE 158
    - Chemotherapeutics for topical use 158*
  - CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 158
    - Corticosteroids, plain 158*
  - ANTI-ACNE PREPARATIONS 161
    - Anti-acne preparations for systemic use 161*
  - OTHER DERMATOLOGICAL PREPARATIONS 161
    - Other dermatological preparations 161*
- GENITO URINARY SYSTEM AND SEX HORMONES 163**
  - OTHER GYNECOLOGICALS 163
    - Contraceptives for topical use 163*
    - Other gynecologicals 163*
  - SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 164
    - Hormonal contraceptives for systemic use 164*
    - Androgens 166*
    - Estrogens 167*
    - Progestogens 169*
    - Progestogens and estrogens in combination 170*
    - Gonadotropins and other ovulation stimulants 172*
    - Antiandrogens 175*
    - Other sex hormones and modulators of the genital system 176*
- UROLOGICALS 177
  - Other urologicals, incl. antispasmodics 177*
- SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS 178**
  - PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES 178
    - Anterior pituitary lobe hormones and analogues 178*
    - Posterior pituitary lobe hormones 178*
    - Hypothalamic hormones 179*
  - CORTICOSTEROIDS FOR SYSTEMIC USE 179
    - Corticosteroids for systemic use, plain 179*
    - Antiadrenal preparations 181*
  - THYROID THERAPY 182
    - Thyroid preparations 182*
    - Antithyroid preparations 182*

## THERAPEUTIC INDEX

---

- PANCREATIC HORMONES 182
  - Glycogenolytic hormones* 182
- CALCIUM HOMEOSTASIS 183
  - Anti-parathyroid agents* 183
- ANTIINFECTIVES FOR SYSTEMIC USE 184**
  - ANTIBACTERIALS FOR SYSTEMIC USE 184
    - Tetracyclines* 184
    - Beta-lactam antibacterials, penicillins* 186
    - Other beta-lactam antibacterials* 192
    - Sulfonamides and trimethoprim* 196
    - Macrolides, lincosamides and streptogramins* 197
    - Aminoglycoside antibacterials* 199
    - Quinolone antibacterials* 199
    - Other antibacterials* 201
  - ANTIMYCOTICS FOR SYSTEMIC USE 203
    - Antimycotics for systemic use* 203
  - ANTIMYCOBACTERIALS 204
    - Drugs for treatment of tuberculosis* 204
    - Drugs for treatment of lepra* 205
  - ANTIVIRALS FOR SYSTEMIC USE 205
    - Direct acting antivirals* 205
  - VACCINES 209
    - Bacterial vaccines* 209
    - Viral vaccines* 210
- ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 211**
  - ANTINEOPLASTIC AGENTS 211
    - Alkylating agents* 211
    - Antimetabolites* 213
    - Plant alkaloids and other natural products* 215
    - Cytotoxic antibiotics and related substances* 218
    - Other antineoplastic agents* 219
  - ENDOCRINE THERAPY 244
    - Hormones and related agents* 244
    - Hormone antagonists and related agents* 246
  - IMMUNOSTIMULANTS 249
    - Immunostimulants* 249
  - IMMUNOSUPPRESSANTS 252
    - Immunosuppressants* 252
- MUSCULO-SKELETAL SYSTEM 338**
  - ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS 338
    - Antiinflammatory and antirheumatic products, non-steroids* 338
    - Specific antirheumatic agents* 343
  - MUSCLE RELAXANTS 344
    - Muscle relaxants, centrally acting agents* 344
    - Muscle relaxants, directly acting agents* 344
  - ANTIGOUT PREPARATIONS 345
    - Antigout preparations* 345
  - DRUGS FOR TREATMENT OF BONE DISEASES 346
    - Drugs affecting bone structure and mineralization* 346
- NERVOUS SYSTEM 354**
  - ANALGESICS 354
    - Opioids* 354
    - Other analgesics and antipyretics* 364
    - Antimigraine preparations* 365
  - ANTIEPILEPTICS 367
    - Antiepileptics* 367
  - ANTI-PARKINSON DRUGS 373
    - Anticholinergic agents* 373

## THERAPEUTIC INDEX

---

- Dopaminergic agents 374*
- PSYCHOLEPTICS 377**
  - Antipsychotics 377*
  - Anxiolytics 382*
  - Hypnotics and sedatives 384*
- PSYCHOANALEPTICS 386**
  - Antidepressants 386*
  - Psychostimulants, agents used for ADHD and nootropics 394*
  - Anti-dementia drugs 397*
- OTHER NERVOUS SYSTEM DRUGS 405**
  - Parasympathomimetics 405*
  - Drugs used in addictive disorders 406*
  - Other nervous system drugs 408*
- ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 409**
  - ANTIPROTOZOALS 409**
    - Agents against amoebiasis and other protozoal diseases 409*
    - Antimalarials 409*
  - ANTHELMINTICS 410**
    - Antinematodal agents 410*
  - ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS 411**
    - Ectoparasiticides, incl. scabicides 411*
- RESPIRATORY SYSTEM 412**
  - DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 412**
    - Adrenergics, inhalants 412*
    - Other drugs for obstructive airway diseases, inhalants 416*
    - Adrenergics for systemic use 419*
    - Other systemic drugs for obstructive airway diseases 420*
  - COUGH AND COLD PREPARATIONS 421**
    - Expectorants, excl. combinations with cough suppressants 421*
    - Cough suppressants, excl. combinations with expectorants 421*
  - ANTIHISTAMINES FOR SYSTEMIC USE 421**
    - Antihistamines for systemic use 421*
- SENSORY ORGANS 422**
  - OPHTHALMOLOGICALS 422**
    - Antiinfectives 422*
    - Antiinflammatory agents 423*
    - Antiglaucoma preparations and miotics 424*
    - Mydriatics and cycloplegics 427*
    - Decongestants and antiallergics 427*
    - Ocular vascular disorder agents 427*
    - Other ophthalmologicals 430*
  - OTOLOGICALS 433**
    - Antiinfectives 433*
    - Corticosteroids and antiinfectives in combination 433*
  - OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS 434**
    - Antiinfectives 434*
- VARIOUS 435**
  - ALLERGENS 435**
    - Allergens 435*
  - ALL OTHER THERAPEUTIC PRODUCTS 435**
    - All other therapeutic products 435*
  - DIAGNOSTIC AGENTS 437**
    - Urine tests 437*
    - Other diagnostic agents 437*
  - GENERAL NUTRIENTS 439**
    - Other nutrients 439*
  - ALL OTHER NON-THERAPEUTIC PRODUCTS 452**
    - All other non-therapeutic products 452*

## THERAPEUTIC INDEX

### PHARMACEUTICAL BENEFITS FOR PALLIATIVE CARE

#### ALIMENTARY TRACT AND METABOLISM 454

STOMATOLOGICAL PREPARATIONS 454

*Stomatological preparations 454*

DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 455

*Belladonna and derivatives, plain 455*

ANTIEMETICS AND ANTINAUSEANTS 455

*Antiemetics and antinauseants 455*

LAXATIVES 456

*Laxatives 456*

#### MUSCULO-SKELETAL SYSTEM 460

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS 460

*Antiinflammatory and antirheumatic products, non-steroids 460*

#### NERVOUS SYSTEM 465

ANALGESICS 465

*Opioids 465*

*Other analgesics and antipyretics 468*

ANTIEPILEPTICS 469

*Antiepileptics 469*

PSYCHOLEPTICS 470

*Anxiolytics 470*

*Hypnotics and sedatives 471*

### PHARMACEUTICAL BENEFITS FOR DENTAL USE

#### ALIMENTARY TRACT AND METABOLISM 473

STOMATOLOGICAL PREPARATIONS 473

*Stomatological preparations 473*

DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 473

*Belladonna and derivatives, plain 473*

*Propulsives 473*

ANTIEMETICS AND ANTINAUSEANTS 474

*Antiemetics and antinauseants 474*

ANTIIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ ANTIINFECTIVE AGENTS 474

*Intestinal antiinfectives 474*

#### BLOOD AND BLOOD FORMING ORGANS 474

BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS 474

*I.V. solutions 474*

#### CARDIOVASCULAR SYSTEM 475

CARDIAC THERAPY 475

*Antiarrhythmics, class I and III 475*

*Cardiac stimulants excl. cardiac glycosides 475*

*Vasodilators used in cardiac diseases 475*

#### DERMATOLOGICALS 475

CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 475

*Corticosteroids, plain 475*

#### SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS 476

CORTICOSTEROIDS FOR SYSTEMIC USE 476

*Corticosteroids for systemic use, plain 476*

PANCREATIC HORMONES 477

*Glycogenolytic hormones 477*

#### ANTIINFECTIVES FOR SYSTEMIC USE 477

ANTIBACTERIALS FOR SYSTEMIC USE 477

*Tetracyclines 477*

*Beta-lactam antibacterials, penicillins 478*

*Other beta-lactam antibacterials 483*

## THERAPEUTIC INDEX

---

*Sulfonamides and trimethoprim 485*  
*Macrolides, lincosamides and streptogramins 486*  
*Other antibacterials 487*

### MUSCULO-SKELETAL SYSTEM 488

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS 488  
*Antiinflammatory and antirheumatic products, non-steroids 488*

### NERVOUS SYSTEM 491

ANALGESICS 491  
*Opioids 491*  
*Other analgesics and antipyretics 496*

#### ANTIEPILEPTICS 497

*Antiepileptics 497*

#### ANTI-PARKINSON DRUGS 498

*Anticholinergic agents 498*

#### PSYCHOLEPTICS 498

*Anxiolytics 498*  
*Hypnotics and sedatives 498*

### RESPIRATORY SYSTEM 499

DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 499  
*Adrenergics for systemic use 499*

### SENSORY ORGANS 499

OPHTHALMOLOGICALS 499  
*Antiinfectives 499*

### VARIOUS 499

ALL OTHER THERAPEUTIC PRODUCTS 499  
*All other therapeutic products 499*  
 ALL OTHER NON-THERAPEUTIC PRODUCTS 499  
*All other non-therapeutic products 499*

## PHARMACEUTICAL BENEFITS FOR OPTOMETRICAL USE

### SENSORY ORGANS 501

OPHTHALMOLOGICALS 501  
*Antiinfectives 501*  
*Antiinflammatory agents 501*  
*Decongestants and antiallergics 502*  
*Other ophthalmologicals 502*





## **Section 2**

**Emergency Drug (Doctor's Bag) Supplies**

**Special Pharmaceutical Benefits**

**General Pharmaceutical Benefits**

**Pharmaceutical Benefits for Palliative Care**

**Pharmaceutical Benefits for Dental Use**

**Pharmaceutical Benefits for Optometrical Use**

**Items Available Under Special Arrangements (s.100)**

## SYMBOLS USED IN THE SCHEDULE

An arrow ( > ) in front of a restriction indicates an additional or amended purpose in this issue.

An asterisk ( \* ) against the dispensed price of a benefit indicates that the manufacturer's pack does not coincide with the maximum quantity.

A double dagger ( ‡ ) in the maximum quantity column indicates an item for which the maximum quantity has been specially determined to correspond to the manufacturer's pack and the manufacturer's standard pack should be prescribed and supplied. For any item where a maximum quantity greater than 1 is marked with a double dagger ( ‡ ), that maximum quantity should be prescribed and supplied.

A gauge sign ( # ) against the dispensed price of a benefit indicates that the product is not preconstituted and that an extemporaneously-prepared dispensing fee is included in the dispensed price and, where appropriate, an amount for purified water.

Where a STATE is indicated after a manufacturer's code, that brand may be available only in the State indicated. NSW-(N); Vic-(V); Qld-(Q); SA-(S); WA-(W); Tas-(T).

## RESTRICTED BENEFITS

All restricted items are printed in ***bold italics***, with separate headings for authority and non-authority items. In each case these items may be prescribed as pharmaceutical benefits only for use for one of the specified indications. Where more than one indication is specified for an Authority required or Restricted pharmaceutical benefit, each indication is separated from the preceding indication by a semi-colon and commences on the next line. In the case of Authority required (STREAMLINED) items, each indication will be prefixed with a four digit streamlined authority code. The drug may be prescribed as a pharmaceutical benefit for a patient who qualifies under any of the specified indications.

A straight line is drawn between entries for different forms and strengths of an item to indicate clearly the different restrictions which apply to these various forms and strengths.

The maximum quantity and/or number of repeats in respect of an item shown in the Schedule may be varied by the Chief Executive Officer of Medicare Australia when approving an Authority Prescription or an Authority to Prescribe. The quantity and number of repeats shown on the authority shall be supplied. (See Explanatory Notes). Payment will be made on the basis of the price shown for that item in the Schedule.

## CODES FOR INJECTABLE ITEMS WITH ALLOWABLE SOLVENTS

The entry in this schedule of those pharmaceutical benefit injectable items which require a solvent includes the codes of the items with the relevant solvents. For each such item the code is for the injectable with 10mL sodium chloride injection 9 mg per mL (0.9%).

## BRAND EQUIVALENCE

'a' located immediately before brand names of a particular strength of an item indicates that the sponsors of these brands have submitted evidence that they have been demonstrated to be bioequivalent or therapeutically equivalent, or that justification for not needing bioequivalence or therapeutic equivalence data has been provided to and accepted by the Therapeutic Goods Administration. It would thus be expected that these brands may be interchanged without differences in clinical effect.

For other brands of an item, i.e., those not indicated as above, it is unknown whether or not they are equivalent. There may be several reasons for this, such as bioequivalence data not being considered necessary when the products were approved for marketing, or that advice or data have not been forthcoming from sponsors. This does not necessarily suggest a lack of safety or efficacy, but in these circumstances caution should be taken if brands are interchanged.

'b' attached to brand names indicates that these brands are also equivalent, but that it is not known if there is equivalence between brands marked 'a' and brands marked 'b'.

## **BRAND PREMIUM POLICY**

The Brand Premium Policy was introduced on 1 December 1990 to increase price competition by allowing pharmaceutical manufacturers to set their own price on multi-branded items listed on the Pharmaceutical Benefits Scheme and to encourage the development of the generic pharmaceutical industry in Australia. The policy does this by increasing prescribers' and patients' consciousness about the price of drugs. In effect, it makes both groups question whether it is necessary for the patient to pay more for the drugs when a cheaper brand is available. The policy also allows companies to establish prices taking into account competition and consumer acceptance.

The policy operates where there is more than one brand of a particular drug available through the Pharmaceutical Benefits Scheme and where the brands are therapeutically interchangeable. Due to this, the policy mainly applies to out of patent drugs.

Basically the policy operates by:

- the Australian Government subsidising a drug to the level of the lowest priced brand (except in those instances where the lowest priced brand has, as part of its price, a therapeutic group premium);
- suppliers of other brands of that drug being able to set a price above the price charged by the supplier(s) of the lowest priced brand(s); and
- the patient paying the brand premium which is the price difference between the lowest price brand and the brand prescribed.

If a prescription is written generically or for the lowest priced brand, and the lowest priced brand is supplied, there is no brand premium payable.

'B' located immediately before an amount in the premium column indicates a brand premium which applies to that particular brand of the item.

If a brand of a drug which is subject to a therapeutic group premium also has a brand premium, there will be two amounts shown on separate lines in the premium column, prefixed by 'T' and 'B' respectively.

If a brand of a drug which is subject to a special patient contribution also has a brand premium, there will be two amounts shown on separate lines in the premium column, prefixed by 'S' and 'B' respectively.

## **THERAPEUTIC GROUP PREMIUM POLICY**

The Therapeutic Group Premium Policy was introduced on 1 February 1998 as an extension of the Brand Premium Policy to encourage greater competition between manufacturers of drugs and to make doctors and patients more aware of the costs of medicines.

The Therapeutic Group Premium policy applies within narrowly defined therapeutic sub-groups where the drugs concerned are of similar safety, efficacy and health outcomes.

Basically the policy operates by:

- the Australian Government subsidising drugs within a defined therapeutic sub-group to the level of the lowest priced drug in the sub-group;
- suppliers of other drugs within that sub-group being able to set prices above the price charged by the supplier(s) of the lowest priced drug; and
- the patient paying the therapeutic group premium which is the price difference between the lowest price drug and the drug prescribed.

'T' located immediately before an amount in the premium column indicates a therapeutic group premium which applies to that particular item.

If a brand of a drug which is subject to a therapeutic group premium also has a brand premium, there will be two amounts shown on separate lines in the premium column, prefixed by 'T' and 'B' respectively.

The success of the Government in controlling prices of products supplied through the Pharmaceutical Benefits Scheme has often been criticised by the pharmaceutical industry. Under both the Brand Premium Policy and the Therapeutic Group Premium Policy, suppliers of multi-branded items and therapeutically similar drugs are able to set their own prices at a level that they think the market will bear. At the same time, the prescriber and the patient can decide whether it is necessary to pay more for a particular brand or drug when a cheaper one is available and is therapeutically interchangeable.

The brand premium or therapeutic group premium does not count toward the patient's safety net.

It should be noted that the brand premium or therapeutic group premium is not a Government charge or revenue. The premium arises from the manufacturer's price and the majority goes to the manufacturer with wholesalers and pharmacists receiving a small percentage.

EMERGENCY DRUG (DOCTOR'S BAG) SUPPLIES

| Code        | Name, Manner of Administration and Form                                                                      | Max.<br>Qty | Dispensed                   | Proprietary Name and<br>Manufacturer |    |
|-------------|--------------------------------------------------------------------------------------------------------------|-------------|-----------------------------|--------------------------------------|----|
|             |                                                                                                              |             | Price for<br>Max. Qty<br>\$ |                                      |    |
| 3451P       | ADRENALINE<br>Injection 1 mg in 1 mL (1 in 1,000)                                                            | 5           | 19.91                       | AP                                   |    |
| 3453R       | ATROPINE SULFATE<br>Injection 600 micrograms in 1 mL                                                         | 10          | 20.11                       | AP                                   |    |
| 3457Y       | BENZTROPINE MESYLATE<br>Injection 2 mg in 2 mL                                                               | 5           | 22.41                       | Cogentin                             | FK |
| 3487M       | BENZYLPENICILLIN<br>Powder for injection 3 g                                                                 | 1           | 11.90                       | BenPen                               | CS |
| 3486L<br>or | BENZYLPENICILLIN<br>Powder for injection 600 mg<br>or                                                        | 10          | * 40.39                     | BenPen                               | CS |
| 3485K       | PROCAINE PENICILLIN<br>Injection 1.5 g                                                                       | 5           | 87.97                       | Cilicaine                            | SI |
| 3455W<br>or | CHLORPROMAZINE HYDROCHLORIDE<br>Injection 50 mg in 2 mL<br>or                                                | 10          | 15.34                       | Largactil                            | SW |
| 3456X       | HALOPERIDOL<br>Injection 5 mg in 1 mL                                                                        | 10          | 21.85                       | Serenace                             | SI |
| 3478C       | CLONAZEPAM<br>Oral liquid 2.5 mg per mL, 10 mL                                                               | ‡ 1         | 10.30                       | Rivotril                             | RO |
| 3472R<br>or | DEXAMETHASONE SODIUM PHOSPHATE<br>Injection equivalent to 4 mg dexamethasone phosphate in 1 mL<br>or         | 5           | 17.65                       | HH                                   |    |
| 3470P<br>or | HYDROCORTISONE SODIUM SUCCINATE<br>Injection equivalent to 100 mg hydrocortisone with 2 mL solvent<br>or     | 2           | * 16.71                     | Solu-Cortef                          | PH |
| 3471Q       | Injection equivalent to 250 mg hydrocortisone with 2 mL solvent                                              | 1           | 15.68                       | Solu-Cortef                          | PH |
| 3458B       | DIAZEPAM<br>Injection 10 mg in 2 mL                                                                          | 5           | 11.86                       | HH                                   |    |
| 3460D       | DIHYDROERGOTAMINE MESYLATE<br>Injection 1 mg in 1 mL                                                         | 5           | 16.63                       | Dihydergot                           | NV |
| 3463G       | DIPHThERIA and TETANUS VACCINE, ADSORBED, DILUTED FOR ADULT<br>USE<br>Injection 0.5 mL in pre-filled syringe | 20          | * 274.59                    | ADT Booster                          | CS |

EMERGENCY DRUG (DOCTOR'S BAG) SUPPLIES

|             |                                                                                                            |             | Dispensed<br>Price for<br>Max. Qty<br>\$ | Proprietary Name and<br>Manufacturer          |          |
|-------------|------------------------------------------------------------------------------------------------------------|-------------|------------------------------------------|-----------------------------------------------|----------|
| Code        | Name, Manner of Administration and Form                                                                    | Max.<br>Qty |                                          |                                               |          |
| 3466K       | FRUSEMIDE<br>Injection 20 mg in 2 mL                                                                       | 5           | 10.05                                    | <sup>a</sup> Frusehexal<br><sup>a</sup> Lasix | HX<br>SW |
| 3467L       | GLUCAGON HYDROCHLORIDE<br>Injection set containing 1 mg (1 i.u.) and 1 mL solvent in<br>disposable syringe | 1           | 42.93                                    | GlucaGen Hypokit                              | NO       |
| 3475X       | GLYCERYL TRINITRATE<br>Sublingual spray (pump pack) 400 micrograms per dose (200<br>doses)                 | ‡ 1         | 19.70                                    | Nitrolingual<br>Pumpspray                     | SW       |
| 3473T       | HYOSCINE BUTYLBROMIDE<br>Injection 20 mg in 1 mL                                                           | 5           | 20.95                                    | Buscopan                                      | BY       |
| 3474W       | LIGNOCAINE HYDROCHLORIDE<br>Injection 100 mg in 5 mL                                                       | 5           | 36.90                                    | PF                                            |          |
| 3476Y<br>or | METOCLOPRAMIDE HYDROCHLORIDE<br>Injection 10 mg in 2 mL<br>or                                              | 10          | 12.56                                    | Maxolon                                       | VT       |
| 3477B       | PROCHLORPERAZINE<br>Injection containing prochlorperazine mesylate 12.5 mg in 1 mL                         | 10          | 15.51                                    | Stemetil                                      | SW       |
| 3479D<br>or | MORPHINE SULFATE<br>Injection 15 mg in 1 mL<br>or                                                          | 5           | 13.89                                    | HH                                            |          |
| 3480E       | Injection 30 mg in 1 mL                                                                                    | 5           | 15.32                                    | HH                                            |          |
| 3481F<br>or | NALOXONE HYDROCHLORIDE<br>Injection 800 micrograms in 2 mL<br>or                                           | 5           | * 110.69                                 | Naloxone Min-I-Jet                            | CS       |
| 3482G       | Injection 2 mg in 5 mL                                                                                     | 2           | * 72.95                                  | Naloxone Min-I-Jet                            | CS       |

EMERGENCY DRUG (DOCTOR'S BAG) SUPPLIES

| Code      | Name, Manner of Administration and Form                                                                               | Max.<br>Qty | Dispensed<br>Price for<br>Max. Qty<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                                                                                                                |                                                      |
|-----------|-----------------------------------------------------------------------------------------------------------------------|-------------|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|
|           |                                                                                                                       |             |                                          |                                                                                                                                                                                                                                                                                                     |                                                      |
| 3488N     | PROMETHAZINE HYDROCHLORIDE<br>Injection 50 mg in 2 mL                                                                 | 10          | * 21.89                                  | HH                                                                                                                                                                                                                                                                                                  |                                                      |
| 3497C     | SALBUTAMOL SULFATE<br>Nebuliser solution single dose units 5 mg (base) in 2.5 mL, 30                                  | ₣ 1         | 12.60                                    | <sup>a</sup> Asmol 5 uni-dose<br><sup>a</sup> Butamol 5<br><sup>a</sup> Chem mart<br>Salbutamol<br><sup>a</sup> GenRx Salbutamol<br><sup>a</sup> Pharmacor<br>Salbutamol 5<br><sup>a</sup> Salbutamol-GA<br><sup>a</sup> Salbutamol Sandoz<br><sup>a</sup> Terry White Chemists<br>Salbutamol       | AF<br>AW<br>CH<br><br>GX<br>CR<br><br>GM<br>SZ<br>TW |
|           |                                                                                                                       |             | 13.33                                    | <sup>a</sup> Ventolin Nebules                                                                                                                                                                                                                                                                       | GK                                                   |
| 3495Y     | SALBUTAMOL SULFATE<br>Oral pressurised inhalation 100 micrograms (base) per dose (200<br>doses), CFC-free formulation | ₣ 1         | 10.39                                    | <sup>a</sup> Airomir<br><sup>a</sup> Asmol CFC-free<br><sup>a</sup> Epaq                                                                                                                                                                                                                            | IA<br>AL<br>AW                                       |
| <i>or</i> | <i>or</i>                                                                                                             |             | 10.98                                    | <sup>a</sup> Ventolin CFC-free                                                                                                                                                                                                                                                                      | GK                                                   |
| 3496B     | Nebuliser solution single dose units 2.5 mg (base) in 2.5 mL, 30                                                      | ₣ 1         | 12.25                                    | <sup>a</sup> Asmol 2.5 uni-dose<br><sup>a</sup> Butamol 2.5<br><sup>a</sup> Chem mart<br>Salbutamol<br><sup>a</sup> GenRx Salbutamol<br><sup>a</sup> Pharmacor<br>Salbutamol 2.5<br><sup>a</sup> Salbutamol-GA<br><sup>a</sup> Salbutamol Sandoz<br><sup>a</sup> Terry White Chemists<br>Salbutamol | AF<br>AW<br>CH<br><br>GX<br>CR<br><br>GM<br>SZ<br>TW |
|           |                                                                                                                       |             | 12.98                                    | <sup>a</sup> PU<br><sup>a</sup> Ventolin Nebules                                                                                                                                                                                                                                                    | GK                                                   |
| 3491R     | TERBUTALINE SULFATE<br>Injection 500 micrograms in 1 mL                                                               | 5           | 30.16                                    | Bricanyl                                                                                                                                                                                                                                                                                            | AP                                                   |
| 3484J     | TRAMADOL HYDROCHLORIDE<br>Injection 100 mg in 2 mL                                                                    | 5           | 10.21                                    | Tramal 100                                                                                                                                                                                                                                                                                          | CS                                                   |
| 3494X     | VERAPAMIL HYDROCHLORIDE<br>Injection 5 mg in 2 mL                                                                     | 5           | 11.95                                    | Isoptin                                                                                                                                                                                                                                                                                             | AB                                                   |

## SPECIAL PHARMACEUTICAL BENEFITS

The special patient contribution is payable by all patients in addition to the relevant patient contribution for concessional and general patients. Other than for bleomycin sulfate, exemptions on medical grounds are available. For eligible veterans under RPBS provisions, see RPBS EXPLANATORY NOTES, paragraph 32.

| Code | Name, Restriction,<br>Manner of Administration and<br>form | Max.<br>Qty | No. of<br>Rpts | Premium | Reimburse-<br>ment Price<br>for Max. Qty<br>\$ | Total<br>Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|------------------------------------------------------------|-------------|----------------|---------|------------------------------------------------|---------------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|------------------------------------------------------------|-------------|----------------|---------|------------------------------------------------|---------------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

### GENERAL PHARMACEUTICAL BENEFITS

#### AMOXYCILLIN

|       |                                                          |     |   |       |         |         |       |        |    |
|-------|----------------------------------------------------------|-----|---|-------|---------|---------|-------|--------|----|
| 1888J | Powder for paediatric oral drops<br>100 mg per mL, 20 mL | ‡ 1 | 1 | s0.61 | # 12.75 | # 13.36 | 14.14 | Amoxil | GK |
|-------|----------------------------------------------------------|-----|---|-------|---------|---------|-------|--------|----|

#### Authority Required

*Treatment of infections suspected or proven to be due to a susceptible organism in patients who require a liquid formulation and in whom the syrup formulations are unsuitable.*

|       |                                                          |     |   |    |         |         |       |        |    |
|-------|----------------------------------------------------------|-----|---|----|---------|---------|-------|--------|----|
| 9714G | Powder for paediatric oral drops<br>100 mg per mL, 20 mL | ‡ 1 | 1 | .. | # 13.36 | # 13.36 | 14.75 | Amoxil | GK |
|-------|----------------------------------------------------------|-----|---|----|---------|---------|-------|--------|----|

#### BLEOMYCIN SULFATE

#### Restricted Benefit

*Germ cell neoplasms;*

*Lymphoma.*

|       |                                                                                                                       |    |    |         |          |          |       |                        |    |
|-------|-----------------------------------------------------------------------------------------------------------------------|----|----|---------|----------|----------|-------|------------------------|----|
| 2315W | Powder for injection 15,000 i.u.<br>(solvent required)<br>(code 6896Y applies to above item<br>with approved solvent) | 10 | .. | s437.01 | 491.77   | 928.78   | 31.30 | <sup>a</sup> Blenamax  | SI |
|       |                                                                                                                       |    |    | s437.00 | * 491.79 | * 928.79 | 31.30 | <sup>a</sup> HH        |    |
|       |                                                                                                                       |    |    | B75.30  | 491.77   | 1004.08  | 31.30 | <sup>a</sup> Blenoxane | BQ |
|       |                                                                                                                       |    |    | s437.01 |          |          |       |                        |    |

#### ESCITALOPRAM OXALATE

#### Restricted Benefit

*Major depressive disorders.*

|       |                                             |     |   |       |       |       |       |         |    |
|-------|---------------------------------------------|-----|---|-------|-------|-------|-------|---------|----|
| 8849R | Oral solution 10 mg (base) per mL,<br>28 mL | ‡ 1 | 5 | s4.30 | 37.66 | 41.96 | 31.30 | Lexapro | LU |
|-------|---------------------------------------------|-----|---|-------|-------|-------|-------|---------|----|

#### Authority Required

*Major depressive disorders, where:*

- (a) *adverse events have occurred with other suitable PBS-listed drugs; or*
- (b) *drug interactions have occurred with other suitable PBS-listed drugs; or*
- (c) *drug interactions are expected to occur with other suitable PBS-listed drugs; or*
- (d) *transfer to another suitable PBS-listed drug would cause patient confusion resulting in problems with compliance; or*
- (e) *transfer to another suitable PBS-listed drug is likely to result in adverse clinical consequences.*

|       |                                             |     |   |    |       |       |       |         |    |
|-------|---------------------------------------------|-----|---|----|-------|-------|-------|---------|----|
| 9700M | Oral solution 10 mg (base) per mL,<br>28 mL | ‡ 1 | 5 | .. | 41.96 | 41.96 | 31.30 | Lexapro | LU |
|-------|---------------------------------------------|-----|---|----|-------|-------|-------|---------|----|



## SPECIAL PHARMACEUTICAL BENEFITS

The special patient contribution is payable by all patients in addition to the relevant patient contribution for concessional and general patients. Other than for bleomycin sulfate, exemptions on medical grounds are available. For eligible veterans under RPBS provisions, see RPBS EXPLANATORY NOTES, paragraph 32.

| Code                                                                                                                  | Name, Restriction,<br>Manner of Administration and<br>form | Max.<br>Qty | No. of<br>Rpts | Premium | Reimburse-<br>ment Price<br>for Max. Qty<br>\$ | Total<br>Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|-------------|----------------|---------|------------------------------------------------|---------------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>LEVETIRACETAM</b>                                                                                                  |                                                            |             |                |         |                                                |                                                   |                                                        |                                      |    |
| <b><u>Authority Required</u></b>                                                                                      |                                                            |             |                |         |                                                |                                                   |                                                        |                                      |    |
| <i>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs.</i> |                                                            |             |                |         |                                                |                                                   |                                                        |                                      |    |
| 8654L                                                                                                                 | Tablet 250 mg                                              | 60          | 5              | s7.13   | 55.99                                          | 63.12                                             | 31.30                                                  | Keppra                               | UC |
| 8655M                                                                                                                 | Tablet 500 mg                                              | 60          | 5              | s11.91  | 89.37                                          | 101.28                                            | 31.30                                                  | Keppra                               | UC |
| 8656N                                                                                                                 | Tablet 1 g                                                 | 60          | 5              | s19.84  | 144.90                                         | 164.74                                            | 31.30                                                  | Keppra                               | UC |

### **Authority Required**

*Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where:*

- (a) *adverse events have occurred with other suitable PBS-listed drugs; or*
- (b) *drug interactions have occurred with other suitable PBS-listed drugs; or*
- (c) *drug interactions are expected to occur with other suitable PBS-listed drugs; or*
- (d) *transfer to another suitable PBS-listed drug would cause patient confusion resulting in problems with compliance; or*
- (e) *transfer to another suitable PBS-listed drug is likely to result in adverse clinical consequences.*

|       |               |    |   |    |        |        |       |        |    |
|-------|---------------|----|---|----|--------|--------|-------|--------|----|
| 9708Y | Tablet 250 mg | 60 | 5 | .. | 63.12  | 63.12  | 31.30 | Keppra | UC |
| 9709B | Tablet 500 mg | 60 | 5 | .. | 101.28 | 101.28 | 31.30 | Keppra | UC |
| 9710C | Tablet 1 g    | 60 | 5 | .. | 164.74 | 164.74 | 31.30 | Keppra | UC |

### **NARATRIPTAN HYDROCHLORIDE**

#### **CAUTION:**

*Naratriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.*

### **Authority Required**

*Migraine attacks in patients receiving, or who have failed a reasonable trial of, prophylactic medication and where attacks in the past have usually failed to respond to oral therapy with ergotamine and other appropriate agents, or in whom these agents are contraindicated.*

#### **NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*

|       |                      |   |   |       |         |         |       |         |    |
|-------|----------------------|---|---|-------|---------|---------|-------|---------|----|
| 8298R | Tablet 2.5 mg (base) | 4 | 5 | s2.78 | * 25.47 | * 28.25 | 26.50 | Naramig | GK |
|-------|----------------------|---|---|-------|---------|---------|-------|---------|----|

### **Authority Required**

*Migraine attacks in patients receiving, or who have failed a reasonable trial of, prophylactic medication and where attacks in the past have usually failed to respond to oral therapy with ergotamine and other appropriate agents, or in whom these agents are contraindicated, and where:*

- (a) *adverse events have occurred with other suitable PBS-listed drugs; or*
- (b) *drug interactions have occurred with other suitable PBS-listed drugs; or*
- (c) *drug interactions are expected to occur with other suitable PBS-listed drugs; or*

continued ➡

# SPECIAL PHARMACEUTICAL BENEFITS

The special patient contribution is payable by all patients in addition to the relevant patient contribution for concessional and general patients. Other than for bleomycin sulfate, exemptions on medical grounds are available. For eligible veterans under RPBS provisions, see RPBS EXPLANATORY NOTES, paragraph 32.

| Code | Name, Restriction,<br>Manner of Administration and<br>form | Max. Qty | No. of<br>Rpts | Premium | Reimburse-<br>ment Price<br>for Max. Qty<br>\$ | Total<br>Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|------------------------------------------------------------|----------|----------------|---------|------------------------------------------------|---------------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|------------------------------------------------------------|----------|----------------|---------|------------------------------------------------|---------------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

- (d) transfer to another suitable PBS-listed drug would cause patient confusion resulting in problems with compliance; or
- (e) transfer to another suitable PBS-listed drug is likely to result in adverse clinical consequences.

**NOTE:**

No applications for increased maximum quantities and/or repeats will be authorised.

|       |                      |   |   |    |         |         |       |         |    |
|-------|----------------------|---|---|----|---------|---------|-------|---------|----|
| 9734H | Tablet 2.5 mg (base) | 4 | 5 | .. | * 28.25 | * 28.25 | 29.28 | Naramig | GK |
|-------|----------------------|---|---|----|---------|---------|-------|---------|----|

**ZOLMITRIPTAN**

**CAUTION:**

Zolmitriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.

**Authority Required**

Migraine attacks in patients receiving, or who have failed a reasonable trial of, prophylactic medication and where attacks in the past have usually failed to respond to oral therapy with ergotamine and other appropriate agents, or in whom these agents are contraindicated.

**NOTE:**

No applications for increased maximum quantities and/or repeats will be authorised.

|       |               |   |   |       |         |         |       |       |    |
|-------|---------------|---|---|-------|---------|---------|-------|-------|----|
| 8266C | Tablet 2.5 mg | 4 | 5 | s2.76 | * 25.41 | * 28.17 | 26.44 | Zomig | AP |
|-------|---------------|---|---|-------|---------|---------|-------|-------|----|

**Authority Required**

Migraine attacks in patients receiving, or who have failed a reasonable trial of, prophylactic medication and where attacks in the past have usually failed to respond to oral therapy with ergotamine and other appropriate agents, or in whom these agents are contraindicated, and where:

- (a) adverse events have occurred with other suitable PBS-listed drugs; or
- (b) drug interactions have occurred with other suitable PBS-listed drugs; or
- (c) drug interactions are expected to occur with other suitable PBS-listed drugs; or
- (d) transfer to another suitable PBS-listed drug would cause patient confusion resulting in problems with compliance; or
- (e) transfer to another suitable PBS-listed drug is likely to result in adverse clinical consequences.

**NOTE:**

No applications for increased maximum quantities and/or repeats will be authorised.

|       |               |   |   |    |         |         |       |       |    |
|-------|---------------|---|---|----|---------|---------|-------|-------|----|
| 9736K | Tablet 2.5 mg | 4 | 5 | .. | * 28.17 | * 28.17 | 29.20 | Zomig | AP |
|-------|---------------|---|---|----|---------|---------|-------|-------|----|

**PHARMACEUTICAL BENEFITS FOR DENTAL USE**

**AMOXYCILLIN**

|       |                                                          |     |    |       |         |         |       |        |    |
|-------|----------------------------------------------------------|-----|----|-------|---------|---------|-------|--------|----|
| 3310F | Powder for paediatric oral drops<br>100 mg per mL, 20 mL | ‡ 1 | .. | s0.61 | # 12.75 | # 13.36 | 14.14 | Amoxil | GK |
|-------|----------------------------------------------------------|-----|----|-------|---------|---------|-------|--------|----|

## ALIMENTARY TRACT AND METABOLISM

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

### STOMATOLOGICAL PREPARATIONS

#### Stomatological preparations

##### • *Antifungives and antiseptics for local oral treatment*

#### AMPHOTERICIN

|       |               |    |   |    |       |       |          |    |
|-------|---------------|----|---|----|-------|-------|----------|----|
| 2931G | Lozenge 10 mg | 20 | 1 | .. | 10.20 | 11.23 | Fungilin | BQ |
|-------|---------------|----|---|----|-------|-------|----------|----|

#### NYSTATIN

|       |                                                |     |   |    |       |       |                       |          |
|-------|------------------------------------------------|-----|---|----|-------|-------|-----------------------|----------|
| 3033P | Oral suspension 100,000 units per mL,<br>24 mL | ± 1 | 1 | .. | 10.42 | 11.45 | Mycostatin<br>Nilstat | BQ<br>SI |
|-------|------------------------------------------------|-----|---|----|-------|-------|-----------------------|----------|

##### • *Other agents for local oral treatment*

#### BENZYDAMINE HYDROCHLORIDE

#### Restricted Benefit

*Radiation induced mucositis.*

|       |                                                     |     |   |    |       |       |         |    |
|-------|-----------------------------------------------------|-----|---|----|-------|-------|---------|----|
| 1121B | Mouth and throat rinse 22.5 mg per<br>15 mL, 500 mL | ± 1 | 1 | .. | 21.09 | 22.12 | Difflam | IA |
|-------|-----------------------------------------------------|-----|---|----|-------|-------|---------|----|

### DRUGS FOR ACID RELATED DISORDERS

#### Antacids

##### • *Combinations and complexes of aluminium, calcium and magnesium compounds*

#### ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE

|       |                      |     |   |    |         |       |           |    |
|-------|----------------------|-----|---|----|---------|-------|-----------|----|
| 2576N | Tablet 200 mg-200 mg | 200 | 5 | .. | * 15.65 | 16.68 | Mylanta P | JT |
|-------|----------------------|-----|---|----|---------|-------|-----------|----|

|       |                                                   |   |   |    |         |       |           |    |
|-------|---------------------------------------------------|---|---|----|---------|-------|-----------|----|
| 2157M | Oral suspension 200 mg-200 mg per<br>5 mL, 500 mL | 2 | 5 | .. | * 15.65 | 16.68 | Mylanta P | JT |
|-------|---------------------------------------------------|---|---|----|---------|-------|-----------|----|

#### ALUMINIUM HYDROXIDE with MAGNESIUM TRISILICATE and MAGNESIUM HYDROXIDE

|       |                                                          |   |   |    |         |       |           |    |
|-------|----------------------------------------------------------|---|---|----|---------|-------|-----------|----|
| 2159P | Oral suspension 250 mg-120 mg-120 mg<br>per 5 mL, 500 mL | 2 | 5 | .. | * 14.01 | 15.04 | Gastrogel | FM |
|-------|----------------------------------------------------------|---|---|----|---------|-------|-----------|----|

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                                                                                                                                                               | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                  |                                                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|
| <b>Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)</b>                                                                                                                                                         |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                       |                                                      |
| <b>• <i>H<sub>2</sub>-receptor antagonists</i></b>                                                                                                                                                                                 |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                       |                                                      |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                       |                                                      |
| The base-priced drugs in this therapeutic group are cimetidine, famotidine, nizatidine and ranitidine hydrochloride (except ranitidine hydrochloride effervescent tablet 150 mg (base) and syrup 150 mg (base) per 10 mL, 300 mL). |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                       |                                                      |
| <b>CIMETIDINE</b>                                                                                                                                                                                                                  |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                       |                                                      |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                       |                                                      |
| Helicobacter pylori eradication therapy should be considered prior to commencing initial treatment of peptic ulcer with this drug.                                                                                                 |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                       |                                                      |
| 1157X                                                                                                                                                                                                                              | Tablet 200 mg                                           | 120         | 5              | ..<br>B1.94 | 19.54<br>21.48                           | 20.57 <sup>a</sup><br>20.57 <sup>a</sup>               | Magicul 200<br>Tagamet                                                                                                                                | AF<br>GK                                             |
| 1158Y                                                                                                                                                                                                                              | Tablet 400 mg                                           | 60          | 5              | ..<br>B1.94 | 19.54<br>21.48                           | 20.57 <sup>a</sup><br>20.57 <sup>a</sup>               | GenRx Cimetidine<br>Magicul 400<br>Tagamet                                                                                                            | GX<br>AF<br>GK                                       |
| 1159B                                                                                                                                                                                                                              | Tablet 800 mg                                           | 30          | 5              | ..          | 19.54                                    | 20.57 <sup>a</sup>                                     | GenRx Cimetidine<br>Magicul 800                                                                                                                       | GX<br>AF                                             |
| <b>FAMOTIDINE</b>                                                                                                                                                                                                                  |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                       |                                                      |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                       |                                                      |
| Helicobacter pylori eradication therapy should be considered prior to commencing initial treatment of peptic ulcer with this drug.                                                                                                 |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                       |                                                      |
| 2487X                                                                                                                                                                                                                              | Tablet 20 mg                                            | 60          | 5              | ..<br>B4.25 | 16.98<br>21.23                           | 18.01 <sup>a</sup><br>18.01 <sup>a</sup>               | Ausfam 20<br>Chem mart<br>Famotidine<br>Famohexal<br>GenRx Famotidine<br>Pamacid 20<br>Pepzan<br>Terry White<br>Chemists<br>Famotidine<br>Pepcidine M | AW<br>CH<br><br>SZ<br>GX<br>AF<br>GM<br>TW<br><br>MK |
| 2488Y                                                                                                                                                                                                                              | Tablet 40 mg                                            | 30          | 5              | ..<br>B4.25 | 16.98<br>21.23                           | 18.01 <sup>a</sup><br>18.01 <sup>a</sup>               | Ausfam 40<br>Chem mart<br>Famotidine<br>Famohexal<br>GenRx Famotidine<br>Pamacid 40<br>Pepzan<br>Terry White<br>Chemists<br>Famotidine<br>Pepcidine   | AW<br>CH<br><br>SZ<br>GX<br>AF<br>GM<br>TW<br><br>MK |

ALIMENTARY TRACT AND METABOLISM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form                                                                                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     |                                         | Proprietary Name and<br>Manufacturer |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|-----------------------------------------|--------------------------------------|
|       |                                                                                                                                                    |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                         |                                      |
|       | NIZATIDINE                                                                                                                                         |             |                |         |                             |                                             |                                         |                                      |
|       | <b>NOTE:</b><br>Helicobacter pylori eradication therapy should be considered prior to commencing initial treatment of peptic ulcer with this drug. |             |                |         |                             |                                             |                                         |                                      |
| 1505F | Capsule 150 mg                                                                                                                                     | 60          | 5              | ..      | 18.63                       | 19.66                                       | a Nizac                                 | LN                                   |
|       |                                                                                                                                                    |             |                | B5.60   | 24.23                       | 19.66                                       | a Tacidine                              | AF                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Tazac                                 | AS                                   |
| 1504E | Capsule 300 mg                                                                                                                                     | 30          | 5              | ..      | 18.63                       | 19.66                                       | a Nizac                                 | LN                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Tacidine                              | AF                                   |
|       |                                                                                                                                                    |             |                | B5.60   | 24.23                       | 19.66                                       | a Tazac                                 | AS                                   |
|       | RANITIDINE HYDROCHLORIDE                                                                                                                           |             |                |         |                             |                                             |                                         |                                      |
|       | <b>NOTE:</b><br>Helicobacter pylori eradication therapy should be considered prior to commencing initial treatment of peptic ulcer with this drug. |             |                |         |                             |                                             |                                         |                                      |
| 1978D | Tablet 150 mg (base)                                                                                                                               | 60          | 5              | ..      | 17.44                       | 18.47                                       | a Ausran                                | SI                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Chem mart                             | CH                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | Ranitidine                              |                                      |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a GenRx Ranitidine                      | GX                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Rani 2                                | AF                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Ranihexal                             | SZ                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Ranoxyl                               | GM                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Terry White<br>Chemists<br>Ranitidine | TW                                   |
|       |                                                                                                                                                    |             |                | B1.71   | 19.15                       | 18.47                                       | a Ulcaid                                | RA                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Zantac                                | GK                                   |
| 1937Y | Effervescent tablet 150 mg (base)                                                                                                                  | 60          | 5              | 13.26   | * 20.73                     | 18.50                                       | Zantac                                  | GK                                   |
| 1977C | Tablet 300 mg (base)                                                                                                                               | 30          | 5              | ..      | 17.44                       | 18.47                                       | a Ausran                                | SI                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Chem mart                             | CH                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | Ranitidine                              |                                      |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a GenRx Ranitidine                      | GX                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Rani 2                                | AF                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Ranihexal                             | SZ                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Ranoxyl                               | GM                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Terry White<br>Chemists<br>Ranitidine | TW                                   |
|       |                                                                                                                                                    |             |                | B1.71   | 19.15                       | 18.47                                       | a Ulcaid                                | RA                                   |
|       |                                                                                                                                                    |             |                |         |                             |                                             | a Zantac                                | GK                                   |
| 8162N | Syrup 150 mg (base) per 10 mL, 300 mL                                                                                                              | 2           | 5              | 12.20   | * 23.49                     | 22.32                                       | Zantac Syrup                            | GK                                   |

continued ➡

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                                                                             | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                                                  |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| <b><i>RANITIDINE HYDROCHLORIDE</i></b>                                                                                                           |                                                         |             |                |         |                             |                                             |                                      |    |
| <b><u>NOTE:</u></b>                                                                                                                              |                                                         |             |                |         |                             |                                             |                                      |    |
| <b><i>Helicobacter pylori eradication therapy should be considered prior to commencing initial treatment of peptic ulcer with this drug.</i></b> |                                                         |             |                |         |                             |                                             |                                      |    |
| <b><u>Authority Required</u></b>                                                                                                                 |                                                         |             |                |         |                             |                                             |                                      |    |
| <b><i>Adverse effects occurring with all of the base-priced drugs;</i></b>                                                                       |                                                         |             |                |         |                             |                                             |                                      |    |
| <b><i>Drug interactions occurring with all of the base-priced drugs;</i></b>                                                                     |                                                         |             |                |         |                             |                                             |                                      |    |
| <b><i>Drug interactions expected to occur with all of the base-priced drugs;</i></b>                                                             |                                                         |             |                |         |                             |                                             |                                      |    |
| <b><i>Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance.</i></b>                                |                                                         |             |                |         |                             |                                             |                                      |    |
| 8903N                                                                                                                                            | Effervescent tablet 150 mg (base)                       | 60          | 5              | ..      | * 20.73                     | 21.76                                       | Zantac                               | GK |
| 8905Q                                                                                                                                            | Syrup 150 mg (base) per 10 mL, 300 mL                   | 2           | 5              | ..      | * 23.49                     | 24.52                                       | Zantac Syrup                         | GK |

### • Prostaglandins

#### MISOPROSTOL

##### CAUTION:

*Misoprostol is a prostaglandin analogue. It should not be used in pregnant women.*

##### Authority Required (STREAMLINED)

2630

*Reduction in the incidence of gastrointestinal complications in patients who have a history of peptic ulcer disease and where NSAID therapy is essential;*

2631

*Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery. The date and the method by which the ulcer was proven must be documented in the patient's medical records when treatment is initiated;*

2632

*Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous 2 years. The date and the method by which the ulcer was proven must be documented in the patient's medical records when treatment is initiated.*

|       |                       |     |   |    |       |       |         |    |
|-------|-----------------------|-----|---|----|-------|-------|---------|----|
| 1648R | Tablet 200 micrograms | 120 | 2 | .. | 51.69 | 31.30 | Cytotec | PH |
|-------|-----------------------|-----|---|----|-------|-------|---------|----|

### • Proton pump inhibitors

#### ESOMEPRAZOLE MAGNESIUM TRIHYDRATE

##### Restricted Benefit

*Initial treatment of gastric ulcer.*

##### NOTE:

*Helicobacter pylori eradication therapy should be considered.*

|       |                                                              |    |   |    |       |       |        |    |
|-------|--------------------------------------------------------------|----|---|----|-------|-------|--------|----|
| 8886Q | Tablet (enteric coated), equivalent to<br>20 mg esomeprazole | 30 | 1 | .. | 38.11 | 31.30 | Nexium | AP |
|-------|--------------------------------------------------------------|----|---|----|-------|-------|--------|----|

##### NOTE:

*No applications for increased maximum quantities and/or repeats will be authorised.*

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                       | Name, Restriction,<br>Manner of Administration and Form          | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------|------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b><u>Restricted Benefit</u></b>                                                           |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Healing of gastro-oesophageal reflux disease.</i>                                       |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                                                        |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i> |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| 8601Q                                                                                      | Tablet (enteric coated), equivalent to 40 mg esomeprazole        | 30          | 1              | ..      | 58.24                                    | 31.30                                                  | Nexium                               | AP |
| <hr/>                                                                                      |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                           |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Maintenance of healed gastro-oesophageal reflux disease.</i>                            |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                                                        |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>No applications for increased maximum quantities will be authorised.</i>                |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| 8600P                                                                                      | Tablet (enteric coated), equivalent to 20 mg esomeprazole        | 30          | 5              | ..      | 38.11                                    | 31.30                                                  | Nexium                               | AP |
| <b>LANSOPRAZOLE</b>                                                                        |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                           |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Initial treatment of peptic ulcer.</i>                                                  |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                                                        |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Helicobacter pylori eradication therapy should be considered.</i>                       |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| 2240X                                                                                      | Capsule 30 mg                                                    | 30          | 1              | ..      | 37.43                                    | 31.30                                                  | Zoton                                | WX |
| <b><u>NOTE:</u></b>                                                                        |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>No applications for increased repeats will be authorised.</i>                           |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| 8528W                                                                                      | Sachet containing granules for oral suspension, 30 mg per sachet | 28          | 1              | r3.62   | 41.64                                    | 31.30                                                  | Zoton                                | WX |
| <b><u>NOTE:</u></b>                                                                        |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>No applications for increased repeats will be authorised.</i>                           |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <hr/>                                                                                      |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                           |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Gastro-oesophageal reflux disease;</i>                                                  |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Scleroderma oesophagus.</i>                                                             |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| 8198L                                                                                      | Capsule 15 mg                                                    | 30          | 5              | ..      | 23.57                                    | 24.60                                                  | Zoton                                | WX |
| 2241Y                                                                                      | Capsule 30 mg                                                    | 30          | 5              | ..      | 37.43                                    | 31.30                                                  | Zoton                                | WX |
| 8529X                                                                                      | Sachet containing granules for oral suspension, 30 mg per sachet | 28          | 5              | r3.62   | 41.64                                    | 31.30                                                  | Zoton                                | WX |

continued 

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

### Authority Required

*Initial treatment of peptic ulcer, in patients unable to take a solid dose form of a proton pump inhibitor.*

### NOTE:

*Helicobacter pylori eradication therapy should be considered.*

|       |                                                                  |    |   |    |       |       |       |    |
|-------|------------------------------------------------------------------|----|---|----|-------|-------|-------|----|
| 8949B | Sachet containing granules for oral suspension, 30 mg per sachet | 28 | 1 | .. | 41.64 | 31.30 | Zoton | WX |
|-------|------------------------------------------------------------------|----|---|----|-------|-------|-------|----|

### NOTE:

*No applications for increased repeats will be authorised.*

### Authority Required

*Gastro-oesophageal reflux disease, in patients unable to take a solid dose form of a proton pump inhibitor;*

*Scleroderma oesophagus, in patients unable to take a solid dose form of a proton pump inhibitor.*

|       |                                                                  |    |   |    |       |       |       |    |
|-------|------------------------------------------------------------------|----|---|----|-------|-------|-------|----|
| 8950C | Sachet containing granules for oral suspension, 30 mg per sachet | 28 | 5 | .. | 41.64 | 31.30 | Zoton | WX |
|-------|------------------------------------------------------------------|----|---|----|-------|-------|-------|----|

### OMEPRAZOLE

### Restricted Benefit

*Initial treatment of peptic ulcer.*

### NOTE:

*Helicobacter pylori eradication therapy should be considered.*

*No applications for increased repeats will be authorised.*

|       |                             |    |   |       |       |       |                               |    |
|-------|-----------------------------|----|---|-------|-------|-------|-------------------------------|----|
| 9109K | Tablet 20 mg (as magnesium) | 30 | 1 | ..    | 28.91 | 29.94 | <sup>a</sup> Acimax Tablets   | AL |
|       |                             |    |   |       |       |       | <sup>a</sup> Omepral          | PM |
|       |                             |    |   | B2.15 | 31.06 | 29.94 | <sup>a</sup> Losec Tablets    | AP |
| 8331L | Tablet 20 mg                | 30 | 1 | ..    | 28.91 | 29.94 | <sup>a</sup> GenRx Omeprazole | GX |
|       |                             |    |   |       |       |       | <sup>a</sup> Meprazol         | SZ |
|       |                             |    |   |       |       |       | <sup>a</sup> Omeprazole-GA    | GM |
|       |                             |    |   |       |       |       | <sup>a</sup> Omeprazole       | RA |
|       |                             |    |   |       |       |       | Ranbaxy                       |    |
|       |                             |    |   |       |       |       | <sup>a</sup> Omeprazole       | WA |
|       |                             |    |   |       |       |       | Winthrop                      |    |

### NOTE:

*Bioequivalence has been demonstrated between omeprazole tablet 20 mg and omeprazole tablet 20 mg (as magnesium).*

|       |               |    |   |    |       |       |          |    |
|-------|---------------|----|---|----|-------|-------|----------|----|
| 1326T | Capsule 20 mg | 30 | 1 | .. | 28.91 | 29.94 | Probitor | SZ |
|-------|---------------|----|---|----|-------|-------|----------|----|

continued ➞



## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                      | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b><u>Restricted Benefit</u></b>          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Gastro-oesophageal reflux disease;</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Scleroderma oesophagus;</i>            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Zollinger-Ellison syndrome.</i>        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8332M                                     | Tablet 10 mg (as magnesium)                             | 30          | 5              | ..      | 22.15                                    | 23.18                                                  | Losec Tablets                        | AP |
| 9110L                                     | Tablet 20 mg (as magnesium)                             | 30          | 5              | ..      | 28.91                                    | 29.94                                                  | <sup>a</sup> Acimax Tablets          | AL |
|                                           |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Omepral                 | PM |
|                                           |                                                         |             |                | 82.15   | 31.06                                    | 29.94                                                  | <sup>a</sup> Losec Tablets           | AP |
| 8333N                                     | Tablet 20 mg                                            | 30          | 5              | ..      | 28.91                                    | 29.94                                                  | <sup>a</sup> GenRx Omeprazole        | GX |
|                                           |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Meprazol                | SZ |
|                                           |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Omeprazole-GA           | GM |
|                                           |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Omeprazole              | RA |
|                                           |                                                         |             |                |         |                                          |                                                        | Ranbaxy                              |    |
|                                           |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Omeprazole              | WA |
|                                           |                                                         |             |                |         |                                          |                                                        | Winthrop                             |    |

**NOTE:**

Bioequivalence has been demonstrated between omeprazole tablet 20 mg and omeprazole tablet 20 mg (as magnesium).

|       |               |    |   |    |       |       |          |    |
|-------|---------------|----|---|----|-------|-------|----------|----|
| 1327W | Capsule 20 mg | 30 | 5 | .. | 28.91 | 29.94 | Probitor | SZ |
|-------|---------------|----|---|----|-------|-------|----------|----|

**PANTOPRAZOLE SODIUM SESQUIHYDRATE****Restricted Benefit**

*Initial treatment of peptic ulcer.*

**NOTE:**

*Helicobacter pylori eradication therapy should be considered.*

|       |                                                              |    |   |    |       |       |       |    |
|-------|--------------------------------------------------------------|----|---|----|-------|-------|-------|----|
| 8007K | Tablet (enteric coated), equivalent to<br>40 mg pantoprazole | 30 | 2 | .. | 38.71 | 31.30 | Somac | NQ |
|-------|--------------------------------------------------------------|----|---|----|-------|-------|-------|----|

**NOTE:**

*No applications for increased repeats will be authorised.*

**Restricted Benefit**

*Gastro-oesophageal reflux disease.*

|       |                                                              |    |   |    |       |       |       |    |
|-------|--------------------------------------------------------------|----|---|----|-------|-------|-------|----|
| 8399C | Tablet (enteric coated), equivalent to<br>20 mg pantoprazole | 30 | 5 | .. | 21.94 | 22.97 | Somac | NQ |
|-------|--------------------------------------------------------------|----|---|----|-------|-------|-------|----|

continued ➡

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                                                                                  | Name, Restriction,<br>Manner of Administration and Form                                                                                                       | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b><u>Restricted Benefit</u></b><br><i>Gastro-oesophageal reflux disease.</i>                                                                         |                                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Scleroderma oesophagus;<br/>Zollinger-Ellison syndrome.</i>                                                    |                                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| 8008L                                                                                                                                                 | Tablet (enteric coated), equivalent to<br>40 mg pantoprazole                                                                                                  | 30          | 5              | ..      | 38.71                                    | 31.30                                                  | Somac                                | NQ |
| <b>RABEPRAZOLE SODIUM</b>                                                                                                                             |                                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Initial treatment of peptic ulcer.</i>                                                                         |                                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b><br><i>Helicobacter pylori eradication therapy should be considered.</i>                                                           |                                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| 8509W                                                                                                                                                 | Tablet 20 mg (enteric coated)                                                                                                                                 | 30          | 2              | ..      | 37.97                                    | 31.30                                                  | Pariet                               | JC |
| <b><u>NOTE:</u></b><br><i>No applications for increased repeats will be authorised.</i>                                                               |                                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <hr/>                                                                                                                                                 |                                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Gastro-oesophageal reflux disease;<br/>Scleroderma oesophagus.</i>                                             |                                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| 8507R                                                                                                                                                 | Tablet 10 mg (enteric coated)                                                                                                                                 | 28          | 5              | ..      | 37.97                                    | 31.30                                                  | Pariet                               | JC |
| 8508T                                                                                                                                                 | Tablet 20 mg (enteric coated)                                                                                                                                 | 30          | 5              | ..      | 37.97                                    | 31.30                                                  | Pariet                               | JC |
| <b>• Combinations for eradication of Helicobacter pylori</b><br><b>ESOMEPRAZOLE MAGNESIUM TRIHYDRATE and</b><br><b>CLARITHROMYCIN and AMOXYCILLIN</b> |                                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Eradication of Helicobacter pylori associated with peptic ulcer disease.</i>                                   |                                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| 8738X                                                                                                                                                 | Pack containing 14 tablets<br>(enteric coated) equivalent to<br>20 mg esomeprazole, 14 tablets<br>clarithromycin 500 mg and 28<br>capsules amoxicillin 500 mg | ± 1         | ..             | ..      | 80.93                                    | 31.30                                                  | Nexium Hp7                           | AP |

# ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                                                                 | Name, Restriction,<br>Manner of Administration and Form                                                           | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |          |
|--------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----------|
| <b>OMEPRAZOLE and CLARITHROMYCIN and AMOXYCILLIN</b>                                                                                 |                                                                                                                   |             |                |             |                                          |                                                        |                                      |          |
| <b>Restricted Benefit</b>                                                                                                            |                                                                                                                   |             |                |             |                                          |                                                        |                                      |          |
| <i>Eradication of Helicobacter pylori associated with peptic ulcer disease.</i>                                                      |                                                                                                                   |             |                |             |                                          |                                                        |                                      |          |
| 8272J                                                                                                                                | Pack containing 14 capsules omeprazole 20 mg, 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg | ≠ 1         | ..             | ..          | 73.75                                    | 31.30                                                  | Klacid Hp 7                          | AB       |
| <ul style="list-style-type: none"> <li>• <b>Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)</b></li> </ul> |                                                                                                                   |             |                |             |                                          |                                                        |                                      |          |
| SODIUM ALGINATE with CALCIUM CARBONATE and SODIUM BICARBONATE                                                                        |                                                                                                                   |             |                |             |                                          |                                                        |                                      |          |
| 2014B                                                                                                                                | Oral liquid 1 g-320 mg-534 mg in 20 mL, 500 mL                                                                    | 2           | 5              | ..          | * 14.25                                  | 15.28                                                  | Gaviscon P                           | RC       |
| SUCRALFATE                                                                                                                           |                                                                                                                   |             |                |             |                                          |                                                        |                                      |          |
| 2055E                                                                                                                                | Tablet equivalent to 1 g anhydrous sucralfate                                                                     | 120         | 2              | ..<br>B2.18 | 23.98<br>26.16                           | 25.01 <sup>a</sup><br>25.01 <sup>a</sup>               | Ulcyte<br>Carafate                   | AF<br>AS |

## DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

### Belladonna and derivatives, plain

- **Belladonna alkaloids, tertiary amines**

ATROPINE SULFATE

|       |                                  |    |   |    |       |       |    |  |
|-------|----------------------------------|----|---|----|-------|-------|----|--|
| 1089H | Injection 600 micrograms in 1 mL | 10 | 1 | .. | 20.11 | 21.14 | AP |  |
|-------|----------------------------------|----|---|----|-------|-------|----|--|

### Propulsives

- **Propulsives**

DOMPERIDONE

|       |              |    |    |    |      |      |          |    |
|-------|--------------|----|----|----|------|------|----------|----|
| 1347X | Tablet 10 mg | 25 | .. | .. | 8.46 | 9.49 | Motilium | JC |
|-------|--------------|----|----|----|------|------|----------|----|

METOCLOPRAMIDE HYDROCHLORIDE

|       |                         |    |    |             |               |              |                   |          |
|-------|-------------------------|----|----|-------------|---------------|--------------|-------------------|----------|
| 1207M | Tablet 10 mg            | 25 | .. | ..<br>B3.01 | 7.61<br>10.62 | 8.64<br>8.64 | Pramin<br>Maxolon | AF<br>VT |
| 1206L | Injection 10 mg in 2 mL | 10 | .. | ..          | 12.56         | 13.59        | Maxolon           | VT       |

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                                            | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>ANTIEMETICS AND ANTINAUSEANTS</b>                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Antiemetics and antinauseants</b>                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Serotonin (5HT<sub>3</sub>) antagonists</b>                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>DOLASETRON MESYLATE</b>                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8191D                                                                                                           | Tablet 200 mg                                           | 2           | ..             | ..      | 50.29                                    | 31.30                                                  | Anzemet                              | SW |
| 8192E                                                                                                           | I.V. injection 100 mg in 5 mL                           | 1           | ..             | ..      | 28.86                                    | 29.89                                                  | Anzemet                              | SW |
| <b>GRANISETRON HYDROCHLORIDE</b>                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8728J                                                                                                           | Tablet 2 mg (base)                                      | 2           | ..             | ..      | * 58.55                                  | 31.30                                                  | Kytril                               | HH |
| 8729K                                                                                                           | Concentrated injection 3 mg (base) in 3 mL              | 1           | ..             | ..      | 37.42                                    | 31.30                                                  | Kytril                               | HH |
| <b><u>Authority Required</u></b>                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Management of nausea and vomiting associated with radiotherapy being used to treat malignancy.</i>           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8873B                                                                                                           | Tablet 2 mg (base)                                      | 5           | 1              | ..      | 137.41                                   | 31.30                                                  | Kytril                               | HH |
| 8730L                                                                                                           | Concentrated injection 3 mg (base) in 3 mL              | 1           | ..             | ..      | 37.42                                    | 31.30                                                  | Kytril                               | HH |
| <b>ONDANSETRON</b>                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8224W                                                                                                           | Tablet 4 mg                                             | 4           | ..             | ..      | 40.38                                    | 31.30                                                  | <sup>a</sup> Ondansetron-RL          | RE |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ondaz                   | HX |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Onsetron 4              | AW |
|                                                                                                                 |                                                         |             |                | 80.62   | 41.00                                    | 31.30                                                  | <sup>a</sup> Zofran                  | GK |
| 8225X                                                                                                           | Tablet 8 mg                                             | 4           | ..             | ..      | 57.50                                    | 31.30                                                  | <sup>a</sup> Ondansetron-RL          | RE |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ondaz                   | HX |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Onsetron 8              | AW |
|                                                                                                                 |                                                         |             |                | 80.69   | 58.19                                    | 31.30                                                  | <sup>a</sup> Zofran                  | GK |
| 8410P                                                                                                           | Wafer 4 mg                                              | 4           | ..             | ..      | 40.38                                    | 31.30                                                  | <sup>a</sup> Ondansetron-RL          | RE |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | Zydis                                |    |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ondaz Zydis             | HX |
|                                                                                                                 |                                                         |             |                | 80.62   | 41.00                                    | 31.30                                                  | <sup>a</sup> Zofran Zydis            | GK |

continued ➞

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                                  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8411Q                                                                                                 | Wafer 8 mg                                              | 4           | ..             | ..      | 57.50                                    | 31.30                                                  | <sup>a</sup> Ondansetron-RL<br>Zydis | RE |
|                                                                                                       |                                                         |             |                | B0.69   | 58.19                                    | 31.30                                                  | <sup>a</sup> Ondaz Zydis             | HX |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Zofran Zydis            | GK |
| 8226Y                                                                                                 | I.V. injection 4 mg in 2 mL                             | 1           | ..             | ..      | 25.38                                    | 26.41                                                  | <sup>a</sup> Ondansetron-RL          | RE |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ondaz                   | HX |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Onsetron                | AW |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> PF                      |    |
|                                                                                                       |                                                         |             |                | B0.70   | 26.08                                    | 26.41                                                  | <sup>a</sup> Zofran                  | GK |
| 8227B                                                                                                 | I.V. injection 8 mg in 4 mL                             | 1           | ..             | ..      | 36.79                                    | 31.30                                                  | <sup>a</sup> Ondansetron-RL          | RE |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ondaz                   | HX |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Onsetron                | AW |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> PF                      |    |
|                                                                                                       |                                                         |             |                | B0.69   | 37.48                                    | 31.30                                                  | <sup>a</sup> Zofran                  | GK |
| <hr/>                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Management of nausea and vomiting associated with radiotherapy being used to treat malignancy.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1594X                                                                                                 | Tablet 4 mg                                             | 10          | 1              | ..      | 88.19                                    | 31.30                                                  | <sup>a</sup> Ondansetron-RL          | RE |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ondaz                   | HX |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Onsetron 4              | AW |
|                                                                                                       |                                                         |             |                | B0.69   | 88.88                                    | 31.30                                                  | <sup>a</sup> Zofran                  | GK |
| 1595Y                                                                                                 | Tablet 8 mg                                             | 10          | 1              | ..      | 134.78                                   | 31.30                                                  | <sup>a</sup> Ondansetron-RL          | RE |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ondaz                   | HX |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Onsetron 8              | AW |
|                                                                                                       |                                                         |             |                | B0.67   | 135.45                                   | 31.30                                                  | <sup>a</sup> Zofran                  | GK |
| 8412R                                                                                                 | Wafer 4 mg                                              | 10          | 1              | ..      | 88.19                                    | 31.30                                                  | <sup>a</sup> Ondansetron-RL          | RE |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | Zydis                                |    |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ondaz Zydis             | HX |
|                                                                                                       |                                                         |             |                | B0.69   | 88.88                                    | 31.30                                                  | <sup>a</sup> Zofran Zydis            | GK |
| 8413T                                                                                                 | Wafer 8 mg                                              | 10          | 1              | ..      | 134.78                                   | 31.30                                                  | <sup>a</sup> Ondansetron-RL          | RE |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | Zydis                                |    |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ondaz Zydis             | HX |
|                                                                                                       |                                                         |             |                | B0.67   | 135.45                                   | 31.30                                                  | <sup>a</sup> Zofran Zydis            | GK |
| 8233H                                                                                                 | Syrup 4 mg per 5 mL, 50 mL                              | ≠ 1         | 1              | ..      | 88.19                                    | 31.30                                                  | Zofran syrup<br>50 mL                | GK |
| 1596B                                                                                                 | I.V. injection 4 mg in 2 mL                             | 1           | ..             | ..      | 25.38                                    | 26.41                                                  | <sup>a</sup> Ondansetron-RL          | RE |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ondaz                   | HX |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Onsetron                | AW |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> PF                      |    |
|                                                                                                       |                                                         |             |                | B0.70   | 26.08                                    | 26.41                                                  | <sup>a</sup> Zofran                  | GK |

continued ➞

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 1597C | I.V. injection 8 mg in 4 mL                             | 1           | ..             | ..      | 36.79                                    | 31.30                                                  | <sup>a</sup> Ondansetron-RL          | RE |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ondaz                   | HX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Onsetron                | AW |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> PF                      |    |
|       |                                                         |             |                | B0.69   | 37.48                                    | 31.30                                                  | <sup>a</sup> Zofran                  | GK |

### TROPISETRON HYDROCHLORIDE

#### Restricted Benefit

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy.

|       |                                    |   |    |    |       |       |         |    |
|-------|------------------------------------|---|----|----|-------|-------|---------|----|
| 2745L | Capsule 5 mg (base)                | 2 | .. | .. | 50.29 | 31.30 | Navoban | NV |
| 2746M | I.V. injection 5 mg (base) in 5 mL | 1 | .. | .. | 28.86 | 29.89 | Navoban | NV |

#### • Other antiemetics

#### APREPITANT

#### NOTE:

Aprepitant is not PBS-subsidised for nausea and vomiting associated with radiotherapy being used to treat malignancy.

#### Authority Required

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy, in combination with a 5HT3 antagonist and dexamethasone, where any 1 of the following chemotherapy agents are to be administered:

- (a) altretamine;
- (b) carmustine;
- (c) cisplatin when a single dose constitutes a cycle of chemotherapy;
- (d) cyclophosphamide at a dose of 1500 mg per square metre per day or greater;
- (e) dacarbazine;
- (f) procarbazine when a single dose constitutes a cycle of chemotherapy;
- (g) streptozocin.

No more than 1 pack containing 1 x 125 mg capsule and 2 x 80 mg capsules will be authorised per cycle of cytotoxic chemotherapy;

Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat breast cancer, in combination with a 5HT3 antagonist and dexamethasone, where cyclophosphamide and an anthracycline are to be co-administered.

No more than 1 pack containing 1 x 125 mg capsule and 2 x 80 mg capsules will be authorised per cycle of cytotoxic chemotherapy.

#### NOTE:

No applications for increased maximum quantities will be authorised. Prescribers should advise Medicare Australia of the number of cycles planned when requesting approval for repeats.

|       |                                                       |     |    |    |        |       |       |    |
|-------|-------------------------------------------------------|-----|----|----|--------|-------|-------|----|
| 8808N | Pack containing 1 capsule 125 mg and 2 capsules 80 mg | ± 1 | .. | .. | 147.91 | 31.30 | Emend | MK |
|-------|-------------------------------------------------------|-----|----|----|--------|-------|-------|----|

ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                                                          | Name, Restriction,<br>Manner of Administration and Form                                   | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                               |                                                                                           |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| PROCHLORPERAZINE                                                                                                              |                                                                                           |             |                |         |                             |                                             |                                      |    |
| <b><u>CAUTION:</u></b>                                                                                                        |                                                                                           |             |                |         |                             |                                             |                                      |    |
| Prochlorperazine may be associated with parkinsonism and tardive dyskinesia and should be used for short-term treatment only. |                                                                                           |             |                |         |                             |                                             |                                      |    |
| 2893G                                                                                                                         | Tablet containing prochlorperazine maleate 5 mg                                           | 25          | ..             | ..      | 8.55                        | 9.58                                        | <sup>a</sup> Stemzine                | AV |
|                                                                                                                               |                                                                                           |             |                | B2.16   | 10.71                       | 9.58                                        | <sup>a</sup> Stemetil                | SW |
| 2369Q                                                                                                                         | Injection containing prochlorperazine mesylate 12.5 mg in 1 mL                            | 10          | ..             | ..      | 15.51                       | 16.54                                       | Stemetil                             | SW |
| 2895J                                                                                                                         | Suppositories containing prochlorperazine equivalent to 25 mg prochlorperazine maleate, 5 | ‡ 1         | 2              | ..      | 18.30                       | 19.33                                       | Stemetil                             | SW |

**NOTE:**

As prochlorperazine may be associated with parkinsonism and tardive dyskinesia it should be used for short-term treatment only. However, authorities for increased maximum quantities and/or repeats of prochlorperazine tablets will be granted for the treatment of emesis associated with malignant disease.

BILE AND LIVER THERAPY

**Bile therapy**

- **Bile acid preparations**  
**URSODEOXYCHOLIC ACID**

**Authority Required (STREAMLINED)**

1700

Primary biliary cirrhosis.

**NOTE:**

Not for use in the treatment of sclerosing cholangitis or cholelithiasis.

|       |                |     |   |    |        |       |  |          |    |
|-------|----------------|-----|---|----|--------|-------|--|----------|----|
| 8448P | Capsule 250 mg | 100 | 2 | .. | 185.97 | 31.30 |  | Ursofalk | OA |
|-------|----------------|-----|---|----|--------|-------|--|----------|----|

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                                                                                            | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                 |          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------|----------|
| <b>LAXATIVES</b>                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <b>Laxatives</b>                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| • <b>Contact laxatives</b>                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <b>BISACODYL</b>                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <b>Restricted Benefit</b>                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function;</i>                                                     |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities;</i> |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult;</i>                    |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>Patients receiving palliative care;</i>                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>Terminal malignant neoplasia;</i>                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>Anorectal congenital abnormalities;</i>                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>Megacolon.</i>                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| 1259G                                                                                                                                                           | Tablet 5 mg                                             | 200         | 2              | ..      | 14.17                                    | 15.20                                                  | Bisalax<br>Lax-Tab                                                   | AS<br>AE |
| 1260H                                                                                                                                                           | Suppositories 10 mg, 10                                 | 3           | 5              | ..      | * 21.44                                  | 22.47                                                  | <sup>a</sup> Petrus Bisacodyl<br>Suppositories                       | PP       |
|                                                                                                                                                                 |                                                         |             |                | B1.14   | * 22.58                                  | 22.47                                                  | <sup>a</sup> Dulcolax                                                | BY       |
| 1258F                                                                                                                                                           | Suppositories 10 mg, 12                                 | 3           | 4              | ..      | * 18.62                                  | 19.65                                                  | Fleet Laxative<br>Suppositories<br>Petrus Bisacodyl<br>Suppositories | FL<br>PP |
| • <b>Bulk producers</b>                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <b>STERCULIA with FRANGULA BARK</b>                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <b>Restricted Benefit</b>                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function;</i>                                                     |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities;</i> |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult;</i>                    |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>Patients receiving palliative care;</i>                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>Terminal malignant neoplasia;</i>                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>Anorectal congenital abnormalities;</i>                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| <i>Megacolon.</i>                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                                                      |          |
| 1104D                                                                                                                                                           | Granules 620 mg-80 mg per g<br>(62%-8%), 500 g          | ± 1         | 1              | ..      | 24.52                                    | 25.55                                                  | Normacol Plus                                                        | NE       |



## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                                                                                            | Name, Restriction,<br>Manner of Administration and Form                  | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| • <b>Osmotically acting laxatives</b>                                                                                                                           |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <b>LACTULOSE</b>                                                                                                                                                |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <i>Hepatic coma or precoma (chronic porto-systemic encephalopathy);</i>                                                                                         |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <i>Constipation in patients with malignant neoplasia.</i>                                                                                                       |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| 3064G                                                                                                                                                           | Mixture 3.34 g per 5 mL, 500 mL                                          | ‡ 1         | 5              | ..      | 13.80                                    | 14.83                                                  | <sup>a</sup> Actilax                 | AF |
|                                                                                                                                                                 |                                                                          |             |                |         |                                          |                                                        | <sup>a</sup> Genlac                  | AW |
|                                                                                                                                                                 |                                                                          |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Lactulose         | GX |
|                                                                                                                                                                 |                                                                          |             |                |         |                                          |                                                        | <sup>a</sup> Lac-Dol                 | GM |
|                                                                                                                                                                 |                                                                          |             |                |         |                                          |                                                        | <sup>a</sup> Lactocur                | HX |
|                                                                                                                                                                 |                                                                          |             |                | B1.67   | 15.47                                    | 14.83                                                  | <sup>a</sup> Duphalac                | SM |
| <b>MACROGOL 3350</b>                                                                                                                                            |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <i>Constipation in patients with malignant neoplasia;</i>                                                                                                       |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <i>Chronic constipation or faecal impaction not adequately controlled with first line interventions such as bulk-forming agents;</i>                            |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <i>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function not responding to other oral therapies.</i>              |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| 9146J                                                                                                                                                           | Sachets containing powder for solution<br>6.563 g with electrolytes, 30  | ‡ 1         | 5              | ..      | 18.10                                    | 19.13                                                  | Movicol-Half                         | NE |
| 8612G                                                                                                                                                           | Sachets containing powder for solution<br>13.125 g with electrolytes, 30 | ‡ 1         | 5              | ..      | 24.36                                    | 25.39                                                  | Movicol                              | NE |
| • <b>Enemas</b>                                                                                                                                                 |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <b>BISACODYL</b>                                                                                                                                                |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <i>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function;</i>                                                     |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities;</i> |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <i>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult;</i>                    |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients receiving palliative care;</i>                                                                                                                      |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <i>Terminal malignant neoplasia;</i>                                                                                                                            |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <i>Anorectal congenital abnormalities;</i>                                                                                                                      |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <i>Megacolon.</i>                                                                                                                                               |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| 1263L                                                                                                                                                           | Enemas 10 mg in 5 mL, 25                                                 | ‡ 1         | 2              | ..      | 37.97                                    | 31.30                                                  | Bisalax                              | AS |

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

### **SORBITOL with SODIUM CITRATE and SODIUM LAURYL SULFOACETATE**

#### **Restricted Benefit**

*Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function;*

*Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities;*

*For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult;*

*Patients receiving palliative care;*

*Terminal malignant neoplasia;*

*Anorectal congenital abnormalities;*

*Megacolon.*

|       |                                            |   |   |    |         |       |          |    |
|-------|--------------------------------------------|---|---|----|---------|-------|----------|----|
| 2091C | Enemas 3.125 g-450 mg-45 mg in 5 mL,<br>12 | 2 | 2 | .. | * 36.15 | 31.30 | Microlax | JT |
|-------|--------------------------------------------|---|---|----|---------|-------|----------|----|

#### **• Other laxatives**

#### **GLYCEROL**

#### **Restricted Benefit**

*Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function;*

*Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities;*

*For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult;*

*Patients receiving palliative care;*

*Terminal malignant neoplasia;*

*Anorectal congenital abnormalities;*

*Megacolon.*

|       |                                        |   |   |    |         |       |    |  |
|-------|----------------------------------------|---|---|----|---------|-------|----|--|
| 2555L | Suppositories 700 mg (for infants), 12 | 3 | 5 | .. | * 17.48 | 18.51 | PP |  |
| 2556M | Suppositories 1.4 g (for children), 12 | 3 | 5 | .. | * 17.87 | 18.90 | PP |  |
| 2557N | Suppositories 2.8 g (for adults), 12   | 3 | 5 | .. | * 18.32 | 19.35 | PP |  |

### ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ ANTIINFECTIVE AGENTS

#### **Intestinal antiinfectives**

#### **• Antibiotics**

#### **NEOMYCIN SULFATE**

|       |               |    |   |    |       |       |         |    |
|-------|---------------|----|---|----|-------|-------|---------|----|
| 2325J | Tablet 500 mg | 25 | 1 | .. | 14.62 | 15.65 | Neosulf | AF |
|-------|---------------|----|---|----|-------|-------|---------|----|

#### **NYSTATIN**

|       |                       |    |    |    |       |       |         |    |
|-------|-----------------------|----|----|----|-------|-------|---------|----|
| 1696G | Tablet 500,000 units  | 50 | .. | .. | 17.55 | 18.58 | Nilstat | SI |
| 1699K | Capsule 500,000 units | 50 | .. | .. | 17.55 | 18.58 | Nilstat | SI |

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                                                                                                       | Name, Restriction,<br>Manner of Administration and Form  | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                           |                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|------------------------------------------------------------------------------------------------|----------------|
| <b>VANCOMYCIN</b>                                                                                                                                                          |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| <b>Authority Required</b>                                                                                                                                                  |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| <i>Antibiotic associated pseudomembranous colitis due to Clostridium difficile which is unresponsive to metronidazole;</i>                                                 |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| <i>Antibiotic associated pseudomembranous colitis due to Clostridium difficile where there is intolerance to metronidazole.</i>                                            |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| <b>NOTE:</b>                                                                                                                                                               |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| <i>Metronidazole has similar efficacy to vancomycin but may have less selective pressure to vancomycin resistant enterococci and is therefore the preferred treatment.</i> |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| 3113W                                                                                                                                                                      | Capsule 125 mg (125,000 i.u.)<br>vancomycin activity     | 40          | ..             | ..          | * 244.81                                 | 31.30                                                  | Vancocin                                                                                       | AS             |
| 3114X                                                                                                                                                                      | Capsule 250 mg (250,000 i.u.)<br>vancomycin activity     | 40          | ..             | ..          | * 465.61                                 | 31.30                                                  | Vancocin                                                                                       | AS             |
| <b>Electrolytes with carbohydrates</b>                                                                                                                                     |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| • <b>Oral rehydration salt formulations</b>                                                                                                                                |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| ELECTROLYTE REPLACEMENT (ORAL)                                                                                                                                             |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| 3196F                                                                                                                                                                      | Sachets containing powder for oral<br>solution 4.9 g, 10 | ‡ 1         | ..             | ..          | 12.90                                    | 13.93                                                  | <sup>a</sup> O.R.S.<br><sup>a</sup> Repalyte New<br>Formulation<br><sup>a</sup> restore O.R.S. | AS<br>SW<br>GM |
| <b>NOTE:</b>                                                                                                                                                               |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| Each sachet contains sodium chloride 470 mg, potassium chloride 300 mg, sodium acid citrate 530 mg and glucose 3.56 g.                                                     |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| <b>Antipropulsives</b>                                                                                                                                                     |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| • <b>Antipropulsives</b>                                                                                                                                                   |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| DIPHENOXYLATE HYDROCHLORIDE with ATROPINE<br>SULFATE                                                                                                                       |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| 2501P                                                                                                                                                                      | Tablet 2.5 mg-25 micrograms                              | 20          | ..             | ..<br>b1.83 | 8.19<br>10.02                            | 9.22<br>9.22                                           | <sup>a</sup> Lofenoxal<br><sup>a</sup> Lomotil                                                 | HC<br>BI       |
| LOPERAMIDE HYDROCHLORIDE                                                                                                                                                   |                                                          |             |                |             |                                          |                                                        |                                                                                                |                |
| 1571Q                                                                                                                                                                      | Capsule 2 mg                                             | 12          | ..             | ..<br>b0.94 | 8.16<br>9.10                             | 9.19<br>9.19                                           | <sup>a</sup> Gastro-Stop<br>Loperamide<br><sup>a</sup> Imodium                                 | AS<br>JT       |

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                     | Name, Restriction,<br>Manner of Administration and Form                                                                                         | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>Intestinal antiinflammatory agents</b>                                |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| • <b>Corticosteroids acting locally</b>                                  |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <b>HYDROCORTISONE ACETATE</b>                                            |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <u><b>Restricted Benefit</b></u>                                         |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Proctitis;</i>                                                        |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Ulcerative colitis.</i>                                               |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 1502C                                                                    | Rectal foam 90 mg per applicatorful, 14 applications, aerosol 21.1 g<br><i>[For other listings for this drug see Generic/Proprietary Index]</i> | 2           | 3              | ..      | * 38.55                                  | 31.30                                                  | Colifoam                             | AS |
| <b>PREDNISOLONE SODIUM PHOSPHATE</b>                                     |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 1920C                                                                    | Retention enema equivalent to 20 mg prednisolone in 100 mL                                                                                      | 28          | 3              | ..      | * 165.79                                 | 31.30                                                  | Predsol                              | SI |
| <b>PREDNISOLONE SODIUM PHOSPHATE</b>                                     |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <u><b>Restricted Benefit</b></u>                                         |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Proctitis;</i>                                                        |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Ulcerative colitis.</i>                                               |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 2554K                                                                    | Suppositories equivalent to 5 mg prednisolone, 10                                                                                               | 3           | 3              | ..      | * 38.39                                  | 31.30                                                  | Predsol                              | SI |
| • <b>Aminosalicylic acid and similar agents</b>                          |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <b>BALSALAZIDE SODIUM</b>                                                |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <u><b>Authority Required (STREAMLINED)</b></u>                           |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 1708                                                                     |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Ulcerative colitis where hypersensitivity to sulfonamides exists;</i> |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 1709                                                                     |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Ulcerative colitis where intolerance to sulfasalazine exists.</i>     |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <u><b>NOTE:</b></u>                                                      |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Not for the treatment of Crohn's disease.</i>                         |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 8845M                                                                    | Capsule 750 mg                                                                                                                                  | 180         | 5              | ..      | 124.42                                   | 31.30                                                  | Colazide                             | PK |
| <b>MESALAZINE</b>                                                        |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <u><b>Restricted Benefit</b></u>                                         |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Acute episode of mild to moderate ulcerative proctitis.</i>           |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <u><b>NOTE:</b></u>                                                      |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Not for the treatment of Crohn's disease.</i>                         |                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 8752P                                                                    | Suppositories 1 g, 28                                                                                                                           | ‡ 1         | ..             | ..      | 127.29                                   | 31.30                                                  | Pentasa                              | FP |

continued ➞

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

**NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*

**Authority Required (STREAMLINED)**

1708

*Ulcerative colitis where hypersensitivity to sulfonamides exists;*

1709

*Ulcerative colitis where intolerance to sulfasalazine exists;*

2268

*Crohn's disease where hypersensitivity to sulfonamides exists;*

2269

*Crohn's disease where intolerance to sulfasalazine exists.*

|       |                                                              |     |   |    |          |       |          |    |
|-------|--------------------------------------------------------------|-----|---|----|----------|-------|----------|----|
| 1611T | Tablet 250 mg (enteric coated)                               | 100 | 5 | .. | 93.00    | 31.30 | Mesasal  | GK |
| 8731M | Tablet 500 mg (enteric coated)                               | 200 | 5 | .. | * 297.01 | 31.30 | Salofalk | OA |
| 2214M | Tablet 500 mg (prolonged release)                            | 100 | 5 | .. | 156.15   | 31.30 | Pentasa  | FP |
| 2234N | Sachet containing prolonged release granules, 1 g per sachet | 100 | 5 | .. | 279.20   | 31.30 | Pentasa  | FP |
| 2287J | Sachet containing prolonged release granules, 2 g per sachet | 60  | 5 | .. | 311.87   | 31.30 | Pentasa  | FP |

**Authority Required (STREAMLINED)**

1708

*Ulcerative colitis where hypersensitivity to sulfonamides exists;*

1709

*Ulcerative colitis where intolerance to sulfasalazine exists.*

**NOTE:**

*Not for the treatment of Crohn's disease.*

|       |                                               |     |   |    |          |       |          |    |
|-------|-----------------------------------------------|-----|---|----|----------|-------|----------|----|
| 8598M | Sachet containing granules, 500 mg per sachet | 200 | 5 | .. | * 297.01 | 31.30 | Salofalk | OA |
| 8599N | Sachet containing granules, 1 g per sachet    | 100 | 5 | .. | 279.20   | 31.30 | Salofalk | OA |

continued ➡

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                         | Name, Restriction,<br>Manner of Administration and Form          | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------|------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b><u>Authority Required (STREAMLINED)</u></b>               |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| 1707                                                         |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Acute episode of mild to moderate ulcerative colitis.</i> |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                          |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Not for the treatment of Crohn's disease.</i>             |                                                                  |             |                |         |                                          |                                                        |                                      |    |
| 8753Q                                                        | Enemas 1 g in 100 mL, 7                                          | 4           | ..             | ..      | * 335.79                                 | 31.30                                                  | Pentasa                              | FP |
| 8616L                                                        | Enemas 2 g in 60 mL, 7                                           | 4           | ..             | ..      | * 335.79                                 | 31.30                                                  | Salofalk                             | OA |
| 8617M                                                        | Enemas 4 g in 60 mL, 7                                           | 4           | ..             | ..      | * 445.47                                 | 31.30                                                  | Salofalk                             | OA |
| 8768L                                                        | Rectal foam 1 g per applicatorful, 14 applications, aerosol 80 g | 4           | ..             | ..      | * 335.79                                 | 31.30                                                  | Salofalk                             | OA |

**NOTE:***No applications for increased maximum quantities and/or repeats will be authorised.***OLSALAZINE SODIUM****Authority Required (STREAMLINED)**

1708

*Ulcerative colitis where hypersensitivity to sulfonamides exists;*

1709

*Ulcerative colitis where intolerance to sulfasalazine exists.***NOTE:***Not for the treatment of Crohn's disease.*

|       |                |     |   |    |        |       |          |    |
|-------|----------------|-----|---|----|--------|-------|----------|----|
| 1728Y | Capsule 250 mg | 100 | 5 | .. | 60.98  | 31.30 | Dipentum | UC |
| 8086N | Tablet 500 mg  | 100 | 5 | .. | 102.86 | 31.30 | Dipentum | UC |

**SULFASALAZINE**

|       |                                |     |   |       |         |       |                             |    |
|-------|--------------------------------|-----|---|-------|---------|-------|-----------------------------|----|
| 2093E | Tablet 500 mg                  | 200 | 5 | ..    | * 52.31 | 31.30 | Salazopyrin                 | PH |
| 2096H | Tablet 500 mg (enteric coated) | 200 | 5 | ..    | * 56.61 | 31.30 | <sup>a</sup> Pyralin EN     | KR |
|       |                                |     |   | B1.58 | * 58.19 | 31.30 | <sup>a</sup> Salazopyrin-EN | PH |

|                                  |
|----------------------------------|
| <b>DIGESTIVES, INCL. ENZYMES</b> |
|----------------------------------|

**Digestives, incl. enzymes****• Enzyme preparations****PANCREATIC EXTRACT**

|       |                                                                                                                 |     |    |    |          |       |            |    |
|-------|-----------------------------------------------------------------------------------------------------------------|-----|----|----|----------|-------|------------|----|
| 8556H | Capsule (containing enteric coated minimicrospheres) providing not less than 5,000 BP units of lipase activity  | 500 | 10 | .. | * 118.79 | 31.30 | Creon 5000 | SM |
| 8020D | Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity | 500 | 10 | .. | * 170.34 | 31.30 | Creon      | SM |

continued ➞

ALIMENTARY TRACT AND METABOLISM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form                                                         | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|-----------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8021E | Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity | 200         | 10             | ..      | * 137.47                                 | 31.30                                                  | Creon Forte                          | SM |
|       | PANCRELIPASE                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 2495H | Capsule (containing enteric coated microspheres) providing not less than 10,000 BP units of lipase activity     | 500         | 10             | ..      | * 173.15                                 | 31.30                                                  | Cotazym-S Forte                      | OR |
| 8366H | Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity     | 200         | 10             | ..      | * 137.47                                 | 31.30                                                  | Panzytrat 25000                      | TM |

DRUGS USED IN DIABETES

Insulins and analogues

• *Insulins and analogues for injection, fast-acting*

INSULIN ASPART

|       |                                                       |   |   |    |          |       |                                                   |              |
|-------|-------------------------------------------------------|---|---|----|----------|-------|---------------------------------------------------|--------------|
| 8571D | Injection (human analogue) 100 units per mL, 10 mL    | 5 | 2 | .. | * 158.84 | 31.30 | NovoRapid                                         | NO           |
| 8435Y | Injections (human analogue) 100 units per mL, 3 mL, 5 | 5 | 1 | .. | * 263.79 | 31.30 | NovoRapid<br>FlexPen<br>NovoRapid Penfill<br>3 mL | NF<br><br>NO |

INSULIN GLULISINE

|       |                                                       |   |   |    |          |       |                 |    |
|-------|-------------------------------------------------------|---|---|----|----------|-------|-----------------|----|
| 1921D | Injections (human analogue) 100 units per mL, 3 mL, 5 | 5 | 1 | .. | * 263.79 | 31.30 | Apidra SoloStar | SW |
|-------|-------------------------------------------------------|---|---|----|----------|-------|-----------------|----|

INSULIN LISPRO

|       |                                                       |   |   |    |          |       |         |    |
|-------|-------------------------------------------------------|---|---|----|----------|-------|---------|----|
| 8084L | Injection (human analogue) 100 units per mL, 10 mL    | 5 | 2 | .. | * 158.84 | 31.30 | Humalog | LY |
| 8212F | Injections (human analogue) 100 units per mL, 3 mL, 5 | 5 | 1 | .. | * 263.79 | 31.30 | Humalog | LY |

INSULIN NEUTRAL

|       |                                              |   |   |    |          |       |                                       |          |
|-------|----------------------------------------------|---|---|----|----------|-------|---------------------------------------|----------|
| 1713E | Injection (bovine) 100 units per mL, 10 mL   | 5 | 2 | .. | * 144.59 | 31.30 | Hypurin Neutral                       | AS       |
| 1531N | Injection (human) 100 units per mL, 10 mL    | 5 | 2 | .. | * 133.39 | 31.30 | Actrapid<br>Humulin R                 | NO<br>LY |
| 1762R | Injections (human) 100 units per mL, 3 mL, 5 | 5 | 1 | .. | * 223.89 | 31.30 | Actrapid Penfill<br>3 mL<br>Humulin R | NO<br>LY |

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                         | Name, Restriction,<br>Manner of Administration and Form                      | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                          |                      |
|----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------------------------|----------------------|
| <b>• Insulins and analogues for injection, intermediate-acting</b>                           |                                                                              |             |                |         |                                          |                                                        |                                                                                               |                      |
| INSULIN ISOPHANE (N.P.H.)                                                                    |                                                                              |             |                |         |                                          |                                                        |                                                                                               |                      |
| 1711C                                                                                        | Injection (bovine) 100 units per mL,<br>10 mL                                | 5           | 2              | ..      | * 144.59                                 | 31.30                                                  | Hypurin Isophane                                                                              | AS                   |
| 1533Q                                                                                        | Injection (human) 100 units per mL,<br>10 mL                                 | 5           | 2              | ..      | * 133.39                                 | 31.30                                                  | Humulin NPH<br>Protaphane                                                                     | LY<br>NO             |
| 1761Q                                                                                        | Injections (human) 100 units per mL,<br>3 mL, 5                              | 5           | 1              | ..      | * 223.89                                 | 31.30                                                  | Humulin NPH<br>Protaphane InnoLet<br>Protaphane<br>NovoLet 3 mL<br>Protaphane Penfill<br>3 mL | LY<br>NI<br>NL<br>NO |
| <b>• Insulins and analogues for injection, intermediate-acting combined with fast-acting</b> |                                                                              |             |                |         |                                          |                                                        |                                                                                               |                      |
| INSULIN ASPART—INSULIN ASPART PROTAMINE<br>SUSPENSION                                        |                                                                              |             |                |         |                                          |                                                        |                                                                                               |                      |
| 8609D                                                                                        | Injections (human analogue) 100 units<br>(30 units-70 units) per mL, 3 mL, 5 | 5           | 1              | ..      | * 263.79                                 | 31.30                                                  | NovoMix 30<br>FlexPen<br>NovoMix 30 Penfill<br>3 mL                                           | NF<br>NO             |
| INSULIN LISPRO—INSULIN LISPRO PROTAMINE<br>SUSPENSION                                        |                                                                              |             |                |         |                                          |                                                        |                                                                                               |                      |
| 8390N                                                                                        | Injections (human analogue) 100 units<br>(25 units-75 units) per mL, 3 mL, 5 | 5           | 1              | ..      | * 263.79                                 | 31.30                                                  | Humalog Mix25                                                                                 | LY                   |
| 8874C                                                                                        | Injections (human analogue) 100 units<br>(50 units-50 units) per mL, 3 mL, 5 | 5           | 1              | ..      | * 263.79                                 | 31.30                                                  | Humalog Mix50                                                                                 | LY                   |
| INSULIN NEUTRAL—INSULIN ISOPHANE (N.P.H.),<br>(MIXED) (Biphasic Isophane)                    |                                                                              |             |                |         |                                          |                                                        |                                                                                               |                      |
| 1426C                                                                                        | Injection (human) 100 units<br>(30 units-70 units) per mL, 10 mL             | 5           | 2              | ..      | * 133.39                                 | 31.30                                                  | Humulin 30/70                                                                                 | LY                   |
| 1763T                                                                                        | Injections (human) 100 units<br>(30 units-70 units) per mL, 3 mL, 5          | 5           | 1              | ..      | * 223.89                                 | 31.30                                                  | Humulin 30/70<br>Mixtard 30/70<br>InnoLet<br>Mixtard 30/70<br>Penfill 3 mL                    | LY<br>NI<br>NO       |
| 2062M                                                                                        | Injections (human) 100 units<br>(50 units-50 units) per mL, 3 mL, 5          | 5           | 1              | ..      | * 223.89                                 | 31.30                                                  | Mixtard 50/50<br>Penfill 3 mL                                                                 | NO                   |



# ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                       | Name, Restriction,<br>Manner of Administration and Form  | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                                                                               |                                                                                  |    |
|------------------------------------------------------------|----------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----|
| <b>• Insulins and analogues for injection, long-acting</b> |                                                          |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                    |                                                                                  |    |
| <b>INSULIN DETEMIR</b>                                     |                                                          |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                    |                                                                                  |    |
| <b><u>Restricted Benefit</u></b>                           |                                                          |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                    |                                                                                  |    |
| <b>Type 1 diabetes.</b>                                    |                                                          |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                    |                                                                                  |    |
| 9040T                                                      | Injections (human analogue) 100 units<br>per mL, 3 mL, 5 | 5           | 1              | ..      | * 432.29                                 | 31.30                                                  | Levemir FlexPen<br>Levemir Penfill                                                                                                                                                                                                                                 | NF<br>NO                                                                         |    |
| INSULIN GLARGINE                                           |                                                          |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                    |                                                                                  |    |
| 9039R                                                      | Injections (human analogue) 100 units<br>per mL, 3 mL, 5 | 5           | 1              | ..      | * 432.29                                 | 31.30                                                  | Lantus<br>Lantus SoloStar                                                                                                                                                                                                                                          | SW<br>AV                                                                         |    |
| <b>Blood glucose lowering drugs, excl. insulins</b>        |                                                          |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                    |                                                                                  |    |
| <b>• Biguanides</b>                                        |                                                          |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                    |                                                                                  |    |
| METFORMIN HYDROCHLORIDE                                    |                                                          |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                    |                                                                                  |    |
| 2430X                                                      | Tablet 500 mg                                            | 100         | 5              | ..      | 12.66                                    | 13.69                                                  | a Chem mart<br>Metformin<br>a Diaformin<br>a Formet 500<br>a GenRx Metformin<br>a Glucohexal<br>a Glucomet 500 mg<br>a Metforbell<br>a Metformin 500<br>a Metformin<br>generichealth<br>a Terry White<br>Chemists<br>Metformin<br>a GN<br>a Glucophage<br>a Diabex | CH<br><br>AF<br>AW<br>GX<br>SZ<br>GM<br>BF<br>CR<br>GQ<br><br>TW<br><br>MQ<br>AL |    |
| 8884N                                                      | Tablet 500 mg (extended release)                         | 90          | 5              | ..      | B1.10<br>B1.40                           | 13.76<br>14.06                                         | 13.69<br>13.69                                                                                                                                                                                                                                                     | a Diabex XR                                                                      | AL |

continued ➞

# ALIMENTARY TRACT AND METABOLISM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer   |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------|----|
| 1801T | Tablet 850 mg                                           | 60          | 5              | ..      | 12.66                                    | 13.69                                                  | a Chem mart<br>Metformin               | CH |
|       |                                                         |             |                |         |                                          |                                                        | a Diaformin 850                        | AF |
|       |                                                         |             |                |         |                                          |                                                        | a Formet 850                           | AW |
|       |                                                         |             |                |         |                                          |                                                        | a GenRx Metformin                      | GX |
|       |                                                         |             |                |         |                                          |                                                        | a Glucohexal                           | SZ |
|       |                                                         |             |                |         |                                          |                                                        | a Glucomet 850 mg                      | GM |
|       |                                                         |             |                |         |                                          |                                                        | a Metforbell                           | BF |
|       |                                                         |             |                |         |                                          |                                                        | a Metformin 850                        | CR |
|       |                                                         |             |                |         |                                          |                                                        | a Metformin<br>generichealth           | GQ |
|       |                                                         |             |                |         |                                          |                                                        | a Terry White<br>Chemists<br>Metformin | TW |
|       |                                                         |             |                |         |                                          |                                                        | a GN                                   |    |
|       |                                                         |             |                | b1.10   | 13.76                                    | 13.69                                                  | a Glucophage                           | MQ |
|       |                                                         |             |                | b1.40   | 14.06                                    | 13.69                                                  | a Diabex 850                           | AL |
| 8607B | Tablet 1 g                                              | 90          | 5              | ..      | 17.61                                    | 18.64                                                  | a Diaformin 1000                       | AF |
|       |                                                         |             |                |         |                                          |                                                        | a Formet 1000                          | AW |
|       |                                                         |             |                |         |                                          |                                                        | a Glucohexal                           | SZ |
|       |                                                         |             |                | b1.41   | 19.02                                    | 18.64                                                  | a Diabex 1000                          | AL |

• **Sulfonamides, urea derivatives**

GLIBENCLAMIDE

**CAUTION:**

Sulfonylureas may cause hypoglycaemia, particularly in the elderly.

|       |             |     |   |       |       |       |          |    |
|-------|-------------|-----|---|-------|-------|-------|----------|----|
| 2939Q | Tablet 5 mg | 100 | 5 | ..    | 11.27 | 12.30 | a Glimel | AF |
|       |             |     |   | b1.21 | 12.48 | 12.30 | a Daonil | SW |

GLICLAZIDE

**CAUTION:**

Sulfonylureas may cause hypoglycaemia, particularly in the elderly.

|       |                                 |     |   |       |       |       |                                         |    |
|-------|---------------------------------|-----|---|-------|-------|-------|-----------------------------------------|----|
| 8535F | Tablet 30 mg (modified release) | 100 | 5 | ..    | 13.29 | 14.32 | a Diamicron MR                          | SE |
|       |                                 |     |   |       |       |       | a Oziclide MR                           | RA |
| 2449X | Tablet 80 mg                    | 100 | 5 | ..    | 13.09 | 14.12 | a Chem mart<br>Gliclazide               | CH |
|       |                                 |     |   |       |       |       | a GenRx Gliclazide                      | GX |
|       |                                 |     |   |       |       |       | a Glyade                                | AF |
|       |                                 |     |   |       |       |       | a Mellihexal                            | SZ |
|       |                                 |     |   |       |       |       | a Nidem                                 | AW |
|       |                                 |     |   |       |       |       | a Terry White<br>Chemists<br>Gliclazide | TW |
|       |                                 |     |   | b2.03 | 15.12 | 14.12 | a Diamicron                             | SE |

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>GLIMEPIRIDE</b>                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Sulfonylureas may cause hypoglycaemia, particularly in the elderly. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8450R                                                               | Tablet 1 mg                                             | 30          | 5              | ..      | 8.67                                     | 9.70                                                   | a Aylide 1                           | AF |
|                                                                     |                                                         |             |                |         |                                          |                                                        | a Diapride 1                         | AW |
|                                                                     |                                                         |             |                |         |                                          |                                                        | a Dimirel                            | AV |
|                                                                     |                                                         |             |                |         |                                          |                                                        | a Glimepiride Sandoz                 | SZ |
|                                                                     |                                                         |             |                | B1.89   | 10.56                                    | 9.70                                                   | a Amaryl                             | SW |
| 8451T                                                               | Tablet 2 mg                                             | 30          | 5              | ..      | 11.12                                    | 12.15                                                  | a Aylide 2                           | AF |
|                                                                     |                                                         |             |                |         |                                          |                                                        | a Diapride 2                         | AW |
|                                                                     |                                                         |             |                |         |                                          |                                                        | a Dimirel                            | AV |
|                                                                     |                                                         |             |                |         |                                          |                                                        | a Glimepiride Sandoz                 | SZ |
|                                                                     |                                                         |             |                | B1.89   | 13.01                                    | 12.15                                                  | a Amaryl                             | SW |
| 8533D                                                               | Tablet 3 mg                                             | 30          | 5              | ..      | 12.57                                    | 13.60                                                  | a Aylide 3                           | AF |
|                                                                     |                                                         |             |                |         |                                          |                                                        | a Diapride 3                         | AW |
|                                                                     |                                                         |             |                |         |                                          |                                                        | a Dimirel                            | AV |
|                                                                     |                                                         |             |                |         |                                          |                                                        | a Glimepiride Sandoz                 | SZ |
|                                                                     |                                                         |             |                | B1.90   | 14.47                                    | 13.60                                                  | a Amaryl                             | SW |
| 8452W                                                               | Tablet 4 mg                                             | 30          | 5              | ..      | 14.03                                    | 15.06                                                  | a Aylide 4                           | AF |
|                                                                     |                                                         |             |                |         |                                          |                                                        | a Diapride 4                         | AW |
|                                                                     |                                                         |             |                |         |                                          |                                                        | a Dimirel                            | AV |
|                                                                     |                                                         |             |                |         |                                          |                                                        | a Glimepiride Sandoz                 | SZ |
|                                                                     |                                                         |             |                | B1.90   | 15.93                                    | 15.06                                                  | a Amaryl                             | SW |
| <b>GLIPIZIDE</b>                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Sulfonylureas may cause hypoglycaemia, particularly in the elderly. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2440K                                                               | Tablet 5 mg                                             | 100         | 5              | ..      | 11.36                                    | 12.39                                                  | a Melizide                           | AF |
|                                                                     |                                                         |             |                | B4.07   | 15.43                                    | 12.39                                                  | a Minidiab                           | PH |
| <b>• Combinations of oral blood glucose lowering drugs</b>          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| METFORMIN HYDROCHLORIDE with GLIBENCLAMIDE                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Sulfonylureas may cause hypoglycaemia, particularly in the elderly. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8838E                                                               | Tablet 250 mg-1.25 mg                                   | 90          | 5              | ..      | 13.18                                    | 14.21                                                  | Glucovance 250mg/<br>1.25mg          | AL |
| 8810Q                                                               | Tablet 500 mg-2.5 mg                                    | 90          | 5              | ..      | 15.56                                    | 16.59                                                  | Glucovance 500mg/<br>2.5mg           | AL |
| 8811R                                                               | Tablet 500 mg-5 mg                                      | 90          | 5              | ..      | 16.74                                    | 17.77                                                  | Glucovance 500mg/<br>5mg             | AL |

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

### **ROSIGLITAZONE MALEATE with METFORMIN HYDROCHLORIDE**

#### **NOTE:**

*Rosiglitazone with metformin fixed dose combination tablet is not PBS-subsidised when used in combination with insulin.*

#### **Authority Required (STREAMLINED)**

2633

*Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with metformin and where a sulfonylurea is contraindicated or not tolerated.*

*The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated.*

#### **NOTE:**

*Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:*

*(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or*

*(b) red cell transfusion within the previous 3 months.*

*A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.*

#### **Authority Required (STREAMLINED)**

2634

*Type 2 diabetes, in combination with a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with maximally tolerated doses of metformin and a sulfonylurea.*

*The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated.*

#### **NOTE:**

*Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:*

*(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or*

*(b) red cell transfusion within the previous 3 months.*

*A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.*

|       |                           |    |   |    |       |       |           |    |
|-------|---------------------------|----|---|----|-------|-------|-----------|----|
| 9059T | Tablet 2 mg (base)-500 mg | 56 | 5 | .. | 64.66 | 31.30 | Avandamet | GK |
| 9060W | Tablet 2 mg (base)-1 g    | 56 | 5 | .. | 68.00 | 31.30 | Avandamet | GK |
| 9061X | Tablet 4 mg (base)-500 mg | 56 | 5 | .. | 94.33 | 31.30 | Avandamet | GK |
| 9062Y | Tablet 4 mg (base)-1 g    | 56 | 5 | .. | 97.66 | 31.30 | Avandamet | GK |

### • **Alpha glucosidase inhibitors**

#### **ACARBOSE**

|       |              |    |   |    |       |       |             |    |
|-------|--------------|----|---|----|-------|-------|-------------|----|
| 8188Y | Tablet 50 mg | 90 | 5 | .. | 30.47 | 31.30 | Glucobay 50 | BN |
|-------|--------------|----|---|----|-------|-------|-------------|----|

continued ➞

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|       |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| 8189B | Tablet 100 mg                                           | 90          | 5              | ..      | 40.49                       | 31.30                                       | Glucobay 100                         | BN |

### • Thiazolidinediones

#### PIOGLITAZONE HYDROCHLORIDE

##### Authority Required (STREAMLINED)

2635

*Dual oral combination therapy with metformin or a sulfonylurea*

*Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated. .*

*The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated.*

##### NOTE:

*Pioglitazone hydrochloride is not PBS-subsidised as monotherapy.*

*Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:*

*(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or*

*(b) red cell transfusion within the previous 3 months.*

*A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.*

##### Authority Required (STREAMLINED)

2638

*Combination therapy with insulin*

*Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with insulin and oral anti-diabetic agents, or insulin alone where metformin is contraindicated. .*

*The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated.*

##### NOTE:

*Pioglitazone hydrochloride is not PBS-subsidised as monotherapy.*

*Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:*

*(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or*

*(b) red cell transfusion within the previous 3 months.*

*A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.*

##### Authority Required (STREAMLINED)

2648

continued ➞

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| <p><b>Triple oral combination therapy with metformin and a sulfonylurea</b><br/>Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with maximally tolerated doses of metformin and a sulfonylurea. .</p> <p>The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated.</p> <p><b>NOTE:</b><br/>Pioglitazone hydrochloride is not PBS-subsidised as monotherapy.</p> <p>Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/>(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/>(b) red cell transfusion within the previous 3 months.<br/>A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.</p> |                                                         |             |                |         |                             |                                             |                                      |    |
| 8694N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Tablet 15 mg (base)                                     | 28          | 5              | ..      | 61.09                       | 31.30                                       | Actos                                | LY |
| 8695P                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Tablet 30 mg (base)                                     | 28          | 5              | ..      | 90.76                       | 31.30                                       | Actos                                | LY |
| 8696Q                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Tablet 45 mg (base)                                     | 28          | 5              | ..      | 116.21                      | 31.30                                       | Actos                                | LY |

### ROSIGLITAZONE MALEATE

#### Authority Required (STREAMLINED)

2635

**Dual oral combination therapy with metformin or a sulfonylurea**

Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated. .

The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated.

#### NOTE:

Rosiglitazone maleate is not PBS-subsidised as monotherapy.

Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:

(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or

(b) red cell transfusion within the previous 3 months.

A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.

#### Authority Required (STREAMLINED)

2648

continued ➞

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| <p><i>Triple oral combination therapy with metformin and a sulfonylurea</i></p> <p><i>Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with maximally tolerated doses of metformin and a sulfonylurea. .</i></p> <p><i>The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated.</i></p> <p><b>NOTE:</b><br/><i>Rosiglitazone maleate is not PBS-subsidised as monotherapy.</i></p> <p><i>Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:</i><br/><i>(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or</i><br/><i>(b) red cell transfusion within the previous 3 months.</i></p> <p><i>A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.</i></p> |                                                         |             |                |         |                             |                                             |                                      |    |
| 8689H                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Tablet 4 mg (base)                                      | 28          | 5              | ..      | 61.09                       | 31.30                                       | Avandia                              | GK |
| 8690J                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Tablet 8 mg (base)                                      | 28          | 5              | ..      | 90.76                       | 31.30                                       | Avandia                              | GK |

### • Dipeptidyl peptidase 4 (DPP-4) inhibitors

#### SITAGLIPTIN

##### **NOTE:**

Sitagliptin is not PBS-subsidised for use in combination with metformin and a sulfonylurea (triple oral therapy), as monotherapy or in combination with a thiazolidinedione (glitazone).

##### **Authority Required**

Dual oral combination therapy with metformin or a sulfonylurea

Type 2 diabetes, in combination with metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of sitagliptin despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.

The date and level of the qualifying HbA1c must be documented in the patient's medical records. The date of the HbA1c measurement, which must be no more than 4 months old at the time treatment is initiated, must be provided when the first authority application is made.

Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:

(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or

(b) red cell transfusion within the previous 3 months.

A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring must be documented in the patient's medical records. The date of measurement of the most recent blood glucose level, which must be no more than 4 months old at the time treatment is initiated, must be provided when the first authority application is made.

|       |                                         |    |   |    |       |       |         |    |
|-------|-----------------------------------------|----|---|----|-------|-------|---------|----|
| 9180E | Tablet 25 mg (as phosphate monohydrate) | 28 | 5 | .. | 90.76 | 31.30 | Januvia | MK |
|-------|-----------------------------------------|----|---|----|-------|-------|---------|----|

continued ➡

## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 9181F | Tablet 50 mg (as phosphate monohydrate)                 | 28          | 5              | ..      | 90.76                                    | 31.30                                                  | Januvia                              | MK |
| 9182G | Tablet 100 mg (as phosphate monohydrate)                | 28          | 5              | ..      | 90.76                                    | 31.30                                                  | Januvia                              | MK |

### VITAMINS

**Vitamin A and D, incl. combinations of the two**

• **Vitamin D and analogues**

**CALCITRIOL**

**Authority Required (STREAMLINED)**

1165

*Hypocalcaemia due to renal disease;*

1166

*Hypoparathyroidism;*

1167

*Hypophosphataemic rickets;*

1467

*Vitamin D-resistant rickets;*

2636

*Treatment for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.*

*A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.*

|       |                        |     |   |    |       |       |                               |    |
|-------|------------------------|-----|---|----|-------|-------|-------------------------------|----|
| 2502Q | Capsule 0.25 microgram | 100 | 3 | .. | 42.82 | 31.30 | <sup>a</sup> Calcitriol-DP    | GM |
|       |                        |     |   |    |       |       | <sup>a</sup> Citrihexal       | HX |
|       |                        |     |   |    |       |       | <sup>a</sup> GenRx Calcitriol | GX |
|       |                        |     |   |    |       |       | <sup>a</sup> Kosteo           | AW |
|       |                        |     |   |    |       |       | <sup>a</sup> Rocaltrol        | RO |
|       |                        |     |   |    |       |       | <sup>a</sup> Sical            | AF |

**Vitamin B<sub>1</sub>, plain and in combination with vitamin B<sub>6</sub> and vitamin B<sub>12</sub>**

• **Vitamin B<sub>1</sub>, plain**

**THIAMINE HYDROCHLORIDE**

**Authority Required (STREAMLINED)**

2384

*Prophylaxis of thiamine deficiency in an Aboriginal or a Torres Strait Islander person.*

|       |               |     |   |    |       |       |         |    |
|-------|---------------|-----|---|----|-------|-------|---------|----|
| 1070H | Tablet 100 mg | 100 | 2 | .. | 10.39 | 11.42 | Betamin | SW |
|-------|---------------|-----|---|----|-------|-------|---------|----|



## ALIMENTARY TRACT AND METABOLISM—CONT.

| Code                                    | Name, Restriction,<br>Manner of Administration and Form                                                                                                                                                                                                       | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>MINERAL SUPPLEMENTS</b>              |                                                                                                                                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
|                                         | <b>Calcium</b>                                                                                                                                                                                                                                                |             |                |         |                                          |                                                        |                                      |    |
|                                         | • <b>Calcium</b>                                                                                                                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
|                                         | <b>CALCIUM</b>                                                                                                                                                                                                                                                |             |                |         |                                          |                                                        |                                      |    |
|                                         | <b>Authority Required (STREAMLINED)</b>                                                                                                                                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
|                                         | 2212                                                                                                                                                                                                                                                          |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Hyperphosphataemia associated with chronic renal failure.</i>                                                                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 8560M                                   | Tablet 250 mg (as citrate)                                                                                                                                                                                                                                    | 240         | 1              | ..      | * 21.77                                  | 22.80                                                  | Citracal                             | BN |
| 3116B                                   | Tablet (chewable) 500 mg (as carbonate)                                                                                                                                                                                                                       | 240         | 1              | ..      | * 25.63                                  | 26.66                                                  | Cal-Sup                              | IA |
|                                         | <b>Potassium</b>                                                                                                                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
|                                         | • <b>Potassium</b>                                                                                                                                                                                                                                            |             |                |         |                                          |                                                        |                                      |    |
|                                         | POTASSIUM CHLORIDE                                                                                                                                                                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| 2642C                                   | Tablet 600 mg (sustained release)                                                                                                                                                                                                                             | 200         | 1              | ..      | * 12.87                                  | 13.90                                                  | <sup>a</sup> Duro-K                  | NM |
|                                         |                                                                                                                                                                                                                                                               |             |                | ..      | 12.87                                    | 13.90                                                  | Span-K                               | AS |
|                                         |                                                                                                                                                                                                                                                               |             |                | B2.80   | * 15.67                                  | 13.90                                                  | <sup>a</sup> Slow-K                  | NV |
|                                         | POTASSIUM CHLORIDE with POTASSIUM BICARBONATE                                                                                                                                                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 3012M                                   | Effervescent tablet 14 mmol potassium<br>and 8 mmol chloride                                                                                                                                                                                                  | 60          | 1              | ..      | 12.64                                    | 13.67                                                  | <sup>a</sup> K-Sol                   | LN |
|                                         |                                                                                                                                                                                                                                                               |             |                | B2.61   | 15.25                                    | 13.67                                                  | <sup>a</sup> Chlorvescent            | AS |
| <b>ANABOLIC AGENTS FOR SYSTEMIC USE</b> |                                                                                                                                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
|                                         | <b>Anabolic steroids</b>                                                                                                                                                                                                                                      |             |                |         |                                          |                                                        |                                      |    |
|                                         | • <b>Estren derivatives</b>                                                                                                                                                                                                                                   |             |                |         |                                          |                                                        |                                      |    |
|                                         | <b>NANDROLONE DECANOATE</b>                                                                                                                                                                                                                                   |             |                |         |                                          |                                                        |                                      |    |
|                                         | <b>Authority Required</b>                                                                                                                                                                                                                                     |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Monotherapy for osteoporosis, where other treatment has failed and where specialist advice confirms that this is the only suitable treatment option for the patient. Specialist advice need only be obtained for the first authority approval;</i>         |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Monotherapy for osteoporosis, where other treatment is not tolerated and where specialist advice confirms that this is the only suitable treatment option for the patient. Specialist advice need only be obtained for the first authority approval;</i>   |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Monotherapy for osteoporosis, where other treatment is contraindicated and where specialist advice confirms that this is the only suitable treatment option for the patient. Specialist advice need only be obtained for the first authority approval;</i> |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Patients receiving PBS-subsidised therapy with this drug for osteoporosis prior to 1 February 2004;</i>                                                                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Patients on long-term treatment with corticosteroids.</i>                                                                                                                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
|                                         | <b>NOTE:</b>                                                                                                                                                                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Monotherapy for the treatment of osteoporosis does not exclude calcium supplementation.</i>                                                                                                                                                                |             |                |         |                                          |                                                        |                                      |    |
| 1671Y                                   | Injection 50 mg in 1 mL, disposable<br>syringe                                                                                                                                                                                                                | 1           | 7              | ..      | 20.77                                    | 21.80                                                  | Deca-Durabolin                       | OR |

## BLOOD AND BLOOD FORMING ORGANS

| Code                                                                                      | Name, Restriction,<br>Manner of Administration and Form                      | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |          |
|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----------|
| <b>ANTITHROMBOTIC AGENTS</b>                                                              |                                                                              |             |                |         |                                          |                                                        |                                      |          |
| <b>Antithrombotic agents</b>                                                              |                                                                              |             |                |         |                                          |                                                        |                                      |          |
| • <b>Vitamin K antagonists</b>                                                            |                                                                              |             |                |         |                                          |                                                        |                                      |          |
| WARFARIN SODIUM                                                                           |                                                                              |             |                |         |                                          |                                                        |                                      |          |
| <b>CAUTION:</b>                                                                           |                                                                              |             |                |         |                                          |                                                        |                                      |          |
| The listed brands have NOT been shown to be bioequivalent and should not be interchanged. |                                                                              |             |                |         |                                          |                                                        |                                      |          |
| 2843P                                                                                     | Tablet 1 mg                                                                  | 50          | 2              | ..      | 11.99                                    | 13.02                                                  | Coumadin<br>Marevan                  | SI<br>FM |
| 2209G                                                                                     | Tablet 2 mg                                                                  | 50          | 2              | ..      | 12.34                                    | 13.37                                                  | Coumadin                             | SI       |
| 2844Q                                                                                     | Tablet 3 mg                                                                  | 50          | 2              | ..      | 12.26                                    | 13.29                                                  | Marevan                              | FM       |
| 2211J                                                                                     | Tablet 5 mg                                                                  | 50          | 2              | ..      | 13.60                                    | 14.63                                                  | Coumadin<br>Marevan                  | SI<br>FM |
| • <b>Heparin group</b>                                                                    |                                                                              |             |                |         |                                          |                                                        |                                      |          |
| DALTEPARIN SODIUM (Low Molecular Weight Heparin<br>Sodium—porcine mucous)                 |                                                                              |             |                |         |                                          |                                                        |                                      |          |
| 8603T                                                                                     | Injection 2,500 units (anti-Xa) in 0.2 mL<br>single dose pre-filled syringe  | 10          | 1              | ..      | 55.18                                    | 31.30                                                  | Fragmin                              | PH       |
| 2816F                                                                                     | Injection 5,000 units (anti-Xa) in 0.2 mL<br>single dose pre-filled syringe  | 10          | 1              | ..      | 57.22                                    | 31.30                                                  | Fragmin                              | PH       |
| 8271H                                                                                     | Injection 7,500 units (anti-Xa) in 0.75 mL<br>single dose pre-filled syringe | 10          | 1              | ..      | 83.22                                    | 31.30                                                  | Fragmin                              | PH       |
| 8269F                                                                                     | Injection 10,000 units (anti-Xa) in 1 mL<br>single dose pre-filled syringe   | 10          | 1              | ..      | 108.95                                   | 31.30                                                  | Fragmin                              | PH       |
| <hr/>                                                                                     |                                                                              |             |                |         |                                          |                                                        |                                      |          |
| <b>DALTEPARIN SODIUM (Low Molecular Weight Heparin<br/>Sodium—porcine mucous)</b>         |                                                                              |             |                |         |                                          |                                                        |                                      |          |
| <b>Restricted Benefit</b><br><b>Haemodialysis.</b>                                        |                                                                              |             |                |         |                                          |                                                        |                                      |          |
| 8641T                                                                                     | Injection 2,500 units (anti-Xa) in 0.2 mL<br>single dose pre-filled syringe  | 20          | 3              | ..      | * 104.31                                 | 31.30                                                  | Fragmin                              | PH       |
| 8642W                                                                                     | Injection 5,000 units (anti-Xa) in 0.2 mL<br>single dose pre-filled syringe  | 20          | 3              | ..      | * 108.45                                 | 31.30                                                  | Fragmin                              | PH       |
| 8643X                                                                                     | Injection 7,500 units (anti-Xa) in<br>0.75 mL single dose pre-filled syringe | 20          | 3              | ..      | * 160.45                                 | 31.30                                                  | Fragmin                              | PH       |

## BLOOD AND BLOOD FORMING ORGANS—CONT.

| Code                             | Name, Restriction,<br>Manner of Administration and Form              | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------|----------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>ENOXAPARIN SODIUM</b>         |                                                                      |             |                |         |                                          |                                                        |                                      |    |
| 8558K                            | Injection 20 mg (2,000 i.u. anti-Xa) in<br>0.2 mL pre-filled syringe | 10          | 1              | ..      | 55.18                                    | 31.30                                                  | Clexane                              | SW |
| 8510X                            | Injection 40 mg (4,000 i.u. anti-Xa) in<br>0.4 mL pre-filled syringe | 10          | 1              | ..      | 57.22                                    | 31.30                                                  | Clexane                              | SW |
| 9195Y                            | Solution for injection 40 mg (4,000 i.u.<br>anti-Xa) in 0.4 mL       | 10          | 1              | ..      | 57.22                                    | 31.30                                                  | Clexane                              | SW |
| 8262W                            | Injection 60 mg (6,000 i.u. anti-Xa) in<br>0.6 mL pre-filled syringe | 10          | 1              | ..      | 79.25                                    | 31.30                                                  | Clexane                              | SW |
| 8263X                            | Injection 80 mg (8,000 i.u. anti-Xa) in<br>0.8 mL pre-filled syringe | 10          | 1              | ..      | 90.27                                    | 31.30                                                  | Clexane                              | SW |
| 8264Y                            | Injection 100 mg (10,000 i.u. anti-Xa) in<br>1 mL pre-filled syringe | 10          | 1              | ..      | 108.65                                   | 31.30                                                  | Clexane                              | SW |
| <hr/>                            |                                                                      |             |                |         |                                          |                                                        |                                      |    |
| <b>ENOXAPARIN SODIUM</b>         |                                                                      |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b> |                                                                      |             |                |         |                                          |                                                        |                                      |    |
| <b><i>Haemodialysis.</i></b>     |                                                                      |             |                |         |                                          |                                                        |                                      |    |
| 8716R                            | Injection 20 mg (2,000 i.u. anti-Xa) in<br>0.2 mL pre-filled syringe | 20          | 3              | ..      | * 104.31                                 | 31.30                                                  | Clexane                              | SW |
| 8639Q                            | Injection 40 mg (4,000 i.u. anti-Xa) in<br>0.4 mL pre-filled syringe | 20          | 3              | ..      | * 108.45                                 | 31.30                                                  | Clexane                              | SW |
| 9196B                            | Solution for injection 40 mg (4,000 i.u.<br>anti-Xa) in 0.4 mL       | 20          | 3              | ..      | * 108.45                                 | 31.30                                                  | Clexane                              | SW |
| 8640R                            | Injection 60 mg (6,000 i.u. anti-Xa) in<br>0.6 mL pre-filled syringe | 20          | 3              | ..      | * 152.51                                 | 31.30                                                  | Clexane                              | SW |
| <b>HEPARIN SODIUM</b>            |                                                                      |             |                |         |                                          |                                                        |                                      |    |
| 1466E                            | Injection 5,000 units in 0.2 mL                                      | 5           | 5              | ..      | 12.60                                    | 13.63                                                  | HH                                   |    |
| 1463B                            | Injection (preservative-free) 5,000 units<br>in 5 mL                 | 50          | 5              | ..      | 52.50                                    | 31.30                                                  | PU                                   |    |
| 1076P                            | Injection 35,000 units in 35 mL                                      | 12          | 5              | ..      | * 209.75                                 | 31.30                                                  | HH                                   |    |

## BLOOD AND BLOOD FORMING ORGANS—CONT.

| Code                                                                                                                                                                                                                                      | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer        |          |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|---------------------------------------------|----------|
| <b>• Platelet aggregation inhibitors excl. heparin</b><br><b>ABCIXIMAB</b>                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                             |          |
| <b>Authority Required (STREAMLINED)</b>                                                                                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                             |          |
| 1716                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                             |          |
| <i>Patients undergoing percutaneous coronary balloon angioplasty;</i>                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                             |          |
| 1717                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                             |          |
| <i>Patients undergoing percutaneous coronary atherectomy;</i>                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                             |          |
| 1718                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                             |          |
| <i>Patients undergoing percutaneous coronary stent placement.</i>                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                             |          |
| 8048N                                                                                                                                                                                                                                     | I.V. injection 10 mg in 5 mL                            | 3           | ..             | ..      | * 1452.68                                | 31.30                                                  | ReoPro                                      | LY       |
| ASPIRIN                                                                                                                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                             |          |
| 8202Q                                                                                                                                                                                                                                     | Tablet 100 mg                                           | 112         | 1              | ..      | 7.70                                     | 8.73                                                   | <sup>a</sup> DBL Aspirin<br>100 mg          | FA       |
|                                                                                                                                                                                                                                           |                                                         |             |                | B1.36   | 9.06                                     | 8.73                                                   | <sup>a</sup> Astrix                         | HH       |
| 1010E                                                                                                                                                                                                                                     | Tablet 300 mg (dispersible)                             | 96          | 1              | ..      | 8.21                                     | 9.24                                                   | Solprin                                     | RC       |
| <b>CLOPIDOGREL HYDROGEN SULFATE</b>                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                             |          |
| <b>Authority Required (STREAMLINED)</b>                                                                                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                             |          |
| 1719                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                             |          |
| <i>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients with a history of symptomatic cerebrovascular ischaemic episodes while on therapy with low-dose aspirin;</i>                           |                                                         |             |                |         |                                          |                                                        |                                             |          |
| 1720                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                             |          |
| <i>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding;</i>                                                    |                                                         |             |                |         |                                          |                                                        |                                             |          |
| 1721                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                             |          |
| <i>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs;</i> |                                                         |             |                |         |                                          |                                                        |                                             |          |
| 1722                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                             |          |
| <i>Prevention of recurrence of myocardial infarction or unstable angina in patients with a history of symptomatic cardiac ischaemic events while on therapy with low-dose aspirin;</i>                                                    |                                                         |             |                |         |                                          |                                                        |                                             |          |
| 1723                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                             |          |
| <i>Prevention of recurrence of myocardial infarction or unstable angina in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding;</i>                                                                   |                                                         |             |                |         |                                          |                                                        |                                             |          |
| 1724                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                             |          |
| <i>Prevention of recurrence of myocardial infarction or unstable angina in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs.</i>                |                                                         |             |                |         |                                          |                                                        |                                             |          |
| <b>NOTE:</b>                                                                                                                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                             |          |
| <i>Not for prophylaxis of DVT or peripheral arterial disease.</i>                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                             |          |
| 8358X                                                                                                                                                                                                                                     | Tablet 75 mg (base)                                     | 28          | 5              | ..      | 82.79                                    | 31.30                                                  | <sup>a</sup> Iscover<br><sup>a</sup> Plavix | BQ<br>SW |

## BLOOD AND BLOOD FORMING ORGANS—CONT.

| Code                                                                                                                                                                                                                                      | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>DIPYRIDAMOLE</b>                                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events:</i>                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>(a) as adjunctive therapy with low-dose aspirin; or</i>                                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>(b) where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding; or</i>                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>(c) where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs.</i>                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8335Q                                                                                                                                                                                                                                     | Capsule 200 mg (sustained release)                      | 60          | 5              | ..      | 36.53                                    | 31.30                                                  | Persantin SR                         | BY |
| <b>DIPYRIDAMOLE with ASPIRIN</b>                                                                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events.</i>                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8382E                                                                                                                                                                                                                                     | Capsule 200 mg (sustained release)-25 mg                | 60          | 5              | ..      | 36.76                                    | 31.30                                                  | Asasantin SR                         | BY |
| <b>EPTIFIBATIDE ACETATE</b>                                                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                                                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1884                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients undergoing non-urgent percutaneous intervention with intracoronary stenting.</i>                                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8683B                                                                                                                                                                                                                                     | Solution for I.V. injection 20 mg (base) in 10 mL       | 2           | ..             | ..      | * 262.11                                 | 31.30                                                  | Integrilin                           | SH |
| 8684C                                                                                                                                                                                                                                     | Solution for I.V. infusion 75 mg (base) in 100 mL       | 3           | ..             | ..      | * 1019.93                                | 31.30                                                  | Integrilin                           | SH |
| <b>TICLOPIDINE HYDROCHLORIDE</b>                                                                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>CAUTION:</u></b>                                                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe neutropenia is common in the early months of therapy. Haematological monitoring should be undertaken at commencement and every two weeks in the first four months of therapy.</i>                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                                                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1719                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients with a history of symptomatic cerebrovascular ischaemic episodes while on therapy with low-dose aspirin;</i>                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1720                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding;</i>                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1721                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs;</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1260                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients established on this drug as a pharmaceutical benefit prior to 1 November 1999.</i>                                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2095G                                                                                                                                                                                                                                     | Tablet 250 mg                                           | 60          | 5              | ..      | 146.05                                   | 31.30                                                  | Tilodene                             | AF |

## BLOOD AND BLOOD FORMING ORGANS—CONT.

| Code                                    | Name, Restriction,<br>Manner of Administration and Form                                                                                                                                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|                                         |                                                                                                                                                                                                    |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |
| TIROFIBAN HYDROCHLORIDE                 |                                                                                                                                                                                                    |             |                |         |                             |                                             |                                      |
| <u>Authority Required (STREAMLINED)</u> |                                                                                                                                                                                                    |             |                |         |                             |                                             |                                      |
|                                         | 1729                                                                                                                                                                                               |             |                |         |                             |                                             |                                      |
|                                         | Patients with high risk unstable angina who have new transient or persistent ST-T ischaemic changes and anginal pain lasting longer than 20 minutes;                                               |             |                |         |                             |                                             |                                      |
|                                         | 1730                                                                                                                                                                                               |             |                |         |                             |                                             |                                      |
|                                         | Patients with high risk unstable angina who have new transient or persistent ST-T ischaemic changes and repetitive episodes of angina at rest or during minimal exercise in the previous 12 hours; |             |                |         |                             |                                             |                                      |
|                                         | 1275                                                                                                                                                                                               |             |                |         |                             |                                             |                                      |
|                                         | Patients with non-Q-wave myocardial infarction.                                                                                                                                                    |             |                |         |                             |                                             |                                      |
| 8350L                                   | Solution concentrate for I.V. infusion<br>12.5 mg (base) in 50 mL                                                                                                                                  | 1           | 2              | ..      | 362.68                      | 31.30                                       | Aggrastat MK                         |

### • Enzymes

#### **DROTRECOCIN ALFA (ACTIVATED)**

##### Authority Required

Adult patients with severe sepsis who have a high risk of death as determined by acute dysfunction in at least 2 organs or modified Apache II score of at least 25.

Acute organ dysfunction is defined as follows:

- (a) (1) For cardiovascular-system dysfunction, an arterial systolic blood pressure of less than or equal to 90 mmHg or mean arterial pressure of less than or equal to 70 mmHg for at least 1 hour despite adequate fluid resuscitation, adequate intravascular volume status or the use of vasopressors in an attempt to maintain a systolic blood pressure of greater than or equal to 90 mmHg or a mean arterial pressure of greater than or equal to 70 mmHg;
- (2) For kidney dysfunction, urine output of less than 0.5 mL per kg of body weight per hour for 1 hour despite adequate fluid resuscitation;
- (3) For respiratory-system dysfunction, a ratio of PaO<sub>2</sub> to FiO<sub>2</sub> of less than or equal to 250;
- (4) For haematologic dysfunction, a platelet count of less than 80,000 per cubic millimetre or which has decreased by 50 percent in the previous 3 days;
- (5) In the case of unexplained metabolic acidosis, a pH of less than or equal to 7.30 or a base deficit of greater than or equal to 5.0 mmol per L in association with a plasma lactate level of greater than 1.5 times the upper limit of the normal value for the reporting laboratory.

##### NOTE:

Medical practitioners should request the appropriate quantity of vials at the time of the authority application, according to the weight of the patient, to achieve a dose of 24 micrograms per kg per hour over a maximum of 96 hours.

|       |                               |   |    |    |        |       |        |    |
|-------|-------------------------------|---|----|----|--------|-------|--------|----|
| 8614J | Powder for I.V. infusion 5 mg | 1 | .. | .. | 466.71 | 31.30 | Xigris | LY |
|-------|-------------------------------|---|----|----|--------|-------|--------|----|

#### **RETEPLASE (Recombinant plasminogen activator)**

##### Restricted Benefit

Treatment of acute myocardial infarction within 6 hours of onset of attack.

|       |                                                                                                                                                      |     |    |    |         |       |                |    |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|----|---------|-------|----------------|----|
| 8253J | Pack containing 2 vials powder for<br>injection 10 units, 2 single use<br>pre-filled syringes with solvent, 2<br>reconstitution spikes and 2 needles | ± 1 | .. | .. | 2066.53 | 31.30 | Rapilysin 10 U | TA |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|----|---------|-------|----------------|----|

## BLOOD AND BLOOD FORMING ORGANS—CONT.

| Code                                                                                                                                                                                          | Name, Restriction,<br>Manner of Administration and Form      | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>TENECTEPLASE</b>                                                                                                                                                                           |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                              |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of acute myocardial infarction within 12 hours of onset of attack.</i>                                                                                                           |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 8526R                                                                                                                                                                                         | Powder for injection 40 mg with solvent                      | 1           | ..             | ..      | 1960.33                                  | 31.30                                                  | Metalyse                             | BY |
| 8527T                                                                                                                                                                                         | Powder for injection 50 mg with solvent                      | 1           | ..             | ..      | 2056.63                                  | 31.30                                                  | Metalyse                             | BY |
| • <b>Direct thrombin inhibitors</b>                                                                                                                                                           |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>BIVALIRUDIN TRIFLUOROACETATE</b>                                                                                                                                                           |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                                                                                                                |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 2147                                                                                                                                                                                          |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients undergoing non-emergency percutaneous coronary intervention.</i>                                                                                                                  |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                           |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <i>Bivalirudin trifluoroacetate has not been evaluated in patients undergoing emergency percutaneous coronary intervention, i.e. as primary or salvage therapy for myocardial infarction.</i> |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 8844L                                                                                                                                                                                         | Powder for I.V. injection 250 mg (base)                      | 1           | ..             | ..      | 671.32                                   | 31.30                                                  | Angiomax                             | CS |
| • <b>Other antithrombotic agents</b>                                                                                                                                                          |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>FONDAPARINUX SODIUM</b>                                                                                                                                                                    |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                                                                                                                |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 2005                                                                                                                                                                                          |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <i>Prevention of venous thromboembolic events in patients undergoing major hip surgery;</i>                                                                                                   |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 2006                                                                                                                                                                                          |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <i>Prevention of venous thromboembolic events in patients undergoing total knee replacement.</i>                                                                                              |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                           |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i>                                                                                                    |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 8775W                                                                                                                                                                                         | Injection 2.5 mg in 0.5 mL single dose<br>pre-filled syringe | 7           | ..             | ..      | 140.11                                   | 31.30                                                  | Arixtra                              | GK |
| <b>ANTHEMORRHAGICS</b>                                                                                                                                                                        |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>Antifibrinolytics</b>                                                                                                                                                                      |                                                              |             |                |         |                                          |                                                        |                                      |    |
| • <b>Amino acids</b>                                                                                                                                                                          |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>TRANEXAMIC ACID</b>                                                                                                                                                                        |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 2180R                                                                                                                                                                                         | Tablet 500 mg                                                | 100         | 2              | ..      | 51.25                                    | 31.30                                                  | Cyklokapron                          | PH |
| <b>ANTIANEMIC PREPARATIONS</b>                                                                                                                                                                |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>Iron preparations</b>                                                                                                                                                                      |                                                              |             |                |         |                                          |                                                        |                                      |    |
| • <b>Iron bivalent, oral preparations</b>                                                                                                                                                     |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>FERROUS SULFATE</b>                                                                                                                                                                        |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 8815Y                                                                                                                                                                                         | Oral liquid 30 mg per mL, 250 mL                             | ‡ 1         | 2              | ..      | 18.92                                    | 19.95                                                  | Ferro-Liquid                         | AE |





## BLOOD AND BLOOD FORMING ORGANS—CONT.

| Code                                                    | Name, Restriction,<br>Manner of Administration and Form                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------|------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS               |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| <b>Blood and related products</b>                       |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| • <b>Blood substitutes and plasma protein fractions</b> |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| GELATIN - SUCCINYLATED                                  |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 8444K                                                   | I.V. infusion 20 g per 500 mL, 500 mL                                              | 3           | ..             | ..      | * 45.32                                  | 31.30                                                  | Gelofusine                           | BR |
| POLYGELINE                                              |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 2334W                                                   | I.V. infusion 17.5 g per 500 mL (3.5%)<br>with electrolytes, 500 mL                | 3           | ..             | ..      | * 45.32                                  | 31.30                                                  | Haemaccel                            | AE |
| <b>I.V. solutions</b>                                   |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| • <b>Solutions for parenteral nutrition</b>             |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| GLUCOSE                                                 |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 2245E                                                   | I.V. infusion 278 mmol (anhydrous) per<br>L (5%), 1 L                              | 5           | 1              | ..      | * 25.49                                  | 26.52                                                  | BX                                   |    |
| • <b>Solutions affecting the electrolyte balance</b>    |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| ELECTROLYTE REPLACEMENT SOLUTION                        |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 3199J                                                   | I.V. infusion 1 L                                                                  | 2           | 1              | ..      | * 21.53                                  | 22.56                                                  | Plasma-Lyte 148                      | BX |
| SODIUM CHLORIDE                                         |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 2264E                                                   | I.V. infusion 154 mmol per L (0.9%), 1 L                                           | 5           | 1              | ..      | * 25.49                                  | 26.52                                                  | BX                                   |    |
| 2260Y                                                   | I.V. infusion 513 mmol per L (3%), 1 L                                             | 2           | 1              | ..      | * 17.79                                  | 18.82                                                  | BX                                   |    |
| SODIUM CHLORIDE COMPOUND                                |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 2266G                                                   | I.V. infusion 1 L                                                                  | 4           | 1              | ..      | * 29.59                                  | 30.62                                                  | BX                                   |    |
| SODIUM CHLORIDE with GLUCOSE                            |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 2281C                                                   | I.V. infusion 31 mmol-222 mmol<br>(anhydrous) per L (0.18%-4%), 1 L                | 5           | 1              | ..      | * 25.49                                  | 26.52                                                  | BX                                   |    |
| 2279Y                                                   | I.V. infusion 19 mmol-104 mmol<br>(anhydrous) per 500 mL<br>(0.225%-3.75%), 500 mL | 5           | 1              | ..      | * 31.59                                  | 31.30                                                  | BX                                   |    |
| 2278X                                                   | I.V. infusion 39 mmol-69 mmol<br>(anhydrous) per 500 mL (0.45%-2.5%),<br>500 mL    | 5           | 1              | ..      | * 31.59                                  | 31.30                                                  | BX                                   |    |
| SODIUM LACTATE COMPOUND                                 |                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 2286H                                                   | I.V. infusion 1 L                                                                  | 5           | 1              | ..      | * 25.49                                  | 26.52                                                  | BX                                   |    |

## CARDIOVASCULAR SYSTEM

| Code                                                                                                                   | Name, Restriction,<br>Manner of Administration and Form   | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |          |
|------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----------|
| <b>CARDIAC THERAPY</b>                                                                                                 |                                                           |             |                |             |                                          |                                                        |                                      |          |
| <b>Cardiac glycosides</b>                                                                                              |                                                           |             |                |             |                                          |                                                        |                                      |          |
| • <b>Digitalis glycosides</b>                                                                                          |                                                           |             |                |             |                                          |                                                        |                                      |          |
| DIGOXIN                                                                                                                |                                                           |             |                |             |                                          |                                                        |                                      |          |
| 2605D                                                                                                                  | Tablet 62.5 micrograms                                    | 200         | 1              | ..<br>B1.79 | 10.23<br>12.02                           | 11.26 <sup>a</sup><br>11.26 <sup>a</sup>               | Sigmaxin-PG<br>Lanoxin-PG            | FM<br>SI |
| 1322N                                                                                                                  | Tablet 250 micrograms                                     | 100         | 1              | ..<br>B1.80 | 10.56<br>12.36                           | 11.59 <sup>a</sup><br>11.59 <sup>a</sup>               | Sigmaxin<br>Lanoxin                  | FM<br>SI |
| 3164M                                                                                                                  | Oral solution for children 50 micrograms<br>per mL, 60 mL | 2           | 3              | ..          | * 28.25                                  | 29.28                                                  | Lanoxin                              | SI       |
| <b>Antiarrhythmics, class I and III</b>                                                                                |                                                           |             |                |             |                                          |                                                        |                                      |          |
| • <b>Antiarrhythmics, class IA</b>                                                                                     |                                                           |             |                |             |                                          |                                                        |                                      |          |
| DISOPYRAMIDE                                                                                                           |                                                           |             |                |             |                                          |                                                        |                                      |          |
| 2923W                                                                                                                  | Capsule 100 mg                                            | 100         | 5              | ..          | 26.72                                    | 27.75                                                  | Rythmodan                            | SW       |
| 2924X                                                                                                                  | Capsule 150 mg                                            | 100         | 5              | ..          | 35.75                                    | 31.30                                                  | Rythmodan                            | SW       |
| • <b>Antiarrhythmics, class IB</b>                                                                                     |                                                           |             |                |             |                                          |                                                        |                                      |          |
| LIGNOCAINE HYDROCHLORIDE                                                                                               |                                                           |             |                |             |                                          |                                                        |                                      |          |
| 2875H                                                                                                                  | Injection 100 mg in 5 mL                                  | 5           | ..             | ..          | 36.90                                    | 31.30                                                  | PF                                   |          |
| 2876J                                                                                                                  | Infusion 500 mg in 5 mL                                   | 10          | ..             | ..          | 29.16                                    | 30.19                                                  | Xylocard 500                         | AP       |
| MEXILETINE HYDROCHLORIDE                                                                                               |                                                           |             |                |             |                                          |                                                        |                                      |          |
| 1682M                                                                                                                  | Capsule 50 mg                                             | 100         | 5              | ..          | 32.79                                    | 31.30                                                  | Mexitil                              | BY       |
| 1683N                                                                                                                  | Capsule 200 mg                                            | 100         | 5              | ..          | 63.36                                    | 31.30                                                  | Mexitil                              | BY       |
| • <b>Antiarrhythmics, class IC</b>                                                                                     |                                                           |             |                |             |                                          |                                                        |                                      |          |
| FLECAINIDE ACETATE                                                                                                     |                                                           |             |                |             |                                          |                                                        |                                      |          |
| <b>CAUTION:</b>                                                                                                        |                                                           |             |                |             |                                          |                                                        |                                      |          |
| <i>Flecainide acetate should be avoided in patients with poor cardiac function.</i>                                    |                                                           |             |                |             |                                          |                                                        |                                      |          |
| <b>Restricted Benefit</b>                                                                                              |                                                           |             |                |             |                                          |                                                        |                                      |          |
| <i>Serious supra-ventricular cardiac arrhythmias;</i>                                                                  |                                                           |             |                |             |                                          |                                                        |                                      |          |
| <i>Serious ventricular cardiac arrhythmias where treatment is initiated in a hospital (in-patient or out-patient).</i> |                                                           |             |                |             |                                          |                                                        |                                      |          |
| 1088G                                                                                                                  | Tablet 50 mg                                              | 60          | 5              | ..          | 39.28                                    | 31.30                                                  | Tambocor                             | IA       |
| 1090J                                                                                                                  | Tablet 100 mg                                             | 60          | 5              | ..          | 46.37                                    | 31.30 <sup>a</sup>                                     | Flecatab <sup>a</sup><br>Tambocor    | AF<br>IA |

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                               | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                                                                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>• Antiarrhythmics, class III</b><br><b>AMIODARONE HYDROCHLORIDE</b><br><b>CAUTION:</b><br><i>Amiodarone hydrochloride has been reported to cause frequent and potentially serious toxicity.</i><br><i>Regular monitoring of hepatic and thyroid function is recommended.</i><br><b>Restricted Benefit</b><br><i>Severe cardiac arrhythmias.</i> |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                |
| 2344J                                                                                                                                                                                                                                                                                                                                              | Tablet 100 mg                                           | 30          | 5              | ..      | 14.59                                    | 15.62                                                  | <sup>a</sup> Aratac 100 AF<br><sup>a</sup> Cardinorm SZ<br><sup>a</sup> Cordarone X 100 SW<br><sup>a</sup> GenRx GX<br>Amiodarone<br><sup>a</sup> Rithmik 100 AW                                                                                                               |
| 2343H                                                                                                                                                                                                                                                                                                                                              | Tablet 200 mg                                           | 30          | 5              | ..      | 21.29                                    | 22.32                                                  | <sup>a</sup> Aratac 200 AF<br><sup>a</sup> Cardinorm SZ<br><sup>a</sup> Chem mart CH<br>Amiodarone<br><sup>a</sup> Cordarone X 200 SW<br><sup>a</sup> GenRx GX<br>Amiodarone<br><sup>a</sup> Rithmik 200 AW<br><sup>a</sup> Terry White TW<br>Chemists<br>Amiodarone           |
| <b>SOTALOL HYDROCHLORIDE</b><br><b>Restricted Benefit</b><br><i>Severe cardiac arrhythmias.</i>                                                                                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                |
| 8398B                                                                                                                                                                                                                                                                                                                                              | Tablet 80 mg                                            | 60          | 5              | ..      | 15.35                                    | 16.38                                                  | <sup>a</sup> GenRx Sotalol GX<br><sup>a</sup> Solavert AW<br><sup>a</sup> Sotahexal SZ<br>B3.53 18.88 16.38 <sup>a</sup> Sotacor BQ                                                                                                                                            |
| 2043M                                                                                                                                                                                                                                                                                                                                              | Tablet 160 mg                                           | 60          | 5              | ..      | 26.07                                    | 27.10                                                  | <sup>a</sup> Cardol AF<br><sup>a</sup> Chem mart Sotalol CH<br><sup>a</sup> GenRx Sotalol GX<br><sup>a</sup> Solavert AW<br><sup>a</sup> Sotab GM<br><sup>a</sup> Sotahexal SZ<br><sup>a</sup> Terry White TW<br>Chemists Sotalol<br>B3.53 29.60 27.10 <sup>a</sup> Sotacor BQ |
| <b>Cardiac stimulants excl. cardiac glycosides</b><br><b>• Adrenergic and dopaminergic agents</b><br><b>ADRENALINE</b>                                                                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                |
| 1016L                                                                                                                                                                                                                                                                                                                                              | Injection 1 mg in 1 mL (1 in 1,000)                     | 5           | 1              | ..      | 19.91                                    | 20.94                                                  | AP                                                                                                                                                                                                                                                                             |

## CARDIOVASCULAR SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

### ADRENALINE

#### Authority Required

*Initial supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient who:*

- (a) *has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician. The name of the specialist consulted must be provided at the time of application for initial supply; or*
- (b) *has been discharged from hospital or an emergency department after treatment with adrenaline for acute allergic reaction with anaphylaxis;*

*Continuing supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis, where the patient has previously been issued with an authority prescription for this drug.*

#### NOTE:

*The auto-injector should be provided in the framework of a comprehensive anaphylaxis prevention program and an emergency action plan including training in recognition of the symptoms of anaphylaxis and the use of the auto-injector device. (For further information see the Australasian Society of Clinical Immunology and Allergy website at [www.allergy.org.au](http://www.allergy.org.au).)*

|       |                                                                           |   |    |    |        |       |            |    |
|-------|---------------------------------------------------------------------------|---|----|----|--------|-------|------------|----|
| 8697R | I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector | 1 | .. | .. | 105.57 | 31.30 | EpiPen Jr. | CS |
| 8698T | I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector | 1 | .. | .. | 105.57 | 31.30 | EpiPen     | CS |

#### NOTE:

*Authorities for increased maximum quantities, up to a maximum of 2, may be authorised for children aged less than 17 years where 2 auto-injectors are necessary to ensure 1 is on hand at all times. No increased maximum quantities will be authorised for patients aged 17 years or older.*

*No repeats will be issued.*

### Vasodilators used in cardiac diseases

#### • Organic nitrates

##### GLYCERYL TRINITRATE

|                                                  |                                                                     |     |   |       |       |       |                           |                                     |
|--------------------------------------------------|---------------------------------------------------------------------|-----|---|-------|-------|-------|---------------------------|-------------------------------------|
| 1459T                                            | Tablets 600 micrograms, 100                                         | ± 1 | 5 | ..    | 11.96 | 12.99 | <sup>a</sup> Lycinate     | FM                                  |
|                                                  |                                                                     |     |   | B1.64 | 13.60 | 12.99 |                           | <sup>a</sup> Anginine Stabilised SI |
| 8171C                                            | Sublingual spray (pump pack)<br>400 micrograms per dose (200 doses) | ± 1 | 5 | ..    | 19.70 | 20.73 | Nitrolingual<br>Pumpspray | SW                                  |
| <b>NOTE:</b><br>The spray should not be inhaled. |                                                                     |     |   |       |       |       |                           |                                     |
| 8027L                                            | Transdermal patch releasing<br>approximately 5 mg per 24 hours      | 30  | 5 | ..    | 28.20 | 29.23 | Minitrans 5               | IA                                  |
| 1515R                                            | Transdermal patch releasing<br>approximately 5 mg per 24 hours      | 30  | 5 | ..    | 28.20 | 29.23 | Transiderm-Nitro<br>25    | NV                                  |
| 8010N                                            | Transdermal patch releasing<br>approximately 5 mg per 24 hours      | 30  | 5 | ..    | 28.20 | 29.23 | Nitro-Dur 5               | SH                                  |

continued ➞

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                 | Name, Restriction,<br>Manner of Administration and Form         | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                              |    |
|------------------------------------------------------|-----------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------|----|
| 8028M                                                | Transdermal patch releasing<br>approximately 10 mg per 24 hours | 30          | 5              | ..      | 35.11                                    | 31.30                                                  | Minitran 10                                                       | IA |
| 1516T                                                | Transdermal patch releasing<br>approximately 10 mg per 24 hours | 30          | 5              | ..      | 35.11                                    | 31.30                                                  | Transiderm-Nitro<br>50                                            | NV |
| 8011P                                                | Transdermal patch releasing<br>approximately 10 mg per 24 hours | 30          | 5              | ..      | 35.11                                    | 31.30                                                  | Nitro-Dur 10                                                      | SH |
| 8119H                                                | Transdermal patch releasing<br>approximately 15 mg per 24 hours | 30          | 5              | ..      | 35.11                                    | 31.30                                                  | Minitran 15                                                       | IA |
| 8026K                                                | Transdermal patch releasing<br>approximately 15 mg per 24 hours | 30          | 5              | ..      | 35.11                                    | 31.30                                                  | Nitro-Dur 15                                                      | SH |
| ISOSORBIDE DINITRATE                                 |                                                                 |             |                |         |                                          |                                                        |                                                                   |    |
| 2587E                                                | Tablet 10 mg                                                    | 200         | 2              | ..      | * 13.71                                  | 14.74                                                  | Sorbidin                                                          | AF |
| 2588F                                                | Sublingual tablet 5 mg                                          | 200         | 2              | ..      | * 14.61                                  | 15.64                                                  | Isordil Sublingual                                                | SI |
| ISOSORBIDE MONONITRATE                               |                                                                 |             |                |         |                                          |                                                        |                                                                   |    |
| 1558B                                                | Tablet 60 mg (sustained release)                                | 30          | 5              | ..      | 12.45                                    | 13.48                                                  | <sup>a</sup> Chem mart<br>Isosorbide<br>Mononitrate               | CH |
|                                                      |                                                                 |             |                |         |                                          |                                                        | <sup>a</sup> Duride                                               | AF |
|                                                      |                                                                 |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Isosorbide<br>Mononitrate                      | GX |
|                                                      |                                                                 |             |                |         |                                          |                                                        | <sup>a</sup> Imtrate 60 mg                                        | GM |
|                                                      |                                                                 |             |                |         |                                          |                                                        | <sup>a</sup> Isomonit                                             | SZ |
|                                                      |                                                                 |             |                |         |                                          |                                                        | <sup>a</sup> Monodur 60 mg                                        | PM |
|                                                      |                                                                 |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Isosorbide<br>Mononitrate | TW |
|                                                      |                                                                 |             |                | B2.22   | 14.67                                    | 13.48                                                  | <sup>a</sup> Imdur Durule                                         | AP |
| 8273K                                                | Tablet 120 mg (sustained release)                               | 30          | 5              | ..      | 21.31                                    | 22.34                                                  | <sup>a</sup> Monodur 120 mg                                       | PM |
|                                                      |                                                                 |             |                | B2.36   | 23.67                                    | 22.34                                                  | <sup>a</sup> Imdur 120 mg                                         | AP |
| • <b>Other vasodilators used in cardiac diseases</b> |                                                                 |             |                |         |                                          |                                                        |                                                                   |    |
| NICORANDIL                                           |                                                                 |             |                |         |                                          |                                                        |                                                                   |    |
| 8228C                                                | Tablets 10 mg, 60                                               | ‡ 1         | 5              | ..      | 22.30                                    | 23.33                                                  | Ikorel                                                            | SW |
| 8229D                                                | Tablets 20 mg, 60                                               | ‡ 1         | 5              | ..      | 29.08                                    | 30.11                                                  | Ikorel                                                            | SW |

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                           | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>PERHEXILINE MALEATE</b>                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Regular monitoring of drug serum levels is recommended.</i>                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b>                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1023                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Angina not responding to other therapy.</i>                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1822X                                                                          | Tablet 100 mg                                           | 100         | 5              | ..      | 53.07                                    | 31.30                                                  | Pexsig                               | SI |
| <b>ANTIHYPERTENSIVES</b>                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Antiadrenergic agents, centrally acting</b>                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Methyldopa</b>                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| METHYLDOPA                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1629R                                                                          | Tablet 250 mg                                           | 100         | 5              | ..      | 12.19                                    | 13.22                                                  | <sup>a</sup> Hydopa                  | AF |
|                                                                                |                                                         |             |                | B2.24   | 14.43                                    | 13.22                                                  | <sup>a</sup> Aldomet                 | MK |
| • <b>Imidazoline receptor agonists</b>                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| CLONIDINE                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 3145M                                                                          | Tablet 100 micrograms                                   | 100         | 5              | ..      | 28.45                                    | 29.48                                                  | Catapres 100                         | BY |
| 3141H                                                                          | Tablet 150 micrograms                                   | 100         | 5              | ..      | 37.01                                    | 31.30                                                  | Catapres                             | BY |
| <b>MOXONIDINE</b>                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Hypertension in patients receiving concurrent antihypertensive therapy.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9019Q                                                                          | Tablet 200 micrograms                                   | 30          | 5              | ..      | 19.10                                    | 20.13                                                  | Physiotens                           | SM |
| 9020R                                                                          | Tablet 400 micrograms                                   | 30          | 5              | ..      | 28.35                                    | 29.38                                                  | Physiotens                           | SM |
| <b>Antiadrenergic agents, peripherally acting</b>                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Alpha-adrenoceptor antagonists</b>                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| PRAZOSIN HYDROCHLORIDE                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1479W                                                                          | Tablet 1 mg (base)                                      | 100         | 5              | ..      | 12.19                                    | 13.22                                                  | <sup>a</sup> Chem mart<br>Prazosin   | CH |
|                                                                                |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Prazosin          | GX |
|                                                                                |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pressin 1               | AF |
|                                                                                |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists | TW |
|                                                                                |                                                         |             |                | B2.31   | 14.50                                    | 13.22                                                  | <sup>a</sup> Prazosin<br>Minipress   | PF |

continued ➞

## CARDIOVASCULAR SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer             |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------------------|----|
| 1480X | Tablet 2 mg (base)                                      | 100         | 5              | ..      | 14.50                                    | 15.53                                                  | <sup>a</sup> Chem mart<br>Prazosin               | CH |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Prazosin                      | GX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pressin 2                           | AF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Prazosin | TW |
|       |                                                         |             |                | B2.38   | 16.88                                    | 15.53                                                  | <sup>a</sup> Minipress                           | PF |
| 1478T | Tablet 5 mg (base)                                      | 100         | 5              | ..      | 20.42                                    | 21.45                                                  | <sup>a</sup> Chem mart<br>Prazosin               | CH |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Prazosin                      | GX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pressin 5                           | AF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Prazosin | TW |
|       |                                                         |             |                | B2.58   | 23.00                                    | 21.45                                                  | <sup>a</sup> Minipress                           | PF |

### Arteriolar smooth muscle, agents acting on

#### • **Hydrazinophthalazine derivatives**

HYDRALAZINE HYDROCHLORIDE

|       |              |     |   |    |         |       |               |    |
|-------|--------------|-----|---|----|---------|-------|---------------|----|
| 1640H | Tablet 25 mg | 200 | 2 | .. | * 15.07 | 16.10 | Alphapress 25 | AF |
| 1639G | Tablet 50 mg | 200 | 2 | .. | * 16.99 | 18.02 | Alphapress 50 | AF |

#### • **Pyrimidine derivatives**

MINOXIDIL

#### Authority Required (STREAMLINED)

2759

*Severe refractory hypertension. Treatment must be initiated by a consultant physician.*

|       |              |     |   |    |       |       |         |    |
|-------|--------------|-----|---|----|-------|-------|---------|----|
| 2313R | Tablet 10 mg | 100 | 5 | .. | 52.40 | 31.30 | Loniten | PH |
|-------|--------------|-----|---|----|-------|-------|---------|----|

### DIURETICS

#### Low-ceiling diuretics, thiazides

#### • **Thiazides, plain**

HYDROCHLOROTHIAZIDE

|       |              |     |   |    |       |       |            |    |
|-------|--------------|-----|---|----|-------|-------|------------|----|
| 1484D | Tablet 25 mg | 100 | 1 | .. | 20.81 | 21.84 | Dithiazide | PL |
|-------|--------------|-----|---|----|-------|-------|------------|----|

#### Low-ceiling diuretics, excl. thiazides

#### • **Sulfonamides, plain**

CHLORTHALIDONE

|       |              |     |   |    |         |       |             |    |
|-------|--------------|-----|---|----|---------|-------|-------------|----|
| 1585K | Tablet 25 mg | 100 | 1 | .. | * 13.21 | 14.24 | Hygroton 25 | NV |
|-------|--------------|-----|---|----|---------|-------|-------------|----|

## CARDIOVASCULAR SYSTEM—CONT.

| Code                          | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| INDAPAMIDE HEMIHYDRATE        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8532C                         | Tablet 1.5 mg (sustained release)                       | 90          | 1              | ..      | 17.85                                    | 18.88                                                  | Natrilix SR                          | SE |
| 2436F                         | Tablet 2.5 mg                                           | 90          | 1              | ..      | 17.05                                    | 18.08                                                  | <sup>a</sup> Chem mart               | CH |
|                               |                                                         |             |                |         |                                          |                                                        | Indapamide                           |    |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dapa-Tabs               | AF |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Indapamide        | GX |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Indahexal               | SZ |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Insig                   | SI |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Napamide 2.5 mg         | GM |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists | TW |
|                               |                                                         |             |                |         |                                          |                                                        | Indapamide                           |    |
|                               |                                                         |             |                | B2.56   | 19.61                                    | 18.08                                                  | <sup>a</sup> Natrilix                | SE |
| <b>High-ceiling diuretics</b> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Sulfonamides, plain</b>  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| FRUSEMIDE                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2414C                         | Tablet 20 mg                                            | 100         | 1              | ..      | * 8.59                                   | 9.62                                                   | Urex-M                               | FM |
|                               |                                                         |             |                | ..      | * 8.59                                   | 9.62                                                   | <sup>a</sup> Lasix-M                 | SW |
|                               |                                                         |             |                | ..      | 8.60                                     | 9.63                                                   | <sup>a</sup> Chem mart               | CH |
|                               |                                                         |             |                |         |                                          |                                                        | Frusemide                            |    |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Frusid                  | GM |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Frusemide         | GX |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists | TW |
|                               |                                                         |             |                |         |                                          |                                                        | Frusemide                            |    |
| 2412Y                         | Tablet 40 mg                                            | 100         | 1              | ..      | 8.36                                     | 9.39                                                   | Urex                                 | FM |
|                               |                                                         |             |                | ..      | 8.36                                     | 9.39                                                   | <sup>a</sup> Chem mart               | CH |
|                               |                                                         |             |                |         |                                          |                                                        | Frusemide                            |    |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Frusehexal 40 mg        | HX |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Frusid                  | GM |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Frusemide         | GX |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lasix                   | SW |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists | TW |
|                               |                                                         |             |                |         |                                          |                                                        | Frusemide                            |    |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Uremide                 | AF |
| 2415D                         | Tablet 500 mg                                           | 50          | 3              | ..      | 18.31                                    | 19.34                                                  | Urex-Forte                           | FM |
| 2411X                         | Oral solution 10 mg per mL, 30 mL                       | ‡ 1         | 3              | ..      | 15.29                                    | 16.32                                                  | Lasix                                | SW |
| 2413B                         | Injection 20 mg in 2 mL                                 | 5           | ..             | ..      | 10.05                                    | 11.08                                                  | <sup>a</sup> Frusehexal              | HX |
|                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lasix                   | SW |



## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                 |          |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|------------------------------------------------------|----------|
| <b>• Aryloxyacetic acid derivatives</b><br><b>ETHACRYNIC ACID</b><br><u><b>Restricted Benefit</b></u><br><i>Patients hypersensitive to other oral diuretics.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| 8748K                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Tablet 25 mg                                            | 200         | 1              | ..          | * 57.25                                  | 31.30                                                  | Edecrin                                              | FK       |
| <b>Potassium-sparing agents</b><br><b>• Aldosterone antagonists</b><br><b>EPLERENONE</b><br><b>CAUTION:</b><br><i>Serum electrolytes should be checked regularly.</i><br><b>Authority Required (STREAMLINED)</b><br>2637<br><i>Heart failure with a left ventricular ejection fraction of 40% or less occurring within 3 to 14 days following an acute myocardial infarction. Treatment with eplerenone must be commenced within 14 days of an acute myocardial infarction.</i><br><i>The date of the acute myocardial infarction and the date of initiation of eplerenone treatment must be documented in the patient's medical records when PBS-subsidised treatment is initiated.</i> |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| 8879H                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Tablet 25 mg                                            | 30          | 5              | ..          | 112.34                                   | 31.30                                                  | Inspra                                               | PF       |
| 8880J                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Tablet 50 mg                                            | 30          | 5              | ..          | 112.34                                   | 31.30                                                  | Inspra                                               | PF       |
| <b>SPIRONOLACTONE</b><br><b>CAUTION:</b><br><i>Serum electrolytes should be checked regularly.</i><br><b>CAUTION:</b><br><i>Appropriate contraceptive measures should be taken by women of child-bearing age in whom spironolactone therapy has been initiated.</i>                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| 2339D                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Tablet 25 mg                                            | 100         | 5              | ..<br>B1.44 | 12.06<br>13.50                           | 13.09<br>13.09                                         | <sup>a</sup> Spiractin 25<br><sup>a</sup> Aldactone  | AF<br>PH |
| 2340E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Tablet 100 mg                                           | 100         | 5              | ..<br>B1.99 | 29.89<br>31.88                           | 30.92<br>30.92                                         | <sup>a</sup> Spiractin 100<br><sup>a</sup> Aldactone | AF<br>PH |
| <b>• Other potassium-sparing agents</b><br><b>AMILORIDE HYDROCHLORIDE</b><br><b>CAUTION:</b><br><i>Serum electrolytes should be checked regularly.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| 3109P                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Tablet 5 mg                                             | 100         | 1              | ..          | * 10.55                                  | 11.58                                                  | Kaluril                                              | AF       |

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                         | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>Diuretics and potassium-sparing agents in combination</b> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Low-ceiling diuretics and potassium-sparing agents</b>  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| HYDROCHLOROTHIAZIDE with AMILORIDE                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| HYDROCHLORIDE                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Serum electrolytes should be checked regularly.              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1486F                                                        | Tablet 50 mg-5 mg                                       | 100         | 1              | ..      | * 13.45                                  | 14.48                                                  | Moduretic                            | MK |
| HYDROCHLOROTHIAZIDE with TRIAMTERENE                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Serum electrolytes should be checked regularly.              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1280J                                                        | Tablet 25 mg-50 mg                                      | 100         | 1              | ..      | 12.46                                    | 13.49                                                  | Hydrene 25/50                        | AF |
| <b>PERIPHERAL VASODILATORS</b>                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Peripheral vasodilators</b>                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Other peripheral vasodilators</b>                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>PHENOXYBENZAMINE HYDROCHLORIDE</b>                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Phaeochromocytoma;</i>                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Neurogenic urinary retention.</i>                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1862B                                                        | Capsule 10 mg                                           | 100         | 5              | ..      | 66.93                                    | 31.30                                                  | Dibenyline                           | GH |
| 1166J                                                        | Capsules 10 mg, 30                                      | 3           | 5              | ..      | * 204.47                                 | 31.30                                                  | Dibenyline                           | GH |
| <b>BETA BLOCKING AGENTS</b>                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Beta blocking agents</b>                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Beta blocking agents, non-selective</b>                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| OXPRENOLOL HYDROCHLORIDE                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2942W                                                        | Tablet 20 mg                                            | 100         | 5              | ..      | 9.57                                     | 10.60                                                  | Corbeton 20                          | AF |
| 2961W                                                        | Tablet 40 mg                                            | 100         | 5              | ..      | 11.35                                    | 12.38                                                  | Corbeton 40                          | AF |
| PINDOLOL                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 3062E                                                        | Tablet 5 mg                                             | 100         | 5              | ..      | 11.05                                    | 12.08                                                  | <sup>a</sup> Barbloc 5               | AF |
|                                                              |                                                         |             |                | B2.14   | 13.19                                    | 12.08                                                  | <sup>a</sup> Visken 5                | NV |
| 3065H                                                        | Tablet 15 mg                                            | 50          | 5              | ..      | 13.28                                    | 14.31                                                  | <sup>a</sup> Barbloc 15              | AF |
|                                                              |                                                         |             |                | B2.12   | 15.40                                    | 14.31                                                  | <sup>a</sup> Visken 15               | NV |
| PROPRANOLOL HYDROCHLORIDE                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2565B                                                        | Tablet 10 mg                                            | 100         | 5              | ..      | 9.76                                     | 10.79                                                  | Deralin 10                           | AF |
|                                                              |                                                         |             |                | B3.14   | 12.90                                    | 10.79                                                  | Inderal                              | AP |

continued 

## CARDIOVASCULAR SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 2566C | Tablet 40 mg                                            | 100         | 5              | ..      | 10.13                                    | 11.16                                                  | Deralin 40                           | AF |
|       |                                                         |             |                | B3.14   | 13.27                                    | 11.16                                                  | Inderal                              | AP |
| 2899N | Tablet 160 mg                                           | 50          | 5              | ..      | 10.58                                    | 11.61                                                  | Deralin 160                          | AF |

### SOTALOL HYDROCHLORIDE

*For listings see Generic/Proprietary Index*

#### • Beta blocking agents, selective

##### ATENOLOL

|       |              |    |   |       |       |       |                             |    |
|-------|--------------|----|---|-------|-------|-------|-----------------------------|----|
| 1081X | Tablet 50 mg | 30 | 5 | ..    | 9.84  | 10.87 | <sup>a</sup> Anselol 50 mg  | GM |
|       |              |    |   |       |       |       | <sup>a</sup> Atehexal       | SZ |
|       |              |    |   |       |       |       | <sup>a</sup> Chem mart      | CH |
|       |              |    |   |       |       |       | Atenolol                    |    |
|       |              |    |   |       |       |       | <sup>a</sup> GenRx Atenolol | GX |
|       |              |    |   |       |       |       | <sup>a</sup> Noten          | AF |
|       |              |    |   |       |       |       | <sup>a</sup> Tensig         | SI |
|       |              |    |   |       |       |       | <sup>a</sup> Terry White    | TW |
|       |              |    |   |       |       |       | Chemists                    |    |
|       |              |    |   |       |       |       | Atenolol                    |    |
|       |              |    |   | B2.79 | 12.63 | 10.87 | <sup>a</sup> Tenormin       | AP |

### BISOPROLOL FUMARATE

#### Authority Required (STREAMLINED)

1734

*Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated.*

|       |               |    |   |    |       |       |       |    |
|-------|---------------|----|---|----|-------|-------|-------|----|
| 8604W | Tablet 2.5 mg | 28 | 5 | .. | 55.08 | 31.30 | Bicor | AL |
| 8605X | Tablet 5 mg   | 28 | 5 | .. | 67.32 | 31.30 | Bicor | AL |
| 8606Y | Tablet 10 mg  | 28 | 5 | .. | 82.63 | 31.30 | Bicor | AL |

### METOPROLOL SUCCINATE

#### Authority Required (STREAMLINED)

1734

*Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated.*

|       |                                                                                                                                             |     |    |    |       |       |                          |    |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------|-----|----|----|-------|-------|--------------------------|----|
| 8818D | Pack containing 15 tablets 23.75 mg (controlled release), 15 tablets 47.5 mg (controlled release) and 15 tablets 95 mg (controlled release) | ≠ 1 | .. | .. | 94.25 | 31.30 | Toprol-XL Titration Pack | AP |
| 8732N | Tablet 23.75 mg (controlled release)                                                                                                        | 15  | .. | .. | 20.61 | 21.64 | Toprol-XL 23.75          | AP |
| 8733P | Tablet 47.5 mg (controlled release)                                                                                                         | 30  | 5  | .. | 72.03 | 31.30 | Toprol-XL 47.5           | AP |
| 8734Q | Tablet 95 mg (controlled release)                                                                                                           | 30  | 5  | .. | 88.53 | 31.30 | Toprol-XL 95             | AP |

continued ➞

CARDIOVASCULAR SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer               |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|----------------------------------------------------|----|
|       |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                                    |    |
| 8735R | Tablet 190 mg (controlled release)                      | 30          | 5              | ..      | 109.17                      | 31.30                                       | Toprol-XL 190                                      | AP |
|       | METOPROLOL TARTRATE                                     |             |                |         |                             |                                             |                                                    |    |
| 1324Q | Tablet 50 mg                                            | 100         | 5              | ..      | 10.41                       | 11.44                                       | <sup>a</sup> Chem mart<br>Metoprolol               | CH |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> GenRx Metoprolol                      | GX |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Metohexal                             | SZ |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Metolol                               | GM |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Metrol 50                             | AW |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Minax 50                              | AF |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Terry White<br>Chemists<br>Metoprolol | TW |
|       |                                                         |             |                | B2.35   | 12.76                       | 11.44                                       | Lopresor 50                                        | NV |
|       |                                                         |             |                | B2.54   | 12.95                       | 11.44                                       | <sup>a</sup> Betaloc                               | AP |
| 1325R | Tablet 100 mg                                           | 60          | 5              | ..      | 11.60                       | 12.63                                       | <sup>a</sup> Chem mart<br>Metoprolol               | CH |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> GenRx Metoprolol                      | GX |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Metohexal                             | SZ |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Metolol                               | GM |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Metrol 100                            | AW |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Minax 100                             | AF |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Terry White<br>Chemists<br>Metoprolol | TW |
|       |                                                         |             |                | B2.35   | 13.95                       | 12.63                                       | Lopresor 100                                       | NV |
|       |                                                         |             |                | B2.54   | 14.14                       | 12.63                                       | <sup>a</sup> Betaloc                               | AP |

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                                     | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                           |    |
|------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------|----|
| • <b>Alpha and beta blocking agents</b>                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                                                |    |
| <b>CARVEDILOL</b>                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                                                |    |
| <b>Authority Required (STREAMLINED)</b>                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                                                |    |
| 1734                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                                                |    |
| <i>Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated;</i> |                                                         |             |                |         |                                          |                                                        |                                                                |    |
| 1735                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                                                |    |
| <i>Patients receiving this drug as a pharmaceutical benefit prior to 1 August 2002.</i>                                                  |                                                         |             |                |         |                                          |                                                        |                                                                |    |
| 8255L                                                                                                                                    | Tablet 3.125 mg                                         | 30          | ..             | ..      | 18.53                                    | 19.56                                                  | <sup>a</sup> Chem mart<br>Carvedilol<br>3.125 mg               | CH |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dilasig 3.125                                     | SI |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dilatrend 3.125                                   | RO |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Carvedilol                                  | GX |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Kredex                                            | MD |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Carvedilol<br>3.125 mg | TW |
| 8256M                                                                                                                                    | Tablet 6.25 mg                                          | 60          | 5              | ..      | 62.71                                    | 31.30                                                  | <sup>a</sup> Chem mart<br>Carvedilol<br>6.25 mg                | CH |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dilasig 6.25                                      | SI |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dilatrend 6.25                                    | RO |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Carvedilol                                  | GX |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Kredex                                            | MD |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Carvedilol<br>6.25 mg  | TW |
| 8257N                                                                                                                                    | Tablet 12.5 mg                                          | 60          | 5              | ..      | 76.87                                    | 31.30                                                  | <sup>a</sup> Chem mart<br>Carvedilol<br>12.5 mg                | CH |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dilasig 12.5                                      | SI |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dilatrend 12.5                                    | RO |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Carvedilol                                  | GX |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Kredex                                            | MD |
|                                                                                                                                          |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Carvedilol<br>12.5 mg  | TW |

continued ➞

## CARDIOVASCULAR SYSTEM—CONT.

| Code                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8258P                   | Tablet 25 mg                                            | 60          | 5              | ..      | 94.60                                    | 31.30                                                  | <sup>a</sup> Chem mart               | CH |
|                         |                                                         |             |                |         |                                          |                                                        | Carvedilol 25 mg                     |    |
|                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dilasig 25              | SI |
|                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dilatrend 25            | RO |
|                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Carvedilol        | GX |
|                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Kredex                  | MD |
|                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                         |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                         |                                                         |             |                |         |                                          |                                                        | Carvedilol 25 mg                     |    |
| LABETALOL HYDROCHLORIDE |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1566K                   | Tablet 100 mg                                           | 100         | 5              | ..      | 15.40                                    | 16.43                                                  | <sup>a</sup> Presolol 100            | AF |
|                         |                                                         |             |                | B2.99   | 18.39                                    | 16.43                                                  | <sup>a</sup> Trandate                | SI |
| 1567L                   | Tablet 200 mg                                           | 100         | 5              | ..      | 21.48                                    | 22.51                                                  | <sup>a</sup> Presolol 200            | AF |
|                         |                                                         |             |                | B2.97   | 24.45                                    | 22.51                                                  | <sup>a</sup> Trandate                | SI |

### CALCIUM CHANNEL BLOCKERS

#### Selective calcium channel blockers with mainly vascular effects

#### • Dihydropyridine derivatives

##### NOTE:

The base-priced drugs in this therapeutic group are amlodipine, felodipine and nifedipine (except nifedipine controlled release tablet 20 mg).

##### AMLODIPINE

|       |                           |    |   |       |       |       |                                |    |
|-------|---------------------------|----|---|-------|-------|-------|--------------------------------|----|
| 2751T | Tablet 5 mg (as besylate) | 30 | 5 | ..    | 16.46 | 17.49 | <sup>a</sup> Amlodipine-GA     | GM |
|       |                           |    |   |       |       |       | <sup>a</sup> Amlodipine        | GQ |
|       |                           |    |   |       |       |       | generichealth                  |    |
|       |                           |    |   |       |       |       | <sup>a</sup> Amlodipine Sandoz | SZ |
|       |                           |    |   |       |       |       | <sup>a</sup> APO-Amlodipine    | TX |
|       |                           |    |   |       |       |       | <sup>a</sup> Chem mart         | CH |
|       |                           |    |   |       |       |       | Amlodipine                     |    |
|       |                           |    |   |       |       |       | <sup>a</sup> Ozlodip           | RA |
|       |                           |    |   |       |       |       | <sup>a</sup> Perivasc          | AF |
|       |                           |    |   |       |       |       | <sup>a</sup> Terry White       | TW |
|       |                           |    |   |       |       |       | Chemists                       |    |
|       |                           |    |   |       |       |       | Amlodipine                     |    |
|       |                           |    |   | B3.05 | 19.51 | 17.49 | <sup>a</sup> Norvasc           | PF |
| 1343Q | Tablet 5 mg (as maleate)  | 30 | 5 | ..    | 16.46 | 17.49 | <sup>a</sup> Amlo 5            | ZP |

##### NOTE:

Bioequivalence has been demonstrated between the tablet containing 5 mg amlodipine (as besylate) and the tablet containing 5 mg amlodipine (as maleate).

continued 

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                                                                       | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                           |                                                                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| 2752W                                                                                                                                                                      | Tablet 10 mg (as besylate)                              | 30          | 5              | ..      | 24.40                                    | 25.43                                                  | a Amlodipine-GA<br>a Amlodipine<br>generichealth<br>a Amlodipine Sandoz<br>a APO-Amlodipine<br>a Chem mart<br>Amlodipine<br>a Ozlodip<br>a Perivasc<br>a Terry White<br>Chemists<br>Amlodipine | GM<br>GQ<br><br>SZ<br>TX<br>CH<br><br>RA<br>AF<br>TW<br><br>PF |
|                                                                                                                                                                            |                                                         |             |                | b4.45   | 28.85                                    | 25.43                                                  | a Norvasc                                                                                                                                                                                      | PF                                                             |
| 1345T                                                                                                                                                                      | Tablet 10 mg (as maleate)                               | 30          | 5              | ..      | 24.40                                    | 25.43                                                  | a Amlo 10                                                                                                                                                                                      | ZP                                                             |
| <b>NOTE:</b><br>Bioequivalence has been demonstrated between the tablet containing 10 mg amlodipine (as besylate) and the tablet containing 10 mg amlodipine (as maleate). |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                |                                                                |
| FELODIPINE                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                |                                                                |
| 2361G                                                                                                                                                                      | Tablet 2.5 mg (extended release)                        | 30          | 5              | ..      | 13.05                                    | 14.08                                                  | a Felodur ER 2.5 mg                                                                                                                                                                            | AL                                                             |
|                                                                                                                                                                            |                                                         |             |                | b3.92   | 16.97                                    | 14.08                                                  | a Plendil ER                                                                                                                                                                                   | AP                                                             |
| 2366M                                                                                                                                                                      | Tablet 5 mg (extended release)                          | 30          | 5              | ..      | 15.71                                    | 16.74                                                  | a Felodil XR 5<br>a Felodur ER 5 mg                                                                                                                                                            | AW<br>AL                                                       |
|                                                                                                                                                                            |                                                         |             |                | b3.92   | 19.63                                    | 16.74                                                  | a Plendil ER                                                                                                                                                                                   | AP                                                             |
| 2367N                                                                                                                                                                      | Tablet 10 mg (extended release)                         | 30          | 5              | ..      | 23.38                                    | 24.41                                                  | a Felodil XR 10<br>a Felodur ER 10 mg                                                                                                                                                          | AW<br>AL                                                       |
|                                                                                                                                                                            |                                                         |             |                | b3.92   | 27.30                                    | 24.41                                                  | a Plendil ER                                                                                                                                                                                   | AP                                                             |
| LERCANIDIPINE HYDROCHLORIDE                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                |                                                                |
| 8534E                                                                                                                                                                      | Tablet 10 mg                                            | 30          | 5              | t2.01   | 22.04                                    | 21.06                                                  | Zanidip                                                                                                                                                                                        | SM                                                             |
| 8679T                                                                                                                                                                      | Tablet 20 mg                                            | 30          | 5              | t4.02   | 33.04                                    | 30.05                                                  | Zanidip                                                                                                                                                                                        | SM                                                             |

### LERCANIDIPINE HYDROCHLORIDE

#### **Authority Required**

*Adverse effects occurring with all of the base-priced drugs;*

*Drug interactions occurring with all of the base-priced drugs;*

*Drug interactions expected to occur with all of the base-priced drugs;*

*Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance.*

|       |              |    |   |    |       |       |         |    |
|-------|--------------|----|---|----|-------|-------|---------|----|
| 8939L | Tablet 10 mg | 30 | 5 | .. | 22.04 | 23.07 | Zanidip | SM |
| 8940M | Tablet 20 mg | 30 | 5 | .. | 33.04 | 31.30 | Zanidip | SM |

## CARDIOVASCULAR SYSTEM—CONT.

| Code       | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| NIFEDIPINE |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1694E      | Tablet 10 mg                                            | 60          | 5              | ..      | 15.43                                    | 16.46                                                  | a Adefin 10                          | AF |
|            |                                                         |             |                |         |                                          |                                                        | a Nypine 10                          | AW |
|            |                                                         |             |                | B1.17   | 16.60                                    | 16.46                                                  | a Adalat 10                          | BN |
| 1695F      | Tablet 20 mg                                            | 60          | 5              | ..      | 17.74                                    | 18.77                                                  | a Adefin 20                          | AF |
|            |                                                         |             |                |         |                                          |                                                        | a Chem mart                          | CH |
|            |                                                         |             |                |         |                                          |                                                        | Nifedipine                           |    |
|            |                                                         |             |                |         |                                          |                                                        | a GenRx Nifedipine                   | GX |
|            |                                                         |             |                |         |                                          |                                                        | a Nifehexal                          | HX |
|            |                                                         |             |                |         |                                          |                                                        | a Nyefax 20 mg                       | GM |
|            |                                                         |             |                |         |                                          |                                                        | a Nypine 20                          | AW |
|            |                                                         |             |                |         |                                          |                                                        | a Terry White<br>Chemists            | TW |
|            |                                                         |             |                |         |                                          |                                                        | Nifedipine                           |    |
|            |                                                         |             |                | B2.21   | 19.95                                    | 18.77                                                  | a Adalat 20                          | BN |
| 8610E      | Tablet 20 mg (controlled release)                       | 30          | 5              | r2.26   | 19.97                                    | 18.74                                                  | Adalat Oros 20mg                     | BN |
| 1906H      | Tablet 30 mg (controlled release)                       | 30          | 5              | ..      | 18.64                                    | 19.67                                                  | a Addos XR 30                        | AW |
|            |                                                         |             |                |         |                                          |                                                        | a Adefin XL 30                       | AF |
|            |                                                         |             |                | B2.54   | 21.18                                    | 19.67                                                  | a Adalat Oros 30                     | BN |
| 1907J      | Tablet 60 mg (controlled release)                       | 30          | 5              | ..      | 21.88                                    | 22.91                                                  | a Addos XR 60                        | AW |
|            |                                                         |             |                |         |                                          |                                                        | a Adefin XL 60                       | AF |
|            |                                                         |             |                | B2.81   | 24.69                                    | 22.91                                                  | a Adalat Oros 60                     | BN |

### NIFEDIPINE

#### **Authority Required**

*Adverse effects occurring with all of the base-priced drugs;*

*Drug interactions occurring with all of the base-priced drugs;*

*Drug interactions expected to occur with all of the base-priced drugs;*

*Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance.*

|       |                                   |    |   |    |       |       |                  |    |
|-------|-----------------------------------|----|---|----|-------|-------|------------------|----|
| 8938K | Tablet 20 mg (controlled release) | 30 | 5 | .. | 19.97 | 21.00 | Adalat Oros 20mg | BN |
|-------|-----------------------------------|----|---|----|-------|-------|------------------|----|

### Selective calcium channel blockers with direct cardiac effects

#### • **Phenylalkylamine derivatives**

VERAPAMIL HYDROCHLORIDE

#### **CAUTION:**

The myocardial depressant effects of this drug and of beta-blocking drugs are additive.

|       |              |     |   |       |       |       |            |    |
|-------|--------------|-----|---|-------|-------|-------|------------|----|
| 1248Q | Tablet 40 mg | 100 | 5 | ..    | 11.08 | 12.11 | a Anpec 40 | AF |
|       |              |     |   | B0.76 | 11.84 | 12.11 | a Isoptin  | AB |
| 1250T | Tablet 80 mg | 100 | 5 | ..    | 15.03 | 16.06 | a Anpec 80 | AF |
|       |              |     |   | B0.76 | 15.79 | 16.06 | a Isoptin  | AB |

continued ➡



## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                                                                          | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 1254B                                                                                                                                                                         | Tablet 120 mg                                           | 100         | 5              | ..      | 19.09                                    | 20.12                                                  | Isoptin                              | AB |
| 1253Y                                                                                                                                                                         | Tablet 160 mg                                           | 60          | 5              | ..      | 18.01                                    | 19.04                                                  | Isoptin                              | AB |
| 2208F                                                                                                                                                                         | Tablet 180 mg (sustained release)                       | 30          | 5              | ..      | 13.29                                    | 14.32                                                  | <sup>a</sup> Cordilox 180 SR         | KN |
|                                                                                                                                                                               |                                                         |             |                | B2.27   | 15.56                                    | 14.32                                                  | <sup>a</sup> Isoptin 180 SR          | AB |
| 1241H                                                                                                                                                                         | Tablet 240 mg (sustained release)                       | 30          | 5              | ..      | 15.72                                    | 16.75                                                  | <sup>a</sup> Anpec SR                | AF |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cordilox SR             | KN |
|                                                                                                                                                                               |                                                         |             |                | B2.26   | 17.98                                    | 16.75                                                  | <sup>a</sup> Isoptin SR              | AB |
| 2206D                                                                                                                                                                         | Capsule 160 mg (sustained release)                      | 30          | 5              | ..      | 12.02                                    | 13.05                                                  | Veracaps SR                          | SI |
| 2207E                                                                                                                                                                         | Capsule 240 mg (sustained release)                      | 30          | 5              | ..      | 15.81                                    | 16.84                                                  | Veracaps SR                          | SI |
| 1060T                                                                                                                                                                         | Injection 5 mg in 2 mL                                  | 5           | ..             | ..      | 11.95                                    | 12.98                                                  | Isoptin                              | AB |
| <b>• Benzothiazepine derivatives</b><br>DILTIAZEM HYDROCHLORIDE<br><b>CAUTION:</b><br>The myocardial depressant effects of this drug and of beta-blocking drugs are additive. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1335G                                                                                                                                                                         | Tablet 60 mg                                            | 90          | 5              | ..      | 15.77                                    | 16.80                                                  | <sup>a</sup> Cardizem                | SW |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Chem mart               | CH |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | Diltiazem                            |    |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Coras                   | AF |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Diltahexal              | SZ |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dilzem 60 mg            | GM |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Diltiazem         | GX |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | Diltiazem                            |    |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Vasocardol              | AV |
| 1312C                                                                                                                                                                         | Capsule 180 mg (controlled delivery)                    | 30          | 5              | ..      | 16.83                                    | 17.86                                                  | <sup>a</sup> Cardizem CD             | SW |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Chem mart               | CH |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | Diltiazem CD                         |    |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Diltahexal CD           | SZ |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dilzem CD               | GM |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Diltiazem         | GX |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | CD                                   |    |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | Diltiazem CD                         |    |
|                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Vasocardol CD           | AV |

continued ➞

## CARDIOVASCULAR SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 1313D | Capsule 240 mg (controlled delivery)                    | 30          | 5              | ..      | 20.64                                    | 21.67                                                  | a Cardizem CD                        | SW |
|       |                                                         |             |                |         |                                          |                                                        | a Chem mart                          | CH |
|       |                                                         |             |                |         |                                          |                                                        | Diltiazem CD                         |    |
|       |                                                         |             |                |         |                                          |                                                        | a Diltahexal CD                      | SZ |
|       |                                                         |             |                |         |                                          |                                                        | a Dilzem CD                          | GM |
|       |                                                         |             |                |         |                                          |                                                        | a GenRx Diltiazem<br>CD              | GX |
|       |                                                         |             |                |         |                                          |                                                        | a Terry White<br>Chemists            | TW |
|       |                                                         |             |                |         |                                          |                                                        | Diltiazem CD                         |    |
|       |                                                         |             |                |         |                                          |                                                        | a Vasocardol CD                      | AV |
| 8480H | Capsule 360 mg (controlled delivery)                    | 30          | 5              | ..      | 25.21                                    | 26.24                                                  | a Cardizem CD                        | SW |
|       |                                                         |             |                |         |                                          |                                                        | a Diltahexal CD                      | SZ |
|       |                                                         |             |                |         |                                          |                                                        | a Vasocardol CD                      | AV |

### AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

#### ACE inhibitors, plain

#### • ACE inhibitors, plain

##### **CAUTION:**

Use of ACE inhibitors during pregnancy is contraindicated since these drugs have been associated with foetal death in utero.

##### CAPTOPRIL

|       |                |    |   |       |       |       |                           |    |
|-------|----------------|----|---|-------|-------|-------|---------------------------|----|
| 1147J | Tablet 12.5 mg | 90 | 5 | ..    | 16.25 | 17.28 | a Acenorm 12.5 mg         | AF |
|       |                |    |   |       |       |       | a Captohexal              | SZ |
|       |                |    |   |       |       |       | a Chem mart               | CH |
|       |                |    |   |       |       |       | Captopril                 |    |
|       |                |    |   |       |       |       | a GenRx Captopril         | GX |
|       |                |    |   |       |       |       | a Terry White<br>Chemists | TW |
|       |                |    |   |       |       |       | Captopril                 |    |
|       |                |    |   |       |       |       | a GM                      |    |
|       |                |    |   | B1.93 | 18.18 | 17.28 | a Capoten                 | BQ |
| 1148K | Tablet 25 mg   | 90 | 5 | ..    | 20.84 | 21.87 | a Acenorm 25 mg           | AF |
|       |                |    |   |       |       |       | a Captohexal              | SZ |
|       |                |    |   |       |       |       | a Chem mart               | CH |
|       |                |    |   |       |       |       | Captopril                 |    |
|       |                |    |   |       |       |       | a GenRx Captopril         | GX |
|       |                |    |   |       |       |       | a Terry White<br>Chemists | TW |
|       |                |    |   |       |       |       | Captopril                 |    |
|       |                |    |   |       |       |       | a GM                      |    |
|       |                |    |   | B2.87 | 23.71 | 21.87 | a Capoten                 | BQ |

continued ➡

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                      | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 1149L                                                                     | Tablet 50 mg                                            | 90          | 5              | ..      | 35.27                                    | 31.30                                                  | a Acenorm 50 mg                      | AF |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Captopril                          | SZ |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Chem mart                          | CH |
|                                                                           |                                                         |             |                |         |                                          |                                                        | Captopril                            |    |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a GenRx Captopril                    | GX |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Terry White                        | TW |
|                                                                           |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                                                           |                                                         |             |                |         |                                          |                                                        | Captopril                            |    |
|                                                                           |                                                         |             |                | B2.87   | 38.14                                    | 31.30                                                  | a GM                                 |    |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Capoten                            | BQ |
| <hr/>                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAPTOPRIL</b>                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>For patients unable to take a solid dose form of an ACE inhibitor.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8760C                                                                     | Oral solution 5 mg per mL, 95 mL                        | ± 1         | 5              | ..      | 111.39                                   | 31.30                                                  | Capoten                              | BQ |
| ENALAPRIL MALEATE                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1370D                                                                     | Tablet 5 mg                                             | 30          | 5              | ..      | 12.71                                    | 13.74                                                  | a Alphapril                          | AF |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Auspril                            | SI |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Chem mart                          | CH |
|                                                                           |                                                         |             |                |         |                                          |                                                        | Enalapril                            |    |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Enahexal                           | SZ |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Enalabell                          | BF |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Enalapril-DP 5mg                   | GM |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Enalapril Winthrop                 | WA |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a GenRx Enalapril                    | GX |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Terry White                        | TW |
|                                                                           |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                                                           |                                                         |             |                | B2.46   | 15.17                                    | 13.74                                                  | a Renitec M                          | MK |
| 1368B                                                                     | Tablet 10 mg                                            | 30          | 5              | ..      | 17.02                                    | 18.05                                                  | a Alphapril                          | AF |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Auspril                            | SI |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Chem mart                          | CH |
|                                                                           |                                                         |             |                |         |                                          |                                                        | Enalapril                            |    |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Enahexal                           | SZ |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Enalabell                          | BF |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Enalapril-DP 10mg                  | GM |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Enalapril Winthrop                 | WA |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a GenRx Enalapril                    | GX |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Terry White                        | TW |
|                                                                           |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                                                           |                                                         |             |                | B2.46   | 19.48                                    | 18.05                                                  | a Amprace 10                         | FR |
|                                                                           |                                                         |             |                |         |                                          |                                                        | a Renitec                            | MK |

continued ➡

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                            |                                                        |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| 1369C | Tablet 20 mg                                            | 30          | 5              | ..      | 20.03                                    | 21.06                                                  | a Alphapril<br>a Auspril<br>a Chem mart<br>Enalapril<br>a Enahexal<br>a Enalabell<br>a Enalapril-DP 20mg<br>a Enalapril Winthrop<br>a GenRx Enalapril<br>a Terry White<br>Chemists<br>Enalapril | AF<br>SI<br>CH<br><br>SZ<br>BF<br>GM<br>WA<br>GX<br>TW |
|       |                                                         |             |                | b2.47   | 22.50                                    | 21.06                                                  | a Amprace 20<br>a Renitec 20                                                                                                                                                                    | FR<br>MK                                               |
|       | FOSINOPRIL SODIUM                                       |             |                |         |                                          |                                                        |                                                                                                                                                                                                 |                                                        |
| 1182F | Tablet 10 mg                                            | 30          | 5              | ..      | 15.47                                    | 16.50                                                  | a Fosinopril Sandoz<br>a Fosinopril<br>Winthrop<br>a Fosipril 10<br>a GenRx Fosinopril<br>a Monace 10<br>a Monopril                                                                             | SZ<br>WA<br><br>AW<br>GX<br>AF<br>BQ                   |
| 1183G | Tablet 20 mg                                            | 30          | 5              | ..      | 20.16                                    | 21.19                                                  | a Fosinopril Sandoz<br>a Fosinopril<br>Winthrop<br>a Fosipril 20<br>a GenRx Fosinopril<br>a Monace 20<br>a Monopril                                                                             | SZ<br>WA<br><br>AW<br>GX<br>AF<br>BQ                   |

CARDIOVASCULAR SYSTEM—CONT.

| Code       | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer    |    |
|------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|-----------------------------------------|----|
|            |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                         |    |
| LISINOPRIL |                                                         |             |                |         |                             |                                             |                                         |    |
| 2456G      | Tablet 5 mg                                             | 30          | 5              | ..      | 13.70                       | 14.73                                       | a Chem mart<br>Lisinopril               | CH |
|            |                                                         |             |                |         |                             |                                             | a Fibsol 5                              | AW |
|            |                                                         |             |                |         |                             |                                             | a GenRx Lisinopril                      | GX |
|            |                                                         |             |                |         |                             |                                             | a Liprace                               | GM |
|            |                                                         |             |                |         |                             |                                             | a Lisinobell                            | BF |
|            |                                                         |             |                |         |                             |                                             | a Lisinopril 5                          | CR |
|            |                                                         |             |                |         |                             |                                             | a Lisinopril Hexal                      | HX |
|            |                                                         |             |                |         |                             |                                             | a Lisinopril Winthrop                   | WA |
|            |                                                         |             |                |         |                             |                                             | a Lisinotrust 5                         | MI |
|            |                                                         |             |                |         |                             |                                             | a Lisodur                               | AF |
|            |                                                         |             |                |         |                             |                                             | a Terry White<br>Chemists<br>Lisinopril | TW |
|            |                                                         |             |                | b1.52   | 15.22                       | 14.73                                       | a Prinivil 5                            | MK |
|            |                                                         |             |                | b2.08   | 15.78                       | 14.73                                       | a Zestril                               | AP |
| 2457H      | Tablet 10 mg                                            | 30          | 5              | ..      | 17.56                       | 18.59                                       | a Chem mart<br>Lisinopril               | CH |
|            |                                                         |             |                |         |                             |                                             | a Fibsol 10                             | AW |
|            |                                                         |             |                |         |                             |                                             | a GenRx Lisinopril                      | GX |
|            |                                                         |             |                |         |                             |                                             | a Liprace                               | GM |
|            |                                                         |             |                |         |                             |                                             | a Lisinobell                            | BF |
|            |                                                         |             |                |         |                             |                                             | a Lisinopril 10                         | CR |
|            |                                                         |             |                |         |                             |                                             | a Lisinopril Hexal                      | HX |
|            |                                                         |             |                |         |                             |                                             | a Lisinopril Winthrop                   | WA |
|            |                                                         |             |                |         |                             |                                             | a Lisinotrust 10                        | MI |
|            |                                                         |             |                |         |                             |                                             | a Lisodur                               | AF |
|            |                                                         |             |                |         |                             |                                             | a Terry White<br>Chemists<br>Lisinopril | TW |
|            |                                                         |             |                | b1.53   | 19.09                       | 18.59                                       | a Prinivil 10                           | MK |
|            |                                                         |             |                | b2.08   | 19.64                       | 18.59                                       | a Zestril                               | AP |

continued ➡

# CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer     |    |
|-------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------|----|
| 2458J                                                                                                                   | Tablet 20 mg                                            | 30          | 5              | ..      | 20.56                                    | 21.59                                                  | a Chem mart<br>Lisinopril                | CH |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Fibsol 20                              | AW |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a GenRx Lisinopril                       | GX |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Liprace                                | GM |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Lisinobell                             | BF |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Lisinopril 20                          | CR |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Lisinopril<br>generichealth            | GQ |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Lisinopril Hexal                       | HX |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Lisinopril Winthrop                    | WA |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Lisinotrust 20                         | MI |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Lisodur                                | AF |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Terry White<br>Chemists<br>Lisinopril  | TW |
|                                                                                                                         |                                                         |             |                | B1.53   | 22.09                                    | 21.59                                                  | a Prinivil 20                            | MK |
|                                                                                                                         |                                                         |             |                | B2.08   | 22.64                                    | 21.59                                                  | a Zestril                                | AP |
| PERINDOPRIL                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                          |    |
| 3050M                                                                                                                   | Tablet containing 2 mg perindopril<br>erbumine          | 30          | 5              | ..      | 12.96                                    | 13.99                                                  | a Chem mart<br>Perindopril               | CH |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a GenRx Perindopril                      | GX |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Indopril 2                             | SI |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Perindo                                | AF |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Perindopril 2                          | CR |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Perindopril-DP                         | GM |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Terry White<br>Chemists<br>Perindopril | TW |
| 9006B                                                                                                                   | Tablet containing 2.5 mg perindopril<br>arginine        | 30          | 5              | ..      | 12.96                                    | 13.99                                                  | a Coversyl 2.5mg                         | SE |
| <b>NOTE:</b><br>Bioequivalence has been demonstrated between perindopril erbumine 2 mg and perindopril arginine 2.5 mg. |                                                         |             |                |         |                                          |                                                        |                                          |    |
| 3051N                                                                                                                   | Tablet containing 4 mg perindopril<br>erbumine          | 30          | 5              | ..      | 18.64                                    | 19.67                                                  | a Chem mart<br>Perindopril               | CH |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a GenRx Perindopril                      | GX |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Indopril 4                             | SI |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Perindo                                | AF |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Perindopril 4                          | CR |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Perindopril-DP                         | GM |
|                                                                                                                         |                                                         |             |                |         |                                          |                                                        | a Terry White<br>Chemists<br>Perindopril | TW |
| 9007C                                                                                                                   | Tablet containing 5 mg perindopril<br>arginine          | 30          | 5              | ..      | 18.64                                    | 19.67                                                  | a Coversyl 5mg                           | SE |

continued 

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                   | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                              |                                              |
|------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| <b>NOTE:</b><br>Bioequivalence has been demonstrated between perindopril erbumine 4 mg and perindopril arginine 5 mg.  |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                   |                                              |
| 8704D                                                                                                                  | Tablet containing 8 mg perindopril<br>erbumine          | 30          | 5              | ..      | 25.16                                    | 26.19                                                  | a Chem mart<br>Perindopril<br>a GenRx Perindopril<br>a Indopril 8<br>a Perindo<br>a Perindopril 8<br>a Perindopril-DP<br>a Terry White<br>Chemists<br>Perindopril | CH<br>GX<br>SI<br>AF<br>CR<br>GM<br>TW       |
| 9008D                                                                                                                  | Tablet containing 10 mg perindopril<br>arginine         | 30          | 5              | ..      | 25.16                                    | 26.19                                                  | a Coversyl 10mg                                                                                                                                                   | SE                                           |
| <b>NOTE:</b><br>Bioequivalence has been demonstrated between perindopril erbumine 8 mg and perindopril arginine 10 mg. |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                   |                                              |
| QUINAPRIL HYDROCHLORIDE                                                                                                |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                   |                                              |
| 1968N                                                                                                                  | Tablet 5 mg (base)                                      | 30          | 5              | ..      | 14.21                                    | 15.24                                                  | a Acquin 5<br>a APO-Quinapril<br>a Filpril<br>a Pharmacor<br>Quinapril 5<br>a Quinapril-DP<br>a Quinapril<br>generichealth<br>a Quinapril Sandoz<br>a Accupril    | AW<br>TX<br>AF<br>CR<br>GM<br>GQ<br>SZ<br>PF |
|                                                                                                                        |                                                         |             |                | b0.38   | 14.59                                    | 15.24                                                  |                                                                                                                                                                   |                                              |
| 1969P                                                                                                                  | Tablet 10 mg (base)                                     | 30          | 5              | ..      | 17.57                                    | 18.60                                                  | a Acquin 10<br>a APO-Quinapril<br>a Filpril<br>a Pharmacor<br>Quinapril 10<br>a Quinapril-DP<br>a Quinapril<br>generichealth<br>a Accupril                        | AW<br>TX<br>AF<br>CR<br>GM<br>GQ<br>PF       |
|                                                                                                                        |                                                         |             |                | b0.52   | 18.09                                    | 18.60                                                  |                                                                                                                                                                   |                                              |
| 1970Q                                                                                                                  | Tablet 20 mg (base)                                     | 30          | 5              | ..      | 20.27                                    | 21.30                                                  | a Acquin 20<br>a APO-Quinapril<br>a Filpril<br>a Pharmacor<br>Quinapril 20<br>a Quinapril-DP<br>a Quinapril<br>generichealth<br>a Quinapril Sandoz<br>a Accupril  | AW<br>TX<br>AF<br>CR<br>GM<br>GQ<br>SZ<br>PF |
|                                                                                                                        |                                                         |             |                | b0.77   | 21.04                                    | 21.30                                                  |                                                                                                                                                                   |                                              |

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                     | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| RAMIPRIL                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1944H                                                    | Tablet 1.25 mg                                          | 30          | 5              | ..      | 11.44                                    | 12.47                                                  | a Prilace 1.25                       | AW |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramace 1.25 mg                     | AV |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramipril Sandoz                    | SZ |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramipril Winthrop                  | WA |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Tritace 1.25 mg                    | SW |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Tryzan Tabs 1.25                   | AF |
| 9120B                                                    | Capsule 1.25 mg                                         | 30          | 5              | ..      | 11.44                                    | 12.47                                                  | a Pharmacor                          | CR |
|                                                          |                                                         |             |                |         |                                          |                                                        | Ramipril 1.25                        |    |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramipril-DP                        | GM |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramipril                           | GQ |
|                                                          |                                                         |             |                |         |                                          |                                                        | generichealth                        |    |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Tryzan Caps 1.25                   | AF |
| <b>NOTE:</b>                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Ramipril 1.25 mg tablets and capsules are bioequivalent. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1945J                                                    | Tablet 2.5 mg                                           | 30          | 5              | ..      | 13.97                                    | 15.00                                                  | a Prilace 2.5                        | AW |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramace 2.5 mg                      | AV |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramipril Sandoz                    | SZ |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramipril Winthrop                  | WA |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Tritace 2.5 mg                     | SW |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Tryzan Tabs 2.5                    | AF |
| 9121C                                                    | Capsule 2.5 mg                                          | 30          | 5              | ..      | 13.97                                    | 15.00                                                  | a Pharmacor                          | CR |
|                                                          |                                                         |             |                |         |                                          |                                                        | Ramipril 2.5                         |    |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramipril-DP                        | GM |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramipril                           | GQ |
|                                                          |                                                         |             |                |         |                                          |                                                        | generichealth                        |    |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Tryzan Caps 2.5                    | AF |
| <b>NOTE:</b>                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Ramipril 2.5 mg tablets and capsules are bioequivalent.  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1946K                                                    | Tablet 5 mg                                             | 30          | 5              | ..      | 16.01                                    | 17.04                                                  | a Prilace 5                          | AW |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramace 5 mg                        | AV |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramipril Sandoz                    | SZ |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramipril Winthrop                  | WA |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Tritace 5 mg                       | SW |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Tryzan Tabs 5                      | AF |
| 9122D                                                    | Capsule 5 mg                                            | 30          | 5              | ..      | 16.01                                    | 17.04                                                  | a Pharmacor                          | CR |
|                                                          |                                                         |             |                |         |                                          |                                                        | Ramipril 5                           |    |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramipril-DP                        | GM |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Ramipril                           | GQ |
|                                                          |                                                         |             |                |         |                                          |                                                        | generichealth                        |    |
|                                                          |                                                         |             |                |         |                                          |                                                        | a Tryzan Caps 5                      | AF |

**NOTE:**

Ramipril 5 mg tablets and capsules are bioequivalent.

continued 



## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                   | Name, Restriction,<br>Manner of Administration and Form                    | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------|----------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 1316G                                                  | Tablet 10 mg                                                               | 30          | 5              | ..      | 23.69                                    | 24.72                                                  | <sup>a</sup> Ramipril Sandoz         | SZ |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Tritace                 | SW |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Tryzan Tabs 10          | AF |
| 8470T                                                  | Capsule 10 mg                                                              | 30          | 5              | ..      | 23.69                                    | 24.72                                                  | <sup>a</sup> GenRx Ramipril          | GX |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Pharmacor               | CR |
|                                                        |                                                                            |             |                |         |                                          |                                                        | Ramipril 10                          |    |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Prilace 10              | AW |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Ramace 10 mg            | AV |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Ramipril-DP             | GM |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Ramipril                | GQ |
|                                                        |                                                                            |             |                |         |                                          |                                                        | generichealth                        |    |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Ramipril Sandoz         | SZ |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Ramipril Winthrop       | WA |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Tritace 10 mg           | SW |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Tryzan Caps 10          | AF |
| <b>NOTE:</b>                                           |                                                                            |             |                |         |                                          |                                                        |                                      |    |
| Ramipril 10 mg tablets and capsules are bioequivalent. |                                                                            |             |                |         |                                          |                                                        |                                      |    |
| 8668F                                                  | Pack containing 7 tablets 2.5 mg, 21<br>tablets 5 mg and 10 capsules 10 mg | ‡ 1         | ..             | ..      | 21.60                                    | 22.63                                                  | Tritace Titration<br>Pack            | SW |
| TRANDOLAPRIL                                           |                                                                            |             |                |         |                                          |                                                        |                                      |    |
| 2791X                                                  | Capsule 500 micrograms                                                     | 28          | 5              | ..      | 11.77                                    | 12.80                                                  | <sup>a</sup> APO-Trandolapril        | TX |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Dolapril 0.5            | AW |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Tranalpha               | AF |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Trandolapril-DP         | GM |
|                                                        |                                                                            |             |                | b1.57   | 13.34                                    | 12.80                                                  | <sup>a</sup> Gopten                  | AB |
|                                                        |                                                                            |             |                | b2.35   | 14.12                                    | 12.80                                                  | <sup>a</sup> Odrik                   | KN |
| 2792Y                                                  | Capsule 1 mg                                                               | 28          | 5              | ..      | 15.35                                    | 16.38                                                  | <sup>a</sup> APO-Trandolapril        | TX |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Dolapril 1              | AW |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Tranalpha               | AF |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Trandolapril-DP         | GM |
|                                                        |                                                                            |             |                | b1.57   | 16.92                                    | 16.38                                                  | <sup>a</sup> Gopten                  | AB |
|                                                        |                                                                            |             |                | b2.36   | 17.71                                    | 16.38                                                  | <sup>a</sup> Odrik                   | KN |
| 2793B                                                  | Capsule 2 mg                                                               | 28          | 5              | ..      | 16.14                                    | 17.17                                                  | <sup>a</sup> APO-Trandolapril        | TX |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Dolapril 2              | AW |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Tranalpha               | AF |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Trandolapril-DP         | GM |
|                                                        |                                                                            |             |                | b1.57   | 17.71                                    | 17.17                                                  | <sup>a</sup> Gopten                  | AB |
|                                                        |                                                                            |             |                | b2.36   | 18.50                                    | 17.17                                                  | <sup>a</sup> Odrik                   | KN |
| 8758Y                                                  | Capsule 4 mg                                                               | 28          | 5              | ..      | 25.28                                    | 26.31                                                  | <sup>a</sup> APO-Trandolapril        | TX |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Dolapril 4              | AW |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Tranalpha               | AF |
|                                                        |                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Trandolapril-DP         | GM |
|                                                        |                                                                            |             |                | b1.57   | 26.85                                    | 26.31                                                  | <sup>a</sup> Gopten                  | AB |

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                                | Name, Restriction,<br>Manner of Administration and Form                             | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                      |                              |
|-------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|
| <b>ACE inhibitors, combinations</b>                                                                                                 |                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                           |                              |
| <b><u>CAUTION:</u></b>                                                                                                              |                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                           |                              |
| Use of ACE inhibitors during pregnancy is contraindicated since these drugs have been associated with foetal death in utero.        |                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                           |                              |
| • <b>ACE inhibitors and diuretics</b>                                                                                               |                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                           |                              |
| <b>ENALAPRIL MALEATE with HYDROCHLOROTHIAZIDE</b>                                                                                   |                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                           |                              |
| <b><u>Restricted Benefit</u></b>                                                                                                    |                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                           |                              |
| <i>Hypertension in patients who are not adequately controlled with 20 mg enalapril maleate.</i>                                     |                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                           |                              |
| 8477E                                                                                                                               | Tablet 20 mg-6 mg                                                                   | 30          | 5              | ..      | 28.50                                    | 29.53                                                  | <sup>a</sup> Enalapril/HCT<br>Sandoz<br><sup>a</sup> Renitec Plus 20/6                                                                                                    | SZ<br><br>MK                 |
| <b>FOSINOPRIL SODIUM with HYDROCHLOROTHIAZIDE</b>                                                                                   |                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                           |                              |
| <b><u>Restricted Benefit</u></b>                                                                                                    |                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                           |                              |
| <i>Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or fosinopril sodium monotherapy.</i> |                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                           |                              |
| 8400D                                                                                                                               | Tablet 10 mg-12.5 mg                                                                | 30          | 5              | ..      | 21.83                                    | 22.86                                                  | <sup>a</sup> Fosinopril/HCT<br>Sandoz 10mg/<br>12.5mg<br><sup>a</sup> Fosinopril/HCT<br>Winthrop 10mg/<br>12.5mg<br><sup>a</sup> Hyforil<br><sup>a</sup> Monoplus 10/12.5 | SZ<br><br>WA<br><br>RA<br>BQ |
| 8401E                                                                                                                               | Tablet 20 mg-12.5 mg                                                                | 30          | 5              | ..      | 29.24                                    | 30.27                                                  | <sup>a</sup> Fosinopril/HCT<br>Sandoz 20mg/<br>12.5mg<br><sup>a</sup> Fosinopril/HCT<br>Winthrop 20mg/<br>12.5mg<br><sup>a</sup> Hyforil<br><sup>a</sup> Monoplus 20/12.5 | SZ<br><br>WA<br><br>RA<br>BQ |
| <b>PERINDOPRIL with INDAPAMIDE HEMIHYDRATE</b>                                                                                      |                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                           |                              |
| 2190G                                                                                                                               | Tablet containing 2.5 mg perindopril<br>arginine-0.625 mg indapamide<br>hemihydrate | 30          | 5              | ..      | 16.31                                    | 17.34                                                  | Coversyl Plus LD<br>2.5mg/0.625mg                                                                                                                                         | SE                           |

continued ➞

| Code                                                                                                                                                                                                        | Name, Restriction,<br>Manner of Administration and Form                          | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                                                                     |                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| <b>PERINDOPRIL with INDAPAMIDE HEMIHYDRATE</b>                                                                                                                                                              |                                                                                  |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                          |                      |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                            |                                                                                  |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                          |                      |
| <i>Hypertension in patients who are not adequately controlled with indapamide and/or perindopril.</i>                                                                                                       |                                                                                  |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                          |                      |
| 8449Q                                                                                                                                                                                                       | Tablet containing 4 mg perindopril<br>erbumine-1.25 mg indapamide<br>hemihydrate | 30          | 5              | ..      | 29.15                                    | 30.18                                                  | <sup>a</sup> Chem mart<br>Perindopril/<br>Indapamide 4/<br>1.25<br><sup>a</sup> GenRx<br>Perindopril/<br>Indapamide 4/<br>1.25<br><sup>a</sup> Perindo Combi 4/<br>1.25<br><sup>a</sup> Terry White<br>Chemists<br>Perindopril/<br>Indapamide 4/<br>1.25 | CH<br>GX<br>AF<br>TW |
| 2845R                                                                                                                                                                                                       | Tablet containing 5 mg perindopril<br>arginine-1.25 mg indapamide<br>hemihydrate | 30          | 5              | ..      | 29.15                                    | 30.18                                                  | <sup>a</sup> Coversyl Plus 5mg/<br>1.25mg                                                                                                                                                                                                                | SE                   |
| <b><u>NOTE:</u></b><br>Bioequivalence has been demonstrated between perindopril erbumine/indapamide hemihydrate tablet 4 mg-1.25 mg<br>and perindopril arginine/indapamide hemihydrate tablet 5 mg-1.25 mg. |                                                                                  |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                          |                      |
| <b>QUINAPRIL HYDROCHLORIDE with<br/>HYDROCHLOROTHIAZIDE</b>                                                                                                                                                 |                                                                                  |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                          |                      |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                            |                                                                                  |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                          |                      |
| <i>Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or quinapril<br/>hydrochloride monotherapy.</i>                                                               |                                                                                  |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                          |                      |
| 8589C                                                                                                                                                                                                       | Tablet 10 mg (base)-12.5 mg                                                      | 30          | 5              | ..      | 19.79                                    | 20.82                                                  | Accuretic 10/<br>12.5mg                                                                                                                                                                                                                                  | PF                   |
| 8590D                                                                                                                                                                                                       | Tablet 20 mg (base)-12.5 mg                                                      | 30          | 5              | ..      | 22.49                                    | 23.52                                                  | Accuretic 20/<br>12.5mg                                                                                                                                                                                                                                  | PF                   |
| • <b>ACE inhibitors and calcium channel blockers</b>                                                                                                                                                        |                                                                                  |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                          |                      |
| <b>LERCANIDIPINE HYDROCHLORIDE with ENALAPRIL<br/>MALEATE</b>                                                                                                                                               |                                                                                  |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                          |                      |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                            |                                                                                  |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                          |                      |
| <i>Hypertension in a patient who is not adequately controlled with either lercanidipine hydrochloride or enalapril<br/>maleate monotherapy.</i>                                                             |                                                                                  |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                          |                      |
| 9144G                                                                                                                                                                                                       | Tablet 10 mg-10 mg                                                               | 30          | 5              | ..      | 31.06                                    | 31.30                                                  | Zan-Extra 10/10                                                                                                                                                                                                                                          | SM                   |
| 9145H                                                                                                                                                                                                       | Tablet 10 mg-20 mg                                                               | 30          | 5              | ..      | 34.07                                    | 31.30                                                  | Zan-Extra 10/20                                                                                                                                                                                                                                          | SM                   |

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                                         | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer       |          |
|----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------------|----------|
| <b>RAMIPRIL with FELODIPINE</b>                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                            |          |
| <b><u>Restricted Benefit</u></b>                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                            |          |
| <i>Hypertension in a patient not adequately controlled with either ramipril or felodipine monotherapy.</i>                                   |                                                         |             |                |         |                                          |                                                        |                                            |          |
| 2626F                                                                                                                                        | Tablet 2.5 mg-2.5 mg (modified release)                 | 30          | 5              | ..      | 21.03                                    | 22.06                                                  | Triasyn 2.5/2.5                            | SW       |
| 2629J                                                                                                                                        | Tablet 5 mg-5 mg (modified release)                     | 30          | 5              | ..      | 25.72                                    | 26.75                                                  | Triasyn 5.0/5.0                            | SW       |
| <b>TRANDOLAPRIL with VERAPAMIL HYDROCHLORIDE</b>                                                                                             |                                                         |             |                |         |                                          |                                                        |                                            |          |
| <b><u>CAUTION:</u></b>                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                            |          |
| <i>The myocardial depressant effects of verapamil hydrochloride and of beta-blocking drugs are additive.</i>                                 |                                                         |             |                |         |                                          |                                                        |                                            |          |
| <b><u>Restricted Benefit</u></b>                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                            |          |
| <i>Hypertension in a patient who is stabilised on treatment with trandolapril 4 mg and verapamil hydrochloride sustained release 240 mg.</i> |                                                         |             |                |         |                                          |                                                        |                                            |          |
| 2857J                                                                                                                                        | Tablet 4 mg-240 mg (sustained release)                  | 28          | 5              | ..      | 34.35                                    | 31.30                                                  | Tarka 4/240                                | AB       |
| <b>Angiotensin II antagonists, plain</b>                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                            |          |
| • <b>Angiotensin II antagonists, plain</b>                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                            |          |
| CANDESARTAN CILEXETIL                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                            |          |
| 8295N                                                                                                                                        | Tablet 4 mg                                             | 30          | 5              | ..      | 20.49                                    | 21.52                                                  | Atacand                                    | AP       |
| 8296P                                                                                                                                        | Tablet 8 mg                                             | 30          | 5              | ..      | 24.30                                    | 25.33                                                  | Atacand                                    | AP       |
| 8297Q                                                                                                                                        | Tablet 16 mg                                            | 30          | 5              | ..      | 30.13                                    | 31.16                                                  | Atacand                                    | AP       |
| 8889W                                                                                                                                        | Tablet 32 mg                                            | 30          | 5              | ..      | 46.19                                    | 31.30                                                  | Atacand                                    | AP       |
| EPROSARTAN MESYLATE                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                            |          |
| 8397Y                                                                                                                                        | Tablet 400 mg (base)                                    | 56          | 5              | 11.52   | * 32.17                                  | 31.30                                                  | Teveten                                    | SM       |
| 8447N                                                                                                                                        | Tablet 600 mg (base)                                    | 28          | 5              | ..      | 30.60                                    | 31.30                                                  | Teveten                                    | SM       |
| <b>EPROSARTAN MESYLATE</b>                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                            |          |
| <b><u>Authority Required</u></b>                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                            |          |
| <i>Adverse effects occurring with all of the base-priced drugs;</i>                                                                          |                                                         |             |                |         |                                          |                                                        |                                            |          |
| <i>Drug interactions occurring with all of the base-priced drugs;</i>                                                                        |                                                         |             |                |         |                                          |                                                        |                                            |          |
| <i>Drug interactions expected to occur with all of the base-priced drugs;</i>                                                                |                                                         |             |                |         |                                          |                                                        |                                            |          |
| <i>Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance.</i>                                   |                                                         |             |                |         |                                          |                                                        |                                            |          |
| 8951D                                                                                                                                        | Tablet 400 mg (base)                                    | 56          | 5              | ..      | * 32.17                                  | 31.30                                                  | Teveten                                    | SM       |
| IRBESARTAN                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                            |          |
| 8246B                                                                                                                                        | Tablet 75 mg                                            | 30          | 5              | ..      | 20.68                                    | 21.71                                                  | <sup>a</sup> Avapro<br><sup>a</sup> Karvea | BQ<br>SW |

continued ➞

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                                  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                    |          |
|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------|----------|
| 8247C                                                                                                                                 | Tablet 150 mg                                           | 30          | 5              | ..      | 24.72                                    | 25.75                                                  | <sup>a</sup> Avapro<br><sup>a</sup> Karvea                              | BQ<br>SW |
| 8248D                                                                                                                                 | Tablet 300 mg                                           | 30          | 5              | ..      | 29.81                                    | 30.84                                                  | <sup>a</sup> Avapro<br><sup>a</sup> Karvea                              | BQ<br>SW |
| OLMESARTAN MEDOXOMIL                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                                                         |          |
| 2147B                                                                                                                                 | Tablet 20 mg                                            | 30          | 5              | ..      | 24.72                                    | 25.75                                                  | Olmotec                                                                 | SH       |
| 2148C                                                                                                                                 | Tablet 40 mg                                            | 30          | 5              | ..      | 29.81                                    | 30.84                                                  | Olmotec                                                                 | SH       |
| TELMISARTAN                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                                                         |          |
| 8355R                                                                                                                                 | Tablet 40 mg                                            | 28          | 5              | ..      | 21.23                                    | 22.26                                                  | Micardis                                                                | BY       |
| 8356T                                                                                                                                 | Tablet 80 mg                                            | 28          | 5              | ..      | 28.48                                    | 29.51                                                  | Micardis                                                                | BY       |
| <b>Angiotensin II antagonists, combinations</b>                                                                                       |                                                         |             |                |         |                                          |                                                        |                                                                         |          |
| • <b>Angiotensin II antagonists and diuretics</b>                                                                                     |                                                         |             |                |         |                                          |                                                        |                                                                         |          |
| <b>CANDESARTAN CILEXETIL with<br/>HYDROCHLOROTHIAZIDE</b>                                                                             |                                                         |             |                |         |                                          |                                                        |                                                                         |          |
| <b><u>Restricted Benefit</u></b>                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                                                         |          |
| <i>Hypertension in patients who are not adequately controlled with 16 mg candesartan cilexetil.</i>                                   |                                                         |             |                |         |                                          |                                                        |                                                                         |          |
| 8504N                                                                                                                                 | Tablet 16 mg-12.5 mg                                    | 30          | 5              | ..      | 32.36                                    | 31.30                                                  | Atacand Plus 16/<br>12.5                                                | AP       |
| <b>EPROSARTAN MESYLATE with<br/>HYDROCHLOROTHIAZIDE</b>                                                                               |                                                         |             |                |         |                                          |                                                        |                                                                         |          |
| <b><u>Restricted Benefit</u></b>                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                                                         |          |
| <i>Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or eprosartan mesylate monotherapy.</i> |                                                         |             |                |         |                                          |                                                        |                                                                         |          |
| 8624X                                                                                                                                 | Tablet 600 mg (base)-12.5 mg                            | 28          | 5              | ..      | 32.69                                    | 31.30                                                  | Teveten Plus 600/<br>12.5                                               | SM       |
| <b>IRBESARTAN with HYDROCHLOROTHIAZIDE</b>                                                                                            |                                                         |             |                |         |                                          |                                                        |                                                                         |          |
| <b><u>Restricted Benefit</u></b>                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                                                         |          |
| <i>Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or irbesartan monotherapy.</i>          |                                                         |             |                |         |                                          |                                                        |                                                                         |          |
| 8404H                                                                                                                                 | Tablet 150 mg-12.5 mg                                   | 30          | 5              | ..      | 26.94                                    | 27.97                                                  | <sup>a</sup> Avapro HCT 150/<br>12.5<br><sup>a</sup> Karvezide 150/12.5 | BQ<br>SW |
| 8405J                                                                                                                                 | Tablet 300 mg-12.5 mg                                   | 30          | 5              | ..      | 32.03                                    | 31.30                                                  | <sup>a</sup> Avapro HCT 300/<br>12.5<br><sup>a</sup> Karvezide 300/12.5 | BQ<br>SW |

continued ➡

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                                   | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer  |    |
|----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|---------------------------------------|----|
| 2136K                                                                                                                                  | Tablet 300 mg-25 mg                                     | 30          | 5              | ..      | 34.26                                    | 31.30                                                  | <sup>a</sup> <i>Avapro HCT 300/25</i> | BQ |
|                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Karvezide 300/25</i>  | SW |
| <b>OLMESARTAN MEDOXOMIL with HYDROCHLOROTHIAZIDE</b>                                                                                   |                                                         |             |                |         |                                          |                                                        |                                       |    |
| <b><u>Restricted Benefit</u></b>                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                       |    |
| <i>Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or olmesartan medoxomil monotherapy.</i> |                                                         |             |                |         |                                          |                                                        |                                       |    |
| 2161R                                                                                                                                  | Tablet 20 mg-12.5 mg                                    | 30          | 5              | ..      | 26.93                                    | 27.96                                                  | <i>Olmotec Plus</i>                   | SH |
| 2166B                                                                                                                                  | Tablet 40 mg-12.5 mg                                    | 30          | 5              | ..      | 32.01                                    | 31.30                                                  | <i>Olmotec Plus</i>                   | SH |
| 2170F                                                                                                                                  | Tablet 40 mg-25 mg                                      | 30          | 5              | ..      | 34.26                                    | 31.30                                                  | <i>Olmotec Plus</i>                   | SH |
| <b>TELMISARTAN with HYDROCHLOROTHIAZIDE</b>                                                                                            |                                                         |             |                |         |                                          |                                                        |                                       |    |
| <b><u>Restricted Benefit</u></b>                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                       |    |
| <i>Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or telmisartan monotherapy.</i>          |                                                         |             |                |         |                                          |                                                        |                                       |    |
| 8622T                                                                                                                                  | Tablet 40 mg-12.5 mg                                    | 28          | 5              | ..      | 23.30                                    | 24.33                                                  | <i>Micardis Plus 40/12.5 mg</i>       | BY |
| 8623W                                                                                                                                  | Tablet 80 mg-12.5 mg                                    | 28          | 5              | ..      | 30.55                                    | 31.30                                                  | <i>Micardis Plus 80/12.5 mg</i>       | BY |

### LIPID MODIFYING AGENTS

## GENERAL STATEMENT FOR LIPID-LOWERING DRUGS PRESCRIBED AS PHARMACEUTICAL BENEFITS

Use the following criteria to determine patient eligibility for subsidisation under the PBS for the following drugs:

- atorvastatin calcium
- fluvastatin sodium
- pravastatin sodium
- rosuvastatin calcium
- simvastatin
- fenofibrate
- gemfibrozil

continued ➞

## CARDIOVASCULAR SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

**By writing a PBS prescription, the prescriber is certifying the patient satisfies the qualifying criteria set out below and the use is in accordance with the registered indications which differ between agents in this class - refer to the current Product Information for details. Note also that patients already established on a particular lipid-lowering drug, where use satisfies the PBS qualifying criteria, but is outside the registered indications for that drug, are not required to switch to another drug in the class to retain PBS eligibility.**

Patients in very high risk categories (see below) may commence drug therapy with statins or fibrates immediately (ie simultaneously with an appropriate diet). For all other patients, dietary therapy should be trialled prior to initiation of drug therapy.


Dietary therapy should be continued concurrently with pharmacological therapy and should be reviewed on at least an annual basis.

Patients identified as being in one of the following very high risk categories may commence drug therapy with statins or fibrates at any cholesterol level:

- coronary heart disease which has become symptomatic
- cerebrovascular disease which has become symptomatic
- peripheral vascular disease which has become symptomatic
- diabetes mellitus with microalbuminuria (defined as urinary albumin excretion rate of >20mcg/min or urinary albumin to creatinine ratio of > 2.5 for males, > 3.5 for females)
- diabetes mellitus in Aboriginal or Torres Strait Islander patients
- diabetes mellitus in patients aged 60 years or more
- family history of coronary heart disease which has become symptomatic before the age of 55 years in two or more first degree relatives
- family history of coronary heart disease which has become symptomatic before the age of 45 years in one or more first degree relatives

**If your patient is not identified as being in any of the above very high risk categories, then use the flow-chart and table below to determine whether your patient satisfies the following criteria for subsidisation under the PBS. Document how the patient meets each of these steps in the patient record. Lipid levels must be measured at an accredited laboratory.**

# CARDIOVASCULAR SYSTEM—CONT.



continued ➡



CARDIOVASCULAR SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

POST-DIETARY QUALIFYING CRITERIA

Dietary therapy should be continued concurrently with pharmacological therapy and should be reviewed on at least an annual basis.

PATIENT CATEGORY

Patients with diabetes mellitus not otherwise included

LIPID LEVELS FOR PBS SUBSIDY

total cholesterol > 5.5 mmol/L

Aboriginal or Torres Strait Islander patients  
Patients with hypertension

total cholesterol > 6.5 mmol/L  
or  
total cholesterol > 5.5 mmol/L and  
HDL cholesterol < 1 mmol/L

Patients with HDL cholesterol < 1 mmol/L

total cholesterol > 6.5 mmol/L

Patients with familial hypercholesterolaemia identified by:

- DNA mutation; or
- tendon xanthomas in the patient or their first or second degree relative

If aged 18 years or less at treatment initiation:  
LDL cholesterol > 4 mmol/L

If aged more than 18 years at treatment initiation:  
LDL cholesterol > 5 mmol/L  
or  
total cholesterol > 6.5 mmol/L  
or  
total cholesterol > 5.5 mmol/L and  
HDL cholesterol < 1 mmol/L

Patients with:

- family history of coronary heart disease which has become symptomatic before the age of 60 years in one or more first degree relatives; or
- family history of coronary heart disease which has become symptomatic before the age of 50 years in one or more second degree relatives

continued ↗

## CARDIOVASCULAR SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|

Patients not eligible under the above:

- men aged 35 to 75 years
- post-menopausal women aged up to 75 years

total cholesterol > 7.5 mmol/L  
or  
triglyceride > 4 mmol/L

Patients not otherwise included

total cholesterol > 9 mmol/L  
or  
triglyceride > 8 mmol/L

### Lipid modifying agents, plain

- **HMG CoA reductase inhibitors**  
**ATORVASTATIN CALCIUM**

#### Restricted Benefit

*For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.*

|       |                             |    |   |    |        |       |         |    |
|-------|-----------------------------|----|---|----|--------|-------|---------|----|
| 8213G | Tablet 10 mg (atorvastatin) | 30 | 5 | .. | 42.27  | 31.30 | Lipitor | PF |
| 8214H | Tablet 20 mg (atorvastatin) | 30 | 5 | .. | 57.57  | 31.30 | Lipitor | PF |
| 8215J | Tablet 40 mg (atorvastatin) | 30 | 5 | .. | 78.62  | 31.30 | Lipitor | PF |
| 8521L | Tablet 80 mg (atorvastatin) | 30 | 5 | .. | 109.82 | 31.30 | Lipitor | PF |

### FLUVASTATIN SODIUM

#### Restricted Benefit

*For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.*

|       |                                                |    |   |       |       |       |                     |    |
|-------|------------------------------------------------|----|---|-------|-------|-------|---------------------|----|
| 8023G | Capsule 20 mg (fluvastatin)                    | 28 | 5 | ..    | 26.22 | 27.25 | <sup>a</sup> Lescol | NV |
|       |                                                |    |   | B1.64 | 27.86 | 27.25 | <sup>a</sup> Vastin | NM |
| 8024H | Capsule 40 mg (fluvastatin)                    | 28 | 5 | ..    | 30.78 | 31.30 | <sup>a</sup> Lescol | NV |
|       |                                                |    |   | B1.79 | 32.57 | 31.30 | <sup>a</sup> Vastin | NM |
| 2863Q | Tablet 80 mg (fluvastatin) (prolonged release) | 28 | 5 | ..    | 47.14 | 31.30 | Lescol XL           | NV |

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                         | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>PRAVASTATIN SODIUM</b>                                                                                    |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b><u>Restricted Benefit</u></b>                                                                             |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <i>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.</i> |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 2833D                                                                                                        | Tablet 10 mg                                            | 30          | 5              | ..      | 21.23                                    | 22.26                                                  | <sup>a</sup> Chem mart CH<br>Pravastatin<br><sup>a</sup> Cholstat 10 AF<br><sup>a</sup> GenRx Pravastatin GX<br><sup>a</sup> Lipostat 10 AW<br><sup>a</sup> Liprachol SZ<br><sup>a</sup> Pravastatin 10 CR<br><sup>a</sup> Pravastatin-DP GM<br><sup>a</sup> Pravastatin-GA 10 GN<br><sup>a</sup> Pravastatin GQ<br>generichealth<br><sup>a</sup> Pravastatin WA<br>Winthrop<br><sup>a</sup> Terry White TW<br>Chemists<br>Pravastatin<br><sup>a</sup> Pravachol BQ                             |
|                                                                                                              |                                                         |             |                | B3.52   | 24.75                                    | 22.26                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 2834E                                                                                                        | Tablet 20 mg                                            | 30          | 5              | ..      | 30.20                                    | 31.23                                                  | <sup>a</sup> Chem mart CH<br>Pravastatin<br><sup>a</sup> Cholstat 20 AF<br><sup>a</sup> GenRx Pravastatin GX<br><sup>a</sup> Lipostat 20 AW<br><sup>a</sup> Liprachol SZ<br><sup>a</sup> Pravastatin 20 CR<br><sup>a</sup> Pravastatin-DP GM<br><sup>a</sup> Pravastatin-GA 20 GN<br><sup>a</sup> Pravastatin GQ<br>generichealth<br><sup>a</sup> Pravastatin WA<br>Winthrop<br><sup>a</sup> Terry White TW<br>Chemists<br>Pravastatin<br><sup>a</sup> Vastoran RA<br><sup>a</sup> Pravachol BQ |
|                                                                                                              |                                                         |             |                | B3.52   | 33.72                                    | 31.23                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

continued ➞

## CARDIOVASCULAR SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer      |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-------------------------------------------|----|
| 8197K | Tablet 40 mg                                            | 30          | 5              | ..      | 43.27                                    | 31.30                                                  | <sup>a</sup> Chem mart                    | CH |
|       |                                                         |             |                |         |                                          |                                                        | Pravastatin                               |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cholstat 40                  | AF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Pravastatin            | GX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lipostat 40                  | AW |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Liprachol                    | SZ |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pravastatin 40               | CR |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pravastatin-DP               | GM |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pravastatin-GA 40            | GN |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pravastatin<br>generichealth | GQ |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pravastatin<br>Winthrop      | WA |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists      | TW |
|       |                                                         |             |                |         |                                          |                                                        | Pravastatin                               |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Vastoran                     | RA |
|       |                                                         |             |                | B3.07   | 46.34                                    | 31.30                                                  | <sup>a</sup> Pravachol                    | BQ |
| 8829Q | Tablet 80 mg                                            | 30          | 5              | ..      | 61.28                                    | 31.30                                                  | <sup>a</sup> Lipostat 80                  | AW |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pravastatin-GA 80            | GN |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pravastatin<br>generichealth | GQ |
|       |                                                         |             |                | B3.37   | 64.65                                    | 31.30                                                  | <sup>a</sup> Pravachol                    | BQ |

### ROSUVASTATIN CALCIUM

#### Restricted Benefit

*For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.*

|       |                             |    |   |    |        |       |         |    |
|-------|-----------------------------|----|---|----|--------|-------|---------|----|
| 9042X | Tablet 5 mg (rosuvastatin)  | 30 | 5 | .. | 50.75  | 31.30 | Crestor | AP |
| 9043Y | Tablet 10 mg (rosuvastatin) | 30 | 5 | .. | 69.48  | 31.30 | Crestor | AP |
| 9044B | Tablet 20 mg (rosuvastatin) | 30 | 5 | .. | 96.00  | 31.30 | Crestor | AP |
| 9045C | Tablet 40 mg (rosuvastatin) | 30 | 5 | .. | 134.01 | 31.30 | Crestor | AP |

### SIMVASTATIN

#### Restricted Benefit

*For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.*

|       |             |    |   |       |       |       |                         |    |
|-------|-------------|----|---|-------|-------|-------|-------------------------|----|
| 2013Y | Tablet 5 mg | 30 | 5 | ..    | 19.49 | 20.52 | <sup>a</sup> Simvabell  | BF |
|       |             |    |   |       |       |       | <sup>a</sup> Simvahexal | SZ |
|       |             |    |   |       |       |       | <sup>a</sup> Simvasyn   | CR |
|       |             |    |   |       |       |       | <sup>a</sup> Zimstat    | AF |
|       |             |    |   | B1.05 | 20.54 | 20.52 | <sup>a</sup> Zocor      | MK |

continued ➡

# CARDIOVASCULAR SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 2011W | Tablet 10 mg                                            | 30          | 5              | ..      | 24.64                                    | 25.67                                                  | <sup>a</sup> Chem mart               | CH |
|       |                                                         |             |                |         |                                          |                                                        | Simvastatin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Simvastatin       | GX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ransim                  | RA |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvabell               | BF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvahexal              | SZ |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvar 10               | AW |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvastatin-DP          | GM |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvastatin             | GQ |
|       |                                                         |             |                |         |                                          |                                                        | generichealth                        |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvastatin             | WA |
|       |                                                         |             |                |         |                                          |                                                        | Winthrop                             |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvasyn                | CR |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvatrust 10           | MI |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|       |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|       |                                                         |             |                |         |                                          |                                                        | Simvastatin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Zimstat                 | AF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GN                      |    |
|       |                                                         |             |                | B1.05   | 25.69                                    | 25.67                                                  | <sup>a</sup> Lipex 10                | FR |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Zocor                   | MK |
| 2012X | Tablet 20 mg                                            | 30          | 5              | ..      | 32.81                                    | 31.30                                                  | <sup>a</sup> Chem mart               | CH |
|       |                                                         |             |                |         |                                          |                                                        | Simvastatin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Simvastatin       | GX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ransim                  | RA |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvabell               | BF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvahexal              | SZ |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvar 20               | AW |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvastatin-DP          | GM |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvastatin             | GQ |
|       |                                                         |             |                |         |                                          |                                                        | generichealth                        |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvastatin             | WA |
|       |                                                         |             |                |         |                                          |                                                        | Winthrop                             |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvasyn                | CR |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvatrust 20           | MI |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|       |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|       |                                                         |             |                |         |                                          |                                                        | Simvastatin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Zimstat                 | AF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GN                      |    |
|       |                                                         |             |                | B1.04   | 33.85                                    | 31.30                                                  | <sup>a</sup> Lipex 20                | FR |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Zocor                   | MK |

continued ➞

# CARDIOVASCULAR SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8173E | Tablet 40 mg                                            | 30          | 5              | ..      | 44.05                                    | 31.30                                                  | <sup>a</sup> Chem mart               | CH |
|       |                                                         |             |                |         |                                          |                                                        | Simvastatin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Simvastatin       | GX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ransim                  | RA |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvabell               | BF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvahexal              | SZ |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvar 40               | AW |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvastatin-DP          | GM |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvastatin             | GQ |
|       |                                                         |             |                |         |                                          |                                                        | generichealth                        |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvastatin             | WA |
|       |                                                         |             |                |         |                                          |                                                        | Winthrop                             |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvasyn                | CR |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvatrust 40           | MI |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|       |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|       |                                                         |             |                |         |                                          |                                                        | Simvastatin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Zimstat                 | AF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GN                      |    |
|       |                                                         |             |                | 80.99   | 44.95                                    | 31.30                                                  | <sup>a</sup> Lipex 40                | FR |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Zocor                   | MK |
| 8313M | Tablet 80 mg                                            | 30          | 5              | ..      | 59.04                                    | 31.30                                                  | <sup>a</sup> Chem mart               | CH |
|       |                                                         |             |                |         |                                          |                                                        | Simvastatin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Simvastatin       | GX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ransim                  | RA |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvabell               | BF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvahexal              | SZ |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvar 80               | AW |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvastatin-DP          | GM |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvastatin             | GQ |
|       |                                                         |             |                |         |                                          |                                                        | generichealth                        |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvastatin             | WA |
|       |                                                         |             |                |         |                                          |                                                        | Winthrop                             |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvasyn                | CR |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Simvatrust 80           | MI |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|       |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|       |                                                         |             |                |         |                                          |                                                        | Simvastatin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Zimstat                 | AF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GN                      |    |
|       |                                                         |             |                | 80.99   | 60.03                                    | 31.30                                                  | <sup>a</sup> Lipex 80                | FR |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Zocor                   | MK |

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                            | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>• Fibrates</b>                                                                                                                                                                                                                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>FENOFIBRATE</b>                                                                                                                                                                                                                                                                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                                                                                                                                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>The risk of serious muscle toxicity is increased if fenofibrate is used concomitantly with HMG CoA reductase inhibitors or other fibrates. Such combination therapy should be used with caution in patients with severe combined dyslipidaemia and high cardiovascular risk without any history of muscular disease and patients monitored closely for chronic signs of muscle toxicity.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                                                                                                                                                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.</i>                                                                                                                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9022W                                                                                                                                                                                                                                                                                                                                                                                           | Tablet 48 mg                                            | 60          | 5              | ..      | 29.62                                    | 30.65                                                  | Lipidil                              | SM |
| 9023X                                                                                                                                                                                                                                                                                                                                                                                           | Tablet 145 mg                                           | 30          | 5              | ..      | 41.32                                    | 31.30                                                  | Lipidil                              | SM |
| <b>GEMFIBROZIL</b>                                                                                                                                                                                                                                                                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                                                                                                                                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>The risk of serious muscle toxicity is increased if gemfibrozil is used concomitantly with HMG CoA reductase inhibitors or other fibrates. Such combination therapy should be used with caution in patients with severe combined dyslipidaemia and high cardiovascular risk without any history of muscular disease and patients monitored closely for chronic signs of muscle toxicity.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                                                                                                                                                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.</i>                                                                                                                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1453L                                                                                                                                                                                                                                                                                                                                                                                           | Tablet 600 mg                                           | 60          | 5              | ..      | 29.27                                    | 30.30                                                  | <sup>a</sup> Ausgem                  | SI |
|                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Chem mart               | CH |
|                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | Gemfibrozil                          |    |
|                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Gemhexal                | SZ |
|                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Gemfibrozil       | GX |
|                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Jezil                   | AF |
|                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lipazil 600 mg          | GM |
|                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pharmacor               | CR |
|                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | Gemfibrozil 600                      |    |
|                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | Gemfibrozil                          |    |
|                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                | B2.31   | 31.58                                    | 30.30                                                  | <sup>a</sup> Lopid                   | PF |
| <b>• Bile acid sequestrants</b>                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CHOLESTYRAMINE</b>                                                                                                                                                                                                                                                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2967E                                                                                                                                                                                                                                                                                                                                                                                           | Sachets 4.7 g (equivalent to 4 g cholestyramine), 50    | 2           | 5              | ..      | * 57.03                                  | 31.30                                                  | Questran Lite                        | BQ |
| 2978R                                                                                                                                                                                                                                                                                                                                                                                           | Sachets 9.4 g (equivalent to 8 g cholestyramine), 50    | ‡ 1         | 5              | ..      | 54.14                                    | 31.30                                                  | Questran Lite                        | BQ |
| <b>COLESTIPOL HYDROCHLORIDE</b>                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1224K                                                                                                                                                                                                                                                                                                                                                                                           | Sachets 5 g, 120                                        | ‡ 1         | 5              | ..      | 67.26                                    | 31.30                                                  | Colestid                             | PH |

## CARDIOVASCULAR SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### • Other lipid modifying agents

#### **EZETIMIBE**

#### **Authority Required (STREAMLINED)**

*Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have:*

2649

(a) *coronary heart disease; or*

2650

(b) *diabetes mellitus; or*

2651

(c) *peripheral vascular disease; or*

2652

(d) *heterozygous familial hypercholesterolaemia; or*

2653

(e) *symptomatic cerebrovascular disease; or*

2667

(f) *family history of coronary heart disease; or*

2668

(g) *hypertension.*

*Inadequate control with a statin is defined as follows:*

(1) *where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or*

(2) *where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated.*

#### **Authority Required (STREAMLINED)**

1989

*Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) is contraindicated;*

2669

continued ➞



## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
| <p><i>Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) must be discontinued or reduced to a dose of 20 mg or less per day, because the patient developed a clinically important product-related adverse event during treatment with a statin.</i></p> <p><i>A clinically important product-related adverse event is defined as follows:</i></p> <p><i>(i) Severe myalgia (muscle symptoms without CK elevation) which is proven to be temporally associated with statin treatment; or</i></p> <p><i>(ii) Myositis (clinically important CK elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or</i></p> <p><i>(iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin.</i></p> |                                                         |             |                |         |                                          |                                                        |                                      |
| <p><b><u>Authority Required (STREAMLINED)</u></b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |
| <p>1991</p> <p><i>Homozygous sitosterolaemia;</i></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |
| <p>2438</p> <p><i>Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs), in combination with an HMG CoA reductase inhibitor (statin).</i></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |
| 8757X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 10 mg                                            | 30          | 5              | ..      | 70.54                                    | 31.30                                                  | Ezetrol MK                           |

### Lipid modifying agents, combinations

#### • HMG CoA reductase inhibitors in combination with other lipid modifying agents

##### *EZETIMIBE with SIMVASTATIN*

#### **Authority Required (STREAMLINED)**

*Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have:*

2654

*(a) coronary heart disease; or*

2655

*(b) diabetes mellitus; or*

2656

*(c) peripheral vascular disease; or*

2657

*(d) heterozygous familial hypercholesterolaemia; or*

2658

*(e) cerebrovascular disease which has become symptomatic; or*

2678

*(f) family history of coronary heart disease; or*

2679

*(g) hypertension;*

*Inadequate control with a statin is defined as follows:*

continued ➞

## CARDIOVASCULAR SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| <p><i>(1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated; or</i></p> <p><i>(2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when the ezetimibe component is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when the ezetimibe component is initiated;</i></p> <p><b>2431</b></p> <p><i>Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs).</i></p> |                                                         |             |                |         |                             |                                             |                                      |    |
| 8881K                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Tablet 10 mg-40 mg                                      | 30          | 5              | ..      | 107.45                      | 31.30                                       | Vytorin                              | MK |
| 8882L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Tablet 10 mg-80 mg                                      | 30          | 5              | ..      | 123.59                      | 31.30                                       | Vytorin                              | MK |

### • HMG CoA reductase inhibitors, other combinations

#### AMLODIPINE BESYLATE with ATORVASTATIN CALCIUM

##### Restricted Benefit

For use in patients who have hypertension and/or angina and who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and:

- (a) who are currently receiving treatment with a dihydropyridine calcium channel blocker; or
- (b) whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate; or
- (c) who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate.

|       |                                  |    |   |    |        |       |              |    |
|-------|----------------------------------|----|---|----|--------|-------|--------------|----|
| 9049G | Tablet 5 mg (base)-10 mg (base)  | 30 | 5 | .. | 51.37  | 31.30 | Caduet 5/10  | PF |
| 9050H | Tablet 5 mg (base)-20 mg (base)  | 30 | 5 | .. | 67.58  | 31.30 | Caduet 5/20  | PF |
| 9051J | Tablet 5 mg (base)-40 mg (base)  | 30 | 5 | .. | 88.63  | 31.30 | Caduet 5/40  | PF |
| 9052K | Tablet 5 mg (base)-80 mg (base)  | 30 | 5 | .. | 119.83 | 31.30 | Caduet 5/80  | PF |
| 9053L | Tablet 10 mg (base)-10 mg (base) | 30 | 5 | .. | 58.56  | 31.30 | Caduet 10/10 | PF |
| 9054M | Tablet 10 mg (base)-20 mg (base) | 30 | 5 | .. | 75.18  | 31.30 | Caduet 10/20 | PF |
| 9055N | Tablet 10 mg (base)-40 mg (base) | 30 | 5 | .. | 96.23  | 31.30 | Caduet 10/40 | PF |
| 9056P | Tablet 10 mg (base)-80 mg (base) | 30 | 5 | .. | 127.43 | 31.30 | Caduet 10/80 | PF |

## DERMATOLOGICALS

| Code                                                                                                   | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| ANTIFUNGALS FOR DERMATOLOGICAL USE                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Antifungals for topical use</b>                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Antibiotics</b>                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| NYSTATIN                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u>Authority Required (STREAMLINED)</u>                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2354                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1698J                                                                                                  | Cream 100,000 units per g, 15 g                         | 2           | 3              | ..      | * 18.13                                  | 19.16                                                  | Mycostatin                           | BQ |
| • <b>Imidazole and triazole derivatives</b>                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| BIFONAZOLE                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u>Authority Required (STREAMLINED)</u>                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2354                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8066M                                                                                                  | Cream 10 mg per g (1%), 15 g                            | 2           | 3              | ..      | * 25.37                                  | 26.40                                                  | Mycospor                             | BN |
| CLOTRIMAZOLE                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u>Authority Required (STREAMLINED)</u>                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2354                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1027C                                                                                                  | Lotion 10 mg per mL (1%), 20 mL                         | 2           | 3              | ..      | * 17.93                                  | 18.96                                                  | Canesten                             | BN |
| KETOCONAZOLE                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u>Authority Required (STREAMLINED)</u>                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2354                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9024Y                                                                                                  | Cream 20 mg per g (2%), 30 g                            | ± 1         | 2              | ..      | 22.69                                    | 23.72                                                  | Nizoral 2% Cream                     | JT |
| 9025B                                                                                                  | Shampoo 10 mg per g (1%), 100 mL                        | ± 1         | 1              | ..      | 17.17                                    | 18.20                                                  | Nizoral 1%                           | JT |
| 1574W                                                                                                  | Shampoo 20 mg per g (2%), 60 mL                         | ± 1         | 1              | ..      | 17.88                                    | 18.91                                                  | Nizoral 2%                           | JT |
| MICONAZOLE                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u>Authority Required (STREAMLINED)</u>                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2354                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9031H                                                                                                  | Tincture 20 mg per mL (2%), 30 mL                       | ± 1         | 2              | ..      | 19.04                                    | 20.07                                                  | Daktarin                             | JT |

## DERMATOLOGICALS—CONT.

| Code                                                                                                                                 | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>MICONAZOLE NITRATE</b>                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b>                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2354                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person.</i>                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9026C                                                                                                                                | Cream 20 mg per g (2%), 15 g                            | 2           | 3              | ..      | * 15.47                                  | 16.50                                                  | Daktarin                             | JT |
| 9027D                                                                                                                                | Cream 20 mg per g (2%), 30 g                            | ± 1         | 2              | ..      | 14.36                                    | 15.39                                                  | Daktarin                             | JT |
| 9028E                                                                                                                                | Cream 20 mg per g (2%), 70 g                            | ± 1         | 1              | ..      | 16.36                                    | 17.39                                                  | Daktarin                             | JT |
| 9029F                                                                                                                                | Powder 20 mg per g (2%), 30 g                           | ± 1         | 2              | ..      | 15.13                                    | 16.16                                                  | Daktarin                             | JT |
| 9030G                                                                                                                                | Lotion 20 mg per mL (2%), 30 g                          | ± 1         | 2              | ..      | 16.29                                    | 17.32                                                  | Daktarin                             | JT |
| • <b>Other antifungals for topical use</b>                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>TERBINAFINE HYDROCHLORIDE</b>                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b>                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2354                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person.</i>                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9160D                                                                                                                                | Cream 10 mg per g (1%), 15 g                            | 2           | 3              | ..      | * 36.93                                  | 31.30                                                  | Lamisil                              | NC |
| <b>Antifungals for systemic use</b>                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Antifungals for systemic use</b>                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>GRISEOFULVIN</b>                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1460W                                                                                                                                | Tablet 125 mg                                           | 100         | 2              | ..      | 25.44                                    | 26.47                                                  | Grisovin                             | SI |
| 2982Y                                                                                                                                | Tablet 500 mg                                           | 28          | 2              | ..      | 26.56                                    | 27.59                                                  | Grisovin 500                         | SI |
| <b>TERBINAFINE HYDROCHLORIDE</b>                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of a dermatophyte infection in an Aboriginal or a Torres Strait Islander person where topical treatment has failed.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2285G                                                                                                                                | Tablet 250 mg (base)                                    | 42          | ..             | ..      | 102.39                                   | 31.30                                                  | <sup>a</sup> GenRx Terbinafine       | GX |
|                                                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Tamsil                  | AW |
|                                                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terbihexal              | SZ |
|                                                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terbinafine 250         | CR |
|                                                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terbinafine-DP          | GM |
|                                                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Zabel                   | AF |
|                                                                                                                                      |                                                         |             |                | B1.46   | 103.85                                   | 31.30                                                  | <sup>a</sup> Lamisil                 | NV |

continued ➡

## DERMATOLOGICALS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                            | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| <b><u>Authority Required</u></b>                                                                                                                                                                                                                                                                                                                                                |                                                         |             |                |         |                             |                                             |                                      |    |
| <i>Proximal or extensive (greater than 80% nail involvement) onychomycosis due to dermatophyte infection where topical treatment has failed. This infection must be proven by microscopy or culture and confirmed by an Approved Pathology Authority. The date of the pathology report must be provided at the time of application and must not be more than 12 months old.</i> |                                                         |             |                |         |                             |                                             |                                      |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                |         |                             |                                             |                                      |    |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i>                                                                                                                                                                                                                                                                                      |                                                         |             |                |         |                             |                                             |                                      |    |
| 2804N                                                                                                                                                                                                                                                                                                                                                                           | Tablet 250 mg (base)                                    | 42          | 1              | ..      | 102.39                      | 31.30                                       | <sup>a</sup> GenRx Terbinafine       | GX |
|                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                             |                                             | <sup>a</sup> Tamsil                  | AW |
|                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                             |                                             | <sup>a</sup> Terbihexal              | SZ |
|                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                             |                                             | <sup>a</sup> Terbinafine 250         | CR |
|                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                             |                                             | <sup>a</sup> Terbinafine-DP          | GM |
|                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                             |                                             | <sup>a</sup> Zabel                   | AF |
|                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                | B1.46   | 103.85                      | 31.30                                       | <sup>a</sup> Lamisil                 | NV |

## ANTIPSORIATICS

**Antipsoriatics for topical use**• **Tars**

COAL TAR - PREPARED

|       |                              |     |   |    |       |       |        |    |
|-------|------------------------------|-----|---|----|-------|-------|--------|----|
| 8864M | Gel 10 mg per g (1%), 100 mL | ± 1 | 2 | .. | 32.65 | 31.30 | Exorex | GM |
|-------|------------------------------|-----|---|----|-------|-------|--------|----|

• **Other antipsoriatics for topical use**

CALCIPOTRIOL

**Restricted Benefit***Chronic stable plaque type psoriasis vulgaris.*

|       |                                                |     |   |    |       |       |          |    |
|-------|------------------------------------------------|-----|---|----|-------|-------|----------|----|
| 8291J | Ointment 50 micrograms per g<br>(0.005%), 30 g | ± 1 | 1 | .. | 27.63 | 28.66 | Daivonex | CS |
| 2080L | Cream 50 micrograms per g (0.005%),<br>30 g    | ± 1 | 1 | .. | 27.63 | 28.66 | Daivonex | CS |

**Restricted Benefit***Chronic stable plaque type psoriasis vulgaris of the scalp.*

|       |                                                        |     |   |    |       |       |          |    |
|-------|--------------------------------------------------------|-----|---|----|-------|-------|----------|----|
| 9163G | Scalp solution 50 micrograms per mL<br>(0.005%), 30 mL | ± 1 | 1 | .. | 27.63 | 28.66 | Daivonex | CS |
|-------|--------------------------------------------------------|-----|---|----|-------|-------|----------|----|

## DERMATOLOGICALS—CONT.

| Code                                                                                                                  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>Antipsoriatics for systemic use</b>                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Retinoids for treatment of psoriasis</b>                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>ACITRETIN</b>                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>This drug is a potent teratogen—pregnancy should be avoided for at least two years after cessation of therapy.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Care must be taken to comply with the provisions of State/Territory law when prescribing acitretin.</i>            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b>                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1366                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe intractable psoriasis;</i>                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1363                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe forms of disorders of keratinisation.</i>                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2019G                                                                                                                 | Capsule 10 mg                                           | 100         | 2              | ..      | 205.34                                   | 31.30                                                  | Neotigason                           | TA |
| 2020H                                                                                                                 | Capsule 25 mg                                           | 100         | 2              | ..      | 392.78                                   | 31.30                                                  | Neotigason                           | TA |

### ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE

#### Chemotherapeutics for topical use

##### • **Sulfonamides**

**SILVER SULFADIAZINE with CHLORHEXIDINE  
GLUCONATE**

##### **Restricted Benefit**

*Prevention and treatment of infection in partial or full skin thickness loss due to burns;*

*Prevention and treatment of infection in partial or full skin thickness loss due to epidermolysis bullosa;*

*Stasis ulcers.*

|       |                                            |     |    |    |       |       |           |    |
|-------|--------------------------------------------|-----|----|----|-------|-------|-----------|----|
| 1996C | Cream 10 mg-2 mg per g (1%-0.2%),<br>50 g  | ± 1 | .. | .. | 18.38 | 19.41 | Silvazine | SN |
| 1997D | Cream 10 mg-2 mg per g (1%-0.2%),<br>100 g | ± 1 | .. | .. | 21.17 | 22.20 | Silvazine | SN |

### CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

#### Corticosteroids, plain

##### • **Corticosteroids, weak (group I)**

**HYDROCORTISONE**

##### **Restricted Benefit**

*Treatment of corticosteroid-responsive dermatoses.*

|       |                              |     |   |    |      |      |                  |    |
|-------|------------------------------|-----|---|----|------|------|------------------|----|
| 1495Q | Cream 10 mg per g (1%), 50 g | ± 1 | 1 | .. | 8.27 | 9.30 | Egocort Cream 1% | EO |
|-------|------------------------------|-----|---|----|------|------|------------------|----|

## DERMATOLOGICALS—CONT.

| Code                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium              | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                            |                      |
|-------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|----------------------|------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|----------------------|
| <b>HYDROCORTISONE ACETATE</b>                                           |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| <b><u>Restricted Benefit</u></b>                                        |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| <i>Treatment of corticosteroid-responsive dermatoses.</i>               |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| 2887Y                                                                   | Cream 10 mg per g (1%), 30 g                            | ‡ 1         | 1              | ..<br>B1.90          | 8.61<br>10.51                            | 9.64<br>9.64                                           | <sup>a</sup> Cortic-DS 1%<br><sup>a</sup> Sigmacort                                                             | FM<br>SI             |
| 2881P                                                                   | Cream 10 mg per g (1%), 50 g                            | ‡ 1         | 1              | ..<br>B0.08<br>B1.91 | 8.27<br>8.35<br>10.18                    | 9.30<br>9.30<br>9.30                                   | <sup>a</sup> Cortic-DS 1%<br><sup>a</sup> Cortef<br><sup>a</sup> Sigmacort                                      | FM<br>DT<br>SI       |
| 2888B                                                                   | Topical ointment 10 mg per g (1%), 30 g                 | ‡ 1         | 1              | ..<br>B1.90          | 8.61<br>10.51                            | 9.64<br>9.64                                           | <sup>a</sup> Cortic-DS 1%<br><sup>a</sup> Sigmacort                                                             | FM<br>SI             |
| 2882Q                                                                   | Topical ointment 10 mg per g (1%), 50 g                 | ‡ 1         | 1              | ..<br>B1.91          | 8.27<br>10.18                            | 9.30<br>9.30                                           | <sup>a</sup> Cortic-DS 1%<br><sup>a</sup> Sigmacort                                                             | FM<br>SI             |
| <i>[For other listings for this drug see Generic/Proprietary Index]</i> |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| • <b>Corticosteroids, moderately potent (group II)</b>                  |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| <b>TRIAMCINOLONE ACETONIDE</b>                                          |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| <b><u>Restricted Benefit</u></b>                                        |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| <i>Treatment of corticosteroid-responsive dermatoses.</i>               |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| 2117K                                                                   | Cream 200 micrograms per g (0.02%),<br>100 g            | 2           | ..             | ..<br>B3.30          | * 14.45<br>* 17.75                       | 15.48<br>15.48                                         | <sup>a</sup> Tricortone<br><sup>a</sup> Aristocort 0.02%                                                        | FM<br>SI             |
| 2118L                                                                   | Ointment 200 micrograms per g<br>(0.02%), 100 g         | 2           | ..             | ..<br>B3.30          | * 14.45<br>* 17.75                       | 15.48<br>15.48                                         | <sup>a</sup> Tricortone<br><sup>a</sup> Aristocort 0.02%                                                        | FM<br>SI             |
| • <b>Corticosteroids, potent (group III)</b>                            |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| <b>BETAMETHASONE DIPROPIONATE</b>                                       |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| <b><u>Restricted Benefit</u></b>                                        |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| <i>Treatment of corticosteroid-responsive dermatoses.</i>               |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| 1115Q                                                                   | Cream 500 micrograms (base) per g<br>(0.05%), 15 g      | ‡ 1         | 1              | ..                   | 9.91                                     | 10.94                                                  | <sup>a</sup> Diprosone<br><sup>a</sup> Eleuphrat                                                                | SH<br>EX             |
| 1119X                                                                   | Ointment 500 micrograms (base) per g<br>(0.05%), 15 g   | ‡ 1         | 1              | ..                   | 9.91                                     | 10.94                                                  | <sup>a</sup> Diprosone<br><sup>a</sup> Eleuphrat                                                                | SH<br>EX             |
| <b>BETAMETHASONE VALERATE</b>                                           |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| <b><u>Restricted Benefit</u></b>                                        |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| <i>Treatment of corticosteroid-responsive dermatoses.</i>               |                                                         |             |                |                      |                                          |                                                        |                                                                                                                 |                      |
| 2812B                                                                   | Cream 200 micrograms (base) per g<br>(0.02%), 100 g     | 2           | ..             | ..<br>B6.18          | * 24.89<br>* 31.07                       | 25.92<br>25.92                                         | <sup>a</sup> Antroquoril<br><sup>a</sup> Celestone-M<br><sup>b</sup> Cortival 1/5<br><sup>b</sup> Betnovate 1/5 | EX<br>SH<br>FM<br>SI |

continued ➡

## DERMATOLOGICALS—CONT.

|       |                                                         |             |                |             | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ |                                      |                               |          |
|-------|---------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|--------------------------------------|-------------------------------|----------|
| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium     |                                          |                                                        | Proprietary Name and<br>Manufacturer |                               |          |
| 2813C | Cream 500 micrograms (base) per g<br>(0.05%), 15 g      | ± 1         | 1              | ..<br>B1.91 | 8.12<br>10.03                            | 9.15<br>9.15                                           | <sup>b</sup><br><sup>b</sup>         | Cortival 1/2<br>Betnovate 1/2 | FM<br>SI |
| 2820K | Ointment 200 micrograms (base) per g<br>(0.02%), 100 g  | 2           | ..             | ..          | * 24.89                                  | 25.92                                                  | <sup>a</sup><br><sup>a</sup>         | Antroquoril<br>Celestone-M    | EX<br>SH |
| 2815E | Ointment 500 micrograms (base) per g<br>(0.05%), 15 g   | ± 1         | 1              | ..<br>B1.91 | 8.12<br>10.03                            | 9.15<br>9.15                                           | <sup>b</sup><br><sup>b</sup>         | Cortival 1/2<br>Betnovate 1/2 | FM<br>SI |

## METHYLPREDNISOLONE ACEPONATE

Restricted Benefit

Treatment of corticosteroid-responsive dermatoses.

|       |                                        |     |    |    |       |       |          |    |
|-------|----------------------------------------|-----|----|----|-------|-------|----------|----|
| 8054X | Cream 1 mg per g (0.1%), 15 g          | ‡ 1 | .. | .. | 11.60 | 12.63 | Advantan | CS |
| 8055Y | Ointment 1 mg per g (0.1%), 15 g       | ‡ 1 | .. | .. | 11.60 | 12.63 | Advantan | CS |
| 8128T | Fatty ointment 1 mg per g (0.1%), 15 g | ‡ 1 | .. | .. | 11.60 | 12.63 | Advantan | CS |

Restricted Benefit

Eczema.

|       |                                |     |    |    |       |       |          |    |
|-------|--------------------------------|-----|----|----|-------|-------|----------|----|
| 8618N | Lotion 1 mg per g (0.1%), 20 g | ‡ 1 | .. | .. | 12.35 | 13.38 | Advantan | CS |
|-------|--------------------------------|-----|----|----|-------|-------|----------|----|

## MOMETASONE FUROATE

Restricted Benefit

Treatment of corticosteroid-responsive dermatoses.

|       |                                     |     |    |    |       |       |                                              |          |
|-------|-------------------------------------|-----|----|----|-------|-------|----------------------------------------------|----------|
| 1913Q | Cream 1 mg per g (0.1%), 15 g       | ‡ 1 | .. | .. | 13.96 | 14.99 | <sup>a</sup> Elocon<br><sup>a</sup> Novasone | SH<br>EX |
| 1915T | Ointment 1 mg per g (0.1%), 15 g    | ‡ 1 | .. | .. | 13.96 | 14.99 | <sup>a</sup> Elocon<br><sup>a</sup> Novasone | SH<br>EX |
| 8043H | Lotion 1 mg per g (0.1% w/w), 30 mL | ‡ 1 | .. | .. | 18.54 | 19.57 | <sup>a</sup> Elocon<br><sup>a</sup> Novasone | SH<br>EX |



## DERMATOLOGICALS—CONT.

| Code                                                                                                                            | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>ANTI-ACNE PREPARATIONS</b>                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Anti-acne preparations for systemic use</b>                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Retinoids for treatment of acne</b>                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>ISOTRETINOIN</b>                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>This drug causes birth defects. Isotretinoin has been reported to cause other frequent and potentially serious toxicity.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Care must be taken to comply with the provisions of State/Territory law when prescribing isotretinoin.</i>                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b>                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1354                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe cystic acne not responsive to other therapy.</i>                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2591J                                                                                                                           | Capsule 10 mg                                           | 60          | 3              | ..      | 94.12                                    | 31.30                                                  | <sup>a</sup> GenRx Isotretinoin      | GX |
|                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Oratane                 | GM |
|                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Roaccutane              | RO |
| 2592K                                                                                                                           | Capsule 20 mg                                           | 60          | 3              | ..      | 143.36                                   | 31.30                                                  | <sup>a</sup> Chem mart               | CH |
|                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | Isotretinoin                         |    |
|                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Isotretinoin      | GX |
|                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Oratane                 | GM |
|                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                                                                                                                 |                                                         |             |                |         |                                          |                                                        | Isotretinoin                         |    |
|                                                                                                                                 |                                                         |             |                | B2.37   | 145.73                                   | 31.30                                                  | <sup>a</sup> Roaccutane              | RO |
| 2549E                                                                                                                           | Capsule 40 mg                                           | 30          | 3              | ..      | 129.96                                   | 31.30                                                  | Oratane                              | GM |

## OTHER DERMATOLOGICAL PREPARATIONS

**Other dermatological preparations**• **Other dermatologicals****DAPSONE**

|       |               |     |   |    |        |       |    |  |
|-------|---------------|-----|---|----|--------|-------|----|--|
| 8801F | Tablet 25 mg  | 100 | 1 | .. | 100.15 | 31.30 | LM |  |
| 1272Y | Tablet 100 mg | 100 | 1 | .. | 113.41 | 31.30 | LM |  |

**IMIQUIMOD****Authority Required**

*Treatment of biopsy confirmed primary (previously untreated) superficial basal cell carcinoma (sBCC) in patients with normal immune function for whom surgical excision, cryotherapy, or curettage with diathermy are inappropriate and topical drug therapy is required.*

*The date of the pathology report and name of the Approved Pathology Authority must be provided at the time of application.*

**NOTE:**

*The patient or carer must be able to understand and administer the imiquimod dosing regimen.*

*No applications for increased maximum quantities and/or repeats will be authorised.*

*Treatment of recurrent (previously treated) lesions will not be authorised.*

continued ➡

## DERMATOLOGICALS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form  | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-------|----------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|       |                                                          |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| 2546B | Cream 50 mg per g (5%), 250 mg single<br>use sachets, 12 | 1           | 1              | ..      | 159.52                      | 31.30                                       | Aldara                               | IA |

**PIMECROLIMUS****Authority Required**

*Treatment of facial or eyelid atopic dermatitis in patients aged at least 3 months with 1 or more of the following contraindications to topical corticosteroids:*

- (i) perioral dermatitis;*
- (ii) periorbital dermatitis;*
- (iii) rosacea;*
- (iv) epidermal atrophy;*
- (v) dermal atrophy;*
- (vi) allergy to topical corticosteroids;*
- (vii) cataracts;*
- (viii) glaucoma;*
- (ix) raised intraocular pressure.*

**Authority Required**

*Short-term (up to 3 weeks) intermittent treatment of atopic dermatitis of the face or eyelids in patients aged at least 3 months who fail to achieve satisfactory disease control with intermittent topical corticosteroid therapy, and where more than 3 months have passed since the initial diagnosis of atopic dermatitis.*

*Failure to achieve satisfactory disease control with intermittent topical corticosteroid therapy is manifest by:*

- (i) failure of the facial skin to clear despite at least 2 weeks of topical hydrocortisone 1% applied every day; or*
- (ii) failure of the facial skin to clear despite at least 1 week of a moderate or potent topical corticosteroid applied every day; or*
- (iii) clearing of the facial skin with at least 2 weeks of topical hydrocortisone 1% applied every day, but almost immediate and significant flare in facial disease (within 48 hours) upon stopping topical corticosteroids, occurring on at least 2 consecutive occasions; or*
- (iv) clearing of the facial skin with at least 1 week of a moderate or potent topical corticosteroid applied every day, but almost immediate and significant flare in facial disease (within 48 hours) upon stopping topical corticosteroids, occurring on at least 2 consecutive occasions.*

|       |                              |     |   |    |       |       |        |    |
|-------|------------------------------|-----|---|----|-------|-------|--------|----|
| 8802G | Cream 10 mg per g (1%), 15 g | ± 1 | 1 | .. | 33.36 | 31.30 | Elidel | NV |
|-------|------------------------------|-----|---|----|-------|-------|--------|----|

**NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised. Only 1 authority application per 6 months, per patient, will be authorised.*

## GENITO URINARY SYSTEM AND SEX HORMONES

| Code                                                                                                         | Name, Restriction,<br>Manner of Administration and Form                                            | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer              |          |
|--------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|---------------------------------------------------|----------|
| <b>OTHER GYNECOLOGICALS</b>                                                                                  |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <b>Contraceptives for topical use</b>                                                                        |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| • <b>Intrauterine contraceptives</b>                                                                         |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <b>LEVONORGESTREL</b>                                                                                        |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <b>Restricted Benefit</b>                                                                                    |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <i>Contraception;</i>                                                                                        |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <i>Idiopathic menorrhagia where oral treatments are ineffective;</i>                                         |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <i>Idiopathic menorrhagia where oral treatments are contraindicated.</i>                                     |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| 8633J                                                                                                        | Intrauterine drug delivery system<br>52 mg (releasing approximately<br>20 micrograms per 24 hours) | 1           | ..             | ..          | 245.98                                   | 31.30                                                  | Mirena                                            | SC       |
| <b>Other gynecologicals</b>                                                                                  |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| • <b>Prolactine inhibitors</b>                                                                               |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <b>BROMOCRIPTINE MESYLATE</b>                                                                                |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <b>Restricted Benefit</b>                                                                                    |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <i>Prevention of the onset of lactation in the puerperium for medical reasons.</i>                           |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| 1444B                                                                                                        | Tablet 2.5 mg (base)                                                                               | 30          | ..             | ..<br>B2.23 | 16.92<br>19.15                           | 17.95<br>17.95                                         | <sup>a</sup> Krypton 2.5<br><sup>a</sup> Parlodel | AF<br>NV |
| <b>Restricted Benefit</b>                                                                                    |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <i>Acromegaly;</i>                                                                                           |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <i>Parkinson's disease;</i>                                                                                  |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <i>Pathological hyperprolactinaemia where surgery is not indicated;</i>                                      |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <i>Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution;</i>      |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <i>Pathological hyperprolactinaemia where radiotherapy is not indicated;</i>                                 |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <i>Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution.</i> |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| 1443Y                                                                                                        | Tablet 2.5 mg (base)                                                                               | 60          | 5              | ..<br>B2.29 | 27.83<br>30.12                           | 28.86<br>28.86                                         | <sup>a</sup> Krypton 2.5<br><sup>a</sup> Parlodel | AF<br>NV |
| 1446D                                                                                                        | Capsule 5 mg (base)                                                                                | 60          | 5              | ..<br>B1.99 | 47.83<br>49.82                           | 31.30<br>31.30                                         | <sup>a</sup> Krypton 5<br><sup>a</sup> Parlodel   | AF<br>NV |
| 1445C                                                                                                        | Capsule 10 mg (base)                                                                               | 100         | 5              | ..<br>B2.39 | 153.12<br>155.51                         | 31.30<br>31.30                                         | <sup>a</sup> Krypton 10<br><sup>a</sup> Parlodel  | AF<br>NV |
| <b>CABERGOLINE</b>                                                                                           |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <b>Restricted Benefit</b>                                                                                    |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| <i>Prevention of the onset of lactation in the puerperium for medical reasons.</i>                           |                                                                                                    |             |                |             |                                          |                                                        |                                                   |          |
| 8115D                                                                                                        | Tablet 500 micrograms                                                                              | 2           | ..             | ..          | 26.58                                    | 27.61                                                  | Dostinex                                          | PH       |

continued ➡

## GENITO URINARY SYSTEM AND SEX HORMONES—CONT.

| Code                                    | Name, Restriction,<br>Manner of Administration and Form                                                      | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------|--------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>Authority Required (STREAMLINED)</b> |                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
|                                         | 2659                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Pathological hyperprolactinaemia where surgery is not indicated;</i>                                      |             |                |         |                                          |                                                        |                                      |    |
|                                         | 2660                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution;</i>      |             |                |         |                                          |                                                        |                                      |    |
|                                         | 2661                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Pathological hyperprolactinaemia where radiotherapy is not indicated;</i>                                 |             |                |         |                                          |                                                        |                                      |    |
|                                         | 2662                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution.</i> |             |                |         |                                          |                                                        |                                      |    |
| 8114C                                   | Tablet 500 micrograms                                                                                        | 8           | 5              | ..      | 75.79                                    | 31.30                                                  | Dostinex                             | PH |
| <b>QUINAGOLIDE HYDROCHLORIDE</b>        |                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b> |                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
|                                         | 2659                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Pathological hyperprolactinaemia where surgery is not indicated;</i>                                      |             |                |         |                                          |                                                        |                                      |    |
|                                         | 2660                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution;</i>      |             |                |         |                                          |                                                        |                                      |    |
|                                         | 2661                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Pathological hyperprolactinaemia where radiotherapy is not indicated;</i>                                 |             |                |         |                                          |                                                        |                                      |    |
|                                         | 2662                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
|                                         | <i>Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution.</i> |             |                |         |                                          |                                                        |                                      |    |
| 8860H                                   | Pack containing 3 tablets 25 micrograms (base) and 3 tablets 50 micrograms (base)                            | ± 1         | ..             | ..      | 11.04                                    | 12.07                                                  | Norprolac                            | FP |
| 8822H                                   | Tablet 75 micrograms (base)                                                                                  | 30          | 5              | ..      | 54.36                                    | 31.30                                                  | Norprolac                            | FP |

### SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

#### **Hormonal contraceptives for systemic use**

#### **• Progestogens and estrogens, fixed combinations**

LEVONORGESTREL with ETHINYLOESTRADIOL

|       |                                                                                   |   |   |        |       |                    |                  |    |
|-------|-----------------------------------------------------------------------------------|---|---|--------|-------|--------------------|------------------|----|
| 1456P | Pack containing 21 tablets<br>125 micrograms-50 micrograms and 7<br>inert tablets | 4 | 2 | ..     | 17.23 | 18.26              | Microgynon 50 ED | SC |
| 1393H | Tablets 150 micrograms-30 micrograms,<br>21                                       | 4 | 2 | B11.45 | 28.68 | 18.26 <sup>a</sup> | Microgynon 30    | SC |

#### **NOTE:**

This product may be interchanged with products with "a" flagging in item 1394J.

continued ➞

## GENITO URINARY SYSTEM AND SEX HORMONES—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form                           | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|-----------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 1394J | Pack containing 21 tablets<br>150 micrograms-30 micrograms and 7<br>inert tablets | 4           | 2              | ..      | 17.23                                    | 18.26                                                  | <sup>a</sup> Levlen ED               | SY |
|       |                                                                                   |             |                |         |                                          |                                                        | <sup>b</sup> Monofeme 28             | WX |
|       |                                                                                   |             |                | B11.45  | 28.68                                    | 18.26                                                  | <sup>a</sup> Microgynon 30 ED        | SC |
|       |                                                                                   |             |                | B11.78  | 29.01                                    | 18.26                                                  | <sup>b</sup> Nordette 28             | WY |

**NOTE:**

The products with "a" flagging may also be interchanged with item 1393H.

### NORETHISTERONE with ETHINYLOESTRADIOL

|       |                                             |   |   |       |         |       |                       |    |
|-------|---------------------------------------------|---|---|-------|---------|-------|-----------------------|----|
| 2772X | Tablets 500 micrograms-35 micrograms,<br>21 | 4 | 2 | B7.92 | * 24.59 | 17.70 | <sup>a</sup> Brevinor | PH |
|-------|---------------------------------------------|---|---|-------|---------|-------|-----------------------|----|

**NOTE:**

This product may be interchanged with the products in item 2774B.

|       |                                                                                   |   |   |       |         |       |                             |    |
|-------|-----------------------------------------------------------------------------------|---|---|-------|---------|-------|-----------------------------|----|
| 2774B | Pack containing 21 tablets<br>500 micrograms-35 micrograms and 7<br>inert tablets | 4 | 2 | ..    | * 16.67 | 17.70 | <sup>a</sup> Norimin 28 Day | KR |
|       |                                                                                   |   |   | B7.92 | * 24.59 | 17.70 | <sup>a</sup> Brevinor       | PH |

**NOTE:**

These products may also be interchanged with item 2772X.

|       |                                |   |   |       |         |       |                         |    |
|-------|--------------------------------|---|---|-------|---------|-------|-------------------------|----|
| 2773Y | Tablets 1 mg-35 micrograms, 21 | 4 | 2 | B7.92 | * 24.59 | 17.70 | <sup>a</sup> Brevinor-1 | PH |
|-------|--------------------------------|---|---|-------|---------|-------|-------------------------|----|

**NOTE:**

This product may be interchanged with the products in item 2775C.

|       |                                                                      |   |   |       |         |       |                               |    |
|-------|----------------------------------------------------------------------|---|---|-------|---------|-------|-------------------------------|----|
| 2775C | Pack containing 21 tablets<br>1 mg-35 micrograms and 7 inert tablets | 4 | 2 | ..    | * 16.67 | 17.70 | <sup>a</sup> Norimin-1 28 Day | KR |
|       |                                                                      |   |   | B7.92 | * 24.59 | 17.70 | <sup>a</sup> Brevinor-1       | PH |

**NOTE:**

These products may also be interchanged with item 2773Y.

### NORETHISTERONE with MESTRANOL

|       |                                                                      |   |   |    |         |       |              |    |
|-------|----------------------------------------------------------------------|---|---|----|---------|-------|--------------|----|
| 3176E | Tablets 1 mg-50 micrograms, 21                                       | 4 | 2 | .. | * 16.67 | 17.70 | Norinyl-1    | PH |
| 3179H | Pack containing 21 tablets<br>1 mg-50 micrograms and 7 inert tablets | 4 | 2 | .. | * 16.67 | 17.70 | Norinyl-1/28 | PH |

### • Progestogens and estrogens, sequential preparations

#### LEVONORGESTREL with ETHINYLOESTRADIOL

|       |                                                                                                                                                                          |   |   |        |       |       |                           |    |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|---|--------|-------|-------|---------------------------|----|
| 1392G | Pack containing 6 tablets<br>50 micrograms-30 micrograms, 5<br>tablets 75 micrograms-40 micrograms,<br>10 tablets<br>125 micrograms-30 micrograms and 7<br>inert tablets | 4 | 2 | ..     | 17.23 | 18.26 | <sup>a</sup> Logynon ED   | SY |
|       |                                                                                                                                                                          |   |   |        |       |       | <sup>b</sup> Trifeme 28   | WX |
|       |                                                                                                                                                                          |   |   | B11.45 | 28.68 | 18.26 | <sup>a</sup> Triquilar ED | SC |
|       |                                                                                                                                                                          |   |   | B11.78 | 29.01 | 18.26 | <sup>b</sup> Triphasil 28 | WY |

## GENITO URINARY SYSTEM AND SEX HORMONES—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                | Name, Restriction,<br>Manner of Administration and Form                              | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| NORETHISTERONE with ETHINYLOESTRADIOL                                                                                                                                                                                                                                                                                                                                                                               |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| 2776D                                                                                                                                                                                                                                                                                                                                                                                                               | Pack containing 12 tablets                                                           | 4           | 2              | ..      | * 16.67                                  | 17.70                                                  | <sup>a</sup> Improvil 28 Day         | KR |
|                                                                                                                                                                                                                                                                                                                                                                                                                     | 500 micrograms-35 micrograms, 9<br>tablets 1 mg-35 micrograms and 7 inert<br>tablets |             |                | B7.92   | * 24.59                                  | 17.70                                                  | <sup>a</sup> Synphasic               | PH |
| • <b>Progestogens</b>                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| ETONOGESTREL                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| 8487Q                                                                                                                                                                                                                                                                                                                                                                                                               | Subcutaneous implant 68 mg                                                           | 1           | ..             | ..      | 215.49                                   | 31.30                                                  | Implanon                             | OR |
| LEVONORGESTREL                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| 2913H                                                                                                                                                                                                                                                                                                                                                                                                               | Tablets 30 micrograms, 28                                                            | 4           | 2              | ..      | 16.89                                    | 17.92                                                  | Microlut 28                          | SC |
| MEDROXYPROGESTERONE ACETATE                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| 3118D                                                                                                                                                                                                                                                                                                                                                                                                               | Injection 150 mg in 1 mL                                                             | 1           | 1              | ..      | 14.21                                    | 15.24                                                  | <sup>a</sup> Depo-Ralovera           | KR |
|                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                      |             |                | B3.34   | 17.55                                    | 15.24                                                  | <sup>a</sup> Depo-Provera            | PH |
| [For other listings for this drug see Generic/Proprietary Index]                                                                                                                                                                                                                                                                                                                                                    |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| NORETHISTERONE                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| 1967M                                                                                                                                                                                                                                                                                                                                                                                                               | Tablets 350 micrograms, 28                                                           | 4           | 2              | ..      | * 16.67                                  | 17.70                                                  | Micronor                             | JC |
|                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                      |             |                | ..      | * 16.67                                  | 17.70                                                  | <sup>a</sup> Locilan 28 Day          | KR |
|                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                      |             |                | B4.00   | * 20.67                                  | 17.70                                                  | <sup>a</sup> Noriday 28 Day          | PH |
| <b>Androgens</b>                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| • <b>3-oxoandrogen (4) derivatives</b>                                                                                                                                                                                                                                                                                                                                                                              |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| TESTOSTERONE                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| <i>Androgen deficiency in males with established pituitary or testicular disorders;</i>                                                                                                                                                                                                                                                                                                                             |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| <i>Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men);</i> |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| <i>Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age.</i>                                                                                                                                                                                                                                                                                                |                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| 8098F                                                                                                                                                                                                                                                                                                                                                                                                               | Subcutaneous implant 100 mg                                                          | 6           | ..             | ..      | * 209.15                                 | 31.30                                                  | OR                                   |    |
| 8099G                                                                                                                                                                                                                                                                                                                                                                                                               | Subcutaneous implant 200 mg                                                          | 3           | ..             | ..      | * 209.12                                 | 31.30                                                  | OR                                   |    |
| 8830R                                                                                                                                                                                                                                                                                                                                                                                                               | Transdermal gel 50 mg in 5 g sachet, 30                                              | ± 1         | 5              | ..      | 94.69                                    | 31.30                                                  | Testogel                             | SC |
| 8460G                                                                                                                                                                                                                                                                                                                                                                                                               | Transdermal patches 12.2 mg (releasing<br>approximately 2.5 mg per 24 hours),<br>60  | ± 1         | 5              | ..      | 95.41                                    | 31.30                                                  | Androderm                            | HH |
| 8619P                                                                                                                                                                                                                                                                                                                                                                                                               | Transdermal patches 24.3 mg (releasing<br>approximately 5 mg per 24 hours), 30       | ± 1         | 5              | ..      | 95.41                                    | 31.30                                                  | Androderm                            | HH |

## GENITO URINARY SYSTEM AND SEX HORMONES—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

### TESTOSTERONE ENANTHATE

#### Authority Required

*Androgen deficiency in males with established pituitary or testicular disorders;*

*Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men);*

*Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age.*

|       |                          |   |   |    |       |       |                   |    |
|-------|--------------------------|---|---|----|-------|-------|-------------------|----|
| 2114G | Injection 250 mg in 1 mL | 3 | 3 | .. | 33.05 | 31.30 | Primoteston Depot | SC |
|-------|--------------------------|---|---|----|-------|-------|-------------------|----|

### TESTOSTERONE ESTERS

#### Authority Required

*Androgen deficiency in males with established pituitary or testicular disorders;*

*Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men);*

*Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age.*

|       |                  |   |   |    |         |       |              |    |
|-------|------------------|---|---|----|---------|-------|--------------|----|
| 2670M | Injection 100 mg | 3 | 3 | .. | * 20.24 | 21.27 | Sustanon 100 | OR |
| 2101N | Injection 250 mg | 3 | 3 | .. | * 33.05 | 31.30 | Sustanon 250 | OR |

### TESTOSTERONE UNDECANOATE

#### Authority Required

*Androgen deficiency in males with established pituitary or testicular disorders;*

*Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8 nmol per L, or 8-15 nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men);*

*Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age.*

|       |                                 |    |   |    |        |       |                   |    |
|-------|---------------------------------|----|---|----|--------|-------|-------------------|----|
| 2115H | Capsule 40 mg                   | 60 | 5 | .. | 37.10  | 31.30 | Andriol Testocaps | OR |
| 9004X | I.M. injection 1,000 mg in 4 mL | 1  | 1 | .. | 146.98 | 31.30 | Reandron 1000     | SC |

### Estrogens

#### • *Natural and semisynthetic estrogens, plain*

#### OESTRADIOL

|       |                                   |     |   |    |       |       |         |    |
|-------|-----------------------------------|-----|---|----|-------|-------|---------|----|
| 8274L | Tablet 2 mg                       | 56  | 2 | .. | 13.57 | 14.60 | Zumenon | SM |
| 1742Q | Vaginal tablets 25 micrograms, 15 | ± 1 | 2 | .. | 22.81 | 23.84 | Vagifem | NO |

continued ➞

## GENITO URINARY SYSTEM AND SEX HORMONES—CONT.

| Code                                                                                                                                                              | Name, Restriction,<br>Manner of Administration and Form                                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>OESTRADIOL</b>                                                                                                                                                 |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                  |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| <i>For use for post-menopausal symptoms where a trial of peri- or post-menopausal low-dose oestrogen therapy has demonstrated intolerance to oral oestrogens.</i> |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                                                                                                                               |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| <i>Oestradiol should be used in conjunction with an oral progestogen in women with an intact uterus.</i>                                                          |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 8286D                                                                                                                                                             | Transdermal gel 1 mg in 1 g sachet, 28                                                             | ‡ 1         | 5              | ..      | 17.33                                    | 18.36                                                  | Sandrena                             | OR |
| 8761D                                                                                                                                                             | Transdermal patches 390 micrograms<br>(releasing approximately<br>25 micrograms per 24 hours), 8   | ‡ 1         | 5              | ..      | 17.33                                    | 18.36                                                  | Estradot 25                          | NV |
| 8311K                                                                                                                                                             | Transdermal patches 750 micrograms<br>(releasing approximately<br>25 micrograms per 24 hours), 8   | ‡ 1         | 5              | ..      | 17.33                                    | 18.36                                                  | Estraderm MX 25                      | NV |
| 8485N                                                                                                                                                             | Transdermal patches 2 mg (releasing<br>approximately 25 micrograms per 24<br>hours), 4             | ‡ 1         | 5              | ..      | 17.33                                    | 18.36                                                  | Climara 25                           | SC |
| 1743R                                                                                                                                                             | Transdermal patches 2 mg (releasing<br>approximately 25 micrograms per 24<br>hours), 8             | ‡ 1         | 5              | ..      | 17.33                                    | 18.36                                                  | Estraderm 25                         | NV |
| 8762E                                                                                                                                                             | Transdermal patches 585 micrograms<br>(releasing approximately<br>37.5 micrograms per 24 hours), 8 | ‡ 1         | 5              | ..      | 17.33                                    | 18.36                                                  | Estradot 37.5                        | NV |
| 8140K                                                                                                                                                             | Transdermal patches 1.5 mg (releasing<br>approximately 50 micrograms per 24<br>hours), 8           | ‡ 1         | 5              | ..      | 17.33                                    | 18.36                                                  | Estraderm MX 50                      | NV |
| 8125P                                                                                                                                                             | Transdermal patches 3.8 mg (releasing<br>approximately 50 micrograms per 24<br>hours), 4           | ‡ 1         | 5              | ..      | 17.33                                    | 18.36                                                  | Climara 50                           | SC |
| 1744T                                                                                                                                                             | Transdermal patches 4 mg (releasing<br>approximately 50 micrograms per 24<br>hours), 8             | ‡ 1         | 5              | ..      | 17.33                                    | 18.36                                                  | Estraderm 50                         | NV |
| 8763F                                                                                                                                                             | Transdermal patches 780 micrograms<br>(releasing approximately<br>50 micrograms per 24 hours), 8   | ‡ 1         | 5              | ..      | 17.33                                    | 18.36                                                  | Estradot 50                          | NV |
| 8486P                                                                                                                                                             | Transdermal patches 5.7 mg (releasing<br>approximately 75 micrograms per 24<br>hours), 4           | ‡ 1         | 5              | ..      | 19.49                                    | 20.52                                                  | Climara 75                           | SC |
| 8764G                                                                                                                                                             | Transdermal patches 1.17 mg (releasing<br>approximately 75 micrograms per 24<br>hours), 8          | ‡ 1         | 5              | ..      | 19.49                                    | 20.52                                                  | Estradot 75                          | NV |

continued ➡



# GENITO URINARY SYSTEM AND SEX HORMONES—CONT.

| Code                             | Name, Restriction,<br>Manner of Administration and Form                                     | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |                |
|----------------------------------|---------------------------------------------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----------------|
| 8312L                            | <i>Transdermal patches 3 mg (releasing approximately 100 micrograms per 24 hours), 8</i>    | ‡ 1         | 5              | ..          | 19.49                                    | 20.52                                                  | <i>Estraderm MX 100</i>              | NV             |
| 8126Q                            | <i>Transdermal patches 7.6 mg (releasing approximately 100 micrograms per 24 hours), 4</i>  | ‡ 1         | 5              | ..          | 19.49                                    | 20.52                                                  | <i>Climara 100</i>                   | SC             |
| 1745W                            | <i>Transdermal patches 8 mg (releasing approximately 100 micrograms per 24 hours), 8</i>    | ‡ 1         | 5              | ..          | 19.49                                    | 20.52                                                  | <i>Estraderm 100</i>                 | NV             |
| 8765H                            | <i>Transdermal patches 1.56 mg (releasing approximately 100 micrograms per 24 hours), 8</i> | ‡ 1         | 5              | ..          | 19.49                                    | 20.52                                                  | <i>Estradot 100</i>                  | NV             |
| OESTRADIOL VALERATE              |                                                                                             |             |                |             |                                          |                                                        |                                      |                |
| 1663M                            | Tablet 1 mg                                                                                 | 56          | 2              | ..          | 11.57                                    | 12.60                                                  | Progynova                            | SC             |
| 1664N                            | Tablet 2 mg                                                                                 | 56          | 2              | ..          | 13.94                                    | 14.97                                                  | Progynova                            | SC             |
| OESTRIOL                         |                                                                                             |             |                |             |                                          |                                                        |                                      |                |
| 1771F                            | Pessaries 500 micrograms, 15                                                                | ‡ 1         | 2              | ..          | 20.83                                    | 21.86                                                  | Ovestin Ovula                        | OR             |
| 1781R                            | Vaginal cream 1 mg per g (0.1%), 15 g                                                       | ‡ 1         | 1              | ..          | 18.66                                    | 19.69                                                  | Ovestin                              | OR             |
| OESTROGENS—CONJUGATED            |                                                                                             |             |                |             |                                          |                                                        |                                      |                |
| 1733F                            | Tablet 300 micrograms                                                                       | 56          | 2              | ..          | * 15.15                                  | 16.18                                                  | Premarin                             | WX             |
| 1734G                            | Tablet 625 micrograms                                                                       | 56          | 2              | ..          | * 15.67                                  | 16.70                                                  | Premarin                             | WX             |
| PIPERAZINE OESTRONE SULFATE      |                                                                                             |             |                |             |                                          |                                                        |                                      |                |
| 1777M                            | Tablet 730 micrograms (equivalent to 625 micrograms sodium oestrone sulfate)                | 56          | 2              | ..<br>B1.47 | 11.57<br>13.04                           | 12.60 <sup>a</sup><br>12.60 <sup>a</sup>               | Genoral 0.625<br>Ogen .625           | KR<br>PH       |
| 1778N                            | Tablet 1.46 mg (equivalent to 1.25 mg sodium oestrone sulfate)                              | 56          | 2              | ..<br>B1.48 | 13.94<br>15.42                           | 14.97 <sup>a</sup><br>14.97 <sup>a</sup>               | Genoral 1.25<br>Ogen 1.25            | KR<br>PH       |
| <b>Progestogens</b>              |                                                                                             |             |                |             |                                          |                                                        |                                      |                |
| • <b>Pregnen (4) derivatives</b> |                                                                                             |             |                |             |                                          |                                                        |                                      |                |
| MEDROXYPROGESTERONE ACETATE      |                                                                                             |             |                |             |                                          |                                                        |                                      |                |
| 2323G                            | Tablet 5 mg                                                                                 | 56          | 2              | ..<br>B1.74 | 14.78<br>16.52                           | 15.81 <sup>a</sup><br>15.81 <sup>a</sup>               | Ralovera<br>Provera                  | KR<br>PH       |
| 2321E                            | Tablet 10 mg                                                                                | 30          | 2              | ..<br>B1.75 | 15.42<br>17.17                           | 16.45 <sup>a</sup><br>16.45 <sup>a</sup>               | Medroxyhexal<br>Ralovera<br>Provera  | SZ<br>KR<br>PH |
| 2319C                            | Injection 50 mg in 1 mL                                                                     | 1           | 1              | ..          | 11.48                                    | 12.51                                                  | Depo-Provera                         | PH             |



## GENITO URINARY SYSTEM AND SEX HORMONES—CONT.

| Code                                                                                                                                                                                               | Name, Restriction,<br>Manner of Administration and Form                                                                                                                                                                                                                                                 | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8169Y                                                                                                                                                                                              | Tablets 625 micrograms-5 mg, 28                                                                                                                                                                                                                                                                         | ± 1         | 5              | ..      | 17.38                                    | 18.41                                                  | Premia 5<br>Continuous               | WX |
| <b>• Progestogens and estrogens, sequential preparations</b><br>OESTRADIOL and OESTRADIOL with DYDROGESTERONE                                                                                      |                                                                                                                                                                                                                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8244X                                                                                                                                                                                              | Pack containing 14 tablets oestradiol<br>2 mg and 14 tablets oestradiol 2 mg<br>with dydrogesterone 10 mg                                                                                                                                                                                               | ± 1         | 5              | ..      | 17.34                                    | 18.37                                                  | Femoston 2/10                        | SM |
| OESTRADIOL and OESTRADIOL with NORETHISTERONE<br>ACETATE                                                                                                                                           |                                                                                                                                                                                                                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1764W                                                                                                                                                                                              | Pack containing 12 tablets oestradiol<br>2 mg, 10 tablets oestradiol 2 mg with<br>norethisterone acetate 1 mg and 6<br>tablets oestradiol 1 mg                                                                                                                                                          | ± 1         | 5              | ..      | 17.26                                    | 18.29                                                  | Trisequens                           | NO |
| <b>OESTRADIOL and OESTRADIOL with NORETHISTERONE<br/>ACETATE</b>                                                                                                                                   |                                                                                                                                                                                                                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b><br><i>For use for post-menopausal symptoms where a trial of peri- or post-menopausal low-dose oestrogen therapy has<br/>demonstrated intolerance to oral oestrogens.</i> |                                                                                                                                                                                                                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8425K                                                                                                                                                                                              | Pack containing 4 transdermal patches<br>oestradiol 780 micrograms (releasing<br>approximately 50 micrograms per<br>24 hours) and 4 transdermal patches<br>oestradiol with norethisterone<br>acetate 620 micrograms-2.7 mg<br>(releasing approximately<br>50 micrograms-140 micrograms per<br>24 hours) | ± 1         | 5              | ..      | 19.49                                    | 20.52                                                  | Estalis sequi 50/<br>140             | NV |
| 8426L                                                                                                                                                                                              | Pack containing 4 transdermal patches<br>oestradiol 780 micrograms (releasing<br>approximately 50 micrograms per<br>24 hours) and 4 transdermal patches<br>oestradiol with norethisterone<br>acetate 510 micrograms-4.8 mg<br>(releasing approximately<br>50 micrograms-250 micrograms per<br>24 hours) | ± 1         | 5              | ..      | 19.49                                    | 20.52                                                  | Estalis sequi 50/<br>250             | NV |

continued ➞

## GENITO URINARY SYSTEM AND SEX HORMONES—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form                                                                                                                                                                                                             | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8029N | <i>Pack containing 4 transdermal patches oestradiol 4 mg (releasing approximately 50 micrograms per 24 hours) and 4 transdermal patches oestradiol with norethisterone acetate 10 mg-30 mg (releasing approximately 50 micrograms- 250 micrograms per 24 hours)</i> | ‡ 1         | 5              | ..      | 19.49                                    | 20.52                                                  | <i>Estracombi</i>                    | NV |

### Gonadotropins and other ovulation stimulants

#### • Gonadotropins

##### FOLLITROPIN ALFA

##### Restricted Benefit

Anovulatory infertility.

##### NOTE:

*Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.*

*Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.*

*Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.*

*Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.*

|       |                                                                                                              |   |   |    |          |       |                   |    |
|-------|--------------------------------------------------------------------------------------------------------------|---|---|----|----------|-------|-------------------|----|
| 8672K | <i>Injection set containing 1 vial powder for injection 75 i.u. and 1 pre-filled syringe solvent 1 mL</i>    | 5 | 5 | .. | * 247.14 | 31.30 | <i>Gonal-f 75</i> | SG |
| 8674M | <i>Injection set containing 1 vial powder for injection 1,050 i.u. and 1 pre-filled syringe solvent 2 mL</i> | 1 | 5 | .. | 655.76   | 31.30 | <i>Gonal-f</i>    | SG |

##### Restricted Benefit

Anovulatory infertility.

##### NOTE:

*Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.*

*Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.*

*Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.*

*Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.*

continued ➞

## GENITO URINARY SYSTEM AND SEX HORMONES—CONT.

| Code                                                                                                                                                                                                                                                | Name, Restriction,<br>Manner of Administration and Form                                                | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                                                                                                                                                     |                                                                                                        |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                                    |                                                                                                        |             |                |         |                             |                                             |                                      |    |
| <i>For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given.</i> |                                                                                                        |             |                |         |                             |                                             |                                      |    |
| 8673L                                                                                                                                                                                                                                               | Injection set containing 10 vials powder for injection 75 i.u. and 10 pre-filled syringes solvent 1 mL | 1           | 5              | ..      | 470.25                      | 31.30                                       | Gonal-f 75                           | SG |
| 8713N                                                                                                                                                                                                                                               | Injection 300 i.u. in 0.5 mL multi-dose cartridge                                                      | 3           | 5              | ..      | * 563.00                    | 31.30                                       | Gonal-f Pen                          | SG |
| 8675N                                                                                                                                                                                                                                               | Injection set containing 1 vial powder for injection 450 i.u. and 1 pre-filled syringe solvent 1 mL    | 3           | 5              | ..      | * 841.46                    | 31.30                                       | Gonal-f                              | SG |
| 8714P                                                                                                                                                                                                                                               | Injection 450 i.u. in 0.75 mL multi-dose cartridge                                                     | 3           | 5              | ..      | * 841.49                    | 31.30                                       | Gonal-f Pen                          | SG |
| 8715Q                                                                                                                                                                                                                                               | Injection 900 i.u. in 1.5 mL multi-dose cartridge                                                      | 2           | 5              | ..      | * 1114.81                   | 31.30                                       | Gonal-f Pen                          | SG |
| <b>FOLLITROPIN BETA</b>                                                                                                                                                                                                                             |                                                                                                        |             |                |         |                             |                                             |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                                    |                                                                                                        |             |                |         |                             |                                             |                                      |    |
| <i>Anovulatory infertility.</i>                                                                                                                                                                                                                     |                                                                                                        |             |                |         |                             |                                             |                                      |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                                 |                                                                                                        |             |                |         |                             |                                             |                                      |    |
| <i>Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.</i>                                                          |                                                                                                        |             |                |         |                             |                                             |                                      |    |
| <i>Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.</i>                                                                 |                                                                                                        |             |                |         |                             |                                             |                                      |    |
| <i>Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.</i>                                                                                                               |                                                                                                        |             |                |         |                             |                                             |                                      |    |
| <i>Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.</i>                                                                                                                              |                                                                                                        |             |                |         |                             |                                             |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                                    |                                                                                                        |             |                |         |                             |                                             |                                      |    |
| <i>For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given.</i> |                                                                                                        |             |                |         |                             |                                             |                                      |    |
| 8565T                                                                                                                                                                                                                                               | Solution for injection 300 i.u. in 0.36 mL multi-dose cartridge                                        | 3           | 5              | ..      | * 563.00                    | 31.30                                       | Puregon 300 IU/<br>0.36 mL           | OR |
| 8566W                                                                                                                                                                                                                                               | Solution for injection 600 i.u. in 0.72 mL multi-dose cartridge                                        | 2           | 5              | ..      | * 748.65                    | 31.30                                       | Puregon 600 IU/<br>0.72 mL           | OR |
| 8871X                                                                                                                                                                                                                                               | Solution for injection 900 i.u. in 1.08 mL multi-dose cartridge                                        | 2           | 5              | ..      | * 1114.79                   | 31.30                                       | Puregon 900 IU/<br>1.08 mL           | OR |

## GENITO URINARY SYSTEM AND SEX HORMONES—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### HUMAN CHORIONIC GONADOTROPHIN

#### **Restricted Benefit**

*Anovulatory infertility.*

#### **NOTE:**

*Except in cases of hypopituitarism or primary amenorrhoea, the patient should have been adequately treated with clomiphene citrate and/or gonadorelin and failed to have conceived.*

*Women who have had apparent ovulation induced by other agents and have failed to conceive should have laparoscopic evidence that there is no other impediment to conception.*

*Oligomenorrhoea should have been present for at least twelve months or amenorrhoea for at least six months prior to treatment.*

*Patients with hyperprolactinaemia should have had appropriate surgical or medical treatment prior to treatment.*

#### **Restricted Benefit**

*For the treatment of infertility in males due to hypogonadotrophic hypogonadism;*

*For the treatment of infertility in males associated with isolated luteinising hormone deficiency;*

*For the treatment of males who have combined deficiency of human growth hormone and gonadotrophins and in whom the absence of secondary sexual characteristics indicates a lag in maturation.*

#### **Restricted Benefit**

*For the treatment of boys over the age of 16 years who show clinical evidence of hypogonadism or delayed puberty. Treatment must not extend beyond 6 months.*

|       |                                                                                                  |   |   |    |       |       |         |    |
|-------|--------------------------------------------------------------------------------------------------|---|---|----|-------|-------|---------|----|
| 1579D | Injection set containing 3 ampoules powder for injection 500 units and 3 ampoules solvent 1 mL   | 1 | 5 | .. | 30.44 | 31.30 | Pregnyl | OR |
| 1581F | Injection set containing 3 ampoules powder for injection 1,500 units and 3 ampoules solvent 1 mL | 1 | 5 | .. | 40.66 | 31.30 | Pregnyl | OR |

#### **Restricted Benefit**

*Cryptorchism not due to organic obstruction in boys over 12 months of age.*

|       |                                                                                                |   |   |    |         |       |         |    |
|-------|------------------------------------------------------------------------------------------------|---|---|----|---------|-------|---------|----|
| 1583H | Injection set containing 3 ampoules powder for injection 500 units and 3 ampoules solvent 1 mL | 2 | 1 | .. | * 53.01 | 31.30 | Pregnyl | OR |
|-------|------------------------------------------------------------------------------------------------|---|---|----|---------|-------|---------|----|

## GENITO URINARY SYSTEM AND SEX HORMONES—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                   | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>• Ovulation stimulants, synthetic</b><br><b>CLOMIPHENE CITRATE</b><br><b>NOTE:</b><br><i>Care must be taken to comply with the provisions of State/Territory law when prescribing clomiphene citrate.</i><br><b>Restricted Benefit</b><br><i>Anovulatory infertility;</i><br><i>Patients undergoing in-vitro fertilisation.</i>                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1211R                                                                                                                                                                                                                                                                                                                                                                                                                  | Tablet 50 mg                                            | 10          | 5              | ..      | * 32.67                                  | 31.30                                                  | <sup>a</sup> Clomhexal               | HX |
|                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Femil                   | AW |
|                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                   | GX |
|                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | Clomiphene                           |    |
|                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                | B0.14   | 32.81                                    | 31.30                                                  | <sup>a</sup> Serophene               | SG |
|                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                | B2.83   | 35.50                                    | 31.30                                                  | <sup>a</sup> Clomid                  | SW |
| <b>Antiandrogens</b><br><b>• Antiandrogens, plain preparations</b><br><b>CYPROTERONE ACETATE</b><br><b>Authority Required (STREAMLINED)</b><br>1230<br><i>Moderate to severe androgenisation in non-pregnant women (acne alone is not a sufficient indication of androgenisation).</i><br><b>CAUTION:</b><br><i>This drug should not be used during pregnancy as it may result in feminisation of the male foetus.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1269T                                                                                                                                                                                                                                                                                                                                                                                                                  | Tablet 50 mg                                            | 20          | 5              | ..      | 52.31                                    | 31.30                                                  | <sup>a</sup> Cyprohexal              | SZ |
|                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cyprone                 | AF |
|                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cyprostat               | SY |
|                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                   | GX |
|                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | Cyproterone<br>Acetate               |    |
|                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Procur                  | GM |
|                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                | B3.13   | 55.44                                    | 31.30                                                  | <sup>a</sup> Androcur                | SC |

continued ➞

## GENITO URINARY SYSTEM AND SEX HORMONES—CONT.

| Code                                                  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b><u>Authority Required (STREAMLINED)</u></b>        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1014                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Advanced carcinoma of the prostate;</i>            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1404                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>To reduce drive in sexual deviations in males.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1270W                                                 | Tablet 50 mg                                            | 100         | 5              | ..      | * 207.29                                 | 31.30                                                  | <sup>a</sup> Cyprohexal              | SZ |
|                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cyprone                 | AF |
|                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cyprostat               | SY |
|                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                   | GX |
|                                                       |                                                         |             |                |         |                                          |                                                        | Cyproterone<br>Acetate               |    |
|                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Procur                  | GM |
|                                                       |                                                         |             |                | B3.00   | * 210.29                                 | 31.30                                                  | <sup>a</sup> Androcur                | SC |
| 8019C                                                 | Tablet 100 mg                                           | 50          | 5              | ..      | 169.33                                   | 31.30                                                  | <sup>a</sup> Cyprohexal              | SZ |
|                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cyprostat-100           | SY |
|                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                   | GX |
|                                                       |                                                         |             |                |         |                                          |                                                        | Cyproterone<br>Acetate               |    |
|                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Procur 100              | GM |
|                                                       |                                                         |             |                | B1.65   | 170.98                                   | 31.30                                                  | <sup>a</sup> Androcur-100            | SC |

### Other sex hormones and modulators of the genital system

#### • Antigonadotropins and similar agents

DANAZOL

**CAUTION:**

*Pregnancy must be excluded prior to administration of this drug.*

#### **Authority Required (STREAMLINED)**

1090

*Endometriosis, visually proven;*

1151

*Hereditary angio-oedema;*

2639

*Short-term treatment (up to 6 months) of intractable primary menorrhagia (Treatment of this indication is limited to 6 months. See Australian Product Information);*

2640

*Short-term treatment (up to 6 months) of severe benign (fibrocystic) breast disease or mastalgia associated with severe symptomatic benign breast disease in patients refractory to other treatments (Treatment of this indication is limited to 6 months. See Australian Product Information).*

|       |                |     |   |    |       |       |          |    |
|-------|----------------|-----|---|----|-------|-------|----------|----|
| 1285P | Capsule 100 mg | 100 | 5 | .. | 58.15 | 31.30 | Azol 100 | AF |
| 1287R | Capsule 200 mg | 100 | 5 | .. | 86.54 | 31.30 | Azol 200 | AF |



## GENITO URINARY SYSTEM AND SEX HORMONES—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

### GESTRINONE

#### **Authority Required**

*Short-term treatment (up to 6 months) of visually proven endometriosis (only 1 course of not more than 6 months' therapy will be authorised).*

|       |                |   |   |    |       |       |             |    |
|-------|----------------|---|---|----|-------|-------|-------------|----|
| 8015W | Capsule 2.5 mg | 8 | 5 | .. | 77.52 | 31.30 | Dimetrioese | SW |
|-------|----------------|---|---|----|-------|-------|-------------|----|

- **Selective estrogen receptor modulators**

#### **RALOXIFENE HYDROCHLORIDE**

*For listings see Generic/Proprietary Index*

### UROLOGICALS

#### **Other urologicals, incl. antispasmodics**

- **Urinary antispasmodics**

#### **OXYBUTYNIN HYDROCHLORIDE**

#### **Restricted Benefit**

*Detrusor overactivity.*

|       |             |     |   |    |       |       |                                                                                                |                |
|-------|-------------|-----|---|----|-------|-------|------------------------------------------------------------------------------------------------|----------------|
| 8039D | Tablet 5 mg | 100 | 5 | .. | 15.54 | 16.57 | <sup>a</sup> Ditropan<br><sup>a</sup> Oxybutynin Sandoz<br><sup>a</sup> Oxybutynin<br>Winthrop | SW<br>SZ<br>WA |
|-------|-------------|-----|---|----|-------|-------|------------------------------------------------------------------------------------------------|----------------|

#### **PROPANTHELINE BROMIDE**

#### **Restricted Benefit**

*Detrusor overactivity.*

|       |              |     |   |    |         |       |              |    |
|-------|--------------|-----|---|----|---------|-------|--------------|----|
| 1953T | Tablet 15 mg | 200 | 5 | .. | * 26.03 | 27.06 | Pro-Banthine | SI |
|-------|--------------|-----|---|----|---------|-------|--------------|----|

- **Other urologicals**

#### **PHENOXYBENZAMINE HYDROCHLORIDE**

#### **Restricted Benefit**

*Phaeochromocytoma;*

*Neurogenic urinary retention.*

|       |               |     |   |    |       |       |            |    |
|-------|---------------|-----|---|----|-------|-------|------------|----|
| 1862B | Capsule 10 mg | 100 | 5 | .. | 66.93 | 31.30 | Dibenylene | GH |
|-------|---------------|-----|---|----|-------|-------|------------|----|

|       |                    |   |   |    |          |       |            |    |
|-------|--------------------|---|---|----|----------|-------|------------|----|
| 1166J | Capsules 10 mg, 30 | 3 | 5 | .. | * 204.47 | 31.30 | Dibenylene | GH |
|-------|--------------------|---|---|----|----------|-------|------------|----|

# SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

## PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES

### Anterior pituitary lobe hormones and analogues

#### • ACTH

TETRACOSACTRIN

|       |                        |   |   |    |         |       |                              |    |
|-------|------------------------|---|---|----|---------|-------|------------------------------|----|
| 2832C | Injection 1 mg in 1 mL | 5 | 5 | .. | * 70.84 | 31.30 | Synacthen Depot<br>1 mg/1 mL | NV |
|-------|------------------------|---|---|----|---------|-------|------------------------------|----|

#### • Thyrotropin

THYROTROPIN ALFA

#### Authority Required

*Ablation of thyroid remnant tissue, in combination with radioactive iodine, in a post thyroidectomy adult aged 18 years or older without known metastatic disease. This drug is only PBS-subsidised for 1 treatment in a patient's lifetime.*

|       |                                |   |    |    |         |       |          |    |
|-------|--------------------------------|---|----|----|---------|-------|----------|----|
| 2700D | Powder for injection 0.9 mg, 2 | 1 | .. | .. | 1900.99 | 31.30 | Thyrogen | GZ |
|-------|--------------------------------|---|----|----|---------|-------|----------|----|

### Posterior pituitary lobe hormones

#### • Vasopressin and analogues

DESMOPRESSIN ACETATE

#### Authority Required (STREAMLINED)

1678

*Cranial diabetes insipidus.*

|       |                                                                             |    |   |    |          |       |                        |    |
|-------|-----------------------------------------------------------------------------|----|---|----|----------|-------|------------------------|----|
| 8662X | Tablet 200 micrograms                                                       | 90 | 5 | .. | * 179.48 | 31.30 | Minirin                | FP |
| 2129C | Intranasal solution 100 micrograms per<br>mL, 2.5 mL                        | 5  | 5 | .. | * 160.74 | 31.30 | Minirin                | FP |
| 8711L | Nasal spray (pump pack) 10 micrograms<br>per actuation, 60 actuations, 6 mL | 2  | 5 | .. | * 160.61 | 31.30 | Minirin Nasal<br>Spray | FP |

#### Authority Required (STREAMLINED)

2641

*Primary nocturnal enuresis in patients aged 6 years or older who are refractory to an enuresis alarm;*

2642

*Primary nocturnal enuresis in patients aged 6 years or older for whom an enuresis alarm is contraindicated. The reason that an alarm is contraindicated must be documented in the patient's medical records when treatment is initiated.*

#### NOTE:

*Not to be used in preference to enuresis alarms.*

|       |                       |    |   |    |       |       |         |    |
|-------|-----------------------|----|---|----|-------|-------|---------|----|
| 8663Y | Tablet 200 micrograms | 30 | 5 | .. | 63.82 | 31.30 | Minirin | FP |
|-------|-----------------------|----|---|----|-------|-------|---------|----|

#### NOTE:

*Only one application per six months with no more than twice the maximum quantity will be authorised for the tablets.*

continued ➞

# SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Name, Restriction,<br>Manner of Administration and Form                     | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8712M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Nasal spray (pump pack) 10 micrograms<br>per actuation, 60 actuations, 6 mL | ± 1         | 5              | ..      | 83.30                                    | 31.30                                                  | Minirin Nasal<br>Spray               | FP |
| <b>Hypothalamic hormones</b><br><b>• Gonadotropin-releasing hormones</b><br>NAFARELIN ACETATE<br><br><u>Authority Required</u><br><i>Initial treatment (up to 6 months) of visually proven endometriosis;</i><br><i>Subsequent treatment (up to 6 months) of visually proven endometriosis, where 2 years or more have elapsed<br/>since the end of the previous course and where a recent bone density assessment has been made. The date of the<br/>assessment must be provided.</i> |                                                                             |             |                |         |                                          |                                                        |                                      |    |
| 2962X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Nasal spray (pump pack)<br>200 micrograms (base) per dose (60<br>doses)     | ± 1         | 5              | ..      | 95.08                                    | 31.30                                                  | Synarel                              | PH |

## CORTICOSTEROIDS FOR SYSTEMIC USE

### Corticosteroids for systemic use, plain

#### • Mineralocorticoids

FLUDROCORTISONE ACETATE

|       |                       |     |   |    |         |       |          |    |
|-------|-----------------------|-----|---|----|---------|-------|----------|----|
| 1433K | Tablet 100 micrograms | 200 | 1 | .. | * 22.07 | 23.10 | Florinef | BQ |
|-------|-----------------------|-----|---|----|---------|-------|----------|----|

#### • Glucocorticoids

BETAMETHASONE ACETATE with BETAMETHASONE  
SODIUM PHOSPHATE

#### Restricted Benefit

*Alopecia areata;*

*For local intra-articular or peri-articular infiltration;*

*Granulomata, dermal;*

*Keloid;*

*Lichen planus hypertrophic;*

*Lichen simplex chronicus;*

*Lupus erythematosus, chronic discoid;*

*Necrobiosis lipoidica;*

*Uveitis.*

|       |                                                                       |   |    |    |       |       |                         |    |
|-------|-----------------------------------------------------------------------|---|----|----|-------|-------|-------------------------|----|
| 2694T | Injection 3 mg-3.9 mg (equivalent to<br>5.7 mg betamethasone) in 1 mL | 5 | .. | .. | 25.74 | 26.77 | Celestone<br>Chronodose | SH |
|-------|-----------------------------------------------------------------------|---|----|----|-------|-------|-------------------------|----|

CORTISONE ACETATE

|       |              |    |   |    |       |       |         |    |
|-------|--------------|----|---|----|-------|-------|---------|----|
| 1246N | Tablet 5 mg  | 50 | 4 | .. | 14.87 | 15.90 | Cortate | AS |
| 1247P | Tablet 25 mg | 60 | 4 | .. | 16.81 | 17.84 | Cortate | AS |

**SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS—CONT.**

| Code                                                                                                 | Name, Restriction,<br>Manner of Administration and Form                     | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                   |          |
|------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|----------|
| DEXAMETHASONE                                                                                        |                                                                             |             |                |             |                                          |                                                        |                                                        |          |
| 1292B                                                                                                | Tablet 500 micrograms                                                       | 30          | 4              | ..          | 8.41                                     | 9.44                                                   | Dexmethsone                                            | AS       |
| 2507Y                                                                                                | Tablet 4 mg                                                                 | 30          | 4              | ..          | 11.97                                    | 13.00                                                  | Dexmethsone                                            | AS       |
| DEXAMETHASONE SODIUM PHOSPHATE                                                                       |                                                                             |             |                |             |                                          |                                                        |                                                        |          |
| 2509C                                                                                                | Injection equivalent to 4 mg<br>dexamethasone phosphate in 1 mL             | 5           | ..             | ..          | 17.65                                    | 18.68                                                  | HH                                                     |          |
| 1291Y                                                                                                | Injection equivalent to 8 mg<br>dexamethasone phosphate in 2 mL             | 5           | 1              | ..          | 27.15                                    | 28.18                                                  | HH                                                     |          |
| HYDROCORTISONE                                                                                       |                                                                             |             |                |             |                                          |                                                        |                                                        |          |
| 1499X                                                                                                | Tablet 4 mg                                                                 | 50          | 4              | ..          | 10.76                                    | 11.79                                                  | Hysone 4                                               | AF       |
| 1500Y                                                                                                | Tablet 20 mg                                                                | 60          | 4              | ..          | 14.40                                    | 15.43                                                  | Hysone 20                                              | AF       |
| HYDROCORTISONE SODIUM SUCCINATE                                                                      |                                                                             |             |                |             |                                          |                                                        |                                                        |          |
| 1501B                                                                                                | Injection equivalent to 100 mg<br>hydrocortisone with 2 mL solvent          | 2           | ..             | ..          | * 16.71                                  | 17.74                                                  | Solu-Cortef                                            | PH       |
| 3096Y                                                                                                | Injection equivalent to 250 mg<br>hydrocortisone with 2 mL solvent          | 1           | ..             | ..          | 15.68                                    | 16.71                                                  | Solu-Cortef                                            | PH       |
| <hr/>                                                                                                |                                                                             |             |                |             |                                          |                                                        |                                                        |          |
| <b>HYDROCORTISONE SODIUM SUCCINATE</b>                                                               |                                                                             |             |                |             |                                          |                                                        |                                                        |          |
| <b><u>Restricted Benefit</u></b><br><i>For use in a hospital.</i>                                    |                                                                             |             |                |             |                                          |                                                        |                                                        |          |
| 1510L                                                                                                | Injection equivalent to 100 mg<br>hydrocortisone with 2 mL solvent          | 6           | ..             | ..          | * 38.15                                  | 31.30                                                  | Solu-Cortef                                            | PH       |
| 1511M                                                                                                | Injection equivalent to 250 mg<br>hydrocortisone with 2 mL solvent          | 6           | ..             | ..          | * 61.61                                  | 31.30                                                  | Solu-Cortef                                            | PH       |
| <b>METHYLPREDNISOLONE ACETATE</b>                                                                    |                                                                             |             |                |             |                                          |                                                        |                                                        |          |
| <b><u>Restricted Benefit</u></b><br><i>For local intra-articular or peri-articular infiltration.</i> |                                                                             |             |                |             |                                          |                                                        |                                                        |          |
| 1928L                                                                                                | Injection 40 mg in 1 mL                                                     | 5           | ..             | ..<br>B0.76 | 24.38<br>25.14                           | 25.41<br>25.41                                         | <sup>a</sup> Depo-Nisolone<br><sup>a</sup> Depo-Medrol | KR<br>PH |
| <b>METHYLPREDNISOLONE SODIUM SUCCINATE</b>                                                           |                                                                             |             |                |             |                                          |                                                        |                                                        |          |
| 2981X                                                                                                | Powder for injection equivalent to 40 mg<br>methylprednisolone with diluent | 5           | ..             | ..          | 33.15                                    | 31.30                                                  | Solu-Medrol                                            | PF       |

continued ➞

**SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS—CONT.**

| Code  | Name, Restriction,<br>Manner of Administration and Form                   | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                   |          |
|-------|---------------------------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|----------|
| 8834Y | Powder for injection equivalent to 1 g<br>methylprednisolone with diluent | 1           | ..             | ..          | 98.67                                    | 31.30                                                  | Solu-Medrol                                            | PF       |
|       | PREDNISOLONE                                                              |             |                |             |                                          |                                                        |                                                        |          |
| 3152X | Tablet 1 mg                                                               | 100         | 4              | ..<br>B0.46 | 8.00<br>8.46                             | 9.03<br>9.03                                           | <sup>a</sup> Predsolone<br><sup>a</sup> Panafcortelone | LN<br>AS |
| 1917X | Tablet 5 mg                                                               | 60          | 4              | ..          | 8.15                                     | 9.18                                                   | Panafcortelone<br>Solone                               | AS<br>FM |
| 1916W | Tablet 25 mg                                                              | 30          | 4              | ..          | 9.90                                     | 10.93                                                  | Panafcortelone<br>Solone                               | AS<br>FM |
|       | PREDNISOLONE SODIUM PHOSPHATE                                             |             |                |             |                                          |                                                        |                                                        |          |
| 8285C | Oral solution equivalent to 5 mg<br>prednisolone per mL, 30 mL            | ‡ 1         | 5              | ..<br>B1.40 | 12.53<br>13.93                           | 13.56<br>13.56                                         | <sup>a</sup> PredMix<br><sup>a</sup> Redipred          | LN<br>AS |
|       | PREDNISONE                                                                |             |                |             |                                          |                                                        |                                                        |          |
| 1934T | Tablet 1 mg                                                               | 100         | 4              | ..<br>B0.65 | 8.57<br>9.22                             | 9.60<br>9.60                                           | <sup>a</sup> Predsone<br><sup>a</sup> Panafcort        | LN<br>AS |
| 1935W | Tablet 5 mg                                                               | 60          | 4              | ..          | 8.92                                     | 9.95                                                   | Panafcort<br>Sone                                      | AS<br>FM |
| 1936X | Tablet 25 mg                                                              | 30          | 4              | ..          | 11.29                                    | 12.32                                                  | Panafcort<br>Sone                                      | AS<br>FM |

**TRIAMCINOLONE ACETONIDE****Restricted Benefit***Alopecia areata;**For local intra-articular or peri-articular infiltration;**Granulomata, dermal;**Keloid;**Lichen planus hypertrophic;**Lichen simplex chronicus;**Lupus erythematosus, chronic discoid;**Necrobiosis lipoidica;**Psoriasis.*

|       |                         |   |    |    |       |       |                     |           |
|-------|-------------------------|---|----|----|-------|-------|---------------------|-----------|
| 2990J | Injection 10 mg in 1 mL | 5 | .. | .. | 25.74 | 26.77 | <b>Kenacort-A10</b> | <b>BQ</b> |
|-------|-------------------------|---|----|----|-------|-------|---------------------|-----------|

**Antiadrenal preparations****• Anticorticosteroids**

AMINOGLUTETHIMIDE

|       |               |     |   |    |        |       |              |    |
|-------|---------------|-----|---|----|--------|-------|--------------|----|
| 1036M | Tablet 250 mg | 100 | 5 | .. | 159.17 | 31.30 | Cytadren 250 | NV |
|-------|---------------|-----|---|----|--------|-------|--------------|----|

# SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS—CONT.

| Code                                                                                                     | Name, Restriction,<br>Manner of Administration and Form                          | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |          |
|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----------|
| THYROID THERAPY                                                                                          |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| <b>Thyroid preparations</b>                                                                              |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| • <b>Thyroid hormones</b>                                                                                |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| <b>LIOETHYRONINE SODIUM</b>                                                                              |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| <b>Authority Required (STREAMLINED)</b>                                                                  |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| 1219                                                                                                     |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| <i>Management of patients with thyroid cancer;</i>                                                       |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| 1858                                                                                                     |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| <i>Replacement therapy for hypothyroid patients who have documented intolerance to thyroxine sodium;</i> |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| 1859                                                                                                     |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| <i>Replacement therapy for hypothyroid patients who have documented resistance to thyroxine sodium;</i>  |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| 1182                                                                                                     |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| <i>Initiation of thyroid therapy in severely hypothyroid patients.</i>                                   |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| 2318B                                                                                                    | Tablet 20 micrograms                                                             | 100         | 2              | ..          | 83.10                                    | 31.30                                                  | Tertroxin                            | SI       |
| THYROXINE SODIUM                                                                                         |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| 2174K                                                                                                    | Tablet equivalent to 50 micrograms<br>anhydrous thyroxine sodium                 | 200         | 1              | ..<br>B1.30 | 24.00<br>25.30                           | 25.03 <sup>a</sup><br>25.03 <sup>a</sup>               | Eutroxsig<br>Oroxine                 | FM<br>SI |
| 2175L                                                                                                    | Tablet equivalent to 100 micrograms<br>anhydrous thyroxine sodium                | 200         | 1              | ..<br>B1.31 | 24.64<br>25.95                           | 25.67 <sup>a</sup><br>25.67 <sup>a</sup>               | Eutroxsig<br>Oroxine                 | FM<br>SI |
| 2173J                                                                                                    | Tablet equivalent to 200 micrograms<br>anhydrous thyroxine sodium                | 200         | 1              | ..<br>B1.29 | 27.86<br>29.15                           | 28.89 <sup>a</sup><br>28.89 <sup>a</sup>               | Eutroxsig<br>Oroxine                 | FM<br>SI |
| <b>Antithyroid preparations</b>                                                                          |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| • <b>Thiouracils</b>                                                                                     |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| PROPYLTHIOURACIL                                                                                         |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| 1955X                                                                                                    | Tablet 50 mg                                                                     | 200         | 2              | ..          | * 47.21                                  | 31.30                                                  | PL                                   |          |
| • <b>Sulfur-containing imidazole derivatives</b>                                                         |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| CARBIMAZOLE                                                                                              |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| 1153Q                                                                                                    | Tablet 5 mg                                                                      | 200         | 2              | ..          | * 30.61                                  | 31.30                                                  | Neo-Mercazole                        | LM       |
| PANCREATIC HORMONES                                                                                      |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| <b>Glycogenolytic hormones</b>                                                                           |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| • <b>Glycogenolytic hormones</b>                                                                         |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| GLUCAGON HYDROCHLORIDE                                                                                   |                                                                                  |             |                |             |                                          |                                                        |                                      |          |
| 1449G                                                                                                    | Injection set containing 1 mg (1 i.u.) and<br>1 mL solvent in disposable syringe | 1           | 1              | ..          | 42.93                                    | 31.30                                                  | GlucaGen Hypokit                     | NO       |

# SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

## CALCIUM HOMEOSTASIS

### Anti-parathyroid agents

#### • Calcitonin preparations

##### SALCATONIN

##### NOTE:

The maximum quantities for salcatonin shown represent the number of individual ampoules and NOT multiples of the manufacturer's packs. The pack size for both strengths is five ampoules.

##### Authority Required (STREAMLINED)

1392

Symptomatic Paget's disease of bone;

1412

Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia.

|       |                            |    |   |    |          |       |               |    |
|-------|----------------------------|----|---|----|----------|-------|---------------|----|
| 2995P | Injection 50 i.u. in 1 mL  | 30 | 5 | .. | * 207.23 | 31.30 | Miacalcic 50  | NV |
| 2997R | Injection 100 i.u. in 1 mL | 15 | 5 | .. | * 160.70 | 31.30 | Miacalcic 100 | NV |

#### • Other anti-parathyroid agents

##### CINACALCET HYDROCHLORIDE

##### Authority Required

Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has after 6 months treatment:

(a) a decrease of at least 30% in iPTH concentrations; or

(b) iPTH greater than 15 pmol per L and an (adjusted) serum calcium concentration of less than 2.6 mmol per L.

##### NOTE:

During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved. During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.

During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability. Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.

|       |                     |    |   |    |         |       |          |    |
|-------|---------------------|----|---|----|---------|-------|----------|----|
| 9157Y | Tablet 30 mg (base) | 28 | 5 | .. | 343.17  | 31.30 | Sensipar | AN |
| 9158B | Tablet 60 mg (base) | 28 | 5 | .. | 669.89  | 31.30 | Sensipar | AN |
| 9159C | Tablet 90 mg (base) | 28 | 5 | .. | 1001.84 | 31.30 | Sensipar | AN |

## ANTIINFECTIVES FOR SYSTEMIC USE

| Code                                                                                                                                                      | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                        |                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| <b>ANTIBACTERIALS FOR SYSTEMIC USE</b>                                                                                                                    |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                             |                      |
|                                                                                                                                                           | <b>Tetracyclines</b>                                    |             |                |             |                                          |                                                        |                                                                                                                                                             |                      |
|                                                                                                                                                           | • <b>Tetracyclines</b>                                  |             |                |             |                                          |                                                        |                                                                                                                                                             |                      |
|                                                                                                                                                           | DOXYCYCLINE                                             |             |                |             |                                          |                                                        |                                                                                                                                                             |                      |
| 9105F                                                                                                                                                     | Tablet 100 mg (as monohydrate)                          | 7           | 1              | ..          | 8.04                                     | 9.07                                                   | <sup>a</sup> Chem mart<br>Doxycycline<br><sup>a</sup> Doxyhexal<br><sup>a</sup> GenRx<br>Doxycycline<br><sup>a</sup> Terry White<br>Chemists<br>Doxycycline | CH<br>SZ<br>GX<br>TW |
| 2709N                                                                                                                                                     | Tablet 100 mg (as hydrochloride)                        | 7           | 1              | ..          | 8.04                                     | 9.07                                                   | <sup>a</sup> Doxsig<br><sup>a</sup> Doxy-100<br><sup>a</sup> Doxylin 100<br>b1.19 9.23 9.07 <sup>a</sup> Vibramycin                                         | SI<br>GM<br>AF<br>PF |
| <b>NOTE:</b><br>Bioequivalence has been demonstrated between doxycycline tablet 100 mg (as hydrochloride) and doxycycline tablet 100 mg (as monohydrate). |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                             |                      |
| 2708M                                                                                                                                                     | Capsule 100 mg (as hydrochloride)                       | 7           | 1              | ..<br>b1.15 | 8.04<br>9.19                             | 9.07<br>9.07                                           | <sup>a</sup> DBL Doxycycline<br><sup>a</sup> Doryx                                                                                                          | FA<br>HH             |

### DOXYCYCLINE

#### Restricted Benefit

*Bronchiectasis in patients aged 8 years or older;*

*Chronic bronchitis in patients aged 8 years or older;*

*Severe acne.*

|       |                                 |    |   |             |               |                |                                                                                                                                                                                    |                            |
|-------|---------------------------------|----|---|-------------|---------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| 9106G | Tablet 50 mg (as monohydrate)   | 25 | 5 | ..          | 9.64          | 10.67          | <sup>a</sup> Chem mart<br>Doxycycline<br><sup>a</sup> Doxyhexal<br><sup>a</sup> Frakas<br><sup>a</sup> GenRx<br>Doxycycline<br><sup>a</sup> Terry White<br>Chemists<br>Doxycycline | CH<br>SZ<br>AW<br>GX<br>TW |
| 2711Q | Tablet 50 mg (as hydrochloride) | 25 | 5 | ..<br>b1.25 | 9.64<br>10.89 | 10.67<br>10.67 | <sup>a</sup> Doxy-50<br><sup>a</sup> Doxylin 50<br><sup>a</sup> Vibra-Tabs                                                                                                         | GM<br>AF<br>PF             |

#### NOTE:

Bioequivalence has been demonstrated between doxycycline tablet 50 mg (as hydrochloride) and doxycycline tablet 50 mg (as monohydrate).

continued ➞



## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                                                                                      | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                        |                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| 2707L                                                                                                                                                     | Capsule 50 mg (as hydrochloride)                        | 25          | 5              | ..<br>B1.31 | 9.64<br>10.95                            | 10.67<br>10.67                                         | <sup>a</sup> DBL Doxycycline<br><sup>a</sup> Doryx                                                                                                          | FA<br>HH             |
| <b>Restricted Benefit</b><br>Pelvic inflammatory disease.                                                                                                 |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                             |                      |
| 9107H                                                                                                                                                     | Tablet 100 mg (as monohydrate)                          | 28          | ..             | ..          | * 14.19                                  | 15.22                                                  | <sup>a</sup> Chem mart<br>Doxycycline<br><sup>a</sup> Doxyhexal<br><sup>a</sup> GenRx<br>Doxycycline<br><sup>a</sup> Terry White<br>Chemists<br>Doxycycline | CH<br>SZ<br>GX<br>TW |
| 2702F                                                                                                                                                     | Tablet 100 mg (as hydrochloride)                        | 28          | ..             | ..<br>B4.76 | * 14.19<br>* 18.95                       | 15.22<br>15.22                                         | <sup>a</sup> Doxsig<br><sup>a</sup> Doxy-100<br><sup>a</sup> Doxylin 100<br><sup>a</sup> Vibramycin                                                         | SI<br>GM<br>AF<br>PF |
| <b>NOTE:</b><br>Bioequivalence has been demonstrated between doxycycline tablet 100 mg (as hydrochloride) and doxycycline tablet 100 mg (as monohydrate). |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                             |                      |
| 2703G                                                                                                                                                     | Capsule 100 mg (as hydrochloride)                       | 28          | ..             | ..<br>B4.60 | * 14.19<br>* 18.79                       | 15.22<br>15.22                                         | <sup>a</sup> DBL Doxycycline<br><sup>a</sup> Doryx                                                                                                          | FA<br>HH             |
| <b>Restricted Benefit</b><br>Urethritis.                                                                                                                  |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                             |                      |
| 9108J                                                                                                                                                     | Tablet 100 mg (as monohydrate)                          | 21          | ..             | ..<br>..    | 12.13<br>* 12.14                         | 13.16<br>13.17                                         | <sup>a</sup> GenRx<br>Doxycycline<br><sup>a</sup> Chem mart<br>Doxycycline<br><sup>a</sup> Doxyhexal<br><sup>a</sup> Terry White<br>Chemists<br>Doxycycline | GX<br>CH<br>SZ<br>TW |
| 2714W                                                                                                                                                     | Tablet 100 mg (as hydrochloride)                        | 21          | ..             | ..<br>B3.57 | * 12.14<br>* 15.71                       | 13.17<br>13.17                                         | <sup>a</sup> Doxsig<br><sup>a</sup> Doxy-100<br><sup>a</sup> Doxylin 100<br><sup>a</sup> Vibramycin                                                         | SI<br>GM<br>AF<br>PF |
| <b>NOTE:</b><br>Bioequivalence has been demonstrated between doxycycline tablet 100 mg (as hydrochloride) and doxycycline tablet 100 mg (as monohydrate). |                                                         |             |                |             |                                          |                                                        |                                                                                                                                                             |                      |
| 2715X                                                                                                                                                     | Capsule 100 mg (as hydrochloride)                       | 21          | ..             | ..<br>B2.09 | 12.09<br>14.18                           | 13.12<br>13.12                                         | <sup>a</sup> DBL Doxycycline<br><sup>a</sup> Doryx                                                                                                          | FA<br>HH             |

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                                         | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>MINOCYCLINE</b>                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| There are concerns about the incidence of benign intracranial hypertension associated with this drug.        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 3037W                                                                                                        | Capsule 100 mg                                          | 11          | ..             | ..      | 9.22                                     | 10.25                                                  | Akamin 100                           | AF |
| <b>NOTE:</b>                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| No applications for increased maximum quantities and/or repeats will be authorised.                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <hr/>                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>MINOCYCLINE</b>                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>There are concerns about the incidence of benign intracranial hypertension associated with this drug.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe acne not responding to other tetracyclines.</i>                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i>                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1616C                                                                                                        | Tablet 50 mg                                            | 60          | 5              | ..      | 15.06                                    | 16.09                                                  | <sup>a</sup> Akamin 50               | AF |
|                                                                                                              |                                                         |             |                | B0.85   | 15.91                                    | 16.09                                                  | <sup>a</sup> Minomycin-50            | SI |
| <b>Beta-lactam antibacterials, penicillins</b>                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Penicillins with extended spectrum</b>                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>AMOXYCILLIN</b>                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1884E                                                                                                        | Capsule 250 mg                                          | 20          | 1              | ..      | 8.12                                     | 9.15                                                   | <sup>a</sup> Alphamox 250            | AF |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Amohexal                | HX |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Amoxycillin-DP          | GM |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> APO-Amoxycillin         | TX |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Chem mart               | CH |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | Amoxycillin                          |    |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cilamox                 | SI |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                   | GX |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | Amoxycillin                          |    |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | Amoxycillin                          |    |
|                                                                                                              |                                                         |             |                | B0.79   | 8.91                                     | 9.15                                                   | <sup>a</sup> Amoxil                  | GK |

continued ➞

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 1889K | Capsule 500 mg                                          | 20          | 1              | ..      | 10.22                                    | 11.25                                                  | a Alphamox 500                       | AF |
|       |                                                         |             |                |         |                                          |                                                        | a Amohexal                           | HX |
|       |                                                         |             |                |         |                                          |                                                        | a Amoxycillin-DP                     | GM |
|       |                                                         |             |                |         |                                          |                                                        | a APO-Amoxycillin                    | TX |
|       |                                                         |             |                |         |                                          |                                                        | a Chem mart                          | CH |
|       |                                                         |             |                |         |                                          |                                                        | Amoxycillin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | a Cilamox                            | SI |
|       |                                                         |             |                |         |                                          |                                                        | a GenRx                              | GX |
|       |                                                         |             |                |         |                                          |                                                        | Amoxycillin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | a Moxacin                            | AS |
|       |                                                         |             |                |         |                                          |                                                        | a Terry White                        | TW |
|       |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|       |                                                         |             |                |         |                                          |                                                        | Amoxycillin                          |    |
|       |                                                         |             |                | B0.80   | 11.02                                    | 11.25                                                  | a Amoxil                             | GK |
| 1878W | Sachet containing oral powder 3 g                       | 1           | ..             | ..      | 8.68                                     | 9.71                                                   | Amoxil                               | GK |
| 1886G | Powder for syrup 125 mg per 5 mL,<br>100 mL             | ‡ 1         | 1              | ..      | # 10.42                                  | 11.81                                                  | a Alphamox 125                       | AF |
|       |                                                         |             |                |         |                                          |                                                        | a Bgramin                            | GM |
|       |                                                         |             |                |         |                                          |                                                        | a Chem mart                          | CH |
|       |                                                         |             |                |         |                                          |                                                        | Amoxycillin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | a GenRx                              | GX |
|       |                                                         |             |                |         |                                          |                                                        | Amoxycillin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | a Ranmoxy                            | RA |
|       |                                                         |             |                |         |                                          |                                                        | a Terry White                        | TW |
|       |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|       |                                                         |             |                |         |                                          |                                                        | Amoxycillin                          |    |
|       |                                                         |             |                | B0.95   | # 11.37                                  | 11.81                                                  | a Amoxil                             | GK |
| 1887H | Powder for syrup 250 mg per 5 mL,<br>100 mL             | ‡ 1         | 1              | ..      | # 11.26                                  | 12.65                                                  | a Alphamox 250                       | AF |
|       |                                                         |             |                |         |                                          |                                                        | a Amohexal                           | HX |
|       |                                                         |             |                |         |                                          |                                                        | a Bgramin                            | GM |
|       |                                                         |             |                |         |                                          |                                                        | a Chem mart                          | CH |
|       |                                                         |             |                |         |                                          |                                                        | Amoxycillin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | a Cilamox                            | SI |
|       |                                                         |             |                |         |                                          |                                                        | a GenRx                              | GX |
|       |                                                         |             |                |         |                                          |                                                        | Amoxycillin                          |    |
|       |                                                         |             |                |         |                                          |                                                        | a Ranmoxy                            | RA |
|       |                                                         |             |                |         |                                          |                                                        | a Terry White                        | TW |
|       |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|       |                                                         |             |                |         |                                          |                                                        | Amoxycillin                          |    |
|       |                                                         |             |                | B0.79   | # 12.05                                  | 12.65                                                  | a Amoxil Forte                       | GK |
| 8705E | Powder for oral suspension 500 mg per<br>5 mL, 100 mL   | ‡ 1         | 1              | ..      | # 14.27                                  | 15.66                                                  | Maxamox                              | SZ |

continued 

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                              | Name, Restriction,<br>Manner of Administration and Form     | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                             |                |
|---------------------------------------------------|-------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------------------|----------------|
| <b>AMOXYCILLIN</b>                                |                                                             |             |                |         |                                          |                                                        |                                                                                  |                |
| <b><u>Restricted Benefit</u></b>                  |                                                             |             |                |         |                                          |                                                        |                                                                                  |                |
| <i>Acute exacerbations of chronic bronchitis.</i> |                                                             |             |                |         |                                          |                                                        |                                                                                  |                |
| 8581P                                             | Tablet 1 g                                                  | 14          | 1              | ..      | 10.36                                    | 11.39                                                  | <sup>a</sup> Amoxycillin<br>Sandoz                                               | BG             |
|                                                   |                                                             |             |                | B1.17   | 11.53                                    | 11.39                                                  | <sup>a</sup> Maxamox                                                             | SZ             |
| <b>AMPICILLIN</b>                                 |                                                             |             |                |         |                                          |                                                        |                                                                                  |                |
| 2390T                                             | Powder for injection 500 mg                                 | 5           | 1              | ..      | 10.65                                    | 11.68                                                  | <sup>a</sup> Austrapen<br><sup>a</sup> Ibimicyn                                  | LN<br>GM       |
| 2977Q                                             | Powder for injection 1 g                                    | 5           | 1              | ..      | 13.64                                    | 14.67                                                  | <sup>a</sup> Aspen Ampicyn<br><sup>a</sup> Austrapen<br><sup>a</sup> Ibimicyn    | AS<br>LN<br>GM |
| <b>• Beta-lactamase sensitive penicillins</b>     |                                                             |             |                |         |                                          |                                                        |                                                                                  |                |
| <b>BENZATHINE BENZYL PENICILLIN</b>               |                                                             |             |                |         |                                          |                                                        |                                                                                  |                |
| 2267H                                             | Injection 900 mg in 2.3 mL single use<br>pre-filled syringe | 10          | ..             | ..      | 292.68                                   | 31.30                                                  | Bicillin L-A                                                                     | AS             |
| <b>BENZYL PENICILLIN</b>                          |                                                             |             |                |         |                                          |                                                        |                                                                                  |                |
| 1775K                                             | Powder for injection 600 mg                                 | 10          | 1              | ..      | * 40.39                                  | 31.30                                                  | BenPen                                                                           | CS             |
| 2647H                                             | Powder for injection 3 g                                    | 10          | ..             | ..      | * 62.49                                  | 31.30                                                  | BenPen                                                                           | CS             |
| <b>PHENOXYMETHYL PENICILLIN</b>                   |                                                             |             |                |         |                                          |                                                        |                                                                                  |                |
| 1787C                                             | Tablet 250 mg                                               | 50          | ..             | ..      | * 11.15                                  | 12.18                                                  | Abbocillin-VK<br>Filmstab                                                        | SI             |
| 3028J                                             | Tablet 500 mg                                               | 50          | ..             | ..      | * 13.63                                  | 14.66                                                  | Abbocillin-VK<br>Filmstab                                                        | SI             |
| 1789E                                             | Capsule 250 mg                                              | 50          | ..             | ..      | 10.98                                    | 12.01                                                  | LPV                                                                              | AS             |
|                                                   |                                                             |             |                | ..      | 10.98                                    | 12.01                                                  | <sup>a</sup> Cilicaine VK<br><sup>a</sup> Cilopen VK<br><sup>a</sup> Penhexal VK | FM<br>GM<br>HX |
| 2965C                                             | Capsule 500 mg                                              | 50          | ..             | ..      | 13.41                                    | 14.44                                                  | LPV                                                                              | AS             |
|                                                   |                                                             |             |                | ..      | 13.41                                    | 14.44                                                  | <sup>a</sup> Cilicaine VK<br><sup>a</sup> Cilopen VK<br><sup>a</sup> Penhexal VK | FM<br>GM<br>HX |
| 9143F                                             | Oral suspension 150 mg (as benzathine)<br>per 5 mL, 100 mL  | 2           | 1              | ..      | * 21.97                                  | 23.00                                                  | Abbocillin-V<br>Cilicaine V                                                      | SI<br>FM       |

continued ➞

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                                                                                                                | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>PHENOXYMETHYLPENICILLIN</b>                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Prophylaxis of recurrent streptococcal infections (including rheumatic fever).</i>                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1703P                                                                                                                                                                               | Tablet 250 mg                                           | 50          | 5              | ..      | * 11.15                                  | 12.18                                                  | Abbocillin-VK<br>Filmtab             | SI |
| 1705R                                                                                                                                                                               | Capsule 250 mg                                          | 50          | 5              | ..      | 10.98                                    | 12.01                                                  | LPV                                  | AS |
|                                                                                                                                                                                     |                                                         |             |                | ..      | 10.98                                    | 12.01                                                  | <sup>a</sup> Cilicaine VK            | FM |
|                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cilopen VK              | GM |
|                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Penhexal VK             | HX |
| <b>PROCAINE PENICILLIN</b>                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1794K                                                                                                                                                                               | Injection 1.5 g                                         | 5           | ..             | ..      | 87.97                                    | 31.30                                                  | Cilicaine                            | SI |
| • <b><i>Beta-lactamase resistant penicillins</i></b>                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>DICLOXACILLIN</b>                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Serious staphylococcal infections.</i>                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8121K                                                                                                                                                                               | Capsule 250 mg                                          | 24          | ..             | ..      | 11.02                                    | 12.05                                                  | <sup>a</sup> Diclocil                | BQ |
|                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dicloxsig               | SI |
|                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Distaph 250             | AF |
| 8122L                                                                                                                                                                               | Capsule 500 mg                                          | 24          | ..             | ..      | 16.51                                    | 17.54                                                  | <sup>a</sup> Diclocil                | BQ |
|                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dicloxsig               | SI |
|                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Distaph 500             | AF |
| <b>FLUCLOXACILLIN</b>                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>CAUTION:</u></b>                                                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1524F                                                                                                                                                                               | Powder for injection 500 mg                             | 5           | ..             | ..      | 15.06                                    | 16.09                                                  | <sup>a</sup> Flubiclox               | GM |
|                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Flucil                  | AS |
| 1525G                                                                                                                                                                               | Powder for injection 1 g                                | 5           | 1              | ..      | 20.23                                    | 21.26                                                  | <sup>a</sup> Flubiclox               | GM |
|                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Flucil                  | AS |
|                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> HH                      |    |

continued ➞

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                                                                                                                       | Name, Restriction,<br>Manner of Administration and Form    | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                              |                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| <b>FLUCLOXACILLIN</b>                                                                                                                                                                      |                                                            |             |                |         |                                          |                                                        |                                                                                                                                                                                                                   |                                          |
| <b>CAUTION:</b>                                                                                                                                                                            |                                                            |             |                |         |                                          |                                                        |                                                                                                                                                                                                                   |                                          |
| <i>Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days.</i> |                                                            |             |                |         |                                          |                                                        |                                                                                                                                                                                                                   |                                          |
| <b>Restricted Benefit</b>                                                                                                                                                                  |                                                            |             |                |         |                                          |                                                        |                                                                                                                                                                                                                   |                                          |
| <i>Serious staphylococcal infections.</i>                                                                                                                                                  |                                                            |             |                |         |                                          |                                                        |                                                                                                                                                                                                                   |                                          |
| 1526H                                                                                                                                                                                      | Capsule 250 mg (as sodium)                                 | 24          | ..             | ..      | 11.02                                    | 12.05                                                  | <sup>a</sup> Flopen<br><sup>a</sup> Staphylex 250                                                                                                                                                                 | AS<br>AF                                 |
| 1527J                                                                                                                                                                                      | Capsule 500 mg (as sodium)                                 | 24          | ..             | ..      | 16.51                                    | 17.54                                                  | <sup>a</sup> Flopen<br><sup>a</sup> Staphylex 500                                                                                                                                                                 | AS<br>AF                                 |
| 9149M                                                                                                                                                                                      | Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL | ‡ 1         | ..             | ..      | # 13.05                                  | 14.44                                                  | LN                                                                                                                                                                                                                |                                          |
| 9150N                                                                                                                                                                                      | Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL | ‡ 1         | ..             | ..      | # 15.88                                  | 17.27                                                  | LN                                                                                                                                                                                                                |                                          |
| • <b>Combinations of penicillins, incl. beta-lactamase inhibitors</b>                                                                                                                      |                                                            |             |                |         |                                          |                                                        |                                                                                                                                                                                                                   |                                          |
| <b>AMOXYCILLIN with CLAVULANIC ACID</b>                                                                                                                                                    |                                                            |             |                |         |                                          |                                                        |                                                                                                                                                                                                                   |                                          |
| <b>CAUTION:</b>                                                                                                                                                                            |                                                            |             |                |         |                                          |                                                        |                                                                                                                                                                                                                   |                                          |
| <i>Hepatotoxicity has been reported with this drug.</i>                                                                                                                                    |                                                            |             |                |         |                                          |                                                        |                                                                                                                                                                                                                   |                                          |
| <b>Restricted Benefit</b>                                                                                                                                                                  |                                                            |             |                |         |                                          |                                                        |                                                                                                                                                                                                                   |                                          |
| <i>Infections where resistance to amoxicillin is suspected;</i>                                                                                                                            |                                                            |             |                |         |                                          |                                                        |                                                                                                                                                                                                                   |                                          |
| <i>Infections where resistance to amoxicillin is proven.</i>                                                                                                                               |                                                            |             |                |         |                                          |                                                        |                                                                                                                                                                                                                   |                                          |
| 1891M                                                                                                                                                                                      | Tablet 500 mg-125 mg                                       | 10          | 1              | ..      | 11.73                                    | 12.76                                                  | <sup>a</sup> Clamohexal Duo<br>500mg/125mg<br><sup>a</sup> Clamoxyl Duo<br><sup>a</sup> Clavulin Duo<br><sup>a</sup> Curam 500/125<br><sup>a</sup> GA-Amclav 500/<br>125<br><sup>a</sup> Moxiclav Duo 500/<br>125 | HX<br><br>AL<br>ME<br>SZ<br>GM<br><br>AW |
|                                                                                                                                                                                            |                                                            |             |                | B1.55   | 13.28                                    | 12.76                                                  | <sup>a</sup> Augmentin Duo                                                                                                                                                                                        | GK                                       |

continued ➞

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer                                       |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|----------------------------------------------------------------------------|----|
|       |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                                                            |    |
| 8254K | Tablet 875 mg-125 mg                                    | 10          | 1              | ..      | 14.17                       | 15.20                                       | <sup>a</sup> Chem mart<br>Amoxycillin and<br>Clavulanic Acid               | CH |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Clamohexal Duo<br>Forte 875mg/<br>125mg                       | HX |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Clamoxyl Duo<br>forte                                         | AL |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Clavulin Duo<br>Forte                                         | ME |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Clavycillin 875/125                                           | CR |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Curam 875/125                                                 | SZ |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> GA-Amclav Forte<br>875/125                                    | GM |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> GenRx<br>Amoxycillin and<br>Clavulanic Acid                   | GX |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Moxiclav Duo<br>Forte 875/125                                 | AW |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Terry White<br>Chemists<br>Amoxycillin and<br>Clavulanic Acid | TW |
|       |                                                         |             |                | B2.04   | 16.21                       | 15.20                                       | <sup>a</sup> Augmentin Duo<br>forte                                        | GK |
| 1892N | Powder for syrup 125 mg-31.25 mg per<br>5 mL, 75 mL     | ± 1         | 1              | ..      | # 12.05                     | 13.44                                       | <sup>a</sup> Clamohexal<br>125mg/31.25mg/<br>5mL                           | HX |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Clamoxyl                                                      | AL |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Clavulin                                                      | ME |
|       |                                                         |             |                | B1.51   | # 13.56                     | 13.44                                       | <sup>a</sup> Augmentin                                                     | GK |
| 8319W | Powder for syrup 400 mg-57 mg per<br>5 mL, 60 mL        | ± 1         | 1              | ..      | # 13.56                     | 14.95                                       | <sup>a</sup> Clamohexal Duo<br>400mg/57mg/<br>5mL                          | HX |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Clamoxyl Duo 400                                              | AL |
|       |                                                         |             |                |         |                             |                                             | <sup>a</sup> Clavulin Duo 400                                              | ME |
|       |                                                         |             |                | B1.54   | # 15.10                     | 14.95                                       | <sup>a</sup> Augmentin Duo<br>400                                          | GK |

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                                                         | Name, Restriction,<br>Manner of Administration and Form                                                                      | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                                                                  |                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| <b>TICARCILLIN with CLAVULANIC ACID</b>                                                                                      |                                                                                                                              |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                       |                                                                                    |
| <b><u>Restricted Benefit</u></b>                                                                                             |                                                                                                                              |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                       |                                                                                    |
| <i>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent;</i> |                                                                                                                              |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                       |                                                                                    |
| <i>Septicaemia, suspected;</i>                                                                                               |                                                                                                                              |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                       |                                                                                    |
| <i>Septicaemia, proven.</i>                                                                                                  |                                                                                                                              |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                       |                                                                                    |
| 2179Q                                                                                                                        | <b>Powder for injection 3 g-100 mg (solvent required)</b><br><i>(code 6884H applies to above item with approved solvent)</i> | 10          | ..             | ..      | 162.89                                   | 31.30                                                  | <b>Timentin</b>                                                                                                                                                                                                                                       | <b>GK</b>                                                                          |
| <b>Other beta-lactam antibacterials</b>                                                                                      |                                                                                                                              |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                       |                                                                                    |
| <b>• First-generation cephalosporins</b>                                                                                     |                                                                                                                              |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                       |                                                                                    |
| <b>CEFALOTIN</b>                                                                                                             |                                                                                                                              |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                       |                                                                                    |
| 2964B                                                                                                                        | Powder for injection 1 g                                                                                                     | 10          | 1              | ..      | 40.35                                    | 31.30                                                  | a Cefalotin Sandoz<br>a Keflin Neutral<br>a HH                                                                                                                                                                                                        | SZ<br>AS                                                                           |
| <b>CEPHALEXIN</b>                                                                                                            |                                                                                                                              |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                       |                                                                                    |
| 3058Y                                                                                                                        | Capsule 250 mg                                                                                                               | 20          | 1              | ..      | 8.42                                     | 9.45                                                   | a Cefalexin Sandoz<br>a Cephabell<br>a Cephalixin Max<br>a Cephatrust 250<br>a Chem mart<br>Cephalexin<br>a Cilex<br>a GenRx Cephalixin<br>a Ialex<br>a Ibilex 250<br>a Rancef<br>a Sporahexal<br>a Terry White<br>Chemists<br>Cephalexin<br>a Keflex | SZ<br>BF<br>XF<br>MI<br>CH<br><br>GM<br>GX<br>LN<br>AF<br>RA<br>HX<br>TW<br><br>AS |
|                                                                                                                              |                                                                                                                              |             |                | B1.87   | 10.29                                    | 9.45                                                   |                                                                                                                                                                                                                                                       |                                                                                    |

continued ➞



[illegible]

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                     | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| • <b>Second-generation cephalosporins</b>                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| CEFACLOR                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Serum sickness-like reactions have been reported with this drug, especially in children. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1169M                                                                                    | Tablet 375 mg (sustained release)                       | 10          | 1              | ..      | 12.46                                    | 13.49                                                  | a Chem mart                          | CH |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Cefaclor CD                        |    |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Douglas Cefaclor-<br>CD            | GM |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a GenRx Cefaclor<br>CD               | GX |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Karlor CD                          | LN |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Keflor CD                          | AF |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Ozcef                              | RA |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Terry White<br>Chemists            | TW |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Cefaclor CD                        |    |
|                                                                                          |                                                         |             |                | B2.28   | 14.74                                    | 13.49                                                  | a Ceclor CD                          | AS |
| 2460L                                                                                    | Powder for oral suspension 125 mg per<br>5 mL, 100 mL   | ‡ 1         | 1              | ..      | # 13.07                                  | 14.46                                                  | a Aclor 125                          | AW |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Cefaclor Sandoz                    | SZ |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Chem mart                          | CH |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Cefaclor                           |    |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a GenRx Cefaclor                     | GX |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Keflor                             | AF |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Ozcef                              | RA |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Terry White<br>Chemists            | TW |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Cefaclor                           |    |
|                                                                                          |                                                         |             |                | B1.99   | # 15.06                                  | 14.46                                                  | a Ceclor                             | AS |
| 2461M                                                                                    | Powder for oral suspension 250 mg per<br>5 mL, 75 mL    | ‡ 1         | 1              | ..      | # 13.40                                  | 14.79                                                  | a Aclor 250                          | AW |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Cefaclor Sandoz                    | SZ |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Chem mart                          | CH |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Cefaclor                           |    |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a GenRx Cefaclor                     | GX |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Keflor                             | AF |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Ozcef                              | RA |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Terry White<br>Chemists            | TW |
|                                                                                          |                                                         |             |                |         |                                          |                                                        | a Cefaclor                           |    |
|                                                                                          |                                                         |             |                | B2.05   | # 15.45                                  | 14.79                                                  | a Ceclor                             | AS |
| CEFUROXIME AXETIL                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8292K                                                                                    | Tablet 250 mg (base)                                    | 14          | 1              | ..      | 18.19                                    | 19.22                                                  | Zinnat                               | GK |

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                                                         | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium      | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                     |                      |
|------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|--------------|------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|----------------------|
| <b>• Third-generation cephalosporins</b>                                                                                     |                                                         |             |                |              |                                          |                                                        |                                                                                                                          |                      |
| <b>CEFOTAXIME</b>                                                                                                            |                                                         |             |                |              |                                          |                                                        |                                                                                                                          |                      |
| <b><u>Restricted Benefit</u></b>                                                                                             |                                                         |             |                |              |                                          |                                                        |                                                                                                                          |                      |
| <i>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent;</i> |                                                         |             |                |              |                                          |                                                        |                                                                                                                          |                      |
| <i>Septicaemia, suspected;</i>                                                                                               |                                                         |             |                |              |                                          |                                                        |                                                                                                                          |                      |
| <i>Septicaemia, proven.</i>                                                                                                  |                                                         |             |                |              |                                          |                                                        |                                                                                                                          |                      |
| 1085D                                                                                                                        | Powder for injection 1 g                                | 10          | ..             | ..<br>B25.10 | 27.27<br>* 52.39                         | 28.30<br>28.32                                         | <sup>a</sup> HH<br><sup>a</sup> Cefotaxime Sandoz                                                                        | SZ                   |
| 1086E                                                                                                                        | Powder for injection 2 g                                | 10          | ..             | ..<br>B46.50 | 44.60<br>* 91.09                         | 31.30<br>31.30                                         | <sup>a</sup> HH<br><sup>a</sup> Cefotaxime Sandoz                                                                        | SZ                   |
| <b>CEFTRIAZONE</b>                                                                                                           |                                                         |             |                |              |                                          |                                                        |                                                                                                                          |                      |
| <b><u>Restricted Benefit</u></b>                                                                                             |                                                         |             |                |              |                                          |                                                        |                                                                                                                          |                      |
| <i>Gonorrhoea.</i>                                                                                                           |                                                         |             |                |              |                                          |                                                        |                                                                                                                          |                      |
| 9058R                                                                                                                        | Powder for injection 500 mg                             | 1           | ..             | ..           | 10.06                                    | 11.09                                                  | Ceftriazone ICP                                                                                                          | IZ                   |
| <b><u>Restricted Benefit</u></b>                                                                                             |                                                         |             |                |              |                                          |                                                        |                                                                                                                          |                      |
| <i>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent;</i> |                                                         |             |                |              |                                          |                                                        |                                                                                                                          |                      |
| <i>Septicaemia, suspected;</i>                                                                                               |                                                         |             |                |              |                                          |                                                        |                                                                                                                          |                      |
| <i>Septicaemia, proven.</i>                                                                                                  |                                                         |             |                |              |                                          |                                                        |                                                                                                                          |                      |
| 1783W                                                                                                                        | Powder for injection 500 mg                             | 5           | ..             | ..           | * 26.34                                  | 27.37                                                  | Ceftriazone ICP                                                                                                          | IZ                   |
| 1784X                                                                                                                        | Powder for injection 1 g                                | 5           | ..             | ..           | * 37.79                                  | 31.30                                                  | <sup>a</sup> Ceftriazone ICP<br><sup>a</sup> Ceftriazone Sandoz<br><sup>a</sup> DBL Ceftriazone<br><sup>a</sup> Rocephin | IZ<br>SZ<br>HH<br>RO |
|                                                                                                                              |                                                         |             |                | ..           | 37.79                                    | 31.30                                                  | <sup>a</sup> XF                                                                                                          |                      |
| 1785Y                                                                                                                        | Powder for injection 2 g                                | 5           | ..             | ..           | * 62.39                                  | 31.30                                                  | <sup>a</sup> Ceftriazone ICP<br><sup>a</sup> Ceftriazone Sandoz<br><sup>a</sup> DBL Ceftriazone<br><sup>a</sup> Rocephin | IZ<br>SZ<br>HH<br>RO |

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                                                                                                                                                                      | Name, Restriction,<br>Manner of Administration and Form                                                       | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                                                                                                                                     |                                              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| <b>• Fourth-generation cephalosporins</b><br><b>CEFEPIME</b>                                                                                                                                                                              |                                                                                                               |             |                |             |                                          |                                                        |                                                                                                                                                                                                                                                                                                                          |                                              |
| <b>Authority Required</b><br><i>Treatment of febrile neutropenia.</i>                                                                                                                                                                     |                                                                                                               |             |                |             |                                          |                                                        |                                                                                                                                                                                                                                                                                                                          |                                              |
| 8315P                                                                                                                                                                                                                                     | Powder for injection 1 g (solvent<br>required)<br>(code 7079N applies to above item with<br>approved solvent) | 10          | ..             | ..          | * 183.39                                 | 31.30                                                  | Maxipime                                                                                                                                                                                                                                                                                                                 | BQ                                           |
| 8316Q                                                                                                                                                                                                                                     | Powder for injection 2 g (solvent<br>required)<br>(code 7085X applies to above item with<br>approved solvent) | 10          | ..             | ..          | * 331.19                                 | 31.30                                                  | Maxipime                                                                                                                                                                                                                                                                                                                 | BQ                                           |
| <b>Sulfonamides and trimethoprim</b><br><b>• Trimethoprim and derivatives</b><br><b>TRIMETHOPRIM</b>                                                                                                                                      |                                                                                                               |             |                |             |                                          |                                                        |                                                                                                                                                                                                                                                                                                                          |                                              |
| 2922T                                                                                                                                                                                                                                     | Tablet 300 mg                                                                                                 | 7           | 1              | ..<br>B1.03 | 8.05<br>9.08                             | 9.08                                                   | <sup>a</sup> Alprim<br><sup>a</sup> Triprim                                                                                                                                                                                                                                                                              | AF<br>SI                                     |
| <b>• Combinations of sulfonamides and trimethoprim, incl. derivatives</b><br><b>TRIMETHOPRIM with SULFAMETHOXAZOLE</b><br><b>CAUTION:</b><br>There is an increased risk of severe adverse reactions with this combination in the elderly. |                                                                                                               |             |                |             |                                          |                                                        |                                                                                                                                                                                                                                                                                                                          |                                              |
| 2949F                                                                                                                                                                                                                                     | Tablet 80 mg-400 mg                                                                                           | 10          | 1              | ..          | 8.24                                     | 9.27                                                   | Resprim                                                                                                                                                                                                                                                                                                                  | AF                                           |
| 2951H                                                                                                                                                                                                                                     | Tablet 160 mg-800 mg                                                                                          | 10          | 1              | ..          | 8.96                                     | 9.99                                                   | <sup>a</sup> Bactrim DS<br><sup>a</sup> Chem mart<br>Trimethoprim<br>with Sulfamethoxazole<br>DS<br><sup>a</sup> GenRx<br>Trimethoprim<br>with Sulfamethoxazole<br>DS<br><sup>a</sup> Resprim Forte<br><sup>a</sup> Terry White<br>Chemists<br>Trimethoprim<br>with Sulfamethoxazole<br>DS<br><sup>a</sup> Septrin Forte | RO<br>CH<br><br>GX<br><br>AF<br>TW<br><br>SI |
| 3103H                                                                                                                                                                                                                                     | Oral suspension 40 mg-200 mg per 5 mL,<br>100 mL                                                              | ‡ 1         | 1              | ..<br>B1.46 | 8.62<br>10.08                            | 9.65                                                   | Bactrim<br>Septrin                                                                                                                                                                                                                                                                                                       | RO<br>SI                                     |

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                       | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer     |    |
|--------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------|----|
| <b>Macrolides, lincosamides and streptogramins</b>                                         |                                                         |             |                |         |                                          |                                                        |                                          |    |
| • <b>Macrolides</b>                                                                        |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <b>AZITHROMYCIN</b>                                                                        |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <b>Restricted Benefit</b>                                                                  |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <i>Uncomplicated urethritis due to Chlamydia trachomatis;</i>                              |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <i>Uncomplicated cervicitis due to Chlamydia trachomatis.</i>                              |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <b>NOTE:</b>                                                                               |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i> |                                                         |             |                |         |                                          |                                                        |                                          |    |
| 8200N                                                                                      | Tablet 500 mg                                           | 2           | ..             | ..      | 23.46                                    | 24.49                                                  | Zithromax                                | PF |
| <hr/>                                                                                      |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <b>Restricted Benefit</b>                                                                  |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <i>Trachoma.</i>                                                                           |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <b>NOTE:</b>                                                                               |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i> |                                                         |             |                |         |                                          |                                                        |                                          |    |
| 8336R                                                                                      | Tablet 500 mg                                           | 2           | 2              | ..      | 23.46                                    | 24.49                                                  | Zithromax                                | PF |
| 8201P                                                                                      | Powder for oral suspension 200 mg per<br>5 mL, 15 mL    | ‡ 1         | ..             | ..      | # 22.98                                  | 24.37                                                  | Zithromax                                | PF |
| <b>CLARITHROMYCIN</b>                                                                      |                                                         |             |                |         |                                          |                                                        |                                          |    |
| 8318T                                                                                      | Tablet 250 mg                                           | 14          | 1              | ..      | 12.25                                    | 13.28                                                  | <sup>a</sup> Chem mart<br>Clarithromycin | CH |
|                                                                                            |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clarac                      | GM |
|                                                                                            |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clarihexal                  | SZ |
|                                                                                            |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clarithro 250               | AW |
|                                                                                            |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                       | GX |
|                                                                                            |                                                         |             |                |         |                                          |                                                        | Clarithromycin                           |    |
|                                                                                            |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Kalixocin                   | AF |
|                                                                                            |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists     | TW |
|                                                                                            |                                                         |             |                |         |                                          |                                                        | Clarithromycin                           |    |
|                                                                                            |                                                         |             |                | ‡1.96   | 14.21                                    | 13.28                                                  | <sup>a</sup> Klacid                      | AB |
| <hr/>                                                                                      |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <b>CLARITHROMYCIN</b>                                                                      |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <b>Restricted Benefit</b>                                                                  |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <i>Bordetella pertussis;</i>                                                               |                                                         |             |                |         |                                          |                                                        |                                          |    |
| <i>Atypical mycobacterial infections.</i>                                                  |                                                         |             |                |         |                                          |                                                        |                                          |    |
| 9192T                                                                                      | Powder for oral liquid 250 mg per 5 mL,<br>50 mL        | ‡ 1         | ..             | ..      | # 36.80                                  | 31.30                                                  | Klacid                                   | AB |

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                         | Name, Restriction,<br>Manner of Administration and Form  | Max.<br>Qty | No. of<br>Rpts | Premium         | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                   |                            |
|------------------------------|----------------------------------------------------------|-------------|----------------|-----------------|------------------------------------------|--------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|----------------------------|
| ERYTHROMYCIN                 |                                                          |             |                |                 |                                          |                                                        |                                                                                                                        |                            |
| 1404X                        | Capsule 250 mg                                           | 25          | 1              | ..<br>B1.35     | 9.00<br>10.35                            | 10.03<br>10.03                                         | <sup>a</sup> DBL Erythromycin<br><sup>a</sup> Eryc                                                                     | FA<br>HH                   |
| ERYTHROMYCIN ETHYL SUCCINATE |                                                          |             |                |                 |                                          |                                                        |                                                                                                                        |                            |
| 2750R                        | Tablet 400 mg (base)                                     | 25          | 1              | ..<br>B2.36     | 8.93<br>11.29                            | 9.96<br>9.96                                           | <sup>a</sup> E-Mycin<br><sup>a</sup> E.E.S. 400 Filmtab                                                                | AF<br>LM                   |
| 2424N                        | Powder for oral liquid 200 mg (base) per<br>5 mL, 100 mL | ‡ 1         | 1              | ..<br>B1.67     | # 11.00<br># 12.67                       | 12.39<br>12.39                                         | <sup>a</sup> E-Mycin 200<br><sup>a</sup> E.E.S. 200                                                                    | AF<br>LM                   |
| 2428T                        | Powder for oral liquid 400 mg (base) per<br>5 mL, 100 mL | ‡ 1         | 1              | ..<br>B1.35     | # 12.23<br># 13.58                       | 13.62<br>13.62                                         | <sup>a</sup> E-Mycin 400<br><sup>a</sup> E.E.S. Granules                                                               | AF<br>LM                   |
| ERYTHROMYCIN LACTOBIONATE    |                                                          |             |                |                 |                                          |                                                        |                                                                                                                        |                            |
| 1397M                        | Powder for I.V. infusion 1 g (base)                      | 5           | ..             | ..              | * 50.94                                  | 31.30                                                  | Erythrocin-I.V.                                                                                                        | LM                         |
| ROXITHROMYCIN                |                                                          |             |                |                 |                                          |                                                        |                                                                                                                        |                            |
| 8129W                        | Tablet for oral suspension 50 mg                         | 10          | 1              | ..              | 12.13                                    | 13.16                                                  | Rulide D                                                                                                               | SW                         |
| 1760P                        | Tablet 150 mg                                            | 10          | 1              | ..<br><br>B1.89 | 11.33<br><br>13.22                       | 12.36<br><br>12.36                                     | <sup>a</sup> Biaxsig<br><sup>a</sup> Roxar 150<br><sup>a</sup> Roxide<br><sup>a</sup> Roximycin<br><sup>a</sup> Rulide | AV<br>AW<br>SZ<br>AF<br>SW |
| 8016X                        | Tablet 300 mg                                            | 5           | 1              | ..<br><br>B1.89 | 11.33<br><br>13.22                       | 12.36<br><br>12.36                                     | <sup>a</sup> Biaxsig<br><sup>a</sup> Roxar 300<br><sup>a</sup> Roxide<br><sup>a</sup> Roximycin<br><sup>a</sup> Rulide | AV<br>AW<br>SZ<br>AF<br>SW |

### • *Lincosamides*

#### *CLINDAMYCIN*

#### Restricted Benefit

*Gram-positive coccal infections where these cannot be safely and effectively treated with a penicillin.*

|       |                |    |    |             |                |                |                                                |          |
|-------|----------------|----|----|-------------|----------------|----------------|------------------------------------------------|----------|
| 3138E | Capsule 150 mg | 24 | .. | ..<br>B1.45 | 19.33<br>20.78 | 20.36<br>20.36 | <sup>a</sup> Cleocin<br><sup>a</sup> Dalacin C | KR<br>PH |
|-------|----------------|----|----|-------------|----------------|----------------|------------------------------------------------|----------|

#### *LINCOMYCIN*

|       |                          |   |    |    |       |       |          |    |
|-------|--------------------------|---|----|----|-------|-------|----------|----|
| 2530E | Injection 600 mg in 2 mL | 5 | .. | .. | 30.65 | 31.30 | Lincocin | PH |
|-------|--------------------------|---|----|----|-------|-------|----------|----|

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                                                                                                                                                                                   | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
| <b>Aminoglycoside antibacterials</b>                                                                                                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |
| • <b>Other aminoglycosides</b>                                                                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |
| GENTAMICIN SULFATE                                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |
| 2824P                                                                                                                                                                                                                                                  | Injection 80 mg (base) in 2 mL                          | 10          | 1              | ..      | * 20.07                                  | 21.10                                                  | <sup>a</sup> HH                      |
|                                                                                                                                                                                                                                                        |                                                         |             |                | ..      | 20.07                                    | 21.10                                                  | <sup>a</sup> PU                      |
| TOBRAMYCIN SULFATE                                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |
| <u><b>Restricted Benefit</b></u>                                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |
| <i>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent;</i>                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |
| <i>Septicaemia, suspected;</i>                                                                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |
| <i>Septicaemia, proven.</i>                                                                                                                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |
| 1356J                                                                                                                                                                                                                                                  | Injection 80 mg (base) in 2 mL                          | 10          | 1              | ..      | * 64.59                                  | 31.30                                                  | HH                                   |
| 8872Y                                                                                                                                                                                                                                                  | Injection 80 mg (base) in 2 mL (without preservative)   | 10          | 1              | ..      | * 64.59                                  | 31.30                                                  | PU                                   |
| <b>Quinolone antibacterials</b>                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |
| • <b>Fluoroquinolones</b>                                                                                                                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |
| CIPROFLOXACIN                                                                                                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |
| <u><b>Restricted Benefit</b></u>                                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |
| <i>Gonorrhoea.</i>                                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |
| <u><b>NOTE:</b></u>                                                                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i>                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |
| 1311B                                                                                                                                                                                                                                                  | Tablet 250 mg                                           | 2           | ..             | ..      | 11.67                                    | 12.70                                                  | Ciproxin 250 BN                      |
| <u><b>Authority Required</b></u>                                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |
| <i>Respiratory tract infection proven or suspected to be caused by Pseudomonas aeruginosa in severely immunocompromised patients;</i>                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |
| <i>Bacterial gastroenteritis in severely immunocompromised patients;</i>                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |
| <i>Treatment of infections proven to be due to Pseudomonas aeruginosa or other gram-negative bacteria resistant to all other oral antimicrobials;</i>                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |
| <i>Treatment of joint and bone infections, epididymo-orchitis, prostatitis or perichondritis of the pinna, suspected or proven to be caused by gram-negative bacteria or gram-positive bacteria resistant to all other appropriate antimicrobials.</i> |                                                         |             |                |         |                                          |                                                        |                                      |
| 1208N                                                                                                                                                                                                                                                  | Tablet 250 mg                                           | 14          | ..             | ..      | 25.90                                    | 26.93                                                  | <sup>a</sup> C-Flox 250 AL           |
|                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cifran RA               |
|                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ciprol 250 AW           |
|                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx GX                |
|                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | Ciprofloxacin                        |
|                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Profloxin SZ            |
|                                                                                                                                                                                                                                                        |                                                         |             |                | 81.45   | 27.35                                    | 26.93                                                  | <sup>a</sup> Ciproxin 250 BN         |

continued ➡

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                 | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 1209P                                | Tablet 500 mg                                           | 14          | ..             | ..      | 44.32                                    | 31.30                                                  | <sup>a</sup> C-Flox 500              | AL |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cifran                  | RA |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ciprofloxacin 500       | CR |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ciprofloxacin-BW        | BF |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ciprol 500              | AW |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                   | GX |
|                                      |                                                         |             |                |         |                                          |                                                        | Ciprofloxacin                        |    |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Profloxin               | SZ |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Proquin                 | GM |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GN                      |    |
|                                      |                                                         |             |                | B1.26   | 45.58                                    | 31.30                                                  | <sup>a</sup> Ciproxin 500            | BN |
| 1210Q                                | Tablet 750 mg                                           | 14          | ..             | ..      | 62.07                                    | 31.30                                                  | <sup>a</sup> C-Flox 750              | AL |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cifran                  | RA |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ciprofloxacin 750       | CR |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ciprofloxacin-BW        | BF |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ciprol 750              | AW |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                   | GX |
|                                      |                                                         |             |                |         |                                          |                                                        | Ciprofloxacin                        |    |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Profloxin               | SZ |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Proquin                 | GM |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GN                      |    |
|                                      |                                                         |             |                | B1.37   | 63.44                                    | 31.30                                                  | <sup>a</sup> Ciproxin 750            | BN |
| <b>NORFLOXACIN</b>                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Acute bacterial enterocolitis;       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Complicated urinary tract infection. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 3010K                                | Tablet 400 mg                                           | 14          | 1              | ..      | 17.29                                    | 18.32                                                  | <sup>a</sup> Chem mart               | CH |
|                                      |                                                         |             |                |         |                                          |                                                        | Norfloxacin                          |    |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                   | GX |
|                                      |                                                         |             |                |         |                                          |                                                        | Norfloxacin                          |    |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Norflohexal             | SZ |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Nufloxib                | AF |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Roxin                   | AW |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                                      |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                      |                                                         |             |                |         |                                          |                                                        | Norfloxacin                          |    |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GM                      |    |
|                                      |                                                         |             |                | B2.83   | 20.12                                    | 18.32                                                  | <sup>a</sup> Noroxin                 | MK |



## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                                                | Name, Restriction,<br>Manner of Administration and Form           | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                             |          |
|---------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------------------|----------|
| <b>Other antibacterials</b>                                                                                         |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| • <b>Glycopeptide antibacterials</b>                                                                                |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| VANCOMYCIN                                                                                                          |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| <b>Restricted Benefit</b>                                                                                           |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| <i>Prophylaxis of endocarditis in patients hypersensitive to penicillin.</i>                                        |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| 3130R                                                                                                               | Powder for injection 500 mg<br>(500,000 i.u.) vancomycin activity | 2           | ..             | ..      | * 46.09                                  | 31.30                                                  | <sup>a</sup> Vancocin CP<br><sup>a</sup> Vancomycin<br>Sandoz<br><sup>a</sup> HH | AS<br>SZ |
| 2269K                                                                                                               | Powder for injection 1 g (1,000,000 i.u.)<br>vancomycin activity  | 1           | ..             | ..      | 46.07                                    | 31.30                                                  | <sup>a</sup> Vancomycin<br>Sandoz<br><sup>a</sup> HH                             | SZ       |
| <hr/>                                                                                                               |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| <b>Restricted Benefit</b>                                                                                           |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| <i>Endophthalmitis;</i>                                                                                             |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| <i>Use initiated in a hospital for infections where vancomycin is an appropriate antibiotic.</i>                    |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| 3131T                                                                                                               | Powder for injection 500 mg<br>(500,000 i.u.) vancomycin activity | 5           | ..             | ..      | * 103.89                                 | 31.30                                                  | <sup>a</sup> Vancocin CP<br><sup>a</sup> Vancomycin<br>Sandoz<br><sup>a</sup> HH | AS<br>SZ |
| 2270L                                                                                                               | Powder for injection 1 g (1,000,000 i.u.)<br>vancomycin activity  | 3           | ..             | ..      | * 123.41                                 | 31.30                                                  | <sup>a</sup> Vancomycin<br>Sandoz<br><sup>a</sup> HH                             | SZ       |
| • <b>Steroid antibacterials</b>                                                                                     |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| FUSIDIC ACID                                                                                                        |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| <b>Restricted Benefit</b>                                                                                           |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| <i>For use in combination with another antibiotic in the treatment of proven serious staphylococcal infections.</i> |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| 2312Q                                                                                                               | Tablet (sodium salt) 250 mg                                       | 36          | 1              | ..      | 84.93                                    | 31.30                                                  | Fucidin                                                                          | CS       |
| • <b>Imidazole derivatives</b>                                                                                      |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| METRONIDAZOLE                                                                                                       |                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| 1636D                                                                                                               | Tablet 200 mg                                                     | 21          | 1              | ..      | 7.53                                     | 8.56                                                   | <sup>a</sup> Metrogyl 200<br><sup>a</sup> Metronide 200                          | AF<br>AV |
|                                                                                                                     |                                                                   |             |                | B1.51   | 9.04                                     | 8.56                                                   | <sup>a</sup> Flagyl                                                              | SW       |
| 1626N                                                                                                               | Tablet 400 mg                                                     | 5           | 2              | ..      | 7.45                                     | 8.48                                                   | Metrogyl 400                                                                     | AF       |
| 1642K                                                                                                               | Suppositories 500 mg, 10                                          | ‡ 1         | ..             | ..      | 21.68                                    | 22.71                                                  | Flagyl                                                                           | SW       |

continued ➞

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                         | Name, Restriction,<br>Manner of Administration and Form                                    | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>METRONIDAZOLE</b>                                                         |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                             |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of anaerobic infections.</i>                                    |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| 1621H                                                                        | Tablet 400 mg                                                                              | 21          | 1              | ..      | 9.60                                     | 10.63                                                  | <sup>a</sup> <i>Metrogyl 400</i>     | AF |
|                                                                              |                                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> <i>Metronide 400</i>    | AV |
|                                                                              |                                                                                            |             |                | B1.57   | 11.17                                    | 10.63                                                  | <sup>a</sup> <i>Flagyl</i>           | SW |
| <b><u>Restricted Benefit</u></b>                                             |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| <i>Prophylaxis in large bowel surgery;</i>                                   |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment, in a hospital, of acute anaerobic sepsis.</i>                  |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| 1638F                                                                        | I.V. infusion 500 mg in 100 mL                                                             | 5           | 1              | ..      | * 31.54                                  | 31.30                                                  | <sup>a</sup> <i>BX</i>               |    |
|                                                                              |                                                                                            |             |                | ..      | * 31.54                                  | 31.30                                                  | <sup>a</sup> <i>DBL</i>              | HH |
|                                                                              |                                                                                            |             |                |         |                                          |                                                        | <i>Metronidazole</i>                 |    |
|                                                                              |                                                                                            |             |                |         |                                          |                                                        | <i>Intravenous</i>                   |    |
|                                                                              |                                                                                            |             |                |         |                                          |                                                        | <i>Infusion</i>                      |    |
|                                                                              |                                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> <i>Metronidazole</i>    | SZ |
|                                                                              |                                                                                            |             |                |         |                                          |                                                        | <i>Sandoz</i>                        |    |
| <b>METRONIDAZOLE BENZOATE</b>                                                |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| 1630T                                                                        | Oral suspension 320 mg per 5 mL<br>(equivalent to 200 mg metronidazole in<br>5 mL), 100 mL | ‡ 1         | ..             | ..      | 15.73                                    | 16.76                                                  | Flagyl S                             | SW |
| <b>TINIDAZOLE</b>                                                            |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| 1465D                                                                        | Tablet 500 mg                                                                              | 4           | ..             | ..      | 8.77                                     | 9.80                                                   | <sup>a</sup> Simplotan               | GP |
|                                                                              |                                                                                            |             |                | B2.51   | 11.28                                    | 9.80                                                   | <sup>a</sup> Fasigyn                 | PF |
| <b>• Nitrofurantoin derivatives</b>                                          |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| <b>NITROFURANTOIN</b>                                                        |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| <b><u>CAUTION:</u></b>                                                       |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| Nitrofurantoin may cause peripheral neuritis and severe pulmonary reactions. |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| 1692C                                                                        | Capsule 50 mg                                                                              | 30          | 1              | ..      | 16.01                                    | 17.04                                                  | Macrochantin                         | PU |
| 1693D                                                                        | Capsule 100 mg                                                                             | 30          | 1              | ..      | 23.75                                    | 24.78                                                  | Macrochantin                         | PU |
| <b>• Other antibacterials</b>                                                |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| <b>HEXAMINE HIPPURATE</b>                                                    |                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| 3124K                                                                        | Tablet 1 g                                                                                 | 100         | 5              | ..      | 40.49                                    | 31.30                                                  | Hiprex                               | IA |

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                                             | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>ANTIMYCOTICS FOR SYSTEMIC USE</b>                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Antimycotics for systemic use</b>                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Antibiotics</b>                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| AMPHOTERICIN                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1047D                                                                                                            | Powder for injection 50 mg                              | 1           | ..             | ..      | 34.22                                    | 31.30                                                  | Fungizone                            | BQ |
| • <b>Imidazole derivatives</b>                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| KETOCONAZOLE                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u>Authority Required</u>                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Symptomatic genital candidiasis recurring after treatment of at least 2 episodes with topical therapy.</i>    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u>CAUTION:</u>                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Hepatotoxicity has been reported with ketoconazole.</i>                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1573T                                                                                                            | Tablet 200 mg                                           | 10          | ..             | ..      | 19.11                                    | 20.14                                                  | Nizoral                              | JC |
| <u>Authority Required</u>                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Oral candidiasis in severely immunocompromised persons where topical therapy has failed;</i>                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Systemic or deep mycoses where other forms of therapy have failed.</i>                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u>CAUTION:</u>                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Hepatotoxicity has been reported with ketoconazole.</i>                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1572R                                                                                                            | Tablet 200 mg                                           | 30          | 5              | ..      | 41.16                                    | 31.30                                                  | Nizoral                              | JC |
| • <b>Triazole derivatives</b>                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| FLUCONAZOLE                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u>Authority Required</u>                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of cryptococcal meningitis in patients unable to take or tolerate amphotericin;</i>                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Maintenance therapy in patients with cryptococcal meningitis and immunosuppression;</i>                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of oropharyngeal candidiasis in immunosuppressed patients;</i>                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of oesophageal candidiasis in immunosuppressed patients;</i>                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients;</i>                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of serious and life-threatening candida infections in patients unable to tolerate amphotericin.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1471K                                                                                                            | Capsule 50 mg                                           | 28          | 5              | ..      | 149.34                                   | 31.30                                                  | <sup>a</sup> DBL Fluconazole         | HH |
|                                                                                                                  |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Diflucan                | PF |
|                                                                                                                  |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dizole 50               | AF |
|                                                                                                                  |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fluconazole Hexal       | HX |
|                                                                                                                  |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fluzole 50              | AW |
|                                                                                                                  |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ozole                   | RA |

continued ➡

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 1472L | Capsule 100 mg                                          | 28          | 5              | ..      | 277.87                                   | 31.30                                                  | <sup>a</sup> DBL Fluconazole         | HH |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Diflucan                | PF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dizole 100              | AF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fluconazole Hexal       | HX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fluconazole<br>Winthrop | WA |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ozole                   | RA |
| 1475P | Capsule 200 mg                                          | 28          | 5              | ..      | 520.33                                   | 31.30                                                  | <sup>a</sup> DBL Fluconazole         | HH |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Diflucan                | PF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dizole 200              | AF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fluconazole Hexal       | HX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fluconazole<br>Winthrop | WA |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fluzole 200             | AW |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Ozole                   | RA |
| 1473M | Solution for I.V. infusion 100 mg in<br>50 mL           | 7           | ..             | ..      | * 165.24                                 | 31.30                                                  | <sup>a</sup> Diflucan                | PF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fluconazole Hexal       | SZ |
| 1474N | Solution for I.V. infusion 200 mg in<br>100 mL          | 7           | ..             | ..      | * 296.28                                 | 31.30                                                  | <sup>a</sup> Diflucan                | PF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fluconazole Hexal       | SZ |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> BX                      |    |
| 1757L | Solution for I.V. infusion 400 mg in<br>200 mL          | 1           | ..             | ..      | 73.32                                    | 31.30                                                  | BX                                   |    |

### ITRACONAZOLE

#### Authority Required

*Systemic aspergillosis;*

*Systemic sporotrichosis;*

*Systemic histoplasmosis;*

*Treatment and maintenance therapy in patients with AIDS who have disseminated pulmonary histoplasmosis infection;*

*Treatment and maintenance therapy in patients with AIDS who have chronic pulmonary histoplasmosis infection;*

*Treatment of oropharyngeal candidiasis in immunosuppressed patients;*

*Treatment of oesophageal candidiasis in immunosuppressed patients.*

|       |                |    |   |    |        |       |          |    |
|-------|----------------|----|---|----|--------|-------|----------|----|
| 8196J | Capsule 100 mg | 60 | 5 | .. | 242.19 | 31.30 | Sporanox | JC |
|-------|----------------|----|---|----|--------|-------|----------|----|

### ANTIMYCOBACTERIALS

#### Drugs for treatment of tuberculosis

##### • Hydrazides

#### ISONIAZID

|       |               |     |   |    |       |       |    |  |
|-------|---------------|-----|---|----|-------|-------|----|--|
| 1554T | Tablet 100 mg | 100 | 2 | .. | 11.20 | 12.23 | FM |  |
|-------|---------------|-----|---|----|-------|-------|----|--|

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                      | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>Drugs for treatment of lepra</b>                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Drugs for treatment of lepra</b>                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| DAPSONE                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8801F                                                                                     | Tablet 25 mg                                            | 100         | 1              | ..      | 100.15                                   | 31.30                                                  | LM                                   |    |
| 1272Y                                                                                     | Tablet 100 mg                                           | 100         | 1              | ..      | 113.41                                   | 31.30                                                  | LM                                   |    |
| <b>RIFAMPICIN</b>                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Prophylaxis of meningococcal disease in close contacts and carriers;</i>               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Prophylactic treatment of contacts of patients with Haemophilus influenzae type B.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1981G                                                                                     | Capsule 150 mg                                          | 10          | ..             | ..      | 10.07                                    | 11.10                                                  | Rimycin 150                          | AF |
| 1984K                                                                                     | Capsule 300 mg                                          | 10          | ..             | ..      | 13.12                                    | 14.15                                                  | Rimycin 300                          | AF |
| 8025J                                                                                     | Syrup 100 mg per 5 mL, 60 mL                            | ± 1         | ..             | ..      | 25.05                                    | 26.08                                                  | Rifadin                              | SW |

### **Authority Required**

*Leprosy in adults.*

|       |                |     |    |    |       |       |             |    |
|-------|----------------|-----|----|----|-------|-------|-------------|----|
| 1982H | Capsule 150 mg | 100 | .. | .. | 36.58 | 31.30 | Rimycin 150 | AF |
| 1983J | Capsule 300 mg | 100 | .. | .. | 64.51 | 31.30 | Rimycin 300 | AF |

## ANTIVIRALS FOR SYSTEMIC USE

### **Direct acting antivirals**

#### • **Nucleosides and nucleotides excl. reverse transcriptase inhibitors**

### **ACICLOVIR**

### **Authority Required**

*Moderate to severe initial genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is desirable but need not delay treatment.*

### **NOTE:**

*Aciclovir 200 mg is not PBS-subsidised for chickenpox, herpes zoster or herpes simplex infections other than genital herpes.*

|       |               |    |    |       |         |       |                              |    |
|-------|---------------|----|----|-------|---------|-------|------------------------------|----|
| 1003T | Tablet 200 mg | 50 | .. | ..    | * 69.11 | 31.30 | <sup>a</sup> Acihexal        | SZ |
|       |               |    |    |       |         |       | <sup>a</sup> Acyclo-V 200    | AF |
|       |               |    |    |       |         |       | <sup>a</sup> Lovir           | GM |
|       |               |    |    | ..    | 69.11   | 31.30 | <sup>a</sup> GenRx Aciclovir | GX |
|       |               |    |    | B4.34 | * 73.45 | 31.30 | <sup>a</sup> Zovirax 200 mg  | GK |

### **NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### Authority Required

*Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.*

### NOTE:

*Aciclovir 200 mg is not PBS-subsidised for chickenpox, herpes zoster or herpes simplex infections other than genital herpes.*

|       |               |    |   |       |        |       |                                      |    |
|-------|---------------|----|---|-------|--------|-------|--------------------------------------|----|
| 1007B | Tablet 200 mg | 90 | 5 | ..    | 121.47 | 31.30 | <sup>a</sup> Aciclovir 200           | CR |
|       |               |    |   |       |        |       | <sup>a</sup> Acihexal                | SZ |
|       |               |    |   |       |        |       | <sup>a</sup> Acyclo-V 200            | AF |
|       |               |    |   |       |        |       | <sup>a</sup> Chem mart               | CH |
|       |               |    |   |       |        |       | Aciclovir                            |    |
|       |               |    |   |       |        |       | <sup>a</sup> GenRx Aciclovir         | GX |
|       |               |    |   |       |        |       | <sup>a</sup> Lovir                   | GM |
|       |               |    |   |       |        |       | <sup>a</sup> Ozvir                   | RA |
|       |               |    |   |       |        |       | <sup>a</sup> Terry White<br>Chemists | TW |
|       |               |    |   |       |        |       | Aciclovir                            |    |
|       |               |    |   | B3.21 | 124.68 | 31.30 | <sup>a</sup> Zovirax 200 mg          | GK |

### Authority Required

*Treatment of patients with herpes zoster within 72 hours of the onset of the rash;*

*Herpes zoster ophthalmicus.*

### NOTE:

*Aciclovir is effective only if commenced within 72 hours of onset of rash.*

*Aciclovir 800 mg is not PBS-subsidised for herpes simplex or chickenpox.*

|       |               |    |    |       |        |       |                              |    |
|-------|---------------|----|----|-------|--------|-------|------------------------------|----|
| 1052J | Tablet 800 mg | 35 | .. | ..    | 145.89 | 31.30 | <sup>a</sup> Aciclovir 800   | CR |
|       |               |    |    |       |        |       | <sup>a</sup> Acihexal        | SZ |
|       |               |    |    |       |        |       | <sup>a</sup> Acyclo-V 800    | AF |
|       |               |    |    |       |        |       | <sup>a</sup> GenRx Aciclovir | GX |
|       |               |    |    |       |        |       | <sup>a</sup> Lovir           | GM |
|       |               |    |    | B1.56 | 147.45 | 31.30 | <sup>a</sup> Zovirax 800 mg  | GK |

### NOTE:

*No applications for repeats will be authorised.*

### Authority Required

*Patients with advanced HIV disease (CD4 cell counts of less than 150 million per litre).*

|       |               |     |   |       |        |       |                             |    |
|-------|---------------|-----|---|-------|--------|-------|-----------------------------|----|
| 8234J | Tablet 800 mg | 120 | 5 | ..    | 445.90 | 31.30 | <sup>a</sup> Acihexal       | SZ |
|       |               |     |   |       |        |       | <sup>a</sup> Acyclo-V 800   | AF |
|       |               |     |   |       |        |       | <sup>a</sup> Lovir          | GM |
|       |               |     |   |       |        |       | <sup>a</sup> Zovirax 800 mg | GK |
|       |               |     |   | B5.19 | 451.09 | 31.30 |                             |    |

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### FAMCICLOVIR

#### **Authority Required**

*Episodic treatment of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.*

#### **NOTE:**

*Famciclovir 125 mg is not PBS-subsidised for chickenpox, herpes zoster or herpes simplex infections other than genital herpes.*

|       |               |    |   |    |        |       |        |    |
|-------|---------------|----|---|----|--------|-------|--------|----|
| 8092X | Tablet 125 mg | 40 | 1 | .. | 136.63 | 31.30 | Famvir | NV |
|-------|---------------|----|---|----|--------|-------|--------|----|

#### **Authority Required**

*Episodic treatment of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.*

#### **NOTE:**

*Famciclovir 250 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.*

|       |               |    |   |    |        |       |        |    |
|-------|---------------|----|---|----|--------|-------|--------|----|
| 2274Q | Tablet 250 mg | 20 | 1 | .. | 136.63 | 31.30 | Famvir | NV |
|-------|---------------|----|---|----|--------|-------|--------|----|

#### **Authority Required**

*Treatment of patients with herpes zoster within 72 hours of the onset of the rash.*

#### **NOTE:**

*Famciclovir is effective only if commenced within 72 hours of onset of rash.*

*Famciclovir 250 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.*

|       |               |    |    |    |        |       |        |    |
|-------|---------------|----|----|----|--------|-------|--------|----|
| 8002E | Tablet 250 mg | 21 | .. | .. | 143.15 | 31.30 | Famvir | NV |
|-------|---------------|----|----|----|--------|-------|--------|----|

#### **NOTE:**

*No applications for repeats will be authorised.*

#### **Authority Required**

*Suppressive therapy of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.*

#### **NOTE:**

*Famciclovir 250 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.*

|       |               |    |   |    |        |       |        |    |
|-------|---------------|----|---|----|--------|-------|--------|----|
| 8217L | Tablet 250 mg | 56 | 5 | .. | 356.50 | 31.30 | Famvir | NV |
|-------|---------------|----|---|----|--------|-------|--------|----|

#### **Authority Required**

*Treatment of immunocompromised patients with herpes zoster within 72 hours of the onset of the rash.*

continued ➞

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

**NOTE:**

*Famciclovir is effective only if commenced within 72 hours of onset of rash.*

*Famciclovir 500 mg is not PBS-subsidised for chickenpox.*

*Famciclovir 500 mg is not PBS-subsidised for herpes zoster, genital herpes or other herpes simplex infections in immunocompetent patients.*

|       |               |    |    |    |        |       |        |    |
|-------|---------------|----|----|----|--------|-------|--------|----|
| 8897G | Tablet 500 mg | 30 | .. | .. | 201.92 | 31.30 | Famvir | NV |
|-------|---------------|----|----|----|--------|-------|--------|----|

**NOTE:**

*No applications for repeats will be authorised.*

**Authority Required**

*Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes in immunocompromised patients. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.*

**Authority Required**

*Episodic treatment of moderate to severe recurrent oral or labial herpes in a patient with HIV infection and a CD4 cell count of less than 500 million per litre. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.*

**Authority Required**

*Suppressive therapy of moderate to severe recurrent oral or labial herpes in a patient with HIV infection and:*

*(a) a CD4 cell count of less than 150 million per litre; or*

*(b) other opportunistic infections or AIDS defining tumours.*

*Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.*

|       |               |    |   |    |        |       |        |    |
|-------|---------------|----|---|----|--------|-------|--------|----|
| 8896F | Tablet 500 mg | 56 | 5 | .. | 356.50 | 31.30 | Famvir | NV |
|-------|---------------|----|---|----|--------|-------|--------|----|

**NOTE:**

*Famciclovir 500 mg is not PBS-subsidised for chickenpox.*

*Famciclovir 500 mg is not PBS-subsidised for herpes zoster, genital herpes or other herpes simplex infections in immunocompetent patients.*

**VALACICLOVIR HYDROCHLORIDE****Authority Required**

*Moderate to severe initial genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is desirable but need not delay treatment.*

**NOTE:**

*Valaciclovir 500 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.*

|       |                      |    |    |    |          |       |         |    |
|-------|----------------------|----|----|----|----------|-------|---------|----|
| 8133C | Tablet 500 mg (base) | 20 | .. | .. | * 105.35 | 31.30 | Valtrex | GK |
|-------|----------------------|----|----|----|----------|-------|---------|----|

**NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*



## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

### Authority Required

*Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment.*

### NOTE:

*Valaciclovir 500 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.*

|       |                      |    |   |    |        |       |         |    |
|-------|----------------------|----|---|----|--------|-------|---------|----|
| 8134D | Tablet 500 mg (base) | 30 | 5 | .. | 155.00 | 31.30 | Valtrex | GK |
|-------|----------------------|----|---|----|--------|-------|---------|----|

### Authority Required

*Treatment of patients with herpes zoster within 72 hours of the onset of the rash;  
Herpes zoster ophthalmicus.*

### NOTE:

*Valaciclovir is effective only if commenced within 72 hours of onset of rash.*

*Valaciclovir 500 mg is not PBS-subsidised for chickenpox or herpes simplex infections other than genital herpes.*

|       |                      |    |    |    |        |       |         |    |
|-------|----------------------|----|----|----|--------|-------|---------|----|
| 8064K | Tablet 500 mg (base) | 42 | .. | .. | 213.63 | 31.30 | Valtrex | GK |
|-------|----------------------|----|----|----|--------|-------|---------|----|

### NOTE:

*No applications for repeats will be authorised.*

## VACCINES

### **Bacterial vaccines**

#### • ***Pneumococcal vaccines***

***PNEUMOCOCCAL VACCINE, POLYVALENT***

### Restricted Benefit

*Splenectomised persons over 2 years of age;  
Persons with Hodgkin's disease;  
Persons at high risk of pneumococcal infections.*

|       |                              |   |    |    |       |       |              |    |
|-------|------------------------------|---|----|----|-------|-------|--------------|----|
| 1903E | Injection 0.5 mL (23 valent) | 1 | .. | .. | 45.70 | 31.30 | Pneumovax 23 | CS |
|-------|------------------------------|---|----|----|-------|-------|--------------|----|

#### • ***Tetanus vaccines***

***DIPHTHERIA and TETANUS VACCINE, ADSORBED,  
DILUTED FOR ADULT USE***

### NOTE:

*For immunisation of adults and children aged greater than or equal to 8 years.*

|       |                                        |   |    |    |       |       |             |    |
|-------|----------------------------------------|---|----|----|-------|-------|-------------|----|
| 8783G | Injection 0.5 mL in pre-filled syringe | 5 | .. | .. | 74.91 | 31.30 | ADT Booster | CS |
|-------|----------------------------------------|---|----|----|-------|-------|-------------|----|

## ANTIINFECTIVES FOR SYSTEMIC USE—CONT.

| Code                                                                                                                             | Name, Restriction,<br>Manner of Administration and Form                                                                                      | Max.<br>Qty | No. of<br>Rpts | Premium   | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer     |                         |
|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|-----------|------------------------------------------|--------------------------------------------------------|------------------------------------------|-------------------------|
| <b>Viral vaccines</b>                                                                                                            |                                                                                                                                              |             |                |           |                                          |                                                        |                                          |                         |
| • <b>Influenza vaccines</b>                                                                                                      |                                                                                                                                              |             |                |           |                                          |                                                        |                                          |                         |
| <b>INFLUENZA VACCINE</b>                                                                                                         |                                                                                                                                              |             |                |           |                                          |                                                        |                                          |                         |
| <b><u>Restricted Benefit</u></b>                                                                                                 |                                                                                                                                              |             |                |           |                                          |                                                        |                                          |                         |
| <i>Children up to 35 months of age at increased risk of adverse consequences from infections of the lower respiratory tract.</i> |                                                                                                                                              |             |                |           |                                          |                                                        |                                          |                         |
| 2265F                                                                                                                            | <b>Injection (trivalent) 0.25 mL (containing<br/>A/Solomon Islands/3/2006,<br/>A/Brisbane/10/2007 and<br/>B/Florida/4/2006 like strains)</b> | <b>1</b>    | <b>..</b>      | <b>..</b> | <b>16.56</b>                             | <b>17.59</b>                                           | <b>Fluvax Junior<br/>Vaxigrip Junior</b> | <b>CS<br/>AX</b>        |
| <hr/>                                                                                                                            |                                                                                                                                              |             |                |           |                                          |                                                        |                                          |                         |
| <b><u>Restricted Benefit</u></b>                                                                                                 |                                                                                                                                              |             |                |           |                                          |                                                        |                                          |                         |
| <i>Persons at special risk of adverse consequences from infections of the lower respiratory tract.</i>                           |                                                                                                                                              |             |                |           |                                          |                                                        |                                          |                         |
| 2852D                                                                                                                            | <b>Injection (trivalent) 0.5 mL (containing<br/>A/Solomon Islands/3/2006,<br/>A/Brisbane/10/2007 and<br/>B/Florida/4/2006 like strains)</b>  | <b>1</b>    | <b>..</b>      | <b>..</b> | <b>19.20</b>                             | <b>20.23</b>                                           | <b>Fluvax<br/>Influvac<br/>Vaxigrip</b>  | <b>CS<br/>SM<br/>AX</b> |

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

| Code                                                                               | Name, Restriction,<br>Manner of Administration and Form                                                          | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |           |
|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|-----------|
| <b>ANTINEOPLASTIC AGENTS</b>                                                       |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| <b>Alkylating agents</b>                                                           |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| • <b>Nitrogen mustard analogues</b>                                                |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| CHLORAMBUCIL                                                                       |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| 1163F                                                                              | Tablet 2 mg                                                                                                      | 100         | 2              | ..      | * 137.55                                 | 31.30                                                  | Leukeran                             | GK        |
| CYCLOPHOSPHAMIDE                                                                   |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| 1266P                                                                              | Tablet 50 mg                                                                                                     | 50          | 2              | ..      | 30.86                                    | 31.30                                                  | Cycloblastin                         | PH        |
| 1079T                                                                              | Powder for injection 500 mg (solvent<br>required)<br>(code 6704W applies to above item with<br>approved solvent) | 2           | ..             | ..      | * 29.33                                  | 30.36                                                  | Endoxan                              | BX        |
| 1080W                                                                              | Powder for injection 1 g (solvent<br>required)<br>(code 6710E applies to above item with<br>approved solvent)    | 1           | ..             | ..      | 26.59                                    | 27.62                                                  | Endoxan                              | BX        |
| 1031G                                                                              | Powder for injection 2 g (solvent<br>required)<br>(code 7055H applies to above item with<br>approved solvent)    | 1           | ..             | ..      | 42.39                                    | 31.30                                                  | Endoxan                              | BX        |
| <b>IFOSFAMIDE</b>                                                                  |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| <b>Restricted Benefit</b>                                                          |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| <i>Relapsed or refractory germ cell tumours following first-line chemotherapy;</i> |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| <i>Relapsed or refractory sarcomas following first-line chemotherapy.</i>          |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| 8076C                                                                              | <b>Powder for I.V. injection 1 g</b>                                                                             | 5           | 5              | ..      | * 261.14                                 | 31.30                                                  | <b>Holoxan</b>                       | <b>BX</b> |
| 8077D                                                                              | <b>Powder for I.V. injection 2 g</b>                                                                             | 5           | 5              | ..      | * 476.74                                 | 31.30                                                  | <b>Holoxan</b>                       | <b>BX</b> |
| MELPHALAN                                                                          |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| 2547C                                                                              | Tablet 2 mg                                                                                                      | 25          | 1              | ..      | 50.45                                    | 31.30                                                  | Alkeran                              | GK        |
| • <b>Alkyl sulphonates</b>                                                         |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| BUSULFAN                                                                           |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| 1128J                                                                              | Tablet 2 mg                                                                                                      | 100         | ..             | ..      | 85.83                                    | 31.30                                                  | Myleran                              | GK        |
| • <b>Ethylene imines</b>                                                           |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| THIOTEPA                                                                           |                                                                                                                  |             |                |         |                                          |                                                        |                                      |           |
| 2345K                                                                              | Powder for injection 15 mg                                                                                       | 2           | 1              | ..      | * 155.23                                 | 31.30                                                  | SI                                   |           |

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                   | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>• Nitrosoureas</b><br><b>CARMUSTINE</b><br><u>Restricted Benefit</u><br><i>Glioblastoma multiforme, suspected or confirmed, at the time of initial surgery.</i><br><u>NOTE:</u><br><i>Carmustine is not PBS-subsidised for use in conjunction with PBS-subsidised temozolomide.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8898H                                                                                                                                                                                                                                                                                  | Implants 7.7 mg, 8                                      | ± 1         | ..             | ..      | 16044.43                                 | 31.30                                                  | Gliadel                              | OA |
| <b>FOTEMUSTINE</b><br><u>Authority Required</u><br><i>Metastatic malignant melanoma.</i>                                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8786K                                                                                                                                                                                                                                                                                  | Powder for injection 208 mg with solvent                | 1           | 4              | ..      | 1100.15                                  | 31.30                                                  | Muphoran                             | SE |
| <b>• Other alkylating agents</b><br><b>TEMOZOLOMIDE</b><br><u>Authority Required</u><br><i>Glioblastoma multiforme concomitantly with radiotherapy.</i><br><u>NOTE:</u><br><i>Temozolomide is not PBS-subsidised for use in conjunction with PBS-subsidised carmustine.</i>            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8819E                                                                                                                                                                                                                                                                                  | Capsule 5 mg                                            | 15          | 2              | ..      | * 207.62                                 | 31.30                                                  | Temodal                              | SH |
| 8820F                                                                                                                                                                                                                                                                                  | Capsule 20 mg                                           | 15          | 2              | ..      | * 567.50                                 | 31.30                                                  | Temodal                              | SH |
| 8821G                                                                                                                                                                                                                                                                                  | Capsule 100 mg                                          | 15          | 2              | ..      | * 2388.86                                | 31.30                                                  | Temodal                              | SH |
| <u>NOTE:</u><br><i>Applications for doses above 150 mg per day will not be authorised. No applications for increased repeats will be authorised.</i>                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <hr/> <u>Authority Required</u><br><i>Recurrence of anaplastic astrocytoma following standard therapy;</i><br><i>Recurrence of glioblastoma multiforme following standard therapy;</i><br><i>Glioblastoma multiforme following radiotherapy.</i>                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8378Y                                                                                                                                                                                                                                                                                  | Capsule 5 mg                                            | 5           | 5              | ..      | 73.32                                    | 31.30                                                  | Temodal                              | SH |
| 8379B                                                                                                                                                                                                                                                                                  | Capsule 20 mg                                           | 5           | 5              | ..      | 203.96                                   | 31.30                                                  | Temodal                              | SH |
| 8380C                                                                                                                                                                                                                                                                                  | Capsule 100 mg                                          | 5           | 5              | ..      | 807.79                                   | 31.30                                                  | Temodal                              | SH |
| 8381D                                                                                                                                                                                                                                                                                  | Capsule 250 mg                                          | 5           | 5              | ..      | 1862.88                                  | 31.30                                                  | Temodal                              | SH |

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                       | Name, Restriction,<br>Manner of Administration and Form    | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                  |    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------|----|
| <b>Antimetabolites</b>                                                                                                                                                                     |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| • <b>Folic acid analogues</b>                                                                                                                                                              |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| METHOTREXATE                                                                                                                                                                               |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| 1622J                                                                                                                                                                                      | Tablet 2.5 mg                                              | 30          | 5              | ..      | 13.11                                    | 14.14                                                  | <sup>a</sup> Methoblastin<br><sup>a</sup> HH          | PH |
| 2272N                                                                                                                                                                                      | Tablet 10 mg                                               | 15          | 1              | ..      | 22.37                                    | 23.40                                                  | Methoblastin                                          | PH |
| 2396D                                                                                                                                                                                      | Injection 5 mg in 2 mL                                     | 5           | ..             | ..      | 37.64                                    | 31.30                                                  | HH                                                    |    |
| 2395C                                                                                                                                                                                      | Injection 50 mg in 2 mL                                    | 5           | ..             | ..      | 36.93                                    | 31.30                                                  | HH<br>PU                                              |    |
| 8863L                                                                                                                                                                                      | Solution concentrate for I.V. infusion<br>500 mg in 20 mL  | 1           | ..             | ..      | 65.18                                    | 31.30                                                  | HH                                                    |    |
| 8851W                                                                                                                                                                                      | Solution concentrate for I.V. infusion<br>1000 mg in 10 mL | 1           | ..             | ..      | 124.37                                   | 31.30                                                  | <sup>a</sup> Methotrexate<br>Ebewe<br><sup>a</sup> HH | IT |
| 8852X                                                                                                                                                                                      | Solution concentrate for I.V. infusion<br>5000 mg in 50 mL | 1           | ..             | ..      | 565.63                                   | 31.30                                                  | Methotrexate<br>Ebewe                                 | IT |
| <hr/>                                                                                                                                                                                      |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| <b>METHOTREXATE</b>                                                                                                                                                                        |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                           |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| <i>For patients requiring doses greater than 20 mg per week.</i>                                                                                                                           |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| 1623K                                                                                                                                                                                      | Tablet 10 mg                                               | 50          | 2              | ..      | 47.00                                    | 31.30                                                  | Methoblastin                                          | PH |
| <b>PEMETREXED DISODIUM</b>                                                                                                                                                                 |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| <b><u>Authority Required</u></b>                                                                                                                                                           |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| <i>Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy.</i>                                                                                 |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| <i>Doses greater than 500 mg per metre squared body surface area (BSA) will not be approved for PBS subsidy. The patient's BSA must be provided at the time of the authority approval.</i> |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| <b><u>Authority Required</u></b>                                                                                                                                                           |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| <i>Mesothelioma in combination with cisplatin.</i>                                                                                                                                         |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| <i>Doses greater than 500 mg per metre squared body surface area (BSA) will not be approved for PBS subsidy. The patient's BSA must be provided at the time of the authority approval.</i> |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                        |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| <i>No applications for increased maximum quantities for the 500 mg vial will be authorised.</i>                                                                                            |                                                            |             |                |         |                                          |                                                        |                                                       |    |
| 9131N                                                                                                                                                                                      | Powder for I.V. infusion 100 mg (base)                     | 1           | 3              | ..      | 359.42                                   | 31.30                                                  | Alimta                                                | LY |
| 9130M                                                                                                                                                                                      | Powder for I.V. infusion 500 mg (base)                     | 1           | 3              | ..      | 1700.98                                  | 31.30                                                  | Alimta                                                | LY |

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                     | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>RALTITREXED</b>                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>For use as a single agent in the treatment of advanced colorectal cancer.</i>                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8284B                                                                                                                                                                                    | Powder for I.V. infusion 2 mg                           | 3           | 2              | ..      | * 855.86                                 | 31.30                                                  | Tomudex                              | HH |
| • <b>Purine analogues</b>                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CLADRIBINE</b>                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Hairy cell leukaemia.</i>                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8800E                                                                                                                                                                                    | Injection 10 mg in 5 mL                                 | 7           | ..             | ..      | * 4629.14                                | 31.30                                                  | Litak                                | OA |
| 1811H                                                                                                                                                                                    | Solution for I.V. infusion 10 mg in 10 mL               | 7           | ..             | ..      | 4629.16                                  | 31.30                                                  | Leustatin                            | JC |
| <b>FLUDARABINE PHOSPHATE</b>                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>B-cell chronic lymphocytic leukaemia in combination with cyclophosphamide where the patient has advanced disease (Binet Stage B or C) or evidence of progressive Stage A disease.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Stage A progressive disease is defined by at least one of the following:</i>                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>persistent rise in lymphocyte count with doubling time less than 12 months;</i>                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>a downward trend in haemoglobin or platelets, or both;</i>                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>more than 50% increase in the size of liver, spleen, or lymph nodes, or appearance of these signs if not previously present;</i>                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>constitutional symptoms attributable to disease.</i>                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>The diagnosis of chronic lymphocytic leukaemia (CLL) must have been established based on:</i>                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>(a) a lymphocytosis, with more than 5,000 million lymphocytes per L in the peripheral blood; and</i>                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>(b) a clonal population of B-cells (CD5/CD19) documented by flow cytometry.</i>                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9184J                                                                                                                                                                                    | Tablet 10 mg                                            | 20          | 5              | ..      | 974.64                                   | 31.30                                                  | Fludara                              | BN |
| 9185K                                                                                                                                                                                    | Powder for I.V. injection 50 mg                         | 5           | 3              | ..      | 1825.93                                  | 31.30                                                  | Fludara                              | BN |
| <b>MERCAPTOPURINE</b>                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1598D                                                                                                                                                                                    | Tablet 50 mg                                            | 100         | 2              | ..      | * 231.87                                 | 31.30                                                  | Purinethol                           | GK |
| <b>THIOGUANINE</b>                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1233X                                                                                                                                                                                    | Tablet 40 mg                                            | 25          | 1              | ..      | 198.23                                   | 31.30                                                  | Lanvis                               | GK |
| • <b>Pyrimidine analogues</b>                                                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAPECITABINE</b>                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Advanced breast cancer after failure of prior therapy which includes a taxane and an anthracycline;</i>                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Advanced breast cancer where therapy with a taxane and/or an anthracycline is contraindicated;</i>                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Advanced breast cancer in combination with docetaxel after failure of prior anthracycline-containing chemotherapy;</i>                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |

continued ➡

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

*Treatment of advanced or metastatic colorectal cancer;*

*Adjuvant treatment of stage III (Dukes C) colon cancer, following complete resection of the primary tumour.*

**NOTE:**

*In the adjuvant setting, the recommended treatment duration is 24 weeks.*

*Capecitabine is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.*

*Capecitabine is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.*

|       |               |     |   |    |        |       |        |    |
|-------|---------------|-----|---|----|--------|-------|--------|----|
| 8361C | Tablet 150 mg | 60  | 2 | .. | 123.50 | 31.30 | Xeloda | RO |
| 8362D | Tablet 500 mg | 120 | 2 | .. | 694.74 | 31.30 | Xeloda | RO |

**CYTARABINE**

|       |                          |    |   |    |         |       |    |  |
|-------|--------------------------|----|---|----|---------|-------|----|--|
| 2884T | Injection 100 mg in 5 mL | 10 | 1 | .. | * 95.09 | 31.30 | PU |  |
|-------|--------------------------|----|---|----|---------|-------|----|--|

**FLUOROURACIL**

|       |                            |    |    |    |         |       |                                                    |    |
|-------|----------------------------|----|----|----|---------|-------|----------------------------------------------------|----|
| 2528C | Injection 500 mg in 10 mL  | 10 | .. | .. | * 57.29 | 31.30 | <sup>a</sup> Fluorouracil Ebewe<br><sup>a</sup> HH | IT |
| 9005Y | Injection 1000 mg in 20 mL | 5  | .. | .. | * 50.14 | 31.30 | Fluorouracil Ebewe                                 | IT |

**GEMCITABINE HYDROCHLORIDE**

**Authority Required**

*Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline;*

*Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy;*

*Locally advanced or metastatic non-small cell lung cancer;*

*Locally advanced or metastatic adenocarcinoma of the pancreas;*

*Locally advanced or metastatic bladder cancer, in combination with cisplatin.*

|       |                                        |   |   |    |          |       |        |    |
|-------|----------------------------------------|---|---|----|----------|-------|--------|----|
| 8049P | Powder for I.V. infusion 200 mg (base) | 4 | 2 | .. | * 235.51 | 31.30 | Gemzar | LY |
| 8050Q | Powder for I.V. infusion 1 g (base)    | 2 | 2 | .. | * 549.11 | 31.30 | Gemzar | LY |

**Plant alkaloids and other natural products**

• **Vinca alkaloids and analogues**

**VINBLASTINE SULFATE**

|       |                                            |   |    |    |        |       |    |  |
|-------|--------------------------------------------|---|----|----|--------|-------|----|--|
| 2199R | Solution for I.V. injection 10 mg in 10 mL | 5 | .. | .. | 105.41 | 31.30 | HH |  |
|-------|--------------------------------------------|---|----|----|--------|-------|----|--|

**VINCRIStINE SULFATE**

|       |                             |    |    |    |          |       |                                    |  |
|-------|-----------------------------|----|----|----|----------|-------|------------------------------------|--|
| 2374Y | I.V. injection 1 mg in 1 mL | 10 | .. | .. | * 160.91 | 31.30 | <sup>a</sup> HH<br><sup>a</sup> PU |  |
|-------|-----------------------------|----|----|----|----------|-------|------------------------------------|--|

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                          | Name, Restriction,<br>Manner of Administration and Form               | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                        |          |
|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------|----------|
| <b>VINORELBINE TARTRATE</b>                                                                   |                                                                       |             |                |         |                                          |                                                        |                                                                             |          |
| <b><u>Authority Required</u></b>                                                              |                                                                       |             |                |         |                                          |                                                        |                                                                             |          |
| <i>Locally advanced or metastatic non-small cell lung cancer.</i>                             |                                                                       |             |                |         |                                          |                                                        |                                                                             |          |
| 9009E                                                                                         | Capsule 20 mg (base)                                                  | 20          | 2              | ..      | * 2091.19                                | 31.30                                                  | Navelbine                                                                   | FB       |
| 9010F                                                                                         | Capsule 30 mg (base)                                                  | 16          | 2              | ..      | * 2481.19                                | 31.30                                                  | Navelbine                                                                   | FB       |
| <b><u>Authority Required</u></b>                                                              |                                                                       |             |                |         |                                          |                                                        |                                                                             |          |
| <i>Advanced breast cancer after failure of prior therapy which includes an anthracycline;</i> |                                                                       |             |                |         |                                          |                                                        |                                                                             |          |
| <i>Locally advanced or metastatic non-small cell lung cancer.</i>                             |                                                                       |             |                |         |                                          |                                                        |                                                                             |          |
| 8280T                                                                                         | Solution for I.V. infusion 10 mg (base)<br>in 1 mL                    | 16          | 2              | ..      | * 1183.27                                | 31.30                                                  | <sup>a</sup> Navelbine<br><sup>a</sup> Vinorelbine Ebewe<br><sup>a</sup> HH | FB<br>IT |
| 8281W                                                                                         | Solution for I.V. infusion 50 mg (base)<br>in 5 mL                    | 4           | 2              | ..      | * 1234.23                                | 31.30                                                  | <sup>a</sup> Navelbine<br><sup>a</sup> Vinorelbine Ebewe<br><sup>a</sup> HH | FB<br>IT |
| <b>• Podophyllotoxin derivatives</b>                                                          |                                                                       |             |                |         |                                          |                                                        |                                                                             |          |
| ETOPOSIDE                                                                                     |                                                                       |             |                |         |                                          |                                                        |                                                                             |          |
| 1396L                                                                                         | Capsule 50 mg                                                         | 20          | ..             | ..      | 470.79                                   | 31.30                                                  | Vepesid                                                                     | BQ       |
| 1389D                                                                                         | Capsule 100 mg                                                        | 10          | ..             | ..      | 413.19                                   | 31.30                                                  | Vepesid                                                                     | BQ       |
| 1390E                                                                                         | Solution for I.V. infusion 100 mg in 5 mL                             | 5           | ..             | ..      | * 172.84                                 | 31.30                                                  | <sup>a</sup> Etoposide Ebewe<br><sup>a</sup> HH                             | IT       |
| ETOPOSIDE PHOSPHATE                                                                           |                                                                       |             |                |         |                                          |                                                        |                                                                             |          |
| 8120J                                                                                         | Powder for I.V. infusion 113.6 mg<br>(equivalent to 100 mg etoposide) | 5           | ..             | ..      | * 172.84                                 | 31.30                                                  | Etopophos                                                                   | BQ       |
| 8515E                                                                                         | Powder for I.V. infusion 1136 mg<br>(equivalent to 1 g etoposide)     | 1           | ..             | ..      | 327.35                                   | 31.30                                                  | Etopophos                                                                   | BQ       |



# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Name, Restriction,<br>Manner of Administration and Form                                                                                   | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                        |                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------|----------------|
| <b>• Taxanes</b><br><b>DOCETAXEL</b><br><u>Authority Required</u><br><i>Adjuvant treatment of node-positive breast cancer in combination with an anthracycline and cyclophosphamide;</i><br><i>Advanced breast cancer after failure of prior therapy which includes an anthracycline;</i><br><i>Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound;</i><br><i>Locally advanced or metastatic non-small cell lung cancer;</i><br><i>Treatment of HER2 positive early breast cancer in combination with trastuzumab.</i><br><u>Authority Required</u><br><i>Treatment of androgen independent (hormone refractory) metastatic carcinoma of the prostate in a patient with a Karnofsky performance-status score of at least 60%. Docetaxel must be used as first-line chemotherapy and administered in three weekly cycles.</i><br><b>NOTE:</b><br><i>A maximum of 10 cycles of treatment with docetaxel will be authorised under this restriction.</i> |                                                                                                                                           |             |                |         |                                          |                                                        |                                                                             |                |
| 8071T                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL | 2           | ..             | ..      | * 660.65                                 | 31.30                                                  | Taxotere                                                                    | SW             |
| 8074Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL     | 1           | ..             | ..      | 1299.91                                  | 31.30                                                  | Taxotere                                                                    | SW             |
| <b>PACLITAXEL</b><br><u>Authority Required</u><br><i>Adjuvant treatment of node-positive breast cancer administered sequentially to an anthracycline and cyclophosphamide;</i><br><i>Advanced breast cancer after failure of prior therapy which includes an anthracycline;</i><br><i>Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound;</i><br><i>Primary treatment of ovarian cancer in combination with a platinum compound;</i><br><i>Locally advanced or metastatic non-small cell lung cancer;</i><br><i>Treatment of HER2 positive early breast cancer in combination with trastuzumab.</i>                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                           |             |                |         |                                          |                                                        |                                                                             |                |
| 3026G                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Solution concentrate for I.V. infusion 30 mg in 5 mL                                                                                      | 5           | ..             | ..      | * 969.64                                 | 31.30                                                  | <sup>a</sup> Anzatax<br><sup>a</sup> Paclitaxel Ebewe<br><sup>a</sup> Taxol | HH<br>IT<br>BQ |
| 8018B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Solution concentrate for I.V. infusion 100 mg in 16.7 mL                                                                                  | 2           | ..             | ..      | * 1284.57                                | 31.30                                                  | <sup>a</sup> Anzatax<br><sup>a</sup> Paclitaxel Ebewe<br><sup>a</sup> Taxol | HH<br>IT<br>BQ |
| 3017T                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Solution concentrate for I.V. infusion 150 mg in 25 mL                                                                                    | 2           | ..             | ..      | * 1868.01                                | 31.30                                                  | <sup>a</sup> Anzatax<br><sup>a</sup> Paclitaxel Ebewe<br><sup>a</sup> Taxol | HH<br>IT<br>BQ |

continued ➡

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                      | Name, Restriction,<br>Manner of Administration and Form                        | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                     |                |
|---------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------------------------------------------------------|----------------|
| 8360B                                                                                                                     | <b>Solution concentrate for I.V. infusion<br/>300 mg in 50 mL</b>              | 1           | ..             | ..      | 1885.41                                  | 31.30                                                  | <sup>a</sup> Anzatax<br><sup>a</sup> Paclitaxel Ebewe<br><sup>a</sup> Taxol              | HH<br>IT<br>BQ |
| <b>Cytotoxic antibiotics and related substances</b>                                                                       |                                                                                |             |                |         |                                          |                                                        |                                                                                          |                |
| <b>• Anthracyclines and related substances</b>                                                                            |                                                                                |             |                |         |                                          |                                                        |                                                                                          |                |
| DOXORUBICIN HYDROCHLORIDE                                                                                                 |                                                                                |             |                |         |                                          |                                                        |                                                                                          |                |
| 1336H                                                                                                                     | Solution for I.V. injection or intravesical<br>administration 10 mg in 5 mL    | 4           | ..             | ..      | * 142.43                                 | 31.30                                                  | <sup>a</sup> Adriamycin<br>Solution<br><sup>a</sup> Doxorubicin Ebewe<br><sup>a</sup> HH | PH<br>IT       |
| 1340M                                                                                                                     | Solution for I.V. injection or intravesical<br>administration 20 mg in 10 mL   | 4           | ..             | ..      | * 245.83                                 | 31.30                                                  | Adriamycin<br>Solution                                                                   | PH             |
| 1342P                                                                                                                     | Solution for I.V. injection or intravesical<br>administration 50 mg in 25 mL   | 3           | ..             | ..      | * 417.32                                 | 31.30                                                  | <sup>a</sup> Adriamycin<br>Solution<br><sup>a</sup> Doxorubicin Ebewe<br><sup>a</sup> HH | PH<br>IT       |
| 8827N                                                                                                                     | Solution for I.V. injection or intravesical<br>administration 100 mg in 50 mL  | 1           | ..             | ..      | 286.20                                   | 31.30                                                  | Doxorubicin Ebewe                                                                        | IT             |
| 8828P                                                                                                                     | Solution for I.V. injection or intravesical<br>administration 200 mg in 100 mL | 1           | ..             | ..      | 551.40                                   | 31.30                                                  | <sup>a</sup> Adriamycin<br><sup>a</sup> Doxorubicin Ebewe                                | PF<br>IT       |
| <b>DOXORUBICIN HYDROCHLORIDE, PEGYLATED<br/>LIPOSOMAL</b>                                                                 |                                                                                |             |                |         |                                          |                                                        |                                                                                          |                |
| <b>Authority Required</b>                                                                                                 |                                                                                |             |                |         |                                          |                                                        |                                                                                          |                |
| <i>Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen;</i>      |                                                                                |             |                |         |                                          |                                                        |                                                                                          |                |
| <i>Metastatic breast cancer, as monotherapy, after failure of prior therapy which includes capecitabine and a taxane;</i> |                                                                                |             |                |         |                                          |                                                        |                                                                                          |                |
| <i>Metastatic breast cancer, as monotherapy, where therapy with capecitabine and/or a taxane is contraindicated.</i>      |                                                                                |             |                |         |                                          |                                                        |                                                                                          |                |
| 8569B                                                                                                                     | <b>Suspension for I.V. infusion 20 mg in<br/>10 mL</b>                         | 1           | ..             | ..      | 702.62                                   | 31.30                                                  | Caelyx                                                                                   | SH             |
| 8570C                                                                                                                     | <b>Suspension for I.V. infusion 50 mg in<br/>25 mL</b>                         | 1           | ..             | ..      | 1621.36                                  | 31.30                                                  | Caelyx                                                                                   | SH             |
| EPIRUBICIN HYDROCHLORIDE                                                                                                  |                                                                                |             |                |         |                                          |                                                        |                                                                                          |                |
| 1375J                                                                                                                     | Solution for injection 10 mg in 5 mL                                           | 4           | ..             | ..      | * 219.35                                 | 31.30                                                  | <sup>a</sup> Epirubicin Ebewe<br><sup>a</sup> Pharmorubicin<br>Solution                  | IT<br>PH       |
| 1376K                                                                                                                     | Solution for injection 20 mg in 10 mL                                          | 4           | ..             | ..      | * 401.07                                 | 31.30                                                  | Pharmorubicin<br>Solution                                                                | PH             |

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                      | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                     |          |
|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------------|----------|
| 1377L                                                                                                                     | Solution for injection 50 mg in 25 mL                   | 4           | ..             | ..      | * 975.67                                 | 31.30                                                  | a Epirubicin Ebewe<br>a Pharmorubicin<br>a HH            | IT<br>PH |
| 9018P                                                                                                                     | Powder for injection 50 mg                              | 4           | ..             | ..      | * 975.67                                 | 31.30                                                  | a HH                                                     |          |
| <b>NOTE:</b><br>The solution for injection 50 mg and powder for injection 50 mg (after reconstitution) are bioequivalent. |                                                         |             |                |         |                                          |                                                        |                                                          |          |
| 8817C                                                                                                                     | Solution for injection 100 mg in 50 mL                  | 2           | ..             | ..      | * 962.65                                 | 31.30                                                  | a Epirubicin Ebewe<br>a HH                               | IT       |
| 8858F                                                                                                                     | Solution for injection 200 mg in 100 mL                 | 1           | ..             | ..      | 948.32                                   | 31.30                                                  | Epirubicin Ebewe                                         | IT       |
| <b>IDARUBICIN HYDROCHLORIDE</b>                                                                                           |                                                         |             |                |         |                                          |                                                        |                                                          |          |
| <b>Restricted Benefit</b><br><i>Acute myelogenous leukaemia.</i>                                                          |                                                         |             |                |         |                                          |                                                        |                                                          |          |
| 2446R                                                                                                                     | Capsule 5 mg                                            | 3           | ..             | ..      | * 246.68                                 | 31.30                                                  | Zavedos                                                  | PH       |
| 2448W                                                                                                                     | Capsule 10 mg                                           | 3           | ..             | ..      | * 451.19                                 | 31.30                                                  | Zavedos                                                  | PH       |
| 8530Y                                                                                                                     | Solution for I.V. injection 5 mg in 5 mL                | 3           | ..             | ..      | 568.45                                   | 31.30                                                  | Zavedos Solution                                         | PH       |
| 8531B                                                                                                                     | Solution for I.V. injection 10 mg in 10 mL              | 6           | ..             | ..      | 2104.37                                  | 31.30                                                  | Zavedos Solution                                         | PH       |
| <b>MITOZANTRONE HYDROCHLORIDE</b>                                                                                         |                                                         |             |                |         |                                          |                                                        |                                                          |          |
| 1932Q                                                                                                                     | Injection 10 mg (base) in 5 mL                          | 1           | ..             | ..      | 157.90                                   | 31.30                                                  | a Mitozantrone<br>a Ebewe<br>a PU                        | IT       |
| 1929M                                                                                                                     | Injection 20 mg (base) in 10 mL                         | 1           | ..             | ..      | 300.18                                   | 31.30                                                  | a Mitozantrone<br>a Ebewe<br>a Onkotrone<br>a HH<br>a PU | IT<br>BX |
| 1930N                                                                                                                     | Injection 25 mg (base) in 12.5 mL                       | 1           | ..             | ..      | 369.02                                   | 31.30                                                  | a Onkotrone<br>a PU                                      | BX       |
| <b>Other antineoplastic agents</b>                                                                                        |                                                         |             |                |         |                                          |                                                        |                                                          |          |
| <b>• Platinum compounds</b>                                                                                               |                                                         |             |                |         |                                          |                                                        |                                                          |          |
| <b>CARBOPLATIN</b>                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                                          |          |
| 1160C                                                                                                                     | Solution for I.V. injection 50 mg in 5 mL               | 2           | ..             | ..      | * 67.87                                  | 31.30                                                  | a Carboplatin Ebewe<br>a HH<br>a PU                      | IT       |
| 1161D                                                                                                                     | Solution for I.V. injection 150 mg in 15 mL             | 6           | ..             | ..      | * 431.51                                 | 31.30                                                  | a Carboplatin Ebewe<br>a HH<br>a PU                      | IT       |

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                 |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------|----|
| 1162E | Solution for I.V. injection 450 mg in 45 mL             | 2           | ..             | ..      | * 279.95                                 | 31.30                                                  | <sup>a</sup> Carboplatin Ebewe<br><sup>a</sup> HH<br><sup>a</sup> PU | IT |
|       | CISPLATIN                                               |             |                |         |                                          |                                                        |                                                                      |    |
| 2578Q | I.V. injection 10 mg in 10 mL                           | 1           | ..             | ..      | 14.42                                    | 15.45                                                  | PU                                                                   |    |
| 2579R | I.V. injection 50 mg in 50 mL                           | 1           | ..             | ..      | 28.60                                    | 29.63                                                  | <sup>a</sup> HH<br><sup>a</sup> PU                                   |    |
| 2580T | I.V. injection 100 mg in 100 mL                         | 1           | ..             | ..      | 60.48                                    | 31.30                                                  | <sup>a</sup> Cisplatin Ebewe<br><sup>a</sup> HH<br><sup>a</sup> PU   | IT |

### OXALIPLATIN

#### Authority Required

*Metastatic colorectal cancer in patients with a WHO performance status of 2 or less, to be used in combination with 5-fluorouracil and folinic acid;*

*Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with 5-fluorouracil and folinic acid, following complete resection of the primary tumour.*

#### NOTE:

*Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.*

*Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.*

|       |                                                       |   |   |    |        |       |                                                                                                                    |                |
|-------|-------------------------------------------------------|---|---|----|--------|-------|--------------------------------------------------------------------------------------------------------------------|----------------|
| 8847P | Solution concentrate for I.V. infusion 50 mg in 10 mL | 1 | 2 | .. | 370.25 | 31.30 | <sup>a</sup> Eloxatin                                                                                              | SW             |
| 8539K | Powder for I.V. infusion 50 mg                        | 1 | 2 | .. | 370.25 | 31.30 | <sup>a</sup> Oxalatin<br><sup>a</sup> Oxaliplatin Ebewe<br><sup>a</sup> Winthrop<br>Oxaliplatin<br><sup>a</sup> HH | ZP<br>IT<br>WA |

#### NOTE:

*The solution concentrate for I.V. infusion 50 mg and powder for I.V. infusion 50 mg (after reconstitution) are bioequivalent.*

|       |                                                        |   |   |    |        |       |                                                                                                                    |                |
|-------|--------------------------------------------------------|---|---|----|--------|-------|--------------------------------------------------------------------------------------------------------------------|----------------|
| 8848Q | Solution concentrate for I.V. infusion 100 mg in 20 mL | 1 | 2 | .. | 701.59 | 31.30 | <sup>a</sup> Eloxatin                                                                                              | SW             |
| 8540L | Powder for I.V. infusion 100 mg                        | 1 | 2 | .. | 701.59 | 31.30 | <sup>a</sup> Oxalatin<br><sup>a</sup> Oxaliplatin Ebewe<br><sup>a</sup> Winthrop<br>Oxaliplatin<br><sup>a</sup> HH | ZP<br>IT<br>WA |

#### NOTE:

*The solution concentrate for I.V. infusion 100 mg and powder for I.V. infusion 100 mg (after reconstitution) are bioequivalent.*

|       |                                                        |   |   |    |         |       |          |    |
|-------|--------------------------------------------------------|---|---|----|---------|-------|----------|----|
| 2310N | Solution concentrate for I.V. infusion 200 mg in 40 mL | 1 | 2 | .. | 1371.19 | 31.30 | Eloxatin | SW |
|-------|--------------------------------------------------------|---|---|----|---------|-------|----------|----|

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>• Monoclonal antibodies</b><br><b>CETUXIMAB</b><br><u>Authority Required</u><br><i>Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx for the week prior to radiotherapy, where cisplatin is contraindicated according to the TGA-approved Product Information;</i><br><i>Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is not tolerated.</i><br><u>NOTE:</u><br><i>No applications for repeats will be authorised.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9136W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Solution for I.V. infusion 100 mg in 20 mL              | 1           | ..             | ..      | 390.63                                   | 31.30                                                  | Erbitux                              | SG |
| 9097T                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Solution for I.V. infusion 100 mg in 50 mL              | 1           | ..             | ..      | 390.63                                   | 31.30                                                  | Erbitux                              | SG |
| 9137X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Solution for I.V. infusion 500 mg in 100 mL             | 1           | ..             | ..      | 1850.93                                  | 31.30                                                  | Erbitux                              | SG |
| <u>Authority Required</u><br><i>Continuing treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is either contraindicated or not tolerated.</i><br><u>NOTE:</u><br><i>A maximum lifetime supply for this indication is limited to a maximum of 8 treatments per site and to 10 treatments per site for patients in whom radiotherapy is interrupted.</i>                                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9138Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Solution for I.V. infusion 100 mg in 20 mL              | 1           | 6              | ..      | 390.63                                   | 31.30                                                  | Erbitux                              | SG |
| 9098W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Solution for I.V. infusion 100 mg in 50 mL              | 1           | 6              | ..      | 390.63                                   | 31.30                                                  | Erbitux                              | SG |
| 9139B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Solution for I.V. infusion 500 mg in 100 mL             | 1           | 6              | ..      | 1850.93                                  | 31.30                                                  | Erbitux                              | SG |
| <b>RITUXIMAB</b><br><u>Authority Required</u><br><i>Relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma;</i><br><i>Relapsed or refractory follicular B-cell non-Hodgkin's lymphoma.</i>                                                                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8293L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Solution for I.V. infusion 100 mg in 10 mL              | 2           | 3              | ..      | 947.64                                   | 31.30                                                  | Mabthera                             | RO |
| 8294M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Solution for I.V. infusion 500 mg in 50 mL              | 1           | 3              | ..      | 2339.56                                  | 31.30                                                  | Mabthera                             | RO |

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|       |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| 8665C | Solution for I.V. infusion 100 mg in 10 mL              | 2           | 7              | ..      | 947.64                      | 31.30                                       | Mabthera                             | RO |
| 8666D | Solution for I.V. infusion 500 mg in 50 mL              | 1           | 7              | ..      | 2339.56                     | 31.30                                       | Mabthera                             | RO |

### **Authority Required**

*Treatment of previously untreated, CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy;*

*Treatment of symptomatic patients with previously untreated, CD20 positive, Stage III or IV, follicular, B-cell non-Hodgkin's lymphoma, in combination with chemotherapy.*

### • **Protein kinase inhibitors**

#### **DASATINIB**

#### **NOTE:**

Any queries concerning the arrangements to prescribe dasatinib may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).

Any queries concerning patients who are enrolled on the Dasatinib Compassionate Program may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe dasatinib should be forwarded to:

Medicare Australia

Prior Written Approval of Specialised Drugs

Reply Paid 9826

GPO Box 9826

HOBART TAS 7001

### **Authority Required**

*Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in any disease phase bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has active leukaemia (as defined by presence on current pathology assessments of either the Philadelphia chromosome on cytogenetic or FISH analysis, or the presence of the transcript BCR-ABL and morphological evidence of leukaemia) and who has failed an adequate trial of imatinib.*

*Failure of an adequate trial of imatinib is defined as:*

*(i) Lack of response to initial imatinib therapy, defined as either:*

*— failure to achieve a haematological response after a minimum of 3 months therapy with imatinib for patients initially treated in chronic phase; or*

*— failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or*

*— failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12 months therapy with imatinib; OR*

*(ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib therapy (Note: a BCR/ABL qPCR greater than 1% alone is not evidence of loss of response);*

**OR**

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

(iii) *Development of accelerated phase or blast crisis in a patient previously prescribed imatinib for any phase of chronic myeloid leukaemia.*

*Accelerated phase is defined by the presence of 1 or more of the following:*

- (1) *Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or*
- (2) *Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%; or*

- (3) *Peripheral basophils greater than or equal to 20%; or*

- (4) *Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or*

- (5) *Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome).*

*Blast crisis is defined as either:*

- (1) *Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or*
- (2) *Extramedullary involvement other than spleen and liver; OR*

*(iv) Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib therapy in patients with accelerated phase or blast crisis chronic myeloid leukaemia;*

*OR*

*(v) Detection of a mutation in BCR-ABL (L248V, G250E, Q252H/R, Y253H/F, E255K/V, H396P/R, and D276G) that infers high level imatinib resistance. (Patients with these mutations but without active leukaemia, will not be approved);*

*OR*

- (vi) *Grade 3 or 4 non-haematological toxicity that is imatinib related.*

*Applications for authorisation must be in writing and must include:*

- (a) *a completed authority prescription form; and*
- (b) *a completed Chronic Myeloid Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and*
- (c) *a signed patient acknowledgement; and*
- (d) *a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of chronic myeloid leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. (The date of the relevant pathology report needs to be provided); and*
- (e) *a copy of the current confirming pathology report(s) from an Approved Pathology Authority or details of the dates of assessment in the case of progressive splenomegaly or extramedullary involvement or details of Grade 3 or 4 non-haematological toxicity.*

### **NOTE:**

*Dasatinib will only be subsidised for patients with chronic myeloid leukaemia who are not receiving concomitant PBS-subsidised imatinib mesylate, nilotinib or interferon alfa therapy.*

*Patients should be commenced on a dose of dasatinib of at least 100 mg (base) daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to dasatinib therapy or a peripheral blood BCR-ABL level of less than 1% at 12 monthly intervals, irrespective of the daily dasatinib dose received.*

*Dasatinib is not PBS-subsidised for patients with CML that is resistant to nilotinib.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### **Authority Required**

*Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial treatment with dasatinib as a pharmaceutical benefit for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to dasatinib in the preceding 12 months.*

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Chronic Myeloid Leukaemia Dasatinib Authority Application Form for continuing treatment; and*
- (3) demonstration of continued response to treatment as evidenced by either:*
  - (a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided; or*
  - (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided.*

### **NOTE:**

*Definitions of response.*

*A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.*

*A bone marrow or peripheral blood BCR-ABL level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.*

*Authority approval requirements.*

*For the purposes of assessing response to PBS-subsidised treatment with dasatinib, either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted. For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with BCR-ABL specific probe must be submitted. The cytogenetic or peripheral blood quantitative PCR analyses must be submitted as follows:*

- (i) between 10 and 12 months of the commencement of treatment with dasatinib, at which time patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and*
- (ii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been sustained.*

*For each authority application where eligibility for continuing PBS-subsidised treatment is to be demonstrated, a copy of the cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or a copy of the quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted as described in (i) and (ii) above. For bone marrow analyses, where the standard karyotyping conducted at the time of application is not informative, a copy of a cytogenetic analysis conducted on the bone marrow using FISH with BCR-ABL specific probe must be submitted with the authority application. A copy of the non-informative standard karyotype analysis must be included with the authority application.*

*Where a patient has previously received PBS-subsidised treatment with dasatinib, no approval will be granted for PBS-subsidised re-treatment where that patient has at any time failed to meet the criteria for continuing treatment.*

|       |              |    |   |    |         |       |         |    |
|-------|--------------|----|---|----|---------|-------|---------|----|
| 2478K | Tablet 20 mg | 60 | 5 | .. | 3245.93 | 31.30 | Sprycel | BQ |
| 2482P | Tablet 50 mg | 60 | 5 | .. | 5250.25 | 31.30 | Sprycel | BQ |
| 2485T | Tablet 70 mg | 60 | 5 | .. | 6464.58 | 31.30 | Sprycel | BQ |



## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### Authority Required

*Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has failed treatment with chemotherapy AND imatinib and where appropriate, allogeneic haemopoietic stem cell transplantation.*

*Failure of treatment is defined as either:*

- (i) Failure to achieve a complete morphological and cytogenetic remission after a minimum of 2 months treatment with intensive chemotherapy and imatinib;*
- (ii) Morphological or cytogenetic relapse of leukaemia after achieving a complete remission induced by chemotherapy and imatinib;*
- (iii) Morphological or cytogenetic relapse or persistence of leukaemia after allogeneic haemopoietic stem cell transplantation.*

*Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR*

*the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.*

*The first authority application must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and*
- (c) a signed patient acknowledgement; and*
- (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided.*

### Authority Required

*Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has been treated prior to 1 December 2007 and has failed treatment with chemotherapy and where appropriate, allogeneic haemopoietic stem cell transplantation.*

*Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR*

*the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.*

*The first authority application must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and*
- (c) a signed patient acknowledgement; and*
- (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided.*

continued ➡

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

### Authority Required

*Continuing treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, where the patient has previously been issued with an authority prescription for dasatinib and does not have progressive disease.*

*Authority applications for continuing treatment may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

### NOTE:

*Dasatinib will only be subsidised for patients with acute lymphoblastic leukaemia who are not receiving concomitant PBS-subsidised imatinib mesylate and who are not appropriate for an allogeneic haemopoietic stem cell transplant.*

|       |              |    |   |    |         |       |         |    |
|-------|--------------|----|---|----|---------|-------|---------|----|
| 9125G | Tablet 20 mg | 60 | 2 | .. | 3245.93 | 31.30 | Sprycel | BQ |
| 9126H | Tablet 50 mg | 60 | 2 | .. | 5250.25 | 31.30 | Sprycel | BQ |
| 9127J | Tablet 70 mg | 60 | 2 | .. | 6464.58 | 31.30 | Sprycel | BQ |

### NOTE:

*No applications for increased repeats will be authorised.*

### ERLOTINIB

### Authority Required

*Initial PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer with a WHO performance status of 3 or less, after prior treatment with platinum-based chemotherapy, where:*

- (1) (a) disease progression has occurred following treatment with docetaxel or pemetrexed; or*
- (b) treatment with docetaxel and pemetrexed is either contraindicated or cannot be tolerated; and*
- (2) further cytotoxic chemotherapy is not appropriate.*

### Authority Required

*Continuing PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer who has previously been issued with an authority prescription for this drug and who does not have progressive disease.*

### Authority Required

*Initial PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer, after prior treatment with platinum-based chemotherapy:*

- (1) where:*
  - (a) disease progression occurred following treatment with docetaxel or pemetrexed; or*
  - (b) treatment with docetaxel and pemetrexed was either contraindicated or could not be tolerated; and*
- (2) who has received treatment with erlotinib under the Erlotinib Access Programme prior to 1 August 2008; and*
- (3) who does not have progressive disease.*

|       |                                  |    |   |    |         |       |         |    |
|-------|----------------------------------|----|---|----|---------|-------|---------|----|
| 9166K | Tablet 25 mg (as hydrochloride)  | 30 | 3 | .. | 793.76  | 31.30 | Tarceva | RO |
| 9167L | Tablet 100 mg (as hydrochloride) | 30 | 3 | .. | 2702.91 | 31.30 | Tarceva | RO |
| 9168M | Tablet 150 mg (as hydrochloride) | 30 | 3 | .. | 3309.23 | 31.30 | Tarceva | RO |

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

## GEFITINIB

### NOTE:

Any queries concerning the arrangements to prescribe gefitinib may be directed to Medicare Australia on 1800 700 270.

Written applications for authority to prescribe gefitinib should be forwarded to:

Medicare Australia

Prior Written Approval of Specialised Drugs

Reply Paid 9826

GPO Box 9826

HOBART TAS 7001

### Authority Required

Initial PBS-subsidised treatment, as monotherapy, of locally advanced or metastatic non-small cell lung cancer in patients with a WHO performance status of 2 or less, where:

- (1) disease progression has occurred following treatment with at least 1 chemotherapy agent; and
- (2) there is evidence that the patient has an activating mutation(s) of the epidermal growth factor receptor (EGFR) gene in tumour material. The mutation(s) must be demonstrated by analysis of the DNA sequence of the EGFR gene.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Gefitinib (Iressa) PBS Authority Application for Use in the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer - Supporting Information Form [may be downloaded from the Medicare Australia website (visit [www.medicareaustralia.gov.au/providers/forms/pbs.htm](http://www.medicareaustralia.gov.au/providers/forms/pbs.htm) and click on 'Medical Practitioners')]; and
- (3) details of the prior chemotherapy including the name(s) of drug(s) and date of the most recent treatment cycle; and
- (4) details of the patient's WHO performance status; and
- (5) a copy of the pathology report providing evidence of the presence of activating mutation(s) of the EGFR gene from an Approved Pathology Authority.

### Authority Required

Continuing PBS-subsidised treatment, as monotherapy, of locally advanced or metastatic non-small cell lung cancer in patients with a WHO performance status of 2 or less, where the patient has previously been issued with an authority prescription for gefitinib.

Applications for continuing treatment may be made in writing or on the telephone by contacting Medicare Australia on 1800 700 270.

|       |               |    |   |    |         |       |        |    |
|-------|---------------|----|---|----|---------|-------|--------|----|
| 8769M | Tablet 250 mg | 30 | 1 | .. | 3850.93 | 31.30 | Iressa | AP |
|-------|---------------|----|---|----|---------|-------|--------|----|

### NOTE:

No applications for increased maximum quantities and/or repeats will be authorised.

## IMATINIB

### NOTE:

Any queries concerning the arrangements to prescribe imatinib mesylate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).

Written applications for authority to prescribe imatinib mesylate should be forwarded to:

continued ☞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### **Medicare Australia**

**Prior Written Approval of Specialised Drugs**

**Reply Paid 9826**

**GPO Box 9826**

**HOBART TAS 7001**

*For the following diseases, written authority is required at initiation and for continuation:*

*Chronic myeloid leukaemia (chronic phase);*

*Dermatofibrosarcoma protuberans;*

*Hypereosinophilic syndrome;*

*Chronic eosinophilic leukaemia;*

*Myelodysplastic or myeloproliferative disorder;*

*Aggressive systemic mastocytosis with eosinophilia.*

### **NOTE:**

*Imatinib mesylate is not PBS-subsidised for the treatment of patients with resectable malignant gastrointestinal stromal tumours.*

### **Authority Required**

*Initial PBS-subsidised treatment, for up to 3 months, of adult patients with a metastatic or unresectable malignant gastrointestinal stromal tumour which has been histologically confirmed by the detection of CD117 on immunohistochemical staining.*

*Patients who have not previously been treated with imatinib mesylate for a metastatic or unresectable malignant gastrointestinal stromal tumour must commence treatment at a dose not exceeding 400 mg per day for at least 3 months. Authority prescriptions for a higher dose will not be approved during this initial 3 month treatment period.*

*Patients who have previously been treated with non-PBS-subsidised imatinib mesylate for a metastatic or unresectable malignant gastrointestinal stromal tumour are eligible to receive up to 3 months treatment at a dose of up to 600 mg per day.*

*Applications for authorisation must be in writing and must include:*

*(1) a completed authority prescription form; and*

*(2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*

*(i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and*

*(ii) a copy of the most recent (within 2 months of the application) computed tomography (CT) scan, magnetic resonance imaging (MRI) or ultrasound assessment of the tumour(s), including whether or not there is evidence of metastatic disease; and*

*(iii) where the application for authority to prescribe is being sought on the basis of an unresectable tumour, written evidence in support of that claim must be provided; and*

*(iv) for patients who commenced treatment with imatinib mesylate for a metastatic or unresectable malignant gastrointestinal stromal tumour prior to 1 December 2004, the date on which therapy with imatinib mesylate was commenced.*

### **Authority Required**

*Continuing PBS-subsidised treatment, at a dose of up to 600 mg per day, of adult patients with a metastatic or unresectable malignant gastrointestinal stromal tumour who have previously been issued with an authority prescription for this drug.*

*Applications for continuing treatment may be made by telephone (1800 700 270, hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

**NOTE:**

*Patients who achieve a response to treatment at an imatinib dose of 400 mg per day should be continued at this dose and assessed for response at regular intervals. Patients who fail to achieve a response to 400 mg per day may have their dose increased to 600 mg per day. Authority applications for doses higher than 600 mg per day will not be approved.*

*A response to treatment is defined as a decrease from baseline in the sum of the products of the perpendicular diameters of all measurable lesions of 50% or greater. (Response definition based on the Southwest Oncology Group standard criteria, see Demetri et al. N Engl J Med 2002; 347: 472-80.)*

|       |                             |    |   |    |         |       |        |    |
|-------|-----------------------------|----|---|----|---------|-------|--------|----|
| 9111M | Tablet 100 mg (as mesylate) | 60 | 2 | .. | 2032.10 | 31.30 | Glivec | NV |
| 9112N | Tablet 400 mg (as mesylate) | 30 | 2 | .. | 3918.26 | 31.30 | Glivec | NV |

**NOTE:**

*No applications for increased repeats will be authorised.*

**Authority Required**

*Initial treatment of patients in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia.*

*Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy from the date the first application for initial treatment was approved.*

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))]; and*
- (3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the bcr-abl transcript in either peripheral blood or bone marrow; and*
- (4) a copy of a signed patient acknowledgement form indicating that the patient understands and acknowledges that PBS-subsidised treatment with imatinib mesylate for the chronic phase of chronic myeloid leukaemia will cease if subsequent testing demonstrates that:*
  - (i) the patient has failed to achieve a major cytogenetic response within the initial 18 months of treatment [see Note defining major cytogenetic response]; or*
  - (ii) the patient has failed to sustain a major cytogenetic response for 12 months from the date of the last pathology report that indicated that a major cytogenetic response had been achieved [see Note defining major cytogenetic response].*

**NOTE:**

*Imatinib mesylate in the chronic phase of chronic myeloid leukaemia will only be subsidised for patients who are not receiving concomitant PBS-subsidised interferon alfa therapy.*

*Patients should be commenced on a dose of imatinib mesylate of 400 mg (base) daily and maintained on a minimum dose of imatinib mesylate of 400 mg (base) daily. Prescribing of lower doses should be carefully considered.*

*Continuing therapy is dependent on patients demonstrating a response to imatinib mesylate therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter, irrespective of the daily imatinib mesylate dose received.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### Authority Required

*Continuing treatment of patients who have received initial treatment with imatinib mesylate as a pharmaceutical benefit for the chronic phase of chronic myeloid leukaemia and who have demonstrated either a major cytogenetic response or less than 1% bcr-abl level in the blood in the preceding 12 months.*

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) demonstration of continued response to treatment as evidenced by either:*
  - (a) major cytogenetic response [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided; or*
  - (b) a peripheral blood level of bcr-abl of less than 1% on the international scale [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided.*

### NOTE:

*Definitions of response.*

*A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.*

*A peripheral blood bcr-abl level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.*

*Authority approval requirements.*

*For the purposes of assessing response to PBS-subsidised treatment with imatinib mesylate, either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of bcr-abl transcript in the peripheral blood using the international scale, must be submitted. For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with bcr-abl specific probe must be submitted. The cytogenetic or peripheral blood quantitative PCR analyses must be submitted as follows:*

- (i) between 10 and 12 months of the commencement of treatment with imatinib mesylate, at which time patients in whom a major cytogenetic response or peripheral blood bcr-abl level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and*
- (ii) within 18 months of the commencement of treatment with imatinib mesylate, in patients who have failed to demonstrate a major cytogenetic response or peripheral blood bcr-abl level of less than 1% at between 10 and 12 months (patients in whom a major cytogenetic response or peripheral blood bcr-abl level of less than 1% is demonstrable by 18 months may also receive authorisation for a further 12 months of treatment); and*
- (iii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood bcr-abl level of less than 1% has been sustained.*

*For each authority application where eligibility for continuing PBS-subsidised treatment is to be demonstrated, a copy of the cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or a copy of the quantitative PCR indicating the relative level of bcr-abl transcript in the peripheral blood using the international scale, must be submitted as described in (i) to (iii) above. For bone marrow analyses, where the standard karyotyping conducted at the time of application is not informative, a copy of a cytogenetic analysis conducted on the bone marrow using FISH with bcr-abl specific probe must be submitted with the authority application. A copy of the non-informative standard karyotype analysis must be included with the authority application.*

*Where a patient has previously received PBS-subsidised treatment with imatinib mesylate, no approval will be granted for PBS-subsidised re-treatment in the chronic phase of chronic myeloid leukaemia, where that patient has at any time failed to meet the criteria for continuing treatment.*

|       |                             |    |   |    |         |       |        |    |
|-------|-----------------------------|----|---|----|---------|-------|--------|----|
| 9113P | Tablet 100 mg (as mesylate) | 60 | 5 | .. | 2032.10 | 31.30 | Glivec | NV |
| 9114Q | Tablet 400 mg (as mesylate) | 30 | 5 | .. | 3918.26 | 31.30 | Glivec | NV |

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

**NOTE:**

No applications for increased repeats will be authorised.

**Authority Required**

*Treatment of patients in the accelerated phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia. Progress to the accelerated phase is defined by the presence of 1 or more of the following:*

- (1) *Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or*
- (2) *Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%; or*
- (3) *Peripheral basophils greater than or equal to 20%; or*
- (4) *Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or*
- (5) *Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome).*

*Applications for authorisation must be in writing and must include:*

- (a) *a completed authority prescription form; and*
- (b) *a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form, stating which of the above criteria are satisfied by the patient; and*
- (c) *a copy of the confirming pathology report from an Approved Pathology Authority in the case of criteria (1), (2), (3) and (5) above, or details of the dates of assessments in the case of progressive splenomegaly.*

**Authority Required**

*Treatment of patients in the blast phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia. Progress to myeloid blast crisis is defined as either:*

- (1) *Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or*
- (2) *Extramedullary involvement other than spleen and liver.*

*Applications for authorisation must be in writing and must include:*

- (a) *a completed authority prescription form; and*
- (b) *a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form, stating which of the above criteria are satisfied by the patient; and*
- (c) *a copy of the confirming pathology report from an Approved Pathology Authority in the case of criterion (1) above, or details of the date of assessment in the case of extramedullary involvement.*

**Authority Required**

*Continuing treatment of patients with chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, where the patient has previously received PBS-subsidised treatment with imatinib mesylate of:*

- (a) *the accelerated phase of chronic myeloid leukaemia; or*
- (b) *the blast phase of chronic myeloid leukaemia.*

|       |                             |    |   |    |         |       |        |    |
|-------|-----------------------------|----|---|----|---------|-------|--------|----|
| 9115R | Tablet 100 mg (as mesylate) | 60 | 2 | .. | 2032.10 | 31.30 | Glivec | NV |
| 9116T | Tablet 400 mg (as mesylate) | 30 | 2 | .. | 3918.26 | 31.30 | Glivec | NV |

**NOTE:**

No applications for increased repeats will be authorised.

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### **Authority Required**

*Initial treatment in combination with chemotherapy as induction or consolidation of a newly diagnosed patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL.*

*The first authority application must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Acute Lymphoblastic Leukaemia Imatinib PBS Authority Application - Supporting Information Form; and*
- (c) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of acute lymphoblastic leukaemia to confirm eligibility for treatment, with either cytogenetic evidence of the Philadelphia chromosome, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow. (The date of the relevant pathology report needs to be provided); and*
- (d) a signed patient acknowledgement.*

### **Authority Required**

*Initial treatment of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript BCR-ABL who was previously treated with imatinib mesylate under the Imatinib Compassionate Program and who meets all the PBS criteria.*

*The first authority application must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Acute Lymphoblastic Leukaemia Imatinib PBS Authority Application - Supporting Information Form; and*
- (c) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of acute lymphoblastic leukaemia to confirm eligibility for treatment, with either cytogenetic evidence of the Philadelphia chromosome, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow. (The date of the relevant pathology report needs to be provided); and*
- (d) a signed patient acknowledgement.*

### **Authority Required**

*Continuing treatment in combination with chemotherapy as maintenance of first complete remission of patients with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL.*

*Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Imatinib mesylate is available with a lifetime maximum of 24 months imatinib mesylate therapy for patients with acute lymphoblastic leukaemia reimbursed through the PBS.*

*Any queries concerning the arrangements to prescribe imatinib mesylate beyond 24 months may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

### **NOTE:**

*Allogeneic stem cell transplantation is the preferred therapy for eligible patients achieving a complete remission of Philadelphia positive acute lymphoblastic leukaemia.*

|       |                             |    |   |    |         |       |        |    |
|-------|-----------------------------|----|---|----|---------|-------|--------|----|
| 9123E | Tablet 100 mg (as mesylate) | 60 | 2 | .. | 2032.10 | 31.30 | Glivec | NV |
| 9124F | Tablet 400 mg (as mesylate) | 30 | 2 | .. | 3918.26 | 31.30 | Glivec | NV |

### **NOTE:**

*No applications for increased repeats will be authorised.*



## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### Authority Required

*Initial PBS-subsidised treatment of a patient with unresectable, locally recurrent or metastatic dermatofibrosarcoma protuberans.*

*Maximum dose: 800 mg per day.*

- (1) Where the application for authority to prescribe is being sought on the basis of unresectable tumour, written evidence in support of that claim must be provided; and*
- (2) Where the application for authority to prescribe is being sought on the basis of locally recurrent disease, the site of the local recurrence must be specified; and*
- (3) Where the application for authority to prescribe is being sought on the basis of metastatic disease, the site(s) of metastatic disease must be provided.*

*Applications for authorisation for initial treatment must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and*
- (c) a signed patient acknowledgement.*

### Authority Required

*Continuing PBS-subsidised treatment of a patient with unresectable, locally recurrent or metastatic dermatofibrosarcoma protuberans who has previously been issued with an authority prescription for imatinib and who has demonstrated a response, but whose disease remains unresectable.*

*Maximum dose: 800 mg per day.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and*
- (c) a statement that the disease has not progressed on imatinib therapy.*

|       |                             |    |   |    |         |       |        |    |
|-------|-----------------------------|----|---|----|---------|-------|--------|----|
| 9172R | Tablet 100 mg (as mesylate) | 60 | 2 | .. | 2032.10 | 31.30 | Glivec | NV |
| 9173T | Tablet 400 mg (as mesylate) | 30 | 2 | .. | 3918.26 | 31.30 | Glivec | NV |

### NOTE:

*No applications for increased repeats will be authorised.*

### Authority Required

*Initial PBS-subsidised treatment of a patient with hypereosinophilic syndrome or chronic eosinophilic leukaemia requiring treatment and confirmed to carry the FIP1L1-PDGfra fusion gene.*

*Maximum dose: 400 mg per day.*

*Applications for authorisation for initial treatment must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and*
- (c) a copy of the pathology report confirming the presence of the FIP1L1-PDGfra fusion gene; and*
- (d) a copy of the full blood examination report confirming the presence of hypereosinophilic syndrome or chronic eosinophilic leukaemia; and*
- (e) details of organ involvement requiring treatment, including a copy of the radiology, nuclear medicine, respiratory function or anatomical pathology reports as appropriate; and*
- (f) a signed patient acknowledgement.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

### Authority Required

*Continuing PBS-subsidised treatment of a patient with hypereosinophilic syndrome or chronic eosinophilic leukaemia who has previously been issued with an authority prescription for imatinib and who has achieved and maintained a complete haematological response.*

*Maximum dose: 400 mg per day.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and*
- (c) a copy of the full blood examination report which demonstrates a complete haematological response, with a normal eosinophil count; and*
- (d) a statement that the disease has not progressed on imatinib therapy.*

|       |                             |    |   |    |         |       |        |    |
|-------|-----------------------------|----|---|----|---------|-------|--------|----|
| 9174W | Tablet 100 mg (as mesylate) | 60 | 2 | .. | 2032.10 | 31.30 | Glivec | NV |
| 9175X | Tablet 400 mg (as mesylate) | 30 | 2 | .. | 3918.26 | 31.30 | Glivec | NV |

### NOTE:

*No applications for increased repeats will be authorised.*

### Authority Required

*Initial PBS-subsidised treatment of a patient with a myelodysplastic or myeloproliferative disorder where:*

- (1) there is confirmed evidence of a platelet-derived growth factor receptor (PDGFR) gene re-arrangement either by standard karyotyping, or FISH or PDGFRB fusion gene transcript; and*
- (2) the patient has previously failed an adequate trial of one or more of the following conventional therapies:*
  - cytarabine;*
  - etoposide;*
  - hydroxyurea.*

*Maximum dose: 400 mg per day.*

*Applications for authorisation for initial treatment must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and*
- (c) a copy of the pathology report confirming the platelet-derived growth factor receptor (PDGFR) gene re-arrangement; and*
- (d) a copy of the bone marrow biopsy report which demonstrates the presence of a myelodysplastic or myeloproliferative disorder; and*
- (e) details of the prior therapy trialled and the response; and*
- (f) a signed patient acknowledgement.*

### Authority Required

*Continuing PBS-subsidised treatment of a patient with a PDGFRB fusion gene-positive myelodysplastic or myeloproliferative disorder who has previously been issued with an authority prescription for imatinib and who has demonstrated a clinically significant response.*

*Maximum dose: 400 mg per day.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and*
- (c) a statement that the disease has not progressed on imatinib therapy.*

continued ➡

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 9176Y | Tablet 100 mg (as mesylate)                             | 60          | 2              | ..      | 2032.10                                  | 31.30                                                  | Glivec                               | NV |
| 9177B | Tablet 400 mg (as mesylate)                             | 30          | 2              | ..      | 3918.26                                  | 31.30                                                  | Glivec                               | NV |

**NOTE:**

No applications for increased repeats will be authorised.

### Authority Required

Initial PBS-subsidised treatment of a patient with aggressive systemic mastocytosis with eosinophilia where:

- (1) there is confirmed evidence of the FIP1L1-PDGFRA fusion gene; and
- (2) the patient has previously failed an adequate trial of one or more of the following conventional therapies:
  - corticosteroids;
  - hydroxyurea.

Maximum dose: 400 mg per day.

Applications for authorisation for initial treatment must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and
- (c) a copy of the pathology report confirming the presence of the FIP1L1-PDGFRA fusion gene; and
- (d) a copy of the bone marrow biopsy report and/or other tissue biopsy report confirming the diagnosis of aggressive systemic mastocytosis and a copy of the full blood examination report demonstrating eosinophilia; and
- (e) details of symptomatic organ involvement requiring treatment, including a copy of the radiology, nuclear medicine, respiratory function or anatomical pathology reports as appropriate; and
- (f) details of prior treatment trialled and the response; and
- (g) a signed patient acknowledgement.

### Authority Required

Continuing PBS-subsidised treatment of a patient with aggressive systemic mastocytosis confirmed to carry the FIP1L1-PDGFRA fusion gene, who has previously been issued with an authority prescription for imatinib and who has demonstrated a clinically significant response.

Maximum dose: 400 mg per day.

Applications for authorisation must be made in writing and must include:

- (a) a completed authority prescription form; and
- (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and
- (c) a statement that the disease has not progressed on imatinib therapy.

|       |                             |    |   |    |         |       |        |    |
|-------|-----------------------------|----|---|----|---------|-------|--------|----|
| 9178C | Tablet 100 mg (as mesylate) | 60 | 2 | .. | 2032.10 | 31.30 | Glivec | NV |
| 9179D | Tablet 400 mg (as mesylate) | 30 | 2 | .. | 3918.26 | 31.30 | Glivec | NV |

**NOTE:**

No applications for increased repeats will be authorised.

### LAPATINIB

**NOTE:**

Any queries concerning the arrangements to prescribe lapatinib may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Lapatinib should not be used in patients with a left ventricular ejection fraction (LVEF) of less than 45% or with symptomatic heart failure. Cardiac function must be tested by a suitable method including, for example, ECHO or MUGA, prior to seeking the initial authority approval and then at 3 monthly intervals during treatment.

continued ➡

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Lapatinib is not PBS-subsidised when used in combination with Commonwealth-subsidised trastuzumab. Once PBS-subsidised lapatinib has been commenced, a patient cannot subsequently receive Commonwealth-subsidised trastuzumab.*

*If disease progression occurs, the prescribing doctor must contact Medicare Australia within one week on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) and lapatinib treatment must be ceased immediately.*

### Authority Required

*Initial treatment, in combination with capecitabine, of a patient with HER2 positive metastatic breast cancer (equivalent to Stage IIIC or Stage IV) who has received prior therapy with an anthracycline and a taxane, each for at least 3 cycles, and whose disease has progressed despite treatment with trastuzumab for metastatic disease.*

*Authority applications for initial treatment must be made in writing and must include:*

- (a) a completed authority prescription form;*
- (b) a pathology report demonstrating HER2 positivity has been demonstrated by in situ hybridisation (ISH);*
- (c) date of last treatment with a taxane and total number of cycles;*
- (d) date of last treatment with an anthracycline and total number of cycles;*
- (e) a signed patient acknowledgment;*
- (f) dates of treatment with trastuzumab; and*
- (g) date of demonstration of progression whilst on treatment with trastuzumab.*

### NOTE:

*Treatment with trastuzumab for metastatic disease is defined as trastuzumab administered alone or in combination with chemotherapy for at least 6 weeks at standard doses.*

### Authority Required

*Initial treatment, in combination with capecitabine, of a patient with HER2 positive metastatic breast cancer who was receiving treatment with lapatinib prior to 1 May 2008.*

*Authority applications for initial PBS-subsidised treatment must be made in writing and must include:*

- (a) a completed authority prescription form;*
- (b) a pathology report demonstrating that HER2 positivity has been demonstrated by in situ hybridisation (ISH);*
- (c) a signed patient acknowledgment; and*
- (d) the date the patient commenced non-PBS-subsidised treatment with lapatinib.*

### Authority Required

*Continuing treatment, in combination with capecitabine, of a patient with HER2 positive metastatic breast cancer who has previously received treatment with PBS-subsidised lapatinib and who does not have progressive disease.*

*Authority applications must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a statement from the prescribing doctor that the disease has not progressed.*

|       |                                           |     |   |    |           |       |        |    |
|-------|-------------------------------------------|-----|---|----|-----------|-------|--------|----|
| 9148L | Tablet 250 mg (as ditosylate monohydrate) | 140 | 2 | .. | * 3387.03 | 31.30 | Tykerb | GK |
|-------|-------------------------------------------|-----|---|----|-----------|-------|--------|----|

### NOTE:

*No applications for increased maximum quantities and/or repeats will be authorised.*

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

## NILOTINIB

### NOTE:

Any queries concerning the arrangements to prescribe nilotinib may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).

Any queries concerning patients who are enrolled on the Nilotinib Compassionate Program may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Applications for authority to prescribe nilotinib should be forwarded to:

Medicare Australia

Prior Written Approval of Specialised Drugs

Reply Paid 9826

GPO Box 9826

HOBART TAS 7001

### Authority Required

Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in chronic or accelerated phase bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has active leukaemia (as defined by presence on current pathology assessments of either the Philadelphia chromosome on cytogenetic or FISH analysis, or the presence of the transcript BCR-ABL and morphological evidence of leukaemia in sites other than peripheral blood) and who has failed an adequate trial of imatinib.

Failure of an adequate trial of imatinib is defined as:

(i) Lack of response to initial imatinib therapy, defined as either:

— failure to achieve a haematological response after a minimum of 3 months therapy with imatinib for patients initially treated in chronic phase; or

— failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or

— failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12 months therapy with imatinib; OR

(ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib therapy (Note: a BCR/ABL qPCR greater than 1% alone is not evidence of loss of response);

OR

(iii) Development of accelerated phase in a patient previously prescribed imatinib for the chronic phase of chronic myeloid leukaemia.

Accelerated phase is defined by the presence of 1 or more of the following:

(1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or

(2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%, provided that blast count is less than 30%; or

(3) Peripheral basophils greater than or equal to 20%; or

(4) Progressive splenomegaly to a size greater than or equal to 10 cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or

(5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome); OR

continued ➡

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

(iv) *Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib therapy in patients with accelerated phase chronic myeloid leukaemia, provided that blast crisis has been excluded on bone marrow biopsy;*

OR

(v) *Detection of a mutation in BCR-ABL (L248V, G250E, Q252H/R, Y253H/F, E255K/V, H396P/R, and D276G) that infers high level imatinib resistance. (Patients with these mutations but without active leukaemia, will not be approved);*

OR

(vi) *Grade 3 or 4 non-haematological toxicity that is imatinib related.*

*Applications for authorisation must be in writing and must include:*

*(a) a completed authority prescription form; and*

*(b) a completed Chronic Myeloid Leukaemia Nilotinib PBS Authority Application - Supporting Information Form; and*

*(c) a signed patient acknowledgement; and*

*(d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of chronic myeloid leukaemia in bone marrow plus qualitative RT-PCR evidence of BCR-ABL transcript. (The date of the relevant pathology report needs to be provided); and*

*(e) details of Grade 3 or 4 non-haematological imatinib related toxicity.*

### **NOTE:**

*Nilotinib will only be subsidised for patients with chronic myeloid leukaemia who are not receiving concomitant PBS-subsidised imatinib mesylate, dasatinib or interferon alfa therapy.*

*Patients should be commenced on a dose of nilotinib of 400 mg twice daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to nilotinib therapy or a peripheral blood BCR-ABL level of less than 1% at 12 monthly intervals, irrespective of the daily nilotinib dose received.*

*Nilotinib is not PBS-subsidised for patients with CML that is resistant to dasatinib.*

*Nilotinib is not TGA-registered and not PBS-subsidised for patients with CML in blast crisis.*

*Requests for doses of greater than nilotinib 400 mg twice daily will not be approved.*

### **Authority Required**

*Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial treatment with nilotinib as a pharmaceutical benefit for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to nilotinib in the preceding 12 months.*

*Applications for authorisation must be in writing and must include:*

*(1) a completed authority prescription form; and*

*(2) a completed Chronic Myeloid Leukaemia Nilotinib Authority Application Form for continuing treatment; and*

*(3) demonstration of continued response to treatment as evidenced by either:*

*(a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided; or*

*(b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### NOTE:

#### Definitions of response.

A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells.

A bone marrow or peripheral blood BCR-ABL level of less than 1% on the international scale (Blood 108: 28-37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response.

#### Authority approval requirements.

For the purposes of assessing response to PBS-subsidised treatment with nilotinib, either cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted. For bone marrow analyses, where the standard karyotyping is not informative for technical reasons, a cytogenetic analysis performed on the bone marrow by the use of fluorescence in situ hybridisation (FISH) with BCR-ABL specific probe must be submitted. The cytogenetic or peripheral blood quantitative PCR analyses must be submitted as follows:

(i) between 10 and 12 months of the commencement of treatment with nilotinib, at which time patients in whom a major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been demonstrated may receive authorisation for a further 12 months of treatment; and

(ii) at no greater than 12 month intervals thereafter, to demonstrate that the major cytogenetic response or peripheral blood BCR-ABL level of less than 1% has been sustained.

For each authority application where eligibility for continuing PBS-subsidised treatment is to be demonstrated, a copy of the cytogenetic analysis indicating the number of Philadelphia positive [t (9;22)] cells in the bone marrow measured by standard karyotyping, or a copy of the quantitative PCR indicating the relative level of BCR-ABL transcript in the peripheral blood using the international scale, must be submitted as described in (i) and (ii) above. For bone marrow analyses, where the standard karyotyping conducted at the time of application is not informative, a copy of a cytogenetic analysis conducted on the bone marrow using FISH with BCR-ABL specific probe must be submitted with the authority application. A copy of the non-informative standard karyotype analysis must be included with the authority application.

Where a patient has previously received PBS-subsidised treatment with nilotinib, no approval will be granted for PBS-subsidised re-treatment where that patient has at any time failed to meet the criteria for continuing treatment.

|       |                                               |     |   |    |           |       |         |    |
|-------|-----------------------------------------------|-----|---|----|-----------|-------|---------|----|
| 9171Q | Capsule 200 mg (as hydrochloride monohydrate) | 112 | 5 | .. | * 5489.99 | 31.30 | Tasigna | NV |
|-------|-----------------------------------------------|-----|---|----|-----------|-------|---------|----|

### • Other antineoplastic agents

#### BORTEZOMIB

### NOTE:

Any queries concerning the arrangements to prescribe bortezomib may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Prescribing information (including Authority Application forms) is available on the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).

Applications for authority to prescribe bortezomib should be forwarded to:

Medicare Australia

Prior Written Approval of Specialised Drugs

Reply Paid 9826

GPO Box 9826

HOBART TAS 7001

continued 

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### **Authority Required**

*Initial PBS-subsidised treatment, as monotherapy or in combination with a corticosteroid, of multiple myeloma in a patient with a WHO performance status of 2 or less, who has progressive disease, who has received at least 1 prior therapy (other than thalidomide), who has undergone or is ineligible for a primary stem cell transplant and who has experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100 mg daily.*

*If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.*

*Thalidomide treatment failure is defined as:*

- (1) confirmed disease progression during or within 6 months of discontinuing thalidomide treatment; or*
- (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.*

*Progressive disease is defined as at least 1 of the following:*

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or*
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or*
- (c) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or*
- (d) an increase in the size or number of lytic bone lesions (not including compression fractures); or*
- (e) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or*
- (f) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).*

*Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of daily living.*

*Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or Grade 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.*

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; the patient's WHO performance status; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease; and nomination of which disease activity parameters will be used to assess response.*

*To enable confirmation by Medicare Australia of response, current diagnostic reports of the following are required:*

- (a) the level of serum monoclonal protein; and*
- (b) if Bence-Jones proteinuria is present, the results of 24-hour urinary light chain M protein excretion.*

*If neither serum M protein or urine Bence-Jones protein are present in measurable quantities, additional diagnostic reports are required, including:*

- (c) bone marrow aspirate and trephine; and*
- (d) if present, the size and location of lytic bone lesions (not including compression fractures); or*
- (e) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or*
- (f) if present, the level of hypercalcaemia, corrected for albumin concentration; or*
- (g) if present, the serum free light chain levels.*

continued 



## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*As these parameters will be used to determine response, results for (a) and (b) should be provided for all patients. Where the patient has oligo-secretory or non-secretory multiple myeloma, (c) must be provided and if relevant (d), (e) or (f). Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, (g) must be provided. Where 1 or more results cannot be provided, the application must state the reason(s) these cannot be provided; and*  
*(3) duration of thalidomide and daily dose prescribed; and*  
*(4) a signed patient acknowledgment.*

### **Authority Required**

*Continuing PBS-subsidised treatment, as monotherapy or in combination with a corticosteroid, of multiple myeloma in a patient who has previously received 4 treatment cycles of bortezomib and who, at the time of application, has demonstrated at least a partial response to bortezomib.*

*If serum M protein and urine Bence-Jones protein levels are measurable, partial response (PR) compared with baseline (prior to treatment with bortezomib) is defined as:*

- (a) at least a 50% reduction in the level of serum M protein (monoclonal protein); or*
- (b) at least a 90% reduction in 24-hour urinary light chain M protein excretion or to less than 200 mg per 24 hours.*

*If serum M protein and urine Bence-Jones protein levels are unmeasurable as in non-secretory/oligo-secretory multiple myeloma, partial response compared with baseline is defined as:*

- (c) at least a 50% reduction in the difference between involved and uninvolved serum free light chain (FLC) levels.*

*If serum M protein and urine Bence-Jones protein and serum FLC are unmeasurable/unavailable, partial response compared with baseline is defined as:*

- (d) at least a 50% reduction in bone marrow plasma cells; or*
- (e) normalisation of corrected serum calcium to less than or equal to 2.65 mmol per L; or*
- (f) no increase in size or number of lytic bone lesions (development of compression fracture does not exclude response); or*
- (g) at least a 50% reduction in the size of soft tissue plasmacytoma (by clinical or applicable radiographic examination, i.e. MRI or CT-Scan).*

*For the purpose of assessing eligibility for continuing PBS-subsidised bortezomib treatment beyond 4 cycles, the patient must have achieved at least a partial response at the completion of cycle 4. The results of the response assessment must be included in a written application to Medicare Australia for further treatment. Where a response assessment is not submitted to Medicare Australia prior to cycle 5, patients will be deemed to have failed to respond to treatment with bortezomib. Continuing PBS-subsidised supply will not be approved if there is a gap of more than 6 months between the initial application and subsequent applications.*

*The same parameters provided for the diagnosis of progressive disease are to be used to demonstrate at least a partial response to treatment.*

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Multiple Myeloma Authority Application - Supporting Information Form; and*
- (3) diagnostic reports demonstrating the patient has achieved at least a partial response.*

*Diagnostic reports must be no more than 1 month old at the time of application.*

*Patients who fail to demonstrate at least a partial response after 8 cycles will not be eligible to receive further PBS-subsidised treatment with bortezomib.*

*No more than 2 cycles of treatment beyond the cycle at which a confirmed complete response was first achieved will be authorised. Confirmation requires 2 determinations a minimum of 6 weeks apart.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form                                                    | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-------|------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|       |                                                                                                            |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| 9117W | Powder for injection 3.5 mg (solvent required)<br>(code 7086Y applies to above item with approved solvent) | 4           | 3              | ..      | * 7001.95                   | 31.30                                       | Velcade                              | JC |

### Authority Required

Continuing PBS-subsidised treatment, as monotherapy or in combination with a corticosteroid, of multiple myeloma in a patient who has previously received 8 treatment cycles with bortezomib and who, at the time of application, has demonstrated at least a partial response to bortezomib but who has not received 2 treatment cycles after first achieving a confirmed complete response.

If serum M protein and urine Bence-Jones protein levels are measurable, partial response (PR) compared with baseline (prior to treatment with bortezomib) is defined as:

- (a) at least a 50% reduction in the level of serum M protein (monoclonal protein); or
- (b) at least a 90% reduction in 24-hour urinary light chain M protein excretion or to less than 200 mg per 24 hours.

If serum M protein and urine Bence-Jones protein levels are unmeasurable as in non-secretory/oligo-secretory multiple myeloma, partial response compared with baseline is defined as:

- (c) the difference between involved and uninvolved serum free light chain (FLC) levels, with at least a 50% reduction in this value.

If serum M protein and urine Bence-Jones protein levels and serum FLC are unmeasurable/unavailable, partial response compared with baseline is defined as:

- (d) at least a 50% reduction in bone marrow plasma cells; or
- (e) normalisation of corrected serum calcium to less than or equal to 2.65 mmol per L; or
- (f) no increase in size or number of lytic bone lesions (development of compression fracture does not exclude response); or
- (g) at least a 50% reduction in the size of soft tissue plasmacytoma (by clinical or applicable radiographic examination, i.e. MRI or CT-Scan).

The same parameters provided for the diagnosis of progressive disease are to be used to demonstrate at least a partial response to treatment.

Diagnostic reports must be within 1 month of the date of application.

For the purpose of assessing eligibility for continuing PBS-subsidised bortezomib treatment beyond 8 cycles, the patient must have achieved at least a partial response at the completion of cycle 8. The results of the response assessment must be included in a written application to Medicare Australia for further treatment. Where a response assessment is not submitted to Medicare Australia prior to cycle 9, patients will be deemed to have failed to respond to treatment with bortezomib. Continuing PBS-subsidised supply will not be approved if there is a gap of more than 10 months between the initial application and an application following completion of 8 treatment cycles.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Multiple Myeloma Authority Application - Supporting Information Form; and
- (3) diagnostic reports demonstrating the patient has achieved at least a partial response.

No more than 2 cycles of treatment beyond the cycle at which the complete response was first achieved will be authorised. Confirmation requires 2 determinations a minimum of 6 weeks apart.

Applications for PBS-subsidised treatment with bortezomib that extends beyond 11 cycles will not be approved.

continued ➞

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

## Authority Required

*Initial PBS-subsidised treatment of multiple myeloma in patients receiving treatment with bortezomib prior to 1 November 2007.*

*Patients who fail to demonstrate at least a partial response after 4 cycles will not be eligible to receive further PBS-subsidised treatment with bortezomib.*

*Diagnostic reports demonstrating at least a partial response must be within 1 month of the date of application.*

*Patients may qualify for PBS-subsidised treatment under this restriction for a maximum of 3 cycles. To receive further treatment the patient must qualify under the continuing treatment criteria.*

*The authority application must be made in writing and must include:*

*(1) a completed authority prescription form; and*

*(2) a completed Multiple Myeloma Authority Application - Supporting Information Form; and*

*(3) a signed patient acknowledgment; and*

*(4) details including relevant reports of the basis of the diagnosis of progressive disease and nomination of which disease activity parameters will be used to assess response; and*

*(5) if relevant, details including relevant reports for patients who have demonstrated a partial response and who have received 4 or more cycles.*

|       |                                                                                                            |   |   |    |           |       |         |    |
|-------|------------------------------------------------------------------------------------------------------------|---|---|----|-----------|-------|---------|----|
| 9118X | Powder for injection 3.5 mg (solvent required)<br>(code 7087B applies to above item with approved solvent) | 4 | 2 | .. | * 7001.95 | 31.30 | Velcade | JC |
|-------|------------------------------------------------------------------------------------------------------------|---|---|----|-----------|-------|---------|----|

## HYDROXYUREA

|       |                |     |    |    |       |       |        |    |
|-------|----------------|-----|----|----|-------|-------|--------|----|
| 3093T | Capsule 500 mg | 100 | .. | .. | 76.03 | 31.30 | Hydrea | BQ |
|-------|----------------|-----|----|----|-------|-------|--------|----|

## IRINOTECAN HYDROCHLORIDE TRIHYDRATE

### Authority Required

*Metastatic colorectal cancer in patients with a WHO performance status of 2 or less.*

### NOTE:

*In first-line usage, effectiveness and tolerance may be improved when irinotecan is combined with an infusional 5-fluorouracil regimen.*

|       |                                |   |   |    |          |       |                                                                             |          |
|-------|--------------------------------|---|---|----|----------|-------|-----------------------------------------------------------------------------|----------|
| 8414W | I.V. injection 40 mg in 2 mL   | 1 | 3 | .. | 142.91   | 31.30 | <sup>a</sup> Camptosar<br><sup>a</sup> Irinotecan Sandoz<br><sup>a</sup> HH | PU<br>SZ |
| 8415X | I.V. injection 100 mg in 5 mL  | 2 | 3 | .. | * 653.23 | 31.30 | <sup>a</sup> Camptosar<br><sup>a</sup> Irinotecan Sandoz<br><sup>a</sup> HH | PU<br>SZ |
| 9119Y | I.V. injection 500 mg in 25 mL | 1 | 3 | .. | 1623.97  | 31.30 | HH                                                                          |          |

## TOPOTECAN HYDROCHLORIDE

### Authority Required

*Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound.*

|       |                                      |   |   |    |         |       |          |    |
|-------|--------------------------------------|---|---|----|---------|-------|----------|----|
| 8199M | Powder for I.V. infusion 4 mg (base) | 5 | 1 | .. | 2125.93 | 31.30 | Hycamtin | GK |
|-------|--------------------------------------|---|---|----|---------|-------|----------|----|

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                 | Name, Restriction,<br>Manner of Administration and Form                           | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>ENDOCRINE THERAPY</b>                                                                                                                             |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <b>Hormones and related agents</b>                                                                                                                   |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| • <b>Progestogens</b>                                                                                                                                |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <b>MEDROXYPROGESTERONE ACETATE</b>                                                                                                                   |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                     |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <i>Hormone-dependent advanced breast cancer.</i>                                                                                                     |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| 2728N                                                                                                                                                | Tablet 500 mg                                                                     | 30          | 2              | ..      | 132.91                                   | 31.30                                                  | Provera                              | PH |
| <b><u>Restricted Benefit</u></b>                                                                                                                     |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <i>Hormone-dependent breast cancer;</i>                                                                                                              |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <i>Endometrial cancer.</i>                                                                                                                           |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| 2725K                                                                                                                                                | Tablet 100 mg                                                                     | 100         | 2              | ..      | 95.20                                    | 31.30                                                  | Provera                              | PH |
| 2316X                                                                                                                                                | Tablet 200 mg                                                                     | 60          | 2              | ..      | 107.32                                   | 31.30                                                  | Provera                              | PH |
| 2727M                                                                                                                                                | Tablet 250 mg                                                                     | 60          | 2              | ..      | 132.67                                   | 31.30                                                  | Provera                              | PH |
| <b>[For other listings for this drug see Generic/Proprietary Index]</b>                                                                              |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <b>MEGESTROL ACETATE</b>                                                                                                                             |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                     |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <i>Hormone-dependent advanced breast cancer.</i>                                                                                                     |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| 2734X                                                                                                                                                | Tablet 160 mg                                                                     | 30          | 2              | ..      | 72.52                                    | 31.30                                                  | Megace                               | BQ |
| • <b>Gonadotropin releasing hormone analogues</b>                                                                                                    |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <b>GOSERELIN ACETATE</b>                                                                                                                             |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Authority Required</u></b>                                                                                                                     |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <i>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate;</i>                                     |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <i>Hormone-dependent locally advanced (equivalent to stage III) or metastatic (equivalent to stage IV) breast cancer in pre-menopausal women;</i>    |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <i>Short-term treatment (up to 6 months) of visually proven endometriosis (only 1 course of not more than 6 months' therapy will be authorised).</i> |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| 1454M                                                                                                                                                | Subcutaneous implant 3.6 mg (base) in pre-filled injection syringe                | 1           | 5              | ..      | 332.57                                   | 31.30                                                  | Zoladex Implant                      | AP |
| <b><u>Authority Required</u></b>                                                                                                                     |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| <i>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate.</i>                                     |                                                                                   |             |                |         |                                          |                                                        |                                      |    |
| 8093Y                                                                                                                                                | Subcutaneous implant (long acting) 10.8 mg (base) in pre-filled injection syringe | 1           | 1              | ..      | 1108.33                                  | 31.30                                                  | Zoladex 10.8 Implant                 | AP |

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                        | Name, Restriction,<br>Manner of Administration and Form                                                                    | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>GOSERELIN ACETATE and BICALUTAMIDE</b>                                                                                                                   |                                                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                   |                                                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| <i>Metastatic (equivalent to stage D) prostatic carcinoma in patients for whom a combination of an antiandrogen and a GnRH (LH-RH) agonist is required.</i> |                                                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                                                                |                                                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i>                                                                  |                                                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| 9064C                                                                                                                                                       | Pack containing 1 subcutaneous implant goserelin 3.6 mg in pre-filled injection syringe and 28 tablets bicalutamide 50 mg  | ± 1         | 5              | ..      | 505.61                                   | 31.30                                                  | ZolaCos CP 3.6/50                    | AP |
| 9065D                                                                                                                                                       | Pack containing 1 subcutaneous implant goserelin 10.8 mg in pre-filled injection syringe and 28 tablets bicalutamide 50 mg | ± 1         | ..             | ..      | 1274.52                                  | 31.30                                                  | ZolaCos CP 10.8/50(28)               | AP |
| 9066E                                                                                                                                                       | Pack containing 1 subcutaneous implant goserelin 10.8 mg in pre-filled injection syringe and 84 tablets bicalutamide 50 mg | ± 1         | 1              | ..      | 1606.90                                  | 31.30                                                  | ZolaCos CP 10.8/50(84)               | AP |
| <b>LEUPRORELIN ACETATE</b>                                                                                                                                  |                                                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                   |                                                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| <i>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate.</i>                                            |                                                                                                                            |             |                |         |                                          |                                                        |                                      |    |
| 8875D                                                                                                                                                       | I.M. injection (modified release), powder for injection 7.5 mg with diluent in pre-filled dual-chamber syringe             | 1           | 5              | ..      | 419.77                                   | 31.30                                                  | Lucrin Depot 7.5mg PDS               | AB |
| 8707G                                                                                                                                                       | Suspension for subcutaneous injection (modified release), 7.5 mg injection set                                             | 1           | 5              | ..      | 419.77                                   | 31.30                                                  | Eligard 1 month                      | HH |
| 8876E                                                                                                                                                       | I.M. injection (modified release), powder for injection 22.5 mg with diluent in pre-filled dual-chamber syringe            | 1           | 1              | ..      | 1108.33                                  | 31.30                                                  | Lucrin Depot 3 Month PDS             | AB |
| 8708H                                                                                                                                                       | Suspension for subcutaneous injection (modified release), 22.5 mg injection set                                            | 1           | 1              | ..      | 1108.33                                  | 31.30                                                  | Eligard 3 month                      | HH |
| 8877F                                                                                                                                                       | I.M. injection (modified release), powder for injection 30 mg with diluent in pre-filled dual-chamber syringe              | 1           | 1              | ..      | 1450.90                                  | 31.30                                                  | Lucrin Depot 4 Month PDS             | AB |
| 8709J                                                                                                                                                       | Suspension for subcutaneous injection (modified release), 30 mg injection set                                              | 1           | 1              | ..      | 1450.90                                  | 31.30                                                  | Eligard 4 month                      | HH |
| 8859G                                                                                                                                                       | Suspension for subcutaneous injection (modified release), 45 mg injection set                                              | 1           | ..             | ..      | 2123.55                                  | 31.30                                                  | Eligard 6 month                      | HH |

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                            | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>Hormone antagonists and related agents</b>                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Anti-estrogens</b>                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>TAMOXIFEN CITRATE</b>                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u><b>Restricted Benefit</b></u>                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of hormone-dependent breast cancer.</i>                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u><b>NOTE:</b></u>                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>This drug is not PBS-subsidised for primary prevention of breast cancer.</i>                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2109B                                                                                                           | Tablet 10 mg (base)                                     | 60          | 5              | ..      | 38.45                                    | 31.30                                                  | <sup>a</sup> Genox 10                | AF |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Tamoxen 10 mg           | GM |
|                                                                                                                 |                                                         |             |                | B1.66   | * 40.13                                  | 31.30                                                  | <sup>a</sup> Nolvadex                | AP |
| 2110C                                                                                                           | Tablet 20 mg (base)                                     | 60          | 5              | ..      | 59.81                                    | 31.30                                                  | <sup>a</sup> Chem mart               | CH |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | Tamoxifen                            |    |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Genox 20                | AF |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Tamoxifen         | GX |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Tamosin                 | SI |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Tamoxen 20 mg           | GM |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Tamoxifen Sandoz        | SZ |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | Tamoxifen                            |    |
|                                                                                                                 |                                                         |             |                | B2.84   | * 62.67                                  | 31.30                                                  | <sup>a</sup> Nolvadex-D              | AP |
| <b>TOREMIFENE CITRATE</b>                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u><b>Restricted Benefit</b></u>                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of hormone-dependent metastatic breast cancer in post-menopausal patients.</i>                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u><b>NOTE:</b></u>                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>This drug is not PBS-subsidised for primary prevention of breast cancer.</i>                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8216K                                                                                                           | Tablet 60 mg (base)                                     | 30          | 5              | ..      | 68.68                                    | 31.30                                                  | Fareston                             | SH |
| • <b>Anti-androgens</b>                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>BICALUTAMIDE</b>                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u><b>Authority Required</b></u>                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Metastatic (equivalent to stage D) prostatic carcinoma in combination with GnRH (LH-RH) agonist therapy.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u><b>NOTE:</b></u>                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i>                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8094B                                                                                                           | Tablet 50 mg                                            | 28          | 5              | ..      | 194.99                                   | 31.30                                                  | <sup>a</sup> APO-Bicalutamide        | TX |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Bicalutamide-GA         | GM |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Bicalutamide            | RA |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | Ranbaxy                              |    |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Calutex                 | SI |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cosamide                | AF |
|                                                                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Cosudex                 | AP |

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                      |                                      |
|-------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| <b>CYPROTERONE ACETATE</b>                                              |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                           |                                      |
| <b>Authority Required (STREAMLINED)</b>                                 |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                           |                                      |
| <b>1014</b>                                                             |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                           |                                      |
| <i>Advanced carcinoma of the prostate;</i>                              |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                           |                                      |
| <b>1404</b>                                                             |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                           |                                      |
| <i>To reduce drive in sexual deviations in males.</i>                   |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                           |                                      |
| 1270W                                                                   | Tablet 50 mg                                            | 100         | 5              | ..      | * 207.29                                 | 31.30                                                  | <sup>a</sup> Cyprohexal<br><sup>a</sup> Cyprone<br><sup>a</sup> Cyprostat<br><sup>a</sup> GenRx<br>Cyproterone<br>Acetate<br><sup>a</sup> Procur<br><sup>a</sup> Androcur | SZ<br>AF<br>SY<br>GX<br><br>GM<br>SC |
| 8019C                                                                   | Tablet 100 mg                                           | 50          | 5              | ..      | B3.00 * 210.29                           | 31.30                                                  | <sup>a</sup> Cyprohexal<br><sup>a</sup> Cyprostat-100<br><sup>a</sup> GenRx<br>Cyproterone<br>Acetate<br><sup>a</sup> Procur 100<br><sup>a</sup> Androcur-100             | SZ<br>SY<br>GX<br><br>GM<br>SC       |
|                                                                         |                                                         |             |                | B1.65   | 170.98                                   | 31.30                                                  |                                                                                                                                                                           |                                      |
| <i>[For other listings for this drug see Generic/Proprietary Index]</i> |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                           |                                      |

## FLUTAMIDE

### Authority Required

*Metastatic (equivalent to stage D) prostatic carcinoma in combination with GnRH (LH-RH) agonist therapy.*

### NOTE:

*No applications for increased maximum quantities and/or repeats will be authorised.*

|       |               |     |   |    |        |       |                                               |          |
|-------|---------------|-----|---|----|--------|-------|-----------------------------------------------|----------|
| 1417N | Tablet 250 mg | 100 | 5 | .. | 212.60 | 31.30 | <sup>a</sup> Eulexin<br><sup>a</sup> Flutamin | SH<br>AF |
|-------|---------------|-----|---|----|--------|-------|-----------------------------------------------|----------|

## NILUTAMIDE

### Authority Required

*Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) prostatic carcinoma, in combination with GnRH (LH-RH) agonist therapy;*

*Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) prostatic carcinoma, in conjunction with surgical orchidectomy.*

|       |               |    |   |    |        |       |          |    |
|-------|---------------|----|---|----|--------|-------|----------|----|
| 8131Y | Tablet 150 mg | 30 | 5 | .. | 225.90 | 31.30 | Anandron | SW |
|-------|---------------|----|---|----|--------|-------|----------|----|

### • Enzyme inhibitors

#### AMINOGLUTETHIMIDE

|       |               |     |   |    |        |       |              |    |
|-------|---------------|-----|---|----|--------|-------|--------------|----|
| 1036M | Tablet 250 mg | 100 | 5 | .. | 159.17 | 31.30 | Cytadren 250 | NV |
|-------|---------------|-----|---|----|--------|-------|--------------|----|

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                      | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>ANASTROZOLE</b>                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of hormone-dependent breast cancer in post-menopausal women.</i>                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>This drug is not PBS-subsidised for primary prevention of breast cancer.</i>                                                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>This drug is not PBS-subsidised for adjuvant hormonal treatment of early breast cancer extended beyond 5 years.</i>                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8179L                                                                                                                                                                                                                                                     | Tablet 1 mg                                             | 30          | 5              | ..      | 183.99                                   | 31.30                                                  | Arimidex                             | AP |
| <b>EXEMESTANE</b>                                                                                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of hormone-dependent advanced breast cancer in post-menopausal women with disease progression following treatment with tamoxifen citrate;</i>                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of hormone-dependent early breast cancer in post-menopausal women following a minimum of 2 years' treatment with tamoxifen citrate.</i>                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>This drug is not PBS-subsidised for primary prevention of breast cancer.</i>                                                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>This drug is not PBS-subsidised for adjuvant hormonal treatment of early breast cancer extended beyond 5 years, i.e. a patient who has received 2 years of tamoxifen therapy may only receive 3 years of PBS-subsidised treatment with exemestane.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8506Q                                                                                                                                                                                                                                                     | Tablet 25 mg                                            | 30          | 5              | ..      | 183.99                                   | 31.30                                                  | Aromasin                             | PH |
| <b>LETROZOLE</b>                                                                                                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of hormone-dependent advanced breast cancer in post-menopausal women;</i>                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of hormone-dependent early breast cancer in post-menopausal women;</i>                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Extended adjuvant treatment of hormone-dependent early breast cancer in post-menopausal women commencing within 6 months of ceasing treatment with tamoxifen citrate.</i>                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>This drug is not PBS-subsidised for primary prevention of breast cancer.</i>                                                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>This drug is not PBS-subsidised for adjuvant hormonal treatment of early breast cancer extended beyond 5 years.</i>                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>This drug is not PBS-subsidised for extended adjuvant early breast cancer treatment where the total duration of letrozole (or any other aromatase inhibitor) treatment extends beyond 5 years.</i>                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8245Y                                                                                                                                                                                                                                                     | Tablet 2.5 mg                                           | 30          | 5              | ..      | 183.99                                   | 31.30                                                  | Femara 2.5 mg                        | NV |



# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

## IMMUNOSTIMULANTS

### Immunostimulants

#### • Interferons

##### INTERFERON ALFA-2a

##### CAUTION:

*Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.*

##### Authority Required

*Hairy cell leukaemia;*

*Myeloproliferative disease with excessive thrombocytosis.*

|       |                                                                      |    |   |    |          |       |           |    |
|-------|----------------------------------------------------------------------|----|---|----|----------|-------|-----------|----|
| 8180M | Injection 3,000,000 i.u. in 0.5 mL single<br>dose pre-filled syringe | 15 | 4 | .. | * 505.79 | 31.30 | Roferon-A | RO |
|-------|----------------------------------------------------------------------|----|---|----|----------|-------|-----------|----|

##### Authority Required

*Myeloproliferative disease with excessive thrombocytosis.*

|       |                                                                      |   |   |    |          |       |           |    |
|-------|----------------------------------------------------------------------|---|---|----|----------|-------|-----------|----|
| 8551C | Injection 4,500,000 i.u. in 0.5 mL single<br>dose pre-filled syringe | 5 | 4 | .. | * 264.29 | 31.30 | Roferon-A | RO |
| 8552D | Injection 6,000,000 i.u. in 0.5 mL single<br>dose pre-filled syringe | 5 | 4 | .. | * 344.29 | 31.30 | Roferon-A | RO |
| 8553E | Injection 9,000,000 i.u. in 0.5 mL single<br>dose pre-filled syringe | 5 | 4 | .. | * 505.69 | 31.30 | Roferon-A | RO |

##### Authority Required

*Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy.*

|       |                                                                      |    |   |    |          |       |           |    |
|-------|----------------------------------------------------------------------|----|---|----|----------|-------|-----------|----|
| 8181N | Injection 3,000,000 i.u. in 0.5 mL single<br>dose pre-filled syringe | 15 | 5 | .. | * 505.79 | 31.30 | Roferon-A | RO |
| 8182P | Injection 4,500,000 i.u. in 0.5 mL single<br>dose pre-filled syringe | 5  | 5 | .. | * 264.29 | 31.30 | Roferon-A | RO |
| 8183Q | Injection 6,000,000 i.u. in 0.5 mL single<br>dose pre-filled syringe | 5  | 5 | .. | * 344.29 | 31.30 | Roferon-A | RO |
| 8184R | Injection 9,000,000 i.u. in 0.5 mL single<br>dose pre-filled syringe | 5  | 5 | .. | * 505.69 | 31.30 | Roferon-A | RO |

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Name, Restriction,<br>Manner of Administration and Form                                          | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>INTERFERON ALFA-2b</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Hairy cell leukaemia.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
| 8572E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Solution for injection 18,000,000 i.u. in 1.2 mL multi-dose injection pen                        | 3           | 4              | ..      | * 605.60                                 | 31.30                                                  | Intron A Redipen                     | SH |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy;</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
| 8348J                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Solution for injection 18,000,000 i.u. in 1.2 mL multi-dose injection pen                        | 3           | 5              | ..      | * 605.60                                 | 31.30                                                  | Intron A Redipen                     | SH |
| 8476D                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Solution for injection 30,000,000 i.u. in 1.2 mL multi-dose injection pen                        | 3           | 5              | ..      | * 1005.32                                | 31.30                                                  | Intron A Redipen                     | SH |
| <b>INTERFERON BETA-1a</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule;</i> |                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
| <i>Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule.</i>                                                                                                                                                                                                                                                                                                                                        |                                                                                                  |             |                |         |                                          |                                                        |                                      |    |
| 8289G                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Injection set comprising 1 vial powder for injection 30 micrograms (6,000,000 i.u.) with diluent | 4           | 5              | ..      | 1056.34                                  | 31.30                                                  | Avonex                               | BD |
| 8805K                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Injection 30 micrograms (6,000,000 i.u.) in 0.5 mL single dose pre-filled syringe                | 4           | 5              | ..      | 1056.34                                  | 31.30                                                  | Avonex                               | BD |
| 8403G                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Injection 44 micrograms (12,000,000 i.u.) in 0.5 mL single dose pre-filled syringe               | 12          | 5              | ..      | 1056.34                                  | 31.30                                                  | Rebif 44                             | SG |

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Name, Restriction,<br>Manner of Administration and Form                                                                                       | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>INTERFERON BETA-1b</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <i>Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule;</i> |                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <i>Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule.</i>                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| 8101J                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Injection set comprising 1 vial powder for injection 8,000,000 i.u. (250 micrograms) and solvent                                              | 15          | 5              | ..      | 1179.73                                  | 31.30                                                  | Betaferon                            | SC |
| <b>• Other immunostimulants</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <b>BCG IMMUNOTHERAPEUTIC (Bacillus Calmette-Guérin/Connaught strain)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of carcinoma in situ of the urinary bladder.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| 1140B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Single dose set comprising 1 vial powder for intravesical administration containing 6.6 to 19.2 × 10 <sup>8</sup> CFU and 1 vial diluent 3 mL | 3           | 1              | ..      | * 459.44                                 | 31.30                                                  | ImmuCyst                             | SW |
| <b>BCG-TICE (Bacillus Calmette-Guérin/ Tice strain)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <i>Primary and relapsing superficial urothelial carcinoma of the bladder.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                               |             |                |         |                                          |                                                        |                                      |    |
| 1131M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Vial containing powder for intravesical administration approximately 5 × 10 <sup>8</sup> CFU                                                  | 3           | 1              | ..      | 555.96                                   | 31.30                                                  | OncoTICE                             | OR |

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

## GLATIRAMER ACETATE

### Authority Required

*Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule;*

*Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule.*

|       |                                                           |    |   |    |         |       |          |    |
|-------|-----------------------------------------------------------|----|---|----|---------|-------|----------|----|
| 8726G | Injection 20 mg in 1 mL single dose<br>pre-filled syringe | 28 | 5 | .. | 1092.22 | 31.30 | Copaxone | SW |
|-------|-----------------------------------------------------------|----|---|----|---------|-------|----------|----|

## IMMUNOSUPPRESSANTS

### Immunosuppressants

#### • Selective immunosuppressants

#### EFALIZUMAB

#### NOTE:

*Any queries concerning the arrangements to prescribe efalizumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Prescribing information (including Authority Application Forms) is available on the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).*

*Applications for authority to prescribe efalizumab should be forwarded to:*

*Medicare Australia*

*Prior Written Approval of Specialised Drugs*

*Reply Paid 9826*

*GPO Box 9826*

*HOBART TAS 7001*

#### NOTE:

#### TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS

*The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents efalizumab, etanercept and infliximab, for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to efalizumab, etanercept and infliximab.*

*From 1 December 2007, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial efalizumab, etanercept or infliximab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.*

*A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 December 2007 is considered to be in their first Cycle as of 1 December 2007.*

*Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.*

continued ➡

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment. A patient who, prior to 1 December 2007, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 December 2007.*

*Initial treatment with efalizumab consists of 16 weeks of therapy, with infliximab consists of 22 weeks of therapy, and with etanercept consists of 12 weeks of active therapy followed by a biological treatment-free period of at least 12 weeks. Response to treatment for all 3 agents must be assessed after 12 weeks of treatment.*

*Following demonstration of response to initial treatment, these biological agents are available as continuing therapy. Ongoing access to continuing treatment is available for as long as the response to therapy is sustained. In the case of efalizumab and infliximab, continuing treatment consists of 24 weeks of continuous active treatment. In the case of etanercept, continuing treatment consists of 12 weeks of active therapy followed by a biological treatment-free period of at least 12 weeks.*

*Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.*

*Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.*

*Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.*

*Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.*

*There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.*

*How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 December 2007.*

*There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.*

*(1) Application for approval for initial treatment.*

*Applications for a course of initial treatment should be made in the following situations:*

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and*
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; and*
- (iii) patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).*

*All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy in the case of efalizumab, 12 weeks of therapy in the case of etanercept, and 22 weeks of treatment in the case of infliximab. Approval will be based on the criteria included in the relevant initial treatment restriction.*

*Grandfather patients (Infliximab only).*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Applications for patients who commenced treatment with infliximab prior to 7 March 2007, may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.*

*Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.*

### *(2) Assessment of response to initial treatment.*

*When prescribing efalizumab or infliximab, where the initial treatment course is for 16 or 22 weeks respectively, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with efalizumab or infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*Applications for continuing treatment with efalizumab or infliximab must also be submitted to Medicare Australia prior to the completion of this initial course of therapy to ensure continuity of treatment for those patients who meet the continuation criterion and wish to continue on treatment with either efalizumab or infliximab.*

*When prescribing etanercept, a PASI assessment must be conducted at the completion of the 12 week initial treatment course. This assessment, which will be used to determine eligibility for future treatment according to the criterion included in the relevant continuing treatment restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.*

### *(3) Application for continuing treatment.*

*As stated above, following the completion of an initial treatment course of efalizumab or infliximab to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with efalizumab or infliximab. Patients are eligible to continue to receive continuous treatment with efalizumab or infliximab in 24 week courses providing they continue to sustain a response.*

*For second and subsequent courses of PBS-subsidised treatment with efalizumab or infliximab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.*

*At the completion of an initial 12 week treatment course of etanercept to which an adequate response has been demonstrated, followed by a biological treatment-free period of at least 12 weeks, patients may qualify to receive continuing treatment with etanercept. Continuing treatment is available in the form of 12 weeks of active etanercept treatment followed by a biological treatment-free period of at least 12 weeks. Patients are eligible to receive continuing treatment with etanercept on this cyclical basis, for as long as they continue to sustain a response. Continuing applications must be submitted at least 12 weeks after cessation of the most recent course of etanercept treatment.*

*A PASI assessment must be conducted for each course of continuing treatment for each biological agent, according to the requirements set out in the relevant restriction. Assessment of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 1 month from the date that course was completed or treatment was ceased.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### NOTE:

#### (4) Swapping therapy.

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent in the same Cycle.

Patients who commenced treatment with infliximab prior to 7 March 2007 access these interchangeability arrangements in the same way as patients who have not.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required 12 week biological treatment-free period applying to patients who have demonstrated a response to their most recent course of etanercept. This means that patients who have demonstrated a response to a 12 week course of etanercept must have a PBS-subsidised biological therapy treatment-free period of at least 12 weeks, immediately following this course of treatment, before swapping to efalizumab or infliximab. Patients who fail to respond to etanercept and who qualify and wish to try a course of efalizumab or infliximab, may do so without having to have any treatment-free period.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.

#### (5) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.

For new patients and patients commencing a new Cycle, the first baseline PASI assessment must be conducted, preferably while the patient is still receiving their most recent prior therapy, but no later than 1 month following cessation of such therapy, as outlined in the relevant restriction. This is not required for any subsequent PASI scores provided for these patients within the same Cycle, nor for patients who received initial PBS-subsidised therapy under a 'grandfather' restriction.

To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.

#### (6) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### **Authority Required**

*Initial treatment [Initial 1, Whole body (New patients — No prior biological agent)]*

*Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:*

- (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and*
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and*
- (c) have signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and*
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:*
  - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or*
  - (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or*
  - (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or*
  - (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).*

*The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:*

- (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.*
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))];*
  - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and*
  - (iii) the signed patient acknowledgement.*

*A maximum of 16 weeks of treatment with efalizumab will be authorised under this restriction.*

*Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.*



## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with efalizumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised efalizumab treatment.*

### **Authority Required**

*Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]*

*Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:*

- (a) have a documented history of severe chronic plaque psoriasis; and*
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and*
- (c) have not failed PBS-subsidised therapy with efalizumab for the treatment of this condition in the current Treatment Cycle.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))];* and
  - (ii) details of prior biological treatment, including dosage, date and duration of treatment.*

*Applications for patients who have demonstrated a response to PBS-subsidised efalizumab treatment within this Treatment Cycle and who wish to re-commence efalizumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised efalizumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.*

*A maximum of 16 weeks of treatment with efalizumab will be authorised under this restriction.*

*Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.*

*A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with efalizumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised efalizumab treatment.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Patients who fail to demonstrate a response to treatment with each of the biological agents, efalizumab, etanercept and infliximab, are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.*

### **Authority Required**

*Initial treatment [Initial 1, Face, hand, foot (New patients — No prior biological agent)]*

*Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:*

- (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and*
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and*
- (c) have signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and*
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:*
  - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or*
  - (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or*
  - (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or*
  - (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).*

*The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:*

- (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:*
  - (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or*
  - (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.*
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))];* and
  - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and*
  - (iii) the signed patient acknowledgement.*

*A maximum of 16 weeks of treatment with efalizumab will be authorised under this restriction.*

*Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.*

*A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with efalizumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised efalizumab treatment.*

*The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.*

### **Authority Required**

*Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]*

*Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:*

- (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and*
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and*
- (c) have not failed PBS-subsidised therapy with efalizumab for the treatment of this condition in the current Treatment Cycle.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))];* and
  - (ii) details of prior biological treatment, including dosage, date and duration of treatment.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Applications for patients who have demonstrated a response to PBS-subsidised efalizumab treatment within this Treatment Cycle and who wish to re-commence efalizumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised efalizumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.*

*A maximum of 16 weeks of treatment with efalizumab will be authorised under this restriction.*

*Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.*

*A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with efalizumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised efalizumab treatment.*

*The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.*

*Patients who fail to demonstrate a response to treatment with each of the biological agents, efalizumab, etanercept and infliximab, are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.*

|       |                                                                                                       |   |   |    |         |       |         |    |
|-------|-------------------------------------------------------------------------------------------------------|---|---|----|---------|-------|---------|----|
| 9000Q | Injection set containing 4 vials powder for injection 125 mg and 4 pre-filled syringes diluent 1.3 mL | 1 | 3 | .. | 1029.14 | 31.30 | Raptiva | SG |
|-------|-------------------------------------------------------------------------------------------------------|---|---|----|---------|-------|---------|----|

### NOTE:

*No applications for increased repeats will be authorised.*

### Authority Required

*Continuing treatment (Whole body)*

*Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:*

- (a) who have a documented history of severe chronic plaque psoriasis; and*
- (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with efalizumab; and*
- (c) who have demonstrated an adequate response to their most recent course of treatment with efalizumab.*

*An adequate response to treatment is defined as:*

*A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with efalizumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.*

*Approval will be based on the PASI assessment of response to the most recent course of treatment with efalizumab.*

*A maximum of 24 weeks of treatment with efalizumab will be authorised under this restriction.*

*Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.*

*A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with efalizumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised efalizumab treatment.*

*Patients who fail to demonstrate a response to treatment with each of the biological agents, efalizumab, etanercept and infliximab, are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.*

### **Authority Required**

*Continuing treatment (Face, hand, foot)*

*Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:*

- (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and*
- (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with efalizumab; and*
- (c) who have demonstrated an adequate response to treatment with efalizumab.*

*An adequate response to efalizumab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:*

- (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or*
- (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with efalizumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].*

*A maximum of 24 weeks of treatment with efalizumab will be authorised under this restriction.*

*Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.*

*A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with efalizumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised efalizumab treatment.*

*The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.*

*Patients who fail to demonstrate a response to treatment with each of the biological agents, efalizumab, etanercept and infliximab, are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.*

|       |                                                                                                       |   |   |    |         |       |         |    |
|-------|-------------------------------------------------------------------------------------------------------|---|---|----|---------|-------|---------|----|
| 9001R | Injection set containing 4 vials powder for injection 125 mg and 4 pre-filled syringes diluent 1.3 mL | 1 | 5 | .. | 1029.14 | 31.30 | Raptiva | SG |
|-------|-------------------------------------------------------------------------------------------------------|---|---|----|---------|-------|---------|----|

**NOTE:**

*No applications for increased repeats will be authorised.*

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                           | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|                                                                                                                                                                                                                                |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |
| <b><u>EVEROLIMUS</u></b>                                                                                                                                                                                                       |                                                         |             |                |         |                             |                                             |                                      |
| <b><u>CAUTION:</u></b>                                                                                                                                                                                                         |                                                         |             |                |         |                             |                                             |                                      |
| <i>Careful monitoring of patients is mandatory.</i>                                                                                                                                                                            |                                                         |             |                |         |                             |                                             |                                      |
| <b><u>Authority Required</u></b>                                                                                                                                                                                               |                                                         |             |                |         |                             |                                             |                                      |
| <i>Maintenance therapy, following initiation and stabilisation of treatment with everolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with:</i> |                                                         |             |                |         |                             |                                             |                                      |
| <i>(a) renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application; or</i>           |                                                         |             |                |         |                             |                                             |                                      |
| <i>(b) cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application.</i>            |                                                         |             |                |         |                             |                                             |                                      |
| 8840G                                                                                                                                                                                                                          | Tablet 0.25 mg                                          | 60          | 3              | ..      | 282.36                      | 31.30                                       | Certican NV                          |
| 8841H                                                                                                                                                                                                                          | Tablet 0.5 mg                                           | 60          | 3              | ..      | 543.40                      | 31.30                                       | Certican NV                          |
| 8842J                                                                                                                                                                                                                          | Tablet 0.75 mg                                          | 120         | 3              | ..      | * 1578.19                   | 31.30                                       | Certican NV                          |

## LEFLUNOMIDE

### CAUTION:

*Leflunomide is a category X drug and must not be given to pregnant women. Pregnancy should be avoided for two years after cessation of therapy, unless special wash-out procedures are carried out.*

### Authority Required (STREAMLINED)

2643

*Initial treatment of severe active rheumatoid arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate. Treatment must be initiated by a physician;*

2681

*Initial treatment of severe active psoriatic arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate. Treatment must be initiated by a physician.*

### NOTE:

*No applications for increased maximum quantities and/or repeats will be authorised.*

|       |                                                                                     |     |    |    |        |       |       |    |
|-------|-------------------------------------------------------------------------------------|-----|----|----|--------|-------|-------|----|
| 8373Q | Pack containing 3 tablets leflunomide<br>100 mg and 30 tablets leflunomide<br>20 mg | ± 1 | .. | .. | 218.58 | 31.30 | Arava | SW |
|-------|-------------------------------------------------------------------------------------|-----|----|----|--------|-------|-------|----|

### Authority Required (STREAMLINED)

2644

*Treatment of severe active rheumatoid arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate. Treatment must be initiated by a physician;*

2682

*Treatment of severe active psoriatic arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate. Treatment must be initiated by a physician.*

|       |              |    |   |    |        |       |                                            |          |
|-------|--------------|----|---|----|--------|-------|--------------------------------------------|----------|
| 8374R | Tablet 10 mg | 30 | 5 | .. | 95.01  | 31.30 | <sup>a</sup> Arabloc<br><sup>a</sup> Arava | AV<br>SW |
| 8375T | Tablet 20 mg | 30 | 5 | .. | 141.53 | 31.30 | <sup>a</sup> Arabloc<br><sup>a</sup> Arava | AV<br>SW |

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| <b>MYCOPHENOLATE MOFETIL</b>                                                                                                                                                                                                                                                                                                                                                                                                            |                                                         |             |                |         |                             |                                             |                                      |    |
| <b>CAUTION:</b>                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         |                             |                                             |                                      |    |
| Careful monitoring of patients is mandatory.                                                                                                                                                                                                                                                                                                                                                                                            |                                                         |             |                |         |                             |                                             |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                               |                                                         |             |                |         |                             |                                             |                                      |    |
| Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate mofetil and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with:                                                                                                                                                                                                      |                                                         |             |                |         |                             |                                             |                                      |    |
| (a) renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application; or                                                                                                                                                                                                                           |                                                         |             |                |         |                             |                                             |                                      |    |
| (b) cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application.                                                                                                                                                                                                                            |                                                         |             |                |         |                             |                                             |                                      |    |
| 8649F                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 250 mg                                          | 300         | 3              | ..      | 627.38                      | 31.30                                       | CellCept                             | RO |
| 8650G                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 500 mg                                           | 150         | 3              | ..      | 627.38                      | 31.30                                       | CellCept                             | RO |
| 8651H                                                                                                                                                                                                                                                                                                                                                                                                                                   | Powder for oral suspension 1 g per<br>5 mL, 165 mL      | ± 1         | 3              | ..      | # 289.42                    | 31.30                                       | CellCept                             | RO |
| <b>MYCOPHENOLATE SODIUM</b>                                                                                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                |         |                             |                                             |                                      |    |
| <b>CAUTION:</b>                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         |                             |                                             |                                      |    |
| Careful monitoring of patients is mandatory.                                                                                                                                                                                                                                                                                                                                                                                            |                                                         |             |                |         |                             |                                             |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                               |                                                         |             |                |         |                             |                                             |                                      |    |
| Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate sodium and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application. |                                                         |             |                |         |                             |                                             |                                      |    |
| 8652J                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet (enteric coated) 180 mg<br>(mycophenolic acid)   | 120         | 3              | ..      | 262.99                      | 31.30                                       | Myfortic                             | NV |
| 8653K                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet (enteric coated) 360 mg<br>(mycophenolic acid)   | 120         | 3              | ..      | 503.10                      | 31.30                                       | Myfortic                             | NV |
| <b>SIROLIMUS</b>                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                             |                                             |                                      |    |
| <b>CAUTION:</b>                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         |                             |                                             |                                      |    |
| Careful monitoring of patients is mandatory.                                                                                                                                                                                                                                                                                                                                                                                            |                                                         |             |                |         |                             |                                             |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                               |                                                         |             |                |         |                             |                                             |                                      |    |
| Maintenance therapy, following initiation and stabilisation of treatment with sirolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application.            |                                                         |             |                |         |                             |                                             |                                      |    |
| 8724E                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 1 mg                                             | 100         | 3              | ..      | 814.82                      | 31.30                                       | Rapamune                             | WX |
| 8833X                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 2 mg                                             | 100         | 3              | ..      | 1583.26                     | 31.30                                       | Rapamune                             | WX |
| 8725F                                                                                                                                                                                                                                                                                                                                                                                                                                   | Oral solution 1 mg per mL, 60 mL                        | ± 1         | 3              | ..      | 529.31                      | 31.30                                       | Rapamune                             | WX |



## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### • **Tumor necrosis factor alpha (TNF-alpha) inhibitors**

#### **ADALIMUMAB**

##### **NOTE:**

Any queries concerning the arrangements to prescribe adalimumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe adalimumab should be forwarded to:

Medicare Australia

Prior Written Approval of Specialised Drugs

Reply Paid 9826

GPO Box 9826

HOBART TAS 7001

Further prescribing information is on the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).

##### **NOTE:**

#### **TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS**

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis.

Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, etanercept, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-1 inhibitor (anakinra) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised infliximab, anakinra, rituximab and abatacept must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are only eligible to receive PBS-subsidised etanercept and adalimumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

From 1 March 2008, under the PBS, all patients will be able to commence a Treatment Cycle where they may trial PBS-subsidised bDMARD agents without having to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Treatment Cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.

A patient who received PBS-subsidised bDMARD treatment prior to 1 March 2008 is considered to be in their first Cycle as of 1 March 2008.

Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next Cycle.

For patients who have failed PBS-subsidised treatment with 3 bDMARDs prior to 1 March 2008 please contact Medicare Australia on 1800 700 270.

The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent Cycle to the date of the first application for initial treatment with a bDMARD under the new Treatment Cycle.

A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same Treatment Cycle.

A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of more than 5 years, may commence a new Treatment Cycle.

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*There is no limit to the number of Treatment Cycles a patient may undertake in their lifetime.*

*If patients fail to respond to a particular bDMARD within a single Treatment Cycle, they are not eligible to receive further PBS-subsidised treatment with that drug until they commence the next Cycle.*

*(1) How to prescribe PBS-subsidised bDMARD therapy after 1 March 2008.*

*(a) Initial treatment.*

*Applications for initial treatment should be made where:*

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this Treatment Cycle and wishes to commence such therapy, excluding rituximab (Initial 1); or*
- (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or*
- (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 2).*

*Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for etanercept, adalimumab, anakinra and abatacept, 22 weeks of therapy for infliximab and 2 infusions of rituximab.*

*From 1 March 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.*

*For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.*

*Rituximab patients:*

*A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.*

*(b) Continuing treatment.*

*Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.*

*It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.*

*Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Rituximab patients:*

*A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.*

*(2) Swapping therapy.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same Treatment Cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same Treatment Cycle.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

### NOTE:

#### (3) Baseline measurements to determine response.

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a Treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

The baseline joint and blood counts should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment.

#### (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent Treatment Cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 non-biological DMARD, at an adequate dose, for a minimum of 3 months at the time the ESR and/or CRP levels and the active joint count are measured.

#### (5) Patients 'grandfathered' onto PBS-subsidised treatment with rituximab or abatacept.

continued ➤

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*From 1 March 2008, a patient who commenced treatment with rituximab for severe rheumatoid arthritis prior to 7 March 2007 or abatacept for severe rheumatoid arthritis prior to 1 November 2007 and who was 'grandfathered' on to PBS-subsidised therapy, and who continues to receive treatment in the same Treatment Cycle, will have further applications for treatment with rituximab or abatacept assessed under the continuing treatment restriction.*

*A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with abatacept will be authorised under this criterion.*

*'Grandfather' arrangements will only apply for the first Treatment Cycle. For the second and subsequent Cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that applies to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.*

### **Authority Required**

#### **Initial 1 (new patients)**

*Application for initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:*

- (a) have severe active rheumatoid arthritis; and*
- (b) have received no prior PBS-subsidised treatment with a bDMARD for this condition in this treatment cycle; and*
- (c) have failed to achieve an adequate response to the following treatments:*
  - (i) methotrexate at a dose of at least 20 mg weekly; and*
  - (ii) methotrexate (at a minimum dose of 7.5 mg weekly), in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; and*
  - (iii) a minimum of 3 months' treatment with:*
    - leflunomide alone; or*
    - leflunomide in combination with methotrexate; or*
    - cyclosporin.*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].*

*The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:*

*an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;*

*AND either*

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or*
- (ii) at least 4 active joints from the following list of major joints:*
  - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*
  - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

*If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and
- (3) a signed patient acknowledgement.

*A maximum of 16 weeks of treatment will be authorised under this restriction.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.*

*Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.*

### **Authority Required**

*Initial 2 (change or re-commencement)*

*Application for an initial course of PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:*

- (a) have a documented history of severe active rheumatoid arthritis; and
- (b) have received prior PBS-subsidised bDMARD treatment for this condition in this treatment cycle and are eligible to receive further bDMARD therapy.

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].

*Applications for patients who have received PBS-subsidised treatment with adalimumab within this treatment cycle and who wish to re-commence therapy with this drug within this same cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.*

*A maximum of 16 weeks of treatment will be authorised under this restriction.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|       |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| 8737W | Injection 40 mg in 0.8 mL pre-filled syringe            | 2           | 3              | ..      | 1773.93                     | 31.30                                       | Humira                               | AB |
| 9099X | Injection 40 mg in 0.8 mL pre-filled pen                | 2           | 3              | ..      | 1773.93                     | 31.30                                       | Humira                               | AB |

### NOTE:

No applications for increased maximum quantities and/or repeats will be authorised.

Applications for treatment with adalimumab where the dosing frequency exceeds 40 mg per fortnight will not be approved.

### Authority Required

#### Continuing treatment

Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
- (b) who have demonstrated an adequate response to treatment with adalimumab; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with adalimumab.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;

AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
  - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
  - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].

A maximum of 24 weeks of treatment will be approved under this restriction.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|       |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| 8741C | Injection 40 mg in 0.8 mL pre-filled syringe            | 2           | 5              | ..      | 1773.93                     | 31.30                                       | Humira                               | AB |
| 9100Y | Injection 40 mg in 0.8 mL pre-filled pen                | 2           | 5              | ..      | 1773.93                     | 31.30                                       | Humira                               | AB |

*All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.*

*Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.*

### NOTE:

*No applications for increased maximum quantities and/or repeats will be authorised.*

*Applications for treatment with adalimumab where the dosing frequency exceeds 40 mg per fortnight will not be approved.*

### NOTE:

#### **TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS**

*The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept and infliximab) for adult patients with severe active psoriatic arthritis.*

*Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time. Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept and infliximab.*

*From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept or infliximab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.*

*Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.*

*Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].*

*The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.*

*Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.*

*Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.*

*There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.*

*How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2006.*

### *(1) Initial treatment.*

*Applications for initial treatment should be made where:*

*(i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and*

*(ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and*

*(iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).*

*All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.*

*Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.*

### *Grandfather patients.*

*Applications for patients who commenced treatment with etanercept prior to 17 March 2005 or adalimumab and infliximab prior to 16 March 2006, may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.*

*Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.*

### *(2) Continuing treatment.*

*Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.*

*Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.*

### *(3) Swapping therapy.*

*Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.*

*Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.*



## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:*

- (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or*
- (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS.*

*To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.*

*To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.*

### *(4) Baseline measurements to determine response.*

*Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.*

*To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.*

### *(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.*

*Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate or sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.*

## **Authority Required**

### **Initial 1**

*Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:*

- (1) have severe active psoriatic arthritis; and*
- (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and*
- (3) have failed to achieve an adequate response to:*
  - (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and*
  - (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or*
  - (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.*

*Patients must have had the psoriatic component of their disease confirmed by a dermatologist or by biopsy at any time.*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities, including severity, can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:*

*an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either*

*(i) an active joint count of at least 20 active (swollen and tender) joints; or*

*(ii) at least 4 active joints from the following list of major joints:*

*— elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*

*— shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.*

*The authority application must be made in writing and must include:*

*(1) a completed authority prescription form; and*

*(2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and*

*(3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.*

### **Authority Required**

#### **Initial 2**

*Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:*

*(1) have a documented history of severe active psoriatic arthritis; and*

*(2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and*

*(3) have not failed treatment with adalimumab during the current Treatment Cycle.*

*Applications for patients who have demonstrated a response to PBS-subsidised adalimumab treatment within this Treatment Cycle and who wish to re-commence adalimumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.*

*Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| <p><i>The authority application must be made in writing and must include:</i></p> <p><i>(1) a completed authority prescription form; and</i></p> <p><i>(2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (<a href="http://www.medicareaustralia.gov.au">www.medicareaustralia.gov.au</a>)].</i></p> <p><i>Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</i></p> <p><i>Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.</i></p> <p><i>Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.</i></p> |                                                         |             |                |         |                             |                                             |                                      |    |
| 9033K                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Injection 40 mg in 0.8 mL pre-filled syringe            | 2           | 3              | ..      | 1773.93                     | 31.30                                       | Humira                               | AB |
| 9101B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Injection 40 mg in 0.8 mL pre-filled pen                | 2           | 3              | ..      | 1773.93                     | 31.30                                       | Humira                               | AB |

### **NOTE:**

No applications for increased maximum quantities and/or repeats will be authorised.

Applications for treatment with adalimumab where the dosing frequency exceeds 40 mg per fortnight will not be approved.

### **Authority Required**

#### **Initial 3**

Initial PBS-subsidised supply for continuing treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:

- (1) have a documented history of severe active psoriatic arthritis; and
- (2) were receiving treatment with adalimumab prior to 16 March 2006; and
- (3) have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab.

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
  - (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and*
  - (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form.*
- Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.*

*A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.*

*Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.*

*Patients may qualify for PBS-subsidised treatment under this restriction once only.*

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

## Authority Required

### Continuing treatment

Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:

- (1) who have a documented history of severe active psoriatic arthritis; and
- (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with adalimumab; and
- (3) who, at the time of application, demonstrate an adequate response to treatment with adalimumab.

An adequate response to treatment with adalimumab is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
  - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
  - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].

All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.

Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.

|       |                                              |   |   |    |         |       |        |    |
|-------|----------------------------------------------|---|---|----|---------|-------|--------|----|
| 9034L | Injection 40 mg in 0.8 mL pre-filled syringe | 2 | 5 | .. | 1773.93 | 31.30 | Humira | AB |
|-------|----------------------------------------------|---|---|----|---------|-------|--------|----|

|       |                                          |   |   |    |         |       |        |    |
|-------|------------------------------------------|---|---|----|---------|-------|--------|----|
| 9102C | Injection 40 mg in 0.8 mL pre-filled pen | 2 | 5 | .. | 1773.93 | 31.30 | Humira | AB |
|-------|------------------------------------------|---|---|----|---------|-------|--------|----|

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### **NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*

*Applications for treatment with adalimumab where the dosing frequency exceeds 40 mg per fortnight will not be approved.*

### **NOTE:**

#### **TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS**

*The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, etanercept and infliximab for adult patients with active ankylosing spondylitis. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab, etanercept and infliximab only.*

*A patient is eligible for PBS-subsidised treatment with only 1 of the 3 TNF-alfa antagonists at any 1 time.*

*From 1 March 2007, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.*

*A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 March 2007 is considered to be in their first cycle as of 1 March 2007.*

*Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than once. A patient who, prior to 1 March 2007, was authorised to receive PBS-subsidised initial treatment for ankylosing spondylitis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2007.*

*Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.*

*A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.*

*A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.*

*There is no limit to the number of treatment cycles a patient may undertake in their lifetime.*

*(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 March 2007.*

*(a) Initial treatment.*

*Applications for initial treatment should be made where:*

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or*
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or*
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).*

*Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for etanercept and adalimumab and 18 weeks of treatment for infliximab.*

*From 1 March 2007, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

continued ➡

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.*

*For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.*

### *(b) Continuing treatment.*

*Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.*

*It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.*

*Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.*

### *(2) Swapping therapy.*

*Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap to an alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.*

*A patient may trial an alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug within the same treatment cycle.*

*To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.*

*To avoid confusion, an application for a patient who wishes to swap to an alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.*

### *(3) Baseline measurements to determine response.*

*Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.*

*For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program. However, this is not required for any subsequent BASDAI results for these patients, nor for patients who were 'grandfathered' on to TNF-alfa antagonist treatment.*

*To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.*

### *(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured.*

*(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab.*

*A patient who commenced treatment with adalimumab for active ankylosing spondylitis prior to 1 November 2006 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.*

*A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.*

*Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab will be assessed under the continuing treatment restriction.*

*Where pre-TNF-alfa antagonist treatment baselines cannot be provided, the following criteria must be met to demonstrate a response to treatment:*

*The BASDAI score must be either:*

- (i) no more than 20% greater than the score included in the initial application for PBS-subsidised treatment; or*
- (ii) no greater than 2.*

*AND*

*One of the following:*

- (a) an ESR measurement no greater than 25 mm per hour; or*
- (b) a CRP measurement no greater than 10 mg per L.*

*'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.*

### **Authority Required**

#### **Initial 1 (new patients)**

*First course of PBS-subsidised treatment with adalimumab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept or infliximab in this treatment cycle; AND*

*(a) who has at least 2 of the following:*

- (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or*
- (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)]; or*
- (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)]; AND*

*(b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.*

*The application must include details of the NSAIDs trialled, their doses and duration of treatment. If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.*

*If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].*

*For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.*

*The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:*

- (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND*
- (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.*

*The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.*

*Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.*

*Authority applications must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:*
  - (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and*
  - (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and*
  - (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and*
  - (iv) a signed patient acknowledgment form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment with the TNF- $\alpha$  antagonists (adalimumab, etanercept or infliximab) for ankylosing spondylitis will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.*

*The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.*

*A maximum of 16 weeks of treatment with adalimumab will be approved under this criterion.*

*Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.*

### **Authority Required**

*Initial 2 (change or re-commencement for all patients)*

*Initial course of PBS-subsidised treatment with adalimumab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised treatment with either adalimumab, etanercept or infliximab for this condition and has not failed PBS-subsidised therapy with adalimumab.*

*To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF- $\alpha$  antagonist therapy within the timeframes specified in the relevant restriction.*

continued ➞



## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <p><i>Where the most recent course of PBS-subsidised TNF-<math>\alpha</math> antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. Where the most recent course of PBS-subsidised TNF-<math>\alpha</math> antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased.</i></p> <p><i>If the response assessment to the previous course of TNF-<math>\alpha</math> antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-<math>\alpha</math> antagonist.</i></p> <p><i>Authority applications must be made in writing and must include:</i></p> <p><i>(a) a completed authority prescription form; and</i></p> <p><i>(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their assessment.</i></p> <p><i>A maximum of 16 weeks of treatment with adalimumab will be approved under this criterion.</i></p> <p><i>Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</i></p> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9077R                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Injection 40 mg in 0.8 mL pre-filled syringe            | 2           | 3              | ..      | 1773.93                                  | 31.30                                                  | Humira                               | AB |
| 9103D                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Injection 40 mg in 0.8 mL pre-filled pen                | 2           | 3              | ..      | 1773.93                                  | 31.30                                                  | Humira                               | AB |

### NOTE:

No applications for increased maximum quantities and/or repeats will be authorised.

Applications for treatment with adalimumab where the dosing frequency exceeds 40 mg per fortnight will not be approved.

### Authority Required

*Initial ('grandfather' patients)*

Initial PBS-subsidised course of adalimumab treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who was receiving treatment with adalimumab prior to 1 November 2006; AND

(a) is receiving treatment with adalimumab at the time of application; AND

(b) has not received prior PBS-subsidised treatment with infliximab or etanercept; AND

(c) whose current Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score is either:

(i) less than or equal to 5 on a 0-10 scale; OR

(ii) improved by at least 2 from baseline; AND

(d) who has:

(i) an ESR measurement no greater than 25 mm per hour; or

(ii) a CRP measurement no greater than 10 mg per L; or

(iii) an ESR or CRP measurement reduced by at least 20% from pre-treatment baseline.

The BASDAI assessment and ESR and/or CRP measurements provided must be no more than 1 month old at the time of application. Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Authority applications must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes the following:*
  - (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and*
  - (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and*
  - (iii) a signed patient acknowledgment form included in the supporting information form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment with the TNF-alfa antagonists (adalimumab, etanercept or infliximab) for ankylosing spondylitis will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.*

*The assessment of the patient's response to this initial course of therapy must be made within the 4 weeks prior to completion of the course in order to ensure continuity of treatment.*

*A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.*

*A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.*

*Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.*

*Patients may only qualify for PBS-subsidised treatment under this criterion once.*

### **Authority Required**

*Continuing treatment for all patients*

*Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:*

- (a) has demonstrated a response to treatment with adalimumab; and*
- (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with adalimumab.*

*Response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:*

- (a) an ESR measurement no greater than 25 mm per hour; or*
- (b) a CRP measurement no greater than 10 mg per L; or*
- (c) an ESR or CRP measurement reduced by at least 20% from baseline.*

*For a 'grandfather' patient who does not have baselines prior to commencing treatment with a TNF-alfa antagonist, see Note 5 for a definition of response to treatment.*

*Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.*

*The first application for continuing treatment following an initial treatment course must be made following a minimum of 12 weeks of treatment with adalimumab.*

*Applications for continuing treatment must be made in writing and should be posted to Medicare Australia no less than 2 weeks prior to the completion of the current treatment course.*

continued ➞

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <p><b>Written applications for authorisation must include:</b></p> <p><b>(a) a completed authority prescription form; and</b></p> <p><b>(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their continuing treatment assessment.</b></p> <p><b>All measurements provided must be no more than 1 month old at the time of application.</b></p> <p><b>A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.</b></p> <p><b>Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.</b></p> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9078T                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Injection 40 mg in 0.8 mL pre-filled syringe            | 2           | 5              | ..      | 1773.93                                  | 31.30                                                  | Humira                               | AB |
| 9104E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Injection 40 mg in 0.8 mL pre-filled pen                | 2           | 5              | ..      | 1773.93                                  | 31.30                                                  | Humira                               | AB |

## NOTE:

No applications for increased maximum quantities and/or repeats will be authorised.

Applications for treatment with adalimumab where the dosing frequency exceeds 40 mg per fortnight will not be approved.

## NOTE:

### TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alpha antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.

From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.

A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.

Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.

A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.

There is no limit to the number of treatment cycles a patient may undertake in their lifetime.

(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2008.

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### (a) Initial treatment.

*Applications for initial treatment should be made where:*

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).

*Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.*

*From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.*

*For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.*

*Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.*

*(b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.*

*It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.*

*Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.*

### (2) Swapping therapy.

*Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.*

*A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.*

*To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.*

**(3) Baseline measurements to determine response.**

*Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or evidence of intestinal inflammation submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.*

*To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.*

**(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.**

*A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.*

**(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.**

*A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.*

*A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.*

*Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.*

*'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.*

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

## Authority Required

### Initial 1 (new patients)

*Initial treatment of Crohn disease in a patient assessed by CDAI.*

*Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:*

- (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and*
- (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and*
- (c) has failed to achieve an adequate response to prior systemic therapy including:*
  - (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and*
  - (ii) immunosuppressive therapy including:*
    - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or*
    - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or*
    - methotrexate at a dose of at least 15 mg weekly for 3 or more months.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application. .*

*If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)). .*

*The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:*

- (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.*

*All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

*The most recent CDAI assessment must be no more than 1 month old at the time of application.*

*Applications for authorisation must be made in writing and must include:*

- (a) two completed authority prescription forms; and*
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and*
  - (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and*
  - (iii) the signed patient acknowledgement.*

*A maximum of 16 weeks treatment will be authorised under this criterion.*

continued ➡

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats. Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

### Authority Required

#### Initial 2

Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.

Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:

- (a) has a documented history of severe refractory Crohn disease; and
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and
- (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.

Authority applications must be made in writing and must include:

- (a) two completed authority prescription forms; and
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:
  - (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and
  - (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.

continued ➡

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats. Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.

A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.

This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.

It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.

### Authority Required

#### Initial 1

Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.

Initial PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:

- (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and
- (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and
- (c) has evidence of intestinal inflammation; and
- (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and
- (e) has failed to achieve an adequate response to prior systemic drug therapy including:
  - (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and
  - (ii) immunosuppressive therapy including:
    - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or
    - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or
    - methotrexate at a dose of at least 15 mg weekly for 3 or more months.

NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).

continued ➞



## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:*

*(a) have evidence of intestinal inflammation, including:*

*(i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR*

*(ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR*

*(iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;*

*AND/OR*

*(b) be assessed clinically as being in a high faecal output state;*

*AND/OR*

*(c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.*

*All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

*Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.*

*Applications for authorisation must be made in writing and must include:*

*(a) two completed authority prescription forms; and*

*(b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*

*(i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and*

*(ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and*

*(iii) date of the most recent clinical assessment; and*

*(iv) the signed patient acknowledgement.*

*All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.*

*A maximum of 16 weeks treatment will be authorised under this criterion.*

*Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats. Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.*

*The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.*

*This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.*

*It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### **Authority Required**

#### ***Initial 2***

*Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.*

*Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:*

- (a) has a documented history of severe refractory Crohn disease; and*
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and*
- (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.*

*Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.*

*Authority applications must be made in writing and must include:*

- (a) two completed authority prescription forms; and*
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and*
  - (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.*

*A maximum of 16 weeks of treatment will be approved under this criterion.*

*Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats. Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.*

*The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.*

*This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.*

*It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.*

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

## Authority Required

### Initial 1

*Initial treatment of Crohn disease in a patient with extensive small intestine disease.*

*Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:*

*(a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and*

*(b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; and*

*(c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and*

*(d) has failed to achieve an adequate response to prior systemic therapy including:*

*(i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and*

*(ii) immunosuppressive therapy including:*

*— azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or*

*— 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or*

*— methotrexate at a dose of at least 15 mg weekly for 3 or more months.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.*

*Details of the accepted toxicities including severity can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).*

*The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:*

*(a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;*

*AND/OR*

*(b) have evidence of active intestinal inflammation, including:*

*(i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR*

*(ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR*

*(iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;*

*AND/OR*

*(c) be assessed clinically as being in a high faecal output state;*

*AND/OR*

*(d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.*

*All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <p><i>Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.</i></p> <p><i>Applications for authorisation must be made in writing and must include:</i></p> <p><i>(a) two completed authority prescription forms; and</i></p> <p><i>(b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (<a href="http://www.medicareaustralia.gov.au">www.medicareaustralia.gov.au</a>)] which includes the following:</i></p> <p><i>(i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and</i></p> <p><i>(ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or</i></p> <p><i>(2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and</i></p> <p><i>(iii) date of the most recent clinical assessment; and</i></p> <p><i>(iv) the signed patient acknowledgement.</i></p> <p><i>All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.</i></p> <p><i>A maximum of 16 weeks treatment of adalimumab will be authorised under his criterion.</i></p> <p><i>Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats. Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</i></p> <p><i>The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.</i></p> <p><i>This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</i></p> <p><i>It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.</i></p> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9186L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Injection 40 mg in 0.8 mL pre-filled syringe, 6         | 1           | ..             | ..      | 5035.93                                  | 31.30                                                  | Humira                               | AB |
| 9187M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Injection 40 mg in 0.8 mL pre-filled pen, 6             | 1           | ..             | ..      | 5035.93                                  | 31.30                                                  | Humira                               | AB |
| <p><b>NOTE:</b></p> <p><i>No applications for increased maximum quantities and/or repeats will be authorised.</i></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9188N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Injection 40 mg in 0.8 mL pre-filled syringe            | 2           | 2              | ..      | 1773.93                                  | 31.30                                                  | Humira                               | AB |
| 9190Q                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Injection 40 mg in 0.8 mL pre-filled pen                | 2           | 2              | ..      | 1773.93                                  | 31.30                                                  | Humira                               | AB |

continued

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### **NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*

### **Authority Required**

#### *Initial 3 (grandfather)*

*Initial PBS-subsidised treatment of Crohn disease in a patient assessed by CDAI who has previously received non-PBS-subsidised therapy with adalimumab.*

*Initial PBS-subsidised supply with adalimumab for continuing treatment by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who:*

- (a) has a documented history of severe refractory Crohn disease and was receiving treatment with adalimumab prior to 9 November 2007; and*
- (b) had a Crohn Disease Activity Index (CAI) Score of greater than or equal to 300 prior to commencing treatment with adalimumab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800 700 270 to discuss; and*
- (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and*
- (d) has demonstrated or sustained an adequate response to treatment with adalimumab. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*An adequate response to adalimumab treatment is defined as a reduction in Crohn Disease Activity Index (CAI) Score to no greater than 150.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current and baseline Crohn Disease Activity Index (CAI) Score calculation sheet including the date of the assessment of the patient's condition; and*
  - (ii) the signed patient acknowledgement.*

*The current CDAI assessment must be no more than 1 month old at the time of application. The baseline CDAI assessment must be from immediately prior to commencing treatment with adalimumab.*

*The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.*

*Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.*

*A maximum of 24 weeks treatment will be approved under this criterion.*

*Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Patients may qualify for PBS-subsidised treatment under this restriction once only.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### Authority Required

*Continuing treatment of Crohn disease in a patient assessed by CDAI.*

*Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:*

- (a) has a documented history of severe refractory Crohn disease; and*
- (b) has demonstrated or sustained an adequate response to treatment with adalimumab.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*An adequate response to adalimumab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition.*

*The CDAI assessment must be no more than 1 month old at the time of application.*

*If the application is the first application for continuing treatment with adalimumab, a CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.*

*The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.*

*Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.*

*Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.*

*A maximum of 24 weeks treatment will be authorised under this criterion.*

*Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

### Authority Required

*Continuing treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.*

*Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:*

- (a) has a documented history of severe refractory Crohn disease with intestinal inflammation and with short gut syndrome or with an ileostomy or colostomy; and*
- (b) has demonstrated or sustained an adequate response to treatment with adalimumab.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*An adequate response to adalimumab treatment is defined as:*

*(a) improvement of intestinal inflammation as demonstrated by:*

*(i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR*

*(ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR*

*(iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or*

*(b) reversal of high faecal output state; or*

*(c) avoidance of the need for surgery or total parenteral nutrition (TPN).*

*Applications for authorisation must be made in writing and must include:*

*(a) a completed authority prescription; and*

*(b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*

*(i) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy or the date of clinical assessment.*

*The patient's assessment must be no more than 1 month old at the time of application.*

*If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.*

*The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.*

*Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.*

*Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.*

*A maximum of 24 weeks of treatment will be authorised under this criterion.*

*Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

### **Authority Required**

*Continuing treatment of Crohn disease in a patient with extensive small intestine disease.*

*Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:*

*(a) has a documented history of severe refractory Crohn disease with extensive intestinal inflammation affecting more than 50 cm of the small intestine; and*

*(b) has demonstrated or sustained an adequate response to treatment with adalimumab.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

continued ➞

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*An adequate response to adalimumab treatment is defined as:*

*(a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or*

*(b) improvement of intestinal inflammation as demonstrated by:*

*(i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR*

*(ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR*

*(iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or*

*(c) reversal of high faecal output state; or*

*(d) avoidance of the need for surgery or total parenteral nutrition (TPN).*

*Applications for authorisation must be made in writing and must include:*

*(a) a completed authority prescription form; and*

*(b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*

*(i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; or*

*(ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy; or*

*(iii) the date of clinical assessment.*

*All assessments must be no more than 1 month old at the time of application.*

*If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.*

*The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.*

*Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.*

*Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.*

*A maximum of 24 weeks treatment will be authorised under this criterion.*

*Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

continued ➞



## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### Authority Required

#### *Initial 3*

*Initial PBS-subsidised treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient, or a patient with extensive small intestine disease, who has previously received non-PBS-subsidised therapy with adalimumab.*

*Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist, of a patient who:*

- (a) has a documented history of severe refractory Crohn disease and was receiving treatment with adalimumab prior to 9 November 2007; and*
- (b) (1) has a history of extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; or*
- (2) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy with a documented history of intestinal inflammation; and*
- (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and*
- (d) has demonstrated or sustained an adequate response to treatment with adalimumab according to the criteria included in the relevant continuation restriction. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*The same criteria used to determine an inadequate response to prior treatment at baseline must be used to determine response to treatment and eligibility for continuing therapy, according to the criteria included in the continuing treatment restriction.*

*An adequate response to adalimumab treatment is defined as:*

- (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or*
- (b) improvement of intestinal inflammation as demonstrated by:*
  - (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR*
  - (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR*
  - (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or*
- (c) reversal of high faecal output state; or*
- (d) avoidance of the need for surgery or total parenteral nutrition (TPN).*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)) ] which includes the following:*
  - (i) (1) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet, where relevant, including the date of the assessment of the patient's condition; or*
  - (2) the reports and dates of the current and baseline pathology or diagnostic imaging test(s) in order to assess response to therapy; or*
  - (3) the date of clinical assessment(s); and*
  - (ii) the signed patient acknowledgement.*

*The patient's assessment must be no more than 1 month old at the time of application. The baseline CDAI assessments must be from immediately prior to commencing treatment with adalimumab. Where a baseline assessment is not available, please call Medicare Australia on 1800 700 270 to discuss.*

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| <p><i>The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</i></p> <p><i>Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</i></p> <p><i>Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</i></p> <p><i>Patients who fail to demonstrate or sustain a response to treatment with adalimumab for Crohn disease as specified in the criteria for continuing treatment with adalimumab, will not be eligible to recommence PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.</i></p> <p><i>A maximum of 24 weeks treatment will be authorised under this criterion.</i></p> <p><i>Where fewer than 5 repeats are requested at the time of this application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</i></p> <p><i>Patients may qualify for PBS-subsidised treatment under this restriction once only.</i></p> |                                                         |             |                |         |                             |                                             |                                      |    |
| 9189P                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Injection 40 mg in 0.8 mL pre-filled syringe            | 2           | 5              | ..      | 1773.93                     | 31.30                                       | Humira                               | AB |
| 9191R                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Injection 40 mg in 0.8 mL pre-filled pen                | 2           | 5              | ..      | 1773.93                     | 31.30                                       | Humira                               | AB |

## NOTE:

No applications for increased maximum quantities and/or repeats will be authorised.

## ETANERCEPT

### NOTE:

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia

Prior Written Approval of Specialised Drugs

Reply Paid 9826

GPO Box 9826

HOBART TAS 7001

Further prescribing information is on the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).

### NOTE:

#### TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, etanercept and infliximab for adult patients with active ankylosing spondylitis. Where the term 'tumour necrosis factor (TNF)  $\alpha$  antagonist' appears in the following NOTES and restrictions, it refers to adalimumab, etanercept and infliximab only.

A patient is eligible for PBS-subsidised treatment with only 1 of the 3 TNF- $\alpha$  antagonists at any 1 time.

From 1 March 2007, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF- $\alpha$  antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF- $\alpha$  antagonist while they continue to show a response to therapy.

continued ➞

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 March 2007 is considered to be in their first cycle as of 1 March 2007.*

*Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than once. A patient who, prior to 1 March 2007, was authorised to receive PBS-subsidised initial treatment for ankylosing spondylitis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2007.*

*Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.*

*A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.*

*A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.*

*There is no limit to the number of treatment cycles a patient may undertake in their lifetime.*

*(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 March 2007.*

*(a) Initial treatment.*

*Applications for initial treatment should be made where:*

*(i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or*

*(ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or*

*(iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).*

*Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for etanercept and adalimumab and 18 weeks of treatment for infliximab.*

*From 1 March 2007, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.*

*For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.*

*(b) Continuing treatment.*

*Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.*

*It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.*

*Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.*

### *(2) Swapping therapy.*

*Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap to an alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.*

*A patient may trial an alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug within the same treatment cycle.*

*To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.*

*To avoid confusion, an application for a patient who wishes to swap to an alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.*

### *(3) Baseline measurements to determine response.*

*Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.*

*For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program. However, this is not required for any subsequent BASDAI results for these patients, nor for patients who were 'grandfathered' on to TNF-alfa antagonist treatment.*

*To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.*

### *(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.*

*A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured.*

### *(5) Patients 'grandfathered' onto PBS-subsidised treatment with etanercept.*

*From 1 March 2007, a patient who commenced treatment with etanercept for active ankylosing spondylitis prior to 1 July 2004 and who was 'grandfathered' onto PBS-subsidised therapy, and who continues to receive treatment in the same treatment cycle, will have further applications for treatment with etanercept assessed under the continuing treatment restriction.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Where pre-TNF- $\alpha$  antagonist treatment baselines were not provided, the following criteria must be met to demonstrate a response to treatment:*

*The BASDAI score must be either:*

- (i) no more than 20% greater than the score included in the initial application for PBS-subsidised treatment; or*
- (ii) no greater than 2.*

*AND*

*One of the following:*

- (a) an ESR measurement no greater than 25 mm per hour; or*
- (b) a CRP measurement no greater than 10 mg per L.*

*'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.*

### **Authority Required**

#### *Initial 1 (new patients)*

*First course of PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept or infliximab in this treatment cycle; AND*

*(a) who has at least 2 of the following:*

- (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or*
- (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)]; or*
- (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)]; AND*

*(b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.*

*The application must include details of the NSAIDs trialled, their doses and duration of treatment. If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.*

*If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.*

*If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [[www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)].*

*For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).*

*The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:*

- (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND*
- (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.*

*The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.*

*Authority applications must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:*
  - (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and*
  - (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and*
  - (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and*
  - (iv) a signed patient acknowledgment form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment with the TNF-alfa antagonists (adalimumab, etanercept or infliximab) for ankylosing spondylitis will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.*

*The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.*

*A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.*

*Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.*

### Authority Required

*Initial 2 (change or re-commencement for all patients)*

*Initial course of PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised treatment with either adalimumab, etanercept or infliximab for this condition and has not failed PBS-subsidised therapy with etanercept.*

*To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.*

*Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased.*

*If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.*

*Authority applications must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their assessment.*

*A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.*

*Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form                                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|----------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8778B | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | 2           | 3              | ..      | * 1828.57                                | 31.30                                                  | Enbrel                               | WX |
| 9081Y | Injection set containing 4 vials powder for injection 50 mg and 4 pre-filled syringes solvent 1 mL | 1           | 3              | ..      | 1773.94                                  | 31.30                                                  | Enbrel                               | WX |
| 9085E | Injections 50 mg in 1 mL single use pre-filled syringes, 4                                         | 1           | 3              | ..      | 1773.94                                  | 31.30                                                  | Enbrel                               | WX |

### NOTE:

No applications for increased maximum quantities and/or repeats will be authorised.

### Authority Required

Continuing treatment for all patients

Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:

(a) has demonstrated a response to treatment with etanercept; and

(b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with etanercept.

Response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:

(a) an ESR measurement no greater than 25 mm per hour; or

(b) a CRP measurement no greater than 10 mg per L; or

(c) an ESR or CRP measurement reduced by at least 20% from baseline.

For a 'grandfather' patient who does not have baselines prior to commencing treatment with a TNF-alfa antagonist, see Note 5 for a definition of response to treatment.

Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.

Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment.

Applications for continuing treatment must be made in writing and should be posted to Medicare Australia no less than 2 weeks prior to the completion of the current treatment course.

Written applications for authorisation must include:

(a) a completed authority prescription form; and

(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their continuing treatment assessment.

All measurements provided must be no more than 1 month old at the time of application.

A maximum of 24 weeks of treatment with etanercept will be authorised under this criterion.

Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form                                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|----------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8779C | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | 2           | 5              | ..      | * 1828.57                                | 31.30                                                  | Enbrel                               | WX |
| 9082B | Injection set containing 4 vials powder for injection 50 mg and 4 pre-filled syringes solvent 1 mL | 1           | 5              | ..      | 1773.94                                  | 31.30                                                  | Enbrel                               | WX |
| 9086F | Injections 50 mg in 1 mL single use pre-filled syringes, 4                                         | 1           | 5              | ..      | 1773.94                                  | 31.30                                                  | Enbrel                               | WX |

**NOTE:**

No applications for increased maximum quantities and/or repeats will be authorised.

**NOTE:**

**TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS**

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept and infliximab) for adult patients with severe active psoriatic arthritis.

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time. Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept and infliximab.

From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept or infliximab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.

Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].

The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.

Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.

Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.

There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.

How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2006.

**(1) Initial treatment.**

continued ➡



## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Applications for initial treatment should be made where:*

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and*
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and*
- (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).*

*All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.*

*Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.*

*Grandfather patients.*

*Applications for patients who commenced treatment with etanercept prior to 17 March 2005 or adalimumab and infliximab prior to 16 March 2006, may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.*

*Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.*

### *(2) Continuing treatment.*

*Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.*

*Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.*

### *(3) Swapping therapy.*

*Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.*

*Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.*

*Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:*

- (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or*
- (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS.*

*To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.*

**(4) Baseline measurements to determine response.**

*Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.*

*To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.*

**(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.**

*Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate or sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.*

### **Authority Required**

#### **Initial 1**

*Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:*

- (1) have severe active psoriatic arthritis; and*
- (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and*
- (3) have failed to achieve an adequate response to:*
  - (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and*
  - (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or*
  - (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.*

*Patients must have had the psoriatic component of their disease confirmed by a dermatologist or by biopsy at any time.*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities, including severity, can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).*

continued ➡

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:*

*an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either*

*(i) an active joint count of at least 20 active (swollen and tender) joints; or*

*(ii) at least 4 active joints from the following list of major joints:*

*— elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*

*— shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.*

*The authority application must be made in writing and must include:*

*(1) a completed authority prescription form; and*

*(2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and*

*(3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.*

### **Authority Required**

#### **Initial 2**

*Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:*

*(1) have a documented history of severe active psoriatic arthritis; and*

*(2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and*

*(3) have not failed treatment with etanercept during the current Treatment Cycle.*

*Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.*

*Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Name, Restriction,<br>Manner of Administration and Form                                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <p><i>The authority application must be made in writing and must include:</i></p> <p>(1) a completed authority prescription form; and</p> <p>(2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (<a href="http://www.medicareaustralia.gov.au">www.medicareaustralia.gov.au</a>)].</p> <p>Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</p> <p>Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.</p> <p>Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.</p> |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 9035M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | 2           | 3              | ..      | * 1828.57                                | 31.30                                                  | Enbrel                               | WX |
| 9083C                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Injection set containing 4 vials powder for injection 50 mg and 4 pre-filled syringes solvent 1 mL | 1           | 3              | ..      | 1773.94                                  | 31.30                                                  | Enbrel                               | WX |
| 9087G                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Injections 50 mg in 1 mL single use pre-filled syringes, 4                                         | 1           | 3              | ..      | 1773.94                                  | 31.30                                                  | Enbrel                               | WX |

### NOTE:

No applications for increased maximum quantities and/or repeats will be authorised.

### Authority Required

#### *Initial 3*

Initial PBS-subsidised supply for continuing treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:

- (1) have a documented history of severe active psoriatic arthritis; and
- (2) were receiving treatment with etanercept prior to 17 March 2005; and
- (3) have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with etanercept.

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and
  - (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))]; and
  - (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form.
- Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.

A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

continued ➡

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Name, Restriction,<br>Manner of Administration and Form                                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                    |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| <p><i>Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.</i></p> <p><i>Patients may qualify for PBS-subsidised treatment under this restriction once only.</i></p>                                                                                                                                                                                                                                                                                                                                                          |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| <b>Continuing treatment</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| (1) who have a documented history of severe active psoriatic arthritis; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with etanercept; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| (3) who, at the time of application, demonstrate an adequate response to treatment with etanercept.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| An adequate response to treatment with etanercept is defined as:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| — elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| — shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| The authority application must be made in writing and must include:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| (1) a completed authority prescription form; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ( <a href="http://www.medicareaustralia.gov.au">www.medicareaustralia.gov.au</a> )].                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.                                                                                                                                                                                                      |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| <p><i>Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.</i></p> <p><i>Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.</i></p> |                                                                                                    |             |                |         |                             |                                             |                                      |    |
| 9036N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | 2           | 5              | ..      | * 1828.57                   | 31.30                                       | Enbrel                               | WX |
| 9084D                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Injection set containing 4 vials powder for injection 50 mg and 4 pre-filled syringes solvent 1 mL | 1           | 5              | ..      | 1773.94                     | 31.30                                       | Enbrel                               | WX |

continued ➞

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form       | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|       |                                                               |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| 9088H | Injections 50 mg in 1 mL single use<br>pre-filled syringes, 4 | 1           | 5              | ..      | 1773.94                     | 31.30                                       | Enbrel                               | WX |

**NOTE:**

No applications for increased maximum quantities and/or repeats will be authorised.

**NOTE:****TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS**

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, etanercept, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-1 inhibitor (anakinra) and the T-cell co-stimulation modulator (abatacept).

Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.

PBS-subsidised infliximab, anakinra, rituximab and abatacept must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are only eligible to receive PBS-subsidised etanercept and adalimumab.

In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.

From 1 March 2008, under the PBS, all patients will be able to commence a Treatment Cycle where they may trial PBS-subsidised bDMARD agents without having to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Treatment Cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.

A patient who received PBS-subsidised bDMARD treatment prior to 1 March 2008 is considered to be in their first Cycle as of 1 March 2008.

Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next Cycle.

For patients who have failed PBS-subsidised treatment with 3 bDMARDs prior to 1 March 2008 please contact Medicare Australia on 1800 700 270.

The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent Cycle to the date of the first application for initial treatment with a bDMARD under the new Treatment Cycle.

A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same Treatment Cycle.

A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of more than 5 years, may commence a new Treatment Cycle.

There is no limit to the number of Treatment Cycles a patient may undertake in their lifetime.

If patients fail to respond to a particular bDMARD within a single Treatment Cycle, they are not eligible to receive further PBS-subsidised treatment with that drug until they commence the next Cycle.

(1) How to prescribe PBS-subsidised bDMARD therapy after 1 March 2008.

continued ➡

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

## (a) Initial treatment.

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this Treatment Cycle and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for etanercept, adalimumab, anakinra and abatacept, 22 weeks of therapy for infliximab and 2 infusions of rituximab.

From 1 March 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

### Rituximab patients:

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

## (b) Continuing treatment.

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

### Rituximab patients:

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

## (2) Swapping therapy.

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same Treatment Cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.*

*A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same Treatment Cycle.*

*In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF- $\alpha$  antagonist treatment.*

*To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.*

*PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.*

*To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.*

### **NOTE:**

*(3) Baseline measurements to determine response.*

*Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a Treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.*

*To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.*

*The baseline joint and blood counts should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment.*

*(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.*

*A patient who wishes to trial a second or subsequent Treatment Cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 non-biological DMARD, at an adequate dose, for a minimum of 3 months at the time the ESR and/or CRP levels and the active joint count are measured.*

*(5) Patients 'grandfathered' onto PBS-subsidised treatment with rituximab or abatacept.*

*From 1 March 2008, a patient who commenced treatment with rituximab for severe rheumatoid arthritis prior to 7 March 2007 or abatacept for severe rheumatoid arthritis prior to 1 November 2007 and who was 'grandfathered' on to PBS-subsidised therapy, and who continues to receive treatment in the same Treatment Cycle, will have further applications for treatment with rituximab or abatacept assessed under the continuing treatment restriction.*



## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with abatacept will be authorised under this criterion.*

*'Grandfather' arrangements will only apply for the first Treatment Cycle. For the second and subsequent Cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that applies to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.*

### **Authority Required**

#### *Initial 1 (new patients)*

*Application for initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:*

- (a) have severe active rheumatoid arthritis; and*
- (b) have received no prior PBS-subsidised treatment with a bDMARD for this condition in this treatment cycle; and*
- (c) have failed to achieve an adequate response to the following treatments:*
  - (i) methotrexate at a dose of at least 20 mg weekly; and*
  - (ii) methotrexate (at a minimum dose of 7.5 mg weekly), in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; and*
  - (iii) a minimum of 3 months' treatment with:*
    - leflunomide alone; or*
    - leflunomide in combination with methotrexate; or*
    - cyclosporin.*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.*

*Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].*

*The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:*

*an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;*

*AND either*

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or*
- (ii) at least 4 active joints from the following list of major joints:*
  - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*
  - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

*If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and*
- (3) a signed patient acknowledgement.*

*A maximum of 16 weeks of treatment will be authorised under this restriction.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.*

*Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.*

### **Authority Required**

*Initial 2 (change or re-commencement)*

*Application for an initial course of PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:*

- (a) have a documented history of severe active rheumatoid arthritis; and*
- (b) have received prior PBS-subsidised bDMARD treatment for this condition in this treatment cycle and are eligible to receive further bDMARD therapy.*

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].*

*Applications for patients who have received PBS-subsidised treatment with etanercept within this treatment cycle and who wish to re-commence therapy with this drug within this same cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.*

*A maximum of 16 weeks of treatment will be authorised under this restriction.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.*

### Authority Required

*Initial treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years; AND*

*(a) who have signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if the predetermined response criteria do not support continuation of PBS-subsidised treatment; AND*

*(b) who have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly; AND*

*(c) who have failed to achieve an adequate response to methotrexate, in combination with 2 other disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; AND*

*(d) who have subsequently failed to achieve an adequate response following a minimum of 3 months' treatment with:*

*(i) leflunomide alone; or*

*(ii) leflunomide in combination with methotrexate; or*

*(iii) cyclosporin.*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or intolerance of a severity necessitating permanent treatment withdrawal develops during the relevant period of use, the patient is exempted from demonstrating an inadequate response to the above treatment regimens. Details of the contraindication or intolerance, including the degree of toxicity, must be provided at the time of application.*

*The following criteria must be met in order to demonstrate failure to achieve an adequate response:*

*an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either*

*(i) an active joint count of at least 20 active (swollen and tender) joints; or*

*(ii) at least 4 active joints from the following list:*

*— elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*

*— shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.*

*The authority application must be in writing and must include sufficient information to determine the patient's eligibility according to the above criteria. The date of joint assessment must be provided.*

*Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 4 months of treatment may be requested by telephone. Under no circumstances will telephone approvals be granted for initial or continuing authority applications, or for treatment that would otherwise extend the initial treatment period beyond 4 months.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                          | Name, Restriction,<br>Manner of Administration and Form                                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <i>The assessment of the patient's response to the initial course of treatment should be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. Applications for continuing treatment with etanercept should be made prior to the completion of 16 weeks of treatment to ensure continuity for those patients who meet the criteria.</i> |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 8637N                                                                                                                                                                                                                                                                                                                                                                                         | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | 2           | 3              | ..      | * 1828.57                                | 31.30                                                  | Enbrel                               | WX |
| 8861J                                                                                                                                                                                                                                                                                                                                                                                         | Injection set containing 4 vials powder for injection 50 mg and 4 pre-filled syringes solvent 1 mL | 1           | 3              | ..      | 1773.94                                  | 31.30                                                  | Enbrel                               | WX |
| 9089J                                                                                                                                                                                                                                                                                                                                                                                         | Injections 50 mg in 1 mL single use pre-filled syringes, 4                                         | 1           | 3              | ..      | 1773.94                                  | 31.30                                                  | Enbrel                               | WX |

### NOTE:

No applications for increased maximum quantities and/or repeats will be authorised.

### Authority Required

#### *Continuing treatment*

Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:

- (a) who have a documented history of severe active rheumatoid arthritis; and
- (b) who have demonstrated an adequate response to treatment with etanercept; and
- (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.

An adequate response to treatment is defined as:

an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;

AND either of the following:

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:
  - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or
  - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].

A maximum of 24 weeks of treatment will be approved under this restriction.

Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

continued ➡

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.*

*Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.*

### **Authority Required**

*Initial PBS-subsidised supply for continuing treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, and who were receiving treatment with etanercept prior to 1 December 2002; AND*

*(a) who have signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if the predetermined response criteria do not support continuation of PBS-subsidised treatment; AND*

*(b) who have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with etanercept.*

*The authority application must be in writing and must include sufficient information to determine the patient's eligibility. The date of assessment of the patient must be provided.*

### **Authority Required**

*Continuing PBS-subsidised treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, who, at the time of application, demonstrate an adequate response to treatment with etanercept as manifested by:*

*an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND 1 or more of the following:*

*(i) an active joint count of fewer than 10 active (swollen and tender) joints; or*

*(ii) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; or*

*(iii) a reduction in the number of the following active joints, from at least 4, by at least 50%:*

*— elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*

*— shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*All authority applications for continuing treatment with etanercept must be in writing and must include sufficient information to determine the patient's response according to the above criteria. The date of assessment of the patient must be provided.*

*Patients who fail to demonstrate an adequate response, as specified in the criteria for continuing treatment with etanercept, will not be eligible to recommence treatment with etanercept within 12 months of the date on which treatment was ceased.*

*Where re-treatment with etanercept after a break in PBS-subsidised treatment with the drug is being sought, the reason for and date of cessation of the previous treatment course with etanercept must be included in the application.*

|       |                                                                                                    |   |   |    |           |       |        |    |
|-------|----------------------------------------------------------------------------------------------------|---|---|----|-----------|-------|--------|----|
| 8638P | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | 2 | 5 | .. | * 1828.57 | 31.30 | Enbrel | WX |
|-------|----------------------------------------------------------------------------------------------------|---|---|----|-----------|-------|--------|----|

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form                                                  | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|----------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8862K | Injection set containing 4 vials powder<br>for injection 50 mg and 4 pre-filled<br>syringes solvent 1 mL | 1           | 5              | ..      | 1773.94                                  | 31.30                                                  | Enbrel                               | WX |
| 9090K | Injections 50 mg in 1 mL single use<br>pre-filled syringes, 4                                            | 1           | 5              | ..      | 1773.94                                  | 31.30                                                  | Enbrel                               | WX |

**NOTE:**

No applications for increased maximum quantities and/or repeats will be authorised.

**NOTE:**

**TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS**

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents efalizumab, etanercept and infliximab, for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to efalizumab, etanercept and infliximab.

From 1 December 2007, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial efalizumab, etanercept or infliximab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.

A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 December 2007 is considered to be in their first Cycle as of 1 December 2007.

Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.

Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment. A patient who, prior to 1 December 2007, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 December 2007.

Initial treatment with efalizumab consists of 16 weeks of therapy, with infliximab consists of 22 weeks of therapy, and with etanercept consists of 12 weeks of active therapy followed by a biological treatment-free period of at least 12 weeks. Response to treatment for all 3 agents must be assessed after 12 weeks of treatment.

Following demonstration of response to initial treatment, these biological agents are available as continuing therapy. Ongoing access to continuing treatment is available for as long as the response to therapy is sustained. In the case of efalizumab and infliximab, continuing treatment consists of 24 weeks of continuous active treatment. In the case of etanercept, continuing treatment consists of 12 weeks of active therapy followed by a biological treatment-free period of at least 12 weeks.

Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.

Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.

Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.

continued ➡

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.*

*There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.*

*How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 December 2007.*

*There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.*

*(1) Application for approval for initial treatment.*

*Applications for a course of initial treatment should be made in the following situations:*

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and*
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; and*
- (iii) patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).*

*All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy in the case of efalizumab, 12 weeks of therapy in the case of etanercept, and 22 weeks of treatment in the case of infliximab. Approval will be based on the criteria included in the relevant initial treatment restriction.*

*Grandfather patients (Infliximab only).*

*Applications for patients who commenced treatment with infliximab prior to 7 March 2007, may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.*

*Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.*

*(2) Assessment of response to initial treatment.*

*When prescribing efalizumab or infliximab, where the initial treatment course is for 16 or 22 weeks respectively, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with efalizumab or infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*Applications for continuing treatment with efalizumab or infliximab must also be submitted to Medicare Australia prior to the completion of this initial course of therapy to ensure continuity of treatment for those patients who meet the continuation criterion and wish to continue on treatment with either efalizumab or infliximab.*

*When prescribing etanercept, a PASI assessment must be conducted at the completion of the 12 week initial treatment course. This assessment, which will be used to determine eligibility for future treatment according to the criterion included in the relevant continuing treatment restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.*

*(3) Application for continuing treatment.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*As stated above, following the completion of an initial treatment course of efalizumab or infliximab to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with efalizumab or infliximab. Patients are eligible to continue to receive continuous treatment with efalizumab or infliximab in 24 week courses providing they continue to sustain a response.*

*For second and subsequent courses of PBS-subsidised treatment with efalizumab or infliximab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.*

*At the completion of an initial 12 week treatment course of etanercept to which an adequate response has been demonstrated, followed by a biological treatment-free period of at least 12 weeks, patients may qualify to receive continuing treatment with etanercept. Continuing treatment is available in the form of 12 weeks of active etanercept treatment followed by a biological treatment-free period of at least 12 weeks. Patients are eligible to receive continuing treatment with etanercept on this cyclical basis, for as long as they continue to sustain a response. Continuing applications must be submitted at least 12 weeks after cessation of the most recent course of etanercept treatment.*

*A PASI assessment must be conducted for each course of continuing treatment for each biological agent, according to the requirements set out in the relevant restriction. Assessment of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 1 month from the date that course was completed or treatment was ceased.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

### **NOTE:**

#### **(4) Swapping therapy.**

*Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.*

*Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.*

*Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent in the same Cycle.*

*Patients who commenced treatment with infliximab prior to 7 March 2007 access these interchangeability arrangements in the same way as patients who have not.*

*PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required 12 week biological treatment-free period applying to patients who have demonstrated a response to their most recent course of etanercept. This means that patients who have demonstrated a response to a 12 week course of etanercept must have a PBS-subsidised biological therapy treatment-free period of at least 12 weeks, immediately following this course of treatment, before swapping to efalizumab or infliximab. Patients who fail to respond to etanercept and who qualify and wish to try a course of efalizumab or infliximab, may do so without having to have any treatment-free period.*

*To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.*

*To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.*

#### **(5) Baseline measurements to determine response.**

continued ➞



## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.

For new patients and patients commencing a new Cycle, the first baseline PASI assessment must be conducted, preferably while the patient is still receiving their most recent prior therapy, but no later than 1 month following cessation of such therapy, as outlined in the relevant restriction. This is not required for any subsequent PASI scores provided for these patients within the same Cycle, nor for patients who received initial PBS-subsidised therapy under a 'grandfather' restriction.

To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.

(6) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.

### Authority Required

Initial treatment [Initial 1, Whole body (New patients — No prior biological agent)]

Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:

- (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and
- (c) have signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:
  - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or
  - (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or
  - (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or
  - (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:*

- (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.*
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))];* and
  - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and*
  - (iii) the signed patient acknowledgement.*

*A maximum of 12 weeks of treatment with etanercept will be authorised under this restriction.*

*Where fewer than 2 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 12 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 12 weeks.*

*A PASI assessment of the patient's response must be made at the completion of this 12 week initial treatment course. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*Patients who demonstrate a response to treatment according to the response criterion included in the continuing treatment restriction for etanercept, may access continuing treatment with etanercept following a biological treatment-free period of at least 12 weeks.*

*Patients who fail to demonstrate such a response to etanercept treatment may trial an alternate biological agent according to the interchangeability arrangements for biological agents for the treatment of severe chronic plaque psoriasis, without having to have a 12 week treatment-free period before doing so.*

### **Authority Required**

*Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]*

*Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:*

- (a) have a documented history of severe chronic plaque psoriasis; and*
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and*
- (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))];* and
  - (ii) details of prior biological treatment, including dosage, date and duration of treatment.*

*Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.*

*A maximum of 12 weeks of treatment with etanercept will be authorised under this restriction.*

*Where fewer than 2 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 12 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 12 weeks.*

*A PASI assessment of the patient's response must be made at the completion of this 12 week course of treatment. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*Patients who demonstrate a response to treatment according to the response criterion included in the continuing treatment restriction for etanercept, may access continuing treatment with etanercept following a biological treatment-free period of at least 12 weeks.*

*Patients who fail to demonstrate such a response to etanercept treatment and who qualify to trial an alternate biological agent according to the interchangeability arrangements for biological agents for the treatment of severe chronic plaque psoriasis, may do so without having to have a 12 week treatment-free period.*

*Patients who fail to demonstrate a response to treatment with each of the biological agents, efalizumab, etanercept and infliximab, are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.*

### **Authority Required**

*Continuing treatment (Whole body)*

*Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:*

- (a) who have a documented history of severe chronic plaque psoriasis; and*
- (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and*
- (c) who have demonstrated an adequate response to their most recent course of treatment with etanercept.*

*An adequate response to treatment is defined as:*

*A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.*

continued 

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*This assessment must be after 12 weeks of etanercept treatment and must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.*

*Approval will be based on the PASI assessment of response to the most recent course of treatment with etanercept.*

*A maximum of 12 weeks of treatment with etanercept will be authorised under this restriction.*

*Where fewer than 2 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 12 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 12 weeks.*

*A PASI assessment of the patient's response must be made at the completion of each 12 week active treatment course. This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*Patients who demonstrate a response to treatment according to the response criterion included in this restriction, may access further continuing treatment with etanercept, following a biological treatment-free period of at least 12 weeks.*

*Continuing treatment is available in the form of 12 weeks of active etanercept treatment followed by a biological treatment-free period of at least 12 weeks. Patients are eligible to receive continuing treatment with etanercept on this cyclical basis, for as long as they continue to sustain a response. Continuing applications for treatment must be submitted at least 12 weeks after cessation of the most recent course of etanercept treatment.*

*Patients who fail to demonstrate such a response to etanercept treatment and who qualify to trial an alternate biological agent according to the interchangeability arrangements for biological agents for the treatment of severe chronic plaque psoriasis, may do so without having to have a 12 week treatment-free period.*

*Patients who fail to demonstrate a response to treatment with each of the biological agents, efalizumab, etanercept and infliximab, are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.*

continued ➞

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

## Authority Required

*Initial treatment [Initial 1, Face, hand, foot (New patients — No prior biological agent)]*

*Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:*

- (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and*
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and*
- (c) have signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and*
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:*
  - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or*
  - (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or*
  - (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or*
  - (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).*

*The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:*

- (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:*
  - (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or*
  - (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.*
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))]; and*
  - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and*
  - (iii) the signed patient acknowledgement.*

*A maximum of 12 weeks of treatment with etanercept will be authorised under this restriction.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Where fewer than 2 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 12 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 12 weeks.*

*A PASI assessment of the patient's response must be made at the completion of this 12 week initial treatment course. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*Patients who demonstrate a response to treatment according to the response criterion included in the continuing treatment restriction for etanercept, may access continuing treatment with etanercept following a biological treatment-free period of at least 12 weeks.*

*Patients who fail to demonstrate such a response to etanercept treatment may trial an alternate biological agent according to the interchangeability arrangements for biological agents for the treatment of severe chronic plaque psoriasis, without having to have a 12 week treatment-free period before doing so.*

*The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.*

### **Authority Required**

*Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]*

*Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:*  
(a) *have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and*

*(b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and*

*(c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.*

*Applications for authorisation must be made in writing and must include:*

*(a) a completed authority prescription form; and*

*(b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*

*(i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))]; and*

*(ii) details of prior biological treatment, including dosage, date and duration of treatment.*

*Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.*

*A maximum of 12 weeks of treatment with etanercept will be authorised under this restriction.*

*Where fewer than 2 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 12 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 12 weeks.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*A PASI assessment of the patient's response must be made at the completion of this 12 week treatment course. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*Patients who demonstrate a response to treatment according to the response criterion included in the continuing treatment restriction for etanercept, may access continuing treatment with etanercept following a biological treatment-free period of at least 12 weeks.*

*Patients who fail to demonstrate such a response to etanercept treatment and who qualify to trial an alternate biological agent according to the interchangeability arrangements for biological agents for the treatment of chronic plaque psoriasis, may do so without having to have a 12 week treatment-free period.*

*The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.*

*Patients who fail to demonstrate a response to treatment with each of the biological agents, efalizumab, etanercept and infliximab, are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.*

### **Authority Required**

*Continuing treatment (Face, hand, foot)*

*Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:*

- (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and*
- (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and*
- (c) who have demonstrated an adequate response to treatment with etanercept.*

*An adequate response to etanercept treatment is defined as the plaque or plaques assessed prior to biological treatment showing:*

- (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or*
- (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.*

*This assessment must be made after 12 weeks of etanercept treatment and must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].*

*A maximum of 12 weeks of treatment with etanercept will be authorised under this restriction.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Name, Restriction,<br>Manner of Administration and Form                                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <p><i>Where fewer than 2 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 12 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 12 weeks.</i></p> <p><i>A PASI assessment of the patient's response must be made at the completion of each 12 week active treatment course. This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.</i></p> <p><i>Patients who demonstrate a response to treatment according to the response criterion included in this restriction, may access further continuing treatment with etanercept, following a biological treatment-free period of at least 12 weeks.</i></p> <p><i>Continuing treatment is available in the form of 12 weeks of active etanercept treatment followed by a biological treatment-free period of at least 12 weeks. Patients are eligible to receive continuing treatment with etanercept on this cyclical basis, for as long as they continue to sustain a response. Continuing applications can only be submitted at least 12 weeks after cessation of the most recent course of etanercept treatment.</i></p> <p><i>Patients who fail to demonstrate such a response to etanercept treatment and who qualify to trial an alternate biological agent according to the interchangeability arrangements for biological agents for the treatment of severe chronic plaque psoriasis, may do so without having to have a 12 week treatment-free period.</i></p> <p><i>The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.</i></p> <p><i>Patients who fail to demonstrate a response to treatment with each of the biological agents, efalizumab, etanercept and infliximab, are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.</i></p> |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 9037P                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | 2           | 2              | ..      | * 1828.57                                | 31.30                                                  | Enbrel                               | WX |
| 9038Q                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Injection set containing 4 vials powder for injection 50 mg and 4 pre-filled syringes solvent 1 mL | 1           | 2              | ..      | 1773.94                                  | 31.30                                                  | Enbrel                               | WX |
| 9091L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Injections 50 mg in 1 mL single use pre-filled syringes, 4                                         | 1           | 2              | ..      | 1773.94                                  | 31.30                                                  | Enbrel                               | WX |

**NOTE:**

No applications for increased maximum quantities and/or repeats will be authorised.

• **Interleukin inhibitors**

ANAKINRA

**NOTE:**

Any queries concerning the arrangements to prescribe anakinra may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe anakinra should be forwarded to:

continued ➞



# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

## Medicare Australia

*Prior Written Approval of Specialised Drugs*

*Reply Paid 9826*

*GPO Box 9826*

*HOBART TAS 7001*

*Further prescribing information is on the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).*

### NOTE:

#### **TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS**

*The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, etanercept, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-1 inhibitor (anakinra) and the T-cell co-stimulation modulator (abatacept).*

*Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.*

*PBS-subsidised infliximab, anakinra, rituximab and abatacept must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are only eligible to receive PBS-subsidised etanercept and adalimumab.*

*In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.*

*From 1 March 2008, under the PBS, all patients will be able to commence a Treatment Cycle where they may trial PBS-subsidised bDMARD agents without having to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Treatment Cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.*

*A patient who received PBS-subsidised bDMARD treatment prior to 1 March 2008 is considered to be in their first Cycle as of 1 March 2008.*

*Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.*

*Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next Cycle.*

*For patients who have failed PBS-subsidised treatment with 3 bDMARDs prior to 1 March 2008 please contact Medicare Australia on 1800 700 270.*

*The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent Cycle to the date of the first application for initial treatment with a bDMARD under the new Treatment Cycle.*

*A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same Treatment Cycle.*

*A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of more than 5 years, may commence a new Treatment Cycle.*

*There is no limit to the number of Treatment Cycles a patient may undertake in their lifetime.*

*If patients fail to respond to a particular bDMARD within a single Treatment Cycle, they are not eligible to receive further PBS-subsidised treatment with that drug until they commence the next Cycle.*

*(1) How to prescribe PBS-subsidised bDMARD therapy after 1 March 2008.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### (a) Initial treatment.

*Applications for initial treatment should be made where:*

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this Treatment Cycle and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 2).

*Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for etanercept, adalimumab, anakinra and abatacept, 22 weeks of therapy for infliximab and 2 infusions of rituximab.*

*From 1 March 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.*

*For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.*

#### *Rituximab patients:*

*A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.*

### (b) Continuing treatment.

*Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.*

*It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.*

*Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

#### *Rituximab patients:*

*A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.*

### (2) Swapping therapy.

*Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same Treatment Cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.*

*A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same Treatment Cycle.*

*In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF- $\alpha$  antagonist treatment.*

*To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.*

*PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.*

*To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.*

### **NOTE:**

*(3) Baseline measurements to determine response.*

*Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a Treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.*

*To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.*

*The baseline joint and blood counts should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment.*

*(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.*

*A patient who wishes to trial a second or subsequent Treatment Cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 non-biological DMARD, at an adequate dose, for a minimum of 3 months at the time the ESR and/or CRP levels and the active joint count are measured.*

*(5) Patients 'grandfathered' onto PBS-subsidised treatment with rituximab or abatacept.*

*From 1 March 2008, a patient who commenced treatment with rituximab for severe rheumatoid arthritis prior to 7 March 2007 or abatacept for severe rheumatoid arthritis prior to 1 November 2007 and who was 'grandfathered' on to PBS-subsidised therapy, and who continues to receive treatment in the same Treatment Cycle, will have further applications for treatment with rituximab or abatacept assessed under the continuing treatment restriction.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with abatacept will be authorised under this criterion.*

*'Grandfather' arrangements will only apply for the first Treatment Cycle. For the second and subsequent Cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that applies to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.*

### **Authority Required**

#### *Initial 1 (new patients)*

*Application for initial PBS-subsidised treatment with anakinra, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:*

- (a) have severe active rheumatoid arthritis; and*
- (b) have received no prior PBS-subsidised treatment with a bDMARD for this condition in this treatment cycle; and*
- (c) have failed to achieve an adequate response to the following treatments:*
  - (i) methotrexate at a dose of at least 20 mg weekly; and*
  - (ii) methotrexate (at a minimum dose of 7.5 mg weekly), in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; and*
  - (iii) a minimum of 3 months' treatment with:*
    - leflunomide alone; or*
    - leflunomide in combination with methotrexate; or*
    - cyclosporin.*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.*

*Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].*

*The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:*

*an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;*

*AND either*

- (i) a total active joint count of at least 20 active (swollen and tender) joints; or*
- (ii) at least 4 active joints from the following list of major joints:*
  - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*
  - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

*If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.*

continued ➞

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and
- (3) a signed patient acknowledgement.

*A maximum of 16 weeks of treatment will be authorised under this restriction.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with anakinra.*

*Patients who fail to demonstrate a response to treatment with anakinra under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial anakinra after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.*

### **Authority Required**

*Initial 2 (change or re-commencement)*

*Application for an initial course of PBS-subsidised treatment with anakinra, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:*

- (a) have a documented history of severe active rheumatoid arthritis; and
- (b) have received prior PBS-subsidised bDMARD treatment for this condition in this treatment cycle and are eligible to receive further bDMARD therapy.

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].

*Applications for patients who have received PBS-subsidised treatment with anakinra within this treatment cycle and who wish to re-commence therapy with this drug within this same cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised anakinra treatment, within the timeframes specified below.*

*A maximum of 16 weeks of treatment will be authorised under this restriction.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Where the most recent course of PBS-subsidised anakinra treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form      | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-------|--------------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|       |                                                              |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| 8773R | Injection 100 mg in 0.67 mL single use<br>pre-filled syringe | 28          | 3              | ..      | 1364.45                     | 31.30                                       | Kineret                              | AN |

*Where the most recent course of PBS-subsidised anakinra treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Patients who fail to demonstrate a response to treatment with anakinra under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial anakinra after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.*

### NOTE:

*No applications for increased maximum quantities and/or repeats will be authorised.*

### Authority Required

#### Continuing treatment

*Continuing PBS-subsidised treatment with anakinra, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:*

- (a) who have a documented history of severe active rheumatoid arthritis; and*
- (b) who have demonstrated an adequate response to treatment with anakinra; and*
- (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with anakinra.*

*An adequate response to treatment is defined as:*

*an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;*

*AND either of the following:*

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or*
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:*
  - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*
  - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].*

*A maximum of 24 weeks of treatment will be approved under this restriction.*

*Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*All applications for continuing treatment with anakinra must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with anakinra, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.*

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*Patients who fail to demonstrate a response to treatment with anakinra under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial anakinra after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.*

|       |                                                              |    |   |    |         |       |         |    |
|-------|--------------------------------------------------------------|----|---|----|---------|-------|---------|----|
| 8774T | Injection 100 mg in 0.67 mL single use<br>pre-filled syringe | 28 | 5 | .. | 1364.45 | 31.30 | Kineret | AN |
|-------|--------------------------------------------------------------|----|---|----|---------|-------|---------|----|

**NOTE:**

No applications for increased maximum quantities and/or repeats will be authorised.

• **Calcineurin inhibitors**

**CYCLOSPORIN**

**CAUTION:**

Careful monitoring of patients is mandatory.

**Authority Required**

Maintenance therapy, following initiation and stabilisation of treatment with cyclosporin, of:

- (a) patients with organ or tissue transplants. Therapy must remain under the supervision and direction of the transplant unit reviewing the patient. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application; or
- (b) patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate. Therapy must remain under the supervision and direction of a dermatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application; or
- (c) patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life. Therapy must remain under the supervision and direction of a dermatologist or specialised unit reviewing the patient. The name of the dermatologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application; or
- (d) patients with nephrotic syndrome in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired. Therapy must remain under the supervision and direction of a nephrologist or specialised unit reviewing the patient. The name of the nephrologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application; or
- (e) patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate. Therapy must remain under the supervision and direction of a rheumatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application;

Management (which includes initiation, stabilisation and review of therapy) by:

- (a) dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate; or
- (b) dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life; or
- (c) rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.

|       |               |     |   |    |         |       |           |    |
|-------|---------------|-----|---|----|---------|-------|-----------|----|
| 8657P | Capsule 10 mg | 120 | 3 | .. | * 93.99 | 31.30 | Neoral 10 | NV |
|-------|---------------|-----|---|----|---------|-------|-----------|----|

continued ➡

# ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8658Q | Capsule 25 mg                                           | 60          | 3              | ..      | * 102.49                                 | 31.30                                                  | <sup>a</sup> Cicloral                | SZ |
|       |                                                         |             |                | B2.28   | * 104.77                                 | 31.30                                                  | <sup>a</sup> Neoral 25               | NV |
| 8659R | Capsule 50 mg                                           | 60          | 3              | ..      | * 206.51                                 | 31.30                                                  | <sup>a</sup> Cicloral                | SZ |
|       |                                                         |             |                | B2.24   | * 208.75                                 | 31.30                                                  | <sup>a</sup> Neoral 50               | NV |
| 8660T | Capsule 100 mg                                          | 60          | 3              | ..      | * 395.87                                 | 31.30                                                  | <sup>a</sup> Cicloral                | SZ |
|       |                                                         |             |                | B2.26   | * 398.13                                 | 31.30                                                  | <sup>a</sup> Neoral 100              | NV |
| 8661W | Oral liquid 100 mg per mL, 50 mL                        | 2           | 3              | ..      | * 712.23                                 | 31.30                                                  | Neoral                               | NV |

## TACROLIMUS

### CAUTION:

Careful monitoring of patients is mandatory.

### Authority Required

Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with:

- (a) liver transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application; or
- (b) renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application; or
- (c) cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application; or
- (d) lung transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application.

|       |                        |     |   |    |         |       |         |    |
|-------|------------------------|-----|---|----|---------|-------|---------|----|
| 8646C | Capsule 500 micrograms | 100 | 3 | .. | 225.42  | 31.30 | Prograf | JC |
| 8647D | Capsule 1 mg           | 100 | 3 | .. | 426.84  | 31.30 | Prograf | JC |
| 8648E | Capsule 5 mg           | 50  | 3 | .. | 1052.87 | 31.30 | Prograf | JC |

### • Other immunosuppressants

#### AZATHIOPRINE

|       |              |     |   |       |       |       |                        |    |
|-------|--------------|-----|---|-------|-------|-------|------------------------|----|
| 2688L | Tablet 25 mg | 100 | 2 | ..    | 36.75 | 31.30 | <sup>a</sup> Azahexal  | SZ |
|       |              |     |   | B1.19 | 37.94 | 31.30 | <sup>a</sup> Imuran    | GK |
| 2687K | Tablet 50 mg | 100 | 2 | ..    | 56.07 | 31.30 | <sup>a</sup> Azahexal  | SZ |
|       |              |     |   |       |       |       | <sup>a</sup> Azamun    | GM |
|       |              |     |   |       |       |       | <sup>a</sup> Azapin    | AW |
|       |              |     |   |       |       |       | <sup>a</sup> GenRx     | GX |
|       |              |     |   |       |       |       | Azathioprine           |    |
|       |              |     |   |       |       |       | <sup>a</sup> Thioprine | AF |
|       |              |     |   |       |       |       | <sup>a</sup> Imuran    | GK |

#### METHOTREXATE

|       |               |    |   |    |       |       |                           |    |
|-------|---------------|----|---|----|-------|-------|---------------------------|----|
| 1622J | Tablet 2.5 mg | 30 | 5 | .. | 13.11 | 14.14 | <sup>a</sup> Methoblastin | PH |
|       |               |    |   |    |       |       | <sup>a</sup> HH           |    |
| 2272N | Tablet 10 mg  | 15 | 1 | .. | 22.37 | 23.40 | Methoblastin              | PH |



ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

METHOTREXATE

Restricted Benefit

For patients requiring doses greater than 20 mg per week.

|       |              |    |   |    |       |       |              |    |
|-------|--------------|----|---|----|-------|-------|--------------|----|
| 1623K | Tablet 10 mg | 50 | 2 | .. | 47.00 | 31.30 | Methoblastin | PH |
|-------|--------------|----|---|----|-------|-------|--------------|----|

## MUSCULO-SKELETAL SYSTEM

| Code                                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer               |    |
|-----------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------|----|
| <b>ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS</b>                                      |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| <b>Antiinflammatory and antirheumatic products, non-steroids</b>                        |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| • <b>Acetic acid derivatives and related substances</b>                                 |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| DICLOFENAC SODIUM                                                                       |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| 1302M                                                                                   | Suppository 100 mg                                      | 40          | 3              | ..      | * 24.49                                  | 25.52                                                  | Voltaren 100                                       | NV |
| <hr/>                                                                                   |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| <b>DICLOFENAC SODIUM</b>                                                                |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| <b><u>Restricted Benefit</u></b>                                                        |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component;</i> |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| <i>Bone pain due to malignant disease.</i>                                              |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| 1299J                                                                                   | Tablet 25 mg (enteric coated)                           | 100         | 3              | ..      | * 12.63                                  | 13.66                                                  | <sup>a</sup> Chem mart<br>Diclofenac               | CH |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clonac 25                             | AW |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Diclohexal                            | SZ |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dinac                                 | GM |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Diclofenac                      | GX |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Diclofenac | TW |
|                                                                                         |                                                         |             |                | ..      | 12.64                                    | 13.67                                                  | <sup>a</sup> Fenac 25                              | AF |
|                                                                                         |                                                         |             |                | B1.96   | * 14.59                                  | 13.66                                                  | <sup>a</sup> Voltaren 25                           | NV |
| 1300K                                                                                   | Tablet 50 mg (enteric coated)                           | 50          | 3              | ..      | 10.62                                    | 11.65                                                  | <sup>a</sup> Chem mart<br>Diclofenac               | CH |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clonac 50                             | AW |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Diclohexal                            | SZ |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dinac                                 | GM |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fenac                                 | AF |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Diclofenac                      | GX |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Diclofenac | TW |
|                                                                                         |                                                         |             |                | B1.96   | 12.58                                    | 11.65                                                  | <sup>a</sup> Voltaren 50                           | NV |
| <hr/>                                                                                   |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| INDOMETHACIN                                                                            |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| 2757D                                                                                   | Suppository 100 mg                                      | 40          | 3              | ..      | * 22.07                                  | 23.10                                                  | Indocid                                            | MK |

continued ➞

# MUSCULO-SKELETAL SYSTEM—CONT.

| Code                                                                                                         | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>INDOMETHACIN</b>                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component;</i>                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Bone pain due to malignant disease.</i>                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2454E                                                                                                        | Capsule 25 mg                                           | 100         | 3              | ..      | * 10.23                                  | 11.26                                                  | <sup>a</sup> Arthrexin               | AF |
|                                                                                                              |                                                         |             |                | B2.34   | * 12.57                                  | 11.26                                                  | <sup>a</sup> Indocid                 | MK |
| <b>SULINDAC</b>                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component;</i>                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Bone pain due to malignant disease.</i>                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2047R                                                                                                        | Tablet 100 mg                                           | 100         | 3              | ..      | * 15.91                                  | 16.94                                                  | Aclin                                | AF |
| 2048T                                                                                                        | Tablet 200 mg                                           | 50          | 3              | ..      | 14.85                                    | 15.88                                                  | Aclin 200                            | AF |
| • <b>Oxicams</b>                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>MELOXICAM</b>                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>The use of meloxicam for the treatment of the following conditions is not subsidised through the PBS:</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>(a) acute pain;</i>                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>(b) soft tissue injury;</i>                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>(c) arthrosis without an inflammatory component.</i>                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Symptomatic treatment of osteoarthritis;</i>                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Symptomatic treatment of rheumatoid arthritis.</i>                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8561N                                                                                                        | Tablet 7.5 mg                                           | 30          | 3              | ..      | 21.68                                    | 22.71                                                  | <sup>a</sup> Chem mart               | CH |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | Meloxicam                            |    |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | 7.5 mg                               |    |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Meloxicam         | GX |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Meloxibell              | BF |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Meloxicam-GA            | GM |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Meloxicam               | RA |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | Ranbaxy                              |    |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Meloxicam Sandoz        | SZ |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Meloxicam               | WA |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | Winthrop                             |    |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Movalis 7.5             | AW |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Moxicam 7.5             | AF |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pharmacor               | CR |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | Meloxicam 7.5                        |    |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | Meloxicam                            |    |
|                                                                                                              |                                                         |             |                |         |                                          |                                                        | 7.5 mg                               |    |
|                                                                                                              |                                                         |             |                | B1.61   | 23.29                                    | 22.71                                                  | <sup>a</sup> Mobic                   | BY |

continued ➡

# MUSCULO-SKELETAL SYSTEM—CONT.

| Code                                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                             |    |
|-----------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------------------------------|----|
| 8562P                                                                                   | Tablet 15 mg                                            | 30          | 3              | ..      | 28.86                                    | 29.89                                                  | <sup>a</sup> Chem mart<br>Meloxicam<br>15 mg                     | CH |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Meloxicam                                     | GX |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Melolibell                                          | BF |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Meloxicam-GA                                        | GM |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Meloxicam<br>Ranbaxy                                | RA |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Meloxicam Sandoz                                    | SZ |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Meloxicam<br>Winthrop                               | WA |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Movalis 15                                          | AW |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Moxicam 15                                          | AF |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pharmacor<br>Meloxicam 15                           | CR |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Meloxicam<br>15 mg       | TW |
|                                                                                         |                                                         |             |                | B1.63   | 30.49                                    | 29.89                                                  | <sup>a</sup> Mobic                                               | BY |
| 8887R                                                                                   | Capsule 7.5 mg                                          | 30          | 3              | ..      | 21.68                                    | 22.71                                                  | Mobic                                                            | BY |
| 8888T                                                                                   | Capsule 15 mg                                           | 30          | 3              | ..      | 28.86                                    | 29.89                                                  | Mobic                                                            | BY |
| <b>PIROXICAM</b>                                                                        |                                                         |             |                |         |                                          |                                                        |                                                                  |    |
| <b>Restricted Benefit</b>                                                               |                                                         |             |                |         |                                          |                                                        |                                                                  |    |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component.</i> |                                                         |             |                |         |                                          |                                                        |                                                                  |    |
| 1895R                                                                                   | Dispersible tablet 10 mg                                | 50          | 3              | ..      | 12.07                                    | 13.10                                                  | <sup>a</sup> GenRx Piroxicam<br>Dispersible                      | GX |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Mobilis D-10                                        | AF |
|                                                                                         |                                                         |             |                | B2.09   | 14.16                                    | 13.10                                                  | <sup>a</sup> Feldene-D                                           | PF |
| 1896T                                                                                   | Dispersible tablet 20 mg                                | 25          | 3              | ..      | 11.77                                    | 12.80                                                  | <sup>a</sup> Chem mart<br>Piroxicam<br>Dispersible               | CH |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Piroxicam<br>Dispersible                      | GX |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Mobilis D-20                                        | AF |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Piroxicam<br>Dispersible | TW |
|                                                                                         |                                                         |             |                | B2.07   | 13.84                                    | 12.80                                                  | <sup>a</sup> Feldene-D                                           | PF |

continued ➡

## MUSCULO-SKELETAL SYSTEM—CONT.

| Code                                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer              |    |
|-----------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|---------------------------------------------------|----|
| 1897W                                                                                   | Capsule 10 mg                                           | 50          | 3              | ..      | 12.07                                    | 13.10                                                  | <sup>a</sup> Chem mart<br>Piroxicam               | CH |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Piroxicam                      | GX |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Mobilis 10                           | AF |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Piroxicam | TW |
|                                                                                         |                                                         |             |                | B2.09   | 14.16                                    | 13.10                                                  | <sup>a</sup> Feldene                              | PF |
| 1898X                                                                                   | Capsule 20 mg                                           | 25          | 3              | ..      | 11.77                                    | 12.80                                                  | <sup>a</sup> Chem mart<br>Piroxicam               | CH |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Piroxicam                      | GX |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Mobilis 20                           | AF |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Piroxicam | TW |
|                                                                                         |                                                         |             |                | B2.07   | 13.84                                    | 12.80                                                  | <sup>a</sup> Feldene                              | PF |
| <b>• Propionic acid derivatives</b>                                                     |                                                         |             |                |         |                                          |                                                        |                                                   |    |
| IBUPROFEN                                                                               |                                                         |             |                |         |                                          |                                                        |                                                   |    |
| 3192B                                                                                   | Tablet 400 mg                                           | 30          | ..             | ..      | 8.76                                     | 9.79                                                   | Brufen                                            | AB |
| <hr/>                                                                                   |                                                         |             |                |         |                                          |                                                        |                                                   |    |
| <b>IBUPROFEN</b>                                                                        |                                                         |             |                |         |                                          |                                                        |                                                   |    |
| <b><u>Restricted Benefit</u></b>                                                        |                                                         |             |                |         |                                          |                                                        |                                                   |    |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component;</i> |                                                         |             |                |         |                                          |                                                        |                                                   |    |
| <i>Bone pain due to malignant disease.</i>                                              |                                                         |             |                |         |                                          |                                                        |                                                   |    |
| 3198H                                                                                   | Tablet 200 mg                                           | 100         | 3              | ..      | * 11.63                                  | 12.66                                                  | Rafen 200                                         | AF |
| 3190X                                                                                   | Tablet 400 mg                                           | 90          | 3              | ..      | * 14.30                                  | 15.33                                                  | Brufen                                            | AB |
| KETOPROFEN                                                                              |                                                         |             |                |         |                                          |                                                        |                                                   |    |
| 1588N                                                                                   | Suppository 100 mg                                      | 40          | 3              | ..      | * 22.81                                  | 23.84                                                  | Orudis                                            | SW |
| <hr/>                                                                                   |                                                         |             |                |         |                                          |                                                        |                                                   |    |
| <b>KETOPROFEN</b>                                                                       |                                                         |             |                |         |                                          |                                                        |                                                   |    |
| <b><u>Restricted Benefit</u></b>                                                        |                                                         |             |                |         |                                          |                                                        |                                                   |    |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component.</i> |                                                         |             |                |         |                                          |                                                        |                                                   |    |
| 1590Q                                                                                   | Capsule 200 mg (sustained release)                      | 28          | 3              | ..      | 16.49                                    | 17.52                                                  | <sup>a</sup> Oruvail SR                           | AV |
|                                                                                         |                                                         |             |                | B2.00   | 18.49                                    | 17.52                                                  | <sup>a</sup> Orudis SR 200                        | SW |

## MUSCULO-SKELETAL SYSTEM—CONT.

| Code                                                                                                                                                                            | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                        |          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------|----------|
| <b>NAPROXEN</b>                                                                                                                                                                 |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component;</i>                                                                                         |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <i>Bone pain due to malignant disease.</i>                                                                                                                                      |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| 1674D                                                                                                                                                                           | Tablet 250 mg                                           | 100         | 3              | ..<br>B2.34 | * 13.29<br>* 15.63                       | 14.32<br>14.32                                         | <sup>a</sup> Inza 250<br><sup>a</sup> Naprosyn              | AF<br>RO |
| 1659H                                                                                                                                                                           | Tablet 500 mg                                           | 50          | 3              | ..<br>B1.36 | 12.48<br>13.84                           | 13.51<br>13.51                                         | <sup>a</sup> Inza 500<br><sup>a</sup> Naprosyn              | AF<br>RO |
| 1614Y                                                                                                                                                                           | Tablet 750 mg (sustained release)                       | 28          | 3              | ..<br>B1.27 | 11.95<br>13.22                           | 12.98<br>12.98                                         | <sup>a</sup> Proxen SR 750<br><sup>a</sup> Naprosyn SR750   | MD<br>RO |
| 1615B                                                                                                                                                                           | Tablet 1 g (sustained release)                          | 28          | 3              | ..<br>B1.34 | 13.94<br>15.28                           | 14.97<br>14.97                                         | <sup>a</sup> Proxen SR 1000<br><sup>a</sup> Naprosyn SR1000 | MD<br>RO |
| <hr/>                                                                                                                                                                           |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                                                                                                  |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| 2270                                                                                                                                                                            |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component in patients unable to take a solid dose form of a non-steroidal anti-inflammatory agent;</i> |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| 2271                                                                                                                                                                            |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <i>Bone pain due to malignant disease in patients unable to take a solid dose form of a non-steroidal anti-inflammatory agent.</i>                                              |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| 1658G                                                                                                                                                                           | Oral suspension 125 mg per 5 mL,<br>474 mL              | ± 1         | 3              | ..          | 77.74                                    | 31.30                                                  | Naprosyn                                                    | RO       |
| <b>NAPROXEN SODIUM</b>                                                                                                                                                          |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component;</i>                                                                                         |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <i>Bone pain due to malignant disease.</i>                                                                                                                                      |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| 1795L                                                                                                                                                                           | Tablet 550 mg                                           | 50          | 3              | ..<br>B2.29 | 12.67<br>14.96                           | 13.70<br>13.70                                         | <sup>a</sup> Crysanal<br><sup>a</sup> Anaprox 550           | MD<br>RO |
| <b><u>NOTE:</u></b>                                                                                                                                                             |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| Naproxen sodium 550 mg is approximately equivalent to 500 mg of naproxen acid.                                                                                                  |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <b>TIAPROFENIC ACID</b>                                                                                                                                                         |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <b><u>CAUTION:</u></b>                                                                                                                                                          |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| Cystitis and other urinary disorders have been reported with this drug.                                                                                                         |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <b><u>NOTE:</u></b>                                                                                                                                                             |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| The recommended maximum dose is 600 mg per day.                                                                                                                                 |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component.</i>                                                                                         |                                                         |             |                |             |                                          |                                                        |                                                             |          |
| 2103Q                                                                                                                                                                           | Tablet 300 mg                                           | 60          | 3              | ..          | 17.15                                    | 18.18                                                  | Surgam                                                      | SW       |

## MUSCULO-SKELETAL SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>• Fenamates</b><br><b>MEFENAMIC ACID</b><br><br><b><u>Restricted Benefit</u></b><br><i>Dysmenorrhoea;</i><br><i>Menorrhagia.</i>                                                                                                                                                                                                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1824B                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Capsule 250 mg                                          | 50          | 2              | ..      | 17.73                                    | 18.76                                                  | Ponstan                              | PD |
| <b>• Coxibs</b><br><b>CELECOXIB</b><br><b><u>NOTE:</u></b><br><i>The use of celecoxib for the treatment of the following conditions is not subsidised through the PBS:</i><br><i>(a) acute pain;</i><br><i>(b) soft tissue injury;</i><br><i>(c) arthrosis without an inflammatory component.</i><br><br><b><u>Restricted Benefit</u></b><br><i>Symptomatic treatment of osteoarthritis;</i><br><i>Symptomatic treatment of rheumatoid arthritis.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8439E                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Capsule 100 mg                                          | 60          | 3              | ..      | 31.88                                    | 31.30                                                  | Celebrex                             | PH |
| 8440F                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Capsule 200 mg                                          | 30          | 3              | ..      | 31.88                                    | 31.30                                                  | Celebrex                             | PH |
| <b>Specific antirheumatic agents</b><br><b>• Quinolines</b><br><b>HYDROXYCHLOROQUINE SULFATE</b>                                                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1512N                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Tablet 200 mg                                           | 100         | 1              | ..      | 37.16                                    | 31.30                                                  | Plaquenil                            | SW |
| <b>• Gold preparations</b><br><b>AURANOFIN</b><br><b><u>CAUTION:</u></b><br><i>Regular blood and urine checks are essential.</i>                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1095P                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Tablet 3 mg                                             | 60          | 5              | ..      | 63.12                                    | 31.30                                                  | Ridaura                              | GH |
| <b>SODIUM AUROTHIOMALATE</b><br><b><u>CAUTION:</u></b><br><i>Regular blood and urine checks are essential.</i>                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2016D                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Injection 10 mg                                         | 10          | ..             | ..      | 52.87                                    | 31.30                                                  | Myocrisin                            | SW |
| 2017E                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Injection 20 mg                                         | 10          | 1              | ..      | 80.03                                    | 31.30                                                  | Myocrisin                            | SW |
| 2018F                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Injection 50 mg                                         | 10          | 1              | ..      | 124.36                                   | 31.30                                                  | Myocrisin                            | SW |

## MUSCULO-SKELETAL SYSTEM—CONT.

| Code                                                                                                                           | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>• Penicillamine and similar agents</b><br>PENICILLAMINE<br><b>CAUTION:</b><br>Regular blood and urine checks are essential. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2721F                                                                                                                          | Tablet 125 mg                                           | 100         | 1              | ..      | 31.20                                    | 31.30                                                  | D-Penamine                           | AL |
| 2838J                                                                                                                          | Tablet 250 mg                                           | 100         | 1              | ..      | 43.08                                    | 31.30                                                  | D-Penamine                           | AL |

- Other specific antirheumatic agents**  
**LEFLUNOMIDE**  
*For listings see Generic/Proprietary Index*

### MUSCLE RELAXANTS

#### Muscle relaxants, centrally acting agents

- **Other centrally acting agents**

#### BACLOFEN

|       |              |     |   |    |       |       |                                                                                                                                                                                     |                                                      |
|-------|--------------|-----|---|----|-------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|
| 2729P | Tablet 10 mg | 100 | 5 | .. | 31.65 | 31.30 | a Baclo<br>a Baclohexal<br>a Chem mart<br>Baclofen<br>a Clofen 10<br>a GenRx Baclofen<br>a Stelax 10<br>a Terry White<br>Chemists<br>Baclofen<br>b2.26<br>33.91 31.30 a Lioresal 10 | GM<br>HX<br>CH<br><br>AF<br>GX<br>AW<br>TW<br><br>NV |
| 2730Q | Tablet 25 mg | 100 | 5 | .. | 59.66 | 31.30 | a Baclo<br>a Baclohexal<br>a Chem mart<br>Baclofen<br>a Clofen 25<br>a GenRx Baclofen<br>a Stelax 25<br>a Terry White<br>Chemists<br>Baclofen<br>b2.18<br>61.84 31.30 a Lioresal 25 | GM<br>HX<br>CH<br><br>AF<br>GX<br>AW<br>TW<br><br>NV |

#### Muscle relaxants, directly acting agents

- **Dantrolene and derivatives**

#### DANTROLENE SODIUM

#### Restricted Benefit

*Treatment of chronic spasticity.*

|       |               |     |   |    |       |       |          |    |
|-------|---------------|-----|---|----|-------|-------|----------|----|
| 1779P | Capsule 25 mg | 100 | 2 | .. | 59.05 | 31.30 | Dantrium | PU |
|-------|---------------|-----|---|----|-------|-------|----------|----|

continued ☞



## MUSCULO-SKELETAL SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 1780Q | Capsule 50 mg                                           | 100         | 2              | ..      | 66.99                                    | 31.30                                                  | Dantrium                             | PU |

### ANTIGOUT PREPARATIONS

#### Antigout preparations

#### • Preparations inhibiting uric acid production

##### ALLOPURINOL

##### NOTE:

The dose should be adjusted in accordance with renal function.

|       |               |     |   |       |         |       |                     |    |
|-------|---------------|-----|---|-------|---------|-------|---------------------|----|
| 2600W | Tablet 100 mg | 200 | 2 | ..    | 12.76   | 13.79 | a Allohexal         | SZ |
|       |               |     |   |       |         |       | a Allosig           | FM |
|       |               |     |   |       |         |       | a Chem mart         | CH |
|       |               |     |   |       |         |       | Allopurinol         |    |
|       |               |     |   |       |         |       | a GenRx Allopurinol | GX |
|       |               |     |   |       |         |       | a Terry White       | TW |
|       |               |     |   |       |         |       | Chemists            |    |
|       |               |     |   |       |         |       | Allopurinol         |    |
|       |               |     |   | ..    | * 12.77 | 13.80 | a Progout 100       | AF |
|       |               |     |   | B1.91 | 14.67   | 13.79 | a Zyloprim          | SI |
| 2604C | Tablet 300 mg | 60  | 2 | ..    | 9.99    | 11.02 | a Allohexal         | SZ |
|       |               |     |   |       |         |       | a Allosig           | FM |
|       |               |     |   |       |         |       | a Chem mart         | CH |
|       |               |     |   |       |         |       | Allopurinol         |    |
|       |               |     |   |       |         |       | a GenRx Allopurinol | GX |
|       |               |     |   |       |         |       | a Progout 300       | AF |
|       |               |     |   |       |         |       | a Terry White       | TW |
|       |               |     |   |       |         |       | Chemists            |    |
|       |               |     |   |       |         |       | Allopurinol         |    |
|       |               |     |   | B1.80 | 11.79   | 11.02 | a Zyloprim          | SI |

#### • Preparations increasing uric acid excretion

##### PROBENECID

|       |               |     |   |    |       |       |         |    |
|-------|---------------|-----|---|----|-------|-------|---------|----|
| 1940D | Tablet 500 mg | 100 | 5 | .. | 69.80 | 31.30 | Pro-Cid | PL |
|-------|---------------|-----|---|----|-------|-------|---------|----|

#### • Preparations with no effect on uric acid metabolism

##### COLCHICINE

|       |                       |     |   |       |       |       |           |    |
|-------|-----------------------|-----|---|-------|-------|-------|-----------|----|
| 1227N | Tablet 500 micrograms | 100 | 2 | ..    | 10.71 | 11.74 | a Lengout | LN |
|       |                       |     |   | B0.90 | 11.61 | 11.74 | a Colgout | AS |

## MUSCULO-SKELETAL SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                        | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                                                                                          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>DRUGS FOR TREATMENT OF BONE DISEASES</b>                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| <b>Drugs affecting bone structure and mineralization</b>                                                                                                                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| • <b>Bisphosphonates</b>                                                                                                                                                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| <b>ALENDRONATE SODIUM</b>                                                                                                                                                                                                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| <b>Authority Required (STREAMLINED)</b>                                                                                                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| 2645                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| <i>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.</i>                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| <i>The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.</i>                                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| <b>Authority Required (STREAMLINED)</b>                                                                                                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| 2646                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| <i>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.</i> |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| <i>A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.</i>                          |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| <b>NOTE:</b>                                                                                                                                                                                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| <i>Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate.</i>                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| 8511Y                                                                                                                                                                                                                                                                                                                                       | Tablet equivalent to 70 mg alendronic acid              | 4           | 5              | ..      | 46.87                                    | 31.30                                                  | a Adronat AF<br>a Alendrobell 70mg BF<br>a Alendronate SZ<br>Sandoz<br>a Alendro Once AW<br>Weekly<br>a APO-Alendronate TX<br>a Chem mart CH<br>Alendronate<br>70mg<br>a Ossmax 70mg RA<br>a Terry White TW<br>Chemists<br>Alendronate<br>70mg<br>a Fosamax Once MK<br>Weekly |
|                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                | B1.42   | 48.29                                    | 31.30                                                  |                                                                                                                                                                                                                                                                               |
| <b>Authority Required (STREAMLINED)</b>                                                                                                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| 1392                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| <i>Symptomatic Paget's disease of bone.</i>                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                               |
| 8090T                                                                                                                                                                                                                                                                                                                                       | Tablet equivalent to 40 mg alendronic acid              | 30          | 5              | ..      | 138.14                                   | 31.30                                                  | Fosamax 40 mg MK                                                                                                                                                                                                                                                              |

## MUSCULO-SKELETAL SYSTEM—CONT.

| Code                                                                                                                                     | Name, Restriction,<br>Manner of Administration and Form                                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>DISODIUM ETIDRONATE</b>                                                                                                               |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b>                                                                                                  |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 1849<br><i>Symptomatic Paget's disease of bone when calcitonin has been found to be unsatisfactory due to lack of efficacy;</i>          |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 1850<br><i>Symptomatic Paget's disease of bone when calcitonin has been found to be unsatisfactory due to unacceptable side effects;</i> |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 1153<br><i>Heterotopic ossification.</i>                                                                                                 |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 2920Q                                                                                                                                    | Tablet 200 mg                                                                                      | 60          | 5              | ..      | 114.74                                   | 31.30                                                  | Didronel                             | PU |
| <b>DISODIUM PAMIDRONATE</b>                                                                                                              |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b>                                                                                                  |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 1392<br><i>Symptomatic Paget's disease of bone.</i>                                                                                      |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 8461H                                                                                                                                    | Concentrated injection 15 mg in 5 mL                                                               | 4           | ..             | ..      | * 263.79                                 | 31.30                                                  | <sup>a</sup> Pamisol                 | HH |
| 8208B                                                                                                                                    | Injection set containing 4 vials powder<br>for I.V. infusion 15 mg and 4<br>ampoules solvent 5 mL  | 1           | ..             | ..      | 263.78                                   | 31.30                                                  | <sup>a</sup> Aredia 15 mg            | NV |
| <b>NOTE:</b><br><i>The concentrated injection 15 mg and powder for I.V. infusion 15 mg (after reconstitution) are bioequivalent.</i>     |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 8462J                                                                                                                                    | Concentrated injection 30 mg in 10 mL                                                              | 2           | ..             | ..      | * 263.79                                 | 31.30                                                  | <sup>a</sup> Pamisol                 | HH |
| 8209C                                                                                                                                    | Injection set containing 2 vials powder<br>for I.V. infusion 30 mg and 2<br>ampoules solvent 10 mL | 1           | ..             | ..      | 263.78                                   | 31.30                                                  | <sup>a</sup> Aredia 30 mg            | NV |
| <b>NOTE:</b><br><i>The concentrated injection 30 mg and powder for I.V. infusion 30 mg (after reconstitution) are bioequivalent.</i>     |                                                                                                    |             |                |         |                                          |                                                        |                                      |    |
| 8463K                                                                                                                                    | Concentrated injection 60 mg in 10 mL                                                              | 1           | ..             | ..      | 263.78                                   | 31.30                                                  | Pamisol                              | HH |

## MUSCULO-SKELETAL SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

### RISEDRONATE SODIUM

#### Authority Required (STREAMLINED)

2645

*Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.*

*The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.*

#### Authority Required (STREAMLINED)

2646

*Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.*

*A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.*

#### NOTE:

*Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate.*

|       |              |    |   |    |       |       |                     |    |
|-------|--------------|----|---|----|-------|-------|---------------------|----|
| 8481J | Tablet 5 mg  | 28 | 5 | .. | 52.91 | 31.30 | Actonel             | SW |
| 8621R | Tablet 35 mg | 4  | 5 | .. | 52.91 | 31.30 | Actonel Once-a-Week | SW |

#### Authority Required (STREAMLINED)

1392

*Symptomatic Paget's disease of bone.*

|       |              |    |   |    |        |       |         |    |
|-------|--------------|----|---|----|--------|-------|---------|----|
| 8482K | Tablet 30 mg | 28 | 1 | .. | 304.19 | 31.30 | Actonel | SW |
|-------|--------------|----|---|----|--------|-------|---------|----|

### SODIUM CLODRONATE TETRAHYDRATE

#### Restricted Benefit

*Maintenance treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy;*

*Multiple myeloma;*

*Bone metastases from breast cancer.*

|       |                                                |     |   |    |        |       |                |    |
|-------|------------------------------------------------|-----|---|----|--------|-------|----------------|----|
| 8132B | Capsule equivalent to 400 mg sodium clodronate | 100 | 2 | .. | 333.65 | 31.30 | Bonefos        | SC |
| 8265B | Tablet equivalent to 800 mg sodium clodronate  | 60  | 2 | .. | 391.01 | 31.30 | Bonefos 800 mg | SC |

## MUSCULO-SKELETAL SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                        | Name, Restriction,<br>Manner of Administration and Form                       | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>TILUDRONATE DISODIUM</b>                                                                                                                                                                                                                                                                                                                 |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                                                                                                                                                                                                                                                              |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| 1392                                                                                                                                                                                                                                                                                                                                        |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <i>Symptomatic Paget's disease of bone.</i>                                                                                                                                                                                                                                                                                                 |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| 8267D                                                                                                                                                                                                                                                                                                                                       | Tablet equivalent to 200 mg tiludronic acid                                   | 56          | 2              | ..      | 304.19                                   | 31.30                                                  | Skelid                               | HH |
| <b>• Bisphosphonates, combinations</b><br><b>ALENDRONATE SODIUM with COLECALCIFEROL</b>                                                                                                                                                                                                                                                     |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                                                                                                                                                                                                                                                              |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| 2645                                                                                                                                                                                                                                                                                                                                        |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.</i>                                                                                                                                                    |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <i>The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.</i>                                                                                                                                                           |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                                                                                                                                                                                                                                                              |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| 2646                                                                                                                                                                                                                                                                                                                                        |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.</i> |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <i>A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.</i>                          |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                                                                                                                         |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <i>Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate.</i>                                                                                                                                                             |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| 9012H                                                                                                                                                                                                                                                                                                                                       | Tablet equivalent to 70 mg alendronic acid with 70 micrograms colecalciferol  | 4           | 5              | ..      | 46.87                                    | 31.30                                                  | Fosamax Plus                         | MK |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                                                                                                                         |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| <i>Fosamax Plus provides a supplemental intake of vitamin D. The amount of colecalciferol present in Fosamax Plus is not sufficient to use as the sole treatment for correction of vitamin D deficiency.</i>                                                                                                                                |                                                                               |             |                |         |                                          |                                                        |                                      |    |
| 9183H                                                                                                                                                                                                                                                                                                                                       | Tablet equivalent to 70 mg alendronic acid with 140 micrograms colecalciferol | 4           | 5              | ..      | 46.87                                    | 31.30                                                  | Fosamax Plus 70 mg/140 mcg           | MK |

## MUSCULO-SKELETAL SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### DISODIUM ETIDRONATE and CALCIUM CARBONATE

#### Authority Required (STREAMLINED)

2646

*Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.*

*A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.*

#### NOTE:

*Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate.*

|       |                                                                                                                              |     |   |    |       |       |          |    |
|-------|------------------------------------------------------------------------------------------------------------------------------|-----|---|----|-------|-------|----------|----|
| 8056B | Pack containing 28 tablets disodium etidronate 200 mg and 76 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium) | ± 1 | 1 | .. | 70.26 | 31.30 | Didrocal | PU |
|-------|------------------------------------------------------------------------------------------------------------------------------|-----|---|----|-------|-------|----------|----|

#### NOTE:

*No applications for increased maximum quantities and/or repeats will be authorised.*

### RISEDRONATE SODIUM and CALCIUM CARBONATE

#### Authority Required (STREAMLINED)

2645

*Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.*

*The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.*

#### Authority Required (STREAMLINED)

2646

*Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.*

*A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.*

#### NOTE:

*Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate.*

|       |                                                                                                                           |     |   |    |       |       |               |    |
|-------|---------------------------------------------------------------------------------------------------------------------------|-----|---|----|-------|-------|---------------|----|
| 8899J | Pack containing 4 tablets risedronate sodium 35 mg and 24 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium) | ± 1 | 5 | .. | 52.91 | 31.30 | Actonel Combi | SW |
|-------|---------------------------------------------------------------------------------------------------------------------------|-----|---|----|-------|-------|---------------|----|

## MUSCULO-SKELETAL SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### **RISEDRONATE SODIUM and CALCIUM CARBONATE with COLECALCIFEROL**

#### **Authority Required (STREAMLINED)**

2645

*Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.*

*The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.*

#### **Authority Required (STREAMLINED)**

2646

*Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.*

*A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.*

#### **NOTE:**

*Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate.*

|       |                                                                                                                                                                                |     |   |    |       |       |                 |    |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|---|----|-------|-------|-----------------|----|
| 9147K | Pack containing 4 tablets risedronate sodium 35 mg and 24 sachets containing granules of calcium carbonate 2.5 g (equivalent to 1 g calcium) with colecalciferol 22 micrograms | £ 1 | 5 | .. | 52.91 | 31.30 | Actonel Combi D | SW |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|---|----|-------|-------|-----------------|----|

## MUSCULO-SKELETAL SYSTEM—CONT.

| Code                                                             | Name, Restriction,<br>Manner of Administration and Form                                                                                                                                                                                                                                                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|                                                                  |                                                                                                                                                                                                                                                                                                                    |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |
| <b>• Other drugs affecting bone structure and mineralization</b> |                                                                                                                                                                                                                                                                                                                    |             |                |         |                             |                                             |                                      |
| <b>CALCITRIOL</b>                                                |                                                                                                                                                                                                                                                                                                                    |             |                |         |                             |                                             |                                      |
| <b><u>Authority Required (STREAMLINED)</u></b>                   |                                                                                                                                                                                                                                                                                                                    |             |                |         |                             |                                             |                                      |
|                                                                  | 1165                                                                                                                                                                                                                                                                                                               |             |                |         |                             |                                             |                                      |
|                                                                  | <i>Hypocalcaemia due to renal disease;</i>                                                                                                                                                                                                                                                                         |             |                |         |                             |                                             |                                      |
|                                                                  | 1166                                                                                                                                                                                                                                                                                                               |             |                |         |                             |                                             |                                      |
|                                                                  | <i>Hypoparathyroidism;</i>                                                                                                                                                                                                                                                                                         |             |                |         |                             |                                             |                                      |
|                                                                  | 1167                                                                                                                                                                                                                                                                                                               |             |                |         |                             |                                             |                                      |
|                                                                  | <i>Hypophosphataemic rickets;</i>                                                                                                                                                                                                                                                                                  |             |                |         |                             |                                             |                                      |
|                                                                  | 1467                                                                                                                                                                                                                                                                                                               |             |                |         |                             |                                             |                                      |
|                                                                  | <i>Vitamin D-resistant rickets;</i>                                                                                                                                                                                                                                                                                |             |                |         |                             |                                             |                                      |
|                                                                  | 2636                                                                                                                                                                                                                                                                                                               |             |                |         |                             |                                             |                                      |
|                                                                  | <i>Treatment for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.</i>                         |             |                |         |                             |                                             |                                      |
|                                                                  | <i>A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.</i> |             |                |         |                             |                                             |                                      |
| 2502Q                                                            | Capsule 0.25 microgram                                                                                                                                                                                                                                                                                             | 100         | 3              | ..      | 42.82                       | 31.30                                       | <sup>a</sup> Calcitriol-DP GM        |
|                                                                  |                                                                                                                                                                                                                                                                                                                    |             |                |         |                             |                                             | <sup>a</sup> Citrihexal HX           |
|                                                                  |                                                                                                                                                                                                                                                                                                                    |             |                |         |                             |                                             | <sup>a</sup> GenRx Calcitriol GX     |
|                                                                  |                                                                                                                                                                                                                                                                                                                    |             |                |         |                             |                                             | <sup>a</sup> Kosteo AW               |
|                                                                  |                                                                                                                                                                                                                                                                                                                    |             |                |         |                             |                                             | <sup>a</sup> Rocaltrol RO            |
|                                                                  |                                                                                                                                                                                                                                                                                                                    |             |                |         |                             |                                             | <sup>a</sup> Sical AF                |

### RALOXIFENE HYDROCHLORIDE

#### **Authority Required (STREAMLINED)**

2647

*Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.*

*A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.*

#### **NOTE:**

*Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate.*

|       |              |    |   |    |       |       |        |    |
|-------|--------------|----|---|----|-------|-------|--------|----|
| 8363E | Tablet 60 mg | 28 | 5 | .. | 58.49 | 31.30 | Evista | LY |
|-------|--------------|----|---|----|-------|-------|--------|----|



## MUSCULO-SKELETAL SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### STRONTIUM RANELATE

#### **Authority Required (STREAMLINED)**

2758

*Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a woman aged 70 years or older with a bone mineral density (BMD) T-score of -3.0 or less.*

*The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.*

#### **Authority Required (STREAMLINED)**

2647

*Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.*

*A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.*

#### **NOTE:**

*Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate.*

|       |                                                    |    |   |    |       |       |            |    |
|-------|----------------------------------------------------|----|---|----|-------|-------|------------|----|
| 3036T | Sachet containing granules for oral suspension 2 g | 28 | 5 | .. | 52.91 | 31.30 | Protos 2 g | SE |
|-------|----------------------------------------------------|----|---|----|-------|-------|------------|----|

## NERVOUS SYSTEM

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|

### ANALGESICS

#### Opioids

#### • *Natural opium alkaloids*

##### CODEINE PHOSPHATE

|       |              |    |    |    |       |       |    |
|-------|--------------|----|----|----|-------|-------|----|
| 1214X | Tablet 30 mg | 20 | .. | .. | 16.44 | 17.47 | FM |
|-------|--------------|----|----|----|-------|-------|----|

##### CODEINE PHOSPHATE with PARACETAMOL

|       |                     |    |    |       |      |      |                   |    |
|-------|---------------------|----|----|-------|------|------|-------------------|----|
| 1215Y | Tablet 30 mg-500 mg | 20 | .. | ..    | 7.65 | 8.68 | a Codalgin Forte  | FM |
|       |                     |    |    |       |      |      | a Codapane Forte  | AL |
|       |                     |    |    |       |      |      | a Comfarol Forte  | SZ |
|       |                     |    |    |       |      |      | a Dolaforte       | CO |
|       |                     |    |    |       |      |      | a Prodeine Forte  | AV |
|       |                     |    |    | B1.43 | 9.08 | 8.68 | a Panadeine Forte | SW |

#### **NOTE:**

Authorities for increased maximum quantities and/or repeats will not be granted except as detailed under the 'Authority required' listing of codeine phosphate with paracetamol below.

#### CODEINE PHOSPHATE with PARACETAMOL

#### **Authority Required**

*Severe disabling pain not responding to non-narcotic analgesics.*

#### **NOTE:**

*Each authority approval will be limited to no more than 240 tablets per month for no more than 6 months.*

|       |                     |    |    |       |         |       |                   |    |
|-------|---------------------|----|----|-------|---------|-------|-------------------|----|
| 8785J | Tablet 30 mg-500 mg | 60 | .. | ..    | * 10.97 | 12.00 | a Codalgin Forte  | FM |
|       |                     |    |    |       |         |       | a Codapane Forte  | AL |
|       |                     |    |    |       |         |       | a Comfarol Forte  | SZ |
|       |                     |    |    |       |         |       | a Dolaforte       | CO |
|       |                     |    |    |       |         |       | a Prodeine Forte  | AV |
|       |                     |    |    | B4.29 | * 15.26 | 12.00 | a Panadeine Forte | SW |

##### HYDROMORPHONE HYDROCHLORIDE

#### **CAUTION:**

The risk of drug dependence is high.

|       |                           |   |    |    |       |       |             |    |
|-------|---------------------------|---|----|----|-------|-------|-------------|----|
| 8420E | Injection 2 mg in 1 mL    | 5 | .. | .. | 13.51 | 14.54 | Dilaudid    | MF |
| 8421F | Injection 10 mg in 1 mL   | 5 | .. | .. | 18.87 | 19.90 | Dilaudid-HP | MF |
| 8422G | Injection 50 mg in 5 mL   | 5 | .. | .. | 47.07 | 31.30 | Dilaudid-HP | MF |
| 8423H | Injection 500 mg in 50 mL | 1 | .. | .. | 74.98 | 31.30 | Dilaudid-HP | MF |

continued ➡

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |
| <b>HYDROMORPHONE HYDROCHLORIDE</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |         |                             |                                             |                                      |
| <b>CAUTION:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         |                             |                                             |                                      |
| <i>The risk of drug dependence is high.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                |         |                             |                                             |                                      |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                             |                                             |                                      |
| <i>Severe disabling pain not responding to non-narcotic analgesics.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                             |                                             |                                      |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                         |             |                |         |                             |                                             |                                      |
| <i>Authorities for increased maximum quantities and/or repeats will be granted only for:</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                         |             |                |         |                             |                                             |                                      |
| <i>(i) severe disabling pain associated with proven malignant neoplasia; or</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         |                             |                                             |                                      |
| <i>(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or</i>                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                             |                                             |                                      |
| <i>(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or</i> |                                                         |             |                |         |                             |                                             |                                      |
| <i>(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.</i>                                                                                                                                                                                                                                                                                                                                                              |                                                         |             |                |         |                             |                                             |                                      |
| 8541M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 2 mg                                             | 20          | ..             | ..      | 13.79                       | 14.82                                       | Dilaudid MF                          |
| 8542N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 4 mg                                             | 20          | ..             | ..      | 18.85                       | 19.88                                       | Dilaudid MF                          |
| 8543P                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 8 mg                                             | 20          | ..             | ..      | 28.61                       | 29.64                                       | Dilaudid MF                          |
| 8424J                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Oral liquid 1 mg per mL, 473 mL                         | 1           | ..             | ..      | 49.09                       | 31.30                                       | Dilaudid MF                          |

### MORPHINE HYDROCHLORIDE

#### CAUTION:

*The risk of drug dependence is high.*

#### Restricted Benefit

*Severe disabling pain not responding to non-narcotic analgesics.*

#### NOTE:

*Authorities for increased maximum quantities and/or repeats will be granted only for:*

*(i) severe disabling pain associated with proven malignant neoplasia; or*

*(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or*

*(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or*

*(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.*

continued 

## NERVOUS SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 2122Q | Oral solution 2 mg per mL, 200 mL                       | 1           | ..             | ..      | 18.73                                    | 19.76                                                  | Ordine 2                             | MF |
| 2123R | Oral solution 5 mg per mL, 200 mL                       | 1           | ..             | ..      | 21.64                                    | 22.67                                                  | Ordine 5                             | MF |
| 2124T | Oral solution 10 mg per mL, 200 mL                      | 1           | ..             | ..      | 26.24                                    | 27.27                                                  | Ordine 10                            | MF |

### MORPHINE SULFATE

#### **CAUTION:**

The risk of drug dependence is high.

|       |                         |   |    |    |       |       |    |  |
|-------|-------------------------|---|----|----|-------|-------|----|--|
| 1644M | Injection 10 mg in 1 mL | 5 | .. | .. | 13.56 | 14.59 | HH |  |
| 1645N | Injection 15 mg in 1 mL | 5 | .. | .. | 13.89 | 14.92 | HH |  |
| 1647Q | Injection 30 mg in 1 mL | 5 | .. | .. | 15.32 | 16.35 | HH |  |

### MORPHINE SULFATE

#### **CAUTION:**

The risk of drug dependence is high.

#### **Restricted Benefit**

Severe disabling pain due to cancer not responding to non-narcotic analgesics.

|       |              |    |    |    |       |       |          |    |
|-------|--------------|----|----|----|-------|-------|----------|----|
| 8669G | Tablet 10 mg | 20 | .. | .. | 14.85 | 15.88 | Sevredol | MF |
| 8670H | Tablet 20 mg | 20 | .. | .. | 15.99 | 17.02 | Sevredol | MF |

#### **Restricted Benefit**

Severe disabling pain not responding to non-narcotic analgesics.

#### **NOTE:**

Authorities for increased maximum quantities and/or repeats will be granted only for:

(i) severe disabling pain associated with proven malignant neoplasia; or

(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or

(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or

(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.

|       |              |    |    |    |       |       |          |    |
|-------|--------------|----|----|----|-------|-------|----------|----|
| 1646P | Tablet 30 mg | 20 | .. | .. | 14.53 | 15.56 | Anamorph | FM |
|-------|--------------|----|----|----|-------|-------|----------|----|

continued ➞

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Name, Restriction,<br>Manner of Administration and Form                             | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                     |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| <b>Restricted Benefit</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                     |             |                |         |                             |                                             |                                      |    |
| <i>Chronic severe disabling pain not responding to non-narcotic analgesics.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                     |             |                |         |                             |                                             |                                      |    |
| <b>NOTE:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                     |             |                |         |                             |                                             |                                      |    |
| <i>Authorities for increased maximum quantities and/or repeats will be granted only for:</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                     |             |                |         |                             |                                             |                                      |    |
| <i>(i) chronic severe disabling pain associated with proven malignant neoplasia; or</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                     |             |                |         |                             |                                             |                                      |    |
| <i>(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or</i>                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                     |             |                |         |                             |                                             |                                      |    |
| <i>(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or</i> |                                                                                     |             |                |         |                             |                                             |                                      |    |
| <i>(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.</i>                                                                                                                                                                                                                                                                                                                                                              |                                                                                     |             |                |         |                             |                                             |                                      |    |
| 8035X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 5 mg (controlled release)                                                    | 20          | ..             | ..      | 15.89                       | 16.92                                       | MS Contin                            | MF |
| 1653B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 10 mg (controlled release)                                                   | 20          | ..             | ..      | 17.35                       | 18.38                                       | MS Contin                            | MF |
| 8489T                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 15 mg (controlled release)                                                   | 20          | ..             | ..      | 20.86                       | 21.89                                       | MS Contin                            | MF |
| 1654C                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 30 mg (controlled release)                                                   | 20          | ..             | ..      | 30.03                       | 31.06                                       | MS Contin                            | MF |
| 1655D                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 60 mg (controlled release)                                                   | 20          | ..             | ..      | 45.84                       | 31.30                                       | MS Contin                            | MF |
| 1656E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 100 mg (controlled release)                                                  | 20          | ..             | ..      | 62.58                       | 31.30                                       | MS Contin                            | MF |
| 8349K                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 10 mg (containing sustained release pellets)                                | 20          | ..             | ..      | 17.07                       | 18.10                                       | Kapanol                              | GK |
| 2839K                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 20 mg (containing sustained release pellets)                                | 20          | ..             | ..      | 22.20                       | 23.23                                       | Kapanol                              | GK |
| 8491X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 30 mg (controlled release)                                                  | 10          | ..             | ..      | 20.86                       | 21.89                                       | MS Mono                              | MF |
| 2840L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 50 mg (containing sustained release pellets)                                | 20          | ..             | ..      | 37.75                       | 31.30                                       | Kapanol                              | GK |
| 8492Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 60 mg (controlled release)                                                  | 10          | ..             | ..      | 30.03                       | 31.06                                       | MS Mono                              | MF |
| 8493B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 90 mg (controlled release)                                                  | 10          | ..             | ..      | 36.15                       | 31.30                                       | MS Mono                              | MF |
| 2841M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 100 mg (containing sustained release pellets)                               | 20          | ..             | ..      | 60.83                       | 31.30                                       | Kapanol                              | GK |
| 8494C                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 120 mg (controlled release)                                                 | 10          | ..             | ..      | 45.84                       | 31.30                                       | MS Mono                              | MF |
| 8490W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Sachet containing controlled release granules for oral suspension, 20 mg per sachet | 20          | ..             | ..      | 48.36                       | 31.30                                       | MS Contin<br>Suspension<br>20 mg     | MF |

continued ➞

## NERVOUS SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form                              | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|--------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8146R | Sachet containing controlled release granules for oral suspension, 30 mg per sachet  | 20          | ..             | ..      | 49.60                                    | 31.30                                                  | MS Contin Suspension 30 mg           | MF |
| 8305D | Sachet containing controlled release granules for oral suspension, 60 mg per sachet  | 20          | ..             | ..      | 54.95                                    | 31.30                                                  | MS Contin Suspension 60 mg           | MF |
| 8306E | Sachet containing controlled release granules for oral suspension, 100 mg per sachet | 20          | ..             | ..      | 67.09                                    | 31.30                                                  | MS Contin Suspension 100 mg          | MF |

### Authority Required

*Chronic severe disabling pain due to cancer.*

|       |                                                                                      |    |    |    |        |       |                             |    |
|-------|--------------------------------------------------------------------------------------|----|----|----|--------|-------|-----------------------------|----|
| 8453X | Tablet 200 mg (controlled release)                                                   | 20 | .. | .. | 104.50 | 31.30 | MS Contin                   | MF |
| 8454Y | Sachet containing controlled release granules for oral suspension, 200 mg per sachet | 20 | .. | .. | 125.62 | 31.30 | MS Contin Suspension 200 mg | MF |

MORPHINE TARTRATE

### CAUTION:

The risk of drug dependence is high.

|       |                            |   |    |    |       |       |    |  |
|-------|----------------------------|---|----|----|-------|-------|----|--|
| 1607N | Injection 120 mg in 1.5 mL | 5 | .. | .. | 25.06 | 26.09 | HH |  |
|-------|----------------------------|---|----|----|-------|-------|----|--|

OXYCODONE

### CAUTION:

*The risk of drug dependence is high.*

### Restricted Benefit

*Severe disabling pain not responding to non-narcotic analgesics.*

### NOTE:

*Authorities for increased maximum quantities and/or repeats will be granted only for:*

*(i) severe disabling pain associated with proven malignant neoplasia; or*

*(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or*

*(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or*

*(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.*

|       |                   |    |    |    |       |       |           |    |
|-------|-------------------|----|----|----|-------|-------|-----------|----|
| 2481N | Suppository 30 mg | 12 | .. | .. | 39.61 | 31.30 | Proladone | PL |
|-------|-------------------|----|----|----|-------|-------|-----------|----|

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |
| <b>OXYCODONE HYDROCHLORIDE</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                         |             |                |         |                             |                                             |                                      |
| <b>CAUTION:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         |                             |                                             |                                      |
| <i>The risk of drug dependence is high.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                |         |                             |                                             |                                      |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                         |             |                |         |                             |                                             |                                      |
| <i>Severe disabling pain not responding to non-narcotic analgesics.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                             |                                             |                                      |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                         |             |                |         |                             |                                             |                                      |
| <i>Authorities for increased maximum quantities and/or repeats will be granted only for:</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                         |             |                |         |                             |                                             |                                      |
| <i>(i) severe disabling pain associated with proven malignant neoplasia; or</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         |                             |                                             |                                      |
| <i>(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or</i>                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                             |                                             |                                      |
| <i>(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or</i> |                                                         |             |                |         |                             |                                             |                                      |
| <i>(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.</i>                                                                                                                                                                                                                                                                                                                                                              |                                                         |             |                |         |                             |                                             |                                      |
| 2622B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Tablet 5 mg                                             | 20          | ..             | ..      | 11.87                       | 12.90                                       | Endone SI                            |
| 8464L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 5 mg                                            | 20          | ..             | ..      | 11.87                       | 12.90                                       | OxyNorm MF                           |
| 8501K                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 10 mg                                           | 20          | ..             | ..      | 14.99                       | 16.02                                       | OxyNorm MF                           |
| 8502L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 20 mg                                           | 20          | ..             | ..      | 19.72                       | 20.75                                       | OxyNorm MF                           |
| 8644Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Oral solution 5 mg per 5 mL, 250 mL                     | 1           | ..             | ..      | 20.29                       | 21.32                                       | OxyNorm Liquid MF<br>5mg/5mL         |

**Restricted Benefit***Chronic severe disabling pain not responding to non-narcotic analgesics.***NOTE:***Authorities for increased maximum quantities and/or repeats will be granted only for:**(i) chronic severe disabling pain associated with proven malignant neoplasia; or**(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or**(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or**(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.*

continued ➞

## NERVOUS SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8681X | Tablet 5 mg (controlled release)                        | 20          | ..             | ..      | 20.75                                    | 21.78                                                  | OxyContin                            | MF |
| 8385H | Tablet 10 mg (controlled release)                       | 20          | ..             | ..      | 21.25                                    | 22.28                                                  | OxyContin                            | MF |
| 8386J | Tablet 20 mg (controlled release)                       | 20          | ..             | ..      | 30.03                                    | 31.06                                                  | OxyContin                            | MF |
| 8387K | Tablet 40 mg (controlled release)                       | 20          | ..             | ..      | 45.84                                    | 31.30                                                  | OxyContin                            | MF |
| 8388L | Tablet 80 mg (controlled release)                       | 20          | ..             | ..      | 71.27                                    | 31.30                                                  | OxyContin                            | MF |

### • Phenylpiperidine derivatives

#### FENTANYL

#### CAUTION:

The risk of drug dependence is high.

#### Restricted Benefit

Chronic severe disabling pain not responding to non-narcotic analgesics.

#### NOTE:

Authorities for increased maximum quantities and/or repeats will be granted only for:

(i) chronic severe disabling pain associated with proven malignant neoplasia; or

(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or

(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or

(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.

|       |                                                                             |   |    |    |        |       |               |    |
|-------|-----------------------------------------------------------------------------|---|----|----|--------|-------|---------------|----|
| 8878G | Transdermal patch 2.1 mg (releasing approximately 12 micrograms per hour)   | 5 | .. | .. | 46.73  | 31.30 | Durogesic 12  | JC |
| 8891Y | Transdermal patch 4.2 mg (releasing approximately 25 micrograms per hour)   | 5 | .. | .. | 55.85  | 31.30 | Durogesic 25  | JC |
| 8892B | Transdermal patch 8.4 mg (releasing approximately 50 micrograms per hour)   | 5 | .. | .. | 94.95  | 31.30 | Durogesic 50  | JC |
| 8893C | Transdermal patch 12.6 mg (releasing approximately 75 micrograms per hour)  | 5 | .. | .. | 126.85 | 31.30 | Durogesic 75  | JC |
| 8894D | Transdermal patch 16.8 mg (releasing approximately 100 micrograms per hour) | 5 | .. | .. | 155.33 | 31.30 | Durogesic 100 | JC |

continued ☞



## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |
| <p><b><u>NOTE:</u></b><br/><i>Durogesic is not recommended in opioid naive patients with non-cancer pain, because of a high incidence of adverse events in these patients. Patients with cancer pain may be initiated on the lowest strength patch (12 micrograms per hour).</i></p> <p>• <b>Diphenylpropylamine derivatives</b><br/><b>METHADONE HYDROCHLORIDE</b><br/><b><u>CAUTION:</u></b><br/><i>The risk of drug dependence is high.</i></p> <p><b><u>Restricted Benefit</u></b><br/><i>Severe disabling pain not responding to non-narcotic analgesics.</i></p> <p><b><u>NOTE:</u></b><br/><i>Authorities for increased maximum quantities and/or repeats will be granted only for:</i></p> <p><i>(i) severe disabling pain associated with proven malignant neoplasia; or</i></p> <p><i>(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or</i></p> <p><i>(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or</i></p> <p><i>(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.</i></p> |                                                         |             |                |         |                             |                                             |                                      |
| 1609Q                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Tablet 10 mg                                            | 20          | ..             | ..      | 15.17                       | 16.20                                       | Physeptone GK                        |
| 1606M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Injection 10 mg in 1 mL                                 | 5           | ..             | ..      | 30.39                       | 31.30                                       | Physeptone GK                        |

• **Oripavine derivatives**

**BUPRENORPHINE**

**CAUTION:**

*The risk of drug dependence is high.*

**Restricted Benefit**

*Chronic severe disabling pain not responding to non-narcotic analgesics.*

**NOTE:**

*Authorities for increased maximum quantities and/or repeats will be granted only for:*

*(i) chronic severe disabling pain associated with proven malignant neoplasia; or*

*(ii) chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months; or*

continued ➞

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Name, Restriction,<br>Manner of Administration and Form                  | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <i>(iii) first application for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner, and the clinical need for continuing narcotic analgesic treatment has been confirmed. The date of the consultation must be no more than 3 months prior to the application for a PBS authority. The full name of the medical practitioner consulted and the date of consultation are to be provided at the time of application; or</i> |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| <i>(iv) subsequent application for treatment of chronic severe disabling pain not responding to non-narcotic analgesics where a PBS authority prescription for treatment beyond 12 months has previously been issued for this patient.</i>                                                                                                                                                                                                                                                                                                                                                              |                                                                          |             |                |         |                                          |                                                        |                                      |    |
| 8865N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Transdermal patch 5 mg (releasing approximately 5 micrograms per hour)   | 2           | ..             | ..      | 26.27                                    | 27.30                                                  | Norspan                              | MF |
| 8866P                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Transdermal patch 10 mg (releasing approximately 10 micrograms per hour) | 2           | ..             | ..      | 40.34                                    | 31.30                                                  | Norspan                              | MF |
| 8867Q                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Transdermal patch 20 mg (releasing approximately 20 micrograms per hour) | 2           | ..             | ..      | 55.65                                    | 31.30                                                  | Norspan                              | MF |

### • Other opioids

#### TRAMADOL HYDROCHLORIDE

##### Restricted Benefit

For acute pain where aspirin and/or paracetamol alone are inappropriate or have failed.

##### NOTE:

No applications for increased maximum quantities and/or repeats will be authorised.

|       |               |    |    |       |       |      |                                                  |    |
|-------|---------------|----|----|-------|-------|------|--------------------------------------------------|----|
| 8455B | Capsule 50 mg | 20 | .. | ..    | 8.73  | 9.76 | <sup>a</sup> Chem mart<br>Tramadol               | CH |
|       |               |    |    |       |       |      | <sup>a</sup> GenRx Tramadol                      | GX |
|       |               |    |    |       |       |      | <sup>a</sup> Terry White<br>Chemists<br>Tramadol | TW |
|       |               |    |    |       |       |      | <sup>a</sup> Tramedo                             | AF |
|       |               |    |    |       |       |      | <sup>a</sup> Zydol                               | AW |
|       |               |    |    | B2.42 | 11.15 | 9.76 | <sup>a</sup> Tramal                              | CS |

continued ➞

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                 | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer                                                                                                                                                       |                                          |
|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
|                                                                                                                      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                                                                                                                                                                            |                                          |
| <b><u>Restricted Benefit</u></b>                                                                                     |                                                         |             |                |         |                             |                                             |                                                                                                                                                                                            |                                          |
| <i>For dosage titration in chronic pain where aspirin and/or paracetamol alone are inappropriate or have failed.</i> |                                                         |             |                |         |                             |                                             |                                                                                                                                                                                            |                                          |
| <b>NOTE:</b>                                                                                                         |                                                         |             |                |         |                             |                                             |                                                                                                                                                                                            |                                          |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i>                           |                                                         |             |                |         |                             |                                             |                                                                                                                                                                                            |                                          |
| 8611F                                                                                                                | Capsule 50 mg                                           | 20          | 2              | ..      | 8.73                        | 9.76                                        | <sup>a</sup> Chem mart<br>Tramadol<br><sup>a</sup> GenRx Tramadol<br><sup>a</sup> Terry White<br>Chemists<br>Tramadol<br><sup>a</sup> Tramedo<br><sup>a</sup> Zydol<br><sup>a</sup> Tramal | CH<br><br>GX<br>TW<br><br>AF<br>AW<br>CS |
|                                                                                                                      |                                                         |             |                | B2.42   | 11.15                       | 9.76                                        |                                                                                                                                                                                            |                                          |

**Restricted Benefit**

*For pain where aspirin and/or paracetamol alone are inappropriate or have failed.*

**NOTE:**

*Authorities for increased maximum quantities and/or repeats will be granted only for severe disabling pain not responding to non-narcotic analgesics.*

|       |                                   |     |    |       |       |       |                             |    |
|-------|-----------------------------------|-----|----|-------|-------|-------|-----------------------------|----|
| 2527B | Tablet 50 mg (sustained release)  | 20  | .. | ..    | 11.20 | 12.23 | Tramal SR 50                | CS |
| 8523N | Tablet 100 mg (sustained release) | 20  | .. | ..    | 13.43 | 14.46 | <sup>a</sup> Tramahexal SR  | SZ |
|       |                                   |     |    |       |       |       | <sup>a</sup> Tramedo SR 100 | AF |
|       |                                   |     |    |       |       |       | <sup>a</sup> Zydol SR 100   | AW |
|       |                                   |     |    | B4.51 | 17.94 | 14.46 | <sup>a</sup> Tramal SR 100  | CS |
| 8524P | Tablet 150 mg (sustained release) | 20  | .. | ..    | 16.02 | 17.05 | <sup>a</sup> Tramahexal SR  | SZ |
|       |                                   |     |    |       |       |       | <sup>a</sup> Tramedo SR 150 | AF |
|       |                                   |     |    |       |       |       | <sup>a</sup> Zydol SR 150   | AW |
|       |                                   |     |    | B5.37 | 21.39 | 17.05 | <sup>a</sup> Tramal SR 150  | CS |
| 8525Q | Tablet 200 mg (sustained release) | 20  | .. | ..    | 18.20 | 19.23 | <sup>a</sup> Tramahexal SR  | SZ |
|       |                                   |     |    |       |       |       | <sup>a</sup> Tramedo SR 200 | AF |
|       |                                   |     |    |       |       |       | <sup>a</sup> Zydol SR 200   | AW |
|       |                                   |     |    | B6.09 | 24.29 | 19.23 | <sup>a</sup> Tramal SR 200  | CS |
| 8843K | Oral drops 100 mg per mL, 10 mL   | ± 1 | .. | ..    | 9.64  | 10.67 | Tramal                      | CS |

**Restricted Benefit**

*Short-term treatment of acute pain.*

**NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*

|       |                          |   |    |    |       |       |            |    |
|-------|--------------------------|---|----|----|-------|-------|------------|----|
| 8582Q | Injection 100 mg in 2 mL | 5 | .. | .. | 10.21 | 11.24 | Tramal 100 | CS |
|-------|--------------------------|---|----|----|-------|-------|------------|----|

# NERVOUS SYSTEM—CONT.

| Code                                     | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer     |    |
|------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------|----|
| <b>Other analgesics and antipyretics</b> |                                                         |             |                |         |                                          |                                                        |                                          |    |
| • <b>Salicylic acid and derivatives</b>  |                                                         |             |                |         |                                          |                                                        |                                          |    |
| ASPIRIN                                  |                                                         |             |                |         |                                          |                                                        |                                          |    |
| 1010E                                    | Tablet 300 mg (dispersible)                             | 96          | 1              | ..      | 8.21                                     | 9.24                                                   | Solprin                                  | RC |
| • <b>Anilides</b>                        |                                                         |             |                |         |                                          |                                                        |                                          |    |
| PARACETAMOL                              |                                                         |             |                |         |                                          |                                                        |                                          |    |
| 1746X                                    | Tablet 500 mg                                           | 100         | 1              | ..      | 7.99                                     | 9.02                                                   | a Chem mart<br>Chemadol                  | CH |
|                                          |                                                         |             |                |         |                                          |                                                        | a Dymadon P                              | PC |
|                                          |                                                         |             |                |         |                                          |                                                        | a Febridol                               | GM |
|                                          |                                                         |             |                |         |                                          |                                                        | a Panamax                                | SW |
|                                          |                                                         |             |                |         |                                          |                                                        | a Paracetamol<br>Sandoz                  | SZ |
|                                          |                                                         |             |                |         |                                          |                                                        | b Parahexal                              | HX |
|                                          |                                                         |             |                |         |                                          |                                                        | a Paralgin                               | FM |
|                                          |                                                         |             |                |         |                                          |                                                        | b Parmol                                 | AW |
|                                          |                                                         |             |                |         |                                          |                                                        | a Pharmacy Choice<br>Paracetamol         | YM |
|                                          |                                                         |             |                |         |                                          |                                                        | a Terry White<br>Chemists<br>Paracetamol | TW |
|                                          |                                                         |             |                |         |                                          |                                                        | b Tylenol                                | JT |
| 1747Y                                    | Oral liquid 120 mg per 5 mL, 100 mL                     | ‡ 1         | 2              | ..      | 8.95                                     | 9.98                                                   | Panamax                                  | SW |
| 1770E                                    | Oral liquid 240 mg per 5 mL, 200 mL                     | ‡ 1         | 2              | ..      | 10.25                                    | 11.28                                                  | Panamax 240 Elixir                       | SW |

continued 

## NERVOUS SYSTEM—CONT.

| Code                                                                                                 | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>PARACETAMOL</b>                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Chronic arthropathies.</i>                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8784H                                                                                                | Tablet 500 mg                                           | 300         | 4              | ..      | * 11.99                                  | 13.02                                                  | <sup>a</sup> Chem mart<br>Chemadol   | CH |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dymadon P               | PC |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Febridol                | GM |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Panamax                 | SW |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Paracetamol             | SZ |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | Sandoz                               |    |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>b</sup> Parahexal               | HX |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Paralgin                | FM |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>b</sup> Parmol                  | AW |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pharmacy Choice         | YM |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | Paracetamol                          |    |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | Paracetamol                          |    |
|                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>b</sup> Tylenol                 | JT |
| <hr/>                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Relief of persistent pain associated with osteoarthritis.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8814X                                                                                                | Tablet 665 mg (modified release)                        | 192         | 5              | ..      | * 12.83                                  | 13.86                                                  | Panadol Osteo                        | GC |
| <b>Antimigraine preparations</b>                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b><i>Ergot alkaloids</i></b>                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| DIHYDROERGOTAMINE MESYLATE                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1323P                                                                                                | Injection 1 mg in 1 mL                                  | 5           | ..             | ..      | 16.63                                    | 17.66                                                  | Dihydergot                           | NV |
| METHYSERGIDE                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2826R                                                                                                | Tablet 1 mg                                             | 100         | 2              | ..      | * 44.53                                  | 31.30                                                  | Deseril                              | NV |

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>• Selective 5HT<sub>1</sub>-receptor agonists</b><br><b>SUMATRIPTAN</b><br><b>CAUTION:</b><br><i>Sumatriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.</i><br><b>Authority Required (STREAMLINED)</b><br>2663<br><i>Migraine attacks in patients receiving, or who have failed a reasonable trial of, prophylactic medication and where attacks in the past have usually failed to respond to oral therapy with ergotamine and other appropriate agents, or in whom these agents are contraindicated.</i><br><b>NOTE:</b><br><i>No applications for increased maximum quantities and/or repeats will be authorised.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8341B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Nasal spray 20 mg in 0.1 mL single dose unit            | 2           | 5              | ..      | 19.63                                    | 20.66                                                  | Imigran                              | GK |
| <b>SUMATRIPTAN SUCCINATE</b><br><b>CAUTION:</b><br><i>Sumatriptan is contraindicated in patients with known or suspected coronary artery disease. The drug should not be used within 24 hours of ergotamine or dihydroergotamine use.</i><br><b>Authority Required (STREAMLINED)</b><br>2663<br><i>Migraine attacks in patients receiving, or who have failed a reasonable trial of, prophylactic medication and where attacks in the past have usually failed to respond to oral therapy with ergotamine and other appropriate agents, or in whom these agents are contraindicated.</i><br><b>NOTE:</b><br><i>No applications for increased maximum quantities and/or repeats will be authorised.</i>                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8144P                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Tablet 50 mg (base)                                     | 4           | 5              | ..      | 25.08                                    | 26.11                                                  | <sup>a</sup> Sumagran 50             | AW |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                         |             |                | ..      | * 25.09                                  | 26.12                                                  | <sup>a</sup> Imigran                 | GK |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Sumatab                 | AF |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Suvalan 50              | ME |
| 8885P                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Tablet 50 mg (base) (fast disintegrating)               | 4           | 5              | ..      | * 25.09                                  | 26.12                                                  | Imigran FDT                          | GK |
| <b>• Other antimigraine preparations</b><br><b>CYPROHEPTADINE HYDROCHLORIDE</b><br><b>Restricted Benefit</b><br><i>Prevention of migraine.</i><br><b>NOTE:</b><br><i>Cyproheptadine hydrochloride is not PBS-subsidised for use in hay fever or atopy.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1798P                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Tablet 4 mg                                             | 100         | 2              | ..      | * 13.77                                  | 14.80                                                  | Periactin                            | FR |
| <b>PIZOTIFEN MALATE</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 3074T                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Tablet 500 micrograms (base)                            | 100         | 2              | ..      | 21.32                                    | 22.35                                                  | Sandomigran 0.5                      | NV |

## NERVOUS SYSTEM—CONT.

| Code                                  | Name, Restriction,<br>Manner of Administration and Form                        | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------|--------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| ANTIEPILEPTICS                        |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| Antiepileptics                        |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| • <b>Barbiturates and derivatives</b> |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| <b>PHENOBARBITONE</b>                 |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>      |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| <i>Epilepsy.</i>                      |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| 1850J                                 | Tablet 30 mg                                                                   | 200         | 4              | ..      | 14.85                                    | 15.88                                                  | SI                                   |    |
| <b>PHENOBARBITONE SODIUM</b>          |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>      |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| <i>Epilepsy.</i>                      |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| 1853M                                 | Injection 200 mg in 1 mL                                                       | 5           | ..             | ..      | 32.82                                    | 31.30                                                  | FM                                   |    |
| PRIMIDONE                             |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| 1939C                                 | Tablet 250 mg                                                                  | 200         | 2              | ..      | 52.12                                    | 31.30                                                  | Mysoline                             | LM |
| • <b>Hydantoin derivatives</b>        |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| PHENYTOIN                             |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| 1249R                                 | Tablet 50 mg                                                                   | 200         | 2              | ..      | 29.69                                    | 30.72                                                  | Dilantin Infatabs                    | PF |
| 2692Q                                 | Paediatric oral suspension 30 mg per 5 mL, 500 mL                              | ‡ 1         | 3              | ..      | 21.18                                    | 22.21                                                  | Dilantin                             | PF |
| PHENYTOIN SODIUM                      |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| 1873N                                 | Capsule 30 mg                                                                  | 200         | 2              | ..      | 28.75                                    | 29.78                                                  | Dilantin Sodium                      | PF |
| 1874P                                 | Capsule 100 mg                                                                 | 200         | 2              | ..      | 29.69                                    | 30.72                                                  | Dilantin Sodium                      | PF |
| • <b>Succinimide derivatives</b>      |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| ETHOSUXIMIDE                          |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| 1413J                                 | Capsule 250 mg                                                                 | 200         | 2              | ..      | 53.67                                    | 31.30                                                  | Zarontin                             | PF |
| 1414K                                 | Paediatric syrup 250 mg per 5 mL, 200 mL                                       | ‡ 1         | 5              | ..      | 24.86                                    | 25.89                                                  | Zarontin                             | PF |
| • <b>Benzodiazepine derivatives</b>   |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| CLONAZEPAM                            |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>      |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| <i>Epilepsy.</i>                      |                                                                                |             |                |         |                                          |                                                        |                                      |    |
| 1807D                                 | Injection 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent) | 5           | ..             | ..      | 18.15                                    | 19.18                                                  | Rivotril                             | RO |

continued ➞

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b><u>Authority Required</u></b><br><i>Neurologically proven epilepsy.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b><br><i>Abuse of clonazepam has been reported. Refer to the current product information.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1805B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Tablet 500 micrograms                                   | 200         | 2              | ..      | * 19.77                                  | 20.80                                                  | <sup>a</sup> Paxam 0.5               | AF |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                | B3.58   | * 23.35                                  | 20.80                                                  | <sup>a</sup> Rivotril                | RO |
| 1806C                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Tablet 2 mg                                             | 200         | 2              | ..      | * 31.91                                  | 31.30                                                  | <sup>a</sup> Paxam 2                 | AF |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                | B4.08   | * 35.99                                  | 31.30                                                  | <sup>a</sup> Rivotril                | RO |
| 1808E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Oral liquid 2.5 mg per mL, 10 mL                        | 2           | ..             | ..      | * 14.61                                  | 15.64                                                  | Rivotril                             | RO |
| <b>NITRAZEPAM</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Authority Required</u></b><br><i>Myoclonic epilepsy;</i><br><i>Malignant neoplasia (late stage);</i><br><i>For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal;</i><br><i>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2732T                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Tablet 5 mg                                             | 50          | 5              | ..      | * 8.93                                   | 9.96                                                   | <sup>a</sup> Alodorm                 | AF |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                | B3.06   | * 11.99                                  | 9.96                                                   | <sup>a</sup> Mogadon                 | VT |
| <b>[For other listings for this drug see Generic/Proprietary Index]</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>• Carboxamide derivatives</b><br>CARBAMAZEPINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2422L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Tablet 100 mg                                           | 200         | 2              | ..      | 18.71                                    | 19.74                                                  | <sup>a</sup> Carbamazepine Sandoz    | SZ |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                | B2.55   | 21.26                                    | 19.74                                                  | <sup>a</sup> Tegretol 100            | NV |
| 2419H                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Tablet 200 mg                                           | 200         | 2              | ..      | 29.77                                    | 30.80                                                  | <sup>a</sup> Carbamazepine Sandoz    | SZ |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                | B2.74   | 32.51                                    | 30.80                                                  | <sup>a</sup> Teril                   | AF |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Tegretol 200            | NV |
| 2426Q                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Tablet 200 mg (controlled release)                      | 200         | 2              | ..      | 30.26                                    | 31.29                                                  | Tegretol CR 200                      | NV |
| 2431Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Tablet 400 mg (controlled release)                      | 200         | 2              | ..      | 50.59                                    | 31.30                                                  | Tegretol CR 400                      | NV |
| 2427R                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Oral suspension 100 mg per 5 mL, 300 mL                 | ‡ 1         | 5              | ..      | 20.92                                    | 21.95                                                  | Tegretol Liquid                      | NV |



## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                 | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer   |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------|----|
| <b>OXCARBAZEPINE</b>                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                        |    |
| <b>Authority Required (STREAMLINED)</b>                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                        |    |
| 1587                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                        |    |
| <i>Treatment of partial epileptic seizures and primary generalised tonic-clonic seizures, which are not controlled satisfactorily by other anti-epileptic drugs.</i> |                                                         |             |                |         |                                          |                                                        |                                        |    |
| 8584T                                                                                                                                                                | Tablet 150 mg                                           | 100         | 5              | ..      | 71.84                                    | 31.30                                                  | Trileptal                              | NV |
| 8585W                                                                                                                                                                | Tablet 300 mg                                           | 100         | 5              | ..      | 114.65                                   | 31.30                                                  | Trileptal                              | NV |
| 8586X                                                                                                                                                                | Tablet 600 mg                                           | 100         | 5              | ..      | 187.55                                   | 31.30                                                  | Trileptal                              | NV |
| 8588B                                                                                                                                                                | Oral suspension 60 mg per mL, 250 mL                    | 2           | 5              | ..      | * 137.69                                 | 31.30                                                  | Trileptal                              | NV |
| • <b>Fatty acid derivatives</b>                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                        |    |
| SODIUM VALPROATE                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                        |    |
| <b>CAUTION:</b>                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                        |    |
| There are reports of fatal hepatotoxicity, particularly in children.                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                        |    |
| There is increasing evidence of dose-related teratogenesis from this drug.                                                                                           |                                                         |             |                |         |                                          |                                                        |                                        |    |
| 2294R                                                                                                                                                                | Crushable tablet 100 mg                                 | 200         | 2              | ..      | * 31.23                                  | 31.30                                                  | Epilim                                 | SW |
| 2289L                                                                                                                                                                | Tablet 200 mg (enteric coated)                          | 200         | 2              | ..      | * 33.43                                  | 31.30                                                  | <sup>a</sup> Sodium Valproate Sandoz   | SZ |
|                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Valpro 200                | AF |
|                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Valproate Winthrop EC 200 | WA |
|                                                                                                                                                                      |                                                         |             |                | b1.14   | * 34.57                                  | 31.30                                                  | <sup>a</sup> Epilim EC                 | SW |
| 2290M                                                                                                                                                                | Tablet 500 mg (enteric coated)                          | 200         | 2              | ..      | * 57.95                                  | 31.30                                                  | <sup>a</sup> Sodium Valproate Sandoz   | SZ |
|                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Valpro 500                | AF |
|                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Valproate Winthrop EC 500 | WA |
|                                                                                                                                                                      |                                                         |             |                | b1.36   | * 59.31                                  | 31.30                                                  | <sup>a</sup> Epilim EC                 | SW |
| 2293Q                                                                                                                                                                | Oral liquid 200 mg per 5 mL, 300 mL                     | 2           | 2              | ..      | * 34.49                                  | 31.30                                                  | Epilim Liquid                          | SW |
| 2295T                                                                                                                                                                | Syrup 200 mg per 5 mL, 300 mL                           | 2           | 2              | ..      | * 34.49                                  | 31.30                                                  | Epilim Syrup                           | SW |
| <b>TIAGABINE HYDROCHLORIDE</b>                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                        |    |
| <b>Authority Required (STREAMLINED)</b>                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                        |    |
| 2664                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                        |    |
| <i>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs.</i>                                                |                                                         |             |                |         |                                          |                                                        |                                        |    |
| 8221Q                                                                                                                                                                | Tablet 5 mg (base)                                      | 100         | 5              | ..      | * 72.21                                  | 31.30                                                  | Gabitril                               | OA |
| 8222R                                                                                                                                                                | Tablet 10 mg (base)                                     | 100         | 5              | ..      | * 138.41                                 | 31.30                                                  | Gabitril                               | OA |
| 8223T                                                                                                                                                                | Tablet 15 mg (base)                                     | 100         | 5              | ..      | * 196.45                                 | 31.30                                                  | Gabitril                               | OA |

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>VIGABATRIN</b>                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Visual field defects have been reported with this drug.</i>                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b>                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1426                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs.</i>         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2667J                                                                                                                 | Tablet 500 mg                                           | 100         | 5              | ..      | 90.89                                    | 31.30                                                  | Sabril                               | SW |
| 2668K                                                                                                                 | Oral powder, sachet 500 mg                              | 60          | 5              | ..      | 60.84                                    | 31.30                                                  | Sabril                               | SW |
| <b>• Other antiepileptics</b>                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>GABAPENTIN</b>                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b>                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2664                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8505P                                                                                                                 | Capsule 100 mg                                          | 100         | 5              | ..      | 23.38                                    | 24.41                                                  | <sup>a</sup> DBL Gabapentin          | HH |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Gabatine 100            | SI |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Gantin                  | AW |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Neurontin               | PF |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Nupentin 100            | AF |
| 1834M                                                                                                                 | Capsule 300 mg                                          | 100         | 5              | ..      | 61.58                                    | 31.30                                                  | <sup>a</sup> DBL Gabapentin          | HH |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Douglas                 | GM |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | Gabapentin                           |    |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | 300mg                                |    |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Gabahexal 300mg         | SZ |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Gabapentin 300          | CR |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Gabatine 300            | SI |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Gantin                  | AW |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Gabapentin        | GX |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Neurontin               | PF |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Nupentin 300            | AF |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pendine 300             | AL |
| 1835N                                                                                                                 | Capsule 400 mg                                          | 100         | 5              | ..      | 81.81                                    | 31.30                                                  | <sup>a</sup> DBL Gabapentin          | HH |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Douglas                 | GM |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | Gabapentin                           |    |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | 400mg                                |    |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Gabahexal 400mg         | SZ |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Gabapentin 400          | CR |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Gabatine 400            | SI |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Gantin                  | AW |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Gabapentin        | GX |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Neurontin               | PF |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Nupentin 400            | AF |
|                                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pendine 400             | AL |

continued ➡

# NERVOUS SYSTEM—CONT.

| Code                                                                                                   | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8559L                                                                                                  | Tablet 600 mg                                           | 100         | 5              | ..      | 126.34                                   | 31.30                                                  | <sup>a</sup> Gabahexal 600mg         | SZ |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Gabaran                 | RA |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Gabapentin        | GX |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Neurontin               | PF |
| 8389M                                                                                                  | Tablet 800 mg                                           | 100         | 5              | ..      | 166.43                                   | 31.30                                                  | <sup>a</sup> Gabaran                 | RA |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Gantin                  | AW |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Gabapentin        | GX |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Neurontin               | PF |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pendine 800             | AF |
| <b>LAMOTRIGINE</b>                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b>                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1426                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8063J                                                                                                  | Tablet 5 mg                                             | 56          | 5              | ..      | 16.32                                    | 17.35                                                  | <sup>a</sup> Elmendos                | ME |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamitrin                | HX |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamogine                | AF |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Seaze 5                 | AW |
|                                                                                                        |                                                         |             |                | 80.76   | 17.08                                    | 17.35                                                  | <sup>a</sup> Lamictal                | GK |
| 2848X                                                                                                  | Tablet 25 mg                                            | 56          | 5              | ..      | 28.97                                    | 30.00                                                  | <sup>a</sup> Elmendos                | ME |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                   | GX |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | Lamotrigine                          |    |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamidus                 | RA |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamitrin                | HX |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamogine                | AF |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamotrigine-DP          | GM |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamotrigine             | GQ |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | generichealth                        |    |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamotrigine             | SZ |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | Sandoz                               |    |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Seaze 25                | AW |
|                                                                                                        |                                                         |             |                | 80.77   | 29.74                                    | 30.00                                                  | <sup>a</sup> Lamictal                | GK |
| 2849Y                                                                                                  | Tablet 50 mg                                            | 56          | 5              | ..      | 43.81                                    | 31.30                                                  | <sup>a</sup> Elmendos                | ME |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                   | GX |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | Lamotrigine                          |    |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamidus                 | RA |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamitrin                | HX |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamogine                | AF |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamotrigine-DP          | GM |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamotrigine             | GQ |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | generichealth                        |    |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lamotrigine             | SZ |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | Sandoz                               |    |
|                                                                                                        |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Seaze 50                | AW |
|                                                                                                        |                                                         |             |                | 80.66   | 44.47                                    | 31.30                                                  | <sup>a</sup> Lamictal                | GK |

continued ➞

## NERVOUS SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 2850B | Tablet 100 mg                                           | 56          | 5              | ..      | 67.06                                    | 31.30                                                  | <sup>a</sup> <i>Elmendos</i>         | ME |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>GenRx</i>            | GX |
|       |                                                         |             |                |         |                                          |                                                        | <i>Lamotrigine</i>                   |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamidus</i>          | RA |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamitrin</i>         | HX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamogine</i>         | AF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamotrigine-DP</i>   | GM |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamotrigine</i>      | GQ |
|       |                                                         |             |                |         |                                          |                                                        | <i>generichealth</i>                 |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamotrigine</i>      | SZ |
| 2851C | Tablet 200 mg                                           | 56          | 5              | ..      | 108.58                                   | 31.30                                                  | <i>Sandoz</i>                        |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Seaze 100</i>        | AW |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamictal</i>         | GK |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                | B0.73   | 67.79                                    | 31.30                                                  | <sup>a</sup> <i>Elmendos</i>         | ME |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>GenRx</i>            | GX |
|       |                                                         |             |                |         |                                          |                                                        | <i>Lamotrigine</i>                   |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamidus</i>          | RA |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamitrin</i>         | HX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamogine</i>         | AF |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamotrigine-DP</i>   | GM |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamotrigine</i>      | GQ |
|       |                                                         |             |                |         |                                          |                                                        | <i>generichealth</i>                 |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamotrigine</i>      | SZ |
|       |                                                         |             |                | B0.72   | 109.30                                   | 31.30                                                  | <i>Sandoz</i>                        |    |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Seaze 200</i>        | AW |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Lamictal</i>         | GK |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |

### LEVETIRACETAM

#### Authority Required

*Treatment of partial epileptic seizures, which are not controlled satisfactorily by other anti-epileptic drugs in a patient unable to take a solid dose form of levetiracetam.*

|       |                                     |     |   |    |        |       |               |    |
|-------|-------------------------------------|-----|---|----|--------|-------|---------------|----|
| 9169N | Oral solution 100 mg per mL, 300 mL | ± 1 | 5 | .. | 110.99 | 31.30 | <i>Keppra</i> | UC |
|-------|-------------------------------------|-----|---|----|--------|-------|---------------|----|

### SULTHIAME

|       |               |     |   |    |       |       |                |    |
|-------|---------------|-----|---|----|-------|-------|----------------|----|
| 2099L | Tablet 50 mg  | 200 | 2 | .. | 40.08 | 31.30 | <i>Ospolot</i> | PL |
| 2100M | Tablet 200 mg | 200 | 2 | .. | 86.42 | 31.30 | <i>Ospolot</i> | PL |

### TOPIRAMATE

#### Authority Required (STREAMLINED)

2797

*Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs.*

#### Authority Required (STREAMLINED)

2799

continued ➡

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
| <b>Prophylaxis of migraine in a patient who has experienced an average of 3 or more migraines per month over a period of at least 6 months, and who:</b><br><b>(a) has a contraindication to beta-blockers, as described in the relevant TGA-approved Product Information; OR</b><br><b>(b) has experienced intolerance of a severity necessitating permanent withdrawal during treatment with a beta-blocker;</b><br><b>AND</b><br><b>(c) has a contraindication to pizotifen because the weight gain associated with this drug poses an unacceptable risk; OR</b><br><b>(d) has experienced intolerance of a severity necessitating permanent withdrawal during treatment with pizotifen.</b><br><b>Details of the contraindication and/or intolerance(s) must be documented in the patient's medical records when treatment is initiated.</b> |                                                         |             |                |         |                                          |                                                        |                                      |  |

|       |              |    |   |    |       |       |         |    |
|-------|--------------|----|---|----|-------|-------|---------|----|
| 8163P | Tablet 25 mg | 60 | 5 | .. | 42.00 | 31.30 | Topamax | JC |
|-------|--------------|----|---|----|-------|-------|---------|----|

|       |              |    |   |    |       |       |         |    |
|-------|--------------|----|---|----|-------|-------|---------|----|
| 8164Q | Tablet 50 mg | 60 | 5 | .. | 62.89 | 31.30 | Topamax | JC |
|-------|--------------|----|---|----|-------|-------|---------|----|

### **Authority Required (STREAMLINED)**

2797

*Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs.*

|       |               |    |   |    |       |       |         |    |
|-------|---------------|----|---|----|-------|-------|---------|----|
| 8165R | Tablet 100 mg | 60 | 5 | .. | 98.60 | 31.30 | Topamax | JC |
|-------|---------------|----|---|----|-------|-------|---------|----|

|       |               |    |   |    |        |       |         |    |
|-------|---------------|----|---|----|--------|-------|---------|----|
| 8166T | Tablet 200 mg | 60 | 5 | .. | 161.56 | 31.30 | Topamax | JC |
|-------|---------------|----|---|----|--------|-------|---------|----|

### **Authority Required (STREAMLINED)**

2798

*Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs in patients unable to take a solid dose form of topiramate.*

|       |               |    |   |    |       |       |                  |    |
|-------|---------------|----|---|----|-------|-------|------------------|----|
| 8371N | Capsule 15 mg | 60 | 5 | .. | 33.52 | 31.30 | Topamax Sprinkle | JC |
|-------|---------------|----|---|----|-------|-------|------------------|----|

|       |               |    |   |    |       |       |                  |    |
|-------|---------------|----|---|----|-------|-------|------------------|----|
| 8372P | Capsule 25 mg | 60 | 5 | .. | 42.91 | 31.30 | Topamax Sprinkle | JC |
|-------|---------------|----|---|----|-------|-------|------------------|----|

|       |               |    |   |    |       |       |                  |    |
|-------|---------------|----|---|----|-------|-------|------------------|----|
| 8520K | Capsule 50 mg | 60 | 5 | .. | 63.89 | 31.30 | Topamax Sprinkle | JC |
|-------|---------------|----|---|----|-------|-------|------------------|----|

## ANTI-PARKINSON DRUGS

### **Anticholinergic agents**

#### **• Tertiary amines**

BENZHEXOL HYDROCHLORIDE

|       |             |     |   |    |       |       |        |    |
|-------|-------------|-----|---|----|-------|-------|--------|----|
| 1109J | Tablet 2 mg | 200 | 2 | .. | 14.89 | 15.92 | Artane | SI |
|-------|-------------|-----|---|----|-------|-------|--------|----|

|       |             |     |   |    |       |       |        |    |
|-------|-------------|-----|---|----|-------|-------|--------|----|
| 1110K | Tablet 5 mg | 200 | 1 | .. | 21.58 | 22.61 | Artane | SI |
|-------|-------------|-----|---|----|-------|-------|--------|----|

BIPERIDEN HYDROCHLORIDE

|       |             |     |   |    |         |       |          |    |
|-------|-------------|-----|---|----|---------|-------|----------|----|
| 2544X | Tablet 2 mg | 200 | 2 | .. | * 20.45 | 21.48 | Akineton | LM |
|-------|-------------|-----|---|----|---------|-------|----------|----|

## NERVOUS SYSTEM—CONT.

| Code                                              | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |          |
|---------------------------------------------------|---------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----------|
| <b>• Ethers of tropine or tropine derivatives</b> |                                                         |             |                |             |                                          |                                                        |                                      |          |
| BENZTROPINE MESYLATE                              |                                                         |             |                |             |                                          |                                                        |                                      |          |
| 2362H                                             | Tablet 2 mg                                             | 60          | 2              | ..          | 12.33                                    | 13.36                                                  | Benztrop                             | PL       |
| 3038X                                             | Injection 2 mg in 2 mL                                  | 5           | ..             | ..          | 22.41                                    | 23.44                                                  | Cogentin                             | FK       |
| <b>Dopaminergic agents</b>                        |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <b>• Dopa and dopa derivatives</b>                |                                                         |             |                |             |                                          |                                                        |                                      |          |
| LEVODOPA with BENSERAZIDE                         |                                                         |             |                |             |                                          |                                                        |                                      |          |
| 8218M                                             | Dispersible tablet 50 mg-12.5 mg                        | 100         | 5              | ..          | 22.57                                    | 23.60                                                  | Madopar Rapid<br>62.5                | RO       |
| 8219N                                             | Dispersible tablet 100 mg-25 mg                         | 100         | 5              | ..          | 38.49                                    | 31.30                                                  | Madopar Rapid 125                    | RO       |
| 2229H                                             | Tablet 100 mg-25 mg                                     | 100         | 5              | ..          | 38.49                                    | 31.30                                                  | Madopar 125                          | RO       |
| 2228G                                             | Tablet 200 mg-50 mg                                     | 100         | 5              | ..          | 49.58                                    | 31.30                                                  | Madopar                              | RO       |
| 2227F                                             | Capsule 50 mg-12.5 mg                                   | 100         | 5              | ..          | 22.57                                    | 23.60                                                  | Madopar 62.5                         | RO       |
| 2225D                                             | Capsule 100 mg-25 mg                                    | 100         | 5              | ..          | 38.49                                    | 31.30                                                  | Madopar 125                          | RO       |
| 2231K                                             | Capsule 100 mg-25 mg (sustained<br>release)             | 100         | 5              | ..          | 41.57                                    | 31.30                                                  | Madopar HBS                          | RO       |
| 2226E                                             | Capsule 200 mg-50 mg                                    | 100         | 5              | ..          | 49.58                                    | 31.30                                                  | Madopar                              | RO       |
| LEVODOPA with CARBIDOPA                           |                                                         |             |                |             |                                          |                                                        |                                      |          |
| 1242J                                             | Tablet 100 mg-25 mg                                     | 100         | 5              | ..<br>B4.73 | 39.86<br>44.59                           | 31.30 <sup>a</sup><br>31.30 <sup>a</sup>               | Kinson<br>Sinemet 100/25             | AF<br>MK |
| 1245M                                             | Tablet 250 mg-25 mg                                     | 100         | 5              | ..<br>B2.76 | 46.80<br>49.56                           | 31.30 <sup>a</sup><br>31.30 <sup>a</sup>               | Levohexal<br>Sinemet                 | HX<br>MK |

### LEVODOPA with CARBIDOPA

#### Authority Required (STREAMLINED)

1257

*Parkinson's disease where fluctuations in motor function are not adequately controlled by frequent dosing with conventional formulations of levodopa with decarboxylase inhibitor.*

|       |                                        |     |   |    |       |       |            |    |
|-------|----------------------------------------|-----|---|----|-------|-------|------------|----|
| 1255C | Tablet 200 mg-50 mg (modified release) | 100 | 5 | .. | 67.44 | 31.30 | Sinemet CR | MK |
|-------|----------------------------------------|-----|---|----|-------|-------|------------|----|

| Code                                                                                                                                                                                   | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----------|
| <b>LEVODOPA with CARBIDOPA and ENTACAPONE</b>                                                                                                                                          |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                                                                                                         |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <b>2059</b>                                                                                                                                                                            |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <i>Parkinson's disease in patients being treated with levodopa—decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect;</i> |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <b>2060</b>                                                                                                                                                                            |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <i>Parkinson's disease in patients stabilised on concomitant treatment with levodopa—decarboxylase inhibitor combinations and entacapone.</i>                                          |                                                         |             |                |             |                                          |                                                        |                                      |          |
| 8797B                                                                                                                                                                                  | Tablet 50 mg-12.5 mg-200 mg                             | 200         | 4              | ..          | * 311.45                                 | 31.30                                                  | Stalevo 50/12.5/<br>200mg            | NV       |
| 8798C                                                                                                                                                                                  | Tablet 100 mg-25 mg-200 mg                              | 200         | 4              | ..          | * 341.49                                 | 31.30                                                  | Stalevo 100/25/<br>200mg             | NV       |
| 8799D                                                                                                                                                                                  | Tablet 150 mg-37.5 mg-200 mg                            | 200         | 4              | ..          | * 371.53                                 | 31.30                                                  | Stalevo 150/37.5/<br>200mg           | NV       |
| <b>• Adamantane derivatives</b>                                                                                                                                                        |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <b>AMANTADINE HYDROCHLORIDE</b>                                                                                                                                                        |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                       |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <i>Parkinson's disease which is not drug induced.</i>                                                                                                                                  |                                                         |             |                |             |                                          |                                                        |                                      |          |
| 3016R                                                                                                                                                                                  | Capsule 100 mg                                          | 100         | 5              | ..          | 43.87                                    | 31.30                                                  | Symmetrel 100                        | NV       |
| <b>• Dopamine agonists</b>                                                                                                                                                             |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <b>BROMOCRIPTINE MESYLATE</b>                                                                                                                                                          |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                       |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <i>Acromegaly;</i>                                                                                                                                                                     |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <i>Parkinson's disease;</i>                                                                                                                                                            |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <i>Pathological hyperprolactinaemia where surgery is not indicated;</i>                                                                                                                |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <i>Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution;</i>                                                                                |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <i>Pathological hyperprolactinaemia where radiotherapy is not indicated;</i>                                                                                                           |                                                         |             |                |             |                                          |                                                        |                                      |          |
| <i>Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution.</i>                                                                           |                                                         |             |                |             |                                          |                                                        |                                      |          |
| 1443Y                                                                                                                                                                                  | Tablet 2.5 mg (base)                                    | 60          | 5              | ..<br>B2.29 | 27.83<br>30.12                           | 28.86 <sup>a</sup><br>28.86 <sup>a</sup>               | Krypton 2.5<br>Parlodel              | AF<br>NV |
| 1446D                                                                                                                                                                                  | Capsule 5 mg (base)                                     | 60          | 5              | ..<br>B1.99 | 47.83<br>49.82                           | 31.30 <sup>a</sup><br>31.30 <sup>a</sup>               | Krypton 5<br>Parlodel                | AF<br>NV |
| 1445C                                                                                                                                                                                  | Capsule 10 mg (base)                                    | 100         | 5              | ..<br>B2.39 | 153.12<br>155.51                         | 31.30 <sup>a</sup><br>31.30 <sup>a</sup>               | Krypton 10<br>Parlodel               | AF<br>NV |
| <b>[For other listings for this drug see Generic/Proprietary Index]</b>                                                                                                                |                                                         |             |                |             |                                          |                                                        |                                      |          |

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                         | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer          |          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-----------------------------------------------|----------|
| <b>CABERGOLINE</b>                                                                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <i>Parkinson's disease.</i>                                                                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                               |          |
| 8393R                                                                                                                                                                                                        | Tablet 1 mg                                             | 30          | 5              | ..      | 69.49                                    | 31.30                                                  | Cabaser                                       | PU       |
| 8394T                                                                                                                                                                                                        | Tablet 2 mg                                             | 30          | 5              | ..      | 91.10                                    | 31.30                                                  | Cabaser                                       | PU       |
| 8395W                                                                                                                                                                                                        | Tablet 4 mg                                             | 30          | 5              | ..      | 112.59                                   | 31.30                                                  | Cabaser                                       | PU       |
| <b>PERGOLIDE MESYLATE</b>                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <i>Parkinson's disease as adjunctive therapy in patients being treated with levodopa—decarboxylase inhibitor combinations.</i>                                                                               |                                                         |             |                |         |                                          |                                                        |                                               |          |
| 2808T                                                                                                                                                                                                        | Tablet 50 micrograms (base)                             | 100         | ..             | ..      | 52.50                                    | 31.30                                                  | Permax                                        | AS       |
| 2809W                                                                                                                                                                                                        | Tablet 250 micrograms (base)                            | 100         | 5              | ..      | 65.75                                    | 31.30                                                  | Permax                                        | AS       |
| 2810X                                                                                                                                                                                                        | Tablet 1 mg (base)                                      | 100         | 5              | ..      | 241.26                                   | 31.30                                                  | Permax                                        | AS       |
| <b>PRAMIPEXOLE HYDROCHLORIDE</b>                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <b><u>CAUTION:</u></b>                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <i>Episodes of sudden onset of sleep without warning, during activity, have been reported with this drug.</i>                                                                                                |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <i>Parkinson's disease as adjunctive therapy in patients being treated with levodopa—decarboxylase inhibitor combinations.</i>                                                                               |                                                         |             |                |         |                                          |                                                        |                                               |          |
| 9151P                                                                                                                                                                                                        | Tablet 125 micrograms                                   | 30          | ..             | ..      | 11.40                                    | 12.43                                                  | Sifrol                                        | BY       |
| 9152Q                                                                                                                                                                                                        | Tablet 250 micrograms                                   | 100         | 5              | ..      | 41.31                                    | 31.30                                                  | Sifrol                                        | BY       |
| 9153R                                                                                                                                                                                                        | Tablet 1 mg                                             | 100         | 5              | ..      | 151.71                                   | 31.30                                                  | Sifrol                                        | BY       |
| • <b>Monoamine oxidase type B inhibitors</b>                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <b>SELEGILINE HYDROCHLORIDE</b>                                                                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <i>Late stage Parkinson's disease as adjunctive therapy in patients being treated with levodopa—decarboxylase inhibitor combinations.</i>                                                                    |                                                         |             |                |         |                                          |                                                        |                                               |          |
| 1973W                                                                                                                                                                                                        | Tablet 5 mg                                             | 100         | 5              | ..      | 55.16                                    | 31.30                                                  | <sup>a</sup> Eldepryl<br><sup>a</sup> Selgene | GM<br>AF |
| • <b>Other dopaminergic agents</b>                                                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <b>ENTACAPONE</b>                                                                                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                               |          |
| 2067                                                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                               |          |
| <i>Parkinson's disease as adjunctive therapy in patients being treated with levodopa—decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect.</i> |                                                         |             |                |         |                                          |                                                        |                                               |          |
| 8367J                                                                                                                                                                                                        | Tablet 200 mg                                           | 200         | 4              | ..      | * 281.39                                 | 31.30                                                  | Comtan                                        | NV       |



## NERVOUS SYSTEM—CONT.

| Code                                              | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>PSYCHOLEPTICS</b>                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Antipsychotics</b>                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Phenothiazine with aliphatic side-chain</b>  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| CHLORPROMAZINE HYDROCHLORIDE                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1196Y                                             | Tablet 10 mg                                            | 100         | 5              | ..      | 9.15                                     | 10.18                                                  | Largactil                            | SW |
| 1197B                                             | Tablet 25 mg                                            | 100         | 5              | ..      | 10.66                                    | 11.69                                                  | Largactil                            | SW |
| 1199D                                             | Tablet 100 mg                                           | 100         | 5              | ..      | 14.52                                    | 15.55                                                  | Largactil                            | SW |
| 1201F                                             | Mixture 25 mg per 5 mL, 100 mL                          | ‡ 1         | 5              | ..      | 10.44                                    | 11.47                                                  | Largactil                            | SW |
| 1195X                                             | Injection 50 mg in 2 mL                                 | 10          | ..             | ..      | 15.34                                    | 16.37                                                  | Largactil                            | SW |
| • <b>Phenothiazine with piperazine structure</b>  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| FLUPHENAZINE DECANOATE                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1046C                                             | Injection 12.5 mg in 0.5 mL                             | 5           | ..             | ..      | 18.79                                    | 19.82                                                  | Modectate                            | BQ |
| 3098C                                             | Injection 25 mg in 1 mL                                 | 5           | ..             | ..      | 25.95                                    | 26.98                                                  | Modectate                            | BQ |
| 1001Q                                             | Injection 50 mg in 2 mL                                 | 5           | ..             | ..      | 37.22                                    | 31.30                                                  | Modectate                            | BQ |
| TRIFLUOPERAZINE HYDROCHLORIDE                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2185B                                             | Tablet 1 mg (base)                                      | 100         | 5              | ..      | 12.88                                    | 13.91                                                  | Stelazine                            | GH |
| 2386N                                             | Tablet 2 mg (base)                                      | 100         | 5              | ..      | 13.05                                    | 14.08                                                  | Stelazine                            | GH |
| 2186C                                             | Tablet 5 mg (base)                                      | 100         | 5              | ..      | 13.43                                    | 14.46                                                  | Stelazine                            | GH |
| • <b>Phenothiazines with piperidine structure</b> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| PERICYAZINE                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 3052P                                             | Tablet 2.5 mg                                           | 100         | 5              | ..      | 9.77                                     | 10.80                                                  | Neulactil                            | SW |
| 3053Q                                             | Tablet 10 mg                                            | 100         | 5              | ..      | 14.03                                    | 15.06                                                  | Neulactil                            | SW |
| • <b>Butyrophenone derivatives</b>                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| HALOPERIDOL                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2761H                                             | Tablet 500 micrograms                                   | 100         | 5              | ..      | 9.62                                     | 10.65                                                  | Serenace                             | SI |
| 2767P                                             | Tablet 1.5 mg                                           | 100         | 5              | ..      | 10.10                                    | 11.13                                                  | Serenace                             | SI |
| 2770T                                             | Tablet 5 mg                                             | 50          | 5              | ..      | 10.11                                    | 11.14                                                  | Serenace                             | SI |
| 2763K                                             | Oral liquid 2 mg per mL, 100 mL                         | ‡ 1         | 5              | ..      | 17.04                                    | 18.07                                                  | Serenace                             | SI |
| 2768Q                                             | Injection 5 mg in 1 mL                                  | 10          | ..             | ..      | 21.85                                    | 22.88                                                  | Serenace                             | SI |

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                          | Name, Restriction,<br>Manner of Administration and Form    | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| HALOPERIDOL DECANOATE                                                                                                                                                                                                         |                                                            |             |                |         |                                          |                                                        |                                      |    |
| 2765M                                                                                                                                                                                                                         | I.M. injection equivalent to 50 mg<br>haloperidol in 1 mL  | 5           | ..             | ..      | 26.24                                    | 27.27                                                  | Haldol decanoate                     | JC |
| 2766N                                                                                                                                                                                                                         | I.M. injection equivalent to 150 mg<br>haloperidol in 3 mL | 5           | ..             | ..      | 45.80                                    | 31.30                                                  | Haldol decanoate                     | JC |
| <b>• Indole derivatives</b><br><b>ZIPRASIDONE HYDROCHLORIDE</b><br><b>Authority Required (STREAMLINED)</b><br><b>1589</b><br><b>Schizophrenia.</b>                                                                            |                                                            |             |                |         |                                          |                                                        |                                      |    |
| 9070J                                                                                                                                                                                                                         | Capsule 20 mg (base)                                       | 60          | 5              | ..      | 94.97                                    | 31.30                                                  | Zeldox                               | PF |
| 9071K                                                                                                                                                                                                                         | Capsule 40 mg (base)                                       | 60          | 5              | ..      | 183.96                                   | 31.30                                                  | Zeldox                               | PF |
| 9072L                                                                                                                                                                                                                         | Capsule 60 mg (base)                                       | 60          | 5              | ..      | 266.67                                   | 31.30                                                  | Zeldox                               | PF |
| 9073M                                                                                                                                                                                                                         | Capsule 80 mg (base)                                       | 60          | 5              | ..      | 347.56                                   | 31.30                                                  | Zeldox                               | PF |
| <b>• Thioxanthene derivatives</b><br><b>FLUPENTHIXOL DECANOATE</b>                                                                                                                                                            |                                                            |             |                |         |                                          |                                                        |                                      |    |
| 2255Q                                                                                                                                                                                                                         | Oily I.M. injection 20 mg in 1 mL                          | 5           | ..             | ..      | 18.79                                    | 19.82                                                  | Fluanxol Depot                       | LU |
| 2256R                                                                                                                                                                                                                         | Oily I.M. injection 40 mg in 2 mL                          | 5           | ..             | ..      | 25.95                                    | 26.98                                                  | Fluanxol Depot                       | LU |
| 2257T                                                                                                                                                                                                                         | Oily I.M. injection 100 mg in 1 mL                         | 5           | ..             | ..      | 44.44                                    | 31.30                                                  | Fluanxol<br>Concentrated<br>Depot    | LU |
| ZUCLOPENTHIXOL DECANOATE                                                                                                                                                                                                      |                                                            |             |                |         |                                          |                                                        |                                      |    |
| 8097E                                                                                                                                                                                                                         | Oily I.M. injection 200 mg in 1 mL                         | 5           | ..             | ..      | 24.91                                    | 25.94                                                  | Clopixol Depot                       | LU |
| <b>• Diazepines, oxazepines and thiazepines</b><br><b>OLANZAPINE</b><br><b>Authority Required (STREAMLINED)</b><br><b>1589</b><br><b>Schizophrenia;</b><br><b>2044</b><br><b>Maintenance treatment of bipolar I disorder.</b> |                                                            |             |                |         |                                          |                                                        |                                      |    |
| 8170B                                                                                                                                                                                                                         | Tablet 2.5 mg                                              | 28          | 5              | ..      | 54.35                                    | 31.30                                                  | Zyprexa                              | LY |
| 8185T                                                                                                                                                                                                                         | Tablet 5 mg                                                | 28          | 5              | ..      | 101.51                                   | 31.30                                                  | Zyprexa                              | LY |
| 8186W                                                                                                                                                                                                                         | Tablet 7.5 mg                                              | 28          | 5              | ..      | 150.73                                   | 31.30                                                  | Zyprexa                              | LY |
| 8187X                                                                                                                                                                                                                         | Tablet 10 mg                                               | 28          | 5              | ..      | 198.97                                   | 31.30                                                  | Zyprexa                              | LY |

continued ➞

## NERVOUS SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8433W | Wafer 5 mg                                              | 28          | 5              | ..      | 101.51                                   | 31.30                                                  | Zyprexa Zydys                        | LY |
| 8434X | Wafer 10 mg                                             | 28          | 5              | ..      | 198.97                                   | 31.30                                                  | Zyprexa Zydys                        | LY |

### QUETIAPINE FUMARATE

#### Authority Required (STREAMLINED)

1589

Schizophrenia;

2765

Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder.

|       |                      |    |   |    |        |       |          |    |
|-------|----------------------|----|---|----|--------|-------|----------|----|
| 8456C | Tablet 25 mg (base)  | 60 | 5 | .. | 53.23  | 31.30 | Seroquel | AP |
| 8457D | Tablet 100 mg (base) | 90 | 5 | .. | 142.28 | 31.30 | Seroquel | AP |
| 8458E | Tablet 200 mg (base) | 60 | 5 | .. | 191.92 | 31.30 | Seroquel | AP |
| 8580N | Tablet 300 mg (base) | 60 | 5 | .. | 271.65 | 31.30 | Seroquel | AP |

#### • **Benzamides**

#### AMISULPRIDE

#### Authority Required (STREAMLINED)

1589

Schizophrenia.

|       |                                    |    |   |    |          |       |                                          |    |
|-------|------------------------------------|----|---|----|----------|-------|------------------------------------------|----|
| 8594H | Tablet 100 mg                      | 30 | 5 | .. | 33.83    | 31.30 | <sup>a</sup> Amisulpride 100<br>Winthrop | WA |
|       |                                    |    |   |    |          |       | <sup>a</sup> Amisulpride<br>Sandoz       | SZ |
|       |                                    |    |   |    |          |       | <sup>a</sup> Solian 100                  | SW |
| 8595J | Tablet 200 mg                      | 60 | 5 | .. | 120.75   | 31.30 | <sup>a</sup> Amisulpride 200<br>Winthrop | WA |
|       |                                    |    |   |    |          |       | <sup>a</sup> Amisulpride<br>Sandoz       | SZ |
|       |                                    |    |   |    |          |       | <sup>a</sup> Solian 200                  | SW |
| 8596K | Tablet 400 mg                      | 60 | 5 | .. | 223.38   | 31.30 | <sup>a</sup> Amisulpride 400<br>Winthrop | WA |
|       |                                    |    |   |    |          |       | <sup>a</sup> Amisulpride<br>Sandoz       | SZ |
|       |                                    |    |   |    |          |       | <sup>a</sup> Solian 400                  | SW |
| 8736T | Oral solution 100 mg per mL, 60 mL | 2  | 5 | .. | * 139.79 | 31.30 | Solian Solution                          | SW |

#### • **Lithium**

#### LITHIUM CARBONATE

For listings see Generic/Proprietary Index

continued ➞

## NERVOUS SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8790P | Tablet 1 mg (orally disintegrating)                     | 56          | 2              | ..      | * 68.19                                  | 31.30                                                  | Risperdal Quicklet                   | JC |
| 8791Q | Oral solution 1 mg per mL, 30 mL                        | ‡ 1         | 2              | ..      | 40.93                                    | 31.30                                                  | Risperdal                            | JC |

### Authority Required (STREAMLINED)

2598

*Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a child or adolescent aged less than 18 years with autism. Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.*

*The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders.*

|       |                                     |    |   |    |          |       |                    |    |
|-------|-------------------------------------|----|---|----|----------|-------|--------------------|----|
| 9079W | Tablet 2 mg                         | 60 | 2 | .. | 139.89   | 31.30 | Risperdal          | JC |
| 9080X | Tablet 2 mg (orally disintegrating) | 56 | 2 | .. | * 130.97 | 31.30 | Risperdal Quicklet | JC |

### Authority Required (STREAMLINED)

1589

*Schizophrenia.*

### Authority Required (STREAMLINED)

2272

*Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder.*

|       |                                     |     |   |    |          |       |                    |    |
|-------|-------------------------------------|-----|---|----|----------|-------|--------------------|----|
| 3169T | Tablet 1 mg                         | 60  | 5 | .. | 72.63    | 31.30 | Risperdal          | JC |
| 8792R | Tablet 1 mg (orally disintegrating) | 56  | 5 | .. | * 68.19  | 31.30 | Risperdal Quicklet | JC |
| 3170W | Tablet 2 mg                         | 60  | 5 | .. | 139.89   | 31.30 | Risperdal          | JC |
| 8794W | Tablet 2 mg (orally disintegrating) | 56  | 5 | .. | * 130.97 | 31.30 | Risperdal Quicklet | JC |
| 3171X | Tablet 3 mg                         | 60  | 5 | .. | 204.95   | 31.30 | Risperdal          | JC |
| 9075P | Tablet 3 mg (orally disintegrating) | 56  | 5 | .. | * 191.79 | 31.30 | Risperdal Quicklet | JC |
| 3172Y | Tablet 4 mg                         | 60  | 5 | .. | 265.14   | 31.30 | Risperdal          | JC |
| 9076Q | Tablet 4 mg (orally disintegrating) | 56  | 5 | .. | * 249.07 | 31.30 | Risperdal Quicklet | JC |
| 8100H | Oral solution 1 mg per mL, 100 mL   | ‡ 1 | 5 | .. | 117.60   | 31.30 | Risperdal          | JC |

### Authority Required (STREAMLINED)

1589

*Schizophrenia.*

|       |               |    |   |    |         |       |           |    |
|-------|---------------|----|---|----|---------|-------|-----------|----|
| 8869T | Tablet 0.5 mg | 60 | 5 | .. | * 40.79 | 31.30 | Risperdal | JC |
|-------|---------------|----|---|----|---------|-------|-----------|----|

continued ➞

## NERVOUS SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form                                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|----------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8870W | Tablet 0.5 mg (orally disintegrating)                                                              | 56          | 5              | ..      | * 38.51                                  | 31.30                                                  | Risperdal Quicklet                   | JC |
| 8780D | Powder for I.M. injection 25 mg<br>(modified release) with 2 mL diluent<br>in pre-filled syringe   | 2           | 5              | ..      | * 320.71                                 | 31.30                                                  | Risperdal Consta                     | JC |
| 8781E | Powder for I.M. injection 37.5 mg<br>(modified release) with 2 mL diluent<br>in pre-filled syringe | 2           | 5              | ..      | * 409.97                                 | 31.30                                                  | Risperdal Consta                     | JC |
| 8782F | Powder for I.M. injection 50 mg<br>(modified release) with 2 mL diluent<br>in pre-filled syringe   | 2           | 5              | ..      | * 499.33                                 | 31.30                                                  | Risperdal Consta                     | JC |

### Anxiolytics

#### • Benzodiazepine derivatives

##### ALPRAZOLAM

##### Authority Required

*Panic disorder where other treatments have failed or are inappropriate.*

|       |                       |    |    |       |       |       |                                      |    |
|-------|-----------------------|----|----|-------|-------|-------|--------------------------------------|----|
| 2130D | Tablet 250 micrograms | 50 | .. | ..    | 9.12  | 10.15 | <sup>a</sup> Alprax 0.25             | AW |
|       |                       |    |    |       |       |       | <sup>a</sup> Kalma 0.25              | AF |
|       |                       |    |    | B0.81 | 9.93  | 10.15 | <sup>a</sup> Zamhexal 0.25mg         | SZ |
|       |                       |    |    |       |       |       | <sup>a</sup> Xanax                   | PH |
| 2131E | Tablet 500 micrograms | 50 | .. | ..    | 11.05 | 12.08 | <sup>a</sup> Alprax 0.5              | AW |
|       |                       |    |    |       |       |       | <sup>a</sup> Kalma 0.5               | AF |
|       |                       |    |    | B0.87 | 11.92 | 12.08 | <sup>a</sup> Zamhexal 0.5mg          | SZ |
|       |                       |    |    |       |       |       | <sup>a</sup> Xanax                   | PH |
| 2132F | Tablet 1 mg           | 50 | 2  | ..    | 14.80 | 15.83 | <sup>a</sup> Alprax 1                | AW |
|       |                       |    |    |       |       |       | <sup>a</sup> Alprazolam-DP           | GM |
|       |                       |    |    |       |       |       | <sup>a</sup> Chem mart               | CH |
|       |                       |    |    |       |       |       | Alprazolam                           |    |
|       |                       |    |    |       |       |       | <sup>a</sup> GenRx Alprazolam        | GX |
|       |                       |    |    |       |       |       | <sup>a</sup> Kalma 1                 | AF |
|       |                       |    |    |       |       |       | <sup>a</sup> Terry White<br>Chemists | TW |
|       |                       |    |    |       |       |       | Alprazolam                           |    |
|       |                       |    |    |       |       |       | <sup>a</sup> Zamhexal 1.0mg          | SZ |
|       |                       |    |    | B1.03 | 15.83 | 15.83 | <sup>a</sup> Xanax                   | PH |

continued ➞

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                 | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium           | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|-------------------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8118G                                                                                                                                                                                                                                                                                                                | Tablet 2 mg                                             | 50          | 2              | ..                | 19.63                                    | 20.66                                                  | <sup>a</sup> Alprax 2                | AW |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | <sup>a</sup> Alprazolam-DP           | GM |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | <sup>a</sup> Chem mart               | CH |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | Alprazolam                           |    |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | <sup>a</sup> GenRx Alprazolam        | GX |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | <sup>a</sup> Kalma 2                 | AF |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | Chemists                             |    |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | Alprazolam                           |    |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                | <sup>b</sup> 1.25 | 20.88                                    | 20.66                                                  | <sup>a</sup> Zamhexal 2mg            | SZ |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | <sup>a</sup> Xanax Tri-Score         | PH |
| DIAZEPAM                                                                                                                                                                                                                                                                                                             |                                                         |             |                |                   |                                          |                                                        |                                      |    |
| 3161J                                                                                                                                                                                                                                                                                                                | Tablet 2 mg                                             | 50          | ..             | ..                | 7.36                                     | 8.39                                                   | <sup>a</sup> Antenex 2               | AF |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                | <sup>b</sup> 0.59 | 7.95                                     | 8.39                                                   | <sup>a</sup> Valpam 2                | AW |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                | <sup>b</sup> 0.86 | 8.22                                     | 8.39                                                   | Ducene                               | SU |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | <sup>a</sup> Valium                  | RO |
| 3162K                                                                                                                                                                                                                                                                                                                | Tablet 5 mg                                             | 50          | ..             | ..                | 7.50                                     | 8.53                                                   | <sup>a</sup> Antenex 5               | AF |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | <sup>a</sup> Diazepam-DP             | GM |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | <sup>a</sup> Ranzepam                | RA |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | <sup>a</sup> Valpam 5                | AW |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                | <sup>b</sup> 0.63 | 8.13                                     | 8.53                                                   | Ducene                               | SU |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                | <sup>b</sup> 0.88 | 8.38                                     | 8.53                                                   | <sup>a</sup> Valium                  | RO |
| 2558P                                                                                                                                                                                                                                                                                                                | Injection 10 mg in 2 mL                                 | 5           | ..             | ..                | 11.86                                    | 12.89                                                  | HH                                   |    |
| <b>NOTE:</b>                                                                                                                                                                                                                                                                                                         |                                                         |             |                |                   |                                          |                                                        |                                      |    |
| Authorities for increased maximum quantities and/or repeats for the oral forms of diazepam will be granted only for                                                                                                                                                                                                  |                                                         |             |                |                   |                                          |                                                        |                                      |    |
| (i) the treatment of disabling spasticity; or                                                                                                                                                                                                                                                                        |                                                         |             |                |                   |                                          |                                                        |                                      |    |
| (ii) malignant neoplasia (late stage); or                                                                                                                                                                                                                                                                            |                                                         |             |                |                   |                                          |                                                        |                                      |    |
| (iii) use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal; or |                                                         |             |                |                   |                                          |                                                        |                                      |    |
| (iv) use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal.                                    |                                                         |             |                |                   |                                          |                                                        |                                      |    |
| Up to six months' treatment (i.e. one month's treatment with five repeats) may be requested.                                                                                                                                                                                                                         |                                                         |             |                |                   |                                          |                                                        |                                      |    |
| OXAZEPAM                                                                                                                                                                                                                                                                                                             |                                                         |             |                |                   |                                          |                                                        |                                      |    |
| 3132W                                                                                                                                                                                                                                                                                                                | Tablet 15 mg                                            | 25          | ..             | ..                | 7.27                                     | 8.30                                                   | <sup>a</sup> Alepam 15               | AF |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                | <sup>b</sup> 1.78 | 9.05                                     | 8.30                                                   | <sup>a</sup> Serepax                 | SI |
| 3133X                                                                                                                                                                                                                                                                                                                | Tablet 30 mg                                            | 25          | ..             | ..                | 7.46                                     | 8.49                                                   | <sup>a</sup> Alepam 30               | AF |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |                   |                                          |                                                        | <sup>a</sup> Murelax                 | FM |
|                                                                                                                                                                                                                                                                                                                      |                                                         |             |                | <sup>b</sup> 1.90 | 9.36                                     | 8.49                                                   | <sup>a</sup> Serepax                 | SI |

continued ➡

## NERVOUS SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     |  | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |  |                                      |

**NOTE:**

Authorities for increased maximum quantities and/or repeats will not be granted except as detailed under the 'Authority required' listing of oxazepam below.

**OXAZEPAM****Authority Required**

*Malignant neoplasia (late stage);*

*For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal;*

*For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal.*

|       |              |    |   |    |        |         |              |          |    |
|-------|--------------|----|---|----|--------|---------|--------------|----------|----|
| 3134Y | Tablet 15 mg | 50 | 5 | .. | * 8.55 | 9.58    | <sup>a</sup> | Alepm 15 | AF |
|       |              |    |   |    | 83.56  | * 12.11 | <sup>a</sup> | Serepax  | SI |
| 3135B | Tablet 30 mg | 50 | 5 | .. | * 8.93 | 9.96    | <sup>a</sup> | Alepm 30 | AF |
|       |              |    |   |    |        |         | <sup>a</sup> | Murelax  | FM |
|       |              |    |   |    |        |         | <sup>a</sup> | Serepax  | SI |

- Other anxiolytics**

**CLOMIPRAMINE HYDROCHLORIDE****Restricted Benefit**

*Cataplexy associated with narcolepsy;*

*Obsessive-compulsive disorder;*

*Phobic disorders in adults.*

|       |              |    |   |       |       |       |              |              |    |
|-------|--------------|----|---|-------|-------|-------|--------------|--------------|----|
| 1561E | Tablet 25 mg | 50 | 2 | ..    | 16.40 | 17.43 | <sup>a</sup> | Chem mart    | CH |
|       |              |    |   |       |       |       |              | Clomipramine |    |
|       |              |    |   |       |       |       | <sup>a</sup> | GenRx        | GX |
|       |              |    |   |       |       |       |              | Clomipramine |    |
|       |              |    |   |       |       |       | <sup>a</sup> | Placil       | AF |
|       |              |    |   |       |       |       | <sup>a</sup> | Terry White  | TW |
|       |              |    |   |       |       |       |              | Chemists     |    |
|       |              |    |   |       |       |       | <sup>a</sup> | Anafranil 25 | NV |
|       |              |    |   | 82.56 | 18.96 | 17.43 |              |              |    |

**Hypnotics and sedatives**

- Benzodiazepine derivatives**

**NITRAZEPAM**

|       |             |    |    |    |       |      |              |         |    |
|-------|-------------|----|----|----|-------|------|--------------|---------|----|
| 2723H | Tablet 5 mg | 25 | .. | .. | 7.46  | 8.49 | <sup>a</sup> | Alodorm | AF |
|       |             |    |    |    | 81.53 | 8.99 | <sup>a</sup> | Mogadon | VT |

continued ➡



## NERVOUS SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

**NOTE:**

Authorities for increased maximum quantities and/or repeats will not be granted except as detailed under the 'Authority required' listing of nitrazepam below.

**NITRAZEPAM****Authority Required**

*Myoclonic epilepsy;*

*Malignant neoplasia (late stage);*

*For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal;*

*For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal.*

|       |             |    |   |    |        |      |                      |    |
|-------|-------------|----|---|----|--------|------|----------------------|----|
| 2732T | Tablet 5 mg | 50 | 5 | .. | * 8.93 | 9.96 | <sup>a</sup> Alodorm | AF |
|       |             |    |   |    | B3.06  | 9.96 | <sup>a</sup> Mogadon | VT |

**TEMAZEPAM**

|       |              |    |    |    |       |      |                       |    |
|-------|--------------|----|----|----|-------|------|-----------------------|----|
| 2089Y | Tablet 10 mg | 25 | .. | .. | 7.46  | 8.49 | <sup>a</sup> Temaze   | AF |
|       |              |    |    |    | B1.38 | 8.49 | <sup>a</sup> Temtabs  | FM |
|       |              |    |    |    |       |      | <sup>a</sup> Normison | SI |

**NOTE:**

Authorities for increased maximum quantities and/or repeats will not be granted except as detailed under the 'Authority required' listing of temazepam below.

**TEMAZEPAM****Authority Required**

*Malignant neoplasia (late stage);*

*For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal;*

*For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal.*

|       |              |    |   |    |        |      |                       |    |
|-------|--------------|----|---|----|--------|------|-----------------------|----|
| 2088X | Tablet 10 mg | 50 | 5 | .. | * 8.93 | 9.96 | <sup>a</sup> Temaze   | AF |
|       |              |    |   |    | B2.76  | 9.96 | <sup>a</sup> Temtabs  | FM |
|       |              |    |   |    |        |      | <sup>a</sup> Normison | SI |

## NERVOUS SYSTEM—CONT.

| Code                                                 | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                 |    |
|------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------------------|----|
| <b>PSYCHOANALEPTICS</b>                              |                                                         |             |                |         |                                          |                                                        |                                                      |    |
| <b>Antidepressants</b>                               |                                                         |             |                |         |                                          |                                                        |                                                      |    |
| • <b>Non-selective monoamine reuptake inhibitors</b> |                                                         |             |                |         |                                          |                                                        |                                                      |    |
| AMITRIPTYLINE HYDROCHLORIDE                          |                                                         |             |                |         |                                          |                                                        |                                                      |    |
| 2417F                                                | Tablet 10 mg                                            | 50          | 2              | ..      | 8.01                                     | 9.04                                                   | Endep 10                                             | AF |
| 2418G                                                | Tablet 25 mg                                            | 50          | 2              | ..      | 8.13                                     | 9.16                                                   | Endep 25                                             | AF |
| 2429W                                                | Tablet 50 mg                                            | 50          | 2              | ..      | 8.46                                     | 9.49                                                   | Endep 50                                             | AF |
| <b>CLOMIPRAMINE HYDROCHLORIDE</b>                    |                                                         |             |                |         |                                          |                                                        |                                                      |    |
| <b>Restricted Benefit</b>                            |                                                         |             |                |         |                                          |                                                        |                                                      |    |
| <i>Cataplexy associated with narcolepsy;</i>         |                                                         |             |                |         |                                          |                                                        |                                                      |    |
| <i>Obsessive-compulsive disorder;</i>                |                                                         |             |                |         |                                          |                                                        |                                                      |    |
| <i>Phobic disorders in adults.</i>                   |                                                         |             |                |         |                                          |                                                        |                                                      |    |
| 1561E                                                | Tablet 25 mg                                            | 50          | 2              | ..      | 16.40                                    | 17.43                                                  | <sup>a</sup> Chem mart<br>Clomipramine               | CH |
|                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx<br>Clomipramine                   | GX |
|                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Placil                                  | AF |
|                                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Clomipramine | TW |
|                                                      |                                                         |             |                | b2.56   | 18.96                                    | 17.43                                                  | <sup>a</sup> Anafranil 25                            | NV |
| <b>DOTHIEPIN HYDROCHLORIDE</b>                       |                                                         |             |                |         |                                          |                                                        |                                                      |    |
| 1357K                                                | Capsule 25 mg                                           | 50          | 2              | ..      | 8.22                                     | 9.25                                                   | <sup>a</sup> Dothep 25                               | AF |
|                                                      |                                                         |             |                | b1.58   | 9.80                                     | 9.25                                                   | <sup>a</sup> Prothiaden                              | AB |
| 1358L                                                | Tablet 75 mg                                            | 30          | 2              | ..      | 8.21                                     | 9.24                                                   | <sup>a</sup> Dothep 75                               | AF |
|                                                      |                                                         |             |                | b0.80   | 9.01                                     | 9.24                                                   | <sup>a</sup> Prothiaden                              | AB |
| <b>DOXEPIN HYDROCHLORIDE</b>                         |                                                         |             |                |         |                                          |                                                        |                                                      |    |
| 1012G                                                | Tablet 50 mg (base)                                     | 50          | 2              | ..      | 9.28                                     | 10.31                                                  | Deptran 50                                           | AF |
| 1011F                                                | Capsule 10 mg (base)                                    | 50          | 2              | ..      | 8.54                                     | 9.57                                                   | Deptran 10                                           | AF |
|                                                      |                                                         |             |                | b1.87   | 10.41                                    | 9.57                                                   | Sinequan                                             | PF |
| 1013H                                                | Capsule 25 mg (base)                                    | 50          | 2              | ..      | 8.97                                     | 10.00                                                  | Deptran 25                                           | AF |
|                                                      |                                                         |             |                | b1.57   | 10.54                                    | 10.00                                                  | Sinequan                                             | PF |
| <b>IMIPRAMINE HYDROCHLORIDE</b>                      |                                                         |             |                |         |                                          |                                                        |                                                      |    |
| 2420J                                                | Tablet 10 mg                                            | 50          | 2              | ..      | 8.24                                     | 9.27                                                   | <sup>a</sup> Tolerade 10                             | LN |
|                                                      |                                                         |             |                | b2.97   | 11.21                                    | 9.27                                                   | <sup>a</sup> Tofranil 10                             | NV |
| 2421K                                                | Tablet 25 mg                                            | 50          | 2              | ..      | 8.24                                     | 9.27                                                   | <sup>a</sup> Tolerade 25                             | LN |
|                                                      |                                                         |             |                | b2.97   | 11.21                                    | 9.27                                                   | <sup>a</sup> Tofranil 25                             | NV |

[illegible]

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                 |          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|------------------------------------------------------|----------|
| <b>ESCITALOPRAM OXALATE</b>                                                                                                                                                                                                                             |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                                        |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <i>Major depressive disorders.</i>                                                                                                                                                                                                                      |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                                        |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <i>Moderate to severe generalised anxiety disorder (GAD), as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and:</i>             |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <i>(a) for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared; or</i>                                                                                                                 |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <i>(b) who has been assessed by a psychiatrist;</i>                                                                                                                                                                                                     |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <i>Continuing PBS subsidised treatment, for moderate to severe generalised anxiety disorder (GAD), of a patient commenced on escitalopram prior to 1 March 2008.</i>                                                                                    |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                                        |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <i>Moderate to severe social anxiety disorder (social phobia, SAD), as described by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, in a patient who has not responded to non-pharmacological therapy and:</i> |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <i>(a) for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared; or</i>                                                                                                                 |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <i>(b) who has been assessed by a psychiatrist;</i>                                                                                                                                                                                                     |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <i>Continuing PBS subsidised treatment, for moderate to severe social anxiety disorder (social phobia, SAD), of a patient commenced on escitalopram prior to 1 March 2008.</i>                                                                          |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| 8700X                                                                                                                                                                                                                                                   | Tablet 10 mg (base)                                     | 28          | 5              | ..<br>B4.89 | 28.98<br>33.87                           | 30.01<br>30.01                                         | <sup>a</sup> Esipram<br><sup>a</sup> Lexapro         | CF<br>LU |
| 8701Y                                                                                                                                                                                                                                                   | Tablet 20 mg (base)                                     | 28          | 5              | ..<br>B7.16 | 29.12<br>36.28                           | 30.15<br>30.15                                         | <sup>a</sup> Esipram<br><sup>a</sup> Lexapro         | CF<br>LU |
| <b>FLUOXETINE HYDROCHLORIDE</b>                                                                                                                                                                                                                         |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                                        |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <i>Major depressive disorders;</i>                                                                                                                                                                                                                      |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| <i>Obsessive-compulsive disorder.</i>                                                                                                                                                                                                                   |                                                         |             |                |             |                                          |                                                        |                                                      |          |
| 8270G                                                                                                                                                                                                                                                   | Tablet 20 mg (base) (dispersible)                       | 28          | 5              | ..<br>B4.13 | 20.38<br>24.51                           | 21.41<br>21.41                                         | <sup>a</sup> Lovan 20 Tab<br><sup>a</sup> Prozac Tab | AL<br>LY |

continued ➞

## NERVOUS SYSTEM—CONT.

| Code                                  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 1434L                                 | Capsule 20 mg (base)                                    | 28          | 5              | ..      | 20.38                                    | 21.41                                                  | <sup>a</sup> Auscap                  | SI |
|                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Chem mart               | CH |
|                                       |                                                         |             |                |         |                                          |                                                        | Fluoxetine                           |    |
|                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fluohexal               | SZ |
|                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fluoxebell              | BF |
|                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fluoxetine 20           | CR |
|                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fluoxetine-DP           | GM |
|                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Fluoxetine        | GX |
|                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Lovan                   | AL |
|                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists | TW |
|                                       |                                                         |             |                |         |                                          |                                                        | Fluoxetine                           |    |
|                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Zactin                  | AF |
|                                       |                                                         |             |                | B4.13   | 24.51                                    | 21.41                                                  | <sup>a</sup> Prozac 20               | LY |
| <b>FLUVOXAMINE MALEATE</b>            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Major depressive disorders;</i>    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Obsessive-compulsive disorder.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8512B                                 | Tablet 50 mg                                            | 30          | 5              | ..      | 19.94                                    | 20.97                                                  | <sup>a</sup> Faverin 50              | AW |
|                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Movox 50                | AL |
|                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Voxam                   | SZ |
|                                       |                                                         |             |                | B2.96   | 22.90                                    | 20.97                                                  | <sup>a</sup> Luvox                   | SM |
| 8174F                                 | Tablet 100 mg                                           | 30          | 5              | ..      | 27.12                                    | 28.15                                                  | <sup>a</sup> Faverin 100             | AW |
|                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Movox 100               | AF |
|                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Voxam                   | SZ |
|                                       |                                                         |             |                | B2.95   | 30.07                                    | 28.15                                                  | <sup>a</sup> Luvox                   | SM |

# NERVOUS SYSTEM—CONT.

| Code                                  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>PAROXETINE HYDROCHLORIDE</b>       |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b><u>Restricted Benefit</u></b>      |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <i>Major depressive disorders;</i>    |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <i>Obsessive-compulsive disorder;</i> |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <i>Panic disorder.</i>                |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 2242B                                 | Tablet 20 mg (base)                                     | 30          | 5              | ..      | 25.05                                    | 26.08                                                  | <sup>a</sup> Chem mart CH<br>Paroxetine<br><sup>a</sup> Extine 20 AW<br><sup>a</sup> GenRx Paroxetine GX<br><sup>a</sup> Paroxetine 20 CR<br><sup>a</sup> Paroxetine-DP GM<br><sup>a</sup> Paroxetine Sandoz SZ<br><sup>a</sup> Paroxetine WA<br>Winthrop<br><sup>a</sup> Paxtine AF<br><sup>a</sup> Terry White TW<br>Chemists<br>Paroxetine<br><sup>a</sup> Aropax GK                                                                                                                                |
|                                       |                                                         |             |                | B0.86   | 25.91                                    | 26.08                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>SERTRALINE HYDROCHLORIDE</b>       |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b><u>Restricted Benefit</u></b>      |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <i>Major depressive disorders.</i>    |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 2236Q                                 | Tablet 50 mg (base)                                     | 30          | 5              | ..      | 24.23                                    | 25.26                                                  | <sup>a</sup> Chem mart CH<br>Sertraline<br><sup>a</sup> Concorz SZ<br><sup>a</sup> Eleva 50 AF<br><sup>a</sup> GenRx Sertraline GX<br><sup>a</sup> Sertra 50 SI<br><sup>a</sup> Sertraline 50 CR<br><sup>a</sup> Sertraline-GA GM<br><sup>a</sup> Sertraline GQ<br>generichealth<br><sup>a</sup> Sertraline WA<br>Winthrop<br><sup>a</sup> Sertratrust 50 MI<br><sup>a</sup> Setrona RA<br><sup>a</sup> Terry White TW<br>Chemists<br>Sertraline<br><sup>a</sup> Xydep 50 AW<br><sup>a</sup> Zoloft PF |
|                                       |                                                         |             |                | B0.41   | 24.64                                    | 25.26                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

continued ➞

## NERVOUS SYSTEM—CONT.

| Code                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer               |    |
|-------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------|----|
| 2237R                                                                   | Tablet 100 mg (base)                                    | 30          | 5              | ..      | 24.23                                    | 25.26                                                  | <sup>a</sup> Chem mart<br>Sertraline               | CH |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Concorz                               | SZ |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Eleva 100                             | AF |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Sertraline                      | GX |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Sertra 100                            | SI |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Sertraline 100                        | CR |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Sertraline-GA                         | GM |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Sertraline<br>generichealth           | GQ |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Sertraline<br>Winthrop                | WA |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Sertratrust 100                       | MI |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Setrona                               | RA |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Sertraline | TW |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Xydep 100                             | AW |
|                                                                         |                                                         |             |                | B0.41   | 24.64                                    | 25.26                                                  | <sup>a</sup> Zoloft                                | PF |
| <hr/>                                                                   |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| <b><u>Restricted Benefit</u></b>                                        |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| Obsessive-compulsive disorder;                                          |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| Panic disorder where other treatments have failed or are inappropriate. |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| 8836C                                                                   | Tablet 50 mg (base)                                     | 30          | 5              | ..      | 24.23                                    | 25.26                                                  | <sup>a</sup> Eleva 50                              | AF |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Xydep 50                              | AW |
|                                                                         |                                                         |             |                | B0.41   | 24.64                                    | 25.26                                                  | <sup>a</sup> Zoloft                                | PF |
| 8837D                                                                   | Tablet 100 mg (base)                                    | 30          | 5              | ..      | 24.23                                    | 25.26                                                  | <sup>a</sup> Eleva 100                             | AF |
|                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Xydep 100                             | AW |
|                                                                         |                                                         |             |                | B0.41   | 24.64                                    | 25.26                                                  | <sup>a</sup> Zoloft                                | PF |

• **Monoamine oxidase inhibitors, non-selective**

**PHENELZINE SULFATE**

**CAUTION:**

*This drug is an irreversible monoamine oxidase inhibitor.*

**Restricted Benefit**

*Depression where all other anti-depressant therapy has failed or is inappropriate.*

|                                                           |                     |     |   |    |       |       |         |    |
|-----------------------------------------------------------|---------------------|-----|---|----|-------|-------|---------|----|
| 2856H                                                     | Tablet 15 mg (base) | 100 | 1 | .. | 99.67 | 31.30 | Nardil  | LM |
| TRANYLCYPROMINE SULFATE                                   |                     |     |   |    |       |       |         |    |
| <b><u>CAUTION:</u></b>                                    |                     |     |   |    |       |       |         |    |
| This drug is an irreversible monoamine oxidase inhibitor. |                     |     |   |    |       |       |         |    |
| 2444P                                                     | Tablet 10 mg (base) | 50  | 2 | .. | 27.74 | 28.77 | Parnate | GH |

## NERVOUS SYSTEM—CONT.

| Code                                         | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| • <b>Monoamine oxidase type A inhibitors</b> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>MOCLOBEMIDE</b>                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Major depressive disorders.</i>           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1900B                                        | Tablet 150 mg                                           | 60          | 5              | ..      | 18.33                                    | 19.36                                                  | <sup>a</sup> Amira 150               | AF |
|                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Chem mart               | CH |
|                                              |                                                         |             |                |         |                                          |                                                        | Moclobemide                          |    |
|                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clobemix                | GM |
|                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                   | GX |
|                                              |                                                         |             |                |         |                                          |                                                        | Moclobemide                          |    |
|                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Mohexal                 | SZ |
|                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                                              |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                              |                                                         |             |                |         |                                          |                                                        | Moclobemide                          |    |
|                                              |                                                         |             |                | B0.72   | 19.05                                    | 19.36                                                  | <sup>a</sup> Aurorix                 | RO |
| 8003F                                        | Tablet 300 mg                                           | 60          | 5              | ..      | 29.75                                    | 30.78                                                  | <sup>a</sup> Amira 300               | AF |
|                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Chem mart               | CH |
|                                              |                                                         |             |                |         |                                          |                                                        | Moclobemide                          |    |
|                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clobemix                | GM |
|                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                   | GX |
|                                              |                                                         |             |                |         |                                          |                                                        | Moclobemide                          |    |
|                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Maosig                  | SI |
|                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Mohexal                 | SZ |
|                                              |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                                              |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                              |                                                         |             |                |         |                                          |                                                        | Moclobemide                          |    |
|                                              |                                                         |             |                | B1.45   | 31.20                                    | 30.78                                                  | <sup>a</sup> Aurorix 300 mg          | RO |
| • <b>Other antidepressants</b>               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>DULOXETINE HYDROCHLORIDE</b>              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Major depressive disorders.</i>           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9155W                                        | Capsule 30 mg (base)                                    | 28          | ..             | ..      | 37.79                                    | 31.30                                                  | Cymbalta                             | LY |
| 9156X                                        | Capsule 60 mg (base)                                    | 28          | 5              | ..      | 49.99                                    | 31.30                                                  | Cymbalta                             | LY |
| <b>LITHIUM CARBONATE</b>                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 3059B                                        | Tablet 250 mg                                           | 200         | 2              | ..      | 15.36                                    | 16.39                                                  | Lithicarb                            | AS |
| 8290H                                        | Tablet 450 mg (slow release)                            | 200         | 2              | ..      | * 33.87                                  | 31.30                                                  | Quilonum SR                          | GK |



## NERVOUS SYSTEM—CONT.

| Code                                                                                                                | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>MIANSERIN HYDROCHLORIDE</b>                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CAUTION:</b>                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Neutropenia and agranulocytosis are more frequent in the elderly, especially in the early months of therapy.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe depression.</i>                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1627P                                                                                                               | Tablet 10 mg                                            | 50          | 5              | ..      | 15.51                                    | 16.54                                                  | <sup>a</sup> Lumin 10                | AF |
|                                                                                                                     |                                                         |             |                | B1.99   | 17.50                                    | 16.54                                                  | <sup>a</sup> Tolvon                  | OR |
| 1628Q                                                                                                               | Tablet 20 mg                                            | 50          | 5              | ..      | 26.09                                    | 27.12                                                  | <sup>a</sup> Lumin 20                | AF |
|                                                                                                                     |                                                         |             |                | B2.97   | 29.06                                    | 27.12                                                  | <sup>a</sup> Tolvon                  | OR |
| <b>MIRTAZAPINE</b>                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Major depressive disorders.</i>                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8855C                                                                                                               | Tablet 15 mg (orally disintegrating)                    | 30          | 5              | ..      | 19.94                                    | 20.97                                                  | Avanza SolTab                        | BP |
| 8513C                                                                                                               | Tablet 30 mg                                            | 30          | 5              | ..      | 26.91                                    | 27.94                                                  | <sup>a</sup> Axit 30                 | AF |
|                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Chem mart               | CH |
|                                                                                                                     |                                                         |             |                |         |                                          |                                                        | Mirtazapine                          |    |
|                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                   | GX |
|                                                                                                                     |                                                         |             |                |         |                                          |                                                        | Mirtazapine                          |    |
|                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Mirtazapine-DP          | GM |
|                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Mirtazapine             | SZ |
|                                                                                                                     |                                                         |             |                |         |                                          |                                                        | Sandoz                               |    |
|                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Mirtazon                | AW |
|                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White             | TW |
|                                                                                                                     |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|                                                                                                                     |                                                         |             |                |         |                                          |                                                        | Mirtazapine                          |    |
|                                                                                                                     |                                                         |             |                | B1.70   | 28.61                                    | 27.94                                                  | <sup>a</sup> Avanza                  | BP |
| 8856D                                                                                                               | Tablet 30 mg (orally disintegrating)                    | 30          | 5              | ..      | 26.91                                    | 27.94                                                  | Avanza SolTab                        | BP |
| 8883M                                                                                                               | Tablet 45 mg                                            | 30          | 5              | ..      | 40.81                                    | 31.30                                                  | <sup>a</sup> Mirtazapine             | SZ |
|                                                                                                                     |                                                         |             |                |         |                                          |                                                        | Sandoz                               |    |
|                                                                                                                     |                                                         |             |                | B1.49   | 42.30                                    | 31.30                                                  | <sup>a</sup> Mirtazon                | AW |
|                                                                                                                     |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Avanza                  | BP |
| 8857E                                                                                                               | Tablet 45 mg (orally disintegrating)                    | 30          | 5              | ..      | 40.81                                    | 31.30                                                  | Avanza SolTab                        | BP |
| <b>REBOXETINE MESILATE</b>                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Major depressive disorders.</i>                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8583R                                                                                                               | Tablet 4 mg (base)                                      | 60          | 5              | ..      | 38.33                                    | 31.30                                                  | Edronax                              | PH |

## NERVOUS SYSTEM—CONT.

| Code                               | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>VENLAFAXINE HYDROCHLORIDE</b>   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Major depressive disorders.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8868R                              | Capsule 37.5 mg (base) (modified release)               | 28          | ..             | ..      | 27.10                                    | 28.13                                                  | Efexor-XR                            | WX |
| 8301X                              | Capsule 75 mg (base) (modified release)                 | 28          | 5              | ..      | 44.51                                    | 31.30                                                  | Efexor-XR                            | WX |
| 8302Y                              | Capsule 150 mg (base) (modified release)                | 28          | 5              | ..      | 52.19                                    | 31.30                                                  | Efexor-XR                            | WX |

### Psychostimulants, agents used for ADHD and nootropics

#### • Centrally acting sympathomimetics

##### ATOMOXETINE HYDROCHLORIDE

##### Authority Required

*Initial treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria, where:*

- (a) *treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:*
  - (1) *The patient has a history of substance abuse or misuse (other than alcohol); and/or*
  - (2) *The patient has comorbid motor tics or Tourette's Syndrome; and/or*
  - (3) *The patient has comorbid severe anxiety diagnosed according to the DSM-IV; or*
- (b) *treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal; or*
- (c) *treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:*
  - (1) *Adverse effects on growth and weight; and/or*
  - (2) *Adverse effects on sleep including insomnia; and/or*
  - (3) *Adverse effects on appetite including anorexia.*

##### Authority Required

*Continuing treatment where the patient has previously been issued with an authority prescription for this drug.*

|       |                      |    |   |    |          |       |           |    |
|-------|----------------------|----|---|----|----------|-------|-----------|----|
| 9092M | Capsule 10 mg (base) | 56 | 5 | .. | * 220.75 | 31.30 | Strattera | LY |
| 9093N | Capsule 18 mg (base) | 56 | 5 | .. | * 220.75 | 31.30 | Strattera | LY |
| 9094P | Capsule 25 mg (base) | 56 | 5 | .. | * 220.75 | 31.30 | Strattera | LY |
| 9095Q | Capsule 40 mg (base) | 56 | 5 | .. | * 220.75 | 31.30 | Strattera | LY |
| 9096R | Capsule 60 mg (base) | 56 | 5 | .. | * 220.75 | 31.30 | Strattera | LY |

## NERVOUS SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|

### DEXAMPHETAMINE SULFATE

#### NOTE:

Care must be taken to comply with the provisions of State/Territory law when prescribing dexamphetamine.

#### Authority Required

Use in attention deficit hyperactivity disorder, in accordance with State/Territory law;  
Narcolepsy.

|       |             |     |   |    |       |       |    |
|-------|-------------|-----|---|----|-------|-------|----|
| 1165H | Tablet 5 mg | 100 | 5 | .. | 17.76 | 18.79 | SI |
|-------|-------------|-----|---|----|-------|-------|----|

### METHYLPHENIDATE HYDROCHLORIDE

#### NOTE:

Care must be taken to comply with the provisions of State/Territory law when prescribing methylphenidate hydrochloride.

#### Authority Required

Use in attention deficit hyperactivity disorder, in accordance with State/Territory law.

|       |              |     |   |       |       |       |                         |    |
|-------|--------------|-----|---|-------|-------|-------|-------------------------|----|
| 8839F | Tablet 10 mg | 100 | 5 | ..    | 15.50 | 16.53 | <sup>a</sup> Attenta    | AF |
|       |              |     |   | B1.37 | 16.87 | 16.53 | <sup>a</sup> Ritalin 10 | NV |

#### Authority Required

Treatment of attention deficit hyperactivity disorder (ADHD) in a patient aged 6 to 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 12 hours.

|       |                                 |    |   |    |       |       |          |    |
|-------|---------------------------------|----|---|----|-------|-------|----------|----|
| 2387P | Tablet 18 mg (extended release) | 30 | 5 | .. | 52.87 | 31.30 | Concerta | JC |
| 2172H | Tablet 27 mg (extended release) | 30 | 5 | .. | 57.23 | 31.30 | Concerta | JC |
| 2388Q | Tablet 36 mg (extended release) | 30 | 5 | .. | 61.93 | 31.30 | Concerta | JC |
| 2432B | Tablet 54 mg (extended release) | 30 | 5 | .. | 72.52 | 31.30 | Concerta | JC |

#### Authority Required

Treatment of attention deficit hyperactivity disorder in a patient aged 6 to 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 8 hours.

|       |                                  |    |   |    |       |       |            |    |
|-------|----------------------------------|----|---|----|-------|-------|------------|----|
| 2276T | Capsule 20 mg (modified release) | 30 | 5 | .. | 52.24 | 31.30 | Ritalin LA | NV |
| 2280B | Capsule 30 mg (modified release) | 30 | 5 | .. | 62.00 | 31.30 | Ritalin LA | NV |
| 2283E | Capsule 40 mg (modified release) | 30 | 5 | .. | 65.49 | 31.30 | Ritalin LA | NV |

### MODAFINIL

#### NOTE:

Any queries concerning the arrangements to prescribe modafinil may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe modafinil should be forwarded to:

continued ➞

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
| <p><b>Medicare Australia</b><br/><b>Prior Written Approval of Specialised Drugs</b><br/><b>Reply Paid 9826</b><br/><b>GPO Box 9826</b><br/><b>HOBART TAS 7001</b></p> <p><i>Further prescribing information is on the Medicare Australia website at <a href="http://www.medicareaustralia.gov.au">www.medicareaustralia.gov.au</a>.</i></p> <p><b>NOTE:</b><br/><i>Modafinil is not PBS-subsidised when used in combination with PBS-subsidised dexamphetamine sulfate.</i></p> <p><b>Authority Required</b><br/><i>Initial treatment, by a qualified sleep medicine practitioner or neurologist, of patients with narcolepsy where:</i><br/><i>(i) therapy with dexamphetamine sulfate poses an unacceptable medical risk; or</i><br/><i>(ii) intolerance to dexamphetamine sulfate of a severity necessitating permanent treatment withdrawal develops.</i><br/><i>The presence of any 1 of the following indicates treatment with dexamphetamine sulfate poses an unacceptable medical risk:</i><br/><i>(a) a psychiatric disorder;</i><br/><i>(b) a cardiac disorder;</i><br/><i>(c) a history of substance abuse;</i><br/><i>(d) glaucoma;</i><br/><i>(e) any other absolute contraindication to dexamphetamine sulfate as specified in the TGA-approved Product Information.</i><br/><i>Patients must meet the following definition of narcolepsy:</i><br/><i>Excessive daytime sleepiness, recurrent naps or lapses into sleep occurring almost daily for at least 3 months and:</i><br/><i>(i) a definite history of cataplexy and a Multiple Sleep Latency Test (MSLT) with a mean sleep latency less than or equal to 8 minutes; or</i><br/><i>(ii) a MSLT with a mean sleep latency less than or equal to 8 minutes and 2 or more sleep onset rapid eye movement (REM) periods; or</i><br/><i>(iii) an electroencephalographic (EEG) recording showing the pathologically rapid development of REM sleep.</i><br/><i>The MSLT must be preceded by nocturnal polysomnography. Sleep prior to the MSLT must be at least 6 hours.</i><br/><i>The authority application must be made in writing and must include the following:</i><br/><i>(a) a completed authority prescription form; and</i><br/><i>(b) a completed Modafinil (Modavigil) PBS Authority Application for Use in the Treatment of Narcolepsy - Supporting Information Form [<a href="http://www.medicareaustralia.gov.au">www.medicareaustralia.gov.au</a>]; and</i><br/><i>(c) details of the contraindication or intolerance to dexamphetamine sulfate; and</i><br/><i>(d) either:</i><br/><i>(i) the result and date of the polysomnography test and MSLT conducted by, or under the supervision of, a qualified sleep medicine practitioner; or</i><br/><i>(ii) the result and date of the EEG, conducted by, or under the supervision of, a neurologist.</i><br/><i>The polysomnography, MSLT or EEG test reports must be provided with the authority application.</i></p> <p><b>Authority Required</b><br/><i>Continuing treatment of narcolepsy, where the patient has previously been issued with an authority prescription for this drug.</i></p> |                                                         |             |                |         |                                          |                                                        |                                      |
| 8816B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Tablet 100 mg                                           | 120         | 5              | ..      | * 346.55                                 | 31.30                                                  | Modavigil CS                         |

## NERVOUS SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### Anti-dementia drugs

#### • Anticholinesterases

##### **DONEPEZIL HYDROCHLORIDE**

#### Authority Required

**INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE** — Patients with an (S)MMSE of 10 or more.

Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).

The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.

If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.

This application must be made in writing, but initial supply may be sought by telephone.

For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.

For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised;

**CONTINUING TREATMENT** — (S)MMSE or ADAS-Cog improvement.

Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:

(a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);

(b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).

The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.

Subsequent applications for continuing treatment can be made by telephone.

#### Authority Required

**INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE** — Patients with an (S)MMSE of 9 or less who require a clinician's assessment.

Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).

Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.

The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.

## NERVOUS SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*This application must be made in writing, but initial supply may be sought by telephone.*

*For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.*

*For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.*

*Patients who qualify under this criterion are from 1 or more of the following groups:*

- (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;*
- (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;*
- (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;*
- (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;*
- (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;*
- (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment;*

**CONTINUING TREATMENT — Clinician assessed improvement.**

*Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.*

*The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.*

*Subsequent applications for continuing treatment can be made by telephone.*

|       |              |    |   |    |        |       |         |    |
|-------|--------------|----|---|----|--------|-------|---------|----|
| 8495D | Tablet 5 mg  | 28 | 5 | .. | 155.02 | 31.30 | Aricept | PF |
| 8496E | Tablet 10 mg | 28 | 5 | .. | 155.02 | 31.30 | Aricept | PF |

### GALANTAMINE HYDROBROMIDE

#### Authority Required

**INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE — Patients with an (S)MMSE of 10 or more.**

*Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).*

*The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.*

*If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.*

*This application must be made in writing, but initial supply may be sought by telephone.*

*For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.*

*For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised;*

continued ➡

## NERVOUS SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### **CONTINUING TREATMENT — (S)MMSE or ADAS-Cog improvement.**

*Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:*

*(a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);*

*(b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).*

*The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.*

*Subsequent applications for continuing treatment can be made by telephone.*

### **Authority Required**

#### **INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE — Patients with an (S)MMSE of 9 or less who require a clinician's assessment.**

*Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).*

*Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale. The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.*

*This application must be made in writing, but initial supply may be sought by telephone.*

*For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.*

*For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.*

*Patients who qualify under this criterion are from 1 or more of the following groups:*

- (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;*
- (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;*
- (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;*
- (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;*
- (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;*
- (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment;*

### **CONTINUING TREATMENT — Clinician assessed improvement.**

*Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.*

*The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.*

continued ➡

## NERVOUS SYSTEM—CONT.

| Code                                                                       | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                            |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| Subsequent applications for continuing treatment can be made by telephone. |                                                         |             |                |         |                             |                                             |                                      |    |
| 8770N                                                                      | Capsule 8 mg (base) (prolonged release)                 | 28          | 5              | ..      | 130.39                      | 31.30                                       | Reminyl                              | JC |
| 8771P                                                                      | Capsule 16 mg (base) (prolonged release)                | 28          | 5              | ..      | 158.16                      | 31.30                                       | Reminyl                              | JC |
| 8772Q                                                                      | Capsule 24 mg (base) (prolonged release)                | 28          | 5              | ..      | 187.34                      | 31.30                                       | Reminyl                              | JC |

### RIVASTIGMINE

#### Authority Required

**INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE** — Patients with an (S)MMSE of 10 or more.

*Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).*

*The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.*

*If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.*

*This application must be made in writing, but initial supply may be sought by telephone.*

*For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.*

*For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised;*

**CONTINUING TREATMENT** — (S)MMSE or ADAS-Cog improvement.

*Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:*

*(a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);*

*(b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).*

*The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.*

*Subsequent applications for continuing treatment can be made by telephone.*

continued ➞



## NERVOUS SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

### Authority Required

**INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE** — Patients with an (S)MMSE of 9 or less who require a clinician's assessment.

Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).

Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale. The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.

This application must be made in writing, but initial supply may be sought by telephone.

For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.

For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.

Patients who qualify under this criterion are from 1 or more of the following groups:

- (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;
- (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;
- (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;
- (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;
- (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;
- (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment;

**CONTINUING TREATMENT** — Clinician assessed improvement.

Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.

The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.

Subsequent applications for continuing treatment can be made by telephone.

|       |                                                                       |    |   |    |        |       |                 |    |
|-------|-----------------------------------------------------------------------|----|---|----|--------|-------|-----------------|----|
| 9161E | Transdermal patch 9 mg (releasing approximately 4.6 mg per 24 hours)  | 30 | 5 | .. | 165.66 | 31.30 | Exelon Patch 5  | NV |
| 9162F | Transdermal patch 18 mg (releasing approximately 9.5 mg per 24 hours) | 30 | 5 | .. | 165.66 | 31.30 | Exelon Patch 10 | NV |

## NERVOUS SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### RIVASTIGMINE HYDROGEN TARTRATE

#### Authority Required

**INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE** — Patients with an (S)MMSE of 10 or more.

*Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).*

*The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.*

*If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.*

*This application must be made in writing, but initial supply may be sought by telephone.*

*For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.*

*For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised;*

**CONTINUING TREATMENT** — (S)MMSE or ADAS-Cog improvement.

*Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:*

*(a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);*

*(b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).*

*The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.*

*Subsequent applications for continuing treatment can be made by telephone.*

#### Authority Required

**INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE** — Patients with an (S)MMSE of 9 or less who require a clinician's assessment.

*Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).*

*Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale. The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.*

continued ➡

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| <p><i>This application must be made in writing, but initial supply may be sought by telephone.</i></p> <p><i>For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.</i></p> <p><i>For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</i></p> <p><i>Patients who qualify under this criterion are from 1 or more of the following groups:</i></p> <p><i>(1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;</i></p> <p><i>(2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;</i></p> <p><i>(3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;</i></p> <p><i>(4) Intellectual (developmental or acquired) disability, eg Down's syndrome;</i></p> <p><i>(5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;</i></p> <p><i>(6) Prominent dysphasia, out of proportion to other cognitive and functional impairment;</i></p> <p><b>CONTINUING TREATMENT — Clinician assessed improvement.</b></p> <p><i>Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</i></p> <p><i>The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</i></p> <p><i>Subsequent applications for continuing treatment can be made by telephone.</i></p> |                                                         |             |                |         |                             |                                             |                                      |    |
| 8497F                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 1.5 mg (base)                                   | 56          | 5              | ..      | 155.02                      | 31.30                                       | Exelon                               | NV |
| 8498G                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 3 mg (base)                                     | 56          | 5              | ..      | 155.02                      | 31.30                                       | Exelon                               | NV |
| 8499H                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 4.5 mg (base)                                   | 56          | 5              | ..      | 155.02                      | 31.30                                       | Exelon                               | NV |
| 8500J                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Capsule 6 mg (base)                                     | 56          | 5              | ..      | 155.02                      | 31.30                                       | Exelon                               | NV |
| 8563Q                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Oral solution 2 mg (base) per mL,<br>120 mL             | ± 1         | 5              | ..      | 155.02                      | 31.30                                       | Exelon                               | NV |

• **Other anti-dementia drugs**  
**MEMANTINE HYDROCHLORIDE**

**Authority Required**

**INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE —**  
*Patients with an (S)MMSE of 10 to 14.*

*Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).*

*The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 to 14.*

continued ➡

## NERVOUS SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

*This application must be made in writing, but initial supply may be sought by telephone.*

*For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.*

*For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised;*

**CONTINUING TREATMENT — (S)MMSE improvement.**

*Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).*

*The initial authority application for continuing treatment must include the relevant result from the (S)MMSE and must be in writing.*

*Subsequent applications for continuing treatment can be made by telephone.*

### **Authority Required**

**INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE —**

*Patients with an (S)MMSE of 9 or less who require a clinician's assessment.*

*Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 to 14 for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by a specialist/consultant physician (including a psychiatrist).*

*Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.*

*The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.*

*This application must be made in writing, but initial supply may be sought by telephone.*

*For telephone applications, up to a maximum of 2 months' initial therapy will be authorised. This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.*

*For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.*

*Patients who qualify under this criterion are from 1 or more of the following groups:*

- (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;*
- (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;*
- (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;*
- (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;*
- (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;*
- (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment;*

**CONTINUING TREATMENT — Clinician assessed improvement.**

*Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.*

*The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.*

## NERVOUS SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

*Subsequent applications for continuing treatment can be made by telephone.*

### Authority Required

**APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE — Patients who commenced treatment prior to 1 March 2008.**

**Continuing treatment, as the sole PBS-subsidised therapy, of a patient commenced on memantine prior to 1 March 2008.**

*Applications for continuing treatment can be made by telephone.*

|       |                              |     |   |    |        |       |       |    |
|-------|------------------------------|-----|---|----|--------|-------|-------|----|
| 1956Y | Tablet 10 mg                 | 56  | 5 | .. | 123.22 | 31.30 | Ebixa | LU |
| 2059J | Oral drops 10 mg per g, 50 g | ± 1 | 5 | .. | 110.67 | 31.30 | Ebixa | LU |

### OTHER NERVOUS SYSTEM DRUGS

#### **Parasympathomimetics**

##### • **Anticholinesterases**

#### **PYRIDOSTIGMINE BROMIDE**

|       |                                  |     |   |    |        |       |                   |    |
|-------|----------------------------------|-----|---|----|--------|-------|-------------------|----|
| 2724J | Tablet 10 mg                     | 100 | 5 | .. | 19.24  | 20.27 | Mestinon          | VT |
| 1959D | Tablet 60 mg                     | 150 | 5 | .. | 55.57  | 31.30 | Mestinon          | VT |
| 2608G | Tablet 180 mg (modified release) | 100 | 5 | .. | 114.04 | 31.30 | Mestinon Timespan | VT |

##### • **Choline esters**

#### **BETHANECHOL CHLORIDE**

|       |              |     |   |    |       |       |          |    |
|-------|--------------|-----|---|----|-------|-------|----------|----|
| 1062X | Tablet 10 mg | 100 | 2 | .. | 20.26 | 21.29 | Uro-Carb | HA |
|-------|--------------|-----|---|----|-------|-------|----------|----|

## NERVOUS SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### Drugs used in addictive disorders

#### • *Drugs used in nicotine dependence*

##### **BUPROPION HYDROCHLORIDE**

##### NOTE:

*Only one course of PBS-subsidised bupropion hydrochloride will be authorised per 12 months. The period between commencing a course of bupropion hydrochloride and varenicline tartrate must be at least 6 months. A course of treatment with bupropion hydrochloride is 9 weeks. No increased maximum quantities or repeats will be authorised. Clinical review is recommended within 2 to 3 weeks of the original prescription being requested.*

##### Authority Required

*Commencement of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and:*

- (a) who has entered a comprehensive support and counselling program; or*
- (b) who is entering a comprehensive support and counselling program during the consultation at which this authority is requested.*

*Details of the program must be specified in the authority application.*

|       |                                   |    |    |    |       |       |                           |    |
|-------|-----------------------------------|----|----|----|-------|-------|---------------------------|----|
| 8465M | Tablet 150 mg (sustained release) | 30 | .. | .. | 76.83 | 31.30 | <sup>a</sup> Bupropion-RL | RE |
|       |                                   |    |    |    |       |       | <sup>a</sup> Clorprax     | HX |
|       |                                   |    |    |    |       |       | <sup>a</sup> Prexaton     | AF |
|       |                                   |    |    |    | 80.85 | 77.68 | <sup>a</sup> Zyban        | GK |

##### Authority Required

*Completion of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has previously been issued with an authority prescription for this drug and who is enrolled in a comprehensive support and counselling program.*

|       |                                   |    |    |    |        |        |                           |    |
|-------|-----------------------------------|----|----|----|--------|--------|---------------------------|----|
| 8710K | Tablet 150 mg (sustained release) | 90 | .. | .. | 168.10 | 31.30  | <sup>a</sup> Bupropion-RL | RE |
|       |                                   |    |    |    |        |        | <sup>a</sup> Clorprax     | HX |
|       |                                   |    |    |    |        |        | <sup>a</sup> Prexaton     | AF |
|       |                                   |    |    |    | 80.86  | 168.96 | <sup>a</sup> Zyban        | GK |

## NERVOUS SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                          | Name, Restriction,<br>Manner of Administration and Form                                                                                                 | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer             |          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------------------|----------|
| <b>VARENICLINE</b>                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <b>NOTE:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <i>Only one course of PBS-subsidised varenicline tartrate will be authorised per year. The period between commencing a course of varenicline tartrate and bupropion hydrochloride must be at least 6 months. A course of treatment with varenicline tartrate is 12 weeks. No increased maximum quantities or repeats will be authorised. Clinical review is recommended within 2 to 3 weeks of the original prescription being requested.</i> |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <i>Commencement of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and:</i>                                                                                                                                                                                                                                                                         |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <i>(a) who has entered a comprehensive support and counselling program; or</i>                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <i>(b) who is entering a comprehensive support and counselling program during the consultation at which this authority is requested.</i>                                                                                                                                                                                                                                                                                                      |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <i>Details of the program must be specified in the authority application.</i>                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| 9128K                                                                                                                                                                                                                                                                                                                                                                                                                                         | Box containing 11 tablets 0.5 mg (as tartrate) and 14 tablets 1 mg (as tartrate) in the first pack and 28 tablets 1 mg (as tartrate) in the second pack | ± 1         | ..             | ..      | 103.33                                   | 31.30                                                  | Champix                                          | PF       |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <i>Completion of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has previously been issued with an authority prescription for this drug and who is enrolled in a comprehensive support and counselling program.</i>                                                                                                                                                                              |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| 9129L                                                                                                                                                                                                                                                                                                                                                                                                                                         | Tablet 1 mg (as tartrate)                                                                                                                               | 112         | ..             | ..      | * 232.63                                 | 31.30                                                  | Champix                                          | PF       |
| <b>• Drugs used in alcohol dependence</b>                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <b>ACAMPROSATE CALCIUM</b>                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <b>Authority Required (STREAMLINED)</b>                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| 2665                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <i>For use within a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence.</i>                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <b>NOTE:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i>                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| 8357W                                                                                                                                                                                                                                                                                                                                                                                                                                         | Tablet 333 mg (enteric coated)                                                                                                                          | 180         | 1              | ..      | 166.15                                   | 31.30                                                  | Campral                                          | AF       |
| <b>NALTREXONE HYDROCHLORIDE</b>                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <b>CAUTION:</b>                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <i>Naltrexone hydrochloride is contraindicated in patients receiving opioid drugs.</i>                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <i>For use within a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence.</i>                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <b>NOTE:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i>                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                         |             |                |         |                                          |                                                        |                                                  |          |
| 8370M                                                                                                                                                                                                                                                                                                                                                                                                                                         | Tablet 50 mg                                                                                                                                            | 30          | 1              | ..      | 143.33                                   | 31.30                                                  | <sup>a</sup> Naltrexone QP<br><sup>a</sup> ReVia | XF<br>BQ |

## NERVOUS SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### Other nervous system drugs

#### • Other nervous system drugs

##### **RILUZOLE**

##### Authority Required

*Initial treatment of amyotrophic lateral sclerosis, as diagnosed by a neurologist, in patients with disease duration of 5 years or less and who have at least 60 percent of predicted forced vital capacity within 2 months prior to commencing riluzole therapy and who:*

- (1) are ambulatory, and*
- (a) have not undergone tracheostomy, and*
- (b) have not experienced respiratory failure; OR*
- (2) are not ambulatory, and*
- (a) have not undergone tracheostomy, and*
- (b) have not experienced respiratory failure, and*
- (c) are either able to use upper limbs or able to swallow.*

*The date of diagnosis and the date and results of spirometry (in terms of percent of predicted forced vital capacity) must be supplied with the initial authority application.*

##### Authority Required

*Continuing treatment of amyotrophic lateral sclerosis in patients who have previously been issued with an authority prescription for this drug and who:*

- (1) are ambulatory, and*
- (a) have not undergone tracheostomy, and*
- (b) have not experienced respiratory failure; OR*
- (2) are not ambulatory, and*
- (a) have not undergone tracheostomy, and*
- (b) have not experienced respiratory failure, and*
- (c) are either able to use upper limbs or able to swallow.*

|       |              |    |   |    |        |       |         |    |
|-------|--------------|----|---|----|--------|-------|---------|----|
| 8664B | Tablet 50 mg | 56 | 5 | .. | 661.57 | 31.30 | Rilutek | SW |
|-------|--------------|----|---|----|--------|-------|---------|----|

##### **TETRABENAZINE**

##### Authority Required (STREAMLINED)

**1161**

*Hyperkinetic extrapyramidal disorders.*

|       |              |     |   |    |        |       |    |
|-------|--------------|-----|---|----|--------|-------|----|
| 1330B | Tablet 25 mg | 112 | 5 | .. | 337.12 | 31.30 | OA |
|-------|--------------|-----|---|----|--------|-------|----|



## ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

### ANTIPROTOZOALS

#### Agents against amoebiasis and other protozoal diseases

##### • Nitroimidazole derivatives

#### METRONIDAZOLE

*For listings see Generic/Proprietary Index*

#### METRONIDAZOLE BENZOATE

*For listings see Generic/Proprietary Index*

#### TINIDAZOLE

*For listings see Generic/Proprietary Index*

##### • Other agents against amoebiasis and other protozoal diseases

#### ATOVAQUONE

#### Authority Required (STREAMLINED)

1433

*Treatment of mild to moderate Pneumocystis carinii pneumonia in adult patients who are intolerant of trimethoprim/sulfamethoxazole therapy.*

|       |                                            |      |    |    |        |       |          |    |
|-------|--------------------------------------------|------|----|----|--------|-------|----------|----|
| 8300W | Oral suspension 750 mg per 5 mL,<br>210 mL | \$ 1 | .. | .. | 862.78 | 31.30 | Wellvone | GK |
|-------|--------------------------------------------|------|----|----|--------|-------|----------|----|

#### PYRIMETHAMINE

|       |              |    |    |    |       |       |          |    |
|-------|--------------|----|----|----|-------|-------|----------|----|
| 1966L | Tablet 25 mg | 50 | .. | .. | 14.28 | 15.31 | Daraprim | GK |
|-------|--------------|----|----|----|-------|-------|----------|----|

#### Antimalarials

##### • Methanolquinolines

#### QUININE BISULFATE

#### CAUTION:

*Severe thrombocytopenia has been reported with this drug.*

#### Authority Required (STREAMLINED)

2142

*Malaria.*

|       |               |    |   |    |       |       |           |    |
|-------|---------------|----|---|----|-------|-------|-----------|----|
| 1972T | Tablet 300 mg | 50 | 2 | .. | 12.02 | 13.05 | Quinbisul | AS |
|-------|---------------|----|---|----|-------|-------|-----------|----|

#### QUININE SULFATE

#### CAUTION:

*Severe thrombocytopenia has been reported with this drug.*

#### Authority Required (STREAMLINED)

2142

*Malaria.*

|       |               |    |   |       |       |       |                      |    |
|-------|---------------|----|---|-------|-------|-------|----------------------|----|
| 1975Y | Tablet 300 mg | 50 | 2 | ..    | 12.02 | 13.05 | <sup>a</sup> Quinsul | LN |
|       |               |    |   | B2.17 | 14.19 | 13.05 | <sup>a</sup> Quinate | AS |

## ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS—CONT.

| Code                                                                                                                                                | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>ANTHELMINTICS</b>                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Antinematodal agents</b>                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Benzimidazole derivatives</b>                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>ALBENDAZOLE</b>                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b>                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2446                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of whipworm infestation in an Aboriginal or a Torres Strait Islander person.</i>                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9047E                                                                                                                                               | Tablet 200 mg                                           | 6           | ..             | ..      | 32.67                                    | 31.30                                                  | Zentel                               | GK |
| <b>Authority Required (STREAMLINED)</b>                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1525                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of tapeworm infestation.</i>                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8503M                                                                                                                                               | Tablet 200 mg                                           | 6           | 1              | ..      | 32.67                                    | 31.30                                                  | Zentel                               | GK |
| <b>Authority Required (STREAMLINED)</b>                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1496                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>For the treatment of hydatid disease in conjunction with surgery or when a surgical cure cannot be achieved or where surgery cannot be used.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8459F                                                                                                                                               | Tablet 400 mg                                           | 60          | 2              | ..      | 184.82                                   | 31.30                                                  | Eskazole                             | GK |
| • <b>Tetrahydropyrimidine derivatives</b>                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>PYRANTEL EMBONATE</b>                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 3047J                                                                                                                                               | Tablet 125 mg (base)                                    | 6           | ..             | ..      | 7.61                                     | 8.64                                                   | Anthel 125                           | AF |
| 3048K                                                                                                                                               | Tablet 250 mg (base)                                    | 6           | ..             | ..      | 9.05                                     | 10.08                                                  | Anthel 250                           | AF |
| • <b>Avermectines</b>                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>IVERMECTIN</b>                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b>                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1242                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Onchocerciasis;</i>                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1388                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Strongyloidiasis.</i>                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8359Y                                                                                                                                               | Tablet 3 mg                                             | 4           | ..             | ..      | 30.88                                    | 31.30                                                  | Stromectol                           | MK |

ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS

Ectoparasiticides, incl. scabicides

• Pyrethrines, incl. synthetic compounds

PERMETHRIN

|       |                              |     |   |    |       |       |         |    |
|-------|------------------------------|-----|---|----|-------|-------|---------|----|
| 3054R | Cream 50 mg per g (5%), 30 g | ± 1 | 1 | .. | 16.34 | 17.37 | Lyclear | JT |
|-------|------------------------------|-----|---|----|-------|-------|---------|----|

## RESPIRATORY SYSTEM

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

### DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

#### Adrenergics, inhalants

#### • Selective beta-2-adrenoceptor agonists

##### *EFORMOTEROL FUMARATE DIHYDRATE*

#### Restricted Benefit

*Patients with frequent episodes of asthma who are currently receiving treatment with oral corticosteroids;*

*Patients with frequent episodes of asthma who are currently receiving treatment with optimal doses of inhaled corticosteroids.*

|       |                                                                                             |     |   |    |       |       |                 |    |
|-------|---------------------------------------------------------------------------------------------|-----|---|----|-------|-------|-----------------|----|
| 8136F | Capsule containing powder for oral inhalation 12 micrograms (for use in Foradile Aerolizer) | 60  | 5 | .. | 36.90 | 31.30 | Foradile        | NV |
| 8239P | Powder for oral inhalation in breath actuated device 6 micrograms per dose (60 doses)       | ‡ 1 | 5 | .. | 25.95 | 26.98 | Oxis Turbuhaler | AP |
| 8240Q | Powder for oral inhalation in breath actuated device 12 micrograms per dose (60 doses)      | ‡ 1 | 5 | .. | 36.01 | 31.30 | Oxis Turbuhaler | AP |

##### SALBUTAMOL SULFATE

|       |                                                                                                     |     |   |       |         |       |                                |    |
|-------|-----------------------------------------------------------------------------------------------------|-----|---|-------|---------|-------|--------------------------------|----|
| 1099W | Capsule containing powder for oral inhalation 200 micrograms (base) (for use in Ventolin Rotahaler) | 200 | 5 | ..    | * 18.07 | 19.10 | Ventolin Rotacaps              | GK |
| 8288F | Oral pressurised inhalation 100 micrograms (base) per dose (200 doses), CFC-free formulation        | 2   | 5 | ..    | * 14.79 | 15.82 | <sup>a</sup> Airomir           | IA |
|       |                                                                                                     |     |   |       |         |       | <sup>a</sup> Asmol CFC-free    | AL |
|       |                                                                                                     |     |   |       |         |       | <sup>a</sup> Epaq              | AW |
|       |                                                                                                     |     |   | B1.18 | * 15.97 | 15.82 | <sup>a</sup> Ventolin CFC-free | GK |

##### SALBUTAMOL SULFATE

#### Restricted Benefit

*Patients unable to achieve co-ordinated use of other metered dose inhalers containing this drug.*

|       |                                                                                                                        |   |   |    |         |       |                   |    |
|-------|------------------------------------------------------------------------------------------------------------------------|---|---|----|---------|-------|-------------------|----|
| 8354Q | Oral pressurised inhalation in breath actuated device 100 micrograms (base) per dose (200 doses), CFC-free formulation | 2 | 5 | .. | * 38.17 | 31.30 | Airomir Autohaler | IA |
|-------|------------------------------------------------------------------------------------------------------------------------|---|---|----|---------|-------|-------------------|----|

continued ➞

## RESPIRATORY SYSTEM—CONT.

| Code                                                                                                                                                | Name, Restriction,<br>Manner of Administration and Form                                             | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                                                                                                                                              |                                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| <b><u>Restricted Benefit</u></b>                                                                                                                    |                                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                   |                                                                |
| <i>Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer;</i>                                |                                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                   |                                                                |
| <i>Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer.</i> |                                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                   |                                                                |
| 2000G                                                                                                                                               | Nebuliser solution single dose units<br>2.5 mg (base) in 2.5 mL, 30                                 | 2           | 5              | ..      | * 18.51                                  | 19.54                                                  | <sup>a</sup> Asmol 2.5 uni-dose<br><sup>a</sup> Butamol 2.5<br><sup>a</sup> Chem mart<br>Salbutamol<br><sup>a</sup> GenRx Salbutamol<br><sup>a</sup> Pharmacor<br>Salbutamol 2.5<br><sup>a</sup> Salbutamol-GA<br><sup>a</sup> Salbutamol Sandoz<br><sup>a</sup> Terry White<br>Chemists<br>Salbutamol<br><sup>a</sup> PU         | AF<br>AW<br>CH<br><br>GX<br>CR<br><br>GM<br>SZ<br>TW<br><br>GK |
|                                                                                                                                                     |                                                                                                     |             |                | B1.46   | * 19.97                                  | 19.54                                                  | <sup>a</sup> Ventolin Nebules                                                                                                                                                                                                                                                                                                     | GK                                                             |
| 2001H                                                                                                                                               | Nebuliser solution single dose units<br>5 mg (base) in 2.5 mL, 30                                   | 2           | 5              | ..      | * 19.21                                  | 20.24                                                  | <sup>a</sup> Asmol 5 uni-dose<br><sup>a</sup> Butamol 5<br><sup>a</sup> Chem mart<br>Salbutamol<br><sup>a</sup> GenRx Salbutamol<br><sup>a</sup> Pharmacor<br>Salbutamol 5<br><sup>a</sup> Salbutamol-GA<br><sup>a</sup> Salbutamol Sandoz<br><sup>a</sup> Terry White<br>Chemists<br>Salbutamol<br><sup>a</sup> Ventolin Nebules | AF<br>AW<br>CH<br><br>GX<br>CR<br><br>GM<br>SZ<br>TW<br><br>GK |
|                                                                                                                                                     |                                                                                                     |             |                | B1.46   | * 20.67                                  | 20.24                                                  | <sup>a</sup> Ventolin Nebules                                                                                                                                                                                                                                                                                                     | GK                                                             |
| 2003K                                                                                                                                               | Nebuliser solution 5 mg (base) per mL<br>(0.5%), 30 mL                                              | 2           | 2              | ..      | * 10.59                                  | 11.62                                                  | PU                                                                                                                                                                                                                                                                                                                                |                                                                |
| <b>SALMETEROL XINAFOATE</b>                                                                                                                         |                                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                   |                                                                |
| <b><u>Restricted Benefit</u></b>                                                                                                                    |                                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                   |                                                                |
| <i>Patients with frequent episodes of asthma who are currently receiving treatment with oral corticosteroids;</i>                                   |                                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                   |                                                                |
| <i>Patients with frequent episodes of asthma who are currently receiving treatment with optimal doses of inhaled corticosteroids.</i>               |                                                                                                     |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                                                                                   |                                                                |
| 8141L                                                                                                                                               | Powder for oral inhalation in breath<br>actuated device 50 micrograms (base)<br>per dose (60 doses) | ‡ 1         | 5              | ..      | 36.90                                    | 31.30                                                  | Serevent Accuhaler                                                                                                                                                                                                                                                                                                                | GK                                                             |

## RESPIRATORY SYSTEM—CONT.

| Code                                                                                                                                                                                                                                      | Name, Restriction,<br>Manner of Administration and Form                                               | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| TERBUTALINE SULFATE                                                                                                                                                                                                                       |                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| 1252X                                                                                                                                                                                                                                     | Powder for oral inhalation in breath actuated device 500 micrograms per dose (200 doses)              | ‡ 1         | 5              | ..      | 17.40                                    | 18.43                                                  | Bricanyl Turbuhaler                  | AP |
| TERBUTALINE SULFATE                                                                                                                                                                                                                       |                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                                                                                                                                                                                 |                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <i>Asthma in patients unable to use this drug delivered from a breath actuated device;</i>                                                                                                                                                |                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <i>Chronic obstructive pulmonary disease in patients unable to use this drug delivered from a breath actuated device.</i>                                                                                                                 |                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| 1251W                                                                                                                                                                                                                                     | Nebuliser solution single dose units 5 mg in 2 mL, 30                                                 | 2           | 5              | ..      | * 40.37                                  | 31.30                                                  | Bricanyl Respules                    | AP |
| • <b>Adrenergics and other drugs for obstructive airway diseases</b>                                                                                                                                                                      |                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <b>BUDESONIDE with EFORMOTEROL FUMARATE DIHYDRATE</b>                                                                                                                                                                                     |                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                                                                                                                                                                                 |                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide;</i>                     |                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide;</i> |                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <i>For single maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with oral corticosteroids;</i>                                                                             |                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <i>For single maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with inhaled corticosteroids;</i>                                                                          |                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <i>For maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with a combination of an inhaled corticosteroid and a long-acting beta-2 agonist.</i>                             |                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| 8796Y                                                                                                                                                                                                                                     | Powder for oral inhalation in breath actuated device 100 micrograms-6 micrograms per dose (120 doses) | ‡ 1         | 5              | ..      | 54.04                                    | 31.30                                                  | Symbicort Turbuhaler 100/6           | AP |
| 8625Y                                                                                                                                                                                                                                     | Powder for oral inhalation in breath actuated device 200 micrograms-6 micrograms per dose (120 doses) | ‡ 1         | 5              | ..      | 58.34                                    | 31.30                                                  | Symbicort Turbuhaler 200/6           | AP |

continued ➞

## RESPIRATORY SYSTEM—CONT.

| Code                                                                                                                                                                                                                                        | Name, Restriction,<br>Manner of Administration and Form                                                               | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                            |                                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide;</i>                       |                                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide.</i>   |                                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                         |                                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| Symbicort 400/12 is not recommended nor PBS-subsidised for use as 'maintenance and reliever' therapy.                                                                                                                                       |                                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| 8750M                                                                                                                                                                                                                                       | Powder for oral inhalation<br>in breath actuated devices<br>400 micrograms-12 micrograms per<br>dose (60 doses), 2    | 1           | 5              | ..      | 86.46                                    | 31.30                                                  | Symbicort<br>Turbuhaler 400/<br>12   | AP |
| <b>FLUTICASONE PROPIONATE with SALMETEROL<br/>XINAFOATE</b>                                                                                                                                                                                 |                                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                            |                                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate;</i>                     |                                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate.</i> |                                                                                                                       |             |                |         |                                          |                                                        |                                      |    |
| 8517G                                                                                                                                                                                                                                       | Oral pressurised inhalation<br>50 micrograms-25 micrograms (base)<br>per dose (120 doses), CFC-free<br>formulation    | ± 1         | 5              | ..      | 46.77                                    | 31.30                                                  | Seretide MDI 50/<br>25               | GK |
| 8518H                                                                                                                                                                                                                                       | Oral pressurised inhalation<br>125 micrograms-25 micrograms<br>(base) per dose (120 doses), CFC-free<br>formulation   | ± 1         | 5              | ..      | 58.88                                    | 31.30                                                  | Seretide MDI 125/<br>25              | GK |
| 8430Q                                                                                                                                                                                                                                       | Powder for oral inhalation<br>in breath actuated device<br>100 micrograms-50 micrograms (base)<br>per dose (60 doses) | ± 1         | 5              | ..      | 46.77                                    | 31.30                                                  | Seretide Accuhaler<br>100/50         | GK |
| 8431R                                                                                                                                                                                                                                       | Powder for oral inhalation<br>in breath actuated device<br>250 micrograms-50 micrograms (base)<br>per dose (60 doses) | ± 1         | 5              | ..      | 58.88                                    | 31.30                                                  | Seretide Accuhaler<br>250/50         | GK |

continued ➞

## RESPIRATORY SYSTEM—CONT.

| Code                                                                                                                                                                                                                                                             | Name, Restriction,<br>Manner of Administration and Form                                                               | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                                                                                                                                                                                                                                                                  |                                                                                                                       |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                                                 |                                                                                                                       |             |                |         |                             |                                             |                                      |    |
| <i>Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate;</i>                                          |                                                                                                                       |             |                |         |                             |                                             |                                      |    |
| <i>Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate;</i>                      |                                                                                                                       |             |                |         |                             |                                             |                                      |    |
| <i>Symptomatic treatment of chronic obstructive pulmonary disease (COPD), where the FEV1 is less than 50% predicted normal and there is a history of repeated exacerbations with significant symptoms despite regular beta-2 agonist bronchodilator therapy.</i> |                                                                                                                       |             |                |         |                             |                                             |                                      |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                                              |                                                                                                                       |             |                |         |                             |                                             |                                      |    |
| <i>Seretide is not indicated for the initiation of bronchodilator therapy in COPD.</i>                                                                                                                                                                           |                                                                                                                       |             |                |         |                             |                                             |                                      |    |
| 8519J                                                                                                                                                                                                                                                            | Oral pressurised inhalation<br>250 micrograms-25 micrograms<br>(base) per dose (120 doses), CFC-free<br>formulation   | ± 1         | 5              | ..      | 78.24                       | 31.30                                       | Seretide MDI 250/<br>25              | GK |
| 8432T                                                                                                                                                                                                                                                            | Powder for oral inhalation<br>in breath actuated device<br>500 micrograms-50 micrograms (base)<br>per dose (60 doses) | ± 1         | 5              | ..      | 78.24                       | 31.30                                       | Seretide Accuhaler<br>500/50         | GK |

### Other drugs for obstructive airway diseases, inhalants

#### • **Glucocorticoids**

##### BECLOMETHASONE DIPROPIONATE

|       |                                                                                             |     |   |    |       |       |          |    |
|-------|---------------------------------------------------------------------------------------------|-----|---|----|-------|-------|----------|----|
| 8406K | Oral pressurised inhalation<br>50 micrograms per dose (200 doses),<br>CFC-free formulation  | ± 1 | 5 | .. | 18.86 | 19.89 | Qvar 50  | IA |
| 8407L | Oral pressurised inhalation<br>100 micrograms per dose (200 doses),<br>CFC-free formulation | ± 1 | 5 | .. | 33.03 | 31.30 | Qvar 100 | IA |

##### BECLOMETHASONE DIPROPIONATE

#### **Restricted Benefit**

*Patients unable to achieve co-ordinated use of other metered dose inhalers containing this drug.*

|       |                                                                                                                          |     |   |    |       |       |                       |    |
|-------|--------------------------------------------------------------------------------------------------------------------------|-----|---|----|-------|-------|-----------------------|----|
| 8408M | Oral pressurised inhalation in breath<br>actuated device 50 micrograms<br>per dose (200 doses), CFC-free<br>formulation  | ± 1 | 5 | .. | 27.44 | 28.47 | Qvar 50 Autohaler     | IA |
| 8409N | Oral pressurised inhalation in breath<br>actuated device 100 micrograms<br>per dose (200 doses), CFC-free<br>formulation | ± 1 | 5 | .. | 38.70 | 31.30 | Qvar 100<br>Autohaler | IA |



## RESPIRATORY SYSTEM—CONT.

| Code                                                                                                                                             | Name, Restriction,<br>Manner of Administration and Form                                  | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |           |
|--------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|-----------|
| <b>BUDESONIDE</b>                                                                                                                                |                                                                                          |             |                |         |                                          |                                                        |                                      |           |
| 2070Y                                                                                                                                            | Powder for oral inhalation in breath actuated device 100 micrograms per dose (200 doses) | ‡ 1         | 5              | ..      | 22.91                                    | 23.94                                                  | Pulmicort Turbuhaler                 | AP        |
| 2071B                                                                                                                                            | Powder for oral inhalation in breath actuated device 200 micrograms per dose (200 doses) | ‡ 1         | 5              | ..      | 30.65                                    | 31.30                                                  | Pulmicort Turbuhaler                 | AP        |
| 2072C                                                                                                                                            | Powder for oral inhalation in breath actuated device 400 micrograms per dose (200 doses) | ‡ 1         | 5              | ..      | 45.41                                    | 31.30                                                  | Pulmicort Turbuhaler                 | AP        |
| <hr/>                                                                                                                                            |                                                                                          |             |                |         |                                          |                                                        |                                      |           |
| <b>BUDESONIDE</b>                                                                                                                                |                                                                                          |             |                |         |                                          |                                                        |                                      |           |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                                                                   |                                                                                          |             |                |         |                                          |                                                        |                                      |           |
| <b>1351</b>                                                                                                                                      |                                                                                          |             |                |         |                                          |                                                        |                                      |           |
| <i>Severe chronic asthma in patients who require long-term steroid therapy and who are unable to use other forms of inhaled steroid therapy.</i> |                                                                                          |             |                |         |                                          |                                                        |                                      |           |
| 2065Q                                                                                                                                            | <i>Nebuliser suspension single dose units 500 micrograms in 2 mL, 30</i>                 | ‡ 1         | 5              | ..      | 37.43                                    | 31.30                                                  | <i>Pulmicort Respules</i>            | <i>AP</i> |
| 2066R                                                                                                                                            | <i>Nebuliser suspension single dose units 1 mg in 2 mL, 30</i>                           | ‡ 1         | 5              | ..      | 48.57                                    | 31.30                                                  | <i>Pulmicort Respules</i>            | <i>AP</i> |
| <b>CICLESONIDE</b>                                                                                                                               |                                                                                          |             |                |         |                                          |                                                        |                                      |           |
| 8853Y                                                                                                                                            | Oral pressurised inhalation 80 micrograms per dose (120 doses), CFC-free formulation     | ‡ 1         | 5              | ..      | 25.72                                    | 26.75                                                  | Alvesco 80                           | NQ        |
| 8854B                                                                                                                                            | Oral pressurised inhalation 160 micrograms per dose (120 doses), CFC-free formulation    | ‡ 1         | 5              | ..      | 41.82                                    | 31.30                                                  | Alvesco 160                          | NQ        |
| <b>FLUTICASONE PROPIONATE</b>                                                                                                                    |                                                                                          |             |                |         |                                          |                                                        |                                      |           |
| 8516F                                                                                                                                            | Oral pressurised inhalation 50 micrograms per dose (120 doses), CFC-free formulation     | ‡ 1         | 5              | ..      | 16.66                                    | 17.69                                                  | Flixotide Junior                     | GK        |
| 8345F                                                                                                                                            | Oral pressurised inhalation 125 micrograms per dose (120 doses), CFC-free formulation    | ‡ 1         | 5              | ..      | 30.23                                    | 31.26                                                  | Flixotide                            | GK        |
| 8346G                                                                                                                                            | Oral pressurised inhalation 250 micrograms per dose (120 doses), CFC-free formulation    | ‡ 1         | 1              | ..      | 49.29                                    | 31.30                                                  | Flixotide                            | GK        |

continued 

## RESPIRATORY SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form                                 | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|-----------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 8147T | Powder for oral inhalation in breath actuated device 100 micrograms per dose (60 doses) | ‡ 1         | 5              | ..      | 16.66                                    | 17.69                                                  | Flixotide Junior Accuhaler           | GK |
| 8148W | Powder for oral inhalation in breath actuated device 250 micrograms per dose (60 doses) | ‡ 1         | 5              | ..      | 30.23                                    | 31.26                                                  | Flixotide Accuhaler                  | GK |
| 8149X | Powder for oral inhalation in breath actuated device 500 micrograms per dose (60 doses) | ‡ 1         | 1              | ..      | 49.29                                    | 31.30                                                  | Flixotide Accuhaler                  | GK |

• **Anticholinergics**

## IPRATROPIUM BROMIDE

|       |                                                                                            |   |   |    |         |       |          |    |
|-------|--------------------------------------------------------------------------------------------|---|---|----|---------|-------|----------|----|
| 8671J | Oral pressurised inhalation<br>21 micrograms per dose (200 doses),<br>CFC-free formulation | 2 | 5 | .. | * 33.23 | 31.30 | Atrovent | BY |
|-------|--------------------------------------------------------------------------------------------|---|---|----|---------|-------|----------|----|

**IPRATROPIUM BROMIDE****Restricted Benefit***Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer;**Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer.*

|       |                                                                                   |   |   |    |         |       |                                                                                                                                                                                                                                                                                       |                                              |
|-------|-----------------------------------------------------------------------------------|---|---|----|---------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| 1542E | Nebuliser solution single dose units<br>250 micrograms (anhydrous) in 1 mL,<br>30 | 2 | 5 | .. | * 36.85 | 31.30 | <sup>a</sup> Aeron 250<br><sup>a</sup> Apoven 250<br><sup>a</sup> Chem mart<br>Ipratropium<br><sup>a</sup> GenRx<br>Ipratropium<br><sup>a</sup> Ipratrin<br><sup>a</sup> Ipravent<br><sup>a</sup> Terry White<br>Chemists<br>Ipratropium<br>b0.72 * 37.57 31.30 <sup>a</sup> Atrovent | AW<br>GM<br>CH<br>GX<br>AF<br>PU<br>TW<br>BY |
|-------|-----------------------------------------------------------------------------------|---|---|----|---------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|

continued ➞

## RESPIRATORY SYSTEM—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form                           | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                                                           |                                        |
|-------|-----------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| 8238N | Nebuliser solution single dose units<br>500 micrograms (anhydrous) in 1 mL,<br>30 | 2           | 5              | ..      | * 42.21                                  | 31.30                                                  | <sup>a</sup> Aeron 500<br><sup>a</sup> Apoven 500<br><sup>a</sup> Chem mart<br>Ipratropium<br><sup>a</sup> GenRx<br>Ipratropium<br><sup>a</sup> Ipratrin Adult<br><sup>a</sup> Ipravent<br><sup>a</sup> Terry White<br>Chemists<br>Ipratropium | AW<br>GM<br>CH<br>GX<br>AF<br>PU<br>TW |
|       |                                                                                   |             |                | B0.62   | * 42.83                                  | 31.30                                                  | <sup>a</sup> Atrovent Adult                                                                                                                                                                                                                    | BY                                     |

**TIOTROPIUM BROMIDE MONOHYDRATE****Restricted Benefit**

*For the long-term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease.*

|       |                                                                                                  |    |   |    |       |       |         |    |
|-------|--------------------------------------------------------------------------------------------------|----|---|----|-------|-------|---------|----|
| 8626B | Capsule containing powder for oral<br>inhalation 18 micrograms (base) (for<br>use in HandiHaler) | 30 | 5 | .. | 76.46 | 31.30 | Spiriva | BY |
|-------|--------------------------------------------------------------------------------------------------|----|---|----|-------|-------|---------|----|

• **Antiallergic agents, excl. corticosteroids**  
NEDOCROMIL SODIUM

|       |                                                                                |     |   |    |       |       |                 |    |
|-------|--------------------------------------------------------------------------------|-----|---|----|-------|-------|-----------------|----|
| 8365G | Oral pressurised inhalation 2 mg per dose<br>(112 doses), CFC-free formulation | ‡ 1 | 5 | .. | 35.28 | 31.30 | Tilade CFC-Free | SW |
|-------|--------------------------------------------------------------------------------|-----|---|----|-------|-------|-----------------|----|

## SODIUM CROMOGLYCATe

|       |                                                                                                            |     |   |    |       |       |                      |    |
|-------|------------------------------------------------------------------------------------------------------------|-----|---|----|-------|-------|----------------------|----|
| 2878L | Capsule containing powder for oral<br>inhalation 20 mg (for use in Intal<br>Spinhaler or Intal Halermatic) | 100 | 5 | .. | 32.53 | 31.30 | Intal SpinCaps       | GM |
| 2872E | Oral pressurised inhalation 1 mg per dose<br>(200 doses)                                                   | ‡ 1 | 5 | .. | 29.15 | 30.18 | Intal                | SW |
| 8767K | Oral pressurised inhalation 1 mg per dose<br>(200 doses), CFC-free formulation                             | ‡ 1 | 5 | .. | 29.15 | 30.18 | Intal CFC-Free       | SW |
| 8334P | Oral pressurised inhalation 5 mg per dose<br>(112 doses), CFC-free formulation                             | ‡ 1 | 5 | .. | 34.69 | 31.30 | Intal Forte CFC-Free | SW |

**Adrenergics for systemic use**

• **Alpha- and beta-adrenoceptor agonists**  
ADRENALINE

|       |                                     |   |   |    |       |       |    |  |
|-------|-------------------------------------|---|---|----|-------|-------|----|--|
| 1016L | Injection 1 mg in 1 mL (1 in 1,000) | 5 | 1 | .. | 19.91 | 20.94 | AP |  |
|-------|-------------------------------------|---|---|----|-------|-------|----|--|

continued ➞

## RESPIRATORY SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

### ADRENALINE

#### Authority Required

*Initial supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient who:*  
 (a) *has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician. The name of the specialist consulted must be provided at the time of application for initial supply; or*

(b) *has been discharged from hospital or an emergency department after treatment with adrenaline for acute allergic reaction with anaphylaxis;*

*Continuing supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis, where the patient has previously been issued with an authority prescription for this drug.*

#### NOTE:

*The auto-injector should be provided in the framework of a comprehensive anaphylaxis prevention program and an emergency action plan including training in recognition of the symptoms of anaphylaxis and the use of the auto-injector device. (For further information see the Australasian Society of Clinical Immunology and Allergy website at [www.allergy.org.au](http://www.allergy.org.au).)*

|       |                                                                              |   |    |    |        |       |            |    |
|-------|------------------------------------------------------------------------------|---|----|----|--------|-------|------------|----|
| 8697R | I.M. injection 150 micrograms in 0.3 mL<br>single dose syringe auto-injector | 1 | .. | .. | 105.57 | 31.30 | EpiPen Jr. | CS |
| 8698T | I.M. injection 300 micrograms in 0.3 mL<br>single dose syringe auto-injector | 1 | .. | .. | 105.57 | 31.30 | EpiPen     | CS |

#### NOTE:

*Authorities for increased maximum quantities, up to a maximum of 2, may be authorised for children aged less than 17 years where 2 auto-injectors are necessary to ensure 1 is on hand at all times. No increased maximum quantities will be authorised for patients aged 17 years or older.*

*No repeats will be issued.*

#### • Selective beta-2-adrenoceptor agonists

##### SALBUTAMOL SULFATE

|       |                                    |   |   |    |         |       |          |    |
|-------|------------------------------------|---|---|----|---------|-------|----------|----|
| 1103C | Syrup 2 mg (base) per 5 mL, 150 mL | 2 | 5 | .. | * 21.77 | 22.80 | Ventolin | GK |
|-------|------------------------------------|---|---|----|---------|-------|----------|----|

##### TERBUTALINE SULFATE

|       |                                  |   |    |    |       |       |          |    |
|-------|----------------------------------|---|----|----|-------|-------|----------|----|
| 1034K | Injection 500 micrograms in 1 mL | 5 | .. | .. | 30.16 | 31.19 | Bricanyl | AP |
|-------|----------------------------------|---|----|----|-------|-------|----------|----|

### Other systemic drugs for obstructive airway diseases

#### • Xanthines

##### THEOPHYLLINE

#### CAUTION:

Because of variable effects of food on absorption of sustained release theophylline preparations, patients stabilised on one brand should not be changed to another without appropriate monitoring.

|       |                                   |     |   |    |       |       |               |    |
|-------|-----------------------------------|-----|---|----|-------|-------|---------------|----|
| 8230E | Tablet 200 mg (sustained release) | 100 | 5 | .. | 11.73 | 12.76 | Nuelin-SR 200 | IA |
| 2634P | Tablet 250 mg (sustained release) | 100 | 5 | .. | 12.89 | 13.92 | Nuelin-SR 250 | IA |
| 8231F | Tablet 300 mg (sustained release) | 100 | 5 | .. | 14.27 | 15.30 | Nuelin-SR 300 | IA |
| 2614N | Syrup 133.3 mg per 25 mL, 500 mL  | ‡ 1 | 5 | .. | 10.39 | 11.42 | Nuelin        | IA |

## RESPIRATORY SYSTEM—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### • **Leukotriene receptor antagonists**

#### **MONTELUKAST SODIUM**

##### **NOTE:**

*Montelukast sodium is not PBS-subsidised for use in children with moderate or severe asthma. It is not intended as an alternative for children who require a corticosteroid as a preventer medication. Montelukast sodium is not PBS-subsidised for use in combination with other preventer medications. PBS subsidy for montelukast sodium will therefore cease for patients who require a preventer medication in addition to montelukast sodium.*

##### **NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*

#### **Authority Required (STREAMLINED)**

2617

*First-line preventer medication, as the single preventer agent for children aged 2 to 5 years with frequent intermittent or mild persistent asthma, as an alternative to sodium cromoglycate or nedocromil sodium.*

|       |                             |    |   |    |       |       |           |    |
|-------|-----------------------------|----|---|----|-------|-------|-----------|----|
| 8627C | Chewable tablet 4 mg (base) | 28 | 5 | .. | 47.50 | 31.30 | Singulair | MK |
|-------|-----------------------------|----|---|----|-------|-------|-----------|----|

#### **Authority Required (STREAMLINED)**

2618

*First-line preventer medication, as the single preventer agent for children aged 6 to 14 years with frequent intermittent or mild persistent asthma, as an alternative to sodium cromoglycate or nedocromil sodium.*

|       |                             |    |   |    |       |       |           |    |
|-------|-----------------------------|----|---|----|-------|-------|-----------|----|
| 8628D | Chewable tablet 5 mg (base) | 28 | 5 | .. | 47.50 | 31.30 | Singulair | MK |
|-------|-----------------------------|----|---|----|-------|-------|-----------|----|

### COUGH AND COLD PREPARATIONS

#### **Expectorants, excl. combinations with cough suppressants**

### • **Mucolytics**

#### **ACETYLCYSTEINE**

##### **Restricted Benefit**

*Bronchiectasis;*

*Cystic fibrosis.*

|       |                                                       |    |   |    |          |       |          |    |
|-------|-------------------------------------------------------|----|---|----|----------|-------|----------|----|
| 8747J | Sterile inhalation solution 200 mg per mL (20%), 5 mL | 30 | 3 | .. | * 146.54 | 31.30 | Mucomyst | BQ |
|-------|-------------------------------------------------------|----|---|----|----------|-------|----------|----|

#### **Cough suppressants, excl. combinations with expectorants**

### • **Opium alkaloids and derivatives**

#### **CODEINE PHOSPHATE**

|       |              |    |    |    |       |       |    |  |
|-------|--------------|----|----|----|-------|-------|----|--|
| 1214X | Tablet 30 mg | 20 | .. | .. | 16.44 | 17.47 | FM |  |
|-------|--------------|----|----|----|-------|-------|----|--|

### ANTI-HISTAMINES FOR SYSTEMIC USE

#### **Antihistamines for systemic use**

### • **Phenothiazine derivatives**

#### **PROMETHAZINE HYDROCHLORIDE**

|       |                         |    |    |    |         |       |    |  |
|-------|-------------------------|----|----|----|---------|-------|----|--|
| 1948M | Injection 50 mg in 2 mL | 10 | .. | .. | * 21.89 | 22.92 | HH |  |
|-------|-------------------------|----|----|----|---------|-------|----|--|

## SENSORY ORGANS

| Code                                                                                       | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |          |
|--------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----------|
| <b>OPHTHALMOLOGICALS</b>                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <b>Antiinfectives</b>                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |          |
| • <b>Antibiotics</b>                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <b>AZITHROMYCIN</b>                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <b><u>Restricted Benefit</u></b>                                                           |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <i>Trachoma.</i>                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <b><u>NOTE:</u></b>                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i> |                                                         |             |                |         |                                          |                                                        |                                      |          |
| 8336R                                                                                      | Tablet 500 mg                                           | 2           | 2              | ..      | 23.46                                    | 24.49                                                  | Zithromax                            | PF       |
| 8201P                                                                                      | Powder for oral suspension 200 mg per 5 mL, 15 mL       | ‡ 1         | ..             | ..      | # 22.98                                  | 24.37                                                  | Zithromax                            | PF       |
| <b>CHLORAMPHENICOL</b>                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |          |
| 2360F                                                                                      | Eye drops 5 mg per mL (0.5%), 10 mL                     | ‡ 1         | 2              | ..      | 8.88                                     | 9.91                                                   | Chloromycetin<br>Chlorsig            | PF<br>SI |
| 1171P                                                                                      | Eye ointment 10 mg per g (1%), 4 g                      | ‡ 1         | ..             | ..      | 9.33                                     | 10.36                                                  | Chloromycetin<br>Chlorsig            | PF<br>SI |
| <b>GENTAMICIN SULFATE</b>                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <b><u>Restricted Benefit</u></b>                                                           |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <i>Invasive ocular infection;</i>                                                          |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <i>Perioperative use in ophthalmic surgery;</i>                                            |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <i>Suspected pseudomonal eye infection.</i>                                                |                                                         |             |                |         |                                          |                                                        |                                      |          |
| 1441W                                                                                      | Eye drops 3 mg (base) per mL (0.3%), 5 mL               | ‡ 1         | 2              | ..      | 18.59                                    | 19.62                                                  | Genoptic                             | AG       |
| <b>TOBRAMYCIN</b>                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <b><u>Restricted Benefit</u></b>                                                           |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <i>Invasive ocular infection;</i>                                                          |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <i>Perioperative use in ophthalmic surgery;</i>                                            |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <i>Suspected pseudomonal eye infection.</i>                                                |                                                         |             |                |         |                                          |                                                        |                                      |          |
| 2328M                                                                                      | Eye drops 3 mg per mL (0.3%), 5 mL                      | ‡ 1         | 2              | ..      | 18.85                                    | 19.88                                                  | Tobrex                               | AQ       |
| 2329N                                                                                      | Eye ointment 3 mg per g (0.3%), 3.5 g                   | ‡ 1         | ..             | ..      | 21.58                                    | 22.61                                                  | Tobrex                               | AQ       |
| • <b>Sulfonamides</b>                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |          |
| <b>SULFACETAMIDE SODIUM</b>                                                                |                                                         |             |                |         |                                          |                                                        |                                      |          |
| 2063N                                                                                      | Eye drops 100 mg per mL (10%), 15 mL                    | ‡ 1         | 2              | ..      | 13.35                                    | 14.38                                                  | Bleph 10                             | AG       |

## SENSORY ORGANS—CONT.

| Code                                                                                                              | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |          |
|-------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----------|
| <b>• Antivirals</b><br><b>ACICLOVIR</b><br><u>Restricted Benefit</u><br><i>Herpes simplex keratitis.</i>          |                                                         |             |                |         |                                          |                                                        |                                      |          |
| 1002R                                                                                                             | Eye ointment 30 mg per g (3%), 4.5 g                    | ‡ 1         | ..             | ..      | 27.47                                    | 28.50                                                  | Zovirax                              | GK       |
| <b>• Other antiinfectives</b><br><b>CIPROFLOXACIN</b><br><u>Authority Required</u><br><i>Bacterial keratitis.</i> |                                                         |             |                |         |                                          |                                                        |                                      |          |
| 1217C                                                                                                             | Eye drops 3 mg per mL (0.3%), 5 mL                      | 2           | ..             | ..      | * 25.91                                  | 26.94                                                  | <sup>a</sup> CiloQuin                | IQ       |
|                                                                                                                   |                                                         |             |                | B1.84   | * 27.75                                  | 26.94                                                  | <sup>a</sup> Ciloxan                 | AQ       |
| <b>OFLOXACIN</b><br><u>Authority Required</u><br><i>Bacterial keratitis.</i>                                      |                                                         |             |                |         |                                          |                                                        |                                      |          |
| 8383F                                                                                                             | Eye drops 3 mg per mL (0.3%), 5 mL                      | 2           | ..             | ..      | * 31.71                                  | 31.30                                                  | Ocuflox                              | AG       |
| <b>Antiinflammatory agents</b><br><b>• Corticosteroids, plain</b><br><b>DEXAMETHASONE</b>                         |                                                         |             |                |         |                                          |                                                        |                                      |          |
| 1288T                                                                                                             | Eye drops 1 mg per mL (0.1%), 5 mL                      | ‡ 1         | 2              | ..      | 10.18                                    | 11.21                                                  | Maxidex                              | AQ       |
| <b>FLUOROMETHOLONE</b>                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |          |
| 1204J                                                                                                             | Eye drops 1 mg per mL (0.1%), 5 mL                      | ‡ 1         | 5              | ..      | 10.18                                    | 11.21                                                  | Flucon<br>FML Liquifilm              | AQ<br>AG |
| <b>FLUOROMETHOLONE ACETATE</b>                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |          |
| 1438Q                                                                                                             | Eye drops 1 mg per mL (0.1%), 5 mL                      | ‡ 1         | 2              | ..      | 10.18                                    | 11.21                                                  | Flarex                               | AQ       |
| <b>HYDROCORTISONE ACETATE</b>                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |          |
| 1497T                                                                                                             | Eye ointment 5 mg per g (0.5%), 5 g                     | ‡ 1         | ..             | ..      | 11.35                                    | 12.38                                                  | Hycor                                | SI       |
| 2441L                                                                                                             | Eye ointment 10 mg per g (1%), 5 g                      | ‡ 1         | ..             | ..      | 12.65                                    | 13.68                                                  | Hycor                                | SI       |

## SENSORY ORGANS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                    | Name, Restriction,<br>Manner of Administration and Form                 | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                               |                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------------|----------------|
| <b>• Corticosteroids and mydriatics in combination</b><br><b>PREDNISOLONE ACETATE with PHENYLEPHRINE</b><br><b>HYDROCHLORIDE</b><br><u>Restricted Benefit</u><br><i>Corneal grafts;</i><br><i>Uveitis.</i>                                                                                                                                                                                              |                                                                         |             |                |             |                                          |                                                        |                                                                    |                |
| 3112T                                                                                                                                                                                                                                                                                                                                                                                                   | Eye drops 10 mg-1.2 mg per mL<br>(1%-0.12%), 10 mL                      | ‡ 1         | 2              | ..          | 21.53                                    | 22.56                                                  | Prednefrin Forte                                                   | AG             |
| <b>• Antiinflammatory agents, non-steroids</b><br><b>FLURBIPROFEN SODIUM</b>                                                                                                                                                                                                                                                                                                                            |                                                                         |             |                |             |                                          |                                                        |                                                                    |                |
| 8699W                                                                                                                                                                                                                                                                                                                                                                                                   | Eye drops 300 micrograms per mL<br>(0.03%), single dose units 0.4 mL, 5 | 1           | ..             | ..          | 14.94                                    | 15.97                                                  | Ocufen                                                             | AG             |
| <b>Antiglaucoma preparations and miotics</b><br><b>• Sympathomimetics in glaucoma therapy</b><br><b>APRACLONIDINE HYDROCHLORIDE</b><br><u>Restricted Benefit</u><br><i>Short-term reduction of intra-ocular pressure in patients already on maximally tolerated anti-glaucoma therapy.</i>                                                                                                              |                                                                         |             |                |             |                                          |                                                        |                                                                    |                |
| 8083K                                                                                                                                                                                                                                                                                                                                                                                                   | Eye drops 5 mg (base) per mL (0.5%),<br>10 mL                           | ‡ 1         | 2              | ..          | 39.79                                    | 31.30                                                  | Iopidine 0.5%                                                      | AQ             |
| <b>BRIMONIDINE TARTRATE</b>                                                                                                                                                                                                                                                                                                                                                                             |                                                                         |             |                |             |                                          |                                                        |                                                                    |                |
| 8351M                                                                                                                                                                                                                                                                                                                                                                                                   | Eye drops 2 mg per mL (0.2%), 5 mL                                      | ‡ 1         | 5              | ..<br>B1.74 | 20.56<br>22.30                           | 21.59<br>21.59                                         | <sup>a</sup> Enidin<br><sup>a</sup> Alphagan                       | PE<br>AG       |
| <b>BRIMONIDINE TARTRATE with TIMOLOL MALEATE</b>                                                                                                                                                                                                                                                                                                                                                        |                                                                         |             |                |             |                                          |                                                        |                                                                    |                |
| <u>Restricted Benefit</u><br><i>Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops;</i><br><i>Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops.</i> |                                                                         |             |                |             |                                          |                                                        |                                                                    |                |
| 8826M                                                                                                                                                                                                                                                                                                                                                                                                   | Eye drops 2 mg-5 mg (base) per mL<br>(0.2%-0.5%), 5 mL                  | ‡ 1         | 5              | ..          | 26.76                                    | 27.79                                                  | Combigan                                                           | AG             |
| <b>• Parasympathomimetics</b><br><b>PILOCARPINE HYDROCHLORIDE</b>                                                                                                                                                                                                                                                                                                                                       |                                                                         |             |                |             |                                          |                                                        |                                                                    |                |
| 2595N                                                                                                                                                                                                                                                                                                                                                                                                   | Eye drops 10 mg per mL (1%), 15 mL                                      | ‡ 1         | 5              | ..<br>B2.97 | 12.48<br>12.48<br>15.45                  | 13.51<br>13.51<br>13.51                                | Isopto Carpine<br><sup>a</sup> Pilopt<br><sup>a</sup> P.V. Carpine | AQ<br>PE<br>AG |

continued ➞



## SENSORY ORGANS—CONT.

| Code                                                                                                                                                                                    | Name, Restriction,<br>Manner of Administration and Form      | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 2596P                                                                                                                                                                                   | Eye drops 20 mg per mL (2%), 15 mL                           | ‡ 1         | 5              | ..      | 13.81                                    | 14.84                                                  | Isopto Carpine                       | AQ |
|                                                                                                                                                                                         |                                                              |             |                | ..      | 13.81                                    | 14.84                                                  | <sup>a</sup> Pilopt                  | PE |
|                                                                                                                                                                                         |                                                              |             |                | B2.96   | 16.77                                    | 14.84                                                  | <sup>a</sup> P.V. Carpine            | AG |
| 2598R                                                                                                                                                                                   | Eye drops 40 mg per mL (4%), 15 mL                           | ‡ 1         | 5              | ..      | 16.83                                    | 17.86                                                  | Isopto Carpine                       | AQ |
|                                                                                                                                                                                         |                                                              |             |                | ..      | 16.83                                    | 17.86                                                  | <sup>a</sup> Pilopt                  | PE |
|                                                                                                                                                                                         |                                                              |             |                | B2.83   | 19.66                                    | 17.86                                                  | <sup>a</sup> P.V. Carpine            | AG |
| 2779G                                                                                                                                                                                   | Eye drops 60 mg per mL (6%), 15 mL                           | ‡ 1         | 5              | ..      | 21.61                                    | 22.64                                                  | <sup>a</sup> Pilopt                  | PE |
|                                                                                                                                                                                         |                                                              |             |                | B2.86   | 24.47                                    | 22.64                                                  | <sup>a</sup> P.V. Carpine            | AG |
| <b>• Carbonic anhydrase inhibitors</b>                                                                                                                                                  |                                                              |             |                |         |                                          |                                                        |                                      |    |
| ACETAZOLAMIDE                                                                                                                                                                           |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 1004W                                                                                                                                                                                   | Tablet 250 mg                                                | 100         | 3              | ..      | 23.36                                    | 24.39                                                  | Diamox                               | SI |
| BRINZOLAMIDE                                                                                                                                                                            |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 8483L                                                                                                                                                                                   | Eye drops 10 mg per mL (1%), 5 mL                            | ‡ 1         | 5              | ..      | 21.27                                    | 22.30                                                  | <sup>a</sup> BrinzoQuin              | IQ |
|                                                                                                                                                                                         |                                                              |             |                | B1.03   | 22.30                                    | 22.30                                                  | <sup>a</sup> Azopt                   | AQ |
| DORZOLAMIDE HYDROCHLORIDE                                                                                                                                                               |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 8488R                                                                                                                                                                                   | Eye drops 20 mg (base) per mL (2%),<br>5 mL                  | ‡ 1         | 5              | ..      | 20.86                                    | 21.89                                                  | Trusopt                              | MK |
| <b>DORZOLAMIDE HYDROCHLORIDE with TIMOLOL<br/>MALEATE</b>                                                                                                                               |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                        |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <i>Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled<br/>with timolol maleate 5 mg (base) per mL (0.5%) eye drops;</i> |                                                              |             |                |         |                                          |                                                        |                                      |    |
| <i>Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled<br/>with timolol maleate 5 mg (base) per mL (0.5%) eye drops.</i> |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 8567X                                                                                                                                                                                   | Eye drops 20 mg (base)-5 mg (base) per<br>mL (2%-0.5%), 5 mL | ‡ 1         | 5              | ..      | 27.06                                    | 28.09                                                  | Cosopt                               | MK |
| <b>• Beta blocking agents</b>                                                                                                                                                           |                                                              |             |                |         |                                          |                                                        |                                      |    |
| BETAXOLOL HYDROCHLORIDE                                                                                                                                                                 |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 2811Y                                                                                                                                                                                   | Eye drops, suspension, 2.5 mg (base) per<br>mL (0.25%), 5 mL | ‡ 1         | 5              | ..      | 14.10                                    | 15.13                                                  | Betoptic S                           | AQ |
| 2825Q                                                                                                                                                                                   | Eye drops, solution, 5 mg (base) per mL<br>(0.5%), 5 mL      | ‡ 1         | 5              | ..      | 14.10                                    | 15.13                                                  | <sup>a</sup> BetoQuin                | IQ |
|                                                                                                                                                                                         |                                                              |             |                | B1.99   | 16.09                                    | 15.13                                                  | <sup>a</sup> Betoptic                | AQ |
| LEVOBUNOLOL HYDROCHLORIDE                                                                                                                                                               |                                                              |             |                |         |                                          |                                                        |                                      |    |
| 1819R                                                                                                                                                                                   | Eye drops 2.5 mg per mL (0.25%), 5 mL                        | ‡ 1         | 5              | ..      | 13.17                                    | 14.20                                                  | Betagan                              | AG |

## SENSORY ORGANS—CONT.

| Code                                                                                                                                                                                                                                 | Name, Restriction,<br>Manner of Administration and Form                 | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----------|
| <b>TIMOLOL MALEATE</b>                                                                                                                                                                                                               |                                                                         |             |                |             |                                          |                                                        |                                      |          |
| 8803H                                                                                                                                                                                                                                | Eye gel 1 mg (base) per g (0.1%), 5 g                                   | ‡ 1         | 5              | ..          | 11.37                                    | 12.40                                                  | Nyogel                               | NV       |
| 1278G                                                                                                                                                                                                                                | Eye drops 2.5 mg (base) per mL (0.25%),<br>5 mL                         | ‡ 1         | 5              | ..<br>B1.18 | 11.37<br>12.55                           | 12.40 <sup>a</sup><br>12.40 <sup>a</sup>               | Tenopt<br>Timoptol                   | SI<br>FR |
| 1279H                                                                                                                                                                                                                                | Eye drops 5 mg (base) per mL (0.5%),<br>5 mL                            | ‡ 1         | 5              | ..<br>B1.17 | 12.19<br>13.36                           | 13.22 <sup>a</sup><br>13.22 <sup>a</sup>               | Tenopt<br>Timoptol                   | SI<br>FR |
| 1925H                                                                                                                                                                                                                                | Eye drops (gellan gum solution) 2.5 mg<br>(base) per mL (0.25%), 2.5 mL | ‡ 1         | 5              | ..          | 11.37                                    | 12.40                                                  | Timoptol XE                          | MK       |
| 1926J                                                                                                                                                                                                                                | Eye drops (gellan gum solution) 5 mg<br>(base) per mL (0.5%), 2.5 mL    | ‡ 1         | 5              | ..          | 12.19                                    | 13.22                                                  | Timoptol XE                          | MK       |
| <b>• Prostaglandin analogues</b>                                                                                                                                                                                                     |                                                                         |             |                |             |                                          |                                                        |                                      |          |
| <b>BIMATOPROST</b>                                                                                                                                                                                                                   |                                                                         |             |                |             |                                          |                                                        |                                      |          |
| 8620Q                                                                                                                                                                                                                                | Eye drops 300 micrograms per mL<br>(0.03%), 3 mL                        | ‡ 1         | 5              | ..          | 38.62                                    | 31.30                                                  | Lumigan                              | AG       |
| <b>LATANOPROST</b>                                                                                                                                                                                                                   |                                                                         |             |                |             |                                          |                                                        |                                      |          |
| 8243W                                                                                                                                                                                                                                | Eye drops 50 micrograms per mL<br>(0.005%), 2.5 mL                      | ‡ 1         | 5              | ..          | 38.62                                    | 31.30                                                  | Xalatan                              | PU       |
| <b>LATANOPROST with TIMOLOL MALEATE</b>                                                                                                                                                                                              |                                                                         |             |                |             |                                          |                                                        |                                      |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                     |                                                                         |             |                |             |                                          |                                                        |                                      |          |
| <i>Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or latanoprost eye drops;</i>                         |                                                                         |             |                |             |                                          |                                                        |                                      |          |
| <i>Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or latanoprost eye drops.</i>                         |                                                                         |             |                |             |                                          |                                                        |                                      |          |
| 8895E                                                                                                                                                                                                                                | Eye drops 50 micrograms-5 mg (base)<br>per mL (0.005%-0.5%), 2.5 mL     | ‡ 1         | 5              | ..          | 43.54                                    | 31.30                                                  | Xalacom                              | PF       |
| <b>TRAVOPROST</b>                                                                                                                                                                                                                    |                                                                         |             |                |             |                                          |                                                        |                                      |          |
| 8597L                                                                                                                                                                                                                                | Eye drops 40 micrograms per mL<br>(0.004%), 2.5 mL                      | ‡ 1         | 5              | ..          | 38.62                                    | 31.30                                                  | Travatan                             | AQ       |
| <b>TRAVOPROST with TIMOLOL MALEATE</b>                                                                                                                                                                                               |                                                                         |             |                |             |                                          |                                                        |                                      |          |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                                                     |                                                                         |             |                |             |                                          |                                                        |                                      |          |
| <i>Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or latanoprost eye drops or travoprost eye drops;</i> |                                                                         |             |                |             |                                          |                                                        |                                      |          |
| <i>Reduction of elevated intra-ocular pressure in patients with ocular hypertension who are not adequately controlled with timolol maleate 5 mg (base) per mL (0.5%) eye drops or latanoprost eye drops or travoprost eye drops.</i> |                                                                         |             |                |             |                                          |                                                        |                                      |          |
| 9057Q                                                                                                                                                                                                                                | Eye drops 40 micrograms-5 mg (base)<br>per mL (0.004%-0.5%), 2.5 mL     | ‡ 1         | 5              | ..          | 43.54                                    | 31.30                                                  | Duotrav                              | AQ       |

## SENSORY ORGANS—CONT.

| Code                                   | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer           |          |
|----------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------------|----------|
| <b>Mydriatics and cycloplegics</b>     |                                                         |             |                |         |                                          |                                                        |                                                |          |
| • <b>Anticholinergics</b>              |                                                         |             |                |         |                                          |                                                        |                                                |          |
| ATROPINE SULFATE                       |                                                         |             |                |         |                                          |                                                        |                                                |          |
| 1093M                                  | Eye drops 10 mg per mL (1%), 15 mL                      | ± 1         | 2              | ..      | 11.17                                    | 12.20                                                  | Atropt                                         | SI       |
| HOMATROPINE HYDROBROMIDE               |                                                         |             |                |         |                                          |                                                        |                                                |          |
| 2541R                                  | Eye drops 20 mg per mL (2%), 15 mL                      | ± 1         | 2              | ..      | 17.54                                    | 18.57                                                  | Isopto Homatropine                             | AQ       |
| <b>Decongestants and antiallergics</b> |                                                         |             |                |         |                                          |                                                        |                                                |          |
| • <b>Other antiallergics</b>           |                                                         |             |                |         |                                          |                                                        |                                                |          |
| SODIUM CROMOGLYCATE                    |                                                         |             |                |         |                                          |                                                        |                                                |          |
| <u><b>Restricted Benefit</b></u>       |                                                         |             |                |         |                                          |                                                        |                                                |          |
| Vernal kerato-conjunctivitis.          |                                                         |             |                |         |                                          |                                                        |                                                |          |
| 1127H                                  | Eye drops 20 mg per mL (2%), 10 mL                      | ± 1         | 5              | ..      | 14.26                                    | 15.29                                                  | <sup>a</sup> Cromolux<br><sup>a</sup> Opticrom | AE<br>SW |

### Ocular vascular disorder agents

#### • Antineovascularisation agents

##### ANECORTAVE ACETATE

##### Authority Required

*Initial treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), as diagnosed by fluorescein angiography, in a patient with a baseline visual acuity equal to or better than 6/60 (20/200).*

*No more than 10 treatments (1 initial and 9 continuing) per eye will be authorised.*

*Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.*

*The first authority application for each eye must be made in writing, and must include:*

*(a) a completed authority prescription form; and*

*(b) a completed Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form [www.medicareaustralia.gov.au]; and*

*(c) a copy of the fluorescein angiogram demonstrating that the CNV is predominantly classic (greater than or equal to 50%).*

*Written applications for authority to prescribe anecortave acetate should be forwarded to:*

**Medicare Australia**

**Prior Written Approval of Specialised Drugs**

**Reply Paid 9826**

**GPO Box 9826**

**HOBART TAS 7001.**

*Alternatively, the first authority application may be faxed to Medicare Australia on (03) 6215 5474 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Medicare Australia will then contact the prescriber by telephone. The original documentation must be posted to the above address after approval has been gained.*

continued ➡

## SENSORY ORGANS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### Authority Required

*Continuing treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD) where the patient has previously been granted an authority prescription for the same eye.*

*No more than 10 treatments (1 initial and 9 continuing) per eye will be authorised.*

*Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia. Authority applications for continuing treatment in the same eye may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

|       |                                          |   |    |    |         |       |         |    |
|-------|------------------------------------------|---|----|----|---------|-------|---------|----|
| 2514H | Suspension for injection 15 mg in 0.5 mL | 1 | .. | .. | 2015.93 | 31.30 | Retaane | AQ |
|-------|------------------------------------------|---|----|----|---------|-------|---------|----|

### **RANIBIZUMAB**

### Authority Required

*Initial treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), as diagnosed by fluorescein angiography.*

*Where a fluorescein angiogram cannot be performed due to a contraindication as listed in the TGA-approved product information, details of the contraindication must be provided. A copy of the report of an alternative method of diagnosis must be included in the application, for example, optical coherence tomography (OCT) or red free photography.*

*Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.*

*The first authority application for each eye must be made in writing, and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form [www.medicareaustralia.gov.au]; and*
- (c) a copy of the fluorescein angiogram or alternative method of diagnosis where applicable.*

*Written applications for authority to prescribe ranibizumab should be forwarded to:*

*Medicare Australia*

*Prior Written Approval of Specialised Drugs*

*Reply Paid 9826*

*GPO Box 9826*

*HOBART TAS 7001.*

*Alternatively, the first authority application may be faxed to Medicare Australia on (03) 6215 5474 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Medicare Australia will then contact the prescriber by telephone. The original documentation must be posted to the above address after approval has been gained.*

### Authority Required

*Continuing treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD) where the patient has previously been granted an authority prescription for the same eye.*

*Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia. Authority applications for continuing treatment in the same eye may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

|       |                                                    |   |   |    |         |       |          |    |
|-------|----------------------------------------------------|---|---|----|---------|-------|----------|----|
| 1382R | Solution for intravitreal injection 3 mg in 0.3 mL | 1 | 2 | .. | 1975.93 | 31.30 | Lucentis | NV |
|-------|----------------------------------------------------|---|---|----|---------|-------|----------|----|

## SENSORY ORGANS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### VERTEPORFIN

#### **Authority Required**

*Initial treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), as diagnosed by fluorescein angiography, in a patient with a baseline visual acuity equal to or better than 6/60 (20/200).*

*Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.*

*The first authority application for each eye must be made in writing, and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form [www.medicareaustralia.gov.au]; and*
- (c) a copy of the fluorescein angiogram demonstrating that the CNV is predominantly classic (greater than or equal to 50%).*

*Written applications for authority to prescribe verteporfin should be forwarded to:*

**Medicare Australia**

**Prior Written Approval of Specialised Drugs**

**Reply Paid 9826**

**GPO Box 9826**

**HOBART TAS 7001.**

*Alternatively, the first authority application may be faxed to Medicare Australia on (03) 6215 5474 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Medicare Australia will then contact the prescriber by telephone. The original documentation must be posted to the above address after approval has been gained.*

*No more than 15 treatments (1 initial and 14 continuing) per eye will be authorised.*

*Medicare Australia should be notified if treatment is abandoned prior to completion of the laser activation step but after infusion of verteporfin. Telephone 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). The reason treatment is abandoned must be provided. Where such notification has been made, the treatment so affected will not count towards the maximum.*

#### **Authority Required**

*Initial PBS-subsidised treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to macular degeneration where the patient has been authorised by the Angiogram Review Panel to receive treatment with verteporfin in the same eye under the MBS Visudyne Therapy Program.*

*Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.*

*The first authority application for each eye must be made in writing, and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form [www.medicareaustralia.gov.au], which includes the date of review by the Angiogram Review Panel and the number of treatments administered in that eye under the MBS Visudyne Therapy Program; and*
- (c) a copy of the fluorescein angiogram demonstrating that the CNV is predominantly classic (greater than or equal to 50%).*

*Written applications for authority to prescribe verteporfin should be forwarded to:*

**Medicare Australia**

**Prior Written Approval of Specialised Drugs**

**Reply Paid 9826**

**GPO Box 9826**

**HOBART TAS 7001.**

## SENSORY ORGANS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Name, Restriction,<br>Manner of Administration and Form                  | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer  |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|---------------------------------------|----|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                          |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                       |    |
| <p><i>Alternatively, the first authority application may be faxed to Medicare Australia on (03) 6215 5474 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Medicare Australia will then contact the prescriber by telephone. The original documentation must be posted to the above address after approval has been gained.</i></p> <p><i>A patient is eligible for a total of 15 subsidised treatments per eye. This maximum includes treatments administered under the MBS Visudyne Therapy Program and the PBS.</i></p> <p><i>Medicare Australia should be notified if treatment is abandoned prior to completion of the laser activation step but after infusion of verteporfin. Telephone 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). The reason treatment is abandoned must be provided. Where such notification has been made, the treatment so affected will not count towards the maximum.</i></p>                                                                                                                                                                                                                                                                                                               |                                                                          |             |                |         |                             |                                             |                                       |    |
| <p><b><u>Authority Required</u></b></p> <p><i>Continuing treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to macular degeneration where the patient has previously been granted an authority prescription for the same eye.</i></p> <p><i>A patient is eligible for a total of 15 subsidised treatments per eye. This maximum includes treatments administered under the MBS Visudyne Therapy Program and the PBS.</i></p> <p><i>Medicare Australia should be notified if treatment is abandoned prior to completion of the laser activation step but after infusion of verteporfin. Telephone 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). The reason treatment is abandoned must be provided. Where such notification has been made, the treatment so affected will not count towards the maximum.</i></p> <p><i>Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia. Authority applications for continuing treatment in the same eye may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</i></p> |                                                                          |             |                |         |                             |                                             |                                       |    |
| 1349B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Powder for I.V. infusion 15 mg                                           | 1           | ..             | ..      | 2245.93                     | 31.30                                       | Visudyne                              | NV |
| <p><b>Other ophthalmologicals</b></p> <p>• <b>Other ophthalmologicals</b></p> <p><b>CARBOMER 974</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                          |             |                |         |                             |                                             |                                       |    |
| <p><b><u>Authority Required (STREAMLINED)</u></b></p> <p>1359</p> <p><i>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.</i></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                          |             |                |         |                             |                                             |                                       |    |
| 8514D                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Ocular lubricating gel 3 mg per g<br>(0.3%), single dose units 0.5 g, 30 | 3           | 5              | ..      | * 35.63                     | 31.30                                       | Poly Gel                              | AQ |
| <p><b>CARBOMER 980</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                          |             |                |         |                             |                                             |                                       |    |
| <p><b><u>Restricted Benefit</u></b></p> <p><i>Severe dry eye syndrome, including Sjogren's syndrome.</i></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                          |             |                |         |                             |                                             |                                       |    |
| 8384G                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Ocular lubricating gel 2 mg per g<br>(0.2%), 10 g                        | ± 1         | 5              | ..      | 10.08                       | 11.11                                       | GelTears                              | BU |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                          |             |                | ..      | 10.08                       | 11.11                                       | <sup>a</sup> PAA                      | NM |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                          |             |                | B1.00   | 11.08                       | 11.11                                       | <sup>a</sup> Viscotears Liquid<br>Gel | NV |

continued ➞

## SENSORY ORGANS—CONT.

| Code                                                                                                   | Name, Restriction,<br>Manner of Administration and Form                         | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b><u>Authority Required (STREAMLINED)</u></b>                                                         |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 1359                                                                                                   |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.</i> |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 8578L                                                                                                  | Eye drops 2 mg per g (0.2%), single dose units 0.6 mL, 30                       | 3           | 5              | ..      | * 35.03                                  | 31.30                                                  | Viscotears                           | NV |
| <b>CARMELLOSE SODIUM</b>                                                                               |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                       |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome, including Sjogren's syndrome.</i>                                          |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 8548X                                                                                                  | Eye drops 5 mg per mL (0.5%), 15 mL                                             | ± 1         | 5              | ..      | 10.16                                    | 11.19                                                  | Refresh Tears Plus                   | AG |
| 8593G                                                                                                  | Eye drops 10 mg per mL (1%), 15 mL                                              | ± 1         | 5              | ..      | 10.16                                    | 11.19                                                  | Refresh Liquigel                     | AG |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                         |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 1359                                                                                                   |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.</i> |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 8823J                                                                                                  | Eye drops 2.5 mg per mL (0.25%), single dose units 0.6 mL, 24                   | 4           | 5              | ..      | * 39.99                                  | 31.30                                                  | TheraTears                           | CX |
| 2338C                                                                                                  | Eye drops 5 mg per mL (0.5%), single dose units 0.4 mL, 30                      | 3           | 5              | ..      | * 35.63                                  | 31.30                                                  | Cellufresh                           | AG |
| 2324H                                                                                                  | Eye drops 10 mg per mL (1%), single dose units 0.4 mL, 30                       | 3           | 5              | ..      | * 35.63                                  | 31.30                                                  | Celluvisc                            | AG |
| 8824K                                                                                                  | Ocular lubricating gel 10 mg per mL (1%), single dose units 0.6 mL, 28          | 3           | 5              | ..      | * 33.65                                  | 31.30                                                  | TheraTears                           | CX |
| <b>HYPROMELLOSE</b>                                                                                    |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                       |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome, including Sjogren's syndrome.</i>                                          |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 8287E                                                                                                  | Eye drops 3 mg per mL (0.3%), 15 mL (contains sodium perborate as preservative) | ± 1         | 5              | ..      | 10.08                                    | 11.11                                                  | <sup>a</sup> In a Wink Moisturising  | NM |
|                                                                                                        |                                                                                 |             |                | B1.86   | 11.94                                    | 11.11                                                  | <sup>a</sup> Genteal                 | NV |
| 2956N                                                                                                  | Eye drops 5 mg per mL (0.5%), 15 mL                                             | ± 1         | 5              | ..      | 10.08                                    | 11.11                                                  | Methopt                              | SI |
| <b>HYPROMELLOSE with CARBOMER 980</b>                                                                  |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                       |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome, including Sjogren's syndrome.</i>                                          |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 8564R                                                                                                  | Ocular lubricating gel 3 mg-2 mg per g (0.3%-0.2%), 10 g                        | ± 1         | 5              | ..      | 10.08                                    | 11.11                                                  | <sup>a</sup> HPMC PAA                | NM |
|                                                                                                        |                                                                                 |             |                | B1.86   | 11.94                                    | 11.11                                                  | <sup>a</sup> Genteal gel             | NV |

## SENSORY ORGANS—CONT.

| Code                                                                                                   | Name, Restriction,<br>Manner of Administration and Form                    | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                       |                |
|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|------------------------------------------------------------|----------------|
| <b>HYPROMELLOSE with DEXTRAN</b>                                                                       |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| <b><u>Restricted Benefit</u></b>                                                                       |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| <i>Severe dry eye syndrome, including Sjogren's syndrome.</i>                                          |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| 1509K                                                                                                  | Eye drops 3 mg-1 mg per mL<br>(0.3%-0.1%), 15 mL                           | ‡ 1         | 5              | ..<br>B1.67 | 10.08<br>11.75                           | 11.11<br>11.11                                         | <sup>a</sup> Poly-Tears<br><sup>a</sup> Tears Naturale     | IQ<br>AQ       |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                         |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| 1359                                                                                                   |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| <i>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.</i> |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| 8299T                                                                                                  | Eye drops 3 mg-1 mg per mL<br>(0.3%-0.1%), single dose units 0.4 mL,<br>28 | 3           | 5              | ..          | * 35.03                                  | 31.30                                                  | Bion Tears                                                 | AQ             |
| <b>PARAFFIN</b>                                                                                        |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| 1754H                                                                                                  | Compound eye ointment 3.5 g                                                | 2           | 5              | ..<br>B2.06 | * 21.07<br>* 23.13                       | 22.10<br>22.10                                         | <sup>a</sup> Poly Visc<br><sup>a</sup> Duratears           | IQ<br>AQ       |
| 1750D                                                                                                  | Pack containing 2 tubes compound eye<br>ointment 3.5 g                     | ‡ 1         | 5              | ..<br>B2.24 | 21.06<br>21.06<br>23.30                  | 22.09<br>22.09<br>22.09                                | Poly Visc<br><sup>a</sup> Ircal<br><sup>a</sup> Lacri-Lube | IQ<br>PE<br>AG |
| <b>POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL</b>                                                   |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| <b><u>Restricted Benefit</u></b>                                                                       |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| <i>Severe dry eye syndrome, including Sjogren's syndrome.</i>                                          |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| 8676P                                                                                                  | Eye drops 4 mg-3 mg per mL<br>(0.4%-0.3%), 15 mL                           | ‡ 1         | 5              | ..          | 10.16                                    | 11.19                                                  | Systane                                                    | AQ             |
| <b><u>Authority Required (STREAMLINED)</u></b>                                                         |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| 1359                                                                                                   |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| <i>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.</i> |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| 9170P                                                                                                  | Eye drops 4 mg-3 mg per mL<br>(0.4%-0.3%), single dose units 0.7 mL,<br>28 | 3           | 5              | ..          | * 33.65                                  | 31.30                                                  | Systane                                                    | AQ             |
| <b>POLYVINYL ALCOHOL</b>                                                                               |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| <b><u>Restricted Benefit</u></b>                                                                       |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| <i>Severe dry eye syndrome, including Sjogren's syndrome.</i>                                          |                                                                            |             |                |             |                                          |                                                        |                                                            |                |
| 2682E                                                                                                  | Eye drops 14 mg per mL (1.4%), 15 mL                                       | ‡ 1         | 5              | ..<br>B1.71 | 10.08<br>11.79                           | 11.11<br>11.11                                         | <sup>a</sup> PVA Tears<br><sup>a</sup> Liquifilm Tears     | PE<br>AG       |

continued ➞



## SENSORY ORGANS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form                                                 | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |          |
|-------|---------------------------------------------------------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----------|
| 8831T | Eye drops 14 mg per mL (1.4%), 15 mL<br>(contains sodium chlorite/hydrogen<br>peroxide as preservative) | ‡ 1         | 5              | ..          | 10.08                                    | 11.11                                                  | Vistil                               | AE       |
| 2681D | Eye drops 30 mg per mL (3%), 15 mL                                                                      | ‡ 1         | 5              | ..<br>B5.94 | 10.08<br>16.02                           | 11.11 <sup>a</sup><br>11.11 <sup>a</sup>               | PVA Forte<br>Liquifilm Forte         | PE<br>AG |
| 8832W | Eye drops 30 mg per mL (3%), 15 mL<br>(contains sodium chlorite/hydrogen<br>peroxide as preservative)   | ‡ 1         | 5              | ..          | 10.08                                    | 11.11                                                  | Vistil Forte                         | AE       |

### TAMARINDUS INDICA SEED POLYSACCHARIDE

#### Authority Required (STREAMLINED)

1359

*Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.*

|       |                                            |   |   |    |         |       |                     |    |
|-------|--------------------------------------------|---|---|----|---------|-------|---------------------|----|
| 2248H | Eye drops 10 mg per mL (1%), 0.5 mL,<br>20 | 3 | 5 | .. | * 35.63 | 31.30 | Visine Professional | JT |
|-------|--------------------------------------------|---|---|----|---------|-------|---------------------|----|

### OTOLOGICALS

#### **Antiinfectives**

##### • **Antiinfectives**

#### CHLORAMPHENICOL

|       |                                                 |     |   |    |       |       |               |    |
|-------|-------------------------------------------------|-----|---|----|-------|-------|---------------|----|
| 1172Q | Ear drops (aqueous) 5 mg per mL (0.5%),<br>5 mL | ‡ 1 | 2 | .. | 10.62 | 11.65 | Chloromycetin | PF |
|-------|-------------------------------------------------|-----|---|----|-------|-------|---------------|----|

#### CIPROFLOXACIN

#### Authority Required

*Treatment of chronic suppurative otitis media in an Aboriginal or a Torres Strait Islander person aged 1 month or older.*

|       |                                    |     |   |    |       |       |         |    |
|-------|------------------------------------|-----|---|----|-------|-------|---------|----|
| 2480M | Ear drops 3 mg per mL (0.3%), 5 mL | ‡ 1 | 1 | .. | 18.85 | 19.88 | Ciloxan | AQ |
|-------|------------------------------------|-----|---|----|-------|-------|---------|----|

#### NEOMYCIN UNDECENOATE with BACITRACIN ZINC

|       |                                                           |     |    |    |      |      |        |    |
|-------|-----------------------------------------------------------|-----|----|----|------|------|--------|----|
| 2296W | Ear ointment 12 mg (3.5 mg<br>base)-400 units per g, 10 g | ‡ 1 | .. | .. | 8.22 | 9.25 | Nemdyn | HA |
|-------|-----------------------------------------------------------|-----|----|----|------|------|--------|----|

#### **Corticosteroids and antiinfectives in combination**

##### • **Corticosteroids and antiinfectives in combination**

#### DEXAMETHASONE with FRAMYCETIN SULFATE and GRAMICIDIN

|       |                                                                |     |   |             |               |                                        |                    |          |
|-------|----------------------------------------------------------------|-----|---|-------------|---------------|----------------------------------------|--------------------|----------|
| 2781J | Ear drops<br>500 micrograms-5 mg-50 micrograms<br>per mL, 8 mL | ‡ 1 | 2 | ..<br>B1.76 | 8.34<br>10.10 | 9.37 <sup>a</sup><br>9.37 <sup>a</sup> | Otodex<br>Sofradex | AV<br>SW |
|-------|----------------------------------------------------------------|-----|---|-------------|---------------|----------------------------------------|--------------------|----------|

SENSORY ORGANS—CONT.

| Code                                                                      | Name, Restriction,<br>Manner of Administration and Form                                                                   | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     |              | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------|--------------------------------------|----|
|                                                                           |                                                                                                                           |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |              |                                      |    |
| TRIAMCINOLONE ACETONIDE with NEOMYCIN<br>SULFATE, GRAMICIDIN and NYSTATIN |                                                                                                                           |             |                |         |                             |                                             |              |                                      |    |
| 2971J                                                                     | Ear drops 1 mg-2.5 mg (base)-<br>250 micrograms-100,000 units per g<br>(0.1%-0.25%-0.025%-100,000 units<br>per g), 7.5 mL | ‡ 1         | 2              | ..      | 10.95                       | 11.98                                       | <sup>a</sup> | Otocomb Otic                         | BC |
|                                                                           |                                                                                                                           |             |                | B1.07   | 12.02                       | 11.98                                       | <sup>a</sup> | Kenacomb Otic                        | BQ |
| 2974M                                                                     | Ear ointment 1 mg-2.5 mg (base)-<br>250 micrograms-100,000 units per g<br>(0.1%-0.25%-0.025%-100,000 units<br>per g), 5 g | ‡ 1         | 2              | ..      | 7.85                        | 8.88                                        | <sup>a</sup> | Otocomb Otic                         | BC |
|                                                                           |                                                                                                                           |             |                | B1.08   | 8.93                        | 8.88                                        | <sup>a</sup> | Kenacomb Otic                        | BQ |

OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS

Antiinfectives

• Antiinfectives

FRAMYCETIN SULFATE

|       |                                               |     |   |    |      |      |  |            |    |
|-------|-----------------------------------------------|-----|---|----|------|------|--|------------|----|
| 1440T | Eye and ear drops 5 mg per mL (0.5%),<br>8 mL | ‡ 1 | 2 | .. | 8.91 | 9.94 |  | Soframycin | SW |
|-------|-----------------------------------------------|-----|---|----|------|------|--|------------|----|

## VARIOUS

| Code                                                                                                                                                                                                                                                          | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>ALLERGENS</b>                                                                                                                                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Allergens</b>                                                                                                                                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Allergen extracts</b>                                                                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| INSECT ALLERGEN EXTRACT—HONEY BEE VENOM                                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2886X                                                                                                                                                                                                                                                         | Injection set containing 550 micrograms                 | 1           | ..             | ..      | 204.71                                   | 31.30                                                  | Albey Bee Venom                      | ES |
| INSECT ALLERGEN EXTRACT—PAPER WASP VENOM                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b><br>Paper wasp venom is not European wasp venom.                                                                                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2918N                                                                                                                                                                                                                                                         | Injection set containing 550 micrograms                 | 1           | ..             | ..      | 204.71                                   | 31.30                                                  | Albey Paper Wasp<br>Venom            | ES |
| INSECT ALLERGEN EXTRACT—YELLOW JACKET<br>VENOM                                                                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2883R                                                                                                                                                                                                                                                         | Injection set containing 550 micrograms                 | 1           | ..             | ..      | 204.71                                   | 31.30                                                  | Albey Yellow<br>Jacket Venom         | ES |
| <b>ALL OTHER THERAPEUTIC PRODUCTS</b>                                                                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>All other therapeutic products</b>                                                                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Antidotes</b>                                                                                                                                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| NALOXONE HYDROCHLORIDE                                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1752F                                                                                                                                                                                                                                                         | Injection 800 micrograms in 2 mL                        | 1           | ..             | ..      | 27.89                                    | 28.92                                                  | Naloxone Min-I-Jet                   | CS |
| 1753G                                                                                                                                                                                                                                                         | Injection 2 mg in 5 mL                                  | 1           | ..             | ..      | 40.93                                    | 31.30                                                  | Naloxone Min-I-Jet                   | CS |
| • <b>Drugs for treatment of hyperkalemia and hyperphosphatemia</b>                                                                                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| SEVELAMER HYDROCHLORIDE                                                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Maintenance therapy, following initiation and stabilisation of treatment with sevelamer hydrochloride, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products and where:</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>(a) serum phosphate is greater than 1.6 mmol per L; or</i>                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>(b) the serum calcium times phosphate product is greater than 4.0.</i>                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>at the commencement of therapy.</i>                                                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2142R                                                                                                                                                                                                                                                         | Tablet 800 mg                                           | 180         | 5              | ..      | 357.30                                   | 31.30                                                  | Renagel                              | GZ |

## VARIOUS—CONT.

| Code                                                                             | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>• Detoxifying agents for antineoplastic treatment</b>                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CALCIUM FOLINATE</b>                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8740B                                                                            | Injection equivalent to 50 mg folinic acid<br>in 5 mL   | 5           | 5              | ..      | * 154.39                                 | 31.30                                                  | <sup>a</sup> Leucovorin<br>Calcium   | HH |
|                                                                                  |                                                         |             |                | ..      | * 154.39                                 | 31.30                                                  | <sup>a</sup> Leucovorin<br>Calcium   | PF |
|                                                                                  |                                                         |             |                | ..      | 154.39                                   | 31.30                                                  | <sup>a</sup> Calcium Folate<br>Ebewe | IT |
| 8812T                                                                            | Injection equivalent to 100 mg folinic<br>acid in 10 mL | 10          | 1              | ..      | 272.99                                   | 31.30                                                  | <sup>a</sup> Leucovorin<br>Calcium   | PF |
|                                                                                  |                                                         |             |                | ..      | * 272.99                                 | 31.30                                                  | <sup>a</sup> Calcium Folate<br>Ebewe | IT |
| 9041W                                                                            | Injection equivalent to 300 mg folinic<br>acid in 30 mL | 4           | 1              | ..      | * 315.23                                 | 31.30                                                  | Leucovorin<br>Calcium                | HH |
| <hr/>                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>CALCIUM FOLINATE</b>                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Antidote to folic acid antagonists.</i>                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2308L                                                                            | Tablet equivalent to 15 mg folinic acid                 | 10          | ..             | ..      | 101.50                                   | 31.30                                                  | Leucovorin<br>Calcium                | HH |
| <b>MESNA</b>                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Adjunctive therapy for use with ifosfamide or high dose cyclophosphamide.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8078E                                                                            | Solution for I.V. injection 400 mg in<br>4 mL           | 15          | 5              | ..      | 72.38                                    | 31.30                                                  | Uromitexan                           | BX |
| 8079F                                                                            | Solution for I.V. injection 1 g in 10 mL                | 15          | 5              | ..      | 157.74                                   | 31.30                                                  | Uromitexan                           | BX |

## VARIOUS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                             | Name, Restriction,<br>Manner of Administration and Form                                                                              | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>• Drugs for treatment of hypercalcemia</b><br><b>SODIUM ACID PHOSPHATE</b><br><br><b>Authority Required (STREAMLINED)</b><br><b>1099</b><br><i>Familial hypophosphataemia;</i><br><br><b>1157</b><br><i>Hypercalcaemia;</i><br><br><b>1167</b><br><i>Hypophosphataemic rickets;</i><br><br><b>1467</b><br><i>Vitamin D-resistant rickets.</i> |                                                                                                                                      |             |                |         |                                          |                                                        |                                      |    |
| 2946C                                                                                                                                                                                                                                                                                                                                            | Compound effervescent tablet<br>containing elemental phosphorus<br>500 mg, sodium 469 mg (20.4 mmol),<br>potassium 123 mg (3.1 mmol) | 100         | 5              | ..      | 81.20                                    | 31.30                                                  | Phosphate Sandoz                     | NV |

## DIAGNOSTIC AGENTS

**Urine tests****• Urine tests**

## COPPER SULFATE

|                                    |                                 |   |   |    |         |       |                           |    |
|------------------------------------|---------------------------------|---|---|----|---------|-------|---------------------------|----|
| 1228P                              | Diagnostic compound tablets, 36 | 2 | 3 | .. | * 71.05 | 31.30 | Clinitest                 | BN |
| GLUCOSE and KETONE INDICATOR—URINE |                                 |   |   |    |         |       |                           |    |
| 3106L                              | Reagent strips, 50              | 2 | 2 | .. | * 16.87 | 17.90 | Keto-Diabur- Test<br>5000 | RD |
| 3107M                              | Reagent strips, 50              | 2 | 2 | .. | * 16.99 | 18.02 | Keto-Diastix              | BN |
| GLUCOSE INDICATOR—URINE            |                                 |   |   |    |         |       |                           |    |
| 2352T                              | Reagent strips, 50              | 2 | 2 | .. | * 19.39 | 20.42 | Clinistix                 | BN |
| 3104J                              | Reagent strips, 50              | 2 | 2 | .. | * 18.41 | 19.44 | Diastix                   | BN |

**Other diagnostic agents****• Tests for diabetes**

## GLUCOSE INDICATOR—BLOOD

|       |                      |   |   |    |         |       |                       |    |
|-------|----------------------|---|---|----|---------|-------|-----------------------|----|
| 9193W | Electrode strips, 25 | 4 | 5 | .. | * 52.75 | 31.30 | On-Call Plus          | PZ |
| 2979T | Electrode strips, 50 | 2 | 5 | .. | * 52.75 | 31.30 | Accu-Chek<br>Performa | RD |
| 2891E | Electrode strips, 50 | 2 | 5 | .. | * 52.75 | 31.30 | Advantage II          | RD |
| 8890X | Electrode strips, 50 | 2 | 5 | .. | * 52.75 | 31.30 | Freestyle Papillon    | MS |

continued ➞

## VARIOUS—CONT.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 1820T | Electrode strips, 50                                    | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | Glucoboy                             | DB |
| 9013J | Electrode strips, 50                                    | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | Glucocard 01<br>Sensor               | OZ |
| 8766J | Electrode strips, 50                                    | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | GlucoCare Super<br>Sensor            | OZ |
| 8749L | Electrode strips, 50                                    | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | GlucoOz                              | OZ |
| 8682Y | Electrode strips, 50                                    | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | MWD Pen Sensor<br>Strips             | WF |
| 8723D | Electrode strips, 50                                    | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | Omnitest EZ                          | BR |
| 9063B | Electrode strips, 50                                    | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | Omnitest Plus                        | BR |
| 2263D | Electrode strips, 50                                    | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | Optium Omega                         | MS |
| 9046D | Electrode strips, 50                                    | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | Touch-In Plus                        | DN |
| 8825L | Electrode strips, 50                                    | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | TrueTrack                            | DB |
| 9154T | Electrode strips, 100                                   | ‡ 1         | 5              | ..      | 52.73                                    | 31.30                                                  | FreeStyle Lite                       | MS |
| 8522M | Electrode strips, 100                                   | ‡ 1         | 5              | ..      | 52.73                                    | 31.30                                                  | Optium glucose                       | MS |
| 8573F | Electrode strips, 100                                   | ‡ 1         | 5              | ..      | 52.73                                    | 31.30                                                  | SofTact                              | MS |
| 8608C | Electrode strips, 100                                   | ‡ 1         | 5              | ..      | 52.73                                    | 31.30                                                  | TrueSense                            | MS |
| 8190C | Reagent strips, 50                                      | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | Accu-Chek Active                     | RD |
| 8739Y | Reagent strips, 50                                      | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | Accu-Chek Go                         | RD |
| 8806L | Reagent strips, 51                                      | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | Accu-Chek Integra                    | RD |
| 2890D | Reagent strips, 50                                      | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | Betachek                             | NA |
| 2860M | Reagent strips, 50                                      | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | Betachek G5                          | NA |
| 8759B | Reagent strips, 50                                      | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | CareSens                             | LB |
| 2914J | Reagent strips, 50                                      | 2           | 5              | ..      | * 45.47                                  | 31.30                                                  | Glucoflex-R                          | NA |
| 2917M | Reagent strips, 50                                      | 2           | 5              | ..      | * 45.47                                  | 31.30                                                  | Glucostix                            | BN |
| 8795X | Reagent strips, 50                                      | 2           | 5              | ..      | * 52.75                                  | 31.30                                                  | SensoCard                            | PX |

continued ➞

## VARIOUS—CONT.

| Code                                                                                            | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>GLUCOSE INDICATOR—BLOOD</b>                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required (STREAMLINED)</b>                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1769                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients who have previously received this product as a pharmaceutical benefit;</i>          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1770                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients who have purchased a meter to be used with this product prior to 1 August 2003.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2926B                                                                                           | Electrode strips, 100                                   | ± 1         | 5              | ..      | 54.23                                    | 31.30                                                  | Precision Plus                       | MS |

## GENERAL NUTRIENTS

**Other nutrients**• **Other nutrients****TRIGLYCERIDES, MEDIUM CHAIN****NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*

**Authority Required**

*Chylous ascites;*

*Chylothorax;*

*Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders;*

*Hyperlipoproteinaemia type 1;*

*Intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect, requiring a ketogenic diet;*

*Long chain fatty acid oxidation disorders.*

|       |            |   |   |    |         |       |         |    |
|-------|------------|---|---|----|---------|-------|---------|----|
| 3128P | Oil 500 mL | 2 | 5 | .. | * 51.95 | 31.30 | MCT Oil | SB |
|-------|------------|---|---|----|---------|-------|---------|----|

• **Fat/carbohydrates/proteins/minerals/vitamins, combinations****AMINO ACIDS—SYNTHETIC, FORMULA****Authority Required**

*Initial treatment for up to 3 months, by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who requires an amino acid based formula as a component of a dietary elimination programme. Treatment with oral steroids should not be commenced during the period of initial treatment.*

*Eosinophilic oesophagitis is demonstrated by the following criteria:*

*(i) Chronic symptoms of reflux that persisted despite a 2-month trial of a proton pump inhibitor or chronic dysphagia; and*

*(ii) A lack of demonstrable anatomic abnormality with the exception of stricture, which can be attributable to eosinophilic oesophagitis; and*

*(iii) Eosinophilic infiltration of the oesophagus, demonstrated by oesophageal biopsy specimens obtained by endoscopy and where the most densely involved oesophageal biopsy had 20 or more eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies.*

*The date of birth of the patient must be included in the authority.*

continued ➞

## VARIOUS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

**Authority Required**

*Continuing treatment by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who has responded to an initial course of PBS-subsidised treatment. Response to initial treatment is demonstrated by oesophageal biopsy specimens obtained by endoscopy, where the most densely involved oesophageal biopsy had 5 or less eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies. The response criteria will not be deemed to have been met if oral steroids were commenced during initial treatment.*

**NOTE:**

*Authorities for increased maximum quantities, up to a maximum of 52, may be authorised.*

|       |                       |    |   |    |          |       |         |    |
|-------|-----------------------|----|---|----|----------|-------|---------|----|
| 2250K | Compound powder 400 g | 12 | 5 | .. | * 531.23 | 31.30 | EleCare | AB |
|-------|-----------------------|----|---|----|----------|-------|---------|----|

**Authority Required**

*Initial treatment, for up to 3 months, for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The date of birth of the patient must be included in the authority application;*

*Initial treatment, in consultation with a paediatric gastroenterologist or specialist allergist, for up to 3 months, of a child up to the age of 2 years with severe intolerance (not infant colic) to cows' milk protein. The date of birth of the patient must be included in the authority application.*

**NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*

|       |                       |   |   |    |          |       |                                     |    |
|-------|-----------------------|---|---|----|----------|-------|-------------------------------------|----|
| 8574G | Compound powder 400 g | 8 | 5 | .. | * 360.71 | 31.30 | EleCare                             | AB |
| 8443J | Compound powder 400 g | 8 | 5 | .. | * 360.71 | 31.30 | Neocate                             | SB |
| 8754R | Compound powder 400 g | 8 | 5 | .. | * 360.71 | 31.30 | Neocate Advance                     | SB |
| 2244D | Compound powder 400 g | 8 | 5 | .. | * 360.71 | 31.30 | Neocate Advance<br>Tropical Flavour | SB |

continued ➞



## VARIOUS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

**Authority Required**

*Continuing treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years, where the child has been assessed by a suitably qualified allergist or paediatrician. The date of birth of the patient must be included in the authority application;*

*Treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged 2 years and over, where the child is assessed by a suitably qualified allergist or paediatrician at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application;*

*Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child up to the age of 2 years, where the child has been assessed by a paediatric gastroenterologist or specialist allergist and soy protein and protein hydrolysate formulae are not tolerated or not likely to be tolerated. The date of birth of the patient must be included in the authority application;*

*Treatment for severe intolerance (not infant colic) to cows' milk protein in a child aged 2 years and over, where the child is assessed by a paediatric gastroenterologist or specialist allergist at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application;*

*Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed;*

*Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition.*

**NOTE:**

*Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.*

|       |                       |   |   |    |          |       |                                     |    |
|-------|-----------------------|---|---|----|----------|-------|-------------------------------------|----|
| 8575H | Compound powder 400 g | 8 | 5 | .. | * 360.71 | 31.30 | EleCare                             | AB |
| 3066J | Compound powder 400 g | 8 | 5 | .. | * 360.71 | 31.30 | Neocate                             | SB |
| 8755T | Compound powder 400 g | 8 | 5 | .. | * 360.71 | 31.30 | Neocate Advance                     | SB |
| 2553J | Compound powder 400 g | 8 | 5 | .. | * 360.71 | 31.30 | Neocate Advance<br>Tropical Flavour | SB |

**AMINO ACID SYNTHETIC FORMULA supplemented with  
LONG CHAIN POLYUNSATURATED FATTY ACIDS**

**Authority Required**

*Initial treatment, for up to 3 months, for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The date of birth of the patient must be included in the authority application;*

*Initial treatment, in consultation with a paediatric gastroenterologist or specialist allergist, for up to 3 months, of a child up to the age of 2 years with severe intolerance (not infant colic) to cows' milk protein. The date of birth of the patient must be included in the authority application.*

**NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*

|       |                       |   |   |    |          |       |             |    |
|-------|-----------------------|---|---|----|----------|-------|-------------|----|
| 2246F | Compound powder 400 g | 8 | 5 | .. | * 367.43 | 31.30 | Neocate LCP | SB |
|-------|-----------------------|---|---|----|----------|-------|-------------|----|

continued ➞

## VARIOUS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

**Authority Required**

*Continuing treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child up to the age of 2 years, where the child has been assessed by a suitably qualified allergist or paediatrician. The date of birth of the patient must be included in the authority application;*

*Treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged 2 years and over, where the child is assessed by a suitably qualified allergist or paediatrician at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application;*

*Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child up to the age of 2 years, where the child has been assessed by a paediatric gastroenterologist or specialist allergist and soy protein and protein hydrolysate formulae are not tolerated or not likely to be tolerated. The date of birth of the patient must be included in the authority application;*

*Treatment for severe intolerance (not infant colic) to cows' milk protein in a child aged 2 years and over, where the child is assessed by a paediatric gastroenterologist or specialist allergist at intervals not greater than 6 months. The date of birth of the patient must be included in the authority application;*

*Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed;*

*Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition.*

**NOTE:**

*Authorities for increased maximum quantities, up to a maximum of 20, may be authorised.*

|       |                       |   |   |    |          |       |             |    |
|-------|-----------------------|---|---|----|----------|-------|-------------|----|
| 2560R | Compound powder 400 g | 8 | 5 | .. | * 367.43 | 31.30 | Neocate LCP | SB |
|-------|-----------------------|---|---|----|----------|-------|-------------|----|

## VARIOUS—CONT.

| Code                                                                                                                                                                                                                                                                                                                                                                                               | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                    |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |
| <b>PROTEIN HYDROLYSATE FORMULA with MEDIUM CHAIN TRIGLYCERIDES</b>                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                             |                                             |                                      |
| <b>NOTE:</b>                                                                                                                                                                                                                                                                                                                                                                                       |                                                         |             |                |         |                             |                                             |                                      |
| No applications for increased maximum quantities and/or repeats will be authorised.                                                                                                                                                                                                                                                                                                                |                                                         |             |                |         |                             |                                             |                                      |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                          |                                                         |             |                |         |                             |                                             |                                      |
| Initial treatment, for up to 3 months, for intolerance (not infant colic) to both cows' milk protein and soy protein in a child up to the age of 2 years. Intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free diet with a soy protein as the principal formula. The date of birth of the patient must be included in the authority application;   |                                                         |             |                |         |                             |                                             |                                      |
| Continuing treatment for intolerance (not infant colic) to both cows' milk protein and soy protein in a child up to the age of 2 years, where clinical improvement has been demonstrated with the protein hydrolysate formula with medium chain triglycerides. The date of birth of the patient must be included in the authority application;                                                     |                                                         |             |                |         |                             |                                             |                                      |
| Continuing treatment for intolerance (not infant colic) to both cows' milk protein and soy protein in a child aged 2 years and over, where the child has been assessed by a suitably qualified allergist or paediatrician. The date of birth of the patient must be included in the authority application.                                                                                         |                                                         |             |                |         |                             |                                             |                                      |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                          |                                                         |             |                |         |                             |                                             |                                      |
| Initial treatment, in consultation with a paediatric gastroenterologist or specialist allergist, for up to 3 months, of a child up to the age of 2 years with severe intolerance (not infant colic) to cows' milk protein. The date of birth of the patient must be included in the authority application;                                                                                         |                                                         |             |                |         |                             |                                             |                                      |
| Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child up to the age of 2 years, where clinical improvement has been demonstrated with the protein hydrolysate formula with medium chain triglycerides and soy protein is not tolerated or is likely not to be tolerated. The date of birth of the patient must be included in the authority application; |                                                         |             |                |         |                             |                                             |                                      |
| Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child aged 2 years and over, where the child has been assessed by a paediatric gastroenterologist or specialist allergist. The date of birth of the patient must be included in the authority application.                                                                                               |                                                         |             |                |         |                             |                                             |                                      |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                          |                                                         |             |                |         |                             |                                             |                                      |
| Biliary atresia;                                                                                                                                                                                                                                                                                                                                                                                   |                                                         |             |                |         |                             |                                             |                                      |
| Chronic liver failure with fat malabsorption;                                                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |         |                             |                                             |                                      |
| Chylous ascites;                                                                                                                                                                                                                                                                                                                                                                                   |                                                         |             |                |         |                             |                                             |                                      |
| Chylothorax;                                                                                                                                                                                                                                                                                                                                                                                       |                                                         |             |                |         |                             |                                             |                                      |
| Cystic fibrosis;                                                                                                                                                                                                                                                                                                                                                                                   |                                                         |             |                |         |                             |                                             |                                      |
| Enterokinase deficiency;                                                                                                                                                                                                                                                                                                                                                                           |                                                         |             |                |         |                             |                                             |                                      |
| Proven fat malabsorption;                                                                                                                                                                                                                                                                                                                                                                          |                                                         |             |                |         |                             |                                             |                                      |
| Severe diarrhoea of greater than 2 weeks' duration in an infant aged less than 4 months. The date of birth of the patient must be included in the authority application;                                                                                                                                                                                                                           |                                                         |             |                |         |                             |                                             |                                      |
| Severe intestinal malabsorption including short bowel syndrome.                                                                                                                                                                                                                                                                                                                                    |                                                         |             |                |         |                             |                                             |                                      |
| 2676W                                                                                                                                                                                                                                                                                                                                                                                              | Compound powder 400 g                                   | 8           | 5              | ..      | * 97.83                     | 31.30                                       | Alfaré NT                            |

continued ➞

## VARIOUS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

**Authority Required**

*Initial treatment, for up to 3 months, for intolerance (not infant colic) to both cows' milk protein and soy protein in a child up to the age of 2 years. Intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free diet with a soy protein as the principal formula. The date of birth of the patient must be included in the authority application;*

*Continuing treatment for intolerance (not infant colic) to both cows' milk protein and soy protein in a child up to the age of 2 years, where clinical improvement has been demonstrated with the protein hydrolysate formula with medium chain triglycerides. The date of birth of the patient must be included in the authority application;*

*Continuing treatment for intolerance (not infant colic) to both cows' milk protein and soy protein in a child aged 2 years and over, where the child has been assessed by a suitably qualified allergist or paediatrician. The date of birth of the patient must be included in the authority application.*

**Authority Required**

*Initial treatment, in consultation with a paediatric gastroenterologist or specialist allergist, for up to 3 months, of a child up to the age of 2 years with severe intolerance (not infant colic) to cows' milk protein. The date of birth of the patient must be included in the authority application;*

*Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child up to the age of 2 years, where clinical improvement has been demonstrated with the protein hydrolysate formula with medium chain triglycerides and soy protein is not tolerated or is likely not to be tolerated. The date of birth of the patient must be included in the authority application;*

*Continuing treatment for severe intolerance (not infant colic) to cows' milk protein in a child aged 2 years and over, where the child has been assessed by a paediatric gastroenterologist or specialist allergist. The date of birth of the patient must be included in the authority application.*

**Authority Required**

*Biliary atresia;*

*Chronic liver failure with fat malabsorption;*

*Chylous ascites;*

*Cystic fibrosis;*

*Enterokinase deficiency;*

*Proven fat malabsorption;*

*Severe diarrhoea of greater than 2 weeks' duration in an infant aged less than 4 months. The date of birth of the patient must be included in the authority application;*

*Severe intestinal malabsorption including short bowel syndrome.*

|       |                       |   |   |    |          |       |              |    |
|-------|-----------------------|---|---|----|----------|-------|--------------|----|
| 8259Q | Compound powder 450 g | 8 | 5 | .. | * 109.43 | 31.30 | Pepti-Junior | NU |
|-------|-----------------------|---|---|----|----------|-------|--------------|----|

## VARIOUS—CONT.

| Code                                                                                                                                                                                                                                          | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>TRIGLYCERIDES—MEDIUM CHAIN, FORMULA</b>                                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>No applications for increased maximum quantities and/or repeats will be authorised.</i>                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Chylous ascites;</i>                                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Chylothorax;</i>                                                                                                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders;</i>                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Hyperlipoproteinaemia type 1;</i>                                                                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Long chain fatty acid oxidation disorders.</i>                                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Monogen is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet.</i>                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8478F                                                                                                                                                                                                                                         | Compound powder 400 g                                   | 8           | 5              | ..      | * 420.87                                 | 31.30                                                  | Monogen                              | SB |
| <b>Restricted Benefit</b>                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Chylous ascites;</i>                                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Chylothorax;</i>                                                                                                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders.</i>                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Caprilon is not indicated for the treatment of intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect requiring a ketogenic diet, long chain fatty acid oxidation disorders or hyperlipoproteinaemia type 1.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8629E                                                                                                                                                                                                                                         | Compound powder 420 g                                   | 8           | 5              | ..      | * 467.03                                 | 31.30                                                  | Caprilon                             | SB |
| <b>• Milk substitutes</b>                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>MILK POWDER—LACTOSE FREE FORMULA</b>                                                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Acute lactose intolerance in infants up to the age of 12 months. The date of birth of the patient must be included in the authority application.</i>                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>No applications for increased maximum quantities and/or repeats will be authorised. No more than 1 application per patient will be authorised.</i>                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8282X                                                                                                                                                                                                                                         | Infant formula powder 900 g                             | 5           | ..             | ..      | * 96.74                                  | 31.30                                                  | S-26 LF                              | WX |
| 2350Q                                                                                                                                                                                                                                         | Lactose-predigested powder infant formula 900 g         | 5           | ..             | ..      | * 88.49                                  | 31.30                                                  | Karicare De-Lact                     | NU |

continued ➞

## VARIOUS—CONT.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

**Authority Required**

*Proven chronic lactose intolerance in infants up to the age of 12 months. The date of birth of the patient must be included in the authority application. Lactose intolerance must have been proven by either:*

- (a) relief of symptoms on supervised withdrawal of lactose from the diet for 3 or 4 days and subsequent re-emergence of symptoms on rechallenge with lactose containing formulae or milk or food; or*  
*(b) not less than 0.5% reducing substance in stool exudate tested with copper sulfate diagnostic compound tablet; or*  
*(c) hydrogen breath test.*

**NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*

|       |                                                 |   |   |    |         |       |                  |    |
|-------|-------------------------------------------------|---|---|----|---------|-------|------------------|----|
| 8283Y | Infant formula powder 900 g                     | 5 | 5 | .. | * 96.74 | 31.30 | S-26 LF          | WX |
| 2349P | Lactose-predigested powder infant formula 900 g | 5 | 5 | .. | * 88.49 | 31.30 | Karicare De-Lact | NU |

**MILK POWDER—LACTOSE MODIFIED****Authority Required**

*Acute lactose intolerance in children aged 1 year and over. The date of birth of the patient must be included in the authority application.*

**NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised. No more than 1 application per patient will be authorised.*

|       |                                  |   |   |    |         |       |             |    |
|-------|----------------------------------|---|---|----|---------|-------|-------------|----|
| 2358D | Lactose-predigested powder 900 g | 3 | 1 | .. | * 62.60 | 31.30 | Digestelact | SJ |
|-------|----------------------------------|---|---|----|---------|-------|-------------|----|

**Authority Required**

*Proven chronic lactose intolerance in children aged 1 year and over who are significantly malnourished. The date of birth of the patient must be included in the authority application. Lactose intolerance must have been proven by either:*

- (a) relief of symptoms on supervised withdrawal of lactose from the diet for 3 or 4 days and subsequent re-emergence of symptoms on rechallenge with lactose containing formulae or milk or food; or*  
*(b) not less than 0.5% reducing substance in stool exudate tested with copper sulfate diagnostic compound tablet; or*  
*(c) hydrogen breath test.*

**NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*

|       |                                  |   |    |    |         |       |             |    |
|-------|----------------------------------|---|----|----|---------|-------|-------------|----|
| 2357C | Lactose-predigested powder 900 g | 3 | 10 | .. | * 62.60 | 31.30 | Digestelact | SJ |
|-------|----------------------------------|---|----|----|---------|-------|-------------|----|

**MILK POWDER—SYNTHETIC****NOTE:**

*No applications for increased maximum quantities and/or repeats will be authorised.*

**Authority Required**

*Hypercalcaemia in children under the age of 4 years.*

|       |                                   |   |   |    |          |       |         |    |
|-------|-----------------------------------|---|---|----|----------|-------|---------|----|
| 3092R | Low calcium compound powder 400 g | 8 | 5 | .. | * 380.95 | 31.30 | Locasol | NU |
|-------|-----------------------------------|---|---|----|----------|-------|---------|----|

## VARIOUS—CONT.

| Code                                                                                                                       | Name, Restriction,<br>Manner of Administration and Form                                                                                   | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| • <b>Other combinations of nutrients</b>                                                                                   |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| <b>AMINO ACID FORMULA without METHIONINE,<br/>THREONINE and VALINE and low in Isoleucine</b>                               |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                           |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| <b>Methylmalonic acidemia;</b>                                                                                             |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| <b>Propionic acidemia.</b>                                                                                                 |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| 3079C                                                                                                                      | Powder 200 g                                                                                                                              | 5           | 5              | ..      | * 1047.99                                | 31.30                                                  | XMTVI Asadon                         | SB |
| <b>AMINO ACID FORMULA without PHENYLALANINE</b>                                                                            |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                           |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| <b>Phenylketonuria.</b>                                                                                                    |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| 8554F                                                                                                                      | Capsules 500 mg, 200                                                                                                                      | 16          | 5              | ..      | * 1275.91                                | 31.30                                                  | Phlexy-10                            | SB |
| 8678R                                                                                                                      | Tablets 1 g, 75                                                                                                                           | 24          | 5              | ..      | * 1426.55                                | 31.30                                                  | Phlexy-10                            | SB |
| 8706F                                                                                                                      | Bars 42 g, 20                                                                                                                             | 10          | 5              | ..      | * 1570.89                                | 31.30                                                  | Phlexy-10                            | SB |
| 2347M                                                                                                                      | Sachets containing powder 20 g, 30                                                                                                        | 7           | 5              | ..      | * 1462.48                                | 31.30                                                  | Phlexy-10 Drink<br>Mix               | SB |
| 3072Q                                                                                                                      | Powder 250 g                                                                                                                              | 8           | 5              | ..      | * 1209.43                                | 31.30                                                  | PK AID II                            | SB |
| <b>AMINO ACID FORMULA without PHENYLALANINE, and<br/>VITAMINS with MINERALS</b>                                            |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                           |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| <b>Phenylketonuria.</b>                                                                                                    |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| 1411G                                                                                                                      | Pack containing 60 sachets of<br>phenylalanine-free amino acid<br>formula powder 17 g, and 60 tablets<br>containing vitamins and minerals | 3           | 5              | ..      | * 1639.64                                | 31.30                                                  | add-ins                              | SB |
| <b>AMINO ACID FORMULA without PHENYLALANINE,<br/>TYROSINE and METHIONINE</b>                                               |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                           |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| <b>Tyrosinaemia.</b>                                                                                                       |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| 2379F                                                                                                                      | Powder 500 g                                                                                                                              | 4           | 5              | ..      | * 2671.55                                | 31.30                                                  | XPTM Tyrosidon                       | SB |
| <b>AMINO ACID FORMULA with VITAMINS, MINERALS and<br/>LONG CHAIN POLYUNSATURATED FATTY ACIDS without<br/>PHENYLALANINE</b> |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                           |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| <b>Phenylketonuria.</b>                                                                                                    |                                                                                                                                           |             |                |         |                                          |                                                        |                                      |    |
| 8479G                                                                                                                      | Infant formula, powder 400 g                                                                                                              | 8           | 5              | ..      | * 703.19                                 | 31.30                                                  | XP Analog LCP                        | SB |

## VARIOUS—CONT.

| Code                                                                                                                          | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>AMINO ACID FORMULA with VITAMINS and MINERALS<br/>without LYSINE and low in TRYPTOPHAN</b>                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>An infant or young child with proven glutaric aciduria type 1.</i>                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2650L                                                                                                                         | Infant formula, powder 400 g                            | 8           | 5              | ..      | * 673.27                                 | 31.30                                                  | XLYS, LOW TRY<br>Analog              | SB |
| <b><u>Restricted Benefit</u></b><br><i>A child aged less than 7 years with proven glutaric aciduria type 1.</i>               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 2646G                                                                                                                         | Powder 500 g                                            | 8           | 5              | ..      | * 1624.23                                | 31.30                                                  | XLYS, LOW TRY<br>Maxamaid            | SB |
| <b>AMINO ACID FORMULA with VITAMINS and MINERALS<br/>without METHIONINE</b>                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>For infants and very young children with pyridoxine non-responsive homocystinuria.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8417B                                                                                                                         | Infant formula, powder 400 g                            | 8           | 5              | ..      | * 768.87                                 | 31.30                                                  | XMET Analog                          | SB |
| <b><u>Restricted Benefit</u></b><br><i>Pyridoxine non-responsive homocystinuria.</i>                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8677Q                                                                                                                         | Sachets 20 g, 30                                        | 4           | 5              | ..      | * 1797.99                                | 31.30                                                  | HCU gel                              | VF |
| 8744F                                                                                                                         | Sachets 25 g, 30                                        | 4           | 5              | ..      | * 3097.95                                | 31.30                                                  | HCU express                          | VF |
| 8328H                                                                                                                         | Powder 500 g                                            | 8           | 5              | ..      | * 1784.31                                | 31.30                                                  | XMET Maxamaid                        | SB |
| 8416Y                                                                                                                         | Powder 500 g                                            | 8           | 5              | ..      | * 2704.31                                | 31.30                                                  | XMET Maxamum                         | SB |
| 9133Q                                                                                                                         | Oral liquid 130 mL, 30                                  | 4           | 5              | ..      | * 3097.95                                | 31.30                                                  | HCU Cooler                           | VF |
| <b>AMINO ACID FORMULA with VITAMINS and MINERALS<br/>without METHIONINE, THREONINE and VALINE and low<br/>in ISOLEUCINE</b>   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Methylmalonic acidemia;<br/>Propionic acidemia.</i>                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8058D                                                                                                                         | Infant formula, powder 400 g                            | 8           | 5              | ..      | * 629.03                                 | 31.30                                                  | XMTVI Analog                         | SB |
| 8059E                                                                                                                         | Powder 500 g                                            | 8           | 5              | ..      | * 1542.31                                | 31.30                                                  | XMTVI Maxamaid                       | SB |
| 8061G                                                                                                                         | Powder 500 g                                            | 8           | 5              | ..      | * 1931.51                                | 31.30                                                  | XMTVI Maxamum                        | SB |



## VARIOUS—CONT.

| Code                                                                                        | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>AMINO ACID FORMULA with VITAMINS and MINERALS<br/>without PHENYLALANINE</b>              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u><br/>Phenylketonuria.</b>                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8555G                                                                                       | Sachets 20 g, 30                                        | 4           | 5              | ..      | * 890.59                                 | 31.30                                                  | PKU-gel                              | VF |
| 8591E                                                                                       | Sachets 25 g, 30                                        | 4           | 5              | ..      | * 1548.71                                | 31.30                                                  | PKU-Express                          | VF |
| 8804J                                                                                       | Sachets 27.8 g, 30                                      | 3           | 5              | ..      | * 1549.01                                | 31.30                                                  | Lophlex                              | SB |
| 8613H                                                                                       | Sachets 29 g, 30                                        | 4           | 5              | ..      | * 891.67                                 | 31.30                                                  | Minaphlex                            | SB |
| 8727H                                                                                       | Sachets 50 g, 30                                        | 3           | 5              | ..      | * 1511.63                                | 31.30                                                  | XP Maxamum                           | SB |
| 2737C                                                                                       | Infant formula, powder 400 g                            | 8           | 5              | ..      | * 605.99                                 | 31.30                                                  | XP Analog                            | SB |
| 8467P                                                                                       | Powder 325 g                                            | 10          | 5              | ..      | * 861.39                                 | 31.30                                                  | Phenex-2                             | AB |
| 8545R                                                                                       | Powder 400 g                                            | 8           | 5              | ..      | * 848.15                                 | 31.30                                                  | Phenex-2                             | AB |
| 2738D                                                                                       | Powder 500 g                                            | 8           | 5              | ..      | * 883.59                                 | 31.30                                                  | XP Maxamaid                          | SB |
| 2739E                                                                                       | Powder 500 g                                            | 8           | 5              | ..      | * 1351.99                                | 31.30                                                  | XP Maxamum                           | SB |
| 8746H                                                                                       | Oral liquid 250 mL                                      | 90          | 5              | ..      | * 1312.84                                | 31.30                                                  | Easiphen                             | SB |
| 2382J                                                                                       | Oral liquid 87 mL, 30                                   | 4           | 5              | ..      | * 1034.35                                | 31.30                                                  | PKU Cooler 10                        | VF |
| 9021T                                                                                       | Oral liquid 125 mL, 30                                  | 3           | 5              | ..      | * 1549.01                                | 31.30                                                  | Lophlex LQ                           | SB |
| 8846N                                                                                       | Oral liquid 130 mL, 30                                  | 4           | 5              | ..      | * 1547.91                                | 31.30                                                  | PKU Cooler 15                        | VF |
| 2474F                                                                                       | Oral liquid 174 mL, 30                                  | 4           | 5              | ..      | * 2053.59                                | 31.30                                                  | PKU Cooler 20                        | VF |
| <b>AMINO ACID FORMULA with VITAMINS and MINERALS<br/>without PHENYLALANINE and TYROSINE</b> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u><br/>Tyrosinaemia.</b>                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8631G                                                                                       | Sachets 20 g, 30                                        | 4           | 5              | ..      | * 1797.99                                | 31.30                                                  | TYR gel                              | VF |
| 8667E                                                                                       | Sachets 25 g, 30                                        | 4           | 5              | ..      | * 3097.95                                | 31.30                                                  | TYR Express                          | VF |
| 8445L                                                                                       | Infant formula, powder 400 g                            | 8           | 5              | ..      | * 768.87                                 | 31.30                                                  | XPhen, Tyr Analog                    | SB |
| 8446M                                                                                       | Powder 500 g                                            | 8           | 5              | ..      | * 1784.31                                | 31.30                                                  | XPhen, Tyr<br>Maxamaid               | SB |
| 3078B                                                                                       | Powder 500 g                                            | 8           | 5              | ..      | * 2704.31                                | 31.30                                                  | XPhen, Tyr<br>Maxamum                | SB |
| 9132P                                                                                       | Oral liquid 130 mL, 30                                  | 4           | 5              | ..      | * 3097.95                                | 31.30                                                  | TYR Cooler                           | VF |

## VARIOUS—CONT.

| Code                                                                                                                                                                                       | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>AMINO ACID FORMULA with VITAMINS and MINERALS<br/>without VALINE, LEUCINE and ISOLEUCINE</b>                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Maple syrup urine disease.</i>                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8592F                                                                                                                                                                                      | Sachets 20 g, 30                                        | 4           | 5              | ..      | * 1797.99                                | 31.30                                                  | MSUD-gel                             | VF |
| 8632H                                                                                                                                                                                      | Sachets 25 g, 30                                        | 4           | 5              | ..      | * 3097.95                                | 31.30                                                  | MSUD Express                         | VF |
| 8745G                                                                                                                                                                                      | Sachets 29 g, 30                                        | 4           | 5              | ..      | * 1800.03                                | 31.30                                                  | Mapleflex                            | SB |
| 8468Q                                                                                                                                                                                      | Infant formula, powder 350 g                            | 8           | 5              | ..      | * 776.23                                 | 31.30                                                  | Ketonex-1                            | AB |
| 2380G                                                                                                                                                                                      | Infant formula, powder 400 g                            | 8           | 5              | ..      | * 768.87                                 | 31.30                                                  | MSUD Analog                          | SB |
| 8469R                                                                                                                                                                                      | Powder 325 g                                            | 10          | 5              | ..      | * 1741.69                                | 31.30                                                  | Ketonex-2                            | AB |
| 8310J                                                                                                                                                                                      | Powder 500 g                                            | 4           | 5              | ..      | * 2671.55                                | 31.30                                                  | MSUD AID III                         | SB |
| 8260R                                                                                                                                                                                      | Powder 500 g                                            | 8           | 5              | ..      | * 1784.31                                | 31.30                                                  | MSUD Maxamaid                        | SB |
| 8057C                                                                                                                                                                                      | Powder 500 g                                            | 8           | 5              | ..      | * 2704.31                                | 31.30                                                  | MSUD Maxamum                         | SB |
| 2375B                                                                                                                                                                                      | Oral liquid 130 mL, 30                                  | 4           | 5              | ..      | * 3097.95                                | 31.30                                                  | MSUD Express<br>Cooler               | VF |
| <b>CARBOHYDRATE, FAT, VITAMINS, MINERALS and<br/>TRACE ELEMENTS</b>                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with<br/>permitted food and formulae.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8576J                                                                                                                                                                                      | Powder 400 g                                            | 8           | 5              | ..      | * 260.07                                 | 31.30                                                  | Pro-Phree                            | AB |
| 8369L                                                                                                                                                                                      | Powder 400 g                                            | 8           | 5              | ..      | * 291.03                                 | 31.30                                                  | Energivit                            | SB |
| <b>CYSTINE with CARBOHYDRATE</b>                                                                                                                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Pyridoxine non-responsive homocystinuria.</i>                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9164H                                                                                                                                                                                      | Sachets 4 g containing 500 mg cystine,<br>30            | 4           | 5              | ..      | * 515.59                                 | 31.30                                                  | Cystine Amino<br>Acid Supplement     | VF |
| <b>ESSENTIAL AMINO ACIDS FORMULA with MINERALS<br/>and VITAMIN C</b>                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Gyrate atrophy of the choroid and retina;<br/>Urea cycle disorders.</i>                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8001D                                                                                                                                                                                      | Powder 200 g                                            | 10          | 5              | ..      | * 633.69                                 | 31.30                                                  | Dialamine                            | SB |
| 2027Q                                                                                                                                                                                      | Powder 400 g                                            | 5           | 5              | ..      | * 633.74                                 | 31.30                                                  | Dialamine                            | SB |

## VARIOUS—CONT.

| Code                                                                                                                                                   | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>ISOLEUCINE with CARBOHYDRATE</b>                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Maple syrup urine disease.</i>                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9134R                                                                                                                                                  | Sachets 4 g containing 50 mg isoleucine,<br>30          | 4           | 5              | ..      | * 515.59                                 | 31.30                                                  | Isoleucine Amino<br>Acid Supplement  | VF |
| <b>MILK PROTEIN and FAT FORMULA with VITAMINS and<br/>MINERALS—CARBOHYDRATE FREE</b>                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients with intractable seizures requiring treatment with a ketogenic diet;</i>                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Glucose transport protein defects;</i>                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Pyruvate dehydrogenase deficiency;</i>                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Infants and young children with glucose-galactose intolerance and multiple monosaccharide intolerance.</i>                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8630F                                                                                                                                                  | Powder 225 g                                            | 24          | 5              | ..      | * 647.99                                 | 31.30                                                  | Carbohydrate Free<br>Mixture         | SB |
| <b>MINERAL MIXTURE</b>                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b>                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>For use with Amino Acid Formula without Phenylalanine.</i>                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Metabolic disorders.</i>                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 1451J                                                                                                                                                  | Powder 250 g                                            | ± 1         | 5              | ..      | 58.11                                    | 31.30                                                  | Metabolic Mineral<br>Mixture         | SB |
| <b>SOY PROTEIN and FAT FORMULA with VITAMINS and<br/>MINERALS—CARBOHYDRATE FREE</b>                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients with intractable seizures requiring treatment with a ketogenic diet;</i>                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Glucose transport protein defects;</i>                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Pyruvate dehydrogenase deficiency;</i>                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Infants and young children with glucose-galactose intolerance and multiple monosaccharide intolerance.</i>                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8577K                                                                                                                                                  | Liquid 384 mL                                           | 120         | 5              | ..      | * 669.59                                 | 31.30                                                  | RCF                                  | AB |
| <b>TRIGLYCERIDES, MEDIUM CHAIN and LONG CHAIN with<br/>GLUCOSE POLYMER</b>                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with<br/>permitted food and formulae.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 3136C                                                                                                                                                  | Compound powder 400 g                                   | 8           | 5              | ..      | * 295.11                                 | 31.30                                                  | Duocal                               | SB |

# VARIOUS—CONT.

| Code                                                                                                                                                                                                   | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>TYROSINE with CARBOHYDRATE</b>                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><i>Phenylketonuria.</i></b>                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9165J                                                                                                                                                                                                  | Sachets 4 g containing 1 g tyrosine, 30                 | 4           | 5              | ..      | * 515.59                                 | 31.30                                                  | Tyrosine Amino<br>Acid Supplement    | VF |
| <b>VALINE with CARBOHYDRATE</b>                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><i>Maple syrup urine disease.</i></b>                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 9135T                                                                                                                                                                                                  | Sachets 4 g containing 50 mg valine, 30                 | 4           | 5              | ..      | * 515.59                                 | 31.30                                                  | Valine Amino Acid<br>Supplement      | VF |
| <b>WHEY PROTEIN FORMULA supplemented with AMINO<br/>ACIDS, VITAMINS and MINERALS, and low in PROTEIN,<br/>PHOSPHATE, POTASSIUM and LACTOSE</b>                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Authority Required</u></b>                                                                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><i>Infants and young children with chronic renal failure requiring treatment with a low protein and a low phosphorus<br/>diet, or a low protein, a low phosphorus and a low potassium diet.</i></b> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 8587Y                                                                                                                                                                                                  | Powder 400 g                                            | 16          | 5              | ..      | * 1065.51                                | 31.30                                                  | Kindergen                            | SB |

## ALL OTHER NON-THERAPEUTIC PRODUCTS

### All other non-therapeutic products

#### • Solvents and diluting agents, incl. irrigating solutions

#### SODIUM CHLORIDE

|       |                                     |   |   |    |       |       |    |  |
|-------|-------------------------------------|---|---|----|-------|-------|----|--|
| 2026P | Injection 9 mg per mL (0.9%), 10 mL | 5 | 1 | .. | 17.73 | 18.76 | PF |  |
|-------|-------------------------------------|---|---|----|-------|-------|----|--|

## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE

---

### PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE

The prescribing of medications listed in this section is in accordance with the requirements for General Pharmaceutical Benefits in the Schedule unless otherwise detailed in the listing for the item.

In addition, certain additional principles have been applied by the Pharmaceutical Benefits Advisory Committee (PBAC) in recommending for whom these medications may be prescribed, and the number of repeats that may be approved by Medicare Australia. These principles have been encompassed in the listings for the items, and further details are provided below to help doctors prescribing under this section.

For the purposes of this section a patient receiving palliative care is defined as:

- *A patient with an active, progressive, far-advanced disease for whom the prognosis is limited and the focus of care is the quality of life.*

The provision for increased maximum quantities and up to 3 repeats on the *initial* authority prescription is intended to provide up to 4 months' therapy in total. Where *continuing* treatment is required the provision of repeats is subject to confirmation by the prescriber that a palliative care physician or palliative care service has been consulted regarding the care of the patient.

Prescribers must heed State/Territory laws when prescribing drugs listed as narcotic, specified or restricted and must notify, or receive approval from, the appropriate health authority.

When a Palliative Care authority application is for a drug of addiction, the following guidelines apply:

- the maximum quantity authorised is generally for 1 month's therapy;
- where supply for a longer period is warranted, quantities are for up to 3 months' therapy;
- telephone approvals are limited to 1 month's therapy.

Doctors should also state (on the prescription) the interval of repeat where repeats are called for, and ensure State/Territory health authorities are notified about ongoing treatment.

Prescribers should be aware that patients receiving palliative care may also access PBS items included in the general part of the Schedule of Pharmaceutical Benefits including narcotic preparations, according to the restrictions that apply to individual items and the requirements that apply to the general part of the Schedule.

**PREPARATIONS WHICH MAY BE PRESCRIBED FOR  
PATIENTS RECEIVING PALLIATIVE CARE-cont.**

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|

**ALIMENTARY TRACT AND METABOLISM**

**STOMATOLOGICAL PREPARATIONS**

**Stomatological preparations**

• **Other agents for local oral treatment**

**BENZYDAMINE HYDROCHLORIDE**

**Authority Required**

*Initial supply (for up to 4 months) for palliative care patients where a painful mouth is a problem;*

*Continuing supply for palliative care patients where a painful mouth is a problem, and where consultation with a palliative care specialist or service has occurred.*

**NOTE:**

*No applications for increased repeats will be authorised.*

|       |                                                  |     |   |    |       |       |         |    |
|-------|--------------------------------------------------|-----|---|----|-------|-------|---------|----|
| 5385K | Mouth and throat rinse 22.5 mg per 15 mL, 500 mL | ± 1 | 3 | .. | 21.09 | 22.12 | Difflam | IA |
|-------|--------------------------------------------------|-----|---|----|-------|-------|---------|----|

**Authority Required**

*Continuing supply for palliative care patients where a painful mouth is a problem.*

**NOTE:**

*No applications for repeats will be authorised.*

|       |                                                  |     |    |    |       |       |         |    |
|-------|--------------------------------------------------|-----|----|----|-------|-------|---------|----|
| 5386L | Mouth and throat rinse 22.5 mg per 15 mL, 500 mL | ± 1 | .. | .. | 21.09 | 22.12 | Difflam | IA |
|-------|--------------------------------------------------|-----|----|----|-------|-------|---------|----|

**CARMELLOSE SODIUM**

**Authority Required**

*Initial supply (for up to 4 months) for palliative care patients where dry mouth is a symptom;*

*Continuing supply for palliative care patients where dry mouth is a symptom, and where consultation with a palliative care specialist or service has occurred.*

**NOTE:**

*No applications for increased repeats will be authorised.*

|       |                                  |     |   |    |       |       |       |    |
|-------|----------------------------------|-----|---|----|-------|-------|-------|----|
| 5333Q | Mouth spray 10 mg per mL, 25 mL  | ± 1 | 3 | .. | 9.77  | 10.80 | Aquae | HA |
| 5334R | Mouth spray 10 mg per mL, 100 mL | ± 1 | 3 | .. | 11.79 | 12.82 | Aquae | HA |

**Authority Required**

*Continuing supply for palliative care patients where dry mouth is a symptom.*

**NOTE:**

*No applications for repeats will be authorised.*

|       |                                  |     |    |    |       |       |       |    |
|-------|----------------------------------|-----|----|----|-------|-------|-------|----|
| 5335T | Mouth spray 10 mg per mL, 25 mL  | ± 1 | .. | .. | 9.77  | 10.80 | Aquae | HA |
| 5336W | Mouth spray 10 mg per mL, 100 mL | ± 1 | .. | .. | 11.79 | 12.82 | Aquae | HA |

## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE-cont.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

### DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

#### **Belladonna and derivatives, plain**

- **Belladonna alkaloids semisynthetic, quaternary ammonium compounds**

#### **HYOSCINE BUTYLBROMIDE**

##### Authority Required

*Initial supply (for up to 4 months) for palliative care patients where colicky pain is a symptom;*

*Continuing supply for palliative care patients where colicky pain is a symptom, and where consultation with a palliative care specialist or service has occurred.*

##### NOTE:

*No applications for increased repeats will be authorised.*

|       |                         |   |   |    |       |       |          |    |
|-------|-------------------------|---|---|----|-------|-------|----------|----|
| 5317W | Injection 20 mg in 1 mL | 5 | 3 | .. | 20.95 | 21.98 | Buscopan | BY |
|-------|-------------------------|---|---|----|-------|-------|----------|----|

##### Authority Required

*Continuing supply for palliative care patients where colicky pain is a symptom.*

##### NOTE:

*No applications for repeats will be authorised.*

|       |                         |   |    |    |       |       |          |    |
|-------|-------------------------|---|----|----|-------|-------|----------|----|
| 5318X | Injection 20 mg in 1 mL | 5 | .. | .. | 20.95 | 21.98 | Buscopan | BY |
|-------|-------------------------|---|----|----|-------|-------|----------|----|

### ANTIEMETICS AND ANTINAUSEANTS

#### **Antiemetics and antinauseants**

- **Other antiemetics**

#### **PROMETHAZINE HYDROCHLORIDE**

##### Authority Required

*Initial supply (for up to 4 months) for palliative care patients where nausea and/or vomiting is a problem;*

*Continuing supply for palliative care patients where nausea and/or vomiting is a problem, and where consultation with a palliative care specialist or service has occurred.*

##### NOTE:

*No applications for increased repeats will be authorised.*

|       |                                   |     |   |    |       |       |           |    |
|-------|-----------------------------------|-----|---|----|-------|-------|-----------|----|
| 5325G | Tablet 10 mg                      | 50  | 3 | .. | 14.24 | 15.27 | Phenergan | SW |
| 5326H | Tablet 25 mg                      | 50  | 3 | .. | 16.33 | 17.36 | Phenergan | SW |
| 5327J | Oral liquid 5 mg per 5 mL, 100 mL | ± 1 | 3 | .. | 14.24 | 15.27 | Phenergan | SW |

continued ➞

## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE-cont.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

### Authority Required

*Continuing supply for palliative care patients where nausea and/or vomiting is a problem.*

### NOTE:

*No applications for repeats will be authorised.*

|       |                                   |     |    |    |       |       |           |    |
|-------|-----------------------------------|-----|----|----|-------|-------|-----------|----|
| 5328K | Tablet 10 mg                      | 50  | .. | .. | 14.24 | 15.27 | Phenergan | SW |
| 5329L | Tablet 25 mg                      | 50  | .. | .. | 16.33 | 17.36 | Phenergan | SW |
| 5330M | Oral liquid 5 mg per 5 mL, 100 mL | ± 1 | .. | .. | 14.24 | 15.27 | Phenergan | SW |

## LAXATIVES

### **Laxatives**

#### • **Contact laxatives**

### **BISACODYL**

### Authority Required

*Initial supply (for up to 4 months) for palliative care patients where constipation is a problem;*

*Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred.*

### NOTE:

*No applications for increased repeats will be authorised.*

|       |                         |     |   |       |         |       |                                                                      |          |
|-------|-------------------------|-----|---|-------|---------|-------|----------------------------------------------------------------------|----------|
| 5301B | Tablet 5 mg             | 200 | 3 | ..    | 14.17   | 15.20 | Bisalax<br>Lax-Tab                                                   | AS<br>AE |
| 5303D | Suppositories 10 mg, 10 | 3   | 3 | ..    | * 21.44 | 22.47 | <sup>a</sup> Petrus Bisacodyl<br>Suppositories                       | PP       |
|       |                         |     |   | B1.14 | * 22.58 | 22.47 | <sup>a</sup> Dulcolax                                                | BY       |
| 5304E | Suppositories 10 mg, 12 | 3   | 3 | ..    | * 18.62 | 19.65 | Fleet Laxative<br>Suppositories<br>Petrus Bisacodyl<br>Suppositories | FL<br>PP |

### Authority Required

*Continuing supply for palliative care patients where constipation is a problem.*

### NOTE:

*No applications for repeats will be authorised.*

|       |                         |     |    |       |         |       |                                                |          |
|-------|-------------------------|-----|----|-------|---------|-------|------------------------------------------------|----------|
| 5305F | Tablet 5 mg             | 200 | .. | ..    | 14.17   | 15.20 | Bisalax<br>Lax-Tab                             | AS<br>AE |
| 5307H | Suppositories 10 mg, 10 | 3   | .. | ..    | * 21.44 | 22.47 | <sup>a</sup> Petrus Bisacodyl<br>Suppositories | PP       |
|       |                         |     |    | B1.14 | * 22.58 | 22.47 | <sup>a</sup> Dulcolax                          | BY       |

continued ➡



## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE-cont.

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                 |          |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------|----------|
| 5308J | Suppositories 10 mg, 12                                 | 3           | ..             | ..      | * 18.62                                  | 19.65                                                  | Fleet Laxative<br>Suppositories<br>Petrus Bisacodyl<br>Suppositories | FL<br>PP |

- **Bulk producers**

*STERCULIA with FRANGULA BARK*

Authority Required

*Initial supply (for up to 4 months) for palliative care patients where constipation is a problem;*

*Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred.*

NOTE:

*No applications for increased repeats will be authorised.*

|       |                                                |     |   |    |       |       |               |    |
|-------|------------------------------------------------|-----|---|----|-------|-------|---------------|----|
| 5322D | Granules 620 mg-80 mg per g<br>(62%-8%), 500 g | ± 1 | 3 | .. | 24.52 | 25.55 | Normacol Plus | NE |
|-------|------------------------------------------------|-----|---|----|-------|-------|---------------|----|

Authority Required

*Continuing supply for palliative care patients where constipation is a problem.*

NOTE:

*No applications for repeats will be authorised.*

|       |                                                |     |    |    |       |       |               |    |
|-------|------------------------------------------------|-----|----|----|-------|-------|---------------|----|
| 5324F | Granules 620 mg-80 mg per g<br>(62%-8%), 500 g | ± 1 | .. | .. | 24.52 | 25.55 | Normacol Plus | NE |
|-------|------------------------------------------------|-----|----|----|-------|-------|---------------|----|

- **Osmotically acting laxatives**

*LACTULOSE*

Authority Required

*Initial supply (for up to 4 months) for palliative care patients where constipation is a problem;*

*Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred.*

NOTE:

*No applications for increased repeats will be authorised.*

|       |                                 |     |   |       |       |       |                                                                                                                                                       |                                  |
|-------|---------------------------------|-----|---|-------|-------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| 5387M | Mixture 3.34 g per 5 mL, 500 mL | ± 1 | 3 | ..    | 13.80 | 14.83 | <sup>a</sup> Actilax<br><sup>a</sup> Genlac<br><sup>a</sup> GenRx Lactulose<br><sup>a</sup> Lac-Dol<br><sup>a</sup> Lactocur<br><sup>a</sup> Duphalac | AF<br>AW<br>GX<br>GM<br>HX<br>SM |
|       |                                 |     |   | 81.67 | 15.47 | 14.83 |                                                                                                                                                       |                                  |

continued ➡

## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE-cont.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

**Authority Required**

*Continuing supply for palliative care patients where constipation is a problem.*

**NOTE:**

*No applications for repeats will be authorised.*

|       |                                 |     |    |       |       |       |                              |    |
|-------|---------------------------------|-----|----|-------|-------|-------|------------------------------|----|
| 5388N | Mixture 3.34 g per 5 mL, 500 mL | ± 1 | .. | ..    | 13.80 | 14.83 | <sup>a</sup> Actilax         | AF |
|       |                                 |     |    |       |       |       | <sup>a</sup> Genlac          | AW |
|       |                                 |     |    |       |       |       | <sup>a</sup> GenRx Lactulose | GX |
|       |                                 |     |    |       |       |       | <sup>a</sup> Lac-Dol         | GM |
|       |                                 |     |    |       |       |       | <sup>a</sup> Lactocur        | HX |
|       |                                 |     |    | B1.67 | 15.47 | 14.83 | <sup>a</sup> Duphalac        | SM |

**MACROGOL 3350****Authority Required**

*Initial supply (for up to 4 months) for palliative care patients where constipation is a problem;*

*Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred.*

**NOTE:**

*No applications for increased repeats will be authorised.*

|       |                                                                          |     |   |    |       |       |         |    |
|-------|--------------------------------------------------------------------------|-----|---|----|-------|-------|---------|----|
| 5389P | Sachets containing powder for solution<br>13.125 g with electrolytes, 30 | ± 1 | 3 | .. | 24.36 | 25.39 | Movicol | NE |
|-------|--------------------------------------------------------------------------|-----|---|----|-------|-------|---------|----|

**Authority Required**

*Continuing supply for palliative care patients where constipation is a problem.*

**NOTE:**

*No applications for repeats will be authorised.*

|       |                                                                          |     |    |    |       |       |         |    |
|-------|--------------------------------------------------------------------------|-----|----|----|-------|-------|---------|----|
| 5390Q | Sachets containing powder for solution<br>13.125 g with electrolytes, 30 | ± 1 | .. | .. | 24.36 | 25.39 | Movicol | NE |
|-------|--------------------------------------------------------------------------|-----|----|----|-------|-------|---------|----|

• **Enemas****BISACODYL****Authority Required**

*Initial supply (for up to 4 months) for palliative care patients where constipation is a problem;*

*Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred.*

**NOTE:**

*No applications for increased repeats will be authorised.*

|       |                          |     |   |    |       |       |         |    |
|-------|--------------------------|-----|---|----|-------|-------|---------|----|
| 5302C | Enemas 10 mg in 5 mL, 25 | ± 1 | 3 | .. | 37.97 | 31.30 | Bisalax | AS |
|-------|--------------------------|-----|---|----|-------|-------|---------|----|

continued ➞

## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE-cont.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

### Authority Required

*Continuing supply for palliative care patients where constipation is a problem.*

### NOTE:

*No applications for repeats will be authorised.*

|       |                          |     |    |    |       |       |         |    |
|-------|--------------------------|-----|----|----|-------|-------|---------|----|
| 5306G | Enemas 10 mg in 5 mL, 25 | ± 1 | .. | .. | 37.97 | 31.30 | Bisalax | AS |
|-------|--------------------------|-----|----|----|-------|-------|---------|----|

**SORBITOL with SODIUM CITRATE and SODIUM LAURYL  
SULFOACETATE**

### Authority Required

*Initial supply (for up to 4 months) for palliative care patients where constipation is a problem;*

*Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred.*

### NOTE:

*No applications for increased repeats will be authorised.*

|       |                                            |   |   |    |         |       |          |    |
|-------|--------------------------------------------|---|---|----|---------|-------|----------|----|
| 5331N | Enemas 3.125 g-450 mg-45 mg in 5 mL,<br>12 | 2 | 3 | .. | * 36.15 | 31.30 | Microlax | JT |
|-------|--------------------------------------------|---|---|----|---------|-------|----------|----|

### Authority Required

*Continuing supply for palliative care patients where constipation is a problem.*

### NOTE:

*No applications for repeats will be authorised.*

|       |                                            |   |    |    |         |       |          |    |
|-------|--------------------------------------------|---|----|----|---------|-------|----------|----|
| 5332P | Enemas 3.125 g-450 mg-45 mg in 5 mL,<br>12 | 2 | .. | .. | * 36.15 | 31.30 | Microlax | JT |
|-------|--------------------------------------------|---|----|----|---------|-------|----------|----|

### • **Other laxatives**

#### **GLYCEROL**

### Authority Required

*Initial supply (for up to 4 months) for palliative care patients where constipation is a problem;*

*Continuing supply for palliative care patients where constipation is a problem, and where consultation with a palliative care specialist or service has occurred.*

### NOTE:

*No applications for increased repeats will be authorised.*

|       |                                        |   |   |    |         |       |    |  |
|-------|----------------------------------------|---|---|----|---------|-------|----|--|
| 5311M | Suppositories 700 mg (for infants), 12 | 3 | 3 | .. | * 17.48 | 18.51 | PP |  |
| 5312N | Suppositories 1.4 g (for children), 12 | 3 | 3 | .. | * 17.87 | 18.90 | PP |  |
| 5313P | Suppositories 2.8 g (for adults), 12   | 3 | 3 | .. | * 18.32 | 19.35 | PP |  |

continued ➞

## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE-cont.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|

### Authority Required

*Continuing supply for palliative care patients where constipation is a problem.*

### NOTE:

*No applications for repeats will be authorised.*

|       |                                        |   |    |    |         |       |    |
|-------|----------------------------------------|---|----|----|---------|-------|----|
| 5314Q | Suppositories 700 mg (for infants), 12 | 3 | .. | .. | * 17.48 | 18.51 | PP |
| 5315R | Suppositories 1.4 g (for children), 12 | 3 | .. | .. | * 17.87 | 18.90 | PP |
| 5316T | Suppositories 2.8 g (for adults), 12   | 3 | .. | .. | * 18.32 | 19.35 | PP |

## MUSCULO-SKELETAL SYSTEM

### ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

#### Antiinflammatory and antirheumatic products, non-steroids

#### • Acetic acid derivatives and related substances

#### DICLOFENAC SODIUM

### Authority Required

*Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem;*

*Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred.*

### NOTE:

*No applications for increased repeats will be authorised.*

|       |                               |     |   |       |         |       |                               |    |
|-------|-------------------------------|-----|---|-------|---------|-------|-------------------------------|----|
| 5361E | Tablet 25 mg (enteric coated) | 100 | 3 | ..    | * 12.63 | 13.66 | <sup>a</sup> Chem mart        | CH |
|       |                               |     |   |       |         |       | Diclofenac                    |    |
|       |                               |     |   |       |         |       | <sup>a</sup> Clonac 25        | AW |
|       |                               |     |   |       |         |       | <sup>a</sup> Diclohexal       | SZ |
|       |                               |     |   |       |         |       | <sup>a</sup> Dinac            | GM |
|       |                               |     |   |       |         |       | <sup>a</sup> GenRx Diclofenac | GX |
|       |                               |     |   |       |         |       | <sup>a</sup> Terry White      | TW |
|       |                               |     |   |       |         |       | Chemists                      |    |
|       |                               |     |   |       |         |       | Diclofenac                    |    |
|       |                               |     |   | ..    | 12.64   | 13.67 | <sup>a</sup> Fenac 25         | AF |
|       |                               |     |   | B1.96 | * 14.59 | 13.66 | <sup>a</sup> Voltaren 25      | NV |
| 5362F | Tablet 50 mg (enteric coated) | 50  | 3 | ..    | 10.62   | 11.65 | <sup>a</sup> Chem mart        | CH |
|       |                               |     |   |       |         |       | Diclofenac                    |    |
|       |                               |     |   |       |         |       | <sup>a</sup> Clonac 50        | AW |
|       |                               |     |   |       |         |       | <sup>a</sup> Diclohexal       | SZ |
|       |                               |     |   |       |         |       | <sup>a</sup> Dinac            | GM |
|       |                               |     |   |       |         |       | <sup>a</sup> Fenac            | AF |
|       |                               |     |   |       |         |       | <sup>a</sup> GenRx Diclofenac | GX |
|       |                               |     |   |       |         |       | <sup>a</sup> Terry White      | TW |
|       |                               |     |   |       |         |       | Chemists                      |    |
|       |                               |     |   |       |         |       | Diclofenac                    |    |
|       |                               |     |   | B1.96 | 12.58   | 11.65 | <sup>a</sup> Voltaren 50      | NV |

continued ☞

**PREPARATIONS WHICH MAY BE PRESCRIBED FOR  
PATIENTS RECEIVING PALLIATIVE CARE-cont.**

| Code                                                                                  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer               |    |
|---------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------|----|
| 5363G                                                                                 | Suppository 100 mg                                      | 40          | 3              | ..      | * 24.49                                  | 25.52                                                  | Voltaren 100                                       | NV |
| <hr/>                                                                                 |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| <b><u>Authority Required</u></b>                                                      |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| <i>Continuing supply for palliative care patients where severe pain is a problem.</i> |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| <b><u>NOTE:</u></b>                                                                   |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| <i>No applications for repeats will be authorised.</i>                                |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| 5364H                                                                                 | Tablet 25 mg (enteric coated)                           | 100         | ..             | ..      | * 12.63                                  | 13.66                                                  | <sup>a</sup> Chem mart<br>Diclofenac               | CH |
|                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clonac 25                             | AW |
|                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Diclohexal                            | SZ |
|                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dinac                                 | GM |
|                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Diclofenac                      | GX |
|                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Diclofenac | TW |
|                                                                                       |                                                         |             |                | ..      | 12.64                                    | 13.67                                                  | <sup>a</sup> Fenac 25                              | AF |
|                                                                                       |                                                         |             |                | B1.96   | * 14.59                                  | 13.66                                                  | <sup>a</sup> Voltaren 25                           | NV |
| 5365J                                                                                 | Tablet 50 mg (enteric coated)                           | 50          | ..             | ..      | 10.62                                    | 11.65                                                  | <sup>a</sup> Chem mart<br>Diclofenac               | CH |
|                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clonac 50                             | AW |
|                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Diclohexal                            | SZ |
|                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dinac                                 | GM |
|                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fenac                                 | AF |
|                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Diclofenac                      | GX |
|                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Diclofenac | TW |
|                                                                                       |                                                         |             |                | B1.96   | 12.58                                    | 11.65                                                  | <sup>a</sup> Voltaren 50                           | NV |
| 5366K                                                                                 | Suppository 100 mg                                      | 40          | ..             | ..      | * 24.49                                  | 25.52                                                  | Voltaren 100                                       | NV |

**INDOMETHACIN**

**Authority Required**

*Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem;*

*Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred.*

**NOTE:**

*No applications for increased repeats will be authorised.*

|       |                    |     |   |       |         |       |                        |    |
|-------|--------------------|-----|---|-------|---------|-------|------------------------|----|
| 5377B | Capsule 25 mg      | 100 | 3 | ..    | * 10.23 | 11.26 | <sup>a</sup> Arthrexin | AF |
|       |                    |     |   | B2.34 | * 12.57 | 11.26 | <sup>a</sup> Indocid   | MK |
| 5378C | Suppository 100 mg | 40  | 3 | ..    | * 22.07 | 23.10 | Indocid                | MK |

continued ➡

## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE-cont.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

### Authority Required

*Continuing supply for palliative care patients where severe pain is a problem.*

### NOTE:

*No applications for repeats will be authorised.*

|       |                    |     |    |       |         |       |                        |    |
|-------|--------------------|-----|----|-------|---------|-------|------------------------|----|
| 5379D | Capsule 25 mg      | 100 | .. | ..    | * 10.23 | 11.26 | <sup>a</sup> Arthrexin | AF |
|       |                    |     |    | B2.34 | * 12.57 | 11.26 | <sup>a</sup> Indocid   | MK |
| 5380E | Suppository 100 mg | 40  | .. | ..    | * 22.07 | 23.10 | Indocid                | MK |

### SULINDAC

### Authority Required

*Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem;*

*Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred.*

### NOTE:

*No applications for increased repeats will be authorised.*

|       |               |     |   |    |         |       |           |    |
|-------|---------------|-----|---|----|---------|-------|-----------|----|
| 5381F | Tablet 100 mg | 100 | 3 | .. | * 15.91 | 16.94 | Aclin     | AF |
| 5382G | Tablet 200 mg | 50  | 3 | .. | 14.85   | 15.88 | Aclin 200 | AF |

### Authority Required

*Continuing supply for palliative care patients where severe pain is a problem.*

### NOTE:

*No applications for repeats will be authorised.*

|       |               |     |    |    |         |       |           |    |
|-------|---------------|-----|----|----|---------|-------|-----------|----|
| 5383H | Tablet 100 mg | 100 | .. | .. | * 15.91 | 16.94 | Aclin     | AF |
| 5384J | Tablet 200 mg | 50  | .. | .. | 14.85   | 15.88 | Aclin 200 | AF |

### • **Propionic acid derivatives**

#### **IBUPROFEN**

### Authority Required

*Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem;*

*Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred.*

### NOTE:

*No applications for increased repeats will be authorised.*

|       |               |     |   |    |         |       |           |    |
|-------|---------------|-----|---|----|---------|-------|-----------|----|
| 5367L | Tablet 200 mg | 100 | 3 | .. | * 11.63 | 12.66 | Rafen 200 | AF |
| 5368M | Tablet 400 mg | 90  | 3 | .. | * 14.30 | 15.33 | Brufen    | AB |

continued ➞

## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE-cont.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

**Authority Required**

*Continuing supply for palliative care patients where severe pain is a problem.*

**NOTE:**

*No applications for repeats will be authorised.*

|       |               |     |    |    |         |       |           |    |
|-------|---------------|-----|----|----|---------|-------|-----------|----|
| 5369N | Tablet 200 mg | 100 | .. | .. | * 11.63 | 12.66 | Rafen 200 | AF |
| 5370P | Tablet 400 mg | 90  | .. | .. | * 14.30 | 15.33 | Brufen    | AB |

**NAPROXEN****Authority Required**

*Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem;*

*Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred.*

**NOTE:**

*No applications for increased repeats will be authorised.*

|       |                                   |     |   |       |         |       |                              |    |
|-------|-----------------------------------|-----|---|-------|---------|-------|------------------------------|----|
| 5345H | Tablet 250 mg                     | 100 | 3 | ..    | * 13.29 | 14.32 | <sup>a</sup> Inza 250        | AF |
|       |                                   |     |   | B2.34 | * 15.63 | 14.32 | <sup>a</sup> Naprosyn        | RO |
| 5346J | Tablet 500 mg                     | 50  | 3 | ..    | 12.48   | 13.51 | <sup>a</sup> Inza 500        | AF |
|       |                                   |     |   | B1.36 | 13.84   | 13.51 | <sup>a</sup> Naprosyn        | RO |
| 5347K | Tablet 750 mg (sustained release) | 28  | 3 | ..    | 11.95   | 12.98 | <sup>a</sup> Proxen SR 750   | MD |
|       |                                   |     |   | B1.27 | 13.22   | 12.98 | <sup>a</sup> Naprosyn SR750  | RO |
| 5348L | Tablet 1 g (sustained release)    | 28  | 3 | ..    | 13.94   | 14.97 | <sup>a</sup> Proxen SR 1000  | MD |
|       |                                   |     |   | B1.34 | 15.28   | 14.97 | <sup>a</sup> Naprosyn SR1000 | RO |

**Authority Required**

*Continuing supply for palliative care patients where severe pain is a problem.*

**NOTE:**

*No applications for repeats will be authorised.*

|       |                                   |     |    |       |         |       |                              |    |
|-------|-----------------------------------|-----|----|-------|---------|-------|------------------------------|----|
| 5349M | Tablet 250 mg                     | 100 | .. | ..    | * 13.29 | 14.32 | <sup>a</sup> Inza 250        | AF |
|       |                                   |     |    | B2.34 | * 15.63 | 14.32 | <sup>a</sup> Naprosyn        | RO |
| 5350N | Tablet 500 mg                     | 50  | .. | ..    | 12.48   | 13.51 | <sup>a</sup> Inza 500        | AF |
|       |                                   |     |    | B1.36 | 13.84   | 13.51 | <sup>a</sup> Naprosyn        | RO |
| 5351P | Tablet 750 mg (sustained release) | 28  | .. | ..    | 11.95   | 12.98 | <sup>a</sup> Proxen SR 750   | MD |
|       |                                   |     |    | B1.27 | 13.22   | 12.98 | <sup>a</sup> Naprosyn SR750  | RO |
| 5352Q | Tablet 1 g (sustained release)    | 28  | .. | ..    | 13.94   | 14.97 | <sup>a</sup> Proxen SR 1000  | MD |
|       |                                   |     |    | B1.34 | 15.28   | 14.97 | <sup>a</sup> Naprosyn SR1000 | RO |

continued ➡

## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE-cont.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

**Authority Required**

*Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem in patients unable to take a solid dose form of a non-steroidal anti-inflammatory agent;*

*Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred, in patients unable to take a solid dose form of a non-steroidal anti-inflammatory agent.*

**NOTE:**

*No applications for increased repeats will be authorised.*

|       |                                            |     |   |    |       |       |          |    |
|-------|--------------------------------------------|-----|---|----|-------|-------|----------|----|
| 5397C | Oral suspension 125 mg per 5 mL,<br>474 mL | ± 1 | 3 | .. | 77.74 | 31.30 | Naprosyn | RO |
|-------|--------------------------------------------|-----|---|----|-------|-------|----------|----|

**Authority Required**

*Continuing supply for palliative care patients where severe pain is a problem in patients unable to take a solid dose form of a non-steroidal anti-inflammatory agent.*

**NOTE:**

*No applications for repeats will be authorised.*

|       |                                            |     |    |    |       |       |          |    |
|-------|--------------------------------------------|-----|----|----|-------|-------|----------|----|
| 5398D | Oral suspension 125 mg per 5 mL,<br>474 mL | ± 1 | .. | .. | 77.74 | 31.30 | Naprosyn | RO |
|-------|--------------------------------------------|-----|----|----|-------|-------|----------|----|

**NAPROXEN SODIUM****Authority Required**

*Initial supply (for up to 4 months) for palliative care patients where severe pain is a problem;*

*Continuing supply for palliative care patients where severe pain is a problem, and where consultation with a palliative care specialist or service has occurred.*

**NOTE:**

*No applications for increased repeats will be authorised.*

|       |               |    |   |       |       |       |                          |    |
|-------|---------------|----|---|-------|-------|-------|--------------------------|----|
| 5353R | Tablet 550 mg | 50 | 3 | ..    | 12.67 | 13.70 | <sup>a</sup> Crysanal    | MD |
|       |               |    |   | B2.29 | 14.96 | 13.70 | <sup>a</sup> Anaprox 550 | RO |

**NOTE:**

*Naproxen sodium 550 mg is approximately equivalent to 500 mg of naproxen acid.*

**Authority Required**

*Continuing supply for palliative care patients where severe pain is a problem.*

**NOTE:**

*No applications for repeats will be authorised.*

|       |               |    |    |       |       |       |                          |    |
|-------|---------------|----|----|-------|-------|-------|--------------------------|----|
| 5354T | Tablet 550 mg | 50 | .. | ..    | 12.67 | 13.70 | <sup>a</sup> Crysanal    | MD |
|       |               |    |    | B2.29 | 14.96 | 13.70 | <sup>a</sup> Anaprox 550 | RO |

**NOTE:**

*Naproxen sodium 550 mg is approximately equivalent to 500 mg of naproxen acid.*



## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE-cont.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

### NERVOUS SYSTEM

#### ANALGESICS

##### Opioids

##### • Natural opium alkaloids

##### MORPHINE SULFATE

##### CAUTION:

*The risk of drug dependence is high.*

##### Authority Required

*Initial supply (for up to 3 months) for palliative care patients with severe disabling pain not responding to non-narcotic analgesics;*

*Continuing supply (for up to 3 months) for palliative care patients with severe disabling pain not responding to non-narcotic analgesics, and where consultation with a palliative care specialist or service has occurred.*

##### NOTE:

*Telephone approvals are limited to 1 month's therapy.*

|       |              |    |   |    |       |       |          |    |
|-------|--------------|----|---|----|-------|-------|----------|----|
| 5393W | Tablet 10 mg | 20 | 2 | .. | 14.85 | 15.88 | Sevredol | MF |
| 5394X | Tablet 20 mg | 20 | 2 | .. | 15.99 | 17.02 | Sevredol | MF |

##### Authority Required

*Continuing supply (for up to 1 month) for palliative care patients with severe disabling pain not responding to non-narcotic analgesics.*

##### NOTE:

*No applications for repeats will be authorised.*

|       |              |    |    |    |       |       |          |    |
|-------|--------------|----|----|----|-------|-------|----------|----|
| 5395Y | Tablet 10 mg | 20 | .. | .. | 14.85 | 15.88 | Sevredol | MF |
| 5396B | Tablet 20 mg | 20 | .. | .. | 15.99 | 17.02 | Sevredol | MF |

##### Authority Required

*Initial supply (for up to 3 months) for palliative care patients with chronic severe disabling pain not responding to non-narcotic analgesics;*

*Continuing supply (for up to 3 months) for palliative care patients with chronic severe disabling pain not responding to non-narcotic analgesics, and where consultation with a palliative care specialist or service has occurred.*

##### NOTE:

*Telephone approvals are limited to 1 month's therapy.*

|       |                                    |    |   |    |        |       |           |    |
|-------|------------------------------------|----|---|----|--------|-------|-----------|----|
| 5391R | Tablet 200 mg (controlled release) | 20 | 2 | .. | 104.50 | 31.30 | MS Contin | MF |
|-------|------------------------------------|----|---|----|--------|-------|-----------|----|

continued ➞

## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE-cont.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|--|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |  |

### Authority Required

*Continuing supply (for up to 1 month) for palliative care patients with chronic severe disabling pain not responding to non-narcotic analgesics.*

### NOTE:

*No applications for repeats will be authorised.*

|       |                                    |    |    |    |        |       |           |    |
|-------|------------------------------------|----|----|----|--------|-------|-----------|----|
| 5392T | Tablet 200 mg (controlled release) | 20 | .. | .. | 104.50 | 31.30 | MS Contin | MF |
|-------|------------------------------------|----|----|----|--------|-------|-----------|----|

### • **Phenylpiperidine derivatives**

#### **FENTANYL**

### CAUTION:

*The risk of drug dependence is high.*

### Authority Required

*Initial supply for dose titration for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects.*

### NOTE:

*No applications for increased repeats will be authorised.*

|       |                                             |   |    |    |          |       |       |    |
|-------|---------------------------------------------|---|----|----|----------|-------|-------|----|
| 5401G | Lozenges 200 micrograms (as citrate), 3     | 3 | .. | .. | * 115.17 | 31.30 | Actiq | OA |
| 5402H | Lozenges 400 micrograms (as citrate), 3     | 3 | .. | .. | * 115.17 | 31.30 | Actiq | OA |
| 5403J | Lozenges 600 micrograms (as citrate), 3     | 3 | .. | .. | * 115.17 | 31.30 | Actiq | OA |
| 5404K | Lozenges 800 micrograms (as citrate), 3     | 3 | .. | .. | * 115.17 | 31.30 | Actiq | OA |
| 5405L | Lozenges 1200 micrograms (as citrate),<br>3 | 3 | .. | .. | * 115.17 | 31.30 | Actiq | OA |
| 5406M | Lozenges 1600 micrograms (as citrate),<br>3 | 3 | .. | .. | * 115.17 | 31.30 | Actiq | OA |

### Authority Required

*First continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects;*

*Second and subsequent continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects, where consultation with a palliative care specialist or service has occurred.*

### NOTE:

*No applications for increased repeats will be authorised.*

*Telephone approvals are limited to 1 month's therapy.*

|       |                                         |    |   |    |          |       |       |    |
|-------|-----------------------------------------|----|---|----|----------|-------|-------|----|
| 5407N | Lozenges 200 micrograms (as citrate), 3 | 20 | 2 | .. | * 679.70 | 31.30 | Actiq | OA |
| 5408P | Lozenges 400 micrograms (as citrate), 3 | 20 | 2 | .. | * 679.70 | 31.30 | Actiq | OA |

continued ➡

**PREPARATIONS WHICH MAY BE PRESCRIBED FOR  
PATIENTS RECEIVING PALLIATIVE CARE-cont.**

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 5409Q | Lozenges 600 micrograms (as citrate), 3                 | 20          | 2              | ..      | * 679.70                                 | 31.30                                                  | Actiq                                | OA |
| 5410R | Lozenges 800 micrograms (as citrate), 3                 | 20          | 2              | ..      | * 679.70                                 | 31.30                                                  | Actiq                                | OA |
| 5411T | Lozenges 1200 micrograms (as citrate),<br>3             | 20          | 2              | ..      | * 679.70                                 | 31.30                                                  | Actiq                                | OA |
| 5412W | Lozenges 1600 micrograms (as citrate),<br>3             | 20          | 2              | ..      | * 679.70                                 | 31.30                                                  | Actiq                                | OA |

**Authority Required**

*Second and subsequent continuing supply (for up to 1 month) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects.*

**NOTE:**

*No applications for increased repeats will be authorised.*

|       |                                             |    |    |    |          |       |       |    |
|-------|---------------------------------------------|----|----|----|----------|-------|-------|----|
| 5413X | Lozenges 200 micrograms (as citrate), 3     | 20 | .. | .. | * 679.70 | 31.30 | Actiq | OA |
| 5414Y | Lozenges 400 micrograms (as citrate), 3     | 20 | .. | .. | * 679.70 | 31.30 | Actiq | OA |
| 5415B | Lozenges 600 micrograms (as citrate), 3     | 20 | .. | .. | * 679.70 | 31.30 | Actiq | OA |
| 5416C | Lozenges 800 micrograms (as citrate), 3     | 20 | .. | .. | * 679.70 | 31.30 | Actiq | OA |
| 5417D | Lozenges 1200 micrograms (as citrate),<br>3 | 20 | .. | .. | * 679.70 | 31.30 | Actiq | OA |
| 5418E | Lozenges 1600 micrograms (as citrate),<br>3 | 20 | .. | .. | * 679.70 | 31.30 | Actiq | OA |

• **Diphenylpropylamine derivatives**

**METHADONE HYDROCHLORIDE**

**CAUTION:**

*The risk of drug dependence is high.*

**Authority Required**

*Initial supply (for up to 3 months) for palliative care patients with chronic severe disabling pain not responding to non-narcotic analgesics;*

*Continuing supply (for up to 3 months) for palliative care patients with chronic severe disabling pain not responding to non-narcotic analgesics, and where consultation with a palliative care specialist or service has occurred.*

**NOTE:**

*Telephone approvals are limited to 1 month's therapy.*

|       |                                    |   |   |    |       |       |    |  |
|-------|------------------------------------|---|---|----|-------|-------|----|--|
| 5399E | Oral liquid 25 mg per 5 mL, 200 mL | 1 | 2 | .. | 17.85 | 18.88 | GK |  |
|-------|------------------------------------|---|---|----|-------|-------|----|--|

continued ➡

## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE-cont.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### Authority Required

*Continuing supply (for up to 1 month) for palliative care patients with chronic severe disabling pain not responding to non-narcotic analgesics.*

### NOTE:

*No applications for repeats will be authorised.*

|       |                                    |   |    |    |       |       |    |
|-------|------------------------------------|---|----|----|-------|-------|----|
| 5400F | Oral liquid 25 mg per 5 mL, 200 mL | 1 | .. | .. | 17.85 | 18.88 | GK |
|-------|------------------------------------|---|----|----|-------|-------|----|

### **Other analgesics and antipyretics**

#### • **Anilides**

#### **PARACETAMOL**

### Authority Required

*Initial supply (for up to 4 months) for palliative care patients for analgesia or fever where alternative therapy cannot be tolerated;*

*Continuing supply for palliative care patients for analgesia or fever where alternative therapy cannot be tolerated, and where consultation with a palliative care specialist or service has occurred.*

### NOTE:

*No applications for increased repeats will be authorised.*

|       |                                  |     |   |    |         |       |               |    |
|-------|----------------------------------|-----|---|----|---------|-------|---------------|----|
| 5343F | Tablet 665 mg (modified release) | 192 | 3 | .. | * 12.83 | 13.86 | Panadol Osteo | GC |
| 5319Y | Suppositories 500 mg, 24         | ± 1 | 3 | .. | 26.39   | 27.42 | Panadol       | GC |

### Authority Required

*Continuing supply for palliative care patients for analgesia or fever where alternative therapy cannot be tolerated.*

### NOTE:

*No applications for repeats will be authorised.*

|       |                                  |     |    |    |         |       |               |    |
|-------|----------------------------------|-----|----|----|---------|-------|---------------|----|
| 5344G | Tablet 665 mg (modified release) | 192 | .. | .. | * 12.83 | 13.86 | Panadol Osteo | GC |
| 5320B | Suppositories 500 mg, 24         | ± 1 | .. | .. | 26.39   | 27.42 | Panadol       | GC |

## PREPARATIONS WHICH MAY BE PRESCRIBED FOR PATIENTS RECEIVING PALLIATIVE CARE-cont.

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     |  | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |  |                                      |

### ANTIEPILEPTICS

#### Antiepileptics

#### • Benzodiazepine derivatives

##### CLONAZEPAM

##### Authority Required

*Initial supply (for up to 4 months) for palliative care patients for the prevention of epilepsy;*

*Continuing supply for palliative care patients for the prevention of epilepsy, where consultation with a palliative care specialist or service has occurred.*

##### NOTE:

*No applications for increased repeats will be authorised.*

|       |                                  |     |   |       |         |       |              |           |    |
|-------|----------------------------------|-----|---|-------|---------|-------|--------------|-----------|----|
| 5337X | Tablet 500 micrograms            | 100 | 3 | ..    | 12.88   | 13.91 | <sup>a</sup> | Paxam 0.5 | AF |
|       |                                  |     |   | B1.79 | 14.67   | 13.91 | <sup>a</sup> | Rivotril  | RO |
| 5338Y | Tablet 2 mg                      | 100 | 3 | ..    | 18.95   | 19.98 | <sup>a</sup> | Paxam 2   | AF |
|       |                                  |     |   | B2.04 | 20.99   | 19.98 | <sup>a</sup> | Rivotril  | RO |
| 5339B | Oral liquid 2.5 mg per mL, 10 mL | 2   | 3 | ..    | * 14.61 | 15.64 |              | Rivotril  | RO |

##### Authority Required

*Continuing supply for palliative care patients for the prevention of epilepsy.*

##### NOTE:

*No applications for repeats will be authorised.*

|       |                                  |     |    |       |         |       |              |           |    |
|-------|----------------------------------|-----|----|-------|---------|-------|--------------|-----------|----|
| 5340C | Tablet 500 micrograms            | 100 | .. | ..    | 12.88   | 13.91 | <sup>a</sup> | Paxam 0.5 | AF |
|       |                                  |     |    | B1.79 | 14.67   | 13.91 | <sup>a</sup> | Rivotril  | RO |
| 5341D | Tablet 2 mg                      | 100 | .. | ..    | 18.95   | 19.98 | <sup>a</sup> | Paxam 2   | AF |
|       |                                  |     |    | B2.04 | 20.99   | 19.98 | <sup>a</sup> | Rivotril  | RO |
| 5342E | Oral liquid 2.5 mg per mL, 10 mL | 2   | .. | ..    | * 14.61 | 15.64 |              | Rivotril  | RO |

**PREPARATIONS WHICH MAY BE PRESCRIBED FOR  
PATIENTS RECEIVING PALLIATIVE CARE-cont.**

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

**PSYCHOLEPTICS**

**Anxiolytics**

• **Benzodiazepine derivatives**

**DIAZEPAM**

**Authority Required**

*Initial supply (for up to 4 months) for palliative care patients where anxiety is a problem;*

*Continuing supply for palliative care patients where anxiety is a problem, and where consultation with a palliative care specialist or service has occurred.*

**NOTE:**

*No applications for increased repeats will be authorised.*

|       |             |    |   |    |       |      |                          |                     |      |                     |    |
|-------|-------------|----|---|----|-------|------|--------------------------|---------------------|------|---------------------|----|
| 5355W | Tablet 2 mg | 50 | 3 | .. | 7.36  | 8.39 | <sup>a</sup> Antenex 2   | AF                  |      |                     |    |
|       |             |    |   |    |       |      | <sup>a</sup> Valpam 2    | AW                  |      |                     |    |
|       |             |    |   |    |       |      | B0.59                    | 7.95                | 8.39 | Ducene              | SU |
|       |             |    |   |    |       |      | B0.86                    | 8.22                | 8.39 | <sup>a</sup> Valium | RO |
| 5356X | Tablet 5 mg | 50 | 3 | .. | 7.50  | 8.53 | <sup>a</sup> Antenex 5   | AF                  |      |                     |    |
|       |             |    |   |    |       |      | <sup>a</sup> Diazepam-DP | GM                  |      |                     |    |
|       |             |    |   |    |       |      | <sup>a</sup> Ranzepam    | RA                  |      |                     |    |
|       |             |    |   |    |       |      | <sup>a</sup> Valpam 5    | AW                  |      |                     |    |
|       |             |    |   |    |       |      | B0.63                    | 8.13                | 8.53 | Ducene              | SU |
|       |             |    |   |    | B0.88 | 8.38 | 8.53                     | <sup>a</sup> Valium | RO   |                     |    |

**Authority Required**

*Continuing supply for palliative care patients where anxiety is a problem.*

**NOTE:**

*No applications for repeats will be authorised.*

|       |             |      |      |                     |      |      |                          |      |      |                     |    |
|-------|-------------|------|------|---------------------|------|------|--------------------------|------|------|---------------------|----|
| 5357Y | Tablet 2 mg | 50   | ..   | ..                  | 7.36 | 8.39 | <sup>a</sup> Antenex 2   | AF   |      |                     |    |
|       |             |      |      |                     |      |      | <sup>a</sup> Valpam 2    | AW   |      |                     |    |
|       |             |      |      |                     |      |      | B0.59                    | 7.95 | 8.39 | Ducene              | SU |
|       |             |      |      |                     |      |      | B0.86                    | 8.22 | 8.39 | <sup>a</sup> Valium | RO |
| 5358B | Tablet 5 mg | 50   | ..   | ..                  | 7.50 | 8.53 | <sup>a</sup> Antenex 5   | AF   |      |                     |    |
|       |             |      |      |                     |      |      | <sup>a</sup> Diazepam-DP | GM   |      |                     |    |
|       |             |      |      |                     |      |      | <sup>a</sup> Ranzepam    | RA   |      |                     |    |
|       |             |      |      |                     |      |      | <sup>a</sup> Valpam 5    | AW   |      |                     |    |
|       |             |      |      |                     |      |      | B0.63                    | 8.13 | 8.53 | Ducene              | SU |
|       | B0.88       | 8.38 | 8.53 | <sup>a</sup> Valium | RO   |      |                          |      |      |                     |    |

**PREPARATIONS WHICH MAY BE PRESCRIBED FOR  
PATIENTS RECEIVING PALLIATIVE CARE-cont.**

| Code                                                                                                                                                         | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|                                                                                                                                                              |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |
| OXAZEPAM                                                                                                                                                     |                                                         |             |                |         |                             |                                             |                                      |
| <u>Authority Required</u>                                                                                                                                    |                                                         |             |                |         |                             |                                             |                                      |
| Initial supply (for up to 4 months) for palliative care patients where anxiety is a problem;                                                                 |                                                         |             |                |         |                             |                                             |                                      |
| Continuing supply for palliative care patients where anxiety is a problem, and where consultation with a palliative care specialist or service has occurred. |                                                         |             |                |         |                             |                                             |                                      |
| <u>NOTE:</u>                                                                                                                                                 |                                                         |             |                |         |                             |                                             |                                      |
| No applications for increased repeats will be authorised.                                                                                                    |                                                         |             |                |         |                             |                                             |                                      |
| 5371Q                                                                                                                                                        | Tablet 15 mg                                            | 50          | 3              | ..      | * 8.55                      | 9.58                                        | <sup>a</sup> Alepam 15 AF            |
|                                                                                                                                                              |                                                         |             |                | B3.56   | * 12.11                     | 9.58                                        | <sup>a</sup> Serepax SI              |
| 5372R                                                                                                                                                        | Tablet 30 mg                                            | 50          | 3              | ..      | * 8.93                      | 9.96                                        | <sup>a</sup> Alepam 30 AF            |
|                                                                                                                                                              |                                                         |             |                |         |                             |                                             | <sup>a</sup> Murelax FM              |
|                                                                                                                                                              |                                                         |             |                | B3.80   | * 12.73                     | 9.96                                        | <sup>a</sup> Serepax SI              |

**Authority Required***Continuing supply for palliative care patients where anxiety is a problem.***NOTE:***No applications for repeats will be authorised.*

|       |              |    |    |       |         |      |              |              |
|-------|--------------|----|----|-------|---------|------|--------------|--------------|
| 5373T | Tablet 15 mg | 50 | .. | ..    | * 8.55  | 9.58 | <sup>a</sup> | Alepam 15 AF |
|       |              |    |    | B3.56 | * 12.11 | 9.58 | <sup>a</sup> | Serepax SI   |
| 5374W | Tablet 30 mg | 50 | .. | ..    | * 8.93  | 9.96 | <sup>a</sup> | Alepam 30 AF |
|       |              |    |    |       |         |      | <sup>a</sup> | Murelax FM   |
|       |              |    |    | B3.80 | * 12.73 | 9.96 | <sup>a</sup> | Serepax SI   |

**Hypnotics and sedatives****• Benzodiazepine derivatives****NITRAZEPAM****Authority Required***Initial supply (for up to 4 months) for palliative care patients where insomnia is a problem;**Continuing supply for palliative care patients where insomnia is a problem, and where consultation with a palliative care specialist or service has occurred.***NOTE:***No applications for increased repeats will be authorised.*

|       |             |    |   |       |         |      |              |            |
|-------|-------------|----|---|-------|---------|------|--------------|------------|
| 5359C | Tablet 5 mg | 50 | 3 | ..    | * 8.93  | 9.96 | <sup>a</sup> | Alodorm AF |
|       |             |    |   | B3.06 | * 11.99 | 9.96 | <sup>a</sup> | Mogadon VT |

continued ➡

**PREPARATIONS WHICH MAY BE PRESCRIBED FOR  
PATIENTS RECEIVING PALLIATIVE CARE-cont.**

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

**Authority Required**

*Continuing supply for palliative care patients where insomnia is a problem.*

**NOTE:**

*No applications for repeats will be authorised.*

|       |             |    |    |       |         |      |                      |    |
|-------|-------------|----|----|-------|---------|------|----------------------|----|
| 5360D | Tablet 5 mg | 50 | .. | ..    | * 8.93  | 9.96 | <sup>a</sup> Alodorm | AF |
|       |             |    |    | B3.06 | * 11.99 | 9.96 | <sup>a</sup> Mogadon | VT |

**TEMAZEPAM**

**Authority Required**

*Initial supply (for up to 4 months) for palliative care patients where insomnia is a problem;*

*Continuing supply for palliative care patients where insomnia is a problem, and where consultation with a palliative care specialist or service has occurred.*

**NOTE:**

*No applications for increased repeats will be authorised.*

|       |              |    |   |       |         |      |                       |    |
|-------|--------------|----|---|-------|---------|------|-----------------------|----|
| 5375X | Tablet 10 mg | 50 | 3 | ..    | * 8.93  | 9.96 | <sup>a</sup> Temaze   | AF |
|       |              |    |   |       |         |      | <sup>a</sup> Temtabs  | FM |
|       |              |    |   | B2.76 | * 11.69 | 9.96 | <sup>a</sup> Normison | SI |

**Authority Required**

*Continuing supply for palliative care patients where insomnia is a problem.*

**NOTE:**

*No applications for repeats will be authorised.*

|       |              |    |    |       |         |      |                       |    |
|-------|--------------|----|----|-------|---------|------|-----------------------|----|
| 5376Y | Tablet 10 mg | 50 | .. | ..    | * 8.93  | 9.96 | <sup>a</sup> Temaze   | AF |
|       |              |    |    |       |         |      | <sup>a</sup> Temtabs  | FM |
|       |              |    |    | B2.76 | * 11.69 | 9.96 | <sup>a</sup> Normison | SI |



**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

**ALIMENTARY TRACT AND METABOLISM**

**STOMATOLOGICAL PREPARATIONS**

**Stomatological preparations**

• ***Antiinfectives and antiseptics for local oral treatment***

**AMPHOTERICIN**

|       |               |    |    |    |       |       |          |    |
|-------|---------------|----|----|----|-------|-------|----------|----|
| 3306B | Lozenge 10 mg | 20 | .. | .. | 10.20 | 11.23 | Fungilin | BQ |
|-------|---------------|----|----|----|-------|-------|----------|----|

**NYSTATIN**

|       |                                                |     |    |    |       |       |                       |          |
|-------|------------------------------------------------|-----|----|----|-------|-------|-----------------------|----------|
| 3343Y | Oral suspension 100,000 units per mL,<br>24 mL | ‡ 1 | .. | .. | 10.42 | 11.45 | Mycostatin<br>Nilstat | BQ<br>SI |
|-------|------------------------------------------------|-----|----|----|-------|-------|-----------------------|----------|

• ***Other agents for local oral treatment***

**BENZYDAMINE HYDROCHLORIDE**

**Restricted Benefit**

*Radiation induced mucositis.*

|       |                                                     |     |    |    |       |       |         |    |
|-------|-----------------------------------------------------|-----|----|----|-------|-------|---------|----|
| 5032W | Mouth and throat rinse 22.5 mg per<br>15 mL, 500 mL | ‡ 1 | .. | .. | 21.09 | 22.12 | Difflam | IA |
|-------|-----------------------------------------------------|-----|----|----|-------|-------|---------|----|

**DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS**

**Belladonna and derivatives, plain**

• ***Belladonna alkaloids, tertiary amines***

**ATROPINE SULFATE**

|       |                                  |    |    |    |       |       |    |  |
|-------|----------------------------------|----|----|----|-------|-------|----|--|
| 5022H | Injection 600 micrograms in 1 mL | 10 | .. | .. | 20.11 | 21.14 | AP |  |
|-------|----------------------------------|----|----|----|-------|-------|----|--|

**Propulsives**

• ***Propulsives***

**METOCLOPRAMIDE HYDROCHLORIDE**

|       |                         |    |    |       |       |       |         |    |
|-------|-------------------------|----|----|-------|-------|-------|---------|----|
| 5151D | Tablet 10 mg            | 25 | .. | ..    | 7.61  | 8.64  | Pramin  | AF |
|       |                         |    |    | B3.01 | 10.62 | 8.64  | Maxolon | VT |
| 5153F | Injection 10 mg in 2 mL | 10 | .. | ..    | 12.56 | 13.59 | Maxolon | VT |

## PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.

| Code                                                                                                                          | Name, Restriction,<br>Manner of Administration and Form                                   | Max.<br>Qty | No. of<br>Rpts | Premium     | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer           |          |
|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------|----------------|-------------|------------------------------------------|--------------------------------------------------------|------------------------------------------------|----------|
| <b>ANTIEMETICS AND ANTINAUSEANTS</b>                                                                                          |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| <b>Antiemetics and antinauseants</b>                                                                                          |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| • <b>Other antiemetics</b>                                                                                                    |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| PROCHLORPERAZINE                                                                                                              |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| <b>CAUTION:</b>                                                                                                               |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| Prochlorperazine may be associated with parkinsonism and tardive dyskinesia and should be used for short-term treatment only. |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| 5205Y                                                                                                                         | Tablet containing prochlorperazine maleate 5 mg                                           | 25          | ..             | ..<br>B2.16 | 8.55<br>10.71                            | 9.58<br>9.58                                           | <sup>a</sup> Stemzine<br><sup>a</sup> Stemetil | AV<br>SW |
| 5206B                                                                                                                         | Injection containing prochlorperazine mesylate 12.5 mg in 1 mL                            | 10          | ..             | ..          | 15.51                                    | 16.54                                                  | Stemetil                                       | SW       |
| 5208D                                                                                                                         | Suppositories containing prochlorperazine equivalent to 25 mg prochlorperazine maleate, 5 | ‡ 1         | ..             | ..          | 18.30                                    | 19.33                                                  | Stemetil                                       | SW       |
| <b>PROMETHAZINE HYDROCHLORIDE</b>                                                                                             |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| 3374N                                                                                                                         | Injection 50 mg in 2 mL                                                                   | 10          | ..             | ..          | * 21.89                                  | 22.92                                                  | HH                                             |          |
| <b>ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ ANTIINFECTIVE AGENTS</b>                                                      |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| <b>Intestinal antiinfectives</b>                                                                                              |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| • <b>Antibiotics</b>                                                                                                          |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| NYSTATIN                                                                                                                      |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| 3342X                                                                                                                         | Tablet 500,000 units                                                                      | 50          | ..             | ..          | 17.55                                    | 18.58                                                  | Nilstat                                        | SI       |
| 3345C                                                                                                                         | Capsule 500,000 units                                                                     | 50          | ..             | ..          | 17.55                                    | 18.58                                                  | Nilstat                                        | SI       |
| <b>BLOOD AND BLOOD FORMING ORGANS</b>                                                                                         |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| <b>BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS</b>                                                                              |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| <b>I.V. solutions</b>                                                                                                         |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| • <b>Solutions for parenteral nutrition</b>                                                                                   |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| GLUCOSE                                                                                                                       |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| 5106R                                                                                                                         | I.V. infusion 278 mmol (anhydrous) per L (5%), 1 L                                        | 5           | ..             | ..          | * 25.49                                  | 26.52                                                  | BX                                             |          |
| • <b>Solutions affecting the electrolyte balance</b>                                                                          |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| SODIUM CHLORIDE                                                                                                               |                                                                                           |             |                |             |                                          |                                                        |                                                |          |
| 5212H                                                                                                                         | I.V. infusion 154 mmol per L (0.9%), 1 L                                                  | 5           | ..             | ..          | * 25.49                                  | 26.52                                                  | BX                                             |          |
| 5213J                                                                                                                         | I.V. infusion 513 mmol per L (3%), 1 L                                                    | 2           | ..             | ..          | * 17.79                                  | 18.82                                                  | BX                                             |          |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code                                | Name, Restriction,<br>Manner of Administration and Form                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|-------------------------------------|------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
| <b>SODIUM CHLORIDE with GLUCOSE</b> |                                                                                    |             |                |         |                                          |                                                        |                                      |
| 5214K                               | I.V. infusion 31 mmol-222 mmol<br>(anhydrous) per L (0.18%-4%), 1 L                | 5           | ..             | ..      | * 25.49                                  | 26.52                                                  | BX                                   |
| 5215L                               | I.V. infusion 19 mmol-104 mmol<br>(anhydrous) per 500 mL<br>(0.225%-3.75%), 500 mL | 5           | ..             | ..      | * 31.59                                  | 31.30                                                  | BX                                   |
| 5216M                               | I.V. infusion 39 mmol-69 mmol<br>(anhydrous) per 500 mL (0.45%-2.5%),<br>500 mL    | 5           | ..             | ..      | * 31.59                                  | 31.30                                                  | BX                                   |

**CARDIOVASCULAR SYSTEM**

**CARDIAC THERAPY**

**Antiarrhythmics, class I and III**

• **Antiarrhythmics, class IB**

**LIGNOCAINE HYDROCHLORIDE**

|       |                          |   |    |    |       |       |    |
|-------|--------------------------|---|----|----|-------|-------|----|
| 5142P | Injection 100 mg in 5 mL | 5 | .. | .. | 36.90 | 31.30 | PF |
|-------|--------------------------|---|----|----|-------|-------|----|

**Cardiac stimulants excl. cardiac glycosides**

• **Adrenergic and dopaminergic agents**

**ADRENALINE**

|       |                                     |   |    |    |       |       |    |
|-------|-------------------------------------|---|----|----|-------|-------|----|
| 5004J | Injection 1 mg in 1 mL (1 in 1,000) | 5 | .. | .. | 19.91 | 20.94 | AP |
|-------|-------------------------------------|---|----|----|-------|-------|----|

**Vasodilators used in cardiac diseases**

• **Organic nitrates**

**GLYCERYL TRINITRATE**

|       |                             |     |    |       |       |       |                                  |    |
|-------|-----------------------------|-----|----|-------|-------|-------|----------------------------------|----|
| 5108W | Tablets 600 micrograms, 100 | ‡ 1 | .. | ..    | 11.96 | 12.99 | <sup>a</sup> Lycinat             | FM |
|       |                             |     |    | B1.64 | 13.60 | 12.99 | <sup>a</sup> Anginine Stabilised | SI |

**DERMATOLOGICALS**

**CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS**

**Corticosteroids, plain**

• **Corticosteroids, weak (group I)**

**HYDROCORTISONE ACETATE**

**Restricted Benefit**

*Treatment of corticosteroid-responsive dermatoses.*

|       |                              |     |    |       |       |      |                           |    |
|-------|------------------------------|-----|----|-------|-------|------|---------------------------|----|
| 5111B | Cream 10 mg per g (1%), 30 g | ‡ 1 | .. | ..    | 8.61  | 9.64 | <sup>a</sup> Cortic-DS 1% | FM |
|       |                              |     |    | B1.90 | 10.51 | 9.64 | <sup>a</sup> Sigmacort    | SI |

continued ➡

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium              | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                       |                |
|-------|---------------------------------------------------------|-------------|----------------|----------------------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------------|----------------|
| 5113D | Cream 10 mg per g (1%), 50 g                            | ‡ 1         | ..             | ..<br>B0.08<br>B1.91 | 8.27<br>8.35<br>10.18                    | 9.30<br>9.30<br>9.30                                   | <sup>a</sup> Cortic-DS 1%<br><sup>a</sup> Cortef<br><sup>a</sup> Sigmacort | FM<br>DT<br>SI |
| 5112C | Topical ointment 10 mg per g (1%), 30 g                 | ‡ 1         | ..             | ..<br>B1.90          | 8.61<br>10.51                            | 9.64<br>9.64                                           | <sup>a</sup> Cortic-DS 1%<br><sup>a</sup> Sigmacort                        | FM<br>SI       |
| 5114E | Topical ointment 10 mg per g (1%), 50 g                 | ‡ 1         | ..             | ..<br>B1.91          | 8.27<br>10.18                            | 9.30<br>9.30                                           | <sup>a</sup> Cortic-DS 1%<br><sup>a</sup> Sigmacort                        | FM<br>SI       |

**SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS**

**CORTICOSTEROIDS FOR SYSTEMIC USE**

**Corticosteroids for systemic use, plain**

• **Glucocorticoids**

**BETAMETHASONE ACETATE with BETAMETHASONE  
SODIUM PHOSPHATE**

**Restricted Benefit**

*For local intra-articular or peri-articular infiltration;*

*Keloid;*

*Lichen planus hypertrophic.*

|       |                                                                       |   |    |    |       |       |                         |    |
|-------|-----------------------------------------------------------------------|---|----|----|-------|-------|-------------------------|----|
| 5034Y | Injection 3 mg-3.9 mg (equivalent to<br>5.7 mg betamethasone) in 1 mL | 5 | .. | .. | 25.74 | 26.77 | Celestone<br>Chronodose | SH |
|-------|-----------------------------------------------------------------------|---|----|----|-------|-------|-------------------------|----|

**HYDROCORTISONE SODIUM SUCCINATE**

**Restricted Benefit**

*For use in a hospital.*

|       |                                                                    |   |    |    |         |       |             |    |
|-------|--------------------------------------------------------------------|---|----|----|---------|-------|-------------|----|
| 5118J | Injection equivalent to 100 mg<br>hydrocortisone with 2 mL solvent | 6 | .. | .. | * 38.15 | 31.30 | Solu-Cortef | PH |
|-------|--------------------------------------------------------------------|---|----|----|---------|-------|-------------|----|

|       |                                                                    |   |    |    |         |       |             |    |
|-------|--------------------------------------------------------------------|---|----|----|---------|-------|-------------|----|
| 5119K | Injection equivalent to 250 mg<br>hydrocortisone with 2 mL solvent | 6 | .. | .. | * 61.61 | 31.30 | Solu-Cortef | PH |
|-------|--------------------------------------------------------------------|---|----|----|---------|-------|-------------|----|

**METHYLPREDNISOLONE ACETATE**

**Restricted Benefit**

*For local intra-articular or peri-articular infiltration.*

|       |                         |   |    |             |                |                |                                                        |          |
|-------|-------------------------|---|----|-------------|----------------|----------------|--------------------------------------------------------|----------|
| 5148Y | Injection 40 mg in 1 mL | 5 | .. | ..<br>B0.76 | 24.38<br>25.14 | 25.41<br>25.41 | <sup>a</sup> Depo-Nisolone<br><sup>a</sup> Depo-Medrol | KR<br>PH |
|-------|-------------------------|---|----|-------------|----------------|----------------|--------------------------------------------------------|----------|

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code                                                             | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>TRIAMCINOLONE ACETONIDE</b>                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>For local intra-articular or peri-articular infiltration;</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Keloid;</i>                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Lichen planus hypertrophic.</i>                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 5233K                                                            | Injection 10 mg in 1 mL                                 | 5           | ..             | ..      | 25.74                                    | 26.77                                                  | Kenacort-A10                         | BQ |

**PANCREATIC HORMONES**

**Glycogenolytic hormones**

• **Glycogenolytic hormones**

**GLUCAGON HYDROCHLORIDE**

|       |                                                                                  |   |    |    |       |       |                  |    |
|-------|----------------------------------------------------------------------------------|---|----|----|-------|-------|------------------|----|
| 5105Q | Injection set containing 1 mg (1 i.u.) and<br>1 mL solvent in disposable syringe | 1 | .. | .. | 42.93 | 31.30 | GlucaGen Hypokit | NO |
|-------|----------------------------------------------------------------------------------|---|----|----|-------|-------|------------------|----|

**ANTIINFECTIVES FOR SYSTEMIC USE**

**ANTIBACTERIALS FOR SYSTEMIC USE**

**Tetracyclines**

• **Tetracyclines**

**DOXYCYCLINE**

|       |                                  |   |    |    |      |      |                                                                                                                 |                              |
|-------|----------------------------------|---|----|----|------|------|-----------------------------------------------------------------------------------------------------------------|------------------------------|
| 5082L | Tablet 100 mg (as monohydrate)   | 7 | .. | .. | 8.04 | 9.07 | a Chem mart<br>Doxycycline<br>a Doxyhexal<br>a GenRx<br>Doxycycline<br>a Terry White<br>Chemists<br>Doxycycline | CH<br><br>SZ<br>GX<br><br>TW |
| 3321T | Tablet 100 mg (as hydrochloride) | 7 | .. | .. | 8.04 | 9.07 | a Doxsig<br>a Doxy-100<br>a Doxylin 100<br>b1.19 9.23 9.07 a Vibramycin                                         | SI<br>GM<br>AF<br>PF         |

**NOTE:**

Bioequivalence has been demonstrated between doxycycline tablet 100 mg (as hydrochloride) and doxycycline tablet 100 mg (as monohydrate).

|       |                                   |   |    |    |      |      |                                              |          |
|-------|-----------------------------------|---|----|----|------|------|----------------------------------------------|----------|
| 3322W | Capsule 100 mg (as hydrochloride) | 7 | .. | .. | 8.04 | 9.07 | a DBL Doxycycline<br>b1.15 9.19 9.07 a Doryx | FA<br>HH |
|-------|-----------------------------------|---|----|----|------|------|----------------------------------------------|----------|

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code                                           | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                                           |
|------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Beta-lactam antibacterials, penicillins</b> |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                |
| • <b>Penicillins with extended spectrum</b>    |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                |
| <b>AMOXYCILLIN</b>                             |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                |
| 3301R                                          | Capsule 250 mg                                          | 20          | ..             | ..      | 8.12                                     | 9.15                                                   | a Alphamox 250 AF<br>a Amohexal HX<br>a Amoxycillin-DP GM<br>a APO-Amoxycillin TX<br>a Chem mart CH<br>Amoxycillin<br>a Cilamox SI<br>a GenRx GX<br>Amoxycillin<br>a Terry White TW<br>Chemists<br>Amoxycillin                 |
|                                                |                                                         |             |                | b0.79   | 8.91                                     | 9.15                                                   | a Amoxil GK                                                                                                                                                                                                                    |
| 3300Q                                          | Capsule 500 mg                                          | 20          | ..             | ..      | 10.22                                    | 11.25                                                  | a Alphamox 500 AF<br>a Amohexal HX<br>a Amoxycillin-DP GM<br>a APO-Amoxycillin TX<br>a Chem mart CH<br>Amoxycillin<br>a Cilamox SI<br>a GenRx GX<br>Amoxycillin<br>a Moxacin AS<br>a Terry White TW<br>Chemists<br>Amoxycillin |
|                                                |                                                         |             |                | b0.80   | 11.02                                    | 11.25                                                  | a Amoxil GK                                                                                                                                                                                                                    |
| 3309E                                          | Sachet containing oral powder 3 g                       | 1           | ..             | ..      | 8.68                                     | 9.71                                                   | Amoxil GK                                                                                                                                                                                                                      |
| 3302T                                          | Powder for syrup 125 mg per 5 mL,<br>100 mL             | ‡ 1         | ..             | ..      | # 10.42                                  | 11.81                                                  | a Alphamox 125 AF<br>a Bgramin GM<br>a Chem mart CH<br>Amoxycillin<br>a GenRx GX<br>Amoxycillin<br>a Ranmoxy RA<br>a Terry White TW<br>Chemists<br>Amoxycillin                                                                 |
|                                                |                                                         |             |                | b0.95   | # 11.37                                  | 11.81                                                  | a Amoxil GK                                                                                                                                                                                                                    |

continued 

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code  | Name, Restriction,<br>Manner of Administration and Form     | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                    |                                                                |
|-------|-------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| 3393N | Powder for syrup 250 mg per 5 mL,<br>100 mL                 | ‡ 1         | ..             | ..      | # 11.26                                  | 12.65                                                  | a Alphamox 250<br>a Amohexal<br>a Bgramin<br>a Chem mart<br>Amoxycillin<br>a Cilamox<br>a GenRx<br>Amoxycillin<br>a Ranmoxy<br>a Terry White<br>Chemists<br>Amoxycillin | AF<br>HX<br>GM<br>CH<br><br>SI<br>GX<br><br>RA<br>TW<br><br>GK |
|       |                                                             |             |                | 80.79   | # 12.05                                  | 12.65                                                  | a Amoxil Forte                                                                                                                                                          | GK                                                             |
| 5225B | Powder for oral suspension 500 mg per<br>5 mL, 100 mL       | ‡ 1         | ..             | ..      | # 14.27                                  | 15.66                                                  | Maxamox                                                                                                                                                                 | SZ                                                             |
|       | AMPICILLIN                                                  |             |                |         |                                          |                                                        |                                                                                                                                                                         |                                                                |
| 3313J | Powder for injection 500 mg                                 | 5           | ..             | ..      | 10.65                                    | 11.68                                                  | a Austrapen<br>a Ibimicyn                                                                                                                                               | LN<br>GM                                                       |
| 3314K | Powder for injection 1 g                                    | 5           | ..             | ..      | 13.64                                    | 14.67                                                  | a Aspen Ampicyn<br>a Austrapen<br>a Ibimicyn                                                                                                                            | AS<br>LN<br>GM                                                 |
|       | • <b><i>Beta-lactamase sensitive penicillins</i></b>        |             |                |         |                                          |                                                        |                                                                                                                                                                         |                                                                |
|       | BENZATHINE BENZYL PENICILLIN                                |             |                |         |                                          |                                                        |                                                                                                                                                                         |                                                                |
| 5027N | Injection 900 mg in 2.3 mL single use<br>pre-filled syringe | 10          | ..             | ..      | 292.68                                   | 31.30                                                  | Bicillin L-A                                                                                                                                                            | AS                                                             |
|       | BENZYL PENICILLIN                                           |             |                |         |                                          |                                                        |                                                                                                                                                                         |                                                                |
| 3398W | Powder for injection 600 mg                                 | 10          | ..             | ..      | * 40.39                                  | 31.30                                                  | BenPen                                                                                                                                                                  | CS                                                             |
| 3399X | Powder for injection 3 g                                    | 10          | ..             | ..      | * 62.49                                  | 31.30                                                  | BenPen                                                                                                                                                                  | CS                                                             |
|       | PHENOXYMETHYL PENICILLIN                                    |             |                |         |                                          |                                                        |                                                                                                                                                                         |                                                                |
| 3360W | Tablet 250 mg                                               | 50          | ..             | ..      | * 11.15                                  | 12.18                                                  | Abbocillin-VK<br>Filmstab                                                                                                                                               | SI                                                             |
| 3361X | Tablet 500 mg                                               | 50          | ..             | ..      | * 13.63                                  | 14.66                                                  | Abbocillin-VK<br>Filmstab                                                                                                                                               | SI                                                             |
| 3363B | Capsule 250 mg                                              | 50          | ..             | ..      | 10.98<br>10.98                           | 12.01<br>12.01                                         | LPV<br>a Cilacaine VK<br>a Cilopen VK<br>a Penhexal VK                                                                                                                  | AS<br>FM<br>GM<br>HX                                           |

continued ➞

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code  | Name, Restriction,<br>Manner of Administration and Form                                                                                                                             | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                        |                |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------|----------------|
| 3364C | Capsule 500 mg                                                                                                                                                                      | 50          | ..             | ..      | 13.41                                    | 14.44                                                  | LPV                                                                         | AS             |
|       |                                                                                                                                                                                     |             |                | ..      | 13.41                                    | 14.44                                                  | <sup>a</sup> Cilicaine VK                                                   | FM             |
|       |                                                                                                                                                                                     |             |                |         |                                          |                                                        | <sup>a</sup> Cilopen VK                                                     | GM             |
|       |                                                                                                                                                                                     |             |                |         |                                          |                                                        | <sup>a</sup> Penhexal VK                                                    | HX             |
| 5012T | Oral suspension 150 mg (as benzathine)<br>per 5 mL, 100 mL                                                                                                                          | 2           | ..             | ..      | * 21.97                                  | 23.00                                                  | Abbocillin-V<br>Cilicaine V                                                 | SI<br>FM       |
|       | PROCAINE PENICILLIN                                                                                                                                                                 |             |                |         |                                          |                                                        |                                                                             |                |
| 3371K | Injection 1.5 g                                                                                                                                                                     | 5           | ..             | ..      | 87.97                                    | 31.30                                                  | Cilicaine                                                                   | SI             |
|       | <b>• Beta-lactamase resistant penicillins</b>                                                                                                                                       |             |                |         |                                          |                                                        |                                                                             |                |
|       | <b>DICLOXACILLIN</b>                                                                                                                                                                |             |                |         |                                          |                                                        |                                                                             |                |
|       | <b><u>Restricted Benefit</u></b>                                                                                                                                                    |             |                |         |                                          |                                                        |                                                                             |                |
|       | <i>Serious staphylococcal infections.</i>                                                                                                                                           |             |                |         |                                          |                                                        |                                                                             |                |
| 5096F | Capsule 250 mg                                                                                                                                                                      | 24          | ..             | ..      | 11.02                                    | 12.05                                                  | <sup>a</sup> Diclocil<br><sup>a</sup> Dicloxsig<br><sup>a</sup> Distaph 250 | BQ<br>SI<br>AF |
| 5097G | Capsule 500 mg                                                                                                                                                                      | 24          | ..             | ..      | 16.51                                    | 17.54                                                  | <sup>a</sup> Diclocil<br><sup>a</sup> Dicloxsig<br><sup>a</sup> Distaph 500 | BQ<br>SI<br>AF |
|       | FLUCLOXACILLIN                                                                                                                                                                      |             |                |         |                                          |                                                        |                                                                             |                |
|       | <b>CAUTION:</b>                                                                                                                                                                     |             |                |         |                                          |                                                        |                                                                             |                |
|       | Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days. |             |                |         |                                          |                                                        |                                                                             |                |
| 5094D | Powder for injection 500 mg                                                                                                                                                         | 5           | ..             | ..      | 15.06                                    | 16.09                                                  | <sup>a</sup> Flubiclox<br><sup>a</sup> Flucil                               | GM<br>AS       |
| 5095E | Powder for injection 1 g                                                                                                                                                            | 5           | ..             | ..      | 20.23                                    | 21.26                                                  | <sup>a</sup> Flubiclox<br><sup>a</sup> Flucil<br><sup>a</sup> HH            | GM<br>AS       |
|       | <b>FLUCLOXACILLIN</b>                                                                                                                                                               |             |                |         |                                          |                                                        |                                                                             |                |
|       | <b>CAUTION:</b>                                                                                                                                                                     |             |                |         |                                          |                                                        |                                                                             |                |
|       | Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days. |             |                |         |                                          |                                                        |                                                                             |                |
|       | <b><u>Restricted Benefit</u></b>                                                                                                                                                    |             |                |         |                                          |                                                        |                                                                             |                |
|       | <i>Serious staphylococcal infections.</i>                                                                                                                                           |             |                |         |                                          |                                                        |                                                                             |                |
| 5090X | Capsule 250 mg (as sodium)                                                                                                                                                          | 24          | ..             | ..      | 11.02                                    | 12.05                                                  | <sup>a</sup> Flopen<br><sup>a</sup> Staphylex 250                           | AS<br>AF       |

continued ➡



**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code                                                                                                                                                                                                                                                                                                                                                                                       | Name, Restriction,<br>Manner of Administration and Form       | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                              |                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| 5091Y                                                                                                                                                                                                                                                                                                                                                                                      | Capsule 500 mg (as sodium)                                    | 24          | ..             | ..      | 16.51                                    | 17.54                                                  | <sup>a</sup> Flopen<br><sup>a</sup> Staphylex 500                                                                                                                                                                 | AS<br>AF                             |
| 5257Q                                                                                                                                                                                                                                                                                                                                                                                      | Powder for oral liquid 125 mg (as<br>sodium) per 5 mL, 100 mL | ‡ 1         | ..             | ..      | # 13.05                                  | 14.44                                                  | LN                                                                                                                                                                                                                |                                      |
| 5258R                                                                                                                                                                                                                                                                                                                                                                                      | Powder for oral liquid 250 mg (as<br>sodium) per 5 mL, 100 mL | ‡ 1         | ..             | ..      | # 15.88                                  | 17.27                                                  | LN                                                                                                                                                                                                                |                                      |
| <p>• <b>Combinations of penicillins, incl. beta-lactamase inhibitors</b><br/> <b>AMOXYCILLIN with CLAVULANIC ACID</b><br/> <b>CAUTION:</b><br/> <i>Hepatotoxicity has been reported with this drug.</i></p> <p><u><b>Restricted Benefit</b></u><br/> <i>Infections where resistance to amoxicillin is suspected;</i><br/> <i>Infections where resistance to amoxicillin is proven.</i></p> |                                                               |             |                |         |                                          |                                                        |                                                                                                                                                                                                                   |                                      |
| 5008N                                                                                                                                                                                                                                                                                                                                                                                      | Tablet 500 mg-125 mg                                          | 10          | ..             | ..      | 11.73                                    | 12.76                                                  | <sup>a</sup> Clamohexal Duo<br>500mg/125mg<br><sup>a</sup> Clamoxyl Duo<br><sup>a</sup> Clavulin Duo<br><sup>a</sup> Curam 500/125<br><sup>a</sup> GA-Amclav 500/<br>125<br><sup>a</sup> Moxiclav Duo 500/<br>125 | HX<br><br>AL<br>ME<br>SZ<br>GM<br>AW |
|                                                                                                                                                                                                                                                                                                                                                                                            |                                                               |             |                | B1.55   | 13.28                                    | 12.76                                                  | <sup>a</sup> Augmentin Duo                                                                                                                                                                                        | GK                                   |

continued ➡

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                       |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------------|----|
| 5006L | Tablet 875 mg-125 mg                                    | 10          | ..             | ..      | 14.17                                    | 15.20                                                  | <sup>a</sup> Chem mart<br>Amoxycillin and<br>Clavulanic Acid               | CH |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clamohexal Duo<br>Forte 875mg/<br>125mg                       | HX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clamoxyl Duo<br>forte                                         | AL |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clavulin Duo<br>Forte                                         | ME |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clavycillin 875/125                                           | CR |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Curam 875/125                                                 | SZ |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GA-Amclav Forte<br>875/125                                    | GM |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx<br>Amoxycillin and<br>Clavulanic Acid                   | GX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Moxiclav Duo<br>Forte 875/125                                 | AW |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Amoxycillin and<br>Clavulanic Acid | TW |
|       |                                                         |             |                | B2.04   | 16.21                                    | 15.20                                                  | <sup>a</sup> Augmentin Duo<br>forte                                        | GK |
| 5009P | Powder for syrup 125 mg-31.25 mg per<br>5 mL, 75 mL     | ‡ 1         | ..             | ..      | # 12.05                                  | 13.44                                                  | <sup>a</sup> Clamohexal<br>125mg/31.25mg/<br>5mL                           | HX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clamoxyl                                                      | AL |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clavulin                                                      | ME |
|       |                                                         |             |                | B1.51   | # 13.56                                  | 13.44                                                  | <sup>a</sup> Augmentin                                                     | GK |
| 5011R | Powder for syrup 400 mg-57 mg per<br>5 mL, 60 mL        | ‡ 1         | ..             | ..      | # 13.56                                  | 14.95                                                  | <sup>a</sup> Clamohexal Duo<br>400mg/57mg/<br>5mL                          | HX |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clamoxyl Duo 400                                              | AL |
|       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clavulin Duo 400                                              | ME |
|       |                                                         |             |                | B1.54   | # 15.10                                  | 14.95                                                  | <sup>a</sup> Augmentin Duo<br>400                                          | GK |

**TICARCILLIN with CLAVULANIC ACID**

**Restricted Benefit**

*Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent.*

|       |                                                                                                                      |    |    |    |        |       |          |    |
|-------|----------------------------------------------------------------------------------------------------------------------|----|----|----|--------|-------|----------|----|
| 5230G | Powder for injection 3 g-100 mg (solvent<br>required)<br>(code 7043Q applies to above item with<br>approved solvent) | 10 | .. | .. | 162.89 | 31.30 | Timentin | GK |
|-------|----------------------------------------------------------------------------------------------------------------------|----|----|----|--------|-------|----------|----|

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code                                     | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                                                                                  |                                                                                    |
|------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| <b>Other beta-lactam antibacterials</b>  |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                       |                                                                                    |
| • <b>First-generation cephalosporins</b> |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                       |                                                                                    |
| CEFALOTIN                                |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                       |                                                                                    |
| 3376Q                                    | Powder for injection 1 g                                | 10          | ..             | ..      | 40.35                                    | 31.30                                                  | a Cefalotin Sandoz<br>a Keflin Neutral<br>a HH                                                                                                                                                                                                                        | SZ<br>AS                                                                           |
| CEPHALEXIN                               |                                                         |             |                |         |                                          |                                                        |                                                                                                                                                                                                                                                                       |                                                                                    |
| 3317N                                    | Capsule 250 mg                                          | 20          | ..             | ..      | 8.42                                     | 9.45                                                   | a Cefalexin Sandoz<br>a Cephabell<br>a Cephalixin Max<br>a Cephatrust 250<br>a Chem mart<br>Cephalixin<br>a Cilex<br>a GenRx Cephalixin<br>a Ialex<br>a Ibilex 250<br>a Rancef<br>a Sporaheal<br>a Terry White<br>Chemists<br>Cephalixin<br>B1.87 10.29 9.45 a Keflex | SZ<br>BF<br>XF<br>MI<br>CH<br><br>GM<br>GX<br>LN<br>AF<br>RA<br>HX<br>TW<br><br>AS |
| 3318P                                    | Capsule 500 mg                                          | 20          | ..             | ..      | 10.34                                    | 11.37                                                  | a Cephabell<br>a Cephalixin Max<br>a Cephatrust 500<br>a Chem mart<br>Cephalixin<br>a Cilex<br>a GenRx Cephalixin<br>a Ialex<br>a Ibilex 500<br>a Rancef<br>a Sporaheal<br>a Terry White<br>Chemists<br>Cephalixin<br>B2.23 12.57 11.37 a Keflex                      | BF<br>XF<br>MI<br>CH<br><br>GM<br>GX<br>LN<br>AF<br>RA<br>HX<br>TW<br><br>AS       |

continued ➞

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 3319Q | Granules for syrup 125 mg per 5 mL,<br>100 mL           | ‡ 1         | ..             | ..      | # 11.41                                  | 12.80                                                  | a Cefalexin Sandoz                   | SZ |
|       |                                                         |             |                |         |                                          |                                                        | a Chem mart                          | CH |
|       |                                                         |             |                |         |                                          |                                                        | Cephalexin                           |    |
|       |                                                         |             |                |         |                                          |                                                        | a Cilex                              | GM |
|       |                                                         |             |                |         |                                          |                                                        | a GenRx Cephalexin                   | GX |
|       |                                                         |             |                |         |                                          |                                                        | a Ialex                              | LN |
|       |                                                         |             |                |         |                                          |                                                        | a Ibilex 125                         | AF |
|       |                                                         |             |                |         |                                          |                                                        | a Terry White                        | TW |
|       |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|       |                                                         |             |                |         |                                          |                                                        | Cephalexin                           |    |
|       |                                                         |             |                |         |                                          |                                                        | a Keflex                             | AS |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 3320R | Granules for syrup 250 mg per 5 mL,<br>100 mL           | ‡ 1         | ..             | ..      | # 12.81                                  | 14.20                                                  | a Cefalexin Sandoz                   | SZ |
|       |                                                         |             |                |         |                                          |                                                        | a Chem mart                          | CH |
|       |                                                         |             |                |         |                                          |                                                        | Cephalexin                           |    |
|       |                                                         |             |                |         |                                          |                                                        | a Cilex                              | GM |
|       |                                                         |             |                |         |                                          |                                                        | a GenRx Cephalexin                   | GX |
|       |                                                         |             |                |         |                                          |                                                        | a Ialex                              | LN |
|       |                                                         |             |                |         |                                          |                                                        | a Ibilex 250                         | AF |
|       |                                                         |             |                |         |                                          |                                                        | a Terry White                        | TW |
|       |                                                         |             |                |         |                                          |                                                        | Chemists                             |    |
|       |                                                         |             |                |         |                                          |                                                        | Cephalexin                           |    |
|       |                                                         |             |                |         |                                          |                                                        | a Keflex                             | AS |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         | # 15.03                                  | 14.20                                                  | a Keflex                             | AS |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |
|       |                                                         |             |                |         |                                          |                                                        |                                      |    |

• **Second-generation cephalosporins**

CEFACTOR

**CAUTION:**

Serum sickness-like reactions have been reported with this drug, especially in children.

|       |                                   |    |    |    |       |       |       |                      |       |   |           |    |
|-------|-----------------------------------|----|----|----|-------|-------|-------|----------------------|-------|---|-----------|----|
| 5045M | Tablet 375 mg (sustained release) | 10 | .. | .. | 12.46 | 13.49 | a     | Chem mart            | CH    |   |           |    |
|       |                                   |    |    |    |       |       |       | Cefaclor CD          |       |   |           |    |
|       |                                   |    |    |    |       |       | a     | Douglas Cefaclor-CD  | GM    |   |           |    |
|       |                                   |    |    |    |       |       | a     | GenRx Cefaclor CD    | GX    |   |           |    |
|       |                                   |    |    |    |       |       | a     | Karlor CD            | LN    |   |           |    |
|       |                                   |    |    |    |       |       | a     | Keflor CD            | AF    |   |           |    |
|       |                                   |    |    |    |       |       | a     | Ozcef                | RA    |   |           |    |
|       |                                   |    |    |    |       |       | a     | Terry White Chemists | TW    |   |           |    |
|       |                                   |    |    |    |       |       |       | Cefaclor CD          |       |   |           |    |
|       |                                   |    |    |    |       |       | B2.28 | 14.74                | 13.49 | a | Ceclor CD | AS |

continued ➡

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                                                                                                                                                    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5046N | Powder for oral suspension 125 mg per<br>5 mL, 100 mL   | ‡ 1         | ..             | ..      | # 13.07                                  | 14.46                                                  | a Aclor 125 AW<br>a Cefaclor Sandoz SZ<br>a Chem mart CH<br>Cefaclor<br>a GenRx Cefaclor GX<br>a Keflor AF<br>a Ozcef RA<br>a Terry White TW<br>Chemists<br>Cefaclor<br>B1.99 # 15.06 14.46 a Ceclor AS |
| 5047P | Powder for oral suspension 250 mg per<br>5 mL, 75 mL    | ‡ 1         | ..             | ..      | # 13.40                                  | 14.79                                                  | a Aclor 250 AW<br>a Cefaclor Sandoz SZ<br>a Chem mart CH<br>Cefaclor<br>a GenRx Cefaclor GX<br>a Keflor AF<br>a Ozcef RA<br>a Terry White TW<br>Chemists<br>Cefaclor<br>B2.05 # 15.45 14.79 a Ceclor AS |
|       | CEFUROXIME AXETIL                                       |             |                |         |                                          |                                                        |                                                                                                                                                                                                         |
| 5052X | Tablet 250 mg (base)                                    | 14          | ..             | ..      | 18.19                                    | 19.22                                                  | Zinnat GK                                                                                                                                                                                               |

• **Third-generation cephalosporins**

**CEFOTAXIME**

**Restricted Benefit**

*Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent.*

|       |                          |    |    |        |         |       |                                   |
|-------|--------------------------|----|----|--------|---------|-------|-----------------------------------|
| 5048Q | Powder for injection 1 g | 10 | .. | ..     | 27.27   | 28.30 | <sup>a</sup> HH                   |
|       |                          |    |    | B25.10 | * 52.39 | 28.32 | <sup>a</sup> Cefotaxime Sandoz SZ |
| 5049R | Powder for injection 2 g | 10 | .. | ..     | 44.60   | 31.30 | <sup>a</sup> HH                   |
|       |                          |    |    | B46.50 | * 91.09 | 31.30 | <sup>a</sup> Cefotaxime Sandoz SZ |

**Sulfonamides and trimethoprim**

• **Combinations of sulfonamides and trimethoprim, incl. derivatives**

TRIMETHOPRIM with SULFAMETHOXAZOLE

**CAUTION:**

There is an increased risk of severe adverse reactions with this combination in the elderly.

|       |                     |    |    |    |      |      |            |
|-------|---------------------|----|----|----|------|------|------------|
| 3389J | Tablet 80 mg-400 mg | 10 | .. | .. | 8.24 | 9.27 | Resprim AF |
|-------|---------------------|----|----|----|------|------|------------|

continued ☞

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code                                                                                                           | Name, Restriction,<br>Manner of Administration and Form  | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer        |    |
|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|---------------------------------------------|----|
| 3390K                                                                                                          | Tablet 160 mg-800 mg                                     | 10          | ..             | ..      | 8.96                                     | 9.99                                                   | <sup>a</sup> Bactrim DS                     | RO |
|                                                                                                                |                                                          |             |                |         |                                          |                                                        | <sup>a</sup> Chem mart                      | CH |
|                                                                                                                |                                                          |             |                |         |                                          |                                                        | Trimethoprim<br>with Sulfamethoxazole<br>DS |    |
|                                                                                                                |                                                          |             |                |         |                                          |                                                        | <sup>a</sup> GenRx                          | GX |
|                                                                                                                |                                                          |             |                |         |                                          |                                                        | Trimethoprim<br>with Sulfamethoxazole<br>DS |    |
|                                                                                                                |                                                          |             |                |         |                                          |                                                        | <sup>a</sup> Resprim Forte                  | AF |
|                                                                                                                |                                                          |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists        | TW |
|                                                                                                                |                                                          |             |                |         |                                          |                                                        | Trimethoprim<br>with Sulfamethoxazole<br>DS |    |
|                                                                                                                |                                                          |             |                | B1.10   | 10.06                                    | 9.99                                                   | <sup>a</sup> Septrin Forte                  | SI |
| 3391L                                                                                                          | Oral suspension 40 mg-200 mg per 5 mL,<br>100 mL         | ‡ 1         | ..             | ..      | 8.62                                     | 9.65                                                   | Bactrim                                     | RO |
|                                                                                                                |                                                          |             |                | B1.46   | 10.08                                    | 9.65                                                   | Septrin                                     | SI |
| <b>Macrolides, lincosamides and streptogramins</b>                                                             |                                                          |             |                |         |                                          |                                                        |                                             |    |
| • <b>Macrolides</b>                                                                                            |                                                          |             |                |         |                                          |                                                        |                                             |    |
| ERYTHROMYCIN                                                                                                   |                                                          |             |                |         |                                          |                                                        |                                             |    |
| 3325B                                                                                                          | Capsule 250 mg                                           | 25          | ..             | ..      | 9.00                                     | 10.03                                                  | <sup>a</sup> DBL Erythromycin               | FA |
|                                                                                                                |                                                          |             |                | B1.35   | 10.35                                    | 10.03                                                  | <sup>a</sup> Eryc                           | HH |
| ERYTHROMYCIN ETHYL SUCCINATE                                                                                   |                                                          |             |                |         |                                          |                                                        |                                             |    |
| 3336N                                                                                                          | Tablet 400 mg (base)                                     | 25          | ..             | ..      | 8.93                                     | 9.96                                                   | <sup>a</sup> E-Mycin                        | AF |
|                                                                                                                |                                                          |             |                | B2.36   | 11.29                                    | 9.96                                                   | <sup>a</sup> E.E.S. 400 Filmtab             | LM |
| 3334L                                                                                                          | Powder for oral liquid 200 mg (base) per<br>5 mL, 100 mL | ‡ 1         | ..             | ..      | # 11.00                                  | 12.39                                                  | <sup>a</sup> E-Mycin 200                    | AF |
|                                                                                                                |                                                          |             |                | B1.67   | # 12.67                                  | 12.39                                                  | <sup>a</sup> E.E.S. 200                     | LM |
| 3337P                                                                                                          | Powder for oral liquid 400 mg (base) per<br>5 mL, 100 mL | ‡ 1         | ..             | ..      | # 12.23                                  | 13.62                                                  | <sup>a</sup> E-Mycin 400                    | AF |
|                                                                                                                |                                                          |             |                | B1.35   | # 13.58                                  | 13.62                                                  | <sup>a</sup> E.E.S. Granules                | LM |
| ERYTHROMYCIN LACTOBIONATE                                                                                      |                                                          |             |                |         |                                          |                                                        |                                             |    |
| 5088T                                                                                                          | Powder for I.V. infusion 1 g (base)                      | 5           | ..             | ..      | * 50.94                                  | 31.30                                                  | Erythrocin-I.V.                             | LM |
| • <b>Lincosamides</b>                                                                                          |                                                          |             |                |         |                                          |                                                        |                                             |    |
| CLINDAMYCIN                                                                                                    |                                                          |             |                |         |                                          |                                                        |                                             |    |
| <b>Restricted Benefit</b>                                                                                      |                                                          |             |                |         |                                          |                                                        |                                             |    |
| <i>Gram-positive coccal infections where these cannot be safely and effectively treated with a penicillin.</i> |                                                          |             |                |         |                                          |                                                        |                                             |    |
| 5057E                                                                                                          | Capsule 150 mg                                           | 24          | ..             | ..      | 19.33                                    | 20.36                                                  | <sup>a</sup> Cleocin                        | KR |
|                                                                                                                |                                                          |             |                | B1.45   | 20.78                                    | 20.36                                                  | <sup>a</sup> Dalacin C                      | PH |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code  | Name, Restriction,<br>Manner of Administration and Form                      | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                                             |          |
|-------|------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------------------|----------|
|       | LINCOMYCIN                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
| 5144R | Injection 600 mg in 2 mL                                                     | 5           | ..             | ..      | 30.65                                    | 31.30                                                  | Lincocin                                                                         | PH       |
|       | <b>Other antibacterials</b>                                                  |             |                |         |                                          |                                                        |                                                                                  |          |
|       | • <b>Glycopeptide antibacterials</b>                                         |             |                |         |                                          |                                                        |                                                                                  |          |
|       | VANCOMYCIN                                                                   |             |                |         |                                          |                                                        |                                                                                  |          |
|       | <b>Restricted Benefit</b>                                                    |             |                |         |                                          |                                                        |                                                                                  |          |
|       | <i>Prophylaxis of endocarditis in patients hypersensitive to penicillin.</i> |             |                |         |                                          |                                                        |                                                                                  |          |
| 3323X | Powder for injection 500 mg<br>(500,000 i.u.) vancomycin activity            | 2           | ..             | ..      | * 46.09                                  | 31.30                                                  | <sup>a</sup> Vancocin CP<br><sup>a</sup> Vancomycin<br>Sandoz<br><sup>a</sup> HH | AS<br>SZ |
| 5083M | Powder for injection 1 g (1,000,000 i.u.)<br>vancomycin activity             | 1           | ..             | ..      | 46.07                                    | 31.30                                                  | <sup>a</sup> Vancomycin<br>Sandoz<br><sup>a</sup> HH                             | SZ       |
|       | • <b>Imidazole derivatives</b>                                               |             |                |         |                                          |                                                        |                                                                                  |          |
|       | METRONIDAZOLE                                                                |             |                |         |                                          |                                                        |                                                                                  |          |
| 3339R | Tablet 200 mg                                                                | 21          | ..             | ..      | 7.53                                     | 8.56                                                   | <sup>a</sup> Metrogyl 200<br><sup>a</sup> Metronide 200                          | AF<br>AV |
|       |                                                                              |             |                | B1.51   | 9.04                                     | 8.56                                                   | <sup>a</sup> Flagyl                                                              | SW       |
| 5159M | Tablet 400 mg                                                                | 5           | ..             | ..      | 7.45                                     | 8.48                                                   | Metrogyl 400                                                                     | AF       |
| 5157K | Suppositories 500 mg, 10                                                     | ‡ 1         | ..             | ..      | 21.68                                    | 22.71                                                  | Flagyl                                                                           | SW       |
|       | <b>METRONIDAZOLE</b>                                                         |             |                |         |                                          |                                                        |                                                                                  |          |
|       | <b>Restricted Benefit</b>                                                    |             |                |         |                                          |                                                        |                                                                                  |          |
|       | <i>Treatment of anaerobic infections.</i>                                    |             |                |         |                                          |                                                        |                                                                                  |          |
| 5155H | Tablet 400 mg                                                                | 21          | ..             | ..      | 9.60                                     | 10.63                                                  | <sup>a</sup> Metrogyl 400<br><sup>a</sup> Metronide 400                          | AF<br>AV |
|       |                                                                              |             |                | B1.57   | 11.17                                    | 10.63                                                  | <sup>a</sup> Flagyl                                                              | SW       |

continued ➞

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code                                                                                    | Name, Restriction,<br>Manner of Administration and Form                                    | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer               |    |
|-----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------|----|
| <b><u>Restricted Benefit</u></b>                                                        |                                                                                            |             |                |         |                                          |                                                        |                                                    |    |
| <i>Treatment, in a hospital, of acute anaerobic sepsis.</i>                             |                                                                                            |             |                |         |                                          |                                                        |                                                    |    |
| 5154G                                                                                   | I.V. infusion 500 mg in 100 mL                                                             | 5           | ..             | ..      | * 31.54                                  | 31.30                                                  | <sup>a</sup> BX                                    |    |
|                                                                                         |                                                                                            |             |                | ..      | * 31.54                                  | 31.30                                                  | <sup>a</sup> DBL                                   | HH |
|                                                                                         |                                                                                            |             |                |         |                                          |                                                        | Metronidazole<br>Intravenous<br>Infusion           |    |
|                                                                                         |                                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Metronidazole<br>Sandoz               | SZ |
| METRONIDAZOLE BENZOATE                                                                  |                                                                                            |             |                |         |                                          |                                                        |                                                    |    |
| 3341W                                                                                   | Oral suspension 320 mg per 5 mL<br>(equivalent to 200 mg metronidazole in<br>5 mL), 100 mL | ‡ 1         | ..             | ..      | 15.73                                    | 16.76                                                  | Flagyl S                                           | SW |
| <b>MUSCULO-SKELETAL SYSTEM</b>                                                          |                                                                                            |             |                |         |                                          |                                                        |                                                    |    |
| <b>ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS</b>                                      |                                                                                            |             |                |         |                                          |                                                        |                                                    |    |
| <b>Antiinflammatory and antirheumatic products, non-steroids</b>                        |                                                                                            |             |                |         |                                          |                                                        |                                                    |    |
| • <b>Acetic acid derivatives and related substances</b>                                 |                                                                                            |             |                |         |                                          |                                                        |                                                    |    |
| DICLOFENAC SODIUM                                                                       |                                                                                            |             |                |         |                                          |                                                        |                                                    |    |
| 5079H                                                                                   | Suppository 100 mg                                                                         | 40          | ..             | ..      | * 24.49                                  | 25.52                                                  | Voltaren 100                                       | NV |
| <b>DICLOFENAC SODIUM</b>                                                                |                                                                                            |             |                |         |                                          |                                                        |                                                    |    |
| <b><u>Restricted Benefit</u></b>                                                        |                                                                                            |             |                |         |                                          |                                                        |                                                    |    |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component;</i> |                                                                                            |             |                |         |                                          |                                                        |                                                    |    |
| <i>Bone pain due to malignant disease.</i>                                              |                                                                                            |             |                |         |                                          |                                                        |                                                    |    |
| 5076E                                                                                   | Tablet 25 mg (enteric coated)                                                              | 100         | ..             | ..      | * 12.63                                  | 13.66                                                  | <sup>a</sup> Chem mart<br>Diclofenac               | CH |
|                                                                                         |                                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Clonac 25                             | AW |
|                                                                                         |                                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Diclohexal                            | SZ |
|                                                                                         |                                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Dinac                                 | GM |
|                                                                                         |                                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Diclofenac                      | GX |
|                                                                                         |                                                                                            |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Diclofenac | TW |
|                                                                                         |                                                                                            |             |                | ..      | 12.64                                    | 13.67                                                  | <sup>a</sup> Fenac 25                              | AF |
|                                                                                         |                                                                                            |             |                | B1.96   | * 14.59                                  | 13.66                                                  | <sup>a</sup> Voltaren 25                           | NV |

continued ➡



**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code                                                                             | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer               |    |
|----------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------|----|
| 5077F                                                                            | Tablet 50 mg (enteric coated)                           | 50          | ..             | ..      | 10.62                                    | 11.65                                                  | <sup>a</sup> Chem mart<br>Diclofenac               | CH |
|                                                                                  |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Clonac 50                             | AW |
|                                                                                  |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Diclohexal                            | SZ |
|                                                                                  |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dinac                                 | GM |
|                                                                                  |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Fenac                                 | AF |
|                                                                                  |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Diclofenac                      | GX |
|                                                                                  |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Diclofenac | TW |
|                                                                                  |                                                         |             |                | B1.96   | 12.58                                    | 11.65                                                  | <sup>a</sup> Voltaren 50                           | NV |
| INDOMETHACIN                                                                     |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| 5128X                                                                            | Suppository 100 mg                                      | 40          | ..             | ..      | * 22.07                                  | 23.10                                                  | Indocid                                            | MK |
| INDOMETHACIN                                                                     |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| <u>Restricted Benefit</u>                                                        |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| Chronic arthropathies (including osteoarthritis) with an inflammatory component; |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| Bone pain due to malignant disease.                                              |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| 5126T                                                                            | Capsule 25 mg                                           | 100         | ..             | ..      | * 10.23                                  | 11.26                                                  | <sup>a</sup> Arthrexin                             | AF |
|                                                                                  |                                                         |             |                | B2.34   | * 12.57                                  | 11.26                                                  | <sup>a</sup> Indocid                               | MK |
| SULINDAC                                                                         |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| <u>Restricted Benefit</u>                                                        |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| Chronic arthropathies (including osteoarthritis) with an inflammatory component; |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| Bone pain due to malignant disease.                                              |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| 5217N                                                                            | Tablet 100 mg                                           | 100         | ..             | ..      | * 15.91                                  | 16.94                                                  | Aclin                                              | AF |
| 5218P                                                                            | Tablet 200 mg                                           | 50          | ..             | ..      | 14.85                                    | 15.88                                                  | Aclin 200                                          | AF |
| • Oxicams                                                                        |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| PIROXICAM                                                                        |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| <u>Restricted Benefit</u>                                                        |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| Chronic arthropathies (including osteoarthritis) with an inflammatory component. |                                                         |             |                |         |                                          |                                                        |                                                    |    |
| 5201R                                                                            | Dispersible tablet 10 mg                                | 50          | ..             | ..      | 12.07                                    | 13.10                                                  | <sup>a</sup> GenRx Piroxicam<br>Dispersible        | GX |
|                                                                                  |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Mobilis D-10                          | AF |
|                                                                                  |                                                         |             |                | B2.09   | 14.16                                    | 13.10                                                  | <sup>a</sup> Feldene-D                             | PF |

continued ➡

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code                                                                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                             |    |
|-----------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------------------------------|----|
| 5202T                                                                                   | Dispersible tablet 20 mg                                | 25          | ..             | ..      | 11.77                                    | 12.80                                                  | <sup>a</sup> Chem mart<br>Piroxicam<br>Dispersible               | CH |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Piroxicam<br>Dispersible                      | GX |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Mobilis D-20                                        | AF |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Piroxicam<br>Dispersible | TW |
|                                                                                         |                                                         |             |                | B2.07   | 13.84                                    | 12.80                                                  | <sup>a</sup> Feldene-D                                           | PF |
| 5203W                                                                                   | Capsule 10 mg                                           | 50          | ..             | ..      | 12.07                                    | 13.10                                                  | <sup>a</sup> Chem mart<br>Piroxicam                              | CH |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Piroxicam                                     | GX |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Mobilis 10                                          | AF |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Piroxicam                | TW |
|                                                                                         |                                                         |             |                | B2.09   | 14.16                                    | 13.10                                                  | <sup>a</sup> Feldene                                             | PF |
| 5204X                                                                                   | Capsule 20 mg                                           | 25          | ..             | ..      | 11.77                                    | 12.80                                                  | <sup>a</sup> Chem mart<br>Piroxicam                              | CH |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> GenRx Piroxicam                                     | GX |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Mobilis 20                                          | AF |
|                                                                                         |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Piroxicam                | TW |
|                                                                                         |                                                         |             |                | B2.07   | 13.84                                    | 12.80                                                  | <sup>a</sup> Feldene                                             | PF |
| <b>• Propionic acid derivatives</b>                                                     |                                                         |             |                |         |                                          |                                                        |                                                                  |    |
| IBUPROFEN                                                                               |                                                         |             |                |         |                                          |                                                        |                                                                  |    |
| 5124Q                                                                                   | Tablet 400 mg                                           | 30          | ..             | ..      | 8.76                                     | 9.79                                                   | Brufen                                                           | AB |
| <hr/>                                                                                   |                                                         |             |                |         |                                          |                                                        |                                                                  |    |
| <b>IBUPROFEN</b>                                                                        |                                                         |             |                |         |                                          |                                                        |                                                                  |    |
| <b><u>Restricted Benefit</u></b>                                                        |                                                         |             |                |         |                                          |                                                        |                                                                  |    |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component;</i> |                                                         |             |                |         |                                          |                                                        |                                                                  |    |
| <i>Bone pain due to malignant disease.</i>                                              |                                                         |             |                |         |                                          |                                                        |                                                                  |    |
| 5121M                                                                                   | Tablet 200 mg                                           | 100         | ..             | ..      | * 11.63                                  | 12.66                                                  | Rafen 200                                                        | AF |
| 5123P                                                                                   | Tablet 400 mg                                           | 90          | ..             | ..      | * 14.30                                  | 15.33                                                  | Brufen                                                           | AB |
| <b>KETOPROFEN</b>                                                                       |                                                         |             |                |         |                                          |                                                        |                                                                  |    |
| 5139L                                                                                   | Suppository 100 mg                                      | 40          | ..             | ..      | * 22.81                                  | 23.84                                                  | Orudis                                                           | SW |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

**KETOPROFEN**

**Restricted Benefit**

*Chronic arthropathies (including osteoarthritis) with an inflammatory component.*

|       |                                    |    |    |       |       |       |                            |    |
|-------|------------------------------------|----|----|-------|-------|-------|----------------------------|----|
| 5136H | Capsule 200 mg (sustained release) | 28 | .. | ..    | 16.49 | 17.52 | <sup>a</sup> Oruvail SR    | AV |
|       |                                    |    |    | B2.00 | 18.49 | 17.52 | <sup>a</sup> Orudis SR 200 | SW |

**NAPROXEN**

**Restricted Benefit**

*Chronic arthropathies (including osteoarthritis) with an inflammatory component;*

*Bone pain due to malignant disease.*

|       |                                   |     |    |       |         |       |                              |    |
|-------|-----------------------------------|-----|----|-------|---------|-------|------------------------------|----|
| 5176K | Tablet 250 mg                     | 100 | .. | ..    | * 13.29 | 14.32 | <sup>a</sup> Inza 250        | AF |
|       |                                   |     |    | B2.34 | * 15.63 | 14.32 | <sup>a</sup> Naprosyn        | RO |
| 5177L | Tablet 500 mg                     | 50  | .. | ..    | 12.48   | 13.51 | <sup>a</sup> Inza 500        | AF |
|       |                                   |     |    | B1.36 | 13.84   | 13.51 | <sup>a</sup> Naprosyn        | RO |
| 5178M | Tablet 750 mg (sustained release) | 28  | .. | ..    | 11.95   | 12.98 | <sup>a</sup> Proxen SR 750   | MD |
|       |                                   |     |    | B1.27 | 13.22   | 12.98 | <sup>a</sup> Naprosyn SR750  | RO |
| 5179N | Tablet 1 g (sustained release)    | 28  | .. | ..    | 13.94   | 14.97 | <sup>a</sup> Proxen SR 1000  | MD |
|       |                                   |     |    | B1.34 | 15.28   | 14.97 | <sup>a</sup> Naprosyn SR1000 | RO |

**NAPROXEN SODIUM**

**Restricted Benefit**

*Chronic arthropathies (including osteoarthritis) with an inflammatory component;*

*Bone pain due to malignant disease.*

|       |               |    |    |       |       |       |                          |    |
|-------|---------------|----|----|-------|-------|-------|--------------------------|----|
| 5186Y | Tablet 550 mg | 50 | .. | ..    | 12.67 | 13.70 | <sup>a</sup> Crysanal    | MD |
|       |               |    |    | B2.29 | 14.96 | 13.70 | <sup>a</sup> Anaprox 550 | RO |

**NOTE:**

*Naproxen sodium 550 mg is approximately equivalent to 500 mg of naproxen acid.*

**NERVOUS SYSTEM**

**ANALGESICS**

**Opioids**

• **Natural opium alkaloids**

CODEINE PHOSPHATE

|       |              |    |    |    |       |       |    |  |
|-------|--------------|----|----|----|-------|-------|----|--|
| 5063L | Tablet 30 mg | 20 | .. | .. | 16.44 | 17.47 | FM |  |
|-------|--------------|----|----|----|-------|-------|----|--|

**NOTE:**

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code                               | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| CODEINE PHOSPHATE with PARACETAMOL |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 3316M                              | Tablet 30 mg-500 mg                                     | 20          | ..             | ..      | 7.65                                     | 8.68                                                   | a Codalgin Forte                     | FM |
|                                    |                                                         |             |                |         |                                          |                                                        | a Codapane Forte                     | AL |
|                                    |                                                         |             |                |         |                                          |                                                        | a Comfarol Forte                     | SZ |
|                                    |                                                         |             |                |         |                                          |                                                        | a Dolaforte                          | CO |
|                                    |                                                         |             |                |         |                                          |                                                        | a Prodeine Forte                     | AV |
|                                    |                                                         |             |                | B1.43   | 9.08                                     | 8.68                                                   | a Panadeine Forte                    | SW |

**HYDROMORPHONE HYDROCHLORIDE**

**CAUTION:**

The risk of drug dependence is high.

|       |                         |   |    |    |       |       |             |    |
|-------|-------------------------|---|----|----|-------|-------|-------------|----|
| 5129Y | Injection 2 mg in 1 mL  | 5 | .. | .. | 13.51 | 14.54 | Dilaudid    | MF |
| 5130B | Injection 10 mg in 1 mL | 5 | .. | .. | 18.87 | 19.90 | Dilaudid-HP | MF |
| 5131C | Injection 50 mg in 5 mL | 5 | .. | .. | 47.07 | 31.30 | Dilaudid-HP | MF |

**NOTE:**

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

**HYDROMORPHONE HYDROCHLORIDE**

**CAUTION:**

The risk of drug dependence is high.

**Restricted Benefit**

*Severe disabling pain not responding to non-narcotic analgesics.*

|       |                                 |    |    |    |       |       |          |    |
|-------|---------------------------------|----|----|----|-------|-------|----------|----|
| 5115F | Tablet 2 mg                     | 20 | .. | .. | 13.79 | 14.82 | Dilaudid | MF |
| 5116G | Tablet 4 mg                     | 20 | .. | .. | 18.85 | 19.88 | Dilaudid | MF |
| 5117H | Tablet 8 mg                     | 20 | .. | .. | 28.61 | 29.64 | Dilaudid | MF |
| 5132D | Oral liquid 1 mg per mL, 473 mL | 1  | .. | .. | 49.09 | 31.30 | Dilaudid | MF |

**NOTE:**

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

**MORPHINE HYDROCHLORIDE**

**CAUTION:**

The risk of drug dependence is high.

**Restricted Benefit**

*Severe disabling pain not responding to non-narcotic analgesics.*

|       |                                    |   |    |    |       |       |           |    |
|-------|------------------------------------|---|----|----|-------|-------|-----------|----|
| 5237P | Oral solution 2 mg per mL, 200 mL  | 1 | .. | .. | 18.73 | 19.76 | Ordine 2  | MF |
| 5238Q | Oral solution 5 mg per mL, 200 mL  | 1 | .. | .. | 21.64 | 22.67 | Ordine 5  | MF |
| 5239R | Oral solution 10 mg per mL, 200 mL | 1 | .. | .. | 26.24 | 27.27 | Ordine 10 | MF |

continued ➡

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|

**NOTE:**

*Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.*

**MORPHINE SULFATE****CAUTION:**

The risk of drug dependence is high.

|       |                         |   |    |    |       |       |    |
|-------|-------------------------|---|----|----|-------|-------|----|
| 5168B | Injection 10 mg in 1 mL | 5 | .. | .. | 13.56 | 14.59 | HH |
| 5169C | Injection 15 mg in 1 mL | 5 | .. | .. | 13.89 | 14.92 | HH |
| 5170D | Injection 30 mg in 1 mL | 5 | .. | .. | 15.32 | 16.35 | HH |

**NOTE:**

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

**MORPHINE SULFATE****CAUTION:**

*The risk of drug dependence is high.*

**Restricted Benefit**

*Severe disabling pain not responding to non-narcotic analgesics.*

|       |              |    |    |    |       |       |          |    |
|-------|--------------|----|----|----|-------|-------|----------|----|
| 5163R | Tablet 30 mg | 20 | .. | .. | 14.53 | 15.56 | Anamorph | FM |
|-------|--------------|----|----|----|-------|-------|----------|----|

**NOTE:**

*Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.*

**Restricted Benefit**

*Chronic severe disabling pain not responding to non-narcotic analgesics.*

|       |                                                         |    |    |    |       |       |           |    |
|-------|---------------------------------------------------------|----|----|----|-------|-------|-----------|----|
| 5162Q | Tablet 5 mg (controlled release)                        | 20 | .. | .. | 15.89 | 16.92 | MS Contin | MF |
| 5164T | Tablet 10 mg (controlled release)                       | 20 | .. | .. | 17.35 | 18.38 | MS Contin | MF |
| 5161P | Tablet 15 mg (controlled release)                       | 20 | .. | .. | 20.86 | 21.89 | MS Contin | MF |
| 5165W | Tablet 30 mg (controlled release)                       | 20 | .. | .. | 30.03 | 31.06 | MS Contin | MF |
| 5166X | Tablet 60 mg (controlled release)                       | 20 | .. | .. | 45.84 | 31.30 | MS Contin | MF |
| 5167Y | Tablet 100 mg (controlled release)                      | 20 | .. | .. | 62.58 | 31.30 | MS Contin | MF |
| 5246D | Capsule 10 mg (containing sustained<br>release pellets) | 20 | .. | .. | 17.07 | 18.10 | Kapanol   | GK |
| 5240T | Capsule 20 mg (containing sustained<br>release pellets) | 20 | .. | .. | 22.20 | 23.23 | Kapanol   | GK |
| 5064M | Capsule 30 mg (controlled release)                      | 10 | .. | .. | 20.86 | 21.89 | MS Mono   | MF |

continued 

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code  | Name, Restriction,<br>Manner of Administration and Form                              | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|--------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 5241W | Capsule 50 mg (containing sustained release pellets)                                 | 20          | ..             | ..      | 37.75                                    | 31.30                                                  | Kapanol                              | GK |
| 5065N | Capsule 60 mg (controlled release)                                                   | 10          | ..             | ..      | 30.03                                    | 31.06                                                  | MS Mono                              | MF |
| 5066P | Capsule 90 mg (controlled release)                                                   | 10          | ..             | ..      | 36.15                                    | 31.30                                                  | MS Mono                              | MF |
| 5242X | Capsule 100 mg (containing sustained release pellets)                                | 20          | ..             | ..      | 60.83                                    | 31.30                                                  | Kapanol                              | GK |
| 5067Q | Capsule 120 mg (controlled release)                                                  | 10          | ..             | ..      | 45.84                                    | 31.30                                                  | MS Mono                              | MF |
| 5171E | Sachet containing controlled release granules for oral suspension, 20 mg per sachet  | 20          | ..             | ..      | 48.36                                    | 31.30                                                  | MS Contin Suspension 20 mg           | MF |
| 5243Y | Sachet containing controlled release granules for oral suspension, 30 mg per sachet  | 20          | ..             | ..      | 49.60                                    | 31.30                                                  | MS Contin Suspension 30 mg           | MF |
| 5244B | Sachet containing controlled release granules for oral suspension, 60 mg per sachet  | 20          | ..             | ..      | 54.95                                    | 31.30                                                  | MS Contin Suspension 60 mg           | MF |
| 5245C | Sachet containing controlled release granules for oral suspension, 100 mg per sachet | 20          | ..             | ..      | 67.09                                    | 31.30                                                  | MS Contin Suspension 100 mg          | MF |

**NOTE:**

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

**OXYCODONE****CAUTION:**

The risk of drug dependence is high.

**Restricted Benefit**

Severe disabling pain not responding to non-narcotic analgesics.

|       |                   |    |    |    |       |       |           |    |
|-------|-------------------|----|----|----|-------|-------|-----------|----|
| 5194J | Suppository 30 mg | 12 | .. | .. | 39.61 | 31.30 | Proladone | PL |
|-------|-------------------|----|----|----|-------|-------|-----------|----|

**NOTE:**

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

**OXYCODONE HYDROCHLORIDE****CAUTION:**

The risk of drug dependence is high.

**Restricted Benefit**

Severe disabling pain not responding to non-narcotic analgesics.

|       |               |    |    |    |       |       |         |    |
|-------|---------------|----|----|----|-------|-------|---------|----|
| 5195K | Tablet 5 mg   | 20 | .. | .. | 11.87 | 12.90 | Endone  | SI |
| 5191F | Capsule 5 mg  | 20 | .. | .. | 11.87 | 12.90 | OxyNorm | MF |
| 5197M | Capsule 10 mg | 20 | .. | .. | 14.99 | 16.02 | OxyNorm | MF |

continued ➞

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 5198N | Capsule 20 mg                                           | 20          | ..             | ..      | 19.72                                    | 20.75                                                  | OxyNorm                              | MF |
| 5190E | Oral solution 5 mg per 5 mL, 250 mL                     | 1           | ..             | ..      | 20.29                                    | 21.32                                                  | OxyNorm Liquid<br>5mg/5mL            | MF |

**NOTE:**

*Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.*

**Restricted Benefit**

*Chronic severe disabling pain not responding to non-narcotic analgesics.*

|       |                                   |    |    |    |       |       |           |    |
|-------|-----------------------------------|----|----|----|-------|-------|-----------|----|
| 5227D | Tablet 5 mg (controlled release)  | 20 | .. | .. | 20.75 | 21.78 | OxyContin | MF |
| 5247E | Tablet 10 mg (controlled release) | 20 | .. | .. | 21.25 | 22.28 | OxyContin | MF |
| 5248F | Tablet 20 mg (controlled release) | 20 | .. | .. | 30.03 | 31.06 | OxyContin | MF |
| 5249G | Tablet 40 mg (controlled release) | 20 | .. | .. | 45.84 | 31.30 | OxyContin | MF |
| 5250H | Tablet 80 mg (controlled release) | 20 | .. | .. | 71.27 | 31.30 | OxyContin | MF |

**NOTE:**

*Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.*

- Other opioids**

**TRAMADOL HYDROCHLORIDE**

**Restricted Benefit**

*For acute pain where aspirin and/or paracetamol alone are inappropriate or have failed;*

*For dosage titration in chronic pain where aspirin and/or paracetamol alone are inappropriate or have failed.*

|       |               |    |    |       |       |      |                                                  |    |
|-------|---------------|----|----|-------|-------|------|--------------------------------------------------|----|
| 5232J | Capsule 50 mg | 20 | .. | ..    | 8.73  | 9.76 | <sup>a</sup> Chem mart<br>Tramadol               | CH |
|       |               |    |    |       |       |      | <sup>a</sup> GenRx Tramadol                      | GX |
|       |               |    |    |       |       |      | <sup>a</sup> Terry White<br>Chemists<br>Tramadol | TW |
|       |               |    |    |       |       |      | <sup>a</sup> Tramedo                             | AF |
|       |               |    |    |       |       |      | <sup>a</sup> Zydol                               | AW |
|       |               |    |    | b2.42 | 11.15 | 9.76 | <sup>a</sup> Tramal                              | CS |

**Restricted Benefit**

*For pain where aspirin and/or paracetamol alone are inappropriate or have failed.*

|       |                                  |    |    |    |       |       |              |    |
|-------|----------------------------------|----|----|----|-------|-------|--------------|----|
| 3338Q | Tablet 50 mg (sustained release) | 20 | .. | .. | 11.20 | 12.23 | Tramal SR 50 | CS |
|-------|----------------------------------|----|----|----|-------|-------|--------------|----|

continued ➞





**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code                                 | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                |    |
|--------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-----------------------------------------------------|----|
| 3349G                                | Oral liquid 240 mg per 5 mL, 200 mL                     | ‡ 1         | ..             | ..      | 10.25                                    | 11.28                                                  | Panamax 240 Elixir                                  | SW |
| <hr/>                                |                                                         |             |                |         |                                          |                                                        |                                                     |    |
| <b>PARACETAMOL</b>                   |                                                         |             |                |         |                                          |                                                        |                                                     |    |
| <b><u>Restricted Benefit</u></b>     |                                                         |             |                |         |                                          |                                                        |                                                     |    |
| <b><i>Chronic arthropathies.</i></b> |                                                         |             |                |         |                                          |                                                        |                                                     |    |
| 5224Y                                | Tablet 500 mg                                           | 300         | ..             | ..      | * 11.99                                  | 13.02                                                  | <sup>a</sup> Chem mart<br>Chemadol                  | CH |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Dymadon P                              | PC |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Febridol                               | GM |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Panamax                                | SW |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Paracetamol<br>Sandoz                  | SZ |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>b</sup> Parahexal                              | HX |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Paralgin                               | FM |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>b</sup> Parmol                                 | AW |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Pharmacy Choice<br>Paracetamol         | YM |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terry White<br>Chemists<br>Paracetamol | TW |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>b</sup> Tylenol                                | JT |
| <hr/>                                |                                                         |             |                |         |                                          |                                                        |                                                     |    |
| <b>ANTIEPILEPTICS</b>                |                                                         |             |                |         |                                          |                                                        |                                                     |    |
| <b>Antiepileptics</b>                |                                                         |             |                |         |                                          |                                                        |                                                     |    |
| • <b>Carboxamide derivatives</b>     |                                                         |             |                |         |                                          |                                                        |                                                     |    |
| CARBAMAZEPINE                        |                                                         |             |                |         |                                          |                                                        |                                                     |    |
| 5039F                                | Tablet 100 mg                                           | 200         | ..             | ..      | 18.71                                    | 19.74                                                  | <sup>a</sup> Carbamazepine<br>Sandoz                | SZ |
|                                      |                                                         |             |                | B2.55   | 21.26                                    | 19.74                                                  | <sup>a</sup> Tegretol 100                           | NV |
| 5040G                                | Tablet 200 mg                                           | 200         | ..             | ..      | 29.77                                    | 30.80                                                  | <sup>a</sup> Carbamazepine<br>Sandoz                | SZ |
|                                      |                                                         |             |                | B2.74   | 32.51                                    | 30.80                                                  | <sup>a</sup> Teril                                  | AF |
|                                      |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Tegretol 200                           | NV |
| 5038E                                | Tablet 200 mg (controlled release)                      | 200         | ..             | ..      | 30.26                                    | 31.29                                                  | Tegretol CR 200                                     | NV |
| 5037D                                | Tablet 400 mg (controlled release)                      | 200         | ..             | ..      | 50.59                                    | 31.30                                                  | Tegretol CR 400                                     | NV |
| 5041H                                | Oral suspension 100 mg per 5 mL,<br>300 mL              | ‡ 1         | ..             | ..      | 20.92                                    | 21.95                                                  | Tegretol Liquid                                     | NV |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code                                              | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>ANTI-PARKINSON DRUGS</b>                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Anticholinergic agents</b>                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Ethers of tropine or tropine derivatives</b> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| BENZTROPINE MESYLATE                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 5031T                                             | Injection 2 mg in 2 mL                                  | 5           | ..             | ..      | 22.41                                    | 23.44                                                  | Cogentin                             | FK |
| <b>PSYCHOLEPTICS</b>                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Anxiolytics</b>                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Benzodiazepine derivatives</b>               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| DIAZEPAM                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 5071X                                             | Tablet 2 mg                                             | 50          | ..             | ..      | 7.36                                     | 8.39                                                   | a Antenex 2                          | AF |
|                                                   |                                                         |             |                |         |                                          |                                                        | a Valpam 2                           | AW |
|                                                   |                                                         |             |                | b0.59   | 7.95                                     | 8.39                                                   | Ducene                               | SU |
|                                                   |                                                         |             |                | b0.86   | 8.22                                     | 8.39                                                   | a Valium                             | RO |
| 5072Y                                             | Tablet 5 mg                                             | 50          | ..             | ..      | 7.50                                     | 8.53                                                   | a Antenex 5                          | AF |
|                                                   |                                                         |             |                |         |                                          |                                                        | a Diazepam-DP                        | GM |
|                                                   |                                                         |             |                |         |                                          |                                                        | a Ranzepam                           | RA |
|                                                   |                                                         |             |                |         |                                          |                                                        | a Valpam 5                           | AW |
|                                                   |                                                         |             |                | b0.63   | 8.13                                     | 8.53                                                   | Ducene                               | SU |
|                                                   |                                                         |             |                | b0.88   | 8.38                                     | 8.53                                                   | a Valium                             | RO |
| 5073B                                             | Injection 10 mg in 2 mL                                 | 5           | ..             | ..      | 11.86                                    | 12.89                                                  | HH                                   |    |
| OXAZEPAM                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 5192G                                             | Tablet 15 mg                                            | 25          | ..             | ..      | 7.27                                     | 8.30                                                   | a Alepam 15                          | AF |
|                                                   |                                                         |             |                | b1.78   | 9.05                                     | 8.30                                                   | a Serepax                            | SI |
| 5193H                                             | Tablet 30 mg                                            | 25          | ..             | ..      | 7.46                                     | 8.49                                                   | a Alepam 30                          | AF |
|                                                   |                                                         |             |                |         |                                          |                                                        | a Murelax                            | FM |
|                                                   |                                                         |             |                | b1.90   | 9.36                                     | 8.49                                                   | a Serepax                            | SI |
| <b>Hypnotics and sedatives</b>                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Benzodiazepine derivatives</b>               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| NITRAZEPAM                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 5189D                                             | Tablet 5 mg                                             | 25          | ..             | ..      | 7.46                                     | 8.49                                                   | a Alodorm                            | AF |
|                                                   |                                                         |             |                | b1.53   | 8.99                                     | 8.49                                                   | a Mogadon                            | VT |
| TEMAZEPAM                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 5221T                                             | Tablet 10 mg                                            | 25          | ..             | ..      | 7.46                                     | 8.49                                                   | a Temaze                             | AF |
|                                                   |                                                         |             |                |         |                                          |                                                        | a Temtabs                            | FM |
|                                                   |                                                         |             |                | b1.38   | 8.84                                     | 8.49                                                   | a Normison                           | SI |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY—cont.**

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|

## RESPIRATORY SYSTEM

### DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

#### Adrenergics for systemic use

- **Alpha- and beta-adrenoceptor agonists**

#### ADRENALINE

|       |                                     |   |    |    |       |       |    |
|-------|-------------------------------------|---|----|----|-------|-------|----|
| 5004J | Injection 1 mg in 1 mL (1 in 1,000) | 5 | .. | .. | 19.91 | 20.94 | AP |
|-------|-------------------------------------|---|----|----|-------|-------|----|

## SENSORY ORGANS

### OPHTHALMOLOGICALS

#### Antiinfectives

- **Antibiotics**

#### CHLORAMPHENICOL

|       |                                     |     |    |    |      |      |                           |          |
|-------|-------------------------------------|-----|----|----|------|------|---------------------------|----------|
| 5055C | Eye drops 5 mg per mL (0.5%), 10 mL | ‡ 1 | .. | .. | 8.88 | 9.91 | Chloromycetin<br>Chlorsig | PF<br>SI |
|-------|-------------------------------------|-----|----|----|------|------|---------------------------|----------|

## VARIOUS

### ALL OTHER THERAPEUTIC PRODUCTS

#### All other therapeutic products

- **Antidotes**

#### NALOXONE HYDROCHLORIDE

|       |                                  |   |    |    |       |       |                    |    |
|-------|----------------------------------|---|----|----|-------|-------|--------------------|----|
| 5174H | Injection 800 micrograms in 2 mL | 1 | .. | .. | 27.89 | 28.92 | Naloxone Min-I-Jet | CS |
| 5175J | Injection 2 mg in 5 mL           | 1 | .. | .. | 40.93 | 31.30 | Naloxone Min-I-Jet | CS |

### ALL OTHER NON-THERAPEUTIC PRODUCTS

#### All other non-therapeutic products

- **Solvents and diluting agents, incl. irrigating solutions**

#### SODIUM CHLORIDE

|       |                                     |   |    |    |       |       |    |
|-------|-------------------------------------|---|----|----|-------|-------|----|
| 5211G | Injection 9 mg per mL (0.9%), 10 mL | 5 | .. | .. | 17.73 | 18.76 | PF |
|-------|-------------------------------------|---|----|----|-------|-------|----|

## PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY

---

### PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY

From 1 January 2008, optometrists accredited to prescribe under State or Territory legislation can apply for approval as PBS prescribers (*authorised optometrists*). Information for optometrists on becoming a PBS prescriber is available on the Medicare Australia website at: [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)

The medications listed in this section are for prescribing by authorised optometrists only. Optometrists must not write PBS prescriptions for medicines listed elsewhere in the PBS Schedule.

The Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for making recommendations regarding preparations for inclusion in the optometrist section.

Some products are included in more than one section of the Schedule. For a prescription to be eligible for subsidy, prescribers must ensure that they prescribe under the PBS only those medicines, and in accordance with the restrictions, listed for their practitioner type. Listing details for the same product may differ between sections and different PBS item codes apply for each prescriber type.

Optometrist PBS prescriptions are identifiable by colour, and include the words 'PBS/RPBS optometrist'. Prescriptions must include the optometrist's PBS prescriber number. The same optometrist prescription form is used to prescribe unrestricted, restricted or authority items. Only one item is allowed per form. Optometrist PBS prescriptions may include repeats.

Regulation 24 does not apply for optometrist prescribing. An optometrist cannot direct that original and repeat supplies of pharmaceutical benefits be supplied at the one time.

Authority prescriptions: Authority prescriptions for authority required items, or for increased quantities or repeats, require prior approval from Medicare Australia or the DVA for each prescription. (Refer to details in the Explanatory Notes section under Prescribing Medicines — Information for PBS prescribers and Supplying Medicines — What Pharmacists Need to Know, for more information on authority prescriptions.) DVA approval for non-Schedule items is not available for optometrist prescribing.

RPBS: Optometrists approved as PBS prescribers may write prescriptions for supply under the RPBS. The list of optometrist medicines under the RPBS is the same as the PBS. There are no optometrist listings in the Repatriation Schedule for prescribing for veterans only. There is no provision for optometrist prescribers to request approval to prescribe items that are not included in the PBS optometrist list (non-Schedule items).

State and Territory requirements: Optometrists may prescribe medications as private prescriptions according to their State/Territory prescribing accreditation. The medicines which can be prescribed differ between States and Territories. It is the optometrist's responsibility to ensure adherence to State/Territory law for all prescriptions (PBS and private) and additionally to all PBS requirements for PBS/RPBS prescriptions.

**PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED  
OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY-cont.**

| Code                                                                                | Name, Restriction,<br>Manner of Administration and Form                 | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |          |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----------|
| <b>SENSORY ORGANS</b>                                                               |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| <b>OPHTHALMOLOGICALS</b>                                                            |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| <b>Antiinfectives</b>                                                               |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| • <b>Antibiotics</b>                                                                |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| CHLORAMPHENICOL                                                                     |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| 5512D                                                                               | Eye drops 5 mg per mL (0.5%), 10 mL                                     | ± 1         | 2              | ..      | 8.88                                     | 9.91                                                   | Chloromycetin<br>Chlorsig            | PF<br>SI |
| 5511C                                                                               | Eye ointment 10 mg per g (1%), 4 g                                      | ± 1         | ..             | ..      | 9.33                                     | 10.36                                                  | Chloromycetin<br>Chlorsig            | PF<br>SI |
| • <b>Sulfonamides</b>                                                               |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| SULFACETAMIDE SODIUM                                                                |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| 5530C                                                                               | Eye drops 100 mg per mL (10%), 15 mL                                    | ± 1         | 2              | ..      | 13.35                                    | 14.38                                                  | Bleph 10                             | AG       |
| • <b>Antivirals</b>                                                                 |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| ACICLOVIR                                                                           |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| <b>Restricted Benefit</b>                                                           |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| <i>Herpes simplex keratitis.</i>                                                    |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| 5501M                                                                               | Eye ointment 30 mg per g (3%), 4.5 g                                    | ± 1         | ..             | ..      | 27.47                                    | 28.50                                                  | Zovirax                              | GK       |
| <b>Antiinflammatory agents</b>                                                      |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| • <b>Corticosteroids, plain</b>                                                     |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| FLUOROMETHOLONE                                                                     |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| 5513E                                                                               | Eye drops 1 mg per mL (0.1%), 5 mL                                      | ± 1         | ..             | ..      | 10.18                                    | 11.21                                                  | Flucon<br>FML Liquifilm              | AQ<br>AG |
| <b>NOTE:</b>                                                                        |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| No applications for increased maximum quantities and/or repeats will be authorised. |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| HYDROCORTISONE ACETATE                                                              |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| 5515G                                                                               | Eye ointment 5 mg per g (0.5%), 5 g                                     | ± 1         | ..             | ..      | 11.35                                    | 12.38                                                  | Hycor                                | SI       |
| 5516H                                                                               | Eye ointment 10 mg per g (1%), 5 g                                      | ± 1         | ..             | ..      | 12.65                                    | 13.68                                                  | Hycor                                | SI       |
| <b>NOTE:</b>                                                                        |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| No applications for increased maximum quantities and/or repeats will be authorised. |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| • <b>Antiinflammatory agents, non-steroids</b>                                      |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| FLURBIPROFEN SODIUM                                                                 |                                                                         |             |                |         |                                          |                                                        |                                      |          |
| 5514F                                                                               | Eye drops 300 micrograms per mL<br>(0.03%), single dose units 0.4 mL, 5 | 1           | ..             | ..      | 14.94                                    | 15.97                                                  | Ocufen                               | AG       |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED  
OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY-cont.**

| Code                                                                                                   | Name, Restriction,<br>Manner of Administration and Form                  | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer           |          |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------------|----------|
| <b>Decongestants and antiallergics</b>                                                                 |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| • <b>Other antiallergics</b>                                                                           |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| <b>SODIUM CROMOGLYCATE</b>                                                                             |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| <u><b>Restricted Benefit</b></u>                                                                       |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| <i>Vernal kerato-conjunctivitis.</i>                                                                   |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| 5529B                                                                                                  | Eye drops 20 mg per mL (2%), 10 mL                                       | ± 1         | 5              | ..      | 14.26                                    | 15.29                                                  | <sup>a</sup> Cromolux<br><sup>a</sup> Opticrom | AE<br>SW |
| <b>Other ophthalmologicals</b>                                                                         |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| • <b>Other ophthalmologicals</b>                                                                       |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| <b>CARBOMER 974</b>                                                                                    |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| <u><b>Authority Required</b></u>                                                                       |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| <i>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.</i> |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| 5502N                                                                                                  | Ocular lubricating gel 3 mg per g<br>(0.3%), single dose units 0.5 g, 30 | 3           | 5              | ..      | * 35.63                                  | 31.30                                                  | Poly Gel                                       | AQ       |
| <b>CARBOMER 980</b>                                                                                    |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| <u><b>Restricted Benefit</b></u>                                                                       |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| <i>Severe dry eye syndrome, including Sjogren's syndrome.</i>                                          |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| 5503P                                                                                                  | Ocular lubricating gel 2 mg per g<br>(0.2%), 10 g                        | ± 1         | 5              | ..      | 10.08                                    | 11.11                                                  | GelTears                                       | BU       |
|                                                                                                        |                                                                          |             |                | ..      | 10.08                                    | 11.11                                                  | <sup>a</sup> PAA                               | NM       |
|                                                                                                        |                                                                          |             |                | B1.00   | 11.08                                    | 11.11                                                  | <sup>a</sup> Viscotears Liquid<br>Gel          | NV       |
| <u><b>Authority Required</b></u>                                                                       |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| <i>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.</i> |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| 5504Q                                                                                                  | Eye drops 2 mg per g (0.2%), single dose<br>units 0.6 mL, 30             | 3           | 5              | ..      | * 35.03                                  | 31.30                                                  | Viscotears                                     | NV       |
| <b>CARMELLOSE SODIUM</b>                                                                               |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| <u><b>Restricted Benefit</b></u>                                                                       |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| <i>Severe dry eye syndrome, including Sjogren's syndrome.</i>                                          |                                                                          |             |                |         |                                          |                                                        |                                                |          |
| 5507W                                                                                                  | Eye drops 5 mg per mL (0.5%), 15 mL                                      | ± 1         | 5              | ..      | 10.16                                    | 11.19                                                  | Refresh Tears Plus                             | AG       |
| 5508X                                                                                                  | Eye drops 10 mg per mL (1%), 15 mL                                       | ± 1         | 5              | ..      | 10.16                                    | 11.19                                                  | Refresh Liquigel                               | AG       |

continued ➡

**PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED  
OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY-cont.**

| Code                                                                                                   | Name, Restriction,<br>Manner of Administration and Form                         | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b><u>Authority Required</u></b>                                                                       |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.</i> |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 5509Y                                                                                                  | Eye drops 2.5 mg per mL (0.25%), single dose units 0.6 mL, 24                   | 4           | 5              | ..      | * 39.99                                  | 31.30                                                  | TheraTears                           | CX |
| 5506T                                                                                                  | Eye drops 5 mg per mL (0.5%), single dose units 0.4 mL, 30                      | 3           | 5              | ..      | * 35.63                                  | 31.30                                                  | Cellufresh                           | AG |
| 5505R                                                                                                  | Eye drops 10 mg per mL (1%), single dose units 0.4 mL, 30                       | 3           | 5              | ..      | * 35.63                                  | 31.30                                                  | Celluvisc                            | AG |
| 5510B                                                                                                  | Ocular lubricating gel 10 mg per mL (1%), single dose units 0.6 mL, 28          | 3           | 5              | ..      | * 33.65                                  | 31.30                                                  | TheraTears                           | CX |
| <b><u>HYPROMELLOSE</u></b>                                                                             |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                       |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome, including Sjogren's syndrome.</i>                                          |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 5518K                                                                                                  | Eye drops 3 mg per mL (0.3%), 15 mL (contains sodium perborate as preservative) | ‡ 1         | 5              | ..      | 10.08                                    | 11.11                                                  | <sup>a</sup> In a Wink Moisturising  | NM |
|                                                                                                        |                                                                                 |             |                | b1.86   | 11.94                                    | 11.11                                                  | <sup>a</sup> Genteal                 | NV |
| 5517J                                                                                                  | Eye drops 5 mg per mL (0.5%), 15 mL                                             | ‡ 1         | 5              | ..      | 10.08                                    | 11.11                                                  | Methopt                              | SI |
| <b><u>HYPROMELLOSE with CARBOMER 980</u></b>                                                           |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                       |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome, including Sjogren's syndrome.</i>                                          |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 5519L                                                                                                  | Ocular lubricating gel 3 mg-2 mg per g (0.3%-0.2%), 10 g                        | ‡ 1         | 5              | ..      | 10.08                                    | 11.11                                                  | <sup>a</sup> HPMC PAA                | NM |
|                                                                                                        |                                                                                 |             |                | b1.86   | 11.94                                    | 11.11                                                  | <sup>a</sup> Genteal gel             | NV |
| <b><u>HYPROMELLOSE with DEXTRAN</u></b>                                                                |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                       |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome, including Sjogren's syndrome.</i>                                          |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 5520M                                                                                                  | Eye drops 3 mg-1 mg per mL (0.3%-0.1%), 15 mL                                   | ‡ 1         | 5              | ..      | 10.08                                    | 11.11                                                  | <sup>a</sup> Poly-Tears              | IQ |
|                                                                                                        |                                                                                 |             |                | b1.67   | 11.75                                    | 11.11                                                  | <sup>a</sup> Tears Naturale          | AQ |
| <b><u>Authority Required</u></b>                                                                       |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.</i> |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 5521N                                                                                                  | Eye drops 3 mg-1 mg per mL (0.3%-0.1%), single dose units 0.4 mL, 28            | 3           | 5              | ..      | * 35.03                                  | 31.30                                                  | Bion Tears                           | AQ |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED  
OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY-cont.**

| Code                                                                                                   | Name, Restriction,<br>Manner of Administration and Form                                                 | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>PARAFFIN</b>                                                                                        |                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| 5523Q                                                                                                  | Compound eye ointment 3.5 g                                                                             | 2           | 5              | ..      | * 21.07                                  | 22.10                                                  | <sup>a</sup> Poly Visc               | IQ |
|                                                                                                        |                                                                                                         |             |                | B2.06   | * 23.13                                  | 22.10                                                  | <sup>a</sup> Duratears               | AQ |
| 5522P                                                                                                  | Pack containing 2 tubes compound eye<br>ointment 3.5 g                                                  | ‡ 1         | 5              | ..      | 21.06                                    | 22.09                                                  | Poly Visc                            | IQ |
|                                                                                                        |                                                                                                         |             |                | ..      | 21.06                                    | 22.09                                                  | <sup>a</sup> Ircal                   | PE |
|                                                                                                        |                                                                                                         |             |                | B2.24   | 23.30                                    | 22.09                                                  | <sup>a</sup> Lacri-Lube              | AG |
| <b>POLYETHYLENE GLYCOL 400 with PROPYLENE GLYCOL</b>                                                   |                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                       |                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome, including Sjogren's syndrome.</i>                                          |                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| 5524R                                                                                                  | Eye drops 4 mg-3 mg per mL<br>(0.4%-0.3%), 15 mL                                                        | ‡ 1         | 5              | ..      | 10.16                                    | 11.19                                                  | Systane                              | AQ |
| <b><u>Authority Required</u></b>                                                                       |                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.</i> |                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| 5532E                                                                                                  | Eye drops 4 mg-3 mg per mL<br>(0.4%-0.3%), single dose units 0.7 mL,<br>28                              | 3           | 5              | ..      | * 33.65                                  | 31.30                                                  | Systane                              | AQ |
| <b>POLYVINYL ALCOHOL</b>                                                                               |                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b>                                                                       |                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome, including Sjogren's syndrome.</i>                                          |                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| 5526W                                                                                                  | Eye drops 14 mg per mL (1.4%), 15 mL                                                                    | ‡ 1         | 5              | ..      | 10.08                                    | 11.11                                                  | <sup>a</sup> PVA Tears               | PE |
|                                                                                                        |                                                                                                         |             |                | B1.71   | 11.79                                    | 11.11                                                  | <sup>a</sup> Liquifilm Tears         | AG |
| 5527X                                                                                                  | Eye drops 14 mg per mL (1.4%), 15 mL<br>(contains sodium chlorite/hydrogen<br>peroxide as preservative) | ‡ 1         | 5              | ..      | 10.08                                    | 11.11                                                  | Vistil                               | AE |
| 5525T                                                                                                  | Eye drops 30 mg per mL (3%), 15 mL                                                                      | ‡ 1         | 5              | ..      | 10.08                                    | 11.11                                                  | <sup>a</sup> PVA Forte               | PE |
|                                                                                                        |                                                                                                         |             |                | B5.94   | 16.02                                    | 11.11                                                  | <sup>a</sup> Liquifilm Forte         | AG |
| 5528Y                                                                                                  | Eye drops 30 mg per mL (3%), 15 mL<br>(contains sodium chlorite/hydrogen<br>peroxide as preservative)   | ‡ 1         | 5              | ..      | 10.08                                    | 11.11                                                  | Vistil Forte                         | AE |
| <b>TAMARINDUS INDICA SEED POLYSACCHARIDE</b>                                                           |                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Authority Required</u></b>                                                                       |                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.</i> |                                                                                                         |             |                |         |                                          |                                                        |                                      |    |
| 5531D                                                                                                  | Eye drops 10 mg per mL (1%), 0.5 mL,<br>20                                                              | 3           | 5              | ..      | * 35.63                                  | 31.30                                                  | Visine Professional                  | JT |



## SECTION 100 ITEMS

In addition to the drugs and medicinal preparations available under normal PBS arrangements listed in this Schedule, a number of drugs are also available as pharmaceutical benefits but are distributed under alternative arrangements where these are considered more appropriate.

These alternative arrangements are provided for under section 100 of the *National Health Act 1953*. Several programs exist for the provision of drugs as pharmaceutical benefits in this way and this section lists those drugs which are available under the following programs:

**HIGHLY SPECIALISED DRUGS PROGRAM**

**BOTULINUM TOXIN PROGRAM**

**HUMAN GROWTH HORMONE PROGRAM**

**IVF/GIFT PROGRAM**

**OPIATE DEPENDENCE TREATMENT PROGRAM**

**SPECIAL AUTHORITY PROGRAM**

Complete details concerning the availability of drugs as benefits under these programs may be obtained by telephoning the relevant contact number(s) shown in each section, or in certain cases, by referring to the telephone number provided for individual drugs listings.

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

## HIGHLY SPECIALISED DRUGS PROGRAM

The Australian Government provides funding for certain specialised medications under the Highly Specialised Drugs Program. Highly Specialised Drugs are medicines for the treatment of chronic conditions which, because of their clinical use or other special features, are restricted to supply through public and private hospitals having access to appropriate specialist facilities. To prescribe these drugs as pharmaceutical benefit items, medical practitioners are required to be affiliated with these specialist hospital units. A general practitioner or non-specialist hospital doctor may only prescribe Highly Specialised Drugs to provide maintenance therapy under the guidance of the treating specialist.

Benefits are available for the listed clinical indications only. There is no facility for individual patient approval for indications outside those listed.

To gain access to a Commonwealth funded drug under this program, a patient must attend a participating hospital and be a day admitted patient, a non-admitted patient or a patient on discharge, be under appropriate specialist medical care, meet the specific medical criteria and be an Australian resident in Australia (or other eligible person).

A patient will be required to pay a contribution for each supply of a highly specialised drug at a similar rate to the Pharmaceutical Benefits Scheme. Commonwealth subsidy is not available for hospital in-patients.

Reciprocal Health Care Agreement – Where a patient is entitled to be treated as an eligible person as a visitor from a country with which Australia has entered into a Reciprocal Health Care Agreement, the supply will be limited to the original prescription only. Repeat prescriptions for these patients are not permitted.

Private Hospitals – **In addition to the above requirements**, for Highly Specialised Drugs prescribed through private hospitals, claiming and approval of authority prescriptions is administered by Medicare Australia. Highly Specialised Drugs are authority required items. Medical practitioners must seek approval to prescribe these items as pharmaceutical benefits prior to their dispensing under the PBS. Approval of authority prescriptions by Medicare Australia may be obtained either by posting an Authority Prescription Form to Medicare Australia, or by using Medicare Australia's Authority Freecall service (1800 888 333). **Prescribers must quote the provider number of the hospital when applying.** Not more than two months' supply (one month's supply in the case of Clozapine), with provision for up to 5 repeats, will be authorised. Prescriptions for Highly Specialised Drugs can be dispensed by an approved private hospital's dispensary or by a community pharmacy.

The remuneration rates for Highly Specialised Drugs prescribed through private hospitals comprise the normal PBS ready- prepared dispensing fee plus a mark-up ascertained as follows:

- 10% for drugs with a price ex-manufacturer of less than \$40;
- \$4 for drugs with a price ex-manufacturer of between \$40 and \$100;
- 4% for drugs with a price ex-manufacturer of between \$100.01 and \$1000;
- \$40 for drugs with a price ex-manufacturer of greater than \$1000.

Public Hospitals – For Highly Specialised Drugs prescribed through public hospitals, claiming and access to the program is administered by the States/Territories Health Departments. Prescriptions for Highly Specialised Drugs can be dispensed by public hospital pharmacies.

If you would like further information about the Highly Specialised Drugs Program, please contact your pharmacy, Medicare Australia (Ph: 132 290) or the Australian Government adviser, the Highly Specialised Drugs Working Party Secretariat (Ph: (02) 6289 2331).

For information on Pharmaceutical Benefits Pricing Authority therapeutic relativity sheets please visit [www.health.gov.au](http://www.health.gov.au) and search for 'relativity sheets'.

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |  |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|

## HIGHLY SPECIALISED DRUGS PROGRAM

### ABACAVIR SULFATE

#### Private hospital authority required

*Treatment of HIV infection in patients with:*

- (a) CD4 cell counts of less than 500 per cubic millimetre; or
- (b) viral load of greater than 10,000 copies per mL.

|       |                                           |    |        |        |    |
|-------|-------------------------------------------|----|--------|--------|----|
| 6264Q | Tablet 300 mg (base)                      | 60 | 423.00 | Ziagen | GK |
| 6265R | Oral solution 20 mg (base) per mL, 240 mL | 1  | 75.20  | Ziagen | GK |

#### NOTE:

*These prices are based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details.*

### ABACAVIR SULFATE with LAMIVUDINE

#### Private hospital authority required

*Treatment of HIV infection in patients over 12 years of age, weighing 40 kg or more, with:*

- (a) CD4 cell counts of less than 500 per cubic millimetre; or
- (b) viral load of greater than 10,000 copies per mL.

|       |                             |    |        |        |    |
|-------|-----------------------------|----|--------|--------|----|
| 6458X | Tablet 600 mg (base)-300 mg | 30 | 564.00 | Kivexa | GK |
|-------|-----------------------------|----|--------|--------|----|

### ABACAVIR SULFATE with LAMIVUDINE and ZIDOVUDINE

#### Private hospital authority required

*Treatment of HIV infection in patients over 12 years of age, weighing 40 kg or more, with:*

- (a) CD4 cell counts of less than 500 per cubic millimetre; or
- (b) viral load of greater than 10,000 copies per mL.

|       |                                    |    |        |          |    |
|-------|------------------------------------|----|--------|----------|----|
| 6327B | Tablet 300 mg (base)-150 mg-300 mg | 60 | 852.00 | Trizivir | GK |
|-------|------------------------------------|----|--------|----------|----|

### ABATACEPT

#### NOTE:

*Any queries concerning the arrangements to prescribe abatacept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Written applications for authority to prescribe abatacept should be forwarded to:*

*Medicare Australia*

*Prior Written Approval of Specialised Drugs*

*Reply Paid 9826*

*GPO Box 9826*

*HOBART TAS 7001*

*Further prescribing information is on the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).*

#### NOTE:

### TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS

*The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, etanercept, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-1 inhibitor (anakinra) and the T-cell co-stimulation modulator (abatacept).*

*Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.*

continued 

| Code | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|
|      | <p><i>PBS-subsidised infliximab, anakinra, rituximab and abatacept must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are only eligible to receive PBS-subsidised etanercept and adalimumab.</i></p> <p><i>In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.</i></p> <p><i>From 1 March 2008, under the PBS, all patients will be able to commence a Treatment Cycle where they may trial PBS-subsidised bDMARD agents without having to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Treatment Cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.</i></p> <p><i>A patient who received PBS-subsidised bDMARD treatment prior to 1 March 2008 is considered to be in their first Cycle as of 1 March 2008.</i></p> <p><i>Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.</i></p> <p><i>Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next Cycle.</i></p> <p><i>For patients who have failed PBS-subsidised treatment with 3 bDMARDs prior to 1 March 2008 please contact Medicare Australia on 1800 700 270.</i></p> <p><i>The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent Cycle to the date of the first application for initial treatment with a bDMARD under the new Treatment Cycle.</i></p> <p><i>A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same Treatment Cycle.</i></p> <p><i>A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of more than 5 years, may commence a new Treatment Cycle.</i></p> <p><i>There is no limit to the number of Treatment Cycles a patient may undertake in their lifetime.</i></p> <p><i>If patients fail to respond to a particular bDMARD within a single Treatment Cycle, they are not eligible to receive further PBS-subsidised treatment with that drug until they commence the next Cycle.</i></p> <p><i>(1) How to prescribe PBS-subsidised bDMARD therapy after 1 March 2008.</i></p> <p><i>(a) Initial treatment.</i></p> <p><i>Applications for initial treatment should be made where:</i></p> <p><i>(i) a patient has received no prior PBS-subsidised bDMARD treatment in this Treatment Cycle and wishes to commence such therapy, excluding rituximab (Initial 1); or</i></p> <p><i>(ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or</i></p> <p><i>(iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 2).</i></p> <p><i>Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for etanercept, adalimumab, anakinra and abatacept, 22 weeks of therapy for infliximab and 2 infusions of rituximab.</i></p> <p><i>From 1 March 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</i></p> <p><i>Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.</i></p> <p><i>Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.</i></p> <p><i>For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.</i></p> |           |                          |                                   |

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

**Rituximab patients:**

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

**(b) Continuing treatment.**

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

**Rituximab patients:**

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

**(2) Swapping therapy.**

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same Treatment Cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same Treatment Cycle.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF- $\alpha$  antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

**NOTE:**

**(3) Baseline measurements to determine response.**

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a Treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

The baseline joint and blood counts should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent Treatment Cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 non-biological DMARD, at an adequate dose, for a minimum of 3 months at the time the ESR and/or CRP levels and the active joint count are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with rituximab or abatacept.

From 1 March 2008, a patient who commenced treatment with rituximab for severe rheumatoid arthritis prior to 7 March 2007 or abatacept for severe rheumatoid arthritis prior to 1 November 2007 and who was 'grandfathered' on to PBS-subsidised therapy, and who continues to receive treatment in the same Treatment Cycle, will have further applications for treatment with rituximab or abatacept assessed under the continuing treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with abatacept will be authorised under this criterion.

'Grandfather' arrangements will only apply for the first Treatment Cycle. For the second and subsequent Cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that applies to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

#### **Public and private hospital authority required**

##### *Initial 1 (new patients)*

Application for initial PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have received no prior PBS-subsidised treatment with a bDMARD for this condition in this treatment cycle; and
- (c) have failed to achieve an adequate response to the following treatments:
  - (i) methotrexate at a dose of at least 20 mg weekly; and
  - (ii) methotrexate (at a minimum dose of 7.5 mg weekly), in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; and
  - (iii) a minimum of 3 months' treatment with:
    - leflunomide alone; or
    - leflunomide in combination with methotrexate; or
    - cyclosporin.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [[www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)].

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:*  
*an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;*

*AND either*

*(i) a total active joint count of at least 20 active (swollen and tender) joints; or*

*(ii) at least 4 active joints from the following list of major joints:*

*— elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*

*— shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

*If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.*

*The authority application must be made in writing and must include:*

*(1) a completed authority prescription form; and*

*(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and*

*(3) a signed patient acknowledgement.*

*A maximum of 16 weeks of treatment will be authorised under this restriction.*

*At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 4 repeats may be authorised.*

*Where fewer than 4 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with abatacept.*

*Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial abatacept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.*

#### **Public and private hospital authority required**

*Initial 2 (change or re-commencement)*

*Application for an initial course of PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:*

*(a) have a documented history of severe active rheumatoid arthritis; and*

*(b) have received prior PBS-subsidised bDMARD treatment for this condition in this treatment cycle and are eligible to receive further bDMARD therapy.*

*The authority application must be made in writing and must include:*

*(1) a completed authority prescription form; and*

*(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*Applications for patients who have received PBS-subsidised treatment with abatacept within this treatment cycle and who wish to re-commence therapy with this drug within this same cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised abatacept treatment, within the timeframes specified below.*

*A maximum of 16 weeks of treatment will be authorised under this restriction.*

*At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 4 repeats may be authorised.*

*Where fewer than 4 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Where the most recent course of PBS-subsidised abatacept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Where the most recent course of PBS-subsidised abatacept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial abatacept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.*

#### **Public and private hospital authority required**

*Initial 3 ('grandfather' patients)*

*Initial PBS-subsidised supply for continuing treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of an adult who:*

- (a) has a documented history of severe active rheumatoid arthritis; and*
- (b) was receiving treatment with abatacept prior to 1 November 2007; and*
- (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with abatacept.*

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes the signed patient acknowledgement.*

*The same indices of disease severity used to establish baseline at the commencement of treatment with a bDMARD must be used for assessment of all continuing applications.*

*The assessment of the patient's response to a continuing course of therapy must be made within 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled in order to ensure continuity of treatment for those patients who meet the continuation criterion.*

*A maximum of 24 weeks of treatment with abatacept will be approved under this criterion.*

*At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 5 repeats may be authorised.*

*Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Patients may qualify for PBS-subsidised treatment under this restriction once only.*



| Code  | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |    |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------------------------|-----------------------------------------|----|
|       | <p><i>Patients who fail to demonstrate a response to treatment with 3 bDMARDs are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new bDMARD Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this Cycle and the date of the first application under the new Cycle.</i></p> <p><b>Public and private hospital authority required</b></p> <p><i>Continuing treatment</i></p> <p><i>Continuing PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:</i></p> <p><i>(a) who have a documented history of severe active rheumatoid arthritis; and</i></p> <p><i>(b) who have demonstrated an adequate response to treatment with abatacept; and</i></p> <p><i>(c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with abatacept.</i></p> <p><i>An adequate response to treatment is defined as:</i></p> <p><i>an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;</i></p> <p><i>AND either of the following:</i></p> <p><i>(i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</i></p> <p><i>(ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</i></p> <p><i>— elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</i></p> <p><i>— shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</i></p> <p><i>The authority application must be made in writing and must include:</i></p> <p><i>(1) a completed authority prescription form; and</i></p> <p><i>(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (<a href="http://www.medicareaustralia.gov.au">www.medicareaustralia.gov.au</a>)].</i></p> <p><i>A maximum of 24 weeks of treatment will be approved under this restriction.</i></p> <p><i>At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 5 repeats may be authorised.</i></p> <p><i>Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</i></p> <p><i>All applications for continuing treatment with abatacept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with abatacept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</i></p> <p><i>Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial abatacept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.</i></p> |              |                                |                                         |    |
| 9621J | Powder for I.V. infusion 250 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1            | 504.43                         | Orencia                                 | BQ |

| Code                                                                                                                                                                                                                                                                | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|--------------------------|-----------------------------------|----|
| <b>ADEFOVIR DIPIVOXIL</b>                                                                                                                                                                                                                                           |                                  |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                   |                                  |           |                          |                                   |    |
| <i>Chronic hepatitis B in a patient who has failed antihepadnaviral therapy and who satisfies all of the following criteria:</i>                                                                                                                                    |                                  |           |                          |                                   |    |
| <i>(1)(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or</i>                                                      |                                  |           |                          |                                   |    |
| <i>(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance;</i>             |                                  |           |                          |                                   |    |
| <i>(2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.</i>                                                                                                                             |                                  |           |                          |                                   |    |
| <i>Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</i> |                                  |           |                          |                                   |    |
| <b>NOTE:</b>                                                                                                                                                                                                                                                        |                                  |           |                          |                                   |    |
| <i>Patients should have undergone a liver biopsy at some point since initial diagnosis to obtain histological evidence of chronic hepatitis.</i>                                                                                                                    |                                  |           |                          |                                   |    |
| <i>Patients may receive treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.</i>                                                                                                                                    |                                  |           |                          |                                   |    |
| 6450L                                                                                                                                                                                                                                                               | Tablet 10 mg                     | 30        | 625.00                   | Hepsera                           | GI |
| <b>APOMORPHINE HYDROCHLORIDE</b>                                                                                                                                                                                                                                    |                                  |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                   |                                  |           |                          |                                   |    |
| <i>Parkinson's disease in patients severely disabled by motor fluctuations which do not respond to other therapy.</i>                                                                                                                                               |                                  |           |                          |                                   |    |
| 9607P                                                                                                                                                                                                                                                               | Injection 20 mg in 2 mL          | 5         | 66.94                    | Apomine                           | HH |
| <b>ATAZANAVIR</b>                                                                                                                                                                                                                                                   |                                  |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                   |                                  |           |                          |                                   |    |
| <i>Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with:</i>                                                                                                                                                      |                                  |           |                          |                                   |    |
| <i>(a) CD4 cell counts of less than 500 per cubic millimetre; or</i>                                                                                                                                                                                                |                                  |           |                          |                                   |    |
| <i>(b) viral load of greater than 10,000 copies per mL.</i>                                                                                                                                                                                                         |                                  |           |                          |                                   |    |
| 6451M                                                                                                                                                                                                                                                               | Capsule 150 mg (as sulfate)      | 60        | 521.91                   | Reyataz                           | BQ |
| 6452N                                                                                                                                                                                                                                                               | Capsule 200 mg (as sulfate)      | 60        | 695.88                   | Reyataz                           | BQ |
| 9614B                                                                                                                                                                                                                                                               | Capsule 300 mg (as sulfate)      | 30        | 521.91                   | Reyataz                           | BQ |
| <b>AZITHROMYCIN</b>                                                                                                                                                                                                                                                 |                                  |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                   |                                  |           |                          |                                   |    |
| <i>Prophylaxis against Mycobacterium avium complex infections in HIV-positive patients with CD4 cell counts of less than 75 per cubic millimetre.</i>                                                                                                               |                                  |           |                          |                                   |    |
| 6221K                                                                                                                                                                                                                                                               | Tablet 600 mg                    | 8         | 67.82                    | Zithromax                         | PF |
| <b>BACLOFEN</b>                                                                                                                                                                                                                                                     |                                  |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                   |                                  |           |                          |                                   |    |
| <i>Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity:</i>                                                                                                          |                                  |           |                          |                                   |    |
| <i>(a) of cerebral origin; or</i>                                                                                                                                                                                                                                   |                                  |           |                          |                                   |    |
| <i>(b) due to multiple sclerosis; or</i>                                                                                                                                                                                                                            |                                  |           |                          |                                   |    |

| Code  | Item and Section 100 Restriction                                     | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------|----------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
|       | (c) due to spinal cord injury; or<br>(d) due to spinal cord disease. |           |                          |                                   |    |
| 6284R | Intrathecal injection 10 mg in 5 mL                                  | 1         | 148.37                   | Lioresal<br>Intrathecal           | NV |

**BOSENTAN MONOHYDRATE****CAUTION:**

*Bosentan monohydrate is a category X drug and must not be given to pregnant women. Pregnancy must be avoided during treatment and for at least 3 months following cessation of treatment with this drug.*

**NOTE:**

*Any queries concerning the arrangements to prescribe bosentan monohydrate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Written applications for authority to prescribe bosentan monohydrate should be forwarded to:*

*Medicare Australia*

*Prior Written Approval of Specialised Drugs*

*Reply Paid 9826*

*GPO Box 9826*

*HOBART TAS 7001*

**NOTE:**

*Bosentan monohydrate is not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with scleroderma, where the total lung capacity is less than 70% of that predicted.*

*Bosentan monohydrate is not PBS-subsidised when used in combination with PBS-subsidised iloprost trometamol, PBS-subsidised epoprostenol sodium, PBS-subsidised sildenafil citrate or PBS-subsidised sitaxentan sodium.*

*The following provides some explanatory notes regarding the availability of PBS-subsidised treatment with:*

*(a) bosentan monohydrate, of primary pulmonary hypertension, pulmonary arterial hypertension secondary to scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), in patients with disease of WHO Functional Class III or IV severity; AND*

*(b) iloprost trometamol, of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND*

*(c) epoprostenol sodium, of primary pulmonary hypertension, in patients with disease of WHO Functional Class III or IV severity; AND*

*(d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND*

*(e) sitaxentan sodium, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.*

**Adult patients:**

*From 1 April 2008, adult patients with primary pulmonary hypertension will be able to access, through the PBS, bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 5 drugs, they may swap between bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

continued ➡

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*Adult patients with pulmonary arterial hypertension secondary to scleroderma will be able to access, through the PBS, bosentan monohydrate, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 4 drugs, they may swap between bosentan monohydrate, iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

*Adult patients with pulmonary arterial hypertension secondary to connective tissue disease other than scleroderma will be able to access, through the PBS, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 3 drugs, they may swap between iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

*Patients with drug-induced pulmonary arterial hypertension are only eligible for treatment with iloprost trometamol. They may not swap to bosentan monohydrate, epoprostenol sodium, sildenafil citrate or sitaxentan sodium.*

*Patients with pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are only eligible for treatment with bosentan monohydrate. They may not swap to epoprostenol sodium, iloprost trometamol, sildenafil citrate or sitaxentan sodium.*

*Patients under 18 years of age:*

*From 1 April 2008, patients aged less than 18 years with primary pulmonary hypertension are eligible to receive PBS-subsidised treatment with bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 5 drugs, they may swap between bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

*1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).*

*Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension, pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology) are defined as follows:*

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or*
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or*
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.*

*2. Definition of WHO Functional Class III or IV disease severity.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

(a) *WHO Functional Class III disease severity is defined as follows:*

*Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.*

(b) *WHO Functional Class IV disease severity is defined as follows:*

*Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.*

### 3. Designated hospitals.

*Refer to the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au) for a list of designated hospitals.*

### 4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.

#### (a) Initiation of treatment.

*The first written application for PBS-subsidised treatment with the first of either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.*

*Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:*

*(1) RHC plus ECHO composite assessments;*

*(2) RHC composite assessment plus 6MWT;*

*(3) RHC composite assessment only.*

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:*

*(1) ECHO composite assessment plus 6MWT;*

*(2) ECHO composite assessment only.*

*Where fewer than 3 tests are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application.*

#### NOTE:

*Where patients were initiated on PBS-subsidised treatment either with bosentan monohydrate on or after 1 March 2004, with iloprost trometamol on or after 1 April 2005, with epoprostenol sodium on or after 1 August 2006, with sildenafil citrate on or after 1 March 2007, with sitaxentan sodium on or after 1 April 2008, or with bosentan monohydrate (for PAH associated with congenital systemic-to-pulmonary shunt) on or after 1 August 2008, the test results provided with the initial application must be no more than 2 months old at the time of application. These results will form the baseline against which response assessments will be made.*

*Where patients received treatment with either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium prior to being commenced on PBS-subsidised treatment with the first of either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, the test requirements above still apply. The results that will form the baseline against which response assessments will be made will be those measured at the time patients commenced non-PBS-subsidised treatment with either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, whichever of the 5 drugs the patient received first.*

#### (b) Continuation of treatment.

*The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:*

*(1) RHC plus ECHO composite assessments plus 6MWT;*

*(2) RHC plus ECHO composite assessments;*

*(3) RHC composite assessment plus 6MWT;*

*(4) ECHO composite assessment plus 6MWT;*

*(5) RHC composite assessment only;*

*(6) ECHO composite assessment only.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a reason why the test(s) could not be conducted must be provided with the application.*

*The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.*

**5. Definition of response to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, sitaxentan sodium or prior vasodilator treatment.**

*For adult patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

*For adult patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

*For adult patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

*For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

**6. Authority approval requirements. [The following 2 sections are only relevant to the PBS listing of bosentan monohydrate. The requirements specific to iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium are given in parts 6 and 7 of the NOTE included in the iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium Schedule entry respectively.]**

**(a) Initiation of PBS-subsidised treatment with bosentan monohydrate, where the patient has not received prior PBS-subsidised treatment with iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium.**

*All applications for initial treatment must be made in writing, must include 2 separate authority prescriptions and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months.*

*Approvals for the first authority prescription will be limited to 1 month of therapy with the 62.5 mg strength tablet, with the quantity approved based on the dosage recommendations in the Therapeutic Goods Administration (TGA)-approved Product Information. No repeats will be authorised for this prescription. The second authority prescription may be written for either the 62.5 mg tablet or the 125 mg tablet strengths. Where the 62.5 mg tablet strength is required, please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) for further advice. Approvals for the second authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. The approved second authority prescription will be returned to the prescriber by Medicare Australia 2 weeks after the date of the approval of the first authority prescription, to allow for the uninterrupted completion of the 6 month initial treatment course. Medicare Australia will contact prescribers prior to dispatch of the second authority prescription to confirm the tablet strength required for the patient.*

**(b) Continuation of treatment.**

*Written applications for continuing treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.*

*Applications for continuing treatment will only be approved for patients who have currently demonstrated a response to treatment with bosentan monohydrate.*

*The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with bosentan monohydrate should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*(c) Swapping between bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate and sitaxentan sodium.*

*For eligible patients, applications to swap between these 5 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.*

*It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.*

*To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.*

*(d) Cessation of treatment.*

*Patients who fail to demonstrate a response to PBS-subsidised bosentan monohydrate treatment at the times where an assessment is required must cease PBS-subsidised bosentan monohydrate therapy.*

*For patients ceasing treatment, approval will only be granted to provide sufficient supply of the 62.5 mg tablet strength to allow gradual dose reduction over a period of no more than 1 month duration. Prescribers should telephone Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) to receive authorisation for this final supply and to ensure no unintended break in treatment occurs.*

**7. Re-treatment with bosentan monohydrate.**

*Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with bosentan monohydrate under any circumstances.*

**8. Further information.**

*A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).*

#### **Public and private hospital authority required**

##### *Initial (new adult patients)*

*Application for initial PBS-subsidised treatment with bosentan monohydrate of adult patients who have not received prior PBS-subsidised treatment with iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium and who have been assessed by a physician from a designated hospital to have:*

*(a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, unless a RHC is contraindicated on clinical grounds; OR*

*(b) WHO Functional Class III pulmonary arterial hypertension secondary to scleroderma and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, unless a RHC is contraindicated on clinical grounds.*

*Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.*

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the test results of the ECHO composite assessment plus 6MWT or the ECHO composite assessment only.*

continued ➞

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Applications for authorisation must be in writing and must include:*

- (1) two completed authority prescription forms [see Note for authority approval requirements]; and  
 (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:

- (i) RHC composite assessment; and  
 (ii) ECHO composite assessment; and  
 (iii) 6MWT; and

(3) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with bosentan monohydrate for primary pulmonary hypertension, pulmonary arterial hypertension secondary to scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), OR with iloprost trometamol for primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with epoprostenol sodium for primary pulmonary hypertension, OR with sildenafil citrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with sitaxentan sodium for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].

Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements]. A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion. Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

#### **Public and private hospital authority required**

##### **Initial (new adult patients)**

Application for initial PBS-subsidised treatment with bosentan monohydrate of adult patients who have not received prior PBS-subsidised treatment with iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, unless a RHC is contraindicated on clinical grounds; OR  
 (b) WHO Functional Class III pulmonary arterial hypertension secondary to scleroderma and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, unless a RHC is contraindicated on clinical grounds; OR  
 (c) WHO Functional Class IV primary pulmonary hypertension; OR  
 (d) WHO Functional Class IV pulmonary arterial hypertension secondary to scleroderma.

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the test results of the ECHO composite assessment plus 6MWT or the ECHO composite assessment only.

continued ➞



| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Applications for authorisation must be in writing and must include:*

- (1) two completed authority prescription forms [see Note for authority approval requirements]; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:

(i) RHC composite assessment; and

(ii) ECHO composite assessment; and

(iii) 6MWT; and

(3) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with bosentan monohydrate for primary pulmonary hypertension, pulmonary arterial hypertension secondary to scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), OR with iloprost trometamol for primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with epoprostenol sodium for primary pulmonary hypertension, OR with sildenafil citrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with sitaxentan sodium for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements]. A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion. Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

#### **Public and private hospital authority required**

*Initial (new patients under 18 years of age)*

Application for initial PBS-subsidised treatment of patients aged less than 18 years who have not received prior PBS-subsidised treatment with epoprostenol sodium or sildenafil citrate and who have been assessed by a physician from a designated hospital to have:

WHO Functional Class III primary pulmonary hypertension and either a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, normal right ventricular function as assessed by ECHO.

Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate prior vasodilator treatment unless intolerance or a contraindication to such treatment exists.

*Applications for authorisation must be in writing and must include:*

- (1) two completed authority prescription forms [see Note for authority approval requirements]; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:

(i) RHC composite assessment; and

(ii) ECHO composite assessment; and

(iii) 6MWT; and

(3) a patient acknowledgment, signed by the parent or authorised guardian, indicating that they understand and acknowledge that PBS-subsidised treatment with bosentan monohydrate, epoprostenol sodium or sildenafil citrate for primary pulmonary hypertension will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].

Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements]. A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion. Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

#### **Public and private hospital authority required**

*Initial (new patients under 18 years of age)*

Application for initial PBS-subsidised treatment of patients aged less than 18 years who have not received prior PBS-subsidised treatment with epoprostenol sodium or sildenafil citrate and who have been assessed by a physician from a designated hospital to have:

- (a) WHO Functional Class III primary pulmonary hypertension and either a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular dysfunction as assessed by ECHO; OR
- (b) WHO Functional Class IV primary pulmonary hypertension.

Applications for authorisation must be in writing and must include:

- (1) two completed authority prescription forms [see Note for authority approval requirements]; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:
  - (i) RHC composite assessment; and
  - (ii) ECHO composite assessment; and
  - (iii) 6MWT; and
- (3) a patient acknowledgment, signed by the parent or authorised guardian, indicating that they understand and acknowledge that PBS-subsidised treatment with bosentan monohydrate, epoprostenol sodium or sildenafil citrate for primary pulmonary hypertension will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements]. A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion. Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

#### **Public and private hospital authority required**

*Initial (new patients)*

Application for initial PBS-subsidised treatment with bosentan monohydrate of a patient who has been assessed by a physician from a designated hospital to have WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Applications for authorisation must be in writing and must include:*

*(1) two completed authority prescription forms [see Note for authority approval requirements]; and*

*(2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:*

*(i) RHC composite assessment; and*

*(ii) ECHO composite assessment; and*

*(iii) 6MWT; and*

*(3) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with bosentan monohydrate for primary pulmonary hypertension, pulmonary arterial hypertension secondary to scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), OR with iloprost trometamol for primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with epoprostenol sodium for primary pulmonary hypertension, OR with sildenafil citrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with sitaxentan sodium for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].*

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the test results of the ECHO composite assessment plus 6MWT or the ECHO composite assessment only.*

*Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements]. A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion. Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

#### **Public and private hospital authority required**

##### **Initial (grandfather patients)**

*Application for initial PBS-subsidised treatment with bosentan monohydrate of a patient who was receiving treatment with bosentan monohydrate prior to 1 August 2008 and who has been assessed by a physician from a designated hospital to have pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).*

continued ➞

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form [see Note for authority approval requirements]; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:

- (i) RHC composite assessment; and
- (ii) ECHO composite assessment; and
- (iii) 6MWT; and

(3) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with bosentan monohydrate for primary pulmonary hypertension, pulmonary arterial hypertension secondary to scleroderma, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), OR with iloprost trometamol for primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with epoprostenol sodium for primary pulmonary hypertension, OR with sildenafil citrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with sitaxentan sodium for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].

In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the test results of the ECHO composite assessment plus 6MWT or the ECHO composite assessment only.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. The number of repeats authorised will be dependent on the duration of prior bosentan monohydrate therapy. Where patients have received less than 6 months of non-PBS-subsidised treatment with bosentan monohydrate, sufficient repeats to allow the patient to complete a total of 6 months of combined PBS-subsidised and non-PBS-subsidised therapy may be requested. Where patients have received 6 months or more of non-PBS-subsidised treatment with bosentan monohydrate, a maximum of 5 repeats may be requested. Where fewer than the maximum allowable number of repeats are requested at the time of application, authority approvals for the remainder of the allowable repeats may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

#### **Public and private hospital authority required**

*Initial (change or re-commencement for adult patients)*

*Application for initial treatment with bosentan monohydrate of adult patients with either of the following:*

- (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma who wish to re-commence PBS-subsidised bosentan monohydrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with bosentan monohydrate; OR
- (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma and whose most recent course of PBS-subsidised treatment was with iloprost trometamol, sildenafil citrate or sitaxentan sodium; OR
- (c) primary pulmonary hypertension and whose most recent course of PBS-subsidised treatment was with epoprostenol sodium.

*Applications for authorisation must be in writing and must include:*

- (1) two completed authority prescription forms [see Note for authority approval requirements]; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, whichever was initiated first, was granted; and
- (3) the date of the first application for PBS-subsidised treatment with bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, whichever was initiated first; and
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium.

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements]. A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion. Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

**Public and private hospital authority required**

*Initial (change or re-commencement for patients under 18 years of age)*

*Application for initial treatment with bosentan monohydrate of patients aged less than 18 years with either of the following:*

*(a) primary pulmonary hypertension who wish to re-commence PBS-subsidised bosentan monohydrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with bosentan monohydrate; OR*

*(b) primary pulmonary hypertension and whose most recent course of PBS-subsidised treatment was with epoprostenol sodium or sildenafil citrate.*

*Applications for authorisation must be in writing and must include:*

*(1) two completed authority prescription forms [see Note for authority approval requirements]; and*

*(2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised bosentan monohydrate, epoprostenol sodium or sildenafil citrate, whichever was initiated first, was granted; and*

*(3) the date of the first application for PBS-subsidised treatment with bosentan monohydrate, epoprostenol sodium or sildenafil citrate, whichever was initiated first; and*

*(4) the results of the patient's response to treatment with their last course of PBS-subsidised bosentan monohydrate, epoprostenol sodium or sildenafil citrate.*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements]. A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion. Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

**Public and private hospital authority required**

*Continuing treatment (all patients)*

*Continuing PBS-subsidised treatment with bosentan monohydrate of patients who have received approval for initial PBS-subsidised treatment with bosentan monohydrate and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of bosentan monohydrate treatment [see Note for definition of response].*

*Applications for authorisation must be in writing and must include:*

*(1) a completed authority prescription form; and*

*(2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:*

*(i) RHC composite assessment; and*

*(ii) ECHO composite assessment; and*

*(iii) 6MWT.*

*Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats will be authorised.*

| Code  | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
|       | <p><i>Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</i></p> <p><b>Public and private hospital authority required</b></p> <p><i>Cessation of treatment (all patients)</i></p> <p><i>Final PBS-subsidised supply for patients with WHO Functional Class III or IV primary pulmonary hypertension or WHO Functional Class III or IV pulmonary arterial hypertension secondary to scleroderma or WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who have not responded to bosentan monohydrate therapy [see Note for definition of response], to allow for gradual cessation of treatment.</i></p> <p><i>Applications for authorisation under this criterion should be made on the telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday) [see Note on authority approval requirements].</i></p> <p><i>Approval will only be granted for the 62.5 mg tablet strength. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment.</i></p> <p><i>Under no circumstances will telephone approvals be granted for treatment that would extend the final treatment period beyond 1 month.</i></p> |           |                          |                                   |    |
| 6429J | Tablet 62.5 mg (base)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 60        | 4035.00                  | Tracleer                          | AT |
| 6430K | Tablet 125 mg (base)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 60        | 4035.00                  | Tracleer                          | AT |

**NOTE:**

*These prices are based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details.*

**CIDOFOVIR****Private hospital authority required**

*Treatment of cytomegalovirus retinitis in patients with AIDS.*

|       |                                                                       |   |        |         |    |
|-------|-----------------------------------------------------------------------|---|--------|---------|----|
| 6247T | Solution for I.V. infusion 375 mg (anhydrous) in 5 mL single use vial | 1 | 900.00 | Vistide | PU |
|-------|-----------------------------------------------------------------------|---|--------|---------|----|

**CINACALCET HYDROCHLORIDE****Private hospital authority required**

*Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 50 pmol per L, not responding to conventional therapy.*

**NOTE:**

*During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved. During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.*

*During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability. Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.*

*"Sustained" means the abnormality was detected on at least 2 blood samples collected over a period of 2 to 4 months.*

continued ➞

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |  |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|

**Private hospital authority required**

*Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 15 pmol per L and less than 50 pmol per L AND an (adjusted) serum calcium concentration at least 2.6 mmol per L, not responding to conventional treatment.*

**NOTE:**

*During the titration phase, intact PTH should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved. During the titration phase, approval will be limited to sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient's response and tolerability.*

*During the maintenance phase, approval will be limited to provide sufficient quantity for 4 weeks treatment up to a maximum of 6 months supply for doses between 30 and 180 mg per day according to the patient's response and tolerability. Intact PTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.*

*"Sustained" means the abnormality was detected on at least 2 blood samples collected over a period of 2 to 4 months.*

|       |                     |    |        |          |    |
|-------|---------------------|----|--------|----------|----|
| 9625N | Tablet 30 mg (base) | 28 | 296.86 | Sensipar | AN |
| 9626P | Tablet 60 mg (base) | 28 | 593.72 | Sensipar | AN |
| 9627Q | Tablet 90 mg (base) | 28 | 890.58 | Sensipar | AN |

**CLARITHROMYCIN****Private hospital authority required**

*Treatment of Mycobacterium avium complex infections.*

|       |               |     |       |        |    |
|-------|---------------|-----|-------|--------|----|
| 6151R | Tablet 250 mg | 100 | 36.12 | Klacid | AB |
| 6152T | Tablet 500 mg | 100 | 72.24 | Klacid | AB |

**CLOZAPINE****Private hospital authority required**

*Schizophrenia in patients who are:*

- (a) non-responsive to other neuroleptic agents; or*
- (b) intolerant of other neuroleptic agents.*

|       |                                  |     |        |                                                       |          |
|-------|----------------------------------|-----|--------|-------------------------------------------------------|----------|
| 6101D | Tablet 25 mg                     | 100 | 70.56  | <sup>a</sup> Clopine 25<br><sup>a</sup> Clozaril 25   | HH<br>NV |
| 6417R | Tablet 50 mg                     | 100 | 141.12 | Clopine 50                                            | HH       |
| 6102E | Tablet 100 mg                    | 100 | 264.60 | <sup>a</sup> Clopine 100<br><sup>a</sup> Clozaril 100 | HH<br>NV |
| 6418T | Tablet 200 mg                    | 100 | 529.20 | Clopine 200                                           | HH       |
| 9632Y | Oral liquid 50 mg per mL, 100 mL | 1   | 135.00 | Clopine Suspension                                    | HH       |

**CYCLOSPORIN****CAUTION:**

*Careful monitoring of patients is mandatory.*

**Private hospital authority required**

*Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required;*

| Code                                                                                                                                                                                                                  | Item and Section 100 Restriction                           | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| <b>Management (which includes initiation, stabilisation and review of therapy) by:</b>                                                                                                                                |                                                            |           |                          |                                   |    |
| (a) dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate; or                                                         |                                                            |           |                          |                                   |    |
| (b) dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life; or          |                                                            |           |                          |                                   |    |
| (c) nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired; or |                                                            |           |                          |                                   |    |
| (d) rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.     |                                                            |           |                          |                                   |    |
| 6232B                                                                                                                                                                                                                 | Capsule 10 mg                                              | 60        | 37.20                    | Neoral 10                         | NV |
| 6352H                                                                                                                                                                                                                 | Capsule 25 mg                                              | 30        | 40.80                    | <sup>a</sup> Cicloral             | SZ |
|                                                                                                                                                                                                                       |                                                            |           |                          | <sup>a</sup> Neoral 25            | NV |
| <b>NOTE:</b>                                                                                                                                                                                                          |                                                            |           |                          |                                   |    |
| A brand premium of \$0.97 applies to Neoral 25 brand. Both brands may not be available in all hospitals.                                                                                                              |                                                            |           |                          |                                   |    |
| 6353J                                                                                                                                                                                                                 | Capsule 50 mg                                              | 30        | 84.87                    | <sup>a</sup> Cicloral             | SZ |
|                                                                                                                                                                                                                       |                                                            |           |                          | <sup>a</sup> Neoral 50            | NV |
| <b>NOTE:</b>                                                                                                                                                                                                          |                                                            |           |                          |                                   |    |
| A brand premium of \$1.05 applies to Neoral 50 brand. Both brands may not be available in all hospitals.                                                                                                              |                                                            |           |                          |                                   |    |
| 6354K                                                                                                                                                                                                                 | Capsule 100 mg                                             | 30        | 172.92                   | <sup>a</sup> Cicloral             | SZ |
|                                                                                                                                                                                                                       |                                                            |           |                          | <sup>a</sup> Neoral 100           | NV |
| <b>NOTE:</b>                                                                                                                                                                                                          |                                                            |           |                          |                                   |    |
| A brand premium of \$1.06 applies to Neoral 100 brand. Both brands may not be available in all hospitals.                                                                                                             |                                                            |           |                          |                                   |    |
| 6125J                                                                                                                                                                                                                 | Oral liquid 100 mg per mL, 50 mL                           | 1         | 315.79                   | Neoral                            | NV |
| <b>Private hospital authority required</b>                                                                                                                                                                            |                                                            |           |                          |                                   |    |
| For use by organ or tissue transplant recipients.                                                                                                                                                                     |                                                            |           |                          |                                   |    |
| 6109M                                                                                                                                                                                                                 | Solution concentrate for I.V. infusion 50 mg in 1 mL       | 10        | 54.10                    | Sandimmun                         | NV |
| <b>DARBEPOETIN ALFA</b>                                                                                                                                                                                               |                                                            |           |                          |                                   |    |
| <b>Private hospital authority required</b>                                                                                                                                                                            |                                                            |           |                          |                                   |    |
| Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia.               |                                                            |           |                          |                                   |    |
| 6320P                                                                                                                                                                                                                 | Injection 10 micrograms in 0.4 mL pre-filled syringe       | 4         | 187.41                   | Aranesp                           | AN |
| 6321Q                                                                                                                                                                                                                 | Injection 20 micrograms in 0.5 mL pre-filled syringe       | 4         | 352.96                   | Aranesp                           | AN |
| 6488L                                                                                                                                                                                                                 | Injection 20 micrograms in 0.5 mL pre-filled injection pen | 1         | 88.24                    | Aranesp SureClick                 | AN |
| 6322R                                                                                                                                                                                                                 | Injection 30 micrograms in 0.3 mL pre-filled syringe       | 4         | 482.87                   | Aranesp                           | AN |
| 6323T                                                                                                                                                                                                                 | Injection 40 micrograms in 0.4 mL pre-filled syringe       | 4         | 586.10                   | Aranesp                           | AN |
| 6489M                                                                                                                                                                                                                 | Injection 40 micrograms in 0.4 mL pre-filled injection pen | 1         | 146.53                   | Aranesp SureClick                 | AN |
| 6324W                                                                                                                                                                                                                 | Injection 50 micrograms in 0.5 mL pre-filled syringe       | 4         | 724.62                   | Aranesp                           | AN |
| 6325X                                                                                                                                                                                                                 | Injection 60 micrograms in 0.3 mL pre-filled syringe       | 4         | 850.87                   | Aranesp                           | AN |
| 6490N                                                                                                                                                                                                                 | Injection 60 micrograms in 0.3 mL pre-filled injection pen | 1         | 212.72                   | Aranesp SureClick                 | AN |

continued ➞



| Code  | Item and Section 100 Restriction                                   | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------|--------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| 6438W | <i>Injection 80 micrograms in 0.4 mL pre-filled syringe</i>        | 4         | 1120.00                  | <i>Aranesp</i>                    | AN |
| 6491P | <i>Injection 80 micrograms in 0.4 mL pre-filled injection pen</i>  | 1         | 280.00                   | <i>Aranesp SureClick</i>          | AN |
| 6326Y | <i>Injection 100 micrograms in 0.5 mL pre-filled syringe</i>       | 4         | 1379.21                  | <i>Aranesp</i>                    | AN |
| 6492Q | <i>Injection 100 micrograms in 0.5 mL pre-filled injection pen</i> | 1         | 344.80                   | <i>Aranesp SureClick</i>          | AN |
| 6365B | <i>Injection 150 micrograms in 0.3 mL pre-filled syringe</i>       | 4         | 2055.00                  | <i>Aranesp</i>                    | AN |
| 6493R | <i>Injection 150 micrograms in 0.3 mL pre-filled injection pen</i> | 1         | 513.75                   | <i>Aranesp SureClick</i>          | AN |

**DARUNAVIR****Private hospital authority required**

*Treatment, in combination with other antiretroviral agents, and co-administered with 100 mg ritonavir twice daily, of HIV infection in an antiretroviral experienced patient with:*

*(a) evidence of HIV replication (viral load greater than 10,000 copies per mL); and/or*

*(b) CD4 cell counts of less than 500 per cubic millimetre.*

*A patient must have failed previous treatment with, or have resistance to, 3 different antiretroviral regimens which have included:*

*(i) at least 1 non-nucleoside reverse transcriptase inhibitor; and*

*(ii) at least 1 nucleoside reverse transcriptase inhibitor; and*

*(iii) at least 2 protease inhibitors.*

|       |                                      |     |         |                 |    |
|-------|--------------------------------------|-----|---------|-----------------|----|
| 9616D | <i>Tablet 300 mg (as ethanolate)</i> | 120 | 1101.38 | <i>Prezista</i> | JC |
|-------|--------------------------------------|-----|---------|-----------------|----|

**DEFERASIROX****Private hospital authority required**

*Chronic iron overload in adults, adolescents and children 6 years and older associated with disorders of erythropoiesis;*

*Chronic iron overload in paediatric patients aged 2 to 5 years, associated with disorders of erythropoiesis, who are intolerant to desferrioxamine or in whom desferrioxamine has proven ineffective.*

|       |                                    |    |        |               |    |
|-------|------------------------------------|----|--------|---------------|----|
| 6499C | <i>Tablet 125 mg (dispersible)</i> | 28 | 233.58 | <i>Exjade</i> | NV |
| 6500D | <i>Tablet 250 mg (dispersible)</i> | 28 | 467.15 | <i>Exjade</i> | NV |
| 9600G | <i>Tablet 500 mg (dispersible)</i> | 28 | 934.30 | <i>Exjade</i> | NV |

**NOTE:**

*These prices are based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details.*

**DEFERIPRONE****Private hospital authority required**

*Iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy;*

*Iron overload in patients with thalassaemia major in whom desferrioxamine therapy has proven ineffective.*

|       |                      |     |        |                  |    |
|-------|----------------------|-----|--------|------------------|----|
| 6416Q | <i>Tablet 500 mg</i> | 100 | 450.56 | <i>Ferriprox</i> | OA |
|-------|----------------------|-----|--------|------------------|----|

| Code                                                                                                                  | Item and Section 100 Restriction                                                             | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer               |    |
|-----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-----------|--------------------------|-------------------------------------------------|----|
| <b>DELAVIRDINE MESYLATE</b>                                                                                           |                                                                                              |           |                          |                                                 |    |
| <b><u>Private hospital authority required</u></b>                                                                     |                                                                                              |           |                          |                                                 |    |
| <i>Treatment of HIV infection in patients with:</i>                                                                   |                                                                                              |           |                          |                                                 |    |
| <i>(a) CD4 cell counts of less than 500 per cubic millimetre; or</i>                                                  |                                                                                              |           |                          |                                                 |    |
| <i>(b) viral load of greater than 10,000 copies per mL.</i>                                                           |                                                                                              |           |                          |                                                 |    |
| 6243N                                                                                                                 | Tablet 100 mg                                                                                | 360       | 271.58                   | Rescriptor                                      | PF |
| <b>DEFERRIOXAMINE MESYLATE</b>                                                                                        |                                                                                              |           |                          |                                                 |    |
| <b><u>Private hospital authority required</u></b>                                                                     |                                                                                              |           |                          |                                                 |    |
| <i>Disorders of erythropoiesis associated with treatment-related chronic iron overload.</i>                           |                                                                                              |           |                          |                                                 |    |
| 6113R                                                                                                                 | Powder for injection 500 mg                                                                  | 10        | 97.02                    | <sup>a</sup> HH<br><sup>a</sup> Desferal 500 mg | NV |
| <b><u>NOTE:</u></b>                                                                                                   |                                                                                              |           |                          |                                                 |    |
| <i>A brand premium of \$8.03 applies to Desferal 500 mg brand. Both brands may not be available in all hospitals.</i> |                                                                                              |           |                          |                                                 |    |
| 6270B                                                                                                                 | Powder for injection 2 g                                                                     | 1         | 38.81                    | <sup>a</sup> HH<br><sup>a</sup> Desferal 2 g    | NV |
| <b><u>NOTE:</u></b>                                                                                                   |                                                                                              |           |                          |                                                 |    |
| <i>A brand premium of \$0.39 applies to Desferal 2 g brand. Both brands may not be available in all hospitals.</i>    |                                                                                              |           |                          |                                                 |    |
| <b>DIDANOSINE</b>                                                                                                     |                                                                                              |           |                          |                                                 |    |
| <b><u>Private hospital authority required</u></b>                                                                     |                                                                                              |           |                          |                                                 |    |
| <i>Treatment of HIV infection in patients with:</i>                                                                   |                                                                                              |           |                          |                                                 |    |
| <i>(a) CD4 cell counts of less than 500 per cubic millimetre; or</i>                                                  |                                                                                              |           |                          |                                                 |    |
| <i>(b) viral load of greater than 10,000 copies per mL.</i>                                                           |                                                                                              |           |                          |                                                 |    |
| 6298L                                                                                                                 | Capsule 125 mg (containing enteric coated beadlets)                                          | 30        | 102.12                   | Videx EC                                        | BQ |
| 6299M                                                                                                                 | Capsule 200 mg (containing enteric coated beadlets)                                          | 30        | 163.40                   | Videx EC                                        | BQ |
| 6300N                                                                                                                 | Capsule 250 mg (containing enteric coated beadlets)                                          | 30        | 204.24                   | Videx EC                                        | BQ |
| 6301P                                                                                                                 | Capsule 400 mg (containing enteric coated beadlets)                                          | 30        | 326.79                   | Videx EC                                        | BQ |
| <b>DISODIUM PAMIDRONATE</b>                                                                                           |                                                                                              |           |                          |                                                 |    |
| <b><u>Private hospital authority required</u></b>                                                                     |                                                                                              |           |                          |                                                 |    |
| <i>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy.</i>                               |                                                                                              |           |                          |                                                 |    |
| 6286W                                                                                                                 | Concentrated injection 15 mg in 5 mL                                                         | 1         | 55.75                    | <sup>a</sup> Pamisol                            | HH |
| 6290C                                                                                                                 | Injection set containing 4 vials powder for I.V. infusion 15 mg and 4 ampoules solvent 5 mL  | 1         | 223.02                   | <sup>a</sup> Aredia 15 mg                       | NV |
| <b><u>NOTE:</u></b>                                                                                                   |                                                                                              |           |                          |                                                 |    |
| <i>The concentrated injection 15 mg and powder for I.V. infusion 15 mg (after reconstitution) are bioequivalent.</i>  |                                                                                              |           |                          |                                                 |    |
| 6287X                                                                                                                 | Concentrated injection 30 mg in 10 mL                                                        | 1         | 111.51                   | <sup>a</sup> Pamisol                            | HH |
| 6279L                                                                                                                 | Injection set containing 2 vials powder for I.V. infusion 30 mg and 2 ampoules solvent 10 mL | 1         | 223.02                   | <sup>a</sup> Aredia 30 mg                       | NV |
| <b><u>NOTE:</u></b>                                                                                                   |                                                                                              |           |                          |                                                 |    |
| <i>The concentrated injection 30 mg and powder for I.V. infusion 30 mg (after reconstitution) are bioequivalent.</i>  |                                                                                              |           |                          |                                                 |    |
| 6288Y                                                                                                                 | Concentrated injection 60 mg in 10 mL                                                        | 1         | 223.02                   | Pamisol                                         | HH |
| continued ➞                                                                                                           |                                                                                              |           |                          |                                                 |    |

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |  |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|--|
|      |                                  |              |                                |                                         |  |

**Private hospital authority required**

*Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy.*

**Private hospital authority required**

*Multiple myeloma;*

*Bone metastases from breast cancer.*

|       |                                                                                            |   |        |                           |    |
|-------|--------------------------------------------------------------------------------------------|---|--------|---------------------------|----|
| 6289B | Concentrated injection 90 mg in 10 mL                                                      | 1 | 334.53 | <sup>a</sup> Pamisol      | HH |
| 6223M | Injection set containing 1 vial powder for I.V. infusion 90 mg and 1 ampoule solvent 10 mL | 1 | 334.53 | <sup>a</sup> Aredia 90 mg | NV |

**NOTE:**

*The concentrated injection 90 mg and powder for I.V. infusion 90 mg (after reconstitution) are bioequivalent.*

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Item and Section 100 Restriction                       | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| <b>DORNASE ALFA</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                        |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |           |                          |                                   |    |
| <i>Use by cystic fibrosis patients who satisfy all of the following criteria:</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |           |                          |                                   |    |
| <i>(1) are 5 years of age or older;</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                        |           |                          |                                   |    |
| <i>(2) have a FVC greater than 40% predicted for age, gender and height;</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                        |           |                          |                                   |    |
| <i>(3) have evidence of chronic suppurative lung disease (cough and sputum most days of the week, or greater than 3 respiratory tract infections of more than 2 weeks' duration in any 12 months, or objective evidence of obstructive airways disease);</i>                                                                                                                                                                                                                                                                          |                                                        |           |                          |                                   |    |
| <i>(4) are participating in a 4 week trial as detailed below or have achieved a 10% or greater improvement in FEV1 (compared to baseline established prior to dornase alfa treatment) after a 4 week trial.</i>                                                                                                                                                                                                                                                                                                                       |                                                        |           |                          |                                   |    |
| <i>In order for patients to be eligible for participation in the HSD program, the following conditions must be met:</i>                                                                                                                                                                                                                                                                                                                                                                                                               |                                                        |           |                          |                                   |    |
| <i>(1) Patients must be assessed at cystic fibrosis clinics/centres which are under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis and the prescribing of dornase alfa under the HSD program is limited to such physicians. If attendance at such units is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;</i>                              |                                                        |           |                          |                                   |    |
| <i>(2) The measurement of lung function is to be conducted by independent (other than the treating doctor) experienced personnel at established lung function testing laboratories, unless this is not possible because of geographical isolation;</i>                                                                                                                                                                                                                                                                                |                                                        |           |                          |                                   |    |
| <i>(3) Prior to dornase alfa therapy, a baseline measurement of FEV1 must be undertaken during a stable period of the disease;</i>                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |           |                          |                                   |    |
| <i>(4) Initial therapy is limited to 4 weeks' treatment with dornase alfa at a dose of 2.5 mg daily;</i>                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                        |           |                          |                                   |    |
| <i>(5) At or towards the end of the initial 4 weeks' trial, patients must be reassessed and a further FEV1 measurement be undertaken (single test under conditions as above). Patients who achieve a 10% or greater improvement in FEV1 (compared to baseline established prior to dornase alfa treatment) are eligible for continued subsidy under the HSD program at a dose of 2.5 mg daily;</i>                                                                                                                                    |                                                        |           |                          |                                   |    |
| <i>(6) Patients who fail to meet a 10% or greater improvement in FEV1 after the initial 4 weeks' treatment at a dose of 2.5 mg daily, may have 1 further trial in the next 12 months but not before 3 months after the initial trial;</i>                                                                                                                                                                                                                                                                                             |                                                        |           |                          |                                   |    |
| <i>(7) Following an initial 6 months' therapy, a global assessment must be undertaken involving the patient, the patient's family (in the case of paediatric patients) and the treating physician(s) to establish that all agree that dornase alfa treatment is continuing to produce worthwhile benefits. (Dornase alfa therapy should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use.) Further reassessments are to be undertaken at six-monthly intervals;</i> |                                                        |           |                          |                                   |    |
| <i>(8) Other aspects of treatment, such as physiotherapy, must be continued;</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                        |           |                          |                                   |    |
| <i>(9) Where there is documented evidence that a patient already receiving dornase alfa therapy would have met the criteria for subsidy (i.e. satisfied the criteria for the 4 week trial and achieved a 10% or greater improvement in FEV1) then the patient is eligible to continue treatment under the HSD program. Where such evidence is not available, patients will need to satisfy the initiation and continuation criteria as for new patients. (Four weeks is considered a suitable wash-out period).</i>                   |                                                        |           |                          |                                   |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                        |           |                          |                                   |    |
| <i>It is highly desirable that all patients be included in the national cystic fibrosis patient data-base.</i>                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |           |                          |                                   |    |
| 6120D                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Solution for inhalation 2.5 mg (2,500 units) in 2.5 mL | 30        | 1180.00                  | Pulmozyme                         | RO |
| <b>DOXORUBICIN HYDROCHLORIDE, PEGYLATED LIPOSOMAL</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                        |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |           |                          |                                   |    |
| <i>Treatment of AIDS-related Kaposi's sarcoma in patients with CD4 cell counts of less than 200 per cubic millimetre and:</i>                                                                                                                                                                                                                                                                                                                                                                                                         |                                                        |           |                          |                                   |    |
| <i>(a) extensive mucocutaneous involvement; or</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |           |                          |                                   |    |
| <i>(b) extensive visceral involvement.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |           |                          |                                   |    |
| 6249X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Suspension for I.V. infusion 20 mg in 10 mL            | 1         | 622.99                   | Caelyx                            | SH |

| Code                                                                                                                                          | Item and Section 100 Restriction   | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-----------|--------------------------|-----------------------------------|----|
| <b>EFAVIRENZ</b>                                                                                                                              |                                    |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                             |                                    |           |                          |                                   |    |
| <i>Treatment of HIV infection in patients with:</i>                                                                                           |                                    |           |                          |                                   |    |
| <i>(a) CD4 cell counts of less than 500 per cubic millimetre; or</i>                                                                          |                                    |           |                          |                                   |    |
| <i>(b) viral load of greater than 10,000 copies per mL.</i>                                                                                   |                                    |           |                          |                                   |    |
| 9618F                                                                                                                                         | Tablet 200 mg                      | 90        | 452.64                   | Stocrin                           | MK |
| 6356M                                                                                                                                         | Tablet 600 mg                      | 30        | 452.64                   | Stocrin                           | MK |
| 6372J                                                                                                                                         | Oral solution 30 mg per mL, 180 mL | 1         | 135.79                   | Stocrin                           | MK |
| <b><u>NOTE:</u></b>                                                                                                                           |                                    |           |                          |                                   |    |
| <i>These prices are based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details.</i> |                                    |           |                          |                                   |    |

**EMTRICITABINE****Private hospital authority required***Treatment of HIV infection in patients with:**(a) CD4 cell counts of less than 500 per cubic millimetre; or**(b) viral load of greater than 10,000 copies per mL.*

|       |                |    |        |         |    |
|-------|----------------|----|--------|---------|----|
| 6137B | Capsule 200 mg | 30 | 282.00 | Emtriva | GI |
|-------|----------------|----|--------|---------|----|

**ENFUVIRTIDE****Private hospital authority required***Treatment, in combination with other antiretroviral agents, of HIV infection in antiretroviral experienced patients with treatment failure characterised by:**(a) evidence of HIV replication, despite ongoing therapy; or**(b) treatment-limiting toxicity to previous antiretroviral agents.**Patients must have failed previous treatment with 3 different antiretroviral regimens. At least 1 of each of the following classes of antiretroviral drugs must have been attempted:**(i) at least 1 non-nucleoside reverse transcriptase inhibitor; and**(ii) at least 1 nucleoside reverse transcriptase inhibitor; and**(iii) at least 1 protease inhibitor.*

|       |                                                                                                                         |     |         |        |    |
|-------|-------------------------------------------------------------------------------------------------------------------------|-----|---------|--------|----|
| 6455R | Pack containing 60 vials powder for injection 90 mg with 60 vials water for injections 1.1 mL (with syringes and swabs) | ± 1 | 2213.00 | Fuzeon | RO |
|-------|-------------------------------------------------------------------------------------------------------------------------|-----|---------|--------|----|

**ENTECAVIR MONOHYDRATE****Private hospital authority required***Patients with chronic hepatitis B who satisfy all of the following criteria:**(1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);**(2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or**(b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;**(3) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.**Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.***NOTE:***PBS-subsidised entecavir monohydrate must be used as monotherapy.*

continued ➞

| Code  | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------|----------------------------------|-----------|--------------------------|-----------------------------------|----|
| 9602J | Tablet 0.5 mg                    | 30        | 384.30                   | Baraclude                         | BQ |

**Private hospital authority required**

*Patients with chronic hepatitis B who have failed lamivudine therapy and who satisfy all of the following criteria:*

*(1)(a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or*

*(b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance;*

*(2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.*

*Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.*

**NOTE:**

*Patients should have undergone a liver biopsy at some point since initial diagnosis to obtain histological evidence of chronic hepatitis.*

*PBS-subsidised entecavir monohydrate must be used as monotherapy.*

|       |             |    |        |           |    |
|-------|-------------|----|--------|-----------|----|
| 9603K | Tablet 1 mg | 30 | 625.00 | Baraclude | BQ |
|-------|-------------|----|--------|-----------|----|

**EPOETIN ALFA**

**Private hospital authority required**

*Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia.*

|       |                                                      |   |         |              |    |
|-------|------------------------------------------------------|---|---------|--------------|----|
| 6251B | Injection 1,000 units in 0.5 mL pre-filled syringe   | 6 | 147.00  | Eprex 1000   | JC |
| 6204M | Injection 2,000 units in 0.5 mL pre-filled syringe   | 6 | 272.00  | Eprex 2000   | JC |
| 6205N | Injection 3,000 units in 0.3 mL pre-filled syringe   | 6 | 351.00  | Eprex 3000   | JC |
| 6206P | Injection 4,000 units in 0.4 mL pre-filled syringe   | 6 | 447.00  | Eprex 4000   | JC |
| 6302Q | Injection 5,000 units in 0.5 mL pre-filled syringe   | 6 | 556.50  | Eprex 5000   | JC |
| 6303R | Injection 6,000 units in 0.6 mL pre-filled syringe   | 6 | 660.60  | Eprex 6000   | JC |
| 6305W | Injection 8,000 units in 0.8 mL pre-filled syringe   | 6 | 856.80  | Eprex 8000   | JC |
| 6207Q | Injection 10,000 units in 1 mL pre-filled syringe    | 6 | 1037.00 | Eprex 10000  | JC |
| 6434P | Injection 20,000 units in 0.5 mL pre-filled syringe  | 6 | 2040.00 | Eprex 20,000 | JC |
| 9623L | Injection 30,000 units in 0.75 mL pre-filled syringe | 6 | 3015.00 | Eprex 30,000 | JC |
| 6339P | Injection 40,000 units in 1 mL pre-filled syringe    | 1 | 660.00  | Eprex 40,000 | JC |

**EPOETIN BETA**

**Private hospital authority required**

*Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100 g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia.*

|       |                                                    |   |        |             |    |
|-------|----------------------------------------------------|---|--------|-------------|----|
| 6479B | Injection 1,000 units in 0.3 mL pre-filled syringe | 6 | 147.00 | NeoRecormon | RO |
| 6480C | Injection 2,000 units in 0.3 mL pre-filled syringe | 6 | 272.00 | NeoRecormon | RO |

continued ➞

| Code  | Item and Section 100 Restriction                    | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------|-----------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| 6481D | Injection 3,000 units in 0.3 mL pre-filled syringe  | 6         | 351.00                   | NeoRecormon                       | RO |
| 6482E | Injection 4,000 units in 0.3 mL pre-filled syringe  | 6         | 447.00                   | NeoRecormon                       | RO |
| 6483F | Injection 5,000 units in 0.3 mL pre-filled syringe  | 6         | 556.50                   | NeoRecormon                       | RO |
| 6484G | Injection 6,000 units in 0.3 mL pre-filled syringe  | 6         | 660.60                   | NeoRecormon                       | RO |
| 6485H | Injection 10,000 units in 0.6 mL pre-filled syringe | 6         | 1037.00                  | NeoRecormon                       | RO |
| 6486J | Injection 20,000 units in 0.6 mL pre-filled syringe | 6         | 2040.00                  | NeoRecormon                       | RO |
| 6487K | Injection 30,000 units in 0.6 mL pre-filled syringe | 1         | 502.50                   | NeoRecormon                       | RO |

#### **EPOPROSTENOL SODIUM**

##### **NOTE:**

Any queries concerning the arrangements to prescribe epoprostenol sodium may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe epoprostenol sodium should be forwarded to:

Medicare Australia

Prior Written Approval of Specialised Drugs

Reply Paid 9826

GPO Box 9826

HOBART TAS 7001

##### **NOTE:**

Epoprostenol sodium is not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with scleroderma, where the total lung capacity is less than 70% of that predicted.

Epoprostenol sodium is not PBS-subsidised when used in combination with PBS-subsidised bosentan monohydrate, PBS-subsidised iloprost trometamol, PBS-subsidised sildenafil citrate or PBS-subsidised sitaxentan sodium.

The following provides some explanatory notes regarding the availability of PBS-subsidised treatment with:

- (a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, in patients with disease of WHO Functional Class III or IV severity; AND
- (b) iloprost trometamol, of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND
- (c) epoprostenol sodium, of primary pulmonary hypertension, in patients with disease of WHO Functional Class III or IV severity; AND
- (d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND
- (e) sitaxentan sodium, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.

##### **Adult patients:**

From 1 April 2008, adult patients with primary pulmonary hypertension will be able to access, through the PBS, bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 5 drugs, they may swap between bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)

Patients may only swap to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.

continued ➞

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Adult patients with pulmonary arterial hypertension secondary to scleroderma will be able to access, through the PBS, bosentan monohydrate, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 4 drugs, they may swap between bosentan monohydrate, iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

*Adult patients with pulmonary arterial hypertension secondary to connective tissue disease other than scleroderma will be able to access, through the PBS, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 3 drugs, they may swap between iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

*Patients with drug-induced pulmonary arterial hypertension are only eligible for treatment with iloprost trometamol. They may not swap to bosentan monohydrate, epoprostenol sodium, sildenafil citrate or sitaxentan sodium.*

*Patients under 18 years of age:*

*From 1 April 2008, patients aged less than 18 years with primary pulmonary hypertension are eligible to receive PBS-subsidised treatment with bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 5 drugs, they may swap between bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

**1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma.**

**Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, are defined as follows:**

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or*
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or*
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.*

**2. Definition of WHO Functional Class III or IV disease severity.**

*(a) WHO Functional Class III disease severity is defined as follows:*

*Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.*

*(b) WHO Functional Class IV disease severity is defined as follows:*

*Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.*

**3. Designated hospitals.**



| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Refer to the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au) for a list of designated hospitals.*

**4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.**

**(a) Initiation of treatment.**

*The first written application for PBS-subsidised treatment with the first of either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.*

*Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:*

- (1) RHC plus ECHO composite assessments;*
- (2) RHC composite assessment plus 6MWT;*
- (3) RHC composite assessment only.*

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:*

- (1) ECHO composite assessment plus 6MWT;*
- (2) ECHO composite assessment only.*

*Where fewer than 3 tests are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application.*

**NOTE:**

*Where patients were initiated on PBS-subsidised treatment either with bosentan monohydrate on or after 1 March 2004, with iloprost trometamol on or after 1 April 2005, with epoprostenol sodium on or after 1 August 2006, with sildenafil citrate on or after 1 March 2007, with sitaxentan sodium on or after 1 April 2008, or with bosentan monohydrate (for PAH associated with congenital systemic-to-pulmonary shunt) on or after 1 August 2008, the test results provided with the initial application must be no more than 2 months old at the time of application. These results will form the baseline against which response assessments will be made.*

*Where patients received treatment with either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium prior to being commenced on PBS-subsidised treatment with the first of either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, the test requirements above still apply. The results that will form the baseline against which response assessments will be made will be those measured at the time patients commenced non-PBS-subsidised treatment with either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, whichever of the 5 drugs the patient received first.*

**(b) Continuation of treatment.**

*The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:*

- (1) RHC plus ECHO composite assessments plus 6MWT;*
- (2) RHC plus ECHO composite assessments;*
- (3) RHC composite assessment plus 6MWT;*
- (4) ECHO composite assessment plus 6MWT;*
- (5) RHC composite assessment only;*
- (6) ECHO composite assessment only.*

*The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a reason why the test(s) could not be conducted must be provided with the application.*

*The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

**5. Definition of response to epoprostenol sodium, bosentan monohydrate, iloprost trometamol, sildenafil citrate, sitaxentan sodium or prior vasodilator treatment.**

*For adult patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

*For adult patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

*For adult patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

*For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

**6. Authority approval requirements.** [The following 2 sections are only relevant to the PBS listing of epoprostenol sodium. The requirements specific to bosentan monohydrate, iloprost trometamol, sildenafil citrate and sitaxentan sodium are given in parts 6 and 7 of the NOTE included in the bosentan monohydrate, iloprost trometamol, sildenafil citrate and sitaxentan sodium Schedule entry respectively.]

*(a) Initiation of PBS-subsidised treatment with epoprostenol sodium, where the patient has not received prior PBS-subsidised treatment with bosentan monohydrate, iloprost trometamol, sildenafil citrate or sitaxentan sodium. All applications for initial treatment must be made in writing, must include an authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.*

*(b) Continuation of treatment.*

*Written applications for continuing treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.*

*Applications for continuing treatment will only be approved for patients who have currently demonstrated a response to treatment with epoprostenol sodium.*

*The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with epoprostenol sodium should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.*

*(c) Swapping between bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate and sitaxentan sodium.*

*For eligible patients, applications to swap between these 5 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.*

*It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.*

*To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.*

*(d) Cessation of treatment.*

*Patients who fail to demonstrate a response to PBS-subsidised epoprostenol sodium treatment at the times where an assessment is required must cease PBS-subsidised epoprostenol sodium therapy.*

**7. Re-treatment with epoprostenol sodium.**

*Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with epoprostenol sodium under any circumstances.*

**8. Further information.**

*A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

### **Public and private hospital authority required**

#### ***Initial (new adult patients)***

*Application for initial PBS-subsidised treatment with epoprostenol sodium of adult patients who have not received prior PBS-subsidised treatment with bosentan monohydrate, iloprost trometamol, sildenafil citrate or sitaxentan sodium and who have been assessed by a physician from a designated hospital to have:*

*WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, unless a RHC is contraindicated on clinical grounds.*

*Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.*

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the test results of the ECHO composite assessment plus 6MWT or the ECHO composite assessment only.*

*Applications for authorisation must be in writing and must include:*

*(1) a completed authority prescription form [see Note for authority approval requirements]; and  
(2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:*

*(i) RHC composite assessment; and*

*(ii) ECHO composite assessment; and*

*(iii) 6MWT; and*

*(3) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with epoprostenol sodium for primary pulmonary hypertension, OR with iloprost trometamol for primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with bosentan monohydrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, OR with sildenafil citrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with sitaxentan sodium for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].*

*Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.*

*Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

### **Public and private hospital authority required**

#### ***Initial (new adult patients)***

*Application for initial PBS-subsidised treatment with epoprostenol sodium of adult patients who have not received prior PBS-subsidised treatment with bosentan monohydrate, iloprost trometamol, sildenafil citrate or sitaxentan sodium and who have been assessed by a physician from a designated hospital to have:*

*(a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, unless a RHC is contraindicated on clinical grounds; OR*

*(b) WHO Functional Class IV primary pulmonary hypertension.*

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the test results of the ECHO composite assessment plus 6MWT or the ECHO composite assessment only.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form [see Note for authority approval requirements]; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:

- (i) RHC composite assessment; and
- (ii) ECHO composite assessment; and
- (iii) 6MWT; and

(3) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with epoprostenol sodium for primary pulmonary hypertension, OR with iloprost trometamol for primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with bosentan monohydrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, OR with sildenafil citrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with sitaxentan sodium for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

#### **Public and private hospital authority required**

*Initial (new patients under 18 years of age)*

Application for initial PBS-subsidised treatment of patients aged less than 18 years who have not received prior PBS-subsidised treatment with bosentan monohydrate or sildenafil citrate and who have been assessed by a physician from a designated hospital to have WHO Functional Class III primary pulmonary hypertension with a mean right atrial pressure of 8 mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, normal right ventricular function as assessed by ECHO.

Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate prior vasodilator treatment unless intolerance or a contraindication to such treatment exists.

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form [see Note for authority approval requirements]; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:

- (i) RHC composite assessment; and
- (ii) ECHO composite assessment; and
- (iii) 6MWT; and

(3) a patient acknowledgment, signed by the parent or authorised guardian, indicating that they understand and acknowledge that PBS-subsidised treatment with epoprostenol sodium, bosentan monohydrate or sildenafil citrate for primary pulmonary hypertension will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].

Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats will be authorised under this criterion. Where fewer than 5 repeats are initially requested, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

**Public and private hospital authority required**

*Initial (new patients under 18 years of age)*

*Application for initial PBS-subsidised treatment of patients aged less than 18 years who have not received prior PBS-subsidised treatment with bosentan monohydrate or sildenafil citrate and who have been assessed by a physician from a designated hospital to have:*

- (a) WHO Functional Class III primary pulmonary hypertension and either a mean right atrial pressure greater than 8 mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular dysfunction as assessed by ECHO; OR*
- (b) WHO Functional Class IV primary pulmonary hypertension.*

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form [see Note for authority approval requirements]; and*
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:*
  - (i) RHC composite assessment; and*
  - (ii) ECHO composite assessment; and*
  - (iii) 6MWT; and*
- (3) a patient acknowledgment, signed by the parent or authorised guardian, indicating that they understand and acknowledge that PBS-subsidised treatment with epoprostenol sodium, bosentan monohydrate or sildenafil citrate for primary pulmonary hypertension will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].*

*Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats will be authorised under this criterion. Where fewer than 5 repeats are initially requested, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

**Public and private hospital authority required**

*Initial (change or re-commencement for all adult patients)*

*Application for initial PBS-subsidised treatment with epoprostenol sodium of adult patients with either of the following:*

- (a) primary pulmonary hypertension who wish to re-commence PBS-subsidised epoprostenol sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with epoprostenol sodium; OR*
- (b) primary pulmonary hypertension and whose most recent course of PBS-subsidised treatment was with bosentan monohydrate, iloprost trometamol, sildenafil citrate or sitaxentan sodium.*

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form [see Note for authority approval requirements]; and*
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised epoprostenol sodium, iloprost trometamol, bosentan monohydrate, sildenafil citrate or sitaxentan sodium, whichever was initiated first, was granted; and*
- (3) the date of the first application for PBS-subsidised treatment with epoprostenol sodium, iloprost trometamol, bosentan monohydrate, sildenafil citrate or sitaxentan sodium, whichever was initiated first; and*
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised epoprostenol sodium, iloprost trometamol, bosentan monohydrate, sildenafil citrate or sitaxentan sodium.*

| Code                                                                                          | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
|                                                                                               | <p><i>The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</i></p> <p><b>Public and private hospital authority required</b></p> <p><i>Initial (change or re-commencement for all patients under 18 years of age)</i></p> <p><i>Application for initial PBS-subsidised treatment with epoprostenol sodium of patients aged less than 18 years with either of the following:</i></p> <p><i>(a) primary pulmonary hypertension who wish to re-commence PBS-subsidised epoprostenol sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with epoprostenol sodium; OR</i></p> <p><i>(b) primary pulmonary hypertension and whose most recent course of PBS-subsidised treatment was with bosentan monohydrate or sildenafil citrate.</i></p> <p><i>Applications for authorisation must be in writing and must include:</i></p> <p><i>(1) a completed authority prescription form [see Note for authority approval requirements]; and</i></p> <p><i>(2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised epoprostenol sodium, bosentan monohydrate or sildenafil citrate, whichever was initiated first, was granted; and</i></p> <p><i>(3) the date of the first application for PBS-subsidised treatment with epoprostenol sodium, bosentan monohydrate or sildenafil citrate, whichever was initiated first; and</i></p> <p><i>(4) the results of the patient's response to treatment with their last course of PBS-subsidised epoprostenol sodium, bosentan monohydrate or sildenafil citrate.</i></p> <p><i>The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</i></p> <p><b>Public and private hospital authority required</b></p> <p><i>Continuing treatment (all patients)</i></p> <p><i>Continuing PBS-subsidised treatment with epoprostenol sodium of patients who have received approval for initial PBS-subsidised treatment with epoprostenol sodium, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of epoprostenol sodium treatment [see Note for definition of response].</i></p> <p><i>Applications for authorisation must be in writing and must include:</i></p> <p><i>(1) a completed authority prescription form; and</i></p> <p><i>(2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:</i></p> <p><i>(i) RHC composite assessment; and</i></p> <p><i>(ii) ECHO composite assessment; and</i></p> <p><i>(iii) 6MWT.</i></p> <p><i>Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</i></p> <p><i>The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</i></p> |           |                          |                                   |    |
| 6477X                                                                                         | Powder for I.V. infusion 500 micrograms (base) with diluent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1         | 41.69                    | Flolan                            | GK |
| continued  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |           |                          |                                   |    |

| Code  | Item and Section 100 Restriction                           | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |           |
|-------|------------------------------------------------------------|-----------|--------------------------|-----------------------------------|-----------|
| 6478Y | <b>Powder for I.V. infusion 1.5 mg (base) with diluent</b> | 1         | 83.37                    | <b>Flolan</b>                     | <b>GK</b> |

**ETANERCEPT****NOTE:**

Any queries concerning the arrangements to prescribe etanercept may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe etanercept should be forwarded to:

Medicare Australia

Prior Written Approval of Specialised Drugs

Reply Paid 9826

GPO Box 9826

HOBART TAS 7001

Further prescribing information is on the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).

**Public and private hospital authority required**

Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of patients under 18 years who have severe active polyarticular course juvenile chronic arthritis; AND

(a) whose parent or authorised guardian has signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if the predetermined response criteria do not support continuation of PBS-subsidised treatment; AND

(b) who have demonstrated either:

(i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or

(ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:

— oral or parenteral methotrexate at a dose of at least 20 mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or

— oral methotrexate at a dose of at least 10 mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months. (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)

Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.

Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.

The following criteria must be met in order to demonstrate failure to achieve an adequate response to either of the above treatment regimens:

(a) an active joint count of at least 20 active (swollen and tender) joints; OR

(b) at least 4 active joints from the following list:

(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or

(ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).

If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, or intolerance develops during the period of use such that permanent withdrawal is necessary and a suitably effective treatment regimen cannot be implemented, this exempts the requirement to demonstrate an inadequate response within the time period specified above for these agents.

The authority application must be in writing and must include the information used to determine the patient's eligibility under the criteria above. The date of the joint assessment must be provided.

Only 16 weeks of treatment will be approved. The assessment of the patient's response to initial treatment should be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.

continued ➞

| Code  | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
|       | <p><b><u>Public and private hospital authority required</u></b></p> <p><i>Initial PBS-subsidised supply for continuing treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of severe active polyarticular course juvenile chronic arthritis in patients receiving treatment with etanercept prior to 1 December 2002; AND</i></p> <p><i>(a) whose parent or authorised guardian has signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if the predetermined response criteria do not support continuation of PBS-subsidised treatment; AND</i></p> <p><i>(b) who have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with etanercept.</i></p> <p><i>The authority application must be in writing and must include sufficient information to determine the patient's eligibility. The date of the joint assessment must be provided.</i></p> <p><i>Only 6 months of treatment will be approved.</i></p> <p><b><u>Public and private hospital authority required</u></b></p> <p><i>Continuing PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of severe active polyarticular course juvenile chronic arthritis in patients who have demonstrated an adequate response to treatment with etanercept as manifested by:</i></p> <p><i>(a) an active joint count of fewer than 10 active (swollen and tender) joints; OR</i></p> <p><i>(b) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; OR</i></p> <p><i>(c) a reduction in the number of the following active joints, from at least 4, by at least 50%:</i></p> <p><i>(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</i></p> <p><i>(ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</i></p> <p><i>All authority applications for continuing treatment with etanercept must be in writing and must include sufficient information to determine the patient's response according to the above criteria. The date of the joint assessment must be provided.</i></p> <p><i>Only 6 months of treatment per application will be approved. Applications for continuing treatment with etanercept should be made prior to the completion of 16 weeks of treatment to ensure continuity for those patients who meet the criteria.</i></p> <p><i>Patients who fail to demonstrate an adequate response, as specified in the criteria for continuing treatment with etanercept, will not be eligible to recommence treatment with etanercept within 12 months of the date on which treatment was ceased.</i></p> <p><i>Withdrawal of treatment with etanercept should be considered in patients who have achieved and sustained complete remission of disease for 12 months. Subsequent applications for PBS-subsidised re-treatment with etanercept will be subject to the authority conditions applying to initial treatment and will not be authorised within 12 months of the date on which treatment with etanercept was ceased.</i></p> <p><i>Where re-treatment with etanercept after a break in PBS-subsidised treatment with the drug is being sought, the reason for and date of cessation of the previous treatment course with etanercept must be included in the application.</i></p> |           |                          |                                   |    |
| 6367D | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1         | 815.00                   | Enbrel                            | WX |

continued ➞



| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |  |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|

**Public and private hospital authority required**

*Continuing PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of severe active polyarticular course juvenile chronic arthritis in patients 18 years or older who have demonstrated an adequate response to treatment with etanercept as manifested by:*

- (a) an active joint count of fewer than 10 active (swollen and tender) joints; OR*
- (b) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; OR*
- (c) a reduction in the number of the following active joints, from at least 4, by at least 50%:*
  - (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*
  - (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*All authority applications for continuing treatment with etanercept must be in writing and must include sufficient information to determine the patient's response according to the above criteria. The date of the joint assessment must be provided.*

*Only 6 months of treatment per application will be approved. Applications for continuing treatment with etanercept should be made prior to the completion of 16 weeks of treatment to ensure continuity for those patients who meet the criteria.*

*Patients who fail to demonstrate an adequate response, as specified in the criteria for continuing treatment with etanercept, will not be eligible to recommence treatment with etanercept within 12 months of the date on which treatment was ceased.*

*Withdrawal of treatment with etanercept should be considered in patients who have achieved and sustained complete remission of disease for 12 months. Subsequent applications for PBS-subsidised re-treatment with etanercept will be subject to the authority conditions applying to initial treatment and will not be authorised within 12 months of the date on which treatment with etanercept was ceased.*

*Where re-treatment with etanercept after a break in PBS-subsidised treatment with the drug is being sought, the reason for and date of cessation of the previous treatment course with etanercept must be included in the application.*

*Where a patient with severe active polyarticular course juvenile chronic arthritis continues treatment with etanercept and is 18 years or older, etanercept 50 mg may be prescribed.*

|       |                                                            |   |         |        |    |
|-------|------------------------------------------------------------|---|---------|--------|----|
| 9615C | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | 1 | 1630.01 | Enbrel | WX |
|-------|------------------------------------------------------------|---|---------|--------|----|

**EVEROLIMUS**

**CAUTION:**

Careful monitoring of patients is mandatory.

**Private hospital authority required**

*Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for:*

- (a) prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required; or*
- (b) prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required.*

|       |                |    |        |          |    |
|-------|----------------|----|--------|----------|----|
| 6459Y | Tablet 0.25 mg | 60 | 240.30 | Certican | NV |
| 6460B | Tablet 0.5 mg  | 60 | 480.60 | Certican | NV |
| 6461C | Tablet 0.75 mg | 60 | 720.90 | Certican | NV |

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |  |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|

## FILGRASTIM

### Private hospital authority required

*For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia;*

*Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy;*

*Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation;*

*A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation;*

*A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation;*

*A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;*

*A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;*

*A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;*

*A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage);*

*A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months));*

*A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months)).*

### Private hospital authority required

*A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in:*

- (a) acute lymphoblastic leukaemia; or*
- (b) breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide); or*
- (c) germ cell tumours; or*
- (d) infants and children with CNS tumours; or*
- (e) neuroblastoma; or*
- (f) non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen); or*
- (g) relapsed Hodgkin disease; or*
- (h) sarcoma.*

|       |                                                                  |    |         |          |    |
|-------|------------------------------------------------------------------|----|---------|----------|----|
| 6126K | Injection 300 micrograms in 1 mL                                 | 10 | 1504.00 | Neupogen | AN |
| 6291D | Injection 300 micrograms in 0.5 mL single use pre-filled syringe | 10 | 1504.00 | Neupogen | AN |

continued ➡

| Code                                                                                                                                                                                       | Item and Section 100 Restriction                                                    | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| 6127L                                                                                                                                                                                      | Injection 480 micrograms in 1.6 mL                                                  | 10        | 2407.00                  | Neupogen                          | AN |
| 6292E                                                                                                                                                                                      | Injection 480 micrograms in 0.5 mL single use pre-filled syringe                    | 10        | 2407.00                  | Neupogen                          | AN |
| <b>FOSAMPRENAVIR CALCIUM</b>                                                                                                                                                               |                                                                                     |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                          |                                                                                     |           |                          |                                   |    |
| Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with:                                                                                    |                                                                                     |           |                          |                                   |    |
| (a) CD4 cell counts of less than 500 per cubic millimetre; or                                                                                                                              |                                                                                     |           |                          |                                   |    |
| (b) viral load of greater than 10,000 copies per mL.                                                                                                                                       |                                                                                     |           |                          |                                   |    |
| 6453P                                                                                                                                                                                      | Tablet 700 mg (base)                                                                | 60        | 568.74                   | Telzir                            | GK |
| <b><u>NOTE:</u></b>                                                                                                                                                                        |                                                                                     |           |                          |                                   |    |
| This price is based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details.                                                        |                                                                                     |           |                          |                                   |    |
| 6454Q                                                                                                                                                                                      | Oral liquid 50 mg (base) per mL, 225 mL                                             | 1         | 101.56                   | Telzir                            | GK |
| <b>FOSCARNET SODIUM</b>                                                                                                                                                                    |                                                                                     |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                          |                                                                                     |           |                          |                                   |    |
| Treatment of cytomegalovirus retinitis in patients with AIDS;                                                                                                                              |                                                                                     |           |                          |                                   |    |
| Treatment of aciclovir-resistant herpes simplex virus infection in immunocompromised patients with HIV infection.                                                                          |                                                                                     |           |                          |                                   |    |
| 6134W                                                                                                                                                                                      | I.V. infusion 24 mg per mL, 250 mL                                                  | 6         | 395.00                   | Foscavir                          | AP |
| <b>GANCICLOVIR</b>                                                                                                                                                                         |                                                                                     |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                          |                                                                                     |           |                          |                                   |    |
| Cytomegalovirus retinitis in severely immunocompromised patients.                                                                                                                          |                                                                                     |           |                          |                                   |    |
| 6256G                                                                                                                                                                                      | Intravitreal implant 4.5 mg                                                         | 1         | 6000.00                  | Vitrasert                         | BU |
| <b>GANCICLOVIR SODIUM</b>                                                                                                                                                                  |                                                                                     |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                          |                                                                                     |           |                          |                                   |    |
| Cytomegalovirus retinitis in severely immunocompromised patients;                                                                                                                          |                                                                                     |           |                          |                                   |    |
| Prophylaxis of cytomegalovirus disease in bone marrow transplant patients at risk of cytomegalovirus disease;                                                                              |                                                                                     |           |                          |                                   |    |
| Prophylaxis of cytomegalovirus disease in solid organ transplant patients at risk of cytomegalovirus disease.                                                                              |                                                                                     |           |                          |                                   |    |
| 6136Y                                                                                                                                                                                      | Powder for I.V. infusion equivalent to 500 mg ganciclovir                           | 5         | 280.00                   | Cymevene                          | RO |
| <b>IBANDRONATE SODIUM</b>                                                                                                                                                                  |                                                                                     |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                          |                                                                                     |           |                          |                                   |    |
| Bone metastases from breast cancer.                                                                                                                                                        |                                                                                     |           |                          |                                   |    |
| 9619G                                                                                                                                                                                      | Concentrated injection for I.V. infusion equivalent to 6 mg ibandronic acid in 6 mL | 1         | 341.36                   | Bondronat                         | HH |
| <b>ILOPROST TROMETAMOL</b>                                                                                                                                                                 |                                                                                     |           |                          |                                   |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                        |                                                                                     |           |                          |                                   |    |
| Any queries concerning the arrangements to prescribe iloprost trometamol may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). |                                                                                     |           |                          |                                   |    |
| Written applications for authority to prescribe iloprost trometamol should be forwarded to:                                                                                                |                                                                                     |           |                          |                                   |    |

continued ➞

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

**Medicare Australia**

**Prior Written Approval of Specialised Drugs**

**Reply Paid 9826**

**GPO Box 9826**

**HOBART TAS 7001**

**NOTE:**

*Iloprost trometamol is not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with scleroderma, where the total lung capacity is less than 70% of that predicted.*

*Iloprost trometamol is not PBS-subsidised when used in combination with PBS-subsidised bosentan monohydrate, PBS-subsidised epoprostenol sodium, PBS-subsidised sildenafil citrate or PBS-subsidised sitaxentan sodium.*

*The following provides some explanatory notes regarding the availability of PBS-subsidised treatment with:*

- (a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, in patients with disease of WHO Functional Class III or IV severity; AND*
- (b) iloprost trometamol, of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND*
- (c) epoprostenol sodium, of primary pulmonary hypertension, in patients with disease of WHO Functional Class III or IV severity; AND*
- (d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND*
- (e) sitaxentan sodium, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.*

**Adult patients:**

*From 1 April 2008, adult patients with primary pulmonary hypertension will be able to access, through the PBS, bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 5 drugs, they may swap between bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

*Adult patients with pulmonary arterial hypertension secondary to scleroderma will be able to access, through the PBS, bosentan monohydrate, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 4 drugs, they may swap between bosentan monohydrate, iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

*Adult patients with pulmonary arterial hypertension secondary to connective tissue disease other than scleroderma will be able to access, through the PBS, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 3 drugs, they may swap between iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Patients may only swap to iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

*Patients with drug-induced pulmonary arterial hypertension are only eligible for treatment with iloprost trometamol. They may not swap to bosentan monohydrate, epoprostenol sodium, sildenafil citrate or sitaxentan sodium.*

*Patients under 18 years of age:*

*From 1 April 2008, patients aged less than 18 years with primary pulmonary hypertension are eligible to receive PBS-subsidised treatment with bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 5 drugs, they may swap between bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

**1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma.**

*Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, are defined as follows:*

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or*
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or*
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.*

**2. Definition of WHO Functional Class III or IV disease severity.**

*(a) WHO Functional Class III disease severity is defined as follows:*

*Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.*

*(b) WHO Functional Class IV disease severity is defined as follows:*

*Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.*

**3. Designated hospitals.**

*Refer to the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au) for a list of designated hospitals.*

**4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.**

*(a) Initiation of treatment.*

*The first written application for PBS-subsidised treatment with the first of either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.*

*Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:*

- (1) RHC plus ECHO composite assessments;*
- (2) RHC composite assessment plus 6MWT;*
- (3) RHC composite assessment only.*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:*

- (1) ECHO composite assessment plus 6MWT;*
- (2) ECHO composite assessment only.*

*Where fewer than 3 tests are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application.*

**NOTE:**

*Where patients were initiated on PBS-subsidised treatment either with bosentan monohydrate on or after 1 March 2004, with iloprost trometamol on or after 1 April 2005, with epoprostenol sodium on or after 1 August 2006, with sildenafil citrate on or after 1 March 2007, with sitaxentan sodium on or after 1 April 2008, or with bosentan monohydrate (for PAH associated with congenital systemic-to-pulmonary shunt) on or after 1 August 2008, the test results provided with the initial application must be no more than 2 months old at the time of application. These results will form the baseline against which response assessments will be made.*

*Where patients received treatment with either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium prior to being commenced on PBS-subsidised treatment with the first of either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, the test requirements above still apply. The results that will form the baseline against which response assessments will be made will be those measured at the time patients commenced non-PBS-subsidised treatment with either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, whichever of the 5 drugs the patient received first.*

**(b) Continuation of treatment.**

*The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:*

- (1) RHC plus ECHO composite assessments plus 6MWT;*
- (2) RHC plus ECHO composite assessments;*
- (3) RHC composite assessment plus 6MWT;*
- (4) ECHO composite assessment plus 6MWT;*
- (5) RHC composite assessment only;*
- (6) ECHO composite assessment only.*

*The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a reason why the test(s) could not be conducted must be provided with the application.*

*The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.*

**5. Definition of response to iloprost trometamol, bosentan monohydrate, epoprostenol sodium, sildenafil citrate, sitaxentan sodium or prior vasodilator treatment.**

*For adult patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

*For adult patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

*For adult patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

**6. Authority approval requirements.** *[The following 2 sections are only relevant to the PBS listing of iloprost trometamol. The requirements specific to bosentan monohydrate, epoprostenol sodium, sildenafil citrate and sitaxentan sodium are given in parts 6 and 7 of the NOTE included in the bosentan monohydrate, epoprostenol sodium, sildenafil citrate and sitaxentan sodium Schedule entry respectively.]*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

(a) *Initiation of PBS-subsidised treatment with iloprost trometamol, where the patient has not received prior PBS-subsidised treatment with bosentan monohydrate, epoprostenol sodium, sildenafil citrate or sitaxentan sodium. All applications for initial treatment must be made in writing, must include an authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months, based on the dosage recommendations in the TGA-approved Product Information.*

(b) *Continuation of treatment.*

*Written applications for continuing treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.*

*Applications for continuing treatment will only be approved for patients who have currently demonstrated a response to treatment with iloprost trometamol.*

*The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with iloprost trometamol should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.*

(c) *Swapping between bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate and sitaxentan sodium.*

*For eligible patients, applications to swap between these 5 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.*

*It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.*

*To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.*

(d) *Cessation of treatment.*

*Patients who fail to demonstrate a response to PBS-subsidised iloprost trometamol treatment at the times where an assessment is required must cease PBS-subsidised iloprost trometamol therapy.*

#### **7. Re-treatment with iloprost trometamol.**

*Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with iloprost trometamol under any circumstances.*

#### **8. Further information.**

*A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).*

#### **Public and private hospital authority required**

##### ***Initial (new patients)***

*Application for initial PBS-subsidised treatment with iloprost trometamol of patients who have not received prior PBS-subsidised treatment with bosentan monohydrate, epoprostenol sodium, sildenafil citrate or sitaxentan sodium and who have been assessed by a physician from a designated hospital to have:*

*(a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, unless a RHC is contraindicated on clinical grounds; OR*

*(b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, unless a RHC is contraindicated on clinical grounds; OR*

*(c) WHO Functional Class III drug-induced pulmonary arterial hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, unless a RHC is contraindicated on clinical grounds.*

*Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the test results of the ECHO composite assessment plus 6MWT or the ECHO composite assessment only.*

*Applications for authorisation must be in writing and must include:*

*(1) a completed authority prescription form [see Note for authority approval requirements]; and*

*(2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:*

*(i) RHC composite assessment; and*

*(ii) ECHO composite assessment; and*

*(iii) 6MWT; and*

*(3) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with iloprost trometamol for primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with bosentan monohydrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, OR with epoprostenol sodium for primary pulmonary hypertension, OR with sildenafil citrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with sitaxentan sodium for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].*

*Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.*

*Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

#### **Public and private hospital authority required**

##### **Initial (new patients)**

*Application for initial PBS-subsidised treatment with iloprost trometamol of patients who have not received prior PBS-subsidised treatment with bosentan monohydrate, epoprostenol sodium, sildenafil citrate or sitaxentan sodium and who have been assessed by a physician from a designated hospital to have:*

*(a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, unless a RHC is contraindicated on clinical grounds; OR*

*(b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, unless a RHC is contraindicated on clinical grounds; OR*

*(c) WHO Functional Class III drug-induced pulmonary arterial hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, unless a RHC is contraindicated on clinical grounds; OR*

*(d) WHO Functional Class IV primary pulmonary hypertension; OR*

*(e) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease; OR*

*(f) WHO Functional Class IV drug-induced pulmonary arterial hypertension.*

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the test results of the ECHO composite assessment plus 6MWT or the ECHO composite assessment only.*



| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form [see Note for authority approval requirements]; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:

- (i) RHC composite assessment; and
- (ii) ECHO composite assessment; and
- (iii) 6MWT; and

(3) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with iloprost trometamol for primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with bosentan monohydrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, OR with epoprostenol sodium for primary pulmonary hypertension, OR with sildenafil citrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with sitaxentan sodium for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].

Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].

The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

#### **Public and private hospital authority required**

*Initial (change or re-commencement for all patients)*

*Application for initial PBS-subsidised treatment with iloprost trometamol of patients with either of the following:*

- (a) primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised iloprost trometamol after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with iloprost trometamol; OR
- (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma and whose most recent course of PBS-subsidised treatment was with bosentan monohydrate; OR
- (c) primary pulmonary hypertension and whose most recent course of PBS-subsidised treatment was with epoprostenol sodium; OR
- (d) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with sildenafil citrate; OR
- (e) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with sitaxentan sodium.

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form [see Note for authority approval requirements]; and
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised iloprost trometamol, bosentan monohydrate, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, whichever was initiated first, was granted; and
- (3) the date of the first application for PBS-subsidised treatment with iloprost trometamol, bosentan monohydrate, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, whichever was initiated first; and
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised iloprost trometamol, bosentan monohydrate, epoprostenol sodium, sildenafil citrate or sitaxentan sodium.

continued ➡

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |  |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

**Public and private hospital authority required**

*Continuing treatment (all patients)*

*Continuing PBS-subsidised treatment with iloprost trometamol of patients who have received approval for initial PBS-subsidised treatment with iloprost trometamol, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of iloprost trometamol treatment [see Note for definition of response].*

*Applications for authorisation must be in writing and must include:*

*(1) a completed authority prescription form; and*

*(2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:*

*(i) RHC composite assessment; and*

*(ii) ECHO composite assessment; and*

*(iii) 6MWT.*

*Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

|       |                                                      |    |         |          |    |
|-------|------------------------------------------------------|----|---------|----------|----|
| 6456T | Solution for inhalation 20 micrograms (base) in 2 mL | 30 | 1076.00 | Ventavis | SC |
|-------|------------------------------------------------------|----|---------|----------|----|

**NOTE:**

*This price is based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details.*

**INDINAVIR SULFATE**

**Private hospital authority required**

*Treatment of HIV infection in patients with:*

*(a) CD4 cell counts of less than 500 per cubic millimetre; or*

*(b) viral load of greater than 10,000 copies per mL.*

|       |                       |     |        |                 |    |
|-------|-----------------------|-----|--------|-----------------|----|
| 6344X | Capsule 100 mg (base) | 180 | 113.75 | Crixivan 100 mg | MK |
| 6201J | Capsule 200 mg (base) | 360 | 455.00 | Crixivan 200 mg | MK |
| 6202K | Capsule 400 mg (base) | 180 | 455.00 | Crixivan 400 mg | MK |

**INFLIXIMAB**

**NOTE:**

*Any queries concerning the arrangements to prescribe infliximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Written applications for authority to prescribe infliximab should be forwarded to:*

continued ➞

| Code | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|
|      | <p><b>Medicare Australia</b><br/> <b>Prior Written Approval of Specialised Drugs</b><br/> <b>Reply Paid 9826</b><br/> <b>GPO Box 9826</b><br/> <b>HOBART TAS 7001</b></p> <p>Further prescribing information is on the Medicare Australia website at <a href="http://www.medicareaustralia.gov.au">www.medicareaustralia.gov.au</a>.</p> <p><b>NOTE:</b><br/> <b>TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS</b></p> <p>The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, etanercept and infliximab for adult patients with active ankylosing spondylitis. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab, etanercept and infliximab only.</p> <p>A patient is eligible for PBS-subsidised treatment with only 1 of the 3 TNF-alfa antagonists at any 1 time.</p> <p>From 1 March 2007, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.</p> <p>A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 March 2007 is considered to be in their first cycle as of 1 March 2007.</p> <p>Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than once. A patient who, prior to 1 March 2007, was authorised to receive PBS-subsidised initial treatment for ankylosing spondylitis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 March 2007.</p> <p>Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.</p> <p>A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.</p> <p>A patient who has failed fewer than 3 TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.</p> <p>There is no limit to the number of treatment cycles a patient may undertake in their lifetime.</p> <p>(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 March 2007.</p> <p>(a) Initial treatment.</p> <p>Applications for initial treatment should be made where:</p> <p>(i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or</p> <p>(ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or</p> <p>(iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).</p> <p>Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for etanercept and adalimumab and 18 weeks of treatment for infliximab.</p> <p>From 1 March 2007, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p> <p>Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.</p> |           |                          |                                   |

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.*

*(b) Continuing treatment.*

*Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.*

*It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.*

*Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.*

*(2) Swapping therapy.*

*Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap to an alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.*

*A patient may trial an alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug within the same treatment cycle.*

*To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.*

*To avoid confusion, an application for a patient who wishes to swap to an alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.*

*(3) Baseline measurements to determine response.*

*Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a TNF-alfa antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.*

*For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program. However, this is not required for any subsequent BASDAI results for these patients, nor for patients who were 'grandfathered' on to TNF-alfa antagonist treatment.*

*To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.*

*(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.*

*A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF-alfa antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured.*

*(5) Patients 'grandfathered' onto PBS-subsidised treatment with infliximab.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*From 1 March 2007, a patient who commenced treatment with infliximab for active ankylosing spondylitis prior to 1 March 2004 and who was 'grandfathered' onto PBS-subsidised therapy, and who continues to receive treatment in the same treatment cycle, will have further applications for treatment with infliximab assessed under the continuing treatment restriction.*

*Where pre-TNF- $\alpha$  antagonist treatment baselines were not provided, the following criteria must be met to demonstrate a response to treatment:*

*The BASDAI score must be either:*

- (i) no more than 20% greater than the score included in the initial application for PBS-subsidised treatment; or*
- (ii) no greater than 2.*

*AND*

*One of the following:*

- (a) an ESR measurement no greater than 25 mm per hour; or*
- (b) a CRP measurement no greater than 10 mg per L.*

*'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.*

#### **Public and private hospital authority required**

##### **Initial 1 (new patients)**

*First course of PBS-subsidised treatment with infliximab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept or infliximab in this treatment cycle; AND*

*(a) who has at least 2 of the following:*

- (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or*
- (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)]; or*
- (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)]; AND*

*(b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.*

*The application must include details of the NSAIDs trialled, their doses and duration of treatment. If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.*

*If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.*

*If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [[www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)].*

*For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).*

*The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:*

- (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND*
- (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.*

*The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.*

*Authority applications must be made in writing and must include:*

*(a) a completed authority prescription form; and*

*(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:*

*(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and*

*(ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and*

*(iii) a completed Exercise Program Self Certification Form included in the supporting information form; and*  
*(iv) a signed patient acknowledgment form. Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment with the TNF- $\alpha$  antagonists (adalimumab, etanercept or infliximab) for ankylosing spondylitis will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.*

*The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.*

*A maximum of 18 weeks of treatment with infliximab will be approved under this criterion.*

*At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.*

*Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 18 weeks of treatment may be requested by telephone.*

#### **Public and private hospital authority required**

*Initial 2 (change or re-commencement for all patients)*

*Initial course of PBS-subsidised treatment with infliximab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised treatment with either adalimumab, etanercept or infliximab for this condition and has not failed PBS-subsidised therapy with infliximab.*

*To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF- $\alpha$  antagonist therapy within the timeframes specified in the relevant restriction.*

*Where the most recent course of PBS-subsidised TNF- $\alpha$  antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. Where the most recent course of PBS-subsidised TNF- $\alpha$  antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased.*

*If the response assessment to the previous course of TNF- $\alpha$  antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF- $\alpha$  antagonist.*

*Authority applications must be made in writing and must include:*

*(a) a completed authority prescription form; and*

*(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their assessment.*

*A maximum of 18 weeks of treatment with infliximab will be approved under this criterion.*

*At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 18 weeks of treatment may be requested by telephone.

**Public and private hospital authority required**

*Continuing treatment for all patients*

*Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:*

- (a) has demonstrated a response to treatment with infliximab; and*
- (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with infliximab.*

*Response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:*

- (a) an ESR measurement no greater than 25 mm per hour; or*
- (b) a CRP measurement no greater than 10 mg per L; or*
- (c) an ESR or CRP measurement reduced by at least 20% from baseline.*

*For a 'grandfather' patient who does not have baselines prior to commencing treatment with a TNF-alfa antagonist, see Note 5 for a definition of response to treatment.*

*Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.*

*Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction after 1 March 2007, the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction prior to 1 March 2007, the patient must have been assessed for response to that course following at least 4 weeks of treatment.*

*Applications for continuing treatment must be made in writing and should be posted to Medicare Australia no less than 2 weeks prior to the completion of the current treatment course.*

*Written applications for authorisation must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes a completed BASDAI Assessment Form with certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their continuing treatment assessment.*

*All measurements provided must be no more than 1 month old at the time of application.*

*A maximum of 24 weeks of treatment with infliximab will be authorised under this criterion.*

*At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.*

*Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.*

|       |                                 |   |        |          |    |
|-------|---------------------------------|---|--------|----------|----|
| 6448J | Powder for I.V. infusion 100 mg | 1 | 751.70 | Remicade | SH |
|-------|---------------------------------|---|--------|----------|----|

**NOTE:**

**TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS**

*The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, etanercept, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-1 inhibitor (anakinra) and the T-cell co-stimulation modulator (abatacept).*

*Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.*

*PBS-subsidised infliximab, anakinra, rituximab and abatacept must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are only eligible to receive PBS-subsidised etanercept and adalimumab.*

continued ➡

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.*

*From 1 March 2008, under the PBS, all patients will be able to commence a Treatment Cycle where they may trial PBS-subsidised bDMARD agents without having to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Treatment Cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.*

*A patient who received PBS-subsidised bDMARD treatment prior to 1 March 2008 is considered to be in their first Cycle as of 1 March 2008.*

*Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.*

*Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next Cycle.*

*For patients who have failed PBS-subsidised treatment with 3 bDMARDs prior to 1 March 2008 please contact Medicare Australia on 1800 700 270.*

*The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent Cycle to the date of the first application for initial treatment with a bDMARD under the new Treatment Cycle.*

*A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same Treatment Cycle.*

*A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of more than 5 years, may commence a new Treatment Cycle.*

*There is no limit to the number of Treatment Cycles a patient may undertake in their lifetime.*

*If patients fail to respond to a particular bDMARD within a single Treatment Cycle, they are not eligible to receive further PBS-subsidised treatment with that drug until they commence the next Cycle.*

*(1) How to prescribe PBS-subsidised bDMARD therapy after 1 March 2008.*

*(a) Initial treatment.*

*Applications for initial treatment should be made where:*

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this Treatment Cycle and wishes to commence such therapy, excluding rituximab (Initial 1); or*
- (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or*
- (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 2).*

*Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for etanercept, adalimumab, anakinra and abatacept, 22 weeks of therapy for infliximab and 2 infusions of rituximab.*

*From 1 March 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.*

*For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.*

*Rituximab patients:*

*A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.*



| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

**(b) Continuing treatment.**

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

**Rituximab patients:**

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

**(2) Swapping therapy.**

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same Treatment Cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same Treatment Cycle.

In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.

To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.

To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.

**NOTE:**

**(3) Baseline measurements to determine response.**

Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a Treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.

The baseline joint and blood counts should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment.

(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.

A patient who wishes to trial a second or subsequent Treatment Cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 non-biological DMARD, at an adequate dose, for a minimum of 3 months at the time the ESR and/or CRP levels and the active joint count are measured.

(5) Patients 'grandfathered' onto PBS-subsidised treatment with rituximab or abatacept.

From 1 March 2008, a patient who commenced treatment with rituximab for severe rheumatoid arthritis prior to 7 March 2007 or abatacept for severe rheumatoid arthritis prior to 1 November 2007 and who was 'grandfathered' on to PBS-subsidised therapy, and who continues to receive treatment in the same Treatment Cycle, will have further applications for treatment with rituximab or abatacept assessed under the continuing treatment restriction.

A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with abatacept will be authorised under this criterion.

'Grandfather' arrangements will only apply for the first Treatment Cycle. For the second and subsequent Cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that applies to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.

#### **Public and private hospital authority required**

##### **Initial 1 (new patients)**

Application for initial PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:

- (a) have severe active rheumatoid arthritis; and
- (b) have received no prior PBS-subsidised treatment with a bDMARD for this condition in this treatment cycle; and
- (c) have failed to achieve an adequate response to the following treatments:
  - (i) methotrexate at a dose of at least 20 mg weekly; and
  - (ii) methotrexate (at a minimum dose of 7.5 mg weekly), in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs), for a minimum of 3 months; and
  - (iii) a minimum of 3 months' treatment with:
    - leflunomide alone; or
    - leflunomide in combination with methotrexate; or
    - cyclosporin.

If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities, including severity, can be found on the Medicare Australia website [www.medicareaustralia.gov.au].

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:*  
*an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L;*

*AND either*

*(i) a total active joint count of at least 20 active (swollen and tender) joints; or*

*(ii) at least 4 active joints from the following list of major joints:*

*— elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*

*— shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

*If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.*

*The authority application must be made in writing and must include:*

*(1) a completed authority prescription form; and*

*(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and*

*(3) a signed patient acknowledgement.*

*A maximum of 22 weeks of treatment will be authorised under this restriction.*

*At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3 mg per kg. Up to a maximum of 3 repeats may be authorised.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.*

*Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.*

#### **Public and private hospital authority required**

*Initial 2 (change or re-commencement)*

*Application for an initial course of PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:*

*(a) have a documented history of severe active rheumatoid arthritis; and*

*(b) have received prior PBS-subsidised bDMARD treatment for this condition in this treatment cycle and are eligible to receive further bDMARD therapy.*

*The authority application must be made in writing and must include:*

*(1) a completed authority prescription form; and*

*(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*Applications for patients who have received PBS-subsidised treatment with infliximab within this treatment cycle and who wish to re-commence therapy with this drug within this same cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised infliximab treatment, within the timeframes specified below.*

*A maximum of 22 weeks of treatment will be authorised under this restriction.*

*At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3 mg per kg. Up to a maximum of 3 repeats may be authorised.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Where the most recent course of PBS-subsidised infliximab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.*

#### **Public and private hospital authority required**

##### **Continuing treatment**

*Continuing PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:*

- (a) who have a documented history of severe active rheumatoid arthritis; and*
- (b) who have demonstrated an adequate response to treatment with infliximab; and*
- (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with infliximab.*

*An adequate response to treatment is defined as:*

*an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;*

*AND either of the following:*

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or*
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:*
  - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*
  - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].*

*A maximum of 24 weeks of treatment will be approved under this restriction.*

*At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3 mg per kg. Up to a maximum of 2 repeats may be authorised.*

| Code  | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |    |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------------------------|-----------------------------------------|----|
|       | <p><i>Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</i></p> <p><i>All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with infliximab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</i></p> <p><i>Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this treatment cycle. Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this cycle and the date of the first application under the new cycle.</i></p> |              |                                |                                         |    |
| 6397Q | Powder for I.V. infusion 100 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1            | 751.70                         | Remicade                                | SH |

**NOTE:****TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS**

*The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents (adalimumab, etanercept and infliximab) for adult patients with severe active psoriatic arthritis.*

*Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time. Where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to adalimumab, etanercept and infliximab.*

*From 1 August 2006, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial adalimumab, etanercept or infliximab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.*

*Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.*

*Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].*

*The 5-year break in therapy will be measured from the date the last approval for PBS-subsidised treatment was granted in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.*

*Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.*

*Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.*

*Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.*

*There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.*

*How to prescribe biological agents for the treatment of severe active psoriatic arthritis after 1 August 2006.*

**(1) Initial treatment.**

continued ➞

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Applications for initial treatment should be made where:*

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and*
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and*
- (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 2).*

*All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy for all agents except for infliximab, for which a maximum of 22 weeks will be authorised. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.*

*Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.*

*Grandfather patients.*

*Applications for patients who commenced treatment with etanercept prior to 17 March 2005 or adalimumab and infliximab prior to 16 March 2006, may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.*

*Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.*

#### *(2) Continuing treatment.*

*Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.*

*Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.*

#### *(3) Swapping therapy.*

*Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.*

*Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.*

*Patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:*

- (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or*
- (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS.*

*To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.*

*To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the biological agent the patient is ceasing.*

#### *(4) Baseline measurements to determine response.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.*

*To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.*

*(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.*

*Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must re-qualify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate or sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured.*

#### **Public and private hospital authority required**

##### **Initial 1**

*Initial PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:*

- (1) have severe active psoriatic arthritis; and*
- (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and*
- (3) have failed to achieve an adequate response to:*
  - (a) methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; and*
  - (b) sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or*
  - (c) leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months.*

*Patients must have had the psoriatic component of their disease confirmed by a dermatologist or by biopsy at any time.*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities, including severity, can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).*

*The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:*

*an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either*

- (i) an active joint count of at least 20 active (swollen and tender) joints; or*
- (ii) at least 4 active joints from the following list of major joints:*
  - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*
  - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.*

continued 

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
  - (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes details of the patient's ESR and CRP measurements and the patient's active joint count which must have been assessed no earlier than 1 month prior to the date of application; and*
  - (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form.*
- Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.*

*At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats may be authorised.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.*

#### **Public and private hospital authority required**

##### ***Initial 2***

*Initial PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:*

- (1) have a documented history of severe active psoriatic arthritis; and*
- (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and*
- (3) have not failed treatment with infliximab during the current Treatment Cycle.*

*Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to re-commence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of a response to the patient's most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.*

*Where the most recent course of PBS-subsidised infliximab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].*

*At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats may be authorised.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.*



| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.*

#### **Public and private hospital authority required**

##### ***Initial 3***

*Initial PBS-subsidised supply for continuing treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:*

- (1) have a documented history of severe active psoriatic arthritis; and*
- (2) were receiving treatment with infliximab prior to 16 March 2006; and*
- (3) have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with infliximab.*

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
  - (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))]; and*
  - (3) a copy of the signed patient acknowledgement form which is included in the Supporting Information Form.*
- Completion of this form declares that the patient understands and acknowledges that PBS-subsidised treatment will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated.*

*A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.*

*At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats may be authorised.*

*Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.*

*Patients may qualify for PBS-subsidised treatment under this restriction once only.*

#### **Public and private hospital authority required**

##### ***Continuing treatment***

*Continuing PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:*

- (1) who have a documented history of severe active psoriatic arthritis; and*
- (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with infliximab; and*
- (3) who, at the time of application, demonstrate an adequate response to treatment with infliximab.*

*An adequate response to treatment with infliximab is defined as:*

*an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following:*

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or*
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:*
  - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*
  - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |  |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|

*All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with infliximab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.*

*At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats may be authorised.*

*Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.*

*Once patients fail to respond to treatment with 3 biological agents, they are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.*

|       |                                 |   |        |          |    |
|-------|---------------------------------|---|--------|----------|----|
| 6496X | Powder for I.V. infusion 100 mg | 1 | 751.70 | Remicade | SH |
|-------|---------------------------------|---|--------|----------|----|

**NOTE:**

**TREATMENT OF ADULT PATIENTS WITH SEVERE REFRACTORY CROHN DISEASE**

*The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab and infliximab for adult patients with severe refractory Crohn disease. Where the term 'tumour necrosis factor (TNF) alfa antagonist' appears in the following NOTES and restrictions, it refers to adalimumab and infliximab only.*

*A patient is eligible for PBS-subsidised treatment with only 1 of the 2 TNF-alfa antagonists at any 1 time.*

*From 1 August 2008, under the PBS, all patients will be able to commence a treatment cycle where they may trial each PBS-subsidised TNF-alfa antagonist without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a TNF-alfa antagonist while they continue to show a response to therapy.*

*A patient who received PBS-subsidised TNF-alfa antagonist treatment prior to 1 August 2008 is considered to be in their first cycle as of 1 August 2008.*

*Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised TNF-alfa antagonist more than twice.*

*Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised TNF-alfa antagonist therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised TNF-alfa antagonist treatment in the most recent cycle to the date of the first application for initial treatment with a TNF-alfa antagonist under the new treatment cycle.*

*A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same treatment cycle.*

*A patient who has failed fewer than 3 trials of TNF-alfa antagonists in a treatment cycle and who has a break in therapy of more than 5 years, may commence a new treatment cycle.*

*There is no limit to the number of treatment cycles a patient may undertake in their lifetime.*

*(1) How to prescribe PBS-subsidised TNF-alfa antagonist therapy after 1 August 2008.*

continued 

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

**(a) Initial treatment.**

*Applications for initial treatment should be made where:*

- (i) a patient has received no prior PBS-subsidised TNF-alfa antagonist treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or*
- (ii) a patient has received prior PBS-subsidised (initial or continuing) TNF-alfa antagonist therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or*
- (iii) a patient wishes to re-commence treatment with a specific TNF-alfa antagonist following a break in PBS-subsidised therapy with that agent (Initial 2).*

*Initial treatment authorisations will be limited to provide for a maximum of 16 weeks of therapy for adalimumab and 14 weeks of therapy for infliximab.*

*From 1 August 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab, and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.*

*For second and subsequent courses of PBS-subsidised TNF-alfa antagonist treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.*

*Adalimumab only: Two completed authority prescriptions must be submitted with every initial application for adalimumab. One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats. The second prescription must be written for 2 doses of 40 mg and 2 repeats.*

*(b) Continuing treatment. Following the completion of an initial treatment course with a specific TNF-alfa antagonist, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing TNF-alfa antagonist treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.*

*It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted TNF-alfa antagonist supply.*

*Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that TNF-alfa antagonist.*

**(2) Swapping therapy.**

*Once initial treatment with the first PBS-subsidised TNF-alfa antagonist is approved, a patient may swap if eligible to the alternate TNF-alfa antagonist within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. Crohn Disease Activity Index (CDAI) Score, evidence of intestinal inflammation), or the prior corticosteroid therapy and immunosuppressive therapy.*

*A patient may trial the alternate TNF-alfa antagonist at any time, regardless of whether they are receiving therapy (initial or continuing) with a TNF-alfa antagonist at the time of the application. However, they cannot swap to a particular TNF-alfa antagonist if they have failed to respond to prior treatment with that drug two times within the same treatment cycle.*

*To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.*

*To avoid confusion, an application for a patient who wishes to swap to the alternate TNF-alfa antagonist should be accompanied by the approved authority prescription or remaining repeats for the TNF-alfa antagonist the patient is ceasing.*

**(3) Baseline measurements to determine response.**

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the CDAI or evidence of intestinal inflammation submitted with the first authority application for a TNF- $\alpha$  antagonist. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and Medicare Australia will assess response according to these revised baseline measurements.*

*To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications.*

*(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.*

*A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised TNF- $\alpha$  antagonist therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with a corticosteroid and at least 1 immunosuppressive agent, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the CDAI score or the indices of intestinal inflammation are measured.*

*(5) Patients 'grandfathered' onto PBS-subsidised treatment with adalimumab or infliximab.*

*A patient who commenced treatment with adalimumab for severe refractory Crohn disease prior to 9 November 2007 or infliximab prior to 7 March 2007 and who continues to receive treatment at the time of application, may qualify for treatment under the initial 'grandfather' treatment restriction.*

*A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with adalimumab or infliximab will be authorised under this criterion.*

*Following completion of the initial PBS-subsidised course, further applications for treatment with adalimumab or infliximab will be assessed under the continuing treatment restriction.*

*'Grandfather' arrangements will only apply for the first treatment cycle. For the second and subsequent cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that apply to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.*

#### **Public and private hospital authority required**

##### ***Initial 1 (new patients)***

***Initial treatment of Crohn disease in a patient assessed by CDAI.***

***Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:***

- (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and***
- (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and***
- (c) has failed to achieve an adequate response to prior systemic therapy including:***
  - (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and***
  - (ii) immunosuppressive therapy including:***
    - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or***
    - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or***
    - methotrexate at a dose of at least 15 mg weekly for 3 or more months.***

***NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].***

***If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application. .***

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)). .*

*The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:*

*(a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.*

*All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

*The most recent CDAI assessment must be no more than 1 month old at the time of application.*

*Applications for authorisation must be made in writing and must include:*

*(a) a completed authority prescription form; and*

*(b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*

*(i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and*

*(ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and*

*(iii) the signed patient acknowledgement.*

*A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.*

*Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.*

*A CDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.*

*This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.*

*It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.*

#### **Public and private hospital authority required**

##### **Initial 2**

*Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.*

*Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:*

*(a) has a documented history of severe refractory Crohn disease; and*

*(b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and*

*(c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.*

*Authority applications must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and*
  - (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.*

*A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.*

*Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.*

*A CDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab so that there is adequate time for a response to be demonstrated.*

*This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.*

*It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.*

#### **Public and private hospital authority required**

*Continuing treatment of Crohn disease in a patient assessed by CDAI.*

*Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:*

- (a) has a documented history of severe refractory Crohn disease; and*
- (b) has demonstrated or sustained an adequate response to treatment with infliximab.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*An adequate response to infliximab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition.*

*The CDAI assessment must be no more than 1 month old at the time of application.*

*If the application is the first application for continuing treatment with infliximab, a CDAI assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.*

*Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.*

*Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.*

*At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.*

*Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

#### **Public and private hospital authority required**

##### ***Initial 1***

*Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.*

*Initial PBS-subsidised treatment with infliximab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:*

- (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and*
- (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and*
- (c) has evidence of intestinal inflammation; and*
- (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and*
- (e) has failed to achieve an adequate response to prior systemic drug therapy including:*
  - (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and*
  - (ii) immunosuppressive therapy including:*
    - azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or*
    - 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or*
    - methotrexate at a dose of at least 15 mg weekly for 3 or more months.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.*

*Details of the accepted toxicities including severity can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).*

continued ➞

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:*

*(a) have evidence of intestinal inflammation, including:*

*(i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR*

*(ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR*

*(iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;*

*AND/OR*

*(b) be assessed clinically as being in a high faecal output state;*

*AND/OR*

*(c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of infliximab.*

*All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

*Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.*

*Applications for authorisation must be made in writing and must include:*

*(a) a completed authority prescription form; and*

*(b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*

*(i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and*

*(ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and*

*(iii) date of the most recent clinical assessment; and*

*(iv) the signed patient acknowledgement.*

*All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.*

*A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.*

*Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.*

*The assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.*

*This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.*

*It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.*

#### **Public and private hospital authority required**

##### **Initial 2**

*Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.*

continued ➡



| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:*

- (a) has a documented history of severe refractory Crohn disease; and*
- (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and*
- (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.*

*Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.*

*If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.*

*Authority applications must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*

- (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and*
- (ii). details of prior TNF alfa antagonist treatment including details of date and duration of treatment.*

*A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.*

*Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.*

*The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.*

*This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.*

*It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.*

#### **Public and private hospital authority required**

*Continuing treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.*

*Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:*

- (a) has a documented history of severe refractory Crohn disease with intestinal inflammation and with short gut syndrome or with an ileostomy or colostomy; and*
- (b) has demonstrated or sustained an adequate response to treatment with infliximab.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*An adequate response to infliximab treatment is defined as:*

*(a) improvement of intestinal inflammation as demonstrated by:*

*(i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR*

*(ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR*

*(iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or*

*(b) reversal of high faecal output state; or*

*(c) avoidance of the need for surgery or total parenteral nutrition (TPN).*

*Applications for authorisation must be made in writing and must include:*

*(a) a completed authority prescription; and*

*(b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*

*(i) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy or the date of clinical assessment.*

*The patient's assessment must be no more than 1 month old at the time of application.*

*If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.*

*The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.*

*Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.*

*Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.*

*At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.*

*Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

#### **Public and private hospital authority required**

##### **Initial 1**

*Initial treatment of Crohn disease in a patient with extensive small intestine disease.*

continued ➞

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:*

*(a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and*

*(b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; and*

*(c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and*

*(d) has failed to achieve an adequate response to prior systemic therapy including:*

*(i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and*

*(ii) immunosuppressive therapy including:*

*— azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or*

*— 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or*

*— methotrexate at a dose of at least 15 mg weekly for 3 or more months.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.*

*Details of the accepted toxicities including severity can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).*

*The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:*

*(a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;*

*AND/OR*

*(b) have evidence of active intestinal inflammation, including:*

*(i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C-reactive protein (CRP) level greater than 15 mg per L; AND/OR*

*(ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR*

*(iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;*

*AND/OR*

*(c) be assessed clinically as being in a high faecal output state;*

*AND/OR*

*(d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of infliximab.*

*All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

*Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and*
  - (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or*
  - (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and*
  - (iii) date of the most recent clinical assessment; and*
  - (iv) the signed patient acknowledgement.*

*All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.*

*A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.*

*Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.*

*The assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.*

*This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.*

*It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.*

#### **Public and private hospital authority required**

*Continuing treatment of Crohn disease in a patient with extensive small intestine disease.*

*Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, or consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:*

- (a) has a documented history of severe refractory Crohn disease with extensive intestinal inflammation affecting more than 50 cm of the small intestine; and*
- (b) has demonstrated or sustained an adequate response to treatment with infliximab.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*An adequate response to infliximab treatment is defined as:*

- (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or*
- (b) improvement of intestinal inflammation as demonstrated by:*
  - (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR*
  - (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR*
  - (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or*
  - (c) reversal of high faecal output state; or*
  - (d) avoidance of the need for surgery or total parenteral nutrition (TPN).*

continued ➡

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; or*
  - (ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy; or*
  - (iii) the date of clinical assessment.*

*All assessments must be no more than 1 month old at the time of application.*

*If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.*

*The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.*

*Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.*

*Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.*

*At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.*

*Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

#### **Public and private hospital authority required**

*Initial 3 (grandfather)*

*Initial PBS-subsidised treatment of Crohn disease in a patient assessed by CDAI who has previously received non-PBS-subsidised therapy with infliximab.*

*Initial PBS-subsidised supply with infliximab for continuing treatment by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who:*

- (a) has a documented history of severe refractory Crohn disease and was receiving treatment with infliximab prior to 7 March 2007; and*
- (b) had a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 prior to commencing treatment with infliximab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800 700 270 to discuss; and*
- (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and*
- (d) has demonstrated or sustained an adequate response to treatment with infliximab. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*An adequate response to infliximab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150.*

continued ➡

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and*
  - (ii) the signed patient acknowledgement.*

*The current CDAI assessment must be no more than 1 month old at the time of application. The baseline CDAI assessment must be from immediately prior to commencing treatment with infliximab.*

*The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.*

*Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.*

*Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.*

*At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.*

*Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Patients may qualify for PBS-subsidised treatment under this restriction once only.*

#### **Public and private hospital authority required**

##### **Initial 3**

*Initial PBS-subsidised treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient, or a patient with extensive small intestine disease, who has previously received non-PBS-subsidised therapy with infliximab.*

*Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist, of a patient who:*

- (a) has a documented history of severe refractory Crohn disease and was receiving treatment with infliximab prior to 7 March 2007; and*
- (b) (1) has a history of extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50 cm of the small intestine; or*
- (2) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy with a documented history of intestinal inflammation; and*
- (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and*
- (d) has demonstrated or sustained an adequate response to treatment with infliximab according to the criteria included in the relevant continuation restriction. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*The same criteria used to determine an inadequate response to prior treatment at baseline must be used to determine response to treatment and eligibility for continuing therapy, according to the criteria included in the continuing treatment restriction.*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |  |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|

*An adequate response to infliximab treatment is defined as:*

*(a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or*

*(b) improvement of intestinal inflammation as demonstrated by:*

*(i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C-reactive protein (CRP) level no greater than 15 mg per L; AND/OR*

*(ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR*

*(iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or*

*(c) reversal of high faecal output state; or*

*(d) avoidance of the need for surgery or total parenteral nutrition (TPN).*

*Applications for authorisation must be made in writing and must include:*

*(a) a completed authority prescription form; and*

*(b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)) ] which includes the following:*

*(i) (1) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet, where relevant, including the date of the assessment of the patient's condition; or*

*(2) the reports and dates of the current and baseline pathology or diagnostic imaging test(s) in order to assess response to therapy; or*

*(3) the date of clinical assessment(s); and*

*(ii) the signed patient acknowledgement.*

*The patient's assessment must be no more than 1 month old at the time of application. The baseline CDAI assessments must be from immediately prior to commencing treatment with infliximab. Where a baseline assessment is not available, please call Medicare Australia on 1800 700 270 to discuss.*

*The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.*

*Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.*

*Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.*

*At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.*

*Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Patients may qualify for PBS-subsidised treatment under this restriction once only.*

|       |                                 |   |        |          |    |
|-------|---------------------------------|---|--------|----------|----|
| 9613Y | Powder for I.V. infusion 100 mg | 1 | 751.70 | Remicade | SH |
|-------|---------------------------------|---|--------|----------|----|

#### **Public and private hospital authority required**

*Initial treatment of Crohn disease in a paediatric patient.*

continued ➞

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*Initial PBS-subsidised treatment by a gastroenterologist, paediatrician or consultant physician as specified in the NOTE below, of a patient aged 6 to 17 years inclusive with moderate to severe refractory Crohn disease who satisfies the following criteria:*

*(a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and*

*(b) whose parent or authorised guardian has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and*

*(c) has failed to achieve an adequate response to 2 of the following 3 conventional prior therapies including:*

*(i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period;*

*(ii) an 8 week course of enteral nutrition;*

*(iii) immunosuppressive therapy including:*

*— azathioprine at a dose of at least 2 mg per kg daily for 3 or more months; or*

*— 6-mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months; or*

*— methotrexate at a dose of at least 10 mg per square metre weekly for 3 or more months.*

**NOTE:** Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.*

*Details of the accepted toxicities including severity can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).*

*The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:*

*(a) severity of disease activity which results in a Paediatric Crohn Disease Activity Index (PCDAI) Score greater than or equal to 30 as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

*(b) The most recent PCDAI assessment must be no more than 1 month old at the time of application.*

*All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

*Applications for authorisation must be made in writing and must include:*

*(a) a completed authority prescription form; and*

*(b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*

*(i) the completed current Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet including the date of assessment of the patient's condition; and*

*(ii) details of previous systemic drug therapy [dosage, date of commencement and duration of therapy], or dates of enteral nutrition; and*

*(iii) the signed patient acknowledgement.*

*A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.*

*Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.*

*A PCDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.*



| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.*

*It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.*

#### **Public and private hospital authority required**

*Continuing treatment of Crohn disease in a patient initiated on PBS-subsidised treatment as a paediatric patient.*

*Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:*

- (a) has a documented history of moderate to severe refractory Crohn disease; and*
- (b) has demonstrated or sustained an adequate response to treatment with infliximab.*

*NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].*

*An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition.*

*The PCDAI assessment must be no more than 1 month old at the time of application.*

*If the application is the first application for continuing treatment with infliximab, a PCDAI assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.*

*The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.*

*Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.*

*Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.*

*Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing treatment with infliximab, will not be eligible to receive PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.*

*At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.*

*Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

#### **Public and private hospital authority required**

*Initial PBS-subsidised treatment of Crohn disease in a paediatric patient who has previously received non-PBS-subsidised therapy with infliximab.*

| Code  | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
|       | <p><i>Initial PBS-subsidised supply with infliximab for continuing treatment by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient aged 6 to 17 years inclusive who:</i></p> <p><i>(a) has a documented history of moderate to severe refractory Crohn disease and was receiving treatment with infliximab prior to 4 July 2007; and</i></p> <p><i>(b) had a Paediatric Crohn Disease Activity Index (PCDAI) Score of greater than 30 prior to commencing treatment with infliximab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800 700 270 to discuss; and</i></p> <p><i>(c) whose parent or authorised guardian has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and</i></p> <p><i>(d) has demonstrated or sustained an adequate response to treatment with infliximab. For advice please contact Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</i></p> <p><i>NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</i></p> <p><i>An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.</i></p> <p><i>Applications for authorisation must be made in writing and must include:</i></p> <p><i>(a) a completed authority prescription form; and</i></p> <p><i>(b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (<a href="http://www.medicareaustralia.gov.au">www.medicareaustralia.gov.au</a>)] which includes the following:</i></p> <p><i>(i) the completed current and baseline Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition; and</i></p> <p><i>(ii) the signed patient acknowledgement.</i></p> <p><i>The current PCDAI assessment must be no more than 1 month old at the time of application. The baseline PCDAI assessment must be from immediately prior to commencing treatment with infliximab.</i></p> <p><i>The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</i></p> <p><i>Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.</i></p> <p><i>Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.</i></p> <p><i>Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing treatment with infliximab, will not be eligible to recommence PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.</i></p> <p><i>At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.</i></p> <p><i>Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</i></p> <p><i>Patients may qualify for PBS-subsidised treatment under this restriction once only.</i></p> |           |                          |                                   |    |
| 9612X | Powder for I.V. infusion 100 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1         | 751.70                   | Remicade                          | SH |

**NOTE:****TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS**

The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents efalizumab, etanercept and infliximab, for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in the following NOTES and restrictions, it only refers to efalizumab, etanercept and infliximab.

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*From 1 December 2007, all patients will be able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial efalizumab, etanercept or infliximab without having to meet the initial treatment criteria, that is they will not need to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.*

*A patient who received PBS-subsidised biological agent treatment for chronic plaque psoriasis prior to 1 December 2007 is considered to be in their first Cycle as of 1 December 2007.*

*Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.*

*Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment. A patient who, prior to 1 December 2007, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice, is exempt from this condition in respect of applications approved prior to 1 December 2007.*

*Initial treatment with efalizumab consists of 16 weeks of therapy, with infliximab consists of 22 weeks of therapy, and with etanercept consists of 12 weeks of active therapy followed by a biological treatment-free period of at least 12 weeks. Response to treatment for all 3 agents must be assessed after 12 weeks of treatment.*

*Following demonstration of response to initial treatment, these biological agents are available as continuing therapy. Ongoing access to continuing treatment is available for as long as the response to therapy is sustained. In the case of efalizumab and infliximab, continuing treatment consists of 24 weeks of continuous active treatment. In the case of etanercept, continuing treatment consists of 12 weeks of active therapy followed by a biological treatment-free period of at least 12 weeks.*

*Patients must be assessed for response to each course of continuing treatment according to the criteria included in the relevant continuing treatment restriction.*

*Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.*

*Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.*

*Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle.*

*There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.*

*How to prescribe biological agents for the treatment of severe chronic plaque psoriasis after 1 December 2007.*

*There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.*

*(1) Application for approval for initial treatment.*

*Applications for a course of initial treatment should be made in the following situations:*

- (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and*
- (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; and*
- (iii) patients who wish to re-commence treatment following a break in PBS-subsidised therapy with that agent (Initial 2).*

*All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of therapy in the case of efalizumab, 12 weeks of therapy in the case of etanercept, and 22 weeks of treatment in the case of infliximab. Approval will be based on the criteria included in the relevant initial treatment restriction.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

**Grandfather patients (Infliximab only).**

*Applications for patients who commenced treatment with infliximab prior to 7 March 2007, may apply for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.*

*Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.*

**(2) Assessment of response to initial treatment.**

*When prescribing efalizumab or infliximab, where the initial treatment course is for 16 or 22 weeks respectively, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to Medicare Australia within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with efalizumab or infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*Applications for continuing treatment with efalizumab or infliximab must also be submitted to Medicare Australia prior to the completion of this initial course of therapy to ensure continuity of treatment for those patients who meet the continuation criterion and wish to continue on treatment with either efalizumab or infliximab.*

*When prescribing etanercept, a PASI assessment must be conducted at the completion of the 12 week initial treatment course. This assessment, which will be used to determine eligibility for future treatment according to the criterion included in the relevant continuing treatment restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.*

**(3) Application for continuing treatment.**

*As stated above, following the completion of an initial treatment course of efalizumab or infliximab to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with efalizumab or infliximab. Patients are eligible to continue to receive continuous treatment with efalizumab or infliximab in 24 week courses providing they continue to sustain a response.*

*For second and subsequent courses of PBS-subsidised treatment with efalizumab or infliximab it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.*

*At the completion of an initial 12 week treatment course of etanercept to which an adequate response has been demonstrated, followed by a biological treatment-free period of at least 12 weeks, patients may qualify to receive continuing treatment with etanercept. Continuing treatment is available in the form of 12 weeks of active etanercept treatment followed by a biological treatment-free period of at least 12 weeks. Patients are eligible to receive continuing treatment with etanercept on this cyclical basis, for as long as they continue to sustain a response. Continuing applications must be submitted at least 12 weeks after cessation of the most recent course of etanercept treatment.*

*A PASI assessment must be conducted for each course of continuing treatment for each biological agent, according to the requirements set out in the relevant restriction. Assessment of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 1 month from the date that course was completed or treatment was ceased.*

*Where a response assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to sustain a response to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

**NOTE:****(4) Swapping therapy.**

Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent in the same Cycle.

Patients who commenced treatment with infliximab prior to 7 March 2007 access these interchangeability arrangements in the same way as patients who have not.

PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required 12 week biological treatment-free period applying to patients who have demonstrated a response to their most recent course of etanercept. This means that patients who have demonstrated a response to a 12 week course of etanercept must have a PBS-subsidised biological therapy treatment-free period of at least 12 weeks, immediately following this course of treatment, before swapping to efalizumab or infliximab. Patients who fail to respond to etanercept and who qualify and wish to try a course of efalizumab or infliximab, may do so without having to have any treatment-free period.

To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.

To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the approved authority prescription or remaining repeats for the agent being ceased.

**(5) Baseline measurements to determine response.**

Medicare Australia will determine whether a response to treatment has been demonstrated, based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.

For new patients and patients commencing a new Cycle, the first baseline PASI assessment must be conducted, preferably while the patient is still receiving their most recent prior therapy, but no later than 1 month following cessation of such therapy, as outlined in the relevant restriction. This is not required for any subsequent PASI scores provided for these patients within the same Cycle, nor for patients who received initial PBS-subsidised therapy under a 'grandfather' restriction.

To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment applications.

**(6) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.**

Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

### **Public and private hospital authority required**

*Initial treatment [Initial 1, Whole body (New patients — No prior biological agent)]*

*Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:*

*(a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and*

*(b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and*

*(c) have signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and*

*(d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:*

*(i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or*

*(ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or*

*(iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or*

*(iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).*

*The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:*

*(a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*

*(b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.*

*(c) The most recent PASI assessment must be no more than 1 month old at the time of application.*

*Applications for authorisation must be made in writing and must include:*

*(a) a completed authority prescription form; and*

*(b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*

*(i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))]; and*

*(ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and*

*(iii) the signed patient acknowledgement.*

*A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.*

*At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.*

#### **Public and private hospital authority required**

*Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]*

*Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:*

- (a) have a documented history of severe chronic plaque psoriasis; and*
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and*
- (c) have not failed PBS-subsidised therapy with infliximab for the treatment of this condition in the current Treatment Cycle.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))]; and*
  - (ii) details of prior biological treatment, including dosage, date and duration of treatment.*

*Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to re-commence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.*

*A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.*

*At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.*

*A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*Patients who fail to demonstrate a response to treatment with each of the biological agents, efalizumab, etanercept and infliximab, are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.*

**Public and private hospital authority required**

*Initial treatment [Initial 3, Whole body (Grandfather patients)]*

*Initial PBS-subsidised supply for continuing treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:*

- (a) have a documented history of severe chronic plaque psoriasis and were receiving treatment with infliximab prior to 7 March 2007; and*
- (b) had a Psoriasis Area and Severity Index (PASI) score of greater than 15 prior to commencing treatment with infliximab; and*
- (c) have signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and*
- (d) have demonstrated a response as specified in the criterion included in the restriction for continuing PBS-subsidised treatment with infliximab (whole body).*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet including the date of the assessment of the patient's condition at baseline (prior to initiation of infliximab therapy) and the most recent PASI assessment [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))]; and*
  - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and*
  - (iii) the signed patient acknowledgement.*

*A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.*

*At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised.*

*Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.*

*A PASI assessment of the patient's response to this initial PBS-subsidised course of therapy must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*The most recent PASI assessment must be no more than 1 month old at the time of application.*

*It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.*

*Patients may qualify for PBS-subsidised treatment under this restriction once only.*



| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

### **Public and private hospital authority required**

#### ***Continuing treatment (Whole body)***

***Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:***

- (a) who have a documented history of severe chronic plaque psoriasis; and***
- (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with infliximab; and***
- (c) who have demonstrated an adequate response to their most recent course of treatment with infliximab.***

***An adequate response to treatment is defined as:***

***A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.***

***This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with infliximab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.***

***Applications for authorisation must be made in writing and must include:***

- (a) a completed authority prescription form; and***
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:***
  - (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.***

***Approval will be based on the PASI assessment of response to the most recent course of treatment with infliximab.***

***A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.***

***At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised.***

***Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.***

***A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.***

***It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.***

***Patients who fail to demonstrate a response to treatment with each of the biological agents, efalizumab, etanercept and infliximab, are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.***

continued ➡

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

**Public and private hospital authority required**

*Initial treatment [Initial 1, Face, hand, foot (New patients — No prior biological agent)]*

*Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:*

- (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and*
- (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and*
- (c) have signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and*
- (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:*
  - (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or*
  - (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or*
  - (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or*
  - (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks.*

*If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.*

*If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)).*

*The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:*

- (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:*
  - (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or*
  - (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.*
- (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.*
- (c) The most recent PASI assessment must be no more than 1 month old at the time of application.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))];*
  - and*
  - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and*
  - (iii) the signed patient acknowledgement.*

*A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.*

*At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.*

*A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.*

*The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.*

#### **Public and private hospital authority required**

*Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]*

*Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:*

- (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and*
- (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and*
- (c) have not failed PBS-subsidised therapy with infliximab for the treatment of this condition in the current Treatment Cycle.*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))];*
  - (ii) details of prior biological treatment, including dosage, date and duration of treatment.*

*Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to re-commence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.*

*A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.*

*At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised.*

*Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.*

*The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.*

*Patients who fail to demonstrate a response to treatment with each of the biological agents, efalizumab, etanercept and infliximab, are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.*

#### **Public and private hospital authority required**

*Initial treatment [Initial 3, Face, hand, foot (Grandfather patients)]*

*Initial PBS-subsidised supply for continuing treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:*

- (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot and were receiving treatment with infliximab prior to 7 March 2007; and*
- (b) whose disease, prior to treatment with infliximab, was of a severity as defined in the initiation criterion included in the initial treatment restriction (Initial 1, New patients — face, hand, foot); and*
- (c) who have signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and*
- (d) who have demonstrated a response as specified in the criterion included in the restriction for continuing PBS-subsidised treatment with infliximab (face, hand, foot).*

*Applications for authorisation must be made in writing and must include:*

- (a) a completed authority prescription form; and*
- (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*
  - (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition at baseline (prior to initiation of infliximab therapy) and the most recent PASI assessment [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))]; and*
  - (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and*
  - (iii) the signed patient acknowledgement.*

*A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.*

*At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised.*

*Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 24 weeks.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*A PASI assessment of the patient's response to this initial PBS-subsidised course of therapy must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.*

*The most recent PASI assessment must be no more than 1 month old at the time of application.*

*It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.*

*The PASI assessment must be performed on the same affected area as assessed at baseline or prior to initiation of infliximab treatment.*

*Patients may qualify for PBS-subsidised treatment under this restriction once only.*

#### **Public and private hospital authority required**

*Continuing treatment (Face, hand, foot)*

*Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:*

*(a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and*

*(b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with infliximab; and*

*(c) who have demonstrated an adequate response to treatment with infliximab.*

*An adequate response to infliximab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:*

*(i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or*

*(ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.*

*This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course. If the application is the first application for continuing treatment with infliximab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.*

*Applications for authorisation must be made in writing and must include:*

*(a) a completed authority prescription form; and*

*(b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes the following:*

*(i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].*

*A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.*

*At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Up to a maximum of 2 repeats will be authorised.*

*Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.*

| Code  | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
|       | <p><i>A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800 700 270 to discuss.</i></p> <p><i>It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.</i></p> <p><i>The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline. Patients who fail to demonstrate a response to treatment with each of the biological agents, efalizumab, etanercept and infliximab, are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.</i></p> |           |                          |                                   |    |
| 9617E | Powder for I.V. infusion 100 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1         | 751.70                   | Remicade                          | SH |

#### INTERFERON ALFA-2a

##### **CAUTION:**

*Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.*

##### **Private hospital authority required**

*Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase;*

*Patients with chronic hepatitis B who satisfy all of the following criteria:*

- (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);*
- (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or*
- (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;*
- (3) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L);*
- (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.*

|       |                                                                   |   |       |           |    |
|-------|-------------------------------------------------------------------|---|-------|-----------|----|
| 6210W | Injection 3,000,000 i.u. in 0.5 mL single dose pre-filled syringe | 1 | 29.80 | Roferon-A | RO |
| 6211X | Injection 4,500,000 i.u. in 0.5 mL single dose pre-filled syringe | 1 | 44.70 | Roferon-A | RO |
| 6212Y | Injection 6,000,000 i.u. in 0.5 mL single dose pre-filled syringe | 1 | 59.58 | Roferon-A | RO |
| 6213B | Injection 9,000,000 i.u. in 0.5 mL single dose pre-filled syringe | 1 | 89.38 | Roferon-A | RO |

#### INTERFERON ALFA-2b

##### **CAUTION:**

*Treatment with interferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.*

##### **Private hospital authority required**

*Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement;*

*Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase;*

continued ➞

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Item and Section 100 Restriction                                          | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| <p><b>Patients with chronic hepatitis B who satisfy all of the following criteria:</b><br/> <b>(1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);</b><br/> <b>(2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or</b><br/> <b>(b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;</b><br/> <b>(3) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L);</b><br/> <b>(4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.</b></p>                                                                                                                                     |                                                                           |           |                          |                                   |    |
| 6246R                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Solution for injection 10,000,000 i.u. in 1 mL single dose vial           | 5         | 496.50                   | Intron A                          | SH |
| 6253D                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Solution for injection 18,000,000 i.u. in 1.2 mL multi-dose injection pen | 1         | 178.74                   | Intron A Redipen                  | SH |
| 6218G                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Solution for injection 18,000,000 i.u. in 3 mL single dose vial           | 1         | 178.74                   | Intron A                          | SH |
| 6219H                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Solution for injection 25,000,000 i.u. in 2.5 mL single dose vial         | 1         | 248.25                   | Intron A                          | SH |
| 6254E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Solution for injection 30,000,000 i.u. in 1.2 mL multi-dose injection pen | 1         | 297.90                   | Intron A Redipen                  | SH |
| 6255F                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Solution for injection 60,000,000 i.u. in 1.2 mL multi-dose injection pen | 1         | 595.80                   | Intron A Redipen                  | SH |
| <b>INTERFERON GAMMA-1b</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                           |           |                          |                                   |    |
| <p><b><u>Private hospital authority required</u></b><br/> <b>Treatment of chronic granulomatous disease in patients with frequent and severe infections despite adequate prophylaxis with antimicrobial agents.</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                           |           |                          |                                   |    |
| 6148N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Injection 2,000,000 i.u. in 0.5 mL                                        | 6         | 1260.09                  | Imukin                            | BY |
| <b>LAMIVUDINE</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                           |           |                          |                                   |    |
| <p><b><u>Private hospital authority required</u></b><br/> <b>Patients with chronic hepatitis B who satisfy all of the following criteria:</b><br/> <b>(1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);</b><br/> <b>(2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or</b><br/> <b>(b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;</b><br/> <b>(3) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.</b><br/> <b>Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</b></p> |                                                                           |           |                          |                                   |    |
| 6257H                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Tablet 100 mg                                                             | 28        | 149.36                   | Zeffix                            | GK |
| <p><b><u>Private hospital authority required</u></b><br/> <b>Treatment of HIV infection in patients with:</b><br/> <b>(a) CD4 cell counts of less than 500 per cubic millimetre; or</b><br/> <b>(b) viral load of greater than 10,000 copies per mL.</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                           |           |                          |                                   |    |
| 6193Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Tablet 150 mg                                                             | 60        | 282.00                   | 3TC                               | GK |
| 6435Q                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Tablet 300 mg                                                             | 30        | 282.00                   | 3TC                               | GK |

continued 

| Code  | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                     | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| <hr/> |                                                                                                                                                                                                                                                                                                                                      |           |                          |                                   |    |
|       | <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                                                                                    |           |                          |                                   |    |
|       | <i>Patients with chronic hepatitis B who satisfy all of the following criteria:</i>                                                                                                                                                                                                                                                  |           |                          |                                   |    |
|       | <i>(1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);</i>                                                                                                                                                              |           |                          |                                   |    |
|       | <i>(2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or</i>                                                                                                                                                                                                                             |           |                          |                                   |    |
|       | <i>(b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;</i>                                                                                                                                                                                                                                     |           |                          |                                   |    |
|       | <i>(3) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.</i>                                                                                                                                                                                              |           |                          |                                   |    |
|       | <i>Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</i>                                                                  |           |                          |                                   |    |
| 6271C | Oral solution 5 mg per mL, 240 mL                                                                                                                                                                                                                                                                                                    | 1         | 64.01                    | Zeffix                            | GK |
| <hr/> |                                                                                                                                                                                                                                                                                                                                      |           |                          |                                   |    |
|       | <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                                                                                    |           |                          |                                   |    |
|       | <i>Treatment of HIV infection in patients with:</i>                                                                                                                                                                                                                                                                                  |           |                          |                                   |    |
|       | <i>(a) CD4 cell counts of less than 500 per cubic millimetre; or</i>                                                                                                                                                                                                                                                                 |           |                          |                                   |    |
|       | <i>(b) viral load of greater than 10,000 copies per mL.</i>                                                                                                                                                                                                                                                                          |           |                          |                                   |    |
| 6194B | Oral solution 10 mg per mL, 240 mL                                                                                                                                                                                                                                                                                                   | 1         | 86.48                    | 3TC                               | GK |
|       | <b>LAMIVUDINE with ZIDOVUDINE</b>                                                                                                                                                                                                                                                                                                    |           |                          |                                   |    |
|       | <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                                                                                    |           |                          |                                   |    |
|       | <i>Treatment of HIV infection in patients with:</i>                                                                                                                                                                                                                                                                                  |           |                          |                                   |    |
|       | <i>(a) CD4 cell counts of less than 500 per cubic millimetre; or</i>                                                                                                                                                                                                                                                                 |           |                          |                                   |    |
|       | <i>(b) viral load of greater than 10,000 copies per mL.</i>                                                                                                                                                                                                                                                                          |           |                          |                                   |    |
| 6234D | Tablet 150 mg-300 mg                                                                                                                                                                                                                                                                                                                 | 60        | 578.60                   | Combivir                          | GK |
|       | <b>LANREOTIDE ACETATE</b>                                                                                                                                                                                                                                                                                                            |           |                          |                                   |    |
|       | <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                                                                                    |           |                          |                                   |    |
|       | <i>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND</i>                                                                                                                                                                                           |           |                          |                                   |    |
|       | <i>(a) after failure of other therapy including dopamine agonists; or</i>                                                                                                                                                                                                                                                            |           |                          |                                   |    |
|       | <i>(b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or</i>                                                                                                                                                                                                 |           |                          |                                   |    |
|       | <i>(c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.</i>                                                                                                                                                                                                                    |           |                          |                                   |    |
|       | <i>In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (6 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.</i> |           |                          |                                   |    |
|       | <i>Treatment must cease if IGF1 is not lower after 3 months treatment.</i>                                                                                                                                                                                                                                                           |           |                          |                                   |    |
| 6332G | Powder for suspension for injection 30 mg (base) with diluent ampoule                                                                                                                                                                                                                                                                | 1         | 750.00                   | Somatuline LA                     | IS |

continued ➞



| Code                                                                                                                                                                                                                                                                                                                                                                 | Item and Section 100 Restriction                          | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                                                                                                                    |                                                           |           |                          |                                   |    |
| <i>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND</i>                                                                                                                                                                                                                           |                                                           |           |                          |                                   |    |
| <i>(a) after failure of other therapy including dopamine agonists; or</i>                                                                                                                                                                                                                                                                                            |                                                           |           |                          |                                   |    |
| <i>(b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or</i>                                                                                                                                                                                                                                 |                                                           |           |                          |                                   |    |
| <i>(c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.</i>                                                                                                                                                                                                                                                    |                                                           |           |                          |                                   |    |
| <i>In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.</i>                                 |                                                           |           |                          |                                   |    |
| <i>Treatment must cease if IGF1 is not lower after 3 months treatment;</i>                                                                                                                                                                                                                                                                                           |                                                           |           |                          |                                   |    |
| <i>Functional carcinoid tumour causing intractable symptoms. The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.</i> |                                                           |           |                          |                                   |    |
| <i>Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120 mg every 28 days. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.</i>         |                                                           |           |                          |                                   |    |
| 6423C                                                                                                                                                                                                                                                                                                                                                                | Injection 60 mg (base) in single dose pre-filled syringe  | 1         | 1345.00                  | Somatuline Autogel                | IS |
| 6424D                                                                                                                                                                                                                                                                                                                                                                | Injection 90 mg (base) in single dose pre-filled syringe  | 1         | 1790.00                  | Somatuline Autogel                | IS |
| 6425E                                                                                                                                                                                                                                                                                                                                                                | Injection 120 mg (base) in single dose pre-filled syringe | 1         | 2240.00                  | Somatuline Autogel                | IS |

**LENOGRASTIM****Private hospital authority required**

*Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for reinfusion into patients with non-myeloid malignancies who have had myeloablative or myelosuppressive therapy;*

*Mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic transplantation to facilitate harvest of such cells in healthy donors;*

*Patients with non-myeloid malignancies receiving marrow-ablative chemotherapy and subsequent peripheral blood progenitor cell or bone marrow transplantation;*

*Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in:*

- (a) acute lymphoblastic leukaemia; or*
- (b) Ewing's sarcoma; or*
- (c) germ cell tumours; or*
- (d) infants and children with CNS tumours; or*
- (e) neuroblastoma; or*
- (f) non-Hodgkin's lymphoma (intermediate or high grade); or*
- (g) osteosarcoma; or*
- (h) relapsed Hodgkin's disease; or*
- (i) rhabdomyosarcoma;*

*Patients with breast cancer receiving standard dose adjuvant chemotherapy who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;*

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Item and Section 100 Restriction                      | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| <i>Patients receiving first-line chemotherapy for Hodgkin's disease who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned.</i> |                                                       |           |                          |                                   |    |
| 6337M                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Powder for injection 13,400,000 i.u. (105 micrograms) | 10        | 512.50                   | Granocyte 13                      | HH |
| 6338N                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Powder for injection 33,600,000 i.u. (263 micrograms) | 10        | 1283.60                  | Granocyte 34                      | HH |
| <b>LOPINAVIR with RITONAVIR</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                       |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                       |           |                          |                                   |    |
| <i>Treatment, in combination with 2 or more other antiretroviral drugs, of HIV infection in patients with:</i>                                                                                                                                                                                                                                                                                                                                                                      |                                                       |           |                          |                                   |    |
| <i>(a) CD4 cell counts of less than 500 per cubic millimetre; or</i>                                                                                                                                                                                                                                                                                                                                                                                                                |                                                       |           |                          |                                   |    |
| <i>(b) viral load of greater than 10,000 copies per mL.</i>                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                       |           |                          |                                   |    |
| 6495W                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Tablet 200 mg-50 mg                                   | 120       | 685.00                   | Kaletra                           | AB |
| 6341R                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Oral liquid 400 mg-100 mg per 5 mL, 60 mL             | 1         | 129.00                   | Kaletra                           | AB |
| <b>MYCOPHENOLATE MOFETIL</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                       |           |                          |                                   |    |
| <b><u>CAUTION:</u></b>                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                       |           |                          |                                   |    |
| <i>Careful monitoring of patients is mandatory.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                       |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                       |           |                          |                                   |    |
| <i>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for:</i>                                                                                                                                                                                                                                                                                                                                                      |                                                       |           |                          |                                   |    |
| <i>(a) prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required; or</i>                                                                                                                                                                                                                                                                                                                                            |                                                       |           |                          |                                   |    |
| <i>(b) prophylaxis of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required.</i>                                                                                                                                                                                                                                                                                                                                             |                                                       |           |                          |                                   |    |
| 6208R                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Capsule 250 mg                                        | 300       | 555.70                   | CellCept                          | RO |
| 6209T                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Tablet 500 mg                                         | 150       | 555.70                   | CellCept                          | RO |
| 6364Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Powder for oral suspension 1 g per 5 mL, 165 mL       | 1         | 244.51                   | CellCept                          | RO |
| <b>MYCOPHENOLATE SODIUM</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                       |           |                          |                                   |    |
| <b><u>CAUTION:</u></b>                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                       |           |                          |                                   |    |
| <i>Careful monitoring of patients is mandatory.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                       |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                       |           |                          |                                   |    |
| <i>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required.</i>                                                                                                                                                                                                                            |                                                       |           |                          |                                   |    |
| 6369F                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Tablet (enteric coated) 180 mg (mycophenolic acid)    | 120       | 222.28                   | Myfortic                          | NV |
| 6370G                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Tablet (enteric coated) 360 mg (mycophenolic acid)    | 120       | 444.56                   | Myfortic                          | NV |

| Code                                                                                                                                                                                                                                                                                                                                                                                   | Item and Section 100 Restriction                       | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| <b>NATALIZUMAB</b>                                                                                                                                                                                                                                                                                                                                                                     |                                                        |           |                          |                                   |    |
| <b>CAUTION:</b>                                                                                                                                                                                                                                                                                                                                                                        |                                                        |           |                          |                                   |    |
| <i>Progressive multifocal leukoencephalopathy (PML) has been reported with this drug.</i>                                                                                                                                                                                                                                                                                              |                                                        |           |                          |                                   |    |
| <b>Private hospital authority required</b>                                                                                                                                                                                                                                                                                                                                             |                                                        |           |                          |                                   |    |
| <i>Initial treatment, as monotherapy, by neurologists, of clinically definite relapsing-remitting multiple sclerosis in an ambulatory (without assistance or support) patient 18 years of age or older, who has experienced at least 2 documented attacks of neurological dysfunction, believed to be due to multiple sclerosis, in the preceding 2 years.</i>                         |                                                        |           |                          |                                   |    |
| <i>The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient.</i> |                                                        |           |                          |                                   |    |
| <i>A maximum quantity of 6 infusions will be issued with the initial authority.</i>                                                                                                                                                                                                                                                                                                    |                                                        |           |                          |                                   |    |
| <b>Private hospital authority required</b>                                                                                                                                                                                                                                                                                                                                             |                                                        |           |                          |                                   |    |
| <i>Continuing treatment, as monotherapy, of clinically definite relapsing-remitting multiple sclerosis in a patient previously issued with an authority prescription for this drug who does not show continuing progression of disability while on treatment with this drug, and who has demonstrated compliance with, and an ability to tolerate, this therapy.</i>                   |                                                        |           |                          |                                   |    |
| <i>A maximum quantity of 3 infusions will be issued with the continuing authority.</i>                                                                                                                                                                                                                                                                                                 |                                                        |           |                          |                                   |    |
| 9624M                                                                                                                                                                                                                                                                                                                                                                                  | Solution concentrate for I.V. infusion 300 mg in 15 mL | 1         | 2038.46                  | Tysabri                           | BD |
| <b>NELFINAVIR MESYLATE</b>                                                                                                                                                                                                                                                                                                                                                             |                                                        |           |                          |                                   |    |
| <b>Private hospital authority required</b>                                                                                                                                                                                                                                                                                                                                             |                                                        |           |                          |                                   |    |
| <i>Treatment of HIV infection in patients with:</i>                                                                                                                                                                                                                                                                                                                                    |                                                        |           |                          |                                   |    |
| <i>(a) CD4 cell counts of less than 500 per cubic millimetre; or</i>                                                                                                                                                                                                                                                                                                                   |                                                        |           |                          |                                   |    |
| <i>(b) viral load of greater than 10,000 copies per mL.</i>                                                                                                                                                                                                                                                                                                                            |                                                        |           |                          |                                   |    |
| 6331F                                                                                                                                                                                                                                                                                                                                                                                  | Tablet 250 mg (base)                                   | 300       | 505.56                   | Viracept                          | RO |
| <b>NEVIRAPINE</b>                                                                                                                                                                                                                                                                                                                                                                      |                                                        |           |                          |                                   |    |
| <b>Private hospital authority required</b>                                                                                                                                                                                                                                                                                                                                             |                                                        |           |                          |                                   |    |
| <i>Treatment of HIV infection in patients with:</i>                                                                                                                                                                                                                                                                                                                                    |                                                        |           |                          |                                   |    |
| <i>(a) CD4 cell counts of less than 500 per cubic millimetre; or</i>                                                                                                                                                                                                                                                                                                                   |                                                        |           |                          |                                   |    |
| <i>(b) viral load of greater than 10,000 copies per mL.</i>                                                                                                                                                                                                                                                                                                                            |                                                        |           |                          |                                   |    |
| 6215D                                                                                                                                                                                                                                                                                                                                                                                  | Tablet 200 mg                                          | 60        | 271.58                   | Viramune                          | BY |
| <b>OCTREOTIDE ACETATE</b>                                                                                                                                                                                                                                                                                                                                                              |                                                        |           |                          |                                   |    |
| <b>Private hospital authority required</b>                                                                                                                                                                                                                                                                                                                                             |                                                        |           |                          |                                   |    |
| <i>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre AND</i>                                                                                                                                                                                                                                             |                                                        |           |                          |                                   |    |
| <i>(a) after failure of other therapy including dopamine agonists; or</i>                                                                                                                                                                                                                                                                                                              |                                                        |           |                          |                                   |    |
| <i>(b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or</i>                                                                                                                                                                                                                                                   |                                                        |           |                          |                                   |    |
| <i>(c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.</i>                                                                                                                                                                                                                                                                      |                                                        |           |                          |                                   |    |
| <i>In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks. Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.</i>                                                                                 |                                                        |           |                          |                                   |    |
| <i>Treatment must cease if IGF1 is not lower after 3 months treatment at a dose of 100 micrograms 3 times daily;</i>                                                                                                                                                                                                                                                                   |                                                        |           |                          |                                   |    |

continued ➡

| Code  | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer                |    |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|--------------------------------------------------|----|
|       | <p><i>Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) causing intractable symptoms. The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.</i></p> <p><i>Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months' therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.</i></p> |           |                          |                                                  |    |
| 6227R | Injection 50 micrograms (base) in 1 mL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 5         | 35.81                    | <sup>a</sup> Sandostatin 0.05<br><sup>a</sup> HH | NV |
| 6228T | Injection 100 micrograms (base) in 1 mL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 5         | 71.60                    | <sup>a</sup> Sandostatin 0.1<br><sup>a</sup> HH  | NV |
| 6229W | Injection 500 micrograms (base) in 1 mL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 5         | 358.41                   | <sup>a</sup> Sandostatin 0.5<br><sup>a</sup> HH  | NV |

**Private hospital authority required**

*Acromegaly in a patient controlled on Sandostatin subcutaneous injections.*

*In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.*

*Treatment must cease if IGF1 is not lower after 3 months of treatment;*

*Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) with symptom control on Sandostatin subcutaneous injections.*

*Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with Sandostatin subcutaneous injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.*

|       |                                                                    |   |         |                 |    |
|-------|--------------------------------------------------------------------|---|---------|-----------------|----|
| 6426F | Injection (modified release) 10 mg (base) vial and diluent syringe | 1 | 1362.20 | Sandostatin LAR | NV |
| 6427G | Injection (modified release) 20 mg (base) vial and diluent syringe | 1 | 1813.00 | Sandostatin LAR | NV |
| 6428H | Injection (modified release) 30 mg (base) vial and diluent syringe | 1 | 2268.70 | Sandostatin LAR | NV |

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |  |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|

**PEGFILGRASTIM****Private hospital authority required**

*For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia;*

*A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;*

*A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned;*

*A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned.*

**Private hospital authority required**

*A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in:*

- (a) acute lymphoblastic leukaemia; or*
- (b) breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide); or*
- (c) germ cell tumours; or*
- (d) infants and children with CNS tumours; or*
- (e) neuroblastoma; or*
- (f) non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen); or*
- (g) relapsed Hodgkin disease; or*
- (h) sarcoma.*

|       |                                                        |   |         |          |    |
|-------|--------------------------------------------------------|---|---------|----------|----|
| 6363X | Injection 6 mg in 0.6 mL single use pre-filled syringe | 1 | 1925.00 | Neulasta | AN |
|-------|--------------------------------------------------------|---|---------|----------|----|

**PEGINTERFERON ALFA-2a****CAUTION:**

*Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.*

**Private hospital authority required**

*Monotherapy in patients with chronic hepatitis B and compensated liver disease who satisfy all of the following criteria:*

- (1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);*
- (2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or*
- (b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;*
- (3) Have received no prior peginterferon alfa therapy for the treatment of hepatitis B;*
- (4) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception;*
- (5) Are not persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L).*

*Treatment is limited to 1 course of treatment for a duration of up to 48 weeks;*

continued ➞

| Code  | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
|       | <p><i>Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:</i></p> <p><i>(1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);</i></p> <p><i>(2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.</i></p> <p><i>The treatment course is limited to up to 48 weeks.</i></p> <p><i>Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop.</i></p> <p><b>NOTE:</b></p> <p><i>Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:</i></p> <p><i>(a) a nurse educator/counsellor for patients; and</i></p> <p><i>(b) 24 hour access by patients to medical advice; and</i></p> <p><i>(c) an established liver clinic; and</i></p> <p><i>(d) facilities for safe liver biopsy.</i></p>                                                                                                                                                                                                                                                                                                                                                                                         |           |                          |                                   |    |
| 6439X | Injection 135 micrograms in 0.5 mL single use pre-filled syringe                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 4         | 1165.90                  | Pegasys                           | RO |
| 6449K | Injection 180 micrograms in 0.5 mL single use pre-filled syringe                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 4         | 1350.23                  | Pegasys                           | RO |
|       | <p><b>PEGINTERFERON ALFA-2b</b></p> <p><b>CAUTION:</b></p> <p><i>Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.</i></p> <p><b>Private hospital authority required</b></p> <p><i>Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:</i></p> <p><i>(1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);</i></p> <p><i>(2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.</i></p> <p><i>The treatment course is limited to up to 48 weeks.</i></p> <p><i>Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop.</i></p> <p><b>NOTE:</b></p> <p><i>Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:</i></p> <p><i>(a) a nurse educator/counsellor for patients; and</i></p> <p><i>(b) 24 hour access by patients to medical advice; and</i></p> <p><i>(c) an established liver clinic; and</i></p> <p><i>(d) facilities for safe liver biopsy.</i></p> |           |                          |                                   |    |
| 6411K | Powder for injection 50 micrograms with diluent in single use injection pen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 4         | 920.00                   | PEG-Intron Redipen                | SH |
| 6412L | Powder for injection 80 micrograms with diluent in single use injection pen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 4         | 1472.00                  | PEG-Intron Redipen                | SH |
| 6413M | Powder for injection 100 micrograms with diluent in single use injection pen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 4         | 1840.00                  | PEG-Intron Redipen                | SH |

continued ➞

| Code  | Item and Section 100 Restriction                                             | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------|------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| 6414N | Powder for injection 120 micrograms with diluent in single use injection pen | 4         | 2208.00                  | PEG-Intron Redipen                | SH |
| 6415P | Powder for injection 150 micrograms with diluent in single use injection pen | 4         | 2760.00                  | PEG-Intron Redipen                | SH |

#### RALTEGRAVIR POTASSIUM

##### Private hospital authority required

*Treatment, in combination with other antiretroviral agents, of HIV infection in an antiretroviral experienced patient with:*

- (a) evidence of HIV replication (viral load greater than 10,000 copies per mL); and/or*
- (b) CD4 cell counts of less than 500 per cubic millimetre.*

*A patient must have failed previous treatment with, or have resistance to, 3 different antiretroviral regimens which have included:*

- (i) at least 1 non-nucleoside reverse transcriptase inhibitor; and*
- (ii) at least 1 nucleoside reverse transcriptase inhibitor; and*
- (iii) at least 1 protease inhibitor.*

|       |                      |    |         |           |    |
|-------|----------------------|----|---------|-----------|----|
| 9629T | Tablet 400 mg (base) | 60 | 1146.90 | Isentress | MK |
|-------|----------------------|----|---------|-----------|----|

#### RIBAVIRIN and PEGINTERFERON ALFA-2a

##### CAUTION:

*Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.*

##### CAUTION:

*Ribavirin is a category X drug and must not be given to pregnant women. Pregnancy in female patients or in the partners of male patients must be avoided during treatment and during the 6 months period after cessation of treatment.*

##### Private hospital authority required

*Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:*

- (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);*
- (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.*

*For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.*

*Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).*

*Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12.*

continued ➡

| Code                                                                                                                                                                    | Item and Section 100 Restriction                                                                                         | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------|--------------------------------|-----------------------------------------|----|
| <b>NOTE:</b>                                                                                                                                                            |                                                                                                                          |              |                                |                                         |    |
| <i>Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:</i> |                                                                                                                          |              |                                |                                         |    |
| <i>(a) a nurse educator/counsellor for patients; and</i>                                                                                                                |                                                                                                                          |              |                                |                                         |    |
| <i>(b) 24 hour access by patients to medical advice; and</i>                                                                                                            |                                                                                                                          |              |                                |                                         |    |
| <i>(c) an established liver clinic; and</i>                                                                                                                             |                                                                                                                          |              |                                |                                         |    |
| <i>(d) facilities for safe liver biopsy.</i>                                                                                                                            |                                                                                                                          |              |                                |                                         |    |
| 6389G                                                                                                                                                                   | Pack containing 84 tablets ribavirin 200 mg and 4 pre-filled syringes<br>peginterferon alfa-2a injection 135 micrograms  | ± 1          | 1295.60                        | Pegasys RBV                             | RO |
| 6390H                                                                                                                                                                   | Pack containing 112 tablets ribavirin 200 mg and 4 pre-filled syringes<br>peginterferon alfa-2a injection 135 micrograms | ± 1          | 1375.88                        | Pegasys RBV                             | RO |
| 6391J                                                                                                                                                                   | Pack containing 140 tablets ribavirin 200 mg and 4 pre-filled syringes<br>peginterferon alfa-2a injection 135 micrograms | ± 1          | 1456.14                        | Pegasys RBV                             | RO |
| 6392K                                                                                                                                                                   | Pack containing 168 tablets ribavirin 200 mg and 4 pre-filled syringes<br>peginterferon alfa-2a injection 135 micrograms | ± 1          | 1536.42                        | Pegasys RBV                             | RO |
| 6393L                                                                                                                                                                   | Pack containing 84 tablets ribavirin 200 mg and 4 pre-filled syringes<br>peginterferon alfa-2a injection 180 micrograms  | ± 1          | 1462.37                        | Pegasys RBV                             | RO |
| 6394M                                                                                                                                                                   | Pack containing 112 tablets ribavirin 200 mg and 4 pre-filled syringes<br>peginterferon alfa-2a injection 180 micrograms | ± 1          | 1542.64                        | Pegasys RBV                             | RO |
| 6395N                                                                                                                                                                   | Pack containing 140 tablets ribavirin 200 mg and 4 pre-filled syringes<br>peginterferon alfa-2a injection 180 micrograms | ± 1          | 1622.91                        | Pegasys RBV                             | RO |
| 6396P                                                                                                                                                                   | Pack containing 168 tablets ribavirin 200 mg and 4 pre-filled syringes<br>peginterferon alfa-2a injection 180 micrograms | ± 1          | 1703.18                        | Pegasys RBV                             | RO |



| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Item and Section 100 Restriction                                                                                                                               | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| <b>RIBAVIRIN and PEGINTERFERON ALFA-2b</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                |           |                          |                                   |    |
| <b>CAUTION:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                |           |                          |                                   |    |
| <i>Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.</i>                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                |           |                          |                                   |    |
| <b>CAUTION:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                |           |                          |                                   |    |
| <i>Ribavirin is a category X drug and must not be given to pregnant women. Pregnancy in female patients or in the partners of male patients must be avoided during treatment and during the 6 months period after cessation of treatment.</i>                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                |           |                          |                                   |    |
| <b>Private hospital authority required</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                |           |                          |                                   |    |
| <i>Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:</i>                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                |           |                          |                                   |    |
| <i>(1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                |           |                          |                                   |    |
| <i>(2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.</i>                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                |           |                          |                                   |    |
| <i>For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.</i>                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                |           |                          |                                   |    |
| <i>Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop.</i>                                                                                                                                                                                                                                                                                     |                                                                                                                                                                |           |                          |                                   |    |
| <i>(An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                |           |                          |                                   |    |
| <i>Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12.</i> |                                                                                                                                                                |           |                          |                                   |    |
| <b>NOTE:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                |           |                          |                                   |    |
| <i>Treatment centres are required to have access to the following appropriate specialist facilities for the provision of clinical support services for hepatitis C:</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                |           |                          |                                   |    |
| <i>(a) a nurse educator/counsellor for patients; and</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                |           |                          |                                   |    |
| <i>(b) 24 hour access by patients to medical advice; and</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                |           |                          |                                   |    |
| <i>(c) an established liver clinic; and</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                |           |                          |                                   |    |
| <i>(d) facilities for safe liver biopsy.</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                |           |                          |                                   |    |
| 6399T                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Pack containing 84 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 50 micrograms with diluent  | ± 1       | 917.38                   | Pegatron                          | SH |
| 6400W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Pack containing 112 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 50 micrograms with diluent | ± 1       | 1059.87                  | Pegatron                          | SH |
| 6401X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Pack containing 84 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 80 micrograms with diluent  | ± 1       | 1211.36                  | Pegatron                          | SH |
| 6402Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Pack containing 140 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 80 micrograms with diluent | ± 1       | 1353.83                  | Pegatron                          | SH |

continued ➞

| Code  | Item and Section 100 Restriction                                                                                                                                | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| 6403B | Pack containing 168 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 80 micrograms with diluent  | ‡ 1       | 1353.83                  | Pegatron                          | SH |
| 6404C | Pack containing 84 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 100 micrograms with diluent  | ‡ 1       | 1407.33                  | Pegatron                          | SH |
| 6405D | Pack containing 112 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 100 micrograms with diluent | ‡ 1       | 1549.81                  | Pegatron                          | SH |
| 6406E | Pack containing 84 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 120 micrograms with diluent  | ‡ 1       | 1603.31                  | Pegatron                          | SH |
| 6407F | Pack containing 140 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 120 micrograms with diluent | ‡ 1       | 1745.79                  | Pegatron                          | SH |
| 6408G | Pack containing 84 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 150 micrograms with diluent  | ‡ 1       | 1897.28                  | Pegatron                          | SH |
| 6409H | Pack containing 140 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 150 micrograms with diluent | ‡ 1       | 2039.76                  | Pegatron                          | SH |
| 6410J | Pack containing 168 capsules ribavirin 200 mg and 4 single use injection pens containing peginterferon alfa-2b powder for injection 150 micrograms with diluent | ‡ 1       | 2039.76                  | Pegatron                          | SH |

**RIFABUTIN****Private hospital authority required**

*Treatment of Mycobacterium avium complex infections in HIV-positive patients;*

*Prophylaxis against Mycobacterium avium complex infections in HIV-positive patients with CD4 cell counts of less than 75 per cubic millimetre.*

|       |                |    |        |           |    |
|-------|----------------|----|--------|-----------|----|
| 6195C | Capsule 150 mg | 30 | 147.00 | Mycobutin | PH |
|-------|----------------|----|--------|-----------|----|

**RITONAVIR****Private hospital authority required**

*Treatment of HIV infection in patients with:*

*(a) CD4 cell counts of less than 500 per cubic millimetre; or*

*(b) viral load of greater than 10,000 copies per mL.*

|       |                                                       |    |        |        |    |
|-------|-------------------------------------------------------|----|--------|--------|----|
| 6203L | Capsule 100 mg                                        | 84 | 106.17 | Norvir | AB |
| 6494T | Oral solution 600 mg per 7.5 mL (80 mg per mL), 90 mL | 1  | 91.00  | Norvir | AB |

**RITUXIMAB****NOTE:**

*Any queries concerning the arrangements to prescribe rituximab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Written applications for authority to prescribe rituximab should be forwarded to:*

continued ➞

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

**Medicare Australia**

**Prior Written Approval of Specialised Drugs**

**Reply Paid 9826**

**GPO Box 9826**

**HOBART TAS 7001**

*Further prescribing information is on the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).*

**NOTE:**

**TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS**

*The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying anti-rheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, etanercept, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-1 inhibitor (anakinra) and the T-cell co-stimulation modulator (abatacept).*

*Patients are eligible for PBS-subsidised treatment with only 1 of the above biological disease modifying anti-rheumatic drugs at any 1 time.*

*PBS-subsidised infliximab, anakinra, rituximab and abatacept must be used in combination with methotrexate at a dose of at least 7.5 mg weekly. Where a patient cannot tolerate 7.5 mg of methotrexate weekly, they are only eligible to receive PBS-subsidised etanercept and adalimumab.*

*In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.*

*From 1 March 2008, under the PBS, all patients will be able to commence a Treatment Cycle where they may trial PBS-subsidised bDMARD agents without having to experience a disease flare when swapping to an alternate agent. Under these interchangeability arrangements, within a single Treatment Cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.*

*A patient who received PBS-subsidised bDMARD treatment prior to 1 March 2008 is considered to be in their first Cycle as of 1 March 2008.*

*Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.*

*Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next Cycle.*

*For patients who have failed PBS-subsidised treatment with 3 bDMARDs prior to 1 March 2008 please contact Medicare Australia on 1800 700 270.*

*The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent Cycle to the date of the first application for initial treatment with a bDMARD under the new Treatment Cycle.*

*A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of less than 5 years, may commence a further course of treatment within the same Treatment Cycle.*

*A patient who has failed fewer than 3 bDMARDs in a Treatment Cycle and who has a break in therapy of more than 5 years, may commence a new Treatment Cycle.*

*There is no limit to the number of Treatment Cycles a patient may undertake in their lifetime.*

*If patients fail to respond to a particular bDMARD within a single Treatment Cycle, they are not eligible to receive further PBS-subsidised treatment with that drug until they commence the next Cycle.*

*(1) How to prescribe PBS-subsidised bDMARD therapy after 1 March 2008.*

continued ➞

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

**(a) Initial treatment.**

Applications for initial treatment should be made where:

- (i) a patient has received no prior PBS-subsidised bDMARD treatment in this Treatment Cycle and wishes to commence such therapy, excluding rituximab (Initial 1); or
- (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or
- (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 2).

Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for etanercept, adalimumab, anakinra and abatacept, 22 weeks of therapy for infliximab and 2 infusions of rituximab.

From 1 March 2008, a patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to Medicare Australia within 4 weeks.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that an application is submitted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course.

**Rituximab patients:**

A further application may be submitted to Medicare Australia 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.

**(b) Continuing treatment.**

Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.

It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.

Assessments of response to a course of PBS-subsidised therapy must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.

**Rituximab patients:**

A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction.

Where a response assessment is not submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.

**(2) Swapping therapy.**

Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same Treatment Cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.

Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.

A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same Treatment Cycle.

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.*

*To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment approved, within the timeframes specified in the relevant restriction.*

*PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.*

*To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the approved authority prescription or remaining repeats for the bDMARD the patient is ceasing.*

**NOTE:**

**(3) Baseline measurements to determine response.**

*Medicare Australia will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a Treatment Cycle and Medicare Australia will assess response according to these revised baseline measurements.*

*To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be provided for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.*

*The baseline joint and blood counts should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment.*

**(4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.**

*A patient who wishes to trial a second or subsequent Treatment Cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 non-biological DMARD, at an adequate dose, for a minimum of 3 months at the time the ESR and/or CRP levels and the active joint count are measured.*

**(5) Patients 'grandfathered' onto PBS-subsidised treatment with rituximab or abatacept.**

*From 1 March 2008, a patient who commenced treatment with rituximab for severe rheumatoid arthritis prior to 7 March 2007 or abatacept for severe rheumatoid arthritis prior to 1 November 2007 and who was 'grandfathered' on to PBS-subsidised therapy, and who continues to receive treatment in the same Treatment Cycle, will have further applications for treatment with rituximab or abatacept assessed under the continuing treatment restriction.*

*A patient may only qualify for PBS-subsidised treatment under this criterion once. A maximum of 24 weeks of treatment with abatacept will be authorised under this criterion.*

*'Grandfather' arrangements will only apply for the first Treatment Cycle. For the second and subsequent Cycles, a 'grandfather' patient must requalify for initial treatment under the criteria that applies to a new patient. See 'Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' above for further details.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

### **Public and private hospital authority required**

#### ***Initial 2 (change or re-commencement)***

*Application for an initial course of PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of an adult who:*

- (a) has a documented history of severe active rheumatoid arthritis; and*
- (b) has failed to respond to at least 1 PBS-subsidised TNF-alfa antagonist in this Treatment Cycle; and*
- (c) has not previously failed to respond to PBS-subsidised rituximab in the current Treatment Cycle.*

*Applications for patients who have demonstrated a response to PBS-subsidised rituximab treatment within this Treatment Cycle and who wish to re-commence rituximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of a response to the patient's most recent course of PBS-subsidised rituximab treatment has been submitted to Medicare Australia.*

*A patient may qualify to receive a further course of treatment (1 infusion at week 0 and 1 infusion at week 2) every 24 weeks with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction. The demonstration of response must be submitted to Medicare Australia within 4 weeks of assessment.*

*The same indices of disease severity used to establish baseline at the commencement of treatment with each initial application must be used for assessment of all continuing applications.*

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].*

*Patients who fail to demonstrate a response to treatment with rituximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle. Patients may re-trial rituximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this Cycle and the date of the first application under the new Cycle.*

*Patients who fail to demonstrate a response to rituximab treatment and who qualify to trial an alternate bDMARD according to the interchangeability arrangements for bDMARDs for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.*

*Patients who fail to demonstrate a response to treatment with 3 bDMARDs are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new bDMARD Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this Cycle and the date of the first application under the new Cycle.*

### **Public and private hospital authority required**

#### ***Initial 3 ('grandfather' patients)***

*Initial PBS-subsidised supply for continuing treatment with rituximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of an adult who:*

- (a) has a documented history of severe active rheumatoid arthritis; and*
- (b) was receiving treatment with rituximab prior to 7 March 2007; and*
- (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with rituximab.*

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes the signed patient acknowledgement form.*

*The same indices of disease severity used to establish baseline at the commencement of treatment with a bDMARD must be used for assessment of all continuing applications.*

continued ➡

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |  |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|

*Patients who fail to demonstrate a response to treatment with 3 bDMARDs are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new bDMARD Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this Cycle and the date of the first application under the new Cycle.*

*Patients can qualify for PBS-subsidised treatment under this criteria once only.*

#### **Public and private hospital authority required**

##### **Continuing treatment**

*Continuing PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5 mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of an adult:*

- (a) who has a documented history of severe active rheumatoid arthritis; and*
- (b) who has demonstrated an adequate response to treatment with rituximab; and*
- (c) whose most recent course of PBS-subsidised bDMARD treatment in this Treatment Cycle was with rituximab.*

*An adequate response to treatment is defined as:*

*an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;*

*AND either of the following:*

- (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or*
- (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:*
  - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*
  - shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*

*The authority application must be made in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].*

*Patients may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction. The demonstration of response must be submitted to Medicare Australia within 4 weeks of assessment.*

*The same indices of disease severity used to establish baseline at the commencement of treatment with each initial application must be used for assessment of all continuing applications.*

*Patients who fail to demonstrate a response to treatment with 3 bDMARDs are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may re-commence a new bDMARD Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised bDMARD was approved in this Cycle and the date of the first application under the new Cycle.*

|       |                                            |   |         |          |    |
|-------|--------------------------------------------|---|---------|----------|----|
| 9611W | Solution for I.V. infusion 500 mg in 50 mL | 1 | 2263.57 | Mabthera | RO |
|-------|--------------------------------------------|---|---------|----------|----|

#### **SAQUINAVIR MESYLATE**

##### **Private hospital authority required**

*Treatment of HIV infection in patients with:*

- (a) CD4 cell counts of less than 500 per cubic millimetre; or*
- (b) viral load of greater than 10,000 copies per mL.*

|       |                      |     |        |          |    |
|-------|----------------------|-----|--------|----------|----|
| 6498B | Tablet 500 mg (base) | 120 | 505.56 | Invirase | RO |
|-------|----------------------|-----|--------|----------|----|

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |  |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|

**SEVELAMER HYDROCHLORIDE****Private hospital authority required**

*Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products and where:*

- (a) serum phosphate is greater than 1.6 mmol per L; or*
- (b) the serum calcium times phosphate product is greater than 4.0.*

*at the commencement of therapy.*

*Management includes initiation, stabilisation and review of therapy as required.*

|       |               |     |        |         |    |
|-------|---------------|-----|--------|---------|----|
| 9620H | Tablet 800 mg | 180 | 310.00 | Renagel | GZ |
|-------|---------------|-----|--------|---------|----|

**SILDENAFIL CITRATE****NOTE:**

*Any queries concerning the arrangements to prescribe sildenafil citrate may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Written applications for authority to prescribe sildenafil citrate should be forwarded to:*

*Medicare Australia*

*Prior Written Approval of Specialised Drugs*

*Reply Paid 9826*

*GPO Box 9826*

*HOBART TAS 7001*

**NOTE:**

*Sildenafil citrate is not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with scleroderma, where the total lung capacity is less than 70% of that predicted.*

*Sildenafil citrate is not PBS-subsidised when used in combination with PBS-subsidised bosentan monohydrate, PBS-subsidised iloprost trometamol, PBS-subsidised epoprostenol sodium or PBS-subsidised sitaxentan sodium.*

*The following provides some explanatory notes regarding the availability of PBS-subsidised treatment with:*

- (a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, in patients with disease of WHO Functional Class III or IV severity; AND*
- (b) iloprost trometamol, of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND*
- (c) epoprostenol sodium, of primary pulmonary hypertension, in patients with disease of WHO Functional Class III or IV severity; AND*
- (d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND*
- (e) sitaxentan sodium, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.*

**Adult patients:**

*From 1 April 2008, adult patients with primary pulmonary hypertension will be able to access, through the PBS, bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 5 drugs, they may swap between bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

continued ☞



| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Adult patients with pulmonary arterial hypertension secondary to scleroderma will be able to access, through the PBS, bosentan monohydrate, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 4 drugs, they may swap between bosentan monohydrate, iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

*Adult patients with pulmonary arterial hypertension secondary to connective tissue disease other than scleroderma will be able to access, through the PBS, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 3 drugs, they may swap between iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

*Patients with drug-induced pulmonary arterial hypertension are only eligible for treatment with iloprost trometamol. They may not swap to bosentan monohydrate, epoprostenol sodium, sildenafil citrate or sitaxentan sodium.*

*Patients under 18 years of age:*

*From 1 April 2008, patients aged less than 18 years with primary pulmonary hypertension are eligible to receive PBS-subsidised treatment with bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 5 drugs, they may swap between bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

**1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma.**

**Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, are defined as follows:**

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or*
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or*
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.*

**2. Definition of WHO Functional Class III or IV disease severity.**

*(a) WHO Functional Class III disease severity is defined as follows:*

*Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.*

*(b) WHO Functional Class IV disease severity is defined as follows:*

*Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.*

**3. Designated hospitals.**

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Refer to the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au) for a list of designated hospitals.*

**4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.**

**(a) Initiation of treatment.**

*The first written application for PBS-subsidised treatment with the first of either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.*

*Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:*

- (1) RHC plus ECHO composite assessments;*
- (2) RHC composite assessment plus 6MWT;*
- (3) RHC composite assessment only.*

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:*

- (1) ECHO composite assessment plus 6MWT;*
- (2) ECHO composite assessment only.*

*Where fewer than 3 tests are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application.*

**NOTE:**

*Where patients were initiated on PBS-subsidised treatment either with bosentan monohydrate on or after 1 March 2004, with iloprost trometamol on or after 1 April 2005, with epoprostenol sodium on or after 1 August 2006, with sildenafil citrate on or after 1 March 2007, with sitaxentan sodium on or after 1 April 2008, or with bosentan monohydrate (for PAH associated with congenital systemic-to-pulmonary shunt) on or after 1 August 2008, the test results provided with the initial application must be no more than 2 months old at the time of application. These results will form the baseline against which response assessments will be made.*

*Where patients received treatment with either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium prior to being commenced on PBS-subsidised treatment with the first of either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, the test requirements above still apply. The results that will form the baseline against which response assessments will be made will be those measured at the time patients commenced non-PBS-subsidised treatment with either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, whichever of the 5 drugs the patient received first.*

**(b) Continuation of treatment.**

*The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:*

- (1) RHC plus ECHO composite assessments plus 6MWT;*
- (2) RHC plus ECHO composite assessments;*
- (3) RHC composite assessment plus 6MWT;*
- (4) ECHO composite assessment plus 6MWT;*
- (5) RHC composite assessment only;*
- (6) ECHO composite assessment only.*

*The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a reason why the test(s) could not be conducted must be provided with the application.*

*The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.*

| Code | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|
|      | <p><b>5. Definition of response to sildenafil citrate, bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sitaxentan sodium or prior vasodilator treatment.</b></p> <p><i>For adult patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.</i></p> <p><i>For adult patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.</i></p> <p><i>For adult patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.</i></p> <p><i>For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.</i></p> <p><b>6. Authority approval requirements.</b> [The following 2 sections are only relevant to the PBS listing of sildenafil citrate. The requirements specific to bosentan monohydrate, iloprost trometamol, epoprostenol sodium and sitaxentan sodium are given in parts 6 and 7 of the NOTE included in the bosentan monohydrate, iloprost trometamol, epoprostenol sodium and sitaxentan sodium Schedule entry respectively.]</p> <p><i>(a) Initiation of PBS-subsidised treatment with sildenafil citrate, where the patient has not received prior PBS-subsidised treatment with bosentan monohydrate, iloprost trometamol, epoprostenol sodium or sitaxentan sodium.</i></p> <p><i>All applications for initial treatment must be made in writing, must include an authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months.</i></p> <p><i>(b) Continuation of treatment.</i></p> <p><i>Written applications for continuing treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.</i></p> <p><i>Applications for continuing treatment will only be approved for patients who have currently demonstrated a response to treatment with sildenafil citrate.</i></p> <p><i>The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with sildenafil citrate should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.</i></p> <p><i>(c) Swapping between bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate and sitaxentan sodium.</i></p> <p><i>For eligible patients, applications to swap between these 5 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.</i></p> <p><i>It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.</i></p> <p><i>To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.</i></p> <p><i>(d) Cessation of treatment.</i></p> <p><i>Patients who fail to demonstrate a response to PBS-subsidised sildenafil citrate treatment at the times where an assessment is required must cease PBS-subsidised sildenafil citrate therapy.</i></p> <p><b>7. Re-treatment with sildenafil citrate.</b></p> <p><i>Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with sildenafil citrate under any circumstances.</i></p> <p><b>8. Further information.</b></p> <p><i>A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at <a href="http://www.medicareaustralia.gov.au">www.medicareaustralia.gov.au</a>.</i></p> |           |                          |                                   |

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

### **Public and private hospital authority required**

#### *Initial (new patients)*

*Application for initial PBS-subsidised treatment with sildenafil citrate of patients who have not received prior PBS-subsidised treatment with bosentan monohydrate, iloprost trometamol, epoprostenol sodium or sitaxentan sodium and who have been assessed by a physician from a designated hospital to have:*

*(a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, unless a RHC is contraindicated on clinical grounds; OR*

*(b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, unless a RHC is contraindicated on clinical grounds.*

*Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.*

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the test results of the ECHO composite assessment plus 6MWT or the ECHO composite assessment only.*

*Applications for authorisation must be in writing and must include:*

*(1) a completed authority prescription form [see Note for authority approval requirements]; and*

*(2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:*

*(i) RHC composite assessment; and*

*(ii) ECHO composite assessment; and*

*(iii) 6MWT; and*

*(3) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with sildenafil citrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with epoprostenol sodium for primary pulmonary hypertension, OR with iloprost trometamol for primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with bosentan monohydrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, OR with sitaxentan sodium for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].*

*Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.*

*Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested.*

*Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

continued ➞

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

### **Public and private hospital authority required**

#### ***Initial (new patients)***

*Application for initial PBS-subsidised treatment with sildenafil citrate of patients who have not received prior PBS-subsidised treatment with bosentan monohydrate, iloprost trometamol, epoprostenol sodium or sitaxentan sodium and who have been assessed by a physician from a designated hospital to have:*

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, unless a RHC is contraindicated on clinical grounds; OR*
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, unless a RHC is contraindicated on clinical grounds.*

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the test results of the ECHO composite assessment plus 6MWT or the ECHO composite assessment only.*

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form [see Note for authority approval requirements]; and*
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:*
  - (i) RHC composite assessment; and*
  - (ii) ECHO composite assessment; and*
  - (iii) 6MWT; and*
- (3) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with sildenafil citrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with epoprostenol sodium for primary pulmonary hypertension, OR with iloprost trometamol for primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with bosentan monohydrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, OR with sitaxentan sodium for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].*

*Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

### **Public and private hospital authority required**

#### ***Initial (change or re-commencement for all patients)***

*Application for initial PBS-subsidised treatment with sildenafil citrate of patients with either of the following:*

- (a) WHO Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised sildenafil citrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with sildenafil citrate; OR*
- (b) WHO Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with iloprost trometamol; OR*
- (c) WHO Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma and whose most recent course of PBS-subsidised treatment was with bosentan monohydrate; OR*
- (d) WHO Class III primary pulmonary hypertension and whose most recent course of PBS-subsidised treatment was with epoprostenol sodium; OR*
- (e) WHO Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with sitaxentan sodium.*

continued ➞

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|--------------------------|-----------------------------------|----|
| <p><i>Applications for authorisation must be in writing and must include:</i></p> <p>(1) a completed authority prescription form [see Note for authority approval requirements]; and</p> <p>(2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised sildenafil citrate, epoprostenol sodium, iloprost trometamol, bosentan monohydrate or sitaxentan sodium, whichever was initiated first, was granted; and</p> <p>(3) the date of the first application for PBS-subsidised treatment with sildenafil citrate, epoprostenol sodium, iloprost trometamol, bosentan monohydrate or sitaxentan sodium, whichever was initiated first; and</p> <p>(4) the results of the patient's response to treatment with their last course of PBS-subsidised sildenafil citrate, epoprostenol sodium, iloprost trometamol, bosentan monohydrate or sitaxentan sodium.</p> <p>The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</p> <p><b>Public and private hospital authority required</b></p> <p><i>Continuing treatment (all patients)</i></p> <p>Continuing PBS-subsidised treatment with sildenafil citrate of patients who have received approval for initial PBS-subsidised treatment with sildenafil citrate, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of sildenafil citrate treatment [see Note for definition of response].</p> <p><i>Applications for authorisation must be in writing and must include:</i></p> <p>(1) a completed authority prescription form; and</p> <p>(2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:</p> <p>(i) RHC composite assessment; and</p> <p>(ii) ECHO composite assessment; and</p> <p>(iii) 6MWT.</p> <p>Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p> <p>The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</p> |                                  |           |                          |                                   |    |
| 9605M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Tablet 20 mg (base)              | 90        | 898.43                   | Revatio                           | PF |
| <p><b>SIROLIMUS</b></p> <p><b>CAUTION:</b></p> <p>Careful monitoring of patients is mandatory.</p> <p><b>Private hospital authority required</b></p> <p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                  |           |                          |                                   |    |
| 6436R                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Tablet 1 mg                      | 100       | 723.33                   | Rapamune                          | WX |
| 6457W                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Tablet 2 mg                      | 100       | 1446.67                  | Rapamune                          | WX |
| 6437T                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Oral solution 1 mg per mL, 60 mL | 1         | 468.00                   | Rapamune                          | WX |

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

## SITAXENTAN SODIUM

### **CAUTION:**

*Sitaxentan sodium is a category X drug and must not be given to pregnant women. Pregnancy must be excluded before the start of treatment and avoided during treatment with this drug.*

### **NOTE:**

*Any queries concerning the arrangements to prescribe sitaxentan sodium may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

*Written applications for authority to prescribe sitaxentan sodium should be forwarded to:*

*Medicare Australia*

*Prior Written Approval of Specialised Drugs*

*Reply Paid 9826*

*GPO Box 9826*

*HOBART TAS 7001*

### **NOTE:**

*Sitaxentan sodium is not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with scleroderma, where the total lung capacity is less than 70% of that predicted.*

*Sitaxentan sodium is not PBS-subsidised when used in combination with PBS-subsidised bosentan monohydrate, PBS-subsidised iloprost trometamol, PBS-subsidised epoprostenol sodium or PBS-subsidised sildenafil citrate.*

*The following provides some explanatory notes regarding the availability of PBS-subsidised treatment with:*

*(a) bosentan monohydrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, in patients with disease of WHO Functional Class III or IV severity; AND*

*(b) iloprost trometamol, of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III or IV severity; AND*

*(c) epoprostenol sodium, of primary pulmonary hypertension, in patients with disease of WHO Functional Class III or IV severity; AND*

*(d) sildenafil citrate, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity; AND*

*(e) sitaxentan sodium, of primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, in patients with disease of WHO Functional Class III severity.*

### **Adult patients:**

*From 1 April 2008, adult patients with primary pulmonary hypertension will be able to access, through the PBS, bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 5 drugs, they may swap between bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

*Adult patients with pulmonary arterial hypertension secondary to scleroderma will be able to access, through the PBS, bosentan monohydrate, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 4 drugs, they may swap between bosentan monohydrate, iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*Adult patients with pulmonary arterial hypertension secondary to connective tissue disease other than scleroderma will be able to access, through the PBS, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 3 drugs, they may swap between iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

*Patients with drug-induced pulmonary arterial hypertension are only eligible for treatment with iloprost trometamol. They may not swap to bosentan monohydrate, epoprostenol sodium, sildenafil citrate or sitaxentan sodium.*

*Patients under 18 years of age:*

*From 1 April 2008, patients aged less than 18 years with primary pulmonary hypertension are eligible to receive PBS-subsidised treatment with bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate (WHO Class III only) or sitaxentan sodium (WHO Class III only). Once these patients are approved initial treatment with 1 of these 5 drugs, they may swap between bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate and sitaxentan sodium at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. It also means that no new baseline measurements will be necessary. (New baselines may be submitted where the patient has failed to respond to their current treatment.)*

*Patients may only swap to bosentan monohydrate, epoprostenol sodium, iloprost trometamol, sildenafil citrate or sitaxentan sodium if they have not failed prior PBS-subsidised treatment with that drug.*

**1. Definition of primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma.**

*Primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, including scleroderma, are defined as follows:*

- (i) mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest and pulmonary capillary wedge pressure (PCWP) less than 18 mmHg; or*
- (ii) mPAP greater than 30 mmHg with exercise and PCWP less than 18 mmHg; or*
- (iii) where a right heart catheter cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function.*

**2. Definition of WHO Functional Class III or IV disease severity.**

*(a) WHO Functional Class III disease severity is defined as follows:*

*Patients with pulmonary hypertension resulting in marked limitation of physical activity who are comfortable at rest and on ordinary physical activity experience dyspnoea or fatigue, chest pain or near syncope.*

*(b) WHO Functional Class IV disease severity is defined as follows:*

*Patients with the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.*

**3. Designated hospitals.**

*Refer to the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au) for a list of designated hospitals.*

**4. Test requirements to establish baseline for initiation of treatment and response to treatment for continuation of treatment.**

*(a) Initiation of treatment.*

*(i) New patients.*

*The first written application for PBS-subsidised treatment with the first of either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium should be accompanied by the results of a right heart catheter (RHC) composite assessment, plus an echocardiograph (ECHO) composite assessment, plus a 6 minute walk test (6MWT) to establish the patient's baseline measurements.*



| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*Where it is not possible to perform all 3 tests above on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment:*

- (1) RHC plus ECHO composite assessments;*
- (2) RHC composite assessment plus 6MWT;*
- (3) RHC composite assessment only.*

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the results of the following test combinations, which are listed in descending order of preference:*

- (1) ECHO composite assessment plus 6MWT;*
- (2) ECHO composite assessment only.*

*Where fewer than 3 tests are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application.*

**NOTE:**

*Where patients were initiated on PBS-subsidised treatment either with bosentan monohydrate on or after 1 March 2004, with iloprost trometamol on or after 1 April 2005, with epoprostenol sodium on or after 1 August 2006, with sildenafil citrate on or after 1 March 2007, with sitaxentan sodium on or after 1 April 2008, or with bosentan monohydrate (for PAH associated with congenital systemic-to-pulmonary shunt) on or after 1 August 2008, the test results provided with the initial application must be no more than 2 months old at the time of application. These results will form the baseline against which response assessments will be made.*

*Where patients received treatment with either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium prior to being commenced on PBS-subsidised treatment with the first of either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, the test requirements above still apply. The results that will form the baseline against which response assessments will be made will be those measured at the time patients commenced non-PBS-subsidised treatment with either bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate or sitaxentan sodium, whichever of the 5 drugs the patient received first.*

*(ii) Patients who received non-PBS-subsidised treatment with sitaxentan sodium prior to 1 April 2008.*

*For patients with primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who were commenced on sitaxentan sodium treatment prior to 1 April 2008 and who have received less than 6 months of treatment with sitaxentan sodium at the time of application, the first application for PBS-subsidised treatment must include, where available, all 3 test results at the time that the patient commenced treatment with sitaxentan sodium, sildenafil citrate, epoprostenol sodium, bosentan monohydrate or iloprost trometamol, whichever was initiated first.*

*For patients with primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who were commenced on sitaxentan sodium treatment prior to 1 April 2008 and who have received 6 or more months of treatment at the time of application, the first application for PBS-subsidised treatment must include, where available, all 3 test results at the time that the patient commenced treatment with sitaxentan sodium, sildenafil citrate, epoprostenol sodium, bosentan monohydrate or iloprost trometamol, whichever was initiated first. The results at the time of application for initial PBS-subsidised treatment must also be provided and must be no older than 3 months.*

*(b) Continuation of treatment.*

*The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment:*

- (1) RHC plus ECHO composite assessments plus 6MWT;*
- (2) RHC plus ECHO composite assessments;*
- (3) RHC composite assessment plus 6MWT;*
- (4) ECHO composite assessment plus 6MWT;*
- (5) RHC composite assessment only;*
- (6) ECHO composite assessment only.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a reason why the test(s) could not be conducted must be provided with the application.*

*The test(s) results provided with the application for continuing treatment must be no more than 2 months old at the time of application.*

**5. Definition of response to sitaxentan sodium, sildenafil citrate, bosentan monohydrate, iloprost trometamol, epoprostenol sodium or prior vasodilator treatment.**

*For adult patients with 2 or more baseline tests, response to treatment is defined as 2 or more tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

*For adult patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

*For adult patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

*For patients aged less than 18 years, response to treatment is defined as at least 1 of the baseline tests demonstrating stability or improvement of disease, as assessed by a physician from a designated hospital.*

**6. Authority approval requirements. [The following 2 sections are only relevant to the PBS listing of sitaxentan sodium. The requirements specific to bosentan monohydrate, iloprost trometamol, epoprostenol sodium and sildenafil citrate are given in parts 6 and 7 of the NOTE included in the bosentan monohydrate, iloprost trometamol, epoprostenol sodium and sildenafil citrate Schedule entry respectively.]**

*(a) Initiation of PBS-subsidised treatment with sitaxentan sodium, where the patient has not received prior PBS-subsidised treatment with bosentan monohydrate, iloprost trometamol, epoprostenol sodium or sildenafil citrate. All applications for initial treatment must be made in writing, must include an authority prescription and must be submitted to Medicare Australia for authorisation. The total duration of initial PBS-subsidised treatment that will be approved with this first written application is up to 6 months.*

*Patients who commence PBS-subsidised sitaxentan sodium treatment after 1 April 2008 and patients who received 6 or more months of sitaxentan sodium treatment prior to 1 April 2008 are eligible to receive up to 6 months of treatment per authority application.*

*Patients who commenced treatment with sitaxentan sodium prior to 1 April 2008 and who have received less than 6 months of treatment at the time of application are eligible to receive sufficient supply to allow the patient to complete a total of 6 months of combined PBS-subsidised and non-PBS-subsidised treatment.*

*All patients with primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who commenced treatment with sitaxentan sodium prior to 1 April 2008 will be eligible to commence PBS-subsidised treatment with sitaxentan sodium. Thereafter, to be eligible for further PBS-subsidised supply, these patients must demonstrate a response to sitaxentan sodium treatment, as defined above under definition of response.*

**(b) Continuation of treatment.**

*Written applications for continuing treatment must be submitted to Medicare Australia for authorisation every 6 months. Approvals will be limited to provide sufficient supply for up to a maximum of 6 months of treatment, based on the dosage recommendations in the TGA-approved Product Information.*

*Applications for continuing treatment will only be approved for patients who have currently demonstrated a response to treatment with sitaxentan sodium.*

*The assessment of the patient's response to the first and subsequent 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. Applications for continuing treatment with sitaxentan sodium should be made prior to the completion of the 6 month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician.*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

*(c) Swapping between bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate and sitaxentan sodium.*

*For eligible patients, applications to swap between these 5 drugs must be made under the relevant initial treatment restriction. Patients should be assessed for response to the treatment they are ceasing at the time the application to swap therapy is being made. Patients who fail to demonstrate a response or for whom no assessment results are submitted with the application to swap therapy may not re-commence PBS-subsidised treatment with the drug they are ceasing.*

*It is important that patients are assessed for response to every course of treatment approved within the timeframes specified in the relevant restriction, in order to maximise the choice of treatment.*

*To avoid confusion, applications for patients who wish to swap to an alternate treatment should be accompanied by the previously approved authority prescription, or remaining repeats, for the treatment the patient is ceasing.*

*(d) Cessation of treatment.*

*Patients who fail to demonstrate a response to PBS-subsidised sitaxentan sodium treatment at the times where an assessment is required must cease PBS-subsidised sitaxentan sodium therapy.*

#### **7. Re-treatment with sitaxentan sodium.**

*Patients who do not respond to treatment are not eligible to receive further PBS-subsidised treatment with sitaxentan sodium under any circumstances.*

#### **8. Further information.**

*A tabulated representation of the above information and the restriction can be obtained from the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).*

### **Public and private hospital authority required**

#### ***Initial (new patients)***

*Application for initial PBS-subsidised treatment with sitaxentan sodium of patients who have not received prior PBS-subsidised treatment with bosentan monohydrate, iloprost trometamol, epoprostenol sodium or sildenafil citrate and who have been assessed by a physician from a designated hospital to have:*

*(a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, unless a RHC is contraindicated on clinical grounds; OR*

*(b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8 mmHg or less, as measured by RHC, unless a RHC is contraindicated on clinical grounds.*

*Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.*

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the test results of the ECHO composite assessment plus 6MWT or the ECHO composite assessment only.*

*Applications for authorisation must be in writing and must include:*

*(1) a completed authority prescription form [see Note for authority approval requirements]; and*

*(2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [[www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au)] which includes results from the 3 tests below, where available:*

*(i) RHC composite assessment; and*

*(ii) ECHO composite assessment; and*

*(iii) 6MWT; and*

*(3) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with sitaxentan sodium for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with sildenafil citrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with epoprostenol sodium for primary pulmonary hypertension, OR with iloprost trometamol for primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with bosentan monohydrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].*

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

*Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.*

*Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested.*

*Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

#### **Public and private hospital authority required**

##### **Initial (new patients)**

*Application for initial PBS-subsidised treatment with sitaxentan sodium of patients who have not received prior PBS-subsidised treatment with bosentan monohydrate, iloprost trometamol, epoprostenol sodium or sildenafil citrate and who have been assessed by a physician from a designated hospital to have:*

- (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, unless a RHC is contraindicated on clinical grounds; OR*
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8 mmHg, as measured by RHC, unless a RHC is contraindicated on clinical grounds.*

*In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted to Medicare Australia for consideration based on the test results of the ECHO composite assessment plus 6MWT or the ECHO composite assessment only.*

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form [see Note for authority approval requirements]; and*
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:*
  - (i) RHC composite assessment; and*
  - (ii) ECHO composite assessment; and*
  - (iii) 6MWT; and*
- (3) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with sitaxentan sodium for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with sildenafil citrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with epoprostenol sodium for primary pulmonary hypertension, OR with iloprost trometamol for primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with bosentan monohydrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].*

*Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested.*

*Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

| Code | Item and Section 100 Restriction | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|
|------|----------------------------------|--------------|--------------------------------|-----------------------------------------|

### **Public and private hospital authority required**

#### ***Initial (grandfather patients)***

*Application for initial PBS-subsidised treatment with sitaxentan sodium of patients who were receiving treatment with sitaxentan sodium prior to 1 April 2008, who have not received prior PBS-subsidised treatment with bosentan monohydrate, iloprost trometamol, epoprostenol sodium or sildenafil citrate and who have been assessed by a physician from a designated hospital to have:*

- (a) WHO Functional Class III primary pulmonary hypertension; OR*
- (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease.*

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form [see Note for authority approval requirements]; and*
- (2) (a) for patients who have received less than 6 months of sitaxentan sodium treatment at the time of application — a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results of the following 3 tests, where available, at the time treatment with sitaxentan sodium was commenced:*
  - (i) RHC composite assessment; and*
  - (ii) ECHO composite assessment; and*
  - (iii) 6MWT; or*
- (b) for patients who have received 6 or more months of sitaxentan sodium treatment at the time of application — a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results of the following 3 tests, both at the time treatment with sitaxentan sodium was commenced and at the time of application, where available:*
  - (i) RHC composite assessment; and*
  - (ii) ECHO composite assessment; and*
  - (iii) 6MWT; and*
- (3) the date of commencement of sitaxentan sodium treatment; and*
- (4) a signed patient acknowledgment indicating that the patient understands and acknowledges that PBS-subsidised treatment with sitaxentan sodium for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with sildenafil citrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with epoprostenol sodium for primary pulmonary hypertension, OR with iloprost trometamol for primary pulmonary hypertension, drug-induced pulmonary arterial hypertension or pulmonary arterial hypertension secondary to connective tissue disease, OR with bosentan monohydrate for primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma, will cease if the treating physician determines that the patient has not achieved a response to treatment [see Note for definition of response].*

*Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. The number of repeats authorised will be dependent on the duration of prior sitaxentan sodium therapy. Where patients have received less than 6 months of non-PBS-subsidised treatment with sitaxentan sodium, sufficient repeats to allow the patient to complete a total of 6 months of combined PBS-subsidised and non-PBS-subsidised therapy may be requested. Where patients have received 6 months or more of non-PBS-subsidised treatment with sitaxentan sodium, a maximum of 5 repeats may be requested. Where fewer than the maximum allowable number of repeats are requested at the time of application, authority approvals for the remainder of the allowable repeats may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

continued ➡

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|

**Public and private hospital authority required**

*Initial (change or re-commencement for all patients)*

*Application for initial PBS-subsidised treatment with sitaxentan sodium of patients with either of the following:*

- (a) WHO Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised sitaxentan sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with sitaxentan sodium; OR*
- (b) WHO Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with iloprost trometamol; OR*
- (c) WHO Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to scleroderma and whose most recent course of PBS-subsidised treatment was with bosentan monohydrate; OR*
- (d) WHO Class III primary pulmonary hypertension and whose most recent course of PBS-subsidised treatment was with epoprostenol sodium; OR*
- (e) WHO Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with sildenafil citrate.*

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form [see Note for authority approval requirements]; and*
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised sitaxentan sodium, sildenafil citrate, epoprostenol sodium, iloprost trometamol or bosentan monohydrate, whichever was initiated first, was granted; and*
- (3) the date of the first application for PBS-subsidised treatment with sitaxentan sodium, sildenafil citrate, epoprostenol sodium, iloprost trometamol or bosentan monohydrate, whichever was initiated first; and*
- (4) the results of the patient's response to treatment with their last course of PBS-subsidised sitaxentan sodium, sildenafil citrate, epoprostenol sodium, iloprost trometamol or bosentan monohydrate.*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

**Public and private hospital authority required**

*Continuing treatment (all patients)*

*Continuing PBS-subsidised treatment with sitaxentan sodium of patients who have received approval for initial PBS-subsidised treatment with sitaxentan sodium, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of sitaxentan sodium treatment [see Note for definition of response].*

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:*
  - (i) RHC composite assessment; and*
  - (ii) ECHO composite assessment; and*
  - (iii) 6MWT.*

*Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].*

*The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested.*

*Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*

|       |               |    |         |         |    |
|-------|---------------|----|---------|---------|----|
| 9622K | Tablet 100 mg | 30 | 2743.80 | Theclin | CS |
|-------|---------------|----|---------|---------|----|

| Code                                                                                                                                                                                                                                                                | Item and Section 100 Restriction             | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| <b>STAVUDINE</b>                                                                                                                                                                                                                                                    |                                              |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                   |                                              |           |                          |                                   |    |
| <i>Treatment of HIV infection in patients with:</i>                                                                                                                                                                                                                 |                                              |           |                          |                                   |    |
| <i>(a) CD4 cell counts of less than 500 per cubic millimetre; or</i>                                                                                                                                                                                                |                                              |           |                          |                                   |    |
| <i>(b) viral load of greater than 10,000 copies per mL.</i>                                                                                                                                                                                                         |                                              |           |                          |                                   |    |
| 6186N                                                                                                                                                                                                                                                               | Capsule 20 mg                                | 60        | 280.00                   | Zerit                             | BQ |
| 6189R                                                                                                                                                                                                                                                               | Capsule 30 mg                                | 60        | 333.68                   | Zerit                             | BQ |
| 6190T                                                                                                                                                                                                                                                               | Capsule 40 mg                                | 60        | 444.90                   | Zerit                             | BQ |
| 6250Y                                                                                                                                                                                                                                                               | Powder for oral solution 1 mg per mL, 200 mL | 1         | 99.14                    | Zerit                             | BQ |
| <b>TACROLIMUS</b>                                                                                                                                                                                                                                                   |                                              |           |                          |                                   |    |
| <b><u>CAUTION:</u></b>                                                                                                                                                                                                                                              |                                              |           |                          |                                   |    |
| <i>Careful monitoring of patients is mandatory.</i>                                                                                                                                                                                                                 |                                              |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                   |                                              |           |                          |                                   |    |
| <i>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for:</i>                                                                                                                                      |                                              |           |                          |                                   |    |
| <i>(a) prophylaxis and treatment of liver allograft rejection. Management includes initiation, stabilisation and review of therapy as required; or</i>                                                                                                              |                                              |           |                          |                                   |    |
| <i>(b) prophylaxis and treatment of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required; or</i>                                                                                                              |                                              |           |                          |                                   |    |
| <i>(c) prophylaxis and treatment of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required; or</i>                                                                                                            |                                              |           |                          |                                   |    |
| <i>(d) prophylaxis and treatment of lung allograft rejection. Management includes initiation, stabilisation and review of therapy as required.</i>                                                                                                                  |                                              |           |                          |                                   |    |
| 6328C                                                                                                                                                                                                                                                               | Capsule 500 micrograms                       | 100       | 187.34                   | Prograf                           | JC |
| 6216E                                                                                                                                                                                                                                                               | Capsule 1 mg                                 | 100       | 374.67                   | Prograf                           | JC |
| 6217F                                                                                                                                                                                                                                                               | Capsule 5 mg                                 | 50        | 936.68                   | Prograf                           | JC |
| <b>TELBIVUDINE</b>                                                                                                                                                                                                                                                  |                                              |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                                                   |                                              |           |                          |                                   |    |
| <i>Treatment, as sole PBS-subsidised therapy, in a patient with HBeAg-positive chronic hepatitis B who is nucleoside analogue naive and satisfies all of the following criteria:</i>                                                                                |                                              |           |                          |                                   |    |
| <i>(1) Histological evidence of chronic hepatitis on liver biopsy (except in patients with coagulation disorders considered severe enough to prevent liver biopsy);</i>                                                                                             |                                              |           |                          |                                   |    |
| <i>(2)(a) Abnormal serum ALT levels in conjunction with documented chronic hepatitis B infection; or</i>                                                                                                                                                            |                                              |           |                          |                                   |    |
| <i>(b) Elevated HBV DNA levels in conjunction with documented chronic hepatitis B infection;</i>                                                                                                                                                                    |                                              |           |                          |                                   |    |
| <i>(3) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.</i>                                                                                                                             |                                              |           |                          |                                   |    |
| <i>Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</i> |                                              |           |                          |                                   |    |
| 9630W                                                                                                                                                                                                                                                               | Tablet 600 mg                                | 28        | 322.84                   | Sebivo                            | NV |

| Code                                                                                                                                                                                                                             | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|--------------------------|-----------------------------------|----|
| <b>TENOFOVIR DISOPROXIL FUMARATE</b>                                                                                                                                                                                             |                                  |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                |                                  |           |                          |                                   |    |
| <i>Treatment of HIV infection in patients with:</i>                                                                                                                                                                              |                                  |           |                          |                                   |    |
| <i>(a) CD4 cell counts of less than 500 per cubic millimetre; or</i>                                                                                                                                                             |                                  |           |                          |                                   |    |
| <i>(b) viral load of greater than 10,000 copies per mL.</i>                                                                                                                                                                      |                                  |           |                          |                                   |    |
| 6358P                                                                                                                                                                                                                            | Tablet 300 mg                    | 30        | 483.10                   | Viread                            | GI |
| <b>TENOFOVIR DISOPROXIL FUMARATE with EMTRICITABINE</b>                                                                                                                                                                          |                                  |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                |                                  |           |                          |                                   |    |
| <i>Treatment of HIV infection in patients with:</i>                                                                                                                                                                              |                                  |           |                          |                                   |    |
| <i>(a) CD4 cell counts of less than 500 per cubic millimetre; or</i>                                                                                                                                                             |                                  |           |                          |                                   |    |
| <i>(b) viral load of greater than 10,000 copies per mL.</i>                                                                                                                                                                      |                                  |           |                          |                                   |    |
| 6468K                                                                                                                                                                                                                            | Tablet 300 mg-200 mg             | 30        | 765.10                   | Truvada                           | GI |
| <b>THALIDOMIDE</b>                                                                                                                                                                                                               |                                  |           |                          |                                   |    |
| <b><u>CAUTION:</u></b>                                                                                                                                                                                                           |                                  |           |                          |                                   |    |
| <i>Thalidomide is a category X drug and must not be given to pregnant women. Pregnancy in female patients or in the partners of male patients must be avoided during treatment and for 1 month after cessation of treatment.</i> |                                  |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                |                                  |           |                          |                                   |    |
| <i>Relapsed or refractory multiple myeloma in patients who have failed at least 1 other treatment.</i>                                                                                                                           |                                  |           |                          |                                   |    |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                              |                                  |           |                          |                                   |    |
| <i>Patients receiving thalidomide under the PBS listing must be registered in the Pharmion Risk Management Program.</i>                                                                                                          |                                  |           |                          |                                   |    |
| 6469L                                                                                                                                                                                                                            | Capsule 50 mg                    | 28        | 420.00                   | Thalidomide Pharmion              | PI |
| <b>TIPRANAVIR</b>                                                                                                                                                                                                                |                                  |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                |                                  |           |                          |                                   |    |
| <i>Treatment, in combination with other antiretroviral agents, and co-administered with 200 mg ritonavir twice daily, of HIV infection in antiretroviral experienced adults with:</i>                                            |                                  |           |                          |                                   |    |
| <i>(a) evidence of HIV replication (viral load greater than 10,000 copies per mL); and/or</i>                                                                                                                                    |                                  |           |                          |                                   |    |
| <i>(b) CD4 cell counts of less than 500 per cubic millimetre.</i>                                                                                                                                                                |                                  |           |                          |                                   |    |
| <i>Patients must have failed previous treatment with, or have resistance to, 3 different antiretroviral regimens which have included:</i>                                                                                        |                                  |           |                          |                                   |    |
| <i>(i) at least 1 non-nucleoside reverse transcriptase inhibitor; and</i>                                                                                                                                                        |                                  |           |                          |                                   |    |
| <i>(ii) at least 1 nucleoside reverse transcriptase inhibitor; and</i>                                                                                                                                                           |                                  |           |                          |                                   |    |
| <i>(iii) at least 2 protease inhibitors.</i>                                                                                                                                                                                     |                                  |           |                          |                                   |    |
| 9610T                                                                                                                                                                                                                            | Capsule 250 mg                   | 120       | 1071.00                  | Aptivus                           | BY |
| <b><u>NOTE:</u></b>                                                                                                                                                                                                              |                                  |           |                          |                                   |    |
| <i>This price is based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details.</i>                                                                                       |                                  |           |                          |                                   |    |
| <b>VALACICLOVIR HYDROCHLORIDE</b>                                                                                                                                                                                                |                                  |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                                                                                |                                  |           |                          |                                   |    |
| <i>Prophylaxis of cytomegalovirus (CMV) infection and disease following renal transplantation in patients at risk of CMV disease.</i>                                                                                            |                                  |           |                          |                                   |    |
| 6280M                                                                                                                                                                                                                            | Tablet 500 mg (base)             | 100       | 423.18                   | Valtrex                           | GK |



| Code                                                                                                                                                                      | Item and Section 100 Restriction                     | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| <b>VALGANCICLOVIR HYDROCHLORIDE</b>                                                                                                                                       |                                                      |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                         |                                                      |           |                          |                                   |    |
| <i>Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome;</i>                                                                                     |                                                      |           |                          |                                   |    |
| <i>Prophylaxis of cytomegalovirus infection and disease in solid organ transplant patients at risk of cytomegalovirus disease.</i>                                        |                                                      |           |                          |                                   |    |
| 6357N                                                                                                                                                                     | Tablet 450 mg (base)                                 | 60        | 2245.80                  | Valcyte                           | RO |
| <b>ZIDOVUDINE</b>                                                                                                                                                         |                                                      |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                         |                                                      |           |                          |                                   |    |
| <i>Treatment of HIV infection in patients with:</i>                                                                                                                       |                                                      |           |                          |                                   |    |
| <i>(a) CD4 cell counts of less than 500 per cubic millimetre; or</i>                                                                                                      |                                                      |           |                          |                                   |    |
| <i>(b) viral load of greater than 10,000 copies per mL.</i>                                                                                                               |                                                      |           |                          |                                   |    |
| 6153W                                                                                                                                                                     | Capsule 100 mg                                       | 100       | 205.46                   | Retrovir                          | GK |
| 6154X                                                                                                                                                                     | Capsule 250 mg                                       | 60        | 308.19                   | Retrovir                          | GK |
| 6155Y                                                                                                                                                                     | Syrup 10 mg per mL, 200 mL                           | 1         | 41.09                    | Retrovir                          | GK |
| <b>ZOLEDRONIC ACID</b>                                                                                                                                                    |                                                      |           |                          |                                   |    |
| <b><u>Private hospital authority required</u></b>                                                                                                                         |                                                      |           |                          |                                   |    |
| <i>Multiple myeloma;</i>                                                                                                                                                  |                                                      |           |                          |                                   |    |
| <i>Bone metastases from breast cancer;</i>                                                                                                                                |                                                      |           |                          |                                   |    |
| <i>Bone metastases from hormone-resistant prostate cancer, with demonstration of biochemical progression of disease despite maximal therapy with hormonal treatments;</i> |                                                      |           |                          |                                   |    |
| <i>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy.</i>                                                                                   |                                                      |           |                          |                                   |    |
| 6371H                                                                                                                                                                     | Injection concentrate for I.V. infusion 4 mg in 5 mL | 1         | 450.00                   | Zometa                            | NV |
| <b><u>NOTE:</u></b>                                                                                                                                                       |                                                      |           |                          |                                   |    |
| <i>This price is based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details.</i>                                |                                                      |           |                          |                                   |    |
| <b>BOTULINUM TOXIN PROGRAM</b>                                                                                                                                            |                                                      |           |                          |                                   |    |
| <b>BOTULINUM TOXIN TYPE A PURIFIED NEUROTOXIN COMPLEX</b>                                                                                                                 |                                                      |           |                          |                                   |    |
| <b><u>NOTE:</u></b>                                                                                                                                                       |                                                      |           |                          |                                   |    |
| <i>Arrangements to prescribe this item should be made by medical practitioners with Medicare Australia, contact telephone number 1800 700 270.</i>                        |                                                      |           |                          |                                   |    |
| <i>Treatment of blepharospasm associated with dystonia, including benign blepharospasm and VIIth nerve disorders (hemifacial spasm) in patients 12 years and older;</i>   |                                                      |           |                          |                                   |    |
| <i>Treatment of dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients 2 years of age or older;</i>                              |                                                      |           |                          |                                   |    |
| <i>Treatment of spasmodic torticollis, either as monotherapy or as adjunctive therapy to current standard care.</i>                                                       |                                                      |           |                          |                                   |    |
| 6103F                                                                                                                                                                     | Lyophilised powder for I.M. injection 100 units vial | 1         | 415.50                   | Botox                             | AG |
| <b><u>NOTE:</u></b>                                                                                                                                                       |                                                      |           |                          |                                   |    |
| <i>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</i>                                      |                                                      |           |                          |                                   |    |

| Code        | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
|             | <b>CLOSTRIDIUM BOTULINUM TYPE A TOXIN—HAEMAGGLUTININ COMPLEX</b><br><b>NOTE:</b><br>Arrangements to prescribe this item should be made by medical practitioners with Medicare Australia, contact telephone number 1800 700 270.<br><br><i>Treatment of dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients 2 years of age or older;</i><br><i>Treatment of spasmodic torticollis, either as monotherapy or as adjunctive therapy to current standard care;</i><br><i>Treatment of moderate to severe spasticity [defined as MAS greater than or equal to 3 using modified Ashworth scale] of the upper limb in adults following a stroke, as second line therapy when standard management has failed (e.g. physiotherapy and/or oral spasticity agents) or as an adjunct to physical therapy.</i><br><i>Maximum number of treatments to be authorised is 4 per upper limb per lifetime. Treatment should not be initiated until 3 to 6 months post-stroke in patients who do not have established severe contracture. Treatment should be discontinued if the patient does not respond (decrease of MAS greater than 1 in at least one joint) after two treatments.</i><br><i>Contraindications to treatment include established severe contracture, known sensitivity to botulinum toxin.</i> |           |                          |                                   |    |
| 6293F       | Lyophilised powder for I.M. injection 500 units vial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1         | 650.00                   | Dysport                           | IS |
|             | <b>NOTE:</b><br>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |           |                          |                                   |    |
|             | <b>HUMAN GROWTH HORMONE PROGRAM</b><br><b>SOMATROPIN (Recombinant human growth hormone)</b><br><br>Short stature in accordance with the 'Guidelines for the Availability of Human Growth Hormone (hGH) as a Pharmaceutical Benefit'.<br><br><b>NOTE:</b><br>These guidelines may be obtained from the Department of Health and Ageing's internet site at <a href="http://www.health.gov.au/internet/main/publishing.nsf/Content/pbs-hghguidelines-contents">http://www.health.gov.au/internet/main/publishing.nsf/Content/pbs-hghguidelines-contents</a> , or from:<br>Growth Hormone Program<br>Access and Systems Branch<br>Department of Health and Ageing<br>GPO Box 9848<br>CANBERRA ACT 2601<br>Contact telephone number (02) 6289 7274                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |           |                          |                                   |    |
| 6266T       | Injection 4 mg (12 i.u.) vial with 3.5 mL diluent (with preservative)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1         | 198.00                   | Zomacton                          | FP |
| 6330E       | Injection 5 mg (15 i.u.) in 1 mL cartridge (with preservative)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 1         | 247.50                   | Genotropin                        | PH |
| 6476W       | Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1         | 247.50                   | Omnitrope                         | SZ |
| 6295H       | Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1         | 247.50                   | Norditropin SimpleXx              | NO |
| 6465G       | Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1         | 315.50                   | Norditropin NordiFlex             | NO |
|             | <b>NOTE:</b><br>This price is based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |           |                          |                                   |    |
| 6169Q       | Injection 18 i.u. (6 mg) cartridge with 3.15 mL diluent (with preservative)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1         | 297.00                   | Humatrope                         | LY |
| continued ➞ |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |           |                          |                                   |    |

| Code                                                                                                                                                | Item and Section 100 Restriction                                                                                        | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------|-----------------------------------|----|
| 6329D                                                                                                                                               | Injection 8 mg (24 i.u.) vial with 1.37 mL diluent cartridge (with preservative) (for use with one.click auto-injector) | 1         | 396.00                   | Saizen 8 mg click.easy            | SG |
| 6296J                                                                                                                                               | Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative)                                          | 1         | 495.00                   | Norditropin SimpleXx              | NO |
| 6466H                                                                                                                                               | Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative)                                          | 1         | 631.00                   | Norditropin NordiFlex             | NO |
| <b>NOTE:</b><br>This price is based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details. |                                                                                                                         |           |                          |                                   |    |
| 9604L                                                                                                                                               | Solution for injection 10 mg (30 i.u.) in 2 mL cartridge (with preservative)                                            | 1         | 495.00                   | NutropinAq                        | IS |
| 6170R                                                                                                                                               | Injection 36 i.u. (12 mg) cartridge with 3.15 mL diluent (with preservative)                                            | 1         | 594.00                   | Humatrope                         | LY |
| 6312F                                                                                                                                               | Injection 12 mg (36 i.u.) in 1 mL cartridge (with preservative)                                                         | 1         | 594.00                   | Genotropin                        | PH |
| 6297K                                                                                                                                               | Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative)                                          | 1         | 742.50                   | Norditropin SimpleXx              | NO |
| 6467J                                                                                                                                               | Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative)                                          | 1         | 946.50                   | Norditropin NordiFlex             | NO |
| <b>NOTE:</b><br>This price is based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details. |                                                                                                                         |           |                          |                                   |    |
| 6345Y                                                                                                                                               | Injection 72 i.u. (24 mg) cartridge with 3.15 mL diluent (with preservative)                                            | 1         | 1188.00                  | Humatrope                         | LY |
| 9628R                                                                                                                                               | Injection 0.6 mg (1.8 i.u.) with diluent in single use syringe (without preservative)                                   | 7         | 207.90                   | Genotropin MiniQuick              | PH |
| 6313G                                                                                                                                               | Injection 0.8 mg (2.4 i.u.) with diluent in single use syringe (without preservative)                                   | 7         | 277.20                   | Genotropin MiniQuick              | PH |
| 6314H                                                                                                                                               | Injection 1 mg (3 i.u.) with diluent in single use syringe (without preservative)                                       | 7         | 346.50                   | Genotropin MiniQuick              | PH |
| 6315J                                                                                                                                               | Injection 1.2 mg (3.6 i.u.) with diluent in single use syringe (without preservative)                                   | 7         | 415.80                   | Genotropin MiniQuick              | PH |
| 6316K                                                                                                                                               | Injection 1.4 mg (4.2 i.u.) with diluent in single use syringe (without preservative)                                   | 7         | 485.10                   | Genotropin MiniQuick              | PH |
| 6317L                                                                                                                                               | Injection 1.6 mg (4.8 i.u.) with diluent in single use syringe (without preservative)                                   | 7         | 554.40                   | Genotropin MiniQuick              | PH |
| 6318M                                                                                                                                               | Injection 1.8 mg (5.4 i.u.) with diluent in single use syringe (without preservative)                                   | 7         | 623.70                   | Genotropin MiniQuick              | PH |
| 6319N                                                                                                                                               | Injection 2 mg (6 i.u.) with diluent in single use syringe (without preservative)                                       | 7         | 693.00                   | Genotropin MiniQuick              | PH |

#### IVF/GIFT PROGRAM

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |  |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|

**CHORIOGONADOTROPIN ALFA**

*Patients who are receiving medical treatment as described in items 13200 or 13203 of the Medicare Benefits Schedule.*

**NOTE:**

*Arrangements to prescribe this item should be made by medical practitioners with Medicare Australia, contact telephone number 1800 700 270.*

|       |                                                                    |   |       |         |    |
|-------|--------------------------------------------------------------------|---|-------|---------|----|
| 9631X | Solution for injection 250 micrograms in 0.5 mL pre-filled syringe | 1 | 54.80 | Ovidrel | SG |
|-------|--------------------------------------------------------------------|---|-------|---------|----|

**NOTE:**

*This price is based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details. Relativity sheets are available on the Department of Health and Ageing's internet site (visit [www.health.gov.au](http://www.health.gov.au) and search for 'relativity sheets').*

**FOLLITROPIN ALFA**

*Patients who are receiving medical treatment as described in items 13200 or 13203 of the Medicare Benefits Schedule.*

**NOTE:**

*Arrangements to prescribe this item should be made by medical practitioners with Medicare Australia, contact telephone number 1800 700 270.*

|       |                                                                                                        |   |        |             |    |
|-------|--------------------------------------------------------------------------------------------------------|---|--------|-------------|----|
| 6373K | Injection set containing 1 vial powder for injection 75 i.u. and 1 pre-filled syringe solvent 1 mL     | 1 | 36.00  | Gonal-f 75  | SG |
| 6374L | Injection set containing 10 vials powder for injection 75 i.u. and 10 pre-filled syringes solvent 1 mL | 1 | 360.00 | Gonal-f 75  | SG |
| 6431L | Injection 300 i.u. in 0.5 mL multi-dose cartridge                                                      | 1 | 144.00 | Gonal-f Pen | SG |
| 6376N | Injection set containing 1 vial powder for injection 450 i.u. and 1 pre-filled syringe solvent 1 mL    | 1 | 216.00 | Gonal-f     | SG |
| 6432M | Injection 450 i.u. in 0.75 mL multi-dose cartridge                                                     | 1 | 216.00 | Gonal-f Pen | SG |
| 6433N | Injection 900 i.u. in 1.5 mL multi-dose cartridge                                                      | 1 | 432.00 | Gonal-f Pen | SG |
| 6375M | Injection set containing 1 vial powder for injection 1,050 i.u. and 1 pre-filled syringe solvent 2 mL  | 1 | 504.00 | Gonal-f     | SG |

**FOLLITROPIN BETA**

*Patients who are receiving medical treatment as described in items 13200 or 13203 of the Medicare Benefits Schedule.*

**NOTE:**

*Arrangements to prescribe this item should be made by medical practitioners with Medicare Australia, contact telephone number 1800 700 270.*

|       |                                                                 |   |        |                            |    |
|-------|-----------------------------------------------------------------|---|--------|----------------------------|----|
| 6335K | Solution for injection 300 i.u. in 0.36 mL multi-dose cartridge | 1 | 144.04 | Puregon 300 IU/<br>0.36 mL | OR |
| 6336L | Solution for injection 600 i.u. in 0.72 mL multi-dose cartridge | 1 | 288.09 | Puregon 600 IU/<br>0.72 mL | OR |
| 6464F | Solution for injection 900 i.u. in 1.08 mL multi-dose cartridge | 1 | 432.11 | Puregon 900 IU/<br>1.08 mL | OR |

| Code | Item and Section 100 Restriction | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer |  |
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|
|------|----------------------------------|-----------|--------------------------|-----------------------------------|--|

### HUMAN CHORIONIC GONADOTROPHIN

*Patients who are receiving medical treatment as described in items 13200 or 13203 of the Medicare Benefits Schedule.*

**NOTE:**

*Arrangements to prescribe this item should be made by medical practitioners with Medicare Australia, contact telephone number 1800 700 270.*

|       |                                                                                                  |   |       |         |    |
|-------|--------------------------------------------------------------------------------------------------|---|-------|---------|----|
| 6176C | Injection set containing 3 ampoules powder for injection 500 units and 3 ampoules solvent 1 mL   | 1 | 19.77 | Pregnyl | OR |
| 6178E | Injection set containing 3 ampoules powder for injection 1,500 units and 3 ampoules solvent 1 mL | 1 | 28.06 | Pregnyl | OR |
| 6181H | Injection set containing 3 ampoules powder for injection 5,000 units and 3 ampoules solvent 1 mL | 1 | 34.47 | Pregnyl | OR |

### PROGESTERONE

*For luteal phase support in patients who are receiving medical treatment as described in item 13200 of the Medicare Benefits Schedule. The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement.*

**NOTE:**

*Arrangements to prescribe this item should be made by medical practitioners with Medicare Australia, contact telephone number 1800 700 270.*

|       |                                                                            |    |        |            |    |
|-------|----------------------------------------------------------------------------|----|--------|------------|----|
| 6366C | Vaginal gel (prolonged release) 90 mg in single dose pre-filled applicator | 15 | 148.50 | Crinone 8% | SG |
|-------|----------------------------------------------------------------------------|----|--------|------------|----|

**NOTE:**

*This price is based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details. Relativity sheets are available on the Department of Health and Ageing's internet site (visit [www.health.gov.au](http://www.health.gov.au) and search for 'relativity sheets').*

|       |                |    |       |    |  |
|-------|----------------|----|-------|----|--|
| 9608Q | Pessary 100 mg | 15 | 43.50 | ON |  |
| 9609R | Pessary 200 mg | 15 | 48.00 | ON |  |

### OPIATE DEPENDENCE TREATMENT PROGRAM

The Australian Government funds the cost of buprenorphine hydrochloride, buprenorphine hydrochloride with naloxone hydrochloride and methadone hydrochloride supplied as pharmaceutical benefits through clinics and pharmacies approved by State and Territory governments. For further information about this program, please contact your State or Territory Government.

### BUPRENORPHINE HYDROCHLORIDE

*Treatment of opiate dependence, including maintenance and detoxification (withdrawal), within a framework of medical, social and psychological treatment.*

**NOTE:**

*Treatment must be in accordance with the law of the relevant State or Territory.*

|       |                                         |   |       |         |    |
|-------|-----------------------------------------|---|-------|---------|----|
| 6307Y | Sublingual tablet 400 micrograms (base) | 7 | 6.16  | Subutex | RC |
| 6308B | Sublingual tablet 2 mg (base)           | 7 | 10.50 | Subutex | RC |
| 6309C | Sublingual tablet 8 mg (base)           | 7 | 30.10 | Subutex | RC |

| Code                                                                                                     | Item and Section 100 Restriction            | Pack Size | Price ex Manufacturer \$ | Proprietary Name and Manufacturer             |    |
|----------------------------------------------------------------------------------------------------------|---------------------------------------------|-----------|--------------------------|-----------------------------------------------|----|
| <b>BUPRENORPHINE HYDROCHLORIDE with NALOXONE HYDROCHLORIDE</b>                                           |                                             |           |                          |                                               |    |
| <i>Treatment of opiate dependence within a framework of medical, social and psychological treatment.</i> |                                             |           |                          |                                               |    |
| <b>NOTE:</b>                                                                                             |                                             |           |                          |                                               |    |
| <i>Treatment must be in accordance with the law of the relevant State or Territory.</i>                  |                                             |           |                          |                                               |    |
| 6470M                                                                                                    | Sublingual tablet 2 mg (base)-0.5 mg (base) | 28        | 42.00                    | Suboxone                                      | RC |
| 6471N                                                                                                    | Sublingual tablet 8 mg (base)-2 mg (base)   | 28        | 120.40                   | Suboxone                                      | RC |
| <b>METHADONE HYDROCHLORIDE</b>                                                                           |                                             |           |                          |                                               |    |
| <b>CAUTION:</b>                                                                                          |                                             |           |                          |                                               |    |
| <i>The risk of drug dependence is high.</i>                                                              |                                             |           |                          |                                               |    |
| <i>Treatment of opiate dependence in accordance with the law of the relevant State or Territory.</i>     |                                             |           |                          |                                               |    |
| 6171T                                                                                                    | Oral liquid 25 mg per 5 mL, 200 mL          | 1         | 7.40                     | <sup>a</sup> Biodone Forte<br><sup>a</sup> GK | MW |
| 6172W                                                                                                    | Oral liquid 25 mg per 5 mL, 1 L             | 1         | 35.28                    | <sup>a</sup> Biodone Forte<br><sup>a</sup> GK | MW |

## SPECIAL AUTHORITY PROGRAM

### TRASTUZUMAB

#### **NOTE:**

Any queries concerning the arrangements to prescribe trastuzumab may be directed to Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Written applications for authority to prescribe trastuzumab should be forwarded to:

Medicare Australia

Prior Written Approval of Specialised Drugs

Reply Paid 9826

GPO Box 9826

HOBART TAS 7001

Further prescribing information is on the Medicare Australia website at [www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au).

#### **Section 100 authority required**

Initial treatment for HER2 positive early breast cancer commencing concurrently with adjuvant chemotherapy following surgery.

The total duration of PBS-subsidised treatment (initial plus continuing) that will be authorised is 52 weeks.

HER2 positivity must be demonstrated by in situ hybridisation (ISH).

Trastuzumab must not be used in patients with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure. Cardiac function must be tested by a suitable method including, for example, ECHO or MUGA, prior to seeking the initial authority approval and then at 3 monthly intervals during treatment.

Authority applications for initial treatment must be made in writing and must include:

(a) a completed authority prescription form; and

(b) a completed Early Breast Cancer - PBS Supporting Information Form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))] which includes:

(i) a copy of the pathology report from an Approved Pathology Authority confirming the presence of HER2 gene amplification by in situ hybridisation (ISH); and

(ii) a copy of the signed patient acknowledgement form [may be downloaded from the Medicare Australia website ([www.medicareaustralia.gov.au](http://www.medicareaustralia.gov.au))].

continued ➞

| Code  | Item and Section 100 Restriction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pack<br>Size | Price ex<br>Manufacturer<br>\$ | Proprietary<br>Name and<br>Manufacturer |    |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------------------------|-----------------------------------------|----|
|       | <p><i>The medical practitioner should request sufficient quantity based on the weight of the patient to provide for a maximum of 3 weeks' treatment (equivalent to the loading dose for the 3 weekly regimen, and the loading dose and 2 weekly doses for the once weekly regimen).</i></p> <p><b>Section 100 authority required</b></p> <p><i>Continuing treatment for HER2 positive early breast cancer where the patient has previously received treatment with PBS-subsidised trastuzumab.</i></p> <p><i>The patient is eligible to receive sufficient trastuzumab to complete 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy.</i></p> <p><i>Trastuzumab must not be used in patients with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure. Cardiac function must be tested by a suitable method including, for example, ECHO or MUGA, at 3 monthly intervals during treatment.</i></p> <p><i>Authority applications for continuing treatment may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</i></p> <p><i>The medical practitioner should request sufficient quantity based on the weight of the patient for 3 weeks' supply (equivalent to 1 dose for the 3 weekly dosing regimen, or 3 doses for the once weekly dosing regimen). Up to a maximum of 3 repeats may be authorised.</i></p> <p><i>Breaks in therapy.</i></p> <p><i>Where a patient has a break in trastuzumab therapy of more than 1 week but less than 6 weeks from when the last dose was due, authority approval will be granted for a new loading dose. Authority applications for new loading doses may be made by telephone on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</i></p> |              |                                |                                         |    |
| 6497Y | Powder for I.V. infusion 150 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 1            | 1030.21                        | Herceptin                               | RO |

Section 3

Container Prices, Fees, Standard Packs and Prices  
for Ready Prepared Pharmaceutical Benefits

CONTAINER PRICES FOR QUANTITIES OF READY PREPARED BENEFITS LESS THAN THE STANDARD PACK:

|             |             |        |
|-------------|-------------|--------|
| Injectables | 150 mL vial | \$0.71 |
| Other Items | 25 mL vial  | \$0.28 |

(The 25 mL is the most commonly used size)

FEES:

|                                                         |        |
|---------------------------------------------------------|--------|
| Dispensing Fee for Ready Prepared Benefits              | \$5.99 |
| Dangerous Drug Fee                                      | \$2.71 |
| Additional Fee for Agreed Price Ready Prepared Benefits | \$1.03 |

NOTE -

*Standard packs and prices (including mark-up, but without dispensing fee and dangerous drug fee) are for items against the price of which an asterisk (\*) is shown in Section 2 of the Schedule.*



(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

| Code | Name | Form/Strength | Pack and Price<br>\$ | Manufacturer |
|------|------|---------------|----------------------|--------------|
|------|------|---------------|----------------------|--------------|

**EMERGENCY DRUG (DOCTOR'S BAG) SUPPLIES**

|       |                                                                 |                          |           |    |
|-------|-----------------------------------------------------------------|--------------------------|-----------|----|
| 3486L | Benzylpenicillin                                                | 600 mg                   | 1 @ 3.44  | CS |
| 3463G | Diphtheria and Tetanus Vaccine, Adsorbed, Diluted For Adult Use | 0.5 mL                   | 5 @ 67.15 | CS |
| 3470P | Hydrocortisone Sodium Succinate                                 | 100 mg with 2 mL solvent | 1 @ 5.36  | PH |
| 3481F | Naloxone Hydrochloride                                          | 800 mcg in 2 mL          | 1 @ 20.94 | CS |
| 3482G |                                                                 | 2 mg in 5 mL             | 1 @ 33.48 | CS |
| 3488N | Promethazine Hydrochloride                                      | 50 mg in 2 mL            | 5 @ 7.95  | HH |

**SPECIAL PHARMACEUTICAL BENEFITS - FOR GENERAL USE**

|       |                           |               |           |                                   |
|-------|---------------------------|---------------|-----------|-----------------------------------|
| 2315W | Bleomycin Sulfate         | 15,000 i.u.   | 1 @ 48.58 | HH<br>(for reimbursement price)   |
|       |                           |               | 1 @ 92.28 | HH<br>(for total dispensed price) |
| 8298R | Naratriptan Hydrochloride | 2.5 mg (base) | 2 @ 9.74  | GK<br>(for reimbursement price)   |
|       |                           |               | 2 @ 11.13 | GK<br>(for total dispensed price) |
| 9734H |                           | 2.5 mg (base) | 2 @ 11.13 | GK<br>(for reimbursement price)   |
|       |                           |               | 2 @ 11.13 | GK<br>(for total dispensed price) |
| 8266C | Zolmitriptan              | 2.5 mg        | 2 @ 9.71  | AP<br>(for reimbursement price)   |
|       |                           |               | 2 @ 11.09 | AP<br>(for total dispensed price) |
| 9736K |                           | 2.5 mg        | 2 @ 11.09 | AP<br>(for reimbursement price)   |
|       |                           |               | 2 @ 11.09 | AP<br>(for total dispensed price) |

**GENERAL PHARMACEUTICAL BENEFITS**

|       |                                                                                   |                                       |            |            |
|-------|-----------------------------------------------------------------------------------|---------------------------------------|------------|------------|
| 8048N | Abciximab                                                                         | 10 mg in 5 mL                         | 1 @ 482.23 | LY         |
| 8747J | Acetylcysteine                                                                    | 200 mg per mL, 5 mL                   | 6 @ 28.11  | BQ         |
| 1003T | Aciclovir                                                                         | 200 mg                                | 25 @ 31.56 | AF, GM, SZ |
|       |                                                                                   |                                       | 25 @ 33.73 | GK         |
| 2600W | Allopurinol                                                                       | 100 mg                                | 100 @ 3.39 | AF         |
| 2576N | Aluminium Hydroxide with Magnesium Hydroxide                                      | 200 mg-200 mg                         | 100 @ 4.83 | JT         |
| 2157M |                                                                                   | 200 mg-200 mg per 5 mL, 500 mL        | 1 @ 4.83   | JT         |
| 2159P | Aluminium Hydroxide with Magnesium Trisilicate and Magnesium Hydroxide            | 250 mg-120 mg-120 mg per 5 mL, 500 mL | 1 @ 4.01   | FM         |
| 3109P | Amiloride Hydrochloride                                                           | 5 mg                                  | 50 @ 2.28  | AF         |
| 3079C | Amino Acid Formula without Methionine, Threonine and Valine and low in Isoleucine | 200 g                                 | 1 @ 208.40 | SB         |
| 8554F | Amino Acid Formula without Phenylalanine                                          | 500 mg, 200                           | 1 @ 79.37  | SB         |
| 8678R |                                                                                   | 1 g, 75                               | 1 @ 59.19  | SB         |
| 8706F |                                                                                   | 42 g, 20                              | 1 @ 156.49 | SB         |
| 2347M |                                                                                   | 20 g, 30                              | 1 @ 208.07 | SB         |
| 3072Q |                                                                                   | 250 g                                 | 1 @ 150.43 | SB         |

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                                                                                                         | Form/Strength                         | Pack and Price<br>\$ | Manufacturer |
|-------|--------------------------------------------------------------------------------------------------------------|---------------------------------------|----------------------|--------------|
| 1411G | Amino Acid Formula without Phenylalanine, and Vitamins with Minerals                                         | Pack containing 60 sachets/60 tablets | 1 @ 544.55           | SB           |
| 2379F | Amino Acid Formula without Phenylalanine, Tyrosine and Methionine                                            | 500 g                                 | 1 @ 666.39           | SB           |
| 8479G | Amino Acid Formula with Vitamins, Minerals and Long Chain Polyunsaturated Fatty Acids without Phenylalanine  | 400 g                                 | 1 @ 87.15            | SB           |
| 2650L | Amino Acid Formula with Vitamins and Minerals without Lysine and low in Tryptophan                           | 400 g                                 | 1 @ 83.41            | SB           |
| 2646G |                                                                                                              | 500 g                                 | 1 @ 202.28           | SB           |
| 8417B | Amino Acid Formula with Vitamins and Minerals without Methionine                                             | 400 g                                 | 1 @ 95.36            | SB           |
| 8677Q |                                                                                                              | 20 g, 30                              | 1 @ 448.00           | VF           |
| 8744F |                                                                                                              | 25 g, 30                              | 1 @ 772.99           | VF           |
| 8328H |                                                                                                              | 500 g                                 | 1 @ 222.29           | SB           |
| 8416Y |                                                                                                              | 500 g                                 | 1 @ 337.29           | SB           |
| 9133Q |                                                                                                              | 130 mL, 30                            | 1 @ 772.99           | VF           |
| 8058D | Amino Acid Formula with Vitamins and Minerals without Methionine, Threonine and Valine and low in Isoleucine | 400 g                                 | 1 @ 77.88            | SB           |
| 8059E |                                                                                                              | 500 g                                 | 1 @ 192.04           | SB           |
| 8061G |                                                                                                              | 500 g                                 | 1 @ 240.69           | SB           |
| 8555G | Amino Acid Formula with Vitamins and Minerals without Phenylalanine                                          | 20 g, 30                              | 1 @ 221.15           | VF           |
| 8591E |                                                                                                              | 25 g, 30                              | 1 @ 385.68           | VF           |
| 8804J |                                                                                                              | 27.8 g, 30                            | 1 @ 514.34           | SB           |
| 8613H |                                                                                                              | 29 g, 30                              | 1 @ 221.42           | SB           |
| 8727H |                                                                                                              | 50 g, 30                              | 1 @ 501.88           | SB           |
| 2737C |                                                                                                              | 400 g                                 | 1 @ 75.00            | SB           |
| 8467P |                                                                                                              | 325 g                                 | 1 @ 85.54            | AB           |
| 8545R |                                                                                                              | 400 g                                 | 1 @ 105.27           | AB           |
| 2738D |                                                                                                              | 500 g                                 | 1 @ 109.70           | SB           |
| 2739E |                                                                                                              | 500 g                                 | 1 @ 168.25           | SB           |
| 8746H |                                                                                                              | 250 mL                                | 18 @ 261.37          | SB           |
| 2382J |                                                                                                              | 87 mL, 30                             | 1 @ 257.09           | VF           |
| 9021T |                                                                                                              | 125 mL, 30                            | 1 @ 514.34           | SB           |
| 8846N |                                                                                                              | 130 mL, 30                            | 1 @ 385.48           | VF           |
| 2474F |                                                                                                              | 174 mL, 30                            | 1 @ 511.90           | VF           |
| 8631G | Amino Acid Formula with Vitamins and Minerals without Phenylalanine and Tyrosine                             | 20 g, 30                              | 1 @ 448.00           | VF           |
| 8667E |                                                                                                              | 25 g, 30                              | 1 @ 772.99           | VF           |
| 8445L |                                                                                                              | 400 g                                 | 1 @ 95.36            | SB           |
| 8446M |                                                                                                              | 500 g                                 | 1 @ 222.29           | SB           |
| 3078B |                                                                                                              | 500 g                                 | 1 @ 337.29           | SB           |
| 9132P |                                                                                                              | 130 mL, 30                            | 1 @ 772.99           | VF           |
| 8592F | Amino Acid Formula with Vitamins and Minerals without Valine, Leucine and Isoleucine                         | 20 g, 30                              | 1 @ 448.00           | VF           |
| 8632H |                                                                                                              | 25 g, 30                              | 1 @ 772.99           | VF           |
| 8745G |                                                                                                              | 29 g, 30                              | 1 @ 448.51           | SB           |
| 8468Q |                                                                                                              | 350 g                                 | 1 @ 96.28            | AB           |

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                                                                                        | Form/Strength                         | Pack and Price<br>\$ | Manufacturer |
|-------|---------------------------------------------------------------------------------------------|---------------------------------------|----------------------|--------------|
| 2380G |                                                                                             | 400 g                                 | 1 @ 95.36            | SB           |
| 8469R |                                                                                             | 325 g                                 | 1 @ 173.57           | AB           |
| 8310J |                                                                                             | 500 g                                 | 1 @ 666.39           | SB           |
| 8260R |                                                                                             | 500 g                                 | 1 @ 222.29           | SB           |
| 8057C |                                                                                             | 500 g                                 | 1 @ 337.29           | SB           |
| 2375B |                                                                                             | 130 mL, 30                            | 1 @ 772.99           | VF           |
| 2250K | Amino Acids—Synthetic, Formula                                                              | 400 g                                 | 1 @ 43.77            | AB           |
| 8574G |                                                                                             | 400 g                                 | 1 @ 44.34            | AB           |
| 8443J |                                                                                             | 400 g                                 | 1 @ 44.34            | SB           |
| 8754R |                                                                                             | 400 g                                 | 1 @ 44.34            | SB           |
| 2244D |                                                                                             | 400 g                                 | 1 @ 44.34            | SB           |
| 8575H |                                                                                             | 400 g                                 | 1 @ 44.34            | AB           |
| 3066J |                                                                                             | 400 g                                 | 1 @ 44.34            | SB           |
| 8755T |                                                                                             | 400 g                                 | 1 @ 44.34            | SB           |
| 2553J |                                                                                             | 400 g                                 | 1 @ 44.34            | SB           |
| 2246F | Amino Acid Synthetic Formula<br>supplemented with Long Chain<br>Polyunsaturated Fatty Acids | 400 g                                 | 1 @ 45.18            | SB           |
| 2560R |                                                                                             | 400 g                                 | 1 @ 45.18            | SB           |
| 8736T | Amisulpride                                                                                 | 100 mg per mL, 60 mL                  | 1 @ 66.90            | SW           |
| 9092M | Atomoxetine Hydrochloride                                                                   | 10 mg (base)                          | 28 @ 107.38          | LY           |
| 9093N |                                                                                             | 18 mg (base)                          | 28 @ 107.38          | LY           |
| 9094P |                                                                                             | 25 mg (base)                          | 28 @ 107.38          | LY           |
| 9095Q |                                                                                             | 40 mg (base)                          | 28 @ 107.38          | LY           |
| 9096R |                                                                                             | 60 mg (base)                          | 28 @ 107.38          | LY           |
| 1140B | Bcg Immunotherapeutic (bacillus<br>Calmette-guérin/ Connaught Strain)                       | 6.6 to 19.2 x 10 <sup>8</sup> CFU set | 1 @ 151.15           | SW           |
| 1775K | Benzylpenicillin                                                                            | 600 mg                                | 1 @ 3.44             | CS           |
| 2647H |                                                                                             | 3 g                                   | 1 @ 5.65             | CS           |
| 2812B | Betamethasone Valerate                                                                      | 200 mcg (base) per g, 100 g           | 1 @ 9.45             | EX, FM, SH   |
|       |                                                                                             |                                       | 1 @ 12.54            | SI           |
| 2820K |                                                                                             | 200 mcg (base) per g, 100 g           | 1 @ 9.45             | EX, SH       |
| 8066M | Bifonazole                                                                                  | 10 mg per g, 15 g                     | 1 @ 9.69             | BN           |
| 2544X | Biperiden Hydrochloride                                                                     | 2 mg                                  | 100 @ 7.23           | LM           |
| 1260H | Bisacodyl                                                                                   | 10 mg, 10                             | 1 @ 5.15             | PP           |
|       |                                                                                             |                                       | 1 @ 5.53             | BY           |
| 1258F |                                                                                             | 10 mg, 12                             | 1 @ 4.21             | FL, PP       |
| 9117W | Bortezomib                                                                                  | 3.5 mg                                | 1 @ 1748.99          | JC           |
| 9118X |                                                                                             | 3.5 mg                                | 1 @ 1748.99          | JC           |
| 8560M | Calcium                                                                                     | 250 mg                                | 120 @ 7.89           | BN           |
| 3116B |                                                                                             | 500 mg                                | 60 @ 4.91            | IA           |
| 8740B | Calcium Folate                                                                              | equiv. to 50 mg folic acid in 5 mL    | 1 @ 29.68            | HH           |
|       |                                                                                             |                                       | 10 @ 234.55          | PF           |
| 8812T |                                                                                             | equiv. to 100 mg folic acid in 10 mL  | 1 @ 26.70            | IT           |
| 9041W |                                                                                             | equiv. to 300 mg folic acid in 30 mL  | 1 @ 77.31            | HH           |
| 1153Q | Carbimazole                                                                                 | 5 mg                                  | 100 @ 12.31          | LM           |
| 8576J | Carbohydrate, Fat, Vitamins, Minerals and<br>Trace Elements                                 | 400 g                                 | 1 @ 31.76            | AB           |
| 8369L |                                                                                             | 400 g                                 | 1 @ 35.63            | SB           |
| 8514D | Carbomer 974                                                                                | 3 mg per g, 0.5 g, 30                 | 1 @ 9.88             | AQ           |
| 8578L | Carbomer 980                                                                                | 2 mg per g, 0.6 mL, 30                | 1 @ 9.68             | NV           |

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                                                                   | Form/Strength                        | Pack and Price<br>\$ | Manufacturer       |
|-------|------------------------------------------------------------------------|--------------------------------------|----------------------|--------------------|
| 1160C | Carboplatin                                                            | 50 mg in 5 mL                        | 1 @ 30.94            | HH, IT, PU         |
| 1161D |                                                                        | 150 mg in 15 mL                      | 1 @ 70.92            | HH, IT, PU         |
| 1162E |                                                                        | 450 mg in 45 mL                      | 1 @ 136.98           | HH, IT, PU         |
| 8823J | Carmellose Sodium                                                      | 2.5 mg per mL, 0.6 mL, 24            | 1 @ 8.50             | CX                 |
| 2338C |                                                                        | 5 mg per mL, 0.4 mL, 30              | 1 @ 9.88             | AG                 |
| 2324H |                                                                        | 10 mg per mL, 0.4 mL, 30             | 1 @ 9.88             | AG                 |
| 8824K | Cefepime                                                               | 10 mg per mL, 0.6 mL, 28             | 1 @ 9.22             | CX                 |
| 8315P |                                                                        | 1 g                                  | 1 @ 17.74            | BQ                 |
| 8316Q |                                                                        | 2 g                                  | 1 @ 32.52            | BQ                 |
| 1085D | Cefotaxime                                                             | 1 g                                  | 1 @ 4.64             | SZ                 |
| 1086E |                                                                        | 2 g                                  | 1 @ 8.51             | SZ                 |
| 1783W |                                                                        | 500 mg                               | 1 @ 4.07             | IZ                 |
| 1784X | Ceftriaxone                                                            | 1 g                                  | 1 @ 6.36             | HH, IZ, RO, SZ     |
| 1785Y |                                                                        | 2 g                                  | 1 @ 11.28            | HH, IZ, RO, SZ     |
| 1256D |                                                                        | 500 mg                               | 5 @ 19.57            | HH                 |
| 1257E | Cephazolin                                                             | 1 g                                  | 5 @ 30.05            | HH, SZ             |
| 1163F |                                                                        | 2 mg                                 | 25 @ 32.89           | GK                 |
| 1585K |                                                                        | 25 mg                                | 50 @ 3.61            | NV                 |
| 2967E | Cholestyramine                                                         | 4.7 g (equiv. to 4 g cholestyramine) | 1 @ 25.52            | BQ                 |
| 1217C | Ciprofloxacin                                                          | 3 mg per mL, 5 mL                    | 1 @ 9.96             | IQ                 |
|       |                                                                        |                                      | 1 @ 10.88            | AQ                 |
| 8800E |                                                                        | 10 mg in 5 mL                        | 1 @ 660.45           | OA                 |
| 1211R | Clomiphene Citrate                                                     | 50 mg                                | 5 @ 13.34            | AW, GX, HX         |
| 1805B | Clonazepam                                                             | 500 mcg                              | 100 @ 6.89           | AF                 |
|       |                                                                        |                                      | 100 @ 8.68           | RO                 |
| 1806C |                                                                        | 2 mg                                 | 100 @ 12.96          | AF                 |
|       |                                                                        |                                      | 100 @ 15.00          | RO                 |
| 1808E | Clotrimazole                                                           | 2.5 mg per mL, 10 mL                 | 1 @ 4.31             | RO                 |
| 1027C |                                                                        | 10 mg per mL, 20 mL                  | 1 @ 5.97             | BN                 |
| 8785J |                                                                        | 30 mg-500 mg                         | 20 @ 1.66            | AL, AV, CO, FM, SZ |
|       |                                                                        |                                      | 20 @ 3.09            | SW                 |
| 1228P | Copper Sulfate                                                         | Tablets, 36                          | 1 @ 32.53            | BN                 |
| 1079T | Cyclophosphamide                                                       | 500 mg                               | 1 @ 11.67            | BX                 |
| 8657P | Cyclosporin                                                            | 10 mg                                | 60 @ 44.00           | NV                 |
| 8658Q |                                                                        | 25 mg                                | 30 @ 48.25           | SZ                 |
|       |                                                                        |                                      | 30 @ 49.39           | NV                 |
| 8659R |                                                                        | 50 mg                                | 30 @ 100.26          | SZ                 |
|       |                                                                        |                                      | 30 @ 101.38          | NV                 |
| 8660T |                                                                        | 100 mg                               | 30 @ 194.94          | SZ                 |
|       |                                                                        |                                      | 30 @ 196.07          | NV                 |
| 8661W | Cyproheptadine Hydrochloride                                           | 100 mg per mL, 50 mL                 | 1 @ 353.12           | NV                 |
| 1798P |                                                                        | 4 mg                                 | 50 @ 3.89            | FR                 |
| 1270W |                                                                        | 50 mg                                | 50 @ 100.65          | AF, GM, GX, SY, SZ |
|       |                                                                        |                                      | 50 @ 102.15          | SC                 |
| 9164H | Cystine with Carbohydrate                                              | 4 g containing 500 mg cystine, 30    | 1 @ 127.40           | VF                 |
| 2884T | Cytarabine                                                             | 100 mg in 5 mL                       | 5 @ 44.55            | PU                 |
| 8641T | Dalteparin Sodium (low Molecular Weight Heparin Sodium—Porcine Mucous) | 2,500 units (anti-Xa) in 0.2 mL      | 10 @ 49.16           | PH                 |
| 8642W | Desmopressin Acetate                                                   | 5,000 units (anti-Xa) in 0.2 mL      | 10 @ 51.23           | PH                 |
| 8643X |                                                                        | 7,500 units (anti-Xa) in 0.75 mL     | 10 @ 77.23           | PH                 |
| 8662X |                                                                        | 200 mcg                              | 30 @ 57.83           | FP                 |

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                                                         | Form/Strength                                | Pack and Price<br>\$ | Manufacturer              |
|-------|--------------------------------------------------------------|----------------------------------------------|----------------------|---------------------------|
| 2129C |                                                              | 100 mcg per mL, 2.5 mL                       | 1 @ 30.95            | FP                        |
| 8711L |                                                              | 10 mcg per actuation, 60 actuations,<br>6 mL | 1 @ 77.31            | FP                        |
| 1302M | Diclofenac Sodium                                            | 100 mg                                       | 20 @ 9.25            | NV                        |
| 1299J |                                                              | 25 mg (e.c.)                                 | 50 @ 3.32            | AW, CH, GM,<br>GX, SZ, TW |
|       |                                                              |                                              | 50 @ 4.30            | NV                        |
| 3164M | Digoxin                                                      | 50 mcg per mL, 60 mL                         | 1 @ 11.13            | SI                        |
| 8461H | Disodium Pamidronate                                         | 15 mg in 5 mL                                | 1 @ 64.45            | HH                        |
| 8462J |                                                              | 30 mg in 10 mL                               | 1 @ 128.90           | HH                        |
| 8071T | Docetaxel                                                    | 20 mg (anhydrous) set                        | 1 @ 327.33           | SW                        |
| 1336H | Doxorubicin Hydrochloride                                    | 10 mg in 5 mL                                | 1 @ 34.11            | HH, IT, PH                |
| 1340M |                                                              | 20 mg in 10 mL                               | 1 @ 59.96            | PH                        |
| 1342P | Doxycycline                                                  | 50 mg in 25 mL                               | 1 @ 137.11           | HH, IT, PH                |
| 9107H |                                                              | 100 mg (as monohydrate)                      | 7 @ 2.05             | CH, GX, SZ,<br>TW         |
| 2702F |                                                              | 100 mg (as hydrochloride)                    | 7 @ 2.05             | AF, GM, SI                |
|       |                                                              |                                              | 7 @ 3.24             | PF                        |
| 2703G |                                                              | 100 mg (as hydrochloride)                    | 7 @ 2.05             | FA                        |
|       |                                                              |                                              | 7 @ 3.20             | HH                        |
| 9108J |                                                              | 100 mg (as monohydrate)                      | 7 @ 2.05             | CH, SZ, TW                |
| 2714W |                                                              | 100 mg (as hydrochloride)                    | 7 @ 2.05             | AF, GM, SI                |
|       |                                                              |                                              | 7 @ 3.24             | PF                        |
| 3199J | Electrolyte Replacement Solution                             | 1 L                                          | 1 @ 7.77             | BX                        |
| 8716R | Enoxaparin Sodium                                            | 20 mg (2,000 i.u. anti-Xa) in 0.2 mL         | 10 @ 49.16           | SW                        |
| 8639Q |                                                              | 40 mg (4,000 i.u. anti-Xa) in 0.4 mL         | 10 @ 51.23           | SW                        |
| 9196B |                                                              | 40 mg (4,000 i.u. anti-Xa) in 0.4 mL         | 10 @ 51.23           | SW                        |
| 8640R |                                                              | 60 mg (6,000 i.u. anti-Xa) in 0.6 mL         | 10 @ 73.26           | SW                        |
| 8367J | Entacapone                                                   | 200 mg                                       | 100 @ 137.70         | NV                        |
| 1375J | Epirubicin Hydrochloride                                     | 10 mg in 5 mL                                | 1 @ 53.34            | IT, PH                    |
| 1376K |                                                              | 20 mg in 10 mL                               | 1 @ 98.77            | PH                        |
| 1377L |                                                              | 50 mg in 25 mL                               | 1 @ 242.42           | HH, IT, PH                |
| 9018P |                                                              | 50 mg                                        | 1 @ 242.42           | HH                        |
| 8817C |                                                              | 100 mg in 50 mL                              | 1 @ 478.33           | HH, IT                    |
| 8397Y | Eprosartan Mesylate                                          | 400 mg (base)                                | 28 @ 13.09           | SM                        |
| 8951D |                                                              | 400 mg (base)                                | 28 @ 13.09           | SM                        |
| 8683B | Eptifibatide Acetate                                         | 20 mg (base) in 10 mL                        | 1 @ 128.06           | SH                        |
| 8684C |                                                              | 75 mg (base) in 100 mL                       | 1 @ 337.98           | SH                        |
| 1397M | Erythromycin Lactobionate                                    | 1 g (base)                                   | 1 @ 8.99             | LM                        |
| 8001D | Essential Amino Acids Formula with<br>Minerals and Vitamin C | 200 g                                        | 1 @ 62.77            | SB                        |
| 2027Q |                                                              | 400 g                                        | 1 @ 125.55           | SB                        |
| 8778B | Etanercept                                                   | 25 mg and 1 mL solvent, 4                    | 1 @ 911.29           | WX                        |
| 8779C |                                                              | 25 mg and 1 mL solvent, 4                    | 1 @ 911.29           | WX                        |
| 9035M |                                                              | 25 mg and 1 mL solvent, 4                    | 1 @ 911.29           | WX                        |
| 9036N |                                                              | 25 mg and 1 mL solvent, 4                    | 1 @ 911.29           | WX                        |
| 8637N |                                                              | 25 mg and 1 mL solvent, 4                    | 1 @ 911.29           | WX                        |
| 8638P |                                                              | 25 mg and 1 mL solvent, 4                    | 1 @ 911.29           | WX                        |
| 9037P |                                                              | 25 mg and 1 mL solvent, 4                    | 1 @ 911.29           | WX                        |
| 8748K | Ethacrynic Acid                                              | 25 mg                                        | 100 @ 25.63          | FK                        |
| 1390E | Etoposide                                                    | 100 mg in 5 mL                               | 1 @ 33.37            | HH, IT                    |
| 8120J | Etoposide Phosphate                                          | 113.6 mg (equiv. to 100 mg etoposide)        | 1 @ 33.37            | BQ                        |
| 8842J | Everolimus                                                   | 0.75 mg                                      | 60 @ 786.10          | NV                        |

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                               | Form/Strength           | Pack and Price<br>\$ | Manufacturer |
|-------|------------------------------------|-------------------------|----------------------|--------------|
| 1473M | Fluconazole                        | 100 mg in 50 mL         | 1 @ 22.75            | PF, SZ       |
| 1474N |                                    | 200 mg in 100 mL        | 1 @ 41.47            | BX, PF, SZ   |
| 1433K | Fludrocortisone Acetate            | 100 mcg                 | 100 @ 8.04           | BQ           |
| 2528C | Fluorouracil                       | 500 mg in 10 mL         | 1 @ 5.13             | HH, IT       |
| 9005Y |                                    | 1000 mg in 20 mL        | 1 @ 8.83             | IT           |
| 2958Q | Folic Acid                         | 500 mcg                 | 100 @ 3.68           | AF           |
| 1437P |                                    | 5 mg                    | 100 @ 3.80           | AF           |
| 8672K | Follitropin Alfa                   | 75 i.u.                 | 1 @ 48.23            | SG           |
| 8713N |                                    | 300 i.u.                | 1 @ 185.67           | SG           |
| 8675N |                                    | 450 i.u.                | 1 @ 278.49           | SG           |
| 8714P |                                    | 450 i.u.                | 1 @ 278.50           | SG           |
| 8715Q |                                    | 900 i.u.                | 1 @ 554.41           | SG           |
| 8565T | Follitropin Beta                   | 300 i.u. in 0.36 mL     | 1 @ 185.67           | OR           |
| 8566W |                                    | 600 i.u. in 0.72 mL     | 1 @ 371.33           | OR           |
| 8871X |                                    | 900 i.u. in 1.08 mL     | 1 @ 554.40           | OR           |
| 2414C | Frusemide                          | 20 mg                   | 50 @ 1.30            | FM           |
|       |                                    |                         | 50 @ 1.30            | SW           |
| 8444K | Gelatin - Succinylated             | 20 g per 500 mL, 500 mL | 1 @ 13.11            | BR           |
| 8049P | Gemcitabine Hydrochloride          | 200 mg (base)           | 1 @ 57.38            | LY           |
| 8050Q |                                    | 1 g (base)              | 1 @ 271.56           | LY           |
| 2824P | Gentamicin Sulfate                 | 80 mg (base) in 2 mL    | 5 @ 7.04             | HH           |
| 2245E | Glucose                            | 278 mmol per L, 1 L     | 1 @ 3.90             | BX           |
| 3106L | Glucose and Ketone Indicator—Urine | Reagent strips, 50      | 1 @ 5.44             | RD           |
| 3107M |                                    | Reagent strips, 50      | 1 @ 5.50             | BN           |
| 9193W | Glucose Indicator—Blood            | Electrode strips, 25    | 1 @ 11.69            | PZ           |
| 2979T |                                    | Electrode strips, 50    | 1 @ 23.38            | RD           |
| 2891E |                                    | Electrode strips, 50    | 1 @ 23.38            | RD           |
| 8890X |                                    | Electrode strips, 50    | 1 @ 23.38            | MS           |
| 1820T |                                    | Electrode strips, 50    | 1 @ 23.38            | DB           |
| 9013J |                                    | Electrode strips, 50    | 1 @ 23.38            | OZ           |
| 8766J |                                    | Electrode strips, 50    | 1 @ 23.38            | OZ           |
| 8749L |                                    | Electrode strips, 50    | 1 @ 23.38            | OZ           |
| 8682Y |                                    | Electrode strips, 50    | 1 @ 23.38            | WF           |
| 8723D |                                    | Electrode strips, 50    | 1 @ 23.38            | BR           |
| 9063B |                                    | Electrode strips, 50    | 1 @ 23.38            | BR           |
| 2263D |                                    | Electrode strips, 50    | 1 @ 23.38            | MS           |
| 9046D |                                    | Electrode strips, 50    | 1 @ 23.38            | DN           |
| 8825L |                                    | Electrode strips, 50    | 1 @ 23.38            | DB           |
| 8190C |                                    | Reagent strips, 50      | 1 @ 23.38            | RD           |
| 8739Y |                                    | Reagent strips, 50      | 1 @ 23.38            | RD           |
| 8806L |                                    | Reagent strips, 51      | 1 @ 23.38            | RD           |
| 2890D |                                    | Reagent strips, 50      | 1 @ 23.38            | NA           |
| 2860M |                                    | Reagent strips, 50      | 1 @ 23.38            | NA           |
| 8759B |                                    | Reagent strips, 50      | 1 @ 23.38            | LB           |
| 2914J |                                    | Reagent strips, 50      | 1 @ 19.74            | NA           |
| 2917M |                                    | Reagent strips, 50      | 1 @ 19.74            | BN           |
| 8795X |                                    | Reagent strips, 50      | 1 @ 23.38            | PX           |
| 2352T | Glucose Indicator—Urine            | Reagent strips, 50      | 1 @ 6.70             | BN           |
| 3104J |                                    | Reagent strips, 50      | 1 @ 6.21             | BN           |
| 2555L | Glycerol                           | 700 mg, 12              | 1 @ 3.83             | PP           |
| 2556M |                                    | 1.4 g, 12               | 1 @ 3.96             | PP           |
| 2557N |                                    | 2.8 g, 12               | 1 @ 4.11             | PP           |
| 8728J | Granisetron Hydrochloride          | 2 mg (base)             | 1 @ 26.28            | HH           |

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                                                                      | Form/Strength                                    | Pack and Price<br>\$ | Manufacturer   |
|-------|---------------------------------------------------------------------------|--------------------------------------------------|----------------------|----------------|
| 1076P | Heparin Sodium                                                            | 35,000 units in 35 mL                            | 1 @ 16.98            | HH             |
| 1583H | Human Chorionic Gonadotrophin                                             | 500 units set                                    | 1 @ 23.51            | OR             |
| 1640H | Hydralazine Hydrochloride                                                 | 25 mg                                            | 100 @ 4.54           | AF             |
| 1639G |                                                                           | 50 mg                                            | 100 @ 5.50           | AF             |
| 1486F | Hydrochlorothiazide with Amiloride<br>Hydrochloride                       | 50 mg-5 mg                                       | 50 @ 3.73            | MK             |
| 1502C | Hydrocortisone Acetate                                                    | 21.1 g                                           | 1 @ 16.28            | AS             |
| 1501B | Hydrocortisone Sodium Succinate                                           | 100 mg with 2 mL solvent                         | 1 @ 5.36             | PH             |
| 1510L |                                                                           | 100 mg with 2 mL solvent                         | 1 @ 5.36             | PH             |
| 1511M |                                                                           | 250 mg with 2 mL solvent                         | 1 @ 9.27             | PH             |
| 8299T | Hypromellose with Dextran                                                 | 3 mg-1 mg per mL, 0.4 mL, 28                     | 1 @ 9.68             | AQ             |
| 3198H | Ibuprofen                                                                 | 200 mg                                           | 50 @ 2.82            | AF             |
| 3190X |                                                                           | 400 mg                                           | 30 @ 2.77            | AB             |
| 2446R | Idarubicin Hydrochloride                                                  | 5 mg                                             | 1 @ 80.23            | PH             |
| 2448W |                                                                           | 10 mg                                            | 1 @ 148.40           | PH             |
| 8076C | Ifosfamide                                                                | 1 g                                              | 1 @ 51.03            | BX             |
| 8077D |                                                                           | 2 g                                              | 1 @ 94.15            | BX             |
| 2757D | Indomethacin                                                              | 100 mg                                           | 20 @ 8.04            | MK             |
| 2454E |                                                                           | 25 mg                                            | 50 @ 2.12            | AF             |
|       |                                                                           |                                                  | 50 @ 3.29            | MK             |
| 8571D | Insulin Aspart                                                            | 100 units per mL, 10 mL                          | 1 @ 30.57            | NO             |
| 8435Y |                                                                           | 100 units per mL, 3 mL, 5                        | 1 @ 51.56            | NF, NO         |
| 8609D | Insulin Aspart—Insulin Aspart Protamine<br>Suspension                     | 100 units (30 units-70 units) per mL,<br>3 mL, 5 | 1 @ 51.56            | NF, NO         |
| 9040T | Insulin Detemir                                                           | 100 units per mL, 3 mL, 5                        | 1 @ 85.26            | NF, NO         |
| 9039R | Insulin Glargine                                                          | 100 units per mL, 3 mL, 5                        | 1 @ 85.26            | AV, SW         |
| 1921D | Insulin Glulisine                                                         | 100 units per mL, 3 mL, 5                        | 1 @ 51.56            | SW             |
| 1711C | Insulin Isophane (n.p.h.)                                                 | 100 units per mL, 10 mL                          | 1 @ 27.72            | AS             |
| 1533Q |                                                                           | 100 units per mL, 10 mL                          | 1 @ 25.48            | LY, NO         |
| 1761Q |                                                                           | 100 units per mL, 3 mL, 5                        | 1 @ 43.58            | LY, NI, NL, NO |
| 8084L | Insulin Lispro                                                            | 100 units per mL, 10 mL                          | 1 @ 30.57            | LY             |
| 8212F |                                                                           | 100 units per mL, 3 mL, 5                        | 1 @ 51.56            | LY             |
| 8390N | Insulin Lispro—Insulin Lispro Protamine<br>Suspension                     | 100 units (25 units-75 units) per mL,<br>3 mL, 5 | 1 @ 51.56            | LY             |
| 8874C |                                                                           | 100 units (50 units-50 units) per mL,<br>3 mL, 5 | 1 @ 51.56            | LY             |
| 1713E | Insulin Neutral                                                           | 100 units per mL, 10 mL                          | 1 @ 27.72            | AS             |
| 1531N |                                                                           | 100 units per mL, 10 mL                          | 1 @ 25.48            | LY, NO         |
| 1762R |                                                                           | 100 units per mL, 3 mL, 5                        | 1 @ 43.58            | LY, NO         |
| 1426C | Insulin Neutral—Insulin Isophane (n.p.h.),<br>(mixed) (biphasic Isophane) | 100 units (30 units-70 units) per mL,<br>10 mL   | 1 @ 25.48            | LY             |
| 1763T |                                                                           | 100 units (30 units-70 units) per mL,<br>3 mL, 5 | 1 @ 43.58            | LY, NI, NO     |
| 2062M |                                                                           | 100 units (50 units-50 units) per mL,<br>3 mL, 5 | 1 @ 43.58            | NO             |
| 8180M | Interferon Alfa-2a                                                        | 3,000,000 i.u. in 0.5 mL                         | 1 @ 33.32            | RO             |
| 8551C |                                                                           | 4,500,000 i.u. in 0.5 mL                         | 1 @ 51.66            | RO             |
| 8552D |                                                                           | 6,000,000 i.u. in 0.5 mL                         | 1 @ 67.66            | RO             |
| 8553E |                                                                           | 9,000,000 i.u. in 0.5 mL                         | 1 @ 99.94            | RO             |
| 8181N |                                                                           | 3,000,000 i.u. in 0.5 mL                         | 1 @ 33.32            | RO             |
| 8182P |                                                                           | 4,500,000 i.u. in 0.5 mL                         | 1 @ 51.66            | RO             |
| 8183Q |                                                                           | 6,000,000 i.u. in 0.5 mL                         | 1 @ 67.66            | RO             |
| 8184R |                                                                           | 9,000,000 i.u. in 0.5 mL                         | 1 @ 99.94            | RO             |

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                                                                      | Form/Strength                         | Pack and Price<br>\$ | Manufacturer                     |
|-------|---------------------------------------------------------------------------|---------------------------------------|----------------------|----------------------------------|
| 8572E | Interferon Alfa-2b                                                        | 18,000,000 i.u. in 1.2 mL             | 1 @ 199.87           | SH                               |
| 8348J |                                                                           | 18,000,000 i.u. in 1.2 mL             | 1 @ 199.87           | SH                               |
| 8476D |                                                                           | 30,000,000 i.u. in 1.2 mL             | 1 @ 333.11           | SH                               |
| 8671J |                                                                           | 21 mcg per dose (200 doses)           | 1 @ 13.62            | BY                               |
| 1542E |                                                                           | 250 mcg (anhydrous) in 1 mL, 30       | 1 @ 15.43            | AF, AW, CH,<br>GM, GX, PU,<br>TW |
|       |                                                                           |                                       | 1 @ 15.79            | BY                               |
| 8238N |                                                                           | 500 mcg (anhydrous) in 1 mL, 30       | 1 @ 18.11            | AF, AW, CH,<br>GM, GX, PU,<br>TW |
|       |                                                                           |                                       | 1 @ 18.42            | BY                               |
| 8415X | Irinotecan Hydrochloride Trihydrate                                       | 100 mg in 5 mL                        | 1 @ 323.62           | HH, PU, SZ                       |
| 9134R | Isoleucine with Carbohydrate                                              | 4 g containing 50 mg isoleucine, 30   | 1 @ 127.40           | VF                               |
| 2587E | Isosorbide Dinitrate                                                      | 10 mg                                 | 100 @ 3.86           | AF                               |
| 2588F |                                                                           | 5 mg                                  | 100 @ 4.31           | SI                               |
| 1588N | Ketoprofen                                                                | 100 mg                                | 20 @ 8.41            | SW                               |
| 9148L | Lapatinib                                                                 | 250 mg (as ditosylate monohydrate)    | 70 @ 1690.52         | GK                               |
| 8797B | Levodopa with Carbidopa and Entacapone                                    | 50 mg-12.5 mg-200 mg                  | 100 @ 152.73         | NV                               |
| 8798C |                                                                           | 100 mg-25 mg-200 mg                   | 100 @ 167.75         | NV                               |
| 8799D |                                                                           | 150 mg-37.5 mg-200 mg                 | 100 @ 182.77         | NV                               |
| 8290H | Lithium Carbonate                                                         | 450 mg (s.r.)                         | 100 @ 13.94          | GK                               |
| 1598D | Mercaptopurine                                                            | 50 mg                                 | 25 @ 56.47           | GK                               |
| 8731M | Mesalazine                                                                | 500 mg (e.c.)                         | 100 @ 145.51         | OA                               |
| 8598M |                                                                           | 500 mg                                | 100 @ 145.51         | OA                               |
| 8753Q |                                                                           | 1 g in 100 mL, 7                      | 1 @ 82.45            | FP                               |
| 8616L |                                                                           | 2 g in 60 mL, 7                       | 1 @ 82.45            | OA                               |
| 8617M |                                                                           | 4 g in 60 mL, 7                       | 1 @ 109.87           | OA                               |
| 8768L |                                                                           | 80 g                                  | 1 @ 82.45            | OA                               |
| 2826R | Methysergide                                                              | 1 mg                                  | 50 @ 19.27           | NV                               |
| 1638F | Metronidazole                                                             | 500 mg in 100 mL                      | 1 @ 5.11             | BX                               |
|       |                                                                           |                                       | 10 @ 39.34           | HH, SZ                           |
| 9026C | Miconazole Nitrate                                                        | 20 mg per g, 15 g                     | 1 @ 4.74             | JT                               |
| 8282X | Milk Powder—Lactose Free Formula                                          | 900 g                                 | 1 @ 18.15            | WX                               |
| 2350Q |                                                                           | 900 g                                 | 1 @ 16.50            | NU                               |
| 8283Y |                                                                           | 900 g                                 | 1 @ 18.15            | WX                               |
| 2349P |                                                                           | 900 g                                 | 1 @ 16.50            | NU                               |
| 2358D | Milk Powder—Lactose Modified                                              | 900 g                                 | 1 @ 18.87            | SJ                               |
| 2357C |                                                                           | 900 g                                 | 1 @ 18.87            | SJ                               |
| 3092R | Milk Powder—Synthetic                                                     | 400 g                                 | 1 @ 46.87            | NU                               |
| 8630F | Milk Protein and Fat Formula with Vitamins and Minerals—Carbohydrate Free | 225 g                                 | 1 @ 26.75            | SB                               |
| 8816B | Modafinil                                                                 | 100 mg                                | 60 @ 170.28          | CS                               |
| 1674D | Naproxen                                                                  | 250 mg                                | 50 @ 3.65            | AF                               |
|       |                                                                           |                                       | 50 @ 4.82            | RO                               |
| 9171Q | Nilotinib                                                                 | 200 mg (as hydrochloride monohydrate) | 28 @ 1371.00         | NV                               |
| 2732T | Nitrazepam                                                                | 5 mg                                  | 25 @ 1.47            | AF                               |
|       |                                                                           |                                       | 25 @ 3.00            | VT                               |
| 1967M | Norethisterone                                                            | 350 mcg                               | 1 @ 2.67             | JC                               |
|       |                                                                           |                                       | 1 @ 2.67             | KR                               |
|       |                                                                           |                                       | 1 @ 3.67             | PH                               |
| 2772X | Norethisterone with Ethinyloestradiol                                     | 500 mcg-35 mcg                        | 1 @ 4.65             | PH                               |



**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                                          | Form/Strength                                  | Pack and Price<br>\$ |        | Manufacturer                               |
|-------|-----------------------------------------------|------------------------------------------------|----------------------|--------|--------------------------------------------|
| 2774B |                                               | Tablet-Pack                                    | 1 @                  | 2.67   | KR                                         |
|       |                                               |                                                | 1 @                  | 4.65   | PH                                         |
| 2773Y |                                               | 1 mg-35 mcg                                    | 1 @                  | 4.65   | PH                                         |
| 2775C |                                               | Tablet-Pack                                    | 1 @                  | 2.67   | KR                                         |
|       |                                               |                                                | 1 @                  | 4.65   | PH                                         |
| 2776D |                                               | Tablet-Pack                                    | 1 @                  | 2.67   | KR                                         |
|       |                                               |                                                | 1 @                  | 4.65   | PH                                         |
| 3176E | Norethisterone with Mestranol                 | 1 mg-50 mcg                                    | 1 @                  | 2.67   | PH                                         |
| 3179H |                                               | Tablet-Pack                                    | 1 @                  | 2.67   | PH                                         |
| 1698J | Nystatin                                      | 100,000 units per g, 15 g                      | 1 @                  | 6.07   | BQ                                         |
| 1733F | Oestrogens—Conjugated                         | 300 mcg                                        | 28 @                 | 4.58   | WX                                         |
| 1734G |                                               | 625 mcg                                        | 28 @                 | 4.84   | WX                                         |
| 8383F | Ofloxacin                                     | 3 mg per mL, 5 mL                              | 1 @                  | 12.86  | AG                                         |
| 3134Y | Oxazepam                                      | 15 mg                                          | 25 @                 | 1.28   | AF                                         |
|       |                                               |                                                | 25 @                 | 3.06   | SI                                         |
| 3135B |                                               | 30 mg                                          | 25 @                 | 1.47   | AF, FM                                     |
|       |                                               |                                                | 25 @                 | 3.37   | SI                                         |
| 8588B | Oxcarbazepine                                 | 60 mg per mL, 250 mL                           | 1 @                  | 65.85  | NV                                         |
| 3026G | Paclitaxel                                    | 30 mg in 5 mL                                  | 1 @                  | 192.73 | BQ, HH, IT                                 |
| 8018B |                                               | 100 mg in 16.7 mL                              | 1 @                  | 639.29 | BQ, HH, IT                                 |
| 3017T |                                               | 150 mg in 25 mL                                | 1 @                  | 931.01 | BQ, HH, IT                                 |
| 8556H | Pancreatic Extract                            | not less than 5,000 BP units lipase activity   | 100 @                | 22.56  | SM                                         |
| 8020D |                                               | not less than 10,000 BP units lipase activity  | 100 @                | 32.87  | SM                                         |
| 8021E |                                               | not less than 25,000 BP units lipase activity  | 100 @                | 65.74  | SM                                         |
| 2495H | Pancrelipase                                  | not less than 10,000 BP units lipase activity  | 250 @                | 83.58  | OR                                         |
| 8366H |                                               | not less than 25,000 BP units lipase activity  | 100 @                | 65.74  | TM                                         |
| 8784H | Paracetamol                                   | 500 mg                                         | 100 @                | 2.00   | AW, CH, FM, GM, HX, JT, PC, SW, SZ, TW, YM |
| 8814X |                                               | 665 mg (m.r.)                                  | 96 @                 | 3.42   | GC                                         |
| 1754H | Paraffin                                      | 3.5 g                                          | 1 @                  | 7.54   | IQ                                         |
|       |                                               |                                                | 1 @                  | 8.57   | AQ                                         |
| 1166J | Phenoxybenzamine Hydrochloride                | 10 mg, 30                                      | 1 @                  | 66.16  | GH                                         |
| 1787C | Phenoxymethylpenicillin                       | 250 mg                                         | 25 @                 | 2.58   | SI                                         |
| 3028J |                                               | 500 mg                                         | 25 @                 | 3.82   | SI                                         |
| 9143F |                                               | 150 mg per 5 mL, 100 mL                        | 1 @                  | 7.99   | FM, SI                                     |
| 1703P |                                               | 250 mg                                         | 25 @                 | 2.58   | SI                                         |
| 9170P | Polyethylene Glycol 400 with Propylene Glycol | 4 mg-3 mg per mL, single dose units 0.7 mL, 28 | 1 @                  | 9.22   | AQ                                         |
| 2334W | Polygeline                                    | 17.5 g per 500 mL, 500 mL                      | 1 @                  | 13.11  | AE                                         |
| 2642C | Potassium Chloride                            | 600 mg                                         | 100 @                | 3.44   | NM                                         |
|       |                                               |                                                | 100 @                | 4.84   | NV                                         |
| 1920C | Prednisolone Sodium Phosphate                 | equiv. to 20 mg prednisolone in 100 mL         | 7 @                  | 39.95  | SI                                         |
| 2554K |                                               | equiv. to 5 mg prednisolone, 10                | 1 @                  | 10.80  | SI                                         |
| 1948M | Promethazine Hydrochloride                    | 50 mg in 2 mL                                  | 5 @                  | 7.95   | HH                                         |
| 1953T | Propantheline Bromide                         | 15 mg                                          | 100 @                | 10.02  | SI                                         |

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                                                          | Form/Strength                       | Pack and Price<br>\$ | Manufacturer                             |
|-------|---------------------------------------------------------------|-------------------------------------|----------------------|------------------------------------------|
| 1955X | Propylthiouracil                                              | 50 mg                               | 100 @ 20.61          | PL                                       |
| 2676W | Protein Hydrolysate Formula with Medium Chain Triglycerides   | 400 g                               | 1 @ 11.48            | NT                                       |
| 8259Q |                                                               | 450 g                               | 1 @ 12.93            | NU                                       |
| 8284B | Raltitrexed                                                   | 2 mg                                | 1 @ 283.29           | HH                                       |
| 1937Y | Ranitidine Hydrochloride                                      | 150 mg (base), effervescent         | 30 @ 7.37            | GK                                       |
| 8162N |                                                               | 150 mg (base) per 10 mL, 300 mL     | 1 @ 8.75             | GK                                       |
| 8903N |                                                               | 150 mg (base), effervescent         | 30 @ 7.37            | GK                                       |
| 8905Q |                                                               | 150 mg (base) per 10 mL, 300 mL     | 1 @ 8.75             | GK                                       |
| 8787L | Risperidone                                                   | 0.5 mg                              | 20 @ 11.60           | JC                                       |
| 8788M |                                                               | 0.5 mg (orally disintegrating)      | 28 @ 16.26           | JC                                       |
| 8790P |                                                               | 1 mg (orally disintegrating)        | 28 @ 31.10           | JC                                       |
| 9080X |                                                               | 2 mg (orally disintegrating)        | 28 @ 62.49           | JC                                       |
| 8792R |                                                               | 1 mg (orally disintegrating)        | 28 @ 31.10           | JC                                       |
| 8794W |                                                               | 2 mg (orally disintegrating)        | 28 @ 62.49           | JC                                       |
| 9075P |                                                               | 3 mg (orally disintegrating)        | 28 @ 92.90           | JC                                       |
| 9076Q |                                                               | 4 mg (orally disintegrating)        | 28 @ 121.54          | JC                                       |
| 8869T |                                                               | 0.5 mg                              | 20 @ 11.60           | JC                                       |
| 8870W |                                                               | 0.5 mg (orally disintegrating)      | 28 @ 16.26           | JC                                       |
| 8780D |                                                               | 25 mg                               | 1 @ 157.36           | JC                                       |
| 8781E |                                                               | 37.5 mg                             | 1 @ 201.99           | JC                                       |
| 8782F |                                                               | 50 mg                               | 1 @ 246.67           | JC                                       |
| 1099W | Salbutamol Sulfate                                            | 200 mcg (base)                      | 100 @ 6.04           | GK                                       |
| 8288F |                                                               | 100 mcg (base) per dose (200 doses) | 1 @ 4.40             | AL, AW, IA                               |
|       |                                                               |                                     | 1 @ 4.99             | GK                                       |
| 8354Q |                                                               | 100 mcg (base) per dose (200 doses) | 1 @ 16.09            | IA                                       |
| 2000G |                                                               | 2.5 mg (base) in 2.5 mL, 30         | 1 @ 6.26             | AF, AW, CH,<br>CR, GM, GX,<br>PU, SZ, TW |
|       |                                                               |                                     | 1 @ 6.99             | GK                                       |
| 2001H |                                                               | 5 mg (base) in 2.5 mL, 30           | 1 @ 6.61             | AF, AW, CH,<br>CR, GM, GX,<br>SZ, TW     |
|       |                                                               |                                     | 1 @ 7.34             | GK                                       |
| 2003K |                                                               | 5 mg (base) per mL, 30 mL           | 1 @ 2.30             | PU                                       |
| 1103C |                                                               | 2 mg (base) per 5 mL, 150 mL        | 1 @ 7.89             | GK                                       |
| 2995P | Salcatonin                                                    | 50 i.u. in 1 mL                     | 5 @ 33.54            | NV                                       |
| 2997R |                                                               | 100 i.u. in 1 mL                    | 5 @ 51.57            | NV                                       |
| 2014B | Sodium Alginate with Calcium Carbonate and Sodium Bicarbonate | 1 g-320 mg-534 mg in 20 mL, 500 mL  | 1 @ 4.13             | RC                                       |
| 2264E | Sodium Chloride                                               | 154 mmol per L, 1 L                 | 1 @ 3.90             | BX                                       |
| 2260Y |                                                               | 513 mmol per L, 1 L                 | 1 @ 5.90             | BX                                       |
| 2266G | Sodium Chloride Compound                                      | 1 L                                 | 1 @ 5.90             | BX                                       |
| 2281C | Sodium Chloride with Glucose                                  | 31 mmol-222 mmol per L, 1 L         | 1 @ 3.90             | BX                                       |
| 2279Y |                                                               | 19 mmol-104 mmol per 500 mL, 500 mL | 1 @ 5.12             | BX                                       |
| 2278X |                                                               | 39 mmol-69 mmol per 500 mL, 500 mL  | 1 @ 5.12             | BX                                       |
| 2286H | Sodium Lactate Compound                                       | 1 L                                 | 1 @ 3.90             | BX                                       |
| 2294R | Sodium Valproate                                              | 100 mg                              | 100 @ 12.62          | SW                                       |
| 2289L |                                                               | 200 mg (e.c.)                       | 100 @ 13.72          | AF, SZ, WA                               |
|       |                                                               |                                     | 100 @ 14.29          | SW                                       |

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                                                                     | Form/Strength                               | Pack and Price<br>\$ | Manufacturer |
|-------|--------------------------------------------------------------------------|---------------------------------------------|----------------------|--------------|
| 2290M |                                                                          | 500 mg (e.c.)                               | 100 @ 25.98          | AF, SZ, WA   |
| 2293Q |                                                                          | 200 mg per 5 mL, 300 mL                     | 100 @ 26.66          | SW           |
| 2295T |                                                                          | 200 mg per 5 mL, 300 mL                     | 1 @ 14.25            | SW           |
| 2091C | Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate              | 3.125 g-450 mg-45 mg in 5 mL, 12            | 1 @ 14.25            | SW           |
| 8577K | Soy Protein and Fat Formula with Vitamins and Minerals—Carbohydrate Free | 3.125 g-450 mg-45 mg in 5 mL, 12            | 1 @ 15.08            | JT           |
| 2093E | Sulfasalazine                                                            | 500 mg                                      | 1 @ 5.53             | AB           |
| 2096H |                                                                          | 500 mg (e.c.)                               | 100 @ 23.16          | PH           |
|       |                                                                          |                                             | 100 @ 25.31          | KR           |
|       |                                                                          |                                             | 100 @ 26.10          | PH           |
| 2047R | Sulindac                                                                 | 100 mg                                      | 50 @ 4.96            | AF           |
| 8144P | Sumatriptan Succinate                                                    | 50 mg (base)                                | 2 @ 9.55             | AF, GK, ME   |
| 8885P |                                                                          | 50 mg (base) (fast disintegrating)          | 2 @ 9.55             | GK           |
| 2248H | Tamarindus Indica Seed Polysaccharide                                    | 10 mg per mL, 0.5 mL, 20                    | 1 @ 9.88             | JT           |
| 2109B | Tamoxifen Citrate                                                        | 10 mg (base)                                | 30 @ 17.07           | AP           |
| 2110C |                                                                          | 20 mg (base)                                | 30 @ 28.34           | AP           |
| 2088X | Temazepam                                                                | 10 mg                                       | 25 @ 1.47            | AF, FM       |
|       |                                                                          |                                             | 25 @ 2.85            | SI           |
| 8819E | Temozolomide                                                             | 5 mg                                        | 5 @ 67.21            | SH           |
| 8820F |                                                                          | 20 mg                                       | 5 @ 187.17           | SH           |
| 8821G |                                                                          | 100 mg                                      | 5 @ 794.29           | SH           |
| 9160D | Terbinafine Hydrochloride                                                | 10 mg per g, 15 g                           | 1 @ 15.47            | NC           |
| 1251W | Terbutaline Sulfate                                                      | 5 mg in 2 mL, 30                            | 1 @ 17.19            | AP           |
| 8098F | Testosterone                                                             | 100 mg                                      | 1 @ 33.86            | OR           |
| 8099G |                                                                          | 200 mg                                      | 1 @ 67.71            | OR           |
| 2670M | Testosterone Esters                                                      | 100 mg                                      | 1 @ 4.75             | OR           |
| 2101N |                                                                          | 250 mg                                      | 1 @ 9.02             | OR           |
| 2832C | Tetracosactrin                                                           | 1 mg in 1 mL                                | 1 @ 12.97            | NV           |
| 2345K | Thiotepa                                                                 | 15 mg                                       | 1 @ 74.62            | SI           |
| 8221Q | Tiagabine Hydrochloride                                                  | 5 mg (base)                                 | 50 @ 33.11           | OA           |
| 8222R |                                                                          | 10 mg (base)                                | 50 @ 66.21           | OA           |
| 8223T |                                                                          | 15 mg (base)                                | 50 @ 95.23           | OA           |
| 1356J | Tobramycin Sulfate                                                       | 80 mg (base) in 2 mL                        | 5 @ 29.30            | HH           |
| 8872Y |                                                                          | 80 mg (base) in 2 mL (without preservative) | 5 @ 29.30            | PU           |
| 2117K | Triamcinolone Acetonide                                                  | 200 mcg per g, 100 g                        | 1 @ 4.23             | FM           |
|       |                                                                          |                                             | 1 @ 5.88             | SI           |
| 2118L |                                                                          | 200 mcg per g, 100 g                        | 1 @ 4.23             | FM           |
|       |                                                                          |                                             | 1 @ 5.88             | SI           |
| 3128P | Triglycerides, Medium Chain                                              | 500 mL                                      | 1 @ 22.98            | SB           |
| 3136C | Triglycerides, Medium Chain and Long Chain with Glucose Polymer          | 400 g                                       | 1 @ 36.14            | SB           |
| 8478F | Triglycerides—Medium Chain, Formula                                      | 400 g                                       | 1 @ 51.86            | SB           |
| 8629E |                                                                          | 420 g                                       | 1 @ 57.63            | SB           |
| 9165J | Tyrosine with Carbohydrate                                               | 4 g containing 1 g tyrosine, 30             | 1 @ 127.40           | VF           |
| 8133C | Valaciclovir Hydrochloride                                               | 500 mg (base)                               | 10 @ 49.68           | GK           |
| 9135T | Valine with Carbohydrate                                                 | 4 g containing 50 mg valine, 30             | 1 @ 127.40           | VF           |
| 3113W | Vancomycin                                                               | 125 mg                                      | 20 @ 119.41          | AS           |
| 3114X |                                                                          | 250 mg                                      | 20 @ 229.81          | AS           |

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                                                                                                                            | Form/Strength        | Pack and Price<br>\$ | Manufacturer |
|-------|---------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|--------------|
| 3130R |                                                                                                                                 | 500 mg               | 1 @ 20.05            | AS, HH, SZ   |
| 3131T |                                                                                                                                 | 500 mg               | 1 @ 19.58            | AS, HH, SZ   |
| 2270L |                                                                                                                                 | 1 g                  | 1 @ 39.14            | HH, SZ       |
| 9129L | Varenicline                                                                                                                     | 1 mg (as tartrate)   | 56 @ 113.32          | PF           |
| 2374Y | Vincristine Sulfate                                                                                                             | 1 mg in 1 mL         | 5 @ 77.46            | HH, PU       |
| 9009E | Vinorelbine Tartrate                                                                                                            | 20 mg (base)         | 1 @ 104.26           | FB           |
| 9010F |                                                                                                                                 | 30 mg (base)         | 1 @ 154.70           | FB           |
| 8280T |                                                                                                                                 | 10 mg (base) in 1 mL | 1 @ 73.58            | FB, HH, IT   |
| 8281W |                                                                                                                                 | 50 mg (base) in 5 mL | 1 @ 307.06           | FB, HH, IT   |
| 8587Y | Whey Protein Formula supplemented with Amino Acids, Vitamins and Minerals, and low in Protein, Phosphate, Potassium and Lactose | 400 g                | 1 @ 66.22            | SB           |

**PREPARATIONS WHICH MAY BE PRESCRIBED  
FOR PATIENTS RECEIVING PALLIATIVE CARE**

|       |                   |                      |           |                        |
|-------|-------------------|----------------------|-----------|------------------------|
| 5303D | Bisacodyl         | 10 mg, 10            | 1 @ 5.15  | PP                     |
|       |                   |                      | 1 @ 5.53  | BY                     |
| 5304E |                   | 10 mg, 12            | 1 @ 4.21  | FL, PP                 |
| 5307H |                   | 10 mg, 10            | 1 @ 5.15  | PP                     |
|       |                   |                      | 1 @ 5.53  | BY                     |
| 5308J |                   | 10 mg, 12            | 1 @ 4.21  | FL, PP                 |
| 5339B | Clonazepam        | 2.5 mg per mL, 10 mL | 1 @ 4.31  | RO                     |
| 5342E |                   | 2.5 mg per mL, 10 mL | 1 @ 4.31  | RO                     |
| 5361E | Diclofenac Sodium | 25 mg (e.c.)         | 50 @ 3.32 | AW, CH, GM, GX, SZ, TW |
|       |                   |                      | 50 @ 4.30 | NV                     |
| 5363G |                   | 100 mg               | 20 @ 9.25 | NV                     |
| 5364H |                   | 25 mg (e.c.)         | 50 @ 3.32 | AW, CH, GM, GX, SZ, TW |
|       |                   |                      | 50 @ 4.30 | NV                     |
| 5366K |                   | 100 mg               | 20 @ 9.25 | NV                     |
| 5401G | Fentanyl          | 200 mcg, 3           | 1 @ 35.49 | OA                     |
| 5402H |                   | 400 mcg, 3           | 1 @ 35.49 | OA                     |
| 5403J |                   | 600 mcg, 3           | 1 @ 35.49 | OA                     |
| 5404K |                   | 800 mcg, 3           | 1 @ 35.49 | OA                     |
| 5405L |                   | 1200 mcg, 3          | 1 @ 35.49 | OA                     |
| 5406M |                   | 1600 mcg, 3          | 1 @ 35.49 | OA                     |
| 5407N |                   | 200 mcg, 3           | 1 @ 33.55 | OA                     |
| 5408P |                   | 400 mcg, 3           | 1 @ 33.55 | OA                     |
| 5409Q |                   | 600 mcg, 3           | 1 @ 33.55 | OA                     |
| 5410R |                   | 800 mcg, 3           | 1 @ 33.55 | OA                     |
| 5411T |                   | 1200 mcg, 3          | 1 @ 33.55 | OA                     |
| 5412W |                   | 1600 mcg, 3          | 1 @ 33.55 | OA                     |
| 5413X |                   | 200 mcg, 3           | 1 @ 33.55 | OA                     |
| 5414Y |                   | 400 mcg, 3           | 1 @ 33.55 | OA                     |
| 5415B |                   | 600 mcg, 3           | 1 @ 33.55 | OA                     |
| 5416C |                   | 800 mcg, 3           | 1 @ 33.55 | OA                     |
| 5417D |                   | 1200 mcg, 3          | 1 @ 33.55 | OA                     |
| 5418E |                   | 1600 mcg, 3          | 1 @ 33.55 | OA                     |
| 5311M | Glycerol          | 700 mg, 12           | 1 @ 3.83  | PP                     |
| 5312N |                   | 1.4 g, 12            | 1 @ 3.96  | PP                     |

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                                                        | Form/Strength                    | Pack and Price<br>\$ |       | Manufacturer |
|-------|-------------------------------------------------------------|----------------------------------|----------------------|-------|--------------|
| 5313P |                                                             | 2.8 g, 12                        | 1 @                  | 4.11  | PP           |
| 5314Q |                                                             | 700 mg, 12                       | 1 @                  | 3.83  | PP           |
| 5315R |                                                             | 1.4 g, 12                        | 1 @                  | 3.96  | PP           |
| 5316T |                                                             | 2.8 g, 12                        | 1 @                  | 4.11  | PP           |
| 5367L | Ibuprofen                                                   | 200 mg                           | 50 @                 | 2.82  | AF           |
| 5368M |                                                             | 400 mg                           | 30 @                 | 2.77  | AB           |
| 5369N |                                                             | 200 mg                           | 50 @                 | 2.82  | AF           |
| 5370P |                                                             | 400 mg                           | 30 @                 | 2.77  | AB           |
| 5377B | Indomethacin                                                | 25 mg                            | 50 @                 | 2.12  | AF           |
|       |                                                             |                                  | 50 @                 | 3.29  | MK           |
| 5378C |                                                             | 100 mg                           | 20 @                 | 8.04  | MK           |
| 5379D |                                                             | 25 mg                            | 50 @                 | 2.12  | AF           |
|       |                                                             |                                  | 50 @                 | 3.29  | MK           |
| 5380E |                                                             | 100 mg                           | 20 @                 | 8.04  | MK           |
| 5345H | Naproxen                                                    | 250 mg                           | 50 @                 | 3.65  | AF           |
|       |                                                             |                                  | 50 @                 | 4.82  | RO           |
| 5349M |                                                             | 250 mg                           | 50 @                 | 3.65  | AF           |
|       |                                                             |                                  | 50 @                 | 4.82  | RO           |
| 5359C | Nitrazepam                                                  | 5 mg                             | 25 @                 | 1.47  | AF           |
|       |                                                             |                                  | 25 @                 | 3.00  | VT           |
| 5360D |                                                             | 5 mg                             | 25 @                 | 1.47  | AF           |
|       |                                                             |                                  | 25 @                 | 3.00  | VT           |
| 5371Q | Oxazepam                                                    | 15 mg                            | 25 @                 | 1.28  | AF           |
|       |                                                             |                                  | 25 @                 | 3.06  | SI           |
| 5372R |                                                             | 30 mg                            | 25 @                 | 1.47  | AF, FM       |
|       |                                                             |                                  | 25 @                 | 3.37  | SI           |
| 5373T |                                                             | 15 mg                            | 25 @                 | 1.28  | AF           |
|       |                                                             |                                  | 25 @                 | 3.06  | SI           |
| 5374W |                                                             | 30 mg                            | 25 @                 | 1.47  | AF, FM       |
|       |                                                             |                                  | 25 @                 | 3.37  | SI           |
| 5343F | Paracetamol                                                 | 665 mg (m.r.)                    | 96 @                 | 3.42  | GC           |
| 5344G |                                                             | 665 mg (m.r.)                    | 96 @                 | 3.42  | GC           |
| 5331N | Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate | 3.125 g-450 mg-45 mg in 5 mL, 12 | 1 @                  | 15.08 | JT           |
| 5332P |                                                             | 3.125 g-450 mg-45 mg in 5 mL, 12 | 1 @                  | 15.08 | JT           |
| 5381F | Sulindac                                                    | 100 mg                           | 50 @                 | 4.96  | AF           |
| 5383H |                                                             | 100 mg                           | 50 @                 | 4.96  | AF           |
| 5375X | Temazepam                                                   | 10 mg                            | 25 @                 | 1.47  | AF, FM       |
|       |                                                             |                                  | 25 @                 | 2.85  | SI           |
| 5376Y |                                                             | 10 mg                            | 25 @                 | 1.47  | AF, FM       |
|       |                                                             |                                  | 25 @                 | 2.85  | SI           |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

|       |                   |              |      |      |                           |
|-------|-------------------|--------------|------|------|---------------------------|
| 3398W | Benzylpenicillin  | 600 mg       | 1 @  | 3.44 | CS                        |
| 3399X |                   | 3 g          | 1 @  | 5.65 | CS                        |
| 5048Q | Cefotaxime        | 1 g          | 1 @  | 4.64 | SZ                        |
| 5049R |                   | 2 g          | 1 @  | 8.51 | SZ                        |
| 5079H | Diclofenac Sodium | 100 mg       | 20 @ | 9.25 | NV                        |
| 5076E |                   | 25 mg (e.c.) | 50 @ | 3.32 | AW, CH, GM,<br>GX, SZ, TW |
|       |                   |              | 50 @ | 4.30 | NV                        |

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                            | Form/Strength                          | Pack and Price<br>\$ | Manufacturer                                        |
|-------|---------------------------------|----------------------------------------|----------------------|-----------------------------------------------------|
| 5088T | Erythromycin Lactobionate       | 1 g (base)                             | 1 @ 8.99             | LM                                                  |
| 5106R | Glucose                         | 278 mmol per L, 1 L                    | 1 @ 3.90             | BX                                                  |
| 5118J | Hydrocortisone Sodium Succinate | 100 mg with 2 mL solvent               | 1 @ 5.36             | PH                                                  |
| 5119K |                                 | 250 mg with 2 mL solvent               | 1 @ 9.27             | PH                                                  |
| 5121M | Ibuprofen                       | 200 mg                                 | 50 @ 2.82            | AF                                                  |
| 5123P |                                 | 400 mg                                 | 30 @ 2.77            | AB                                                  |
| 5128X | Indomethacin                    | 100 mg                                 | 20 @ 8.04            | MK                                                  |
| 5126T |                                 | 25 mg                                  | 50 @ 2.12            | AF                                                  |
|       |                                 |                                        | 50 @ 3.29            | MK                                                  |
| 5139L | Ketoprofen                      | 100 mg                                 | 20 @ 8.41            | SW                                                  |
| 5154G | Metronidazole                   | 500 mg in 100 mL                       | 1 @ 5.11             | BX                                                  |
|       |                                 |                                        | 10 @ 39.34           | HH, SZ                                              |
| 5176K | Naproxen                        | 250 mg                                 | 50 @ 3.65            | AF                                                  |
|       |                                 |                                        | 50 @ 4.82            | RO                                                  |
| 5224Y | Paracetamol                     | 500 mg                                 | 100 @ 2.00           | AW, CH, FM,<br>GM, HX, JT,<br>PC, SW, SZ,<br>TW, YM |
| 3360W | Phenoxymethylpenicillin         | 250 mg                                 | 25 @ 2.58            | SI                                                  |
| 3361X |                                 | 500 mg                                 | 25 @ 3.82            | SI                                                  |
| 5012T |                                 | 150 mg per 5 mL, 100 mL                | 1 @ 7.99             | FM, SI                                              |
| 3374N | Promethazine Hydrochloride      | 50 mg in 2 mL                          | 5 @ 7.95             | HH                                                  |
| 5212H | Sodium Chloride                 | 154 mmol per L, 1 L                    | 1 @ 3.90             | BX                                                  |
| 5213J |                                 | 513 mmol per L, 1 L                    | 1 @ 5.90             | BX                                                  |
| 5214K | Sodium Chloride with Glucose    | 31 mmol-222 mmol per L, 1 L            | 1 @ 3.90             | BX                                                  |
| 5215L |                                 | 19 mmol-104 mmol per 500 mL,<br>500 mL | 1 @ 5.12             | BX                                                  |
| 5216M |                                 | 39 mmol-69 mmol per 500 mL,<br>500 mL  | 1 @ 5.12             | BX                                                  |
| 5217N | Sulindac                        | 100 mg                                 | 50 @ 4.96            | AF                                                  |
| 3323X | Vancomycin                      | 500 mg                                 | 1 @ 20.05            | AS, HH, SZ                                          |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY AUTHORISED  
OPTOMETRISTS FOR OPTOMETRICAL TREATMENT ONLY**

|       |                                               |                                                   |          |    |
|-------|-----------------------------------------------|---------------------------------------------------|----------|----|
| 5502N | Carbomer 974                                  | 3 mg per g, 0.5 g, 30                             | 1 @ 9.88 | AQ |
| 5504Q | Carbomer 980                                  | 2 mg per g, 0.6 mL, 30                            | 1 @ 9.68 | NV |
| 5509Y | Carmellose Sodium                             | 2.5 mg per mL, 0.6 mL, 24                         | 1 @ 8.50 | CX |
| 5506T |                                               | 5 mg per mL, 0.4 mL, 30                           | 1 @ 9.88 | AG |
| 5505R |                                               | 10 mg per mL, 0.4 mL, 30                          | 1 @ 9.88 | AG |
| 5510B |                                               | 10 mg per mL, 0.6 mL, 28                          | 1 @ 9.22 | CX |
| 5521N | Hypromellose with Dextran                     | 3 mg-1 mg per mL, 0.4 mL, 28                      | 1 @ 9.68 | AQ |
| 5523Q | Paraffin                                      | 3.5 g                                             | 1 @ 7.54 | IQ |
|       |                                               |                                                   | 1 @ 8.57 | AQ |
| 5532E | Polyethylene Glycol 400 with Propylene Glycol | 4 mg-3 mg per mL, single dose units<br>0.7 mL, 28 | 1 @ 9.22 | AQ |
| 5531D | Tamarindus Indica Seed Polysaccharide         | 10 mg per mL, 0.5 mL, 20                          | 1 @ 9.88 | JT |

## Section 4

Drug Tariff

Container Prices

Standard Formulae Preparations

Table of Codes, Maximum Quantities, and Number of  
Repeats for Extemporaneously Prepared  
Pharmaceutical Benefits

***Special Note:***

Purified Water BP is the minimum requirement for water in all PBS extemporaneous preparations.

## Drug Tariff

| Drug                                                        | Standard | Recovery Prices |              |               |                |
|-------------------------------------------------------------|----------|-----------------|--------------|---------------|----------------|
|                                                             |          | 0.1 g/mL<br>\$  | 1 g/mL<br>\$ | 10 g/mL<br>\$ | 100 g/mL<br>\$ |
| Acacia Mucilage (by weight)                                 | APF 15   | 0.01            | 0.08         | 0.64          | 5.67           |
| Acacia, powdered                                            | BP       | 0.02            | 0.15         | 1.18          | 10.47          |
| Acetic Acid (6 per cent)                                    | BP       | 0.01            | 0.01         | 0.11          | 1.02           |
| Acetic Acid (33 per cent)                                   | BP       | 0.01            | 0.05         | 0.38          | 3.38           |
| Acetone                                                     | BP       | 0.01            | 0.08         | 0.60          | 5.30           |
| (use as additive only)                                      |          |                 |              |               |                |
| Alum                                                        | BP       | 0.02            | 0.14         | 1.11          | 9.85           |
| Aluminium Acetate Solution                                  | BP       | 0.02            | 0.12         | 0.99          | 8.80           |
| Anise Water Concentrated 1 in 40                            | BP       | 0.01            | 0.05         | 0.39          | 3.49           |
| (use as additive only)                                      |          |                 |              |               |                |
| Aqueous Cream                                               | APF      | 0.01            | 0.07         | 0.54          | 4.82           |
| (for use only as a base combined with active ingredients)   |          |                 |              |               |                |
| Ascorbic Acid                                               | BP       | 0.05            | 0.36         | 2.91          | 25.86          |
| (for use only as an ingredient of ferrous sulfate mixtures) |          |                 |              |               |                |
| Aspirin                                                     | BP       | 0.08            | 0.62         | 4.98          | 44.28          |
| Belladonna Tincture                                         | BP       | 0.05            | 0.36         | 2.85          | 25.30          |
| Benzocaine                                                  | BP       | 0.08            | 0.63         | 5.07          | 45.08          |
| Benzoic Acid                                                | BP       | 0.06            | 0.47         | 3.78          | 33.58          |
| Benzoic Acid Compound Ointment                              | APF      | 0.01            | 0.10         | 0.76          | 6.71           |
| Benzoic Acid Solution                                       | BP       | 0.01            | 0.09         | 0.74          | 6.62           |
| Benzoin Compound Tincture                                   | BP       | 0.02            | 0.17         | 1.38          | 12.23          |
| Boric Acid                                                  | BP       | 0.01            | 0.05         | 0.43          | 3.80           |
| (use as additive only)                                      |          |                 |              |               |                |
| Boric Acid, Olive Oil and Zinc Oxide Ointment               | QHF      | 0.01            | 0.06         | 0.45          | 3.99           |
| Calcium Hydroxide                                           | BP       | 0.02            | 0.16         | 1.29          | 11.50          |
| Calcium Hydroxide Solution                                  | BP       | 0.01            | 0.01         | 0.07          | 0.66           |
| Castor Oil                                                  | BP       | 0.01            | 0.06         | 0.44          | 3.90           |
| (use as additive only)                                      |          |                 |              |               |                |
| Cetomacrogol Aqueous Cream                                  | APF      | 0.01            | 0.02         | 0.19          | 1.73           |
| (for use only as a base combined with active ingredients)   |          |                 |              |               |                |
| Cetrimide Aqueous Cream                                     | APF      | 0.02            | 0.12         | 0.94          | 8.40           |
| (for use only as a base combined with active ingredients)   |          |                 |              |               |                |
| Chlorhexidine Acetate                                       | BP       | 0.43            | 3.45         | 27.58         | 245.13         |
| (use as additive only)                                      |          |                 |              |               |                |
| Chlorhexidine Aqueous Cream                                 | APF      | 0.03            | 0.22         | 1.74          | 15.44          |
| (for use only as a base combined with active ingredients)   |          |                 |              |               |                |
| Chloroform                                                  | BP       | 0.02            | 0.14         | 1.13          | 10.06          |
| (use as additive only)                                      |          |                 |              |               |                |
| Chloroform Spirit                                           | BP       | 0.01            | 0.03         | 0.25          | 2.26           |
| Chloroform Water Concentrated 1 in 40                       | APF 15   | 0.01            | 0.03         | 0.25          | 2.26           |
| Citric Acid Monohydrate                                     | BP       | 0.01            | 0.06         | 0.49          | 4.38           |
| Coal Tar                                                    | BP       | 0.10            | 0.79         | 6.30          | 56.00          |
| Coal Tar Solution                                           | BP       | 0.01            | 0.10         | 0.82          | 7.25           |
| Cocaine Hydrochloride                                       | BP       | 5.47            | 43.75        | 350.00        | 3111.11        |
| Coconut Oil                                                 | BP       | 0.01            | 0.10         | 0.78          | 6.89           |



| Drug                                                                                             | Standard | Recovery Prices |              |               |                |
|--------------------------------------------------------------------------------------------------|----------|-----------------|--------------|---------------|----------------|
|                                                                                                  |          | 0.1 g/mL<br>\$  | 1 g/mL<br>\$ | 10 g/mL<br>\$ | 100 g/mL<br>\$ |
| Codeine Linctus                                                                                  | APF      | 0.01            | 0.05         | 0.40          | 3.59           |
| Codeine Phosphate<br>(may only be prescribed in linctuses,<br>mixtures or mixtures for children) | BP       | 1.34            | 10.73        | 85.87         | 763.26         |
| Collodion Flexible                                                                               | BP       | 0.05            | 0.38         | 3.02          | 26.83          |
| Dithranol                                                                                        | BP       | 3.37            | 26.95        | 215.61        | 1916.57        |
| Emulsifying Ointment<br>(for use only as a base combined with<br>active ingredients)             | BP       | 0.01            | 0.06         | 0.49          | 4.36           |
| Ephedrine Hydrochloride<br>(may only be prescribed in nasal<br>instillations)                    | BP       | 0.56            | 4.49         | 35.88         | 318.93         |
| Ethanol (90 per cent)<br>(use as additive only)                                                  | BP       | 0.01            | 0.02         | 0.18          | 1.63           |
| Ethanol (96 per cent)<br>(use as additive only)                                                  | BP       | 0.01            | 0.03         | 0.22          | 1.96           |
| Ether Solvent<br>(use as additive only)                                                          | BP       | 0.01            | 0.11         | 0.87          | 7.71           |
| Eucalyptus Oil<br>(use as additive only)                                                         | BP       | 0.01            | 0.11         | 0.84          | 7.49           |
| Ferrous Sulfate                                                                                  | BP       | 0.10            | 0.78         | 6.21          | 55.20          |
| Formaldehyde Solution                                                                            | BP       | 0.02            | 0.19         | 1.51          | 13.42          |
| Gentian Alkaline Mixture                                                                         | APF      | 0.01            | 0.05         | 0.41          | 3.66           |
| Glycerol                                                                                         | BP       | 0.01            | 0.05         | 0.38          | 3.39           |
| Honey Purified<br>(use as additive only)                                                         | BP 1993  | 0.01            | 0.02         | 0.15          | 1.37           |
| Hydroxybenzoate Compound Solution                                                                | APF      | 0.06            | 0.48         | 3.87          | 34.43          |
| Iodine                                                                                           | BP       | 0.38            | 3.02         | 24.15         | 214.67         |
| Iodine Alcoholic Solution                                                                        | BP       | 0.02            | 0.15         | 1.18          | 10.52          |
| Iodine Aqueous Oral Solution                                                                     | BP       | 0.02            | 0.18         | 1.44          | 12.76          |
| Kaolin Mixture                                                                                   | BPC 1968 | 0.01            | 0.08         | 0.61          | 5.47           |
| Kaolin and Opium Mixture                                                                         | APF 14   | 0.01            | 0.08         | 0.66          | 5.83           |
| Lactic Acid                                                                                      | BP       | 0.05            | 0.41         | 3.25          | 28.90          |
| Lavender Spike Oil                                                                               | BPC 1968 | 0.07            | 0.59         | 4.73          | 42.02          |
| Liquorice Liquid Extract                                                                         | BP       | 0.03            | 0.21         | 1.64          | 14.61          |
| Magnesium Carbonate Light                                                                        | BP       | 0.02            | 0.18         | 1.46          | 13.00          |
| Magnesium Sulfate<br>(may only be prescribed for other than<br>oral use)                         | BP       | 0.01            | 0.01         | 0.09          | 0.77           |
| Magnesium Trisilicate                                                                            | BP       | 0.03            | 0.23         | 1.83          | 16.29          |
| Menthol, Racemic or Levomenthol                                                                  | BP       | 0.20            | 1.58         | 12.66         | 112.53         |
| Methyl Hydroxybenzoate                                                                           | BP       | 0.28            | 2.24         | 17.94         | 159.47         |
| Methyl Hydroxybenzoate Solution                                                                  | APF      | 0.03            | 0.23         | 1.81          | 16.09          |
| Methylated Industrial Spirit<br>(use as additive only)                                           | BP       | 0.01            | 0.04         | 0.28          | 2.48           |
| Olive Oil<br>(use as additive only)                                                              | BP       | 0.01            | 0.10         | 0.76          | 6.79           |
| Paraffin Hard                                                                                    | BP       | 0.01            | 0.06         | 0.46          | 4.13           |
| Paraffin Liquid<br>(may only be prescribed for other than<br>oral use)                           | BP       | 0.01            | 0.03         | 0.22          | 1.98           |
| Paraffin Light Liquid                                                                            | BP       | 0.02            | 0.12         | 0.95          | 8.41           |
| Paraffin Soft White                                                                              | BP       | 0.01            | 0.03         | 0.25          | 2.19           |

| Drug                                                      | Standard | Recovery Prices |              |               |                |
|-----------------------------------------------------------|----------|-----------------|--------------|---------------|----------------|
|                                                           |          | 0.1 g/mL<br>\$  | 1 g/mL<br>\$ | 10 g/mL<br>\$ | 100 g/mL<br>\$ |
| Paraffin Soft Yellow                                      | BP       | 0.01            | 0.05         | 0.41          | 3.67           |
| Peppermint Oil                                            | BP       | 0.09            | 0.74         | 5.95          | 52.90          |
| (use as additive only)                                    |          |                 |              |               |                |
| Peppermint Water Concentrated 1 in 40                     | APF 16   | 0.03            | 0.23         | 1.84          | 16.39          |
| (use as additive only)                                    |          |                 |              |               |                |
| Phenobarbitone Sodium                                     | BP       | 10.22           | 81.75        | 654.00        | 5813.33        |
| (may only be prescribed for the treatment of epilepsy)    |          |                 |              |               |                |
| Phenol Liquefied                                          | BP       | 0.05            | 0.42         | 3.36          | 29.90          |
| (not available for ear drops)                             |          |                 |              |               |                |
| Podophyllum Resin                                         | BP       | 0.91            | 7.25         | 57.96         | 515.20         |
| Potassium Citrate                                         | BP       | 0.01            | 0.09         | 0.69          | 6.10           |
| Potassium Iodide                                          | BP       | 0.06            | 0.47         | 3.75          | 33.29          |
| Potassium Permanganate                                    | BP       | 0.02            | 0.15         | 1.16          | 10.32          |
| Propyl Hydroxybenzoate                                    | BP       | 0.24            | 1.90         | 15.18         | 134.93         |
| Propylene Glycol                                          | BP       | 0.01            | 0.07         | 0.55          | 4.88           |
| Red Syrup                                                 | APF 15   | 0.01            | 0.11         | 0.88          | 7.87           |
| Resorcinol                                                | BP       | 0.12            | 0.93         | 7.44          | 66.10          |
| Salicylic Acid                                            | BP       | 0.02            | 0.18         | 1.47          | 13.09          |
| Salicylic Acid Ointment                                   | APF      | 0.01            | 0.09         | 0.71          | 6.34           |
| Salicylic Acid Ointment                                   | BP       | 0.01            | 0.09         | 0.71          | 6.34           |
| Simple Ointment (white)                                   | BP       | 0.02            | 0.14         | 1.09          | 9.68           |
| (for use only as a base combined with active ingredients) |          |                 |              |               |                |
| Simple Ointment (yellow)                                  | BP       | 0.02            | 0.16         | 1.29          | 11.44          |
| (for use only as a base combined with active ingredients) |          |                 |              |               |                |
| Sodium Bicarbonate                                        | BP       | 0.01            | 0.07         | 0.56          | 5.00           |
| Sodium Chloride                                           | BP       | 0.02            | 0.12         | 0.94          | 8.36           |
| Sodium Chloride Solution                                  | BP       | 0.01            | 0.01         | 0.07          | 0.61           |
| Sodium Citrate                                            | BP       | 0.01            | 0.11         | 0.91          | 8.07           |
| Sodium Thiosulfate                                        | BP       | 0.02            | 0.19         | 1.54          | 13.68          |
| (use as additive only)                                    |          |                 |              |               |                |
| Starch                                                    | BP       | 0.01            | 0.09         | 0.71          | 6.33           |
| Sulfur Ointment                                           | BP 1980  | 0.02            | 0.15         | 1.19          | 10.55          |
| (for use only as a base combined with active ingredients) |          |                 |              |               |                |
| Sulfur Precipitated                                       | BP 1980  | 0.03            | 0.23         | 1.83          | 16.27          |
| Syrup                                                     | BP       | 0.01            | 0.03         | 0.23          | 2.09           |
| Talc Purified, sterilised                                 | BP       | 0.02            | 0.14         | 1.10          | 9.77           |
| Thymol                                                    | BP       | 0.17            | 1.37         | 10.95         | 97.32          |
| Thymol Compound Mouth Wash                                | APF 15   | 0.01            | 0.08         | 0.63          | 5.64           |
| Tragacanth Compound Powder                                | BP 1980  | 0.07            | 0.52         | 4.16          | 36.95          |
| Tragacanth Mucilage                                       | APF 13   | 0.01            | 0.03         | 0.24          | 2.10           |
| Tragacanth Mucilage                                       | BPC 1973 | 0.01            | 0.02         | 0.17          | 1.55           |
| Tragacanth, powdered                                      | BP       | 0.10            | 0.76         | 6.05          | 53.82          |
| Trichloroacetic Acid                                      | BP 1980  | 0.25            | 1.99         | 15.88         | 141.12         |
| Triethanolamine                                           | BP       | 0.05            | 0.38         | 3.02          | 26.83          |
| Water For Injections, sterilised (b)                      | BP       | 0               | 0            | 0             | 8.09           |
| (extemporaneously prepared eye drops and eye lotions)     |          |                 |              |               |                |
| Water Purified                                            | BP       | 0.01            | 0.01         | 0.06          | 0.49           |
| Wool Alcohols Ointment (white)                            | BP       | 0.02            | 0.13         | 1.00          | 8.93           |

| Drug                                                      | Standard | Recovery Prices |              |               |                |
|-----------------------------------------------------------|----------|-----------------|--------------|---------------|----------------|
|                                                           |          | 0.1 g/mL<br>\$  | 1 g/mL<br>\$ | 10 g/mL<br>\$ | 100 g/mL<br>\$ |
| <hr/>                                                     |          |                 |              |               |                |
| (for use only as a base combined with active ingredients) |          |                 |              |               |                |
| Wool Alcohols Ointment (yellow)                           | BP       | 0.02            | 0.13         | 1.00          | 8.93           |
| (for use only as a base combined with active ingredients) |          |                 |              |               |                |
| Wool Fat                                                  | BP       | 0.02            | 0.12         | 0.98          | 8.72           |
| Wool Fat Hydrous                                          | BP       | 0.01            | 0.10         | 0.79          | 7.00           |
| Zinc Compound Paste                                       | BP       | 0.02            | 0.15         | 1.17          | 10.36          |
| Zinc Cream                                                | BP       | 0.01            | 0.06         | 0.49          | 4.32           |
| (for use only as a base combined with active ingredients) |          |                 |              |               |                |
| Zinc Oxide                                                | BP       | 0.01            | 0.09         | 0.72          | 6.39           |
| Zinc and Salicylic Acid Paste                             | BP       | 0.02            | 0.12         | 0.99          | 8.83           |
| Zinc Sulfate                                              | BP       | 0.02            | 0.19         | 1.48          | 13.17          |

**Container Prices**

\$

DISPENSING BOTTLES -

|       |      |
|-------|------|
| 25mL  | 0.47 |
| 50mL  | 0.47 |
| 100mL | 0.46 |
| 200mL | 0.72 |
| 500mL | 1.02 |

POISON BOTTLES -

|       |      |
|-------|------|
| 25mL  | 0.43 |
| 50mL  | 0.41 |
| 100mL | 0.45 |
| 200mL | 0.63 |
| 500mL | 1.15 |

SCREW CAP JARS -

|      |      |
|------|------|
| 25g  | 0.57 |
| 50g  | 0.63 |
| 100g | 0.72 |
| 200g | 0.76 |
| 500g | 1.15 |

DROPPER CONTAINERS -

|                |      |
|----------------|------|
| 15mL polythene | 0.73 |
| 15mL glass     | 0.75 |

---

|                                                                    |      |
|--------------------------------------------------------------------|------|
| Dispensing Fee for Extemporaneously Prepared Benefits              | 8.03 |
| Additional Fee for Agreed Price Extemporaneously Prepared Benefits | 1.39 |

## Standard Formula Preparations

The following list is not intended to indicate in any way which particular formula an approved pharmacist should use in filling a prescription.

The prices shown in the column 'Dispensed Price for Max. Qty' are for the ingredients, the container and the dispensing fee. The prices shown in the column 'Maximum Recordable Value for Safety Net' are for the ingredients, the container and the dispensing fee and, where applicable, the additional fee for agreed price benefits.

---

### KEY TO REFERENCES:

|            |                                            |
|------------|--------------------------------------------|
| <b>APF</b> | <b>Australian Pharmaceutical Formulary</b> |
| <b>BP</b>  | <b>British Pharmacopoeia</b>               |
| <b>BPC</b> | <b>British Pharmaceutical Codex</b>        |
| <b>QHF</b> | <b>Queensland Hospital Formulary</b>       |

---

| Code                                                                                            | Item                                           | Reference            | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ |
|-------------------------------------------------------------------------------------------------|------------------------------------------------|----------------------|------------------------------------------|--------------------------------------------------------|
| <b>CREAMS</b><br><b>(Maximum Quantity 100 g and 1 Repeat)</b>                                   |                                                |                      |                                          |                                                        |
| 7502W                                                                                           | Salicylic Acid and Sulfur Aqueous              | APF                  | 14.20                                    | 15.59                                                  |
| <b>DUSTING POWDERS</b><br><b>(Maximum Quantity 100 g and 1 Repeat)</b>                          |                                                |                      |                                          |                                                        |
| 7458M                                                                                           | Zinc, Starch and Talc                          | APF 15 & BPC<br>1973 | 17.86                                    | 19.25                                                  |
| <b>EAR DROPS</b><br><b>(Maximum Quantity 15 mL and 2 Repeats)</b>                               |                                                |                      |                                          |                                                        |
| 7642F                                                                                           | Aluminium Acetate                              | APF                  | 9.76                                     | 11.15                                                  |
| 7643G                                                                                           | Aluminium Acetate                              | BP                   | 10.24                                    | 11.63                                                  |
| 7314Y                                                                                           | Sodium Bicarbonate                             | APF & BP             | 9.10                                     | 10.49                                                  |
| 7313X                                                                                           | Spirit                                         | APF                  | 10.19                                    | 11.58                                                  |
| <b>INHALATIONS</b><br><b>(Maximum Quantity 50 mL and 1 Repeat)</b>                              |                                                |                      |                                          |                                                        |
| 7484X                                                                                           | Benzoin and Menthol                            | APF                  | 16.90                                    | 18.29                                                  |
| 7308P                                                                                           | Menthol                                        | APF                  | 10.94                                    | 12.33                                                  |
| 7310R                                                                                           | Menthol and Eucalyptus                         | BP 1980              | 11.44                                    | 12.83                                                  |
| <b>LINCTUSES CONTAINING CODEINE PHOSPHATE</b><br><b>(Maximum Quantity 100 mL and 0 Repeats)</b> |                                                |                      |                                          |                                                        |
| 7530H                                                                                           | Codeine                                        | APF                  | 12.08                                    | 13.47                                                  |
| <b>LOTIONS</b><br><b>(Maximum Quantity 200 mL and 2 Repeats)</b>                                |                                                |                      |                                          |                                                        |
| 7709R                                                                                           | Aluminium Acetate Aqueous                      | APF                  | 10.59                                    | 11.98                                                  |
| <b>MIXTURES, OTHER</b><br><b>(Maximum Quantity 200 mL and 4 Repeats)</b>                        |                                                |                      |                                          |                                                        |
| 7604F                                                                                           | Gentian Alkaline                               | APF                  | 16.07                                    | 17.46                                                  |
| 7348R                                                                                           | Kaolin                                         | BPC 1968             | 19.68                                    | 21.07                                                  |
| 7301G                                                                                           | Kaolin and Opium                               | APF 14               | 20.41                                    | 21.80                                                  |
| 7342K                                                                                           | Magnesium Trisilicate                          | BPC 1968             | 14.71                                    | 16.10                                                  |
| 7343L                                                                                           | Magnesium Trisilicate and Belladonna           | BPC 1968             | 17.46                                    | 18.85                                                  |
| <b>MOUTH WASHES</b><br><b>(Maximum Quantity 200 mL and 1 Repeat)</b>                            |                                                |                      |                                          |                                                        |
| 7457L                                                                                           | Thymol Compound                                | APF 15               | 19.95                                    | 21.34                                                  |
| <b>OINTMENTS</b><br><b>(Maximum Quantity 100 g and 1 Repeat)</b>                                |                                                |                      |                                          |                                                        |
| 7914M                                                                                           | Benzoic Acid Compound                          | APF                  | 15.46                                    | 16.85                                                  |
| 7914M                                                                                           | Benzoic Acid Compound (extemporaneous formula) | BP                   | 15.46                                    | 16.85                                                  |
| 7902X                                                                                           | Boric Acid, Olive Oil and Zinc Oxide           | QHF                  | 12.74                                    | 14.13                                                  |

—CONTAINER RATES ARE INCLUDED—

| Code                                          | Item                                    | Reference   | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ |
|-----------------------------------------------|-----------------------------------------|-------------|------------------------------------------|--------------------------------------------------------|
| 7926E                                         | Salicylic Acid                          | APF         | 15.09                                    | 16.48                                                  |
| 7928G                                         | Salicylic Acid (extemporaneous formula) | BP          | 15.09                                    | 16.48                                                  |
| <b>PAINTS</b>                                 |                                         |             |                                          |                                                        |
| <b>(Maximum Quantity 25 mL and 1 Repeat)</b>  |                                         |             |                                          |                                                        |
| 7567G                                         | Podophyllin Compound                    | APF 16 & BP | 39.07                                    | 31.30                                                  |
| 7568H                                         | Salicylic Acid                          | APF         | 16.47                                    | 17.86                                                  |
| <b>PASTES, OTHER</b>                          |                                         |             |                                          |                                                        |
| <b>(Maximum Quantity 100 g and 1 Repeat)</b>  |                                         |             |                                          |                                                        |
| 7558T                                         | Zinc                                    | APF         | 21.08                                    | 22.47                                                  |
| 7558T                                         | Zinc Compound (extemporaneous formula)  | BP          | 21.08                                    | 22.47                                                  |
| <b>POWDER FOR INTERNAL USE</b>                |                                         |             |                                          |                                                        |
| <b>(Maximum Quantity 100 g and 2 Repeats)</b> |                                         |             |                                          |                                                        |
| 7545D                                         | Magnesium Trisilicate                   | BP          | 25.08                                    | 26.47                                                  |

## Table of Codes, Maximum Quantities, and Number of Repeats for Extemporaneously Prepared Benefits

| Code | Preparation                                        | Maximum Quantity | Number of Repeats |
|------|----------------------------------------------------|------------------|-------------------|
| 13Q  | Creams                                             | 100 g            | 1                 |
| 48M  | Dusting Powders                                    | 100 g            | 1                 |
| 15T  | Ear Drops                                          | 15 mL            | 2                 |
| 19B  | Eye Drops containing Cocaine Hydrochloride         | 15 mL            | ..                |
| 22E  | Eye Drops, Other                                   | 15 mL            | 5                 |
| 23F  | Eye Lotions                                        | 200 mL           | 2                 |
| 29M  | Inhalations                                        | 50 mL            | 1                 |
| 64J  | Linctuses containing Codeine Phosphate             | 100 mL           | ..                |
| 34T  | Linctuses, Other                                   | 100 mL           | 2                 |
| 39C  | Lotions                                            | 200 mL           | 2                 |
| 65K  | Mixtures containing Codeine Phosphate              | 200 mL           | ..                |
| 40D  | Mixtures, Other                                    | 200 mL           | 4                 |
| 66L  | Mixtures for Children containing Codeine Phosphate | 100 mL           | ..                |
| 41E  | Mixtures for Children, Other                       | 100 mL           | 4                 |
| 30N  | Mouth Washes                                       | 200 mL           | 1                 |
| 42F  | Nasal Instillations                                | 15 mL            | 2                 |
| 43G  | Ointments, Waxes                                   | 100 g            | 1                 |
| 44H  | Paints                                             | 25 mL            | 1                 |
| 63H  | Pastes containing Cocaine Hydrochloride            | 25 g             | ..                |
| 45J  | Pastes, Other                                      | 100 g            | 1                 |
| 49N  | Powders for Internal Use                           | 100 g            | 2                 |
| 52R  | Solutions                                          | 200 mL           | 2                 |





**Australian Government**

**Department of Veterans' Affairs**

# **REPATRIATION SCHEDULE OF PHARMACEUTICAL BENEFITS**

**1 OCTOBER 2008**


The benefits listed in this Schedule may only be prescribed to Department of Veterans' Affairs beneficiaries holding a:

- Repatriation Health Card For All Conditions (gold); or
- Repatriation Health Card For Specific Conditions (white); or
- Repatriation Pharmaceutical Benefits Card (orange);

**BENEFICIARIES' ENTITLEMENT CARDS AND ELIGIBILITY**

The diagram below outlines the drug eligibility of Department of Veterans' Affairs

**REPATRIATION PHARMACEUTICAL BENEFITS**



**FOR REPATRIATION PHARMACEUTICAL BENEFITS**

beneficiaries in accordance with their treatment entitlement.

|                                                                                                               |   |                                                                                                   |   |                                                                                                                                                                                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------------------|---|---------------------------------------------------------------------------------------------------|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PBS Schedule listings written on the common PBS/RPBS prescription form, ticked as 'RPBS' (restrictions apply) | + | Repatriation Schedule listings written on the common PBS/RPBS prescription form, ticked as 'RPBS' | + | Items for which prescribing approval has been authorised on the common PBS/RPBS authority prescription form for:<br>(i) PBS and Repatriation Schedules 'Authority required' items;<br>(ii) greater quantities/repeats of drugs listed in PBS and Repatriation Schedules; or<br>(iii) items not listed in PBS or Repatriation Schedules. |
|---------------------------------------------------------------------------------------------------------------|---|---------------------------------------------------------------------------------------------------|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Only for disabilities that have been accepted for treatment by the Department of Veterans' Affairs**

|                                                                                                               |   |                                                                                                   |   |                                                                                                                                                                                                                                                                                                                                       |
|---------------------------------------------------------------------------------------------------------------|---|---------------------------------------------------------------------------------------------------|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PBS Schedule listings written on the common PBS/RPBS prescription form, ticked as 'RPBS' (restrictions apply) | + | Repatriation Schedule listings written on the common PBS/RPBS prescription form, ticked as 'RPBS' | + | Items for which prescribing approval has been authorised on a common PBS/RPBS authority prescription form for:<br>(i) PBS and Repatriation Schedules 'Authority required' items;<br>(ii) greater quantities/repeats of drugs listed in PBS and Repatriation Schedules; or<br>(iii) items not listed in PBS or Repatriation Schedules. |
|---------------------------------------------------------------------------------------------------------------|---|---------------------------------------------------------------------------------------------------|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

# RPBS Explanatory Notes

## Introduction

### The Australian Repatriation System

1. The Australian Repatriation system is based primarily on the principle of compensation to veterans and eligible dependants for injury or death related to war service. In certain cases, treatment is also provided for accepted injuries or conditions that are not service-related or have occurred as a result of other than war service.
2. Through the *Veterans' Entitlements Act 1986* the Department of Veterans' Affairs provides programs of compensation, income support and treatment for eligible veterans and their dependants. One of the defined benefits for eligible veterans is the Repatriation Pharmaceutical Benefits Scheme. This range of medications and dressings is more comprehensive than is available through the Pharmaceutical Benefits Scheme.

### RPBS prescribing provisions

3. Unless otherwise stated, Repatriation Pharmaceutical Benefits Scheme (RPBS) prescriptions must conform with the requirements of Pharmaceutical Benefits Scheme (PBS) prescriptions, as detailed in Section 1 – Explanatory Notes in the *Schedule of Pharmaceutical Benefits* book. The prescriber shall ensure that a prescription contains the following details:
  - the category of benefit, i.e., RPBS, by placing a cross in the relevant box;
  - the patient's full name and address;
  - the prescription date;
  - the DVA file number of the patient as evidence of entitlement;
  - in the case of authority prescriptions, the Authority approval number or the four digit streamlined authority code;
  - the item, form, strength, quantity and directions;
  - the number of repeats, if applicable;
  - indicate when brand substitution is not permitted; and
  - the name, signature, the prescriber number and address of the prescriber.

### Prior Approval Arrangements

4. The prior approval of the Department is required to prescribe the following:
  - 'Authority required' items (excluding 'Authority required (STREAMLINED)' items) listed in either the PBS or RPBS Schedule;
  - increased quantities and/or repeats of items listed in either the PBS or RPBS Schedule;
  - items listed under section 100 of the *National Health Act 1953*; and
  - other items not listed in either Schedule (non-Schedule items).
5. The above items are to be prescribed on the common PBS/RPBS authority prescription form in accordance with the directions stated in the Explanatory Notes in the *Schedule of Pharmaceutical Benefits* (See also information regarding dental prescribing and prescribing by optometrists under the RPBS in these Notes.)

6. All Authority required prescriptions and requests for non-Schedule items must receive prior approval from the Department. This can be achieved by either:
  - using the Department's national free call number 1800 552 580; or
  - by mailing the written authority prescription to the Veterans' Affairs Pharmaceutical Advisory Centre (VAPAC) at the reply paid address shown at the end of these RPBS Explanatory Notes.

Prior approval is not required from DVA to prescribe an Authority required (STREAMLINED) item (except where increased quantities and/or repeats are required). Instead the authority prescription form must include a four digit streamlined authority code.

7. Some requests for prior approval (including some non-Schedule items) need to be referred by VAPAC to the Repatriation Pharmaceutical Reference Committee for consideration. In such cases a VAPAC pharmacist will advise the prescriber to submit a request in writing that provides the following information:
  - A current clinical report on the patient's condition (such as age, co-morbidities, renal, liver failure) and clinical reports including pathology, biochemistry, diagnostic and other investigations if appropriate.
  - Details of past and current therapy for the condition. Include details of PBS, RPBS and non-Schedule items utilised, and the results of those therapies.
  - Details of the proposed treatment regimen. Include intended dose and duration of treatment and objective measures of response.
  - When the proposed use of the item is outside the TGA-approved indications for use in Australia, provide copies of articles from peer reviewed publications supporting the proposed treatment.
  - Signed, informed patient consent where the item is to be used for a non-TGA-approved indication.
  - For items without Australian marketing approval, a copy of the TGA Special Access Scheme approval to prescribe the drug.
8. Requests for prior approval to prescribe a non-Schedule (PBS or RPBS) item that is of the same therapeutic class (ATC level 3) as an item that is listed on the Schedule, will not be approved unless unequivocal clinical evidence is presented to demonstrate that the requested item is essential for effective treatment of the nominated patient.
9. A pharmacist should not supply an item prescribed on an RPBS Authority Prescription Form unless the form has been approved and stamped by VAPAC, or has been endorsed by the prescriber with a telephone Authority approval number provided by VAPAC. Medicare Australia will not accept RPBS Authority prescriptions that have not been approved by the Department of Veterans' Affairs for payment.

## **Palliative Care Drugs**

10. The following medications may be available, or made available in increased quantities or doses under prior approval arrangements for use only in the palliative care of terminal disease:
  - clonazepam
  - cyclizine
  - dexamethasone
  - disodium pamidronate
  - fentanyl
  - glycopyrrolate
  - hyoscine butylbromide
  - hyoscine hydrobromide
  - ketamine
  - midazolam
  - octreotide

For further information telephone VAPAC on 1800 552 580.

## **Dental Prescribing**

11. Under Department of Veterans' Affairs arrangements, financial responsibility for pharmaceutical benefits prescribed by a Local Dental Officer (LDO) is limited to treatment to which holders of the following cards are entitled:
  - a Gold Repatriation Health Card – For All Conditions; or
  - a White Repatriation Health Card – For Specific Conditions; or
  - an Orange Repatriation Pharmaceutical Benefits Card.

Where possible the LDO shall prescribe in accordance with the provisions governing dental prescribing under the Pharmaceutical Benefits Scheme (PBS).

12. Prescriptions for PBS Dental Schedule items for Gold, White and Orange Card holders are to be dispensed at the PBS concessional rate. Claims for payment by the dispensing pharmacist are to be included with other Repatriation prescriptions. The card holder is required to meet the cost of any applicable brand premium.
13. When a non-PBS Dental Schedule item is prescribed for an eligible card holder, the LDO's private prescription form should be used. The dispensing pharmacist may charge the patient the full cost of the prescription. The patient may claim a refund for the full cost of a non-Schedule item from the Department if an itemised receipt (not a cash register receipt) and a copy of the prescription are provided.

## **Prescribing by optometrists**

14. Optometrists approved as 'PBS prescribers' may write RPBS prescriptions as outlined in Section 1 for medicines listed in Section 2 of the PBS Schedule as pharmaceutical benefits for optometrical use.
15. Medicines in the optometrist list include non-Authority and Authority required items. Procedures for obtaining VAPAC approval to prescribe 'Authority required' optometrist items or increased quantities and/or repeats of optometrist items under the RPBS are the same as indicated under prior approval arrangements above.

16. The list of medicines for prescribing by optometrists under the RPBS is the same as applies under the PBS. There are no optometrist listings in the RPBS Schedule for prescribing for veterans only. There is no provision for optometrist prescribers to request approval to prescribe items that are not included in the PBS optometrist list (non-Schedule items).
17. Optometrist PBS/RPBS prescription forms are for use for prescribing non-Authority or Authority required optometrist items under the RPBS with one item per form only.

## **Provisions governing pricing and payment for RPBS benefits**

### **Introduction**

18. Unless otherwise stated, the pricing and payment principles and arrangements for approved pharmacists supplying pharmaceutical benefits under the RPBS will be the same as those arrangements applying under the PBS.
19. Where a pharmaceutical benefit that is not listed on the PBS or RPBS Schedule is dispensed on an RPBS Authority prescription, a pharmacist will price the benefit and enter the serial number, prescription identifying number and price on the sticker or stamp imprint affixed to the prescription.

### **Pricing of Schedule Items**

20. Items supplied under the RPBS from the PBS Schedule, both ready-prepared and extemporaneously-prepared, will be paid on the same basis as benefits supplied under the PBS. Items supplied under the RPBS from the Repatriation Schedule, including wound dressings, will be paid on the basis of the price as given in the Repatriation Pharmaceutical Benefits section (Section 1 – RPBS Schedule, Drugs, Medicines and Dressings) of the *Schedule of Pharmaceutical Benefits*.

### **Pricing of Non-Schedule Ready Prepared Items**

21. Non-Schedule ready-prepared items are to be priced on the basis of the invoiced, GST-exclusive wholesale price to pharmacists plus the appropriate PBS mark-up and the PBS dispensing fee. Where the item price to pharmacists is greater than \$100.00, a copy of the invoice pertaining to the supply of that item is to be submitted together with the appropriate copy of the authority prescription as part of the claim for payment.

### **Pricing of Non-Schedule Extemporaneously Prepared Items**

22. When an ingredient drug is not listed in the PBS Drug Tariff, the recovery price will be based on the invoiced wholesale price to pharmacists, increased by a mark-up of 100%, calculated in accordance with the directions contained in the pricing instructions for pricing of PBS extemporaneously-prepared benefits in this Schedule. The price paid by the pharmacist for the commercial pack from which the ingredient is used shall be endorsed on the prescription form.

### **Miscellaneous Pricing Rules**

23. The price to pharmacists used as the basis of pricing will be the invoiced, GST-exclusive price from the wholesaler.
24. If multiple quantities of a manufacturer's original pack are supplied, the PBS mark-up is applied to the price to pharmacist of each pack and then totalled. The PBS dispensing fee, and the PBS dangerous drug fee if applicable, are then added to the total of the marked-up prices.
25. When the quantity prescribed corresponds with the quantity of a manufacturer's original pack, in no circumstances will the price payable for one pack exceed that payable for multiples or combinations of packs to supply the quantity prescribed.
26. The list of ingredient drugs and prices included in the PBS Drug Tariff are common to both the PBS and RPBS. Certain restrictions apply regarding the prescribing and dispensing of some of these ingredient drugs as pharmaceutical benefits, e.g., use as additive only.

27. For items prescribed generically, including non-Schedule and wound dressings, the pharmacist should indicate on the prescription the quantity and brand supplied. If prescriptions are not endorsed, the Department will pay the lowest priced acceptable product available.

## **General**

### **Packaging Material, Postage or Freight**

28. Payment to a pharmacist for the costs of packaging materials, postage or freight required to supply a pharmaceutical benefit is to be paid by the patient, who may then claim reimbursement from the Department through the provision of a pharmacist's itemised receipt.

### **Payment for Items Supplied at Short Intervals**

29. For all items dispensed at specific short intervals of time, the Department will pay a separate PBS dispensing fee for each occasion that the drug is supplied and which is acknowledged on receipt by the patient or agent.
30. The price payable on the items supplied will be based on the individual dose quantity supplied. Where applicable, a PBS dangerous drug fee and a minimum container charge will be payable for each supply.

### **Receipts for Patient Charges**

31. Where a charge is paid by a patient in any of the circumstances of paragraphs 13 or 24, the pharmacist is required to provide a printed receipt to the patient with the details of the items or services provided, the amount paid, date of supply and the patient's name and address. The patient may apply for reimbursement from the Department.

### **Special Patient Contributions**

32. The Special Patient Contribution for items listed as Special Pharmaceutical Benefits in the PBS Schedule is not payable by veterans entitled to pharmaceutical benefits under the RPBS. Eligible veterans receiving Special Pharmaceutical Benefits under the RPBS are required to pay only the concessional patient contribution and any applicable brand premium. If a Safety Net Entitlement card is held, the veteran should receive a Special Pharmaceutical Benefit free of charge, subject to any brand premium applicable. Medicare Australia will reimburse the dispensing pharmacist the total dispensed price, less the concessional patient contribution and/or brand premium if applicable.

### **Therapeutic Group Premiums — Authority Processing**

33. Items attracting a therapeutic group premium are dual listed. Dispensing pharmacists are therefore required to select the appropriate code for those items that are dual listed as authority and non-authority items, in order to correctly charge the patient and claim from Medicare Australia. Those authority prescriptions that grant exemption from a therapeutic group premium will have the letters 'TPX' at the beginning of the telephone Authority approval number, or, in the case of a written approval, will be stamped with the words "This prescription does not attract a therapeutic group premium".



## **DEPARTMENT OF VETERANS' AFFAIRS**

### **Authority Prescription Applications**

Applications for authority to prescribe under the Repatriation Pharmaceutical Benefits Scheme (RPBS) should be sent to the Veterans' Affairs Pharmaceutical Advisory Centre (VAPAC) using the free postal service:

REPLY PAID No. 372  
VAPAC (Veterans' Affairs Pharmaceutical Advisory Centre)  
GPO Box 9998  
BRISBANE QLD 4001

**For RPBS enquiries and telephone approvals 24 hours a day the Freecall number is:**

**1800 552 580**

**Departmental pharmacists answer applications for prior approval for non-Schedule items and Authority application calls.**

# REPATRIATION PHARMACEUTICAL BENEFITS

*This Schedule is effective from 1 October 2008 and all previous issues are cancelled.*

*New Schedules take effect on the first day of each month.*

## SUMMARY OF CHANGES

### DELETIONS

#### *Deletions - Items*

|       |                                                                                                                     |
|-------|---------------------------------------------------------------------------------------------------------------------|
| 4534P | <b>Alefacept</b> , Pack containing 4 vials powder for I.V. injection 7.5 mg with 4 vials solvent ( <i>Amevive</i> ) |
| 4535Q | <b>Alefacept</b> , Pack containing 4 vials powder for I.M. injection 15 mg with 4 vials solvent ( <i>Amevive</i> )  |
| 4377J | <b>Oxymetazoline hydrochloride</b> , Nasal drops 500 micrograms per mL (0.05%), 15 mL ( <i>Drixine</i> )            |

### ALTERATIONS

#### *Alterations - Maximum Quantity*

|       |                                                                                         | <i>From</i> | <i>To</i> |
|-------|-----------------------------------------------------------------------------------------|-------------|-----------|
| 4697F | <b>Dressing—hydrocolloid (cavity wound)</b> , Powder 6 g ( <i>Comfeel Powder 4706</i> ) | 2           | 5         |
| 4895P | <b>Dressing—hydrocolloid (cavity wound)</b> , Paste 50 g ( <i>Comfeel Paste 4701</i> )  | 6           | 2         |

#### *Alterations - Number of Repeats*

|       |                                                                                         | <i>From</i> | <i>To</i> |
|-------|-----------------------------------------------------------------------------------------|-------------|-----------|
| 4697F | <b>Dressing—hydrocolloid (cavity wound)</b> , Powder 6 g ( <i>Comfeel Powder 4706</i> ) | ..          | 2         |
| 4895P | <b>Dressing—hydrocolloid (cavity wound)</b> , Paste 50 g ( <i>Comfeel Paste 4701</i> )  | ..          | 3         |

## **Therapeutic Index for RPBS Schedule**

## THERAPEUTIC INDEX

---

### ALIMENTARY TRACT AND METABOLISM 680

STOMATOLOGICAL PREPARATIONS 680

*Stomatological preparations* 680

DRUGS FOR ACID RELATED DISORDERS 680

*Antacids* 680

DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 680

*Drugs for functional bowel disorders* 680

*Belladonna and derivatives, plain* 681

LAXATIVES 681

*Laxatives* 681

ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 682

*Antioesity preparations, excl. diet products* 682

VITAMINS 682

*Vitamin B<sub>1</sub>, plain and in combination with vitamin B<sub>6</sub> and vitamin B<sub>12</sub>* 682

*Vitamin B-complex, incl. combinations* 683

MINERAL SUPPLEMENTS 683

*Calcium* 683

*Other mineral supplements* 683

### BLOOD AND BLOOD FORMING ORGANS 683

ANTITHROMBOTIC AGENTS 683

*Antithrombotic agents* 683

BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS 684

*Irrigating solutions* 684

### CARDIOVASCULAR SYSTEM 684

VASOPROTECTIVES 684

*Agents for treatment of hemorrhoids and anal fissures for topical use* 684

### DERMATOLOGICALS 685

ANTIFUNGALS FOR DERMATOLOGICAL USE 685

*Antifungals for topical use* 685

*Antifungals for systemic use* 686

EMOLLIENTS AND PROTECTIVES 686

*Emollients and protectives* 686

*Protectives against UV-radiation* 687

ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 688

*Antipruritics, incl. antihistamines, anesthetics, etc.* 688

ANTIPSORIATICS 688

*Antipsoriatics for topical use* 688

ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE 688

*Antibiotics for topical use* 688

*Chemotherapeutics for topical use* 689

CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 689

*Corticosteroids, plain* 689

*Corticosteroids, combinations with antibiotics* 689

ANTISEPTICS AND DISINFECTANTS 690

*Antiseptics and disinfectants* 690

OTHER DERMATOLOGICAL PREPARATIONS 690

*Other dermatological preparations* 690

### GENITO URINARY SYSTEM AND SEX HORMONES 692

GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS 692

*Antiinfectives and antiseptics, excl. comb. with corticosteroids* 692

OTHER GYNECOLOGICALS 693

*Other gynecologicals* 693

SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 693

*Estrogens* 693

UROLOGICALS 694

*Other urologicals, incl. antispasmodics* 694

*Drugs used in benign prostatic hypertrophy* 695

### ANTIINFECTIVES FOR SYSTEMIC USE 695

## THERAPEUTIC INDEX

---

- ANTIBACTERIALS FOR SYSTEMIC USE 695
  - Macrolides, lincosamides and streptogramins 695*
- ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 696
- ANTINEOPLASTIC AGENTS 696
  - Antimetabolites 696*
- IMMUNOSUPPRESSANTS 696
  - Immunosuppressants 696*
- MUSCULO-SKELETAL SYSTEM 697
- ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS 697
  - Antiinflammatory and antirheumatic products, non-steroids 697*
- TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 697
  - Topical products for joint and muscular pain 697*
- DRUGS FOR TREATMENT OF BONE DISEASES 697
  - Drugs affecting bone structure and mineralization 697*
- NERVOUS SYSTEM 698
- ANALGESICS 698
  - Opioids 698*
  - Other analgesics and antipyretics 698*
- PSYCHOLEPTICS 700
  - Anxiolytics 700*
  - Hypnotics and sedatives 700*
- OTHER NERVOUS SYSTEM DRUGS 701
  - Drugs used in addictive disorders 701*
- ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 701
- ANTHELMINTICS 701
  - Antinematodal agents 701*
- RESPIRATORY SYSTEM 701
- NASAL PREPARATIONS 701
  - Decongestants and other nasal preparations for topical use 701*
  - Nasal decongestants for systemic use 702*
- COUGH AND COLD PREPARATIONS 702
  - Expectorants, excl. combinations with cough suppressants 702*
  - Cough suppressants, excl. combinations with expectorants 703*
- ANTIHISTAMINES FOR SYSTEMIC USE 703
  - Antihistamines for systemic use 703*
- SENSORY ORGANS 703
- OPHTHALMOLOGICALS 703
  - Decongestants and antiallergics 703*
- OTOLOGICALS 704
  - Corticosteroids and antiinfectives in combination 704*
  - Other otologicals 704*
- VARIOUS 705
- ALL OTHER THERAPEUTIC PRODUCTS 705
  - All other therapeutic products 705*
- ALL OTHER NON-THERAPEUTIC PRODUCTS 706
  - All other non-therapeutic products 706*



## **Section 1**

Drugs, Medicines and Dressings

## REPATRIATION

| Code                                                                              | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer           |          |
|-----------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------------|----------|
| <b>ALIMENTARY TRACT AND METABOLISM</b>                                            |                                                         |             |                |         |                                          |                                                        |                                                |          |
| <b>STOMATOLOGICAL PREPARATIONS</b>                                                |                                                         |             |                |         |                                          |                                                        |                                                |          |
| <b>Stomatological preparations</b>                                                |                                                         |             |                |         |                                          |                                                        |                                                |          |
| • <b>Antiinfectives and antiseptics for local oral treatment</b>                  |                                                         |             |                |         |                                          |                                                        |                                                |          |
| CHLORHEXIDINE GLUCONATE                                                           |                                                         |             |                |         |                                          |                                                        |                                                |          |
| 4161B                                                                             | Mouth wash 2 mg per mL (0.2%),<br>250 mL                | ‡ 1         | ..             | ..      | 11.46<br>11.98                           | 5.00<br>5.00                                           | Plaqacide<br>Savacol Mouth and<br>Throat Rinse | OB<br>OM |
| 4160Y                                                                             | Mouth wash 2 mg per mL (0.2%),<br>250 mL                | ‡ 1         | ..             | ..      | 13.34                                    | 5.00                                                   | Periogard<br>(Chlorohex)<br>Mouth Rinse        | OM       |
| • <b>Other agents for local oral treatment</b>                                    |                                                         |             |                |         |                                          |                                                        |                                                |          |
| CARMELLOSE SODIUM                                                                 |                                                         |             |                |         |                                          |                                                        |                                                |          |
| 4568K                                                                             | Mouth spray 10 mg per mL, 25 mL                         | ‡ 1         | 1              | ..      | 9.77                                     | 5.00                                                   | Aquae                                          | HA       |
| 4569L                                                                             | Mouth spray 10 mg per mL, 100 mL                        | ‡ 1         | ..             | ..      | 11.79                                    | 5.00                                                   | Aquae                                          | HA       |
| <b>DRUGS FOR ACID RELATED DISORDERS</b>                                           |                                                         |             |                |         |                                          |                                                        |                                                |          |
| <b>Antacids</b>                                                                   |                                                         |             |                |         |                                          |                                                        |                                                |          |
| • <b>Calcium compounds</b>                                                        |                                                         |             |                |         |                                          |                                                        |                                                |          |
| CALCIUM CARBONATE with GLYCINE                                                    |                                                         |             |                |         |                                          |                                                        |                                                |          |
| <b>NOTE:</b><br>For patients with chronic renal failure.                          |                                                         |             |                |         |                                          |                                                        |                                                |          |
| 4055K                                                                             | Tablet 420 mg-180 mg                                    | 200         | 5              | ..      | * 22.75                                  | 5.00                                                   | Titralac                                       | MM       |
| • <b>Combinations and complexes of aluminium, calcium and magnesium compounds</b> |                                                         |             |                |         |                                          |                                                        |                                                |          |
| ALUMINIUM HYDROXIDE with MAGNESIUM<br>HYDROXIDE and SIMETHICONE                   |                                                         |             |                |         |                                          |                                                        |                                                |          |
| 4453J                                                                             | Tablet 400 mg-400 mg-40 mg                              | 200         | 5              | ..      | * 45.69                                  | 5.00                                                   | Mylanta Double<br>Strength                     | JT       |
| 4118R                                                                             | Oral suspension 400 mg-400 mg-30 mg<br>per 5 mL, 500 mL | 2           | 5              | ..      | * 22.21                                  | 5.00                                                   | Mylanta Double<br>Strength                     | JT       |
| <b>DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS</b>                            |                                                         |             |                |         |                                          |                                                        |                                                |          |
| <b>Drugs for functional bowel disorders</b>                                       |                                                         |             |                |         |                                          |                                                        |                                                |          |
| • <b>Synthetic anticholinergics, esters with tertiary amino group</b>             |                                                         |             |                |         |                                          |                                                        |                                                |          |
| MEBEVERINE HYDROCHLORIDE                                                          |                                                         |             |                |         |                                          |                                                        |                                                |          |
| 4328T                                                                             | Tablet 135 mg                                           | 90          | ..             | ..      | 27.69<br>30.98                           | 5.00<br>5.00                                           | <sup>a</sup> Colese<br><sup>a</sup> Colofac    | AF<br>SM |



# REPATRIATION

| Code                                                                       | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>Belladonna and derivatives, plain</b>                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Belladonna alkaloids semisynthetic, quaternary ammonium compounds</b> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| HYOSCINE BUTYLBROMIDE                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4279F                                                                      | Injection 20 mg in 1 mL                                 | 5           | ..             | ..      | 20.95                                    | 5.00                                                   | Buscopan                             | BY |
| <b>LAXATIVES</b>                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Laxatives</b>                                                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Softeners, emollients</b>                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| DOCUSATE SODIUM                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4200C                                                                      | Tablet 50 mg                                            | 100         | 2              | ..      | 12.30                                    | 5.00                                                   | Coloxyl 50                           | FM |
| • <b>Contact laxatives</b>                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| DOCUSATE SODIUM with SENNA                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4198Y                                                                      | Tablet 50 mg-8 mg                                       | 90          | 2              | ..      | 13.98                                    | 5.00                                                   | Coloxyl with Senna                   | FM |
| 4028B                                                                      | Tablet 50 mg-8 mg                                       | 100         | 2              | ..      | 13.98                                    | 5.00                                                   | DP soflax                            | GM |
| SENNA STANDARDISED                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4455L                                                                      | Tablet 7.5 mg                                           | 100         | 1              | ..      | 13.43                                    | 5.00                                                   | Senokot                              | RC |
| • <b>Bulk producers</b>                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| ISPAGHULA HUSK                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4285M                                                                      | Sachets 3.5 g, 30                                       | ± 1         | 1              | ..      | 17.21                                    | 5.00                                                   | Fybogel                              | RC |
| PSYLLIUM HYDROPHILIC MUCILLOID                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4419N                                                                      | Oral powder (orange-flavoured, sugar-free) 283 g        | ± 1         | 1              | ..      | 21.24                                    | 5.00                                                   | Metamucil Smooth Texture Orange      | PY |
| 4422R                                                                      | Oral powder (non-flavoured) 336 g                       | ± 1         | 1              | ..      | 21.24                                    | 5.00                                                   | Metamucil Regular                    | PY |
| PSYLLIUM HYDROPHILIC MUCILLOID with HIGH AMYLOSE MAIZE STARCH              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4416K                                                                      | Oral powder 2.7 g-0.7 g per 7.5 g, 440 g                | ± 1         | 1              | ..      | 20.84                                    | 5.00                                                   | Nucolox                              | SI |
| STERCULIA with FRANGULA BARK                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4558X                                                                      | Granules 620 mg-80 mg per g (62%-8%), 500 g             | ± 1         | 1              | ..      | 24.52                                    | 5.00                                                   | Normacol Plus                        | NE |
| • <b>Enemas</b>                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| SORBITOL with SODIUM CITRATE and SODIUM LAURYL SULFOACETATE                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4462W                                                                      | Enemas 3.125 g-450 mg-45 mg in 5 mL, 4                  | ± 1         | ..             | ..      | 11.67                                    | 5.00                                                   | Micro lax                            | JT |

## REPATRIATION

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|

• **Other laxatives**

**GLYCEROL**

**Restricted Benefit**

*Short-term use when oral laxative therapy has failed or is inappropriate.*

|       |                                      |   |    |    |         |      |    |
|-------|--------------------------------------|---|----|----|---------|------|----|
| 4246L | Suppositories 2.8 g (for adults), 12 | 3 | .. | .. | * 18.32 | 5.00 | PP |
|-------|--------------------------------------|---|----|----|---------|------|----|

### ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS

**Antibesity preparations, excl. diet products**

• **Peripherally acting antiobesity products**

**ORLISTAT**

**Authority Required**

*For the treatment of obese patients.*

*Total treatment will not exceed 12 months from initial application.*

*Patients are eligible for 1 continuous treatment in a lifetime.*

*The patient must be receiving, or enrolled to receive, professional dietetic and weight management advice (where this is available).*

*Initial treatment for patients who meet the following criteria to qualify:*

*(a) Body Mass Index (BMI) greater than or equal to 35 with no known co-morbidities; or*

*(b) BMI greater than or equal to 30 with 1 or more of the following co-morbidities:*

*(i) diabetes;*

*(ii) ischaemic heart disease;*

*(iii) psychiatric conditions;*

*(iv) hypertension.*

*The prescriber must provide the following:*

*(a) initial body weight; and*

*(b) BMI.*

*Continuing treatment for patients who have previously been issued with an authority prescription for orlistat. After 3 months and up to 6 months following commencement of orlistat treatment, patient's initial body weight must have been reduced by 2.5 kg or 2.5% (whichever is the lesser).*

*Continuing treatment for patients who have previously been issued with an authority prescription for orlistat. After 6 months and up to 12 months following commencement of orlistat treatment, patient's initial body weight must have been reduced by 5 kg or 5% (whichever is the lesser).*

**NOTE:**

*The patient should be ideally enrolled in an exercise program and be receiving supplemental vitamins.*

|       |                |    |   |    |        |      |         |    |
|-------|----------------|----|---|----|--------|------|---------|----|
| 4570M | Capsule 120 mg | 84 | 2 | .. | 128.21 | 5.00 | Xenical | RO |
|-------|----------------|----|---|----|--------|------|---------|----|

### VITAMINS

**Vitamin B<sub>1</sub>, plain and in combination with vitamin B<sub>6</sub> and vitamin B<sub>12</sub>**

• **Vitamin B<sub>1</sub>, plain**

**THIAMINE HYDROCHLORIDE**

|       |               |     |   |    |       |      |         |    |
|-------|---------------|-----|---|----|-------|------|---------|----|
| 4043T | Tablet 100 mg | 100 | 2 | .. | 10.39 | 5.00 | Betamin | SW |
|-------|---------------|-----|---|----|-------|------|---------|----|

## REPATRIATION

| Code                                         | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>Vitamin B-complex, incl. combinations</b> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Vitamin B-complex, plain</b>            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| VITAMIN B GROUP COMPLEX                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4493L                                        | Oral liquid 200 mL                                      | ‡ 1         | 2              | ..      | 12.91                                    | 5.00                                                   | Accomin Adult<br>Tonic               | WT |

### MINERAL SUPPLEMENTS

#### Calcium

#### • Calcium

#### CALCIUM

#### Restricted Benefit

*Hypocalcaemia;*

*Osteoporosis;*

*Proven calcium malabsorption.*

|       |                                         |     |   |    |         |      |          |    |
|-------|-----------------------------------------|-----|---|----|---------|------|----------|----|
| 4332B | Tablet 250 mg (as citrate)              | 120 | 1 | .. | 13.88   | 5.00 | Citracal | BN |
| 4333C | Tablet (chewable) 500 mg (as carbonate) | 120 | 1 | .. | * 15.81 | 5.00 | Cal-Sup  | IA |

#### Restricted Benefit

*Hyperphosphataemia in chronic renal failure.*

|       |                                         |     |   |    |         |      |          |    |
|-------|-----------------------------------------|-----|---|----|---------|------|----------|----|
| 4093K | Tablet 250 mg (as citrate)              | 240 | 1 | .. | * 21.77 | 5.00 | Citracal | BN |
| 4094L | Tablet (chewable) 500 mg (as carbonate) | 240 | 1 | .. | * 25.63 | 5.00 | Cal-Sup  | IA |

#### Other mineral supplements

#### • Magnesium

#### MAGNESIUM ASPARTATE

#### Restricted Benefit

*Patients with documented hypomagnesaemia.*

|       |               |    |    |    |       |      |        |    |
|-------|---------------|----|----|----|-------|------|--------|----|
| 4321K | Tablet 500 mg | 50 | .. | .. | 13.96 | 5.00 | Magmin | BB |
|-------|---------------|----|----|----|-------|------|--------|----|

### BLOOD AND BLOOD FORMING ORGANS

#### ANTITHROMBOTIC AGENTS

#### Antithrombotic agents

#### • Platelet aggregation inhibitors excl. heparin

#### ASPIRIN

|       |                                                       |    |   |    |       |      |               |    |
|-------|-------------------------------------------------------|----|---|----|-------|------|---------------|----|
| 4076M | Tablet 100 mg (with glycine)                          | 90 | 1 | .. | 15.24 | 5.00 | Cardiprin 100 | RC |
| 4077N | Tablet 100 mg (enteric coated)                        | 84 | 1 | .. | 13.28 | 5.00 | Cartia        | GK |
| 4078P | Capsule 100 mg (containing enteric<br>coated pellets) | 84 | 1 | .. | 14.19 | 5.00 | Astrix        | HH |

continued ➞

## REPATRIATION

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|

**NOTE:**

The enteric coated preparations are for patients with a significant risk of gastrointestinal bleeding.

**CLOPIDOGREL HYDROGEN SULFATE****Authority Required**

*For use in patients pre- and post-angioplasty.*

|       |                     |    |   |    |       |      |                                             |          |
|-------|---------------------|----|---|----|-------|------|---------------------------------------------|----------|
| 4179Y | Tablet 75 mg (base) | 28 | 3 | .. | 82.79 | 5.00 | <sup>a</sup> Iscover<br><sup>a</sup> Plavix | BQ<br>SW |
|-------|---------------------|----|---|----|-------|------|---------------------------------------------|----------|

|                                           |
|-------------------------------------------|
| BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS |
|-------------------------------------------|

**Irrigating solutions**

- Salt solutions**

**SODIUM CHLORIDE**

|       |                                                   |     |   |    |       |      |    |
|-------|---------------------------------------------------|-----|---|----|-------|------|----|
| 4460R | Irrigation solution 9 mg per mL (0.9%),<br>500 mL | ± 1 | 2 | .. | 9.90  | 5.00 | BX |
| 4461T | Irrigation solution 9 mg per mL (0.9%),<br>1 L    | ± 1 | 2 | .. | 10.22 | 5.00 | BX |

**CARDIOVASCULAR SYSTEM**

|                 |
|-----------------|
| VASOPROTECTIVES |
|-----------------|

**Agents for treatment of hemorrhoids and anal fissures for topical use**

- Corticosteroids**

HYDROCORTISONE with CINCHOCAINE  
HYDROCHLORIDE

**CAUTION:**

Long-term use may lead to skin atrophy.

|       |                                               |     |    |    |       |      |             |    |
|-------|-----------------------------------------------|-----|----|----|-------|------|-------------|----|
| 4036K | Ointment 5 mg-5 mg per g (0.5%-0.5%),<br>30 g | ± 1 | .. | .. | 19.61 | 5.00 | Proctosedyl | SW |
| 4038M | Suppositories 5 mg-5 mg, 12                   | ± 1 | .. | .. | 18.51 | 5.00 | Proctosedyl | SW |

- Other agents for treatment of hemorrhoids and anal fissures for topical use**

**ZINC OXIDE**

|       |                            |     |   |    |       |      |        |    |
|-------|----------------------------|-----|---|----|-------|------|--------|----|
| 4039N | Compound ointment 50 g     | ± 1 | 1 | .. | 14.01 | 5.00 | Anusol | JT |
| 4040P | Compound suppositories, 12 | ± 1 | 1 | .. | 12.92 | 5.00 | Anusol | JT |

## REPATRIATION

| Code                                        | Name, Restriction,<br>Manner of Administration and Form                                                                                      | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>DERMATOLOGICALS</b>                      |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>ANTIFUNGALS FOR DERMATOLOGICAL USE</b>   |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>Antifungals for topical use</b>          |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| • <b>Antibiotics</b>                        |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| NYSTATIN                                    |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4001N                                       | Cream 100,000 units per g, 15 g                                                                                                              | ‡ 1         | 1              | ..      | 12.06                                    | 5.00                                                   | Mycostatin                           | BQ |
| • <b>Imidazole and triazole derivatives</b> |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| BIFONAZOLE                                  |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4003Q                                       | Cream 10 mg per g (1%), 15 g                                                                                                                 | ‡ 1         | ..             | ..      | 15.68                                    | 5.00                                                   | Mycospor                             | BN |
| CLOTRIMAZOLE                                |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4004R                                       | Cream 10 mg per g (1%), 20 g                                                                                                                 | ‡ 1         | 1              | ..      | 8.54                                     | 5.00                                                   | Clonea                               | AF |
| 4005T                                       | Lotion 10 mg per mL (1%), 20 mL                                                                                                              | ‡ 1         | 1              | ..      | 11.96                                    | 5.00                                                   | Canesten                             | BN |
| <b>KETOCONAZOLE</b>                         |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                   |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| <i>Severe seborrhoeic dermatitis.</i>       |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4008Y                                       | Shampoo 20 mg per g (2%), 60 mL                                                                                                              | ‡ 1         | ..             | ..      | 17.88                                    | 5.00                                                   | Nizoral 2%                           | JT |
| 4007X                                       | Shampoo 20 mg per g (2%), 100 mL                                                                                                             | ‡ 1         | ..             | ..      | 18.94                                    | 5.00                                                   | Sebizole                             | GM |
|                                             |                                                                                                                                              |             |                | ..      | 18.96                                    | 5.00                                                   | Hexal Konazol 2% Shampoo             | HX |
| MICONAZOLE                                  |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4341L                                       | Tincture 20 mg per mL (2%), 30 mL                                                                                                            | ‡ 1         | 1              | ..      | 19.04                                    | 5.00                                                   | Daktarin                             | JT |
| MICONAZOLE NITRATE                          |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4454K                                       | Cream 20 mg per g (2%), 30 g                                                                                                                 | ‡ 1         | 1              | ..      | 14.36                                    | 5.00                                                   | Daktarin                             | JT |
| • <b>Other antifungals for topical use</b>  |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>AMOROLFINE HYDROCHLORIDE</b>             |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                   |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| <i>Onychomycosis.</i>                       |                                                                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4010C                                       | Nail treatment kit containing nail lacquer 50 mg (base) per mL (5%), 5 mL, 60 isopropyl alcohol cleaning pads, 10 spatulas and 30 nail files | ‡ 1         | 1              | ..      | 93.95                                    | 5.00                                                   | Loceryl                              | GA |

# REPATRIATION

| Code                                                                                                                                                                               | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>CICLOPIROX OLAMINE</b>                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Severe seborrhoeic dermatitis.</i>                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 44106D                                                                                                                                                                             | Shampoo 15 mg per g (1.5%), 60 mL                       | ‡ 1         | ..             | ..      | 16.13                                    | 5.00                                                   | Stieprox Liquid                      | SX |
| <b>TERBINAFINE</b>                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Tinea pedis.</i>                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4463X                                                                                                                                                                              | Gel 10 mg per g (1%), 15 g                              | ‡ 1         | ..             | ..      | 22.92                                    | 5.00                                                   | Lamisil DermGel                      | NC |
| <b>TERBINAFINE HYDROCHLORIDE</b>                                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>Tinea pedis.</i>                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4473K                                                                                                                                                                              | Cream 10 mg per g (1%), 15 g                            | ‡ 1         | 1              | ..      | 21.46                                    | 5.00                                                   | Lamisil                              | NC |
| <b>TOLNAFTATE</b>                                                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4481W                                                                                                                                                                              | Spray aerosol 10 mg per g (1%), 100 g                   | ‡ 1         | ..             | ..      | 14.25                                    | 5.00                                                   | Tinaderm                             | SH |
| <b>Antifungals for systemic use</b>                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Antifungals for systemic use</b>                                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>TERBINAFINE HYDROCHLORIDE</b>                                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Authority Required</u></b><br><i>Onychomycosis due to dermatophyte infection proven by microscopy or culture and confirmed by an approved pathology provider.</i>            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4011D                                                                                                                                                                              | Tablet 250 mg (base)                                    | 42          | 1              | ..      | 102.39                                   | 5.00                                                   | <sup>a</sup> Tamsil                  | AW |
|                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terbihexal              | SZ |
|                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Terbinafine-DP          | GM |
|                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Zabel                   | AF |
|                                                                                                                                                                                    |                                                         |             |                | ..      | 103.85                                   | 5.00                                                   | <sup>a</sup> Lamisil                 | NV |
| <b>EMOLLIENTS AND PROTECTIVES</b>                                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Emollients and protectives</b>                                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Silicone products</b>                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>DIMETHICONE with GLYCEROL</b>                                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>Restricted Benefit</u></b><br><i>For colostomy and ileostomy use;</i><br><i>For use by paraplegic and quadriplegic patients;</i><br><i>For use with surgical appliances.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4556T                                                                                                                                                                              | Cream 150 mg-20 mg per g (15%-2%),<br>75 g              | ‡ 1         | ..             | ..      | 11.71                                    | 5.00                                                   | Silic 15                             | EO |

continued ➞

## REPATRIATION

| Code  | Name, Restriction,<br>Manner of Administration and Form                                                            | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                         |                  |
|-------|--------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------|------------------|
| 4551M | <b><i>Cream 150 mg-20 mg per g (15%-2%),<br/>500 g</i></b>                                                         | ± 1         | ..             | ..      | 24.68                                    | 5.00                                                   | <b><i>Silic 15</i></b>                                       | <b><i>EO</i></b> |
|       | <b>• Soft paraffin and fat products</b><br>WOOL ALCOHOLS                                                           |             |                |         |                                          |                                                        |                                                              |                  |
| 4041Q | Ointment 100 g                                                                                                     | ± 1         | 1              | ..      | 12.37                                    | 5.00                                                   | Eucerin                                                      | BE               |
|       | <b>• Carbamide products</b><br>UREA                                                                                |             |                |         |                                          |                                                        |                                                              |                  |
| 4042R | Cream 100 mg per g (10%), 100 g                                                                                    | ± 1         | 2              | ..      | 11.65                                    | 5.00                                                   | Aquacare H.P.                                                | AG               |
|       |                                                                                                                    |             |                | ..      | 11.73                                    | 5.00                                                   | Urederm                                                      | HA               |
|       |                                                                                                                    |             |                | ..      | 12.10                                    | 5.00                                                   | Calmurid                                                     | OL               |
|       |                                                                                                                    |             |                |         |                                          |                                                        | Nutraplus                                                    | GA               |
|       | <b>• Other emollients and protectives</b><br>CARMELLOSE SODIUM with PECTIN and GELATIN                             |             |                |         |                                          |                                                        |                                                              |                  |
| 4518T | Paste 167 mg-167 mg-167 mg per g<br>(16.7%-16.7%- 16.7%), 5 g                                                      | ± 1         | ..             | ..      | 11.42                                    | 5.00                                                   | Orabase                                                      | BQ               |
|       | SKIN EMOLLIENT                                                                                                     |             |                |         |                                          |                                                        |                                                              |                  |
| 4122Y | Bath oil 500 mL                                                                                                    | ± 1         | 2              | ..      | 16.92                                    | 5.00                                                   | Alpha Keri Bath<br>Oil                                       | MT               |
|       |                                                                                                                    |             |                | ..      | 19.33                                    | 5.00                                                   | QV Bath Oil                                                  | EO               |
|       |                                                                                                                    |             |                | ..      | 19.42                                    | 5.00                                                   | Hamilton Skin<br>Therapy Oil                                 | HA               |
| 4107E | Lotion 500 mL                                                                                                      | ± 1         | 2              | ..      | 16.92                                    | 5.00                                                   | Alpha Keri Lotion                                            | MT               |
|       | <b>Protectives against UV-radiation</b><br><b>• Protectives against UV-radiation for topical use</b><br>SUNSCREENS |             |                |         |                                          |                                                        |                                                              |                  |
| 4543D | Solid stick 4.5 g                                                                                                  | ± 1         | 2              | ..      | 11.68                                    | 5.00                                                   | Hamilton Solastick<br>30+                                    | HA               |
| 4544E | Cream 100 g                                                                                                        | ± 1         | 2              | ..      | 15.09                                    | 5.00                                                   | Hamilton<br>Sunscreen<br>Family<br>Sunscreen Cream<br>SPF 15 | HA               |
|       |                                                                                                                    |             |                | ..      | 16.69                                    | 5.00                                                   | SunSense Cream<br>SPF 30+                                    | EO               |

continued ➞

## REPATRIATION

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                        |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------|----|
| 4546G | Lotion (non-alcoholic) 125 mL                           | ‡ 1         | 2              | ..      | 15.09                                    | 5.00                                                   | Hamilton<br>Sunscreen<br>Family<br>Sunscreen Milk<br>SPF 15 | HA |
|       |                                                         |             |                | ..      | 15.55                                    | 5.00                                                   | Aquasun Lotion<br>SPF 18                                    | PF |
|       |                                                         |             |                | ..      | 16.56                                    | 5.00                                                   | SunSense Ultra<br>SPF 30+                                   | EO |

### ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.

#### Antipruritics, incl. antihistamines, anesthetics, etc.

- **Anesthetics for topical use**

LIGNOCAINE HYDROCHLORIDE with  
CARBOXYMETHYLCELLULOSE

|       |                                                  |     |    |    |       |      |                   |    |
|-------|--------------------------------------------------|-----|----|----|-------|------|-------------------|----|
| 4308R | Mucilage 20 mg-25 mg per mL<br>(2%-2.5%), 200 mL | ‡ 1 | .. | .. | 78.92 | 5.00 | Xylocaine Viscous | AP |
|-------|--------------------------------------------------|-----|----|----|-------|------|-------------------|----|

- **Other antipruritics**

PINE TAR with TRIETHANOLAMINE LAURYL SULFATE

**NOTE:**

For patients who have failed to respond to simple moisturising agents.

|       |                                                  |     |   |    |       |      |                               |    |
|-------|--------------------------------------------------|-----|---|----|-------|------|-------------------------------|----|
| 4408B | Solution 23 mg-60 mg per mL<br>(2.3%-6%), 500 mL | ‡ 1 | 2 | .. | 19.87 | 5.00 | Hamilton Pine Tar<br>Solution | HA |
|       |                                                  |     |   | .. | 20.50 | 5.00 | Pinetarsol                    | EO |

### ANTIPSORIATICS

#### Antipsoriatics for topical use

- **Tars**

ALLANTOIN with SULFUR, PHENOL, COAL TAR  
SOLUTION and MENTHOL

|       |                                                                                |     |   |    |       |      |              |    |
|-------|--------------------------------------------------------------------------------|-----|---|----|-------|------|--------------|----|
| 4505D | Gel 25 mg-5 mg-5 mg-0.05 mL-7.5 mg<br>per g (2.5%-0.5%-0.5%-5%-0.75%),<br>30 g | ‡ 1 | 2 | .. | 14.64 | 5.00 | Egopsoryl-TA | EO |
|-------|--------------------------------------------------------------------------------|-----|---|----|-------|------|--------------|----|

### ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE

#### Antibiotics for topical use

- **Other antibiotics for topical use**

MUPIROCIN

**Restricted Benefit**

*For the topical treatment of secondarily infected traumatic skin lesions.*

|       |                                              |     |    |    |       |      |           |    |
|-------|----------------------------------------------|-----|----|----|-------|------|-----------|----|
| 4348W | Cream 20 mg (as calcium) per g (2%),<br>15 g | ‡ 1 | .. | .. | 15.85 | 5.00 | Bactroban | GK |
|-------|----------------------------------------------|-----|----|----|-------|------|-----------|----|

continued ➞



## REPATRIATION

| Code                                           | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 4350Y                                          | Ointment 20 mg per g (2%), 15 g                         | ± 1         | ..             | ..      | 15.85                                    | 5.00                                                   | Bactroban                            | GK |
| <b>Chemotherapeutics for topical use</b>       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Antivirals</b>                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>PODOPHYLLOTOXIN</b>                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>For the treatment of ano-genital warts.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4566H                                          | Paint 5 mg per mL (0.5%), 3.5 mL (with 30 swabs)        | ± 1         | ..             | ..      | 38.03                                    | 5.00                                                   | Condyline Paint                      | HA |
| • <b>Other chemotherapeutics</b>               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| METRONIDAZOLE                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4030D                                          | Gel 7.5 mg per g (0.75%), 50 g                          | ± 1         | ..             | ..      | 30.44                                    | 5.00                                                   | Rozex                                | GA |
| 4340K                                          | Cream 7.5 mg per g (0.75%), 30 g                        | ± 1         | 1              | ..      | 21.61                                    | 5.00                                                   | Rozex                                | GA |

### CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

#### **Corticosteroids, plain**

#### • **Corticosteroids, potent (group III)**

##### BETAMETHASONE VALERATE

|       |                                         |     |   |    |       |      |           |    |
|-------|-----------------------------------------|-----|---|----|-------|------|-----------|----|
| 4131K | Cream 1 mg (base) per g (0.1%), 30 g    | ± 1 | 2 | .. | 22.00 | 5.00 | Betnovate | SI |
| 4132L | Ointment 1 mg (base) per g (0.1%), 30 g | ± 1 | 2 | .. | 22.00 | 5.00 | Betnovate | SI |

##### MOMETASONE FUROATE

|       |                                  |     |    |    |       |      |        |    |
|-------|----------------------------------|-----|----|----|-------|------|--------|----|
| 4342M | Cream 1 mg per g (0.1%), 45 g    | ± 1 | .. | .. | 26.38 | 5.00 | Elocon | SH |
| 4343N | Ointment 1 mg per g (0.1%), 45 g | ± 1 | .. | .. | 26.38 | 5.00 | Elocon | SH |

#### **NOTE:**

Application to large areas of skin for longer than four weeks is not recommended.

#### **Corticosteroids, combinations with antibiotics**

#### • **Corticosteroids, moderately potent, combinations with antibiotics**

##### TRIAMCINOLONE ACETONIDE with NEOMYCIN SULFATE, GRAMICIDIN and NYSTATIN

|       |                                                                                                                                 |     |    |    |       |      |          |    |
|-------|---------------------------------------------------------------------------------------------------------------------------------|-----|----|----|-------|------|----------|----|
| 4482X | Ointment 1 mg-2.5 mg<br>(base)-250 micrograms- 100,000 units<br>per g (0.1%-0.25% (base)-0.025%-<br>100,000 units in 1 g), 15 g | ± 1 | .. | .. | 18.66 | 5.00 | Kenacomb | BQ |
|-------|---------------------------------------------------------------------------------------------------------------------------------|-----|----|----|-------|------|----------|----|

#### **CAUTION:**

For the short-term treatment of localised infective eczema only.

## REPATRIATION

| Code                                                                                               | Name, Restriction,<br>Manner of Administration and Form                                      | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>ANTISEPTICS AND DISINFECTANTS</b>                                                               |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>Antiseptics and disinfectants</b>                                                               |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| • <b>Iodine products</b>                                                                           |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| POVIDONE-IODINE                                                                                    |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4411E                                                                                              | Solution 100 mg per mL (10%), 100 mL                                                         | ‡ 1         | ..             | ..      | 20.39                                    | 5.00                                                   | Betadine Antiseptic Liquid           | FH |
| <b>OTHER DERMATOLOGICAL PREPARATIONS</b>                                                           |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| <b>Other dermatological preparations</b>                                                           |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| • <b>Antihidrotics</b>                                                                             |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| DIPHEMANIL METHYLSULFATE                                                                           |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4191N                                                                                              | Dusting powder 20 mg per g (2%), 50 g                                                        | ‡ 1         | 1              | ..      | 16.72                                    | 5.00                                                   | Prantal                              | SH |
| • <b>Medicated shampoos</b>                                                                        |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| PINE TAR with CADE OIL, COAL TAR SOLUTION, ARACHIS OIL EXTRACT OF CRUDE COAL TAR and OLEYL ALCOHOL |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4405W                                                                                              | Scalp cleanser<br>3 mg-3 mg-1 mg-3 mg-10 mg per mL<br>(0.3%-0.3%-0.1%-0.3%-1%), 300 mL       | ‡ 1         | 2              | ..      | 20.60                                    | 5.00                                                   | Polytar                              | SX |
| SALICYLIC ACID with BENZALKONIUM CHLORIDE, ALCOHOL, COAL TAR and POLYOXYETHYLENE ETHERS            |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4560B                                                                                              | Scalp cleanser<br>20 mg-2 mg-130 mg-50 mg-216 mg<br>per mL (2%-0.2%-13%-5%-21.6%),<br>250 mL | ‡ 1         | 2              | ..      | 18.78                                    | 5.00                                                   | Ionil-T                              | GA |
| SALICYLIC ACID with BENZALKONIUM CHLORIDE, ALCOHOL and POLYOXYETHYLENE ETHERS                      |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4445Y                                                                                              | Scalp cleanser<br>20 mg-2 mg-130 mg-216 mg per mL<br>(2%-0.2%-13%-21.6%), 250 mL             | ‡ 1         | 2              | ..      | 18.43                                    | 5.00                                                   | Ionil                                | GA |
| SALICYLIC ACID with COAL TAR SOLUTION and PINE TAR                                                 |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4447C                                                                                              | Scalp cleanser 20 mg-10 mg-10 mg per<br>mL (2%-1%-1%), 250 mL                                | ‡ 1         | 2              | ..      | 17.28                                    | 5.00                                                   | Sebitar                              | EO |
| SELENIUM SULFIDE                                                                                   |                                                                                              |             |                |         |                                          |                                                        |                                      |    |
| 4452H                                                                                              | Shampoo 25 mg per mL (2.5%), 125 mL                                                          | ‡ 1         | ..             | ..      | 13.71                                    | 5.00                                                   | Selsun                               | AB |

## REPATRIATION

| Code                                                                                                                                                                                                                                                                                                        | Name, Restriction,<br>Manner of Administration and Form  | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>• Wart and anti-corn preparations</b><br>SALICYLIC ACID with PODOPHYLLIN RESIN                                                                                                                                                                                                                           |                                                          |             |                |         |                                          |                                                        |                                      |    |
| 4450F                                                                                                                                                                                                                                                                                                       | Paint 100 mg-200 mg per mL<br>(10%-20%), 6 mL            | ‡ 1         | 1              | ..      | 14.88                                    | 5.00                                                   | Posalfilin                           | NE |
| <b>• Other dermatologicals</b><br>ALLANTOIN with GLYCEROL and ICHTHAMMOL<br><b>NOTE:</b><br>For patients who have failed to respond to simple moisturising agents.                                                                                                                                          |                                                          |             |                |         |                                          |                                                        |                                      |    |
| 4281H                                                                                                                                                                                                                                                                                                       | Cream 5 mg-10 mg-10 mg per g<br>(0.5%-1%-1%), 50 g       | ‡ 1         | 2              | ..      | 16.92                                    | 5.00                                                   | Egoderm Cream                        | EO |
| 4280G                                                                                                                                                                                                                                                                                                       | Ointment 5 mg-10 mg-10 mg per g<br>(0.5%-1%-1%), 50 g    | ‡ 1         | 2              | ..      | 16.92                                    | 5.00                                                   | Egoderm Ointment                     | EO |
| CATIONIC CONDITIONER with PANTHENOL<br><b>NOTE:</b><br>To be used in conjunction with the scalp cleanser salicylic acid with coal tar solution and pine tar (code 4447C).                                                                                                                                   |                                                          |             |                |         |                                          |                                                        |                                      |    |
| 4510J                                                                                                                                                                                                                                                                                                       | Cream 200 g                                              | ‡ 1         | 2              | ..      | 13.82                                    | 5.00                                                   | SebiRinse                            | EO |
| HYDROLYZED COLLAGEN PROTEINS<br><b>NOTE:</b><br>To be used in conjunction with the two scalp cleansers:<br>salicylic acid, benzalkonium chloride, alcohol and polyoxyethylene ethers (code 4445Y); and<br>salicylic acid, benzalkonium chloride, alcohol, coal tar and polyoxyethylene ethers (code 4560B). |                                                          |             |                |         |                                          |                                                        |                                      |    |
| 4271T                                                                                                                                                                                                                                                                                                       | Hair conditioner 250 mL                                  | ‡ 1         | 2              | ..      | 12.95                                    | 5.00                                                   | Ionil Rinse                          | GA |
| <b>IMIQUIMOD</b><br><b>Authority Required</b><br><i>Primary treatment of histopathologically confirmed superficial basal cell carcinoma where other standard treatments are inappropriate and topical drug therapy is required.</i>                                                                         |                                                          |             |                |         |                                          |                                                        |                                      |    |
| 4559Y                                                                                                                                                                                                                                                                                                       | Cream 50 mg per g (5%), 250 mg single<br>use sachets, 12 | 1           | 1              | ..      | 159.52                                   | 5.00                                                   | Aldara                               | IA |
| SKIN CLEANSER                                                                                                                                                                                                                                                                                               |                                                          |             |                |         |                                          |                                                        |                                      |    |
| 4549K                                                                                                                                                                                                                                                                                                       | Lotion 500 mL                                            | ‡ 1         | 2              | ..      | 20.31                                    | 5.00                                                   | Hamilton Skin<br>Therapy Wash        | HA |
| ZINC OXIDE with STARCH and CHLORPHENESIN                                                                                                                                                                                                                                                                    |                                                          |             |                |         |                                          |                                                        |                                      |    |
| 4497Q                                                                                                                                                                                                                                                                                                       | Dusting powder 100 g                                     | ‡ 1         | 1              | ..      | 11.83                                    | 5.00                                                   | Z.S.C.                               | SI |

## REPATRIATION

| Code                                                             | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| GENITO URINARY SYSTEM AND SEX HORMONES                           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Antiinfectives and antiseptics, excl. comb. with corticosteroids |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • Antibiotics                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| NYSTATIN                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4012E                                                            | Cream pessaries 100,000 units, 15                       | ‡ 1         | 1              | ..      | 13.36                                    | 5.00                                                   | Nilstat                              | SI |
| 4013F                                                            | Vaginal cream 100,000 units per dose, 15 doses, 75 g    | ‡ 1         | 1              | ..      | 13.36                                    | 5.00                                                   | Nilstat                              | SI |
| • Imidazole derivatives                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| CLOTRIMAZOLE                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4014G                                                            | Pessaries 100 mg, 6                                     | ‡ 1         | ..             | ..      | 14.65                                    | 5.00                                                   | Clofeme                              | HX |
|                                                                  |                                                         |             |                | ..      | 16.44                                    | 5.00                                                   | Canesten                             | BN |
| 4015H                                                            | Pessary 500 mg                                          | 1           | ..             | ..      | 15.25                                    | 5.00                                                   | Clofeme                              | HX |
|                                                                  |                                                         |             |                | ..      | 17.63                                    | 5.00                                                   | Canesten 1                           | BN |
| 4016J                                                            | Vaginal cream 50 mg per 5 g (1%), 35 g                  | ‡ 1         | ..             | ..      | 14.65                                    | 5.00                                                   | Chem mart                            | CH |
|                                                                  |                                                         |             |                |         |                                          |                                                        | Clotrimazole 6                       |    |
|                                                                  |                                                         |             |                |         |                                          |                                                        | Day Cream                            |    |
|                                                                  |                                                         |             |                |         |                                          |                                                        | GenRx                                | GX |
|                                                                  |                                                         |             |                |         |                                          |                                                        | Clotrimazole 6                       |    |
|                                                                  |                                                         |             |                |         |                                          |                                                        | Day Cream                            |    |
|                                                                  |                                                         |             |                |         |                                          |                                                        | healthsense                          | HS |
|                                                                  |                                                         |             |                |         |                                          |                                                        | Clotrimazole 6                       |    |
|                                                                  |                                                         |             |                |         |                                          |                                                        | Day Cream                            |    |
|                                                                  |                                                         |             |                |         |                                          |                                                        | Terry White                          | TW |
|                                                                  |                                                         |             |                | ..      | 14.76                                    | 5.00                                                   | Chemists                             |    |
|                                                                  |                                                         |             |                |         |                                          |                                                        | Clotrimazole 6                       |    |
|                                                                  |                                                         |             |                | ..      | 16.05                                    | 5.00                                                   | Day Cream                            |    |
|                                                                  |                                                         |             |                |         |                                          |                                                        | Hexal Clofeme 6                      | HX |
|                                                                  |                                                         |             |                |         |                                          |                                                        | Canesten                             | BN |

continued ➞

## REPATRIATION

| Code               | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer                   |    |
|--------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|----|
| 4017K              | Vaginal cream 100 mg per 5 g (2%), 20 g                 | ± 1         | ..             | ..      | 14.65                                    | 5.00                                                   | Chem mart<br>Clotrimazole 3<br>Day Cream               | CH |
|                    |                                                         |             |                |         |                                          |                                                        | Femizol Vaginal<br>Cream                               | GM |
|                    |                                                         |             |                |         |                                          |                                                        | GenRx<br>Clotrimazole 3<br>Day Cream                   | GX |
|                    |                                                         |             |                |         |                                          |                                                        | healthsense<br>Clotrimazole 3<br>Day Cream             | HS |
|                    |                                                         |             |                |         |                                          |                                                        | Terry White<br>Chemists<br>Clotrimazole 3<br>Day Cream | TW |
|                    |                                                         |             |                | ..      | 14.76                                    | 5.00                                                   | Hexal Clofeme 3<br>Day Cream                           | HX |
|                    |                                                         |             |                | ..      | 17.03                                    | 5.00                                                   | Canesten 3                                             | BN |
| MICONAZOLE NITRATE |                                                         |             |                |         |                                          |                                                        |                                                        |    |
| 4020N              | Pessaries 100 mg, 7                                     | ± 1         | ..             | ..      | 14.42                                    | 5.00                                                   | Monistat 7                                             | JC |
| 4021P              | Vaginal cream 100 mg per 5 g (2%), 40 g                 | ± 1         | ..             | ..      | 14.42                                    | 5.00                                                   | Monistat 7                                             | JC |

### OTHER GYNECOLOGICALS

#### Other gynecologicals

#### • Other gynecologicals

RICINOLEIC ACID with ACETIC ACID and  
HYDROXYQUINOLINE SULFATE

|       |                                                                                 |     |    |    |       |      |         |    |
|-------|---------------------------------------------------------------------------------|-----|----|----|-------|------|---------|----|
| 4434J | Vaginal jelly<br>7 mg-9.4 mg-250 micrograms per g<br>(0.7%-0.94%-0.025%), 100 g | ± 1 | .. | .. | 32.47 | 5.00 | Aci-Jel | JC |
|-------|---------------------------------------------------------------------------------|-----|----|----|-------|------|---------|----|

### SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

#### Estrogens

#### • Natural and semisynthetic estrogens, plain

#### OESTRADIOL

#### Restricted Benefit

*Post-menopausal symptoms in women who have failed to respond using oral or topical oestrogens.*

|       |                |   |    |    |        |      |    |  |
|-------|----------------|---|----|----|--------|------|----|--|
| 4365R | Implant 50 mg  | 1 | .. | .. | 75.93  | 5.00 | OR |  |
| 4366T | Implant 100 mg | 1 | .. | .. | 115.66 | 5.00 | OR |  |



## REPATRIATION

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

### SODIUM CITRO-TARTRATE

#### Restricted Benefit

*For relief of urinary symptoms when antibiotic or other therapy alone is inappropriate.*

|       |                                                     |     |   |    |       |      |                        |          |
|-------|-----------------------------------------------------|-----|---|----|-------|------|------------------------|----------|
| 4049D | Sachets containing oral effervescent powder 4 g, 28 | ± 1 | 4 | .. | 13.12 | 5.00 | Uracol<br>Ural Sachets | GM<br>SI |
|-------|-----------------------------------------------------|-----|---|----|-------|------|------------------------|----------|

### Drugs used in benign prostatic hypertrophy

#### • **Alpha-adrenoreceptor antagonists**

##### TAMSULOSIN HYDROCHLORIDE

#### Authority Required

*Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated.*

|       |                                           |    |   |    |       |      |           |    |
|-------|-------------------------------------------|----|---|----|-------|------|-----------|----|
| 4070F | Tablet 400 micrograms (prolonged release) | 30 | 5 | .. | 62.93 | 5.00 | Flomaxtra | CS |
|-------|-------------------------------------------|----|---|----|-------|------|-----------|----|

##### TERAZOSIN HYDROCHLORIDE

#### Authority Required

*Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated.*

|       |                                                           |     |    |    |       |      |        |    |
|-------|-----------------------------------------------------------|-----|----|----|-------|------|--------|----|
| 4396J | Starter pack containing 7 tablets 1 mg and 7 tablets 2 mg | ± 1 | .. | .. | 19.62 | 5.00 | Hytrin | AB |
| 4397K | Tablet 2 mg                                               | 28  | 5  | .. | 41.26 | 5.00 | Hytrin | AB |
| 4398L | Tablet 5 mg                                               | 28  | 5  | .. | 57.76 | 5.00 | Hytrin | AB |
| 4399M | Tablet 10 mg                                              | 28  | 5  | .. | 85.63 | 5.00 | Hytrin | AB |

#### • **Testosterone-5-alpha reductase inhibitors**

##### FINASTERIDE

#### Authority Required

*Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated.*

|       |             |    |   |    |        |      |         |    |
|-------|-------------|----|---|----|--------|------|---------|----|
| 4233T | Tablet 5 mg | 30 | 5 | .. | 111.26 | 5.00 | Proscar | MK |
|-------|-------------|----|---|----|--------|------|---------|----|

### ANTIINFECTIVES FOR SYSTEMIC USE

#### ANTIBACTERIALS FOR SYSTEMIC USE

#### Macrolides, lincosamides and streptogramins

#### • **Macrolides**

##### AZITHROMYCIN

#### Restricted Benefit

*Upper and lower respiratory tract infections.*

|       |               |   |    |    |       |      |           |    |
|-------|---------------|---|----|----|-------|------|-----------|----|
| 4115N | Tablet 500 mg | 3 | .. | .. | 34.67 | 5.00 | Zithromax | PF |
|-------|---------------|---|----|----|-------|------|-----------|----|

## REPATRIATION

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

### ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

#### ANTINEOPLASTIC AGENTS

##### Antimetabolites

##### • **Pyrimidine analogues**

##### FLUOROURACIL

|       |                              |     |    |    |       |      |        |    |
|-------|------------------------------|-----|----|----|-------|------|--------|----|
| 4222F | Cream 50 mg per g (5%), 20 g | ‡ 1 | .. | .. | 50.45 | 5.00 | Efudix | VT |
|-------|------------------------------|-----|----|----|-------|------|--------|----|

#### IMMUNOSUPPRESSANTS

##### Immunosuppressants

##### • **Tumor necrosis factor alpha (TNF-alpha) inhibitors**

##### INFLIXIMAB

##### NOTE:

*Any queries concerning the arrangements to prescribe infliximab may be directed to the Veterans' Affairs Pharmaceutical Approvals Centre (VAPAC) on 1800 552 580.*

*Written applications for authority to prescribe infliximab should be forwarded to:*

*Reply Paid 372*

*Veterans' Affairs Pharmaceutical Approvals Centre (VAPAC)*

*GPO Box 9998*

*BRISBANE QLD 4001*

##### Authority Required

*Initial treatment, in combination with methotrexate, of specific accepted war-caused or service-related disability of refractory rheumatoid arthritis. Initial treatment may be prescribed by rheumatologists or consultant physicians for the reduction of signs and symptoms and prevention of structural joint damage in adult patients with active rheumatoid arthritis who satisfy all of the following criteria:*

- (1) (a) Proven raised erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP); and*
- (1) (b) Proven erosive rheumatoid arthritis without end-stage disease;*
- (2) Failure of an adequate trial of methotrexate and 2 other disease modifying anti-rheumatic drugs (such as sulfasalazine, hydroxychloroquine, leflunomide or cyclosporin) — unless these drugs were contraindicated or intolerance had developed;*
- (3) No history of active tuberculosis requiring treatment in the last 3 years;*
- (4) No history of opportunistic infection in the last 2 months;*
- (5) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.*

*Applications for authorisation must be in writing and must include:*

- (1) a completed authority prescription form; and*
- (2) a completed Infliximab (Remicade) RPBS Authority Application - Supporting Information form (contact the VAPAC on 1800 552 580 for a copy of the form).*

##### Authority Required

*Continuing treatment, in combination with methotrexate, of specific accepted war-caused or service-related disability of refractory rheumatoid arthritis. Continuing treatment may be prescribed by rheumatologists or consultant physicians, following initial therapy of 3 doses, in patients who satisfy the following criteria:*

- (1) There is improvement in ESR and/or CRP; and*
- (2) An ACR20 (American College of Rheumatology) response is achieved by 14 weeks after the commencement of therapy.*

continued ➞



## REPATRIATION

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

*Applications for authorisation must be in writing and must include:*

*(1) a completed authority prescription form; and*

*(2) a completed Infliximab (Remicade) RPBS Authority Application - Supporting Information form (contact the VAPAC on 1800 552 580 for a copy of the form).*

|       |                                 |   |   |    |        |      |          |    |
|-------|---------------------------------|---|---|----|--------|------|----------|----|
| 4284L | Powder for I.V. infusion 100 mg | 1 | 2 | .. | 846.55 | 5.00 | Remicade | SH |
|-------|---------------------------------|---|---|----|--------|------|----------|----|

### MUSCULO-SKELETAL SYSTEM

#### ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

**Antiinflammatory and antirheumatic products, non-steroids**

- **Acetic acid derivatives and related substances**

**DICLOFENAC SODIUM with MISOPROSTOL**

#### Authority Required

*Patients requiring an NSAID in whom a risk of upper gastrointestinal complications is high or with a history of peptic ulcer disease.*

|       |                             |    |   |    |       |      |              |    |
|-------|-----------------------------|----|---|----|-------|------|--------------|----|
| 4190M | Tablet 50 mg-200 micrograms | 60 | 2 | .. | 37.35 | 5.00 | Arthrotec 50 | PH |
|-------|-----------------------------|----|---|----|-------|------|--------------|----|

#### TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN

**Topical products for joint and muscular pain**

- **Preparations with salicylic acid derivatives**

**METHYL SALICYLATE**

|       |                                   |     |   |    |       |      |            |    |
|-------|-----------------------------------|-----|---|----|-------|------|------------|----|
| 4022Q | Compound cream APF, 100 g         | ‡ 1 | 1 | .. | 13.59 | 5.00 | Gold Cross | BI |
| 4023R | Ointment BP, 100 g                | ‡ 1 | 1 | .. | 11.74 | 5.00 | Gold Cross | BI |
| 4025W | Compound ointment APF 1934, 100 g | ‡ 1 | 1 | .. | 10.38 | 5.00 | Gold Cross | BI |
| 4026X | Liniment APF, 100 mL              | ‡ 1 | 1 | .. | 9.51  | 5.00 | Gold Cross | BI |
| 4027Y | Compound liniment APF, 100 mL     | ‡ 1 | 1 | .. | 11.08 | 5.00 | Gold Cross | BI |

#### DRUGS FOR TREATMENT OF BONE DISEASES

**Drugs affecting bone structure and mineralization**

- **Bisphosphonates**

**RISEDRONATE SODIUM**

#### Authority Required

*For preservation of bone mineral density in patients on long-term glucocorticoid therapy where patients are undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day. Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic (bone mineral density t-score of less than -1.0).*

|       |              |    |   |    |       |      |                     |    |
|-------|--------------|----|---|----|-------|------|---------------------|----|
| 4443W | Tablet 5 mg  | 28 | 5 | .. | 52.91 | 5.00 | Actonel             | SW |
| 4444X | Tablet 35 mg | 4  | 5 | .. | 52.91 | 5.00 | Actonel Once-a-Week | SW |

## REPATRIATION

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

### • **Bisphosphonates, combinations**

#### **RISEDRONATE SODIUM and CALCIUM CARBONATE**

##### Authority Required

*For preservation of bone mineral density in patients on long-term glucocorticoid therapy where patients are undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day. Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic (bone mineral density t-score of less than -1.0).*

|       |                                                                                                                           |     |   |    |       |      |               |    |
|-------|---------------------------------------------------------------------------------------------------------------------------|-----|---|----|-------|------|---------------|----|
| 4059P | Pack containing 4 tablets risedronate sodium 35 mg and 24 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium) | ± 1 | 5 | .. | 52.91 | 5.00 | Actonel Combi | SW |
|-------|---------------------------------------------------------------------------------------------------------------------------|-----|---|----|-------|------|---------------|----|

## NERVOUS SYSTEM

### ANALGESICS

#### **Opioids**

### • **Natural opium alkaloids**

#### **MORPHINE SULFATE**

##### CAUTION:

*The risk of drug dependence is high.*

##### Restricted Benefit

*Chronic severe disabling pain not responding to non-narcotic analgesics.*

##### NOTE:

*Authorities for increased maximum quantities and/or repeats will be granted only for*

*(i) chronic severe disabling pain associated with proven malignant neoplasia; or*

*(ii) chronic severe disabling pain where treatment has been initiated by a specialist with appropriate expertise in pain management.*

|       |                                    |    |    |    |        |      |           |    |
|-------|------------------------------------|----|----|----|--------|------|-----------|----|
| 4349X | Tablet 200 mg (controlled release) | 20 | .. | .. | 104.50 | 5.00 | MS Contin | MF |
|-------|------------------------------------|----|----|----|--------|------|-----------|----|

### • **Diphenylpropylamine derivatives**

#### **DEXTROPROPOXYPHENE NAPSYLATE**

##### CAUTION:

*Chronic use of this preparation is likely to cause drug dependence.*

|       |                |    |    |    |         |      |          |    |
|-------|----------------|----|----|----|---------|------|----------|----|
| 4081T | Capsule 100 mg | 50 | .. | .. | * 18.19 | 5.00 | Doloxene | AS |
|-------|----------------|----|----|----|---------|------|----------|----|

#### **Other analgesics and antipyretics**

### • **Salicylic acid and derivatives**

#### **CODEINE PHOSPHATE with ASPIRIN**

|       |                            |    |   |    |       |      |          |    |
|-------|----------------------------|----|---|----|-------|------|----------|----|
| 4061R | Tablet soluble 8 mg-300 mg | 50 | 2 | .. | 13.14 | 5.00 | Aspalgin | FM |
|-------|----------------------------|----|---|----|-------|------|----------|----|

## REPATRIATION

| Code                                                                                                  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>• Anilides</b>                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| CODEINE PHOSPHATE with PARACETAMOL                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4171M                                                                                                 | Tablet 8 mg-500 mg                                      | 50          | 2              | ..      | 11.31                                    | 5.00                                                   | Panamax Co.                          | SW |
|                                                                                                       |                                                         |             |                | ..      | 12.43                                    | 5.00                                                   | Codalgin                             | FM |
| 4170L                                                                                                 | Tablet 15 mg-500 mg                                     | 20          | 2              | ..      | 8.80                                     | 5.00                                                   | Prodeine 15                          | SW |
| <b>• Other analgesics and antipyretics</b>                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| GABAPENTIN                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u>Authority Required</u>                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>To be approved for the treatment of refractory neuropathic pain not controlled by other drugs.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4591P                                                                                                 | Capsule 100 mg                                          | 100         | 5              | ..      | 23.38                                    | 5.00                                                   | <sup>a</sup> <i>Gantin</i>           | AW |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Neurontin</i>        | PF |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Nupentin 100</i>     | AF |
| 4592Q                                                                                                 | Capsule 300 mg                                          | 100         | 5              | ..      | 61.58                                    | 5.00                                                   | <sup>a</sup> <i>DBL Gabapentin</i>   | HH |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Douglas</i>          | GM |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <i>Gabapentin</i>                    |    |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <i>300mg</i>                         |    |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Gabahexal 300mg</i>  | SZ |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Gantin</i>           | AW |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>GenRx Gabapentin</i> | GX |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Neurontin</i>        | PF |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Nupentin 300</i>     | AF |
| 4593R                                                                                                 | Capsule 400 mg                                          | 100         | 5              | ..      | 81.81                                    | 5.00                                                   | <sup>a</sup> <i>DBL Gabapentin</i>   | HH |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Douglas</i>          | GM |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <i>Gabapentin</i>                    |    |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <i>400mg</i>                         |    |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Gabahexal 400mg</i>  | SZ |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Gantin</i>           | AW |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>GenRx Gabapentin</i> | GX |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Neurontin</i>        | PF |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Nupentin 400</i>     | AF |
| 4594T                                                                                                 | Tablet 600 mg                                           | 100         | 5              | ..      | 126.34                                   | 5.00                                                   | <i>Neurontin</i>                     | PF |
| 4595W                                                                                                 | Tablet 800 mg                                           | 100         | 5              | ..      | 166.43                                   | 5.00                                                   | <sup>a</sup> <i>Gantin</i>           | AW |
|                                                                                                       |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> <i>Neurontin</i>        | PF |
| PREGABALIN                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <u>Authority Required</u>                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>For the treatment of refractory neuropathic pain not controlled by other drugs.</i>                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4322L                                                                                                 | Capsule 75 mg                                           | 56          | 5              | ..      | 84.53                                    | 5.00                                                   | <i>Lyrica</i>                        | PF |
| 4323M                                                                                                 | Capsule 150 mg                                          | 56          | 5              | ..      | 123.81                                   | 5.00                                                   | <i>Lyrica</i>                        | PF |
| 4324N                                                                                                 | Capsule 300 mg                                          | 56          | 5              | ..      | 182.71                                   | 5.00                                                   | <i>Lyrica</i>                        | PF |

## REPATRIATION

| Code                                                                                                                                                                                                                                                                                                                                                                                                                                              | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>PSYCHOLEPTICS</b>                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Anxiolytics</b>                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Benzodiazepine derivatives</b>                                                                                                                                                                                                                                                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>BROMAZEPAM</b>                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Patients with terminal disease;                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Patients with refractory phobic or anxiety states.                                                                                                                                                                                                                                                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| For short-term use and palliative care. This drug should not be used as the first line of treatment. Other PBS-listed benzodiazepines should have been adequately tried and found to be ineffective or inappropriate. Authorities for increased quantities and/or repeats may be granted to patients with terminal disease, and other patients who have been shown to be dependent on this item by an unsuccessful attempt at gradual withdrawal. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4150K                                                                                                                                                                                                                                                                                                                                                                                                                                             | Tablet 3 mg                                             | 60          | ..             | ..      | * 26.95                                  | 5.00                                                   | Lexotan                              | RO |
| 4151L                                                                                                                                                                                                                                                                                                                                                                                                                                             | Tablet 6 mg                                             | 60          | ..             | ..      | * 32.97                                  | 5.00                                                   | Lexotan                              | RO |
| • <b>Azaspirodecanedione derivatives</b>                                                                                                                                                                                                                                                                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>BUSPIRONE HYDROCHLORIDE</b>                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| For the short-term treatment of anxiety.                                                                                                                                                                                                                                                                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4144D                                                                                                                                                                                                                                                                                                                                                                                                                                             | Tablet 5 mg                                             | 50          | ..             | ..      | 37.56                                    | 5.00                                                   | Buspar                               | BQ |
| 4145E                                                                                                                                                                                                                                                                                                                                                                                                                                             | Tablet 10 mg                                            | 50          | ..             | ..      | 54.41                                    | 5.00                                                   | Buspar                               | BQ |
| <b>Hypnotics and sedatives</b>                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Benzodiazepine derivatives</b>                                                                                                                                                                                                                                                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>FLUNITRAZEPAM</b>                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Authority Required</b>                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Patients with terminal disease;                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| Patients with refractory phobic or anxiety states.                                                                                                                                                                                                                                                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| For short-term use and palliative care. This drug should not be used as the first line of treatment. Other PBS-listed benzodiazepines should have been adequately tried and found to be ineffective or inappropriate. Authorities for increased quantities and/or repeats may be granted to patients with terminal disease, and other patients who have been shown to be dependent on this item by an unsuccessful attempt at gradual withdrawal. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4216X                                                                                                                                                                                                                                                                                                                                                                                                                                             | Tablet 1 mg                                             | 30          | ..             | ..      | 13.08                                    | 5.00                                                   | Hypnodorm                            | AF |
| • <b>Benzodiazepine related drugs</b>                                                                                                                                                                                                                                                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>ZOPICLONE</b>                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Restricted Benefit</b>                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| For the short-term treatment of insomnia.                                                                                                                                                                                                                                                                                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4522B                                                                                                                                                                                                                                                                                                                                                                                                                                             | Tablet 7.5 mg                                           | 30          | ..             | ..      | 21.33                                    | 5.00                                                   | <sup>a</sup> Imrest                  | AF |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                         |             |                | ..      | 22.91                                    | 5.00                                                   | <sup>a</sup> Imovane                 | SW |

## REPATRIATION

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |  |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|--|

### OTHER NERVOUS SYSTEM DRUGS

#### Drugs used in addictive disorders

#### • *Drugs used in nicotine dependence*

##### NICOTINE

##### Authority Required

*Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program.*

##### NOTE:

*Studies have shown that successful therapy with this drug is enhanced by patient participation in a support and counselling program.*

|       |                                                                      |   |    |    |                    |              |                         |          |
|-------|----------------------------------------------------------------------|---|----|----|--------------------|--------------|-------------------------|----------|
| 4576W | Transdermal patches releasing<br>approximately 5 mg per 16 hours, 7  | 2 | .. | .. | * 50.39            | 5.00         | Nicorette Patch         | JT       |
| 4571N | Transdermal patches releasing<br>approximately 7 mg per 24 hours, 7  | 2 | .. | .. | * 45.77<br>* 73.89 | 5.00<br>5.00 | QuitX<br>Nicabate CQ 7  | AF<br>GK |
| 4577X | Transdermal patches releasing<br>approximately 10 mg per 16 hours, 7 | 2 | .. | .. | * 54.35            | 5.00         | Nicorette Patch         | JT       |
| 4572P | Transdermal patches releasing<br>approximately 14 mg per 24 hours, 7 | 2 | .. | .. | * 49.09<br>* 73.89 | 5.00<br>5.00 | QuitX<br>Nicabate CQ 14 | AF<br>GK |
| 4578Y | Transdermal patches releasing<br>approximately 15 mg per 16 hours, 7 | 2 | 2  | .. | * 59.53            | 5.00         | Nicorette Patch         | JT       |
| 4573Q | Transdermal patches releasing<br>approximately 21 mg per 24 hours, 7 | 2 | 2  | .. | * 53.09<br>* 73.89 | 5.00<br>5.00 | QuitX<br>Nicabate CQ 21 | AF<br>GK |

### ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

#### ANTHELMINTICS

#### Antinematodal agents

#### • *Benzimidazole derivatives*

##### MEBENDAZOLE

|       |               |   |    |    |       |      |        |    |
|-------|---------------|---|----|----|-------|------|--------|----|
| 4325P | Tablet 100 mg | 6 | .. | .. | 19.62 | 5.00 | Vermox | JC |
|-------|---------------|---|----|----|-------|------|--------|----|

### RESPIRATORY SYSTEM

#### NASAL PREPARATIONS

#### Decongestants and other nasal preparations for topical use

#### • *Sympathomimetics, plain*

##### OXYMETAZOLINE HYDROCHLORIDE

|       |                                                     |     |    |    |       |      |                         |    |
|-------|-----------------------------------------------------|-----|----|----|-------|------|-------------------------|----|
| 4378K | Nasal spray 500 micrograms per mL<br>(0.05%), 15 mL | ‡ 1 | .. | .. | 16.20 | 5.00 | Drixine                 | SH |
| 4379L | Nasal spray 500 micrograms per mL<br>(0.05%), 18 mL | ‡ 1 | .. | .. | 16.33 | 5.00 | Logicin Rapid<br>Relief | SI |

## REPATRIATION

| Code                                                                                                                                                                                                            | Name, Restriction,<br>Manner of Administration and Form                              | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer     |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------|----|
| <b>• Antiallergic agents, excl. corticosteroids</b><br>LEVOCABASTINE HYDROCHLORIDE                                                                                                                              |                                                                                      |             |                |         |                                          |                                                        |                                          |    |
| 4311X                                                                                                                                                                                                           | Nasal spray 500 micrograms per mL<br>(0.05%), 10 mL (100 doses)                      | ‡ 1         | 2              | ..      | 17.81                                    | 5.00                                                   | Livostin                                 | JT |
| SODIUM CROMOGLYCATE                                                                                                                                                                                             |                                                                                      |             |                |         |                                          |                                                        |                                          |    |
| 4468E                                                                                                                                                                                                           | Nasal spray metered dose pump 20 mg<br>per mL (2%), 26 mL                            | ‡ 1         | 5              | ..      | 19.93                                    | 5.00                                                   | Rynacrom                                 | SW |
| <b>• Corticosteroids</b><br>BUDESONIDE<br><u>Restricted Benefit</u><br><i>Severe intractable rhinitis.</i>                                                                                                      |                                                                                      |             |                |         |                                          |                                                        |                                          |    |
| 4092J                                                                                                                                                                                                           | Aqueous nasal spray (pump pack)<br>64 micrograms per dose (120 doses)                | ‡ 1         | ..             | ..      | 31.30                                    | 5.00                                                   | Budamax Aqueous                          | PM |
| <b>• Other nasal preparations</b><br>IPRATROPIUM BROMIDE<br><u>Restricted Benefit</u><br><i>Severe intractable rhinorrhoea, associated with perennial rhinitis, unresponsive to insufflated nasal steroids.</i> |                                                                                      |             |                |         |                                          |                                                        |                                          |    |
| 4089F                                                                                                                                                                                                           | Aqueous nasal spray (pump pack)<br>21 micrograms (anhydrous) per dose<br>(180 doses) | ‡ 1         | 5              | ..      | 22.03                                    | 5.00                                                   | Atrovent Nasal<br>Aqueous                | BY |
| 4090G                                                                                                                                                                                                           | Aqueous nasal spray (pump pack)<br>42 micrograms (anhydrous) per dose<br>(180 doses) | ‡ 1         | 5              | ..      | 28.46                                    | 5.00                                                   | Atrovent Nasal<br>Forte                  | BY |
| <b>Nasal decongestants for systemic use</b><br><b>• Sympathomimetics</b><br>PSEUDOEPHEDRINE HYDROCHLORIDE                                                                                                       |                                                                                      |             |                |         |                                          |                                                        |                                          |    |
| 4029C                                                                                                                                                                                                           | Tablet 60 mg                                                                         | 12          | ..             | ..      | 10.59                                    | 5.00                                                   | Logicin Sinus                            | SI |
| 4420P                                                                                                                                                                                                           | Tablet 60 mg                                                                         | 30          | ..             | ..      | 15.67                                    | 5.00                                                   | Sudafed Sinus<br>& Nasal<br>Decongestant | JT |

### COUGH AND COLD PREPARATIONS

#### Expectorants, excl. combinations with cough suppressants

##### • Expectorants

SENEGA and AMMONIA

|       |                |     |   |    |      |      |            |    |
|-------|----------------|-----|---|----|------|------|------------|----|
| 4074K | Mixture 200 mL | ‡ 1 | 4 | .. | 8.75 | 5.00 | Gold Cross | BI |
|-------|----------------|-----|---|----|------|------|------------|----|

## REPATRIATION

| Code                                                            | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>Cough suppressants, excl. combinations with expectorants</b> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Opium alkaloids and derivatives</b>                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| PHOLCODINE                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4071G                                                           | Linctus 1 mg per mL (0.1%), 100 mL                      | ‡ 1         | 2              | ..      | 8.59                                     | 5.00                                                   | Gold Cross                           | BI |
|                                                                 |                                                         |             |                | ..      | 13.47                                    | 5.00                                                   | Duro-Tuss                            | IA |
| <b>ANTI-HISTAMINES FOR SYSTEMIC USE</b>                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>Antihistamines for systemic use</b>                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Phenothiazine derivatives</b>                              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| PROMETHAZINE HYDROCHLORIDE                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4072H                                                           | Tablet 10 mg                                            | 50          | 2              | ..      | 14.24                                    | 5.00                                                   | Phenergan                            | SW |
| 4073J                                                           | Tablet 25 mg                                            | 50          | 2              | ..      | 16.33                                    | 5.00                                                   | Phenergan                            | SW |
| <b>CAUTION:</b><br>Significant side effects may occur.          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| • <b>Piperazine derivatives</b>                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| CETIRIZINE HYDROCHLORIDE                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4175R                                                           | Tablet 10 mg                                            | 30          | ..             | ..      | 32.44                                    | 5.00                                                   | Alzene                               | AF |
|                                                                 |                                                         |             |                | ..      | 39.02                                    | 5.00                                                   | Zyrtec                               | JT |
| • <b>Other antihistamines for systemic use</b>                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| FEXOFENADINE HYDROCHLORIDE                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4237B                                                           | Tablet 60 mg                                            | 60          | ..             | ..      | * 40.70                                  | 5.00                                                   | <sup>a</sup> Xergic                  | AF |
|                                                                 |                                                         |             |                | ..      | * 47.75                                  | 5.00                                                   | <sup>a</sup> Telfast                 | SW |
| 4238C                                                           | Tablet 120 mg                                           | 30          | ..             | ..      | 34.28                                    | 5.00                                                   | <sup>a</sup> Xergic                  | AF |
|                                                                 |                                                         |             |                | ..      | 41.09                                    | 5.00                                                   | <sup>a</sup> Telfast 120             | SW |
| LORATADINE                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4313B                                                           | Tablet 10 mg                                            | 30          | ..             | ..      | 43.22                                    | 5.00                                                   | <sup>a</sup> Lorano                  | HX |
|                                                                 |                                                         |             |                | ..      | 44.31                                    | 5.00                                                   | <sup>a</sup> Allereze                | AF |
|                                                                 |                                                         |             |                |         |                                          |                                                        | <sup>a</sup> Claratyne               | SH |

## SENSORY ORGANS

### OPHTHALMOLOGICALS

#### Decongestants and antiallergics

#### • **Sympathomimetics used as decongestants**

ANTAZOLINE with NAPHAZOLINE

|       |                                                                               |     |   |    |       |      |                   |    |
|-------|-------------------------------------------------------------------------------|-----|---|----|-------|------|-------------------|----|
| 4031E | Eye drops 5 mg (sulfate)-250 micrograms (nitrate) per mL (0.5%-0.025%), 10 mL | ‡ 1 | 1 | .. | 13.43 | 5.00 | Antistine-Privine | NV |
|-------|-------------------------------------------------------------------------------|-----|---|----|-------|------|-------------------|----|

continued ➡

## REPATRIATION

| Code        | Name, Restriction,<br>Manner of Administration and Form                                       | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------|-----------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 4032F       | Eye drops 5 mg<br>(phosphate)-500 micrograms<br>(hydrochloride) per mL (0.5%-0.05%),<br>15 mL | ‡ 1         | 1              | ..      | 13.38                                    | 5.00                                                   | Albalon-A                            | AG |
|             | NAPHAZOLINE HYDROCHLORIDE                                                                     |             |                |         |                                          |                                                        |                                      |    |
| 4035J       | Eye drops 1 mg per mL (0.1%), 15 mL                                                           | ‡ 1         | 1              | ..      | 12.59                                    | 5.00                                                   | Naphcon Forte                        | AQ |
|             |                                                                                               |             |                | ..      | 13.44                                    | 5.00                                                   | Albalon Liquifilm                    | AG |
|             | NAPHAZOLINE HYDROCHLORIDE with PHENIRAMINE<br>MALEATE                                         |             |                |         |                                          |                                                        |                                      |    |
| 4355F       | Eye drops 250 micrograms-3 mg per mL<br>(0.025%-0.3%), 15 mL                                  | ‡ 1         | 1              | ..      | 13.71                                    | 5.00                                                   | Naphcon-A                            | AQ |
|             | ZINC SULFATE with PHENYLEPHRINE HYDROCHLORIDE                                                 |             |                |         |                                          |                                                        |                                      |    |
| 4034H       | Eye drops 2.5 mg-1.2 mg per mL<br>(0.25%-0.12%), 15 mL                                        | ‡ 1         | 5              | ..      | 12.59                                    | 5.00                                                   | Zincfrin                             | AQ |
|             | • <b>Other antiallergics</b>                                                                  |             |                |         |                                          |                                                        |                                      |    |
|             | LEVOCABASTINE HYDROCHLORIDE                                                                   |             |                |         |                                          |                                                        |                                      |    |
| 4310W       | Eye drops 500 micrograms per mL<br>(0.05%), 4 mL (120 doses)                                  | ‡ 1         | 1              | ..      | 17.81                                    | 5.00                                                   | Livostin                             | JT |
| OTOLOGICALS |                                                                                               |             |                |         |                                          |                                                        |                                      |    |
|             | <b>Corticosteroids and antiinfectives in combination</b>                                      |             |                |         |                                          |                                                        |                                      |    |
|             | • <b>Corticosteroids and antiinfectives in combination</b>                                    |             |                |         |                                          |                                                        |                                      |    |
|             | <b>CIPROFLOXACIN HYDROCHLORIDE with<br/>HYDROCORTISONE</b>                                    |             |                |         |                                          |                                                        |                                      |    |
|             | <b>Authority Required</b>                                                                     |             |                |         |                                          |                                                        |                                      |    |
|             | <i>Indicated where first-line treatment has not been successful or is inappropriate.</i>      |             |                |         |                                          |                                                        |                                      |    |
| 4528H       | Ear drops 2 mg (base)-10 mg per mL<br>(0.2%-1%), 10 mL                                        | ‡ 1         | 2              | ..      | 29.37                                    | 5.00                                                   | Ciproxin HC                          | AQ |
|             | <b>Other otologicals</b>                                                                      |             |                |         |                                          |                                                        |                                      |    |
|             | • <b>Indifferent preparations</b>                                                             |             |                |         |                                          |                                                        |                                      |    |
|             | CARBAMIDE PEROXIDE                                                                            |             |                |         |                                          |                                                        |                                      |    |
| 4176T       | Ear drops 65 mg per mL (6.5%), 12 mL                                                          | ‡ 1         | ..             | ..      | 13.97                                    | 5.00                                                   | Ear Clear for Ear<br>Wax Removal     | KY |
|             | DICHLOROBENZENE with CHLORBUTOL and<br>TURPENTINE OIL                                         |             |                |         |                                          |                                                        |                                      |    |
| 4180B       | Ear drops 20 mg-50 mg-0.1 mL per mL<br>(2%-5%-10%), 11 mL                                     | ‡ 1         | ..             | ..      | 13.65                                    | 5.00                                                   | Cerumol                              | AC |



REPATRIATION

| Code            | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |    |
|-----------------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|----|
|                 |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |    |
| DOCUSATE SODIUM |                                                         |             |                |         |                             |                                             |                                      |    |
| 4199B           | Ear drops 5 mg per mL (0.5%), 10 mL                     | ‡ 1         | ..             | ..      | 14.04                       | 5.00                                        | Waxsol                               | NE |

VARIOUS

ALL OTHER THERAPEUTIC PRODUCTS

All other therapeutic products

- *Drugs for treatment of hyperkalemia and hyperphosphatemia*

SODIUM POLYSTYRENE SULFONATE

|       |                   |     |   |    |       |      |            |    |
|-------|-------------------|-----|---|----|-------|------|------------|----|
| 4470G | Oral powder 454 g | ‡ 1 | 2 | .. | 65.13 | 5.00 | Resonium-A | SW |
|-------|-------------------|-----|---|----|-------|------|------------|----|

REPATRIATION

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|

ALL OTHER NON-THERAPEUTIC PRODUCTS

All other non-therapeutic products

- Other non-therapeutic auxiliary products

REPATRIATION PHARMACEUTICAL BENEFITS SCHEME (RPBS)  
WOUND ASSESSMENT AND DRESSING IDENTIFICATION

It is essential to define the aetiology of the wound before selecting a dressing. Recommendations are based on wound type, colour of wound base, depth of wound, and amount of exudate.

This wound chart adheres to the MOIST WOUND concept of healing and wound dressings are described below as ABSORBING or MOISTURE DONATING.

Most wound healing products are designed to remain in situ for several days, with the exception of those for infected wounds which should be changed daily. The quantities and repeats listed in the Repatriation Schedule are considered to be adequate to manage the treatment of a wound for two weeks to one month, when an assessment of the wound's healing process should be undertaken.

DRESSINGS

PINK EPITHELIALISING WOUND

Aim: To protect and promote epithelialisation. Epithelialising wounds normally are superficial and only produce a light exudate.

- |               |                                                                                                                                 |                                                                                                  |
|---------------|---------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| (A) Covering  | <ul style="list-style-type: none"><li>• Film;</li><li>• Film Island</li></ul>                                                   | <ul style="list-style-type: none"><li>• Gauze—Paraffin;</li><li>• Non-adherent</li></ul>         |
| (B) Absorbing | <ul style="list-style-type: none"><li>• Foam (Light Exudate);</li><li>• Hydroactive (Superficial Wound—Light Exudate)</li></ul> | <ul style="list-style-type: none"><li>• Hydrocolloid (Superficial Wound—Light Exudate)</li></ul> |

continued ➡

REPATRIATION

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

RED GRANULATING WOUND

Aims: (1) to protect the granulating tissue; (2) to encourage epithelialisation; (3) to absorb excess exudate.

LIGHT EXUDATE:

(A) Absorbing

Superficial

- Foam (Light Exudate);
- Hydroactive (Superficial Wound—Light Exudate);
- Hydrocolloid (Superficial Wound—Light Exudate)

Cavity

- Hydrocolloid (Cavity Wound)

(B) Moisture donating

- Hydrogel—Amorphous;
- Hydrogel—Sheet

- Hydrogel—Amorphous

HIGH EXUDATE:

(A) Absorbing

Superficial

- Alginate (Superficial Wound);
- Foam—Heavy Exudate;
- Hydroactive (Superficial Wound—Moderate Exudate);
- Hydrocolloid (Superficial Wound—Moderate/High Exudate)

Cavity

- Alginate (Cavity Wound);
- Foam—Moderate Exudate (see “cavity conforming” product);
- Hydroactive (Cavity Wound);
- Hydrocolloid (Cavity Wound)

(B) Moisture donating

NOT APPROPRIATE

continued ➞

REPATRIATION

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|--------------------------------------|
|      |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                      |

YELLOW SLOUGHY WOUND

Aims: (1) to remove slough; (2) to encourage granulation; (3) to absorb excess exudate.

LIGHT EXUDATE:

(A) Absorbing

Superficial

- Cadexomer Iodine;
- Foam—Light Exudate;
- Foam with Charcoal;
- Hydroactive (Superficial Wound—Moderate Exudate);
- Hydrocolloid (Superficial Wound—Moderate Exudate)

Cavity

- Cadexomer Iodine;
- Hydrocolloid (Cavity Wound)

(B) Moisture Donating

- Hydrogel—Amorphous;
- Hydrogel—Sheet

- Hydrogel—Amorphous

HIGH EXUDATE:

(A) Absorbing

Superficial

- Alginate (Superficial Wound);
- Cadexomer Iodine;
- Foam—Heavy Exudate;
- Hydroactive (Superficial Wound—Moderate/High Exudate);
- Hydrocolloid (Superficial Wound—Moderate/High Exudate)

Cavity

- Alginate (Cavity Wound);
- Cadexomer Iodine;
- Hydrocolloid (Cavity Wound)

(B) Moisture donating

NOT APPROPRIATE

continued ➞

# REPATRIATION

| Code | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|
|------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|

## BLACK NECROTIC WOUND

Aim: To remove eschar by — (1) sharp debridement, e.g., scissor/scalpel and/or (2) rehydration and autolytic debridement. (These wounds usually produce a LIGHT EXUDATE.)

|                             |                                                                                                                                                                   |                                                                                               |
|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| <b>DRY / LIGHT EXUDATE:</b> | <b>Superficial</b>                                                                                                                                                | <b>Cavity</b>                                                                                 |
| (A) Absorbing               | <ul style="list-style-type: none"> <li>Hydroactive (Superficial Wound—Light Exudate);</li> <li>Hydrocolloid (Superficial Wound—Light/Moderate Exudate)</li> </ul> | <ul style="list-style-type: none"> <li>Hydrocolloid (Cavity Wound)</li> </ul>                 |
| (B) Moisture donating       | <ul style="list-style-type: none"> <li>Hydrogel—Amorphous;</li> <li>Hydrogel—Sheet</li> </ul>                                                                     | <ul style="list-style-type: none"> <li>Hydrogel—Amorphous;</li> <li>Hydrogel—Sheet</li> </ul> |

## INFECTED WOUNDS

Aims: (1) to clear the infection with systemic antibiotics; (2) to absorb excess exudate; (3) to remove slough if present; (4) to decrease bacterial burden - by applying a Silver dressing or Cadexomer Iodine dressing.

## MALODOROUS WOUNDS

Aims: (1) to clear infection if present; (2) to remove slough if present; (3) to clear colonising odour-producing bacteria in slough — by applying metronidazole gel, a Silver dressing or a Cadexomer Iodine dressing; (4) to absorb excess exudate.

Products: Activated Charcoal; Alginate with Charcoal; Foam with Charcoal; Silver dressing; Cadexomer Iodine dressing.

## MINOR SKIN TRAUMA

Aims: (1) to stop bleeding; (2) to prevent infection; (3) to minimise the surface defect; (4) to promote epithelialisation.

## ORDERING HARTMANN PRODUCTS

Hartmann wound dressings are available through the Hartmann Alliance only. If you would like to order Hartmann Wound Care products, please call Hartmann National Customer Care on 1800 805 839.

### BANDAGE—ABSORBENT WOOL

|       |                                              |   |    |    |         |      |                  |    |
|-------|----------------------------------------------|---|----|----|---------|------|------------------|----|
| 4651T | Bandage (natural, non-sterile) 10 cm x 2.7 m | 6 | .. | .. | * 34.01 | 5.00 | Soffban 7224     | BV |
| 4653X | Bandage 10 cm x 3 m                          | 6 | .. | .. | 19.89   | 5.00 | Surepress 650948 | CC |

## REPATRIATION

| Code                                                                                                                        | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>BANDAGE—CALICO</b>                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4717G                                                                                                                       | Bandage, triangular, large                              | ‡ 1         | ..             | ..      | 13.06                                    | 5.00                                                   | Handy 5608                           | BV |
| <b>BANDAGE—COMPRESSION</b>                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <i>Treatment of varices and oedema associated with venous disease and lymphoedema; contraindicated in arterial disease.</i> |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4654Y                                                                                                                       | Bandage, short stretch, 8 cm x 5 m                      | 5           | ..             | ..      | * 70.29                                  | 5.00                                                   | Comprilan 1027                       | BV |
| 4736G                                                                                                                       | Bandage, high stretch, 7.5 cm x 3 m                     | 5           | ..             | ..      | * 85.14                                  | 5.00                                                   | Tensopress<br>66004347               | BV |
| 4656C                                                                                                                       | Bandage, high stretch, 7.5 cm x 3.5 m                   | 5           | ..             | ..      | * 67.94                                  | 5.00                                                   | Setopress 3504                       | SS |
| 4748X                                                                                                                       | Bandage, high stretch, 10 cm x 3 m                      | 5           | ..             | ..      | * 72.49                                  | 5.00                                                   | Surepress 650947                     | CC |
|                                                                                                                             |                                                         |             |                | ..      | * 110.79                                 | 5.00                                                   | Tensopress<br>66004348               | BV |
| 4657D                                                                                                                       | Bandage, high stretch, 10 cm x 3.5 m                    | 5           | ..             | ..      | * 55.24                                  | 5.00                                                   | Eloflex 2480                         | BV |
|                                                                                                                             |                                                         |             |                | ..      | * 78.14                                  | 5.00                                                   | Setopress 3505                       | SS |
| 4658E                                                                                                                       | Bandage, four layer                                     | 5           | ..             | ..      | * 199.79                                 | 5.00                                                   | Profore 66050016                     | SN |
| 4598B                                                                                                                       | Bandage, four layer                                     | 5           | ..             | ..      | * 134.74                                 | 5.00                                                   | Profore Lite<br>66050415             | SN |

### **BANDAGE—COMPRESSION**

#### **NOTE:**

*Treatment of varices and oedema associated with venous disease and lymphoedema; contraindicated in arterial disease.*

#### **Restricted Benefit**

*Initial treatment of venous ulcers.*

|       |                                             |   |    |    |       |      |                      |    |
|-------|---------------------------------------------|---|----|----|-------|------|----------------------|----|
| 4938X | Bandage, two layer, 18 cm-22 cm (red)       | 1 | .. | .. | 45.73 | 5.00 | ProGuide<br>66000780 | SN |
| 4939Y | Bandage, two layer, 22 cm-28 cm<br>(yellow) | 1 | .. | .. | 45.73 | 5.00 | ProGuide<br>66000781 | SN |
| 4940B | Bandage, two layer, 28 cm-32 cm<br>(green)  | 1 | .. | .. | 45.73 | 5.00 | ProGuide<br>66000782 | SN |

#### **Restricted Benefit**

*Continuation of treatment of venous ulcers where patient's ability to tolerate dressing has been demonstrated.*

|       |                                       |   |    |    |          |      |                      |    |
|-------|---------------------------------------|---|----|----|----------|------|----------------------|----|
| 4941C | Bandage, two layer, 18 cm-22 cm (red) | 4 | .. | .. | * 161.03 | 5.00 | ProGuide<br>66000780 | SN |
|-------|---------------------------------------|---|----|----|----------|------|----------------------|----|

continued ➞

| Code                                    | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium   | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |           |
|-----------------------------------------|---------------------------------------------------------|-------------|----------------|-----------|------------------------------------------|--------------------------------------------------------|--------------------------------------|-----------|
| 4942D                                   | <b>Bandage, two layer, 22 cm-28 cm<br/>(yellow)</b>     | <b>4</b>    | <b>..</b>      | <b>..</b> | <b>* 161.03</b>                          | <b>5.00</b>                                            | <b>ProGuide<br/>66000781</b>         | <b>SN</b> |
| 4943E                                   | <b>Bandage, two layer, 28 cm-32 cm<br/>(green)</b>      | <b>4</b>    | <b>..</b>      | <b>..</b> | <b>* 161.03</b>                          | <b>5.00</b>                                            | <b>ProGuide<br/>66000782</b>         | <b>SN</b> |
| <b>BANDAGE—RETENTION—COHESIVE—HEAVY</b> |                                                         |             |                |           |                                          |                                                        |                                      |           |
| 4811F                                   | Bandage 5 cm x 1.3 m                                    | 2           | ..             | ..        | * 13.59                                  | 5.00                                                   | Peg 7420                             | BK        |
| 4812G                                   | Bandage 7.5 cm x 1.3 m                                  | 2           | ..             | ..        | * 16.87                                  | 5.00                                                   | Peg 7422                             | BK        |
| 4659F                                   | Bandage 7.5 cm x 3 m                                    | 2           | ..             | ..        | * 19.63                                  | 5.00                                                   | Coplus 3629                          | BV        |
| 4813H                                   | Bandage 10 cm x 1.3 m                                   | 2           | ..             | ..        | * 20.61                                  | 5.00                                                   | Peg 7423                             | BK        |
| 4660G                                   | Bandage 10 cm x 2 m                                     | 2           | ..             | ..        | * 18.93                                  | 5.00                                                   | Coban 1584                           | MM        |
| 4814J                                   | Bandage 15 cm x 1.3 m                                   | 2           | ..             | ..        | * 27.75                                  | 5.00                                                   | Peg 7425                             | BK        |
| <b>BANDAGE—RETENTION—COHESIVE—LIGHT</b> |                                                         |             |                |           |                                          |                                                        |                                      |           |
| 4718H                                   | Bandages 2.5 cm x 4 m, 2                                | ‡ 1         | ..             | ..        | 12.09                                    | 5.00                                                   | Handygauze<br>Cohesive 8631          | BV        |
| 4719J                                   | Bandage 6 cm x 4 m                                      | 2           | ..             | ..        | * 14.27                                  | 5.00                                                   | Handygauze<br>Cohesive 8633          | BV        |
| 4662J                                   | Bandage 10 cm x 4 m                                     | 2           | ..             | ..        | * 16.71                                  | 5.00                                                   | Handygauze<br>Cohesive 8635          | BV        |
| <b>BANDAGE—RETENTION—COTTON CREPE</b>   |                                                         |             |                |           |                                          |                                                        |                                      |           |
| 4727T                                   | Bandage 5 cm x 2.3 m                                    | 2           | ..             | ..        | * 17.01                                  | 5.00                                                   | Telfa 8252F                          | KE        |
|                                         |                                                         |             |                | ..        | * 17.85                                  | 5.00                                                   | Elastocrepe<br>36102520              | BV        |
| 4728W                                   | Bandage 7.5 cm x 2.3 m                                  | 2           | ..             | ..        | * 21.79                                  | 5.00                                                   | Telfa 8253F                          | KE        |
|                                         |                                                         |             |                | ..        | * 21.97                                  | 5.00                                                   | Elastocrepe<br>36102420              | BV        |
| 4729X                                   | Bandage 10 cm x 2.3 m                                   | 2           | ..             | ..        | * 24.95                                  | 5.00                                                   | Telfa 8254F                          | KE        |
|                                         |                                                         |             |                | ..        | * 27.39                                  | 5.00                                                   | Elastocrepe<br>36102320              | BV        |
| <b>BANDAGE—TUBULAR</b>                  |                                                         |             |                |           |                                          |                                                        |                                      |           |
| 4855M                                   | Bandage 6.25 cm x 1 m                                   | ‡ 1         | ..             | ..        | 17.74                                    | 5.00                                                   | Tubigrip B 1520                      | SS        |
| 4856N                                   | Bandage 6.75 cm x 1 m                                   | ‡ 1         | ..             | ..        | 17.74                                    | 5.00                                                   | Tubigrip C 1545                      | SS        |
| 4857P                                   | Bandage 7.5 cm x 1 m                                    | ‡ 1         | ..             | ..        | 17.74                                    | 5.00                                                   | Tubigrip D 1546                      | SS        |
| 4858Q                                   | Bandage 8.75 cm x 1 m                                   | ‡ 1         | ..             | ..        | 17.74                                    | 5.00                                                   | Tubigrip E 1547                      | SS        |
| 4859R                                   | Bandage 10 cm x 1 m                                     | ‡ 1         | ..             | ..        | 17.74                                    | 5.00                                                   | Tubigrip F 1548                      | SS        |
| 4663K                                   | Bandage, straight, size C                               | ‡ 1         | ..             | ..        | 14.68                                    | 5.00                                                   | Elastoplast 2225                     | BE        |

continued ➞

## REPATRIATION

| Code                                                                                                              | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 4664L                                                                                                             | Bandage, straight, size D                               | ‡ 1         | ..             | ..      | 14.68                                    | 5.00                                                   | Elastoplast 2226                     | BE |
| 4665M                                                                                                             | Bandage, straight, size E                               | ‡ 1         | ..             | ..      | 14.68                                    | 5.00                                                   | Elastoplast 2227                     | BE |
| 4667P                                                                                                             | Bandage, lightweight, 8.75 cm x 1 m                     | ‡ 1         | ..             | ..      | 16.64                                    | 5.00                                                   | Tensogrip<br>36361259                | BV |
| BANDAGE—TUBULAR (FINGER)                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4798M                                                                                                             | Complete pack including applicator                      | ‡ 1         | ..             | ..      | 17.34                                    | 5.00                                                   | Tubegauz 0501633                     | SS |
| 4726R                                                                                                             | Refill                                                  | ‡ 1         | ..             | ..      | 13.30                                    | 5.00                                                   | Tubegauz 0501658                     | SS |
| BANDAGE—TUBULAR (LIGHTWEIGHT)                                                                                     |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4671W                                                                                                             | Bandage, small limb size (red), 10 m                    | ‡ 1         | ..             | ..      | 27.93                                    | 5.00                                                   | Tubifast 2434                        | SS |
| 4672X                                                                                                             | Bandage, medium limb size (green), 10 m                 | ‡ 1         | ..             | ..      | 31.59                                    | 5.00                                                   | Tubifast 2436                        | SS |
| 4673Y                                                                                                             | Bandage, large limb size (blue), 10 m                   | ‡ 1         | ..             | ..      | 35.15                                    | 5.00                                                   | Tubifast 2438                        | SS |
| BANDAGE—TUBULAR (LONG STOCKING)                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4674B                                                                                                             | Bandage, small size                                     | 2           | ..             | ..      | * 39.75                                  | 5.00                                                   | Tubigrip 1482                        | SS |
| 4797L                                                                                                             | Bandage, medium size                                    | 2           | ..             | ..      | * 39.75                                  | 5.00                                                   | Tubigrip 1483                        | SS |
| 4799N                                                                                                             | Bandage, large size                                     | 2           | ..             | ..      | * 39.75                                  | 5.00                                                   | Tubigrip 1484                        | SS |
| 4675C                                                                                                             | Bandage, XX/large size                                  | 2           | ..             | ..      | * 39.75                                  | 5.00                                                   | Tubigrip 1486                        | SS |
| BANDAGE—TUBULAR (SHORT STOCKING)                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4661H                                                                                                             | Bandage, small B/C size                                 | 2           | ..             | ..      | * 30.01                                  | 5.00                                                   | Tubigrip 1479                        | SS |
| 4815K                                                                                                             | Bandage, medium C/D size                                | 2           | ..             | ..      | * 30.01                                  | 5.00                                                   | Tubigrip 1480                        | SS |
| 4816L                                                                                                             | Bandage, large D/E size                                 | 2           | ..             | ..      | * 30.01                                  | 5.00                                                   | Tubigrip 1481                        | SS |
| BANDAGE—ZINC PASTE                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b><br>Used as an adjunct in the management of leg ulceration and associated eczema and skin conditions. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4668Q                                                                                                             | Bandage 7.5 cm x 6 m                                    | 2           | ..             | ..      | * 28.77                                  | 5.00                                                   | Zincaband 3604                       | SS |
| 4669R                                                                                                             | Bandage 7.5 cm x 6 m                                    | 2           | 3              | ..      | * 29.23                                  | 5.00                                                   | Steripaste 3610                      | XP |
| 4750B                                                                                                             | Bandage 7.5 cm x 6 m                                    | 2           | 3              | ..      | * 63.11                                  | 5.00                                                   | Viscopaste 4948                      | SN |
| 4749Y                                                                                                             | Bandage 8 cm x 5 m (compression)                        | 2           | 3              | ..      | * 38.13                                  | 5.00                                                   | Gelocast Elastic<br>1080             | BV |
| 4670T                                                                                                             | Bandage 10 cm x 9.1 m                                   | 2           | 3              | ..      | * 28.35                                  | 5.00                                                   | Flexidress 650941                    | CC |
| 4760M                                                                                                             | Bandages 80 cm (stockings), 4                           | ‡ 1         | 3              | ..      | 72.69                                    | 5.00                                                   | ZipZoc 66051550                      | SN |



## REPATRIATION

| Code                                                                                                                                                             | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| COTTON WOOL ROLL                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4701K                                                                                                                                                            | Roll 100 g                                              | ‡ 1         | 2              | ..      | 10.08                                    | 5.00                                                   | JJ 02013                             | JJ |
| DRESSING—ACTIVATED CHARCOAL (MALODOROUS WOUND)                                                                                                                   |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4742N                                                                                                                                                            | Dressings 10 cm x 10 cm, 10                             | ‡ 1         | ..             | ..      | 78.55                                    | 5.00                                                   | CarboFLEX 403202                     | CC |
| 4681J                                                                                                                                                            | Dressing 10.5 cm x 10.5 cm                              | 10          | ..             | ..      | * 84.79                                  | 5.00                                                   | Actisorb Plus MAC031                 | JJ |
| 4743P                                                                                                                                                            | Dressings 15 cm x 20 cm, 5                              | ‡ 1         | ..             | ..      | 89.44                                    | 5.00                                                   | CarboFLEX 403204                     | CC |
| DRESSING—ALGINATE (CAVITY WOUND)                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b><br>This dressing should be used only on moderately to heavily exuding wounds and should remain in place until saturated or for a maximum of 3 days. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4832H                                                                                                                                                            | Rope 2 g                                                | 10          | ..             | ..      | * 108.69                                 | 5.00                                                   | Sorbsan 1411                         | UM |
|                                                                                                                                                                  |                                                         |             |                | ..      | * 114.83                                 | 5.00                                                   | Kaltostat 168117                     | CC |
| 4685N                                                                                                                                                            | Ropes 2 g (30 cm), 5                                    | 2           | ..             | ..      | * 81.69                                  | 5.00                                                   | Restore CalciCare 9940               | HO |
| 4682K                                                                                                                                                            | Ropes 2 g (40 cm), 6                                    | 2           | ..             | ..      | * 137.29                                 | 5.00                                                   | Comfeel SeaSorb Filler 3740          | CT |
| DRESSING—ALGINATE (SUPERFICIAL WOUND)                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b><br>This dressing should be used only on moderately to heavily exuding wounds and should remain in place until saturated or for a maximum of 3 days. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4699H                                                                                                                                                            | Dressings 5 cm x 5 cm, 10                               | ‡ 1         | 1              | ..      | 40.09                                    | 5.00                                                   | Restore CalciCare 9938               | HO |
|                                                                                                                                                                  |                                                         |             |                | ..      | 44.68                                    | 5.00                                                   | Algisite M 66000519                  | SN |
|                                                                                                                                                                  |                                                         |             |                | ..      | 48.97                                    | 5.00                                                   | Kaltostat 168210                     | CC |
| 4684M                                                                                                                                                            | Dressing 5 cm x 5 cm                                    | 10          | 1              | ..      | * 46.49                                  | 5.00                                                   | Comfeel SeaSorb Dressing 3705        | CT |
| 4683L                                                                                                                                                            | Dressings 7.5 cm x 12 cm, 10                            | ‡ 1         | 1              | ..      | 90.65                                    | 5.00                                                   | Kaltostat 168212                     | CC |
| 4831G                                                                                                                                                            | Dressing 10 cm x 10 cm                                  | 10          | 1              | ..      | * 83.99                                  | 5.00                                                   | Sorbsan 1410                         | UM |
|                                                                                                                                                                  |                                                         |             |                | ..      | * 89.69                                  | 5.00                                                   | Comfeel SeaSorb Dressing 3710        | CT |
| 4700J                                                                                                                                                            | Dressings 10 cm x 10 cm, 10                             | ‡ 1         | 1              | ..      | 71.21                                    | 5.00                                                   | Restore CalciCare 9937               | HO |
|                                                                                                                                                                  |                                                         |             |                | ..      | 83.93                                    | 5.00                                                   | Algisite M 66000520                  | SN |

continued ➞

## REPATRIATION

| Code  | Name, Restriction,<br>Manner of Administration and Form                                                                                                                                          | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer     |    |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------|----|
| 4691X | Dressings 15 cm x 20 cm, 10                                                                                                                                                                      | ‡ 1         | 1              | ..      | 203.20                                   | 5.00                                                   | Algisite M<br>66000521                   | SN |
|       | DRESSING—FILM                                                                                                                                                                                    |             |                |         |                                          |                                                        |                                          |    |
| 4686P | Dressings 6 cm x 7 cm, 8                                                                                                                                                                         | ‡ 1         | ..             | ..      | 15.21                                    | 5.00                                                   | Nexcare Tegaderm<br>Transparent<br>H1624 | MM |
| 4687Q | Dressings 10 cm x 12 cm, 4                                                                                                                                                                       | ‡ 1         | ..             | ..      | 19.22                                    | 5.00                                                   | Nexcare Tegaderm<br>Transparent<br>H1626 | MM |
| 4893M | Dressings 10 cm x 12 cm, 10                                                                                                                                                                      | ‡ 1         | ..             | ..      | 27.71                                    | 5.00                                                   | Op-Site Flexigrid<br>4629                | SN |
| 4688R | Dressing 15 cm x 20 cm                                                                                                                                                                           | 6           | ..             | ..      | * 30.23                                  | 5.00                                                   | Tegaderm<br>Transparent 1628             | MM |
|       | DRESSING—FILM ISLAND                                                                                                                                                                             |             |                |         |                                          |                                                        |                                          |    |
| 4689T | Dressing 5 cm x 7 cm                                                                                                                                                                             | 10          | ..             | ..      | * 15.79                                  | 5.00                                                   | Tegaderm<br>Transparent<br>Island 3582   | MM |
| 4898T | Dressings 5 cm x 7.2 cm, 5                                                                                                                                                                       | 2           | ..             | ..      | * 24.19                                  | 5.00                                                   | Cutifilm Plus<br>76309                   | SN |
| 4899W | Dressings 8 cm x 10 cm, 5                                                                                                                                                                        | 2           | ..             | ..      | * 38.15                                  | 5.00                                                   | Cutifilm Plus<br>76308                   | SN |
| 4690W | Dressing 9 cm x 10 cm                                                                                                                                                                            | 10          | ..             | ..      | * 27.29                                  | 5.00                                                   | Tegaderm<br>Transparent<br>Island 3586   | MM |
|       | DRESSING—FOAM—HEAVY EXUDATE                                                                                                                                                                      |             |                |         |                                          |                                                        |                                          |    |
|       | <b>NOTE:</b><br>This dressing should remain in place until saturated or up to a maximum of 7 days. Allow a minimum of 2 cm to 3 cm in excess of the wound size of the dressing around the wound. |             |                |         |                                          |                                                        |                                          |    |
| 4795J | Dressings 10 cm x 10 cm, 10                                                                                                                                                                      | ‡ 1         | 1              | ..      | 74.63                                    | 5.00                                                   | Lyof foam Extra<br>603088                | XP |
|       |                                                                                                                                                                                                  |             |                | ..      | 111.36                                   | 5.00                                                   | Allevyn 66007637                         | SN |
| 4880W | Dressings 20 cm x 15 cm, 10                                                                                                                                                                      | ‡ 1         | 1              | ..      | 188.68                                   | 5.00                                                   | Lyof foam Extra<br>603090                | XP |
|       | DRESSING—FOAM—MODERATE EXUDATE                                                                                                                                                                   |             |                |         |                                          |                                                        |                                          |    |
|       | <b>NOTE:</b><br>This dressing should remain in place until saturated or up to a maximum of 7 days. Allow a minimum of 2 cm to 3 cm in excess of the wound size of the dressing around the wound. |             |                |         |                                          |                                                        |                                          |    |
| 4890J | Dressings 7.5 cm x 7.5 cm, 10                                                                                                                                                                    | ‡ 1         | 1              | ..      | 42.41                                    | 5.00                                                   | Lyof foam Flat<br>603092                 | XP |

continued ➞

## REPATRIATION

| Code                                                                                                                                                                                                                  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 4891K                                                                                                                                                                                                                 | Dressings 10 cm x 10 cm, 10                             | ‡ 1         | 1              | ..      | 49.05                                    | 5.00                                                   | Lyof foam Flat<br>603093             | XP |
| 4590N                                                                                                                                                                                                                 | Dressings 12.5 cm x 12.5 cm, 10                         | ‡ 1         | ..             | ..      | 104.94                                   | 5.00                                                   | Allevyn Adhesive<br>66000044         | SN |
| <b>NOTE:</b><br>Care should be taken when changing <i>Allevyn Adhesive</i> dressings to avoid skin tears.                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4878R                                                                                                                                                                                                                 | Dressings 20 cm x 15 cm, 10                             | ‡ 1         | 1              | ..      | 101.43                                   | 5.00                                                   | Lyof foam Flat<br>603095             | XP |
| 4694C                                                                                                                                                                                                                 | Dressing, cavity, conforming, 20 g                      | 1           | 1              | ..      | 75.72                                    | 5.00                                                   | Cavicare 4563                        | SN |
| DRESSING—FOAM with CHARCOAL (MALODOROUS WOUND)                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b><br>This dressing should remain in place on wounds with odour until saturated or up to a maximum of 7 days. Allow a minimum of 2 cm to 3 cm in excess of the wound size of the dressing around the wound. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4892L                                                                                                                                                                                                                 | Dressings 10 cm x 10 cm, 10                             | 2           | ..             | ..      | * 173.63                                 | 5.00                                                   | Lyof foam C 603025                   | SS |
| DRESSING—FOAM with SILICONE—HEAVY EXUDATE                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4642H                                                                                                                                                                                                                 | Dressings 7.5 cm x 7.5 cm, 5                            | ‡ 1         | ..             | ..      | 30.34                                    | 5.00                                                   | Mepilex Border<br>295200             | MH |
| 4643J                                                                                                                                                                                                                 | Dressings 10 cm x 10 cm, 5                              | ‡ 1         | ..             | ..      | 42.25                                    | 5.00                                                   | Mepilex Border<br>295300             | MH |
| DRESSING—FOAM with SILICONE—LIGHT EXUDATE                                                                                                                                                                             |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4644K                                                                                                                                                                                                                 | Dressings 6 cm x 8.5 cm, 5                              | ‡ 1         | ..             | ..      | 27.63                                    | 5.00                                                   | Mepilex Lite<br>284000               | MH |
| 4645L                                                                                                                                                                                                                 | Dressings 10 cm x 10 cm, 5                              | ‡ 1         | ..             | ..      | 37.78                                    | 5.00                                                   | Mepilex Lite<br>284100               | MH |
| DRESSING—FOAM with SILICONE—MODERATE EXUDATE                                                                                                                                                                          |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4626L                                                                                                                                                                                                                 | Dressings 10 cm x 10 cm, 5                              | ‡ 1         | ..             | ..      | 42.25                                    | 5.00                                                   | Mepilex 294100                       | MH |
| DRESSING—GAUZE (ABSORBENT PAD)                                                                                                                                                                                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4707R                                                                                                                                                                                                                 | Pads 5 cm x 5 cm, 100                                   | ‡ 1         | ..             | ..      | 13.45                                    | 5.00                                                   | Handy 5672                           | BV |
| 4708T                                                                                                                                                                                                                 | Pads 10 cm x 10 cm, 100                                 | ‡ 1         | ..             | ..      | 26.97                                    | 5.00                                                   | Handy 5674                           | BV |
| DRESSING—GAUZE—EYE PAD                                                                                                                                                                                                |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4768Y                                                                                                                                                                                                                 | Pads, 12                                                | ‡ 1         | ..             | ..      | 12.40                                    | 5.00                                                   | Curity 4112                          | KE |
| DRESSING—GAUZE—PARAFFIN                                                                                                                                                                                               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4759L                                                                                                                                                                                                                 | Dressings 10 cm x 10 cm, 10                             | ‡ 1         | ..             | ..      | 17.43                                    | 5.00                                                   | Jelonet 7404                         | SN |

## REPATRIATION

| Code                                                                                                                                                                                                                                                                              | Name, Restriction,<br>Manner of Administration and Form                         | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| DRESSING—GAUZE—PARAFFIN with CHLORHEXIDINE<br>ACETATE                                                                                                                                                                                                                             |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 4845B                                                                                                                                                                                                                                                                             | Dressings 10 cm x 10 cm, 10                                                     | ‡ 1         | 2              | ..      | 24.14                                    | 5.00                                                   | Bactigras 7457                       | SN |
| DRESSING—GAUZE—POVIDONE-IODINE PAD                                                                                                                                                                                                                                                |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 4779M                                                                                                                                                                                                                                                                             | Pads 22.5 cm x 7.5 cm, 12                                                       | ‡ 1         | 2              | ..      | 33.11                                    | 5.00                                                   | Betadine                             | FH |
| DRESSING—HYDROACTIVE (CAVITY WOUND)                                                                                                                                                                                                                                               |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 4918W                                                                                                                                                                                                                                                                             | Dressings 5 cm x 6 cm, 10                                                       | ‡ 1         | 1              | ..      | 75.52                                    | 5.00                                                   | Allevyn Plus<br>Cavity 66047571      | SN |
| 4919X                                                                                                                                                                                                                                                                             | Dressings 10 cm x 10 cm, 5                                                      | 2           | 1              | ..      | * 158.91                                 | 5.00                                                   | Allevyn Plus<br>Cavity 66047573      | SN |
| DRESSING—HYDROACTIVE (DEBRIDEMENT)                                                                                                                                                                                                                                                |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 4949L                                                                                                                                                                                                                                                                             | Dressings 4 cm, 8                                                               | ‡ 1         | ..             | ..      | 67.47                                    | 5.00                                                   | TenderWet 24<br>Active               | HR |
| 4948K                                                                                                                                                                                                                                                                             | Dressings 5.5 cm, 8                                                             | ‡ 1         | ..             | ..      | 68.23                                    | 5.00                                                   | TenderWet Active<br>Cavity           | HR |
| 4950M                                                                                                                                                                                                                                                                             | Dressings 7.5 cm x 7.5 cm, 8                                                    | ‡ 1         | ..             | ..      | 91.76                                    | 5.00                                                   | TenderWet 24<br>Active               | HR |
| <b>NOTE:</b><br>Hartmann products are not available through pharmacy wholesalers. To order please contact the Hartmann Alliance (refer to 'Ordering Hartmann Products' at the foot of the 'Wound Assessment and Dressing Identification' chart at the beginning of this section). |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| DRESSING—HYDROACTIVE (SUPERFICIAL<br>WOUND—HIGH EXUDATE)                                                                                                                                                                                                                          |                                                                                 |             |                |         |                                          |                                                        |                                      |    |
| 4692Y                                                                                                                                                                                                                                                                             | Dressings (foam alternative) 10 cm x<br>10 cm, 10                               | ‡ 1         | ..             | ..      | 54.47                                    | 5.00                                                   | CombiDERM<br>651031                  | CC |
| 4693B                                                                                                                                                                                                                                                                             | Dressings (foam alternative) 15 cm x<br>18 cm, 5                                | ‡ 1         | ..             | ..      | 71.29                                    | 5.00                                                   | CombiDERM<br>651027                  | CC |
| 4695D                                                                                                                                                                                                                                                                             | Dressings, island, 11 cm x 11 cm, 10                                            | ‡ 1         | ..             | ..      | 85.53                                    | 5.00                                                   | Tielle MT2440                        | JJ |
| 4696E                                                                                                                                                                                                                                                                             | Dressings, island, 18 cm x 18 cm, 5                                             | ‡ 1         | ..             | ..      | 101.50                                   | 5.00                                                   | Tielle MT2442                        | JJ |
| 4927H                                                                                                                                                                                                                                                                             | Non-adhesive waterproof semi-permeable<br>absorbent foam pads 10 cm x 10 cm, 10 | ‡ 1         | 1              | ..      | 87.50                                    | 5.00                                                   | Biatain Non-<br>adhesive 3410        | CT |
| 4928J                                                                                                                                                                                                                                                                             | Non-adhesive waterproof semi-permeable<br>absorbent foam pads 15 cm x 15 cm, 5  | ‡ 1         | 2              | ..      | 86.02                                    | 5.00                                                   | Biatain Non-<br>adhesive 3413        | CT |
| 4929K                                                                                                                                                                                                                                                                             | Adhesive waterproof semi-permeable<br>absorbent foam pads 12 cm x 12 cm, 10     | ‡ 1         | 1              | ..      | 96.52                                    | 5.00                                                   | Biatain Adhesive<br>3420             | CT |
| 4930L                                                                                                                                                                                                                                                                             | Adhesive waterproof semi-permeable<br>absorbent foam pads 18 cm x 18 cm, 5      | ‡ 1         | 2              | ..      | 93.39                                    | 5.00                                                   | Biatain Adhesive<br>3423             | CT |

## REPATRIATION

| Code                                                                                                                                                                                | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| <b>DRESSING—HYDROACTIVE (SUPERFICIAL WOUND—LIGHT EXUDATE)</b>                                                                                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4905E                                                                                                                                                                               | Dressings 5 cm x 6 cm, 10                               | ‡ 1         | 1              | ..      | 52.74                                    | 5.00                                                   | Allevyn Thin<br>66047576             | SN |
| 4906F                                                                                                                                                                               | Dressings 10 cm x 10 cm, 5                              | 2           | 1              | ..      | * 95.75                                  | 5.00                                                   | Allevyn Thin<br>66047578             | SN |
| <b>DRESSING—HYDROACTIVE (SUPERFICIAL WOUND—MODERATE EXUDATE)</b>                                                                                                                    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4885D                                                                                                                                                                               | Dressings 5 cm x 6 cm, 10                               | ‡ 1         | 1              | ..      | 41.81                                    | 5.00                                                   | Cutinova Hydro<br>66047441           | SN |
| 4886E                                                                                                                                                                               | Dressings 10 cm x 10 cm, 5                              | 2           | 1              | ..      | * 67.85                                  | 5.00                                                   | Cutinova Hydro<br>66047443           | SN |
| <b>DRESSING—HYDROCOLLOID (CAVITY WOUND)</b>                                                                                                                                         |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b><br>This dressing should remain in place until saturated or strike through occurs for a maximum of 7 days.                                                       |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4896Q                                                                                                                                                                               | Paste 30 g                                              | 10          | ..             | ..      | * 144.69                                 | 5.00                                                   | DuoDERM Paste<br>H7930               | CC |
| 4895P                                                                                                                                                                               | Paste 50 g                                              | 2           | 3              | ..      | * 42.79                                  | 5.00                                                   | Comfeel Paste 4701                   | CT |
| 4697F                                                                                                                                                                               | Powder 6 g                                              | 5           | 2              | ..      | * 46.99                                  | 5.00                                                   | Comfeel Powder<br>4706               | CT |
| <b>DRESSING—HYDROCOLLOID (SUPERFICIAL WOUND—LIGHT EXUDATE)</b>                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b><u>NOTE:</u></b><br>This dressing should be applied to a thickness of 3 mm to 5 mm. It should be covered with a hydrocolloid dressing and may be left in place for up to 7 days. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4888G                                                                                                                                                                               | Dressings 5 cm x 7 cm, 10                               | ‡ 1         | 1              | ..      | 41.29                                    | 5.00                                                   | Comfeel Plus<br>Transparent 3530     | CT |
| 4889H                                                                                                                                                                               | Dressings 9 cm x 14 cm, 10                              | ‡ 1         | 1              | ..      | 84.09                                    | 5.00                                                   | Comfeel Plus<br>Transparent 3536     | CT |
| 4908H                                                                                                                                                                               | Dressings 10 cm x 10 cm, 5                              | 2           | 1              | ..      | * 52.85                                  | 5.00                                                   | Restore Extra Thin<br>9921           | HO |
| 4907G                                                                                                                                                                               | Dressings 10 cm x 10 cm, 10                             | ‡ 1         | 1              | ..      | 71.29                                    | 5.00                                                   | DuoDERM Extra<br>Thin H7955          | CC |
| 4924E                                                                                                                                                                               | Dressings 10 cm x 10 cm, 10                             | ‡ 1         | 1              | ..      | 69.35                                    | 5.00                                                   | Comfeel Plus<br>Transparent 3533     | CT |
| 4947J                                                                                                                                                                               | Dressings 10 cm x 10 cm, 10                             | ‡ 1         | 1              | ..      | 47.72                                    | 5.00                                                   | Hydrocoll Thin<br>900942/1           | HR |

continued ➞

| Code                                                                                                                                                                                                                                                                              | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer       |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------------|----|
| <b>NOTE:</b><br>Hartmann products are not available through pharmacy wholesalers. To order please contact the Hartmann Alliance (refer to 'Ordering Hartmann Products' at the foot of the 'Wound Assessment and Dressing Identification' chart at the beginning of this section). |                                                         |             |                |         |                                          |                                                        |                                            |    |
| DRESSING—HYDROCOLLOID (SUPERFICIAL<br>WOUND—MODERATE EXUDATE)                                                                                                                                                                                                                     |                                                         |             |                |         |                                          |                                                        |                                            |    |
| <b>NOTE:</b><br>This dressing should remain in place until saturated or strike through occurs for a maximum of 7 days.                                                                                                                                                            |                                                         |             |                |         |                                          |                                                        |                                            |    |
| 4897R                                                                                                                                                                                                                                                                             | Dressings 10 cm x 10 cm, 5                              | 2           | 1              | ..      | * 58.39                                  | 5.00                                                   | Restore Plus 9956                          | HO |
|                                                                                                                                                                                                                                                                                   |                                                         |             |                | ..      | * 80.97                                  | 5.00                                                   | DuoDERM CGF<br>H7660                       | CC |
| 4921B                                                                                                                                                                                                                                                                             | Dressings 10 cm x 10 cm, 10                             | ‡ 1         | 1              | ..      | 68.57                                    | 5.00                                                   | Repicare Ultra<br>66000434                 | SN |
| 4945G                                                                                                                                                                                                                                                                             | Dressings 10 cm x 10 cm, 10                             | ‡ 1         | 1              | ..      | 47.72                                    | 5.00                                                   | Hydrocoll 900938/1                         | HR |
| <b>NOTE:</b><br>Hartmann products are not available through pharmacy wholesalers. To order please contact the Hartmann Alliance (refer to 'Ordering Hartmann Products' at the foot of the 'Wound Assessment and Dressing Identification' chart at the beginning of this section). |                                                         |             |                |         |                                          |                                                        |                                            |    |
| 4678F                                                                                                                                                                                                                                                                             | Butterfly shape 7 cm                                    | 5           | ..             | ..      | * 54.74                                  | 5.00                                                   | Comfeel Plus<br>Pressure<br>Relieving 3350 | CT |
| 4679G                                                                                                                                                                                                                                                                             | Round 10 cm                                             | 5           | ..             | ..      | * 59.19                                  | 5.00                                                   | Comfeel Plus<br>Pressure<br>Relieving 3353 | CT |
| 4946H                                                                                                                                                                                                                                                                             | Dressings 15 cm x 15 cm, 10                             | ‡ 1         | 1              | ..      | 89.48                                    | 5.00                                                   | Hydrocoll 900939/1                         | HR |
| <b>NOTE:</b><br>Hartmann products are not available through pharmacy wholesalers. To order please contact the Hartmann Alliance (refer to 'Ordering Hartmann Products' at the foot of the 'Wound Assessment and Dressing Identification' chart at the beginning of this section). |                                                         |             |                |         |                                          |                                                        |                                            |    |
| 4853K                                                                                                                                                                                                                                                                             | Dressings 15 cm x 20 cm, 3                              | 3           | 1              | ..      | * 132.83                                 | 5.00                                                   | Restore Plus 9957                          | HO |
| 4854L                                                                                                                                                                                                                                                                             | Dressings 20 cm x 20 cm, 3                              | 3           | 1              | ..      | * 158.00                                 | 5.00                                                   | Restore Plus 9958                          | HO |
| 4920Y                                                                                                                                                                                                                                                                             | Dressings 20 cm x 20 cm, 5                              | 2           | 1              | ..      | * 221.89                                 | 5.00                                                   | DuoDERM CGF<br>H7662                       | CC |
| 4923D                                                                                                                                                                                                                                                                             | Dressings with alginate 10 cm x 10 cm,<br>10            | ‡ 1         | 1              | ..      | 81.56                                    | 5.00                                                   | Comfeel Plus Ulcer<br>Dressing 3110        | CT |
| 4842W                                                                                                                                                                                                                                                                             | Dressings, sacral, 5                                    | 2           | 1              | ..      | * 99.17                                  | 5.00                                                   | Restore Plus Sacral<br>9959                | HO |
| DRESSING—HYDROFIBRE (ALTERNATE TO ALGINATES)                                                                                                                                                                                                                                      |                                                         |             |                |         |                                          |                                                        |                                            |    |
| 4698G                                                                                                                                                                                                                                                                             | Ropes 2 g (30 cm), 5                                    | ‡ 1         | 1              | ..      | 83.28                                    | 5.00                                                   | Aquacel 177904                             | CC |
| 4649Q                                                                                                                                                                                                                                                                             | Dressings 10 cm x 10 cm, 10                             | ‡ 1         | 1              | ..      | 100.55                                   | 5.00                                                   | Aquacel 177902                             | CC |

continued 

## REPATRIATION

| Code                                                                                                                                                                                                                                                                         | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| 4922C                                                                                                                                                                                                                                                                        | Dressings 15 cm x 15 cm, 5                              | 2           | 1              | ..      | * 208.27                                 | 5.00                                                   | Aquacel 177903                       | CC |
| DRESSING—HYDROGEL—AMORPHOUS                                                                                                                                                                                                                                                  |                                                         |             |                |         |                                          |                                                        |                                      |    |
| <b>NOTE:</b>                                                                                                                                                                                                                                                                 |                                                         |             |                |         |                                          |                                                        |                                      |    |
| This dressing should be applied to a thickness of 3 mm to 5 mm and remain in situ in infected wounds for 24 hours and in clean wounds for up to 3 days. It should be covered with a secondary dressing such as foam or film. It should not be covered with gauze or combine. |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4912M                                                                                                                                                                                                                                                                        | Tubes 15 g, 10                                          | ‡ 1         | 1              | ..      | 64.05                                    | 5.00                                                   | DuoDERM Gel H7990                    | CC |
|                                                                                                                                                                                                                                                                              |                                                         |             |                | ..      | 71.66                                    | 5.00                                                   | Comfeel Purlon Gel 3900              | CT |
| 4894N                                                                                                                                                                                                                                                                        | Tube 25 g                                               | 4           | 3              | ..      | * 53.43                                  | 5.00                                                   | Intrasite Gel 7313                   | SN |
| 4913N                                                                                                                                                                                                                                                                        | Tubes 30 g, 3                                           | 3           | 1              | ..      | * 96.68                                  | 5.00                                                   | DuoDERM Gel H7987                    | CC |
| 4914P                                                                                                                                                                                                                                                                        | Tube 50 g                                               | 3           | 3              | ..      | * 32.69                                  | 5.00                                                   | Solugel 10336                        | JJ |
| 4599C                                                                                                                                                                                                                                                                        | Tube 50 g                                               | 3           | 3              | ..      | * 26.30                                  | 5.00                                                   | SoloSite Gel 36361338                | SN |

### DRESSING—HYDROGEL—SHEET

#### **NOTE:**

This dressing should be applied to a thickness of 3 mm to 5 mm and remain in situ in infected wounds for 24 hours and in clean wounds for up to 3 days. It should be covered with a secondary dressing such as foam or film. It should not be covered with gauze or combine.

|       |                               |   |    |    |         |      |                  |    |
|-------|-------------------------------|---|----|----|---------|------|------------------|----|
| 4911L | Dressings 9.5 cm x 10.2 cm, 5 | 2 | .. | .. | * 82.77 | 5.00 | Nu-Gel 2497      | JJ |
| 4806Y | Dressings 10 cm x 10 cm, 5    | 2 | .. | .. | * 52.85 | 5.00 | Aquaclear 900796 | HR |

#### **NOTE:**

Hartmann products are not available through pharmacy wholesalers. To order please contact the Hartmann Alliance (refer to 'Ordering Hartmann Products' at the foot of the 'Wound Assessment and Dressing Identification' chart at the beginning of this section).

### DRESSING—NON-ADHERENT

|       |                              |     |    |    |         |      |                                   |    |
|-------|------------------------------|-----|----|----|---------|------|-----------------------------------|----|
| 4860T | Dressings 5 cm x 5 cm, 5     | 2   | .. | .. | * 14.25 | 5.00 | Melolin 36361357                  | SN |
| 4819P | Dressings 5 cm x 5 cm, 5     | 2   | .. | .. | * 13.59 | 5.00 | Cutilin Non-Stick Wound Pad 76301 | SN |
| 4755G | Dressings 5 cm x 7.5 cm, 10  | ‡ 1 | .. | .. | 10.59   | 5.00 | Telfa 1970C                       | KE |
| 4758K | Dressings 7.5 cm x 10 cm, 6  | ‡ 1 | .. | .. | 10.80   | 5.00 | Telfa 2140C                       | KE |
| 4944F | Dressings 7.5 cm x 10 cm, 10 | ‡ 1 | .. | .. | 14.81   | 5.00 | Atrauman 499513                   | HR |

#### **NOTE:**

Hartmann products are not available through pharmacy wholesalers. To order please contact the Hartmann Alliance (refer to 'Ordering Hartmann Products' at the foot of the 'Wound Assessment and Dressing Identification' chart at the beginning of this section).

continued ➞

## REPATRIATION

| Code                                                                                                                                                       | Name, Restriction,<br>Manner of Administration and Form        | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer           |           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|------------------------------------------------|-----------|
| 4862X                                                                                                                                                      | Dressings 10 cm x 10 cm, 5                                     | 2           | ..             | ..      | * 21.33                                  | 5.00                                                   | Cutilin Non-Stick<br>Wound Pad<br>76300        | SN        |
| 4861W                                                                                                                                                      | Dressings 10 cm x 10 cm, 10                                    | ₡ 1         | ..             | ..      | 29.09                                    | 5.00                                                   | Melolin 66974933                               | SN        |
| 4843X                                                                                                                                                      | Dressings, self-adhesive, 5 cm x 7.5 cm,<br>10                 | ₡ 1         | 2              | ..      | 12.23                                    | 5.00                                                   | Telfa 6020C                                    | KE        |
| 4844Y                                                                                                                                                      | Dressings, self-adhesive, 7.5 cm x 10 cm,<br>6                 | ₡ 1         | 2              | ..      | 11.59                                    | 5.00                                                   | Telfa 7650C                                    | KE        |
| DRESSING—TULLE NON-GAUZE—PARAFFIN                                                                                                                          |                                                                |             |                |         |                                          |                                                        |                                                |           |
| 4909J                                                                                                                                                      | Dressing 7.6 cm x 7.6 cm                                       | 10          | 1              | ..      | * 15.29                                  | 5.00                                                   | Adaptic 2012                                   | JJ        |
| DRESSING with CADEXOMER IODINE                                                                                                                             |                                                                |             |                |         |                                          |                                                        |                                                |           |
| <b>NOTE:</b><br>Suitable for yellow sloughy infected and malodorous wounds.                                                                                |                                                                |             |                |         |                                          |                                                        |                                                |           |
| 4931M                                                                                                                                                      | Sachets 3 g, 7                                                 | ₡ 1         | 2              | ..      | 59.67                                    | 5.00                                                   | Iodosorb Powder<br>66051070                    | SN        |
| 4932N                                                                                                                                                      | Tubes 10 g, 4                                                  | ₡ 1         | 2              | ..      | 95.96                                    | 5.00                                                   | Iodosorb Ointment<br>66051240                  | SN        |
| 4933P                                                                                                                                                      | Tubes 20 g, 2                                                  | ₡ 1         | 2              | ..      | 95.07                                    | 5.00                                                   | Iodosorb Ointment<br>66051230                  | SN        |
| 4935R                                                                                                                                                      | Sachets 5 g (6 cm x 4 cm), 5                                   | ₡ 1         | 2              | ..      | 90.71                                    | 5.00                                                   | Iodosorb 66051330                              | SN        |
| 4936T                                                                                                                                                      | Sachets 10 g (8 cm x 6 cm), 3                                  | ₡ 1         | 2              | ..      | 131.01                                   | 5.00                                                   | Iodosorb 66051340                              | SN        |
| 4937W                                                                                                                                                      | Sachets 17 g (10 cm x 8 cm), 2                                 | ₡ 1         | ..             | ..      | 137.36                                   | 5.00                                                   | Iodosorb 66051360                              | SN        |
| <b>DRESSING with SILVER</b>                                                                                                                                |                                                                |             |                |         |                                          |                                                        |                                                |           |
| <b>Authority Required</b>                                                                                                                                  |                                                                |             |                |         |                                          |                                                        |                                                |           |
| <i>For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings.</i> |                                                                |             |                |         |                                          |                                                        |                                                |           |
| 4646M                                                                                                                                                      | <b>Hydroactive dressings non-adhesive<br/>10 cm x 10 cm, 5</b> | ₡ 1         | ..             | ..      | 175.46                                   | 5.00                                                   | <b>Contreet Foam<br/>Non-Adhesive<br/>9622</b> | <b>CT</b> |
| 4647N                                                                                                                                                      | <b>Hydroactive dressings adhesive 12.5 cm<br/>x 12.5 cm, 5</b> | ₡ 1         | ..             | ..      | 190.86                                   | 5.00                                                   | <b>Contreet Foam<br/>Adhesive 9632</b>         | <b>CT</b> |
| 4648P                                                                                                                                                      | <b>Tulle dressings 10 cm x 10 cm, 3</b>                        | ₡ 1         | ..             | ..      | 43.35                                    | 5.00                                                   | <b>Atrauman Ag<br/>499572</b>                  | <b>HR</b> |
| GAUZE and COTTON TISSUE (COMBINE ROLL)                                                                                                                     |                                                                |             |                |         |                                          |                                                        |                                                |           |
| 4767X                                                                                                                                                      | Wrapped pack 9 cm x 10 m                                       | ₡ 1         | ..             | ..      | 14.96                                    | 5.00                                                   | BSN 2902165                                    | BV        |
| 4761N                                                                                                                                                      | Wrapped pack 10 cm x 10 m                                      | ₡ 1         | ..             | ..      | 14.67                                    | 5.00                                                   | JJ 12010                                       | JJ        |



## REPATRIATION

| Code                                     | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed<br>Price for<br>Max. Qty<br>\$ | Maximum<br>Recordable<br>Value for<br>Safety Net<br>\$ | Proprietary Name and<br>Manufacturer |    |
|------------------------------------------|---------------------------------------------------------|-------------|----------------|---------|------------------------------------------|--------------------------------------------------------|--------------------------------------|----|
| GLOVES PLASTIC (DISPOSABLE)              |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4772E                                    | Gloves, small, 100                                      | ‡ 1         | ..             | ..      | 11.77                                    | 5.00                                                   | Handy 4207                           | BV |
| 4773F                                    | Gloves, medium, 100                                     | ‡ 1         | ..             | ..      | 11.77                                    | 5.00                                                   | Handy 4208                           | BV |
| 4774G                                    | Gloves, large, 100                                      | ‡ 1         | ..             | ..      | 11.77                                    | 5.00                                                   | Handy 4209                           | BV |
| LUBRICATING AGENT                        |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4318G                                    | Jelly 60 g                                              | ‡ 1         | ..             | ..      | 10.48                                    | 5.00                                                   | Surgical<br>Lubricating Gel          | BI |
| PRESSURE REDUCING PRODUCTS               |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4676D                                    | Sheet 10 cm x 10 cm x 3 mm                              | 2           | ..             | ..      | * 28.07                                  | 5.00                                                   | Spenco Dermal Pad<br>10-553          | KC |
| 4677E                                    | Sheet 10 cm x 10 cm x 12 mm                             | 2           | ..             | ..      | * 48.89                                  | 5.00                                                   | Spenco Dermal Pad<br>10-561          | KC |
| TAPES—NON-WOVEN RETENTION (POLYACRYLATE) |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4915Q                                    | Roll 2.5 cm x 9.1 m                                     | ‡ 1         | ..             | ..      | 12.44                                    | 5.00                                                   | Medipore 2961                        | MM |
| 4863Y                                    | Roll 2.5 cm x 10 m                                      | ‡ 1         | ..             | ..      | 15.93                                    | 5.00                                                   | Hypafix 71443-0                      | BV |
| 4917T                                    | Roll 2.5 cm x 10 m                                      | ‡ 1         | ..             | ..      | 10.61                                    | 5.00                                                   | Mefix 310250                         | MH |
| 4916R                                    | Roll 5 cm x 10 m                                        | ‡ 1         | ..             | ..      | 23.19                                    | 5.00                                                   | Hypafix 71443-1                      | BV |
| TAPES—PLASTER ADHESIVE ELASTIC           |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4780N                                    | Roll 2.5 cm x 2.5 m                                     | ‡ 1         | ..             | ..      | 12.33                                    | 5.00                                                   | Leukoplast 1071                      | BV |
| 4781P                                    | Roll 5 cm x 2.5 m                                       | ‡ 1         | ..             | ..      | 18.13                                    | 5.00                                                   | Leukoplast 1072                      | BV |
| 4782Q                                    | Roll 7.5 cm x 2.5 m                                     | ‡ 1         | ..             | ..      | 21.70                                    | 5.00                                                   | Leukoplast 1073                      | BV |
| 4735F                                    | Roll 10 cm x 2.5 m                                      | ‡ 1         | ..             | ..      | 21.92                                    | 5.00                                                   | Elastoplast 1004                     | BV |
| TAPES—PLASTER ADHESIVE HYPOALLERGENIC    |                                                         |             |                |         |                                          |                                                        |                                      |    |
| 4783R                                    | Roll 1.25 cm x 5 m                                      | ‡ 1         | ..             | ..      | 9.91                                     | 5.00                                                   | Leukopor 2471                        | BV |
| 4785W                                    | Roll 1.25 cm x 5 m                                      | ‡ 1         | ..             | ..      | 10.19                                    | 5.00                                                   | Leukosilk 1021                       | BV |
| 4794H                                    | Roll 2.5 cm x 5 m                                       | ‡ 1         | ..             | ..      | 12.30                                    | 5.00                                                   | Leukopor 2472                        | BV |
| 4787Y                                    | Roll 2.5 cm x 5 m                                       | ‡ 1         | ..             | ..      | 12.81                                    | 5.00                                                   | Leukosilk 1022                       | BV |
| 4788B                                    | Stretch roll 5 cm x 5 m                                 | ‡ 1         | ..             | ..      | 16.78                                    | 5.00                                                   | Leukoflex 1124                       | BV |
| 4790D                                    | Roll 5 cm x 5 m                                         | ‡ 1         | ..             | ..      | 15.78                                    | 5.00                                                   | Leukopor 2474                        | BV |
| 4789C                                    | Roll 5 cm x 5 m                                         | ‡ 1         | ..             | ..      | 16.62                                    | 5.00                                                   | Leukosilk 1024                       | BV |

continued 

REPATRIATION

| Code  | Name, Restriction,<br>Manner of Administration and Form | Max.<br>Qty | No. of<br>Rpts | Premium | Dispensed                   | Maximum                                     | Proprietary Name and<br>Manufacturer           |    |
|-------|---------------------------------------------------------|-------------|----------------|---------|-----------------------------|---------------------------------------------|------------------------------------------------|----|
|       |                                                         |             |                |         | Price for<br>Max. Qty<br>\$ | Recordable<br>Value for<br>Safety Net<br>\$ |                                                |    |
| 4848E | Roll (dispenser) 1.9 cm x 5.4 m                         | ‡ 1         | ..             | ..      | 10.62                       | 5.00                                        | Nexcare Durable<br>Cloth First Aid<br>Tape 799 | MM |
| 4849F | Roll (dispenser) 1.9 cm x 7.3 m                         | ‡ 1         | ..             | ..      | 10.62                       | 5.00                                        | Nexcare Gentle<br>Paper First Aid<br>Tape 789  | MM |

## Section 2

### Standard Packs and Prices

**NOTE—**

*Standard packs and prices (including mark-up, but without dispensing fee and dangerous drug fee) are for items against the price of which an asterisk (\*) is shown in Section 1 of the Schedule.*

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                                                         | Form/Strength                           | Pack and Price<br>\$ | Manufacturer |
|-------|--------------------------------------------------------------|-----------------------------------------|----------------------|--------------|
| 4579B | Alprostadil                                                  | 10 mcg                                  | 2 @ 25.40            | PH           |
| 4580C |                                                              | 20 mcg                                  | 2 @ 32.40            | PH           |
| 4453J | Aluminium Hydroxide with Magnesium Hydroxide and Simethicone | 400 mg-400 mg-40 mg                     | 100 @ 19.85          | JT           |
| 4118R |                                                              | 400 mg-400 mg-30 mg per 5 mL,<br>500 mL | 1 @ 8.11             | JT           |
| 4651T | Bandage—Absorbent Wool                                       | 10 cm x 2.7 m                           | 1 @ 4.67             | BV           |
| 4654Y | Bandage—Compression                                          | 8 cm x 5 m                              | 1 @ 12.86            | BV           |
| 4736G |                                                              | 7.5 cm x 3 m                            | 1 @ 15.83            | BV           |
| 4656C |                                                              | 7.5 cm x 3.5 m                          | 1 @ 12.39            | SS           |
| 4748X |                                                              | 10 cm x 3 m                             | 1 @ 13.30            | CC           |
|       |                                                              |                                         | 1 @ 20.96            | BV           |
| 4657D |                                                              | 10 cm x 3.5 m                           | 1 @ 9.85             | BV           |
|       |                                                              |                                         | 1 @ 14.43            | SS           |
| 4658E |                                                              | Four layer                              | 1 @ 38.76            | SN           |
| 4598B |                                                              | Four layer                              | 1 @ 25.75            | SN           |
| 4941C |                                                              | Two layer, 18 cm-22 cm                  | 1 @ 38.76            | SN           |
| 4942D |                                                              | Two layer, 22 cm-28 cm                  | 1 @ 38.76            | SN           |
| 4943E |                                                              | Two layer, 28 cm-32 cm                  | 1 @ 38.76            | SN           |
| 4811F | Bandage—Retention—Cohesive—Heavy                             | 5 cm x 1.3 m                            | 1 @ 3.80             | BK           |
| 4812G |                                                              | 7.5 cm x 1.3 m                          | 1 @ 5.44             | BK           |
| 4659F |                                                              | 7.5 cm x 3 m                            | 1 @ 6.82             | BV           |
| 4813H |                                                              | 10 cm x 1.3 m                           | 1 @ 7.31             | BK           |
| 4660G |                                                              | 10 cm x 2 m                             | 1 @ 6.47             | MM           |
| 4814J |                                                              | 15 cm x 1.3 m                           | 1 @ 10.88            | BK           |
| 4719J | Bandage—Retention—Cohesive—Light                             | 6 cm x 4 m                              | 1 @ 4.14             | BV           |
| 4662J |                                                              | 10 cm x 4 m                             | 1 @ 5.36             | BV           |
| 4727T | Bandage—Retention—Cotton Crepe                               | 5 cm x 2.3 m                            | 1 @ 5.51             | KE           |
|       |                                                              |                                         | 1 @ 5.93             | BV           |
| 4728W |                                                              | 7.5 cm x 2.3 m                          | 1 @ 7.90             | KE           |
|       |                                                              |                                         | 1 @ 7.99             | BV           |
| 4729X |                                                              | 10 cm x 2.3 m                           | 1 @ 9.48             | KE           |
|       |                                                              |                                         | 1 @ 10.70            | BV           |
| 4674B | Bandage—Tubular (long Stocking)                              | Small                                   | 1 @ 16.88            | SS           |
| 4797L |                                                              | Medium                                  | 1 @ 16.88            | SS           |
| 4799N |                                                              | Large                                   | 1 @ 16.88            | SS           |
| 4675C |                                                              | XX/large                                | 1 @ 16.88            | SS           |
| 4661H | Bandage—Tubular (short Stocking)                             | Small B/C                               | 1 @ 12.01            | SS           |
| 4815K |                                                              | Medium C/D                              | 1 @ 12.01            | SS           |
| 4816L |                                                              | Large D/E                               | 1 @ 12.01            | SS           |
| 4668Q | Bandage—Zinc Paste                                           | 7.5 cm x 6 m                            | 1 @ 11.39            | SS           |
| 4669R |                                                              | 7.5 cm x 6 m                            | 1 @ 11.62            | XP           |
| 4750B |                                                              | 7.5 cm x 6 m                            | 1 @ 28.56            | SN           |
| 4749Y |                                                              | 8 cm x 5 m                              | 1 @ 16.07            | BV           |
| 4670T |                                                              | 10 cm x 9.1 m                           | 1 @ 11.18            | CC           |
| 4150K | Bromazepam                                                   | 3 mg                                    | 30 @ 10.48           | RO           |
| 4151L |                                                              | 6 mg                                    | 30 @ 13.49           | RO           |
| 4333C | Calcium                                                      | 500 mg                                  | 60 @ 4.91            | IA           |
| 4093K |                                                              | 250 mg                                  | 120 @ 7.89           | BN           |
| 4094L |                                                              | 500 mg                                  | 60 @ 4.91            | IA           |
| 4055K | Calcium Carbonate with Glycine                               | 420 mg-180 mg                           | 100 @ 8.38           | MM           |
| 4081T | Dextropropoxyphene Napsylate                                 | 100 mg                                  | 10 @ 2.44            | AS           |

**(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)**

| Code  | Name                                                       | Form/Strength                | Pack and Price<br>\$ | Manufacturer |
|-------|------------------------------------------------------------|------------------------------|----------------------|--------------|
| 4681J | Dressing—Activated Charcoal (malodorous Wound)             | 10.5 cm x 10.5 cm            | 1 @ 7.88             | JJ           |
| 4832H | Dressing—Alginate (cavity Wound)                           | 2 g                          | 1 @ 10.27            | UM           |
| 4685N |                                                            | 2 g (30 cm), 5               | 5 @ 54.42            | CC           |
| 4682K |                                                            | 2 g (40 cm), 6               | 1 @ 37.85            | HO           |
| 4684M | Dressing—Alginate (superficial Wound)                      | 5 cm x 5 cm                  | 1 @ 65.65            | CT           |
| 4831G |                                                            | 10 cm x 10 cm                | 1 @ 4.05             | CT           |
| 4688R | Dressing—Film                                              | 15 cm x 20 cm                | 1 @ 7.80             | UM           |
| 4689T | Dressing—Film Island                                       | 5 cm x 7 cm                  | 1 @ 8.37             | CT           |
| 4898T |                                                            | 5 cm x 7.2 cm, 5             | 1 @ 4.04             | MM           |
| 4899W |                                                            | 8 cm x 10 cm, 5              | 1 @ 0.98             | MM           |
| 4690W |                                                            | 9 cm x 10 cm                 | 1 @ 9.10             | SN           |
| 4892L | Dressing—Foam with Charcoal (malodorous Wound)             | 10 cm x 10 cm, 10            | 1 @ 16.08            | SN           |
| 4919X | Dressing—Hydroactive (cavity Wound)                        | 10 cm x 10 cm, 5             | 1 @ 2.13             | MM           |
| 4906F | Dressing—Hydroactive (superficial Wound—Light Exudate)     | 10 cm x 10 cm, 5             | 1 @ 83.82            | SS           |
| 4886E | Dressing—Hydroactive (superficial Wound—Moderate Exudate)  | 10 cm x 10 cm, 5             | 1 @ 76.46            | SN           |
| 4896Q | Dressing—Hydrocolloid (cavity Wound)                       | 30 g                         | 1 @ 44.88            | SN           |
| 4895P |                                                            | 50 g                         | 1 @ 30.93            | SN           |
| 4697F |                                                            | 6 g                          | 1 @ 13.87            | CC           |
| 4908H | Dressing—Hydrocolloid (superficial Wound—Light Exudate)    | 10 cm x 10 cm, 5             | 1 @ 18.40            | CT           |
| 4897R | Dressing—Hydrocolloid (superficial Wound—Moderate Exudate) | 10 cm x 10 cm, 5             | 1 @ 8.20             | CT           |
| 4678F |                                                            | 7 cm                         | 1 @ 23.43            | HO           |
| 4679G |                                                            | 10 cm                        | 1 @ 26.20            | HO           |
| 4853K |                                                            | 15 cm x 20 cm, 3             | 1 @ 37.49            | CC           |
| 4854L |                                                            | 20 cm x 20 cm, 3             | 1 @ 9.75             | CT           |
| 4920Y |                                                            | 20 cm x 20 cm, 5             | 1 @ 10.64            | CT           |
| 4842W |                                                            | 5                            | 1 @ 42.28            | HO           |
| 4922C | Dressing—Hydrofibre (alternate To Alginates)               | 15 cm x 15 cm, 5             | 1 @ 50.67            | HO           |
| 4894N | Dressing—Hydrogel—Amorphous                                | 25 g                         | 1 @ 107.95           | CC           |
| 4913N |                                                            | 30 g, 3                      | 1 @ 46.59            | HO           |
| 4914P |                                                            | 50 g                         | 1 @ 101.14           | CC           |
| 4599C |                                                            | 50 g                         | 1 @ 11.86            | SN           |
| 4911L | Dressing—Hydrogel—Sheet                                    | 9.5 cm x 10.2 cm, 5          | 1 @ 30.23            | CC           |
| 4806Y |                                                            | 10 cm x 10 cm, 5             | 1 @ 8.90             | JJ           |
| 4860T | Dressing—Non-adherent                                      | 5 cm x 5 cm, 5               | 1 @ 6.77             | SN           |
| 4819P |                                                            | 5 cm x 5 cm, 5               | 1 @ 38.39            | JJ           |
| 4862X |                                                            | 10 cm x 10 cm, 5             | 1 @ 23.43            | HR           |
| 4909J | Dressing—Tulle Non-gauze—Paraffin                          | 7.6 cm x 7.6 cm              | 1 @ 4.13             | SN           |
| 4237B | Fexofenadine Hydrochloride                                 | 60 mg                        | 1 @ 3.80             | SN           |
| 4246L | Glycerol                                                   | 2.8 g, 12                    | 1 @ 7.67             | SN           |
| 4576W | Nicotine                                                   | Approx. 5 mg per 16 hours, 7 | 1 @ 0.93             | JJ           |
| 4571N |                                                            | Approx. 7 mg per 24 hours, 7 | 20 @ 11.57           | AF           |
|       |                                                            |                              | 20 @ 13.92           | SW           |
|       |                                                            |                              | 1 @ 4.11             | PP           |
|       |                                                            |                              | 1 @ 22.20            | JT           |
|       |                                                            |                              | 1 @ 19.89            | AF           |
|       |                                                            |                              | 1 @ 33.95            | GK           |

(APPLY WASTAGE FACTOR IN CALCULATING BROKEN QUANTITY PRICES)

| Code  | Name                       | Form/Strength                 | Pack and Price<br>\$ | Manufacturer |
|-------|----------------------------|-------------------------------|----------------------|--------------|
| 4577X |                            | Approx. 10 mg per 16 hours, 7 | 1 @ 24.18            | JT           |
| 4572P |                            | Approx. 14 mg per 24 hours, 7 | 1 @ 21.55            | AF           |
|       |                            |                               | 1 @ 33.95            | GK           |
| 4578Y |                            | Approx. 15 mg per 16 hours, 7 | 1 @ 26.77            | JT           |
| 4573Q |                            | Approx. 21 mg per 24 hours, 7 | 1 @ 23.55            | AF           |
|       |                            |                               | 1 @ 33.95            | GK           |
| 4676D | Pressure Reducing Products | 10 cm x 10 cm x 3 mm          | 1 @ 11.04            | KC           |
| 4677E |                            | 10 cm x 10 cm x 12 mm         | 1 @ 21.45            | KC           |

## **GENERIC/PROPRIETARY INDEX**

## GENERIC/PROPRIETARY INDEX

3

3TC (GK)

.Section 100 .....599

A

ABACAVIR SULFATE

.Section 100 .....507

ABACAVIR SULFATE WITH LAMIVUDINE

.Section 100 .....507

ABACAVIR SULFATE WITH LAMIVUDINE AND

ZIDOVUDINE

.Section 100 .....507

ABATACEPT

.Section 100 .....507

Abbacillin-V (SI)

.Antifungives for systemic use .....188

.Dental .....480

Abbacillin-VK Filmtab (SI)

.Antifungives for systemic use .....188

.Dental .....479

ABCIXIMAB

.....108

Abilify (BQ)

.....380

ACAMPROSATE CALCIUM

.....407

ACARBOSE

.....100

Accomin Adult Tonic (WT)

.Repatriation Schedule .....683

Accu-Chek Active (RD)

.....438

Accu-Chek Go (RD)

.....438

Accu-Chek Integra (RD)

.....438

Accu-Chek Performa (RD)

.....437

Accupril (PF)

.....135

Accutec 10/12.5mg (PF)

.....139

Accutec 20/12.5mg (PF)

.....139

Acenorm 12.5 mg (AF)

.....130

Acenorm 25 mg (AF)

.....130

Acenorm 50 mg (AF)

.....131

ACETAZOLAMIDE

.....425

ACETYLCYSTEINE

.....421

ACICLOVIR

.Antifungives for systemic use .....205

.Sensory organs .....423

.Optometrical .....501

Aciclovir 200 (CR)

.....206

Aciclovir 800 (CR)

.....206

Acihexal (SZ)

.....205

Aci-Jel (JC)

.Repatriation Schedule .....693

Acimax Tablets (AL)

.....80

ACITRETIN

.....158

Aclin (AF)

.Musculo-skeletal system .....339

.Palliative Care .....462

.Dental .....489

Aclin 200 (AF)

.Musculo-skeletal system .....339

.Palliative Care .....462

.Dental .....489

Aclor 125 (AW)

.Antifungives for systemic use .....194

.Dental .....485

Aclor 250 (AW)

.Antifungives for systemic use .....194

.Dental .....485

Acquin 10 (AW)

.....135

Acquin 20 (AW)

.....135

Acquin 5 (AW)

.....135

Actilax (AF)

.Alimentary tract and metabolism .....89

.Palliative Care .....457

Actiq (OA)

.Palliative Care .....466

Actisorb Plus MAC031 (JJ)

.Repatriation Schedule .....713

Actonel (SW)

.Musculo-skeletal system .....348

.Repatriation Schedule .....697

Actonel Combi (SW)

.Musculo-skeletal system .....350

.Repatriation Schedule .....698

Actonel Combi D (SW)

.....351

Actonel Once-a-Week (SW)

.Musculo-skeletal system .....348

.Repatriation Schedule .....697

Actos (LY)

.....102

Actrapid (NO)

.....95

Actrapid Penfill 3 mL (NO)

.....95

Acyclo-V 200 (AF)

.....205

Acyclo-V 800 (AF)

.....206

Adalat 10 (BN)

.....128

Adalat 20 (BN)

.....128

Adalat Oros 20mg (BN)

.....128

Adalat Oros 30 (BN)

.....128

Adalat Oros 60 (BN)

.....128

ADALIMUMAB

.....265

Adaptic 2012 (JJ)

.Repatriation Schedule .....720

add-ins (SB)

.....447

Addos XR 30 (AW)

.....128

Addos XR 60 (AW)

.....128

Adefin 10 (AF)

.....128

Adefin 20 (AF)

.....128

Adefin XL 30 (AF)

.....128

Adefin XL 60 (AF)

.....128

ADEFOVIR DIPIVOXIL

.Section 100 .....514

ADRENALINE

.Doctor's Bag Supplies .....69

.Cardiovascular system .....115

.Respiratory system .....419

.Dental .....475

.Dental .....499

Adriamycin (PF)

.....218



## GENERIC/PROPRIETARY INDEX

|                                                      |     |                                                  |     |
|------------------------------------------------------|-----|--------------------------------------------------|-----|
| <i>Adriamycin Solution (PH)</i> .....                | 218 | <i>Allegron (AS)</i> .....                       | 387 |
| <i>Adronat (AF)</i> .....                            | 346 | <i>Allereze (AF)</i> .....                       |     |
| <i>ADT Booster (CS)</i> .....                        |     | <i>.Repatriation Schedule</i> .....              | 703 |
| <i>.Doctor's Bag Supplies</i> .....                  | 69  | <i>Allewyn 66007637 (SN)</i> .....               |     |
| <i>.Antiinfectives for systemic use</i> .....        | 209 | <i>.Repatriation Schedule</i> .....              | 714 |
| <i>Advantage II (RD)</i> .....                       | 437 | <i>Allewyn Adhesive 66000044 (SN)</i> .....      |     |
| <i>Advantan (CS)</i> .....                           | 160 | <i>.Repatriation Schedule</i> .....              | 715 |
| <i>Aeron 250 (AW)</i> .....                          | 418 | <i>Allewyn Plus Cavity 66047571 (SN)</i> .....   |     |
| <i>Aeron 500 (AW)</i> .....                          | 419 | <i>.Repatriation Schedule</i> .....              | 716 |
| <i>Aggrastat (MK)</i> .....                          | 110 | <i>Allewyn Plus Cavity 66047573 (SN)</i> .....   |     |
| <i>Airomir (IA)</i> .....                            |     | <i>.Repatriation Schedule</i> .....              | 716 |
| <i>.Doctor's Bag Supplies</i> .....                  | 71  | <i>Allewyn Thin 66047576 (SN)</i> .....          |     |
| <i>.Respiratory system</i> .....                     | 412 | <i>.Repatriation Schedule</i> .....              | 717 |
| <i>Airomir Autohaler (IA)</i> .....                  | 412 | <i>Allewyn Thin 66047578 (SN)</i> .....          |     |
| <i>Akamin 100 (AF)</i> .....                         | 186 | <i>.Repatriation Schedule</i> .....              | 717 |
| <i>Akamin 50 (AF)</i> .....                          | 186 | <i>Allohexal (SZ)</i> .....                      | 345 |
| <i>Akineton (LM)</i> .....                           | 373 | <i>ALLOPURINOL</i> .....                         | 345 |
| <i>Albalon-A (AG)</i> .....                          |     | <i>Allosig (FM)</i> .....                        | 345 |
| <i>.Repatriation Schedule</i> .....                  | 704 | <i>Alodorm (AF)</i> .....                        |     |
| <i>Albalon Liquifilm (AG)</i> .....                  |     | <i>.Nervous system</i> .....                     | 368 |
| <i>.Repatriation Schedule</i> .....                  | 704 | <i>.Nervous system</i> .....                     | 384 |
| <i>ALBENDAZOLE</i> .....                             | 410 | <i>.Palliative Care</i> .....                    | 471 |
| <i>Albey Bee Venom (ES)</i> .....                    | 435 | <i>.Dental</i> .....                             | 498 |
| <i>Albey Paper Wasp Venom (ES)</i> .....             | 435 | <i>Alphagan (AG)</i> .....                       | 424 |
| <i>Albey Yellow Jacket Venom (ES)</i> .....          | 435 | <i>Alpha Keri Bath Oil (MT)</i> .....            |     |
| <i>Aldactone (PH)</i> .....                          | 121 | <i>.Repatriation Schedule</i> .....              | 687 |
| <i>Aldara (IA)</i> .....                             |     | <i>Alpha Keri Lotion (MT)</i> .....              |     |
| <i>.Dermatologicals</i> .....                        | 162 | <i>.Repatriation Schedule</i> .....              | 687 |
| <i>.Repatriation Schedule</i> .....                  | 691 | <i>Alphamox 125 (AF)</i> .....                   |     |
| <i>Aldomet (MK)</i> .....                            | 118 | <i>.Antiinfectives for systemic use</i> .....    | 187 |
| <i>Alendrobell 70mg (BF)</i> .....                   | 346 | <i>.Dental</i> .....                             | 478 |
| <i>Alendronate Sandoz (SZ)</i> .....                 | 346 | <i>Alphamox 250 (AF)</i> .....                   |     |
| <i>ALENDRONATE SODIUM</i> .....                      | 346 | <i>.Antiinfectives for systemic use</i> .....    | 186 |
| <i>ALENDRONATE SODIUM WITH</i> .....                 |     | <i>.Dental</i> .....                             | 478 |
| <i>COLECALCIFEROL</i> .....                          | 349 | <i>Alphamox 500 (AF)</i> .....                   |     |
| <i>Alendro Once Weekly (AW)</i> .....                | 346 | <i>.Antiinfectives for systemic use</i> .....    | 187 |
| <i>Alepam 15 (AF)</i> .....                          |     | <i>.Dental</i> .....                             | 478 |
| <i>.Nervous system</i> .....                         | 383 | <i>Alphapress 25 (AF)</i> .....                  | 119 |
| <i>.Palliative Care</i> .....                        | 471 | <i>Alphapress 50 (AF)</i> .....                  | 119 |
| <i>.Dental</i> .....                                 | 498 | <i>Alphapril (AF)</i> .....                      | 131 |
| <i>Alepam 30 (AF)</i> .....                          |     | <i>Alprax 0.25 (AW)</i> .....                    | 382 |
| <i>.Nervous system</i> .....                         | 383 | <i>Alprax 0.5 (AW)</i> .....                     | 382 |
| <i>.Palliative Care</i> .....                        | 471 | <i>Alprax 1 (AW)</i> .....                       | 382 |
| <i>.Dental</i> .....                                 | 498 | <i>Alprax 2 (AW)</i> .....                       | 383 |
| <i>Alfaré (NT)</i> .....                             | 443 | <i>ALPRAZOLAM</i> .....                          | 382 |
| <i>Algisite M 66000519 (SN)</i> .....                |     | <i>Alprazolam-DP (GM)</i> .....                  | 382 |
| <i>.Repatriation Schedule</i> .....                  | 713 | <i>Alprim (AF)</i> .....                         | 196 |
| <i>Algisite M 66000520 (SN)</i> .....                |     | <i>ALPROSTADIL</i> .....                         |     |
| <i>.Repatriation Schedule</i> .....                  | 713 | <i>.Repatriation Schedule</i> .....              | 694 |
| <i>Algisite M 66000521 (SN)</i> .....                |     | <i>ALUMINIUM HYDROXIDE WITH MAGNESIUM</i> .....  |     |
| <i>.Repatriation Schedule</i> .....                  | 714 | <i>HYDROXIDE</i> .....                           | 75  |
| <i>Alimta (LY)</i> .....                             | 213 | <i>ALUMINIUM HYDROXIDE WITH MAGNESIUM</i> .....  |     |
| <i>Alkeran (GK)</i> .....                            | 211 | <i>HYDROXIDE AND SIMETHICONE</i> .....           |     |
| <i>ALLANTOIN WITH GLYCEROL AND ICHTHAMMOL</i> .....  |     | <i>.Repatriation Schedule</i> .....              | 680 |
| <i>.Repatriation Schedule</i> .....                  | 691 | <i>ALUMINIUM HYDROXIDE WITH MAGNESIUM</i> .....  |     |
| <i>ALLANTOIN WITH SULFUR, PHENOL, COAL TAR</i> ..... |     | <i>TRISILICATE AND MAGNESIUM HYDROXIDE</i> ..... | 75  |
| <i>SOLUTION AND MENTHOL</i> .....                    |     | <i>Alvesco 160 (NQ)</i> .....                    | 417 |
| <i>.Repatriation Schedule</i> .....                  | 688 | <i>Alvesco 80 (NQ)</i> .....                     | 417 |

## GENERIC/PROPRIETARY INDEX

|                                                                              |     |                                             |     |
|------------------------------------------------------------------------------|-----|---------------------------------------------|-----|
| <i>Alzene (AF)</i>                                                           |     | <i>Amlodipine Sandoz (SZ)</i>               | 126 |
| .Repatriation Schedule                                                       | 703 | <i>Amohexal (HX)</i>                        |     |
| AMANTADINE HYDROCHLORIDE                                                     | 375 | .Anti-infectives for systemic use           | 186 |
| <i>Amaryl (SW)</i>                                                           | 99  | .Dental                                     | 478 |
| AMILORIDE HYDROCHLORIDE                                                      | 121 | AMOROLFINE HYDROCHLORIDE                    |     |
| AMINO ACID FORMULA WITHOUT METHIONINE,<br>THREONINE AND VALINE AND LOW IN    |     | .Repatriation Schedule                      | 685 |
| ISOLEUCINE                                                                   | 447 | <i>Amoxil (GK)</i>                          |     |
| AMINO ACID FORMULA WITHOUT                                                   |     | .Special Pharmaceutical Benefits            | 72  |
| PHENYLALANINE                                                                | 447 | .Special Pharmaceutical Benefits            | 74  |
| AMINO ACID FORMULA WITHOUT                                                   |     | .Anti-infectives for systemic use           | 186 |
| PHENYLALANINE, AND VITAMINS WITH                                             |     | .Dental                                     | 478 |
| MINERALS                                                                     | 447 | <i>Amoxil Forte (GK)</i>                    |     |
| AMINO ACID FORMULA WITHOUT                                                   |     | .Anti-infectives for systemic use           | 187 |
| PHENYLALANINE, TYROSINE AND METHIONINE                                       | 447 | .Dental                                     | 479 |
| AMINO ACID FORMULA WITH VITAMINS,<br>MINERALS AND LONG CHAIN POLYUNSATURATED |     | AMOXYCILLIN                                 |     |
| FATTY ACIDS WITHOUT PHENYLALANINE                                            | 447 | .Special Pharmaceutical Benefits            | 72  |
| AMINO ACID FORMULA WITH VITAMINS AND                                         |     | .Special Pharmaceutical Benefits            | 74  |
| MINERALS WITHOUT LYSINE AND LOW IN                                           |     | .Anti-infectives for systemic use           | 186 |
| TRYPTOPHAN                                                                   | 448 | .Dental                                     | 478 |
| AMINO ACID FORMULA WITH VITAMINS AND                                         |     | <i>Amoxycillin-DP (GM)</i>                  |     |
| MINERALS WITHOUT METHIONINE                                                  | 448 | .Anti-infectives for systemic use           | 186 |
| AMINO ACID FORMULA WITH VITAMINS AND                                         |     | .Dental                                     | 478 |
| MINERALS WITHOUT METHIONINE, THREONINE                                       |     | <i>Amoxycillin Sandoz (BG)</i>              | 188 |
| AND VALINE AND LOW IN ISOLEUCINE                                             | 448 | AMOXYCILLIN WITH CLAVULANIC ACID            |     |
| AMINO ACID FORMULA WITH VITAMINS AND                                         |     | .Anti-infectives for systemic use           | 190 |
| MINERALS WITHOUT PHENYLALANINE                                               | 449 | .Dental                                     | 481 |
| AMINO ACID FORMULA WITH VITAMINS AND                                         |     | AMPHOTERICIN                                |     |
| MINERALS WITHOUT PHENYLALANINE AND                                           |     | .Alimentary tract and metabolism            | 75  |
| TYROSINE                                                                     | 449 | .Anti-infectives for systemic use           | 203 |
| AMINO ACID FORMULA WITH VITAMINS AND                                         |     | .Dental                                     | 473 |
| MINERALS WITHOUT VALINE, LEUCINE AND                                         |     | AMPICILLIN                                  |     |
| ISOLEUCINE                                                                   | 450 | .Anti-infectives for systemic use           | 188 |
| AMINO ACIDS—SYNTHETIC, FORMULA                                               | 439 | .Dental                                     | 479 |
| AMINO ACID SYNTHETIC FORMULA                                                 |     | <i>Amprace 10 (FR)</i>                      | 131 |
| SUPPLEMENTED WITH LONG CHAIN                                                 |     | <i>Amprace 20 (FR)</i>                      | 132 |
| POLYUNSATURATED FATTY ACIDS                                                  | 441 | <i>Anafranil 25 (NV)</i>                    |     |
| AMINOGLUTETHIMIDE                                                            |     | .Nervous system                             | 384 |
| .Systemic hormonal preparations, excl. sex hormones and                      |     | .Nervous system                             | 386 |
| insulins                                                                     | 181 | ANAKINRA                                    | 328 |
| .Antineoplastic and immunomodulating agents                                  | 247 | <i>Anamorph (FM)</i>                        |     |
| AMIODARONE HYDROCHLORIDE                                                     | 115 | .Nervous system                             | 356 |
| <i>Amira 150 (AF)</i>                                                        | 392 | .Dental                                     | 493 |
| <i>Amira 300 (AF)</i>                                                        | 392 | <i>Anadron (SW)</i>                         | 247 |
| AMISULPRIDE                                                                  | 379 | <i>Anaprox 550 (RO)</i>                     |     |
| <i>Amisulpride 100 Winthrop (WA)</i>                                         | 379 | .Musculo-skeletal system                    | 342 |
| <i>Amisulpride 200 Winthrop (WA)</i>                                         | 379 | .Palliative Care                            | 464 |
| <i>Amisulpride 400 Winthrop (WA)</i>                                         | 379 | .Dental                                     | 491 |
| <i>Amisulpride Sandoz (SZ)</i>                                               | 379 | ANASTROZOLE                                 | 248 |
| AMITRIPTYLINE HYDROCHLORIDE                                                  | 386 | <i>Andriol Testocaps (OR)</i>               | 167 |
| <i>Amlo 10 (ZP)</i>                                                          | 127 | <i>Androcur (SC)</i>                        |     |
| <i>Amlo 5 (ZP)</i>                                                           | 126 | .Genito urinary system and sex hormones     | 175 |
| AMLODIPINE                                                                   | 126 | .Antineoplastic and immunomodulating agents | 247 |
| AMLODIPINE BESYLATE WITH ATORVASTATIN                                        |     | <i>Androcur-100 (SC)</i>                    |     |
| CALCIUM                                                                      | 154 | .Genito urinary system and sex hormones     | 176 |
| <i>Amlodipine-GA (GM)</i>                                                    | 126 | .Antineoplastic and immunomodulating agents | 247 |
| <i>Amlodipine generichealth (GQ)</i>                                         | 126 | <i>Androderm (HH)</i>                       | 166 |
|                                                                              |     | ANECORTAVE ACETATE                          | 427 |
|                                                                              |     | <i>Anginine Stabilised (SI)</i>             |     |

## GENERIC/PROPRIETARY INDEX

|                                        |     |                                                   |     |
|----------------------------------------|-----|---------------------------------------------------|-----|
| .Cardiovascular system .....           | 116 | Aquasun Lotion SPF 18 (PF) .....                  |     |
| .Dental .....                          | 475 | .Repatriation Schedule .....                      | 688 |
| Angiomax (CS) .....                    | 111 | Arabloc (AV) .....                                |     |
| Anpec 40 (AF) .....                    | 128 | .Antineoplastic and immunomodulating agents ..... | 263 |
| Anpec 80 (AF) .....                    | 128 | .Musculo-skeletal system .....                    |     |
| Anpec SR (AF) .....                    | 129 | Aranesp (AN) .....                                |     |
| Anselol 50 mg (GM) .....               | 123 | .Section 100 .....                                | 528 |
| ANTAZOLINE WITH NAPHAZOLINE .....      |     | Aranesp SureClick (AN) .....                      |     |
| .Repatriation Schedule .....           | 703 | .Section 100 .....                                | 528 |
| Antenex 2 (AF) .....                   |     | Aratac 100 (AF) .....                             | 115 |
| .Nervous system .....                  | 383 | Aratac 200 (AF) .....                             | 115 |
| .Palliative Care .....                 | 470 | Arava (SW) .....                                  |     |
| .Dental .....                          | 498 | .Antineoplastic and immunomodulating agents ..... | 263 |
| Antenex 5 (AF) .....                   |     | .Musculo-skeletal system .....                    |     |
| .Nervous system .....                  | 383 | Aredia 15 mg (NV) .....                           |     |
| .Palliative Care .....                 | 470 | .Musculo-skeletal system .....                    | 347 |
| .Dental .....                          | 498 | .Section 100 .....                                | 530 |
| Anthel 125 (AF) .....                  | 410 | Aredia 30 mg (NV) .....                           |     |
| Anthel 250 (AF) .....                  | 410 | .Musculo-skeletal system .....                    | 347 |
| Antistine-Privine (NV) .....           |     | .Section 100 .....                                | 530 |
| .Repatriation Schedule .....           | 703 | Aredia 90 mg (NV) .....                           |     |
| Antroquoril (EX) .....                 | 159 | .Section 100 .....                                | 531 |
| Anusol (JT) .....                      |     | Aricept (PF) .....                                | 398 |
| .Repatriation Schedule .....           | 684 | Arimidex (AP) .....                               | 248 |
| Anzatax (HH) .....                     | 217 | ARIPIPRAZOLE .....                                | 380 |
| Anzemet (SW) .....                     | 84  | Aristocort 0.02% (SI) .....                       | 159 |
| Apidra SoloStar (SW) .....             | 95  | Arixtra (GK) .....                                | 111 |
| APO-Alendronate (TX) .....             | 346 | Aromasin (PH) .....                               | 248 |
| APO-Amlodipine (TX) .....              | 126 | Aropax (GK) .....                                 | 390 |
| APO-Amoxycillin (TX) .....             |     | Artane (SI) .....                                 | 373 |
| .Antiinfectives for systemic use ..... | 186 | Arthrexin (AF) .....                              |     |
| .Dental .....                          | 478 | .Musculo-skeletal system .....                    | 339 |
| APO-Bicalutamide (TX) .....            | 246 | .Palliative Care .....                            | 461 |
| Apomine (HH) .....                     |     | .Dental .....                                     | 489 |
| .Section 100 .....                     | 514 | Arthrotec 50 (PH) .....                           |     |
| APOMORPHINE HYDROCHLORIDE .....        |     | .Repatriation Schedule .....                      | 697 |
| .Section 100 .....                     | 514 | Asasantin SR (BY) .....                           | 109 |
| APO-Quinapril (TX) .....               | 135 | Asmol 2.5 uni-dose (AF) .....                     |     |
| APO-Trandolapril (TX) .....            | 137 | .Doctor's Bag Supplies .....                      | 71  |
| Apoven 250 (GM) .....                  | 418 | .Respiratory system .....                         | 413 |
| Apoven 500 (GM) .....                  | 419 | Asmol 5 uni-dose (AF) .....                       |     |
| APRACLOPIDINE HYDROCHLORIDE .....      | 424 | .Doctor's Bag Supplies .....                      | 71  |
| APREPITANT .....                       | 86  | .Respiratory system .....                         | 413 |
| Aptivus (BY) .....                     |     | Asmol CFC-free (AL) .....                         |     |
| .Section 100 .....                     | 632 | .Doctor's Bag Supplies .....                      | 71  |
| Aquacare H.P. (AG) .....               |     | .Respiratory system .....                         | 412 |
| .Repatriation Schedule .....           | 687 | Aspalgin (FM) .....                               |     |
| Aquacel 177902 (CC) .....              |     | .Repatriation Schedule .....                      | 698 |
| .Repatriation Schedule .....           | 718 | Aspen Ampicyn (AS) .....                          |     |
| Aquacel 177903 (CC) .....              |     | .Antiinfectives for systemic use .....            | 188 |
| .Repatriation Schedule .....           | 719 | .Dental .....                                     | 479 |
| Aquacel 177904 (CC) .....              |     | ASPIRIN .....                                     |     |
| .Repatriation Schedule .....           | 718 | .Blood and blood forming organs .....             | 108 |
| Aquaclear 900796 (HR) .....            |     | .Nervous system .....                             | 364 |
| .Repatriation Schedule .....           | 719 | .Dental .....                                     | 496 |
| Aquae (HA) .....                       |     | .Repatriation Schedule .....                      | 683 |
| .Palliative Care .....                 | 454 | Astrix (HH) .....                                 |     |
| .Repatriation Schedule .....           | 680 | .Blood and blood forming organs .....             | 108 |

# GENERIC/PROPRIETARY INDEX

|                                         |     |                                         |     |
|-----------------------------------------|-----|-----------------------------------------|-----|
| .Repatriation Schedule .....            | 683 | <i>Avapro HCT 300/25 (BQ)</i> .....     | 142 |
| <i>Atacand (AP)</i> .....               | 140 | <i>Avonex (BD)</i> .....                | 250 |
| <i>Atacand Plus 16/12.5 (AP)</i> .....  | 141 | <i>Axit 30 (AF)</i> .....               | 393 |
| ATAZANAVIR                              |     | <i>Aylide 1 (AF)</i> .....              | 99  |
| . Section 100 .....                     | 514 | <i>Aylide 2 (AF)</i> .....              | 99  |
| <i>Atehexal (SZ)</i> .....              | 123 | <i>Aylide 3 (AF)</i> .....              | 99  |
| ATENOLOL .....                          | 123 | <i>Aylide 4 (AF)</i> .....              | 99  |
| ATOMOXETINE HYDROCHLORIDE .....         | 394 | <i>Azahexal (SZ)</i> .....              | 336 |
| ATORVASTATIN CALCIUM .....              | 146 | <i>Azamun (GM)</i> .....                | 336 |
| ATOVAQUONE .....                        | 409 | <i>Azapin (AW)</i> .....                | 336 |
| <i>Atrauman 499513 (HR)</i>             |     | AZATHIOPRINE .....                      | 336 |
| .Repatriation Schedule .....            | 719 | AZITHROMYCIN                            |     |
| <i>Atrauman Ag 499572 (HR)</i>          |     | . Antiinfectives for systemic use ..... | 197 |
| .Repatriation Schedule .....            | 720 | . Sensory organs .....                  | 422 |
| ATROPINE SULFATE                        |     | . Section 100 .....                     | 514 |
| . Doctor's Bag Supplies .....           | 69  | . Repatriation Schedule .....           | 695 |
| . Alimentary tract and metabolism ..... | 83  | <i>Azol 100 (AF)</i> .....              | 176 |
| . Sensory organs .....                  | 427 | <i>Azol 200 (AF)</i> .....              | 176 |
| . Dental .....                          | 473 | <i>Azopt (AQ)</i> .....                 | 425 |
| <i>Atropt (SI)</i> .....                | 427 |                                         |     |
| <i>Atrovent (BY)</i> .....              | 418 | <b>B</b>                                |     |
| <i>Atrovent Adult (BY)</i> .....        | 419 | <i>Baclo (GM)</i> .....                 | 344 |
| <i>Atrovent Nasal Aqueous (BY)</i>      |     | BACLOFEN                                |     |
| .Repatriation Schedule .....            | 702 | . Musculo-skeletal system .....         | 344 |
| <i>Atrovent Nasal Forte (BY)</i>        |     | . Section 100 .....                     | 514 |
| .Repatriation Schedule .....            | 702 | <i>Baclohexal (HX)</i> .....            | 344 |
| <i>Attenta (AF)</i> .....               | 395 | <i>Bactigras 7457 (SN)</i>              |     |
| <i>Augmentin (GK)</i>                   |     | .Repatriation Schedule .....            | 716 |
| . Antiinfectives for systemic use ..... | 191 | <i>Bactrim (RO)</i>                     |     |
| . Dental .....                          | 482 | . Antiinfectives for systemic use ..... | 196 |
| <i>Augmentin Duo (GK)</i>               |     | . Dental .....                          | 486 |
| . Antiinfectives for systemic use ..... | 190 | <i>Bactrim DS (RO)</i>                  |     |
| . Dental .....                          | 481 | . Antiinfectives for systemic use ..... | 196 |
| <i>Augmentin Duo 400 (GK)</i>           |     | . Dental .....                          | 486 |
| . Antiinfectives for systemic use ..... | 191 | <i>Bactroban (GK)</i>                   |     |
| . Dental .....                          | 482 | . Repatriation Schedule .....           | 688 |
| <i>Augmentin Duo forte (GK)</i>         |     | BALSALAZIDE SODIUM .....                | 92  |
| . Antiinfectives for systemic use ..... | 191 | BANDAGE—ABSORBENT WOOL                  |     |
| . Dental .....                          | 482 | . Repatriation Schedule .....           | 709 |
| AURANOFIN .....                         | 343 | BANDAGE—CALICO .....                    | 710 |
| <i>Aurorix (RO)</i> .....               | 392 | . Repatriation Schedule .....           | 710 |
| <i>Aurorix 300 mg (RO)</i> .....        | 392 | BANDAGE—COMPRESSION .....               | 710 |
| <i>Auscap (SI)</i> .....                | 389 | . Repatriation Schedule .....           | 710 |
| <i>Ausfam 20 (AW)</i> .....             | 76  | BANDAGE—RETENTION—COHESIVE—HEAVY .....  | 711 |
| <i>Ausfam 40 (AW)</i> .....             | 76  | . Repatriation Schedule .....           | 711 |
| <i>Ausgem (SI)</i> .....                | 151 | BANDAGE—RETENTION—COHESIVE—LIGHT .....  | 711 |
| <i>Auspril (SI)</i> .....               | 131 | . Repatriation Schedule .....           | 711 |
| <i>Ausran (SI)</i> .....                | 77  | BANDAGE—RETENTION—COTTON CREPE .....    | 711 |
| <i>Austrapen (LN)</i>                   |     | . Repatriation Schedule .....           | 711 |
| . Antiinfectives for systemic use ..... | 188 | BANDAGE—TUBULAR .....                   | 711 |
| . Dental .....                          | 479 | . Repatriation Schedule .....           | 711 |
| <i>Avandamet (GK)</i> .....             | 100 | BANDAGE—TUBULAR (FINGER) .....          | 712 |
| <i>Avandia (GK)</i> .....               | 103 | BANDAGE—TUBULAR (LIGHTWEIGHT) .....     | 712 |
| <i>Avanza (BP)</i> .....                | 393 | . Repatriation Schedule .....           | 712 |
| <i>Avanza SolTab (BP)</i> .....         | 393 | BANDAGE—TUBULAR (LONG STOCKING)         |     |
| <i>Avapro (BQ)</i> .....                | 140 |                                         |     |
| <i>Avapro HCT 150/12.5 (BQ)</i> .....   | 141 |                                         |     |
| <i>Avapro HCT 300/12.5 (BQ)</i> .....   | 141 |                                         |     |

## GENERIC/PROPRIETARY INDEX

|                                                         |     |                                        |     |
|---------------------------------------------------------|-----|----------------------------------------|-----|
| .Repatriation Schedule .....                            | 712 | Betnovate (SI)                         |     |
| BANDAGE—TUBULAR (SHORT STOCKING)                        |     | .Repatriation Schedule .....           | 689 |
| .Repatriation Schedule .....                            | 712 | Betnovate 1/2 (SI) .....               | 160 |
| BANDAGE—ZINC PASTE                                      |     | Betnovate 1/5 (SI) .....               | 159 |
| .Repatriation Schedule .....                            | 712 | Betoptic (AQ) .....                    | 425 |
| Baraclude (BQ)                                          |     | Betoptic S (AQ) .....                  | 425 |
| .Section 100 .....                                      | 534 | BetoQuin (IQ) .....                    | 425 |
| Barbloc 15 (AF) .....                                   | 122 | Bgramin (GM)                           |     |
| Barbloc 5 (AF) .....                                    | 122 | .Antiinfectives for systemic use ..... | 187 |
| BCG IMMUNOTHERAPEUTIC (BACILLUS                         |     | .Dental .....                          | 478 |
| CALMETTE-GUÉRIN/ CONNAUGHT STRAIN)                      | 251 | Biatain Adhesive 3420 (CT)             |     |
| BCG-TICE (BACILLUS CALMETTE-GUÉRIN/ TICE                |     | .Repatriation Schedule .....           | 716 |
| STRAIN) .....                                           | 251 | Biatain Adhesive 3423 (CT)             |     |
| BECLOMETHASONE DIPROPIONATE .....                       | 416 | .Repatriation Schedule .....           | 716 |
| BenPen (CS)                                             |     | Biatain Non-adhesive 3410 (CT)         |     |
| .Doctor's Bag Supplies .....                            | 69  | .Repatriation Schedule .....           | 716 |
| .Antiinfectives for systemic use .....                  | 188 | Biatain Non-adhesive 3413 (CT)         |     |
| .Dental .....                                           | 479 | .Repatriation Schedule .....           | 716 |
| BENZATHINE BENZYL PENICILLIN                            |     | Biaxig (AV) .....                      | 198 |
| .Antiinfectives for systemic use .....                  | 188 | BICALUTAMIDE .....                     | 246 |
| .Dental .....                                           | 479 | Bicalutamide-GA (GM) .....             | 246 |
| BENZHEXOL HYDROCHLORIDE .....                           | 373 | Bicalutamide Ranbaxy (RA) .....        | 246 |
| Benztrop (PL) .....                                     | 374 | Bicillin L-A (AS)                      |     |
| BENZTROPINE MESYLATE                                    |     | .Antiinfectives for systemic use ..... | 188 |
| .Doctor's Bag Supplies .....                            | 69  | .Dental .....                          | 479 |
| .Nervous system .....                                   | 374 | Bicor (AL) .....                       | 123 |
| .Dental .....                                           | 498 | BIFONAZOLE                             |     |
| BENZYDAMINE HYDROCHLORIDE                               |     | .Dermatologicals .....                 | 155 |
| .Alimentary tract and metabolism .....                  | 75  | .Repatriation Schedule .....           | 685 |
| .Palliative Care .....                                  | 454 | BIMATOPROST .....                      | 426 |
| .Dental .....                                           | 473 | Biodone Forte (MW)                     |     |
| BENZYL PENICILLIN                                       |     | .Section 100 .....                     | 638 |
| .Doctor's Bag Supplies .....                            | 69  | Bion Tears (AQ)                        |     |
| .Antiinfectives for systemic use .....                  | 188 | .Sensory organs .....                  | 432 |
| .Dental .....                                           | 479 | .Optometrical .....                    | 503 |
| Betachek (NA) .....                                     | 438 | BIPERIDEN HYDROCHLORIDE .....          | 373 |
| Betachek G5 (NA) .....                                  | 438 | BISACODYL                              |     |
| Betadine (FH)                                           |     | .Alimentary tract and metabolism ..... | 88  |
| .Repatriation Schedule .....                            | 716 | .Alimentary tract and metabolism ..... | 89  |
| Betadine Antiseptic Liquid (FH)                         |     | .Palliative Care .....                 | 456 |
| .Repatriation Schedule .....                            | 690 | .Palliative Care .....                 | 458 |
| Betaferon (SC) .....                                    | 251 | Bisalax (AS)                           |     |
| Betagan (AG) .....                                      | 425 | .Alimentary tract and metabolism ..... | 88  |
| Betaloc (AP) .....                                      | 124 | .Palliative Care .....                 | 456 |
| BETAMETHASONE ACETATE WITH                              |     | BISOPROLOL FUMARATE .....              | 123 |
| BETAMETHASONE SODIUM PHOSPHATE                          |     | BIVALIRUDIN TRIFLUOROACETATE .....     | 111 |
| .Systemic hormonal preparations, excl. sex hormones and |     | Blenamax (SI)                          |     |
| insulins .....                                          | 179 | .Special Pharmaceutical Benefits ..... | 72  |
| .Dental .....                                           | 476 | Blenoxane (BQ)                         |     |
| BETAMETHASONE DIPROPIONATE .....                        | 159 | .Special Pharmaceutical Benefits ..... | 72  |
| BETAMETHASONE VALERATE                                  |     | BLEOMYCIN SULFATE                      |     |
| .Dermatologicals .....                                  | 159 | .Special Pharmaceutical Benefits ..... | 72  |
| .Repatriation Schedule .....                            | 689 | Bleph 10 (AG)                          |     |
| Betamin (SW)                                            |     | .Sensory organs .....                  | 422 |
| .Alimentary tract and metabolism .....                  | 104 | .Optometrical .....                    | 501 |
| .Repatriation Schedule .....                            | 682 | Bondronat (HH)                         |     |
| BETAXOLOL HYDROCHLORIDE .....                           | 425 | .Section 100 .....                     | 547 |
| BETHANECHOL CHLORIDE .....                              | 405 | Bonefos (SC) .....                     | 348 |

## GENERIC/PROPRIETARY INDEX

|                                                                      |     |                                                             |     |
|----------------------------------------------------------------------|-----|-------------------------------------------------------------|-----|
| <i>Bonefos 800 mg (SC)</i> .....                                     | 348 | <i>.Respiratory system</i> .....                            | 413 |
| <b>BORTEZOMIB</b> .....                                              | 239 | <i>Butamol 5 (AW)</i> .....                                 |     |
| <b>BOSENTAN MONOHYDRATE</b> .....                                    |     | <i>.Doctor's Bag Supplies</i> .....                         | 71  |
| <i>.Section 100</i> .....                                            | 515 | <i>.Respiratory system</i> .....                            | 413 |
| <i>Botox (AG)</i> .....                                              |     |                                                             |     |
| <i>.Section 100</i> .....                                            | 633 |                                                             |     |
| <b>BOTULINUM TOXIN TYPE A PURIFIED NEUROTOXIN COMPLEX</b> .....      |     |                                                             |     |
| <i>.Section 100</i> .....                                            | 633 |                                                             |     |
| <i>Brevinor (PH)</i> .....                                           | 165 |                                                             |     |
| <i>Brevinor-1 (PH)</i> .....                                         | 165 |                                                             |     |
| <i>Bricanyl (AP)</i> .....                                           |     |                                                             |     |
| <i>.Doctor's Bag Supplies</i> .....                                  | 71  |                                                             |     |
| <i>.Respiratory system</i> .....                                     | 420 |                                                             |     |
| <i>Bricanyl Respules (AP)</i> .....                                  | 414 |                                                             |     |
| <i>Bricanyl Turbuhaler (AP)</i> .....                                | 414 |                                                             |     |
| <b>BRIMONIDINE TARTRATE</b> .....                                    | 424 |                                                             |     |
| <b>BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE</b> .....               | 424 |                                                             |     |
| <b>BRINZOLAMIDE</b> .....                                            | 425 |                                                             |     |
| <i>BrinzoQuin (IQ)</i> .....                                         | 425 |                                                             |     |
| <b>BROMAZEPAM</b> .....                                              |     |                                                             |     |
| <i>.Repatriation Schedule</i> .....                                  | 700 |                                                             |     |
| <b>BROMOCRIPTINE MESYLATE</b> .....                                  |     |                                                             |     |
| <i>.Genito urinary system and sex hormones</i> .....                 | 163 |                                                             |     |
| <i>.Nervous system</i> .....                                         | 375 |                                                             |     |
| <i>Brufen (AB)</i> .....                                             |     |                                                             |     |
| <i>.Musculo-skeletal system</i> .....                                | 341 |                                                             |     |
| <i>.Palliative Care</i> .....                                        | 462 |                                                             |     |
| <i>.Dental</i> .....                                                 | 490 |                                                             |     |
| <i>BSN 2902165 (BV)</i> .....                                        |     |                                                             |     |
| <i>.Repatriation Schedule</i> .....                                  | 720 |                                                             |     |
| <i>Budamax Aqueous (PM)</i> .....                                    |     |                                                             |     |
| <i>.Repatriation Schedule</i> .....                                  | 702 |                                                             |     |
| <b>BUDESONIDE</b> .....                                              |     |                                                             |     |
| <i>.Respiratory system</i> .....                                     | 417 |                                                             |     |
| <i>.Repatriation Schedule</i> .....                                  | 702 |                                                             |     |
| <b>BUDESONIDE WITH EFORMOTEROL FUMARATE DIHYDRATE</b> .....          | 414 |                                                             |     |
| <b>BUPRENORPHINE</b> .....                                           | 361 |                                                             |     |
| <b>BUPRENORPHINE HYDROCHLORIDE</b> .....                             |     |                                                             |     |
| <i>.Section 100</i> .....                                            | 637 |                                                             |     |
| <b>BUPRENORPHINE HYDROCHLORIDE WITH NALOXONE HYDROCHLORIDE</b> ..... |     |                                                             |     |
| <i>.Section 100</i> .....                                            | 638 |                                                             |     |
| <b>BUPROPION HYDROCHLORIDE</b> .....                                 | 406 |                                                             |     |
| <i>Bupropion-RL (RE)</i> .....                                       | 406 |                                                             |     |
| <i>Buscopan (BY)</i> .....                                           |     |                                                             |     |
| <i>.Doctor's Bag Supplies</i> .....                                  | 70  |                                                             |     |
| <i>.Palliative Care</i> .....                                        | 455 |                                                             |     |
| <i>.Repatriation Schedule</i> .....                                  | 681 |                                                             |     |
| <i>Buspar (BQ)</i> .....                                             |     |                                                             |     |
| <i>.Repatriation Schedule</i> .....                                  | 700 |                                                             |     |
| <b>BUSPIRONE HYDROCHLORIDE</b> .....                                 |     |                                                             |     |
| <i>.Repatriation Schedule</i> .....                                  | 700 |                                                             |     |
| <b>BUSULFAN</b> .....                                                | 211 |                                                             |     |
| <i>Butamol 2.5 (AW)</i> .....                                        |     |                                                             |     |
| <i>.Doctor's Bag Supplies</i> .....                                  | 71  |                                                             |     |
|                                                                      |     |                                                             |     |
|                                                                      |     | <b>C</b>                                                    |     |
|                                                                      |     | <i>Cabaser (PU)</i> .....                                   | 376 |
|                                                                      |     | <b>CABERGOLINE</b> .....                                    |     |
|                                                                      |     | <i>.Genito urinary system and sex hormones</i> .....        | 163 |
|                                                                      |     | <i>.Nervous system</i> .....                                | 376 |
|                                                                      |     | <i>Caduet 10/10 (PF)</i> .....                              | 154 |
|                                                                      |     | <i>Caduet 10/20 (PF)</i> .....                              | 154 |
|                                                                      |     | <i>Caduet 10/40 (PF)</i> .....                              | 154 |
|                                                                      |     | <i>Caduet 10/80 (PF)</i> .....                              | 154 |
|                                                                      |     | <i>Caduet 5/10 (PF)</i> .....                               | 154 |
|                                                                      |     | <i>Caduet 5/20 (PF)</i> .....                               | 154 |
|                                                                      |     | <i>Caduet 5/40 (PF)</i> .....                               | 154 |
|                                                                      |     | <i>Caduet 5/80 (PF)</i> .....                               | 154 |
|                                                                      |     | <i>Caelyx (SH)</i> .....                                    |     |
|                                                                      |     | <i>.Antineoplastic and immunomodulating agents</i> .....    | 218 |
|                                                                      |     | <i>.Section 100</i> .....                                   | 532 |
|                                                                      |     | <b>CALCIPOTRIOL</b> .....                                   | 157 |
|                                                                      |     | <b>CALCITRIOL</b> .....                                     |     |
|                                                                      |     | <i>.Alimentary tract and metabolism</i> .....               | 104 |
|                                                                      |     | <i>.Musculo-skeletal system</i> .....                       | 352 |
|                                                                      |     | <i>Calcitriol-DP (GM)</i> .....                             |     |
|                                                                      |     | <i>.Alimentary tract and metabolism</i> .....               | 104 |
|                                                                      |     | <i>.Musculo-skeletal system</i> .....                       | 352 |
|                                                                      |     | <b>CALCIUM</b> .....                                        |     |
|                                                                      |     | <i>.Alimentary tract and metabolism</i> .....               | 105 |
|                                                                      |     | <i>.Repatriation Schedule</i> .....                         | 683 |
|                                                                      |     | <b>CALCIUM CARBONATE WITH GLYCINE</b> .....                 |     |
|                                                                      |     | <i>.Repatriation Schedule</i> .....                         | 680 |
|                                                                      |     | <b>CALCIUM FOLINATE</b> .....                               | 436 |
|                                                                      |     | <i>Calcium Folate Ebewe (IT)</i> .....                      | 436 |
|                                                                      |     | <i>Calmurid (OL)</i> .....                                  |     |
|                                                                      |     | <i>.Repatriation Schedule</i> .....                         | 687 |
|                                                                      |     | <i>Cal-Sup (IA)</i> .....                                   |     |
|                                                                      |     | <i>.Alimentary tract and metabolism</i> .....               | 105 |
|                                                                      |     | <i>.Repatriation Schedule</i> .....                         | 683 |
|                                                                      |     | <i>Calutex (SI)</i> .....                                   | 246 |
|                                                                      |     | <i>Campral (AF)</i> .....                                   | 407 |
|                                                                      |     | <i>Camptosar (PU)</i> .....                                 | 243 |
|                                                                      |     | <b>CANDESARTAN CILEXETIL</b> .....                          | 140 |
|                                                                      |     | <b>CANDESARTAN CILEXETIL WITH HYDROCHLOROTHIAZIDE</b> ..... | 141 |
|                                                                      |     | <i>Canesten (BN)</i> .....                                  |     |
|                                                                      |     | <i>.Dermatologicals</i> .....                               | 155 |
|                                                                      |     | <i>.Repatriation Schedule</i> .....                         | 685 |
|                                                                      |     | <i>.Repatriation Schedule</i> .....                         | 692 |
|                                                                      |     | <i>Canesten 1 (BN)</i> .....                                |     |
|                                                                      |     | <i>.Repatriation Schedule</i> .....                         | 692 |
|                                                                      |     | <i>Canesten 3 (BN)</i> .....                                |     |
|                                                                      |     | <i>.Repatriation Schedule</i> .....                         | 693 |
|                                                                      |     | <b>CAPECITABINE</b> .....                                   | 214 |
|                                                                      |     | <i>Capoten (BQ)</i> .....                                   | 130 |

## GENERIC/PROPRIETARY INDEX

|                                                                       |     |                                                                               |     |
|-----------------------------------------------------------------------|-----|-------------------------------------------------------------------------------|-----|
| <i>Caprilon (SB)</i> .....                                            | 445 | <i>.Dental</i> .....                                                          | 485 |
| <i>Captohexal (SZ)</i> .....                                          | 130 | <i>Ceclor CD (AS)</i> .....                                                   |     |
| <i>CAPTOPRIL</i> .....                                                | 130 | <i>.Antiinfectives for systemic use</i> .....                                 | 194 |
| <i>Carafate (AS)</i> .....                                            | 83  | <i>.Dental</i> .....                                                          | 484 |
| <b>CARBAMAZEPINE</b>                                                  |     | <b>CEFACLOR</b>                                                               |     |
| <i>.Nervous system</i> .....                                          | 368 | <i>.Antiinfectives for systemic use</i> .....                                 | 194 |
| <i>.Dental</i> .....                                                  | 497 | <i>.Dental</i> .....                                                          | 484 |
| <i>Carbamazepine Sandoz (SZ)</i>                                      |     | <i>Cefaclor Sandoz (SZ)</i>                                                   |     |
| <i>.Nervous system</i> .....                                          | 368 | <i>.Antiinfectives for systemic use</i> .....                                 | 194 |
| <i>.Dental</i> .....                                                  | 497 | <i>.Dental</i> .....                                                          | 485 |
| <b>CARBAMIDE PEROXIDE</b>                                             |     | <i>Cefalexin Sandoz (SZ)</i>                                                  |     |
| <i>.Repatriation Schedule</i> .....                                   | 704 | <i>.Antiinfectives for systemic use</i> .....                                 | 192 |
| <b>CARBIMAZOLE</b> .....                                              | 182 | <i>.Dental</i> .....                                                          | 483 |
| <i>CarboFLEX 403202 (CC)</i>                                          |     | <b>CEFALOTIN</b>                                                              |     |
| <i>.Repatriation Schedule</i> .....                                   | 713 | <i>.Antiinfectives for systemic use</i> .....                                 | 192 |
| <i>CarboFLEX 403204 (CC)</i>                                          |     | <i>.Dental</i> .....                                                          | 483 |
| <i>.Repatriation Schedule</i> .....                                   | 713 | <i>Cefalotin Sandoz (SZ)</i>                                                  |     |
| <b>CARBOHYDRATE, FAT, VITAMINS, MINERALS AND TRACE ELEMENTS</b> ..... | 450 | <i>.Antiinfectives for systemic use</i> .....                                 | 192 |
| <i>Carbohydrate Free Mixture (SB)</i> .....                           | 451 | <i>.Dental</i> .....                                                          | 483 |
| <b>CARBOMER 974</b>                                                   |     | <i>Cefazolin Sandoz (SZ)</i> .....                                            | 193 |
| <i>.Sensory organs</i> .....                                          | 430 | <b>CEFEPIME</b> .....                                                         | 196 |
| <i>.Optometrical</i> .....                                            | 502 | <b>CEFOTAXIME</b>                                                             |     |
| <b>CARBOMER 980</b>                                                   |     | <i>.Antiinfectives for systemic use</i> .....                                 | 195 |
| <i>.Sensory organs</i> .....                                          | 430 | <i>.Dental</i> .....                                                          | 485 |
| <i>.Optometrical</i> .....                                            | 502 | <i>Cefotaxime Sandoz (SZ)</i>                                                 |     |
| <b>CARBOPLATIN</b> .....                                              | 219 | <i>.Antiinfectives for systemic use</i> .....                                 | 195 |
| <i>Carboplatin Ebewe (IT)</i> .....                                   | 219 | <i>.Dental</i> .....                                                          | 485 |
| <i>Cardinorm (SZ)</i> .....                                           | 115 | <b>CEFTRIAXONE</b> .....                                                      | 195 |
| <i>Cardiprin 100 (RC)</i>                                             |     | <i>Ceftriaxone ICP (IZ)</i> .....                                             | 195 |
| <i>.Repatriation Schedule</i> .....                                   | 683 | <i>Ceftriaxone Sandoz (SZ)</i> .....                                          | 195 |
| <i>Cardizem (SW)</i> .....                                            | 129 | <b>CEFUROXIME AXETIL</b>                                                      |     |
| <i>Cardizem CD (SW)</i> .....                                         | 129 | <i>.Antiinfectives for systemic use</i> .....                                 | 194 |
| <i>Cardol (AF)</i>                                                    |     | <i>.Dental</i> .....                                                          | 485 |
| <i>.Cardiovascular system</i> .....                                   | 115 | <i>Celapram (AF)</i> .....                                                    | 387 |
| <i>.Cardiovascular system</i> .....                                   |     | <i>Celebrex (PH)</i> .....                                                    | 343 |
| <i>CareSens (LB)</i> .....                                            | 438 | <b>CELECOXIB</b> .....                                                        | 343 |
| <b>CARMELLOSE SODIUM</b>                                              |     | <i>Celestone Chronodose (SH)</i>                                              |     |
| <i>.Sensory organs</i> .....                                          | 431 | <i>.Systemic hormonal preparations, excl. sex hormones and insulins</i> ..... | 179 |
| <i>.Palliative Care</i> .....                                         | 454 | <i>.Dental</i> .....                                                          | 476 |
| <i>.Optometrical</i> .....                                            | 502 | <i>Celestone-M (SH)</i> .....                                                 | 159 |
| <i>.Repatriation Schedule</i> .....                                   | 680 | <i>Celica (RA)</i> .....                                                      | 387 |
| <b>CARMELLOSE SODIUM WITH PECTIN AND GELATIN</b>                      |     | <i>CellCept (RO)</i>                                                          |     |
| <i>.Repatriation Schedule</i> .....                                   | 687 | <i>.Antineoplastic and immunomodulating agents</i> .....                      | 264 |
| <b>CARMUSTINE</b> .....                                               | 212 | <i>.Section 100</i> .....                                                     | 602 |
| <i>Cartia (GK)</i>                                                    |     | <i>Cellufresh (AG)</i>                                                        |     |
| <i>.Repatriation Schedule</i> .....                                   | 683 | <i>.Sensory organs</i> .....                                                  | 431 |
| <b>CARVEDILOL</b> .....                                               | 125 | <i>.Optometrical</i> .....                                                    | 503 |
| <i>Catapres (BY)</i> .....                                            | 118 | <i>Celluvisc (AG)</i>                                                         |     |
| <i>Catapres 100 (BY)</i> .....                                        | 118 | <i>.Sensory organs</i> .....                                                  | 431 |
| <b>CATIONIC CONDITIONER WITH PANTHENOL</b>                            |     | <i>.Optometrical</i> .....                                                    | 503 |
| <i>.Repatriation Schedule</i> .....                                   | 691 | <i>Cephabeil (BF)</i>                                                         |     |
| <i>Caverject Impulse (PH)</i>                                         |     | <i>.Antiinfectives for systemic use</i> .....                                 | 192 |
| <i>.Repatriation Schedule</i> .....                                   | 694 | <i>.Dental</i> .....                                                          | 483 |
| <i>Cavicare 4563 (SN)</i>                                             |     | <b>CEPHALEXIN</b>                                                             |     |
| <i>.Repatriation Schedule</i> .....                                   | 715 | <i>.Antiinfectives for systemic use</i> .....                                 | 192 |
| <i>Ceclor (AS)</i>                                                    |     | <i>.Dental</i> .....                                                          | 483 |
| <i>.Antiinfectives for systemic use</i> .....                         | 194 | <i>Cephalexin Max (XF)</i>                                                    |     |

## GENERIC/PROPRIETARY INDEX

|                                                             |     |                                                                   |     |
|-------------------------------------------------------------|-----|-------------------------------------------------------------------|-----|
| .Antiinfectives for systemic use .....                      | 192 | .Repatriation Schedule .....                                      | 693 |
| .Dental .....                                               | 483 | <i>Chem mart Clotrimazole 6 Day Cream (CH)</i> .....              |     |
| <i>Cephadrust 250 (MI)</i> .....                            |     | .Repatriation Schedule .....                                      | 692 |
| .Antiinfectives for systemic use .....                      | 192 | <i>Chem mart Diclofenac (CH)</i> .....                            |     |
| .Dental .....                                               | 483 | .Musculo-skeletal system .....                                    | 338 |
| <i>Cephadrust 500 (MI)</i> .....                            |     | .Palliative Care .....                                            | 460 |
| .Antiinfectives for systemic use .....                      | 193 | .Dental .....                                                     | 488 |
| .Dental .....                                               | 483 | <i>Chem mart Diltiazem (CH)</i> .....                             | 129 |
| <b>CEPHAZOLIN</b> .....                                     | 193 | <i>Chem mart Diltiazem CD (CH)</i> .....                          | 129 |
| <i>Certican (NV)</i> .....                                  |     | <i>Chem mart Doxycycline (CH)</i> .....                           |     |
| .Antineoplastic and immunomodulating agents .....           | 263 | .Antiinfectives for systemic use .....                            | 184 |
| .Section 100 .....                                          | 545 | .Dental .....                                                     | 477 |
| <i>Cerumol (AC)</i> .....                                   |     | <i>Chem mart Enalapril (CH)</i> .....                             | 131 |
| .Repatriation Schedule .....                                | 704 | <i>Chem mart Famotidine (CH)</i> .....                            | 76  |
| <b>CETIRIZINE HYDROCHLORIDE</b> .....                       |     | <i>Chem mart Fluoxetine (CH)</i> .....                            | 389 |
| .Repatriation Schedule .....                                | 703 | <i>Chem mart Frusemide (CH)</i> .....                             | 120 |
| <b>CETUXIMAB</b> .....                                      | 221 | <i>Chem mart Gemfibrozil (CH)</i> .....                           | 151 |
| <i>C-Flox 250 (AL)</i> .....                                | 199 | <i>Chem mart Gliclazide (CH)</i> .....                            | 98  |
| <i>C-Flox 500 (AL)</i> .....                                | 200 | <i>Chem mart Indapamide (CH)</i> .....                            | 120 |
| <i>C-Flox 750 (AL)</i> .....                                | 200 | <i>Chem mart Ipratropium (CH)</i> .....                           | 418 |
| <i>Champix (PF)</i> .....                                   | 407 | <i>Chem mart Isosorbide Mononitrate (CH)</i> .....                | 117 |
| <i>Chem mart Aciclovir (CH)</i> .....                       | 206 | <i>Chem mart Isotretinoin (CH)</i> .....                          | 161 |
| <i>Chem mart Alendronate 70mg (CH)</i> .....                | 346 | <i>Chem mart Lisinopril (CH)</i> .....                            | 133 |
| <i>Chem mart Allopurinol (CH)</i> .....                     | 345 | <i>Chem mart Meloxicam 15 mg (CH)</i> .....                       | 340 |
| <i>Chem mart Alprazolam (CH)</i> .....                      | 382 | <i>Chem mart Meloxicam 7.5 mg (CH)</i> .....                      | 339 |
| <i>Chem mart Amiodarone (CH)</i> .....                      | 115 | <i>Chem mart Metformin (CH)</i> .....                             | 97  |
| <i>Chem mart Amlodipine (CH)</i> .....                      | 126 | <i>Chem mart Metoprolol (CH)</i> .....                            | 124 |
| <i>Chem mart Amoxycillin (CH)</i> .....                     |     | <i>Chem mart Mirtazapine (CH)</i> .....                           | 393 |
| .Antiinfectives for systemic use .....                      | 186 | <i>Chem mart Moclobemide (CH)</i> .....                           | 392 |
| .Dental .....                                               | 478 | <i>Chem mart Nifedipine (CH)</i> .....                            | 128 |
| <i>Chem mart Amoxycillin and Clavulanic Acid (CH)</i> ..... |     | <i>Chem mart Norfloxacin (CH)</i> .....                           | 200 |
| .Antiinfectives for systemic use .....                      | 191 | <i>Chem mart Paroxetine (CH)</i> .....                            | 390 |
| .Dental .....                                               | 482 | <i>Chem mart Perindopril/ Indapamide 4/1.25 (CH)</i> .....        | 139 |
| <i>Chem mart Atenolol (CH)</i> .....                        | 123 | <i>Chem mart Perindopril (CH)</i> .....                           | 134 |
| <i>Chem mart Baclofen (CH)</i> .....                        | 344 | <i>Chem mart Piroxicam (CH)</i> .....                             |     |
| <i>Chem mart Captopril (CH)</i> .....                       | 130 | .Musculo-skeletal system .....                                    | 341 |
| <i>Chem mart Carvedilol 12.5 mg (CH)</i> .....              | 125 | .Dental .....                                                     | 490 |
| <i>Chem mart Carvedilol 25 mg (CH)</i> .....                | 126 | <i>Chem mart Piroxicam Dispersible (CH)</i> .....                 |     |
| <i>Chem mart Carvedilol 3.125 mg (CH)</i> .....             | 125 | .Musculo-skeletal system .....                                    | 340 |
| <i>Chem mart Carvedilol 6.25 mg (CH)</i> .....              | 125 | .Dental .....                                                     | 490 |
| <i>Chem mart Cefaclor (CH)</i> .....                        |     | <i>Chem mart Pravastatin (CH)</i> .....                           | 147 |
| .Antiinfectives for systemic use .....                      | 194 | <i>Chem mart Prazosin (CH)</i> .....                              | 118 |
| .Dental .....                                               | 485 | <i>Chem mart Ranitidine (CH)</i> .....                            | 77  |
| <i>Chem mart Cefaclor CD (CH)</i> .....                     |     | <i>Chem mart Salbutamol (CH)</i> .....                            |     |
| .Antiinfectives for systemic use .....                      | 194 | .Doctor's Bag Supplies .....                                      | 71  |
| .Dental .....                                               | 484 | .Respiratory system .....                                         | 413 |
| <i>Chem mart Cephalexin (CH)</i> .....                      |     | <i>Chem mart Sertraline (CH)</i> .....                            | 390 |
| .Antiinfectives for systemic use .....                      | 192 | <i>Chem mart Simvastatin (CH)</i> .....                           | 149 |
| .Dental .....                                               | 483 | <i>Chem mart Sotalol (CH)</i> .....                               |     |
| <i>Chem mart Chemadol (CH)</i> .....                        |     | .Cardiovascular system .....                                      | 115 |
| .Nervous system .....                                       | 364 | .Cardiovascular system .....                                      |     |
| .Dental .....                                               | 496 | <i>Chem mart Tamoxifen (CH)</i> .....                             | 246 |
| <i>Chem mart Citalopram (CH)</i> .....                      | 387 | <i>Chem mart Tramadol (CH)</i> .....                              |     |
| <i>Chem mart Clarithromycin (CH)</i> .....                  | 197 | .Nervous system .....                                             | 362 |
| <i>Chem mart Clomipramine (CH)</i> .....                    |     | .Dental .....                                                     | 495 |
| .Nervous system .....                                       | 384 | <i>Chem mart Trimethoprim with Sulfamethoxazole DS (CH)</i> ..... |     |
| .Nervous system .....                                       | 386 | .Antiinfectives for systemic use .....                            | 196 |
| <i>Chem mart Clotrimazole 3 Day Cream (CH)</i> .....        |     | .Dental .....                                                     | 486 |



## GENERIC/PROPRIETARY INDEX

|                                                   |     |                                                                           |     |
|---------------------------------------------------|-----|---------------------------------------------------------------------------|-----|
| CHLORAMBUCIL .....                                | 211 | .Dental .....                                                             | 479 |
| CHLORAMPHENICOL .....                             |     | <i>CiloQuin (IQ)</i> .....                                                | 423 |
| .Sensory organs .....                             | 422 | <i>Ciloxan (AQ)</i> .....                                                 |     |
| .Sensory organs .....                             | 433 | .Sensory organs .....                                                     | 423 |
| .Dental .....                                     | 499 | .Sensory organs .....                                                     | 433 |
| .Optometrical .....                               | 501 | CIMETIDINE .....                                                          | 76  |
| CHLORHEXIDINE GLUCONATE .....                     |     | CINACALCET HYDROCHLORIDE .....                                            |     |
| .Repatriation Schedule .....                      | 680 | .Systemic hormonal preparations, excl. sex hormones and<br>insulins ..... | 183 |
| <i>Chloromycetin (PF)</i> .....                   |     | .Section 100 .....                                                        | 526 |
| .Sensory organs .....                             | 422 | <i>Cipramil (LU)</i> .....                                                | 387 |
| .Sensory organs .....                             | 433 | CIPROFLOXACIN .....                                                       |     |
| .Dental .....                                     | 499 | .Anti-infectives for systemic use .....                                   | 199 |
| .Optometrical .....                               | 501 | .Sensory organs .....                                                     | 423 |
| CHLORPROMAZINE HYDROCHLORIDE .....                |     | .Sensory organs .....                                                     | 433 |
| .Doctor's Bag Supplies .....                      | 69  | <i>Ciprofloxacin 500 (CR)</i> .....                                       | 200 |
| .Nervous system .....                             | 377 | <i>Ciprofloxacin 750 (CR)</i> .....                                       | 200 |
| <i>Chlorsig (SI)</i> .....                        |     | <i>Ciprofloxacin-BW (BF)</i> .....                                        | 200 |
| .Sensory organs .....                             | 422 | CIPROFLOXACIN HYDROCHLORIDE WITH<br>HYDROCORTISONE .....                  |     |
| .Dental .....                                     | 499 | .Repatriation Schedule .....                                              | 704 |
| .Optometrical .....                               | 501 | <i>Ciprol 250 (AW)</i> .....                                              | 199 |
| CHLORTHALIDONE .....                              | 119 | <i>Ciprol 500 (AW)</i> .....                                              | 200 |
| <i>Chlorvescent (AS)</i> .....                    | 105 | <i>Ciprol 750 (AW)</i> .....                                              | 200 |
| CHOLESTYRAMINE .....                              | 151 | <i>Ciproxin 250 (BN)</i> .....                                            | 199 |
| <i>Cholstat 10 (AF)</i> .....                     | 147 | <i>Ciproxin 500 (BN)</i> .....                                            | 200 |
| <i>Cholstat 20 (AF)</i> .....                     | 147 | <i>Ciproxin 750 (BN)</i> .....                                            | 200 |
| <i>Cholstat 40 (AF)</i> .....                     | 148 | <i>Ciproxin HC (AQ)</i> .....                                             |     |
| CHORIOGNADOTROPIN ALFA .....                      |     | .Repatriation Schedule .....                                              | 704 |
| .Section 100 .....                                | 636 | CISPLATIN .....                                                           | 220 |
| <i>Cialis (LY)</i> .....                          |     | <i>Cisplatin Ebewe (IT)</i> .....                                         | 220 |
| .Repatriation Schedule .....                      | 694 | <i>Citalobell (BF)</i> .....                                              | 387 |
| <i>Ciazil (GM)</i> .....                          | 387 | <i>Citalopram 20 (CR)</i> .....                                           | 387 |
| CICLESONIDE .....                                 | 417 | CITALOPRAM HYDROBROMIDE .....                                             | 387 |
| CICLOPIROX OLAMINE .....                          |     | <i>Citalopram Winthrop (WA)</i> .....                                     | 387 |
| .Repatriation Schedule .....                      | 686 | <i>Citracal (BN)</i> .....                                                |     |
| <i>Cicloral (SZ)</i> .....                        |     | .Alimentary tract and metabolism .....                                    | 105 |
| .Antineoplastic and immunomodulating agents ..... | 336 | .Repatriation Schedule .....                                              | 683 |
| .Section 100 .....                                | 528 | <i>Citrihexal (HX)</i> .....                                              |     |
| CIDOFOVIR .....                                   |     | .Alimentary tract and metabolism .....                                    | 104 |
| .Section 100 .....                                | 526 | .Musculo-skeletal system .....                                            | 352 |
| <i>Cifran (RA)</i> .....                          | 199 | CLADRIBINE .....                                                          | 214 |
| <i>Cilamox (SI)</i> .....                         |     | <i>Clamohexal 125mg/31.25mg/5mL (HX)</i> .....                            |     |
| .Anti-infectives for systemic use .....           | 186 | .Anti-infectives for systemic use .....                                   | 191 |
| .Dental .....                                     | 478 | .Dental .....                                                             | 482 |
| <i>Cilex (GM)</i> .....                           |     | <i>Clamohexal Duo 400mg/57mg/5mL (HX)</i> .....                           |     |
| .Anti-infectives for systemic use .....           | 192 | .Anti-infectives for systemic use .....                                   | 191 |
| .Dental .....                                     | 483 | .Dental .....                                                             | 482 |
| <i>Cilicaine (SI)</i> .....                       |     | <i>Clamohexal Duo 500mg/125mg (HX)</i> .....                              |     |
| .Doctor's Bag Supplies .....                      | 69  | .Anti-infectives for systemic use .....                                   | 190 |
| .Anti-infectives for systemic use .....           | 189 | .Dental .....                                                             | 481 |
| .Dental .....                                     | 480 | <i>Clamohexal Duo Forte 875mg/125mg (HX)</i> .....                        |     |
| <i>Cilicaine V (FM)</i> .....                     |     | .Anti-infectives for systemic use .....                                   | 191 |
| .Anti-infectives for systemic use .....           | 188 | .Dental .....                                                             | 482 |
| .Dental .....                                     | 480 | <i>Clamoxyl (AL)</i> .....                                                |     |
| <i>Cilicaine VK (FM)</i> .....                    |     | .Anti-infectives for systemic use .....                                   | 191 |
| .Anti-infectives for systemic use .....           | 188 | .Dental .....                                                             | 482 |
| .Dental .....                                     | 479 | <i>Clamoxyl Duo (AL)</i> .....                                            |     |
| <i>Cilopen VK (GM)</i> .....                      |     |                                                                           |     |
| .Anti-infectives for systemic use .....           | 188 |                                                                           |     |

## GENERIC/PROPRIETARY INDEX

|                                        |     |                                                                    |     |
|----------------------------------------|-----|--------------------------------------------------------------------|-----|
| .Antiinfectives for systemic use ..... | 190 | .Dental .....                                                      | 488 |
| .Dental .....                          | 481 | <i>Clonac 50 (AW)</i> .....                                        |     |
| <i>Clamoxyl Duo 400 (AL)</i> .....     |     | .Musculo-skeletal system .....                                     | 338 |
| .Antiinfectives for systemic use ..... | 191 | .Palliative Care .....                                             | 460 |
| .Dental .....                          | 482 | .Dental .....                                                      | 489 |
| <i>Clamoxyl Duo forte (AL)</i> .....   |     | CLONAZEPAM .....                                                   |     |
| .Antiinfectives for systemic use ..... | 191 | .Doctor's Bag Supplies .....                                       | 69  |
| .Dental .....                          | 482 | .Nervous system .....                                              | 367 |
| <i>Clarac (GM)</i> .....               | 197 | .Palliative Care .....                                             | 469 |
| <i>Claratyne (SH)</i> .....            |     | <i>Clonea (AF)</i> .....                                           |     |
| .Repatriation Schedule .....           | 703 | .Repatriation Schedule .....                                       | 685 |
| <i>Clarihexal (SZ)</i> .....           | 197 | CLONIDINE .....                                                    | 118 |
| <i>Clarithro 250 (AW)</i> .....        | 197 | CLOPIDOGREL HYDROGEN SULFATE .....                                 |     |
| CLARITHROMYCIN .....                   |     | .Blood and blood forming organs .....                              | 108 |
| .Antiinfectives for systemic use ..... | 197 | .Repatriation Schedule .....                                       | 684 |
| .Section 100 .....                     | 527 | <i>Clopine 100 (HH)</i> .....                                      |     |
| <i>Clavulin (ME)</i> .....             |     | .Section 100 .....                                                 | 527 |
| .Antiinfectives for systemic use ..... | 191 | <i>Clopine 200 (HH)</i> .....                                      |     |
| .Dental .....                          | 482 | .Section 100 .....                                                 | 527 |
| <i>Clavulin Duo (ME)</i> .....         |     | <i>Clopine 25 (HH)</i> .....                                       |     |
| .Antiinfectives for systemic use ..... | 190 | .Section 100 .....                                                 | 527 |
| .Dental .....                          | 481 | <i>Clopine 50 (HH)</i> .....                                       |     |
| <i>Clavulin Duo 400 (ME)</i> .....     |     | .Section 100 .....                                                 | 527 |
| .Antiinfectives for systemic use ..... | 191 | <i>Clopine Suspension (HH)</i> .....                               |     |
| .Dental .....                          | 482 | .Section 100 .....                                                 | 527 |
| <i>Clavulin Duo Forte (ME)</i> .....   |     | <i>Clopixol Depot (LU)</i> .....                                   | 378 |
| .Antiinfectives for systemic use ..... | 191 | <i>Clorprax (HX)</i> .....                                         | 406 |
| .Dental .....                          | 482 | CLOSTRIDIUM BOTULINUM TYPE A<br>TOXIN—HAEMAGGLUTININ COMPLEX ..... |     |
| <i>Clavycillin 875/125 (CR)</i> .....  |     | .Section 100 .....                                                 | 634 |
| .Antiinfectives for systemic use ..... | 191 | CLOTRIMAZOLE .....                                                 |     |
| .Dental .....                          | 482 | .Dermatologicals .....                                             | 155 |
| <i>Cleocin (KR)</i> .....              |     | .Repatriation Schedule .....                                       | 685 |
| .Antiinfectives for systemic use ..... | 198 | .Repatriation Schedule .....                                       | 692 |
| .Dental .....                          | 486 | CLOZAPINE .....                                                    |     |
| <i>Clexane (SW)</i> .....              | 107 | .Section 100 .....                                                 | 527 |
| <i>Climara 100 (SC)</i> .....          | 169 | <i>Clozaril 100 (NV)</i> .....                                     |     |
| <i>Climara 25 (SC)</i> .....           | 168 | .Section 100 .....                                                 | 527 |
| <i>Climara 50 (SC)</i> .....           | 168 | <i>Clozaril 25 (NV)</i> .....                                      |     |
| <i>Climara 75 (SC)</i> .....           | 168 | .Section 100 .....                                                 | 527 |
| CLINDAMYCIN .....                      |     | COAL TAR - PREPARED .....                                          | 157 |
| .Antiinfectives for systemic use ..... | 198 | <i>Coban 1584 (MM)</i> .....                                       |     |
| .Dental .....                          | 486 | .Repatriation Schedule .....                                       | 711 |
| <i>Clinistix (BN)</i> .....            | 437 | <i>Codalgin (FM)</i> .....                                         |     |
| <i>Clinitest (BN)</i> .....            | 437 | .Repatriation Schedule .....                                       | 699 |
| <i>Clobemix (GM)</i> .....             | 392 | <i>Codalgin Forte (FM)</i> .....                                   |     |
| <i>Clofeme (HX)</i> .....              |     | .Nervous system .....                                              | 354 |
| .Repatriation Schedule .....           | 692 | .Dental .....                                                      | 492 |
| <i>Clofen 10 (AF)</i> .....            | 344 | <i>Codapane Forte (AL)</i> .....                                   |     |
| <i>Clofen 25 (AF)</i> .....            | 344 | .Nervous system .....                                              | 354 |
| <i>Clomhexal (HX)</i> .....            | 175 | .Dental .....                                                      | 492 |
| <i>Clomid (SW)</i> .....               | 175 | CODEINE PHOSPHATE .....                                            |     |
| CLOMIPHENE CITRATE .....               | 175 | .Nervous system .....                                              | 354 |
| CLOMIPRAMINE HYDROCHLORIDE .....       |     | .Respiratory system .....                                          | 421 |
| .Nervous system .....                  | 384 | .Dental .....                                                      | 491 |
| .Nervous system .....                  | 386 | CODEINE PHOSPHATE WITH ASPIRIN .....                               |     |
| <i>Clonac 25 (AW)</i> .....            |     | .Repatriation Schedule .....                                       | 698 |
| .Musculo-skeletal system .....         | 338 | CODEINE PHOSPHATE WITH PARACETAMOL .....                           |     |
| .Palliative Care .....                 | 460 |                                                                    |     |

## GENERIC/PROPRIETARY INDEX

|                                                  |     |                                                  |     |
|--------------------------------------------------|-----|--------------------------------------------------|-----|
| .Nervous system .....                            | 354 | <i>Concerta (JC)</i> .....                       | 395 |
| .Dental .....                                    | 492 | <i>Concorz (SZ)</i> .....                        | 390 |
| .Repatriation Schedule .....                     | 699 | <i>Condylone Paint (HA)</i>                      |     |
| <i>Cogentin (FK)</i>                             |     | .Repatriation Schedule .....                     | 689 |
| .Doctor's Bag Supplies .....                     | 69  | <i>Contreet Foam Adhesive 9632 (CT)</i>          |     |
| .Nervous system .....                            | 374 | .Repatriation Schedule .....                     | 720 |
| .Dental .....                                    | 498 | <i>Contreet Foam Non-Adhesive 9622 (CT)</i>      |     |
| <i>Colazide (PK)</i> .....                       | 92  | .Repatriation Schedule .....                     | 720 |
| <b>COLCHICINE</b> .....                          | 345 | <i>Copaxone (SW)</i> .....                       | 252 |
| <i>Colese (AF)</i>                               |     | <i>Coplus 3629 (BV)</i>                          |     |
| .Repatriation Schedule .....                     | 680 | .Repatriation Schedule .....                     | 711 |
| <i>Colestid (PH)</i> .....                       | 151 | <b>COPPER SULFATE</b> .....                      | 437 |
| <b>COLESTIPOL HYDROCHLORIDE</b> .....            | 151 | <i>Coras (AF)</i> .....                          | 129 |
| <i>Colgout (AS)</i> .....                        | 345 | <i>Corbeton 20 (AF)</i> .....                    | 122 |
| <i>Colifoam (AS)</i> .....                       | 92  | <i>Corbeton 40 (AF)</i> .....                    | 122 |
| <i>Colofac (SM)</i>                              |     | <i>Cordarone X 100 (SW)</i> .....                | 115 |
| .Repatriation Schedule .....                     | 680 | <i>Cordarone X 200 (SW)</i> .....                | 115 |
| <i>Coloxyl 50 (FM)</i>                           |     | <i>Cordilox 180 SR (KN)</i> .....                | 129 |
| .Repatriation Schedule .....                     | 681 | <i>Cordilox SR (KN)</i> .....                    | 129 |
| <i>Coloxyl with Senna (FM)</i>                   |     | <i>Cortate (AS)</i> .....                        | 179 |
| .Repatriation Schedule .....                     | 681 | <i>Cortef (DT)</i>                               |     |
| <i>CombiDERM 651027 (CC)</i>                     |     | .Dermatologicals .....                           | 159 |
| .Repatriation Schedule .....                     | 716 | .Dental .....                                    | 476 |
| <i>CombiDERM 651031 (CC)</i>                     |     | <i>Cortic-DS 1% (FM)</i>                         |     |
| .Repatriation Schedule .....                     | 716 | .Dermatologicals .....                           | 159 |
| <i>Combigan (AG)</i> .....                       | 424 | .Dental .....                                    | 475 |
| <i>Combivir (GK)</i>                             |     | <b>CORTISONE ACETATE</b> .....                   | 179 |
| .Section 100 .....                               | 600 | <i>Cortival 1/2 (FM)</i> .....                   | 160 |
| <i>Comfarol Forte (SZ)</i>                       |     | <i>Cortival 1/5 (FM)</i> .....                   | 159 |
| .Nervous system .....                            | 354 | <i>Cosamide (AF)</i> .....                       | 246 |
| .Dental .....                                    | 492 | <i>Cosopt (MK)</i> .....                         | 425 |
| <i>Comfeel Paste 4701 (CT)</i>                   |     | <i>Cosudex (AP)</i> .....                        | 246 |
| .Repatriation Schedule .....                     | 717 | <i>Cotazym-S Forte (OR)</i> .....                | 95  |
| <i>Comfeel Plus Pressure Relieving 3350 (CT)</i> |     | <b>COTTON WOOL ROLL</b>                          |     |
| .Repatriation Schedule .....                     | 718 | .Repatriation Schedule .....                     | 713 |
| <i>Comfeel Plus Pressure Relieving 3353 (CT)</i> |     | <i>Coumadin (SI)</i> .....                       | 106 |
| .Repatriation Schedule .....                     | 718 | <i>Coversyl 10mg (SE)</i> .....                  | 135 |
| <i>Comfeel Plus Transparent 3530 (CT)</i>        |     | <i>Coversyl 2.5mg (SE)</i> .....                 | 134 |
| .Repatriation Schedule .....                     | 717 | <i>Coversyl 5mg (SE)</i> .....                   | 134 |
| <i>Comfeel Plus Transparent 3533 (CT)</i>        |     | <i>Coversyl Plus 5mg/1.25mg (SE)</i> .....       | 139 |
| .Repatriation Schedule .....                     | 717 | <i>Coversyl Plus LD 2.5mg/0.625mg (SE)</i> ..... | 138 |
| <i>Comfeel Plus Transparent 3536 (CT)</i>        |     | <i>Creon (SM)</i> .....                          | 94  |
| .Repatriation Schedule .....                     | 717 | <i>Creon 5000 (SM)</i> .....                     | 94  |
| <i>Comfeel Plus Ulcer Dressing 3110 (CT)</i>     |     | <i>Creon Forte (SM)</i> .....                    | 95  |
| .Repatriation Schedule .....                     | 718 | <i>Crestor (AP)</i> .....                        | 148 |
| <i>Comfeel Powder 4706 (CT)</i>                  |     | <i>Crinone 8% (SG)</i>                           |     |
| .Repatriation Schedule .....                     | 717 | .Section 100 .....                               | 637 |
| <i>Comfeel Purilon Gel 3900 (CT)</i>             |     | <i>Crixivan 100 mg (MK)</i>                      |     |
| .Repatriation Schedule .....                     | 719 | .Section 100 .....                               | 554 |
| <i>Comfeel SeaSorb Dressing 3705 (CT)</i>        |     | <i>Crixivan 200 mg (MK)</i>                      |     |
| .Repatriation Schedule .....                     | 713 | .Section 100 .....                               | 554 |
| <i>Comfeel SeaSorb Dressing 3710 (CT)</i>        |     | <i>Crixivan 400 mg (MK)</i>                      |     |
| .Repatriation Schedule .....                     | 713 | .Section 100 .....                               | 554 |
| <i>Comfeel SeaSorb Filler 3740 (CT)</i>          |     | <i>Cromolux (AE)</i>                             |     |
| .Repatriation Schedule .....                     | 713 | .Sensory organs .....                            | 427 |
| <i>Comprilan 1027 (BV)</i>                       |     | .Optometrical .....                              | 502 |
| .Repatriation Schedule .....                     | 710 | <i>Crysanal (MD)</i>                             |     |
| <i>Comtan (NV)</i> .....                         | 376 | .Musculo-skeletal system .....                   | 342 |

## GENERIC/PROPRIETARY INDEX

|                                                                           |     |
|---------------------------------------------------------------------------|-----|
| .Palliative Care .....                                                    | 464 |
| .Dental .....                                                             | 491 |
| <i>Curam 500/125 (SZ)</i>                                                 |     |
| .Anti-infectives for systemic use .....                                   | 190 |
| .Dental .....                                                             | 481 |
| <i>Curam 875/125 (SZ)</i>                                                 |     |
| .Anti-infectives for systemic use .....                                   | 191 |
| .Dental .....                                                             | 482 |
| <i>Curity 4112 (KE)</i>                                                   |     |
| .Repatriation Schedule .....                                              | 715 |
| <i>Cutifilm Plus 76308 (SN)</i>                                           |     |
| .Repatriation Schedule .....                                              | 714 |
| <i>Cutifilm Plus 76309 (SN)</i>                                           |     |
| .Repatriation Schedule .....                                              | 714 |
| <i>Cutilin Non-Stick Wound Pad 76300 (SN)</i>                             |     |
| .Repatriation Schedule .....                                              | 720 |
| <i>Cutilin Non-Stick Wound Pad 76301 (SN)</i>                             |     |
| .Repatriation Schedule .....                                              | 719 |
| <i>Cutinova Hydro 66047441 (SN)</i>                                       |     |
| .Repatriation Schedule .....                                              | 717 |
| <i>Cutinova Hydro 66047443 (SN)</i>                                       |     |
| .Repatriation Schedule .....                                              | 717 |
| <i>Cycloblastin (PH)</i>                                                  | 211 |
| <b>CYCLOPHOSPHAMIDE</b>                                                   | 211 |
| <b>CYCLOSPORIN</b>                                                        |     |
| .Antineoplastic and immunomodulating agents .....                         | 335 |
| .Section 100 .....                                                        | 527 |
| <i>Cyklokapron (PH)</i>                                                   | 111 |
| <i>Cymbalta (LY)</i>                                                      | 392 |
| <i>Cymevene (RO)</i>                                                      |     |
| .Section 100 .....                                                        | 547 |
| <b>CYPROHEPTADINE HYDROCHLORIDE</b>                                       | 366 |
| <i>Cyprohexal (SZ)</i>                                                    |     |
| .Genito urinary system and sex hormones .....                             | 175 |
| .Antineoplastic and immunomodulating agents .....                         | 247 |
| <i>Cyprone (AF)</i>                                                       |     |
| .Genito urinary system and sex hormones .....                             | 175 |
| .Antineoplastic and immunomodulating agents .....                         | 247 |
| <i>Cyprostat (SY)</i>                                                     |     |
| .Genito urinary system and sex hormones .....                             | 175 |
| .Antineoplastic and immunomodulating agents .....                         | 247 |
| <i>Cyprostat-100 (SY)</i>                                                 |     |
| .Genito urinary system and sex hormones .....                             | 176 |
| .Antineoplastic and immunomodulating agents .....                         | 247 |
| <b>CYPROTERONE ACETATE</b>                                                |     |
| .Genito urinary system and sex hormones .....                             | 175 |
| .Antineoplastic and immunomodulating agents .....                         | 247 |
| <i>Cystine Amino Acid Supplement (VF)</i>                                 | 450 |
| <b>CYSTINE WITH CARBOHYDRATE</b>                                          | 450 |
| <i>Cytadren 250 (NV)</i>                                                  |     |
| .Systemic hormonal preparations, excl. sex hormones and<br>insulins ..... | 181 |
| .Antineoplastic and immunomodulating agents .....                         | 247 |
| <b>CYTARABINE</b>                                                         | 215 |
| <i>Cytotec (PH)</i>                                                       | 78  |

### D

|                                                                                   |     |
|-----------------------------------------------------------------------------------|-----|
| <i>Daivonex (CS)</i>                                                              | 157 |
| <i>Daktarin (JT)</i>                                                              |     |
| .Dermatologicals .....                                                            | 155 |
| .Repatriation Schedule .....                                                      | 685 |
| <i>Dalacin C (PH)</i>                                                             |     |
| .Anti-infectives for systemic use .....                                           | 198 |
| .Dental .....                                                                     | 486 |
| <b>DALTEPARIN SODIUM (LOW MOLECULAR WEIGHT<br/>HEPARIN SODIUM—PORCINE MUCOUS)</b> | 106 |
| <b>DANAZOL</b>                                                                    | 176 |
| <i>Dantrium (PU)</i>                                                              | 344 |
| <b>DANTROLENE SODIUM</b>                                                          | 344 |
| <i>Daonil (SW)</i>                                                                | 98  |
| <i>Dapa-Tabs (AF)</i>                                                             | 120 |
| <b>DAPSONE</b>                                                                    |     |
| .Dermatologicals .....                                                            | 161 |
| .Anti-infectives for systemic use .....                                           | 205 |
| <i>Daraprim (GK)</i>                                                              | 409 |
| <b>DARBEPOETIN ALFA</b>                                                           |     |
| .Section 100 .....                                                                | 528 |
| <b>DARUNAVIR</b>                                                                  |     |
| .Section 100 .....                                                                | 529 |
| <b>DASATINIB</b>                                                                  | 222 |
| <i>DBL Aspirin 100 mg (FA)</i>                                                    | 108 |
| <i>DBL Ceftriaxone (HH)</i>                                                       | 195 |
| <i>DBL Doxycycline (FA)</i>                                                       |     |
| .Anti-infectives for systemic use .....                                           | 184 |
| .Dental .....                                                                     | 477 |
| <i>DBL Erythromycin (FA)</i>                                                      |     |
| .Anti-infectives for systemic use .....                                           | 198 |
| .Dental .....                                                                     | 486 |
| <i>DBL Fluconazole (HH)</i>                                                       | 203 |
| <i>DBL Gabapentin (HH)</i>                                                        |     |
| .Nervous system .....                                                             | 370 |
| .Repatriation Schedule .....                                                      | 699 |
| <i>DBL Metronidazole Intravenous Infusion (HH)</i>                                |     |
| .Anti-infectives for systemic use .....                                           | 202 |
| .Dental .....                                                                     | 488 |
| <i>Deca-Durabolin (OR)</i>                                                        | 105 |
| <b>DEFERASIROX</b>                                                                |     |
| .Section 100 .....                                                                | 529 |
| <b>DEFERIPRONE</b>                                                                |     |
| .Section 100 .....                                                                | 529 |
| <b>DELAVIRDINE MESYLATE</b>                                                       |     |
| .Section 100 .....                                                                | 530 |
| <i>Depo-Medrol (PH)</i>                                                           |     |
| .Systemic hormonal preparations, excl. sex hormones and<br>insulins .....         | 180 |
| .Dental .....                                                                     | 476 |
| <i>Depo-Nisalone (KR)</i>                                                         |     |
| .Systemic hormonal preparations, excl. sex hormones and<br>insulins .....         | 180 |
| .Dental .....                                                                     | 476 |
| <i>Depo-Provera (PH)</i>                                                          | 166 |

## GENERIC/PROPRIETARY INDEX

|                                                                |     |                                                       |     |
|----------------------------------------------------------------|-----|-------------------------------------------------------|-----|
| <i>Depo-Ralovera (KR)</i> .....                                | 166 | DICHLOROBENZENE WITH CHLORBUTOL AND<br>TURPENTINE OIL |     |
| <i>Deptran 10 (AF)</i> .....                                   | 386 | <i>.Repatriation Schedule</i> .....                   | 704 |
| <i>Deptran 25 (AF)</i> .....                                   | 386 | <i>Dicloclil (BQ)</i>                                 |     |
| <i>Deptran 50 (AF)</i> .....                                   | 386 | <i>.Antiinfectives for systemic use</i> .....         | 189 |
| <i>Deralin 10 (AF)</i> .....                                   | 122 | <i>.Dental</i> .....                                  | 480 |
| <i>Deralin 160 (AF)</i> .....                                  | 123 | DICLOFENAC SODIUM                                     |     |
| <i>Deralin 40 (AF)</i> .....                                   | 123 | <i>.Musculo-skeletal system</i> .....                 | 338 |
| <i>Deseril (NV)</i> .....                                      | 365 | <i>.Palliative Care</i> .....                         | 460 |
| <i>Desferal 2 g (NV)</i>                                       |     | <i>.Dental</i> .....                                  | 488 |
| <i>.Section 100</i> .....                                      | 530 | DICLOFENAC SODIUM WITH MISOPROSTOL                    |     |
| <i>Desferal 500 mg (NV)</i>                                    |     | <i>.Repatriation Schedule</i> .....                   | 697 |
| <i>.Section 100</i> .....                                      | 530 | <i>Diclohexal (SZ)</i>                                |     |
| DEXFERRIOXAMINE MESYLATE                                       |     | <i>.Musculo-skeletal system</i> .....                 | 338 |
| <i>.Section 100</i> .....                                      | 530 | <i>.Palliative Care</i> .....                         | 460 |
| DESMOPRESSIN ACETATE .....                                     | 178 | <i>.Dental</i> .....                                  | 488 |
| DEXAMETHASONE                                                  |     | DICLOXACILLIN                                         |     |
| <i>.Systemic hormonal preparations, excl. sex hormones and</i> |     | <i>.Antiinfectives for systemic use</i> .....         | 189 |
| <i>insulins</i> .....                                          | 180 | <i>.Dental</i> .....                                  | 480 |
| <i>.Sensory organs</i> .....                                   | 423 | <i>Dicloxsig (SI)</i>                                 |     |
| DEXAMETHASONE SODIUM PHOSPHATE                                 |     | <i>.Antiinfectives for systemic use</i> .....         | 189 |
| <i>.Doctor's Bag Supplies</i> .....                            | 69  | <i>.Dental</i> .....                                  | 480 |
| <i>.Systemic hormonal preparations, excl. sex hormones and</i> |     | DIDANOSINE                                            |     |
| <i>insulins</i> .....                                          | 180 | <i>.Section 100</i> .....                             | 530 |
| DEXAMETHASONE WITH FRAMYCETIN SULFATE                          |     | <i>Didrocal (PU)</i> .....                            | 350 |
| AND GRAMICIDIN .....                                           | 433 | <i>Didronel (PU)</i> .....                            | 347 |
| DEXAMPHETAMINE SULFATE .....                                   | 395 | <i>Diffiam (IA)</i>                                   |     |
| <i>Dexmethsone (AS)</i> .....                                  | 180 | <i>.Alimentary tract and metabolism</i> .....         | 75  |
| DEXTROPROPOXYPHENE NAPSYLATE                                   |     | <i>.Palliative Care</i> .....                         | 454 |
| <i>.Repatriation Schedule</i> .....                            | 698 | <i>.Dental</i> .....                                  | 473 |
| <i>Diabex (AL)</i> .....                                       | 97  | <i>Diflucan (PF)</i> .....                            | 203 |
| <i>Diabex 1000 (AL)</i> .....                                  | 98  | <i>Digestelact (SJ)</i> .....                         | 446 |
| <i>Diabex 850 (AL)</i> .....                                   | 98  | DIGOXIN .....                                         | 114 |
| <i>Diabex XR (AL)</i> .....                                    | 97  | <i>Dihydergot (NV)</i>                                |     |
| <i>Diaformin (AF)</i> .....                                    | 97  | <i>.Doctor's Bag Supplies</i> .....                   | 69  |
| <i>Diaformin 1000 (AF)</i> .....                               | 98  | <i>.Nervous system</i> .....                          | 365 |
| <i>Diaformin 850 (AF)</i> .....                                | 98  | DIHYDROERGOTAMINE MESYLATE                            |     |
| <i>Dialamine (SB)</i> .....                                    | 450 | <i>.Doctor's Bag Supplies</i> .....                   | 69  |
| <i>Diamicron (SE)</i> .....                                    | 98  | <i>.Nervous system</i> .....                          | 365 |
| <i>Diamicron MR (SE)</i> .....                                 | 98  | <i>Dilantin (PF)</i> .....                            | 367 |
| <i>Diamox (SI)</i> .....                                       | 425 | <i>Dilantin Infatabs (PF)</i> .....                   | 367 |
| <i>Diapride 1 (AW)</i> .....                                   | 99  | <i>Dilantin Sodium (PF)</i> .....                     | 367 |
| <i>Diapride 2 (AW)</i> .....                                   | 99  | <i>Dilasig 12.5 (SI)</i> .....                        | 125 |
| <i>Diapride 3 (AW)</i> .....                                   | 99  | <i>Dilasig 25 (SI)</i> .....                          | 126 |
| <i>Diapride 4 (AW)</i> .....                                   | 99  | <i>Dilasig 3.125 (SI)</i> .....                       | 125 |
| <i>Diastix (BN)</i> .....                                      | 437 | <i>Dilasig 6.25 (SI)</i> .....                        | 125 |
| DIAZEPAM                                                       |     | <i>Dilatrend 12.5 (RO)</i> .....                      | 125 |
| <i>.Doctor's Bag Supplies</i> .....                            | 69  | <i>Dilatrend 25 (RO)</i> .....                        | 126 |
| <i>.Nervous system</i> .....                                   | 383 | <i>Dilatrend 3.125 (RO)</i> .....                     | 125 |
| <i>.Palliative Care</i> .....                                  | 470 | <i>Dilatrend 6.25 (RO)</i> .....                      | 125 |
| <i>.Dental</i> .....                                           | 498 | <i>Dilaudid (MF)</i>                                  |     |
| <i>Diazepam-DP (GM)</i>                                        |     | <i>.Nervous system</i> .....                          | 354 |
| <i>.Nervous system</i> .....                                   | 383 | <i>.Dental</i> .....                                  | 492 |
| <i>.Palliative Care</i> .....                                  | 470 | <i>Dilaudid-HP (MF)</i>                               |     |
| <i>.Dental</i> .....                                           | 498 | <i>.Nervous system</i> .....                          | 354 |
| <i>Dibenyline (GH)</i>                                         |     | <i>.Dental</i> .....                                  | 492 |
| <i>.Cardiovascular system</i> .....                            | 122 | <i>Diltahexal (SZ)</i> .....                          | 129 |
| <i>.Genito urinary system and sex hormones</i> .....           | 177 | <i>Diltahexal CD (SZ)</i> .....                       | 129 |

## GENERIC/PROPRIETARY INDEX

|                                                  |     |                                                  |     |
|--------------------------------------------------|-----|--------------------------------------------------|-----|
| <b>DILTIAZEM HYDROCHLORIDE</b> .....             | 129 | <b>DONEPEZIL HYDROCHLORIDE</b> .....             | 397 |
| <i>Dilzem 60 mg (GM)</i> .....                   | 129 | DORNASE ALFA                                     |     |
| <i>Dilzem CD (GM)</i> .....                      | 129 | Section 100 .....                                | 532 |
| <b>DIMETHICONE WITH GLYCEROL</b>                 |     | <i>Doryx (HH)</i>                                |     |
| Repatriation Schedule .....                      | 686 | Antiinfectives for systemic use .....            | 184 |
| <i>Dimetrioze (SW)</i> .....                     | 177 | Dental .....                                     | 477 |
| <i>Dimirel (AV)</i> .....                        | 99  | <b>DORZOLAMIDE HYDROCHLORIDE</b> .....           | 425 |
| <i>Dinac (GM)</i>                                |     | <b>DORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL</b>    |     |
| Musculo-skeletal system .....                    | 338 | <b>MALEATE</b> .....                             | 425 |
| Palliative Care .....                            | 460 | <i>Dostinex (PH)</i> .....                       | 163 |
| Dental .....                                     | 488 | <i>Dothep 25 (AF)</i> .....                      | 386 |
| <i>Dipentum (UC)</i> .....                       | 94  | <i>Dothep 75 (AF)</i> .....                      | 386 |
| <b>DIPHEMANIL METHYLSULFATE</b>                  |     | <b>DOTHIPIEPIN HYDROCHLORIDE</b> .....           | 386 |
| Repatriation Schedule .....                      | 690 | <i>Douglas Cefaclor-CD (GM)</i>                  |     |
| <b>DIPHENOXYLATE HYDROCHLORIDE WITH</b>          |     | Antiinfectives for systemic use .....            | 194 |
| <b>ATROPINE SULFATE</b> .....                    | 91  | Dental .....                                     | 484 |
| <b>DIPHThERIA AND TETANUS VACCINE, ADSORBED,</b> |     | <i>Douglas Gabapentin 300mg (GM)</i>             |     |
| <b>DILUTED FOR ADULT USE</b>                     |     | Nervous system .....                             | 370 |
| Doctor's Bag Supplies .....                      | 69  | Repatriation Schedule .....                      | 699 |
| Antiinfectives for systemic use .....            | 209 | <i>Douglas Gabapentin 400mg (GM)</i>             |     |
| <i>Diprosone (SH)</i> .....                      | 159 | Nervous system .....                             | 370 |
| <b>DIPYRIDAMOLE</b> .....                        | 109 | Repatriation Schedule .....                      | 699 |
| <b>DIPYRIDAMOLE WITH ASPIRIN</b> .....           | 109 | <b>DOXEPIIN HYDROCHLORIDE</b> .....              | 386 |
| <b>DISODIUM ETIDRONATE</b> .....                 | 347 | <i>Doxorubicin Ebewe (IT)</i> .....              | 218 |
| <b>DISODIUM ETIDRONATE AND CALCIUM</b>           |     | <b>DOXORUBICIN HYDROCHLORIDE</b> .....           | 218 |
| <b>CARBONATE</b> .....                           | 350 | <b>DOXORUBICIN HYDROCHLORIDE, PEGYLATED</b>      |     |
| <b>DISODIUM PAMIDRONATE</b>                      |     | <b>LIPOSOMAL</b>                                 |     |
| Musculo-skeletal system .....                    | 347 | Antineoplastic and immunomodulating agents ..... | 218 |
| Section 100 .....                                | 530 | Section 100 .....                                | 532 |
| <b>DISOPYRAMIDE</b> .....                        | 114 | <i>Doxsig (SI)</i>                               |     |
| <i>Distaph 250 (AF)</i>                          |     | Antiinfectives for systemic use .....            | 184 |
| Antiinfectives for systemic use .....            | 189 | Dental .....                                     | 477 |
| Dental .....                                     | 480 | <i>Doxy-100 (GM)</i>                             |     |
| <i>Distaph 500 (AF)</i>                          |     | Antiinfectives for systemic use .....            | 184 |
| Antiinfectives for systemic use .....            | 189 | Dental .....                                     | 477 |
| Dental .....                                     | 480 | <i>Doxy-50 (GM)</i> .....                        | 184 |
| <i>Dithiazide (PL)</i> .....                     | 119 | <b>DOXYCYCLINE</b>                               |     |
| <i>Diopropan (SW)</i> .....                      | 177 | Antiinfectives for systemic use .....            | 184 |
| <i>Dizole 100 (AF)</i> .....                     | 204 | Dental .....                                     | 477 |
| <i>Dizole 200 (AF)</i> .....                     | 204 | <i>Doxyhexal (SZ)</i>                            |     |
| <i>Dizole 50 (AF)</i> .....                      | 203 | Antiinfectives for systemic use .....            | 184 |
| <b>DOCETAXEL</b> .....                           | 217 | Dental .....                                     | 477 |
| <b>DOCUSATE SODIUM</b>                           |     | <i>Doxylin 100 (AF)</i>                          |     |
| Repatriation Schedule .....                      | 681 | Antiinfectives for systemic use .....            | 184 |
| Repatriation Schedule .....                      | 705 | Dental .....                                     | 477 |
| <b>DOCUSATE SODIUM WITH SENNA</b>                |     | <i>Doxylin 50 (AF)</i> .....                     | 184 |
| Repatriation Schedule .....                      | 681 | <i>D-Penamine (AL)</i> .....                     | 344 |
| <i>Dolaforte (CO)</i>                            |     | <i>DP soflax (GM)</i>                            |     |
| Nervous system .....                             | 354 | Repatriation Schedule .....                      | 681 |
| Dental .....                                     | 492 | <b>DRESSING—ACTIVATED CHARCOAL</b>               |     |
| <i>Dolapril 0.5 (AW)</i> .....                   | 137 | <b>(MALODOROUS WOUND)</b>                        |     |
| <i>Dolapril 1 (AW)</i> .....                     | 137 | Repatriation Schedule .....                      | 713 |
| <i>Dolapril 2 (AW)</i> .....                     | 137 | <b>DRESSING—ALGINATE (CAVITY WOUND)</b>          |     |
| <i>Dolapril 4 (AW)</i> .....                     | 137 | Repatriation Schedule .....                      | 713 |
| <b>DOLASETRON MESYLATE</b> .....                 | 84  | <b>DRESSING—ALGINATE (SUPERFICIAL WOUND)</b>     |     |
| <i>Doloxene (AS)</i>                             |     | Repatriation Schedule .....                      | 713 |
| Repatriation Schedule .....                      | 698 | <b>DRESSING—FILM</b>                             |     |
| <b>DOMPERIDONE</b> .....                         | 83  | Repatriation Schedule .....                      | 714 |

## GENERIC/PROPRIETARY INDEX

|                                                                                               |     |                                                                      |     |
|-----------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------|-----|
| DRESSING—FILM ISLAND<br>.Repatriation Schedule .....                                          | 714 | .Repatriation Schedule .....                                         | 719 |
| DRESSING—FOAM—HEAVY EXUDATE<br>.Repatriation Schedule .....                                   | 714 | DRESSING—TULLE NON-GAUZE—PARAFFIN<br>.Repatriation Schedule .....    | 720 |
| DRESSING—FOAM—MODERATE EXUDATE<br>.Repatriation Schedule .....                                | 714 | DRESSING WITH CADEXOMER IODINE<br>.Repatriation Schedule .....       | 720 |
| DRESSING—FOAM WITH CHARCOAL<br>(MALODOROUS WOUND)<br>.Repatriation Schedule .....             | 715 | DRESSING WITH SILVER<br>.Repatriation Schedule .....                 | 720 |
| DRESSING—FOAM WITH SILICONE—HEAVY<br>EXUDATE<br>.Repatriation Schedule .....                  | 715 | <i>Drixine (SH)</i><br>.Repatriation Schedule .....                  | 701 |
| DRESSING—FOAM WITH SILICONE—LIGHT<br>EXUDATE<br>.Repatriation Schedule .....                  | 715 | <b>DROTRECUGIN ALFA (ACTIVATED)</b> .....                            | 110 |
| DRESSING—FOAM WITH SILICONE—MODERATE<br>EXUDATE<br>.Repatriation Schedule .....               | 715 | <i>Ducene (SU)</i><br>.Nervous system .....                          | 383 |
| DRESSING—GAUZE (ABSORBENT PAD)<br>.Repatriation Schedule .....                                | 715 | .Palliative Care .....                                               | 470 |
| DRESSING—GAUZE—EYE PAD<br>.Repatriation Schedule .....                                        | 715 | .Dental .....                                                        | 498 |
| DRESSING—GAUZE—PARAFFIN<br>.Repatriation Schedule .....                                       | 715 | <i>Dulcolax (BY)</i><br>.Alimentary tract and metabolism .....       | 88  |
| DRESSING—GAUZE—PARAFFIN WITH<br>CHLORHEXIDINE ACETATE<br>.Repatriation Schedule .....         | 716 | .Palliative Care .....                                               | 456 |
| DRESSING—GAUZE—POVIDONE-IODINE PAD<br>.Repatriation Schedule .....                            | 716 | <b>DULOXETINE HYDROCHLORIDE</b> .....                                | 392 |
| DRESSING—HYDROACTIVE (CAVITY WOUND)<br>.Repatriation Schedule .....                           | 716 | <i>Duocal (SB)</i> .....                                             | 451 |
| DRESSING—HYDROACTIVE (DEBRIDEMENT)<br>.Repatriation Schedule .....                            | 716 | <i>DuoDERM CGF H7660 (CC)</i><br>.Repatriation Schedule .....        | 718 |
| DRESSING—HYDROACTIVE (SUPERFICIAL<br>WOUND—HIGH EXUDATE)<br>.Repatriation Schedule .....      | 716 | <i>DuoDERM CGF H7662 (CC)</i><br>.Repatriation Schedule .....        | 718 |
| DRESSING—HYDROACTIVE (SUPERFICIAL<br>WOUND—LIGHT EXUDATE)<br>.Repatriation Schedule .....     | 717 | <i>DuoDERM Extra Thin H7955 (CC)</i><br>.Repatriation Schedule ..... | 717 |
| DRESSING—HYDROACTIVE (SUPERFICIAL<br>WOUND—MODERATE EXUDATE)<br>.Repatriation Schedule .....  | 717 | <i>DuoDERM Gel H7987 (CC)</i><br>.Repatriation Schedule .....        | 719 |
| DRESSING—HYDROCOLLOID (CAVITY WOUND)<br>.Repatriation Schedule .....                          | 717 | <i>DuoDERM Gel H7990 (CC)</i><br>.Repatriation Schedule .....        | 719 |
| DRESSING—HYDROCOLLOID (SUPERFICIAL<br>WOUND—LIGHT EXUDATE)<br>.Repatriation Schedule .....    | 717 | <i>DuoDERM Paste H7930 (CC)</i><br>.Repatriation Schedule .....      | 717 |
| DRESSING—HYDROCOLLOID (SUPERFICIAL<br>WOUND—MODERATE EXUDATE)<br>.Repatriation Schedule ..... | 718 | <i>Duotrav (AQ)</i> .....                                            | 426 |
| DRESSING—HYDROFIBRE (ALTERNATE TO<br>ALGINATES)<br>.Repatriation Schedule .....               | 718 | <i>Duphalac (SM)</i><br>.Alimentary tract and metabolism .....       | 89  |
| DRESSING—HYDROGEL—AMORPHOUS<br>.Repatriation Schedule .....                                   | 719 | .Palliative Care .....                                               | 457 |
| DRESSING—HYDROGEL—SHEET<br>.Repatriation Schedule .....                                       | 719 | <i>Duphaston (SM)</i> .....                                          | 170 |
| DRESSING—NON-ADHERENT                                                                         |     | <i>Duratears (AQ)</i><br>.Sensory organs .....                       | 432 |
|                                                                                               |     | .Optometrical .....                                                  | 504 |
|                                                                                               |     | <i>Duride (AF)</i> .....                                             | 117 |
|                                                                                               |     | <i>Durogesic 100 (JC)</i> .....                                      | 360 |
|                                                                                               |     | <i>Durogesic 12 (JC)</i> .....                                       | 360 |
|                                                                                               |     | <i>Durogesic 25 (JC)</i> .....                                       | 360 |
|                                                                                               |     | <i>Durogesic 50 (JC)</i> .....                                       | 360 |
|                                                                                               |     | <i>Durogesic 75 (JC)</i> .....                                       | 360 |
|                                                                                               |     | <i>Duro-K (NM)</i> .....                                             | 105 |
|                                                                                               |     | <i>Duro-Tuss (IA)</i><br>.Repatriation Schedule .....                | 703 |
|                                                                                               |     | <b>HYDROGESTERONE</b> .....                                          | 170 |
|                                                                                               |     | <i>Dymadon P (PC)</i><br>.Nervous system .....                       | 364 |
|                                                                                               |     | .Dental .....                                                        | 496 |
|                                                                                               |     | <i>Dysport (IS)</i><br>.Section 100 .....                            | 634 |

## E

## GENERIC/PROPRIETARY INDEX

|                                    |     |                                             |     |
|------------------------------------|-----|---------------------------------------------|-----|
| E.E.S. 200 (LM)                    |     | .Repatriation Schedule                      | 689 |
| .Anti-infectives for systemic use  | 198 | Eloflex 2480 (BV)                           |     |
| .Dental                            | 486 | .Repatriation Schedule                      | 710 |
| E.E.S. 400 Filmtab (LM)            |     | Eloxatin (SW)                               | 220 |
| .Anti-infectives for systemic use  | 198 | Emend (MK)                                  | 86  |
| .Dental                            | 486 | EMTRICITABINE                               |     |
| E.E.S. Granules (LM)               |     | .Section 100                                | 533 |
| .Anti-infectives for systemic use  | 198 | Emtriva (GI)                                |     |
| .Dental                            | 486 | .Section 100                                | 533 |
| Ear Clear for Ear Wax Removal (KY) |     | E-Mycin (AF)                                |     |
| .Repatriation Schedule             | 704 | .Anti-infectives for systemic use           | 198 |
| Easiphen (SB)                      | 449 | .Dental                                     | 486 |
| Ebixa (LU)                         | 405 | E-Mycin 200 (AF)                            |     |
| Edecrin (FK)                       | 121 | .Anti-infectives for systemic use           | 198 |
| Edronax (PH)                       | 393 | .Dental                                     | 486 |
| EFALIZUMAB                         | 252 | E-Mycin 400 (AF)                            |     |
| EFAVIRENZ                          |     | .Anti-infectives for systemic use           | 198 |
| .Section 100                       | 533 | .Dental                                     | 486 |
| Efexor-XR (WX)                     | 394 | Enahexal (SZ)                               | 131 |
| EFORMOTEROL FUMARATE DIHYDRATE     | 412 | Enalabell (BF)                              | 131 |
| Efidix (VT)                        |     | Enalapril/HCT Sandoz (SZ)                   | 138 |
| .Repatriation Schedule             | 696 | Enalapril-DP 10mg (GM)                      | 131 |
| Egocort Cream 1% (EO)              | 158 | Enalapril-DP 20mg (GM)                      | 132 |
| Egoderm Cream (EO)                 |     | Enalapril-DP 5mg (GM)                       | 131 |
| .Repatriation Schedule             | 691 | ENALAPRIL MALEATE                           | 131 |
| Egoderm Ointment (EO)              |     | ENALAPRIL MALEATE WITH                      |     |
| .Repatriation Schedule             | 691 | HYDROCHLOROTHIAZIDE                         | 138 |
| Egopsoryl-TA (EO)                  |     | Enalapril Winthrop (WA)                     | 131 |
| .Repatriation Schedule             | 688 | Enbrel (WX)                                 |     |
| Elastocrepe 36102320 (BV)          |     | .Antineoplastic and immunomodulating agents | 303 |
| .Repatriation Schedule             | 711 | .Section 100                                | 544 |
| Elastocrepe 36102420 (BV)          |     | Endep 10 (AF)                               | 386 |
| .Repatriation Schedule             | 711 | Endep 25 (AF)                               | 386 |
| Elastocrepe 36102520 (BV)          |     | Endep 50 (AF)                               | 386 |
| .Repatriation Schedule             | 711 | Endone (SI)                                 |     |
| Elastoplast 1004 (BV)              |     | .Nervous system                             | 359 |
| .Repatriation Schedule             | 721 | .Dental                                     | 494 |
| Elastoplast 2225 (BE)              |     | Endoxan (BX)                                | 211 |
| .Repatriation Schedule             | 711 | Energivit (SB)                              | 450 |
| Elastoplast 2226 (BE)              |     | ENFUVRTIDE                                  |     |
| .Repatriation Schedule             | 712 | .Section 100                                | 533 |
| Elastoplast 2227 (BE)              |     | Enidin (PE)                                 | 424 |
| .Repatriation Schedule             | 712 | ENOXAPARIN SODIUM                           | 107 |
| Eldepryl (GM)                      | 376 | ENTACAPONE                                  | 376 |
| EleCare (AB)                       | 440 | ENTECAVIR MONOHYDRATE                       |     |
| ELECTROLYTE REPLACEMENT (ORAL)     | 91  | .Section 100                                | 533 |
| ELECTROLYTE REPLACEMENT SOLUTION   | 113 | Epaq (AW)                                   |     |
| Eleuphrat (EX)                     | 159 | .Doctor's Bag Supplies                      | 71  |
| Eleva 100 (AF)                     | 391 | .Respiratory system                         | 412 |
| Eleva 50 (AF)                      | 390 | Epilim (SW)                                 | 369 |
| Elidel (NV)                        | 162 | Epilim EC (SW)                              | 369 |
| Eligard 1 month (HH)               | 245 | Epilim Liquid (SW)                          | 369 |
| Eligard 3 month (HH)               | 245 | Epilim Syrup (SW)                           | 369 |
| Eligard 4 month (HH)               | 245 | EpiPen (CS)                                 |     |
| Eligard 6 month (HH)               | 245 | .Cardiovascular system                      | 116 |
| Elmends (ME)                       | 371 | .Respiratory system                         | 420 |
| Elocon (SH)                        |     | EpiPen Jr. (CS)                             |     |
| .Dermatologicals                   | 160 | .Cardiovascular system                      | 116 |



## GENERIC/PROPRIETARY INDEX

|                                           |     |                                                   |     |
|-------------------------------------------|-----|---------------------------------------------------|-----|
| .Respiratory system .....                 | 420 | ESOMEPRAZOLE MAGNESIUM TRIHYDRATE .....           | 78  |
| <i>Epirubicin Ebewe (IT)</i> .....        | 218 | ESOMEPRAZOLE MAGNESIUM TRIHYDRATE AND             |     |
| <i>EPIDUBICIN HYDROCHLORIDE</i> .....     | 218 | CLARITHROMYCIN AND AMOXYCILLIN .....              | 82  |
| <i>EPLERENONE</i> .....                   | 121 | ESSENTIAL AMINO ACIDS FORMULA WITH                |     |
| <i>EPOETIN ALFA</i> .....                 |     | MINERALS AND VITAMIN C .....                      | 450 |
| .Section 100 .....                        | 534 | <i>Estalis continuous 50/140 (NV)</i> .....       | 170 |
| <i>EPOETIN BETA</i> .....                 |     | <i>Estalis continuous 50/250 (NV)</i> .....       | 170 |
| .Section 100 .....                        | 534 | <i>Estalis sequi 50/140 (NV)</i> .....            | 171 |
| <i>EPOPROSTENOL SODIUM</i> .....          |     | <i>Estalis sequi 50/250 (NV)</i> .....            | 171 |
| .Section 100 .....                        | 535 | <i>Estracombi (NV)</i> .....                      | 172 |
| <i>Eprex 1000 (JC)</i> .....              |     | <i>Estraderm 100 (NV)</i> .....                   | 169 |
| .Section 100 .....                        | 534 | <i>Estraderm 25 (NV)</i> .....                    | 168 |
| <i>Eprex 10000 (JC)</i> .....             |     | <i>Estraderm 50 (NV)</i> .....                    | 168 |
| .Section 100 .....                        | 534 | <i>Estraderm MX 100 (NV)</i> .....                | 169 |
| <i>Eprex 20,000 (JC)</i> .....            |     | <i>Estraderm MX 25 (NV)</i> .....                 | 168 |
| .Section 100 .....                        | 534 | <i>Estraderm MX 50 (NV)</i> .....                 | 168 |
| <i>Eprex 2000 (JC)</i> .....              |     | <i>Estradot 100 (NV)</i> .....                    | 169 |
| .Section 100 .....                        | 534 | <i>Estradot 25 (NV)</i> .....                     | 168 |
| <i>Eprex 30,000 (JC)</i> .....            |     | <i>Estradot 37.5 (NV)</i> .....                   | 168 |
| .Section 100 .....                        | 534 | <i>Estradot 50 (NV)</i> .....                     | 168 |
| <i>Eprex 3000 (JC)</i> .....              |     | <i>Estradot 75 (NV)</i> .....                     | 168 |
| .Section 100 .....                        | 534 | ETANERCEPT .....                                  |     |
| <i>Eprex 40,000 (JC)</i> .....            |     | .Antineoplastic and immunomodulating agents ..... | 298 |
| .Section 100 .....                        | 534 | .Section 100 .....                                | 543 |
| <i>Eprex 4000 (JC)</i> .....              |     | ETHACRYNIC ACID .....                             | 121 |
| .Section 100 .....                        | 534 | ETHOSUXIMIDE .....                                | 367 |
| <i>Eprex 5000 (JC)</i> .....              |     | ETONOGESTREL .....                                | 166 |
| .Section 100 .....                        | 534 | <i>Etopophos (BQ)</i> .....                       | 216 |
| <i>Eprex 6000 (JC)</i> .....              |     | ETOPOSIDE .....                                   | 216 |
| .Section 100 .....                        | 534 | <i>Etoposide Ebewe (IT)</i> .....                 | 216 |
| <i>Eprex 8000 (JC)</i> .....              |     | ETOPOSIDE PHOSPHATE .....                         | 216 |
| .Section 100 .....                        | 534 | <i>Eucerin (BE)</i> .....                         |     |
| <i>EPROSARTAN MESYLATE</i> .....          | 140 | .Repatriation Schedule .....                      | 687 |
| <i>EPROSARTAN MESYLATE WITH</i>           |     | <i>Eulexin (SH)</i> .....                         | 247 |
| <i>HYDROCHLOROTHIAZIDE</i> .....          | 141 | <i>Eutroxsig (FM)</i> .....                       | 182 |
| <i>EPTIFIBATIDE ACETATE</i> .....         | 109 | EVEROLIMUS .....                                  |     |
| <i>Erbitux (SG)</i> .....                 | 221 | .Antineoplastic and immunomodulating agents ..... | 263 |
| <i>ERLOTINIB</i> .....                    | 226 | .Section 100 .....                                | 545 |
| <i>Eryc (HH)</i> .....                    |     | <i>Evista (LY)</i> .....                          |     |
| .Antiinfectives for systemic use .....    | 198 | .Genito urinary system and sex hormones .....     |     |
| .Dental .....                             | 486 | .Musculo-skeletal system .....                    | 352 |
| <i>Erythrocine-I.V. (LM)</i> .....        |     | <i>Exelon (NV)</i> .....                          | 403 |
| .Antiinfectives for systemic use .....    | 198 | <i>Exelon Patch 10 (NV)</i> .....                 | 401 |
| .Dental .....                             | 486 | <i>Exelon Patch 5 (NV)</i> .....                  | 401 |
| <i>ERYTHROMYCIN</i> .....                 |     | <i>EXEMESTANE</i> .....                           | 248 |
| .Antiinfectives for systemic use .....    | 198 | <i>Exjade (NV)</i> .....                          |     |
| .Dental .....                             | 486 | .Section 100 .....                                | 529 |
| <i>ERYTHROMYCIN ETHYL SUCCINATE</i> ..... |     | <i>Exorex (GM)</i> .....                          | 157 |
| .Antiinfectives for systemic use .....    | 198 | <i>Extine 20 (AW)</i> .....                       | 390 |
| .Dental .....                             | 486 | <i>EZETIMIBE</i> .....                            | 152 |
| <i>ERYTHROMYCIN LACTOBIONATE</i> .....    |     | <i>EZETIMIBE WITH SIMVASTATIN</i> .....           | 153 |
| .Antiinfectives for systemic use .....    | 198 | <i>Ezetrol (MK)</i> .....                         | 153 |
| .Dental .....                             | 486 |                                                   |     |
| <i>ESCITALOPRAM OXALATE</i> .....         |     |                                                   |     |
| .Special Pharmaceutical Benefits .....    | 72  |                                                   |     |
| .Nervous system .....                     | 388 |                                                   |     |
| <i>Esipram (CF)</i> .....                 | 388 |                                                   |     |
| <i>Eskazole (GK)</i> .....                | 410 |                                                   |     |

## F

|                             |     |
|-----------------------------|-----|
| <i>FAMCICLOVIR</i> .....    | 207 |
| <i>Famohexal (SZ)</i> ..... | 76  |

## GENERIC/PROPRIETARY INDEX

|                                                         |     |                                                         |     |
|---------------------------------------------------------|-----|---------------------------------------------------------|-----|
| <b>FAMOTIDINE</b> .....                                 | 76  | <i>Flagyl</i> (SW)                                      |     |
| <i>Famvir</i> (NV) .....                                | 207 | .Anti-infectives for systemic use .....                 | 201 |
| <i>Fareston</i> (SH) .....                              | 246 | .Antiparasitic products, insecticides and repellents .. |     |
| <i>Fasigyn</i> (PF)                                     |     | .Dental .....                                           | 487 |
| .Anti-infectives for systemic use .....                 | 202 | <i>Flagyl S</i> (SW)                                    |     |
| .Antiparasitic products, insecticides and repellents .. |     | .Anti-infectives for systemic use .....                 | 202 |
| <i>Faverin 100</i> (AW) .....                           | 389 | .Antiparasitic products, insecticides and repellents .. |     |
| <i>Faverin 50</i> (AW) .....                            | 389 | .Dental .....                                           | 488 |
| <i>Febridol</i> (GM)                                    |     | <i>Flarex</i> (AQ) .....                                | 423 |
| .Nervous system .....                                   | 364 | <b>FLECAINIDE ACETATE</b> .....                         | 114 |
| .Dental .....                                           | 496 | <i>Flecatab</i> (AF) .....                              | 114 |
| <i>Feldene</i> (PF)                                     |     | <i>Fleet Laxative Suppositories</i> (FL)                |     |
| .Musculo-skeletal system .....                          | 341 | .Alimentary tract and metabolism .....                  | 88  |
| .Dental .....                                           | 490 | .Palliative Care .....                                  | 456 |
| <i>Feldene-D</i> (PF)                                   |     | <i>Flexidress 650941</i> (CC)                           |     |
| .Musculo-skeletal system .....                          | 340 | .Repatriation Schedule .....                            | 712 |
| .Dental .....                                           | 489 | <i>Flixotide</i> (GK) .....                             | 417 |
| <i>Felodil XR 10</i> (AW) .....                         | 127 | <i>Flixotide Accuhaler</i> (GK) .....                   | 418 |
| <i>Felodil XR 5</i> (AW) .....                          | 127 | <i>Flixotide Junior</i> (GK) .....                      | 417 |
| <b>FELODIPINE</b> .....                                 | 127 | <i>Flixotide Junior Accuhaler</i> (GK) .....            | 418 |
| <i>Felodur ER 10 mg</i> (AL) .....                      | 127 | <i>Flolan</i> (GK)                                      |     |
| <i>Felodur ER 2.5 mg</i> (AL) .....                     | 127 | .Section 100 .....                                      | 542 |
| <i>Felodur ER 5 mg</i> (AL) .....                       | 127 | <i>Flomaxtra</i> (CS)                                   |     |
| <i>Femara 2.5 mg</i> (NV) .....                         | 248 | .Repatriation Schedule .....                            | 695 |
| <i>Femizol Vaginal Cream</i> (GM)                       |     | <i>Flopen</i> (AS)                                      |     |
| .Repatriation Schedule .....                            | 693 | .Anti-infectives for systemic use .....                 | 190 |
| <i>Femoston 2/10</i> (SM) .....                         | 171 | .Dental .....                                           | 480 |
| <i>Fenac</i> (AF)                                       |     | <i>Florinef</i> (BQ) .....                              | 179 |
| .Musculo-skeletal system .....                          | 338 | <i>Fluanxol Concentrated Depot</i> (LU) .....           | 378 |
| .Palliative Care .....                                  | 460 | <i>Fluanxol Depot</i> (LU) .....                        | 378 |
| .Dental .....                                           | 489 | <i>Flubiclox</i> (GM)                                   |     |
| <i>Fenac 25</i> (AF)                                    |     | .Anti-infectives for systemic use .....                 | 189 |
| .Musculo-skeletal system .....                          | 338 | .Dental .....                                           | 480 |
| .Palliative Care .....                                  | 460 | <i>Flucil</i> (AS)                                      |     |
| .Dental .....                                           | 488 | .Anti-infectives for systemic use .....                 | 189 |
| <b>FENOFIBRATE</b> .....                                | 151 | .Dental .....                                           | 480 |
| <b>FENTANYL</b>                                         |     | <b>FLUCLOXACILLIN</b>                                   |     |
| .Nervous system .....                                   | 360 | .Anti-infectives for systemic use .....                 | 189 |
| .Palliative Care .....                                  | 466 | .Dental .....                                           | 480 |
| <i>Fermil</i> (AW) .....                                | 175 | <i>Flucon</i> (AQ)                                      |     |
| <i>Ferriprox</i> (OA)                                   |     | .Sensory organs .....                                   | 423 |
| .Section 100 .....                                      | 529 | .Optometical .....                                      | 501 |
| <i>Ferro-f-tab</i> (AE) .....                           | 112 | <b>FLUCONAZOLE</b> .....                                | 203 |
| <i>Ferro-Liquid</i> (AE) .....                          | 111 | <i>Fluconazole Hexal</i> (HX) .....                     | 203 |
| <i>Ferrosig</i> (SI) .....                              | 112 | <i>Fluconazole Hexal</i> (SZ) .....                     | 204 |
| <b>FERROUS FUMARATE WITH FOLIC ACID</b> .....           | 112 | <i>Fluconazole Winthrop</i> (WA) .....                  | 204 |
| <b>FERROUS SULFATE</b> .....                            | 111 | <i>Fludara</i> (BN) .....                               | 214 |
| <i>Ferrum H</i> (AS) .....                              | 112 | <b>FLUDARABINE PHOSPHATE</b> .....                      | 214 |
| <b>PEXOFENADINE HYDROCHLORIDE</b>                       |     | <b>FLUDROCORTISONE ACETATE</b> .....                    | 179 |
| .Repatriation Schedule .....                            | 703 | <b>FLUNITRAZEPAM</b>                                    |     |
| <i>Fibsol 10</i> (AW) .....                             | 133 | .Repatriation Schedule .....                            | 700 |
| <i>Fibsol 20</i> (AW) .....                             | 134 | <i>Fluohepal</i> (SZ) .....                             | 389 |
| <i>Fibsol 5</i> (AW) .....                              | 133 | <b>FLUOROMETHOLONE</b>                                  |     |
| <b>FILGRASTIM</b>                                       |     | .Sensory organs .....                                   | 423 |
| .Section 100 .....                                      | 546 | .Optometical .....                                      | 501 |
| <i>Filpril</i> (AF) .....                               | 135 | <b>FLUOROMETHOLONE ACETATE</b> .....                    | 423 |
| <b>FINASTERIDE</b>                                      |     | <b>FLUOROURACIL</b>                                     |     |
| .Repatriation Schedule .....                            | 695 | .Antineoplastic and immunomodulating agents .....       | 215 |

## GENERIC/PROPRIETARY INDEX

|                                                |     |                                         |     |
|------------------------------------------------|-----|-----------------------------------------|-----|
| .Repatriation Schedule .....                   | 696 | FOTEMUSTINE .....                       | 212 |
| Fluorouracil Ebewe (IT) .....                  | 215 | Fragmin (PH) .....                      | 106 |
| Fluoxebell (BF) .....                          | 389 | Frakas (AW) .....                       | 184 |
| Fluoxetine 20 (CR) .....                       | 389 | FRAMYCETIN SULFATE .....                | 434 |
| Fluoxetine-DP (GM) .....                       | 389 | FreeStyle Lite (MS) .....               | 438 |
| FLUOXETINE HYDROCHLORIDE .....                 | 388 | Freestyle Papillon (MS) .....           | 437 |
| FLUPENTHIXOL DECANOATE .....                   | 378 | Frusehexal (HX) .....                   |     |
| FLUPHENAZINE DECANOATE .....                   | 377 | .Doctor's Bag Supplies .....            | 70  |
| FLURBIPROFEN SODIUM .....                      |     | .Cardiovascular system .....            | 120 |
| .Sensory organs .....                          | 424 | Frusehexal 40 mg (HX) .....             | 120 |
| .Optometrical .....                            | 501 | FRUSEMIDE .....                         |     |
| FLUTAMIDE .....                                | 247 | .Doctor's Bag Supplies .....            | 70  |
| Flutamin (AF) .....                            | 247 | .Cardiovascular system .....            | 120 |
| FLUTICASONE PROPIONATE .....                   | 417 | Frusid (GM) .....                       | 120 |
| FLUTICASONE PROPIONATE WITH SALMETEROL .....   |     | Fucidin (CS) .....                      | 201 |
| XINAFOATE .....                                | 415 | Fungilin (BQ) .....                     |     |
| FLUVASTATIN SODIUM .....                       | 146 | .Alimentary tract and metabolism .....  | 75  |
| Fluvax (CS) .....                              | 210 | .Dental .....                           | 473 |
| Fluvax Junior (CS) .....                       | 210 | Fungizone (BQ) .....                    | 203 |
| FLUVOXAMINE MALEATE .....                      | 389 | FUSIDIC ACID .....                      | 201 |
| Fluzole 200 (AW) .....                         | 204 | Fuzeon (RO) .....                       |     |
| Fluzole 50 (AW) .....                          | 203 | .Section 100 .....                      | 533 |
| FML Liquifilm (AG) .....                       |     | Fybogel (RC) .....                      |     |
| .Sensory organs .....                          | 423 | .Repatriation Schedule .....            | 681 |
| .Optometrical .....                            | 501 |                                         |     |
| FOLIC ACID .....                               | 112 | <b>G</b> .....                          |     |
| FOLLITROPIN ALFA .....                         |     | GA-Amclav 500/125 (GM) .....            |     |
| .Genito urinary system and sex hormones .....  | 172 | .Anti-infectives for systemic use ..... | 190 |
| .Section 100 .....                             | 636 | .Dental .....                           | 481 |
| FOLLITROPIN BETA .....                         |     | GA-Amclav Forte 875/125 (GM) .....      |     |
| .Genito urinary system and sex hormones .....  | 173 | .Anti-infectives for systemic use ..... | 191 |
| .Section 100 .....                             | 636 | .Dental .....                           | 482 |
| FONDAPARINUX SODIUM .....                      | 111 | Gabahexal 300mg (SZ) .....              |     |
| Foradile (NV) .....                            | 412 | .Nervous system .....                   | 370 |
| Formet 1000 (AW) .....                         | 98  | .Repatriation Schedule .....            | 699 |
| Formet 500 (AW) .....                          | 97  | Gabahexal 400mg (SZ) .....              |     |
| Formet 850 (AW) .....                          | 98  | .Nervous system .....                   | 370 |
| Fosamax 40 mg (MK) .....                       | 346 | .Repatriation Schedule .....            | 699 |
| Fosamax Once Weekly (MK) .....                 | 346 | Gabahexal 600mg (SZ) .....              | 371 |
| Fosamax Plus (MK) .....                        | 349 | GABAPENTIN .....                        |     |
| Fosamax Plus 70 mg/140 mcg (MK) .....          | 349 | .Nervous system .....                   | 370 |
| FOSAMPRENAVIR CALCIUM .....                    |     | .Repatriation Schedule .....            | 699 |
| .Section 100 .....                             | 547 | Gabapentin 300 (CR) .....               | 370 |
| FOSCARNET SODIUM .....                         |     | Gabapentin 400 (CR) .....               | 370 |
| .Section 100 .....                             | 547 | Gabaran (RA) .....                      | 371 |
| Foscavir (AP) .....                            |     | Gabatine 100 (SI) .....                 | 370 |
| .Section 100 .....                             | 547 | Gabatine 300 (SI) .....                 | 370 |
| Fosinopril/HCT Sandoz 10mg/12.5mg (SZ) .....   | 138 | Gabatine 400 (SI) .....                 | 370 |
| Fosinopril/HCT Sandoz 20mg/12.5mg (SZ) .....   | 138 | Gabitril (OA) .....                     | 369 |
| Fosinopril/HCT Winthrop 10mg/12.5mg (WA) ..... | 138 | GALANTAMINE HYDROBROMIDE .....          | 398 |
| Fosinopril/HCT Winthrop 20mg/12.5mg (WA) ..... | 138 | GANCICLOVIR .....                       |     |
| Fosinopril Sandoz (SZ) .....                   | 132 | .Section 100 .....                      | 547 |
| FOSINOPRIL SODIUM .....                        | 132 | GANCICLOVIR SODIUM .....                |     |
| FOSINOPRIL SODIUM WITH .....                   |     | .Section 100 .....                      | 547 |
| HYDROCHLOROTHIAZIDE .....                      | 138 | Gantin (AW) .....                       |     |
| Fosinopril Winthrop (WA) .....                 | 132 | .Nervous system .....                   | 370 |
| Fosipril 10 (AW) .....                         | 132 |                                         |     |
| Fosipril 20 (AW) .....                         | 132 |                                         |     |

## GENERIC/PROPRIETARY INDEX

|                                            |     |                                                   |     |
|--------------------------------------------|-----|---------------------------------------------------|-----|
| .Repatriation Schedule .....               | 699 | GenRx Ciprofloxacin (GX) .....                    | 199 |
| Gastrogel (FM) .....                       | 75  | GenRx Citalopram (GX) .....                       | 387 |
| Gastro-Stop Loperamide (AS) .....          | 91  | GenRx Clarithromycin (GX) .....                   | 197 |
| GAUZE AND COTTON TISSUE (COMBINE ROLL)     |     | GenRx Clomiphene (GX) .....                       | 175 |
| .Repatriation Schedule .....               | 720 | GenRx Clomipramine (GX)                           |     |
| Gaviscon P (RC) .....                      | 83  | .Nervous system .....                             | 384 |
| GEFITINIB .....                            | 227 | .Nervous system .....                             | 386 |
| GELATIN - SUCCINYLATED .....               | 113 | GenRx Clotrimazole 3 Day Cream (GX)               |     |
| Gelocast Elastic 1080 (BV)                 |     | .Repatriation Schedule .....                      | 693 |
| .Repatriation Schedule .....               | 712 | GenRx Clotrimazole 6 Day Cream (GX)               |     |
| Gelofusine (BR) .....                      | 113 | .Repatriation Schedule .....                      | 692 |
| GelTears (BU)                              |     | GenRx Cyproterone Acetate (GX)                    |     |
| .Sensory organs .....                      | 430 | .Genito urinary system and sex hormones .....     | 175 |
| .Optometrical .....                        | 502 | .Antineoplastic and immunomodulating agents ..... | 247 |
| GEMCITABINE HYDROCHLORIDE .....            | 215 | GenRx Diclofenac (GX)                             |     |
| GEMFIBROZIL .....                          | 151 | .Musculo-skeletal system .....                    | 338 |
| Gemhexal (SZ) .....                        | 151 | .Palliative Care .....                            | 460 |
| Gemzar (LY) .....                          | 215 | .Dental .....                                     | 488 |
| Genlac (AW)                                |     | GenRx Diltiazem (GX) .....                        | 129 |
| .Alimentary tract and metabolism .....     | 89  | GenRx Diltiazem CD (GX) .....                     | 129 |
| .Palliative Care .....                     | 457 | GenRx Doxycycline (GX)                            |     |
| Genoptic (AG) .....                        | 422 | .Antiinfectives for systemic use .....            | 184 |
| Genoral 0.625 (KR) .....                   | 169 | .Dental .....                                     | 477 |
| Genoral 1.25 (KR) .....                    | 169 | GenRx Enalapril (GX) .....                        | 131 |
| Genotropin (PH)                            |     | GenRx Famotidine (GX) .....                       | 76  |
| .Section 100 .....                         | 634 | GenRx Fluoxetine (GX) .....                       | 389 |
| Genotropin MiniQuick (PH)                  |     | GenRx Fosinopril (GX) .....                       | 132 |
| .Section 100 .....                         | 635 | GenRx Frusemide (GX) .....                        | 120 |
| Genox 10 (AF) .....                        | 246 | GenRx Gabapentin (GX)                             |     |
| Genox 20 (AF) .....                        | 246 | .Nervous system .....                             | 370 |
| GenRx Aciclovir (GX) .....                 | 205 | .Repatriation Schedule .....                      | 699 |
| GenRx Allopurinol (GX) .....               | 345 | GenRx Gliclazide (GX) .....                       | 151 |
| GenRx Alprazolam (GX) .....                | 382 | GenRx Glimepiride (GX) .....                      | 98  |
| GenRx Amiodarone (GX) .....                | 115 | GenRx Indapamide (GX) .....                       | 120 |
| GenRx Amoxycillin (GX)                     |     | GenRx Ipratropium (GX) .....                      | 418 |
| .Antiinfectives for systemic use .....     | 186 | GenRx Isosorbide Mononitrate (GX) .....           | 117 |
| .Dental .....                              | 478 | GenRx Isotretinoin (GX) .....                     | 161 |
| GenRx Amoxycillin and Clavulanic Acid (GX) |     | GenRx Lactulose (GX)                              |     |
| .Antiinfectives for systemic use .....     | 191 | .Alimentary tract and metabolism .....            | 89  |
| .Dental .....                              | 482 | .Palliative Care .....                            | 457 |
| GenRx Atenolol (GX) .....                  | 123 | GenRx Lamotrigine (GX) .....                      | 371 |
| GenRx Azathioprine (GX) .....              | 336 | GenRx Lisinopril (GX) .....                       | 133 |
| GenRx Baclofen (GX) .....                  | 344 | GenRx Meloxicam (GX) .....                        | 339 |
| GenRx Calcitriol (GX)                      |     | GenRx Metformin (GX) .....                        | 97  |
| .Alimentary tract and metabolism .....     | 104 | GenRx Metoprolol (GX) .....                       | 124 |
| .Musculo-skeletal system .....             | 352 | GenRx Mirtazapine (GX) .....                      | 393 |
| GenRx Captopril (GX) .....                 | 130 | GenRx Moclobemide (GX) .....                      | 392 |
| GenRx Carvedilol (GX) .....                | 125 | GenRx Nifedipine (GX) .....                       | 128 |
| GenRx Cefaclor (GX)                        |     | GenRx Norfloxacin (GX) .....                      | 200 |
| .Antiinfectives for systemic use .....     | 194 | GenRx Omeprazole (GX) .....                       | 80  |
| .Dental .....                              | 485 | GenRx Paroxetine (GX) .....                       | 390 |
| GenRx Cefaclor CD (GX)                     |     | GenRx Perindopril/ Indapamide 4/1.25 (GX) .....   | 139 |
| .Antiinfectives for systemic use .....     | 194 | GenRx Perindopril (GX) .....                      | 134 |
| .Dental .....                              | 484 | GenRx Piroxicam (GX)                              |     |
| GenRx Cephalixin (GX)                      |     | .Musculo-skeletal system .....                    | 341 |
| .Antiinfectives for systemic use .....     | 192 | .Dental .....                                     | 490 |
| .Dental .....                              | 483 | GenRx Piroxicam Dispersible (GX)                  |     |
| GenRx Cimetidine (GX) .....                | 76  | .Musculo-skeletal system .....                    | 340 |

## GENERIC/PROPRIETARY INDEX

|                                                                           |     |                                               |     |
|---------------------------------------------------------------------------|-----|-----------------------------------------------|-----|
| .Dental .....                                                             | 489 | <i>Glucohexal (SZ)</i> .....                  | 97  |
| <i>GenRx Pravastatin (GX)</i> .....                                       | 147 | <i>Glucomet 500 mg (GM)</i> .....             | 97  |
| <i>GenRx Prazosin (GX)</i> .....                                          | 118 | <i>Glucomet 850 mg (GM)</i> .....             | 98  |
| <i>GenRx Ramipril (GX)</i> .....                                          | 137 | <i>GlucoOz (OZ)</i> .....                     | 438 |
| <i>GenRx Ranitidine (GX)</i> .....                                        | 77  | <i>Glucophage (MQ)</i> .....                  | 97  |
| <i>GenRx Salbutamol (GX)</i> .....                                        |     | GLUCOSE .....                                 |     |
| .Doctor's Bag Supplies .....                                              | 71  | .Blood and blood forming organs .....         | 113 |
| .Respiratory system .....                                                 | 413 | .Dental .....                                 | 474 |
| <i>GenRx Sertraline (GX)</i> .....                                        | 390 | GLUCOSE AND KETONE INDICATOR—URINE .....      | 437 |
| <i>GenRx Simvastatin (GX)</i> .....                                       | 149 | GLUCOSE INDICATOR—BLOOD .....                 | 437 |
| <i>GenRx Sotalol (GX)</i> .....                                           |     | GLUCOSE INDICATOR—URINE .....                 | 437 |
| .Cardiovascular system .....                                              | 115 | <i>Glucostix (BN)</i> .....                   | 438 |
| .Cardiovascular system .....                                              |     | <i>Glucovance 250mg/1.25mg (AL)</i> .....     | 99  |
| <i>GenRx Tamoxifen (GX)</i> .....                                         | 246 | <i>Glucovance 500mg/2.5mg (AL)</i> .....      | 99  |
| <i>GenRx Terbinafine (GX)</i> .....                                       | 156 | <i>Glucovance 500mg/5mg (AL)</i> .....        | 99  |
| <i>GenRx Tramadol (GX)</i> .....                                          |     | <i>Glyade (AF)</i> .....                      | 98  |
| .Nervous system .....                                                     | 362 | GLYCEROL .....                                |     |
| .Dental .....                                                             | 495 | .Alimentary tract and metabolism .....        | 90  |
| <i>GenRx Trimethoprim with Sulfamethoxazole DS (GX)</i> .....             |     | .Palliative Care .....                        | 459 |
| .Antifungives for systemic use .....                                      | 196 | .Repatriation Schedule .....                  | 682 |
| .Dental .....                                                             | 486 | GLYCERYL TRINITRATE .....                     |     |
| GENTAMICIN SULFATE .....                                                  |     | .Doctor's Bag Supplies .....                  | 70  |
| .Antifungives for systemic use .....                                      | 199 | .Cardiovascular system .....                  | 116 |
| .Sensory organs .....                                                     | 422 | .Dental .....                                 | 475 |
| <i>Genteal (NV)</i> .....                                                 |     | <i>Gold Cross (BI)</i> .....                  |     |
| .Sensory organs .....                                                     | 431 | .Repatriation Schedule .....                  | 697 |
| .Optometrical .....                                                       | 503 | .Repatriation Schedule .....                  | 702 |
| <i>Genteal gel (NV)</i> .....                                             |     | <i>Gonal-f (SG)</i> .....                     |     |
| .Sensory organs .....                                                     | 431 | .Genito urinary system and sex hormones ..... | 172 |
| .Optometrical .....                                                       | 503 | .Section 100 .....                            | 636 |
| GESTRINONE .....                                                          | 177 | <i>Gonal-f 75 (SG)</i> .....                  |     |
| GLATIRAMER ACETATE .....                                                  | 252 | .Genito urinary system and sex hormones ..... | 172 |
| <i>Gladel (OA)</i> .....                                                  | 212 | .Section 100 .....                            | 636 |
| GLIBENCLAMIDE .....                                                       | 98  | <i>Gonal-f Pen (SG)</i> .....                 |     |
| GLICLAZIDE .....                                                          | 98  | .Genito urinary system and sex hormones ..... | 173 |
| <i>Glimel (AF)</i> .....                                                  | 98  | .Section 100 .....                            | 636 |
| GLIMEPIRIDE .....                                                         | 99  | <i>Gopten (AB)</i> .....                      | 137 |
| <i>Glimepiride Sandoz (SZ)</i> .....                                      | 99  | GOSERELIN ACETATE .....                       | 244 |
| GLIPIZIDE .....                                                           | 99  | GOSERELIN ACETATE AND BICALUTAMIDE .....      | 245 |
| <i>Glivec (NV)</i> .....                                                  | 229 | GRANISETRON HYDROCHLORIDE .....               | 84  |
| GLOVES PLASTIC (DISPOSABLE) .....                                         |     | <i>Granocyte 13 (HH)</i> .....                |     |
| .Repatriation Schedule .....                                              | 721 | .Section 100 .....                            | 602 |
| <i>GlucaGen Hypokit (NO)</i> .....                                        |     | <i>Granocyte 34 (HH)</i> .....                |     |
| .Doctor's Bag Supplies .....                                              | 70  | .Section 100 .....                            | 602 |
| .Systemic hormonal preparations, excl. sex hormones and<br>insulins ..... | 182 | GRISEOFULVIN .....                            | 156 |
| .Dental .....                                                             | 477 | <i>Grisovin (SI)</i> .....                    | 156 |
| GLUCAGON HYDROCHLORIDE .....                                              |     | <i>Grisovin 500 (SI)</i> .....                | 156 |
| .Doctor's Bag Supplies .....                                              | 70  |                                               |     |
| .Systemic hormonal preparations, excl. sex hormones and<br>insulins ..... | 182 |                                               |     |
| .Dental .....                                                             | 477 |                                               |     |
| <i>Glucobay 100 (BN)</i> .....                                            | 101 |                                               |     |
| <i>Glucobay 50 (BN)</i> .....                                             | 100 |                                               |     |
| <i>Glucobay (DB)</i> .....                                                | 438 |                                               |     |
| <i>Glucocard 01 Sensor (OZ)</i> .....                                     | 438 |                                               |     |
| <i>GlucoCare Super Sensor (OZ)</i> .....                                  | 438 |                                               |     |
| <i>Glucoflex-R (NA)</i> .....                                             | 438 |                                               |     |

## H

|                                              |     |
|----------------------------------------------|-----|
| <i>Haemacel (AE)</i> .....                   | 113 |
| <i>Haldol decanoate (JC)</i> .....           | 378 |
| HALOPERIDOL .....                            |     |
| .Doctor's Bag Supplies .....                 | 69  |
| .Nervous system .....                        | 377 |
| HALOPERIDOL DECANOATE .....                  | 378 |
| <i>Hamilton Pine Tar Solution (HA)</i> ..... |     |

## GENERIC/PROPRIETARY INDEX

|                                                       |     |                                                         |     |
|-------------------------------------------------------|-----|---------------------------------------------------------|-----|
| .Repatriation Schedule .....                          | 688 | .Genito urinary system and sex hormones .....           | 174 |
| Hamilton Skin Therapy Oil (HA)                        |     | .Section 100 .....                                      | 637 |
| .Repatriation Schedule .....                          | 687 | Humatrope (LY)                                          |     |
| Hamilton Skin Therapy Wash (HA)                       |     | .Section 100 .....                                      | 634 |
| .Repatriation Schedule .....                          | 691 | Humira (AB) .....                                       | 270 |
| Hamilton Solastick 30+ (HA)                           |     | Humulin 30/70 (LY) .....                                | 96  |
| .Repatriation Schedule .....                          | 687 | Humulin NPH (LY) .....                                  | 96  |
| Hamilton Sunscreen Family Sunscreen Cream SPF 15 (HA) |     | Humulin R (LY) .....                                    | 95  |
| .Repatriation Schedule .....                          | 687 | Hycamtin (GK) .....                                     | 243 |
| Hamilton Sunscreen Family Sunscreen Milk SPF 15 (HA)  |     | Hycor (SI)                                              |     |
| .Repatriation Schedule .....                          | 688 | .Sensory organs .....                                   | 423 |
| Handy 4207 (BV)                                       |     | .Optometrical .....                                     | 501 |
| .Repatriation Schedule .....                          | 721 | Hydopa (AF) .....                                       | 118 |
| Handy 4208 (BV)                                       |     | HYDRALAZINE HYDROCHLORIDE .....                         | 119 |
| .Repatriation Schedule .....                          | 721 | Hydrea (BQ) .....                                       | 243 |
| Handy 4209 (BV)                                       |     | Hydrene 25/50 (AF) .....                                | 122 |
| .Repatriation Schedule .....                          | 721 | HYDROCHLOROTHIAZIDE .....                               | 119 |
| Handy 5608 (BV)                                       |     | HYDROCHLOROTHIAZIDE WITH AMILORIDE                      |     |
| .Repatriation Schedule .....                          | 710 | HYDROCHLORIDE .....                                     | 122 |
| Handy 5672 (BV)                                       |     | HYDROCHLOROTHIAZIDE WITH TRIAMTERENE .....              | 122 |
| .Repatriation Schedule .....                          | 715 | Hydrocoll 900938/1 (HR)                                 |     |
| Handy 5674 (BV)                                       |     | .Repatriation Schedule .....                            | 718 |
| .Repatriation Schedule .....                          | 715 | Hydrocoll 900939/1 (HR)                                 |     |
| Handygauze Cohesive 8631 (BV)                         |     | .Repatriation Schedule .....                            | 718 |
| .Repatriation Schedule .....                          | 711 | Hydrocoll Thin 900942/1 (HR)                            |     |
| Handygauze Cohesive 8633 (BV)                         |     | .Repatriation Schedule .....                            | 717 |
| .Repatriation Schedule .....                          | 711 | HYDROCORTISONE                                          |     |
| Handygauze Cohesive 8635 (BV)                         |     | .Dermatologicals .....                                  | 158 |
| .Repatriation Schedule .....                          | 711 | .Systemic hormonal preparations, excl. sex hormones and |     |
| HCU Cooler (VF) .....                                 | 448 | insulins .....                                          | 180 |
| HCU express (VF) .....                                | 448 | HYDROCORTISONE ACETATE                                  |     |
| HCU gel (VF) .....                                    | 448 | .Alimentary tract and metabolism .....                  | 92  |
| healthsense Clotrimazole 3 Day Cream (HS)             |     | .Dermatologicals .....                                  | 159 |
| .Repatriation Schedule .....                          | 693 | .Sensory organs .....                                   | 423 |
| healthsense Clotrimazole 6 Day Cream (HS)             |     | .Dental .....                                           | 475 |
| .Repatriation Schedule .....                          | 692 | .Optometrical .....                                     | 501 |
| HEPARIN SODIUM .....                                  | 107 | HYDROCORTISONE SODIUM SUCCINATE                         |     |
| Hepsera (GI)                                          |     | .Doctor's Bag Supplies .....                            | 69  |
| .Section 100 .....                                    | 514 | .Systemic hormonal preparations, excl. sex hormones and |     |
| Herceptin (RO)                                        |     | insulins .....                                          | 180 |
| .Section 100 .....                                    | 639 | .Dental .....                                           | 476 |
| Hexal Clofeme 3 Day Cream (HX)                        |     | HYDROCORTISONE WITH CINCHOCAINE                         |     |
| .Repatriation Schedule .....                          | 693 | HYDROCHLORIDE                                           |     |
| Hexal Clofeme 6 Day Cream (HX)                        |     | .Repatriation Schedule .....                            | 684 |
| .Repatriation Schedule .....                          | 692 | HYDROLYZED COLLAGEN PROTEINS                            |     |
| Hexal Konazol 2% Shampoo (HX)                         |     | .Repatriation Schedule .....                            | 691 |
| .Repatriation Schedule .....                          | 685 | HYDROMORPHONE HYDROCHLORIDE                             |     |
| HEXAMINE HIPPURATE .....                              | 202 | .Nervous system .....                                   | 354 |
| Hiprex (IA) .....                                     | 202 | .Dental .....                                           | 492 |
| Holoxan (BX) .....                                    | 211 | HYDROXOCOBALAMIN .....                                  | 112 |
| HOMATROPINE HYDROBROMIDE .....                        | 427 | HYDROXYCHLOROQUINE SULFATE .....                        | 343 |
| HPMC PAA (NM)                                         |     | HYDROXYUREA .....                                       | 243 |
| .Sensory organs .....                                 | 431 | Hyforil (RA) .....                                      | 138 |
| .Optometrical .....                                   | 503 | Hygroton 25 (NV) .....                                  | 119 |
| Humalog (LY) .....                                    | 95  | HYOSCINE BUTYLBROMIDE                                   |     |
| Humalog Mix25 (LY) .....                              | 96  | .Doctor's Bag Supplies .....                            | 70  |
| Humalog Mix50 (LY) .....                              | 96  | .Palliative Care .....                                  | 455 |
| HUMAN CHORIONIC GONADOTROPHIN                         |     | .Repatriation Schedule .....                            | 681 |

## GENERIC/PROPRIETARY INDEX

|                                   |     |                                         |     |
|-----------------------------------|-----|-----------------------------------------|-----|
| <i>Hypafix 71443-0 (BV)</i>       |     | .Dermatologicals                        | 161 |
| .Repatriation Schedule            | 721 | .Repatriation Schedule                  | 691 |
| <i>Hypafix 71443-1 (BV)</i>       |     | <i>ImmuCyst (SW)</i>                    | 251 |
| .Repatriation Schedule            | 721 | <i>Imodium (JT)</i>                     | 91  |
| <i>Hypnodorm (AF)</i>             |     | <i>Imovane (SW)</i>                     |     |
| .Repatriation Schedule            | 700 | .Repatriation Schedule                  | 700 |
| HYPROMELLOSE                      |     | <i>Implanon (OR)</i>                    | 166 |
| .Sensory organs                   | 431 | <i>Improvil 28 Day (KR)</i>             | 166 |
| .Optometrical                     | 503 | <i>Imrest (AF)</i>                      |     |
| HYPROMELLOSE WITH CARBOMER 980    |     | .Repatriation Schedule                  | 700 |
| .Sensory organs                   | 431 | <i>Imtrate 60 mg (GM)</i>               | 117 |
| .Optometrical                     | 503 | <i>Imukin (BY)</i>                      |     |
| HYPROMELLOSE WITH DEXTRAN         |     | .Section 100                            | 599 |
| .Sensory organs                   | 432 | <i>Imuran (GK)</i>                      | 336 |
| .Optometrical                     | 503 | <i>In a Wink Moisturising (NM)</i>      |     |
| <i>Hypurin Isophane (AS)</i>      | 96  | .Sensory organs                         | 431 |
| <i>Hypurin Neutral (AS)</i>       | 95  | .Optometrical                           | 503 |
| <i>Hysone 20 (AF)</i>             | 180 | <i>Indahexal (SZ)</i>                   | 120 |
| <i>Hysone 4 (AF)</i>              | 180 | INDAPAMIDE HEMIHYDRATE                  | 120 |
| <i>Hytrin (AB)</i>                |     | <i>Inderal (AP)</i>                     | 122 |
| .Repatriation Schedule            | 695 | INDINAVIR SULFATE                       |     |
|                                   |     | .Section 100                            | 554 |
| <b>I</b>                          |     | <i>Indocid (MK)</i>                     |     |
| <i>Ialax (LN)</i>                 |     | .Musculo-skeletal system                | 338 |
| .Anti-infectives for systemic use | 192 | .Palliative Care                        | 461 |
| .Dental                           | 483 | .Dental                                 | 489 |
| IBANDRONATE SODIUM                |     | INDOMETHACIN                            |     |
| .Section 100                      | 547 | .Musculo-skeletal system                | 338 |
| <i>Ibilex 125 (AF)</i>            |     | .Palliative Care                        | 461 |
| .Anti-infectives for systemic use | 193 | .Dental                                 | 489 |
| .Dental                           | 484 | <i>Indopril 2 (SI)</i>                  | 134 |
| <i>Ibilex 250 (AF)</i>            |     | <i>Indopril 4 (SI)</i>                  | 134 |
| .Anti-infectives for systemic use | 192 | <i>Indopril 8 (SI)</i>                  | 135 |
| .Dental                           | 483 | INFLIXIMAB                              |     |
| <i>Ibilex 500 (AF)</i>            |     | .Section 100                            | 554 |
| .Anti-infectives for systemic use | 193 | .Repatriation Schedule                  | 696 |
| .Dental                           | 483 | INFLUENZA VACCINE                       | 210 |
| <i>Ibimicyc (GM)</i>              |     | <i>Influvac (SM)</i>                    | 210 |
| .Anti-infectives for systemic use | 188 | INSECT ALLERGEN EXTRACT—HONEY BEE       |     |
| .Dental                           | 479 | VENOM                                   | 435 |
| IBUPROFEN                         |     | INSECT ALLERGEN EXTRACT—PAPER WASP      |     |
| .Musculo-skeletal system          | 341 | VENOM                                   | 435 |
| .Palliative Care                  | 462 | INSECT ALLERGEN EXTRACT—YELLOW JACKET   |     |
| .Dental                           | 490 | VENOM                                   | 435 |
| IDARUBICIN HYDROCHLORIDE          | 219 | <i>Insig (SI)</i>                       | 120 |
| IFOSFAMIDE                        | 211 | <i>Inspira (PF)</i>                     | 121 |
| <i>Ikorel (SW)</i>                | 117 | INSULIN ASPART                          | 95  |
| ILOPROST TROMETAMOL               |     | INSULIN ASPART—INSULIN ASPART PROTAMINE |     |
| .Section 100                      | 547 | SUSPENSION                              | 96  |
| IMATINIB                          | 227 | INSULIN DETEMIR                         | 97  |
| <i>Imdur 120 mg (AP)</i>          | 117 | INSULIN GLARGINE                        | 97  |
| <i>Imdur Durule (AP)</i>          | 117 | INSULIN GLULISINE                       | 95  |
| <i>Imigran (GK)</i>               | 366 | INSULIN ISOPHANE (N.P.H.)               | 96  |
| <i>Imigran FDT (GK)</i>           | 366 | INSULIN LISPRO                          | 95  |
| IMIPRAMINE HYDROCHLORIDE          | 386 | INSULIN LISPRO—INSULIN LISPRO PROTAMINE |     |
| IMIQUIMOD                         |     | SUSPENSION                              | 96  |
|                                   |     | INSULIN NEUTRAL                         | 95  |

## GENERIC/PROPRIETARY INDEX

|                                                                              |     |                                                    |     |
|------------------------------------------------------------------------------|-----|----------------------------------------------------|-----|
| INSULIN NEUTRAL—INSULIN ISOPHANE (N.P.H.), (MIXED) (BIPHASIC ISOPHANE) ..... | 96  | .Repatriation Schedule .....                       | 702 |
| <i>Intal</i> (SW) .....                                                      | 419 | <i>Ipravent</i> (PU) .....                         | 418 |
| <i>Intal CFC-Free</i> (SW) .....                                             | 419 | IRBESARTAN .....                                   | 140 |
| <i>Intal Forte CFC-Free</i> (SW) .....                                       | 419 | IRBESARTAN WITH HYDROCHLOROTHIAZIDE .....          | 141 |
| <i>Intal Spincaps</i> (GM) .....                                             | 419 | <i>Ircal</i> (PE) .....                            |     |
| <i>Integrilin</i> (SH) .....                                                 | 109 | .Sensory organs .....                              | 432 |
| INTERFERON ALFA-2A .....                                                     |     | .Optometrical .....                                | 504 |
| .Antineoplastic and immunomodulating agents .....                            | 249 | <i>Iressa</i> (AP) .....                           | 227 |
| .Section 100 .....                                                           | 598 | IRINOTECAN HYDROCHLORIDE TRIHYDRATE .....          | 243 |
| INTERFERON ALFA-2B .....                                                     |     | <i>Irinotecan Sandoz</i> (SZ) .....                | 243 |
| .Antineoplastic and immunomodulating agents .....                            | 250 | IRON POLYMALTOSE COMPLEX .....                     | 112 |
| .Section 100 .....                                                           | 598 | IRON SUCROSE .....                                 | 112 |
| INTERFERON BETA-1A .....                                                     | 250 | <i>Iscover</i> (BQ) .....                          |     |
| INTERFERON BETA-1B .....                                                     | 251 | .Blood and blood forming organs .....              | 108 |
| INTERFERON GAMMA-1B .....                                                    |     | .Repatriation Schedule .....                       | 684 |
| .Section 100 .....                                                           | 599 | <i>Isentress</i> (MK) .....                        |     |
| <i>Intrasite Gel 7313</i> (SN) .....                                         |     | .Section 100 .....                                 | 607 |
| .Repatriation Schedule .....                                                 | 719 | <i>Isoleucine Amino Acid Supplement</i> (VF) ..... | 451 |
| <i>Intron A</i> (SH) .....                                                   |     | ISOLEUCINE WITH CARBOHYDRATE .....                 | 451 |
| .Section 100 .....                                                           | 599 | <i>Isomonit</i> (SZ) .....                         | 117 |
| <i>Intron A Redipen</i> (SH) .....                                           |     | ISONIAZID .....                                    | 204 |
| .Antineoplastic and immunomodulating agents .....                            | 250 | <i>Isoptin</i> (AB) .....                          |     |
| .Section 100 .....                                                           | 599 | .Doctor's Bag Supplies .....                       | 71  |
| <i>Invega</i> (JC) .....                                                     | 380 | .Cardiovascular system .....                       | 128 |
| <i>Invirase</i> (RO) .....                                                   |     | <i>Isoptin 180 SR</i> (AB) .....                   | 129 |
| .Section 100 .....                                                           | 615 | <i>Isoptin SR</i> (AB) .....                       | 129 |
| <i>Inza 250</i> (AF) .....                                                   |     | <i>Isopto Carpine</i> (AQ) .....                   | 424 |
| .Musculo-skeletal system .....                                               | 342 | <i>Isopto Homatropine</i> (AQ) .....               | 427 |
| .Palliative Care .....                                                       | 463 | <i>Isordil Sublingual</i> (SI) .....               | 117 |
| .Dental .....                                                                | 491 | ISOSORBIDE DINITRATE .....                         | 117 |
| <i>Inza 500</i> (AF) .....                                                   |     | ISOSORBIDE MONONITRATE .....                       | 117 |
| .Musculo-skeletal system .....                                               | 342 | ISOTRETINOIN .....                                 | 161 |
| .Palliative Care .....                                                       | 463 | ISPAGHULA HUSK .....                               |     |
| .Dental .....                                                                | 491 | .Repatriation Schedule .....                       | 681 |
| <i>Iodosorb 66051330</i> (SN) .....                                          |     | ITRACONAZOLE .....                                 | 204 |
| .Repatriation Schedule .....                                                 | 720 | IVERMECTIN .....                                   | 410 |
| <i>Iodosorb 66051340</i> (SN) .....                                          |     |                                                    |     |
| .Repatriation Schedule .....                                                 | 720 | <b>J</b> .....                                     |     |
| <i>Iodosorb 66051360</i> (SN) .....                                          |     | <i>Januvia</i> (MK) .....                          | 103 |
| .Repatriation Schedule .....                                                 | 720 | <i>Jelonet 7404</i> (SN) .....                     |     |
| <i>Iodosorb Ointment 66051230</i> (SN) .....                                 |     | .Repatriation Schedule .....                       | 715 |
| .Repatriation Schedule .....                                                 | 720 | <i>Jezil</i> (AF) .....                            | 151 |
| <i>Iodosorb Ointment 66051240</i> (SN) .....                                 |     | <i>JJ 02013</i> (JJ) .....                         |     |
| .Repatriation Schedule .....                                                 | 720 | .Repatriation Schedule .....                       | 713 |
| <i>Iodosorb Powder 66051070</i> (SN) .....                                   |     | <i>JJ 12010</i> (JJ) .....                         |     |
| .Repatriation Schedule .....                                                 | 720 | .Repatriation Schedule .....                       | 720 |
| <i>Ionil</i> (GA) .....                                                      |     |                                                    |     |
| .Repatriation Schedule .....                                                 | 690 | <b>K</b> .....                                     |     |
| <i>Ionil Rinse</i> (GA) .....                                                |     | <i>Kaletra</i> (AB) .....                          |     |
| .Repatriation Schedule .....                                                 | 691 | .Section 100 .....                                 | 602 |
| <i>Ionil-T</i> (GA) .....                                                    |     | <i>Kalixocin</i> (AF) .....                        | 197 |
| .Repatriation Schedule .....                                                 | 690 | <i>Kalma 0.25</i> (AF) .....                       | 382 |
| <i>Iopidine 0.5%</i> (AQ) .....                                              | 424 | <i>Kalma 0.5</i> (AF) .....                        | 382 |
| <i>Ipratrin</i> (AF) .....                                                   | 418 | <i>Kalma 1</i> (AF) .....                          | 382 |
| <i>Ipratrin Adult</i> (AF) .....                                             | 419 | <i>Kalma 2</i> (AF) .....                          | 383 |
| IPRATROPIUM BROMIDE .....                                                    |     |                                                    |     |
| .Respiratory system .....                                                    | 418 |                                                    |     |



## GENERIC/PROPRIETARY INDEX

|                                                                |     |                                                |     |
|----------------------------------------------------------------|-----|------------------------------------------------|-----|
| <i>Kaltostat 168117 (CC)</i>                                   |     | <i>.Antiinfectives for systemic use</i>        | 197 |
| <i>.Repatriation Schedule</i>                                  | 713 | <i>.Section 100</i>                            | 527 |
| <i>Kaltostat 168210 (CC)</i>                                   |     | <i>Klacid Hp 7 (AB)</i>                        | 83  |
| <i>.Repatriation Schedule</i>                                  | 713 | <i>Kliogest (NO)</i>                           | 170 |
| <i>Kaltostat 168212 (CC)</i>                                   |     | <i>Kliovance (NO)</i>                          | 170 |
| <i>.Repatriation Schedule</i>                                  | 713 | <i>Kosteo (AW)</i>                             |     |
| <i>Kaluril (AF)</i>                                            | 121 | <i>.Alimentary tract and metabolism</i>        | 104 |
| <i>Kapanol (GK)</i>                                            |     | <i>.Musculo-skeletal system</i>                | 352 |
| <i>.Nervous system</i>                                         | 357 | <i>Kredex (MD)</i>                             | 125 |
| <i>.Dental</i>                                                 | 493 | <i>Krypton 10 (AF)</i>                         |     |
| <i>Karicare De-Lact (NU)</i>                                   | 445 | <i>.Genito urinary system and sex hormones</i> | 163 |
| <i>Karlor CD (LN)</i>                                          |     | <i>.Nervous system</i>                         | 375 |
| <i>.Antiinfectives for systemic use</i>                        | 194 | <i>Krypton 2.5 (AF)</i>                        |     |
| <i>.Dental</i>                                                 | 484 | <i>.Genito urinary system and sex hormones</i> | 163 |
| <i>Karvea (SW)</i>                                             | 140 | <i>.Nervous system</i>                         | 375 |
| <i>Karvezide 150/12.5 (SW)</i>                                 | 141 | <i>Krypton 5 (AF)</i>                          |     |
| <i>Karvezide 300/12.5 (SW)</i>                                 | 141 | <i>.Genito urinary system and sex hormones</i> | 163 |
| <i>Karvezide 300/25 (SW)</i>                                   | 142 | <i>.Nervous system</i>                         | 375 |
| <i>Keflex (AS)</i>                                             |     | <i>K-Sol (LN)</i>                              | 105 |
| <i>.Antiinfectives for systemic use</i>                        | 192 | <i>Kytril (HH)</i>                             | 84  |
| <i>.Dental</i>                                                 | 483 |                                                |     |
| <i>Keflin Neutral (AS)</i>                                     |     | <b>L</b>                                       |     |
| <i>.Antiinfectives for systemic use</i>                        | 192 | <i>LABETALOL HYDROCHLORIDE</i>                 | 126 |
| <i>.Dental</i>                                                 | 483 | <i>Lac-Dol (GM)</i>                            |     |
| <i>Keflor (AF)</i>                                             |     | <i>.Alimentary tract and metabolism</i>        | 89  |
| <i>.Antiinfectives for systemic use</i>                        | 194 | <i>.Palliative Care</i>                        | 457 |
| <i>.Dental</i>                                                 | 485 | <i>Lacri-Lube (AG)</i>                         |     |
| <i>Keflor CD (AF)</i>                                          |     | <i>.Sensory organs</i>                         | 432 |
| <i>.Antiinfectives for systemic use</i>                        | 194 | <i>.Optometrical</i>                           | 504 |
| <i>.Dental</i>                                                 | 484 | <i>Lactocur (HX)</i>                           |     |
| <i>Kefzol (AS)</i>                                             | 193 | <i>.Alimentary tract and metabolism</i>        | 89  |
| <i>Kenacomb (BQ)</i>                                           |     | <i>.Palliative Care</i>                        | 457 |
| <i>.Repatriation Schedule</i>                                  | 689 | <b>LACTULOSE</b>                               |     |
| <i>Kenacomb Otic (BQ)</i>                                      | 434 | <i>.Alimentary tract and metabolism</i>        | 89  |
| <i>Kenacort-A10 (BQ)</i>                                       |     | <i>.Palliative Care</i>                        | 457 |
| <i>.Systemic hormonal preparations, excl. sex hormones and</i> |     | <i>Lamictal (GK)</i>                           | 371 |
| <i>insulins</i>                                                | 181 | <i>Lamidus (RA)</i>                            | 371 |
| <i>.Dental</i>                                                 | 477 | <i>Lamisil (NC)</i>                            |     |
| <i>Keppra (UC)</i>                                             |     | <i>.Dermatologicals</i>                        | 156 |
| <i>.Special Pharmaceutical Benefits</i>                        | 73  | <i>.Repatriation Schedule</i>                  | 686 |
| <i>.Nervous system</i>                                         | 372 | <i>Lamisil (NV)</i>                            |     |
| <b>KETOCONAZOLE</b>                                            |     | <i>.Dermatologicals</i>                        | 156 |
| <i>.Dermatologicals</i>                                        | 155 | <i>.Repatriation Schedule</i>                  | 686 |
| <i>.Antiinfectives for systemic use</i>                        | 203 | <i>Lamisil DermGel (NC)</i>                    |     |
| <i>.Repatriation Schedule</i>                                  | 685 | <i>.Repatriation Schedule</i>                  | 686 |
| <i>Keto-Diabur- Test 5000 (RD)</i>                             | 437 | <i>Lamitrin (HX)</i>                           | 371 |
| <i>Keto-Diastix (BN)</i>                                       | 437 | <b>LAMIVUDINE</b>                              |     |
| <i>Ketonex-1 (AB)</i>                                          | 450 | <i>.Section 100</i>                            | 599 |
| <i>Ketonex-2 (AB)</i>                                          | 450 | <b>LAMIVUDINE WITH ZIDOVUDINE</b>              |     |
| <b>KETOPROFEN</b>                                              |     | <i>.Section 100</i>                            | 600 |
| <i>.Musculo-skeletal system</i>                                | 341 | <i>Lamogine (AF)</i>                           | 371 |
| <i>.Dental</i>                                                 | 490 | <b>LAMOTRIGINE</b>                             | 371 |
| <i>Kindergen (SB)</i>                                          | 452 | <i>Lamotrigine-DP (GM)</i>                     | 371 |
| <i>Kineret (AN)</i>                                            | 334 | <i>Lamotrigine generichealth (GQ)</i>          | 371 |
| <i>Kinson (AF)</i>                                             | 374 | <i>Lamotrigine Sandoz (SZ)</i>                 | 371 |
| <i>Kivexa (GK)</i>                                             |     | <i>Lanoxin (SI)</i>                            | 114 |
| <i>.Section 100</i>                                            | 507 |                                                |     |
| <i>Klacid (AB)</i>                                             |     |                                                |     |

## GENERIC/PROPRIETARY INDEX

|                                                    |     |                                                |     |
|----------------------------------------------------|-----|------------------------------------------------|-----|
| <i>Lanoxin-PG (SI)</i> .....                       | 114 | <i>Levemir Penfill (NO)</i> .....              | 97  |
| LANREOTIDE ACETATE                                 |     | LEVETIRACETAM                                  |     |
| . Section 100 .....                                | 600 | . Special Pharmaceutical Benefits .....        | 73  |
| LANSOPRAZOLE .....                                 | 79  | . Nervous system .....                         | 372 |
| <i>Lantus (SW)</i> .....                           | 97  | <i>Leven ED (SY)</i> .....                     | 165 |
| <i>Lantus SoloStar (AV)</i> .....                  | 97  | LEVOBUNOLOL HYDROCHLORIDE .....                | 425 |
| <i>Lanvis (GK)</i> .....                           | 214 | LEVOCABASTINE HYDROCHLORIDE                    |     |
| LAPATINIB .....                                    | 235 | . Repatriation Schedule .....                  | 702 |
| <i>Largactil (SW)</i>                              |     | . Repatriation Schedule .....                  | 704 |
| . Doctor's Bag Supplies .....                      | 69  | LEVODOPA WITH BENSERAZIDE .....                | 374 |
| . Nervous system .....                             | 377 | LEVODOPA WITH CARBIDOPA .....                  | 374 |
| <i>Lasix (SW)</i>                                  |     | LEVODOPA WITH CARBIDOPA AND                    |     |
| . Doctor's Bag Supplies .....                      | 70  | ENTACAPONE .....                               | 375 |
| . Cardiovascular system .....                      | 120 | <i>Levohexal (HX)</i> .....                    | 374 |
| <i>Lasix-M (SW)</i> .....                          | 120 | LEVONORGESTREL                                 |     |
| LATANOPROST .....                                  | 426 | . Genito urinary system and sex hormones ..... | 163 |
| LATANOPROST WITH TIMOLOL MALEATE .....             | 426 | . Genito urinary system and sex hormones ..... | 166 |
| <i>Lax-Tab (AE)</i>                                |     | LEVONORGESTREL WITH ETHINYLOESTRADIOL          |     |
| . Alimentary tract and metabolism .....            | 88  | . Genito urinary system and sex hormones ..... | 164 |
| . Palliative Care .....                            | 456 | . Genito urinary system and sex hormones ..... | 165 |
| LEFLUNOMIDE                                        |     | <i>Lexapro (LU)</i>                            |     |
| . Antineoplastic and immunomodulating agents ..... | 263 | . Special Pharmaceutical Benefits .....        | 72  |
| . Musculo-skeletal system .....                    | 344 | . Nervous system .....                         | 388 |
| <i>Lengout (LN)</i> .....                          | 345 | <i>Lexotan (RO)</i>                            |     |
| LENOGRASTIM                                        |     | . Repatriation Schedule .....                  | 700 |
| . Section 100 .....                                | 601 | LIGNOCAINE HYDROCHLORIDE                       |     |
| LERCANIDIPINE HYDROCHLORIDE .....                  | 127 | . Doctor's Bag Supplies .....                  | 70  |
| LERCANIDIPINE HYDROCHLORIDE WITH                   |     | . Cardiovascular system .....                  | 114 |
| ENALAPRIL MALEATE .....                            | 139 | . Dental .....                                 | 475 |
| <i>Lescol (NV)</i> .....                           | 146 | LIGNOCAINE HYDROCHLORIDE WITH                  |     |
| <i>Lescol XL (NV)</i> .....                        | 146 | CARBOXYMETHYLCELLULOSE                         |     |
| LETROZOLE .....                                    | 248 | . Repatriation Schedule .....                  | 688 |
| <i>Leucovorin Calcium (HH)</i> .....               | 436 | <i>Lincocin (PH)</i>                           |     |
| <i>Leucovorin Calcium (PF)</i> .....               | 436 | . Antiinfectives for systemic use .....        | 198 |
| <i>Leukeran (GK)</i> .....                         | 211 | . Dental .....                                 | 487 |
| <i>Leukoflex 1124 (BV)</i>                         |     | LINCOMYCIN                                     |     |
| . Repatriation Schedule .....                      | 721 | . Antiinfectives for systemic use .....        | 198 |
| <i>Leukoplast 1071 (BV)</i>                        |     | . Dental .....                                 | 487 |
| . Repatriation Schedule .....                      | 721 | <i>Lioresal 10 (NV)</i> .....                  | 344 |
| <i>Leukoplast 1072 (BV)</i>                        |     | <i>Lioresal 25 (NV)</i> .....                  | 344 |
| . Repatriation Schedule .....                      | 721 | <i>Lioresal Intrathecal (NV)</i>               |     |
| <i>Leukoplast 1073 (BV)</i>                        |     | . Section 100 .....                            | 515 |
| . Repatriation Schedule .....                      | 721 | LIOTHYRONINE SODIUM .....                      | 182 |
| <i>Leukopor 2471 (BV)</i>                          |     | <i>Lipazil 600 mg (GM)</i> .....               | 151 |
| . Repatriation Schedule .....                      | 721 | <i>Lipex 10 (FR)</i> .....                     | 149 |
| <i>Leukopor 2472 (BV)</i>                          |     | <i>Lipex 20 (FR)</i> .....                     | 149 |
| . Repatriation Schedule .....                      | 721 | <i>Lipex 40 (FR)</i> .....                     | 150 |
| <i>Leukopor 2474 (BV)</i>                          |     | <i>Lipex 80 (FR)</i> .....                     | 150 |
| . Repatriation Schedule .....                      | 721 | <i>Lipidil (SM)</i> .....                      | 151 |
| <i>Leukosilk 1021 (BV)</i>                         |     | <i>Lipitor (PF)</i> .....                      | 146 |
| . Repatriation Schedule .....                      | 721 | <i>Lipostat 10 (AW)</i> .....                  | 147 |
| <i>Leukosilk 1022 (BV)</i>                         |     | <i>Lipostat 20 (AW)</i> .....                  | 147 |
| . Repatriation Schedule .....                      | 721 | <i>Lipostat 40 (AW)</i> .....                  | 148 |
| <i>Leukosilk 1024 (BV)</i>                         |     | <i>Lipostat 80 (AW)</i> .....                  | 148 |
| . Repatriation Schedule .....                      | 721 | <i>Liprace (GM)</i> .....                      | 133 |
| LEUPRORELIN ACETATE .....                          | 245 | <i>Liprachol (SZ)</i> .....                    | 147 |
| <i>Leustatin (JC)</i> .....                        | 214 | <i>Liquifilm Forte (AG)</i>                    |     |
| <i>Levemir FlexPen (NF)</i> .....                  | 97  | . Sensory organs .....                         | 433 |

## GENERIC/PROPRIETARY INDEX

|                                      |     |                                     |     |
|--------------------------------------|-----|-------------------------------------|-----|
| .Optometrical .....                  | 504 | .Repatriation Schedule .....        | 721 |
| Liquifilm Tears (AG) .....           |     | Lucentis (NV) .....                 | 428 |
| .Sensory organs .....                | 432 | Lucrin Depot 3 Month PDS (AB) ..... | 245 |
| .Optometrical .....                  | 504 | Lucrin Depot 4 Month PDS (AB) ..... | 245 |
| Lisinobell (BF) .....                | 133 | Lucrin Depot 7.5mg PDS (AB) .....   | 245 |
| LISINOPRIL .....                     | 133 | Lumigan (AG) .....                  | 426 |
| Lisinopril 10 (CR) .....             | 133 | Lumin 10 (AF) .....                 | 393 |
| Lisinopril 20 (CR) .....             | 134 | Lumin 20 (AF) .....                 | 393 |
| Lisinopril 5 (CR) .....              | 133 | Luvox (SM) .....                    | 389 |
| Lisinopril generichealth (GQ) .....  | 134 | Lycinate (FM) .....                 |     |
| Lisinopril Hexal (HX) .....          | 133 | .Cardiovascular system .....        | 116 |
| Lisinopril Winthrop (WA) .....       | 133 | .Dental .....                       | 475 |
| Lisinotrust 10 (MI) .....            | 133 | Lyclear (JT) .....                  | 411 |
| Lisinotrust 20 (MI) .....            | 134 | Lyofam C 603025 (SS) .....          |     |
| Lisinotrust 5 (MI) .....             | 133 | .Repatriation Schedule .....        | 715 |
| Lisodur (AF) .....                   | 133 | Lyofam Extra 603088 (XP) .....      |     |
| Litak (OA) .....                     | 214 | .Repatriation Schedule .....        | 714 |
| Lithicarb (AS) .....                 |     | Lyofam Extra 603090 (XP) .....      |     |
| .Nervous system .....                |     | .Repatriation Schedule .....        | 714 |
| .Nervous system .....                | 392 | Lyofam Flat 603092 (XP) .....       |     |
| LITHIUM CARBONATE .....              |     | .Repatriation Schedule .....        | 714 |
| .Nervous system .....                | 379 | Lyofam Flat 603093 (XP) .....       |     |
| .Nervous system .....                | 392 | .Repatriation Schedule .....        | 715 |
| Livostin (JT) .....                  |     | Lyofam Flat 603095 (XP) .....       |     |
| .Repatriation Schedule .....         | 702 | .Repatriation Schedule .....        | 715 |
| .Repatriation Schedule .....         | 704 | Lyrica (PF) .....                   |     |
| Locasol (NU) .....                   | 446 | .Repatriation Schedule .....        | 699 |
| Loceryl (GA) .....                   |     |                                     |     |
| .Repatriation Schedule .....         | 685 |                                     |     |
| Locilan 28 Day (KR) .....            | 166 |                                     |     |
| Lofenoxal (HC) .....                 | 91  |                                     |     |
| Logicin Rapid Relief (SI) .....      |     |                                     |     |
| .Repatriation Schedule .....         | 701 |                                     |     |
| Logicin Sinus (SI) .....             |     |                                     |     |
| .Repatriation Schedule .....         | 702 |                                     |     |
| Logynon ED (SY) .....                | 165 |                                     |     |
| Lomotil (BI) .....                   | 91  |                                     |     |
| Loniten (PH) .....                   | 119 |                                     |     |
| LOPERAMIDE HYDROCHLORIDE .....       | 91  |                                     |     |
| Lophlex (SB) .....                   | 449 |                                     |     |
| Lophlex LQ (SB) .....                | 449 |                                     |     |
| Lopid (PF) .....                     | 151 |                                     |     |
| LOPINAVIR WITH RITONAVIR .....       |     |                                     |     |
| .Section 100 .....                   | 602 |                                     |     |
| Lopresor 100 (NV) .....              | 124 |                                     |     |
| Lopresor 50 (NV) .....               | 124 |                                     |     |
| Lorano (HX) .....                    |     |                                     |     |
| .Repatriation Schedule .....         | 703 |                                     |     |
| LORATADINE .....                     |     |                                     |     |
| .Repatriation Schedule .....         | 703 |                                     |     |
| Lossec Tablets (AP) .....            | 80  |                                     |     |
| Lovan (AL) .....                     | 389 |                                     |     |
| Lovan 20 Tab (AL) .....              | 388 |                                     |     |
| Lovir (GM) .....                     | 205 |                                     |     |
| LPV (AS) .....                       |     |                                     |     |
| .Antifungives for systemic use ..... | 188 |                                     |     |
| .Dental .....                        | 479 |                                     |     |
| LUBRICATING AGENT .....              |     |                                     |     |

## M

|                                                   |     |
|---------------------------------------------------|-----|
| Mabthera (RO) .....                               |     |
| .Antineoplastic and immunomodulating agents ..... | 221 |
| .Section 100 .....                                | 615 |
| Macrodantin (PU) .....                            | 202 |
| MACROGOL 3350 .....                               |     |
| .Alimentary tract and metabolism .....            | 89  |
| .Palliative Care .....                            | 458 |
| Madopar (RO) .....                                | 374 |
| Madopar 125 (RO) .....                            | 374 |
| Madopar 62.5 (RO) .....                           | 374 |
| Madopar HBS (RO) .....                            | 374 |
| Madopar Rapid 125 (RO) .....                      | 374 |
| Madopar Rapid 62.5 (RO) .....                     | 374 |
| Magicul 200 (AF) .....                            | 76  |
| Magicul 400 (AF) .....                            | 76  |
| Magicul 800 (AF) .....                            | 76  |
| Magmin (BB) .....                                 |     |
| .Repatriation Schedule .....                      | 683 |
| MAGNESIUM ASPARTATE .....                         |     |
| .Repatriation Schedule .....                      | 683 |
| Maosig (SI) .....                                 | 392 |
| Mapleflex (SB) .....                              | 450 |
| Marevan (FM) .....                                | 106 |
| Maxamox (SZ) .....                                |     |
| .Antifungives for systemic use .....              | 187 |
| .Dental .....                                     | 479 |
| Maxidex (AQ) .....                                | 423 |

## GENERIC/PROPRIETARY INDEX

|                                                          |     |                                                                   |     |
|----------------------------------------------------------|-----|-------------------------------------------------------------------|-----|
| <i>Maxipime (BQ)</i> .....                               | 196 | <i>.Repatriation Schedule</i> .....                               | 681 |
| <i>Maxolon (VT)</i> .....                                |     | <i>Metamucil Smooth Texture Orange (PY)</i> .....                 |     |
| <i>.Doctor's Bag Supplies</i> .....                      | 70  | <i>.Repatriation Schedule</i> .....                               | 681 |
| <i>.Alimentary tract and metabolism</i> .....            | 83  | <i>Metforbell (BF)</i> .....                                      | 97  |
| <i>.Dental</i> .....                                     | 473 | <i>Metformin 500 (CR)</i> .....                                   | 97  |
| <i>MCT Oil (SB)</i> .....                                | 439 | <i>Metformin 850 (CR)</i> .....                                   | 98  |
| MEBENDAZOLE .....                                        |     | <i>Metformin generichealth (GQ)</i> .....                         | 97  |
| <i>.Repatriation Schedule</i> .....                      | 701 | METFORMIN HYDROCHLORIDE .....                                     | 97  |
| MEBEVERINE HYDROCHLORIDE .....                           |     | METFORMIN HYDROCHLORIDE WITH                                      |     |
| <i>.Repatriation Schedule</i> .....                      | 680 | GLIBENCLAMIDE .....                                               | 99  |
| <i>Medipore 2961 (MM)</i> .....                          |     | METHADONE HYDROCHLORIDE .....                                     |     |
| <i>.Repatriation Schedule</i> .....                      | 721 | <i>.Nervous system</i> .....                                      | 361 |
| <i>Medroxyhexal (SZ)</i> .....                           | 169 | <i>.Palliative Care</i> .....                                     | 467 |
| MEDROXYPROGESTERONE ACETATE .....                        |     | <i>.Section 100</i> .....                                         | 638 |
| <i>.Genito urinary system and sex hormones</i> .....     | 166 | <i>Methoblastin (PH)</i> .....                                    |     |
| <i>.Genito urinary system and sex hormones</i> .....     | 169 | <i>.Antineoplastic and immunomodulating agents</i> .....          | 213 |
| <i>.Antineoplastic and immunomodulating agents</i> ..... | 244 | <i>.Antineoplastic and immunomodulating agents</i> .....          | 336 |
| MEFENAMIC ACID .....                                     | 343 | <i>Methopt (SI)</i> .....                                         |     |
| <i>Mefix 310250 (MH)</i> .....                           |     | <i>.Sensory organs</i> .....                                      | 431 |
| <i>.Repatriation Schedule</i> .....                      | 721 | <i>.Optometrical</i> .....                                        | 503 |
| <i>Megace (BQ)</i> .....                                 | 244 | METHOTREXATE .....                                                |     |
| <i>Megafol 0.5 (AF)</i> .....                            | 112 | <i>.Antineoplastic and immunomodulating agents</i> .....          | 213 |
| <i>Megafol 5 (AF)</i> .....                              | 112 | <i>.Antineoplastic and immunomodulating agents</i> .....          | 336 |
| MEGESTROL ACETATE .....                                  | 244 | <i>Methotrexate Ebewe (IT)</i> .....                              | 213 |
| <i>Melizide (AF)</i> .....                               | 99  | METHYLDOPA .....                                                  | 118 |
| <i>Mellihexal (SZ)</i> .....                             | 98  | METHYLPHENIDATE HYDROCHLORIDE .....                               | 395 |
| <i>Melolin 36361357 (SN)</i> .....                       |     | METHYLPREDNISOLONE ACEPONATE .....                                | 160 |
| <i>.Repatriation Schedule</i> .....                      | 719 | METHYLPREDNISOLONE ACETATE .....                                  |     |
| <i>Melolin 66974933 (SN)</i> .....                       |     | <i>.Systemic hormonal preparations, excl. sex hormones and</i>    |     |
| <i>.Repatriation Schedule</i> .....                      | 720 | <i>insulins</i> .....                                             | 180 |
| <i>Meloxibell (BF)</i> .....                             | 339 | <i>.Dental</i> .....                                              | 476 |
| MELOXICAM .....                                          | 339 | METHYLPREDNISOLONE SODIUM SUCCINATE ....                          | 180 |
| <i>Meloxicam-GA (GM)</i> .....                           | 339 | METHYL SALICYLATE .....                                           |     |
| <i>Meloxicam Ranbaxy (RA)</i> .....                      | 339 | <i>.Repatriation Schedule</i> .....                               | 697 |
| <i>Meloxicam Sandoz (SZ)</i> .....                       | 339 | METHYSERGIDE .....                                                | 365 |
| <i>Meloxicam Winthrop (WA)</i> .....                     | 339 | METOCLOPRAMIDE HYDROCHLORIDE .....                                |     |
| MELPHALAN .....                                          | 211 | <i>.Doctor's Bag Supplies</i> .....                               | 70  |
| MEMANTINE HYDROCHLORIDE .....                            | 403 | <i>.Alimentary tract and metabolism</i> .....                     | 83  |
| <i>Mepilex 294100 (MH)</i> .....                         |     | <i>.Dental</i> .....                                              | 473 |
| <i>.Repatriation Schedule</i> .....                      | 715 | <i>Metohepal (SZ)</i> .....                                       | 124 |
| <i>Mepilex Border 295200 (MH)</i> .....                  |     | <i>Metolol (GM)</i> .....                                         | 124 |
| <i>.Repatriation Schedule</i> .....                      | 715 | METOPROLOL SUCCINATE .....                                        | 123 |
| <i>Mepilex Border 295300 (MH)</i> .....                  |     | METOPROLOL TARTRATE .....                                         | 124 |
| <i>.Repatriation Schedule</i> .....                      | 715 | <i>Metrogyl 200 (AF)</i> .....                                    |     |
| <i>Mepilex Lite 284000 (MH)</i> .....                    |     | <i>.Antiinfectives for systemic use</i> .....                     | 201 |
| <i>.Repatriation Schedule</i> .....                      | 715 | <i>.Antiparasitic products, insecticides and repellents ..</i>    |     |
| <i>Mepilex Lite 284100 (MH)</i> .....                    |     | <i>.Dental</i> .....                                              | 487 |
| <i>.Repatriation Schedule</i> .....                      | 715 | <i>Metrogyl 400 (AF)</i> .....                                    |     |
| <i>Meprazol (SZ)</i> .....                               | 80  | <i>.Antiinfectives for systemic use</i> .....                     | 201 |
| MERCAPTOPYRINE .....                                     | 214 | <i>.Antiparasitic products, insecticides and repellents ..</i>    |     |
| MESALAZINE .....                                         | 92  | <i>.Dental</i> .....                                              | 487 |
| <i>Mesasal (GK)</i> .....                                | 93  | <i>Metrol 100 (AW)</i> .....                                      | 124 |
| MESNA .....                                              | 436 | <i>Metrol 50 (AW)</i> .....                                       | 124 |
| <i>Mestinon (VT)</i> .....                               | 405 | METRONIDAZOLE .....                                               |     |
| <i>Mestinon Timespan (VT)</i> .....                      | 405 | <i>.Antiinfectives for systemic use</i> .....                     | 201 |
| <i>Metabolic Mineral Mixture (SB)</i> .....              | 451 | <i>.Antiparasitic products, insecticides and repellents</i> ..... | 409 |
| <i>Metalyse (BY)</i> .....                               | 111 | <i>.Dental</i> .....                                              | 487 |
| <i>Metamucil Regular (PY)</i> .....                      |     | <i>.Repatriation Schedule</i> .....                               | 689 |

## GENERIC/PROPRIETARY INDEX

|                                                                           |     |  |
|---------------------------------------------------------------------------|-----|--|
| METRONIDAZOLE BENZOATE                                                    |     |  |
| .Anti-infectives for systemic use                                         | 202 |  |
| .Antiparasitic products, insecticides and repellents                      | 409 |  |
| .Dental                                                                   | 488 |  |
| Metronidazole Sandoz (SZ)                                                 |     |  |
| .Anti-infectives for systemic use                                         | 202 |  |
| .Dental                                                                   | 488 |  |
| Metronide 200 (AV)                                                        |     |  |
| .Anti-infectives for systemic use                                         | 201 |  |
| .Antiparasitic products, insecticides and repellents                      |     |  |
| .Dental                                                                   | 487 |  |
| Metronide 400 (AV)                                                        |     |  |
| .Anti-infectives for systemic use                                         | 202 |  |
| .Antiparasitic products, insecticides and repellents                      |     |  |
| .Dental                                                                   | 487 |  |
| MEXILETINE HYDROCHLORIDE                                                  | 114 |  |
| Mexitil (BY)                                                              | 114 |  |
| Miacalcic 100 (NV)                                                        | 183 |  |
| Miacalcic 50 (NV)                                                         | 183 |  |
| MIANSERIN HYDROCHLORIDE                                                   | 393 |  |
| Micardis (BY)                                                             | 141 |  |
| Micardis Plus 40/12.5 mg (BY)                                             | 142 |  |
| Micardis Plus 80/12.5 mg (BY)                                             | 142 |  |
| MICONAZOLE                                                                |     |  |
| .Dermatologicals                                                          | 155 |  |
| .Repatriation Schedule                                                    | 685 |  |
| MICONAZOLE NITRATE                                                        |     |  |
| .Dermatologicals                                                          | 156 |  |
| .Repatriation Schedule                                                    | 685 |  |
| .Repatriation Schedule                                                    | 693 |  |
| Microgynon 30 (SC)                                                        | 164 |  |
| Microgynon 30 ED (SC)                                                     | 165 |  |
| Microgynon 50 ED (SC)                                                     | 164 |  |
| Microlox (JT)                                                             |     |  |
| .Alimentary tract and metabolism                                          | 90  |  |
| .Palliative Care                                                          | 459 |  |
| .Repatriation Schedule                                                    | 681 |  |
| Microlut 28 (SC)                                                          | 166 |  |
| Micronor (JC)                                                             | 166 |  |
| MILK POWDER—LACTOSE FREE FORMULA                                          | 445 |  |
| MILK POWDER—LACTOSE MODIFIED                                              | 446 |  |
| MILK POWDER—SYNTHETIC                                                     | 446 |  |
| MILK PROTEIN AND FAT FORMULA WITH VITAMINS AND MINERALS—CARBOHYDRATE FREE | 451 |  |
| Minaphlex (SB)                                                            | 449 |  |
| Minax 100 (AF)                                                            | 124 |  |
| Minax 50 (AF)                                                             | 124 |  |
| MINERAL MIXTURE                                                           | 451 |  |
| Minidiab (PH)                                                             | 99  |  |
| Minipress (PF)                                                            | 118 |  |
| Minirin (FP)                                                              | 178 |  |
| Minirin Nasal Spray (FP)                                                  | 178 |  |
| Minitran 10 (IA)                                                          | 117 |  |
| Minitran 15 (IA)                                                          | 117 |  |
| Minitran 5 (IA)                                                           | 116 |  |
| MINOCYCLINE                                                               | 186 |  |
| Minomycin-50 (SI)                                                         | 186 |  |
| MINOXIDIL                                                                 | 119 |  |
| Mirena (SC)                                                               | 163 |  |
| MIRTAZAPINE                                                               | 393 |  |
| Mirtazapine-DP (GM)                                                       | 393 |  |
| Mirtazapine Sandoz (SZ)                                                   | 393 |  |
| Mirtazon (AW)                                                             | 393 |  |
| MISOPROSTOL                                                               | 78  |  |
| Mitozantrone Ebewe (IT)                                                   | 219 |  |
| MITOZANTRONE HYDROCHLORIDE                                                | 219 |  |
| Mixtard 30/70 InnoLet (NI)                                                | 96  |  |
| Mixtard 30/70 Penfill 3 mL (NO)                                           | 96  |  |
| Mixtard 50/50 Penfill 3 mL (NO)                                           | 96  |  |
| Mobic (BY)                                                                | 339 |  |
| Mobilis 10 (AF)                                                           |     |  |
| .Musculo-skeletal system                                                  | 341 |  |
| .Dental                                                                   | 490 |  |
| Mobilis 20 (AF)                                                           |     |  |
| .Musculo-skeletal system                                                  | 341 |  |
| .Dental                                                                   | 490 |  |
| Mobilis D-10 (AF)                                                         |     |  |
| .Musculo-skeletal system                                                  | 340 |  |
| .Dental                                                                   | 489 |  |
| Mobilis D-20 (AF)                                                         |     |  |
| .Musculo-skeletal system                                                  | 340 |  |
| .Dental                                                                   | 490 |  |
| MOCLOBEMIDE                                                               | 392 |  |
| MODAFINIL                                                                 | 395 |  |
| Modavigil (CS)                                                            | 396 |  |
| Moderate (BQ)                                                             | 377 |  |
| Moduretic (MK)                                                            | 122 |  |
| Mogadon (VT)                                                              |     |  |
| .Nervous system                                                           | 368 |  |
| .Nervous system                                                           | 384 |  |
| .Palliative Care                                                          | 471 |  |
| .Dental                                                                   | 498 |  |
| Mohexal (SZ)                                                              | 392 |  |
| MOMETASONE FUROATE                                                        |     |  |
| .Dermatologicals                                                          | 160 |  |
| .Repatriation Schedule                                                    | 689 |  |
| Monace 10 (AF)                                                            | 132 |  |
| Monace 20 (AF)                                                            | 132 |  |
| Monistat 7 (JC)                                                           |     |  |
| .Repatriation Schedule                                                    | 693 |  |
| Monodur 120 mg (PM)                                                       | 117 |  |
| Monodur 60 mg (PM)                                                        | 117 |  |
| Monofeme 28 (WX)                                                          | 165 |  |
| Monogen (SB)                                                              | 445 |  |
| Monoplus 10/12.5 (BQ)                                                     | 138 |  |
| Monoplus 20/12.5 (BQ)                                                     | 138 |  |
| Monopril (BQ)                                                             | 132 |  |
| MONTELUKAST SODIUM                                                        | 421 |  |
| MORPHINE HYDROCHLORIDE                                                    |     |  |
| .Nervous system                                                           | 355 |  |
| .Dental                                                                   | 492 |  |
| MORPHINE SULFATE                                                          |     |  |
| .Doctor's Bag Supplies                                                    | 70  |  |
| .Nervous system                                                           | 356 |  |
| .Palliative Care                                                          | 465 |  |
| .Dental                                                                   | 493 |  |



## GENERIC/PROPRIETARY INDEX

|                                                    |     |                                                            |     |
|----------------------------------------------------|-----|------------------------------------------------------------|-----|
| .Musculo-skeletal system .....                     | 342 | <i>Neulactil (SW)</i> .....                                | 377 |
| .Palliative Care .....                             | 463 | <i>Neulasta (AN)</i> .....                                 |     |
| .Dental .....                                      | 491 | Section 100 .....                                          | 605 |
| <i>Naprosyn SR750 (RO)</i> .....                   |     | <i>Neupogen (AN)</i> .....                                 |     |
| .Musculo-skeletal system .....                     | 342 | Section 100 .....                                          | 546 |
| .Palliative Care .....                             | 463 | <i>Neurontin (PF)</i> .....                                |     |
| .Dental .....                                      | 491 | .Nervous system .....                                      | 370 |
| NAPROXEN .....                                     |     | .Repatriation Schedule .....                               | 699 |
| .Musculo-skeletal system .....                     | 342 | NEVIRAPINE .....                                           |     |
| .Palliative Care .....                             | 463 | Section 100 .....                                          | 603 |
| .Dental .....                                      | 491 | <i>Nexcare Durable Cloth First Aid Tape 799 (MM)</i> ..... |     |
| NAPROXEN SODIUM .....                              |     | .Repatriation Schedule .....                               | 722 |
| .Musculo-skeletal system .....                     | 342 | <i>Nexcare Gentle Paper First Aid Tape 789 (MM)</i> .....  |     |
| .Palliative Care .....                             | 464 | .Repatriation Schedule .....                               | 722 |
| .Dental .....                                      | 491 | <i>Nexcare Tegaderm Transparent H1624 (MM)</i> .....       |     |
| <i>Naramig (GK)</i> .....                          |     | .Repatriation Schedule .....                               | 714 |
| .Special Pharmaceutical Benefits .....             | 73  | <i>Nexcare Tegaderm Transparent H1626 (MM)</i> .....       |     |
| NARATRIPTAN HYDROCHLORIDE .....                    |     | .Repatriation Schedule .....                               | 714 |
| .Special Pharmaceutical Benefits .....             | 73  | <i>Nexium (AP)</i> .....                                   | 78  |
| <i>Nardil (LM)</i> .....                           | 391 | <i>Nexium Hp7 (AP)</i> .....                               | 82  |
| NATALIZUMAB .....                                  |     | <i>Nicabate CQ 14 (GK)</i> .....                           |     |
| Section 100 .....                                  | 603 | .Repatriation Schedule .....                               | 701 |
| <i>Natrilix (SE)</i> .....                         | 120 | <i>Nicabate CQ 21 (GK)</i> .....                           |     |
| <i>Natrilix SR (SE)</i> .....                      | 120 | .Repatriation Schedule .....                               | 701 |
| <i>Navelbine (FB)</i> .....                        | 216 | <i>Nicabate CQ 7 (GK)</i> .....                            |     |
| <i>Navoban (NV)</i> .....                          | 86  | .Repatriation Schedule .....                               | 701 |
| NEDOCROMIL SODIUM .....                            | 419 | NICORANDIL .....                                           | 117 |
| NELFINAVIR MESYLATE .....                          |     | <i>Nicorette Patch (JT)</i> .....                          |     |
| Section 100 .....                                  | 603 | .Repatriation Schedule .....                               | 701 |
| <i>Nemdyn (HA)</i> .....                           | 433 | NICOTINE .....                                             |     |
| <i>Neo-B12 (HH)</i> .....                          | 112 | .Repatriation Schedule .....                               | 701 |
| <i>Neocate (SB)</i> .....                          | 440 | <i>Nidem (AW)</i> .....                                    | 98  |
| <i>Neocate Advance (SB)</i> .....                  | 440 | NIFEDIPINE .....                                           | 128 |
| <i>Neocate Advance Tropical Flavour (SB)</i> ..... | 440 | <i>Nifehexal (HX)</i> .....                                | 128 |
| <i>Neocate LCP (SB)</i> .....                      | 441 | NILOTINIB .....                                            | 237 |
| <i>Neo-Mercazole (LM)</i> .....                    | 182 | <i>Nilstat (SI)</i> .....                                  |     |
| NEOMYCIN SULFATE .....                             | 90  | .Alimentary tract and metabolism .....                     | 75  |
| NEOMYCIN UNDECENOATE WITH BACITRACIN .....         |     | .Alimentary tract and metabolism .....                     | 90  |
| ZINC .....                                         | 433 | .Dental .....                                              | 473 |
| <i>Neoral (NV)</i> .....                           |     | .Dental .....                                              | 474 |
| .Antineoplastic and immunomodulating agents .....  | 336 | .Repatriation Schedule .....                               | 692 |
| Section 100 .....                                  | 528 | NILUTAMIDE .....                                           | 247 |
| <i>Neoral 10 (NV)</i> .....                        |     | NITRAZEPAM .....                                           |     |
| .Antineoplastic and immunomodulating agents .....  | 335 | .Nervous system .....                                      | 368 |
| Section 100 .....                                  | 528 | .Nervous system .....                                      | 384 |
| <i>Neoral 100 (NV)</i> .....                       |     | .Palliative Care .....                                     | 471 |
| .Antineoplastic and immunomodulating agents .....  | 336 | .Dental .....                                              | 498 |
| Section 100 .....                                  | 528 | <i>Nitro-Dur 10 (SH)</i> .....                             | 117 |
| <i>Neoral 25 (NV)</i> .....                        |     | <i>Nitro-Dur 15 (SH)</i> .....                             | 117 |
| .Antineoplastic and immunomodulating agents .....  | 336 | <i>Nitro-Dur 5 (SH)</i> .....                              | 116 |
| Section 100 .....                                  | 528 | NITROFURANTOIN .....                                       | 202 |
| <i>Neoral 50 (NV)</i> .....                        |     | <i>Nitrolingual Pumpspray (SW)</i> .....                   |     |
| .Antineoplastic and immunomodulating agents .....  | 336 | .Doctor's Bag Supplies .....                               | 70  |
| Section 100 .....                                  | 528 | .Cardiovascular system .....                               | 116 |
| <i>NeoRecormon (RO)</i> .....                      |     | <i>Nizac (LN)</i> .....                                    | 77  |
| Section 100 .....                                  | 534 | NIZATIDINE .....                                           | 77  |
| <i>Neosulf (AF)</i> .....                          | 90  | <i>Nizoral (JC)</i> .....                                  | 203 |
| <i>Neotigason (TA)</i> .....                       | 158 | <i>Nizoral 1% (JT)</i> .....                               | 155 |

## GENERIC/PROPRIETARY INDEX

|                                                |     |                                                |     |
|------------------------------------------------|-----|------------------------------------------------|-----|
| <i>Nizoral 2% (JT)</i>                         |     | <i>.Repatriation Schedule</i>                  | 699 |
| <i>.Dermatologicals</i>                        | 155 | <i>Nupentin 300 (AF)</i>                       |     |
| <i>.Repatriation Schedule</i>                  | 685 | <i>.Nervous system</i>                         | 370 |
| <i>Nizoral 2% Cream (JT)</i>                   | 155 | <i>.Repatriation Schedule</i>                  | 699 |
| <i>Nolvadex (AP)</i>                           | 246 | <i>Nupentin 400 (AF)</i>                       |     |
| <i>Nolvadex-D (AP)</i>                         | 246 | <i>.Nervous system</i>                         | 370 |
| <i>Nordette 28 (WY)</i>                        | 165 | <i>.Repatriation Schedule</i>                  | 699 |
| <i>Norditropin NordiFlex (NO)</i>              |     | <i>Nutraplus (GA)</i>                          |     |
| <i>.Section 100</i>                            | 634 | <i>.Repatriation Schedule</i>                  | 687 |
| <i>Norditropin SimpleXx (NO)</i>               |     | <i>NutropinAq (IS)</i>                         |     |
| <i>.Section 100</i>                            | 634 | <i>.Section 100</i>                            | 635 |
| <b>NORETHISTERONE</b>                          |     | <i>Nyefax 20 mg (GM)</i>                       | 128 |
| <i>.Genito urinary system and sex hormones</i> | 166 | <i>Nyogel (NV)</i>                             | 426 |
| <i>.Genito urinary system and sex hormones</i> | 170 | <i>Nypine 10 (AW)</i>                          | 128 |
| <b>NORETHISTERONE WITH ETHINYLOESTRADIOL</b>   |     | <i>Nypine 20 (AW)</i>                          | 128 |
| <i>.Genito urinary system and sex hormones</i> | 165 | <b>NYSTATIN</b>                                |     |
| <i>.Genito urinary system and sex hormones</i> | 166 | <i>.Alimentary tract and metabolism</i>        | 75  |
| <b>NORETHISTERONE WITH MESTRANOL</b>           | 165 | <i>.Alimentary tract and metabolism</i>        | 90  |
| <i>Norflohexal (SZ)</i>                        | 200 | <i>.Dermatologicals</i>                        | 155 |
| <b>NORFLOXACIN</b>                             | 200 | <i>.Dental</i>                                 | 473 |
| <i>Noriday 28 Day (PH)</i>                     | 166 | <i>.Dental</i>                                 | 474 |
| <i>Norimin-1 28 Day (KR)</i>                   | 165 | <i>.Repatriation Schedule</i>                  | 685 |
| <i>Norimin 28 Day (KR)</i>                     | 165 | <i>.Repatriation Schedule</i>                  | 692 |
| <i>Norinyl-1/28 (PH)</i>                       | 165 |                                                |     |
| <i>Norinyl-1 (PH)</i>                          | 165 |                                                |     |
| <i>Normacol Plus (NE)</i>                      |     | <b>O</b>                                       |     |
| <i>.Alimentary tract and metabolism</i>        | 88  | <i>O.R.S. (AS)</i>                             | 91  |
| <i>.Palliative Care</i>                        | 457 | <b>OCTREOTIDE ACETATE</b>                      |     |
| <i>.Repatriation Schedule</i>                  | 681 | <i>.Section 100</i>                            | 603 |
| <i>Normison (SI)</i>                           |     | <i>Ocufen (AG)</i>                             |     |
| <i>.Nervous system</i>                         | 385 | <i>.Sensory organs</i>                         | 424 |
| <i>.Palliative Care</i>                        | 472 | <i>.Optometrical</i>                           | 501 |
| <i>.Dental</i>                                 | 498 | <i>Ocuflox (AG)</i>                            | 423 |
| <i>Noroxin (MK)</i>                            | 200 | <i>Odrik (KN)</i>                              | 137 |
| <i>Norprolac (FP)</i>                          | 164 | <b>OESTRADIOL</b>                              |     |
| <i>Norspan (MF)</i>                            | 362 | <i>.Genito urinary system and sex hormones</i> | 167 |
| <b>NORTRIPTYLINE HYDROCHLORIDE</b>             | 387 | <i>.Repatriation Schedule</i>                  | 693 |
| <i>Norvasc (PF)</i>                            | 126 | <b>OESTRADIOL AND OESTRADIOL WITH</b>          |     |
| <i>Norvir (AB)</i>                             |     | <b>DYDROGESTERONE</b>                          | 171 |
| <i>.Section 100</i>                            | 610 | <b>OESTRADIOL AND OESTRADIOL WITH</b>          |     |
| <i>Noten (AF)</i>                              | 123 | <b>NORETHISTERONE ACETATE</b>                  | 171 |
| <i>Novasone (EX)</i>                           | 160 | <b>OESTRADIOL VALERATE</b>                     | 169 |
| <i>NovoMix 30 FlexPen (NF)</i>                 | 96  | <b>OESTRADIOL WITH NORETHISTERONE</b>          |     |
| <i>NovoMix 30 Penfill 3 mL (NO)</i>            | 96  | <b>ACETATE</b>                                 | 170 |
| <i>NovoRapid (NO)</i>                          | 95  | <b>OESTRIOL</b>                                | 169 |
| <i>NovoRapid FlexPen (NF)</i>                  | 95  | <b>OESTROGENS—CONJUGATED</b>                   | 169 |
| <i>NovoRapid Penfill 3 mL (NO)</i>             | 95  | <b>OESTROGENS—CONJUGATED WITH</b>              |     |
| <i>Nuclolex (SI)</i>                           |     | <b>MEDROXYPROGESTERONE ACETATE</b>             | 170 |
| <i>.Repatriation Schedule</i>                  | 681 | <b>OFLOXACIN</b>                               | 423 |
| <i>Nuelin (IA)</i>                             | 420 | <i>Ogen .625 (PH)</i>                          | 169 |
| <i>Nuelin-SR 200 (IA)</i>                      | 420 | <i>Ogen 1.25 (PH)</i>                          | 169 |
| <i>Nuelin-SR 250 (IA)</i>                      | 420 | <b>OLANZAPINE</b>                              | 378 |
| <i>Nuelin-SR 300 (IA)</i>                      | 420 | <b>OLMESARTAN MEDOXOMIL</b>                    | 141 |
| <i>Nufloxib (AF)</i>                           | 200 | <b>OLMESARTAN MEDOXOMIL WITH</b>               |     |
| <i>Nu-Gel 2497 (JJ)</i>                        |     | <b>HYDROCHLOROTHIAZIDE</b>                     | 142 |
| <i>.Repatriation Schedule</i>                  | 719 | <i>Olmetec (SH)</i>                            | 141 |
| <i>Nupentin 100 (AF)</i>                       |     | <i>Olmetec Plus (SH)</i>                       | 142 |
| <i>.Nervous system</i>                         | 370 |                                                |     |



## GENERIC/PROPRIETARY INDEX

|                                   |     |                                          |     |
|-----------------------------------|-----|------------------------------------------|-----|
| OLSALAZINE SODIUM .....           | 94  | Otocomb Otic (BC) .....                  | 434 |
| Omepral (PM) .....                | 80  | Otodex (AV) .....                        | 433 |
| OMEPRAZOLE .....                  | 80  | Ovestin (OR) .....                       | 169 |
| OMEPRAZOLE AND CLARITHROMYCIN AND |     | Ovestin Ovula (OR) .....                 | 169 |
| AMOXYCILLIN .....                 | 83  | Ovidrel (SG)                             |     |
| Omeprazole-GA (GM) .....          | 80  | . Section 100 .....                      | 636 |
| Omeprazole Ranbaxy (RA) .....     | 80  | Oxalatin (ZP) .....                      | 220 |
| Omeprazole Winthrop (WA) .....    | 80  | OXALIPLATIN .....                        | 220 |
| Omnitest EZ (BR) .....            | 438 | Oxaliplatin Ebewe (IT) .....             | 220 |
| Omnitest Plus (BR) .....          | 438 | OXAZEPAM                                 |     |
| Omnitrope (SZ)                    |     | . Nervous system .....                   | 383 |
| . Section 100 .....               | 634 | . Palliative Care .....                  | 471 |
| On-Call Plus (PZ) .....           | 437 | . Dental .....                           | 498 |
| OncoTICE (OR) .....               | 251 | OXCARBAZEPINE .....                      | 369 |
| ONDANSETRON .....                 | 84  | Oxis Turbuhaler (AP) .....               | 412 |
| Ondansetron-RL (RE) .....         | 84  | OXPRENOLOL HYDROCHLORIDE .....           | 122 |
| Ondansetron-RL Zydys (RE) .....   | 84  | OXYBUTYNIN HYDROCHLORIDE .....           | 177 |
| Ondaz (HX) .....                  | 84  | Oxybutynin Sandoz (SZ) .....             | 177 |
| Ondaz Zydys (HX) .....            | 84  | Oxybutynin Winthrop (WA) .....           | 177 |
| Onkotrone (BX) .....              | 219 | OXYCODONE                                |     |
| Onsetron (AW) .....               | 85  | . Nervous system .....                   | 358 |
| Onsetron 4 (AW) .....             | 84  | . Dental .....                           | 494 |
| Onsetron 8 (AW) .....             | 84  | OXYCODONE HYDROCHLORIDE                  |     |
| Op-Site Flexigrid 4629 (SN)       |     | . Nervous system .....                   | 359 |
| . Repatriation Schedule .....     | 714 | . Dental .....                           | 494 |
| Opticrom (SW)                     |     | OxyContin (MF)                           |     |
| . Sensory organs .....            | 427 | . Nervous system .....                   | 360 |
| . Optometrical .....              | 502 | . Dental .....                           | 495 |
| Optium glucose (MS) .....         | 438 | OXYMETAZOLINE HYDROCHLORIDE              |     |
| Optium Omega (MS) .....           | 438 | . Repatriation Schedule .....            | 701 |
| Orabase (BQ)                      |     | OxyNorm (MF)                             |     |
| . Repatriation Schedule .....     | 687 | . Nervous system .....                   | 359 |
| Oratane (GM) .....                | 161 | . Dental .....                           | 494 |
| Ordine 10 (MF)                    |     | OxyNorm Liquid 5mg/5mL (MF)              |     |
| . Nervous system .....            | 356 | . Nervous system .....                   | 359 |
| . Dental .....                    | 492 | . Dental .....                           | 495 |
| Ordine 2 (MF)                     |     | Ozcef (RA)                               |     |
| . Nervous system .....            | 356 | . Anti-infectives for systemic use ..... | 194 |
| . Dental .....                    | 492 | . Dental .....                           | 484 |
| Ordine 5 (MF)                     |     | Oziclide MR (RA) .....                   | 98  |
| . Nervous system .....            | 356 | Ozlodip (RA) .....                       | 126 |
| . Dental .....                    | 492 | Ozole (RA) .....                         | 203 |
| Orencia (BQ)                      |     | Ozvir (RA) .....                         | 206 |
| . Section 100 .....               | 513 |                                          |     |
| ORLISTAT                          |     | <b>P</b>                                 |     |
| . Repatriation Schedule .....     | 682 | P.V. Carpine (AG) .....                  | 424 |
| Oroxine (SI) .....                | 182 | PAA (NM)                                 |     |
| Orudis (SW)                       |     | . Sensory organs .....                   | 430 |
| . Musculo-skeletal system .....   | 341 | . Optometrical .....                     | 502 |
| . Dental .....                    | 490 | PACLITAXEL .....                         | 217 |
| Orudis SR 200 (SW)                |     | . Paclitaxel Ebewe (IT) .....            | 217 |
| . Musculo-skeletal system .....   | 341 | PALIPERIDONE .....                       | 380 |
| . Dental .....                    | 491 | Pamacid 20 (AF) .....                    | 76  |
| Oruvail SR (AV)                   |     | Pamacid 40 (AF) .....                    | 76  |
| . Musculo-skeletal system .....   | 341 | Pamisol (HH)                             |     |
| . Dental .....                    | 491 | . Musculo-skeletal system .....          | 347 |
| Ospolot (PL) .....                | 372 |                                          |     |
| Ossmax 70mg (RA) .....            | 346 |                                          |     |

## GENERIC/PROPRIETARY INDEX

|                                               |     |                                                     |     |
|-----------------------------------------------|-----|-----------------------------------------------------|-----|
| .Section 100 .....                            | 530 | <i>Paxtine (AF)</i> .....                           | 390 |
| <i>Panadeine Forte (SW)</i> .....             |     | <i>Peg 7420 (BK)</i> .....                          |     |
| .Nervous system .....                         | 354 | .Repatriation Schedule .....                        | 711 |
| .Dental .....                                 | 492 | <i>Peg 7422 (BK)</i> .....                          |     |
| <i>Panadol (GC)</i> .....                     |     | .Repatriation Schedule .....                        | 711 |
| .Palliative Care .....                        | 468 | <i>Peg 7423 (BK)</i> .....                          |     |
| <i>Panadol Osteo (GC)</i> .....               |     | .Repatriation Schedule .....                        | 711 |
| .Nervous system .....                         | 365 | <i>Peg 7425 (BK)</i> .....                          |     |
| .Palliative Care .....                        | 468 | .Repatriation Schedule .....                        | 711 |
| <i>Panafcort (AS)</i> .....                   | 181 | <i>Pegasys (RO)</i> .....                           |     |
| <i>Panafcortelone (AS)</i> .....              | 181 | .Section 100 .....                                  | 606 |
| <i>Panamax (SW)</i> .....                     |     | <i>Pegasys RBV (RO)</i> .....                       |     |
| .Nervous system .....                         | 364 | .Section 100 .....                                  | 608 |
| .Dental .....                                 | 496 | <i>Pegatron (SH)</i> .....                          |     |
| <i>Panamax 240 Elixir (SW)</i> .....          |     | .Section 100 .....                                  | 609 |
| .Nervous system .....                         | 364 | PEGFILGRASTIM .....                                 |     |
| .Dental .....                                 | 497 | .Section 100 .....                                  | 605 |
| <i>Panamax Co. (SW)</i> .....                 |     | PEGINTERFERON ALFA-2A .....                         |     |
| .Repatriation Schedule .....                  | 699 | .Section 100 .....                                  | 605 |
| PANCREATIC EXTRACT .....                      | 94  | PEGINTERFERON ALFA-2B .....                         |     |
| PANCRELIPASE .....                            | 95  | .Section 100 .....                                  | 606 |
| PANTOPRAZOLE SODIUM SESQUIHYDRATE .....       | 81  | <i>PEG-Intron Redipen (SH)</i> .....                |     |
| <i>Panzytrat 25000 (TM)</i> .....             | 95  | .Section 100 .....                                  | 606 |
| PARACETAMOL .....                             |     | PEMETREXED DISODIUM .....                           | 213 |
| .Nervous system .....                         | 364 | <i>Pendine 300 (AL)</i> .....                       | 370 |
| .Palliative Care .....                        | 468 | <i>Pendine 400 (AL)</i> .....                       | 370 |
| .Dental .....                                 | 496 | <i>Pendine 800 (AF)</i> .....                       | 371 |
| <i>Paracetamol Sandoz (SZ)</i> .....          |     | <i>Penhexal VK (HX)</i> .....                       |     |
| .Nervous system .....                         | 364 | .Antiinfectives for systemic use .....              | 188 |
| .Dental .....                                 | 496 | .Dental .....                                       | 479 |
| PARAFFIN .....                                |     | PENICILLAMINE .....                                 | 344 |
| .Sensory organs .....                         | 432 | <i>Pentasa (FP)</i> .....                           | 92  |
| .Optometrical .....                           | 504 | <i>Pepcidine (MK)</i> .....                         | 76  |
| <i>Paraheaxal (HX)</i> .....                  |     | <i>Pepcidine M (MK)</i> .....                       | 76  |
| .Nervous system .....                         | 364 | <i>Pepti-Junior (NU)</i> .....                      | 444 |
| .Dental .....                                 | 496 | <i>Pepzan (GM)</i> .....                            | 76  |
| <i>Paralgin (FM)</i> .....                    |     | PERGOLIDE MESYLATE .....                            | 376 |
| .Nervous system .....                         | 364 | PERHEXILINE MALEATE .....                           | 118 |
| .Dental .....                                 | 496 | <i>Periactin (FR)</i> .....                         | 366 |
| <i>Pariet (JC)</i> .....                      | 82  | PERICYAZINE .....                                   | 377 |
| <i>Parlodel (NV)</i> .....                    |     | <i>Perindo (AF)</i> .....                           | 134 |
| .Genito urinary system and sex hormones ..... | 163 | <i>Perindo Combi 4/1.25 (AF)</i> .....              | 139 |
| .Nervous system .....                         | 375 | PERINDOPRIL .....                                   | 134 |
| <i>Parmol (AW)</i> .....                      |     | <i>Perindopril 2 (CR)</i> .....                     | 134 |
| .Nervous system .....                         | 364 | <i>Perindopril 4 (CR)</i> .....                     | 134 |
| .Dental .....                                 | 496 | <i>Perindopril 8 (CR)</i> .....                     | 135 |
| <i>Parnate (GH)</i> .....                     | 391 | <i>Perindopril-DP (GM)</i> .....                    | 134 |
| <i>Paroxetine 20 (CR)</i> .....               | 390 | PERINDOPRIL WITH INDAPAMIDE                         |     |
| <i>Paroxetine-DP (GM)</i> .....               | 390 | HEMIHYDRATE .....                                   | 138 |
| PAROXETINE HYDROCHLORIDE .....                | 390 | <i>Periogard (Chlorohex) Mouth Rinse (OM)</i> ..... |     |
| <i>Paroxetine Sandoz (SZ)</i> .....           | 390 | .Repatriation Schedule .....                        | 680 |
| <i>Paroxetine Winthrop (WA)</i> .....         | 390 | <i>Perivasc (AF)</i> .....                          | 126 |
| <i>Paxam 0.5 (AF)</i> .....                   |     | <i>Permax (AS)</i> .....                            | 376 |
| .Nervous system .....                         | 368 | PERMETHRIN .....                                    | 411 |
| .Palliative Care .....                        | 469 | <i>Persantin SR (BY)</i> .....                      | 109 |
| <i>Paxam 2 (AF)</i> .....                     |     | <i>Petrus Bisacodyl Suppositories (PP)</i> .....    |     |
| .Nervous system .....                         | 368 | .Alimentary tract and metabolism .....              | 88  |
| .Palliative Care .....                        | 469 | .Palliative Care .....                              | 456 |

## GENERIC/PROPRIETARY INDEX

|                                                                                                           |     |                                                            |     |
|-----------------------------------------------------------------------------------------------------------|-----|------------------------------------------------------------|-----|
| <i>Pexsig (SI)</i> .....                                                                                  | 118 | PIROXICAM                                                  |     |
| <i>Pharmacor Gemfibrozil 600 (CR)</i> .....                                                               | 151 | .Musculo-skeletal system .....                             | 340 |
| <i>Pharmacor Meloxicam 15 (CR)</i> .....                                                                  | 340 | .Dental .....                                              | 489 |
| <i>Pharmacor Meloxicam 7.5 (CR)</i> .....                                                                 | 339 | <b>PIZOTIFEN MALATE</b> .....                              | 366 |
| <i>Pharmacor Quinapril 10 (CR)</i> .....                                                                  | 135 | <i>PK AID II (SB)</i> .....                                | 447 |
| <i>Pharmacor Quinapril 20 (CR)</i> .....                                                                  | 135 | <i>PKU Cooler 10 (VF)</i> .....                            | 449 |
| <i>Pharmacor Quinapril 5 (CR)</i> .....                                                                   | 135 | <i>PKU Cooler 15 (VF)</i> .....                            | 449 |
| <i>Pharmacor Ramipril 1.25 (CR)</i> .....                                                                 | 136 | <i>PKU Cooler 20 (VF)</i> .....                            | 449 |
| <i>Pharmacor Ramipril 10 (CR)</i> .....                                                                   | 137 | <i>PKU-Express (VF)</i> .....                              | 449 |
| <i>Pharmacor Ramipril 2.5 (CR)</i> .....                                                                  | 136 | <i>PKU-gel (VF)</i> .....                                  | 449 |
| <i>Pharmacor Ramipril 5 (CR)</i> .....                                                                    | 136 | <i>Placil (AF)</i>                                         |     |
| <i>Pharmacor Salbutamol 2.5 (CR)</i>                                                                      |     | .Nervous system .....                                      | 384 |
| .Doctor's Bag Supplies .....                                                                              | 71  | .Nervous system .....                                      | 386 |
| .Respiratory system .....                                                                                 | 413 | <i>Plaqacide (OB)</i>                                      |     |
| <i>Pharmacor Salbutamol 5 (CR)</i>                                                                        |     | .Repatriation Schedule .....                               | 680 |
| .Doctor's Bag Supplies .....                                                                              | 71  | <i>Plaquenil (SW)</i> .....                                | 343 |
| .Respiratory system .....                                                                                 | 413 | <i>Plasma-Lyte 148 (BX)</i> .....                          | 113 |
| <i>Pharmacy Choice Paracetamol (YM)</i>                                                                   |     | <i>Plavix (SW)</i>                                         |     |
| .Nervous system .....                                                                                     | 364 | .Blood and blood forming organs .....                      | 108 |
| .Dental .....                                                                                             | 496 | .Repatriation Schedule .....                               | 684 |
| <i>Pharmorubicin Solution (PH)</i> .....                                                                  | 218 | <i>Plendil ER (AP)</i> .....                               | 127 |
| <b>PHENELZINE SULFATE</b> .....                                                                           | 391 | <b>PNEUMOCOCCAL VACCINE, POLYVALENT</b> .....              | 209 |
| <i>Phenergan (SW)</i>                                                                                     |     | <i>Pneumovax 23 (CS)</i> .....                             | 209 |
| .Palliative Care .....                                                                                    | 455 | <b>PODOPHYLLOTOXIN</b>                                     |     |
| .Repatriation Schedule .....                                                                              | 703 | .Repatriation Schedule .....                               | 689 |
| <i>Phenex-2 (AB)</i> .....                                                                                | 449 | <b>POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL</b>       |     |
| <b>PHENOBARBITONE</b> .....                                                                               | 367 | .Sensory organs .....                                      | 432 |
| <b>PHENOBARBITONE SODIUM</b> .....                                                                        | 367 | .Optometrical .....                                        | 504 |
| <b>PHENOXYBENZAMINE HYDROCHLORIDE</b>                                                                     |     | <i>Poly Gel (AQ)</i>                                       |     |
| .Cardiovascular system .....                                                                              | 122 | .Sensory organs .....                                      | 430 |
| .Genito urinary system and sex hormones .....                                                             | 177 | .Optometrical .....                                        | 502 |
| <b>PHENOXYMETHYLPENICILLIN</b>                                                                            |     | <b>POLYGLINE</b> .....                                     | 113 |
| .Anti-infectives for systemic use .....                                                                   | 188 | <i>Polytar (SX)</i>                                        |     |
| .Dental .....                                                                                             | 479 | .Repatriation Schedule .....                               | 690 |
| <b>PHENYTOIN</b> .....                                                                                    | 367 | <i>Poly-Tears (IQ)</i>                                     |     |
| <b>PHENYTOIN SODIUM</b> .....                                                                             | 367 | .Sensory organs .....                                      | 432 |
| <i>Phlexy-10 (SB)</i> .....                                                                               | 447 | .Optometrical .....                                        | 503 |
| <i>Phlexy-10 Drink Mix (SB)</i> .....                                                                     | 447 | <b>POLYVINYL ALCOHOL</b>                                   |     |
| <b>PHOLCODINE</b>                                                                                         |     | .Sensory organs .....                                      | 432 |
| .Repatriation Schedule .....                                                                              | 703 | .Optometrical .....                                        | 504 |
| <i>Phosphate Sandoz (NV)</i> .....                                                                        | 437 | <i>Poly Visc (IQ)</i>                                      |     |
| <i>Physeptone (GK)</i> .....                                                                              | 361 | .Sensory organs .....                                      | 432 |
| <i>Physiotens (SM)</i> .....                                                                              | 118 | .Optometrical .....                                        | 504 |
| <b>PILOCARPINE HYDROCHLORIDE</b> .....                                                                    | 424 | <i>Ponstan (PD)</i> .....                                  | 343 |
| <i>Pilopt (PE)</i> .....                                                                                  | 424 | <i>Posalfilin (NE)</i>                                     |     |
| <b>PIMECROLIMUS</b> .....                                                                                 | 162 | .Repatriation Schedule .....                               | 691 |
| <b>PINDOLOL</b> .....                                                                                     | 122 | <b>POTASSIUM CHLORIDE</b> .....                            | 105 |
| <i>Pinetarsol (EO)</i>                                                                                    |     | <b>POTASSIUM CHLORIDE WITH POTASSIUM BICARBONATE</b> ..... | 105 |
| .Repatriation Schedule .....                                                                              | 688 | <b>POVIDONE-IODINE</b>                                     |     |
| <b>PINE TAR WITH CADE OIL, COAL TAR SOLUTION, ARACHIS OIL EXTRACT OF CRUDE COAL TAR AND OLEYL ALCOHOL</b> |     | .Repatriation Schedule .....                               | 690 |
| .Repatriation Schedule .....                                                                              | 690 | <i>Pramin (AF)</i>                                         |     |
| <b>PINE TAR WITH TRIETHANOLAMINE LAURYL SULFATE</b>                                                       |     | .Alimentary tract and metabolism .....                     | 83  |
| .Repatriation Schedule .....                                                                              | 688 | .Dental .....                                              | 473 |
| <b>PIOGLITAZONE HYDROCHLORIDE</b> .....                                                                   | 101 | <b>PRAMIPEXOLE HYDROCHLORIDE</b> .....                     | 376 |
| <b>PIPERAZINE OESTRONE SULFATE</b> .....                                                                  | 169 | <i>Prantal (SH)</i>                                        |     |
|                                                                                                           |     | .Repatriation Schedule .....                               | 690 |

## GENERIC/PROPRIETARY INDEX

|                                                         |     |                                                   |     |
|---------------------------------------------------------|-----|---------------------------------------------------|-----|
| <i>Pravachol (BQ)</i> .....                             | 147 | PROCAINE PENICILLIN .....                         |     |
| <i>Pravastatin 10 (CR)</i> .....                        | 147 | .Doctor's Bag Supplies .....                      | 69  |
| <i>Pravastatin 20 (CR)</i> .....                        | 147 | .Anti-infectives for systemic use .....           | 189 |
| <i>Pravastatin 40 (CR)</i> .....                        | 148 | .Dental .....                                     | 480 |
| <i>Pravastatin-DP (GM)</i> .....                        | 147 | PROCHLORPERAZINE .....                            |     |
| <i>Pravastatin-GA 10 (GN)</i> .....                     | 147 | .Doctor's Bag Supplies .....                      | 70  |
| <i>Pravastatin-GA 20 (GN)</i> .....                     | 147 | .Alimentary tract and metabolism .....            | 87  |
| <i>Pravastatin-GA 40 (GN)</i> .....                     | 148 | .Dental .....                                     | 474 |
| <i>Pravastatin-GA 80 (GN)</i> .....                     | 148 | <i>Pro-Cid (PL)</i> .....                         | 345 |
| <i>Pravastatin generichealth (GQ)</i> .....             | 147 | <i>Proctosedyl (SW)</i> .....                     |     |
| PRAVASTATIN SODIUM .....                                | 147 | .Repatriation Schedule .....                      | 684 |
| <i>Pravastatin Winthrop (WA)</i> .....                  | 147 | <i>Procur (GM)</i> .....                          |     |
| PRAZOSIN HYDROCHLORIDE .....                            | 118 | .Genito urinary system and sex hormones .....     | 175 |
| <i>Precision Plus (MS)</i> .....                        | 439 | .Antineoplastic and immunomodulating agents ..... | 247 |
| <i>PredMix (LN)</i> .....                               | 181 | <i>Procur 100 (GM)</i> .....                      |     |
| <i>Prednefrin Forte (AG)</i> .....                      | 424 | .Genito urinary system and sex hormones .....     | 176 |
| PREDNISOLONE .....                                      | 181 | .Antineoplastic and immunomodulating agents ..... | 247 |
| PREDNISOLONE ACETATE WITH PHENYLEPHRINE                 |     | <i>Prodeine 15 (SW)</i> .....                     |     |
| HYDROCHLORIDE .....                                     | 424 | .Repatriation Schedule .....                      | 699 |
| PREDNISOLONE SODIUM PHOSPHATE .....                     |     | <i>Prodeine Forte (AV)</i> .....                  |     |
| .Alimentary tract and metabolism .....                  | 92  | .Nervous system .....                             | 354 |
| .Systemic hormonal preparations, excl. sex hormones and |     | .Dental .....                                     | 492 |
| insulins .....                                          | 181 | <i>Proflorin (SZ)</i> .....                       | 199 |
| PREDNISONONE .....                                      | 181 | <i>Profore 66050016 (SN)</i> .....                |     |
| <i>Predsol (SI)</i> .....                               | 92  | .Repatriation Schedule .....                      | 710 |
| <i>Predsolone (LN)</i> .....                            | 181 | <i>Profore Lite 66050415 (SN)</i> .....           |     |
| <i>Predstone (LN)</i> .....                             | 181 | .Repatriation Schedule .....                      | 710 |
| PREGABALIN .....                                        |     | PROGESTERONE .....                                |     |
| .Repatriation Schedule .....                            | 699 | .Section 100 .....                                | 637 |
| <i>Pregnyl (OR)</i> .....                               |     | <i>Progout 100 (AF)</i> .....                     | 345 |
| .Genito urinary system and sex hormones .....           | 174 | <i>Progout 300 (AF)</i> .....                     | 345 |
| .Section 100 .....                                      | 637 | <i>Prograf (JC)</i> .....                         |     |
| <i>Premarin (WX)</i> .....                              | 169 | .Antineoplastic and immunomodulating agents ..... | 336 |
| <i>Premia 2.5 Continuous (WX)</i> .....                 | 170 | .Section 100 .....                                | 631 |
| <i>Premia 5 Continuous (WX)</i> .....                   | 171 | <i>ProGuide 66000780 (SN)</i> .....               |     |
| <i>Presolol 100 (AF)</i> .....                          | 126 | .Repatriation Schedule .....                      | 710 |
| <i>Presolol 200 (AF)</i> .....                          | 126 | <i>ProGuide 66000781 (SN)</i> .....               |     |
| <i>Pressin 1 (AF)</i> .....                             | 118 | .Repatriation Schedule .....                      | 710 |
| <i>Pressin 2 (AF)</i> .....                             | 119 | <i>ProGuide 66000782 (SN)</i> .....               |     |
| <i>Pressin 5 (AF)</i> .....                             | 119 | .Repatriation Schedule .....                      | 710 |
| PRESSURE REDUCING PRODUCTS .....                        |     | <i>Progynova (SC)</i> .....                       | 169 |
| .Repatriation Schedule .....                            | 721 | <i>Proladone (PL)</i> .....                       |     |
| <i>Prexaton (AF)</i> .....                              | 406 | .Nervous system .....                             | 358 |
| <i>Prezista (JC)</i> .....                              |     | .Dental .....                                     | 494 |
| .Section 100 .....                                      | 529 | PROMETHAZINE HYDROCHLORIDE .....                  |     |
| <i>Prilace 1.25 (AW)</i> .....                          | 136 | .Doctor's Bag Supplies .....                      | 71  |
| <i>Prilace 10 (AW)</i> .....                            | 137 | .Respiratory system .....                         | 421 |
| <i>Prilace 2.5 (AW)</i> .....                           | 136 | .Palliative Care .....                            | 455 |
| <i>Prilace 5 (AW)</i> .....                             | 136 | .Dental .....                                     | 474 |
| PRIMIDONE .....                                         | 367 | .Repatriation Schedule .....                      | 703 |
| <i>Primolut N (SC)</i> .....                            | 170 | PROPANTHELINE BROMIDE .....                       | 177 |
| <i>Primoteston Depot (SC)</i> .....                     | 167 | <i>Pro-Phree (AB)</i> .....                       | 450 |
| <i>Prinivil 10 (MK)</i> .....                           | 133 | PROPRANOLOL HYDROCHLORIDE .....                   | 122 |
| <i>Prinivil 20 (MK)</i> .....                           | 134 | PROPYLTHIOURACIL .....                            | 182 |
| <i>Prinivil 5 (MK)</i> .....                            | 133 | <i>Proquin (GM)</i> .....                         | 200 |
| <i>Pro-Banthine (SI)</i> .....                          | 177 | <i>Proscar (MK)</i> .....                         |     |
| PROBENECID .....                                        | 345 | .Repatriation Schedule .....                      | 695 |
| <i>Probitor (SZ)</i> .....                              | 80  | <i>Protaphane (NO)</i> .....                      | 96  |

## GENERIC/PROPRIETARY INDEX

|                                                   |     |                                               |     |
|---------------------------------------------------|-----|-----------------------------------------------|-----|
| <i>Protaphane InnoLet (NI)</i> .....              | 96  | .Nervous system .....                         |     |
| <i>Protaphane NovoLet 3 mL (NL)</i> .....         | 96  | .Nervous system .....                         | 392 |
| <i>Protaphane Penfill 3 mL (NO)</i> .....         | 96  | QUINAGOLIDE HYDROCHLORIDE .....               | 164 |
| PROTEIN HYDROLYSATE FORMULA WITH MEDIUM           |     | <i>Quinapril-DP (GM)</i> .....                | 135 |
| CHAIN TRIGLYCERIDES .....                         | 443 | <i>Quinapril generichealth (GQ)</i> .....     | 135 |
| <i>Prothiaden (AB)</i> .....                      | 386 | QUINAPRIL HYDROCHLORIDE .....                 | 135 |
| <i>Protos 2 g (SE)</i> .....                      | 353 | QUINAPRIL HYDROCHLORIDE WITH                  |     |
| <i>Provera (PH)</i>                               |     | HYDROCHLOROTHIAZIDE .....                     | 139 |
| .Genito urinary system and sex hormones .....     | 169 | <i>Quinapril Sandoz (SZ)</i> .....            | 135 |
| .Antineoplastic and immunomodulating agents ..... | 244 | <i>Quinate (AS)</i> .....                     | 409 |
| <i>Proxen SR 1000 (MD)</i>                        |     | <i>Quinbisul (AS)</i> .....                   | 409 |
| .Musculo-skeletal system .....                    | 342 | QUININE BISULFATE .....                       | 409 |
| .Palliative Care .....                            | 463 | QUININE SULFATE .....                         | 409 |
| .Dental .....                                     | 491 | <i>Quinsul (LN)</i> .....                     | 409 |
| <i>Proxen SR 750 (MD)</i>                         |     | <i>QuitX (AF)</i>                             |     |
| .Musculo-skeletal system .....                    | 342 | .Repatriation Schedule .....                  | 701 |
| .Palliative Care .....                            | 463 | <i>Qvar 100 (IA)</i> .....                    | 416 |
| .Dental .....                                     | 491 | <i>Qvar 100 Autohaler (IA)</i> .....          | 416 |
| <i>Prozac 20 (LY)</i> .....                       | 389 | <i>Qvar 50 (IA)</i> .....                     | 416 |
| <i>Prozac Tab (LY)</i> .....                      | 388 | <i>Qvar 50 Autohaler (IA)</i> .....           | 416 |
| PSEUDOEPHEDRINE HYDROCHLORIDE                     |     | QV Bath Oil (EO)                              |     |
| .Repatriation Schedule .....                      | 702 | .Repatriation Schedule .....                  | 687 |
| PSYLLIUM HYDROPHILIC MUCILLOID                    |     |                                               |     |
| .Repatriation Schedule .....                      | 681 | <b>R</b>                                      |     |
| PSYLLIUM HYDROPHILIC MUCILLOID WITH HIGH          |     | RABEPRAZOLE SODIUM .....                      | 82  |
| AMYLOSE MAIZE STARCH                              |     | <i>Rafen 200 (AF)</i>                         |     |
| .Repatriation Schedule .....                      | 681 | .Musculo-skeletal system .....                | 341 |
| <i>Pulmicort Respules (AP)</i> .....              | 417 | .Palliative Care .....                        | 462 |
| <i>Pulmicort Turbuhaler (AP)</i> .....            | 417 | .Dental .....                                 | 490 |
| <i>Pulmozyme (RO)</i>                             |     | <i>Ralovera (KR)</i> .....                    | 169 |
| .Section 100 .....                                | 532 | RALOXIFENE HYDROCHLORIDE                      |     |
| <i>Puregon 300 IU/0.36 mL (OR)</i>                |     | .Genito urinary system and sex hormones ..... | 177 |
| .Genito urinary system and sex hormones .....     | 173 | .Musculo-skeletal system .....                | 352 |
| .Section 100 .....                                | 636 | RALTEGRAVIR POTASSIUM                         |     |
| <i>Puregon 600 IU/0.72 mL (OR)</i>                |     | .Section 100 .....                            | 607 |
| .Genito urinary system and sex hormones .....     | 173 | RALTITREXED .....                             | 214 |
| .Section 100 .....                                | 636 | <i>Ramace 1.25 mg (AV)</i> .....              | 136 |
| <i>Purinethol (GK)</i> .....                      | 214 | <i>Ramace 10 mg (AV)</i> .....                | 137 |
| <i>PVA Forte (PE)</i>                             |     | <i>Ramace 2.5 mg (AV)</i> .....               | 136 |
| .Sensory organs .....                             | 433 | <i>Ramace 5 mg (AV)</i> .....                 | 136 |
| .Optometical .....                                | 504 | RAMIPRIL .....                                | 136 |
| <i>PVA Tears (PE)</i>                             |     | <i>Ramipril-DP (GM)</i> .....                 | 136 |
| .Sensory organs .....                             | 432 | <i>Ramipril generichealth (GQ)</i> .....      | 136 |
| .Optometical .....                                | 504 | <i>Ramipril Sandoz (SZ)</i> .....             | 136 |
| <i>Pyralin EN (KR)</i> .....                      | 94  | <i>Ramipril Winthrop (WA)</i> .....           | 136 |
| PYRANTEL EMBONATE .....                           | 410 | RAMIPRIL WITH FELODIPINE .....                | 140 |
| PYRIDOSTIGMINE BROMIDE .....                      | 405 | <i>Rancef (RA)</i>                            |     |
| PYRIMETHAMINE .....                               | 409 | .Anti-infectives for systemic use .....       | 192 |
|                                                   |     | .Dental .....                                 | 483 |
| <b>Q</b>                                          |     | <i>Rani 2 (AF)</i> .....                      | 77  |
| <i>Questran Lite (BQ)</i> .....                   | 151 | RANIBIZUMAB .....                             | 428 |
| QUETIAPINE FUMARATE .....                         | 379 | <i>Ranihexal (SZ)</i> .....                   | 77  |
| <i>Quilonum SR (GK)</i>                           |     | RANITIDINE HYDROCHLORIDE .....                | 77  |
|                                                   |     | <i>Ranmoxxy (RA)</i>                          |     |
|                                                   |     | .Anti-infectives for systemic use .....       | 187 |
|                                                   |     | .Dental .....                                 | 478 |

## GENERIC/PROPRIETARY INDEX

|                                                          |     |                                                          |     |
|----------------------------------------------------------|-----|----------------------------------------------------------|-----|
| <i>Ranoxyl (GM)</i> .....                                | 77  | <i>Restore Plus 9957 (HO)</i> .....                      |     |
| <i>Ransim (RA)</i> .....                                 | 149 | <i>.Repatriation Schedule</i> .....                      | 718 |
| <i>Ranzepam (RA)</i> .....                               |     | <i>Restore Plus 9958 (HO)</i> .....                      |     |
| <i>.Nervous system</i> .....                             | 383 | <i>.Repatriation Schedule</i> .....                      | 718 |
| <i>.Palliative Care</i> .....                            | 470 | <i>Restore Plus Sacral 9959 (HO)</i> .....               |     |
| <i>.Dental</i> .....                                     | 498 | <i>.Repatriation Schedule</i> .....                      | 718 |
| <i>Rapamune (WX)</i> .....                               |     | <i>Retaane (AQ)</i> .....                                | 428 |
| <i>.Antineoplastic and immunomodulating agents</i> ..... | 264 | <b>RETEPLASE (RECOMBINANT PLASMINOGEN</b>                |     |
| <i>.Section 100</i> .....                                | 622 | <b>ACTIVATOR)</b> .....                                  | 110 |
| <i>Rapilysin 10 U (TA)</i> .....                         | 110 | <i>Retrovir (GK)</i> .....                               |     |
| <i>Raptiva (SG)</i> .....                                | 260 | <i>.Section 100</i> .....                                | 633 |
| <i>RCF (AB)</i> .....                                    | 451 | <i>Revatio (PF)</i> .....                                |     |
| <i>Reandron 1000 (SC)</i> .....                          | 167 | <i>.Section 100</i> .....                                | 622 |
| <i>Rebif 44 (SG)</i> .....                               | 250 | <i>ReVia (BQ)</i> .....                                  | 407 |
| <b>REBOXETINE MESILATE</b> .....                         | 393 | <i>Reyataz (BQ)</i> .....                                |     |
| <i>Redipred (AS)</i> .....                               | 181 | <i>.Section 100</i> .....                                | 514 |
| <i>Refresh Liquigel (AG)</i> .....                       |     | <b>RIBAVIRIN AND PEGINTERFERON ALFA-2A</b>               |     |
| <i>.Sensory organs</i> .....                             | 431 | <i>.Section 100</i> .....                                | 607 |
| <i>.Optometrical</i> .....                               | 502 | <b>RIBAVIRIN AND PEGINTERFERON ALFA-2B</b>               |     |
| <i>Refresh Tears Plus (AG)</i> .....                     |     | <i>.Section 100</i> .....                                | 609 |
| <i>.Sensory organs</i> .....                             | 431 | <b>RICINOLEIC ACID WITH ACETIC ACID AND</b>              |     |
| <i>.Optometrical</i> .....                               | 502 | <b>HYDROXYQUINOLINE SULFATE</b>                          |     |
| <i>Remicade (SH)</i> .....                               |     | <i>.Repatriation Schedule</i> .....                      | 693 |
| <i>.Section 100</i> .....                                | 559 | <i>Ridaura (GH)</i> .....                                | 343 |
| <i>.Repatriation Schedule</i> .....                      | 697 | <b>RIFABUTIN</b>                                         |     |
| <i>Reminyl (JC)</i> .....                                | 400 | <i>.Section 100</i> .....                                | 610 |
| <i>Renagel (GZ)</i> .....                                |     | <i>Rifadin (SW)</i> .....                                | 205 |
| <i>.Various</i> .....                                    | 435 | <b>RIFAMPICIN</b> .....                                  | 205 |
| <i>.Section 100</i> .....                                | 616 | <i>Rilutek (SW)</i> .....                                | 408 |
| <i>Renitec (MK)</i> .....                                | 131 | <b>RILUZOLE</b> .....                                    | 408 |
| <i>Renitec 20 (MK)</i> .....                             | 132 | <i>Rimycin 150 (AF)</i> .....                            | 205 |
| <i>Renitec M (MK)</i> .....                              | 131 | <i>Rimycin 300 (AF)</i> .....                            | 205 |
| <i>Renitec Plus 20/6 (MK)</i> .....                      | 138 | <b>RISEDRONATE SODIUM</b>                                |     |
| <i>ReoPro (LY)</i> .....                                 | 108 | <i>.Musculo-skeletal system</i> .....                    | 348 |
| <i>Repalyte New Formulation (SW)</i> .....               | 91  | <i>.Repatriation Schedule</i> .....                      | 697 |
| <i>Replicare Ultra 66000434 (SN)</i> .....               |     | <b>RISEDRONATE SODIUM AND CALCIUM</b>                    |     |
| <i>.Repatriation Schedule</i> .....                      | 718 | <b>CARBONATE</b>                                         |     |
| <i>Rescriptor (PF)</i> .....                             |     | <i>.Musculo-skeletal system</i> .....                    | 350 |
| <i>.Section 100</i> .....                                | 530 | <i>.Repatriation Schedule</i> .....                      | 698 |
| <i>Resonium-A (SW)</i> .....                             |     | <b>RISEDRONATE SODIUM AND CALCIUM</b>                    |     |
| <i>.Repatriation Schedule</i> .....                      | 705 | <b>CARBONATE WITH COLECALCIFEROL</b> .....               | 351 |
| <i>Resprim (AF)</i> .....                                |     | <i>Risperdal (JC)</i> .....                              | 380 |
| <i>.Antifectives for systemic use</i> .....              | 196 | <i>Risperdal Consta (JC)</i> .....                       | 382 |
| <i>.Dental</i> .....                                     | 485 | <i>Risperdal Quicklet (JC)</i> .....                     | 380 |
| <i>Resprim Forte (AF)</i> .....                          |     | <b>RISPERIDONE</b> .....                                 | 380 |
| <i>.Antifectives for systemic use</i> .....              | 196 | <i>Ritalin 10 (NV)</i> .....                             | 395 |
| <i>.Dental</i> .....                                     | 486 | <i>Ritalin LA (NV)</i> .....                             | 395 |
| <i>Restore CalciCare 9937 (HO)</i> .....                 |     | <i>Rithmik 100 (AW)</i> .....                            | 115 |
| <i>.Repatriation Schedule</i> .....                      | 713 | <i>Rithmik 200 (AW)</i> .....                            | 115 |
| <i>Restore CalciCare 9938 (HO)</i> .....                 |     | <b>RITONAVIR</b>                                         |     |
| <i>.Repatriation Schedule</i> .....                      | 713 | <i>.Section 100</i> .....                                | 610 |
| <i>Restore CalciCare 9940 (HO)</i> .....                 |     | <b>RITUXIMAB</b>                                         |     |
| <i>.Repatriation Schedule</i> .....                      | 713 | <i>.Antineoplastic and immunomodulating agents</i> ..... | 221 |
| <i>Restore Extra Thin 9921 (HO)</i> .....                |     | <i>.Section 100</i> .....                                | 610 |
| <i>.Repatriation Schedule</i> .....                      | 717 | <b>RIVASTIGMINE</b> .....                                | 400 |
| <i>restore O.R.S. (GM)</i> .....                         | 91  | <b>RIVASTIGMINE HYDROGEN TARTRATE</b> .....              | 402 |
| <i>Restore Plus 9956 (HO)</i> .....                      |     | <i>Rivotril (RO)</i> .....                               |     |
| <i>.Repatriation Schedule</i> .....                      | 718 | <i>.Doctor's Bag Supplies</i> .....                      | 69  |

## GENERIC/PROPRIETARY INDEX

|                                                   |     |                                                         |     |
|---------------------------------------------------|-----|---------------------------------------------------------|-----|
| .Nervous system .....                             | 367 | SALICYLIC ACID WITH PODOPHYLLIN RESIN                   |     |
| .Palliative Care .....                            | 469 | .Repatriation Schedule .....                            | 691 |
| <i>Roaccutane (RO)</i> .....                      | 161 | SALMETEROL XINAFOATE .....                              | 413 |
| <i>Rocaltrol (RO)</i> .....                       |     | <i>Salofalk (OA)</i> .....                              | 93  |
| .Alimentary tract and metabolism .....            | 104 | <i>Sandimmun (NV)</i> .....                             |     |
| .Musculo-skeletal system .....                    | 352 | .Section 100 .....                                      | 528 |
| <i>Rocephin (RO)</i> .....                        | 195 | <i>Sandomigran 0.5 (NV)</i> .....                       | 366 |
| <i>Roferon-A (RO)</i> .....                       |     | <i>Sandostatin 0.05 (NV)</i> .....                      |     |
| .Antineoplastic and immunomodulating agents ..... | 249 | .Section 100 .....                                      | 604 |
| .Section 100 .....                                | 598 | <i>Sandostatin 0.1 (NV)</i> .....                       |     |
| ROSIGLITAZONE MALEATE .....                       | 102 | .Section 100 .....                                      | 604 |
| ROSIGLITAZONE MALEATE WITH METFORMIN              |     | <i>Sandostatin 0.5 (NV)</i> .....                       |     |
| HYDROCHLORIDE .....                               | 100 | .Section 100 .....                                      | 604 |
| ROSUVASTATIN CALCIUM .....                        | 148 | <i>Sandostatin LAR (NV)</i> .....                       |     |
| <i>Roxar 150 (AW)</i> .....                       | 198 | .Section 100 .....                                      | 604 |
| <i>Roxar 300 (AW)</i> .....                       | 198 | <i>Sandrena (OR)</i> .....                              | 168 |
| <i>Roxide (SZ)</i> .....                          | 198 | SAQUINAVIR MESYLATE                                     |     |
| <i>Roximycin (AF)</i> .....                       | 198 | .Section 100 .....                                      | 615 |
| <i>Roxin (AW)</i> .....                           | 200 | <i>Savacol Mouth and Throat Rinse (OM)</i> .....        |     |
| ROXITHROMYCIN .....                               | 198 | .Repatriation Schedule .....                            | 680 |
| <i>Rozex (GA)</i> .....                           |     | <i>Seaze 100 (AW)</i> .....                             | 372 |
| .Repatriation Schedule .....                      | 689 | <i>Seaze 200 (AW)</i> .....                             | 372 |
| <i>Rulide (SW)</i> .....                          | 198 | <i>Seaze 25 (AW)</i> .....                              | 371 |
| <i>Rulide D (SW)</i> .....                        | 198 | <i>Seaze 5 (AW)</i> .....                               | 371 |
| <i>Rynacrom (SW)</i> .....                        |     | <i>Seaze 50 (AW)</i> .....                              | 371 |
| .Repatriation Schedule .....                      | 702 | <i>SebiRinse (EO)</i> .....                             |     |
| <i>Rythmodan (SW)</i> .....                       | 114 | .Repatriation Schedule .....                            | 691 |
| S                                                 |     | <i>Sebitar (EO)</i> .....                               |     |
|                                                   |     | .Repatriation Schedule .....                            | 690 |
| <i>S-26 LF (WX)</i> .....                         | 445 | <i>Sebivo (NV)</i> .....                                |     |
| <i>Sabril (SW)</i> .....                          | 370 | .Section 100 .....                                      | 631 |
| <i>Saizen 8 mg click.easy (SG)</i> .....          |     | <i>Sebizole (GM)</i> .....                              |     |
| .Section 100 .....                                | 635 | .Repatriation Schedule .....                            | 685 |
| <i>Salazopyrin (PH)</i> .....                     | 94  | SELEGILINE HYDROCHLORIDE .....                          | 376 |
| <i>Salazopyrin-EN (PH)</i> .....                  | 94  | SELENIUM SULFIDE                                        |     |
| <i>Salbutamol-GA (GM)</i> .....                   |     | .Repatriation Schedule .....                            | 690 |
| .Doctor's Bag Supplies .....                      | 71  | <i>Selgene (AF)</i> .....                               | 376 |
| .Respiratory system .....                         | 413 | <i>Selsun (AB)</i> .....                                |     |
| <i>Salbutamol Sandoz (SZ)</i> .....               |     | .Repatriation Schedule .....                            | 690 |
| .Doctor's Bag Supplies .....                      | 71  | SENEGA AND AMMONIA                                      |     |
| .Respiratory system .....                         | 413 | .Repatriation Schedule .....                            | 702 |
| SALBUTAMOL SULFATE                                |     | SENNA STANDARDISED                                      |     |
| .Doctor's Bag Supplies .....                      | 71  | .Repatriation Schedule .....                            | 681 |
| .Respiratory system .....                         | 412 | <i>Senokot (RC)</i> .....                               |     |
| .Respiratory system .....                         | 420 | .Repatriation Schedule .....                            | 681 |
| SALCATONIN .....                                  | 183 | <i>Sensipar (AN)</i> .....                              |     |
| SALICYLIC ACID WITH BENZALKONIUM CHLORIDE,        |     | .Systemic hormonal preparations, excl. sex hormones and |     |
| ALCOHOL, COAL TAR AND POLYOXYETHYLENE             |     | insulins .....                                          | 183 |
| ETHERS                                            |     | .Section 100 .....                                      | 527 |
| .Repatriation Schedule .....                      | 690 | <i>SensoCard (PX)</i> .....                             | 438 |
| SALICYLIC ACID WITH BENZALKONIUM CHLORIDE,        |     | <i>Septtrin (SI)</i> .....                              |     |
| ALCOHOL AND POLYOXYETHYLENE ETHERS                |     | .Antiinfectives for systemic use .....                  | 196 |
| .Repatriation Schedule .....                      | 690 | .Dental .....                                           | 486 |
| SALICYLIC ACID WITH COAL TAR SOLUTION AND         |     | <i>Septtrin Forte (SI)</i> .....                        |     |
| PINE TAR                                          |     | .Antiinfectives for systemic use .....                  | 196 |
| .Repatriation Schedule .....                      | 690 | .Dental .....                                           | 486 |
|                                                   |     | <i>Serenace (SI)</i> .....                              |     |
|                                                   |     | .Doctor's Bag Supplies .....                            | 69  |

## GENERIC/PROPRIETARY INDEX

|                                                                         |     |                                                                                      |     |
|-------------------------------------------------------------------------|-----|--------------------------------------------------------------------------------------|-----|
| .Nervous system .....                                                   | 377 | <i>Simvar 20 (AW)</i> .....                                                          | 149 |
| <i>Serepax (SI)</i> .....                                               |     | <i>Simvar 40 (AW)</i> .....                                                          | 150 |
| .Nervous system .....                                                   | 383 | <i>Simvar 80 (AW)</i> .....                                                          | 150 |
| .Palliative Care .....                                                  | 471 | <b>SIMVASTATIN</b> .....                                                             | 148 |
| .Dental .....                                                           | 498 | <i>Simvastatin-DP (GM)</i> .....                                                     | 149 |
| <i>Seretide Accuhaler 100/50 (GK)</i> .....                             | 415 | <i>Simvastatin generichealth (GQ)</i> .....                                          | 149 |
| <i>Seretide Accuhaler 250/50 (GK)</i> .....                             | 415 | <i>Simvastatin Winthrop (WA)</i> .....                                               | 149 |
| <i>Seretide Accuhaler 500/50 (GK)</i> .....                             | 416 | <i>Simvasyn (CR)</i> .....                                                           | 148 |
| <i>Seretide MDI 125/25 (GK)</i> .....                                   | 415 | <i>Simvatrust 10 (MI)</i> .....                                                      | 149 |
| <i>Seretide MDI 250/25 (GK)</i> .....                                   | 416 | <i>Simvatrust 20 (MI)</i> .....                                                      | 149 |
| <i>Seretide MDI 50/25 (GK)</i> .....                                    | 415 | <i>Simvatrust 40 (MI)</i> .....                                                      | 150 |
| <i>Serevent Accuhaler (GK)</i> .....                                    | 413 | <i>Simvatrust 80 (MI)</i> .....                                                      | 150 |
| <i>Serophene (SG)</i> .....                                             | 175 | <i>Sinemet (MK)</i> .....                                                            | 374 |
| <i>Seroquel (AP)</i> .....                                              | 379 | <i>Sinemet 100/25 (MK)</i> .....                                                     | 374 |
| <i>Sertra 100 (SI)</i> .....                                            | 391 | <i>Sinemet CR (MK)</i> .....                                                         | 374 |
| <i>Sertra 50 (SI)</i> .....                                             | 390 | <i>Sinequan (PF)</i> .....                                                           | 386 |
| <i>Sertraline 100 (CR)</i> .....                                        | 391 | <i>Singulair (MK)</i> .....                                                          | 421 |
| <i>Sertraline 50 (CR)</i> .....                                         | 390 | <b>SIROLIMUS</b> .....                                                               |     |
| <i>Sertraline-GA (GM)</i> .....                                         | 390 | .Antineoplastic and immunomodulating agents .....                                    | 264 |
| <i>Sertraline generichealth (GQ)</i> .....                              | 390 | .Section 100 .....                                                                   | 622 |
| <b>SERTRALINE HYDROCHLORIDE</b> .....                                   | 390 | <b>SITAGLIPTIN</b> .....                                                             | 103 |
| <i>Sertraline Winthrop (WA)</i> .....                                   | 390 | <b>SITAXENTAN SODIUM</b> .....                                                       |     |
| <i>Sertratrust 100 (MI)</i> .....                                       | 391 | .Section 100 .....                                                                   | 623 |
| <i>Sertratrust 50 (MI)</i> .....                                        | 390 | <i>Skelid (HH)</i> .....                                                             | 349 |
| <i>Setopress 3504 (SS)</i> .....                                        |     | <b>SKIN CLEANSER</b> .....                                                           |     |
| .Repatriation Schedule .....                                            | 710 | .Repatriation Schedule .....                                                         | 691 |
| <i>Setopress 3505 (SS)</i> .....                                        |     | <b>SKIN EMOLLIENT</b> .....                                                          |     |
| .Repatriation Schedule .....                                            | 710 | .Repatriation Schedule .....                                                         | 687 |
| <i>Setrona (RA)</i> .....                                               | 390 | <i>Slow-K (NV)</i> .....                                                             | 105 |
| <b>SEVELAMER HYDROCHLORIDE</b> .....                                    |     | <i>Sodibic (AS)</i> .....                                                            |     |
| .Various .....                                                          | 435 | .Repatriation Schedule .....                                                         | 694 |
| .Section 100 .....                                                      | 616 | <b>SODIUM ACID PHOSPHATE</b> .....                                                   | 437 |
| <i>Sevredol (MF)</i> .....                                              |     | <b>SODIUM ALGINATE WITH CALCIUM CARBONATE</b><br><b>AND SODIUM BICARBONATE</b> ..... | 83  |
| .Nervous system .....                                                   | 356 | <b>SODIUM AUROTHIOMALATE</b> .....                                                   | 343 |
| .Palliative Care .....                                                  | 465 | <b>SODIUM BICARBONATE</b> .....                                                      |     |
| <i>Sical (AF)</i> .....                                                 |     | .Repatriation Schedule .....                                                         | 694 |
| .Alimentary tract and metabolism .....                                  | 104 | <b>SODIUM CHLORIDE</b> .....                                                         |     |
| .Musculo-skeletal system .....                                          | 352 | .Blood and blood forming organs .....                                                | 113 |
| <i>Sifrol (BY)</i> .....                                                | 376 | .Various .....                                                                       | 452 |
| <i>Sigmacort (SI)</i> .....                                             |     | .Dental .....                                                                        | 474 |
| .Dermatologicals .....                                                  | 159 | .Dental .....                                                                        | 499 |
| .Dental .....                                                           | 475 | .Repatriation Schedule .....                                                         | 684 |
| <i>Sigmaxin (FM)</i> .....                                              | 114 | <b>SODIUM CHLORIDE COMPOUND</b> .....                                                | 113 |
| <i>Sigmaxin-PG (FM)</i> .....                                           | 114 | <b>SODIUM CHLORIDE WITH GLUCOSE</b> .....                                            |     |
| <b>SILDENAFIL CITRATE</b> .....                                         |     | .Blood and blood forming organs .....                                                | 113 |
| .Section 100 .....                                                      | 616 | .Dental .....                                                                        | 475 |
| .Repatriation Schedule .....                                            | 694 | <b>SODIUM CITRO-TARTRATE</b> .....                                                   |     |
| <i>Silic 15 (EO)</i> .....                                              |     | .Repatriation Schedule .....                                                         | 695 |
| .Repatriation Schedule .....                                            | 686 | <b>SODIUM CLODRONATE TETRAHYDRATE</b> .....                                          | 348 |
| <i>Silvazine (SN)</i> .....                                             | 158 | <b>SODIUM CROMOGLYCATE</b> .....                                                     |     |
| <b>SILVER SULFADIAZINE WITH CHLORHEXIDINE</b><br><b>GLUCONATE</b> ..... | 158 | .Respiratory system .....                                                            | 419 |
| <i>Simplotan (GP)</i> .....                                             |     | .Sensory organs .....                                                                | 427 |
| .Antifungives for systemic use .....                                    | 202 | .Optometrical .....                                                                  | 502 |
| .Antiparasitic products, insecticides and repellents ..                 |     | .Repatriation Schedule .....                                                         | 702 |
| <i>Simvabell (BF)</i> .....                                             | 148 | <b>SODIUM LACTATE COMPOUND</b> .....                                                 | 113 |
| <i>Simvahexal (SZ)</i> .....                                            | 148 | <b>SODIUM POLYSTYRENE SULFONATE</b> .....                                            |     |
| <i>Simvar 10 (AW)</i> .....                                             | 149 | .Repatriation Schedule .....                                                         | 705 |



## GENERIC/PROPRIETARY INDEX

|                                                         |     |                                                          |     |
|---------------------------------------------------------|-----|----------------------------------------------------------|-----|
| <b>SODIUM VALPROATE</b> .....                           | 369 | .Cardiovascular system .....                             | 115 |
| <i>Sodium Valproate Sandoz (SZ)</i> .....               | 369 | .Cardiovascular system .....                             | 123 |
| <i>Soffban 7224 (BV)</i> .....                          |     | <b>SOY PROTEIN AND FAT FORMULA WITH VITAMINS</b>         |     |
| .Repatriation Schedule .....                            | 709 | <b>AND MINERALS—CARBOHYDRATE FREE</b> .....              | 451 |
| <i>Sofradex (SW)</i> .....                              | 433 | <i>Span-K (AS)</i> .....                                 | 105 |
| <i>Soframycin (SW)</i> .....                            | 434 | <i>Spenco Dermal Pad 10-553 (KC)</i> .....               |     |
| <i>SofTact (MS)</i> .....                               | 438 | .Repatriation Schedule .....                             | 721 |
| <i>Solavert (AW)</i> .....                              |     | <i>Spenco Dermal Pad 10-561 (KC)</i> .....               |     |
| .Cardiovascular system .....                            | 115 | .Repatriation Schedule .....                             | 721 |
| .Cardiovascular system .....                            |     | <i>Spiractin 100 (AF)</i> .....                          | 121 |
| <i>Solian 100 (SW)</i> .....                            | 379 | <i>Spiractin 25 (AF)</i> .....                           | 121 |
| <i>Solian 200 (SW)</i> .....                            | 379 | <i>Spiriva (BY)</i> .....                                | 419 |
| <i>Solian 400 (SW)</i> .....                            | 379 | <b>SPIRONOLACTONE</b> .....                              | 121 |
| <i>Solian Solution (SW)</i> .....                       | 379 | <i>Sporahexal (HX)</i> .....                             |     |
| <i>Solone (FM)</i> .....                                | 181 | .Anti-infectives for systemic use .....                  | 192 |
| <i>SoloSite Gel 36361338 (SN)</i> .....                 |     | .Dental .....                                            | 483 |
| .Repatriation Schedule .....                            | 719 | <i>Sporanox (JC)</i> .....                               | 204 |
| <i>Solprin (RC)</i> .....                               |     | <i>Sprycel (BQ)</i> .....                                | 224 |
| .Blood and blood forming organs .....                   | 108 | <i>Stalevo 100/25/200mg (NV)</i> .....                   | 375 |
| .Nervous system .....                                   | 364 | <i>Stalevo 150/37.5/200mg (NV)</i> .....                 | 375 |
| .Dental .....                                           | 496 | <i>Stalevo 50/12.5/200mg (NV)</i> .....                  | 375 |
| <i>Solu-Cortef (PH)</i> .....                           |     | <i>Staphylex 250 (AF)</i> .....                          |     |
| .Doctor's Bag Supplies .....                            | 69  | .Anti-infectives for systemic use .....                  | 190 |
| .Systemic hormonal preparations, excl. sex hormones and |     | .Dental .....                                            | 480 |
| insulins .....                                          | 180 | <i>Staphylex 500 (AF)</i> .....                          |     |
| .Dental .....                                           | 476 | .Anti-infectives for systemic use .....                  | 190 |
| <i>Solugel 10336 (JJ)</i> .....                         |     | .Dental .....                                            | 481 |
| .Repatriation Schedule .....                            | 719 | <b>STAVUDINE</b> .....                                   |     |
| <i>Solu-Medrol (PF)</i> .....                           | 180 | .Section 100 .....                                       | 631 |
| <i>Somac (NQ)</i> .....                                 | 81  | <i>Stelax 10 (AW)</i> .....                              | 344 |
| <b>SOMATROPIN (RECOMBINANT HUMAN GROWTH</b>             |     | <i>Stelax 25 (AW)</i> .....                              | 344 |
| <b>HORMONE)</b> .....                                   |     | <i>Stelazine (GH)</i> .....                              | 377 |
| .Section 100 .....                                      | 634 | <i>Stemetil (SW)</i> .....                               |     |
| <i>Somatuline Autogel (IS)</i> .....                    |     | .Doctor's Bag Supplies .....                             | 70  |
| .Section 100 .....                                      | 601 | .Alimentary tract and metabolism .....                   | 87  |
| <i>Somatuline LA (IS)</i> .....                         |     | .Dental .....                                            | 474 |
| .Section 100 .....                                      | 600 | <i>Stemzine (AV)</i> .....                               |     |
| <i>Sone (FM)</i> .....                                  | 181 | .Alimentary tract and metabolism .....                   | 87  |
| <i>Sorbidin (AF)</i> .....                              | 117 | .Dental .....                                            | 474 |
| <b>SORBITOL WITH SODIUM CITRATE AND SODIUM</b>          |     | <b>STERCULIA WITH FRANGULA BARK</b> .....                |     |
| <b>LAURYL SULFOACETATE</b> .....                        |     | .Alimentary tract and metabolism .....                   | 88  |
| .Alimentary tract and metabolism .....                  | 90  | .Palliative Care .....                                   | 457 |
| .Palliative Care .....                                  | 459 | .Repatriation Schedule .....                             | 681 |
| .Repatriation Schedule .....                            | 681 | <i>Steripaste 3610 (XP)</i> .....                        |     |
| <i>Sorbsan 1410 (UM)</i> .....                          |     | .Repatriation Schedule .....                             | 712 |
| .Repatriation Schedule .....                            | 713 | <i>Stieprox Liquid (SX)</i> .....                        |     |
| <i>Sorbsan 1411 (UM)</i> .....                          |     | .Repatriation Schedule .....                             | 686 |
| .Repatriation Schedule .....                            | 713 | <i>Stocrin (MK)</i> .....                                |     |
| <i>Sotab (GM)</i> .....                                 |     | .Section 100 .....                                       | 533 |
| .Cardiovascular system .....                            | 115 | <i>Strattera (LY)</i> .....                              | 394 |
| .Cardiovascular system .....                            |     | <i>Stromectol (MK)</i> .....                             | 410 |
| <i>Sotacor (BQ)</i> .....                               |     | <b>STRONTIUM RANELATE</b> .....                          | 353 |
| .Cardiovascular system .....                            | 115 | <i>Suboxone (RC)</i> .....                               |     |
| .Cardiovascular system .....                            |     | .Section 100 .....                                       | 638 |
| <i>Sotahexal (SZ)</i> .....                             |     | <i>Subutex (RC)</i> .....                                |     |
| .Cardiovascular system .....                            | 115 | .Section 100 .....                                       | 637 |
| .Cardiovascular system .....                            |     | <b>SUCRALFATE</b> .....                                  | 83  |
| <b>SOTALOL HYDROCHLORIDE</b> .....                      |     | <i>Sudafed Sinus &amp; Nasal Decongestant (JT)</i> ..... |     |

## GENERIC/PROPRIETARY INDEX

|                                                   |     |                                                    |     |
|---------------------------------------------------|-----|----------------------------------------------------|-----|
| .Repatriation Schedule .....                      | 702 | <i>Tamoxen 10 mg (GM)</i> .....                    | 246 |
| SULFACETAMIDE SODIUM .....                        |     | <i>Tamoxen 20 mg (GM)</i> .....                    | 246 |
| .Sensory organs .....                             | 422 | TAMOXIFEN CITRATE .....                            | 246 |
| .Optometrical .....                               | 501 | <i>Tamoxifen Sandoz (SZ)</i> .....                 | 246 |
| SULFASALAZINE .....                               | 94  | Tamsil (AW) .....                                  |     |
| SULINDAC .....                                    |     | .Dermatologicals .....                             | 156 |
| .Musculo-skeletal system .....                    | 339 | .Repatriation Schedule .....                       | 686 |
| .Palliative Care .....                            | 462 | TAMSULOSIN HYDROCHLORIDE .....                     |     |
| .Dental .....                                     | 489 | .Repatriation Schedule .....                       | 695 |
| SULTHIAME .....                                   | 372 | TAPES—NON-WOVEN RETENTION                          |     |
| <i>Sumagran 50 (AW)</i> .....                     | 366 | (POLYACRYLATE) .....                               |     |
| <i>Sumatab (AF)</i> .....                         | 366 | .Repatriation Schedule .....                       | 721 |
| SUMATRIPTAN .....                                 | 366 | TAPES—PLASTER ADHESIVE ELASTIC .....               |     |
| SUMATRIPTAN SUCCINATE .....                       | 366 | .Repatriation Schedule .....                       | 721 |
| SUNSCREENS .....                                  |     | TAPES—PLASTER ADHESIVE HYPOALLERGENIC .....        |     |
| .Repatriation Schedule .....                      | 687 | .Repatriation Schedule .....                       | 721 |
| <i>SunSense Cream SPF 30+ (EO)</i> .....          |     | <i>Tarceva (RO)</i> .....                          | 226 |
| .Repatriation Schedule .....                      | 687 | <i>Tarka 4/240 (AB)</i> .....                      | 140 |
| <i>SunSense Ultra SPF 30+ (EO)</i> .....          |     | <i>Tasigna (NV)</i> .....                          | 239 |
| .Repatriation Schedule .....                      | 688 | <i>Taxol (BQ)</i> .....                            | 217 |
| <i>Surepress 650947 (CC)</i> .....                |     | <i>Taxotere (SW)</i> .....                         | 217 |
| .Repatriation Schedule .....                      | 710 | <i>Tazac (AS)</i> .....                            | 77  |
| <i>Surepress 650948 (CC)</i> .....                |     | Tears Naturale (AQ) .....                          |     |
| .Repatriation Schedule .....                      | 709 | .Sensory organs .....                              | 432 |
| <i>Surgam (SW)</i> .....                          | 342 | .Optometrical .....                                | 503 |
| <i>Surgical Lubricating Gel (BI)</i> .....        |     | <i>Tegaderm Transparent 1628 (MM)</i> .....        |     |
| .Repatriation Schedule .....                      | 721 | .Repatriation Schedule .....                       | 714 |
| <i>Sustanon 100 (OR)</i> .....                    | 167 | <i>Tegaderm Transparent Island 3582 (MM)</i> ..... |     |
| <i>Sustanon 250 (OR)</i> .....                    | 167 | .Repatriation Schedule .....                       | 714 |
| <i>Suvalan 50 (ME)</i> .....                      | 366 | <i>Tegaderm Transparent Island 3586 (MM)</i> ..... |     |
| <i>Symbicort Turbuhaler 100/6 (AP)</i> .....      | 414 | .Repatriation Schedule .....                       | 714 |
| <i>Symbicort Turbuhaler 200/6 (AP)</i> .....      | 414 | <i>Tegretol 100 (NV)</i> .....                     |     |
| <i>Symbicort Turbuhaler 400/12 (AP)</i> .....     | 415 | .Nervous system .....                              | 368 |
| <i>Symmetrel 100 (NV)</i> .....                   | 375 | .Dental .....                                      | 497 |
| <i>Synacthen Depot 1 mg/1 mL (NV)</i> .....       | 178 | <i>Tegretol 200 (NV)</i> .....                     |     |
| <i>Synarel (PH)</i> .....                         | 179 | .Nervous system .....                              | 368 |
| <i>Synphasic (PH)</i> .....                       | 166 | .Dental .....                                      | 497 |
| <i>Systane (AQ)</i> .....                         |     | <i>Tegretol CR 200 (NV)</i> .....                  |     |
| .Sensory organs .....                             | 432 | .Nervous system .....                              | 368 |
| .Optometrical .....                               | 504 | .Dental .....                                      | 497 |
| <b>T</b>                                          |     |                                                    |     |
| <i>Tacidine (AF)</i> .....                        | 77  | <i>Tegretol CR 400 (NV)</i> .....                  |     |
| TACROLIMUS .....                                  |     | .Nervous system .....                              | 368 |
| .Antineoplastic and immunomodulating agents ..... | 336 | .Dental .....                                      | 497 |
| .Section 100 .....                                | 631 | <i>Tegretol Liquid (NV)</i> .....                  |     |
| TADALAFIL .....                                   |     | .Nervous system .....                              | 368 |
| .Repatriation Schedule .....                      | 694 | .Dental .....                                      | 497 |
| <i>Tagamet (GK)</i> .....                         | 76  | TELBIVUDINE .....                                  |     |
| <i>Talam (AW)</i> .....                           | 387 | .Section 100 .....                                 | 631 |
| <i>Talohexal (SZ)</i> .....                       | 387 | <i>Telfa 1970C (KE)</i> .....                      |     |
| TAMARINDUS INDICA SEED POLYSACCHARIDE .....       |     | .Repatriation Schedule .....                       | 719 |
| .Sensory organs .....                             | 433 | <i>Telfa 2140C (KE)</i> .....                      |     |
| .Optometrical .....                               | 504 | .Repatriation Schedule .....                       | 719 |
| <i>Tambocor (IA)</i> .....                        | 114 | <i>Telfa 6020C (KE)</i> .....                      |     |
| <i>Tamodin (SI)</i> .....                         | 246 | .Repatriation Schedule .....                       | 720 |
|                                                   |     | <i>Telfa 7650C (KE)</i> .....                      |     |
|                                                   |     | .Repatriation Schedule .....                       | 720 |
|                                                   |     | <i>Telfa 8252F (KE)</i> .....                      |     |
|                                                   |     | .Repatriation Schedule .....                       | 711 |

## GENERIC/PROPRIETARY INDEX

|                                      |     |                                                                  |     |
|--------------------------------------|-----|------------------------------------------------------------------|-----|
| <i>Telfa</i> 8253F (KE)              |     | .Dermatologicals                                                 | 156 |
| .Repatriation Schedule               | 711 | .Repatriation Schedule                                           | 686 |
| <i>Telfa</i> 8254F (KE)              |     | .Repatriation Schedule                                           | 686 |
| .Repatriation Schedule               | 711 | TERBUTALINE SULFATE                                              |     |
| <i>Telfast</i> (SW)                  |     | .Doctor's Bag Supplies                                           | 71  |
| .Repatriation Schedule               | 703 | .Respiratory system                                              | 414 |
| <i>Telfast</i> 120 (SW)              |     | .Respiratory system                                              | 420 |
| .Repatriation Schedule               | 703 | <i>Teril</i> (AF)                                                |     |
| TELMISARTAN                          | 141 | .Nervous system                                                  | 368 |
| TELMISARTAN WITH HYDROCHLOROTHIAZIDE | 142 | .Dental                                                          | 497 |
| <i>Telzir</i> (GK)                   |     | <i>Terry White Chemists Aciclovir</i> (TW)                       | 206 |
| .Section 100                         | 547 | <i>Terry White Chemists Alendronate 70mg</i> (TW)                | 346 |
| <i>Temaze</i> (AF)                   |     | <i>Terry White Chemists Allopurinol</i> (TW)                     | 345 |
| .Nervous system                      | 385 | <i>Terry White Chemists Alprazolam</i> (TW)                      | 382 |
| .Palliative Care                     | 472 | <i>Terry White Chemists Amiodarone</i> (TW)                      | 115 |
| .Dental                              | 498 | <i>Terry White Chemists Amlodipine</i> (TW)                      | 126 |
| TEMAZEPAM                            |     | <i>Terry White Chemists Amoxycillin</i> (TW)                     |     |
| .Nervous system                      | 385 | .Anti-infectives for systemic use                                | 186 |
| .Palliative Care                     | 472 | .Dental                                                          | 478 |
| .Dental                              | 498 | <i>Terry White Chemists Amoxycillin and Clavulanic Acid</i> (TW) |     |
| <i>Temodal</i> (SH)                  | 212 | .Anti-infectives for systemic use                                | 191 |
| TEMOZOLOMIDE                         | 212 | .Dental                                                          | 482 |
| <i>Temtabs</i> (FM)                  |     | <i>Terry White Chemists Atenolol</i> (TW)                        | 123 |
| .Nervous system                      | 385 | <i>Terry White Chemists Baclofen</i> (TW)                        | 344 |
| .Palliative Care                     | 472 | <i>Terry White Chemists Captopril</i> (TW)                       | 130 |
| .Dental                              | 498 | <i>Terry White Chemists Carvedilol 12.5 mg</i> (TW)              | 125 |
| <i>TenderWet</i> 24 Active (HR)      |     | <i>Terry White Chemists Carvedilol 25 mg</i> (TW)                | 126 |
| .Repatriation Schedule               | 716 | <i>Terry White Chemists Carvedilol 3.125 mg</i> (TW)             | 125 |
| <i>TenderWet</i> Active Cavity (HR)  |     | <i>Terry White Chemists Carvedilol 6.25 mg</i> (TW)              | 125 |
| .Repatriation Schedule               | 716 | <i>Terry White Chemists Cefaclor</i> (TW)                        |     |
| TENECTEPLASE                         | 111 | .Anti-infectives for systemic use                                | 194 |
| TENOFOVIR DISOPROXIL FUMARATE        |     | .Dental                                                          | 485 |
| .Section 100                         | 632 | <i>Terry White Chemists Cefaclor CD</i> (TW)                     |     |
| TENOFOVIR DISOPROXIL FUMARATE WITH   |     | .Anti-infectives for systemic use                                | 194 |
| EMTRICITABINE                        |     | .Dental                                                          | 484 |
| .Section 100                         | 632 | <i>Terry White Chemists Cephalexin</i> (TW)                      |     |
| <i>Tenopt</i> (SI)                   | 426 | .Anti-infectives for systemic use                                | 192 |
| <i>Tenormin</i> (AP)                 | 123 | .Dental                                                          | 483 |
| <i>Tensig</i> (SI)                   | 123 | <i>Terry White Chemists Citalopram</i> (TW)                      | 387 |
| <i>Tensogrip</i> 36361259 (BV)       |     | <i>Terry White Chemists Clarithromycin</i> (TW)                  | 197 |
| .Repatriation Schedule               | 712 | <i>Terry White Chemists Clomipramine</i> (TW)                    |     |
| <i>Tensopress</i> 66004347 (BV)      |     | .Nervous system                                                  | 384 |
| .Repatriation Schedule               | 710 | .Nervous system                                                  | 386 |
| <i>Tensopress</i> 66004348 (BV)      |     | <i>Terry White Chemists Clotrimazole 3 Day Cream</i> (TW)        |     |
| .Repatriation Schedule               | 710 | .Repatriation Schedule                                           | 693 |
| TERAZOSIN HYDROCHLORIDE              |     | <i>Terry White Chemists Clotrimazole 6 Day Cream</i> (TW)        |     |
| .Repatriation Schedule               | 695 | .Repatriation Schedule                                           | 692 |
| <i>Terbihexal</i> (SZ)               |     | <i>Terry White Chemists Diclofenac</i> (TW)                      |     |
| .Dermatologicals                     | 156 | .Musculo-skeletal system                                         | 338 |
| .Repatriation Schedule               | 686 | .Palliative Care                                                 | 460 |
| TERBINAFINE                          |     | .Dental                                                          | 488 |
| .Repatriation Schedule               | 686 | <i>Terry White Chemists Diltiazem</i> (TW)                       | 129 |
| <i>Terbinafine</i> 250 (CR)          | 156 | <i>Terry White Chemists Diltiazem CD</i> (TW)                    | 129 |
| <i>Terbinafine-DP</i> (GM)           |     | <i>Terry White Chemists Doxycycline</i> (TW)                     |     |
| .Dermatologicals                     | 156 | .Anti-infectives for systemic use                                | 184 |
| .Repatriation Schedule               | 686 | .Dental                                                          | 477 |
| TERBINAFINE HYDROCHLORIDE            |     | <i>Terry White Chemists Enalapril</i> (TW)                       | 131 |
| .Dermatologicals                     | 156 | <i>Terry White Chemists Famotidine</i> (TW)                      | 76  |

## GENERIC/PROPRIETARY INDEX

|                                                                              |     |                                                             |     |
|------------------------------------------------------------------------------|-----|-------------------------------------------------------------|-----|
| <i>Terry White Chemists Fluoxetine (TW)</i> .....                            | 389 | <i>Teveten Plus 600/12.5 (SM)</i> .....                     | 141 |
| <i>Terry White Chemists Frusemide (TW)</i> .....                             | 120 | THALIDOMIDE .....                                           |     |
| <i>Terry White Chemists Gemfibrozil (TW)</i> .....                           | 151 | . Section 100 .....                                         | 632 |
| <i>Terry White Chemists Gliclazide (TW)</i> .....                            | 98  | <i>Thalidomide Pharmion (PI)</i> .....                      |     |
| <i>Terry White Chemists Indapamide (TW)</i> .....                            | 120 | . Section 100 .....                                         | 632 |
| <i>Terry White Chemists Ipratropium (TW)</i> .....                           | 418 | <i>Thelin (CS)</i> .....                                    |     |
| <i>Terry White Chemists Isosorbide Mononitrate (TW)</i> .....                | 117 | . Section 100 .....                                         | 630 |
| <i>Terry White Chemists Isotretinoin (TW)</i> .....                          | 161 | THEOPHYLLINE .....                                          | 420 |
| <i>Terry White Chemists Lisinopril (TW)</i> .....                            | 133 | <i>TheraTears (CX)</i> .....                                |     |
| <i>Terry White Chemists Meloxicam 15 mg (TW)</i> .....                       | 340 | . Sensory organs .....                                      | 431 |
| <i>Terry White Chemists Meloxicam 7.5 mg (TW)</i> .....                      | 339 | . Optometrical .....                                        | 503 |
| <i>Terry White Chemists Metformin (TW)</i> .....                             | 97  | THIAMINE HYDROCHLORIDE .....                                |     |
| <i>Terry White Chemists Metoprolol (TW)</i> .....                            | 124 | . Alimentary tract and metabolism .....                     | 104 |
| <i>Terry White Chemists Mirtazapine (TW)</i> .....                           | 393 | . Repatriation Schedule .....                               | 682 |
| <i>Terry White Chemists Moclobemide (TW)</i> .....                           | 392 | THIOGUANINE .....                                           | 214 |
| <i>Terry White Chemists Nifedipine (TW)</i> .....                            | 128 | <i>Thioprine (AF)</i> .....                                 | 336 |
| <i>Terry White Chemists Norfloxacin (TW)</i> .....                           | 200 | THIOTEPA .....                                              | 211 |
| <i>Terry White Chemists Paracetamol (TW)</i> .....                           |     | <i>Thyrogen (GZ)</i> .....                                  | 178 |
| . Nervous system .....                                                       | 364 | THYROTROPIN ALFA .....                                      | 178 |
| . Dental .....                                                               | 496 | THYROXINE SODIUM .....                                      | 182 |
| <i>Terry White Chemists Paroxetine (TW)</i> .....                            | 390 | TIAGABINE HYDROCHLORIDE .....                               | 369 |
| <i>Terry White Chemists Perindopril/ Indapamide 4/1.25 (TW)</i> .....        | 139 | TIAPROFENIC ACID .....                                      | 342 |
| <i>Terry White Chemists Perindopril (TW)</i> .....                           | 134 | TICARCILLIN WITH CLAVULANIC ACID .....                      |     |
| <i>Terry White Chemists Piroxicam (TW)</i> .....                             |     | . Antiinfectives for systemic use .....                     | 192 |
| . Musculo-skeletal system .....                                              | 341 | . Dental .....                                              | 482 |
| . Dental .....                                                               | 490 | TICLOPIDINE HYDROCHLORIDE .....                             | 109 |
| <i>Terry White Chemists Piroxicam Dispersible (TW)</i> .....                 |     | <i>Tielle MT2440 (JJ)</i> .....                             |     |
| . Musculo-skeletal system .....                                              | 340 | . Repatriation Schedule .....                               | 716 |
| . Dental .....                                                               | 490 | <i>Tielle MT2442 (JJ)</i> .....                             |     |
| <i>Terry White Chemists Pravastatin (TW)</i> .....                           | 147 | . Repatriation Schedule .....                               | 716 |
| <i>Terry White Chemists Prazosin (TW)</i> .....                              | 118 | <i>Tilade CFC-Free (SW)</i> .....                           | 419 |
| <i>Terry White Chemists Ranitidine (TW)</i> .....                            | 77  | <i>Tilodene (AF)</i> .....                                  | 109 |
| <i>Terry White Chemists Salbutamol (TW)</i> .....                            |     | TILUDRONATE DISODIUM .....                                  | 349 |
| . Doctor's Bag Supplies .....                                                | 71  | <i>Timentin (GK)</i> .....                                  |     |
| . Respiratory system .....                                                   | 413 | . Antiinfectives for systemic use .....                     | 192 |
| <i>Terry White Chemists Sertraline (TW)</i> .....                            | 390 | . Dental .....                                              | 482 |
| <i>Terry White Chemists Simvastatin (TW)</i> .....                           | 149 | TIMOLOL MALEATE .....                                       | 426 |
| <i>Terry White Chemists Sotalol (TW)</i> .....                               |     | <i>Timoptol (FR)</i> .....                                  | 426 |
| . Cardiovascular system .....                                                | 115 | <i>Timoptol XE (MK)</i> .....                               | 426 |
| . Cardiovascular system .....                                                |     | <i>Tinaderm (SH)</i> .....                                  |     |
| <i>Terry White Chemists Tamoxifen (TW)</i> .....                             | 246 | . Repatriation Schedule .....                               | 686 |
| <i>Terry White Chemists Tramadol (TW)</i> .....                              |     | TINIDAZOLE .....                                            |     |
| . Nervous system .....                                                       | 362 | . Antiinfectives for systemic use .....                     | 202 |
| . Dental .....                                                               | 495 | . Antiparasitic products, insecticides and repellents ..... | 409 |
| <i>Terry White Chemists Trimethoprim with Sulfamethoxazole DS (TW)</i> ..... |     | TIOTROPIUM BROMIDE MONOHYDRATE .....                        | 419 |
| . Antiinfectives for systemic use .....                                      | 196 | TIPRANAVIR .....                                            |     |
| . Dental .....                                                               | 486 | . Section 100 .....                                         | 632 |
| <i>Tertroxin (SI)</i> .....                                                  | 182 | TIROFIBAN HYDROCHLORIDE .....                               | 110 |
| <i>Testogel (SC)</i> .....                                                   | 166 | <i>Titralac (MM)</i> .....                                  |     |
| TESTOSTERONE .....                                                           | 166 | . Repatriation Schedule .....                               | 680 |
| TESTOSTERONE ENANTHATE .....                                                 | 167 | TOBRAMYCIN .....                                            | 422 |
| TESTOSTERONE ESTERS .....                                                    | 167 | TOBRAMYCIN SULFATE .....                                    | 199 |
| TESTOSTERONE UNDECANOATE .....                                               | 167 | <i>Tobrex (AQ)</i> .....                                    | 422 |
| TETRABENAZINE .....                                                          | 408 | <i>Tofranal 10 (NV)</i> .....                               | 386 |
| TETRACOSACTRIN .....                                                         | 178 | <i>Tofranal 25 (NV)</i> .....                               | 386 |
| <i>Teveten (SM)</i> .....                                                    | 140 | <i>Tolerade 10 (LN)</i> .....                               | 386 |
|                                                                              |     | <i>Tolerade 25 (LN)</i> .....                               | 386 |
|                                                                              |     | TOLNAFTATE .....                                            |     |

## GENERIC/PROPRIETARY INDEX

|                                            |     |                                                         |     |
|--------------------------------------------|-----|---------------------------------------------------------|-----|
| .Repatriation Schedule .....               | 686 | TRANDOLAPRIL WITH VERAPAMIL                             |     |
| <i>Tolvon</i> (OR) .....                   | 393 | HYDROCHLORIDE .....                                     | 140 |
| <i>Tomudex</i> (HH) .....                  | 214 | TRANEXAMIC ACID .....                                   | 111 |
| <i>Topamax</i> (JC) .....                  | 373 | <i>Transiderm-Nitro 25</i> (NV) .....                   | 116 |
| <i>Topamax Sprinkle</i> (JC) .....         | 373 | <i>Transiderm-Nitro 50</i> (NV) .....                   | 117 |
| TOPIRAMATE .....                           | 372 | TRANLYCYPROMINE SULFATE .....                           | 391 |
| TOPOTECAN HYDROCHLORIDE .....              | 243 | TRASTUZUMAB                                             |     |
| <i>Toprol-XL 190</i> (AP) .....            | 124 | .Section 100 .....                                      | 638 |
| <i>Toprol-XL 23.75</i> (AP) .....          | 123 | <i>Travatan</i> (AQ) .....                              | 426 |
| <i>Toprol-XL 47.5</i> (AP) .....           | 123 | TRAVOPROST .....                                        | 426 |
| <i>Toprol-XL 95</i> (AP) .....             | 123 | TRAVOPROST WITH TIMOLOL MALEATE .....                   | 426 |
| <i>Toprol-XL Titration Pack</i> (AP) ..... | 123 | TRIAMCINOLONE ACETONIDE                                 |     |
| TOREMIFENE CITRATE .....                   | 246 | .Dermatologicals .....                                  | 159 |
| <i>Touch-In Plus</i> (DN) .....            | 438 | .Systemic hormonal preparations, excl. sex hormones and |     |
| <i>Tracleer</i> (AT) .....                 |     | insulins .....                                          | 181 |
| .Section 100 .....                         | 526 | .Dental .....                                           | 477 |
| TRAMADOL HYDROCHLORIDE                     |     | TRIAMCINOLONE ACETONIDE WITH NEOMYCIN                   |     |
| .Doctor's Bag Supplies .....               | 71  | SULFATE, GRAMICIDIN AND NYSTATIN                        |     |
| .Nervous system .....                      | 362 | .Sensory organs .....                                   | 434 |
| .Dental .....                              | 495 | .Repatriation Schedule .....                            | 689 |
| <i>Tramahexal SR</i> (SZ) .....            |     | <i>Triasyn 2.5/2.5</i> (SW) .....                       | 140 |
| .Nervous system .....                      | 363 | <i>Triasyn 5.0/5.0</i> (SW) .....                       | 140 |
| .Dental .....                              | 496 | <i>Tricortone</i> (FM) .....                            | 159 |
| <i>Tramal</i> (CS) .....                   |     | <i>Trifeme 28</i> (WX) .....                            | 165 |
| .Nervous system .....                      | 362 | TRIFLUOPERAZINE HYDROCHLORIDE .....                     | 377 |
| .Dental .....                              | 495 | TRIGLYCERIDES, MEDIUM CHAIN .....                       | 439 |
| <i>Tramal 100</i> (CS) .....               |     | TRIGLYCERIDES, MEDIUM CHAIN AND LONG                    |     |
| .Doctor's Bag Supplies .....               | 71  | CHAIN WITH GLUCOSE POLYMER .....                        | 451 |
| .Nervous system .....                      | 363 | TRIGLYCERIDES—MEDIUM CHAIN, FORMULA .....               | 445 |
| .Dental .....                              | 496 | <i>Trileptal</i> (NV) .....                             | 369 |
| <i>Tramal SR 100</i> (CS) .....            |     | TRIMETHOPRIM .....                                      | 196 |
| .Nervous system .....                      | 363 | TRIMETHOPRIM WITH SULFAMETHOXAZOLE                      |     |
| .Dental .....                              | 496 | .Antifungives for systemic use .....                    | 196 |
| <i>Tramal SR 150</i> (CS) .....            |     | .Dental .....                                           | 485 |
| .Nervous system .....                      | 363 | <i>Triphasil 28</i> (WY) .....                          | 165 |
| .Dental .....                              | 496 | <i>Triprim</i> (SI) .....                               | 196 |
| <i>Tramal SR 200</i> (CS) .....            |     | <i>Triquilar ED</i> (SC) .....                          | 165 |
| .Nervous system .....                      | 363 | <i>Trisequens</i> (NO) .....                            | 171 |
| .Dental .....                              | 496 | <i>Tritace</i> (SW) .....                               | 137 |
| <i>Tramal SR 50</i> (CS) .....             |     | <i>Tritace 1.25 mg</i> (SW) .....                       | 136 |
| .Nervous system .....                      | 363 | <i>Tritace 10 mg</i> (SW) .....                         | 137 |
| .Dental .....                              | 495 | <i>Tritace 2.5 mg</i> (SW) .....                        | 136 |
| <i>Tramedo</i> (AF) .....                  |     | <i>Tritace 5 mg</i> (SW) .....                          | 136 |
| .Nervous system .....                      | 362 | <i>Tritace Titration Pack</i> (SW) .....                | 137 |
| .Dental .....                              | 495 | <i>Trizivir</i> (GK) .....                              |     |
| <i>Tramedo SR 100</i> (AF) .....           |     | .Section 100 .....                                      | 507 |
| .Nervous system .....                      | 363 | TROPISETRON HYDROCHLORIDE .....                         | 86  |
| .Dental .....                              | 496 | <i>TrueSense</i> (MS) .....                             | 438 |
| <i>Tramedo SR 150</i> (AF) .....           |     | <i>TrueTrack</i> (DB) .....                             | 438 |
| .Nervous system .....                      | 363 | <i>Trusopt</i> (MK) .....                               | 425 |
| .Dental .....                              | 496 | <i>Truvada</i> (GI) .....                               |     |
| <i>Tramedo SR 200</i> (AF) .....           |     | .Section 100 .....                                      | 632 |
| .Nervous system .....                      | 363 | <i>Tryzan Caps 1.25</i> (AF) .....                      | 136 |
| .Dental .....                              | 496 | <i>Tryzan Caps 10</i> (AF) .....                        | 137 |
| <i>Tranalpha</i> (AF) .....                | 137 | <i>Tryzan Caps 2.5</i> (AF) .....                       | 136 |
| <i>Trandate</i> (SI) .....                 | 126 | <i>Tryzan Caps 5</i> (AF) .....                         | 136 |
| TRANDOLAPRIL .....                         | 137 | <i>Tryzan Tabs 1.25</i> (AF) .....                      | 136 |
| <i>Trandolapril-DP</i> (GM) .....          | 137 | <i>Tryzan Tabs 10</i> (AF) .....                        | 137 |

## GENERIC/PROPRIETARY INDEX

|                                                  |     |
|--------------------------------------------------|-----|
| <i>Tryzan Tabs 2.5 (AF)</i> .....                | 136 |
| <i>Tryzan Tabs 5 (AF)</i> .....                  | 136 |
| <i>Tubegauz 0501633 (SS)</i> .....               |     |
| <i>.Repatriation Schedule</i> .....              | 712 |
| <i>Tubegauz 0501658 (SS)</i> .....               |     |
| <i>.Repatriation Schedule</i> .....              | 712 |
| <i>Tubifast 2434 (SS)</i> .....                  |     |
| <i>.Repatriation Schedule</i> .....              | 712 |
| <i>Tubifast 2436 (SS)</i> .....                  |     |
| <i>.Repatriation Schedule</i> .....              | 712 |
| <i>Tubifast 2438 (SS)</i> .....                  |     |
| <i>.Repatriation Schedule</i> .....              | 712 |
| <i>Tubigrip 1479 (SS)</i> .....                  |     |
| <i>.Repatriation Schedule</i> .....              | 712 |
| <i>Tubigrip 1480 (SS)</i> .....                  |     |
| <i>.Repatriation Schedule</i> .....              | 712 |
| <i>Tubigrip 1481 (SS)</i> .....                  |     |
| <i>.Repatriation Schedule</i> .....              | 712 |
| <i>Tubigrip 1482 (SS)</i> .....                  |     |
| <i>.Repatriation Schedule</i> .....              | 712 |
| <i>Tubigrip 1483 (SS)</i> .....                  |     |
| <i>.Repatriation Schedule</i> .....              | 712 |
| <i>Tubigrip 1484 (SS)</i> .....                  |     |
| <i>.Repatriation Schedule</i> .....              | 712 |
| <i>Tubigrip 1486 (SS)</i> .....                  |     |
| <i>.Repatriation Schedule</i> .....              | 712 |
| <i>Tubigrip B 1520 (SS)</i> .....                |     |
| <i>.Repatriation Schedule</i> .....              | 711 |
| <i>Tubigrip C 1545 (SS)</i> .....                |     |
| <i>.Repatriation Schedule</i> .....              | 711 |
| <i>Tubigrip D 1546 (SS)</i> .....                |     |
| <i>.Repatriation Schedule</i> .....              | 711 |
| <i>Tubigrip E 1547 (SS)</i> .....                |     |
| <i>.Repatriation Schedule</i> .....              | 711 |
| <i>Tubigrip F 1548 (SS)</i> .....                |     |
| <i>.Repatriation Schedule</i> .....              | 711 |
| <i>Tykerb (GK)</i> .....                         | 236 |
| <i>Tylenol (JT)</i> .....                        |     |
| <i>.Nervous system</i> .....                     | 364 |
| <i>.Dental</i> .....                             | 496 |
| <i>TYR Cooler (VF)</i> .....                     | 449 |
| <i>TYR Express (VF)</i> .....                    | 449 |
| <i>TYR gel (VF)</i> .....                        | 449 |
| <i>Tyrosine Amino Acid Supplement (VF)</i> ..... | 452 |
| <b>TYROSINE WITH CARBOHYDRATE</b> .....          | 452 |
| <i>Tysabri (BD)</i> .....                        |     |
| <i>.Section 100</i> .....                        | 603 |

## U

|                                     |     |
|-------------------------------------|-----|
| <i>Ulcaid (RA)</i> .....            | 77  |
| <i>Ulcyste (AF)</i> .....           | 83  |
| <i>Uracol (GM)</i> .....            |     |
| <i>.Repatriation Schedule</i> ..... | 695 |
| <i>Ural Sachets (SI)</i> .....      |     |
| <i>.Repatriation Schedule</i> ..... | 695 |
| <b>UREA</b> .....                   |     |

|                                     |     |
|-------------------------------------|-----|
| <i>.Repatriation Schedule</i> ..... | 687 |
| <i>Urederm (HA)</i> .....           |     |
| <i>.Repatriation Schedule</i> ..... | 687 |
| <i>Uremide (AF)</i> .....           | 120 |
| <i>Urex (FM)</i> .....              | 120 |
| <i>Urex-Forte (FM)</i> .....        | 120 |
| <i>Urex-M (FM)</i> .....            | 120 |
| <i>Uro-Carb (HA)</i> .....          | 405 |
| <i>Uromitexan (BX)</i> .....        | 436 |
| <b>URSODEOXYCHOLIC ACID</b> .....   | 87  |
| <i>Ursofalk (OA)</i> .....          | 87  |

## V

|                                                |     |
|------------------------------------------------|-----|
| <i>Vagifem (NO)</i> .....                      | 167 |
| <b>VALACICLOVIR HYDROCHLORIDE</b> .....        |     |
| <i>.Antiinfectives for systemic use</i> .....  | 208 |
| <i>.Section 100</i> .....                      | 632 |
| <i>Valcyte (RO)</i> .....                      |     |
| <i>.Section 100</i> .....                      | 633 |
| <b>VALGANCICLOVIR HYDROCHLORIDE</b> .....      |     |
| <i>.Section 100</i> .....                      | 633 |
| <i>Valine Amino Acid Supplement (VF)</i> ..... | 452 |
| <b>VALINE WITH CARBOHYDRATE</b> .....          | 452 |
| <i>Valium (RO)</i> .....                       |     |
| <i>.Nervous system</i> .....                   | 383 |
| <i>.Palliative Care</i> .....                  | 470 |
| <i>.Dental</i> .....                           | 498 |
| <i>Valpam 2 (AW)</i> .....                     |     |
| <i>.Nervous system</i> .....                   | 383 |
| <i>.Palliative Care</i> .....                  | 470 |
| <i>.Dental</i> .....                           | 498 |
| <i>Valpam 5 (AW)</i> .....                     |     |
| <i>.Nervous system</i> .....                   | 383 |
| <i>.Palliative Care</i> .....                  | 470 |
| <i>.Dental</i> .....                           | 498 |
| <i>Valpro 200 (AF)</i> .....                   | 369 |
| <i>Valpro 500 (AF)</i> .....                   | 369 |
| <i>Valproate Winthrop EC 200 (WA)</i> .....    | 369 |
| <i>Valproate Winthrop EC 500 (WA)</i> .....    | 369 |
| <i>Valtrex (GK)</i> .....                      |     |
| <i>.Antiinfectives for systemic use</i> .....  | 208 |
| <i>.Section 100</i> .....                      | 632 |
| <i>Vancocin (AS)</i> .....                     | 91  |
| <i>Vancocin CP (AS)</i> .....                  |     |
| <i>.Antiinfectives for systemic use</i> .....  | 201 |
| <i>.Dental</i> .....                           | 487 |
| <b>VANCOMYCIN</b> .....                        |     |
| <i>.Alimentary tract and metabolism</i> .....  | 91  |
| <i>.Antiinfectives for systemic use</i> .....  | 201 |
| <i>.Dental</i> .....                           | 487 |
| <i>Vancomycin Sandoz (SZ)</i> .....            |     |
| <i>.Antiinfectives for systemic use</i> .....  | 201 |
| <i>.Dental</i> .....                           | 487 |
| <b>VARENICLINE</b> .....                       | 407 |
| <i>Vasocardol (AV)</i> .....                   | 129 |
| <i>Vasocardol CD (AV)</i> .....                | 129 |

## GENERIC/PROPRIETARY INDEX

|                                              |     |                                                 |     |
|----------------------------------------------|-----|-------------------------------------------------|-----|
| <i>Vastin (NM)</i> .....                     | 146 | <i>.Section 100</i> .....                       | 526 |
| <i>Vastoran (RA)</i> .....                   | 147 | <i>Vistil (AE)</i> .....                        |     |
| <i>Vaxigrip (AX)</i> .....                   | 210 | <i>.Sensory organs</i> .....                    | 433 |
| <i>Vaxigrip Junior (AX)</i> .....            | 210 | <i>.Optometrical</i> .....                      | 504 |
| <i>Velcade (JC)</i> .....                    | 242 | <i>Vistil Forte (AE)</i> .....                  |     |
| <b>VENLAFAXINE HYDROCHLORIDE</b> .....       | 394 | <i>.Sensory organs</i> .....                    | 433 |
| <i>Venofer (AS)</i> .....                    | 112 | <i>.Optometrical</i> .....                      | 504 |
| <i>Ventavis (SC)</i> .....                   |     | <i>Visudyne (NV)</i> .....                      | 430 |
| <i>.Section 100</i> .....                    | 554 | <b>VITAMIN B GROUP COMPLEX</b> .....            |     |
| <i>Ventolin (GK)</i> .....                   | 420 | <i>.Repatriation Schedule</i> .....             | 683 |
| <i>Ventolin CFC-free (GK)</i> .....          |     | <i>Vitrasert (BU)</i> .....                     |     |
| <i>.Doctor's Bag Supplies</i> .....          | 71  | <i>.Section 100</i> .....                       | 547 |
| <i>.Respiratory system</i> .....             | 412 | <i>Voltaren 100 (NV)</i> .....                  |     |
| <i>Ventolin Nebules (GK)</i> .....           |     | <i>.Musculo-skeletal system</i> .....           | 338 |
| <i>.Doctor's Bag Supplies</i> .....          | 71  | <i>.Palliative Care</i> .....                   | 461 |
| <i>.Respiratory system</i> .....             | 413 | <i>.Dental</i> .....                            | 488 |
| <i>Ventolin Rotacaps (GK)</i> .....          | 412 | <i>Voltaren 25 (NV)</i> .....                   |     |
| <i>Vepesid (BQ)</i> .....                    | 216 | <i>.Musculo-skeletal system</i> .....           | 338 |
| <i>Veracaps SR (SI)</i> .....                | 129 | <i>.Palliative Care</i> .....                   | 460 |
| <b>VERAPAMIL HYDROCHLORIDE</b> .....         |     | <i>.Dental</i> .....                            | 488 |
| <i>.Doctor's Bag Supplies</i> .....          | 71  | <i>Voltaren 50 (NV)</i> .....                   |     |
| <i>.Cardiovascular system</i> .....          | 128 | <i>.Musculo-skeletal system</i> .....           | 338 |
| <i>Vermox (JC)</i> .....                     |     | <i>.Palliative Care</i> .....                   | 460 |
| <i>.Repatriation Schedule</i> .....          | 701 | <i>.Dental</i> .....                            | 489 |
| <b>VERTEPORFIN</b> .....                     | 429 | <i>Voxam (SZ)</i> .....                         | 389 |
| <i>Viagra (PF)</i> .....                     |     | <i>Vytorin (MK)</i> .....                       | 154 |
| <i>.Repatriation Schedule</i> .....          | 694 |                                                 |     |
| <i>Vibramycin (PF)</i> .....                 |     |                                                 |     |
| <i>.Antinfectives for systemic use</i> ..... | 184 | <b>W</b>                                        |     |
| <i>.Dental</i> .....                         | 477 | <b>WARFARIN SODIUM</b> .....                    | 106 |
| <i>Vibra-Tabs (PF)</i> .....                 | 184 | <i>Waxsol (NE)</i> .....                        |     |
| <i>Videx EC (BQ)</i> .....                   |     | <i>.Repatriation Schedule</i> .....             | 705 |
| <i>.Section 100</i> .....                    | 530 | <i>Wellvone (GK)</i> .....                      | 409 |
| <b>VIGABATRIN</b> .....                      | 370 | <b>WHEY PROTEIN FORMULA SUPPLEMENTED WITH</b>   |     |
| <b>VINBLASTINE SULFATE</b> .....             | 215 | <b>AMINO ACIDS, VITAMINS AND MINERALS, AND</b>  |     |
| <b>VINCISTINE SULFATE</b> .....              | 215 | <b>LOW IN PROTEIN, PHOSPHATE, POTASSIUM AND</b> |     |
| <i>Vinorelbine Ebewe (IT)</i> .....          | 216 | <b>LACTOSE</b> .....                            | 452 |
| <b>VINORELBINE TARTRATE</b> .....            | 216 | <i>Winthrop Oxaliplatin (WA)</i> .....          | 220 |
| <i>Viracept (RO)</i> .....                   |     | <b>WOOL ALCOHOLS</b> .....                      |     |
| <i>.Section 100</i> .....                    | 603 | <i>.Repatriation Schedule</i> .....             | 687 |
| <i>Viramune (BY)</i> .....                   |     |                                                 |     |
| <i>.Section 100</i> .....                    | 603 | <b>X</b>                                        |     |
| <i>Viread (GI)</i> .....                     |     |                                                 |     |
| <i>.Section 100</i> .....                    | 632 | <i>Xalacom (PF)</i> .....                       | 426 |
| <i>Viscopaste 4948 (SN)</i> .....            |     | <i>Xalatan (PU)</i> .....                       | 426 |
| <i>.Repatriation Schedule</i> .....          | 712 | <i>Xanax (PH)</i> .....                         | 382 |
| <i>Viscotears (NV)</i> .....                 |     | <i>Xanax Tri-Score (PH)</i> .....               | 383 |
| <i>.Sensory organs</i> .....                 | 431 | <i>Xeloda (RO)</i> .....                        | 215 |
| <i>.Optometrical</i> .....                   | 502 | <i>Xenical (RO)</i> .....                       |     |
| <i>Viscotears Liquid Gel (NV)</i> .....      |     | <i>.Repatriation Schedule</i> .....             | 682 |
| <i>.Sensory organs</i> .....                 | 430 | <i>Xergic (AF)</i> .....                        |     |
| <i>.Optometrical</i> .....                   | 502 | <i>.Repatriation Schedule</i> .....             | 703 |
| <i>Visine Professional (JT)</i> .....        |     | <i>Xigris (LY)</i> .....                        | 110 |
| <i>.Sensory organs</i> .....                 | 433 | <i>XLYS, LOW TRY Analog (SB)</i> .....          | 448 |
| <i>.Optometrical</i> .....                   | 504 | <i>XLYS, LOW TRY Maxamaid (SB)</i> .....        | 448 |
| <i>Visken 15 (NV)</i> .....                  | 122 | <i>XMET Analog (SB)</i> .....                   | 448 |
| <i>Visken 5 (NV)</i> .....                   | 122 | <i>XMET Maxamaid (SB)</i> .....                 | 448 |
| <i>Vistide (PU)</i> .....                    |     |                                                 |     |

## GENERIC/PROPRIETARY INDEX

|                                       |     |                                          |     |
|---------------------------------------|-----|------------------------------------------|-----|
| <i>XMET Maxamum (SB)</i> .....        | 448 | ZINC OXIDE WITH STARCH AND CHLORPHENESIN |     |
| <i>XMTVI Analog (SB)</i> .....        | 448 | .Repatriation Schedule .....             | 691 |
| <i>XMTVI Asadon (SB)</i> .....        | 447 | ZINC SULFATE WITH PHENYLEPHRINE          |     |
| <i>XMTVI Maxamaid (SB)</i> .....      | 448 | HYDROCHLORIDE                            |     |
| <i>XMTVI Maxamum (SB)</i> .....       | 448 | .Repatriation Schedule .....             | 704 |
| <i>XP Analog (SB)</i> .....           | 449 | <i>Zinnat (GK)</i>                       |     |
| <i>XP Analog LCP (SB)</i> .....       | 447 | .Anti-infectives for systemic use .....  | 194 |
| <i>XPhen, Tyr Analog (SB)</i> .....   | 449 | .Dental .....                            | 485 |
| <i>XPhen, Tyr Maxamaid (SB)</i> ..... | 449 | <b>ZIPRASIDONE HYDROCHLORIDE</b> .....   | 378 |
| <i>XPhen, Tyr Maxamum (SB)</i> .....  | 449 | <i>ZipZoc 66051550 (SN)</i>              |     |
| <i>XP Maxamaid (SB)</i> .....         | 449 | .Repatriation Schedule .....             | 712 |
| <i>XP Maxamum (SB)</i> .....          | 449 | <i>Zithromax (PF)</i>                    |     |
| <i>XPTM Tyrosidon (SB)</i> .....      | 447 | .Anti-infectives for systemic use .....  | 197 |
| <i>Xydep 100 (AW)</i> .....           | 391 | .Sensory organs .....                    | 422 |
| <i>Xydep 50 (AW)</i> .....            | 390 | .Section 100 .....                       | 514 |
| <i>Xylocaine Viscous (AP)</i>         |     | .Repatriation Schedule .....             | 695 |
| .Repatriation Schedule .....          | 688 | <i>Zocor (MK)</i> .....                  | 148 |
| <i>Xylocard 500 (AP)</i> .....        | 114 | <i>Zofran (GK)</i> .....                 | 84  |
| <b>Z</b>                              |     |                                          |     |
| <i>Z.S.C. (SI)</i>                    |     | <i>Zofran syrup 50 mL (GK)</i> .....     | 85  |
| .Repatriation Schedule .....          | 691 | <i>Zofran Zydys (GK)</i> .....           | 84  |
| <i>Zabel (AF)</i>                     |     | <i>ZolaCos CP 10.8/50(28) (AP)</i> ..... | 245 |
| .Dermatologicals .....                | 156 | <i>ZolaCos CP 10.8/50(84) (AP)</i> ..... | 245 |
| .Repatriation Schedule .....          | 686 | <i>ZolaCos CP 3.6/50 (AP)</i> .....      | 245 |
| <i>Zactin (AF)</i> .....              | 389 | <i>Zoladex 10.8 Implant (AP)</i> .....   | 244 |
| <i>Zamhexal 0.25mg (SZ)</i> .....     | 382 | <i>Zoladex Implant (AP)</i> .....        | 244 |
| <i>Zamhexal 0.5mg (SZ)</i> .....      | 382 | <b>ZOLEDRONIC ACID</b>                   |     |
| <i>Zamhexal 1.0mg (SZ)</i> .....      | 382 | .Section 100 .....                       | 633 |
| <i>Zamhexal 2mg (SZ)</i> .....        | 383 | <b>ZOLMITRIPTAN</b>                      |     |
| <i>Zan-Extra 10/10 (SM)</i> .....     | 139 | .Special Pharmaceutical Benefits .....   | 74  |
| <i>Zan-Extra 10/20 (SM)</i> .....     | 139 | <i>Zoloft (PF)</i> .....                 | 390 |
| <i>Zanidip (SM)</i> .....             | 127 | <i>Zomacton (FP)</i>                     |     |
| <i>Zantac (GK)</i> .....              | 77  | .Section 100 .....                       | 634 |
| <i>Zantac Syrup (GK)</i> .....        | 77  | <i>Zometa (NV)</i>                       |     |
| <i>Zarontin (PF)</i> .....            | 367 | .Section 100 .....                       | 633 |
| <i>Zavedos (PH)</i> .....             | 219 | <i>Zomig (AP)</i>                        |     |
| <i>Zavedos Solution (PH)</i> .....    | 219 | .Special Pharmaceutical Benefits .....   | 74  |
| <i>Zeffix (GK)</i>                    |     | <b>ZOPICLONE</b>                         |     |
| .Section 100 .....                    | 599 | .Repatriation Schedule .....             | 700 |
| <i>Zeldox (PF)</i> .....              | 378 | <i>Zoton (WX)</i> .....                  | 79  |
| <i>Zentel (GK)</i> .....              | 410 | <i>Zovirax (GK)</i>                      |     |
| <i>Zerit (BQ)</i>                     |     | .Sensory organs .....                    | 423 |
| .Section 100 .....                    | 631 | .Optomietrical .....                     | 501 |
| <i>Zestril (AP)</i> .....             | 133 | <i>Zovirax 200 mg (GK)</i> .....         | 205 |
| <i>Ziagen (GK)</i>                    |     | <i>Zovirax 800 mg (GK)</i> .....         | 206 |
| .Section 100 .....                    | 507 | <b>ZUCLOPENTHIXOL DECANOATE</b> .....    | 378 |
| <b>ZIDOVUDINE</b>                     |     | <i>Zumenon (SM)</i> .....                | 167 |
| .Section 100 .....                    | 633 | <i>Zyban (GK)</i> .....                  | 406 |
| <i>Zimstat (AF)</i> .....             | 148 | <i>Zydol (AW)</i>                        |     |
| <i>Zincaband 3604 (SS)</i>            |     | .Nervous system .....                    | 362 |
| .Repatriation Schedule .....          | 712 | .Dental .....                            | 495 |
| <i>Zincfrin (AQ)</i>                  |     | <i>Zydol SR 100 (AW)</i>                 |     |
| .Repatriation Schedule .....          | 704 | .Nervous system .....                    | 363 |
| <b>ZINC OXIDE</b>                     |     | .Dental .....                            | 496 |
| .Repatriation Schedule .....          | 684 | <i>Zydol SR 150 (AW)</i>                 |     |
|                                       |     | .Nervous system .....                    | 363 |
|                                       |     | .Dental .....                            | 496 |
|                                       |     | <i>Zydol SR 200 (AW)</i>                 |     |
|                                       |     | .Nervous system .....                    | 363 |



GENERIC/PROPRIETARY INDEX

---

|                                 |     |
|---------------------------------|-----|
| .Dental .....                   | 496 |
| <i>Zyloprim (SI)</i> .....      | 345 |
| <i>Zyprexa (LY)</i> .....       | 378 |
| <i>Zyprexa Zydis (LY)</i> ..... | 379 |
| Zyrtec (JT)                     |     |
| .Repatriation Schedule .....    | 703 |

**GENERIC/PROPRIETARY INDEX**

---

## **THERAPEUTIC GROUP PREMIUM POLICY**

### **PHARMACEUTICAL BENEFIT ITEMS WHICH HAVE A THERAPEUTIC GROUP PREMIUM WITH EFFECT FROM 1 OCTOBER 2008**

The Schedule of Pharmaceutical Benefits shows differences in price in some therapeutic groups where alternative drugs may have a therapeutic group premium.

The Therapeutic Group Premium Policy applies within narrowly defined therapeutic sub-groups where the drugs concerned are of similar safety and health outcomes.

The Australian Government, through the PBS, subsidises up to the price of the lowest priced drug in the group. This means that consumers may have to pay for more expensive drugs (those with a therapeutic group premium). This extra amount does not count towards their PBS safety net threshold.

Therapeutic group premiums apply where a prescriber has prescribed a drug within a therapeutic group that attracts a therapeutic group premium and has not sought an exemption from Medicare Australia on clinical grounds.

The exemption provisions are:

- adverse effects occurring with all of the base-priced drugs; or
- drug interactions occurring with all of the base-priced drugs; or
- drug interactions expected to occur with all of the base-priced drugs; or
- transfer to a base-priced drug would cause patient confusion resulting in problems with compliance.

The premiums are not a Government charge but reflect the fact that the supplier(s) of the drug charge a price higher than the Government is willing to subsidise.

Under the Therapeutic Group Premium Policy drug substitution by pharmacists is not permitted.

For ease of prescribing and dispensing, and in the interests of your patients, the following list shows those PBS drugs that attract a therapeutic group premium.

| Premium<br>Priced<br>Brand | Form and Strength | Max.<br>Qty | Therapeutic<br>Group<br>Premium<br>\$ |
|----------------------------|-------------------|-------------|---------------------------------------|
|----------------------------|-------------------|-------------|---------------------------------------|

***H<sub>2</sub>-RECEPTOR ANTAGONISTS***

|                     |                                       |    |      |
|---------------------|---------------------------------------|----|------|
| <i>Zantac</i>       | Effervescent tablet 150 mg (base)     | 60 | 3.26 |
| <i>Zantac Syrup</i> | Syrup 150 mg (base) per 10 mL, 300 mL | 2  | 2.20 |

The base-priced drugs in this therapeutic group are cimetidine, famotidine, nizatidine, and ranitidine hydrochloride (except ranitidine hydrochloride effervescent tablet 150 mg (base) and syrup 150 mg (base) per 10 mL, 300 mL).

***DIHYDROPYRIDINE-DERIVATIVE CALCIUM CHANNEL BLOCKERS***

|                         |                                   |    |      |
|-------------------------|-----------------------------------|----|------|
| <i>Adalat Oros 20mg</i> | Tablet 20 mg (controlled release) | 30 | 2.26 |
| <i>Zanidip</i>          | Tablet 10 mg                      | 30 | 2.01 |
| <i>Zanidip</i>          | Tablet 20 mg                      | 30 | 4.02 |

The base-priced drugs in this therapeutic group are amlodipine, felodipine and nifedipine (except nifedipine controlled release tablet 20 mg).

***PROTON PUMP INHIBITORS***

|              |                                                                  |    |      |
|--------------|------------------------------------------------------------------|----|------|
| <i>Zoton</i> | Sachet containing granules for oral suspension, 30 mg per sachet | 28 | 3.62 |
|--------------|------------------------------------------------------------------|----|------|

The base-priced drugs in this therapeutic group are esomeprazole magnesium trihydrate, omeprazole, pantoprazole sodium sesquihydrate, rabeprazole sodium and lansoprazole (except lansoprazole sachet containing granules for oral suspension, 30 mg per sachet).

***ANGIOTENSIN II ANTAGONISTS***

|                |                      |    |      |
|----------------|----------------------|----|------|
| <i>Teveten</i> | Tablet 400 mg (base) | 56 | 1.52 |
|----------------|----------------------|----|------|

The base-priced drugs in this therapeutic group are candesartan cilexetil, irbesartan, olmesartan medoxomil, telmisartan and eprosartan mesylate (except eprosartan mesylate tablet 400 mg (base)).

## **BRAND PREMIUM POLICY**

### **BRANDS OF PHARMACEUTICAL BENEFIT ITEMS WHICH HAVE A BRAND PREMIUM AND THAT MAY BE SUBSTITUTED WITH EFFECT FROM 1 OCTOBER 2008**

The Schedule of Pharmaceutical Benefits shows differences in price between some alternative brands of the same drug product.

Manufacturers can develop generic equivalents and apply to have them listed on the PBS. In doing this, manufacturers need to ensure that they comply with the relevant legislation applicable to patents. These brands are clinically equivalent and must undergo the same strict quality controls. Although these brands are designed to act on the body in exactly the same way, they are usually cheaper than the originator brands.

The Australian Government, through the PBS, subsidises up to the price of the lowest priced brand (except in those instances where the lowest priced brand has, as part of its price, a therapeutic group premium). This means that consumers may have to pay extra for more expensive brands (those with a brand premium). This extra amount does not count towards their PBS safety net threshold.

Brand substitution by pharmacists without reference to the prescriber is permitted for PBS prescriptions where:

- the patient agrees to the substitution;
- the brands are identified in the Schedule of Pharmaceutical Benefits as being interchangeable;
- the prescriber has not indicated on the prescription form that substitution is not to occur; and
- substitution is permitted under the relevant State or Territory legislation.

Prescription forms supplied by Medicare Australia contain a box to be ticked where brand substitution is not to take place.

Prescribers not using these prescription forms should endorse the prescription if brand substitution is not permitted. Where a stamp is used for this purpose, the prescriber will be required to initial the stamped statement.

For ease of prescribing and dispensing, and in the interests of your patients, the following list shows those PBS drugs that attract a brand premium and that can be substituted where permitted. They are listed alphabetically, by brand name, with the brand premium and benchmark brand(s) cited in the last column.

| Premium<br>Priced<br>Brand | Form and Strength                        | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                      |
|----------------------------|------------------------------------------|-------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Accupril</i>            | Tablet 5 mg (base)                       | 30          | 0.38                   | <i>Acquin 5; APO-Quinapril; Filpril; Pharmacor Quinapril 5; Quinapril-DP; Quinapril generichealth; Quinapril Sandoz</i>                                      |
|                            | Tablet 10 mg (base)                      | 30          | 0.52                   | <i>Acquin 10; APO-Quinapril; Filpril; Pharmacor Quinapril 10; Quinapril-DP; Quinapril generichealth</i>                                                      |
|                            | Tablet 20 mg (base)                      | 30          | 0.77                   | <i>Acquin 20; APO-Quinapril; Filpril; Pharmacor Quinapril 20; Quinapril-DP; Quinapril generichealth; Quinapril Sandoz</i>                                    |
| <i>Adalat Oros 30</i>      | Tablet 30 mg (controlled release)        | 30          | 2.54                   | <i>Addos XR 30; Adefin XL 30</i>                                                                                                                             |
| <i>Adalat Oros 60</i>      | Tablet 60 mg (controlled release)        | 30          | 2.81                   | <i>Addos XR 60; Adefin XL 60</i>                                                                                                                             |
| <i>Adalat 10</i>           | Tablet 10 mg                             | 60          | 1.17                   | <i>Adefin 10; Nypine 10</i>                                                                                                                                  |
| <i>Adalat 20</i>           | Tablet 20 mg                             | 60          | 2.21                   | <i>Adefin 20; Chem mart Nifedipine; GenRx Nifedipine; Nifehexal; Nyefax 20 mg; Nypine 20; Terry White Chemists Nifedipine</i>                                |
| <i>Aldactone</i>           | Tablet 25 mg                             | 100         | 1.44                   | <i>Spiractin 25</i>                                                                                                                                          |
|                            | Tablet 100 mg                            | 100         | 1.99                   | <i>Spiractin 100</i>                                                                                                                                         |
| <i>Aldomet</i>             | Tablet 250 mg                            | 100         | 2.24                   | <i>Hydopa</i>                                                                                                                                                |
| <i>Alphagan</i>            | Eye drops 2 mg per mL (0.2%), 5 mL       | 1           | 1.74                   | <i>Enidin</i>                                                                                                                                                |
| <i>Amaryl</i>              | Tablet 1 mg                              | 30          | 1.89                   | <i>Aylide 1; Diapride 1; Dimirel; Glimepiride Sandoz</i>                                                                                                     |
|                            | Tablet 2 mg                              | 30          | 1.89                   | <i>Aylide 2; Diapride 2; Dimirel; Glimepiride Sandoz</i>                                                                                                     |
|                            | Tablet 3 mg                              | 30          | 1.90                   | <i>Aylide 3; Diapride 3; Dimirel; Glimepiride Sandoz</i>                                                                                                     |
|                            | Tablet 4 mg                              | 30          | 1.90                   | <i>Aylide 4; Diapride 4; Dimirel; Glimepiride Sandoz</i>                                                                                                     |
| <i>Amoxil</i>              | Capsule 250 mg                           | 20          | 0.79                   | <i>Alphamox 250; Amohexal; Amoxycillin-DP; APO-Amoxycillin; Chem mart Amoxycillin; Cilamox; GenRx Amoxycillin; Terry White Chemists Amoxycillin</i>          |
|                            | Capsule 500 mg                           | 20          | 0.80                   | <i>Alphamox 500; Amohexal; Amoxycillin-DP; APO-Amoxycillin; Chem mart Amoxycillin; Cilamox; GenRx Amoxycillin; Moxacin; Terry White Chemists Amoxycillin</i> |
|                            | Powder for syrup 125 mg per 5 mL, 100 mL | 1           | 0.95                   | <i>Alphamox 125; Bgramin; Chem mart Amoxycillin; GenRx Amoxycillin; Ranmoxy; Terry White Chemists Amoxycillin</i>                                            |
| <i>Amoxil Forte</i>        | Powder for syrup 250 mg per 5 mL, 100 mL | 1           | 0.79                   | <i>Alphamox 250; Amohexal; Bgramin; Chem mart Amoxycillin; Cilamox; GenRx Amoxycillin; Ranmoxy; Terry White Chemists Amoxycillin</i>                         |
| <i>Amprace 10</i>          | Tablet 10 mg                             | 30          | 2.46                   | <i>Alphapril; Auspril; Chem mart Enalapril; Enahexal; Enalabell; Enalapril-DP 10mg; Enalapril Winthrop; GenRx Enalapril; Terry White Chemists Enalapril</i>  |

| Premium<br>Priced<br>Brand | Form and Strength                                                           | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                                                                                                                                                                          |
|----------------------------|-----------------------------------------------------------------------------|-------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Amprace 20</i>          | Tablet 20 mg                                                                | 30          | 2.47                   | <i>Alphapril; Auspril; Chem mart Enalapril; Enahexal; Enalabell; Enalapril-DP 20mg; Enalapril Winthrop; GenRx Enalapril; Terry White Chemists Enalapril</i>                                                                                                                                                      |
| <i>Anafranil 25</i>        | Tablet 25 mg                                                                | 50          | 2.56                   | <i>Chem mart Clomipramine; GenRx Clomipramine; Placil; Terry White Chemists Clomipramine</i>                                                                                                                                                                                                                     |
| <i>Anaprox 550</i>         | Tablet 550 mg                                                               | 50          | 2.29                   | <i>Crysanal</i>                                                                                                                                                                                                                                                                                                  |
| <i>Androcur</i>            | Tablet 50 mg                                                                | 20          | 3.13                   | <i>Cyprohexal; Cyprone; Cyprostat; GenRx Cyproterone Acetate; Procur</i>                                                                                                                                                                                                                                         |
|                            | Tablet 50 mg                                                                | 100         | 3.00                   | <i>Cyprohexal; Cyprone; Cyprostat; GenRx Cyproterone Acetate; Procur</i>                                                                                                                                                                                                                                         |
| <i>Androcur-100</i>        | Tablet 100 mg                                                               | 50          | 1.65                   | <i>Cyprohexal; Cyprostat-100; GenRx Cyproterone Acetate; Procur 100</i>                                                                                                                                                                                                                                          |
| <i>Anginine Stabilised</i> | Tablets 600 micrograms, 100                                                 | 1           | 1.64                   | <i>Lycinate</i>                                                                                                                                                                                                                                                                                                  |
| <i>Aristocort 0.02%</i>    | Cream 200 micrograms per g (0.02%), 100 g                                   | 2           | 3.30                   | <i>Tricortone</i>                                                                                                                                                                                                                                                                                                |
|                            | Ointment 200 micrograms per g (0.02%), 100 g                                | 2           | 3.30                   | <i>Tricortone</i>                                                                                                                                                                                                                                                                                                |
| <i>Aropax</i>              | Tablet 20 mg (base)                                                         | 30          | 0.86                   | <i>Chem mart Paroxetine; Extine 20; GenRx Paroxetine; Paroxetine 20; Paroxetine-DP; Paroxetine Sandoz; Paroxetine Winthrop; Paxtine; Terry White Chemists Paroxetine</i>                                                                                                                                         |
| <i>Astrix</i>              | Tablet 100 mg                                                               | 112         | 1.36                   | <i>DBL Aspirin 100 mg</i>                                                                                                                                                                                                                                                                                        |
| <i>Atrovent</i>            | Nebuliser solution single dose units 250 micrograms (anhydrous) in 1 mL, 30 | 2           | 0.72                   | <i>Aeron 250; Apoven 250; Chem mart Ipratropium; GenRx Ipratropium; Ipratrin; Ipravent; Terry White Chemists Ipratropium</i>                                                                                                                                                                                     |
| <i>Atrovent Adult</i>      | Nebuliser solution single dose units 500 micrograms (anhydrous) in 1 mL, 30 | 2           | 0.62                   | <i>Aeron 500; Apoven 500; Chem mart Ipratropium; GenRx Ipratropium; Ipratrin Adult; Ipravent; Terry White Chemists Ipratropium</i>                                                                                                                                                                               |
| <i>Augmentin</i>           | Powder for syrup 125 mg-31.25 mg per 5 mL, 75 mL                            | 1           | 1.51                   | <i>Clamohexal 125mg/31.25mg/5mL; Clamoxyl; Clavulin</i>                                                                                                                                                                                                                                                          |
| <i>Augmentin Duo</i>       | Tablet 500 mg-125 mg                                                        | 10          | 1.55                   | <i>Clamohexal Duo 500mg/125mg; Clamoxyl Duo; Clavulin Duo; Curam 500/125; GA-Amclav 500/125; Moxiclav Duo 500/125</i>                                                                                                                                                                                            |
| <i>Augmentin Duo forte</i> | Tablet 875 mg-125 mg                                                        | 10          | 2.04                   | <i>Chem mart Amoxycillin and Clavulanic Acid; Clamohexal Duo Forte 875mg/125mg; Clamoxyl Duo forte; Clavulin Duo Forte; Clavycillin 875/125; Curam 875/125; GA-Amclav Forte 875/125; GenRx Amoxycillin and Clavulanic Acid; Moxiclav Duo Forte 875/125; Terry White Chemists Amoxycillin and Clavulanic Acid</i> |
| <i>Augmentin Duo 400</i>   | Powder for syrup 400 mg-57 mg per 5 mL, 60 mL                               | 1           | 1.54                   | <i>Clamohexal Duo 400mg/57mg/5mL; Clamoxyl Duo 400; Clavulin Duo 400</i>                                                                                                                                                                                                                                         |
| <i>Aurorix</i>             | Tablet 150 mg                                                               | 60          | 0.72                   | <i>Amira 150; Chem mart Moclobemide; Clobemix; GenRx Moclobemide; Mohexal; Terry White Chemists Moclobemide</i>                                                                                                                                                                                                  |

| Premium<br>Priced<br>Brand | Form and Strength                                                 | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                  |
|----------------------------|-------------------------------------------------------------------|-------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Aurorix 300 mg</i>      | Tablet 300 mg                                                     | 60          | 1.45                   | <i>Amira 300; Chem mart Moclobemide; Clobemix; GenRx Moclobemide; Maosig; Mohexal; Terry White Chemists Moclobemide</i>                  |
| <i>Avanza</i>              | Tablet 30 mg                                                      | 30          | 1.70                   | <i>Axit 30; Chem mart Mirtazapine; GenRx Mirtazapine; Mirtazapine-DP; Mirtazapine Sandoz; Mirtazon; Terry White Chemists Mirtazapine</i> |
| <i>Azopt</i>               | Tablet 45 mg                                                      | 30          | 1.49                   | <i>Mirtazapine Sandoz; Mirtazon</i>                                                                                                      |
| <i>Betaloc</i>             | Eye drops 10 mg per mL (1%), 5 mL                                 | 1           | 1.03                   | <i>BrinzoQuin</i>                                                                                                                        |
|                            | Tablet 100 mg                                                     | 60          | 2.54                   | <i>Chem mart Metoprolol; GenRx Metoprolol; Metohexal; Metolol; Metrol 100; Minax 100; Terry White Chemists Metoprolol</i>                |
|                            | Tablet 50 mg                                                      | 100         | 2.54                   | <i>Chem mart Metoprolol; GenRx Metoprolol; Metohexal; Metolol; Metrol 50; Minax 50; Terry White Chemists Metoprolol</i>                  |
| <i>Betnovate 1/2</i>       | Cream 500 micrograms (base) per g (0.05%), 15 g                   | 1           | 1.91                   | <i>Cortival 1/2</i>                                                                                                                      |
|                            | Ointment 500 micrograms (base) per g (0.05%), 15 g                | 1           | 1.91                   | <i>Cortival 1/2</i>                                                                                                                      |
| <i>Betnovate 1/5</i>       | Cream 200 micrograms (base) per g (0.02%), 100 g                  | 2           | 6.18                   | <i>Cortival 1/5</i>                                                                                                                      |
| <i>Betoptic</i>            | Eye drops, solution, 5 mg (base) per mL (0.5%), 5 mL              | 1           | 1.99                   | <i>BetoQuin</i>                                                                                                                          |
| <i>Blenoxane</i>           | Powder for injection 15,000 i.u. (solvent required)               | 10          | 75.30                  | <i>Blenamax; HH brand</i>                                                                                                                |
| <i>Brevinor</i>            | Tablets 500 micrograms-35 micrograms, 21                          | 4           | 7.92                   | <i>Norimin 28 Day</i>                                                                                                                    |
|                            | Pack containing 21 tablets                                        | 4           | 7.92                   | <i>Norimin 28 Day</i>                                                                                                                    |
|                            | 500 micrograms-35 micrograms and 7 inert tablets                  |             |                        |                                                                                                                                          |
| <i>Brevinor-1</i>          | Tablets 1 mg-35 micrograms, 21                                    | 4           | 7.92                   | <i>Norimin-1 28 Day</i>                                                                                                                  |
|                            | Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets | 4           | 7.92                   | <i>Norimin-1 28 Day</i>                                                                                                                  |
| <i>Capoten</i>             | Tablet 12.5 mg                                                    | 90          | 1.93                   | <i>Acenorm 12.5 mg; Captohexal; Chem mart Captopril; GenRx Captopril; Terry White Chemists Captopril; GM brand</i>                       |
|                            | Tablet 25 mg                                                      | 90          | 2.87                   | <i>Acenorm 25 mg; Captohexal; Chem mart Captopril; GenRx Captopril; Terry White Chemists Captopril; GM brand</i>                         |
|                            | Tablet 50 mg                                                      | 90          | 2.87                   | <i>Acenorm 50 mg; Captohexal; Chem mart Captopril; GenRx Captopril; Terry White Chemists Captopril; GM brand</i>                         |
| <i>Carafate</i>            | Tablet equivalent to 1 g anhydrous sucralfate                     | 120         | 2.18                   | <i>UlcYTE</i>                                                                                                                            |
| <i>Ceclor</i>              | Powder for oral suspension 125 mg per 5 mL, 100 mL                | 1           | 1.99                   | <i>Aclor 125; Cefaclor Sandoz; Chem mart Cefaclor; GenRx Cefaclor; Keflor; Ozcef; Terry White Chemists Cefaclor</i>                      |
|                            | Powder for oral suspension 250 mg per 5 mL, 75 mL                 | 1           | 2.05                   | <i>Aclor 250; Cefaclor Sandoz; Chem mart Cefaclor; GenRx Cefaclor; Keflor; Ozcef; Terry White Chemists Cefaclor</i>                      |
| <i>Ceclor CD</i>           | Tablet 375 mg (sustained release)                                 | 10          | 2.28                   | <i>Chem mart Cefaclor CD; Douglas Cefaclor-CD; GenRx Cefaclor CD; Karlor CD; Keflor CD; Ozcef; Terry White Chemists Cefaclor CD</i>      |



| Premium<br>Priced<br>Brand | Form and Strength                                         | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                                                           |
|----------------------------|-----------------------------------------------------------|-------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Cefotaxime Sandoz</i>   | Powder for injection 1 g                                  | 10          | 25.10                  | HH brand                                                                                                                                                                                          |
|                            | Powder for injection 2 g                                  | 10          | 46.50                  | HH brand                                                                                                                                                                                          |
| <i>Chlorvescent</i>        | Effervescent tablet 14 mmol potassium and 8 mmol chloride | 60          | 2.61                   | K-Sol                                                                                                                                                                                             |
| <i>Ciloxan</i>             | Eye drops 3 mg per mL (0.3%), 5 mL                        | 2           | 1.84                   | <i>CiloQuin</i>                                                                                                                                                                                   |
| <i>Cipramil</i>            | Tablet 20 mg (base)                                       | 28          | 3.49                   | <i>Celapram; Celica; Chem mart Citalopram; Ciazil; Citalobell; Citalopram 20; Citalopram Winthrop; GenRx Citalopram; Talam; Talohexal; Terry White Chemists Citalopram</i>                        |
| <i>Ciproxin 250</i>        | Tablet 250 mg                                             | 14          | 1.45                   | <i>C-Flox 250; Cifran; Ciprol 250; GenRx Ciprofloxacin; Profloxin</i>                                                                                                                             |
| <i>Ciproxin 500</i>        | Tablet 500 mg                                             | 14          | 1.26                   | <i>C-Flox 500; Cifran; Ciprofloxacin 500; Ciprofloxacin-BW; Ciprol 500; GenRx Ciprofloxacin; Profloxin; Proquin; GN brand</i>                                                                     |
| <i>Ciproxin 750</i>        | Tablet 750 mg                                             | 14          | 1.37                   | <i>C-Flox 750; Cifran; Ciprofloxacin 750; Ciprofloxacin-BW; Ciprol 750; GenRx Ciprofloxacin; Profloxin; Proquin; GN brand</i>                                                                     |
| <i>Clomid</i>              | Tablet 50 mg                                              | 10          | 2.83                   | <i>Clomhexal; Fermil; GenRx Clomiphene</i>                                                                                                                                                        |
| <i>Colgout</i>             | Tablet 500 micrograms                                     | 100         | 0.90                   | <i>Lengout</i>                                                                                                                                                                                    |
| <i>Dalacin C</i>           | Capsule 150 mg                                            | 24          | 1.45                   | <i>Cleocin</i>                                                                                                                                                                                    |
| <i>Daonil</i>              | Tablet 5 mg                                               | 100         | 1.21                   | <i>Glimel</i>                                                                                                                                                                                     |
| <i>Depo-Medrol</i>         | Injection 40 mg in 1 mL                                   | 5           | 0.76                   | <i>Depo-Nisolone</i>                                                                                                                                                                              |
| <i>Depo-Provera</i>        | Injection 150 mg in 1 mL                                  | 1           | 3.34                   | <i>Depo-Ralovera</i>                                                                                                                                                                              |
| <i>Diabex</i>              | Tablet 500 mg                                             | 100         | 1.40                   | <i>Chem mart Metformin; Diaformin; Formet 500; GenRx Metformin; Glucohexal; Glucomet 500 mg; Metforbell; Metformin 500; Metformin generichealth; Terry White Chemists Metformin; GN brand</i>     |
| <i>Diabex 850</i>          | Tablet 850 mg                                             | 60          | 1.40                   | <i>Chem mart Metformin; Diaformin 850; Formet 850; GenRx Metformin; Glucohexal; Glucomet 850 mg; Metforbell; Metformin 850; Metformin generichealth; Terry White Chemists Metformin; GN brand</i> |
| <i>Diabex 1000</i>         | Tablet 1 g                                                | 90          | 1.41                   | <i>Diaformin 1000; Formet 1000; Glucohexal</i>                                                                                                                                                    |
| <i>Diamicron</i>           | Tablet 80 mg                                              | 100         | 2.03                   | <i>Chem mart Gliclazide; GenRx Gliclazide; Glyade; Mellihexal; Nidem; Terry White Chemists Gliclazide</i>                                                                                         |
| <i>Doryx</i>               | Capsule 100 mg (as hydrochloride)                         | 7           | 1.15                   | <i>DBL Doxycycline</i>                                                                                                                                                                            |
|                            | Capsule 50 mg (as hydrochloride)                          | 25          | 1.31                   | <i>DBL Doxycycline</i>                                                                                                                                                                            |
|                            | Capsule 100 mg (as hydrochloride)                         | 28          | 4.60                   | <i>DBL Doxycycline</i>                                                                                                                                                                            |
|                            | Capsule 100 mg (as hydrochloride)                         | 21          | 2.09                   | <i>DBL Doxycycline</i>                                                                                                                                                                            |
| <i>Dulcolax</i>            | Suppositories 10 mg, 10                                   | 3           | 1.14                   | <i>Petrus Bisacodyl Suppositories</i>                                                                                                                                                             |
| <i>Duphalac</i>            | Mixture 3.34 g per 5 mL, 500 mL                           | 1           | 1.67                   | <i>Actilax; Genlac; GenRx Lactulose; Lac-Dol; Lactocur</i>                                                                                                                                        |
| <i>Duratears</i>           | Compound eye ointment 3.5 g                               | 2           | 2.06                   | <i>Poly Visc</i>                                                                                                                                                                                  |
| <i>E.E.S. Granules</i>     | Powder for oral liquid 400 mg (base) per 5 mL, 100 mL     | 1           | 1.35                   | <i>E-Mycin 400</i>                                                                                                                                                                                |

| Premium<br>Priced<br>Brand | Form and Strength                                                               | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                                                           |
|----------------------------|---------------------------------------------------------------------------------|-------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>E.E.S. 200</i>          | Powder for oral liquid 200 mg (base) per 5 mL, 100 mL                           | 1           | 1.67                   | <i>E-Mycin 200</i>                                                                                                                                                                                |
| <i>E.E.S. 400 Filmtab</i>  | Tablet 400 mg (base)                                                            | 25          | 2.36                   | <i>E-Mycin</i>                                                                                                                                                                                    |
| <i>Epilim EC</i>           | Tablet 200 mg (enteric coated)                                                  | 200         | 1.14                   | <i>Sodium Valproate Sandoz; Valpro 200; Valproate Winthrop EC 200</i>                                                                                                                             |
|                            | Tablet 500 mg (enteric coated)                                                  | 200         | 1.36                   | <i>Sodium Valproate Sandoz; Valpro 500; Valproate Winthrop EC 500</i>                                                                                                                             |
| <i>Eryc</i>                | Capsule 250 mg                                                                  | 25          | 1.35                   | <i>DBL Erythromycin</i>                                                                                                                                                                           |
| <i>Fasigyn</i>             | Tablet 500 mg                                                                   | 4           | 2.51                   | <i>Simplotan</i>                                                                                                                                                                                  |
| <i>Feldene</i>             | Capsule 10 mg                                                                   | 50          | 2.09                   | <i>Chem mart Piroxicam; GenRx Piroxicam; Mobilis 10; Terry White Chemists Piroxicam</i>                                                                                                           |
|                            | Capsule 20 mg                                                                   | 25          | 2.07                   | <i>Chem mart Piroxicam; GenRx Piroxicam; Mobilis 20; Terry White Chemists Piroxicam</i>                                                                                                           |
| <i>Feldene-D</i>           | Dispersible tablet 10 mg                                                        | 50          | 2.09                   | <i>GenRx Piroxicam Dispersible; Mobilis D-10</i>                                                                                                                                                  |
|                            | Dispersible tablet 20 mg                                                        | 25          | 2.07                   | <i>Chem mart Piroxicam Dispersible; GenRx Piroxicam Dispersible; Mobilis D-20; Terry White Chemists Piroxicam Dispersible</i>                                                                     |
| <i>Flagyl</i>              | Tablet 200 mg                                                                   | 21          | 1.51                   | <i>Metrogyl 200; Metronide 200</i>                                                                                                                                                                |
|                            | Tablet 400 mg                                                                   | 21          | 1.57                   | <i>Metrogyl 400; Metronide 400</i>                                                                                                                                                                |
| <i>Fosamax Once Weekly</i> | Tablet equivalent to 70 mg alendronic acid                                      | 4           | 1.42                   | <i>Adronat; Alendrobell 70mg; Alendronate Sandoz; Alendro Once Weekly; APO-Alendronate; Chem mart Alendronate 70mg; Ossmax 70mg; Terry White Chemists Alendronate 70mg</i>                        |
| <i>Genteal</i>             | Eye drops 3 mg per mL (0.3%), 15 mL (contains sodium perborate as preservative) | 1           | 1.86                   | <i>In a Wink Moisturising</i>                                                                                                                                                                     |
| <i>Genteal gel</i>         | Ocular lubricating gel 3 mg-2 mg per g (0.3%-0.2%), 10 g                        | 1           | 1.86                   | <i>HPMC PAA</i>                                                                                                                                                                                   |
| <i>Glucophage</i>          | Tablet 500 mg                                                                   | 100         | 1.10                   | <i>Chem mart Metformin; Diaformin; Formet 500; GenRx Metformin; Glucohexal; Glucomet 500 mg; Metforbell; Metformin 500; Metformin generichealth; Terry White Chemists Metformin; GN brand</i>     |
|                            | Tablet 850 mg                                                                   | 60          | 1.10                   | <i>Chem mart Metformin; Diaformin 850; Formet 850; GenRx Metformin; Glucohexal; Glucomet 850 mg; Metforbell; Metformin 850; Metformin generichealth; Terry White Chemists Metformin; GN brand</i> |
| <i>Gopten</i>              | Capsule 500 micrograms                                                          | 28          | 1.57                   | <i>APO-Trandolapril; Dolapril 0.5; Tranalpha; Trandolapril-DP</i>                                                                                                                                 |
|                            | Capsule 1 mg                                                                    | 28          | 1.57                   | <i>APO-Trandolapril; Dolapril 1; Tranalpha; Trandolapril-DP</i>                                                                                                                                   |
|                            | Capsule 2 mg                                                                    | 28          | 1.57                   | <i>APO-Trandolapril; Dolapril 2; Tranalpha; Trandolapril-DP</i>                                                                                                                                   |
|                            | Capsule 4 mg                                                                    | 28          | 1.57                   | <i>APO-Trandolapril; Dolapril 4; Tranalpha; Trandolapril-DP</i>                                                                                                                                   |
| <i>Imdur 120 mg</i>        | Tablet 120 mg (sustained release)                                               | 30          | 2.36                   | <i>Monodur 120 mg</i>                                                                                                                                                                             |

| Premium<br>Priced<br>Brand | Form and Strength                                                                                               | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                                                   |
|----------------------------|-----------------------------------------------------------------------------------------------------------------|-------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Imdur Durule</i>        | Tablet 60 mg (sustained release)                                                                                | 30          | 2.22                   | <i>Chem mart Isosorbide Mononitrate; Duride; GenRx Isosorbide Mononitrate; Imtrate 60 mg; Isomonit; Monodur 60 mg; Terry White Chemists Isosorbide Mononitrate</i>                        |
| <i>Imodium</i>             | Capsule 2 mg                                                                                                    | 12          | 0.94                   | <i>Gastro-Stop Loperamide</i>                                                                                                                                                             |
| <i>Imuran</i>              | Tablet 25 mg                                                                                                    | 100         | 1.19                   | <i>Azahexal</i>                                                                                                                                                                           |
|                            | Tablet 50 mg                                                                                                    | 100         | 1.09                   | <i>Azahexal; Azamun; Azapin; GenRx Azathioprine; Thioprine</i>                                                                                                                            |
| <i>Indocid</i>             | Capsule 25 mg                                                                                                   | 100         | 2.34                   | <i>Arthrexin</i>                                                                                                                                                                          |
| <i>Isoptin</i>             | Tablet 40 mg                                                                                                    | 100         | 0.76                   | <i>Anpec 40</i>                                                                                                                                                                           |
|                            | Tablet 80 mg                                                                                                    | 100         | 0.76                   | <i>Anpec 80</i>                                                                                                                                                                           |
| <i>Isoptin SR</i>          | Tablet 240 mg (sustained release)                                                                               | 30          | 2.26                   | <i>Anpec SR; Cordilox SR</i>                                                                                                                                                              |
| <i>Isoptin 180 SR</i>      | Tablet 180 mg (sustained release)                                                                               | 30          | 2.27                   | <i>Cordilox 180 SR</i>                                                                                                                                                                    |
| <i>Keflex</i>              | Capsule 250 mg                                                                                                  | 20          | 1.87                   | <i>Cefalexin Sandoz; Cephabeil; Cephalixin Max; Cephatrust 250; Chem mart Cephalixin; Cilex; GenRx Cephalixin; Ialex; Ibilex 250; Rancef; Sporahexal; Terry White Chemists Cephalixin</i> |
|                            | Capsule 500 mg                                                                                                  | 20          | 2.23                   | <i>Cephabeil; Cephalixin Max; Cephatrust 500; Chem mart Cephalixin; Cilex; GenRx Cephalixin; Ialex; Ibilex 500; Rancef; Sporahexal; Terry White Chemists Cephalixin</i>                   |
|                            | Granules for syrup 125 mg per 5 mL, 100 mL                                                                      | 1           | 1.94                   | <i>Cefalexin Sandoz; Chem mart Cephalixin; Cilex; GenRx Cephalixin; Ialex; Ibilex 125; Terry White Chemists Cephalixin</i>                                                                |
|                            | Granules for syrup 250 mg per 5 mL, 100 mL                                                                      | 1           | 2.22                   | <i>Cefalexin Sandoz; Chem mart Cephalixin; Cilex; GenRx Cephalixin; Ialex; Ibilex 250; Terry White Chemists Cephalixin</i>                                                                |
| <i>Kenacomb Otic</i>       | Ear drops 1 mg-2.5 mg (base)-250 micrograms-100,000 units per g (0.1%-0.25%-0.025%-100,000 units per g), 7.5 mL | 1           | 1.07                   | <i>Otocomb Otic</i>                                                                                                                                                                       |
|                            | Ear ointment 1 mg-2.5 mg (base)-250 micrograms-100,000 units per g (0.1%-0.25%-0.025%-100,000 units per g), 5 g | 1           | 1.08                   | <i>Otocomb Otic</i>                                                                                                                                                                       |
| <i>Klacid</i>              | Tablet 250 mg                                                                                                   | 14          | 1.96                   | <i>Chem mart Clarithromycin; Clarac; Clarihexal; Clarithro 250; GenRx Clarithromycin; Kalixocin; Terry White Chemists Clarithromycin</i>                                                  |
| <i>Lacri-Lube</i>          | Pack containing 2 tubes compound eye ointment 3.5 g                                                             | 1           | 2.24                   | <i>Ircal</i>                                                                                                                                                                              |
| <i>Lamictal</i>            | Tablet 5 mg                                                                                                     | 56          | 0.76                   | <i>Elmendos; Lamitrin; Lamogine; Seaze 5</i>                                                                                                                                              |
|                            | Tablet 25 mg                                                                                                    | 56          | 0.77                   | <i>Elmendos; GenRx Lamotrigine; Lamidus; Lamitrin; Lamogine; Lamotrigine-DP; Lamotrigine generichealth; Lamotrigine Sandoz; Seaze 25</i>                                                  |

| Premium<br>Priced<br>Brand | Form and Strength      | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                                                                                                                                                                                                                        |
|----------------------------|------------------------|-------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            | Tablet 50 mg           | 56          | 0.66                   | <i>Elmendo</i> s; <i>GenRx</i> <i>Lamotrigine</i> ; <i>Lamidu</i> s; <i>Lamitrin</i> ; <i>Lamogine</i> ; <i>Lamotrigine-DP</i> ; <i>Lamotrigine generichealth</i> ; <i>Lamotrigine Sandoz</i> ; <i>Seaze 50</i>                                                                                                                                                |
|                            | Tablet 100 mg          | 56          | 0.73                   | <i>Elmendo</i> s; <i>GenRx</i> <i>Lamotrigine</i> ; <i>Lamidu</i> s; <i>Lamitrin</i> ; <i>Lamogine</i> ; <i>Lamotrigine-DP</i> ; <i>Lamotrigine generichealth</i> ; <i>Lamotrigine Sandoz</i> ; <i>Seaze 100</i>                                                                                                                                               |
|                            | Tablet 200 mg          | 56          | 0.72                   | <i>Elmendo</i> s; <i>GenRx</i> <i>Lamotrigine</i> ; <i>Lamidu</i> s; <i>Lamitrin</i> ; <i>Lamogine</i> ; <i>Lamotrigine-DP</i> ; <i>Lamotrigine generichealth</i> ; <i>Lamotrigine Sandoz</i> ; <i>Seaze 200</i>                                                                                                                                               |
| <i>Lamisil</i>             | Tablet 250 mg (base)   | 42          | 1.46                   | <i>GenRx</i> <i>Terbinafine</i> ; <i>Tamsil</i> ; <i>Terbihexal</i> ; <i>Terbinafine 250</i> ; <i>Terbinafine-DP</i> ; <i>Zabel</i>                                                                                                                                                                                                                            |
| <i>Lanoxin</i>             | Tablet 250 micrograms  | 100         | 1.80                   | <i>Sigmaxin</i>                                                                                                                                                                                                                                                                                                                                                |
| <i>Lanoxin-PG</i>          | Tablet 62.5 micrograms | 200         | 1.79                   | <i>Sigmaxin-PG</i>                                                                                                                                                                                                                                                                                                                                             |
| <i>Lexapro</i>             | Tablet 10 mg (base)    | 28          | 4.89                   | <i>Esipram</i>                                                                                                                                                                                                                                                                                                                                                 |
|                            | Tablet 20 mg (base)    | 28          | 7.16                   | <i>Esipram</i>                                                                                                                                                                                                                                                                                                                                                 |
| <i>Lioresal 10</i>         | Tablet 10 mg           | 100         | 2.26                   | <i>Baclo</i> ; <i>Baclohexal</i> ; <i>Chem mart</i> <i>Baclofen</i> ; <i>Clofen 10</i> ; <i>GenRx</i> <i>Baclofen</i> ; <i>Stelax 10</i> ; <i>Terry White Chemists</i> <i>Baclofen</i>                                                                                                                                                                         |
| <i>Lioresal 25</i>         | Tablet 25 mg           | 100         | 2.18                   | <i>Baclo</i> ; <i>Baclohexal</i> ; <i>Chem mart</i> <i>Baclofen</i> ; <i>Clofen 25</i> ; <i>GenRx</i> <i>Baclofen</i> ; <i>Stelax 25</i> ; <i>Terry White Chemists</i> <i>Baclofen</i>                                                                                                                                                                         |
| <i>Lipex 10</i>            | Tablet 10 mg           | 30          | 1.05                   | <i>Chem mart</i> <i>Simvastatin</i> ; <i>GenRx</i> <i>Simvastatin</i> ; <i>Ransim</i> ; <i>Simvabell</i> ; <i>Simvahexal</i> ; <i>Simvar 10</i> ; <i>Simvastatin-DP</i> ; <i>Simvastatin generichealth</i> ; <i>Simvastatin Winthrop</i> ; <i>Simvasyn</i> ; <i>Simvatrust 10</i> ; <i>Terry White Chemists</i> <i>Simvastatin</i> ; <i>Zimstat</i> ; GN brand |
| <i>Lipex 20</i>            | Tablet 20 mg           | 30          | 1.04                   | <i>Chem mart</i> <i>Simvastatin</i> ; <i>GenRx</i> <i>Simvastatin</i> ; <i>Ransim</i> ; <i>Simvabell</i> ; <i>Simvahexal</i> ; <i>Simvar 20</i> ; <i>Simvastatin-DP</i> ; <i>Simvastatin generichealth</i> ; <i>Simvastatin Winthrop</i> ; <i>Simvasyn</i> ; <i>Simvatrust 20</i> ; <i>Terry White Chemists</i> <i>Simvastatin</i> ; <i>Zimstat</i> ; GN brand |
| <i>Lipex 40</i>            | Tablet 40 mg           | 30          | 0.90                   | <i>Chem mart</i> <i>Simvastatin</i> ; <i>GenRx</i> <i>Simvastatin</i> ; <i>Ransim</i> ; <i>Simvabell</i> ; <i>Simvahexal</i> ; <i>Simvar 40</i> ; <i>Simvastatin-DP</i> ; <i>Simvastatin generichealth</i> ; <i>Simvastatin Winthrop</i> ; <i>Simvasyn</i> ; <i>Simvatrust 40</i> ; <i>Terry White Chemists</i> <i>Simvastatin</i> ; <i>Zimstat</i> ; GN brand |

| Premium<br>Priced<br>Brand | Form and Strength                                                              | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                                                                                                  |
|----------------------------|--------------------------------------------------------------------------------|-------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Lipex 80</i>            | Tablet 80 mg                                                                   | 30          | 0.99                   | <i>Chem mart Simvastatin; GenRx Simvastatin; Ransim; Simvabell; Simvahexal; Simvar 80; Simvastatin-DP; Simvastatin generichealth; Simvastatin Winthrop; Simvasyn; Simvatrust 80; Terry White Chemists Simvastatin; Zimstat; GN brand</i> |
| <i>Liquifilm Forte</i>     | Eye drops 30 mg per mL (3%), 15 mL                                             | 1           | 5.94                   | <i>PVA Forte</i>                                                                                                                                                                                                                         |
| <i>Liquifilm Tears</i>     | Eye drops 14 mg per mL (1.4%), 15 mL                                           | 1           | 1.71                   | <i>PVA Tears</i>                                                                                                                                                                                                                         |
| <i>Lomotil</i>             | Tablet 2.5 mg-25 micrograms                                                    | 20          | 1.83                   | <i>Lofenoxal</i>                                                                                                                                                                                                                         |
| <i>Lopid</i>               | Tablet 600 mg                                                                  | 60          | 2.31                   | <i>Ausgem; Chem mart Gemfibrozil; Gemhexal; GenRx Gemfibrozil; Jezil; Lipazil 600 mg; Pharmacor Gemfibrozil 600; Terry White Chemists Gemfibrozil</i>                                                                                    |
| <i>Losec Tablets</i>       | Tablet 20 mg (as magnesium)                                                    | 30          | 2.15                   | <i>Acimax Tablets; GenRx Omeprazole; Meprazol; Omepral; Omeprazole-GA; Omeprazole Winthrop</i>                                                                                                                                           |
| <i>Luvox</i>               | Tablet 50 mg                                                                   | 30          | 2.96                   | <i>Faverin 50; Movox 50; Voxam</i>                                                                                                                                                                                                       |
|                            | Tablet 100 mg                                                                  | 30          | 2.95                   | <i>Faverin 100; Movox 100; Voxam</i>                                                                                                                                                                                                     |
| <i>Maxamox</i>             | Tablet 1 g                                                                     | 14          | 1.17                   | <i>Amoxycillin Sandoz</i>                                                                                                                                                                                                                |
| <i>Microgynon 30</i>       | Tablets 150 micrograms-30 micrograms, 21                                       | 4           | 11.45                  | <i>Levlen ED</i>                                                                                                                                                                                                                         |
| <i>Microgynon 30 ED</i>    | Pack containing 21 tablets<br>150 micrograms-30 micrograms and 7 inert tablets | 4           | 11.45                  | <i>Levlen ED</i>                                                                                                                                                                                                                         |
| <i>Minidiab</i>            | Tablet 5 mg                                                                    | 100         | 4.07                   | <i>Melizide</i>                                                                                                                                                                                                                          |
| <i>Minipress</i>           | Tablet 1 mg (base)                                                             | 100         | 2.31                   | <i>Chem mart Prazosin; GenRx Prazosin; Pressin 1; Terry White Chemists Prazosin</i>                                                                                                                                                      |
|                            | Tablet 2 mg (base)                                                             | 100         | 2.38                   | <i>Chem mart Prazosin; GenRx Prazosin; Pressin 2; Terry White Chemists Prazosin</i>                                                                                                                                                      |
|                            | Tablet 5 mg (base)                                                             | 100         | 2.58                   | <i>Chem mart Prazosin; GenRx Prazosin; Pressin 5; Terry White Chemists Prazosin</i>                                                                                                                                                      |
| <i>Minomycin-50</i>        | Tablet 50 mg                                                                   | 60          | 0.85                   | <i>Akamin 50</i>                                                                                                                                                                                                                         |
| <i>Mobic</i>               | Tablet 7.5 mg                                                                  | 30          | 1.61                   | <i>Chem mart Meloxicam 7.5 mg; GenRx Meloxicam; Meloxibell; Meloxicam-GA; Meloxicam Ranbaxy; Meloxicam Sandoz; Meloxicam Winthrop; Movalis 7.5; Moxicam 7.5; Pharmacor Meloxicam 7.5; Terry White Chemists Meloxicam 7.5 mg</i>          |
|                            | Tablet 15 mg                                                                   | 30          | 1.63                   | <i>Chem mart Meloxicam 15 mg; GenRx Meloxicam; Meloxibell; Meloxicam-GA; Meloxicam Ranbaxy; Meloxicam Sandoz; Meloxicam Winthrop; Movalis 15; Moxicam 15; Pharmacor Meloxicam 15; Terry White Chemists Meloxicam 15 mg</i>               |
| <i>Mogadon</i>             | Tablet 5 mg                                                                    | 50          | 3.06                   | <i>Alodorm</i>                                                                                                                                                                                                                           |
|                            | Tablet 5 mg                                                                    | 25          | 1.53                   | <i>Alodorm</i>                                                                                                                                                                                                                           |
| <i>Naprosyn</i>            | Tablet 250 mg                                                                  | 100         | 2.34                   | <i>Inza 250</i>                                                                                                                                                                                                                          |
|                            | Tablet 500 mg                                                                  | 50          | 1.36                   | <i>Inza 500</i>                                                                                                                                                                                                                          |
| <i>Naprosyn SR1000</i>     | Tablet 1 g (sustained release)                                                 | 28          | 1.34                   | <i>Proxen SR 1000</i>                                                                                                                                                                                                                    |

| Premium<br>Priced<br>Brand | Form and Strength                                                              | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                     |
|----------------------------|--------------------------------------------------------------------------------|-------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Naprosyn SR750</i>      | Tablet 750 mg (sustained release)                                              | 28          | 1.27                   | <i>Proxen SR 750</i>                                                                                                                                        |
| <i>Natrilix</i>            | Tablet 2.5 mg                                                                  | 90          | 2.56                   | <i>Chem mart Indapamide; Dapa-Tabs; GenRx Indapamide; Indahexal; Insig; Napamide 2.5 mg; Terry White Chemists Indapamide</i>                                |
| <i>Neoral 25</i>           | Capsule 25 mg                                                                  | 60          | 2.28                   | <i>Cicloral</i>                                                                                                                                             |
| <i>Neoral 50</i>           | Capsule 50 mg                                                                  | 60          | 2.24                   | <i>Cicloral</i>                                                                                                                                             |
| <i>Neoral 100</i>          | Capsule 100 mg                                                                 | 60          | 2.26                   | <i>Cicloral</i>                                                                                                                                             |
| <i>Nolvadex</i>            | Tablet 10 mg (base)                                                            | 60          | 1.66                   | <i>Genox 10; Tamoxen 10 mg</i>                                                                                                                              |
| <i>Nolvadex-D</i>          | Tablet 20 mg (base)                                                            | 60          | 2.84                   | <i>Chem mart Tamoxifen; Genox 20; GenRx Tamoxifen; Tamosin; Tamoxen 20 mg; Tamoxifen Sandoz; Terry White Chemists Tamoxifen</i>                             |
| <i>Nordette 28</i>         | Pack containing 21 tablets<br>150 micrograms-30 micrograms and 7 inert tablets | 4           | 11.78                  | <i>Monofeme 28</i>                                                                                                                                          |
| <i>Noriday 28 Day</i>      | Tablets 350 micrograms, 28                                                     | 4           | 4.00                   | <i>Locilan 28 Day</i>                                                                                                                                       |
| <i>Normison</i>            | Tablet 10 mg                                                                   | 25          | 1.38                   | <i>Temaze; Temtabs</i>                                                                                                                                      |
|                            | Tablet 10 mg                                                                   | 50          | 2.76                   | <i>Temaze; Temtabs</i>                                                                                                                                      |
| <i>Noroxin</i>             | Tablet 400 mg                                                                  | 14          | 2.83                   | <i>Chem mart Norfloxacin; GenRx Norfloxacin; Norflohexal; Nufloxib; Roxin; Terry White Chemists Norfloxacin; GM brand</i>                                   |
| <i>Norvasc</i>             | Tablet 5 mg (as besylate)                                                      | 30          | 3.05                   | <i>Amlodipine-GA; Amlodipine generichealth; Amlodipine Sandoz; APO-Amlodipine; Chem mart Amlodipine; Ozlodip; Perivasc; Terry White Chemists Amlodipine</i> |
|                            | Tablet 10 mg (as besylate)                                                     | 30          | 4.45                   | <i>Amlodipine-GA; Amlodipine generichealth; Amlodipine Sandoz; APO-Amlodipine; Chem mart Amlodipine; Ozlodip; Perivasc; Terry White Chemists Amlodipine</i> |
| <i>Odrik</i>               | Capsule 500 micrograms                                                         | 28          | 2.35                   | <i>APO-Trandolapril; Dolapril 0.5; Tranalpha; Trandolapril-DP</i>                                                                                           |
|                            | Capsule 1 mg                                                                   | 28          | 2.36                   | <i>APO-Trandolapril; Dolapril 1; Tranalpha; Trandolapril-DP</i>                                                                                             |
|                            | Capsule 2 mg                                                                   | 28          | 2.36                   | <i>APO-Trandolapril; Dolapril 2; Tranalpha; Trandolapril-DP</i>                                                                                             |
| <i>Ogen .625</i>           | Tablet 730 micrograms (equivalent to 625 micrograms sodium oestrone sulfate)   | 56          | 1.47                   | <i>Genoral 0.625</i>                                                                                                                                        |
| <i>Ogen 1.25</i>           | Tablet 1.46 mg (equivalent to 1.25 mg sodium oestrone sulfate)                 | 56          | 1.48                   | <i>Genoral 1.25</i>                                                                                                                                         |
| <i>Oroxine</i>             | Tablet equivalent to 50 micrograms anhydrous thyroxine sodium                  | 200         | 1.30                   | <i>Eutroxsig</i>                                                                                                                                            |
|                            | Tablet equivalent to 100 micrograms anhydrous thyroxine sodium                 | 200         | 1.31                   | <i>Eutroxsig</i>                                                                                                                                            |
|                            | Tablet equivalent to 200 micrograms anhydrous thyroxine sodium                 | 200         | 1.29                   | <i>Eutroxsig</i>                                                                                                                                            |
| <i>Orudis SR 200</i>       | Capsule 200 mg (sustained release)                                             | 28          | 2.00                   | <i>Oruvail SR</i>                                                                                                                                           |
| <i>P.V. Carpine</i>        | Eye drops 10 mg per mL (1%), 15 mL                                             | 1           | 2.97                   | <i>Pilopt</i>                                                                                                                                               |
|                            | Eye drops 20 mg per mL (2%), 15 mL                                             | 1           | 2.96                   | <i>Pilopt</i>                                                                                                                                               |
|                            | Eye drops 40 mg per mL (4%), 15 mL                                             | 1           | 2.83                   | <i>Pilopt</i>                                                                                                                                               |
|                            | Eye drops 60 mg per mL (6%), 15 mL                                             | 1           | 2.86                   | <i>Pilopt</i>                                                                                                                                               |

| Premium<br>Priced<br>Brand | Form and Strength                | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                                                                                              |
|----------------------------|----------------------------------|-------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Panadeine Forte</i>     | Tablet 30 mg-500 mg              | 20          | 1.43                   | <i>Codalgin Forte; Codapane Forte; Comfarol Forte; Dolaforte; Prodeine Forte</i>                                                                                                                                                     |
|                            | Tablet 30 mg-500 mg              | 60          | 4.29                   | <i>Codalgin Forte; Codapane Forte; Comfarol Forte; Dolaforte; Prodeine Forte</i>                                                                                                                                                     |
| <i>Panafcort</i>           | Tablet 1 mg                      | 100         | 0.65                   | <i>Predsone</i>                                                                                                                                                                                                                      |
| <i>Panafcortelone</i>      | Tablet 1 mg                      | 100         | 0.46                   | <i>Predsolone</i>                                                                                                                                                                                                                    |
| <i>Parlodel</i>            | Tablet 2.5 mg (base)             | 30          | 2.23                   | <i>Krypton 2.5</i>                                                                                                                                                                                                                   |
|                            | Tablet 2.5 mg (base)             | 60          | 2.29                   | <i>Krypton 2.5</i>                                                                                                                                                                                                                   |
|                            | Capsule 5 mg (base)              | 60          | 1.99                   | <i>Krypton 5</i>                                                                                                                                                                                                                     |
|                            | Capsule 10 mg (base)             | 100         | 2.39                   | <i>Krypton 10</i>                                                                                                                                                                                                                    |
| <i>Pepcidine</i>           | Tablet 40 mg                     | 30          | 4.25                   | <i>Ausfam 40; Chem mart Famotidine; Famohexal; GenRx Famotidine; Pamacid 40; Pepzan; Terry White Chemists Famotidine</i>                                                                                                             |
| <i>Pepcidine M</i>         | Tablet 20 mg                     | 60          | 4.25                   | <i>Ausfam 20; Chem mart Famotidine; Famohexal; GenRx Famotidine; Pamacid 20; Pepzan; Terry White Chemists Famotidine</i>                                                                                                             |
| <i>Plendil ER</i>          | Tablet 2.5 mg (extended release) | 30          | 3.92                   | <i>Felodur ER 2.5 mg</i>                                                                                                                                                                                                             |
|                            | Tablet 5 mg (extended release)   | 30          | 3.92                   | <i>Felodil XR 5; Felodur ER 5 mg</i>                                                                                                                                                                                                 |
|                            | Tablet 10 mg (extended release)  | 30          | 3.92                   | <i>Felodil XR 10; Felodur ER 10 mg</i>                                                                                                                                                                                               |
| <i>Pravachol</i>           | Tablet 10 mg                     | 30          | 3.52                   | <i>Chem mart Pravastatin; Cholstat 10; GenRx Pravastatin; Lipostat 10; Liprachol; Pravastatin 10; Pravastatin-DP; Pravastatin-GA 10; Pravastatin generichealth; Pravastatin Winthrop; Terry White Chemists Pravastatin</i>           |
|                            | Tablet 20 mg                     | 30          | 3.52                   | <i>Chem mart Pravastatin; Cholstat 20; GenRx Pravastatin; Lipostat 20; Liprachol; Pravastatin 20; Pravastatin-DP; Pravastatin-GA 20; Pravastatin generichealth; Pravastatin Winthrop; Terry White Chemists Pravastatin; Vastoran</i> |
|                            | Tablet 40 mg                     | 30          | 3.07                   | <i>Chem mart Pravastatin; Cholstat 40; GenRx Pravastatin; Lipostat 40; Liprachol; Pravastatin 40; Pravastatin-DP; Pravastatin-GA 40; Pravastatin generichealth; Pravastatin Winthrop; Terry White Chemists Pravastatin; Vastoran</i> |
|                            | Tablet 80 mg                     | 30          | 3.37                   | <i>Lipostat 80; Pravastatin-GA 80; Pravastatin generichealth</i>                                                                                                                                                                     |
| <i>Prinivil 5</i>          | Tablet 5 mg                      | 30          | 1.52                   | <i>Chem mart Lisinopril; Fibsol 5; GenRx Lisinopril; Liprace; Lisinobell; Lisinopril 5; Lisinopril Hexal; Lisinopril Winthrop; Lisinotrust 5; Lisodur; Terry White Chemists Lisinopril</i>                                           |

| Premium<br>Priced<br>Brand | Form and Strength                                           | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                                                                                 |
|----------------------------|-------------------------------------------------------------|-------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Prinivil 10</i>         | Tablet 10 mg                                                | 30          | 1.53                   | <i>Chem mart Lisinopril; Fibsol 10; GenRx Lisinopril; Liprace; Lisinobell; Lisinopril 10; Lisinopril Hexal; Lisinopril Winthrop; Lisinotrust 10; Lisodur; Terry White Chemists Lisinopril</i>                           |
| <i>Prinivil 20</i>         | Tablet 20 mg                                                | 30          | 1.53                   | <i>Chem mart Lisinopril; Fibsol 20; GenRx Lisinopril; Liprace; Lisinobell; Lisinopril 20; Lisinopril generichealth; Lisinopril Hexal; Lisinopril Winthrop; Lisinotrust 20; Lisodur; Terry White Chemists Lisinopril</i> |
| <i>Prothiaden</i>          | Capsule 25 mg                                               | 50          | 1.58                   | <i>Dothep 25</i>                                                                                                                                                                                                        |
|                            | Tablet 75 mg                                                | 30          | 0.80                   | <i>Dothep 75</i>                                                                                                                                                                                                        |
| <i>Provera</i>             | Tablet 5 mg                                                 | 56          | 1.74                   | <i>Ralovera</i>                                                                                                                                                                                                         |
|                            | Tablet 10 mg                                                | 30          | 1.75                   | <i>Medroxyhexal; Ralovera</i>                                                                                                                                                                                           |
|                            | Tablet 10 mg                                                | 100         | 1.64                   | <i>Ralovera</i>                                                                                                                                                                                                         |
| <i>Prozac Tab</i>          | Tablet 20 mg (base) (dispersible)                           | 28          | 4.13                   | <i>Lovan 20 Tab</i>                                                                                                                                                                                                     |
| <i>Prozac 20</i>           | Capsule 20 mg (base)                                        | 28          | 4.13                   | <i>Auscap; Chem mart Fluoxetine; Fluohexal; Fluoxebell; Fluoxetine 20; Fluoxetine-DP; GenRx Fluoxetine; Lovan; Terry White Chemists Fluoxetine; Zactin</i>                                                              |
| <i>Quinate</i>             | Tablet 300 mg                                               | 50          | 2.17                   | <i>Quinsul</i>                                                                                                                                                                                                          |
| <i>Redipred</i>            | Oral solution equivalent to 5 mg prednisolone per mL, 30 mL | 1           | 1.40                   | <i>PredMix</i>                                                                                                                                                                                                          |
| <i>Renitec</i>             | Tablet 10 mg                                                | 30          | 2.46                   | <i>Alphapril; Auspril; Chem mart Enalapril; Enahexal; Enalabell; Enalapril-DP 10mg; Enalapril Winthrop; GenRx Enalapril; Terry White Chemists Enalapril</i>                                                             |
| <i>Renitec M</i>           | Tablet 5 mg                                                 | 30          | 2.46                   | <i>Alphapril; Auspril; Chem mart Enalapril; Enahexal; Enalabell; Enalapril-DP 5mg; Enalapril Winthrop; GenRx Enalapril; Terry White Chemists Enalapril</i>                                                              |
| <i>Renitec 20</i>          | Tablet 20 mg                                                | 30          | 2.47                   | <i>Alphapril; Auspril; Chem mart Enalapril; Enahexal; Enalabell; Enalapril-DP 20mg; Enalapril Winthrop; GenRx Enalapril; Terry White Chemists Enalapril</i>                                                             |
| <i>Ritalin 10</i>          | Tablet 10 mg                                                | 100         | 1.37                   | <i>Attenta</i>                                                                                                                                                                                                          |
| <i>Rivotril</i>            | Tablet 500 micrograms                                       | 200         | 3.58                   | <i>Paxam 0.5</i>                                                                                                                                                                                                        |
|                            | Tablet 2 mg                                                 | 200         | 4.08                   | <i>Paxam 2</i>                                                                                                                                                                                                          |
|                            | Tablet 500 micrograms                                       | 100         | 1.79                   | <i>Paxam 0.5</i>                                                                                                                                                                                                        |
|                            | Tablet 2 mg                                                 | 100         | 2.04                   | <i>Paxam 2</i>                                                                                                                                                                                                          |
| <i>Roaccutane</i>          | Capsule 20 mg                                               | 60          | 2.37                   | <i>Chem mart Isotretinoin; GenRx Isotretinoin; Oratane; Terry White Chemists Isotretinoin</i>                                                                                                                           |
| <i>Rulide</i>              | Tablet 150 mg                                               | 10          | 1.89                   | <i>Biaxsig; Roxar 150; Roxide; Roximycin</i>                                                                                                                                                                            |
|                            | Tablet 300 mg                                               | 5           | 1.89                   | <i>Biaxsig; Roxar 300; Roxide; Roximycin</i>                                                                                                                                                                            |
| <i>Salazopyrin-EN</i>      | Tablet 500 mg (enteric coated)                              | 200         | 1.58                   | <i>Pyralin EN</i>                                                                                                                                                                                                       |



| Premium<br>Priced<br>Brand | Form and Strength                                        | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                                                    |
|----------------------------|----------------------------------------------------------|-------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Seprtin Forte</i>       | Tablet 160 mg-800 mg                                     | 10          | 1.10                   | <i>Bactrim DS; Chem mart Trimethoprim with Sulfamethoxazole DS; GenRx Trimethoprim with Sulfamethoxazole DS; Resprim Forte; Terry White Chemists Trimethoprim with Sulfamethoxazole DS</i> |
| <i>Serepax</i>             | Tablet 15 mg                                             | 25          | 1.78                   | <i>Alepam 15</i>                                                                                                                                                                           |
|                            | Tablet 30 mg                                             | 25          | 1.90                   | <i>Alepam 30; Murelax</i>                                                                                                                                                                  |
|                            | Tablet 15 mg                                             | 50          | 3.56                   | <i>Alepam 15</i>                                                                                                                                                                           |
|                            | Tablet 30 mg                                             | 50          | 3.80                   | <i>Alepam 30; Murelax</i>                                                                                                                                                                  |
| <i>Serophene</i>           | Tablet 50 mg                                             | 10          | 0.14                   | <i>Clomhexal; Fermil; GenRx Clomiphene</i>                                                                                                                                                 |
| <i>Sigmacort</i>           | Cream 10 mg per g (1%), 50 g                             | 1           | 1.91                   | <i>Cortic-DS 1%</i>                                                                                                                                                                        |
|                            | Cream 10 mg per g (1%), 50 g                             | 1           | 1.91                   | <i>Cortic-DS 1%</i>                                                                                                                                                                        |
|                            | Cream 10 mg per g (1%), 30 g                             | 1           | 1.90                   | <i>Cortic-DS 1%</i>                                                                                                                                                                        |
|                            | Topical ointment 10 mg per g (1%), 30 g                  | 1           | 1.90                   | <i>Cortic-DS 1%</i>                                                                                                                                                                        |
|                            | Topical ointment 10 mg per g (1%), 50 g                  | 1           | 1.91                   | <i>Cortic-DS 1%</i>                                                                                                                                                                        |
| <i>Sinemet</i>             | Tablet 250 mg-25 mg                                      | 100         | 2.76                   | <i>Levohexal</i>                                                                                                                                                                           |
| <i>Sinemet 100/25</i>      | Tablet 100 mg-25 mg                                      | 100         | 4.73                   | <i>Kinson</i>                                                                                                                                                                              |
| <i>Slow-K</i>              | Tablet 600 mg (sustained release)                        | 200         | 2.80                   | <i>Duro-K</i>                                                                                                                                                                              |
| <i>Sofradex</i>            | Ear drops 500 micrograms-5 mg-50 micrograms per mL, 8 mL | 1           | 1.76                   | <i>Otodex</i>                                                                                                                                                                              |
| <i>Sotacor</i>             | Tablet 80 mg                                             | 60          | 3.53                   | <i>GenRx Sotalol; Solavert; Sotahexal</i>                                                                                                                                                  |
|                            | Tablet 160 mg                                            | 60          | 3.53                   | <i>Cardol; Chem mart Sotalol; GenRx Sotalol; Solavert; Sotab; Sotahexal; Terry White Chemists Sotalol</i>                                                                                  |
| <i>Stemetil</i>            | Tablet containing prochlorperazine maleate 5 mg          | 25          | 2.16                   | <i>Stemzine</i>                                                                                                                                                                            |
| <i>Synphasic</i>           | Pack containing 12 tablets                               | 4           | 7.92                   | <i>Improvil 28 Day</i>                                                                                                                                                                     |
|                            | 500 micrograms-35 micrograms, 9 tablets                  |             |                        |                                                                                                                                                                                            |
|                            | 1 mg-35 micrograms and 7 inert tablets                   |             |                        |                                                                                                                                                                                            |
| <i>Tagamet</i>             | Tablet 200 mg                                            | 120         | 1.94                   | <i>Magicul 200</i>                                                                                                                                                                         |
|                            | Tablet 400 mg                                            | 60          | 1.94                   | <i>GenRx Cimetidine; Magicul 400</i>                                                                                                                                                       |
| <i>Tazac</i>               | Capsule 150 mg                                           | 60          | 5.60                   | <i>Nizac; Tacidine</i>                                                                                                                                                                     |
|                            | Capsule 300 mg                                           | 30          | 5.60                   | <i>Nizac; Tacidine</i>                                                                                                                                                                     |
| <i>Tears Naturale</i>      | Eye drops 3 mg-1 mg per mL (0.3%-0.1%), 15 mL            | 1           | 1.67                   | <i>Poly-Tears</i>                                                                                                                                                                          |
| <i>Tegretol 100</i>        | Tablet 100 mg                                            | 200         | 2.55                   | <i>Carbamazepine Sandoz</i>                                                                                                                                                                |
| <i>Tegretol 200</i>        | Tablet 200 mg                                            | 200         | 2.74                   | <i>Carbamazepine Sandoz; Teril</i>                                                                                                                                                         |
| <i>Tenormin</i>            | Tablet 50 mg                                             | 30          | 2.79                   | <i>Anselol 50 mg; Atehexal; Chem mart Atenolol; GenRx Atenolol; Noten; Tensig; Terry White Chemists Atenolol</i>                                                                           |
|                            |                                                          |             |                        |                                                                                                                                                                                            |
| <i>Timoptol</i>            | Eye drops 2.5 mg (base) per mL (0.25%), 5 mL             | 1           | 1.18                   | <i>Tenopt</i>                                                                                                                                                                              |
|                            | Eye drops 5 mg (base) per mL (0.5%), 5 mL                | 1           | 1.17                   | <i>Tenopt</i>                                                                                                                                                                              |
| <i>Tofranil 10</i>         | Tablet 10 mg                                             | 50          | 2.97                   | <i>Tolerade 10</i>                                                                                                                                                                         |
| <i>Tofranil 25</i>         | Tablet 25 mg                                             | 50          | 2.97                   | <i>Tolerade 25</i>                                                                                                                                                                         |
| <i>Tolvon</i>              | Tablet 10 mg                                             | 50          | 1.99                   | <i>Lumin 10</i>                                                                                                                                                                            |
|                            | Tablet 20 mg                                             | 50          | 2.97                   | <i>Lumin 20</i>                                                                                                                                                                            |
| <i>Tramal</i>              | Capsule 50 mg                                            | 20          | 2.42                   | <i>Chem mart Tramadol; GenRx Tramadol; Terry White Chemists Tramadol; Tramedo; Zydol</i>                                                                                                   |
| <i>Tramal SR 100</i>       | Tablet 100 mg (sustained release)                        | 20          | 4.51                   | <i>Tramahexal SR; Tramedo SR 100; Zydol SR 100</i>                                                                                                                                         |
| <i>Tramal SR 150</i>       | Tablet 150 mg (sustained release)                        | 20          | 5.37                   | <i>Tramahexal SR; Tramedo SR 150; Zydol SR 150</i>                                                                                                                                         |
| <i>Tramal SR 200</i>       | Tablet 200 mg (sustained release)                        | 20          | 6.09                   | <i>Tramahexal SR; Tramedo SR 200; Zydol SR 200</i>                                                                                                                                         |

| Premium<br>Priced<br>Brand   | Form and Strength                                                                            | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                                               |
|------------------------------|----------------------------------------------------------------------------------------------|-------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Trandate</i>              | Tablet 100 mg                                                                                | 100         | 2.99                   | <i>Presolol 100</i>                                                                                                                                                                   |
|                              | Tablet 200 mg                                                                                | 100         | 2.97                   | <i>Presolol 200</i>                                                                                                                                                                   |
| <i>Triphasil 28</i>          | Pack containing 6 tablets                                                                    | 4           | 11.78                  | <i>Trifeme 28</i>                                                                                                                                                                     |
|                              | 50 micrograms-30 micrograms, 5 tablets                                                       |             |                        |                                                                                                                                                                                       |
|                              | 75 micrograms-40 micrograms, 10 tablets                                                      |             |                        |                                                                                                                                                                                       |
|                              | 125 micrograms-30 micrograms and 7 inert tablets                                             |             |                        |                                                                                                                                                                                       |
| <i>Triprim</i>               | Tablet 300 mg                                                                                | 7           | 1.03                   | <i>Alprim</i>                                                                                                                                                                         |
| <i>Triquilar ED</i>          | Pack containing 6 tablets                                                                    | 4           | 11.45                  | <i>Logynon ED</i>                                                                                                                                                                     |
|                              | 50 micrograms-30 micrograms, 5 tablets                                                       |             |                        |                                                                                                                                                                                       |
|                              | 75 micrograms-40 micrograms, 10 tablets                                                      |             |                        |                                                                                                                                                                                       |
|                              | 125 micrograms-30 micrograms and 7 inert tablets                                             |             |                        |                                                                                                                                                                                       |
| <i>Valium</i>                | Tablet 2 mg                                                                                  | 50          | 0.86                   | <i>Antenex 2; Valpam 2</i>                                                                                                                                                            |
|                              | Tablet 5 mg                                                                                  | 50          | 0.88                   | <i>Antenex 5; Diazepam-DP; Ranzepam; Valpam 5</i>                                                                                                                                     |
| <i>Vastin</i>                | Capsule 20 mg (fluvastatin)                                                                  | 28          | 1.64                   | <i>Lescol</i>                                                                                                                                                                         |
|                              | Capsule 40 mg (fluvastatin)                                                                  | 28          | 1.79                   | <i>Lescol</i>                                                                                                                                                                         |
| <i>Ventolin CFC-free</i>     | Oral pressurised inhalation 100 micrograms (base) per dose (200 doses), CFC-free formulation | 2           | 1.18                   | <i>Airomir; Asmol CFC-free; Epaq</i>                                                                                                                                                  |
| <i>Ventolin Nebules</i>      | Nebuliser solution single dose units 2.5 mg (base) in 2.5 mL, 30                             | 2           | 1.46                   | <i>Asmol 2.5 uni-dose; Butamol 2.5; Chem mart Salbutamol; GenRx Salbutamol; Pharmacor Salbutamol 2.5; Salbutamol-GA; Salbutamol Sandoz; Terry White Chemists Salbutamol; PU brand</i> |
|                              | Nebuliser solution single dose units 5 mg (base) in 2.5 mL, 30                               | 2           | 1.46                   | <i>Asmol 5 uni-dose; Butamol 5; Chem mart Salbutamol; GenRx Salbutamol; Pharmacor Salbutamol 5; Salbutamol-GA; Salbutamol Sandoz; Terry White Chemists Salbutamol</i>                 |
| <i>Vibramycin</i>            | Tablet 100 mg (as hydrochloride)                                                             | 7           | 1.19                   | <i>Chem mart Doxycycline; Doxsig; Doxy-100; Doxyhexal; Doxylin 100; GenRx Doxycycline; Terry White Chemists Doxycycline</i>                                                           |
|                              | Tablet 100 mg (as hydrochloride)                                                             | 28          | 4.76                   | <i>Chem mart Doxycycline; Doxsig; Doxy-100; Doxyhexal; Doxylin 100; GenRx Doxycycline; Terry White Chemists Doxycycline</i>                                                           |
|                              | Tablet 100 mg (as hydrochloride)                                                             | 21          | 3.57                   | <i>Chem mart Doxycycline; Doxsig; Doxy-100; Doxyhexal; Doxylin 100; GenRx Doxycycline; Terry White Chemists Doxycycline</i>                                                           |
| <i>Vibra-Tabs</i>            | Tablet 50 mg (as hydrochloride)                                                              | 25          | 1.25                   | <i>Chem mart Doxycycline; Doxy-50; Doxyhexal; Doxylin 50; Frakas; GenRx Doxycycline; Terry White Chemists Doxycycline</i>                                                             |
| <i>Viscotears Liquid Gel</i> | Ocular lubricating gel 2 mg per g (0.2%), 10 g                                               | 1           | 1.00                   | <i>PAA</i>                                                                                                                                                                            |
| <i>Visken 5</i>              | Tablet 5 mg                                                                                  | 100         | 2.14                   | <i>Barbloc 5</i>                                                                                                                                                                      |
| <i>Visken 15</i>             | Tablet 15 mg                                                                                 | 50          | 2.12                   | <i>Barbloc 15</i>                                                                                                                                                                     |
| <i>Voltaren 25</i>           | Tablet 25 mg (enteric coated)                                                                | 100         | 1.96                   | <i>Chem mart Diclofenac; Clonac 25; Diclohexal; Dinac; Fenac 25; GenRx Diclofenac; Terry White Chemists Diclofenac</i>                                                                |

| Premium<br>Priced<br>Brand | Form and Strength             | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                                                                                                  |
|----------------------------|-------------------------------|-------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Voltaren 50</i>         | Tablet 50 mg (enteric coated) | 50          | 1.96                   | <i>Chem mart Diclofenac; Clonac 50; Diclohexal; Dinac; Fenac; GenRx Diclofenac; Terry White Chemists Diclofenac</i>                                                                                                                      |
| <i>Xanax</i>               | Tablet 250 micrograms         | 50          | 0.81                   | <i>Alprax 0.25; Kalma 0.25; Zamhexal 0.25mg</i>                                                                                                                                                                                          |
|                            | Tablet 500 micrograms         | 50          | 0.87                   | <i>Alprax 0.5; Kalma 0.5; Zamhexal 0.5mg</i>                                                                                                                                                                                             |
|                            | Tablet 1 mg                   | 50          | 1.03                   | <i>Alprax 1; Alprazolam-DP; Chem mart Alprazolam; GenRx Alprazolam; Kalma 1; Terry White Chemists Alprazolam; Zamhexal 1.0mg</i>                                                                                                         |
| <i>Xanax Tri-Score</i>     | Tablet 2 mg                   | 50          | 1.25                   | <i>Alprax 2; Alprazolam-DP; Chem mart Alprazolam; GenRx Alprazolam; Kalma 2; Terry White Chemists Alprazolam; Zamhexal 2mg</i>                                                                                                           |
| <i>Zantac</i>              | Tablet 150 mg (base)          | 60          | 1.71                   | <i>Ausran; Chem mart Ranitidine; GenRx Ranitidine; Rani 2; Ranihexal; Ranoxyl; Terry White Chemists Ranitidine; Ulcaid</i>                                                                                                               |
|                            | Tablet 300 mg (base)          | 30          | 1.71                   | <i>Ausran; Chem mart Ranitidine; GenRx Ranitidine; Rani 2; Ranihexal; Ranoxyl; Terry White Chemists Ranitidine; Ulcaid</i>                                                                                                               |
| <i>Zestril</i>             | Tablet 10 mg                  | 30          | 2.08                   | <i>Chem mart Lisinopril; Fibsol 10; GenRx Lisinopril; Liprace; Lisinobell; Lisinopril 10; Lisinopril Hexal; Lisinopril Winthrop; Lisinotrust 10; Lisodur; Terry White Chemists Lisinopril</i>                                            |
|                            | Tablet 20 mg                  | 30          | 2.08                   | <i>Chem mart Lisinopril; Fibsol 20; GenRx Lisinopril; Liprace; Lisinobell; Lisinopril 20; Lisinopril generichealth; Lisinopril Hexal; Lisinopril Winthrop; Lisinotrust 20; Lisodur; Terry White Chemists Lisinopril</i>                  |
|                            | Tablet 5 mg                   | 30          | 2.08                   | <i>Chem mart Lisinopril; Fibsol 5; GenRx Lisinopril; Liprace; Lisinobell; Lisinopril 5; Lisinopril Hexal; Lisinopril Winthrop; Lisinotrust 5; Lisodur; Terry White Chemists Lisinopril</i>                                               |
| <i>Zocor</i>               | Tablet 10 mg                  | 30          | 1.05                   | <i>Chem mart Simvastatin; GenRx Simvastatin; Ransim; Simvabell; Simvahexal; Simvar 10; Simvastatin-DP; Simvastatin generichealth; Simvastatin Winthrop; Simvasyn; Simvatrust 10; Terry White Chemists Simvastatin; Zimstat; GN brand</i> |

| Premium<br>Priced<br>Brand | Form and Strength           | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                                                                                                                                                |
|----------------------------|-----------------------------|-------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Zofran                     | Tablet 20 mg                | 30          | 1.04                   | Chem mart Simvastatin;<br>GenRx Simvastatin; Ransim;<br>Simvabell; Simvahexal; Simvar<br>20; Simvastatin-DP; Simvastatin<br>generichealth; Simvastatin Winthrop;<br>Simvasyn; Simvatrust 20; Terry White<br>Chemists Simvastatin; Zimstat; GN<br>brand |
|                            | Tablet 40 mg                | 30          | 0.90                   | Chem mart Simvastatin;<br>GenRx Simvastatin; Ransim;<br>Simvabell; Simvahexal; Simvar<br>40; Simvastatin-DP; Simvastatin<br>generichealth; Simvastatin Winthrop;<br>Simvasyn; Simvatrust 40; Terry White<br>Chemists Simvastatin; Zimstat; GN<br>brand |
|                            | Tablet 80 mg                | 30          | 0.99                   | Chem mart Simvastatin;<br>GenRx Simvastatin; Ransim;<br>Simvabell; Simvahexal; Simvar<br>80; Simvastatin-DP; Simvastatin<br>generichealth; Simvastatin Winthrop;<br>Simvasyn; Simvatrust 80; Terry White<br>Chemists Simvastatin; Zimstat; GN<br>brand |
|                            | Tablet 5 mg                 | 30          | 1.05                   | Simvabell; Simvahexal; Simvasyn;<br>Zimstat                                                                                                                                                                                                            |
|                            | Tablet 4 mg                 | 4           | 0.62                   | Ondansetron-RL; Ondaz; Onsetron 4                                                                                                                                                                                                                      |
|                            | Tablet 8 mg                 | 4           | 0.69                   | Ondansetron-RL; Ondaz; Onsetron 8                                                                                                                                                                                                                      |
|                            | I.V. injection 4 mg in 2 mL | 1           | 0.70                   | Ondansetron-RL; Ondaz; Onsetron;<br>PF brand                                                                                                                                                                                                           |
|                            | I.V. injection 8 mg in 4 mL | 1           | 0.69                   | Ondansetron-RL; Ondaz; Onsetron;<br>PF brand                                                                                                                                                                                                           |
|                            | Tablet 4 mg                 | 10          | 0.69                   | Ondansetron-RL; Ondaz; Onsetron 4                                                                                                                                                                                                                      |
|                            | Tablet 8 mg                 | 10          | 0.67                   | Ondansetron-RL; Ondaz; Onsetron 8                                                                                                                                                                                                                      |
| Zofran Zydis               | Wafer 4 mg                  | 4           | 0.62                   | Ondansetron-RL Zydis; Ondaz Zydis                                                                                                                                                                                                                      |
|                            | Wafer 8 mg                  | 4           | 0.69                   | Ondansetron-RL Zydis; Ondaz Zydis                                                                                                                                                                                                                      |
|                            | Wafer 4 mg                  | 10          | 0.69                   | Ondansetron-RL Zydis; Ondaz Zydis                                                                                                                                                                                                                      |
|                            | Wafer 8 mg                  | 10          | 0.67                   | Ondansetron-RL Zydis; Ondaz Zydis                                                                                                                                                                                                                      |
| Zoloft                     | Tablet 50 mg (base)         | 30          | 0.41                   | Chem mart Sertraline; Concorz;<br>Eleva 50; GenRx Sertraline; Sertra<br>50; Sertraline 50; Sertraline-GA;<br>Sertraline generichealth; Sertraline<br>Winthrop; Sertratrust 50; Setrona;<br>Terry White Chemists Sertraline;<br>Xydep 50                |
|                            | Tablet 100 mg (base)        | 30          | 0.41                   | Chem mart Sertraline; Concorz;<br>Eleva 100; GenRx Sertraline; Sertra<br>100; Sertraline 100; Sertraline-GA;<br>Sertraline generichealth; Sertraline<br>Winthrop; Sertratrust 100; Setrona;<br>Terry White Chemists Sertraline;<br>Xydep 100           |
| Zovirax 200 mg             | Tablet 200 mg               | 50          | 4.34                   | Acihexal; Acyclo-V 200; GenRx<br>Aciclovir; Lovir                                                                                                                                                                                                      |

| Premium<br>Priced<br>Brand | Form and Strength                 | Max.<br>Qty | Brand<br>Premium<br>\$ | Benchmark Priced Brands                                                                                                   |
|----------------------------|-----------------------------------|-------------|------------------------|---------------------------------------------------------------------------------------------------------------------------|
|                            | Tablet 200 mg                     | 90          | 3.21                   | Aciclovir 200; Acihexal; Acyclo-V 200; Chem mart Aciclovir; GenRx Aciclovir; Lovir; Ozvir; Terry White Chemists Aciclovir |
| Zovirax 800 mg             | Tablet 800 mg                     | 35          | 1.56                   | Aciclovir 800; Acihexal; Acyclo-V 800; GenRx Aciclovir; Lovir                                                             |
|                            | Tablet 800 mg                     | 120         | 5.19                   | Acihexal; Acyclo-V 800; Lovir                                                                                             |
| Zyban                      | Tablet 150 mg (sustained release) | 30          | 0.85                   | Bupropion-RL; Clorprax; Prexaton                                                                                          |
|                            | Tablet 150 mg (sustained release) | 90          | 0.86                   | Bupropion-RL; Clorprax; Prexaton                                                                                          |
| Zyloprim                   | Tablet 100 mg                     | 200         | 1.91                   | Allohexal; Allosig; Chem mart Allopurinol; GenRx Allopurinol; Progout 100; Terry White Chemists Allopurinol               |
|                            | Tablet 300 mg                     | 60          | 1.80                   | Allohexal; Allosig; Chem mart Allopurinol; GenRx Allopurinol; Progout 300; Terry White Chemists Allopurinol               |